ATC;Drug;Gene;Genotype;Alleles;Effect;Outcome;Sentence;Population
;SITAGLIPTIN;DPP4;rs2909451;TT;Efficacy;decreased response to ⮕ SITAGLIPTIN;Genotype TT is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;SITAGLIPTIN;KCNJ11;rs2285676;GG;Efficacy;increased response to ⮕ SITAGLIPTIN;Genotype GG is associated with increased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;SITAGLIPTIN;KCNQ1;rs163184;GG;Efficacy;decreased response to ⮕ SITAGLIPTIN;Genotype GG is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *1/*18 is associated with increased concentrations of efavirenz in people with HIV Infections as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;SITAGLIPTIN;DPP4;rs4664443;GG;Efficacy;decreased response to ⮕ SITAGLIPTIN;Genotype GG is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;SITAGLIPTIN;CYP2C9;rs1799853;TT;Efficacy;decreased response to ⮕ SITAGLIPTIN;Genotype TT is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;SITAGLIPTIN;GLP1R;rs3765467;AG;Efficacy;increased response to ⮕ SITAGLIPTIN;Genotype AG is associated with increased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR / LUMACAFTOR;Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;FLUOXETINE;CYP2C19;CYP2C19 intermediate metabolizer;;Efficacy;intermediate metabolizer increased response to ⮕ FLUOXETINE;CYP2C19 intermediate metabolizer is associated with increased response to fluoxetine in people with Major Depressive Disorder as compared to CYP2C19 normal metabolizer.; in people with Other:Major Depressive Disorder
;PAROXETINE;CYP2C19;CYP2C19 ultrarapid metabolizer;;Efficacy;ultrarapid metabolizer decreased response to ⮕ PAROXETINE;CYP2C19 ultrarapid metabolizer is associated with decreased response to paroxetine in people with Major Depressive Disorder as compared to CYP2C19 normal metabolizer.; in people with Other:Major Depressive Disorder
;SITAGLIPTIN;GLP1R;rs6923761;AA;Efficacy;decreased response to ⮕ SITAGLIPTIN;Genotype AA is associated with decreased response to sitagliptin in people with Diabetes Mellitus, Type 2.; in people with Other:Diabetes Mellitus, Type 2
;EXENATIDE, LIRAGLUTIDE;GLP1R;rs3765467;GG;Efficacy;increased clinical benefit to ⮕ EXENATIDE, LIRAGLUTIDE;Genotype GG is associated with increased clinical benefit to exenatide or liraglutide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.;or in people with Other:Diabetes Mellitus, Type 2
;CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;Efficacy;poor metabolizer decreased response to ⮕ CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19 poor metabolizer is associated with decreased response to citalopram, fluoxetine, paroxetine or sertraline in people with Major Depressive Disorder as compared to CYP2C19 normal metabolizer.;or in people with Other:Major Depressive Disorder
;ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;GLP1R;rs6923761;A;Efficacy;decreased clinical benefit to ⮕ ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;Allele A is associated with decreased clinical benefit to albiglutide, dulaglutide or Glucagon-like peptide-1 (GLP-1) analogues in people with Diabetes Mellitus, Type 2 as compared to allele G.;or in people with Other:Diabetes Mellitus, Type 2
;EXENATIDE;TCF7L2;rs7903146;CT + TT;Efficacy;increased response to ⮕ EXENATIDE;Genotypes CT + TT is associated with increased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Other:Diabetes Mellitus, Type 2
;LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;Metabolism/PK;decreased exposure to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased exposure to lansoprazole in people with history of gastric bypass surgery.; in people with Other:history of gastric bypass surgery
;ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs140226575;A;Efficacy;increased clinical benefit to ⮕ ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;Allele A is associated with increased clinical benefit to albiglutide, dulaglutide or Glucagon-like peptide-1 (GLP-1) analogues in people with Diabetes Mellitus, Type 2 as compared to allele G.;or in people with Other:Diabetes Mellitus, Type 2
;PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;increased concentrations of ⮕ PROPAFENONE;CYP2D6 *10/*10 is associated with increased concentrations of propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.; in people with Disease:Cardiac rhythm disease
;PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;increased response to ⮕ PROPAFENONE;CYP2D6 *10/*10 is associated with increased response to propafenone in people with Arrhythmias, Cardiac as compared to CYP2D6 *1/*1.; in people with Disease:Cardiac rhythm disease
;ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78979036;A;Efficacy;increased clinical benefit to ⮕ ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;Allele A is associated with increased clinical benefit to albiglutide, dulaglutide or Glucagon-like peptide-1 (GLP-1) analogues in people with Diabetes Mellitus, Type 2 as compared to allele G.;or in people with Other:Diabetes Mellitus, Type 2
;METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;Efficacy;increased response to ⮕ METHADONE;CYP2D6 *1/*2xN + *2/*2xN are associated with increased response to methadone in people with Opioid-Related Disorders as compared to CYP2D6 *1/*1.; in people with Other:Opioid-Related Disorders
;LURBINECTEDIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;Metabolism/PK;decreased concentrations of ⮕ LURBINECTEDIN;CYP3A4 *1/*1 is associated with decreased concentrations of lurbinectedin in people with Neoplasms as compared to CYP3A4 *1/*22 + *22/*22.; in people with Other:Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Liver transplantation as compared to CYP3A5 *3/*3.; in people with Other:Liver transplantation
;ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78052828;T;Efficacy;increased clinical benefit to ⮕ ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;Allele T is associated with increased clinical benefit to albiglutide, dulaglutide or Glucagon-like peptide-1 (GLP-1) analogues in people with Diabetes Mellitus, Type 2 as compared to allele C.;or in people with Other:Diabetes Mellitus, Type 2
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *3 is associated with increased concentrations of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.; in people with Disease:Severe Cutaneous Adverse Reactions
;ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs58428187;C;Efficacy;increased clinical benefit to ⮕ ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;Allele C is associated with increased clinical benefit to albiglutide, dulaglutide or Glucagon-like peptide-1 (GLP-1) analogues in people with Diabetes Mellitus, Type 2 as compared to allele T.;or in people with Other:Diabetes Mellitus, Type 2
;RALOXIFENE 6-GLUCURONIDE, RALOXIFENE-4?-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Metabolism/PK;increased concentrations of ⮕ RALOXIFENE 6-GLUCURONIDE, RALOXIFENE-4⮕-GLUCURONIDE;UGT1A1 *28/*28 is associated with increased concentrations of raloxifene 6-glucuronide and raloxifene-4?-glucuronide in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.;and in women with Disease:Osteoporosis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Hepatitis C, HIV Infections and HIV Infections as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*41;*41;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *41 is associated with decreased metabolism of dextromethorphan in healthy individuals.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;Metabolism/PK;decreased clearance of ⮕ TRAMADOL;CYP2D6 *1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17 are associated with decreased clearance of tramadol as compared to CYP2D6 *1/*1.;  
;ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ ARIPIPRAZOLE;CYP2D6 intermediate metabolizer is associated with increased concentrations of aripiprazole in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;increased clearance of ⮕ LURBINECTEDIN;CYP3A5 *1/*1 is associated with increased clearance of lurbinectedin in people with Neoplasms as compared to CYP3A5 *1/*3 + *3/*3.; in people with Other:Neoplasms
;LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;decreased concentrations of ⮕ LURBINECTEDIN;CYP3A5 *1/*1 is associated with decreased concentrations of lurbinectedin in people with Neoplasms as compared to CYP3A5 *1/*3 + *3/*3.; in people with Other:Neoplasms
;LEFLUNOMIDE;PON1;rs705379;GG;Efficacy;increased clinical benefit to ⮕ LEFLUNOMIDE;Genotype GG is associated with increased clinical benefit to leflunomide in people with Rheumatoid arthritis as compared to genotypes AA + AG.; in people with Other:Rheumatoid arthritis
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;Metabolism/PK;decreased metabolism of ⮕ TRAMADOL;CYP2D6 *4/*4 + *4/*6 are associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Dosage;decreased dose of ⮕ IRINOTECAN;UGT1A1 *1/*28 + *28/*28 are associated with decreased dose of irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Colorectal Neoplasms
;DABIGATRAN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;decreased exposure to ⮕ DABIGATRAN;CYP3A5 *1/*1 is associated with decreased exposure to Dabigatran in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.; in healthy individuals 
;(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;*6/*6;Metabolism/PK;increased concentrations of ⮕ (S)-METHADONE;CYP2B6 *6/*6 is associated with increased concentrations of (S)-methadone as compared to CYP2B6 *1/*1 + *1/*5 + *1/*6 + *1/*7.;  
;ANTIEPILEPTICS;SCN1A;rs2298771;C;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Allele C is associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele T.; in people with Other:Epilepsy
;ANTIEPILEPTICS;SCN1A;rs10167228;T;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Allele T is associated with increased resistance to antiepileptics in people with Epilepsy as compared to allele C.; in people with Other:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*1/*5;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;METHADONE;;low activity;;Metabolism/PK;low activity increased trough concentration of ⮕ METHADONE;CYP3A low activity is associated with increased trough concentration of methadone as compared to CYP3A high activity.;  
;TELMISARTAN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;Metabolism/PK;decreased concentrations of ⮕ TELMISARTAN;UGT1A3 *2 is associated with decreased concentrations of telmisartan in healthy individuals as compared to UGT1A3 *1/*1.; in healthy individuals 
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.; in people with Other:Neoplasms
;BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Other;increased  ⮕ BILIRUBIN;UGT1A1 *28/*28 is associated with increased bilirubin in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Other:Neoplasms
;CARVEDILOL;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Metabolism/PK;increased metabolism of ⮕ CARVEDILOL;UGT1A1 *28 is associated with increased metabolism of carvedilol in people with Angina Pectoris as compared to UGT1A1 *1.; in people with Other:Angina Pectoris
;LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ LUMACAFTOR;Genotype del/del is associated with response to lumacaftor.;  
;OLANZAPINE;GSTM3;rs36120609;TCCTC/TCCTC;Metabolism/PK;decreased concentrations of ⮕ OLANZAPINE;Genotype TCCTC/TCCTC is associated with decreased concentrations of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3/*3 + *1/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;OLANZAPINE;GSTM3;rs36120609;TCCTC/TCCTC;Metabolism/PK;increased clearance of ⮕ OLANZAPINE;Genotype TCCTC/TCCTC is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes TC/TC + TC/TCCTC.; in healthy individuals 
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;*17/*17 + *29/*29;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *17/*17 + *29/*29 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;LIRAGLUTIDE;CNR1;rs1049353;CT + TT;Efficacy;increased clinical benefit to ⮕ LIRAGLUTIDE;Genotypes CT + TT is associated with increased clinical benefit to liraglutide in people with Diabetes Mellitus, Type 2 and Obesity as compared to genotype CC.;" in people with ""Other:Diabetes Mellitus, Type 2"", ""Other:Obesity"""
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;decreased concentrations of ⮕ ALLOPURINOL;HLA-B *58:01 is associated with decreased concentrations of allopurinol.;  
;FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ FLUVOXAMINE, PAROXETINE;SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;or in people with Disease:Major Depressive Disorder
;CLONIDINE;ADRA2C;rs11269124;GGGGAGCTTTCCCAGAGACCC/del + del/del;Efficacy;increased response to ⮕ CLONIDINE;Genotypes GGGGAGCTTTCCCAGAGACCC/del + del/del are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype GGGGAGCTTTCCCAGAGACCC/GGGGAGCTTTCCCAGAGACCC.; in people with Disease:Liver Cirrhosis
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 + *1/*10 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*14;*14;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *14 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *10/*10.; in healthy individuals 
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT.; in people with Other:Cardiovascular Disease, Other:Dyslipidaemia
;DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 poor metabolizer is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA.; in people with Other:Cardiovascular Disease, Other:Dyslipidaemia
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *3/*4 + *4/*4 + *4/*5 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *2/*3 + *2/*4 + *4/*9 + *4/*10 + *4/*41 + *5/*41 + *6/*41 + *1/*1 + *1/*2 + *2/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*9 + *2/*41 + *9/*41 + *17/*41 + *41/*41.; in healthy individuals 
;ASPIRIN;P2RY1;rs1371097;T;Efficacy;decreased clinical benefit to ⮕ ASPIRIN;Allele T is associated with decreased clinical benefit to aspirin in people with Stroke as compared to allele C.; in people with Other:Stroke
;ASPIRIN;ABCB1;rs1045642;GG;Efficacy;increased clinical benefit to ⮕ ASPIRIN;Genotype GG is associated with increased clinical benefit to aspirin in people with Stroke as compared to genotypes AA + AG.; in people with Other:Stroke
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Metabolism/PK;increased concentrations of ⮕ SN-38;UGT1A1 *28 is associated with increased concentrations of SN-38 in people with Colonic Neoplasms as compared to UGT1A1 *1.; in people with Other:Colonic Neoplasms
;DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 poor metabolizer is associated with decreased metabolism of dextromethorphan in children as compared to CYP2D6 ultrarapid metabolizer.; in children 
;RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ RIBAVIRIN, SOFOSBUVIR;Genotype TT/TT is associated with increased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;and in people with Other:Chronic hepatitis C virus infection
;RIFAMPIN;SLCO1B1;rs4149032;TT;Metabolism/PK;increased concentrations of ⮕ RIFAMPIN;Genotype TT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotypes CC + CT.; in people with Other:Tuberculosis
;MODAFINIL;COMT;rs4680;GG;Efficacy;increased response to ⮕ MODAFINIL;Genotype GG is associated with increased response to modafinil in people with methamphetamine dependence as compared to genotypes AA + AG.; in people with Other:Methamphetamine dependence
;ISONIAZID;;rs1495741;AA;Metabolism/PK;increased concentrations of ⮕ ISONIAZID;Genotype AA is associated with increased concentrations of isoniazid in people with Tuberculosis as compared to genotypes AG + GG.; in people with Other:Tuberculosis
;VALSARTAN;AGT;rs699;GG;Efficacy;decreased clinical benefit to ⮕ VALSARTAN;Genotype GG is associated with decreased clinical benefit to valsartan in people with Hypertension as compared to genotypes AA + AG.; in people with Other:Hypertension
;MELOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ MELOXICAM;CYP2C9 *1/*3 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;NALTREXONE;OPRM1;rs1799971;G;Efficacy;increased clinical benefit to ⮕ NALTREXONE;Allele G is associated with increased clinical benefit to naltrexone in men with Alcohol abuse as compared to allele A.; in men with Other:Alcohol abuse
;IVACAFTOR;CFTR;rs113993960;del;Efficacy;increased response to ⮕ IVACAFTOR;Allele del is associated with increased response to ivacaftor.;  
;IVACAFTOR;CFTR;rs113993960;del;Efficacy;increased response to ⮕ IVACAFTOR;Allele del is associated with increased response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ELEXACAFTOR;CFTR;CFTR deficiency;;Metabolism/PK;deficiency decreased concentrations of ⮕ ELEXACAFTOR;CFTR deficiency is associated with decreased concentrations of elexacaftor in people with Cystic Fibrosis.; in people with Other:Cystic Fibrosis
;ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;SLCO1B1 *15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;REMIFENTANIL;ADRA2A;rs1800544;CG + GG;Dosage;increased dose of ⮕ REMIFENTANIL;Genotypes CG + GG is associated with increased dose of remifentanil in women with Pain, Postoperative as compared to genotype CC.; in women with Other:Pain, Postoperative
;WARFARIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Dosage;increased dose of ⮕ WARFARIN;UGT1A1 *1/*28 + *28/*28 is associated with increased dose of warfarin in people with Thromboembolism as compared to UGT1A1 *1/*1.; in people with Other:Thromboembolism
;REMIFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ REMIFENTANIL;Genotypes AG + GG is associated with increased dose of remifentanil in women with Pain, Postoperative as compared to genotype AA.; in women with Other:Pain, Postoperative
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Other:Liver transplantation
;POSACONAZOLE, TACROLIMUS;ABCB1;rs1045642;GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ POSACONAZOLE, TACROLIMUS;Genotype GG is associated with decreased dose-adjusted trough concentrations of posaconazole null tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*6;*6;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *6 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ LACOSAMIDE;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of lacosamide in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer and intermediate metabolizer phenotype) .; in people with Other:Epilepsy
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*7;*7;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *7 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ SERTRALINE;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased concentrations of sertraline in people with Depressive Disorder as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Depressive Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.; in people with Disease:Kidney Transplantation
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ ESCITALOPRAM;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased concentrations of escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Depressive Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Organ Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.; in people with Disease:Ulcerative Colitis
;COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*10;*4/*4 + *4/*10;Metabolism/PK;decreased metabolism of ⮕ COUMARIN;CYP2A6 *4/*4 + *4/*10 are associated with decreased metabolism of coumarin as compared to CYP2A6 *1/*1.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2;*1/*2 + *2/*2;Dosage;decreased dose of ⮕ NICOTINE;CYP2A6 *1/*2 + *2/*2 is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to CYP2A6 *1/*1.; in people with Disease:Tobacco Use Disorder
;MOXIFLOXACIN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36;Metabolism/PK;decreased clearance of ⮕ MOXIFLOXACIN;UGT1A1 *1/*36 is associated with decreased clearance of moxifloxacin in people with Tuberculosis as compared to UGT1A1 *1/*1 + *1/*28 + *28/*28 + *28/*37.; in people with Disease:Tuberculosis
;DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 poor metabolizer is associated with decreased metabolism of dextromethorphan in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Other:Breast Neoplasms
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;Metabolism/PK;increased clearance of ⮕ NICOTINE;CYP2A6 *46/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.;  
;BUPRENORPHINE;SLC39A10;rs149319538;C;Efficacy;increased clinical benefit to ⮕ BUPRENORPHINE;Allele C is associated with increased clinical benefit to buprenorphine in people with Opioid-Related Disorders as compared to allele T.; in people with Other:Opioid-Related Disorders
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.; in children with Disease:Heart Diseases
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.; in people with Disease:Venous thromboembolism
;SIMVASTATIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage, Metabolism/PK;decreased dose of ⮕ SIMVASTATIN, WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.;and  
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*7;*4/*4 + *6/*6 + *3/*4 + *3/*3;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *4/*4 + *6/*6 + *3/*4 + *3/*3 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*7 + *1/*6 + *1/*4 + *1/*3 + *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.; in people with Disease:Atrial Fibrillation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *4 is associated with decreased metabolism of dextromethorphan in women as compared to CYP2D6 *1.; in women 
;LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*1/*1;Metabolism/PK;normal metabolizer decreased concentrations of ⮕ LETROZOLE;CYP2A6 *1/*1 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *9/*9 (assigned as poor metabolizers and intermediate metabolizers phenotype) .; in women with Disease:Breast Neoplasms
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *1/*2 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 is associated with decreased dose of warfarin in people with Heart valve replacement, Atrial Fibrillation, Stroke, Pulmonary Embolism or Venous Thrombosis as compared to CYP2C9 *1/*1.; in people with Other:Heart valve replacement, Other:Atrial Fibrillation, Other:Stroke, Other:Pulmonary Embolism, Other:Venous Thrombosis
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with Heart valve replacement, Atrial Fibrillation, Stroke, Pulmonary Embolism or Venous Thrombosis as compared to allele C.; in people with Other:Heart valve replacement, Other:Atrial Fibrillation, Other:Stroke, Other:Pulmonary Embolism, Other:Venous Thrombosis
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;RIVAROXABAN;ABCB1;rs4148738;CC;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Genotype CC is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.; in people with Other:Atrial Fibrillation
;RIVAROXABAN;ABCB1;rs1128503;AA;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Genotype AA is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.; in people with Other:Atrial Fibrillation
;DIAZEPAM;CYP2B6;CYP2B6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DIAZEPAM;CYP2B6 poor metabolizer is associated with decreased clearance of diazepam in healthy individuals as compared to CYP2B6 intermediate metabolizer and normal metabolizer.; in healthy individuals 
;METHOTREXATE;TYMS;rs2853542;GG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.; in people with Disease:Rheumatoid arthritis
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;TPMT *1/*2 + *1/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;Dosage;decreased dose of ⮕ MERCAPTOPURINE, THIOGUANINE;TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;or in children with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;ATIC;rs4673993;TT;Efficacy;decreased clinical benefit to ⮕ METHOTREXATE;Genotype TT is associated with decreased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotypes CC + CT.; in people with Other:Rheumatoid arthritis
;FLUOXETINE;HTR1A;rs6295;GG;Efficacy;increased response to ⮕ FLUOXETINE;Genotype GG is associated with increased response to fluoxetine in people with Major Depressive Disorder as compared to genotypes CC + CG.; in people with Efficacy:Major Depressive Disorder
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;Efficacy;poor metabolizer increased discontinuation of ⮕ RISPERIDONE;CYP2D6 *4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6 (assigned as poor metabolizer phenotype) is associated with increased discontinuation of risperidone in people with Schizophrenia, Schizoaffective disorder, Bipolar Disorder or Depressive Disorder as compared to CYP2D6 *1/*1 + *1/*41 + *1/*9 + *1/*10 + *4/*10 + *1/*4 + *1/*5 + *4/*41 + *1/*3 + *1/*6 + *41/*41 + *4/*9 + *10/*41 + *5/*41 + *3/*41 + *10/*10 + *9/*41 + *6/*9 + *5/*9 + *5/*10 (assigned as normal metabolizer and intermediate metabolizer and ultrarapid metabolizer phenotype) .; in people with Other:Schizophrenia, Other:Schizoaffective disorder, Other:Bipolar Disorder, Other:Depressive Disorder
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;*6/*60 + *6/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *6/*60 + *6/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;DIHYDROPYRIDINE DERIVATIVES;NUMA1;rs10898815;AA + AG;Other;increased discontinuation of ⮕ DIHYDROPYRIDINE DERIVATIVES;Genotypes AA + AG is associated with increased discontinuation of Dihydropyridine derivatives as compared to genotype GG.;  
;WARFARIN;CYP4F2;rs2108622;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.; in people with Other:Heart valve replacement
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Heart transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;SULFONAMIDES, UREA DERIVATIVES;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2  + *2/*3 + *3/*3;Efficacy;poor metabolizer increased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Diabetes Mellitus, Type 2
;CORTICOSTEROIDS;NR3C1;rs10482634;GG;Efficacy;increased resistance to ⮕ CORTICOSTEROIDS;Genotype GG is associated with increased resistance to corticosteroids in children with Nephrotic Syndrome as compared to genotype AA.; in children with Other:Nephrotic Syndrome
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;*11 + *2 + *3 + *5 + *6;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *11 + *2 + *3 + *5 + *6 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Heart transplantation
;VALPROIC ACID;UGT1A6;rs6759892;TT;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotypes GG + GT.; in people with Other:Epilepsy
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;Metabolism/PK;increased metabolism of ⮕ NICOTINE;CYP2A6 *46/*46 is associated with increased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.; in children Disease:Liver transplantation
;METHYLPHENIDATE;SYT1;rs2251214;AA + AG;Efficacy;increased clinical benefit to ⮕ METHYLPHENIDATE;Genotypes AA + AG is associated with increased clinical benefit to methylphenidate in people with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.; in people with Other:Attention Deficit Disorder with Hyperactivity
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.; in children Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children liver transplantation as compared to CYP3A5 *3/*3.; in children Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;Efficacy;decreased response to ⮕ CHOP, RITUXIMAB;Genotypes AA + AG is associated with decreased response to CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.;and in people with Other:Non-Hodgkin Lymphoma
;CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;Efficacy;decreased response to ⮕ CHOP, RITUXIMAB;Genotypes AA + AG is associated with decreased response to CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.;and in people with Other:Non-Hodgkin Lymphoma
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*11;*1/*11 + *2/*11;Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *1/*11 + *2/*11 is associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;N-DESMETHYLTAMOXIFEN;SEPTIN3;rs11914200;AG;Metabolism/PK;decreased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype AG is associated with decreased metabolism of N-desmethyltamoxifen as compared to genotype GG.;  
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ FENTANYL;CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Neoplasms, Disease:Pain
;CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;Metabolism/PK;decreased clearance of ⮕ CITALOPRAM;CYP2D6 *1/*10 + *10/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;N-DESMETHYLTAMOXIFEN;SREBF2;rs133290;AC;Metabolism/PK;decreased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype AC is associated with decreased metabolism of N-desmethyltamoxifen as compared to genotype CC.;  
;HYDROXYPHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*11;*1/*11 + *2/*11;Metabolism/PK;decreased concentrations of ⮕ HYDROXYPHENYTOIN;CYP2C9 *1/*11 + *2/*11 is associated with decreased concentrations of hydroxyphenytoin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1.; in people with Disease:Venous thromboembolism
;N-DESMETHYLTAMOXIFEN;TCF20;rs5751251;GG;Metabolism/PK;increased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype GG is associated with increased metabolism of N-desmethyltamoxifen as compared to genotypes CC + CG.;  
;N-DESMETHYLTAMOXIFEN;SREBF2;rs2267439;TT;Metabolism/PK;increased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype TT is associated with increased metabolism of N-desmethyltamoxifen as compared to genotypes CC + CT.;  
;PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Metabolism/PK;decreased metabolism of ⮕ PIROXICAM;CYP2C9 *1/*3 + *3/*3 are associated with decreased metabolism of piroxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;N-DESMETHYLTAMOXIFEN;SREBF2;rs9607850;TT;Metabolism/PK;increased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype TT is associated with increased metabolism of N-desmethyltamoxifen as compared to genotype CC.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage, Metabolism/PK;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Other:Kidney Transplantation
;N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;rs8140869;AG;Metabolism/PK;decreased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;Genotype AG is associated with decreased metabolism of N-desmethyltamoxifen as compared to genotype GG.;  
;RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;GG;Efficacy;decreased response to ⮕ RIBAVIRIN, SOFOSBUVIR;Genotype GG is associated with decreased response to ribavirin and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.;and in people with Disease:Chronic hepatitis C virus infection
;VARENICLINE;CYP2A6;CYP2A6 high activity;;Efficacy;high activity increased response to ⮕ VARENICLINE;CYP2A6 high activity is associated with increased response to varenicline in people with Tobacco Use Disorder.; in people with Other:Tobacco Use Disorder
;ETOPOSIDE;;rs446112;AA;Other;increased resistance to ⮕ ETOPOSIDE;Genotype AA is associated with increased resistance to etoposide as compared to genotypes AG + GG.;  
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Genotypes GT + TT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype GG.; in people with Other:Diabetes Mellitus, Other:Hypercholesterolemia
;FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ FLUVOXAMINE, PAROXETINE;SLC6A4 HTTLPR long form (L allele) is associated with increased response to fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;or in people with Disease:Major Depressive Disorder
;MELOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ MELOXICAM;CYP2C9 *1/*3 + *2/*2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;OPIOIDS;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;Efficacy;poor metabolizer and ultrarapid metabolizer decreased response to ⮕ OPIOIDS;CYP2D6 poor and ultrarapid metabolizers are associated with decreased response to opioids in people with Pain as compared to CYP2D6 intermediate metabolizer and normal metabolizer.; in people with Disease:Pain
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) .; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ PAROXETINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele).; in people with Disease:Panic Disorder
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ PAROXETINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to paroxetine.;  
;AFATINIB;EGFR;rs28929495;GG;Efficacy;decreased clinical benefit to ⮕ AFATINIB;Genotype GG is associated with decreased clinical benefit to afatinib in people with Non-Small Cell Lung Carcinoma.; in people with Other:Non-Small Cell Lung Carcinoma
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.;and in children with Disease:Cystic Fibrosis
;3-AMINOISOBUTYRATE;DPYD;rs3918290;TT;Metabolism/PK;decreased concentrations of ⮕ 3-AMINOISOBUTYRATE;Genotype TT is associated with decreased concentrations of 3-aminoisobutyrate as compared to genotype CC.;  
;HYDRALAZINE;NAT2;NAT2 rapid acetylator;;Dosage, Efficacy;rapid acetylator increased dose of ⮕ HYDRALAZINE;NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.; in people with Other:Hypertension
;MEXILETINE;CYP2D6;CYP2D6*41;*41;Efficacy;decreased response to ⮕ MEXILETINE;CYP2D6 *41 is associated with decreased response to mexiletine in people with Myotonic Dystrophy and Nondystrophic myotonia.; in people with Other:Myotonic Dystrophy, Other:Nondystrophic myotonia
;3-AMINOISOBUTYRATE;UPB1;rs143493067;AA;Metabolism/PK;decreased concentrations of ⮕ 3-AMINOISOBUTYRATE;Genotype AA is associated with decreased concentrations of 3-aminoisobutyrate as compared to genotype GG.;  
;3-AMINOISOBUTYRATE;AGXT2;rs114286107;TT;Metabolism/PK;increased concentrations of ⮕ 3-AMINOISOBUTYRATE;Genotype TT is associated with increased concentrations of 3-aminoisobutyrate.;  
;MELOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3 + *2;Metabolism/PK;decreased metabolism of ⮕ MELOXICAM;CYP2C9 *3 + *2 are associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;MELOXICAM;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;PD, Metabolism/PK;decreased metabolism of ⮕ MELOXICAM;CYP2C9 *1/*13 is associated with decreased metabolism of meloxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ FENTANYL;CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Pain, Postoperative
;URACIL;DPYD;rs3918290;TT;Metabolism/PK;increased concentrations of ⮕ URACIL;Genotype TT is associated with increased concentrations of uracil as compared to genotype CC.;  
;2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;ACAD11;rs41272317;AA;Metabolism/PK;increased concentrations of ⮕ 2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;Genotype AA is associated with increased concentrations of 2-aminoheptanoate, 2-aminooctanoic acid and 2-hydroxylaurate as compared to genotype CC.;and  
;CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;rs140130028;TT;Metabolism/PK;increased concentrations of ⮕ CYSTEINE-S-SULFATE, L-ORNITHINE;Genotype TT is associated with increased concentrations of cysteine-s-sulfate and l-ornithine as compared to genotype CC.;and  
;5,6-DIHYDROTHYMINE;UPB1;rs143493067;AA;Metabolism/PK;increased concentrations of ⮕ 5,6-DIHYDROTHYMINE;Genotype AA is associated with increased concentrations of 5,6-dihydrothymine as compared to genotype GG.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.; in people with Disease:Kidney Transplantation
;10-MONOHYDROXY OXCARBAZEPINE;ABCC2;rs2273697;G;Metabolism/PK;increased clearance of ⮕ 10-MONOHYDROXY OXCARBAZEPINE;Allele G is associated with increased clearance of 10-monohydroxy oxcarbazepine in children with Epilepsy as compared to allele A.; in children with Other:Epilepsy
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *5/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *10/*10.; in healthy individuals 
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *1/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;CYP2B6 *6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.; in healthy individuals 
;RIVAROXABAN;CYP3A5;rs776746;TT;Toxicity;decreased concentrations of ⮕ RIVAROXABAN;Genotype TT is associated with decreased concentrations of rivaroxaban in people with Venous thromboembolism as compared to genotypes CC + CT.; in people with Other:Venous thromboembolism
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin in people with Heart valve replacement as compared to genotype AA.; in people with Other:Heart valve replacement
;PRAZIQUANTEL;CYP1A2;CYP1A2*1, CYP1A2*30;*1/*30 + *30/*30;Metabolism/PK;increased metabolism of ⮕ PRAZIQUANTEL;CYP1A2 *1/*30 + *30/*30 is associated with increased metabolism of praziquantel in people with Schistosomiasis as compared to CYP1A2 *1/*1.; in people with Other:Schistosomiasis
;PRAZIQUANTEL;CYP2C9;CYP2C9*1, CYP2C9*9;*1/*9 + *9/*9;Metabolism/PK;increased metabolism of ⮕ PRAZIQUANTEL;CYP2C9 *1/*9 + *9/*9 is associated with increased metabolism of praziquantel in people with Schistosomiasis as compared to CYP2C9 *1/*1.; in people with Other:Schistosomiasis
;ARIPIPRAZOLE;CYP2D6;rs1065852;AA + AG;Efficacy;increased clinical benefit to ⮕ ARIPIPRAZOLE;Genotypes AA + AG is associated with increased clinical benefit to aripiprazole in children with Tic Disorders as compared to genotype GG.; in children with Other:Tic Disorders
;ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;Efficacy;increased clinical benefit to ⮕ ARIPIPRAZOLE;Genotypes CT + TT is associated with increased clinical benefit to aripiprazole in children with Tic Disorders as compared to genotype CC.; in children with Other:Tic Disorders
;QUINAPRIL;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ QUINAPRIL;Genotype del/del is associated with increased response to quinapril as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;  
;ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;Efficacy;decreased clearance of ⮕ ARIPIPRAZOLE;Genotypes CT + TT is associated with decreased clearance of aripiprazole in children with Tic Disorders as compared to genotype CC.; in children with Other:Tic Disorders
;CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;Efficacy;decreased clinical benefit to ⮕ CYCLOPHOSPHAMIDE;Genotypes CC + CT is associated with decreased clinical benefit to cyclophosphamide in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype TT.; in people with Other:Leukemia, Lymphocytic, Chronic, B-Cell
;CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;Efficacy;decreased clinical benefit to ⮕ CYCLOPHOSPHAMIDE;CYP3A5 *3 is associated with decreased clinical benefit to cyclophosphamide in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP3A5 *1.; in people with Other:Leukemia, Lymphocytic, Chronic, B-Cell
;ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*17/*17;Metabolism/PK;increased clearance of ⮕ ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19 *17/*17 is associated with increased clearance of esomeprazole and pantoprazole in healthy individuals as compared to CYP2C19 *2/*3.;and in healthy individuals 
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Dosage, Efficacy, Toxicity;decreased dose of ⮕ AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;or in people with Disease:Inflammatory Bowel Diseases
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;MELOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ MELOXICAM;CYP2C9 *3/*3 is associated with decreased clearance of meloxicam in healthy individuals as compared to CYP2C9 *1/*1 + *1/*3.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Liver transplantation as compared to genotype CC.; in people with Other:Liver transplantation
;TACROLIMUS;UGT1A4;rs2011425;TT;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotype TT is associated with decreased concentrations of tacrolimus in people with Liver transplantation as compared to genotypes GG + GT.; in people with Other:Liver transplantation
;TACROLIMUS;CYP3A4;rs35599367;GG;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotype GG is associated with decreased concentrations of tacrolimus in people with Liver transplantation as compared to genotypes AA + AG.; in people with Other:Liver transplantation
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.; in healthy individuals 
;ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.; in people with Other:Diabetes Mellitus, Other:Hypercholesterolemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Liver transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Liver transplantation
;WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.;  
;ALOGLIPTIN;PNPLA3;rs738409;CG + GG;Efficacy;increased clinical benefit to ⮕ ALOGLIPTIN;Genotypes CG + GG is associated with increased clinical benefit to alogliptin in people with Diabetes Mellitus, Type 2, Fatty liver disease and Body Weight Changes as compared to genotype CC.;" in people with ""Other:Diabetes Mellitus, Type 2"", ""Other:Fatty liver disease"", ""Other:Body Weight Changes"""
;AMLODIPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ AMLODIPINE;CYP3A4 *1/*22 + *22/*22 is associated with increased dose-adjusted trough concentrations of amlodipine in people with Hypertension as compared to CYP3A4 *1/*1.; in people with Other:Hypertension
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;CTT/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;SERTRALINE;DRD3;rs167770;AG;Efficacy;increased clinical benefit to ⮕ SERTRALINE;Genotype AG is associated with increased clinical benefit to sertraline in people with Obsessive-Compulsive Disorder as compared to genotype AA.; in people with Other:Obsessive-Compulsive Disorder
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;SERTRALINE;DRD3;rs11721264;AG;Efficacy;increased clinical benefit to ⮕ SERTRALINE;Genotype AG is associated with increased clinical benefit to sertraline in people with Obsessive-Compulsive Disorder as compared to genotype GG.; in people with Other:Obsessive-Compulsive Disorder
;ILOPERIDONE, ILOPERIDONE METABOLITE P88;CYP2D6;rs1065852;AA;Metabolism/PK;increased concentrations of ⮕ ILOPERIDONE, ILOPERIDONE METABOLITE P88;Genotype AA is associated with increased concentrations of iloperidone and iloperidone metabolite p88 in people with Schizophrenia as compared to genotypes AG + GG.;and in people with Other:Schizophrenia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;CYP2C19 *2 + *3 are associated with decreased response to aspirin and clopidogrel as compared to CYP2C19 *1/*1.;and  
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4;Metabolism/PK;decreased concentrations of ⮕ EFAVIRENZ;CYP2B6 *1/*4 are associated with decreased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.;and in children with Disease:Cystic Fibrosis
;VALPROIC ACID;CACNA1H;rs3751664;T;Efficacy;increased resistance to ⮕ VALPROIC ACID;Allele T is associated with increased resistance to valproic acid in people with Epilepsy as compared to allele C.; in people with Other:Epilepsy
;FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;decreased response to ⮕ FLUVOXAMINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).; in people with Disease:Depressive Disorder
;PENICILLIN G;IFNG;rs1861494;CC;Efficacy;decreased clinical benefit to ⮕ PENICILLIN G;Genotype CC is associated with decreased clinical benefit to penicillin g in people with Syphilis as compared to genotypes CT + TT.; in people with Other:Syphilis
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1.;and in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.;  
;PENICILLIN G;IFNG;rs2430561;TT;Efficacy;decreased clinical benefit to ⮕ PENICILLIN G;Genotype TT is associated with decreased clinical benefit to penicillin g in people with Syphilis as compared to genotypes AA + AT.; in people with Other:Syphilis
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *1/*2xN;Dosage;ultrarapid metabolizer increased dose of ⮕ IMIPRAMINE;CYP2D6 *1/*1xN + *1/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of imipramine in people with Major Depressive Disorder as compared to CYP2D6 *1/*1 + *1/*2.; in people with Disease:Major Depressive Disorder
;ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;Metabolism/PK;slow acetylator decreased metabolism of ⮕ ISONIAZID;NAT2 *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*5 + *4/*6 + *4/*7.; in people with Other:Tuberculosis
;SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN;CYP3A4 *1/*22 is associated with increased concentrations of simvastatin in people with Hypercholesterolemia as compared to CYP3A4 *1/*1.; in people with Disease:Hypercholesterolemia
;FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ FLUVOXAMINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;RIVAROXABAN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased exposure to ⮕ RIVAROXABAN;Genotypes GT + TT is associated with increased exposure to rivaroxaban in healthy individuals as compared to genotype GG.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage, Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Liver transplantation
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;decreased clearance of ⮕ ATOMOXETINE;CYP2D6 *10/*10 + *1/*10 are associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.;and in men with Disease:Cystic Fibrosis
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased clearance of warfarin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;AVATROMBOPAG;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;intermediate metabolizer increased exposure to ⮕ AVATROMBOPAG;CYP2C9 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with increased exposure to avatrombopag in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*3 + *5 + *2 + *1;Dosage;dose of ⮕ WARFARIN;CYP2C9 *3 + *5 + *2 + *1 is associated with dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*2.;  
;AVATROMBOPAG;ABCB1;rs1128503;AA + AG;Metabolism/PK;increased exposure to ⮕ AVATROMBOPAG;Genotypes AA + AG is associated with increased exposure to avatrombopag in healthy individuals as compared to genotype GG.; in healthy individuals 
;VENETOCLAX;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ VENETOCLAX;Genotype CC is associated with increased dose-adjusted trough concentrations of venetoclax in people with Leukemia, Myeloid, Acute as compared to genotypes CT + TT.; in people with Other:Leukemia, Myeloid, Acute
;CLOZAPINE;NFIB;rs28379954;CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ CLOZAPINE;Genotype CT is associated with decreased dose-adjusted trough concentrations of clozapine in people with Schizophrenia as compared to genotype TT.; in people with Other:Schizophrenia
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;increased concentrations of ⮕ ATOMOXETINE;CYP2D6 *10/*10 + *1/*10 are associated with increased concentrations of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;PITAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Metabolism/PK;increased exposure to ⮕ PITAVASTATIN;SLCO1B1 *15 is associated with increased exposure to pitavastatin in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A4;rs2740574;TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype TT is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Kidney Transplantation
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;METHYLPHENIDATE;SLC6A2;rs998424;GG;Efficacy;increased clinical benefit to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased clinical benefit to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.; in children with Other:Attention Deficit Disorder with Hyperactivity
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 is associated with decreased metabolism of voriconazole in people with as compared to CYP2C19 *1/*1.; in people with 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Lupus Nephritis as compared to CYP3A5 *1/*3 + *1/*1.; in people with Disease:Lupus Nephritis
;LITHIUM;;rs7405404;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;Efficacy;increased response to ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6 *4/*4 + *3/*5 is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.;  
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ EFAVIRENZ;Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) .; in people with Disease:HIV infectious disease
;FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Dosage;increased dose of ⮕ FENTANYL;CYP2D6 *10/*10 is associated with increased dose of fentanyl in people with Gastrointestinal Neoplasms and Pain, Postoperative as compared to CYP2D6 *1/*1.;" in people with ""Other:Gastrointestinal Neoplasms"", ""Other:Pain, Postoperative"""
;VARENICLINE;HYKK;rs7164594;CT + TT;Efficacy;increased response to ⮕ VARENICLINE;Genotypes CT + TT are associated with increased response to varenicline in people with Tobacco Use Disorder as compared to genotype CC.; in people with Other:Tobacco Use Disorder
;SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ SIROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN;CYP2D6 *10/*10 is associated with decreased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.; in women with Disease:Breast Neoplasms
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;decreased response to ⮕ CAPTOPRIL;Genotype del/del is associated with decreased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Diabetes Mellitus, Type 2
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;Metabolism/PK;decreased metabolism of ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6 *4/*4 + *3/*5 is associated with decreased metabolism of 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *1/*4 + *1/*3 + *1/*6 + *2/*4 + *2/*5 + *9/*10 + *1/*41 + *1/*10 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.;  
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*1;Metabolism/PK;high activity increased metabolism of ⮕ MERCAPTOPURINE;NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*3 + *1/*5 + *2/*3 + *3/*3 + *3/*5 (assigned as intermediate and low activity phenotype) .; in children with Disease:Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ EFAVIRENZ;Allele T (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele G (assigned as normal metabolizer phenotype) .; in people with Disease:HIV infectious disease
;ENALAPRIL, LOSARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ ENALAPRIL, LOSARTAN;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to enalapril and losartan in men with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.;and in men with Disease:Coronary Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.; in people with Disease:Kidney Transplantation
;BENAZEPRIL;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ BENAZEPRIL;Genotype del/del is associated with increased response to benazepril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Essential hypertension
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;BUPROPION;CYP2B6;rs8109525;GG;Efficacy;increased response to ⮕ BUPROPION;Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AA + AG.; in people with Other:Tobacco Use Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*1/*1;Dosage;high activity increased dose of ⮕ MERCAPTOPURINE;NUDT15 *1/*1 (assigned as high activity phenotype) is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*5 + *3/*3 + *3/*5 + *2/*3 (assigned as intermediate and low activity phenotype) .; in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin in people with heart valve replacement as compared to CYP2C9 *1/*1.; in people with Disease:Heart valve replacement
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in children with Nephrotic Syndrome as compared to CYP3A5 *1/*1.; in children with Disease:Nephrotic Syndrome
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.; in women with Disease:Breast Neoplasms
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ ATOMOXETINE;CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.; in healthy individuals 
;MESALAZINE, THIOGUANINE;NAT1;NAT1*3, NAT1*4, NAT1*10;*10;Metabolism/PK;decreased concentrations of ⮕ MESALAZINE, THIOGUANINE;NAT1 *10 is associated with decreased concentrations of mesalazine and thioguanine in children with Colitis, Ulcerative, Crohn Disease and Inflammatory Bowel Diseases as compared to NAT1 *4 + *3.;and in children with Disease:Ulcerative Colitis, Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases
;PIOGLITAZONE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased metabolism of ⮕ PIOGLITAZONE;CYP2C9 *1/*3 is associated with increased metabolism of pioglitazone as compared to CYP2C9 *1.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Colitis, Ulcerative as compared to genotypes CT + TT.; in people with Disease:Ulcerative Colitis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Organ Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in children with Organ Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Organ Transplantation
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .; in healthy individuals 
;EXEMESTANE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ EXEMESTANE;CYP3A4 *1/*22 is associated with increased concentrations of exemestane in women with Breast Neoplasms as compared to CYP3A4 *1/*1.; in women with Disease:Breast Neoplasms
;WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;Dosage;increased dose of ⮕ WARFARIN;CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Heart transplantation
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4 + *5 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;*4 + *5 + *10 +*14;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4 + *5 + *10 +*14 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;METOPROLOL;CYP2D6;CYP2D6*4;*4;Dosage;decreased dose of ⮕ METOPROLOL;CYP2D6 *4 is associated with decreased dose of metoprolol in people with Heart Failure.; in people with Disease:Heart Failure
;CETUXIMAB;VEGFA;rs144854329;del/del;Efficacy;increased response to ⮕ CETUXIMAB;Genotype del/del is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA + GGTCCCACTCTTCCCACA/del.; in people with Disease:Colorectal Neoplasms
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *1/*28 + *28/*28 are associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Other:Neoplasms
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreased clearance of ⮕ IBUPROFEN;CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.;or in people with Disease:Helicobacter Infections
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Metabolism/PK;decreased clearance of ⮕ IBUPROFEN;CYP2C9 *2 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Arthritis, Rheumatoid or Colitis, Ulcerative as compared to CYP3A5 *3/*3.; in people with Disease:Rheumatoid arthritis, Disease:Ulcerative Colitis
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;increased trough concentration of ⮕ TACROLIMUS;Genotype CC is associated with increased trough concentration of tacrolimus in people with Colitis, Ulcerative as compared to genotypes CT + TT.; in people with Disease:Ulcerative Colitis
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;decreased clearance of ⮕ SN-38;UGT1A1 *1/*28 + *28/*28 are associated with decreased clearance of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Other:Neoplasms
;LORNOXICAM;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Metabolism/PK;decreased metabolism of ⮕ LORNOXICAM;CYP2C9 *1/*13 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.; in healthy individuals 
;PILOCARPINE;CYP2A6;CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4/*7 + *4/*9 + *4/*10 + *7/*9;Metabolism/PK;decreased metabolism of ⮕ PILOCARPINE;CYP2A6 *4/*7 + *4/*9 + *4/*10 + *7/*9 are associated with decreased metabolism of pilocarpine in healthy individuals.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;LORNOXICAM;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Metabolism/PK;decreased clearance of ⮕ LORNOXICAM;CYP2C9 *1/*13 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;LORNOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ LORNOXICAM;CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;LORNOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased clearance of ⮕ LORNOXICAM;CYP2C9 *1/*3 is associated with decreased clearance of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;ATENOLOL;ADRB1;rs1801253;C;Efficacy;increased response to ⮕ ATENOLOL;Allele C is associated with increased response to atenolol in healthy individuals as compared to allele G.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*1/*6;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*6 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Dosage;increased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*3 + *3/*3 are associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.; in people with Disease:Kidney Transplantation
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;Metabolism/PK;decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased metabolism of venlafaxine as compared to CYP2D6 *1/*1.;  
;LETROZOLE;;rs7937;C;;increased concentrations of ⮕ LETROZOLE;Allele C is associated with increased concentrations of letrozole in women with Breast Neoplasms as compared to allele T.; in women with Other:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.; in people with Other:total knee or hip arthroplasty
;PROPOFOL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*1 + *1/*2;Metabolism/PK;decreased concentrations of ⮕ PROPOFOL;CYP2C9 *1/*1 + *1/*2 is associated with decreased concentrations of propofol in people with as compared to CYP2C9 *2/*2.; in people with 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;clearance of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with clearance of warfarin in people with Heart Diseases as compared to CYP2C9 *1/*1.; in people with Disease:Heart Diseases
;LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.;or in people with Disease:Helicobacter Infections
;NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ NOROXYCODONE, OXYCODONE;CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with increased concentrations of noroxycodone or oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.;or  
;CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Dosage, Efficacy;decreased dose of ⮕ CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.;or in people with Disease:Depression
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;DISULFIRAM;SLC6A3;rs28363170;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;Efficacy;increased response to ⮕ DISULFIRAM;Genotype GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotypes GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/del + del/del.; in people with Other:Cocaine dependence
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Dosage;increased dose of ⮕ WARFARIN;CYP2C9 *1/*2 is associated with increased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 *1.; in people with Other:total knee or hip arthroplasty
;BENAZEPRIL, PERINDOPRIL;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ BENAZEPRIL, PERINDOPRIL;Genotype del/del is associated with increased response to benazepril or perindopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;or in people with Disease:Diabetes Mellitus
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4;Metabolism/PK;poor metabolizer decreased clearance of ⮕ RISPERIDONE;CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased clearance of risperidone in people with Psychotic Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5.; in people with Disease:Psychotic Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.; in children 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.; in children 
;THIOGUANINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Metabolism/PK;increased concentrations of ⮕ THIOGUANINE;TPMT *1/*3A + *1/*3C are associated with increased concentrations of thioguanine in people with Crohn Disease as compared to TPMT *1/*1.; in people with Disease:Crohn Disease
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Colitis, Ulcerative as compared to genotypes CT + TT.; in people with Disease:Ulcerative Colitis
;PROGUANIL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased metabolism of ⮕ PROGUANIL;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased metabolism of proguanil in children with Malaria as compared to CYP2C19 *1/*1.; in children with Disease:Malaria
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;TPMT *1/*3A + *1/*3C + *3A/*3A are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;ARTEMETHER;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;decreased metabolism of ⮕ ARTEMETHER;CYP2B6 *6/*6 is associated with decreased metabolism of artemether in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;FLUOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ FLUOXETINE;CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;FLUOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ FLUOXETINE;CYP2D6 poor metabolizer is associated with decreased metabolism of fluoxetine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLCLOZAPINE;CYP2C19 *17 is associated with increased concentrations of n-desmethylclozapine in people with schizoaffective disorder and Schizophrenia as compared to CYP2C19 *1.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;Efficacy;increased response to ⮕ CLOZAPINE;CYP2C19 *17/*17 is associated with increased response to clozapine in people with schizoaffective disorder and Schizophrenia.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;EFAVIRENZ;CYP2B6;rs36118214;GG;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;CYP2B6 *6 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;CYP2B6 *1/*30 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*29;*1/*29;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;CYP2B6 *1/*29 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;Dosage, Metabolism/PK;increased metabolism of ⮕ ROSIGLITAZONE;CYP2C8 *3 is associated with increased metabolism of rosiglitazone in healthy individuals.; in healthy individuals 
;CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2C19 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;QUINAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;Efficacy;increased response to ⮕ QUINAPRIL;Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del are associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.; in people with Disease:Coronary Artery Disease
;CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE;CYP2C19 *1/*2 + *2/*2 are associated with decreased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2C19 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1/*1.; in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;TESTOSTERONE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;Efficacy, Metabolism/PK;increased clearance of ⮕ TESTOSTERONE;UGT1A4 *3a is associated with increased clearance of testosterone as compared to UGT1A4 *1a.;  
;CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE;CYP3A5 *1/*3 + *3/*3 are associated with increased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP3A5 *1/*1.; in people with Disease:Non-Hodgkin Lymphoma
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator decreased metabolism of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.; in people with Other:Hypertension
;ACENOCOUMAROL;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 + *3 is associated with dose of acenocoumarol.;  
;LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;*2 + *3a;Efficacy, Metabolism/PK;decreased clearance of ⮕ LAMOTRIGINE;UGT1A4 *2 + *3a are associated with decreased clearance of lamotrigine as compared to UGT1A4 *1a.;  
;CURCUMIN, IVACAFTOR;CFTR;rs77010898;AA + AG;Efficacy;response to ⮕ CURCUMIN, IVACAFTOR;Genotypes AA + AG are associated with response to curcumin and ivacaftor in people with Cystic Fibrosis as compared to genotype GG.;and in people with Disease:Cystic Fibrosis
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;increased concentrations of ⮕ AMITRIPTYLINE;CYP2C19 *1/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;3-HYDROXYCOTININE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*12;Metabolism/PK;decreased concentrations of ⮕ 3-HYDROXYCOTININE;CYP2A6 *1/*12 is associated with decreased concentrations of 3-hydroxycotinine as compared to CYP2A6 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ AMITRIPTYLINE;CYP2C19 *1/*2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;decreased response to ⮕ CAPTOPRIL;Genotype del/del is associated with decreased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in men with Disease:Chronic Obstructive Pulmonary Disease
;TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;Efficacy;decreased response to ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with decreased response to tacrolimus in people with liver transplantation.; in people with Disease:Liver transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Dosage, Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Disease:Neoplasms
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*18, CYP2D6*21, CYP2D6*41, CYP2D6*49, CYP2D6*52;*10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*49 + *10/*52 + *49/*52 + *10/*41 + *10/*10 + *5/*5 + *41/*41 + *10/*21 + *10/*18 are associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;*9 + *29 + *45 + *46 + *17 + *10;Toxicity, Metabolism/PK;decreased metabolism of ⮕ METOPROLOL;CYP2D6 *9 + *29 + *45 + *46 + *17 + *10 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.; in people with Disease:Hypertension
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to CYP2C19 *1.; in people with Other:Coronary Disease
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased clearance of ⮕ ESCITALOPRAM;CYP2C19 *1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased clearance of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; in people with Disease:Major Depressive Disorder
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Dosage, Metabolism/PK;ultrarapid metabolizer decreased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Disease:Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;METHOTREXATE;HLA-G;rs371194629;del/del;Efficacy;increased response to ⮕ METHOTREXATE;Genotype del/del is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del.; in people with Efficacy:Rheumatoid arthritis
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *3 + *5  + *6;Toxicity, Metabolism/PK;decreased metabolism of ⮕ METOPROLOL;CYP2D6 *4 + *3 + *5 + *6 is associated with decreased metabolism of metoprolol in people with Hypertension as compared to CYP2D6 *1.; in people with Disease:Hypertension
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *28/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.; in people with Disease:Neoplasms
;ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Efficacy;decreased response to ⮕ ESOMEPRAZOLE;CYP2C19 *17 is associated with decreased response to esomeprazole in children with eosinophilic esophagitis as compared to CYP2C19 *1/*1.; in children with Other:eosinophilic esophagitis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Dosage, Metabolism/PK;intermediate metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Neoplasms as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Disease:Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;Dosage;decreased dose of ⮕ IRINOTECAN;UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with decreased dose of irinotecan in people with Neoplasms as compared to UGT1A1 *1/*28 + *1/*6.; in people with Disease:Neoplasms
;CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ CAPTOPRIL;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.; in men with Disease:Chronic Obstructive Pulmonary Disease
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ PHENPROCOUMON;CYP2C9 *2 + *3 is associated with decreased dose of phenprocoumon in children as compared to CYP2C9 *1.; in children 
;IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR, TEZACAFTOR;Genotype del/del is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.; in people with Other:Heart valve replacement
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;increased metabolism of ⮕ TRAMADOL;CYP2D6 *1/*1xN is associated with increased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.; in infants 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Efficacy;decreased clinical benefit to ⮕ LOSARTAN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased clinical benefit to losartan in people with Hypertension as compared to CYP2C9 *1/*1.; in people with Other:Hypertension
;CHIGLITAZAR;PPARA;rs1800234;CC + CT;Efficacy;decreased clinical benefit to ⮕ CHIGLITAZAR;Genotypes CC + CT is associated with decreased clinical benefit to chiglitazar in people with Diabetes Mellitus, Type 2 as compared to genotype TT.; in people with Other:Diabetes Mellitus, Type 2
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*1b;*1b;Metabolism/PK;decreased concentrations of ⮕ LAMOTRIGINE;UGT1A4 *1b is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to UGT1A4 *1a.; in people with Other:Epilepsy
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5 + *10;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *5 + *10 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *3 + *4 are associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*4 + *3/*4;Metabolism/PK;decreased metabolism of ⮕ ZUCLOPENTHIXOL;CYP2D6 *1/*4 + *3/*4 are associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1/*1.; in people with Other:Schizophrenia
;AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT low activity;;Metabolism/PK;low activity decreased metabolism of ⮕ AZATHIOPRINE, MERCAPTOPURINE;TPMT low activity phenotype is associated with decreased metabolism of azathioprine and mercaptopurine as compared to TPMT high activity phenotype.;and  
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ RISPERIDONE;CYP2D6 poor metabolizer are associated with decreased clearance of risperidone in healthy individuals.; in healthy individuals 
;MERCAPTOPURINE;TPMT;TPMT intermediate activity;;Efficacy;intermediate activity increased response to ⮕ MERCAPTOPURINE;TPMT intermediate activity phenotype is associated with increased response to mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT high activity phenotype.; in children with Disease:Acute lymphoblastic leukemia
;FENTANYL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ FENTANYL;Genotype T/T is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to genotypes C/C + C/T.; in women with Disease:Pain, Postoperative
;SULFASALAZINE;NAT2;NAT2 slow acetylator;;Other;slow acetylator increased discontinuation of ⮕ SULFASALAZINE;NAT2 slow acetylator is associated with increased discontinuation of sulfasalazine in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;FENTANYL;CYP3A4;rs2242480;T/T;Metabolism/PK;increased concentrations of ⮕ FENTANYL;Genotype T/T is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to genotypes C/C + C/T.; in people with Disease:Pain, Postoperative
;ETHANOL;OPRM1;rs1799971;G;Dosage;increased dose of ⮕ ETHANOL;Allele G is associated with increased dose of ethanol in children as compared to allele A.; in children 
;SUFENTANIL;CYP3A4;rs2242480;T/T;Efficacy;increased response to ⮕ SUFENTANIL;Genotype T/T is associated with increased response to sufentanil in people with Pain, Postoperative as compared to genotypes C/C + C/T.; in people with Other:Pain, Postoperative
;SUFENTANIL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ SUFENTANIL;Genotype T/T is associated with decreased dose of sufentanil in women with Pain as compared to genotypes C/C + C/T.; in women with Disease:Pain
;SUFENTANIL;CYP3A4;rs2242480;T/T;Metabolism/PK;decreased concentrations of ⮕ SUFENTANIL;Genotype T/T is associated with decreased concentrations of sufentanil in women with Pain as compared to genotypes C/C + C/T.; in women with Disease:Pain
;TACROLIMUS;CYP3A4;rs2242480;C/C;Other, Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype C/C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes C/T + T/T.; in people with Disease:Kidney Transplantation
;FENTANYL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ FENTANYL;Genotype T/T is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to genotypes C/C + C/T.; in women with Other:Pain, Postoperative
;SUFENTANIL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ SUFENTANIL;Genotype T/T is associated with decreased dose of sufentanil in people with Pain, Postoperative as compared to genotypes C/C + C/T.; in people with Other:Pain, Postoperative
;FENTANYL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ FENTANYL;Genotype T/T is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotypes C/C + C/T.; in people with Disease:Pain, Postoperative
;BETA BLOCKING AGENTS;GRK5;rs4752292;T;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Allele T is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.; in people with Other:Coronary Artery Disease
;INTERFERON BETA-1A;HLA-B;HLA-B*15:01;*15:01;Efficacy;decreased response to ⮕ INTERFERON BETA-1A;HLA-B *15:01 is associated with decreased response to interferon beta-1a in people with Multiple Sclerosis.; in people with Disease:Multiple Sclerosis
;RUBELLA VACCINES;HLA-B;HLA-B*35:03;*35:03;Efficacy;increased response to ⮕ RUBELLA VACCINES;HLA-B *35:03 is associated with increased response to Rubella vaccines in children.; in children 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B;HLA-B*38:01;*38:01;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B *38:01 is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.;and in people with Disease:Hepatitis C virus infection
;HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;rs671531;GG;Efficacy;decreased response to ⮕ HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);Genotype GG is associated with decreased response to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotypes AA + AG.; in people with Other:HIV infectious disease
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*18;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A4 *1/*18 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;Metabolism/PK;increased metabolism of ⮕ CYCLOSPORINE;CYP3A4 *18/*18 is associated with increased metabolism of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*1 + *1/*18.; in people with Disease:Kidney Transplantation
;USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;Efficacy;increased response to ⮕ USTEKINUMAB;HLA-C *06:02 is associated with increased response to ustekinumab in people with Psoriasis.; in people with Disease:Psoriasis
;METHOTREXATE;HLA-C;HLA-C*06:02;*06:02;Efficacy;increased response to ⮕ METHOTREXATE;HLA-C *06:02 is associated with increased response to methotrexate in people with Psoriasis.; in people with Disease:Psoriasis
;FENTANYL;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;Dosage, Efficacy;decreased dose of ⮕ FENTANYL;CYP3A4 *18/*18 is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to CYP3A4 *1/*1.; in people with Disease:Pain, Postoperative
;RUBELLA VACCINES;HLA-C;HLA-C*15:02;*15:02;Efficacy;increased response to ⮕ RUBELLA VACCINES;HLA-C *15:02 is associated with increased response to Rubella vaccines in children.; in children 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C *02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01 is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to HLA-C *01:02:01 + *03:02 + *07:01:01 + *08:01 + *12:02:01 + *14:02:01 + *16:01:01.;and in people with Disease:Hepatitis C virus infection
;MEASLES VACCINES;HLA-DQA1;HLA-DQA1*01:04;*01:04;Efficacy;increased response to ⮕ MEASLES VACCINES;HLA-DQA1 *01:04 is associated with increased response to Measles vaccines in children.; in children 
;MEASLES VACCINES;HLA-DRB1;HLA-DRB1*01:01;*01:01;Efficacy;response to ⮕ MEASLES VACCINES;HLA-DRB1 *01:01 is associated with response to Measles vaccines in children.; in children 
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;CYP3A4 *1/*1 is associated with increased concentrations of cyclosporine in men as compared to CYP3A4 *1/*18.; in men 
;INTERFERON BETA-1A;HLA-DRB1;HLA-DRB1*04:01;*04:01;Efficacy;increased response to ⮕ INTERFERON BETA-1A;HLA-DRB1 *04:01 is associated with increased response to interferon beta-1a in people with Multiple Sclerosis.; in people with Disease:Multiple Sclerosis
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1 *04:01 is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid.;or in people with Other:Rheumatoid arthritis
;HEPATITIS VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;Efficacy;decreased response to ⮕ HEPATITIS VACCINES;HLA-DRB1 *07:01 is associated with decreased response to Hepatitis vaccines in children.; in children 
;INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;Efficacy;decreased response to ⮕ INFLUENZA VACCINES;HLA-DRB1 *07:01 is associated with decreased response to Influenza vaccines.;  
;MEASLES VACCINES;HLA-DRB1;HLA-DRB1*08:01;*08:01;Efficacy;response to ⮕ MEASLES VACCINES;HLA-DRB1 *08:01 is associated with response to Measles vaccines in children.; in children 
;INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*13:01;*13:01;Efficacy;increased response to ⮕ INFLUENZA VACCINES;HLA-DRB1 *13:01 is associated with increased response to Influenza vaccines.;  
;MONTELUKAST;CYP2C8;CYP2C8*1, CYP2C8*4;*4;Metabolism/PK;increased concentrations of ⮕ MONTELUKAST;CYP2C8 *4 is associated with increased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.; in healthy individuals 
;MONTELUKAST;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Metabolism/PK;decreased concentrations of ⮕ MONTELUKAST;CYP2C8 *3 is associated with decreased concentrations of montelukast in healthy individuals as compared to CYP2C8 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP2C8 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*1.; in people with Disease:Kidney Transplantation
;METHOTREXATE;GGH;rs11545078;AA + AG;Toxicity;increased discontinuation of ⮕ METHOTREXATE;Genotypes AA + AG is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Side Effect:Rheumatoid arthritis
;IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;Dosage;decreased dose of ⮕ IBUPROFEN;CYP2C8 *1/*3 is associated with decreased dose of ibuprofen.;  
;ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;Metabolism/PK;decreased concentrations of ⮕ ROSIGLITAZONE;CYP2C8 *1/*3 is associated with decreased concentrations of rosiglitazone in healthy individuals as compared to CYP2C8 *1/*1.; in healthy individuals 
;IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Metabolism/PK;decreased metabolism of ⮕ IBUPROFEN;CYP2C8 *3 is associated with decreased metabolism of ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.; in healthy individuals 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;*1/*6 + *1/*18 + *6/*6 + *6/*18;Metabolism/PK;decreased metabolism of ⮕ METHADONE;CYP2B6 *1/*6 + *1/*18 + *6/*6 + *6/*18 are associated with decreased metabolism of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*5 + *1/*7.; in people with Other:Opioid-Related Disorders
;DISULFIRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;Efficacy;low activity increased response to ⮕ DISULFIRAM;SLC6A4 HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C (assigned as low activity phenotype) is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to SLC6A4 L allele-rs25531T / L allele-rs25531T (assigned as high activity phenotype) .; in people with Other:Cocaine dependence
;SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;Metabolism/PK;decreased concentrations of ⮕ SERTRALINE;CYP2B6 *1/*4 + *4/*4 are associated with decreased concentrations of sertraline as compared to CYP2B6 *1/*1.;  
;SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6 + *9;Metabolism/PK;increased concentrations of ⮕ SERTRALINE;CYP2B6 *6 + *9 are associated with increased concentrations of sertraline as compared to CYP2B6 *1/*1.;  
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased concentrations of ⮕ SERTRALINE;CYP2C19 *1/*17 + *17/*17 are associated with decreased concentrations of sertraline as compared to CYP2C19 *1/*1.;  
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;Metabolism/PK;increased concentrations of ⮕ SERTRALINE;CYP2C19 *2 + *3 + *4 are associated with increased concentrations of sertraline as compared to CYP2C19 *1/*1.;  
;SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9;Metabolism/PK;increased half-life time of ⮕ SERTRALINE;CYP2B6 *9/*9 is associated with increased half-life time of sertraline as compared to CYP2B6 *1/*1.;  
;ATORVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Metabolism/PK;decreased concentrations of ⮕ ATORVASTATIN;CYP3A5 *1/*3 + *3/*3 are associated with decreased concentrations of atorvastatin in healthy individuals as compared to CYP3A5 *1/*1.; in healthy individuals 
;ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*1/*5 + *5/*5;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;SLCO1B1 *1/*5 + *5/*5 are associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;Efficacy;decreased response to ⮕ PRAVASTATIN;SLCO1B1 *1/*15 is associated with decreased response to pravastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1.; in people with Other:Hypercholesterolemia
;RIFAMPIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;*2 + *3 + *11;Efficacy;increased response to ⮕ RIFAMPIN, WARFARIN;CYP2C9 *2 + *3 + *11 is associated with increased response to rifampin and warfarin in people with Tuberculosis as compared to CYP2C9 *1/*1.;and in people with Other:Tuberculosis
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Metabolism/PK;increased concentrations of ⮕ PRAVASTATIN;SLCO1B1 *15 is associated with increased concentrations of pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;PITAVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;Metabolism/PK;increased concentrations of ⮕ PITAVASTATIN, PRAVASTATIN;SLCO1B1 *15/*15 is associated with increased concentrations of pitavastatin or pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.;or in healthy individuals 
;ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;Efficacy;poor metabolizer increased response to ⮕ ACYCLOVIR;NUDT15 *2/*2 +*2/*3 +*3/*3 + *5/*5 (assigned as poor metabolizer phenotype) are associated with increased response to acyclovir as compared to NUDT15 *1/*1 (assigned as normal metabolizer phenotype) .;  
;TACROLIMUS;ABCB1;rs1045642;GG;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotype GG is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.; in people with Disease:Liver transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol in children.; in children 
;FLUVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;Efficacy;increased response to ⮕ FLUVASTATIN;SLCO1B1 *14 is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.; in people with Disease:Hypercholesterolemia
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol in children.; in children 
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;*31;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;SLCO1B1 *31 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;*20;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;SLCO1B1 *20 is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;CONJUGATED ESTROGENS;SLCO1B1;rs4149056;TT;Metabolism/PK;decreased concentrations of ⮕ CONJUGATED ESTROGENS;Genotype TT is associated with decreased concentrations of conjugated estrogens in women with Menopause as compared to genotypes CC + CT.; in women with Disease:Menopause
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;*23;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;SLCO1B1 *23 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;ACENOCOUMAROL;CYP2C18;rs1998591;GG;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype GG is associated with increased dose of acenocoumarol in children as compared to genotypes AA + AG.; in children 
;ACENOCOUMAROL;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype AA is associated with decreased dose of acenocoumarol in children as compared to genotypes AG + GG.; in children 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Efficacy;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.; in people with Other:Stroke
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;SLCO1B1 *15 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;ROSUVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;Metabolism/PK;decreased metabolism of ⮕ ROSUVASTATIN;SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*15.; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 +*3/*3 + *2/*3;Metabolism/PK;poor metabolizer increased exposure to ⮕ ESCITALOPRAM;CYP2C19 *2/*2 +*3/*3 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased exposure to escitalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .; in healthy individuals 
;ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;SLCO1B1 *15/*15 is associated with increased concentrations of atorvastatin in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*15.; in healthy individuals 
;ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;SLCO1B1 *15 is associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1/*1 + *1/*37 + *37/*37.; in people with Other:Hypercholesterolemia
;ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;*15/*15 + *1/*15 + *15/*37 + *14/*37;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ ATRASENTAN;SLCO1B1 *15/*15 + *1/*15 + *15/*37 + *14/*37 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased concentrations of atrasentan as compared to SLCO1B1 *1/*1 + *37/*37 + *1/*37 (assigned as normal metabolizer phenotype) .;  
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased concentrations of ⮕ ESCITALOPRAM;CYP2C19 *1/*17 + *17/*17 are associated with decreased concentrations of escitalopram as compared to CYP2C19 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased steady-state concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased steady-state concentration of tacrolimus in people with Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Transplantation
;3,4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased concentrations of ⮕ 3,4-DEHYDROCILOSTAZOL;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of 3,4-dehydrocilostazol in people with Cerebral Infarction as compared to CYP3A5 *3/*3.; in people with Other:Cerebral Infarction
;BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;Efficacy;increased response to ⮕ BETA BLOCKING AGENTS;Allele del is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele GGGGCGGGGCCG.; in children with Other:Cardiomyopathy, Dilated
;HYDROXYBUPROPION;CYP2B6;CYP2B6*6;*6;Metabolism/PK;decreased exposure to ⮕ HYDROXYBUPROPION;CYP2B6 *6 is associated with decreased exposure to hydroxybupropion in healthy individuals.; in healthy individuals 
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*3 + *4 + *4xN + *5 + *6 + *10 + *41;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;CYP2D6 *3 + *4 + *4xN + *5 + *6 + *10 + *41 are associated with increased concentrations of aripiprazole as compared to CYP2D6 *1 + *1xN.;  
;ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ ATOMOXETINE;CYP2D6 poor metabolizer and intermediate metabolizer genotypes is associated with increased concentrations of atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.; in people with Other:Attention Deficit Disorder with Hyperactivity
;DOCETAXEL, THALIDOMIDE;SULT1C4;rs1402467;G;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.;and in people with Disease:Prostatic Neoplasms
;ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Dosage;intermediate metabolizer and poor metabolizer decreased dose of ⮕ ATOMOXETINE;CYP2D6 poor metabolizer and intermediate metabolizer genotypes is associated with decreased dose of atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.; in people with Other:Attention Deficit Disorder with Hyperactivity
;ATOMOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;increased concentrations of ⮕ ATOMOXETINE;CYP2C19 *2 is associated with increased concentrations of atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2C19 *1.; in people with Other:Attention Deficit Disorder with Hyperactivity
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17;*17;Metabolism/PK;increased exposure to ⮕ ENDOXIFEN;CYP2D6 *17 is associated with increased exposure to endoxifen in healthy individuals as compared to CYP2D6 *1 + *2.; in healthy individuals 
;AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Other;increased discontinuation of ⮕ AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19 *17/*17 is associated with increased discontinuation of amitriptyline or clomipramine in people with Bipolar Disorder as compared to CYP2C19 *1/*1.;or in people with Other:Bipolar Disorder
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;Dosage;intermediate metabolizer decreased dose of ⮕ MERCAPTOPURINE;NUDT15 *1/*2 + *1/*3 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3 + *6 + *7.; in people with Other:Kidney Transplantation
;BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Metabolism/PK;decreased metabolism of ⮕ BREXPIPRAZOLE;CYP2D6 *2 is associated with decreased metabolism of brexpiprazole as compared to CYP2D6 *1.;  
;BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;*9 +*10 + *14 + *17 + *29 + *41;Metabolism/PK;decreased metabolism of ⮕ BREXPIPRAZOLE;CYP2D6 *9 +*10 + *14 + *17 + *29 + *41 is associated with decreased metabolism of brexpiprazole as compared to CYP2D6 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Kidney Transplantation
;N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL;CYP2D6 *1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10 are associated with increased concentrations of n-desmethyltramadol in people with Head and Neck Neoplasms as compared to CYP2D6 *1/*1 + *1/*2.; in people with Other:Head and Neck Neoplasms
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin.;  
;VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ VENLAFAXINE;SLC6A4 HTTLPR long form (L allele) is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Other:Major Depressive Disorder
;VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;Efficacy;increased response to ⮕ VENLAFAXINE;SLC6A4 L allele-rs25531T/L allele-rs25531T is associated with increased response to venlafaxine in people with Anxiety Disorders.; in people with Other:Anxiety Disorders
;VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;Efficacy;decreased response to ⮕ VENLAFAXINE;SLC6A4 L allele-rs25531T/L allele-rs25531T is associated with decreased response to venlafaxine in people with Depression.; in people with Other:Depression
;METHOTREXATE;ABCC2;rs717620;CT + TT;Toxicity;decreased discontinuation of ⮕ METHOTREXATE;Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Side Effect:Rheumatoid arthritis
;KETOROLAC;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;increased response to ⮕ KETOROLAC;CYP2C9 *2 + *3 are associated with increased response to ketorolac in people with Pain, Postoperative as compared to CYP2C9 *1.; in people with Other:Pain, Postoperative
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Efficacy;decreased response to ⮕ TRAMADOL;CYP2D6 *4 is associated with decreased response to tramadol in people with Pain, Postoperative as compared to CYP2D6 *1.; in people with Other:Pain, Postoperative
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs3212948;C;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Allele C is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.;and in people with Disease:Colorectal Neoplasms
;SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;decreased response to ⮕ SERTRALINE;SLC6A4 HTTLPR short form (S allele) is associated with decreased response to sertraline in people with Panic Disorder as compared to SLC6A4 HTTLPR long form (L allele).; in people with Other:Panic Disorder
;ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP3A4 *22/*22 is associated with decreased concentrations of endoxifen in people with Breast Neoplasms as compared to CYP3A4 *1/*1 + *1/*22.; in people with Other:Breast Neoplasms
;MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased clearance of ⮕ MIDAZOLAM;CYP3A5 *1/*1 + *1/*3 is associated with decreased clearance of midazolam in people with Neoplasms as compared to CYP3A5 *3/*3.; in people with Other:Neoplasms
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;*17/*29 + *17/*17;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *17/*29 + *17/*17 (assigned as poor metabolizer phenotype) is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) .; in women with Other:Breast Neoplasms
;LIRAGLUTIDE;GLP1R;rs10305420;TT;Efficacy;increased clinical benefit to ⮕ LIRAGLUTIDE;Genotype TT is associated with increased clinical benefit to liraglutide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.; in people with Other:Diabetes Mellitus, Type 2
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Other:Kidney Transplantation
;OXYCODONE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased metabolism of ⮕ OXYCODONE;CYP2C19 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer.;  
;OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased metabolism of ⮕ OXYCODONE;CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased metabolism of oxycodone as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;  
;OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;decreased metabolism of ⮕ OXYCODONE;CYP3A4 *22 is associated with decreased metabolism of oxycodone as compared to CYP3A4 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with lung transplantation as compared to CYP3A5 *3/*3.; in people with Other:Lung transplantation
;GLICLAZIDE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ GLICLAZIDE;CYP2C19 poor metabolizers and intermediate metabolizers are associated with decreased clearance of gliclazide in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;rs4073;AA + AT;Efficacy;decreased response to ⮕ BEVACIZUMAB, CYCLOPHOSPHAMIDE;Genotypes AA + AT are associated with decreased response to bevacizumab and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.;and in women with Disease:Ovarian Neoplasms
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *4/*4 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.;  
;N-DESMETHYLCLOZAPINE;CYP3A4;CYP3A4 low activity;;Metabolism/PK;low activity decreased concentrations of ⮕ N-DESMETHYLCLOZAPINE;CYP3A4 low activity is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to CYP3A4 high activity.; in people with Other:Schizophrenia
;DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;Other;increased discontinuation of ⮕ DIHYDROPYRIDINE DERIVATIVES;Genotype TT is associated with increased discontinuation of Dihydropyridine derivatives as compared to genotype CC.;  
;N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 low activity;;Metabolism/PK;low activity decreased concentrations of ⮕ N-DESMETHYLCLOZAPINE;CYP1A2 low activity is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to CYP1A2 high activity.; in people with Other:Schizophrenia
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;*1/*35 + *9/*35 + *17/*35;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *1/*35 + *9/*35 + *17/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12;Metabolism/PK;decreased clearance of ⮕ NICOTINE;CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *4/*9 + *9/*9 + *9/*12 are associated with decreased clearance of nicotine in healthy individuals as compared to CYP2A6 *1/*1.; in healthy individuals 
;DISULFIRAM;ALDH2;ALDH2 deficiency;;Efficacy;deficiency increased response to ⮕ DISULFIRAM;ALDH2 deficiency is associated with increased response to disulfiram in people with Alcoholism as compared to ALDH2 non-deficient.; in people with Other:Alcohol abuse
;COUMARIN, NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9;Metabolism/PK;decreased metabolism of ⮕ COUMARIN, NICOTINE;CYP2A6 *1/*4 + *1/*7 + *1/*9 + *1/*10 + *4/*4 + *7/*7 + *9/*9 are associated with decreased metabolism of coumarin or nicotine in healthy individuals as compared to CYP2A6 *1/*1.;or in healthy individuals 
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46 + *46/*46;Metabolism/PK;increased metabolism of ⮕ NICOTINE;CYP2A6 *1/*46 + *46/*46 are associated with increased metabolism of nicotine as compared to CYP2A6 *1/*1.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*9 + *1/*12.;  
;ROSUVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;Metabolism/PK;decreased metabolism of ⮕ ROSUVASTATIN;SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;CYP2C9 *1/*3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;PITAVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15 + *15/*37;Metabolism/PK;increased concentrations of ⮕ PITAVASTATIN;SLCO1B1 *15/*15 + *15/*37 are associated with increased concentrations of pitavastatin in healthy individuals as compared to SLCO1B1 *37/*37.; in healthy individuals 
;WARFARIN;VKORC1;rs11150606;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele T.;  
;PITAVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ PITAVASTATIN;CYP2C9 *1/*3 is associated with increased concentrations of pitavastatin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;*1 + *46 + *9 + *14 + *38;Metabolism/PK;increased metabolism of ⮕ NICOTINE;CYP2A6 *1 + *46 + *9 + *14 + *38 are associated with increased metabolism of nicotine as compared to CYP2A6 *2 + *4.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;*1 + *9 + *12 + *38;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *1 + *9 + *12 + *38 are associated with decreased metabolism of nicotine as compared to CYP2A6 *46.;  
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;OXALIPLATIN;MTHFR;rs1801131;GG + GT;Efficacy;increased response to ⮕ OXALIPLATIN;Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.; in people with Disease:Colorectal Neoplasms
;ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;Efficacy;low activity increased response to ⮕ ALPRAZOLAM;CYP3A4 low activity is associated with increased response to alprazolam in men with Alcoholism and Anxiety Disorders as compared to CYP3A4 high activity.; in men with Other:Alcohol abuse, Other:Anxiety Disorders
;TACROLIMUS;CYP3A4;rs2242480;C/C;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype C/C is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype C/T.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A4;rs2242480;C/C;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype C/C is associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotypes C/T + T/T.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes C/T + T/T is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype C/C.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2242480;C/C;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype C/C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes C/T + T/T.; in people with Disease:Kidney Transplantation
;FENTANYL;CYP3A4;rs2242480;T/T;Dosage;decreased dose of ⮕ FENTANYL;Genotype T/T is associated with decreased dose of fentanyl in women with Pain, Postoperative as compared to genotypes C/C + C/T.; in women with Disease:Pain, Postoperative
;ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 intermediate metabolizer is associated with decreased concentrations of endoxifen in people with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in people with Other:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;Dosage;normal metabolizer and intermediate metabolizer increased dose of ⮕ TACROLIMUS;CYP3A5 intermediate metabolizer and normal metabolizer is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 poor metabolizer.; in children with Other:Kidney Transplantation
;DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*8;*1/*3 + *1/*8;Metabolism/PK;decreased metabolism of ⮕ DICLOFENAC;CYP2C9 *1/*3 + *1/*8 are associated with decreased metabolism of diclofenac in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;CLOZAPINE;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ CLOZAPINE;Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of clozapine in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6;Metabolism/PK;increased concentrations of ⮕ DOLUTEGRAVIR;UGT1A1 *28/*28 + *6/*6 is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to UGT1A1 *1/*1.; in people with Other:HIV infectious disease
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;Genotypes AA + AG is associated with decreased response to aspirin and clopidogrel in people with percutaneous coronary interventions and drug-eluting stents as compared to genotype GG.;and in people with Other:percutaneous coronary interventions and drug-eluting stents
;(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;*6 + *7 + *9 + *18;Metabolism/PK;decreased clearance of ⮕ (S)-METHADONE;CYP2B6 *6 + *7 + *9 + *18 is associated with decreased clearance of (S)-methadone in children with Scoliosis as compared to CYP2B6 *1/*1.; in children with Other:Scoliosis
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Dosage;decreased dose of ⮕ MERCAPTOPURINE, THIOGUANINE;TPMT *1/*3C is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;or in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE, THIOGUANINE;TPMT *1/*3A is associated with decreased dose of mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;or in children with Disease:Acute lymphoblastic leukemia
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7;Other, Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *4/*4 + *4/*7 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.;  
;HYDRALAZINE;NAT2;NAT2 rapid acetylator;;Dosage, Efficacy;rapid acetylator increased dose of ⮕ HYDRALAZINE;NAT2 rapid acetylator is associated with increased dose of hydralazine in people with Hypertension as compared to NAT2 slow acetylator.; in people with Other:Hypertension
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*13 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.; in people with Other:Atrial Fibrillation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma or Leukemia, Myeloid, Acute as compared to CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) .;" in children with ""Other:Acute lymphoblastic leukemia"", ""Other:Lymphoma"", ""Other:Leukemia, Myeloid, Acute"""
;ROSUVASTATIN;SLCO1B1;rs11045854;A;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator increased concentrations of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.; in people with Other:Hypertension
;VENLAFAXINE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 intermediate metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.; in Other:Elderly Adult
;ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ ESCITALOPRAM;CYP2C19 intermediate metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.; in Other:Elderly Adult
;SOMATROPIN RECOMBINANT;COL1A1;rs1800012;AA;Dosage;decreased dose of ⮕ SOMATROPIN RECOMBINANT;Genotype AA is associated with decreased dose of somatropin recombinant in people with growth hormone deficiency as compared to genotype CC.; in people with Other:growth hormone deficiency
;LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;Metabolism/PK;decreased clearance of ⮕ LETROZOLE;CYP2A6 *1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12 are associated with decreased clearance of letrozole in women with Breast Neoplasms as compared to CYP2A6 *1/*1.; in women with Disease:Breast Neoplasms
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46;Metabolism/PK;increased clearance of ⮕ NICOTINE;CYP2A6 *1/*46 is associated with increased clearance of nicotine as compared to CYP2A6 *1/*1.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;Metabolism/PK;low activity and intermediate activity decreased metabolism of ⮕ NICOTINE;CYP2A6 *1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27 + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35 (assigned as intermediate and low activity phenotype) are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 +*1/*46 + *46/*46 (assigned as normal metabolizer phenotype) .;  
;VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801133;A;Efficacy;increased response to ⮕ VITAMIN B-COMPLEX, INCL. COMBINATIONS;Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.; in people with Other:Major Depressive Disorder
;ROSUVASTATIN;SLCO1B1;rs2306283;GG;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotype GG is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotype AA.; in healthy individuals 
;WARFARIN;VKORC1;rs2359612;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801131;G;Efficacy;increased response to ⮕ VITAMIN B-COMPLEX, INCL. COMBINATIONS;Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major.; in people with Other:Major Depressive Disorder
;ATOMOXETINE;SLC6A2;rs12708954;A;Efficacy;increased response to ⮕ ATOMOXETINE;Allele A is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;C;Metabolism/PK;decreased concentrations of ⮕ CYCLOSPORINE, TACROLIMUS;Allele C is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele T.;or in people with Side Effect:Kidney Transplantation
;ROSUVASTATIN;SLCO1B1;rs4149056;CC;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;RIZATRIPTAN;DRD2;rs6275;AA + AG;Efficacy;decreased response to ⮕ RIZATRIPTAN;Genotypes AA + AG are associated with decreased response to rizatriptan in people with Migraine without Aura as compared to genotype GG.; in people with Other:Migraine without Aura
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.; in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs61162043;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin.;  
;SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1057910;CC;Efficacy;increased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotype CC is associated with increased response to sulfonamides, urea derivatives.;  
;NICOTINE;OPRM1;rs1799971;AG + GG;Efficacy;decreased response to ⮕ NICOTINE;Genotypes AG + GG are associated with decreased response to nicotine in women with Tobacco Use Disorder as compared to genotype AA.; in women with Other:Tobacco Use Disorder
;RISPERIDONE;DRD3;rs6280;CC + CT;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes CC + CT is associated with increased response to risperidone in children with Autistic Disorder as compared to genotype TT.; in children with Disease:Autism
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;ROSUVASTATIN;FOXA3;rs16980091;T;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;ROSUVASTATIN;SLCO1B1;rs34671512;C;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele A.; in healthy individuals 
;SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased concentrations of ⮕ SIROLIMUS;CYP3A5 *1/*3 is associated with decreased concentrations of sirolimus as compared to CYP3A5 *3/*3.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;CYSTEAMINE;CFTR;rs113993960;CTT/del + del/del;Efficacy;increased response to ⮕ CYSTEAMINE;Genotypes CTT/del + del/del are associated with increased response to cysteamine in people with Cystic Fibrosis as compared to genotype CTT/CTT.; in people with Disease:Cystic Fibrosis
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ ESCITALOPRAM;CYP2C19 *2/*2 + *2/*3 are associated with increased response to escitalopram in people with Panic Disorder as compared to CYP2C19 *1/*1.; in people with Disease:Panic Disorder
;DEXTROPROPOXYPHENE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased exposure to ⮕ DEXTROPROPOXYPHENE;CYP3A5 *3/*3 is associated with increased exposure to dextropropoxyphene in healthy individuals as compared to CYP3A5 *1/*3.; in healthy individuals 
;FELODIPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased exposure to ⮕ FELODIPINE;CYP3A5 *3/*3 is associated with increased exposure to felodipine in healthy individuals as compared to CYP3A5 *1/*3.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator increased concentrations of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with increased concentrations of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.; in people with Other:Hypertension
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Dosage;decreased dose of ⮕ AZATHIOPRINE;TPMT *1/*3A + *1/*3C is associated with decreased dose of azathioprine in people with Transplantation as compared to TPMT *1/*1.; in people with Disease:Transplantation
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.; in people with Disease:Myocardial Infarction
;CODEINE;CYP2D6;CYP2D6*17;*17;Metabolism/PK;decreased metabolism of ⮕ CODEINE;CYP2D6 *17 is associated with decreased metabolism of codeine in people with Anemia, Sickle Cell.; in people with Disease:Anemia, Sickle Cell
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin.;  
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3;Metabolism/PK;decreased clearance of ⮕ RABEPRAZOLE;CYP2C19 *2/*2 + *3/*3 is associated with decreased clearance of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Dosage;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased response to ⮕ PANTOPRAZOLE;CYP2C19 *1/*2 is associated with increased response to pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *1/*2 + *17/*17;Dosage;dose of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *1/*2 + *17/*17 are associated with dose of voriconazole in people with Cystic Fibrosis and lung transplantation as compared to CYP2C19 *1/*1.; in people with Disease:Cystic Fibrosis, Disease:Lung transplantation
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased clearance of ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.; in healthy individuals 
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased clearance of ⮕ PANTOPRAZOLE;CYP2C19 *2/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Metabolism/PK;increased clearance of ⮕ PANTOPRAZOLE;CYP2C19 *17 is associated with increased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1.; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased clearance of ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with increased clearance of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in men as compared to CYP2C9 *1/*1.; in men 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *5 + *6;Metabolism/PK;decreased metabolism of ⮕ ARIPIPRAZOLE;CYP2D6 *4 + *5 + *6 is associated with decreased metabolism of aripiprazole as compared to CYP2D6 *1.;  
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*17;Efficacy;decreased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE;CYP2C19 *1/*1 + *1/*17 are associated with decreased response to lansoprazole or omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.;or in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.; in people with Disease:Gastroesophageal Reflux
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17 + *1/*2;Dosage;dose of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 + *1/*2 are associated with dose of voriconazole in people with Cystic Fibrosis and lung transplantation as compared to CYP2C19 *1.; in people with Disease:Cystic Fibrosis, Disease:Lung transplantation
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*17;Metabolism/PK;increased metabolism of ⮕ PANTOPRAZOLE;CYP2C19 *1/*1 + *1/*17 is associated with increased metabolism of pantoprazole in children as compared to CYP2C19 *1/*2 + *2/*17.; in children 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;GSTM1 non-null, GSTM1 null;;Efficacy;decreased response to ⮕ ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1 null is associated with decreased response to anthracyclines and related substances, capecitabine, cyclophosphamide, fluorouracil and taxanes in women with Breast Neoplasms as compared to GSTM1 non-null.;and in women with Disease:Breast Neoplasms
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE;CYP2C19 *2/*2 + *2/*3 is associated with increased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.; in people with Disease:Gastroesophageal Reflux
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TOLPERISONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;Metabolism/PK;increased exposure to ⮕ TOLPERISONE;CYP2D6 *4 + *5 are associated with increased exposure to tolperisone in healthy individuals as compared to CYP2D6 *1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.; in people with Disease:Gastroesophageal Reflux
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3.; in people with Disease:Gastroesophageal Reflux
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;MIANSERIN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *5/*10;Metabolism/PK;increased concentrations of ⮕ MIANSERIN;CYP2D6 *1/*10 + *5/*10 are associated with increased concentrations of mianserin in people with Depression as compared to CYP2D6 *1/*1.; in people with Disease:Depression
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased concentrations of tacrolimus in healthy individuals as compared to CYP3A5 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.; in healthy individuals 
;SALVIANOLIC ACID B;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ SALVIANOLIC ACID B;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.; in people with Other:Coronary Disease
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ MEPHENYTOIN;CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of mephenytoin in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;Metabolism/PK;metabolism of ⮕ VALPROIC ACID;UGT1A6 *1a is associated with metabolism of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.; in children with Disease:Epilepsy
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 + *3/*3 are associated with increased dose-adjusted trough concentrations of tacrolimus in people with Myasthenia Gravis as compared to CYP3A5 *1/*1.; in people with Disease:Myasthenia Gravis
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *1/*2 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.;or in healthy individuals 
;VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;Dosage;decreased dose of ⮕ VALPROIC ACID;UGT1A6 *1a is associated with decreased dose of valproic acid in children with Epilepsy as compared to UGT1A6 *2a + *3a + *4a + *8.; in children with Disease:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8/*8;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *8/*8 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;Metabolism/PK;increased clearance of ⮕ CYCLOSPORINE;CYP3A4 *1/*1 is associated with increased clearance of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*22 + *22/*22.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ SIROLIMUS, TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;or in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Dosage;decreased dose of ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6 *4/*4 is associated with decreased dose of Selective serotonin reuptake inhibitors in people with Depression as compared to CYP2D6 *1/*1.; in people with Disease:Depression
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin.;  
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*18;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *18 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1.; in people with Disease:Kidney Transplantation
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Dosage, Efficacy;increased dose of ⮕ TRAMADOL;CYP2D6 *10/*10 is associated with increased dose of tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.; in people with Other:Pain, Postoperative
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;Metabolism/PK;decreased metabolism of ⮕ TRAMADOL;CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41 are associated with decreased metabolism of tramadol in infants as compared to CYP2D6 *1/*1.; in infants 
;ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;Metabolism/PK;normal metabolizer and ultrarapid metabolizer increased concentrations of ⮕ ENDOXIFEN;CYP2D6 normal metabolizer and ultra-metabolizer are associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 poor metabolizers and intermediate metabolizers.; in women with Disease:Breast Neoplasms
;IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;increased concentrations of ⮕ IMIPRAMINE;CYP2C19 *2 is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.; in people with Disease:Major Depressive Disorder
;O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ O-DESMETHYLTRAMADOL;CYP2D6 poor metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain and Osteoarthritis as compared to CYP2D6 normal metabolizer.; in people with Disease:Low Back Pain, Disease:Osteoarthritis
;RASAGILINE;ABCB1;rs1045642;AA + AG;Metabolism/PK;decreased clearance of ⮕ RASAGILINE;Genotypes AA + AG is associated with decreased clearance of rasagiline in healthy individuals as compared to genotype GG.; in healthy individuals 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to antidepressants in women Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele).; in women Disease:Depressive Disorder
;ISONIAZID;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator decreased concentrations of ⮕ ISONIAZID;NAT2 slow acetylator is associated with decreased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 rapid acetylator.; in people with Disease:Tuberculosis
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ ESCITALOPRAM;SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in men with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in men with Disease:Major Depressive Disorder
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*2 is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*17.; in people with Disease:Fungal infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;Metabolism/PK;decreased metabolism of ⮕ OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*2 is associated with decreased metabolism of omeprazole, pantoprazole or rabeprazole as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.;or  
;CORTICOSTEROIDS;NR1I2;rs3842689;del/del;Efficacy;increased resistance to ⮕ CORTICOSTEROIDS;Genotype del/del is associated with increased resistance to corticosteroids in children with as compared to genotype GAGAAG/GAGAAG.; in children with 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 poor metabolizers and intermediate metabolizers are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.; in people with Disease:Fungal infectious disease
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;Metabolism/PK;decreased metabolism of ⮕ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *26 is associated with decreased metabolism of mephenytoin and omeprazole as compared to CYP2C19 *1.;and  
;IRBESARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ IRBESARTAN;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to irbesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.; in people with Disease:Hypertension
;TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;Metabolism/PK;decreased metabolism of ⮕ TRIMIPRAMINE;CYP2D6 *3 + *4 + *5 + *6 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased exposure to ⮕ ESCITALOPRAM;CYP2C19 *1/*17 + *17/*17 are associated with decreased exposure to escitalopram as compared to CYP2C19 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;Metabolism/PK;increased exposure to ⮕ ESCITALOPRAM;CYP2C19 *2 + *3 + *4 are associated with increased exposure to escitalopram as compared to CYP2C19 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.; in people with Disease:Cardiovascular Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;SIPOGLITAZAR;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2;Efficacy, Metabolism/PK;increased response to ⮕ SIPOGLITAZAR;UGT2B15 *2/*2 is associated with increased response to sipoglitazar as compared to UGT2B15 *1/*1 + *1/*2.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ PAROXETINE;SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;NORTRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;decreased concentrations of ⮕ NORTRIPTYLINE;CYP2C19 *2/*2 + *2/*3 are associated with decreased concentrations of nortriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.; in healthy individuals 
;SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*9 + *1/*6 + *6/*6;Metabolism/PK;increased concentrations of ⮕ SERTRALINE;CYP2B6 *6/*9 + *1/*6 + *6/*6 is associated with increased concentrations of sertraline in people with Depressive Disorder, Major as compared to CYP2B6 *1/*1.; in people with Disease:Major Depressive Disorder
;METFORMIN;SLC22A1;rs72552763;del/del;Metabolism/PK;decreased exposure to ⮕ METFORMIN;Genotype del/del is associated with decreased exposure to metformin in healthy individuals as compared to genotype GAT/GAT.; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10;Metabolism/PK;increased concentrations of ⮕ VENLAFAXINE;CYP2D6 *10/*10 is associated with increased concentrations of venlafaxine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.; in people with Disease:Stroke
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.; in people with Disease:Cerebral sinovenous thrombosis
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Thrombosis of cerebral veins as compared to CYP2C9 *1.; in people with Disease:Cerebral sinovenous thrombosis
;TACROLIMUS;CYP3A5;CYP3A5*1;*1;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation.; in children with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ SERTRALINE;CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;  
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ SERTRALINE;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of sertraline as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 are associated with increased resistance to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.; in people with Disease:Stroke
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*3/*4 + *4/*4;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *3/*4 + *4/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*2xN + *1/*10 + *9/*41 + *2/*10 + *2/*2 + *1/*1xN + *1/*41 + *1/*9 + *1/*5 + *1/*4 + *10/*10 + *2/*4 + *2/*5 + *2/*41 + *2/*9.; in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*17 + *2/*2 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *3/*4 + *4/*5 + *4/*6;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *4/*4 + *3/*4 + *4/*5 + *4/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.; in women with Disease:Breast Neoplasms
;MORPHINE;SLC22A1;rs72552763;GAT/del + del/del;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotypes GAT/del + del/del is associated with decreased clearance of morphine in children as compared to genotype GAT/GAT.; in children 
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;*4/*41 + *4/*10 + *4/*17 + *5/*41;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *4/*41 + *4/*10 + *4/*17 + *5/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.; in women with Disease:Breast Neoplasms
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*2 + *1/*1 + *2/*2.; in women with Disease:Breast Neoplasms
;IMATINIB;GSTT1;GSTT1 non-null, GSTT1 null;null/null;Efficacy;decreased response to ⮕ IMATINIB;GSTT1 null/null is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to GSTT1 non-null/non-null + non-null/null.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;GLUCOCORTICOIDS;HSD3B1;rs1047303;AA + AC;Efficacy;increased resistance to ⮕ GLUCOCORTICOIDS;Genotypes AA + AC are associated with increased resistance to glucocorticoids in people with Asthma as compared to genotype CC.; in people with Other:Asthma
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.; in children 
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Metabolism/PK;increased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *17/*17 is associated with increased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.; in children 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*17/*17;Metabolism/PK;decreased concentrations of ⮕ VORICONAZOLE;CYP2C19 *17/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.; in people with Disease:Fungal infectious disease
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 + *1/*17 + *1/*41.; in women with Disease:Breast Neoplasms
;SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;concentrations of ⮕ SIMVASTATIN;CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.;  
;MORPHINE;SLC22A1;rs72552763;del/del;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotype del/del is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes GAT/GAT + GAT/del.; in children with Other:adenotonsillectomy
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;SLCO1B1 *5 is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ NORTRIPTYLINE;CYP2D6 *10/*10 is associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome
;FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;decreased response to ⮕ FLUVOXAMINE, PAROXETINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to fluvoxamine or paroxetine in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).;or in people with Disease:Mood Disorder
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome
;SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ SILDENAFIL;CYP3A4 *1/*22 is associated with increased concentrations of sildenafil in people with Heart Failure as compared to CYP3A4 *1/*1.; in people with Disease:Heart Failure
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in people with HIV.; in people with Disease:HIV infectious disease
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *28/*28 + *1/*28 is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;CYP2B6 *6 is associated with metabolism of efavirenz in people with HIV.; in people with Disease:HIV infectious disease
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;Efficacy;increased response to ⮕ FLUOROURACIL;Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype 33.; in people with Disease:Rectal Neoplasms
;BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Metabolism/PK;increased concentrations of ⮕ BILIRUBIN;UGT1A1 *1/*6 + *6/*6 is associated with increased concentrations of bilirubin in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;METHADONE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Metabolism/PK;increased concentrations of ⮕ METHADONE;CYP2C9 *1/*2 + *1/*3 are associated with increased concentrations of methadone as compared to CYP2C9 *1/*1.;  
;BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;increased concentrations of ⮕ BILIRUBIN;UGT1A1 *1/*28 + *28/*28 is associated with increased concentrations of bilirubin in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ METHADONE;CYP3A5 *3/*3 is associated with increased concentrations of methadone as compared to CYP3A5 *1/*1 + *1/*3.;  
;METHADONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased concentrations of ⮕ METHADONE;CYP2C19 *1/*2 + *1/*3 are associated with increased concentrations of methadone as compared to CYP2C19 *1/*1.;  
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;SLCO1B1 *14 is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to SLCO1B1 *1 + *37.; in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*1;*1/*1;Dosage, Metabolism/PK;increased dose of ⮕ WARFARIN;CYP2C9 *1/*1 is associated with increased dose of warfarin in children as compared to CYP2C9 *1/*3.; in children 
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6 + *1/*6;Metabolism/PK;decreased metabolism of ⮕ SN-38;UGT1A1 *6/*6 + *1/*6 is associated with decreased metabolism of SN-38 in people with Neoplasms.; in people with Disease:Neoplasms
;ROSUVASTATIN;RXRA;rs1805343;A;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele A is associated with increased exposure to rosuvastatin in healthy individuals.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*17 +  *4/*41 + *4/*10;Dosage;decreased dose of ⮕ VENLAFAXINE;CYP2D6 *3/*9 + *4/*17 + *4/*41 + *4/*10 are associated with decreased dose of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.; in people with Disease:Major Depressive Disorder
;PACLITAXEL;CYP2C8;CYP2C8*3;*3;Metabolism/PK;decreased exposure to ⮕ PACLITAXEL;CYP2C8 *3 is associated with decreased exposure to paclitaxel in women with Breast Neoplasms.; in women with Disease:Breast Neoplasms
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;metabolism of ⮕ CLOBAZAM;CYP2C19 *1/*1 is associated with metabolism of clobazam in children as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.; in children 
;BUPROPION;CYP2B6;CYP2B6*4;*4;Other, Metabolism/PK;increased clearance of ⮕ BUPROPION;CYP2B6 *4 is associated with increased clearance of bupropion in healthy individuals.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;GLATIRAMER ACETATE;CCR5;rs333;del;Efficacy;decreased response to ⮕ GLATIRAMER ACETATE;Allele del is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele GTCAGTATCAATTCTGGAAGAATTTCCAGACA.; in people with Disease:Multiple Sclerosis
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;*1/*13 + *1/*16 + *1/*60;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*13 + *1/*16 + *1/*60 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1 + *1/*3.; in people with Other:Atrial Fibrillation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation.; in people with Disease:Kidney Transplantation
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;poor metabolizer decreased clearance of ⮕ SERTRALINE;CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with decreased clearance of sertraline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;Metabolism/PK;dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*1 are associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A4 *1/*22 + *22/*22.; in people with Disease:Liver transplantation
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *2 + *3 + *8 + *9 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of lansoprazole in children with Asthma as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Disease:Asthma
;GLIPIZIDE;TCF7L2;rs7903146;T;Efficacy;increased response to ⮕ GLIPIZIDE;Allele T is associated with increased response to glipizide as compared to allele C.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2C19 *1.; in people with Disease:Carotid Artery Diseases
;CLOPIDOGREL;SLC14A2;rs12456693;T;Efficacy;increased response to ⮕ CLOPIDOGREL;Allele T is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to allele C.; in people with Disease:Coronary Artery Disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis B as compared to genotypes G/TT + GG.;and in people with Disease:Hepatitis B virus infection
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;CISPLATIN, FLUOROURACIL;TPMT;TPMT*3C;*3C;Efficacy;decreased response to ⮕ CISPLATIN, FLUOROURACIL;TPMT *3C is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms.;and in men with Disease:Head and Neck Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 are associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;CAVOSONSTAT;CFTR;rs113993960;del/del;Efficacy;response to ⮕ CAVOSONSTAT;Genotype del/del is associated with response to cavosonstat in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.; in people with Disease:Cystic Fibrosis
;BUPROPION;CYP2B6;CYP2B6*6;*6;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *6 is associated with decreased metabolism of bupropion.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 are associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; in people with Disease:Coronary Artery Disease
;RISPERIDONE;CYP2D6;CYP2D6*5, CYP2D6*10;*10 + *5;Metabolism/PK;increased concentrations of ⮕ RISPERIDONE;CYP2D6 *10 + *5 are associated with increased concentrations of risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;Metabolism/PK;increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *2 + *3 are associated with increased trough concentration of voriconazole in children as compared to CYP2C19 *1 + *17.; in children 
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Metabolism/PK;decreased metabolism of ⮕ ZUCLOPENTHIXOL;CYP2D6 *4 is associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;NEVIRAPINE;NR1I2;rs3842689;GAGAAG/del + del/del;Dosage, Metabolism/PK;increased clearance of ⮕ NEVIRAPINE;Genotypes GAGAAG/del + del/del are associated with increased clearance of nevirapine in people with HIV Infections as compared to genotype GAGAAG/GAGAAG.; in people with Disease:HIV infectious disease
;GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*41;*4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN;Metabolism/PK;poor metabolizer increased concentrations of ⮕ GEFITINIB;CYP2D6 *4/*4 + *4/*5 + *3/*4 + *4/*6 + *3/*5 + *4/*4xN (assigned as poor metabolizer phenotype) is associated with increased concentrations of gefitinib in healthy individuals as compared to CYP2D6 *1/*4 + *1/*2 + *2/*4 + *1/*3 + *2/*5 + *2/*41 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10;Metabolism/PK;increased exposure to ⮕ TRAMADOL;CYP2D6 *10/*10 is associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1 + *2.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;VORICONAZOLE;ABCB1;rs1045642;AA;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;Genotype AA is associated with decreased metabolism of voriconazole in healthy individuals as compared to genotype GG.; in healthy individuals 
;IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR / LUMACAFTOR;Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.; in people with Disease:Fungal infectious disease
;MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;decreased clearance of ⮕ MIDAZOLAM;CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;Metabolism/PK;increased concentrations of ⮕ SN-38;UGT1A1 *6 + *28 is associated with increased concentrations of SN-38 in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TELMISARTAN;UGT1A3;UGT1A3*1, UGT1A3*3;*3;Metabolism/PK;decreased concentrations of ⮕ TELMISARTAN;UGT1A3 *3 is associated with decreased concentrations of telmisartan in healthy individuals as compared to UGT1A3 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in children with Transplantation as compared to CYP3A4 *1/*1.; in children with Disease:Transplantation
;IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;response to ⮕ IVACAFTOR / LUMACAFTOR;Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *5 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.; in people with Disease:Ulcerative Colitis
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.; in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2 + *2/*3;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*8 + *2/*2 + *2/*3 is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; in people with Disease:Coronary Artery Disease
;MEASLES VACCINES;HLA-B;HLA-B*51:01;*51:01;Efficacy;decreased response to ⮕ MEASLES VACCINES;HLA-B *51:01 is associated with decreased response to Measles vaccines in children.; in children 
;BUCINDOLOL;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;Efficacy;increased response to ⮕ BUCINDOLOL;Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes GGGGCGGGGCCG/del + del/del.; in people with Disease:Heart Failure
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Kidney Transplantation
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Dosage;intermediate metabolizer and poor metabolizer decreased dose of ⮕ RISPERIDONE;CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased dose of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer and ultra-metabolizer genotypes.; in people with Disease:Psychotic Disorder
;MEASLES VACCINES;HLA-B;HLA-B*07:02;*07:02;Efficacy;increased response to ⮕ MEASLES VACCINES;HLA-B *07:02 is associated with increased response to Measles vaccines in children.; in children 
;MEASLES VACCINES;HLA-B;HLA-B*13:01;*13:01;Efficacy;decreased response to ⮕ MEASLES VACCINES;HLA-B *13:01 is associated with decreased response to Measles vaccines in children.; in children 
;MEASLES VACCINES;HLA-B;HLA-B*08:01;*08:01;Efficacy;decreased response to ⮕ MEASLES VACCINES;HLA-B *08:01 is associated with decreased response to Measles vaccines in children.; in children 
;ROSUVASTATIN;ABCB11;rs7579275;G;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele G is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele A.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.; in children 
;INFLUENZA VACCINES;HLA-DQB1;HLA-DQB1*03:03;*03:03;Efficacy;decreased response to ⮕ INFLUENZA VACCINES;HLA-DQB1 *03:03 is associated with decreased response to Influenza vaccines.;  
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;MEASLES VACCINES;HLA-DQA1;HLA-DQA1*02:01;*02:01;Efficacy;decreased response to ⮕ MEASLES VACCINES;HLA-DQA1 *02:01 is associated with decreased response to Measles vaccines in children.; in children 
;MEASLES VACCINES;HLA-DRB1;HLA-DRB1*03:01;*03:01;Efficacy;decreased response to ⮕ MEASLES VACCINES;HLA-DRB1 *03:01 is associated with decreased response to Measles vaccines in children.; in children 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*20;*1/*20;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*20 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 + *22/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A4 *1/*1.;  
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;FLUOROURACIL;DPYD;DPYD poor metabolizer;;Dosage;poor metabolizer decreased dose of ⮕ FLUOROURACIL;DPYD poor metabolizer is associated with decreased dose of fluorouracil in people with Colorectal Neoplasms, Gastrointestinal Neoplasms and Rectal Neoplasms as compared to DPYD normal metabolizer.; in people with Disease:Colorectal Neoplasms, Disease:Gastrointestinal Neoplasms, Disease:Rectal Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 + *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.; in people with Disease:Kidney Transplantation
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3.; in people with Other:heart transplantation
;CISPLATIN, FLUOROURACIL;TPMT;TPMT*3B;*3B;Efficacy;decreased response to ⮕ CISPLATIN, FLUOROURACIL;TPMT *3B is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms.;and in men with Disease:Head and Neck Neoplasms
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.;or in people with Disease:Helicobacter Infections
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.; in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.; in people with Disease:Coronary Artery Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.; in children with Other:heart transplantation
;ROSUVASTATIN;ABCB11;rs2287622;G;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele G is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele A.; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;Metabolism/PK;decreased metabolism of ⮕ PHENPROCOUMON;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.; in people with Disease:Ulcerative Colitis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased dose of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;*4/*5 + *4/*4;Metabolism/PK;decreased metabolism of ⮕ AMITRIPTYLINE;CYP2D6 *4/*5 + *4/*4 are associated with decreased metabolism of amitriptyline as compared to CYP2D6 *9 + *10 + *1 + *2.;  
;SIROLIMUS, TEMSIROLIMUS;ABCB1;rs1128503;GG;Metabolism/PK;decreased exposure to ⮕ SIROLIMUS, TEMSIROLIMUS;Genotype GG is associated with decreased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.;and in people with Disease:Urinary Bladder Neoplasms
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 + *1/*2 + *1/*3 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased concentrations of ⮕ METHADONE;CYP2B6 *6/*6 is associated with increased concentrations of methadone as compared to CYP2B6 *1/*1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;GRANISETRON;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ GRANISETRON;CYP3A5 *3/*3 is associated with decreased clearance of granisetron as compared to CYP3A5 *1/*1 + *1/*3.;  
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*40;*40;Efficacy;decreased response to ⮕ CODEINE;CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.; in children with Disease:Anemia, Sickle Cell
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Efficacy;decreased response to ⮕ CODEINE;CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.; in children with Disease:Anemia, Sickle Cell
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Other;increased discontinuation of ⮕ TACROLIMUS;CYP3A5 *1/*1 is associated with increased discontinuation of tacrolimus in people with Arthritis, Rheumatoid as compared to CYP3A5 *3/*3.; in people with Disease:Rheumatoid arthritis
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*6;*6;Efficacy;decreased response to ⮕ CODEINE;CYP2D6 *6 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.; in children with Disease:Anemia, Sickle Cell
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Efficacy;decreased response to ⮕ CODEINE;CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.; in children with Disease:Anemia, Sickle Cell
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 are associated with decreased response to aspirin and clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.;and in people with Disease:Stroke
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;Efficacy;decreased response to ⮕ CODEINE;CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.; in children with Disease:Anemia, Sickle Cell
;GRANISETRON;CYP1A1;CYP1A1*1, CYP1A1*2A;*2A;Metabolism/PK;increased clearance of ⮕ GRANISETRON;CYP1A1 *2A is associated with increased clearance of granisetron as compared to CYP1A1 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid as compared to CYP3A5 *1/*3 + *1/*1.; in people with Disease:Rheumatoid arthritis
;CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ CLOMIPRAMINE;CYP2C19 *2/*2 is associated with decreased metabolism of clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 + *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.; in people with Disease:Kidney Transplantation
;HMG COA REDUCTASE INHIBITORS;UGT1A1;UGT1A1*28;*28;Toxicity;decreased discontinuation of ⮕ HMG COA REDUCTASE INHIBITORS;UGT1A1 *28 is associated with decreased discontinuation of hmg coa reductase inhibitors in people with Hyperlipidemias.; in people with Disease:Hyperlipidemias
;ROCURONIUM;SLCO1A2;rs7967354;CC;Dosage;decreased dose of ⮕ ROCURONIUM;Genotype CC is associated with decreased dose of rocuronium in women as compared to genotypes CT + TT.; in women 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *2/*3;Dosage;decreased dose of ⮕ PHENPROCOUMON;CYP2C9 *1/*2 + *2/*2 + *1/*3 + *2/*3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1/*1.;  
;ROSUVASTATIN;ABCC2;rs8187692;A;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele A is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;Metabolism/PK;increased concentrations of ⮕ NORTRIPTYLINE;CYP2D6 *3 + *4 + *5 + *6 are associated with increased concentrations of nortriptyline in people with Mental Disorders as compared to CYP2D6 *1/*1.; in people with Disease:Mental Disorders
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;increased concentrations of ⮕ AMITRIPTYLINE;CYP2C19 *2/*2 is associated with increased concentrations of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;CAPECITABINE, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;Efficacy;increased response to ⮕ CAPECITABINE, FLUOROURACIL;Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to capecitabine or fluorouracil in people with Rectal Neoplasms.;or in people with Disease:Rectal Neoplasms
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ AMITRIPTYLINE;CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;FENTANYL;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased exposure to ⮕ FENTANYL;CYP3A4 *1/*22 is associated with increased exposure to fentanyl in healthy individuals as compared to CYP3A4 *1/*1.; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in men with Disease:Helicobacter Infections
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in men with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in men with Disease:Helicobacter Infections
;CARVEDILOL;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*10;*3/*10 + *4/*4;Dosage;increased dose of ⮕ CARVEDILOL;CYP2D6 *3/*10 + *4/*4 is associated with increased dose of carvedilol in people with Heart Failure.; in people with Disease:Heart Failure
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.;or in people with Disease:Helicobacter Infections
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3/*3 + *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.; in people with Disease:Helicobacter Infections
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.;or in people with Disease:Helicobacter Infections
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT/TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;and in people with Disease:Chronic hepatitis C virus infection
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;increased response to ⮕ LANSOPRAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.; in people with Disease:Helicobacter Infections
;VORICONAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;increased exposure to ⮕ VORICONAZOLE;CYP3A4 *22 is associated with increased exposure to voriconazole as compared to CYP3A4 *1/*1.;  
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *4/*4 is associated with decreased metabolism of haloperidol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*4.; in healthy individuals 
;ROSUVASTATIN;SLC10A1;rs56903885;T;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;VITAMIN K1;CYP4F2;CYP4F2*1, CYP4F2*3;*1/*3 + *3/*3;Metabolism/PK;increased exposure to ⮕ VITAMIN K1;CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1.; in healthy individuals 
;TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TROPISETRON;CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype del/del is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;and in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Efficacy;increased response to ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Ulcerative Colitis
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased concentrations of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;Metabolism/PK;decreased metabolism of ⮕ TROPISETRON;CYP2D6 *1/*10 is associated with decreased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ AMITRIPTYLINE;CYP2C19 *2 is associated with decreased metabolism of amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.; in people with Disease:Mental Disorders
;IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased concentrations of ⮕ IMIPRAMINE;CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *2/*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *2/*3 + *2/*2 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;MORPHINE;SLC22A1;SLC22A1 low activity;;Metabolism/PK;low activity increased concentrations of ⮕ MORPHINE;SLC22A1 low activity is associated with increased concentrations of morphine in healthy individuals as compared to SLC22A1 high activity.; in healthy individuals 
;VARENICLINE;CYP2A6;CYP2A6 normal metabolizer;;Efficacy;normal metabolizer increased response to ⮕ VARENICLINE;CYP2A6 normal metabolizer is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to CYP2A6 poor metabolizer.; in people with Disease:Tobacco Use Disorder
;AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;Metabolism/PK;increased dose of ⮕ AZATHIOPRINE;GSTM1 null is associated with increased dose of azathioprine in people with Inflammatory Bowel Diseases as compared to GSTM1 non-null.; in people with Disease:Inflammatory Bowel Diseases
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2, UGT1A8*3;*1a/*3;Metabolism/PK;poor metabolizer increased metabolism of ⮕ RALOXIFENE;UGT1A8 *1a/*3 (assigned as poor metabolizer phenotype) is associated with increased metabolism of raloxifene in women as compared to UGT1A8 *1a/*1a + *1a/*2 + *2/*2 (assigned as intermediate metabolizer and normal metabolizer phenotype) .; in women 
;PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Efficacy;decreased clinical benefit to ⮕ PHENAZEPAM;CYP2C19 *17 is associated with decreased clinical benefit to phenazepam in men with Alcoholism and Anxiety Disorders as compared to CYP2C19 *1.; in men with Other:Alcohol abuse, Other:Anxiety Disorders
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;*5 + *6 + *11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ROSUVASTATIN;NR1I2;rs12721616;T;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;DIMETHYL FUMARATE;GSTP1;rs1695;GG;Efficacy;decreased response to ⮕ DIMETHYL FUMARATE;Genotype GG is associated with decreased response to dimethyl fumarate in people with Psoriasis as compared to genotypes AA + AG.; in people with Disease:Psoriasis
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ CELECOXIB;CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*3.; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*3 + *1/*4 + *1/*5;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.; in people with Disease:Major Depressive Disorder
;ROSUVASTATIN;SLCO1B1;rs11045874;C;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased metabolism of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Ulcerative Colitis
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ CELECOXIB;CYP2C9 *3/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased clearance of ⮕ CELECOXIB;CYP2C9 *1/*3 is associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ ESCITALOPRAM;SLC6A4 HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;Other;increased discontinuation of ⮕ MERCAPTOPURINE;TPMT *1/*3A + *1/*3C + *3A/*3A is associated with increased discontinuation of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;*2 + *3 + *5 + *8 + *11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 + *5 + *8 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;Metabolism/PK;ultrarapid metabolizer increased concentrations of ⮕ O-DESMETHYLTRAMADOL;CYP2D6 ultrarapid metabolizer is associated with increased concentrations of o-desmethyl-tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 normal metabolizer.; in people with Disease:Low Back Pain, Disease:Osteoarthritis
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;Efficacy;decreased response to ⮕ PRIMAQUINE;CYP2D6 *4/*41 + *5/*6 are associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.; in people with Disease:Malaria
;CLOPIDOGREL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;intermediate metabolizer metabolism of ⮕ CLOPIDOGREL;CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with metabolism of clopidogrel in healthy individuals.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *3 is associated with decreased response to clopidogrel as compared to CYP2C19 *1.;  
;TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ TAMOXIFEN;CYP2C19 *2 is associated with decreased metabolism of tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.; in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Efficacy;increased response to ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.;  
;DOXEPIN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4 + *3/*5 + *4/*5;Metabolism/PK;decreased metabolism of ⮕ DOXEPIN;CYP2D6 *4/*4 + *3/*5 + *4/*5 are associated with decreased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;MEPHEDRONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4;Metabolism/PK;increased concentrations of ⮕ MEPHEDRONE;CYP2D6 *1/*9 + *1/*4 + *1/*41 + *2/*4 + *1/*5 + *2/*10 + *1/*41 + *1/*3 + *2/*4 + *1/*4 are associated with increased concentrations of mephedrone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.; in healthy individuals 
;DOXEPIN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*35xN, CYP2D6*41;*1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1;Metabolism/PK;increased metabolism of ⮕ DOXEPIN;CYP2D6 *1xN/*9 + *1xN/*10 + *1xN/*41 + *2xN/*41 + *1xN/*1 + *2xN/*1 + *1xN/*35 + *2xN/*35 + *35xN/*1 are associated with increased metabolism of doxepin in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *1/*9 + *1/*10 + *2/*41 + *35/*41.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Other;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with increased resistance to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.; in people with Disease:Coronary Artery Disease
;CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;Dosage;dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotypes AA + AG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;or in people with Disease:Colorectal Neoplasms
;USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;Efficacy;increased response to ⮕ USTEKINUMAB;HLA-C *06:02 is associated with increased response to ustekinumab in people with Psoriasis.; in people with Disease:Psoriasis
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype TT/TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.;and in people with Disease:Hepatitis C virus infection
;PHENYTOIN;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;Dosage;dose of ⮕ PHENYTOIN;CYP2C19 *2 + *3 is associated with dose of phenytoin in children with Epilepsy.; in children with Disease:Epilepsy
;CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;Efficacy;decreased response to ⮕ CLOZAPINE;SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C is associated with decreased response to clozapine in people with Schizophrenia as compared to SLC6A4 L allele-rs25531T.; in people with Disease:Schizophrenia
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Dosage;dose of ⮕ PHENYTOIN;CYP2C9 *3 is associated with dose of phenytoin in children with Epilepsy.; in children with Disease:Epilepsy
;ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) is associated with increased response to antipsychotics, haloperidol, olanzapine or risperidone in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).;or in people with Disease:Schizophrenia
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome
;FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;increased response to ⮕ FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;and in people with Disease:Rheumatoid arthritis
;TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ TICAGRELOR;CYP3A4 *1/*22 is associated with increased concentrations of ticagrelor in healthy individuals as compared to CYP3A4 *1/*1.; in healthy individuals 
;FLUVASTATIN;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.; in people with Disease:Coronary Artery Disease
;ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;increased metabolism of ⮕ ONDANSETRON;CYP2D6 *1/*1xN is associated with increased metabolism of ondansetron.;  
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""RIBAVIRIN""";HLA-B;HLA-B*44:02;*44:02;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""RIBAVIRIN""";HLA-B *44:02 is associated with increased response to interferon alfa-2a, recombinant and ribavirin in people with Hepatitis C.;and in people with Disease:Hepatitis C virus infection
;ONDANSETRON, TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Efficacy;decreased response to ⮕ ONDANSETRON, TROPISETRON;CYP2D6 *1/*1xN is associated with decreased response to ondansetron or tropisetron in people with Neoplasms.;or in people with Disease:Neoplasms
;CYCLOSPORINE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Metabolism/PK;decreased concentrations of ⮕ CYCLOSPORINE, TACROLIMUS;CYP3A5 *1 is associated with decreased concentrations of cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3.;or in people with Other:Kidney Transplantation
;PRAVASTATIN;ACE;rs1799752;del/del;Efficacy;response to ⮕ PRAVASTATIN;Genotype del/del is associated with response to pravastatin in people with non-hypercholesterolaemic patients scheduled for angioplasty as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Other:non-hypercholesterolaemic patients scheduled for angioplasty
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;Dosage;decreased dose of ⮕ MERCAPTOPURINE;NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2B6 *1/*18 is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*1/*9;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2B6 *1/*9 is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ FLUOXETINE, SERTRALINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).;or in people with Disease:Major Depressive Disorder
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;Dosage;dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotype CT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;or in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17 are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1.;  
;ROSUVASTATIN;SLCO1B1;rs12305884;A;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6 *10 is associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.;and in women with Disease:Breast Neoplasms
;(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased concentrations of ⮕ (S)-METHADONE;CYP2B6 *6/*6 is associated with increased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 + *1/*6.; in people with Disease:Opioid-Related Disorders
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with liver transplantation.; in children with Disease:Liver transplantation
;METOPROLOL;ADRA2C;rs61767072;del;Efficacy;increased response to ⮕ METOPROLOL;Allele del is associated with increased response to metoprolol in people with Heart Failure as compared to allele GGGGCGGGGCCG.; in people with Disease:Heart Failure
;ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased concentrations of ⮕ ENDOXIFEN;CYP3A4 *1/*22 + *22/*22 are associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.; in women with Disease:Breast Neoplasms
;IMATINIB;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ IMATINIB;Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.; in people with Other:Gastrointestinal Stromal Tumors
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2;Metabolism/PK;decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *2/*2 is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *1/*1.; in healthy individuals 
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;Dosage;dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotype AT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.;or in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *2/*2 + *2/*3 are associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased metabolism of clopidogrel as compared to CYP2C19 *1/*1.;  
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TACROLIMUS;CYP3A5 *3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 (assigned as intermediate metabolizer and normal metabolizer phenotype) .; in people with Other:Lung transplantation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased metabolism of ⮕ VINCRISTINE;CYP3A5 *1/*3 is associated with increased metabolism of vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to CYP3A5 *3/*3.; in children with Disease:Acute lymphoblastic leukemia
;ENDOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*4;Metabolism/PK;increased concentrations of ⮕ ENDOXIFEN;CYP2D6 *9/*4 is associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *4/*10 + *4/*41.; in women with Disease:Breast Neoplasms
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *1/*5 + *1/*6;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *1/*4 + *1/*5 + *1/*6 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in women with Disease:Breast Neoplasms
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*41 + *10/*10 + *41/*41;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *9/*41 + *10/*10 + *41/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in women with Disease:Breast Neoplasms
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ PHENPROCOUMON;CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*9 + *1/*10 + *1/*41;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *1/*9 + *1/*10 + *1/*41 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in women with Disease:Breast Neoplasms
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;TPMT *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;Dosage;dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotype CG is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;or in people with Disease:Colorectal Neoplasms
;SIROLIMUS, TEMSIROLIMUS;NR1I2;rs6785049;GG;Metabolism/PK;increased exposure to ⮕ SIROLIMUS, TEMSIROLIMUS;Genotype GG is associated with increased exposure to sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.;and in people with Disease:Urinary Bladder Neoplasms
;FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;CYP2C9 *3 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*4, CYP2D6*5;*4/*4 + *1/*4 + *1/*5;Metabolism/PK;decreased metabolism of ⮕ NORTRIPTYLINE;CYP2D6 *4/*4 + *1/*4 + *1/*5 are associated with decreased metabolism of nortriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2xN.; in healthy individuals 
;ROSUVASTATIN;SLCO1B1;rs11045873;A;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.; in people with Disease:Laparoscopic sleeve gastrectomy
;TACROLIMUS;;rs4646458;G;Dosage;dose of ⮕ TACROLIMUS;Allele G is associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;Dosage;decreased dose of ⮕ NORTRIPTYLINE;CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with decreased dose of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.; in people with Disease:Major Depressive Disorder
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.; in healthy individuals 
;ROCURONIUM;IAPP, SLCO1A2;rs11045995;CC;Dosage;decreased dose of ⮕ ROCURONIUM;Genotype CC is associated with decreased dose of rocuronium in women as compared to genotypes CT + TT.; in women 
;MEASLES VACCINES;HLA-B;HLA-B*44:02;*44:02;Efficacy;response to ⮕ MEASLES VACCINES;HLA-B *44:02 is associated with response to Measles vaccines in children.; in children 
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *3 + *4 + *5 + *6 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.; in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of tacrolimus in people with laparoscopic sleeve gastrectomy as compared to CYP3A5 *3/*3.; in people with Disease:Laparoscopic sleeve gastrectomy
;METOPROLOL;CYP2D6;rs5030655;del/del;Efficacy;increased response to ⮕ METOPROLOL;Genotype del/del is associated with increased response to metoprolol.;  
;AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ AMOXICILLIN, OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.;and in people with Disease:Helicobacter Infections
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;response to ⮕ ALLOPURINOL;HLA-B *58:01 is associated with response to allopurinol.;  
;AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ AMOXICILLIN, OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3.;and in people with Disease:Helicobacter Infections
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*2/*3;Toxicity;decreased dose of ⮕ MERCAPTOPURINE;NUDT15 *2/*3 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*2 + *1/*3 + *1/*5;Toxicity;decreased dose of ⮕ MERCAPTOPURINE;NUDT15 *1/*2 + *1/*3 + *1/*5 are associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;ESTRONE SULFATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;Metabolism/PK;increased  ⮕ ESTRONE SULFATE;SLCO1B1 *5 is associated with increased estrone sulfate in women with Breast Neoplasms as compared to SLCO1B1 *1/*1.; in women with Other:Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;CXCL5;rs352046;CC;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Acute coronary syndrome as compared to genotypes CG + GG.; in people with Disease:Acute coronary syndrome
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ PAROXETINE;CYP2D6 *10/*10 is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ AMOXICILLIN, OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to amoxicillin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.;and in people with Disease:Helicobacter Infections
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage, Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.; in people with Disease:Venous thromboembolism
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;Toxicity;increased discontinuation of ⮕ ATAZANAVIR / RITONAVIR;UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.; in people with Disease:Atrial Fibrillation
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*1/*3 + *1/*13 + *3/*3;Metabolism/PK;decreased clearance of ⮕ CELECOXIB;CYP2C9 *1/*3 + *1/*13 + *3/*3 are associated with decreased clearance of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;DEXTROMETHORPHAN, DEXTRORPHAN;TCF20;rs5758651;C;Metabolism/PK;increased concentrations of ⮕ DEXTROMETHORPHAN, DEXTRORPHAN;Allele C is associated with increased concentrations of dextromethorphan and dextrorphan in healthy individuals as compared to allele T.;and in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *6 + *5 + *11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;*2 + *6 + *5 + *11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *6 + *5 + *11 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1 + *1/*8 + *1/*9 + *9/*9.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel.;  
;CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;decreased concentrations of ⮕ CYCLOSPORINE;CYP3A5 *1/*1 is associated with decreased concentrations of cyclosporine in women as compared to CYP3A5 *3/*3.; in women 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.;and in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes G/TT + GG.;and in people with Disease:Hepatitis C virus infection
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with dose of warfarin.;  
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;*4 + *6 + *8;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *4 + *6 + *8 are associated with decreased concentrations of endoxifen in women with as compared to CYP2D6 *1/*1.; in women with 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes G/TT + GG.;and in people with Disease:Hepatitis C virus infection
;METFORMIN;CSMD1;rs2954625;CT + TT;Efficacy;decreased response to ⮕ METFORMIN;Genotypes CT + TT are associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype CC.; in people with Disease:Diabetes Mellitus
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased discontinuation of ⮕ ATAZANAVIR / RITONAVIR;UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.; in people with Other:HIV infectious disease
;ESTRONE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5/*5;Efficacy;increased concentrations of ⮕ ESTRONE;SLCO1B1 *5/*5 is associated with increased concentrations of estrone in women with Breast Neoplasms as compared to SLCO1B1 *1/*1 + *1/*5.; in women with Other:Breast Neoplasms
;VORICONAZOLE;ABCB1;rs1045642;AA;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;Genotype AA is associated with decreased trough concentration of voriconazole in children as compared to genotypes AG + GG.; in children 
;MERCAPTOPURINE;NT5C2;rs72846714;AA + AG;Metabolism/PK;decreased metabolism of ⮕ MERCAPTOPURINE;Genotypes AA + AG are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;BUPROPION;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;increased exposure to ⮕ BUPROPION;CYP2C19 *2 is associated with increased exposure to bupropion in healthy individuals as compared to CYP2C19 *1.; in healthy individuals 
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *1/*6 + *6/*6 are associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*2;*2/*2;Metabolism/PK;increased concentrations of ⮕ HALOPERIDOL;CYP2D6 *2/*2 is associated with increased concentrations of haloperidol in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*2.; in people with Disease:Schizophrenia
;CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;CYP3A5 *3/*3 is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Kidney Transplantation
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;Efficacy;decreased response to ⮕ IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1 *60 is associated with decreased response to irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.;and in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*1/*8 + *8/*8;Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *1/*8 + *8/*8 are associated with decreased clearance of warfarin as compared to CYP2C9 *1/*1.;  
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10.; in women with Disease:Breast Neoplasms
;SERTRALINE;CYP2C18;rs11188059;GG;Metabolism/PK;decreased concentrations of ⮕ SERTRALINE;Genotype GG is associated with decreased concentrations of sertraline as compared to genotype AA.;  
;SIMVASTATIN;CYP2D6;CYP2D6*1, CYP2D6*14;*14;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN;CYP2D6 *14 is associated with increased concentrations of simvastatin in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4 + *7 + *9;Efficacy;decreased response to ⮕ IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6 *4 + *7 + *9 are associated with decreased response to irinotecan, oxaliplatin and tegafur / gimeracil / oteracil in people with Colorectal Neoplasms as compared to CYP2A6 *1/*1.;and in people with Disease:Colorectal Neoplasms
;DONEPEZIL;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DONEPEZIL;CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) is associated with decreased clearance of donepezil in people with Alzheimer Disease.; in people with Disease:Alzheimer Disease
;NICOTINE;CYP2A6;CYP2A6 high activity;;Efficacy;high activity increased response to ⮕ NICOTINE;CYP2A6 high activity is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to CYP2A6 low activity.; in people with Other:Tobacco Use Disorder
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;Dosage;decreased dose of ⮕ AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT *1/*2 + *1/*3A is associated with decreased dose of azathioprine, mercaptopurine or purine analogues in children with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;or in children with Disease:Inflammatory Bowel Diseases
;FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*29;*29;Metabolism/PK;decreased clearance of ⮕ FENTANYL;CYP2D6 *29 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.; in people with Other:Burns
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*10x2;*10/*10 + *10/*10x2;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 + *10/*10x2 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *1/*1xN + *2/*1xN + *1/*2xN.; in women with Disease:Breast Neoplasms
;LEVONORGESTREL;CYP2B6;rs3745274;GT + TT;Metabolism/PK;decreased concentrations of ⮕ LEVONORGESTREL;Genotypes GT + TT are associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype GG.; in women with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;ADALIMUMAB;;rs9828223;T;Efficacy;decreased response to ⮕ ADALIMUMAB;Allele T is associated with decreased response to adalimumab in people with Crohn Disease as compared to allele C.; in people with Other:Crohn Disease
;DEXTROMETHORPHAN, DEXTRORPHAN;IP6K2;rs61740999;AG;Metabolism/PK;increased concentrations of ⮕ DEXTROMETHORPHAN, DEXTRORPHAN;Genotype AG is associated with increased concentrations of dextromethorphan and dextrorphan in healthy individuals as compared to genotype GG.;and in healthy individuals 
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;increased response to ⮕ FLUOROURACIL;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.; in people with Other:Colorectal Neoplasms
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29/*29;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE;CYP2D6 *29/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*29.; in healthy individuals 
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*29;*17/*29;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE;CYP2D6 *17/*29 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*17.; in healthy individuals 
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ ESCITALOPRAM;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;PROGESTERONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;Metabolism/PK;increased exposure to ⮕ PROGESTERONE;CYP2C19 *1/*2 + *2/*17 are associated with increased exposure to progesterone in women as compared to CYP2C19 *1/*1.; in women 
;DEBRISOQUINE, METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17;*17/*17;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE, METOPROLOL;CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine or metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.;or in healthy individuals 
;DONEPEZIL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN + *1xN/*1xN;Metabolism/PK;ultrarapid metabolizer increased clearance of ⮕ DONEPEZIL;CYP2D6 *1/*1xN + *1xN/*1xN (assigned as ultrarapid metabolizer phenotype) is associated with increased clearance of donepezil in people with Alzheimer Disease.; in people with Disease:Alzheimer Disease
;CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6 *1/*6 + *6/*6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.;and in people with Disease:Leukemia, Lymphocytic, Chronic, B-Cell
;LEVONORGESTREL;CYP2B6;rs4803419;CT;Metabolism/PK;decreased concentrations of ⮕ LEVONORGESTREL;Genotype CT is associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype CC.; in women with Disease:HIV infectious disease
;ATORVASTATIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;decreased clearance of ⮕ ATORVASTATIN;Genotype CC is associated with decreased clearance of atorvastatin.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;poor metabolizer increased dose of ⮕ CLOPIDOGREL;CYP2C19 *2 (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to CYP2C19 *1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;CILOSTAZOL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Metabolism/PK;increased concentrations of ⮕ CILOSTAZOL;CYP2C19 *2 + *3 are associated with increased concentrations of cilostazol in healthy individuals as compared to CYP2C19 *1.; in healthy individuals 
;CODEINE, DEBRISOQUINE, DEXTROMETHORPHAN, METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*17;*5/*17;Metabolism/PK;decreased metabolism of ⮕ CODEINE, DEBRISOQUINE, DEXTROMETHORPHAN, METOPROLOL;CYP2D6 *5/*17 is associated with decreased metabolism of codeine, debrisoquine, dextromethorphan or metoprolol in healthy individuals as compared to CYP2D6 *17/*17 + *1/*1.;or in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *2 + *3 are associated with decreased metabolism of clopidogrel in healthy individuals as compared to CYP2C19 *1.; in healthy individuals 
;SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;increased exposure to ⮕ SORAFENIB;UGT1A1 *1/*28 + *28/*28 are associated with increased exposure to sorafenib in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*29;*29/*29;Metabolism/PK;decreased metabolism of ⮕ METOPROLOL;CYP2D6 *29/*29 is associated with decreased metabolism of metoprolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ FLUOXETINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased dose of ⮕ CLOBAZAM;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.; in people with Disease:Epilepsy
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *17 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1.; in healthy individuals 
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;metabolism of ⮕ CLOBAZAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in people with Disease:Epilepsy
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;Metabolism/PK;decreased clearance of ⮕ OMEPRAZOLE;CYP2C19 *2 is associated with decreased clearance of omeprazole in infants with Gastroesophageal Reflux as compared to CYP2C19 *1 + *17.; in infants with Disease:Gastroesophageal Reflux
;ATENOLOL, ENALAPRIL;ACE;rs1799752;del/del;Efficacy;increased resistance to ⮕ ATENOLOL, ENALAPRIL;Genotype del/del is associated with increased resistance to atenolol and enalapril in people with Kidney Diseases as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;and in people with Disease:Kidney Disorder
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*3C + *1/*2 + *1/*3A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;TPMT *1/*3C + *1/*2 + *1/*3A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.; in children with Disease:Acute lymphoblastic leukemia
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;metabolism of ⮕ CLOBAZAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in people with Disease:Epilepsy
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;decreased resistance to ⮕ CLOBAZAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased resistance to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in people with Disease:Epilepsy
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.; in women with Disease:HIV infectious disease
;LOPINAVIR;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;Metabolism/PK;decreased clearance of ⮕ LOPINAVIR;CYP3A4 *22/*22 is associated with decreased clearance of lopinavir in people with HIV Infections as compared to CYP3A4 *1/*1 + *1/*22.; in people with Other:HIV infectious disease
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;metabolism of ⮕ CLOBAZAM;CYP2C19 *1/*1 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.; in people with Disease:Epilepsy
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;increased response to ⮕ CLOBAZAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.; in people with Disease:Epilepsy
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*4/*9 + *9/*9;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *4/*9 + *9/*9 are associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 + *1/*4 + *1/*9.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Metabolism/PK;poor metabolizer increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*1 (assigned as poor metabolizer phenotype) is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;EFAVIRENZ;ABCB1;rs3842;C;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.; in people with Disease:HIV infectious disease
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;metabolism of ⮕ CLOBAZAM;CYP2C19 *1/*2 is associated with metabolism of clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.; in people with Disease:Epilepsy
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;decreased response to ⮕ CAPTOPRIL;Genotype del/del is associated with decreased response to captopril in healthy individuals as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in healthy individuals 
;CITALOPRAM, FLUOXETINE;SERPINE1;rs2227631;G;Efficacy;decreased response to ⮕ CITALOPRAM, FLUOXETINE;Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.;and in people with Disease:Major Depressive Disorder
;PHENYTOIN;CYP2C9;rs71486745;GT/del + del/del;Dosage, Metabolism/PK;decreased dose of ⮕ PHENYTOIN;Genotypes GT/del + del/del are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GTGT.; in people with Disease:Epilepsy
;ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;rs201279313;TTA/del;Efficacy;increased response to ⮕ ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;Genotype TTA/del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to genotype TTA/TTA.;or in people with Disease:Hypertension
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;Metabolism/PK;increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*17 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Disease:Kidney Transplantation
;CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ CAPTOPRIL;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.; in people with Disease:Diabetes Mellitus
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;decreased response to ⮕ FLUOROURACIL;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.; in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.; in people with Disease:Kidney Transplantation
;TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Efficacy, Metabolism/PK;decreased response to ⮕ TAMOXIFEN;CYP2C19 *17 is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.; in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;Dosage;increased dose of ⮕ WARFARIN;CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3.;  
;TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy, Metabolism/PK;increased response to ⮕ TAMOXIFEN;CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.; in women with Disease:Breast Neoplasms
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;decreased response to ⮕ CAPTOPRIL;Genotype del/del is associated with decreased response to captopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Heart Failure
;MERCAPTOPURINE;CNNM2;rs58700372;CC + CT;Metabolism/PK;decreased metabolism of ⮕ MERCAPTOPURINE;Genotypes CC + CT are associated with decreased metabolism of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Other:Acute lymphoblastic leukemia
;OXYCODONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;increased dose of ⮕ OXYCODONE;CYP3A5 *3/*3 is associated with increased dose of oxycodone in people with Neoplasms as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*1 + *1/*17 is associated with decreased trough concentration of voriconazole in people with Hematologic Diseases as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *3/*3.; in people with Disease:Hematologic Disorder
;MONTELUKAST;UGT1A3;UGT1A3*1, UGT1A3*2;*2;Metabolism/PK;decreased concentrations of ⮕ MONTELUKAST;UGT1A3 *2 is associated with decreased concentrations of montelukast in healthy individuals as compared to UGT1A3 *1/*1.; in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Metabolism/PK;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.;  
;FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/del;Efficacy;decreased response to ⮕ FLUOROURACIL;Genotype TTAAAGTTA/del is associated with decreased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.; in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;Efficacy;decreased response to ⮕ PRIMAQUINE;CYP2D6 *4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41 is associated with decreased response to primaquine in people with Malaria as compared to CYP2D6 *1/*10 + *1/*41 + *1/*9 + *2/*10 + *2/*41 + *1/*1 + *1/*2 + *2/*2.; in people with Disease:Malaria
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.;  
;SERTRALINE;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ SERTRALINE;Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.; in people with Disease:Depressive Disorder
;ROSUVASTATIN;ABCC2;rs17216177;C;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele C is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele T.; in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ PHENYTOIN;CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1.;  
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;Metabolism/PK;decreased clearance of ⮕ PRIMAQUINE;CYP2D6 *4/*41 + *5/*6 are associated with decreased clearance of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.; in people with Disease:Malaria
;CILOSTAZOL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;intermediate metabolizer decreased concentrations of ⮕ CILOSTAZOL;CYP3A5 *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of cilostazol in healthy individuals as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *10/*10 + *5/*10 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*5.; in women with Disease:Breast Neoplasms
;RASAGILINE;SLC22A1;rs12208357;CT;Metabolism/PK;decreased clearance of ⮕ RASAGILINE;Genotype CT is associated with decreased clearance of rasagiline in healthy individuals as compared to genotype CC.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in children with Disease:Kidney Transplantation
;ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.;or in people with Disease:Helicobacter Infections
;TACROLIMUS;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1A/*1A;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;CYP3A7 *1A/*1A is associated with decreased concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A7 *1A/*1C + *1C/*1C.; in children with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;COTININE, NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*2 + *4 + *9 + *12;Metabolism/PK;decreased clearance of ⮕ COTININE, NICOTINE;CYP2A6 *2 + *4 + *9 + *12 are associated with decreased clearance of cotinine and nicotine in healthy individuals as compared to CYP2A6 *1.;and in healthy individuals 
;KETAMINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased clearance of ⮕ KETAMINE;CYP2B6 *6 is associated with decreased clearance of ketamine in people with Neoplasms and Pain as compared to CYP2B6 *1.; in people with Disease:Neoplasms, Disease:Pain
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE;CYP2D6 *10/*10 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19 *2/*2 + *2/*3 are associated with increased response to esomeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.;or in people with Disease:Helicobacter Infections
;ROSUVASTATIN;ABCC2;rs7899457;T;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 are associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;or in people with Disease:Helicobacter Infections
;ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.;or in people with Disease:Helicobacter Infections
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;ROSUVASTATIN;ABCC2;rs8187706;A;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*1;Metabolism/PK;increased clearance of ⮕ FLURBIPROFEN;CYP2C9 *1/*1 is associated with increased clearance of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*3.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;PITAVASTATIN;ABCC2;rs717620;T;Metabolism/PK;decreased exposure to ⮕ PITAVASTATIN;Allele T is associated with decreased exposure to pitavastatin in healthy individuals as compared to allele C.; in healthy individuals 
;ETHANOL;SLC6A3;rs28363170;del;Other;increased response to ⮕ ETHANOL;Allele del is associated with increased response to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.; in healthy individuals 
;ETHANOL;DRD2;rs1800497;A;Dosage;increased dose of ⮕ ETHANOL;Allele A is associated with increased dose of ethanol in children as compared to allele G.; in children 
;VARDENAFIL;CYP3A5;rs776746;TT;Other, Metabolism/PK;increased clearance of ⮕ VARDENAFIL;Genotype TT is associated with increased clearance of vardenafil in men as compared to genotypes CC + CT.; in men 
;SIPOGLITAZAR;UGT2B15;UGT2B15*1, UGT2B15*2;*2;Metabolism/PK;decreased clearance of ⮕ SIPOGLITAZAR;UGT2B15 *2 is associated with decreased clearance of sipoglitazar in healthy individuals as compared to UGT2B15 *1.; in healthy individuals 
;ETHANOL;SLC6A3;rs28363170;del;Toxicity;increased exposure to ⮕ ETHANOL;Allele del is associated with increased exposure to ethanol in healthy individuals as compared to allele GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT.; in healthy individuals 
;ETHANOL;OPRM1;rs1799971;G;Dosage;increased dose of ⮕ ETHANOL;Allele G is associated with increased dose of ethanol in children as compared to allele A.; in children 
;IMATINIB;SLC22A1;rs683369;CC;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ IMATINIB;Genotype CC is associated with decreased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CG + GG.; in people with Other:Gastrointestinal Stromal Tumors
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;increased resistance to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with increased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased resistance to ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased resistance to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*1.; in people with Disease:Gastroesophageal Reflux
;ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;Metabolism/PK;increased clearance of ⮕ ACETAMINOPHEN;UGT1A6 *2a is associated with increased clearance of acetaminophen in people with beta-Thalassemia as compared to UGT1A6 *1a.; in people with Disease:Beta-thalassemia and related diseases
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.; in people with Disease:Atrial Fibrillation, Disease:Atrial Flutter, Disease:Venous Thrombosis
;ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a/*2a + *1a/*2a;Metabolism/PK;increased metabolism of ⮕ ACETAMINOPHEN;UGT1A6 *2a/*2a + *1a/*2a is associated with increased metabolism of acetaminophen in healthy individuals as compared to UGT1A6 *1a.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;ACETAMINOPHEN;UGT2B15;UGT2B15*1, UGT2B15*2;*2;Metabolism/PK;decreased metabolism of ⮕ ACETAMINOPHEN;UGT2B15 *2 is associated with decreased metabolism of acetaminophen in healthy individuals as compared to UGT2B15 *1.; in healthy individuals 
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;METHADONE;OPRK1;rs3802281;TT;Dosage;decreased dose of ⮕ METHADONE;Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.; in people with Other:Heroin Dependence
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17;*1/*17;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE;CYP2D6 *1/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17;*17/*17;Metabolism/PK;decreased metabolism of ⮕ DEBRISOQUINE;CYP2D6 *17/*17 is associated with decreased metabolism of debrisoquine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*17.; in healthy individuals 
;AZATHIOPRINE;TPMT;rs1142345;CT;Dosage;decreased dose of ⮕ AZATHIOPRINE;Genotype CT is associated with decreased dose of azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.; in children with Other:Ulcerative Colitis, Other:Crohn Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;Metabolism/PK;decreased metabolism of ⮕ TOLTERODINE;CYP2D6 *3 + *4 are associated with decreased metabolism of tolterodine in women as compared to CYP2D6 *1/*1.; in women 
;CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;Efficacy;decreased response to ⮕ CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6 *1xN + *2xN are associated with decreased response to citalopram, mianserin, mirtazapine, nortriptyline, paroxetine or venlafaxine in people with Mood Disorders.;or in people with Disease:Mood Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentrations of tacrolimus in people with Autoimmune Diseases as compared to CYP3A5 *3/*3.; in people with Disease:Autoimmune Diseases
;HYDROXYUREA;SIN3A;rs7166737;GG;Efficacy;decreased response to ⮕ HYDROXYUREA;Genotype GG is associated with decreased response to hydroxyurea in people with Beta-thalassemia and related diseases as compared to genotypes AA + AG.; in people with Other:Beta-thalassemia and related diseases
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;decreased clearance of ⮕ RABEPRAZOLE;CYP2C19 *2/*2 + *2/*3 is associated with decreased clearance of rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ FLUOXETINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator decreased metabolism of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.; in people with Other:Hypertension
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799964;TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CC + CT.; in people with Disease:Spondylitis, Ankylosing
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;increased response to ⮕ WARFARIN;CYP2C9 *1/*3 is associated with increased response to warfarin as compared to CYP2C9 *1/*1.;  
;PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ PROPAFENONE;CYP2D6 *10/*10 is associated with decreased metabolism of propafenone in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*6;*1/*1 + *1/*6;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*6 is associated with increased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *6/*6.; in healthy individuals 
;CAPECITABINE, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased response to ⮕ CAPECITABINE, RALTITREXED;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to capecitabine and raltitrexed in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.;and in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*7;*1/*1 + *1/*7;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*7 is associated with increased clearance of tacrolimus in healthy individuals as compared to CYP3A5 *7/*7.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*1;Dosage;increased dose of ⮕ WARFARIN;CYP2C9 *1/*1 is associated with increased dose of warfarin as compared to CYP2C9 *1/*3.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 + *3 are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.; in Other:Elderly Adult
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;G/TT + TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotypes G/TT + TT/TT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;and in people with Disease:Chronic hepatitis C virus infection
;VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizer;;Metabolism/PK;normal metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 normal metabolizer is associated with decreased metabolism of venlafaxine in Elderly Adult.; in Other:Elderly Adult
;RASAGILINE;SLC22A1;rs34059508;AG;Metabolism/PK;increased clearance of ⮕ RASAGILINE;Genotype AG is associated with increased clearance of rasagiline in healthy individuals as compared to genotype GG.; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19 normal metabolizer;;Metabolism/PK;normal metabolizer decreased metabolism of ⮕ ESCITALOPRAM;CYP2C19 normal metabolizer is associated with decreased metabolism of escitalopram in Elderly Adult.; in Other:Elderly Adult
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.; in people with Disease:Epilepsy
;LOVASTATIN ACID;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15;*5/*15 + *15/*15;Metabolism/PK;increased exposure to ⮕ LOVASTATIN ACID;SLCO1B1 *5/*15 + *15/*15 are associated with increased exposure to lovastatin acid in healthy individuals as compared to SLCO1B1 *1/*1.; in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;Metabolism/PK;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.; in children with 
;FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ FLURBIPROFEN;CYP2C9 *1/*3 is associated with increased concentrations of flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;AMBRISENTAN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*17;*2 + *3 + *4;Metabolism/PK;decreased clearance of ⮕ AMBRISENTAN;CYP2C19 *2 + *3 + *4 are associated with decreased clearance of ambrisentan in healthy individuals as compared to CYP2C19 *1 + *17.; in healthy individuals 
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1 + *1/*6.; in healthy individuals 
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased clearance of ⮕ CYCLOPHOSPHAMIDE;CYP2B6 *6 is associated with decreased clearance of cyclophosphamide in children with Lymphoma, B-Cell as compared to CYP2B6 *1/*1.; in children with Disease:Lymphoma, B-Cell
;SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ SERTRALINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with posttraumatic stress disorder as compared to SLC6A4 HTTLPR short form (S allele).; in people with Other:posttraumatic stress disorder
;RASAGILINE;ABCC2;rs2273697;AA;Metabolism/PK;decreased clearance of ⮕ RASAGILINE;Genotype AA is associated with decreased clearance of rasagiline in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;BUPROPION;HTR2A;rs2770296;CC;Efficacy;increased response to ⮕ BUPROPION;Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Other:Major Depressive Disorder
;CAPECITABINE, FLUOROURACIL;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;Efficacy;increased response to ⮕ CAPECITABINE, FLUOROURACIL;Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.;or in people with Disease:Colorectal Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer;*2/*2 + *2/*3;Metabolism/PK;poor metabolizer increased trough concentration of ⮕ VORICONAZOLE;Genotypes *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .; in people with Disease:Fungal infectious disease
;PRAVASTATIN;KIF6;rs20455;AG + GG;Efficacy;increased response to ⮕ PRAVASTATIN;Genotypes AG + GG are associated with increased response to pravastatin in people with Myocardial Infarction as compared to genotype AA.; in people with Disease:Myocardial Infarction
;FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;increased response to ⮕ FLUVOXAMINE;SLC6A4 HTTLPR short form (S allele) is associated with increased response to fluvoxamine in people with Depressive Disorder, Major.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *2/*2 is associated with decreased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.; in children 
;DONEPEZIL;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DONEPEZIL;CYP2D6 poor metabolizer is associated with decreased metabolism of donepezil in people with Alzheimer Disease as compared to CYP2D6 normal metabolizer.; in people with Disease:Alzheimer Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *10/*10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *4/*5 + *4/*6;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4/*4 + *4/*5 + *4/*6 are associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;FLUOXETINE;ABCB1;rs2032582;A;Efficacy;increased response to ⮕ FLUOXETINE;Allele A is associated with increased response to fluoxetine in children with Depressive Disorder as compared to allele C.; in children with Disease:Depressive Disorder
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6 *4/*4 + *4/*5 are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with as compared to CYP2D6 *1/*1.;and in women with 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased exposure to ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased exposure to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Kidney Transplantation
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;increased exposure to ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 + *1/*10 is associated with increased exposure to dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Efficacy;increased response to ⮕ BUPROPION;CYP2B6 *1/*6 + *6/*6 are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1.; in people with Other:Tobacco Use Disorder
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;DIPYRONE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ DIPYRONE;CYP2C19 *2 is associated with decreased metabolism of dipyrone in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ FLUOXETINE, SERTRALINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).;or in people with Disease:Major Depressive Disorder
;TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *4/*4 + *4/*7 + *4/*9;Metabolism/PK;decreased metabolism of ⮕ TEGAFUR;CYP2A6 *1/*4 + *4/*4 + *4/*7 + *4/*9 are associated with decreased metabolism of tegafur in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2A6 *1/*1 + *1/*7 + *1/*9 + *7/*7 + *7/*9.; in people with Disease:Non-Small Cell Lung Carcinoma
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;increased response to ⮕ ESCITALOPRAM;SLC6A4 HTTLPR short form (S allele) is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).; in people with Disease:Major Depressive Disorder
;AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;Efficacy;decreased clinical benefit to ⮕ AZATHIOPRINE;GSTM1 null is associated with decreased clinical benefit to azathioprine in children with Colitis, Ulcerative or Crohn Disease as compared to GSTM1 non-null.; in children with Other:Ulcerative Colitis, Other:Crohn Disease
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*10 + *5/*10;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4/*10 + *5/*10 are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2.; in children 
;NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;Dosage;decreased dose of ⮕ NILOTINIB;UGT1A1 *6/*6 + *6/*28 is associated with decreased dose of nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*6 + *1/*28 + *27/*28.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;COTININE, NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6;Metabolism/PK;increased clearance of ⮕ COTININE, NICOTINE;CYP2B6 *1/*6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 *1/*1.;and in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased clearance of ⮕ METHADONE;CYP2B6 *6 is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1.; in people with Disease:Opioid-Related Disorders
;BUPROPION;DBH;rs2873804;CC;Efficacy;increased response to ⮕ BUPROPION;Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Other:Major Depressive Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Rheumatoid arthritis, Disease:Systemic lupus erythematosus
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;and in people with Disease:Neoplasm of esophagus, Disease:Stomach Neoplasms
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator decreased metabolism of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with decreased metabolism of hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.; in people with Other:Hypertension
;PACLITAXEL, PLATINUM COMPOUNDS;GSTM1;GSTM1 non-null, GSTM1 null;non-null;Efficacy;decreased response to ⮕ PACLITAXEL, PLATINUM COMPOUNDS;GSTM1 non-null is associated with decreased response to paclitaxel and Platinum compounds in women with Ovarian Neoplasms as compared to GSTM1 null.;and in women with Disease:Ovarian Neoplasms
;BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;Efficacy;increased response to ⮕ BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1 non-null/non-null is associated with increased response to bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null.;and in people with Disease:Hodgkin Disease
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ CITALOPRAM;CYP2C19 *2 is associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.; in people with Disease:Major Depressive Disorder
;ENALAPRIL, LISINOPRIL;ACE;rs1799752;del/del;Efficacy;increased clinical benefit to ⮕ ENALAPRIL, LISINOPRIL;Genotype del/del is associated with increased clinical benefit to enalapril or lisinopril in men with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;or in men with Other:Hypertension
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *1/*3 + *3/*3 are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.; in people with Disease:Kidney Transplantation
;TRIMIPRAMINE;CYP2C9;CYP2C9*3;*3/*3;Metabolism/PK;decreased metabolism of ⮕ TRIMIPRAMINE;CYP2C9 *3/*3 is associated with decreased metabolism of trimipramine in healthy individuals.; in healthy individuals 
;BUPROPION;SLC18A2;rs363225;CC;Efficacy;increased response to ⮕ BUPROPION;Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Other:Major Depressive Disorder
;TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;Metabolism/PK;decreased clearance of ⮕ TRIMIPRAMINE;CYP2D6 *3 + *4 + *5 + *6 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*6;*1/*4 + *4/*6;Metabolism/PK;increased clearance of ⮕ METHADONE;CYP2B6 *1/*4 + *4/*6 is associated with increased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ OMEPRAZOLE;CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;RALTEGRAVIR;UGT1A9;UGT1A9*3a;*3a;Metabolism/PK;increased exposure to ⮕ RALTEGRAVIR;UGT1A9 *3a is associated with increased exposure to raltegravir in people with HIV.; in people with Disease:HIV infectious disease
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased response to ⮕ OMEPRAZOLE;CYP2C19 *2/*2 + *2/*3 is associated with increased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.; in healthy individuals 
;FLUVOXAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ FLUVOXAMINE;CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Metabolism/PK;decreased clearance of ⮕ METHADONE;CYP2B6 *1/*6 + *6/*6 is associated with decreased clearance of methadone in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;FLUVOXAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ FLUVOXAMINE;CYP2D6 poor metabolizer is associated with decreased clearance of fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;SERTRALINE;CYP2C18;rs2860840;TT;Metabolism/PK;decreased concentrations of ⮕ SERTRALINE;Genotype TT is associated with decreased concentrations of sertraline as compared to genotype CC.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to CYP2C9 *1/*1.; in people with Disease:Rheumatic Heart Disease
;ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ ARIPIPRAZOLE;CYP2D6 poor metabolizer is associated with decreased metabolism of aripiprazole in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;increased concentrations of ⮕ 4-HYDROXYTAMOXIFEN;CYP3A4 *22 is associated with increased concentrations of 4-hydroxytamoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.; in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;increased concentrations of ⮕ TAMOXIFEN;CYP3A4 *22 is associated with increased concentrations of tamoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.; in women with Disease:Breast Neoplasms
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3 + *2/*3.; in healthy individuals 
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;increased response to ⮕ FLUOROURACIL;Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.; in people with Other:Rectal Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*1 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*3 + *2/*3.; in people with Disease:Fungal infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotypes CT + TT.; in people with Disease:Spondylitis, Ankylosing
;HYDROXYAMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased concentrations of ⮕ HYDROXYAMITRIPTYLINE;CYP2D6 *10/*10 is associated with decreased concentrations of hydroxyamitriptyline in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.; in healthy individuals 
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;increased exposure to ⮕ AMITRIPTYLINE;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased exposure to amitriptyline in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;ACETYLCYSTEINE;EPHX1;EPHX1 poor metabolizer;;Efficacy;poor metabolizer increased response to ⮕ ACETYLCYSTEINE;EPHX1 poor metabolizer is associated with increased response to acetylcysteine in people with Pulmonary Disease, Chronic Obstructive as compared to genotype fast/normal (assigned as intermediate metabolizer and normal metabolizer phenotype) .; in people with Disease:Chronic Obstructive Pulmonary Disease
;BUPROPION;SLC18A2;rs363226;GG;Efficacy;increased response to ⮕ BUPROPION;Genotype GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CG.; in people with Other:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;increased response to ⮕ METHOTREXATE;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.; in people with Disease:Rheumatoid arthritis
;OLANZAPINE;GSTM3;rs1799735;CCT/CCT;Metabolism/PK;increased clearance of ⮕ OLANZAPINE;Genotype CCT/CCT is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.; in healthy individuals 
;LEVODOPA, METHYLPHENIDATE;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;Efficacy;increased response to ⮕ LEVODOPA, METHYLPHENIDATE;Genotype ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA is associated with increased response to levodopa and methylphenidate in people with Parkinson Disease as compared to genotypes ACATACACACTCAGACACACATACCATGCA/del + del/del.;and in people with Disease:Parkinson Disease
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;Metabolism/PK;decreased clearance of ⮕ ATOMOXETINE;CYP2D6 *4/*4xN + *4/*4 are associated with decreased clearance of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *3/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.; in children with Disease:Heart Diseases
;LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;Efficacy;increased response to ⮕ LEVODOPA;Genotype ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA is associated with increased response to levodopa in people with Parkinson Disease as compared to genotypes ACATACACACTCAGACACACATACCATGCA/del + del/del.; in people with Disease:Parkinson Disease
;FLUOROURACIL;DPYD;DPYD deficiency;;Metabolism/PK;deficiency clearance of ⮕ FLUOROURACIL;DPYD deficiency is associated with clearance of fluorouracil in people with Head and Neck Neoplasms.; in people with Disease:Head and Neck Neoplasms
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;Metabolism/PK;increased concentrations of ⮕ ATOMOXETINE;CYP2D6 *4/*4xN + *4/*4 are associated with increased concentrations of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*1 + *1/ *2 + *2/*4 + *1/*4 + *1/*3 + *2/*5 + *10/*41 + *9/*29 + *5/*17 + *4/*9.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;BUPROPION;FKBP5;rs17614642;TT;Efficacy;decreased response to ⮕ BUPROPION;Genotype TT is associated with decreased response to bupropion in people with Depressive Disorder, Major as compared to genotype CT.; in people with Other:Major Depressive Disorder
;ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3 + *6 + *7;Metabolism/PK;decreased metabolism of ⮕ ATAZANAVIR;CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.; in children with Disease:Heart Diseases
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 *1/*1.; in children with Disease:Heart Diseases
;INTERFERON BETA-1A;ACE;rs1799752;del/del;Efficacy;decreased response to ⮕ INTERFERON BETA-1A;Genotype del/del is associated with decreased response to interferon beta-1a in men Multiple Sclerosis.; in men Disease:Multiple Sclerosis
;ETHANOL;OPRM1;rs1799971;AG;Efficacy;increased response to ⮕ ETHANOL;Genotype AG is associated with increased response to ethanol in men as compared to genotype AA.; in men 
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Metabolism/PK;increased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *2/*2 are associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.; in healthy individuals 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;WARFARIN;EPHX1;rs2260863;CG;Dosage;increased dose of ⮕ WARFARIN;Genotype CG is associated with increased dose of warfarin as compared to genotype CC.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Lung transplantation
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased metabolism of ⮕ PANTOPRAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.; in healthy individuals 
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ CAPTOPRIL;Genotype del/del is associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Diabetes Mellitus, Type 2
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 are associated with increased response to omeprazole in people with Esophagitis and Gastroesophageal Reflux as compared to CYP2C19 *1/*1.; in people with Disease:Esophagitis, Disease:Gastroesophageal Reflux
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;LOSARTAN;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ LOSARTAN;Genotype del/del is associated with increased response to losartan in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Diabetes Mellitus, Type 2
;TACROLIMUS;CYP3A4;rs35599367;GG;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotype GG is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Disease:Kidney Transplantation
;THALIDOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Dosage;increased dose of ⮕ THALIDOMIDE;CYP2C19 *2 is associated with increased dose of thalidomide in people with Erythema Nodosum and Leprosy as compared to CYP2C19 *1/*1.; in people with Disease:Erythema Nodosum, Disease:Leprosy
;CARVEDILOL;CYP2D6;CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ CARVEDILOL;CYP2D6 *10 is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to CYP2D6 *1.; in people with Disease:Angina Pectoris
;EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;Metabolism/PK;increased clearance of ⮕ EFAVIRENZ;CYP2B6 *1/*1 is associated with increased clearance of efavirenz in people with HIV.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to CYP2C9 *1/*1.; in people with Other:Atrial Fibrillation, Other:Pulmonary Embolism, Other:Venous Thrombosis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 is associated with increased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.; in people with Disease:Kidney Transplantation
;NICOTINE;CYP2A6;CYP2A6 low activity;;Dosage;low activity decreased dose of ⮕ NICOTINE;CYP2A6 low activity is associated with decreased dose of nicotine in people with Tobacco Use Disorder.; in people with Disease:Tobacco Use Disorder
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*2 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *2/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;IMATINIB;CYP3A5;rs776746;CC;Metabolism/PK;increased trough concentration of ⮕ IMATINIB;Genotype CC is associated with increased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;PACLITAXEL;SLCO1B1;SLCO1B1*5, SLCO1B1*15;*5 + *15;Metabolism/PK;increased exposure to ⮕ PACLITAXEL;SLCO1B1 *5 + *15 is associated with increased exposure to paclitaxel in women with Breast Neoplasms.; in women with Disease:Breast Neoplasms
;IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3 + *2/*2;Metabolism/PK;decreased metabolism of ⮕ IMIPRAMINE;CYP2C19 *2/*3 + *2/*2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.; in people with Disease:Major Depressive Disorder
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;LAMOTRIGINE;UGT2B7;rs7668258;CC;Dosage, Metabolism/PK;increased clearance of ⮕ LAMOTRIGINE;Genotype CC is associated with increased clearance of lamotrigine as compared to genotypes CT + TT.;  
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;BUPRENORPHINE;UGT2B7;UGT2B7;*2;Efficacy;decreased response to ⮕ BUPRENORPHINE;Genotype *2 is associated with decreased response to buprenorphine in people with Pain as compared to genotype *1.; in people with Disease:Pain
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Dosage;increased dose of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 is associated with increased dose of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *2/*2 is associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;IMATINIB;ABCB1;rs1045642;AG;Metabolism/PK;decreased trough concentration of ⮕ IMATINIB;Genotype AG is associated with decreased trough concentration of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;Metabolism/PK;decreased clearance of ⮕ TOLBUTAMIDE;CYP2C9 *1/*3 + *2/*3 + *3/*3 are associated with decreased clearance of tolbutamide in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *6/*6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*6;*1/*4 + *4/*6;Metabolism/PK;increased metabolism of ⮕ BUPROPION;CYP2B6 *1/*4 + *4/*6 are associated with increased metabolism of bupropion in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with concentrations of endoxifen in women with Breast Neoplasms.; in women with Disease:Breast Neoplasms
;ZAFIRLUKAST;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*1/*3 + *1/*13;Metabolism/PK;increased exposure to ⮕ ZAFIRLUKAST;CYP2C9 *1/*3 + *1/*13 are associated with increased exposure to zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;DEXLANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;decreased metabolism of ⮕ DEXLANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 are associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;ZAFIRLUKAST;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*1/*3 + *1/*13;Metabolism/PK;decreased clearance of ⮕ ZAFIRLUKAST;CYP2C9 *1/*3 + *1/*13 are associated with decreased clearance of zafirlukast in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ NELFINAVIR;CYP2C19 *1/*2 is associated with decreased metabolism of nelfinavir in people with as compared to CYP2C19 *1/*1.; in people with 
;HYDROXYBUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;decreased concentrations of ⮕ HYDROXYBUPROPION;CYP2B6 *6/*6 is associated with decreased concentrations of hydroxybupropion as compared to CYP2B6 *1/*1 + *1/*6.;  
;NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;increased concentrations of ⮕ NELFINAVIR;CYP2C19 *1/*2 is associated with increased concentrations of nelfinavir in people with Pancreatic Neoplasms as compared to CYP2C19 *1/*1.; in people with Disease:Pancreatic Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*1/*6 + *1/*18;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *1/*6 + *1/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.; in people with Disease:Tobacco Use Disorder
;IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;Efficacy;increased response to ⮕ IVACAFTOR, TEZACAFTOR;Genotype del/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype TT/TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;or in people with Disease:Chronic hepatitis C virus infection
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*6/*6 + *6/*18;Metabolism/PK;decreased metabolism of ⮕ BUPROPION;CYP2B6 *6/*6 + *6/*18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 *1/*1 + *1/*4 + *1/*5 + *1/*22 + *22/*22.; in people with Disease:Tobacco Use Disorder
;IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;CTT/del;Efficacy;increased response to ⮕ IVACAFTOR, TEZACAFTOR;Genotype CTT/del is associated with increased response to ivacaftor and tezacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Dosage;increased dose of ⮕ WARFARIN;CYP2C19 *1/*2 + *1/*3 are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *2/*2 + *2/*3.; in people with Disease:Atrial Fibrillation
;WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Dosage;increased dose of ⮕ WARFARIN;CYP2C19 *1/*1 is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.; in people with Disease:Atrial Fibrillation
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ ATOMOXETINE;CYP2D6 *10/*10 is associated with decreased clearance of atomoxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*10.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *6/*6.; in people with Disease:Kidney Transplantation
;ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Dosage;poor metabolizer decreased dose of ⮕ ATOMOXETINE;CYP2D6 poor metabolizer is associated with decreased dose of atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;GEMCITABINE;CDA;rs60369023;A;Other, Metabolism/PK;decreased metabolism of ⮕ GEMCITABINE;Allele A is associated with decreased metabolism of gemcitabine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs1045642;GG;Metabolism/PK;decreased concentrations of ⮕ APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;Genotype GG is associated with decreased concentrations of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotypes AA + AG.;or in people with Other:Thromboembolism
;ATAZANAVIR;NR1I2;rs2472677;TT;Metabolism/PK;decreased concentrations of ⮕ ATAZANAVIR;Genotype TT is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + CT.; in people with Disease:HIV infectious disease
;IMATINIB;ABCB1;rs2032582;A;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;ANTIDEPRESSANTS;FKBP5;rs1360780;CC;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Genotype CC is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Disease:Major Depressive Disorder
;IMATINIB;ABCB1;rs1128503;A;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A5;rs776746;TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotype TT is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotypes CC + CT.; in people with Disease:Liver transplantation
;ANTIDEPRESSANTS;GNB3;rs5443;CC + CT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes CC + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;IMATINIB;ABCB1;rs1045642;A;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele A is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AC + CC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;METHADONE;OPRK1;rs963549;CC;Dosage;decreased dose of ⮕ METHADONE;Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.; in people with Other:Heroin Dependence
;ANTIPSYCHOTICS;ABCB1;rs1128503;AA;Dosage, Metabolism/PK;increased dose of ⮕ ANTIPSYCHOTICS;Genotype AA is associated with increased dose of antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;IMATINIB;ABCG2;rs2231142;T;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele T is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Efficacy;decreased resistance to ⮕ EFAVIRENZ;Genotypes GT + TT are associated with decreased resistance to efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;TACROLIMUS;PPARA;rs4823613;G;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Allele G is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele A.; in people with Other:Kidney Transplantation
;INFLIXIMAB;SLCO1C1;rs3794271;G;Efficacy;decreased response to ⮕ INFLIXIMAB;Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;TACROLIMUS;POR;rs1057868;T;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Other:Kidney Transplantation
;DALCETRAPIB;ADCY9;rs1967309;AA;Efficacy;increased response to ⮕ DALCETRAPIB;Genotype AA is associated with increased response to dalcetrapib in people with as compared to genotype GG.; in people with 
;ANTIDEPRESSANTS;BDNF;rs6265;CT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype CT is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + TT.; in people with Disease:Major Depressive Disorder
;BETA BLOCKING AGENTS, FLECAINIDE;ADRB1;rs1801253;G;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS, FLECAINIDE;Allele G is associated with decreased response to Beta Blocking Agents and flecainide in people with Tachycardia as compared to allele C.;and in people with Disease:Tachycardia
;METHOTREXATE;ABCC2;rs717620;T;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele T is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; in children with Disease:Acute lymphoblastic leukemia
;RITUXIMAB;FCGR3A;rs396991;AA;Efficacy;increased clinical benefit to ⮕ RITUXIMAB;Genotype AA is associated with increased clinical benefit to rituximab in people with Neuromyelitis Optica as compared to genotypes AC + CC.; in people with Other:Neuromyelitis Optica
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*18;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *18 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;rs13273672;CC;Efficacy;decreased clinical benefit to ⮕ DRUGS USED IN ALCOHOL DEPENDENCE;Genotype CC is associated with decreased clinical benefit to Drugs used in alcohol dependence in people with Alcoholism as compared to genotypes CT + TT.; in people with Disease:Alcohol abuse
;CHORIONIC GONADOTROPIN;FSHR;rs6166;CC;Dosage;increased dose of ⮕ CHORIONIC GONADOTROPIN;Genotype CC is associated with increased dose of gonadotropin,chorionic in women as compared to genotype CT.; in women 
;BEPRIDIL;CYP2D6;CYP2D6*10;*10;Metabolism/PK;increased clearance of ⮕ BEPRIDIL;CYP2D6 *10 is associated with increased clearance of bepridil in people with Arrhythmias, Cardiac.; in people with Disease:Cardiac rhythm disease
;TACROLIMUS;CYP3A4;rs35599367;GG;Dosage;increased dose of ⮕ TACROLIMUS;Genotype GG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Disease:Kidney Transplantation
;NICARDIPINE, NIMODIPINE;CACNA1B;rs2739260;AG + GG;Efficacy;increased clinical benefit to ⮕ NICARDIPINE, NIMODIPINE;Genotypes AG + GG is associated with increased clinical benefit to nicardipine or nimodipine in people with Bipolar Disorder as compared to genotype AA.;or in people with Other:Bipolar Disorder
;CITALOPRAM, ESCITALOPRAM;GLDC;rs10975641;G;Efficacy;increased response to ⮕ CITALOPRAM, ESCITALOPRAM;Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.;and in people with Disease:Major Depressive Disorder
;CORTISONE ACETATE;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1C;Dosage;decreased dose of ⮕ CORTISONE ACETATE;CYP3A7 *1C is associated with decreased dose of cortisone acetate in children with Adrenal Hyperplasia, Congenital as compared to CYP3A7 *1A.; in children with Disease:Adrenal Hyperplasia, Congenital
;DAUNORUBICIN;G6PD;G6PD A- 202A_376G;A-202A_376G;Metabolism/PK;decreased metabolism of ⮕ DAUNORUBICIN;G6PD A-202A_376G is associated with decreased metabolism of daunorubicin.;  
;TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7 + *7/*7;Metabolism/PK;decreased clearance of ⮕ TEGAFUR;CYP2A6 *4/*4 + *4/*7 + *7/*7 are associated with decreased clearance of tegafur in people with Neoplasms as compared to CYP2A6 *1/*1.; in people with Disease:Neoplasms
;EFAVIRENZ;CYP2A6;CYP2A6*2;*2;Other, Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2A6 *2 is associated with decreased metabolism of efavirenz in people with HIV.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *3/*3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 *1/*1.; in people with Other:mechanical heart valve replacement
;METFORMIN;HNF1B;rs11868513;AA + AG;Efficacy;increased response to ⮕ METFORMIN;Genotypes AA + AG are associated with increased response to metformin as compared to genotype GG.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;IBUPROFEN;CYP2C9;CYP2C9*3;*3;Metabolism/PK;decreased clearance of ⮕ IBUPROFEN;CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.; in healthy individuals 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;ATORVASTATIN;CYP3A4;rs2242480;C/C;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype C/C is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to genotype C/T.; in people with Disease:Hyperlipidemias
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.; in healthy individuals 
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;GLATIRAMER ACETATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Efficacy;decreased response to ⮕ GLATIRAMER ACETATE;HLA-DRB1 *15:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.; in people with Disease:Multiple Sclerosis
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 + *3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage, Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.; in people with Disease:Cardiovascular Disease
;WARFARIN;CYP2C9;CYP2C9*3;*3;Metabolism/PK;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.; in people with Disease:Cardiovascular Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17 + *2/*17 + *3/*17;Efficacy;increased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*1 + *1/*17 + *2/*17 + *3/*17 is associated with increased response to clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.; in people with Disease:Angina Pectoris
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;CAFFEINE;NAT2;NAT2*4;*4;Metabolism/PK;increased metabolism of ⮕ CAFFEINE;NAT2 *4 is associated with increased metabolism of caffeine in healthy individuals.; in healthy individuals 
;ATORVASTATIN;CYP3A4;rs2242480;C/C;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype C/C is associated with decreased response to atorvastatin in people with Hyperlipidemias as compared to genotype T/T.; in people with Disease:Hyperlipidemias
;DIAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Other, Metabolism/PK;decreased metabolism of ⮕ DIAZEPAM;CYP2C19 *2 + *3 is associated with decreased metabolism of diazepam as compared to CYP2C19 *1.;  
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";IL18;rs1946518;T;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";Allele T is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.;or in people with Disease:Chronic hepatitis C virus infection
;FLUOXETINE, PAROXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;Efficacy;increased response to ⮕ FLUOXETINE, PAROXETINE;Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine and paroxetine in people with Depression.;and in people with Disease:Depression
;IBUPROFEN;CYP2C9;CYP2C9*3;*3;Metabolism/PK;decreased clearance of ⮕ IBUPROFEN;CYP2C9 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C9 *1.; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;Metabolism/PK;decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 *4/*4 is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;POR;rs1057868;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in healthy individuals as compared to genotype CT.; in healthy individuals 
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Efficacy;increased response to ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.;  
;THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT poor metabolizer is associated with increased concentrations of thioguanosine diphosphate, thioguanosine monophosphate and thioguanosine triphosphate in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.;and in people with Disease:Inflammatory Bowel Diseases
;VALPROIC ACID;CYP2A6;CYP2A6*1, CYP2A6*4;*4;Metabolism/PK;decreased metabolism of ⮕ VALPROIC ACID;CYP2A6 *4 is associated with decreased metabolism of valproic acid in people with Epilepsy as compared to CYP2A6 *1/*1.; in people with Disease:Epilepsy
;TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4;Metabolism/PK;decreased metabolism of ⮕ TEGAFUR;CYP2A6 *4 is associated with decreased metabolism of tegafur.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*7;*1/*7;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *1/*7 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; in people with Other:a stable international normalized ratio of between two and three
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; in people with Other:a stable international normalized ratio of between two and three
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 + *3 is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1.; in people with Disease:Coronary Artery Disease
;WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3/*3;Dosage;increased dose of ⮕ WARFARIN;CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1.; in people with Other:a stable international normalized ratio of between two and three
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2/*3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 *1/*1.; in people with Other:a stable international normalized ratio of between two and three
;PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;Efficacy;increased response to ⮕ PACLITAXEL;CYP2C8 *1/*3 + *3/*3 is associated with increased response to paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1/*1.; in women with Disease:Breast Neoplasms
;CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*1/*4 + *1/*9 + *4/*4 + *4/*9;Other, Metabolism/PK;decreased metabolism of ⮕ CAFFEINE;CYP2A6 *1/*4 + *1/*9 + *4/*4 + *4/*9 are associated with decreased metabolism of caffeine as compared to CYP2A6 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 *1/*1.; in people with Disease:Thromboembolism
;TOCILIZUMAB;IL6R;rs4845625;CT + TT;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotypes CT + TT is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Other:Rheumatoid arthritis
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Efficacy;increased response to ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with increased response to acenocoumarol in healthy individuals as compared to CYP2C9 *1.; in healthy individuals 
;ROSUVASTATIN;ABCC2;rs17216198;T;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;ATORVASTATIN;CYP3A4;rs2242480;T/T;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype T/T is associated with increased response to atorvastatin in people with Hyperlipidemias as compared to genotype C/T.; in people with Disease:Hyperlipidemias
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG are associated with decreased response to clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.; in people with Disease:Cardiovascular Disease
;FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;CYP2C9 *2 is associated with increased concentrations of fluvastatin in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;Efficacy;increased response to ⮕ MIRTAZAPINE;CYP2B6 *6/*6 is associated with increased response to mirtazapine in people with Depression.; in people with Disease:Depression
;SULFAPYRIDINE;NAT2;NAT2*7;*7/*7;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *7/*7 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;METHOTREXATE;SLC19A1;rs1051266;CT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in people with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage, Metabolism/PK;decreased clearance of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.; in people with Disease:Cardiovascular Disease
;WARFARIN;CYP2C9;CYP2C9*2;*2;Metabolism/PK;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.; in people with Disease:Cardiovascular Disease
;ISONIAZID;NAT2;NAT2*4;*4;Metabolism/PK;increased metabolism of ⮕ ISONIAZID;NAT2 *4 is associated with increased metabolism of isoniazid in healthy individuals.; in healthy individuals 
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";IL18;rs187238;C;Efficacy;"decreased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""INTERFERONS"", ""PEGINTERFERON ALFA-2A"", ""PEGINTERFERON ALFA-2B"", ""RIBAVIRIN""";Allele C is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant, interferons, peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to allele G.;or in people with Disease:Chronic hepatitis C virus infection
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;CYP2B6 *6 is associated with decreased metabolism of efavirenz in human liver microsomes as compared to CYP2B6 *1.; in Other:human liver microsomes
;ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;Dosage;increased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.;  
;ISONIAZID;NAT2;NAT2*4;*4/*4;Metabolism/PK;increased metabolism of ⮕ ISONIAZID;NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.; in people with Disease:Tuberculosis
;ISONIAZID;NAT2;NAT2*4;*4/*4;Metabolism/PK;increased metabolism of ⮕ ISONIAZID;NAT2 *4/*4 is associated with increased metabolism of isoniazid in people with Tuberculosis.; in people with Disease:Tuberculosis
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;IBUPROFEN;CYP2C8;CYP2C8*3;*3;Metabolism/PK;decreased clearance of ⮕ IBUPROFEN;CYP2C8 *3 is associated with decreased clearance of ibuprofen in healthy individuals as compared to CYP2C8 *1A.; in healthy individuals 
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *3 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;Dosage;increased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*1 is associated with increased dose of acenocoumarol.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol as compared to CYP2C9 *1.;  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;Efficacy;decreased response to ⮕ LOSARTAN;CYP2C9 *1/*3 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1.; in people with Disease:Kidney Disorder
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;CYP2C9 *1/*3 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;TROPISETRON;CYP2D6;CYP2D6*3;*3/*3;Efficacy;decreased metabolism of ⮕ TROPISETRON;CYP2D6 *3/*3 is associated with decreased metabolism of tropisetron in people with Neoplasms.; in people with Disease:Neoplasms
;METOPROLOL;CYP2D6;CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ METOPROLOL;CYP2D6 *10 is associated with decreased metabolism of metoprolol in healthy individuals as compared to CYP2D6 *1.; in healthy individuals 
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2;Efficacy;decreased response to ⮕ LOSARTAN;CYP2C9 *1/*2 is associated with decreased response to losartan in people with Kidney Diseases as compared to CYP2C9 *1/*1.; in people with Disease:Kidney Disorder
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Metabolism/PK;decreased metabolism of ⮕ PHENPROCOUMON;CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon in healthy individuals as compared to CYP2C9 *1.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 is associated with decreased response to clopidogrel in people with Myocardial Ischemia as compared to CYP2C19 *1.; in people with Disease:Myocardial Ischemia
;OLMESARTAN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15;Metabolism/PK;decreased clearance of ⮕ OLMESARTAN;SLCO1B1 *15 is associated with decreased clearance of olmesartan in healthy individuals as compared to SLCO1B1 *37.; in healthy individuals 
;TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Dosage;decreased dose of ⮕ TACROLIMUS;CYP2C19 *2/*2 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.; in people with Disease:Kidney Transplantation
;METOPROLOL;CYP2D6;CYP2D6*10;*10;Metabolism/PK;decreased clearance of ⮕ METOPROLOL;CYP2D6 *10 is associated with decreased clearance of metoprolol as compared to CYP2D6 *1.;  
;ROSUVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;Metabolism/PK;decreased metabolism of ⮕ ROSUVASTATIN;SLCO1B1 *15/*15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 *37/*37.; in healthy individuals 
;SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*4;*1/*4;Efficacy;increased response to ⮕ SIMVASTATIN;CYP3A4 *1/*4 is associated with increased response to simvastatin in people with Hyperlipidemias as compared to CYP3A4 *1/*1.; in people with Disease:Hyperlipidemias
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;CYP2C9 *1/*13 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Metabolism/PK;decreased metabolism of ⮕ PHENPROCOUMON;CYP2C9 *2 + *3 are associated with decreased metabolism of phenprocoumon as compared to CYP2C9 *1.;  
;ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;Efficacy;decreased response to ⮕ ONDANSETRON;CYP2D6 *1xN + *2xN are associated with decreased response to ondansetron in women as compared to CYP2D6 *1.; in women 
;NATEGLINIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ NATEGLINIDE;CYP2C9 *1/*3 is associated with decreased metabolism of nateglinide in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;Dosage;decreased dose of ⮕ PHENPROCOUMON;CYP2C9 *3 is associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.;  
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ PHENPROCOUMON;CYP2C9 *2 + *3 are associated with decreased dose of phenprocoumon as compared to CYP2C9 *1.;  
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in healthy individuals as compared to CYP2C19 *2/*3 + *2/*2.; in healthy individuals 
;CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;CYP2D6 *1/*4 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.; in people with Disease:Heart Diseases
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Helicobacter Infections
;ROSUVASTATIN;ABCC2;rs3740066;T;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1;Efficacy;decreased response to ⮕ PANTOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*2 + *2/*17 + *2/*2.; in people with Disease:Helicobacter Infections
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Gastroesophageal Reflux
;CARVEDILOL;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6;Dosage;increased dose of ⮕ CARVEDILOL;CYP2D6 *4/*5 + *4/*6 is associated with increased dose of carvedilol in people with Heart Failure.; in people with Disease:Heart Failure
;CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;Efficacy;increased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*1 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*2 + *2/*2.; in people with Disease:Coronary Artery Disease
;OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased response to ⮕ OMEPRAZOLE, PANTOPRAZOLE;CYP2C19 *1/*2 is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.;or in people with Disease:Helicobacter Infections
;CARVEDILOL;CYP2D6;CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.; in people with Disease:Heart Diseases
;CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*5;*1/*5;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;CYP2D6 *1/*5 is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to CYP2D6 *1/*1.; in people with Disease:Heart Diseases
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1/*1.; in children 
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3;Efficacy;increased response to ⮕ RABEPRAZOLE;CYP2C19 *2/*2 + *3/*3 is associated with increased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;CYP2D6 *10/*10 is associated with decreased clearance of carvedilol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3;*3;Metabolism/PK;decreased metabolism of ⮕ ZUCLOPENTHIXOL;CYP2D6 *3 is associated with decreased metabolism of zuclopenthixol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;increased response to ⮕ RISPERIDONE;CYP2D6 *4/*4 is associated with increased response to risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1.; in people with Disease:Schizophrenia
;FLUOXETINE;CYP2D6;rs3892097;CC;Efficacy;increased response to ⮕ FLUOXETINE;Genotype CC is associated with increased response to fluoxetine in men with Alcoholism and Depressive Disorder, Major as compared to genotype CT.; in men with Efficacy:Alcohol abuse, Efficacy:Major Depressive Disorder
;AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Dosage, Efficacy;decreased dose of ⮕ AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6 *4/*4 is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.;or in people with Disease:Depression
;SUFENTANIL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Dosage;increased dose of ⮕ SUFENTANIL;CYP3A5 *1/*3 + *3/*3 are associated with increased dose of sufentanil in people with Pain, Postoperative as compared to CYP3A5 *1/*1.; in people with Other:Pain, Postoperative
;METFORMIN;;rs6719578;CG;Efficacy;increased response to ⮕ METFORMIN;Genotype CG is associated with increased response to metformin as compared to genotype GG.;  
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Efficacy, Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *10 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *6/*6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;Metabolism/PK;decreased metabolism of ⮕ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *2/*3 is associated with decreased metabolism of mephenytoin or omeprazole in healthy individuals as compared to CYP2C19 *1/*1.;or in healthy individuals 
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ HALOPERIDOL;CYP2D6 *10 is associated with decreased metabolism of haloperidol in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *4 is associated with decreased metabolism of risperidone in people with Schizophrenia as compared to CYP2D6 *1.; in people with Disease:Schizophrenia
;METHOTREXATE;ATIC;rs4673993;CC;Efficacy;increased response to ⮕ METHOTREXATE;Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;LORNOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ LORNOXICAM;CYP2C9 *1/*3 is associated with decreased metabolism of lornoxicam in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Ulcer as compared to CYP2C19 *1/*2 + *1/*3.; in people with Disease:Ulcer
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *1/*2.; in healthy individuals 
;ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Efficacy;decreased response to ⮕ ESOMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to esomeprazole in healthy individuals as compared to CYP2C19 *1/*2.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4;Metabolism/PK;decreased clearance of ⮕ TRAMADOL;CYP2D6 *4/*4 is associated with decreased clearance of tramadol in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with decreased response to clopidogrel in people with Cardiovascular Diseases.; in people with Disease:Cardiovascular Disease
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *1/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*1.; in children 
;DEXLANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ DEXLANSOPRAZOLE;CYP2C19 *2/*2 is associated with decreased metabolism of dexlansoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;LOVASTATIN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10 + *5;Metabolism/PK;decreased metabolism of ⮕ LOVASTATIN;CYP2D6 *10 + *5 are associated with decreased metabolism of lovastatin in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;BENZBROMARONE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased clearance of ⮕ BENZBROMARONE;CYP2C9 *1/*3 is associated with decreased clearance of benzbromarone in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;LABETALOL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ LABETALOL;CYP2C19 *2/*2 is associated with decreased metabolism of labetalol in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Metabolism/PK;increased metabolism of ⮕ CELECOXIB;CYP2C9 *1/*2 is associated with increased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *2/*2 + *2/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Helicobacter Infections
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*22;*1/*22;Metabolism/PK;increased metabolism of ⮕ BUPROPION;CYP2B6 *1/*22 is associated with increased metabolism of bupropion as compared to CYP2B6 *1/*1.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Metabolism/PK;increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of voriconazole in healthy individuals as compared to CYP2C19 *2/*2.; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 *2/*2 is associated with decreased metabolism of lansoprazole in children as compared to CYP2C19 *1/*2.; in children 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ FLUOXETINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to fluoxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;Dosage;decreased dose of ⮕ VORICONAZOLE;CYP2C19 *1/*2 is associated with decreased dose of voriconazole in people with Cystic Fibrosis and lung transplantation as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; in people with Disease:Cystic Fibrosis, Disease:Lung transplantation
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased response to ⮕ PAROXETINE;SLC6A4 HTTLPR long form (L allele) is associated with increased response to paroxetine in women with Panic Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in women with Disease:Panic Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 is associated with decreased dose of warfarin in children as compared to CYP2C9 *1.; in children 
;FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased response to ⮕ FLUOXETINE, PAROXETINE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased response to fluoxetine or paroxetine in people with Depressive Disorder, Major.;or in people with Disease:Major Depressive Disorder
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator decreased metabolism of ⮕ HYDRALAZINE;NAT2 slow acetylator is associated with decreased metabolism of hydralazine in men with Hypertension as compared to NAT2 rapid acetylator.; in men with Other:Hypertension
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Efficacy;increased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*17 + *17/*17 is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.; in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Efficacy, Toxicity;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.; in people with Other:percutaneous coronary intervention
;PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;Metabolism/PK;decreased clearance of ⮕ PIOGLITAZONE;CYP2C8 *1/*1 is associated with decreased clearance of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.; in healthy individuals 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A;HLA-A*01:01;*01:01;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A *01:01 is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.;and in people with Disease:Hepatitis C virus infection
;CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).;or in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;EFAVIRENZ;CYP2B6;rs70950385;CA/CA;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype CA/CA is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype AG/AG.; in healthy individuals 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;CYP2C19 *2/*2 is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*2.;and in people with Disease:Acute coronary syndrome
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;MEPHENYTOIN;CYP2C19;rs28399504;G;Metabolism/PK;decreased metabolism of ⮕ MEPHENYTOIN;Allele G is associated with decreased metabolism of mephenytoin as compared to allele A.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*5;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6 *10/*10 + *5/*5 are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.;or in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3 + *2/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*3 + *2/*3 + *3/*3 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *2/*2 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *3/*3 are associated with decreased dose of acenocoumarol as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.;  
;LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*40:01;*40:01;Efficacy;response to ⮕ LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B *40:01 is associated with response to lamivudine, nevirapine and stavudine in people with HIV Infections.;and in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;poor metabolizer increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;  
;BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;Metabolism/PK;increased concentrations of ⮕ BELINOSTAT;UGT1A1 *1/*60 + *60/*60 is associated with increased concentrations of Belinostat in people with Neoplasms.; in people with Disease:Neoplasms
;BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;Metabolism/PK;decreased metabolism of ⮕ BELINOSTAT;UGT1A1 *1/*60 + *60/*60 is associated with decreased metabolism of Belinostat in people with Neoplasms.; in people with Disease:Neoplasms
;DOXEPIN;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;decreased clearance of ⮕ DOXEPIN;CYP2C19 *2/*2 is associated with decreased clearance of doxepin in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;Metabolism/PK;increased concentrations of ⮕ NORTRIPTYLINE;CYP2D6 *2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4 are associated with increased concentrations of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*2 + *1/*10 + *1/*1.; in people with Disease:Major Depressive Disorder
;BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT;Efficacy;increased response to ⮕ BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Allele TT is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele G.;or in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased concentrations of ⮕ AMITRIPTYLINE;CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of amitriptyline in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Metabolism/PK;increased clearance of ⮕ VORICONAZOLE;CYP2C19 *1/*1 is associated with increased clearance of voriconazole in healthy individuals as compared to CYP2C19 *1/*2 + *2/*2.; in healthy individuals 
;DEFERASIROX;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;decreased concentrations of ⮕ DEFERASIROX;UGT1A1 *1/*28 + *28/*28 is associated with decreased concentrations of deferasirox in people with Anemia as compared to UGT1A1 *1/*1.; in people with Disease:Anemia
;CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;rs4244285;A;Efficacy;response to ⮕ CLOPIDOGREL, PRASUGREL, TICAGRELOR;Allele A is associated with response to clopidogrel, prasugrel and ticagrelor in people with Acute coronary syndrome.;and in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;increased resistance to ⮕ CLOPIDOGREL;CYP2C19 *2/*2 is associated with increased resistance to clopidogrel in people with Acute coronary syndrome and Stroke as compared to CYP2C19 *1/*1.; in people with Disease:Acute coronary syndrome, Disease:Stroke
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*11;*11;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;CYP2B6 *11 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 *1/*1.; in healthy individuals 
;VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Dosage;decreased dose of ⮕ VALPROIC ACID;CYP2C9 *1/*2 + *1/*3 are associated with decreased dose of valproic acid in people with Bipolar Disorder and Psychotic Disorders as compared to CYP2C9 *1/*1.; in people with Disease:Bipolar Disorder, Disease:Psychotic Disorder
;WARFARIN;POR;rs41301394;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;METHADONE;DRD2;rs6275;AA + AG;;increased dose of ⮕ METHADONE;Genotypes AA + AG are associated with increased dose of methadone in people with treatment for heroin addiction as compared to genotype GG.; in people with Other:treatment for heroin addiction
;CARBOPLATIN, PACLITAXEL;GSTP1;rs1695;G;Toxicity;decreased response to ⮕ CARBOPLATIN, PACLITAXEL;Allele G is associated with decreased response to carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to allele A.;and in people with Other:Ovarian Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19 ultrarapid metabolizer;;Metabolism/PK;ultrarapid metabolizer decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 ultrarapid metabolizer is associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 normal metabolizer.; in people with Disease:Fungal infectious disease
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *1/*6 + *6/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;decreased dose of ⮕ ACENOCOUMAROL;CYP2C9 *2 is associated with decreased dose of acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1.; in people with Disease:Atrial Fibrillation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*1 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*18 + *18/*18.; in people with Disease:Kidney Transplantation
;CISPLATIN;MIR335;rs3807348;AA + AG;Efficacy;increased response to ⮕ CISPLATIN;Genotypes AA + AG is associated with increased response to cisplatin in people with Mesothelioma as compared to genotype GG.; in people with Other:Mesothelioma
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased metabolism of ⮕ CELECOXIB;CYP2C9 *1/*3 is associated with decreased metabolism of celecoxib in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE, DOXORUBICIN;Genotype CTGGTGAGGAGAGAACC/del is associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.;and in women with Disease:Breast Neoplasms
;BUPRENORPHINE, METHADONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;decreased response to ⮕ BUPRENORPHINE, METHADONE;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with decreased response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).;or in people with Disease:Opioid-Related Disorders
;WARFARIN;VKORC1;VKORC1 low activity;;Dosage;low activity decreased dose of ⮕ WARFARIN;VKORC1 low activity is associated with decreased dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 are associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;Efficacy;intermediate metabolizer and poor metabolizer decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) are associated with decreased response to clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17;Metabolism/PK;decreased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 + *2/*17 is associated with decreased metabolism of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1.; in people with Disease:Fungal infectious disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased trough concentration of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with liver transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Liver transplantation
;ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3 + *6 + *7;Metabolism/PK;decreased metabolism of ⮕ ATAZANAVIR;CYP3A5 *3 + *6 + *7 are associated with decreased metabolism of atazanavir in healthy individuals as compared to CYP3A5 *1.; in healthy individuals 
;CLOZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Dosage;decreased concentrations of ⮕ CLOZAPINE;CYP3A5 *1/*3 is associated with decreased concentrations of clozapine in people with schizoaffective disorder or Schizophrenia as compared to CYP3A5 *3/*3.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3.; in people with Other:heart transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.; in children with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;decreased trough concentration of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentration of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Hematopoietic stem cell transplantation
;SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ SIROLIMUS, TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of sirolimus or tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;or in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus as compared to CYP3A5 *1/*1 + *1/*3.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.; in people with Disease:Kidney Transplantation
;NIMODIPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Efficacy;increased exposure to ⮕ NIMODIPINE;CYP3A5 *3/*3 is associated with increased exposure to nimodipine in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*3 + *1/*1.; in people with Disease:Heart transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased trough concentration of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.; in people with Disease:Ulcerative Colitis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ CARBAMAZEPINE;CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Epilepsy
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ FENTANYL;CYP3A5 *3/*3 is associated with increased concentrations of fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Neoplasms, Disease:Pain
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Hematopoietic stem cell transplantation
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ FENTANYL;CYP3A5 *3/*3 is associated with decreased clearance of fentanyl in people with Pain, Postoperative as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Pain, Postoperative
;MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased metabolism of ⮕ MIDAZOLAM;CYP3A5 *1/*3 is associated with increased metabolism of midazolam in people with Neoplasms as compared to CYP3A5 *3/*3.; in people with Disease:Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased metabolism of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;Dosage;decreased dose of ⮕ CYCLOSPORINE;CYP3A5 *3 is associated with decreased dose of cyclosporine in people with Kidney Transplantation as compared to CYP3A5 *1.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Hematopoietic stem cell transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*9;*9;Metabolism/PK;decreased clearance of ⮕ FENTANYL;CYP2D6 *9 is associated with decreased clearance of fentanyl in people with Burns as compared to CYP2D6 *1.; in people with Other:Burns
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Disease:Kidney Transplantation
;SIMVASTATIN;F3;rs3917643;CT;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype CT is associated with increased response to simvastatin in people with Myocardial Ischemia as compared to genotype TT.; in people with Disease:Myocardial Ischemia
;IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;increased response to ⮕ IVACAFTOR / LUMACAFTOR;Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.; in people with Disease:Cystic Fibrosis
;ACETYLCHOLINE, NITROPRUSSIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased response to ⮕ ACETYLCHOLINE, NITROPRUSSIDE;Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to acetylcholine or nitroprusside in healthy individuals as compared to allele del.;or in healthy individuals 
;FLUVASTATIN;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.; in people with Disease:Coronary Artery Disease
;IVACAFTOR;CFTR;rs113993960;CTT/del;Efficacy;increased response to ⮕ IVACAFTOR;Genotype CTT/del is associated with increased response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;Efficacy;increased response to ⮕ ENALAPRIL;Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del are associated with increased response to enalapril in people with Arteriosclerosis as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.; in people with Disease:Arteriosclerosis
;BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased response to ⮕ BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;or in people with Disease:Stomach Neoplasms
;IMATINIB;CYP3A5;rs776746;C;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele C is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A4 *1/*22 + *22/*22 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Other:Kidney Transplantation
;METOCLOPRAMIDE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*1/*10 + *10/*10 + *5/*10;Metabolism/PK;decreased clearance of ⮕ METOCLOPRAMIDE;CYP2D6 *1/*10 + *10/*10 + *5/*10 is associated with decreased clearance of metoclopramide in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2.; in healthy individuals 
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 + *22/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Other:Kidney Transplantation
;FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;CYP3A5 poor metabolizer;;Metabolism/PK;poor metabolizer decreased dose of ⮕ FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5 poor metabolizer is associated with decreased dose of fentanyl, meperidine or midazolam in people with sedation as compared to CYP3A5 intermediate metabolizer.;or in people with Other:sedation
;FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased dose of ⮕ FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19 poor metabolizers and intermediate metabolizers is associated with decreased dose of fentanyl, meperidine or midazolam in people with sedation as compared to CYP2C19 normal metabolizer.;or in people with Other:sedation
;FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;UGT1A1 poor metabolizer;;Metabolism/PK;poor metabolizer decreased dose of ⮕ FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1 poor metabolizer is associated with decreased dose of fentanyl, meperidine or midazolam in people with sedation as compared to UGT1A1 normal metabolizer.;or in people with Other:sedation
;TACROLIMUS;CYP3A4;rs35599367;AG;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype AG is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;increased concentrations of ⮕ 4-HYDROXYTAMOXIFEN;CYP2C19 *1/*17 + *17/*17 is associated with increased concentrations of 4-hydroxytamoxifen in people with Breast Neoplasms as compared to CYP2C19 *1/*1.; in people with Other:Breast Neoplasms
;TAMSULOSIN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*4 + *4/*10;Efficacy;intermediate metabolizer increased clinical benefit to ⮕ TAMSULOSIN;CYP2D6 *1/*4 + *4/*10 (assigned as intermediate metabolizer phenotype) is associated with increased clinical benefit to tamsulosin as compared to CYP2D6 *1/*1 + *1/*3 + *1/*41 + *1/*9 + *1/*10 (assigned as normal metabolizer phenotype) .;  
;IMATINIB;CYP3A4;rs2242480;C;Efficacy;increased clinical benefit to ⮕ IMATINIB;Allele C is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;FULVESTRANT;CYP2C9;CYP2C9 poor metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ FULVESTRANT;CYP2C9 intermediate metabolizer and poor metabolizer is associated with increased concentrations of fulvestrant in people with Breast Neoplasms and Neoplasm Metastasis as compared to CYP2C9 normal metabolizer and ultrarapid metabolizer.; in people with Other:Breast Neoplasms, Other:Metastatic neoplasm
;ANASTROZOLE;CYP2C9;CYP2C9 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased concentrations of ⮕ ANASTROZOLE;CYP2C9 intermediate metabolizer and poor metabolizer is associated with decreased concentrations of anastrozole in people with Breast Neoplasms and Neoplasm Metastasis as compared to CYP2C9 normal metabolizer and ultrarapid metabolizer.; in people with Other:Breast Neoplasms, Other:Metastatic neoplasm
;ANASTROZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;intermediate metabolizer decreased concentrations of ⮕ ANASTROZOLE;CYP3A4 *1/*22 (assigned as intermediate metabolizer phenotype) is associated with decreased concentrations of anastrozole in people with Breast Neoplasms and Neoplasm Metastasis as compared to CYP3A4 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Breast Neoplasms, Other:Metastatic neoplasm
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with decreased dose of warfarin as compared to CYP2C9 *1/*1.;  
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;intermediate metabolizer and poor metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Leukemia as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Other:Leukemia
;ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:05;Efficacy;increased clinical benefit to ⮕ ABATACEPT;HLA-DRB1 *04:05 is associated with increased clinical benefit to abatacept in people with Arthritis, Rheumatoid.; in people with Other:Rheumatoid arthritis
;ESOMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;poor metabolizer increased exposure to ⮕ ESOMEPRAZOLE;CYP2C19 poor metabolizer is associated with increased exposure to esomeprazole in healthy individuals as compared to CYP2C19 intermediate metabolizer.; in healthy individuals 
;ESOMEPRAZOLE;CYP2C19;CYP2C19 rapid metabolizer;;Metabolism/PK;rapid metabolizer decreased exposure to ⮕ ESOMEPRAZOLE;CYP2C19 rapid metabolizer is associated with decreased exposure to esomeprazole in healthy individuals as compared to CYP2C19 intermediate metabolizer.; in healthy individuals 
;ETANERCEPT;SLCO1C1;rs3794271;G;Efficacy;decreased response to ⮕ ETANERCEPT;Allele G is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;APATINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased clearance of ⮕ APATINIB;CYP3A5 *1/*1 + *1/*3 is associated with decreased clearance of apatinib in people with Neoplasms as compared to CYP3A5 *3/*3.; in people with Other:Neoplasms
;ESCITALOPRAM;CYP2C19;CYP2C19 rapid metabolizer;;Metabolism/PK;ultrarapid metabolizer and rapid metabolizer increased clearance of ⮕ ESCITALOPRAM;CYP2C19 ultrarapid metabolizer and rapid metabolizer is associated with increased clearance of escitalopram in children as compared to CYP2C19 normal metabolizer.; in children 
;ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ ESCITALOPRAM;CYP2C19 intermediate metabolizer and poor metabolizer is associated with decreased clearance of escitalopram in children as compared to CYP2C19 normal metabolizer.; in children 
;SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ SERTRALINE;CYP2C19 intermediate metabolizer and poor metabolizer is associated with decreased clearance of sertraline in children as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer and rapid metabolizer.; in children 
;DULOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ DULOXETINE;CYP2D6 poor metabolizer is associated with increased dose-adjusted trough concentrations of duloxetine as compared to CYP2D6 normal metabolizer.;  
;AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs7975232;A;Efficacy;increased response to ⮕ AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;Allele A is associated with increased response to amoxicillin, clarithromycin and omeprazole in people with Helicobacter Infections as compared to allele C.;and in people with Other:Helicobacter Infections
;AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs2228570;A;Efficacy;increased response to ⮕ AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;Allele A is associated with increased response to amoxicillin, clarithromycin and omeprazole in people with Helicobacter Infections as compared to allele G.;and in people with Other:Helicobacter Infections
;METOPROLOL;CYP2D6;rs1065852;A;Metabolism/PK;increased concentrations of ⮕ METOPROLOL;Allele A is associated with increased concentrations of metoprolol in healthy individuals as compared to allele G.; in healthy individuals 
;BUPROPION, NALTREXONE;ANKK1, DRD2;rs1800497;AA + AG;Efficacy;increased response to ⮕ BUPROPION, NALTREXONE;Genotypes AA + AG are associated with increased response to bupropion and naltrexone in people with Obesity as compared to genotype GG.;and in people with Other:Obesity
;ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs1065852;A;Metabolism/PK;decreased clearance of ⮕ ALPHA-HYDROXYMETOPROLOL;Allele A is associated with decreased clearance of alpha-hydroxymetoprolol in healthy individuals as compared to allele G.; in healthy individuals 
;TOLPERISONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of ⮕ TOLPERISONE;CYP2D6 *10/*10 is associated with decreased clearance of tolperisone in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.; in healthy individuals 
;TOLPERISONE;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ TOLPERISONE;CYP2C19 poor metabolizer is associated with decreased clearance of tolperisone in healthy individuals as compared to CYP2C19 normal metabolizer and intermediate metabolizer.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased clearance of tacrolimus in people with heart transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Heart transplantation
;DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;intermediate metabolizer decreased clearance of ⮕ DAPOXETINE;CYP2D6 *10/*10 (assigned as intermediate metabolizer phenotype) is associated with decreased clearance of dapoxetine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ RISPERIDONE;CYP2D6 intermediate metabolizer is associated with increased concentrations of risperidone in children with Autism Spectrum Disorder as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in children with Other:Autism Spectrum Disorder
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*1 is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*22.; in people with Other:Kidney Transplantation
;DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*41;*10/*41;Metabolism/PK;intermediate metabolizer decreased clearance of ⮕ DAPOXETINE;CYP2D6 *10/*41 (assigned as intermediate metabolizer phenotype) is associated with decreased clearance of dapoxetine in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;DOCETAXEL, THALIDOMIDE;PPARD;rs6922548;G;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.;and in people with Disease:Prostatic Neoplasms
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6;Metabolism/PK;increased concentrations of ⮕ SN-38;UGT1A1 *6 is associated with increased concentrations of SN-38 in people with Rectal Neoplasms as compared to UGT1A1 *1/*1.; in people with Other:Rectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1;*1;Metabolism/PK;increased time to response to ⮕ TACROLIMUS;CYP3A5 *1 is associated with increased time to response to tacrolimus in people with Kidney Transplantation.; in people with Other:Kidney Transplantation
;O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased concentrations of ⮕ O-DESMETHYLTRAMADOL;CYP2D6 intermediate metabolizer and poor metabolizer is associated with decreased concentrations of o-desmethyltramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in people with Other:Pain, Postoperative
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Other:Kidney Transplantation
;NALDEMEDINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ NALDEMEDINE;CYP3A5 *3/*3 is associated with increased concentrations of naldemedine in people with Neoplasms, Pain and Constipation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Neoplasms, Other:Pain, Other:Constipation
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ METHADONE;CYP2B6 *6/*6 is associated with increased dose-adjusted trough concentrations of methadone as compared to CYP2B6 *1/*1 + *6/*6.;  
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;*10/*10 + *10/*65 + *10/*41;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ RISPERIDONE;CYP2D6 *10/*10 + *10/*65 + *10/*41 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of risperidone in people with Schizophrenia as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *2/*2 + *2/*41 (assigned as normal metabolizer phenotype) .; in people with Other:Schizophrenia
;DOCETAXEL, THALIDOMIDE;PPARD;rs7769719;G;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele G is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.;and in people with Disease:Prostatic Neoplasms
;TACROLIMUS;CYP3A5;rs776746;TT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Disease:Kidney Transplantation
;WARFARIN;NEDD4;rs2288344;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin as compared to allele T.;  
;QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;decreased clearance of ⮕ QUETIAPINE;CYP3A5 *3/*3 is associated with decreased clearance of quetiapine in people with Bipolar Disorder as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Bipolar Disorder
;TACROLIMUS;CYP3A5;rs776746;TT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;DDHD1;rs17126068;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele A.;  
;TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer;;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 normal metabolizer and intermediate metabolizer is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to CYP3A5 poor metabolizer.; in people with Other:Lung transplantation
;PRIMAQUINE 5,6-ORTHOQUINONE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased concentrations of ⮕ PRIMAQUINE 5,6-ORTHOQUINONE;CYP2D6 intermediate metabolizer is associated with decreased concentrations of primaquine 5,6-orthoquinone in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;Efficacy;decreased response to ⮕ CISPLATIN, IRINOTECAN;Genotype AA is associated with decreased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;PRIMAQUINE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ PRIMAQUINE;CYP2D6 intermediate metabolizer is associated with decreased metabolism of primaquine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;DESVENLAFAXINE, VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased exposure to ⮕ DESVENLAFAXINE, VENLAFAXINE;CYP2D6 poor metabolizer is associated with increased exposure to desvenlafaxine and venlafaxine in people with Depressive Disorder, Major.;and in people with Other:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL;VKORC1;rs9923231;T;Efficacy;increased response to ⮕ ACENOCOUMAROL;Allele T is associated with increased response to acenocoumarol in healthy individuals as compared to allele C.; in healthy individuals 
;METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased clinical benefit to methotrexate in people with Arthritis, Rheumatoid as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.; in people with Other:Rheumatoid arthritis
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *22 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Other:Kidney Transplantation
;SALBUTAMOL;;rs7903366;T;Efficacy;decreased response to ⮕ SALBUTAMOL;Allele T is associated with decreased response to salbutamol in children with Asthma as compared to allele C.; in children with Other:Asthma
;PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;Metabolism/PK;increased exposure to ⮕ PRAZIQUANTEL;CYP2C19 *1/*2 + *1/*3 is associated with increased exposure to praziquantel in children with Schistosomiasis as compared to CYP2C19 *1/*1 + *1/*17.; in children with Other:Schistosomiasis
;PALIPERIDONE, RISPERIDONE;ABCB1;rs1045642;GG;Metabolism/PK;increased exposure to ⮕ PALIPERIDONE, RISPERIDONE;Genotype GG is associated with increased exposure to paliperidone or risperidone in healthy individuals as compared to genotypes AA + AG.;or in healthy individuals 
;LOSARTAN;CYP2C9;rs1057910;C;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;Allele C is associated with decreased metabolism of losartan in people with no disease as compared to allele A.; in people with PK:no disease
;SULFAPYRIDINE;NAT2;NAT2*5;*5/*5;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *5/*5 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy;poor metabolizer decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased response to clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.; in people with Disease:Stroke
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased exposure to ⮕ RISPERIDONE;CYP2D6 poor metabolizer is associated with increased exposure to risperidone in people with Bipolar Disorder, Depression, Psychotic Disorders or Substance-Related Disorders as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in people with Disease:Bipolar Disorder, Disease:Depression, Disease:Psychotic Disorder, Disease:Substance-Related Disorders
;ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;Metabolism/PK;slow acetylator decreased metabolism of ⮕ ISONIAZID;NAT2 *16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .; in people with Disease:Tuberculosis
;SALBUTAMOL;;rs7081864;A;Efficacy;decreased response to ⮕ SALBUTAMOL;Allele A is associated with decreased response to salbutamol in children with Asthma as compared to allele G.; in children with Other:Asthma
;SULFINPYRAZONE;UGT1A9;rs72551330;T;Metabolism/PK;increased metabolism of ⮕ SULFINPYRAZONE;Allele T is associated with increased metabolism of sulfinpyrazone as compared to allele C.;  
;SULFAMETHOXAZOLE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*4;Metabolism/PK;rapid acetylator increased metabolism of ⮕ SULFAMETHOXAZOLE;NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased metabolism of sulfamethoxazole in people with Kidney Transplantation as compared to NAT2 *16/*6 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) .; in people with Other:Kidney Transplantation
;ICOTINIB;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;decreased metabolism of ⮕ ICOTINIB;CYP2C19 *1/*2 + *1/*3 is associated with decreased metabolism of icotinib in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AA;Efficacy;decreased clinical benefit to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with decreased clinical benefit to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylarthropathy as compared to genotypes AG + GG.; in people with Other:Spondylarthropathies
;WARFARIN;VKORC1;rs9923231;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes AA + AG.; in people with Other:Atrial Fibrillation, Other:Pulmonary Embolism, Other:Venous Thrombosis
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*9;*1/*4 + *1/*9;Metabolism/PK;intermediate metabolizer increased exposure to ⮕ TRAMADOL;CYP2D6 *1/*4 + *1/*9 (assigned as intermediate metabolizer phenotype) are associated with increased exposure to tramadol in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ IMIPRAMINE;CYP2C19 poor metabolizer is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;SULFAPYRIDINE;NAT2;NAT2*4, NAT2*5;*5;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *5 is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.; in healthy individuals 
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19 ultrarapid metabolizer is associated with increased metabolism of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to CYP2C19 intermediate metabolizer.; in healthy individuals 
;METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;Metabolism/PK;ultrarapid metabolizer increased concentrations of ⮕ METHADONE;CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer.; in people with Other:Opioid-Related Disorders
;LITHIUM;GSK3B;rs6438552;GG;Efficacy;increased response to ⮕ LITHIUM;Genotype GG is associated with increased response to lithium in people with Bipolar Disorder.; in people with Disease:Bipolar Disorder
;TACROLIMUS;ABCB1;rs1045642;AA;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype AA is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Other:Kidney Transplantation
;LITHIUM;NR1D1, THRA;rs2071427;TT;Efficacy;increased response to ⮕ LITHIUM;Genotype TT is associated with increased response to lithium in people with Bipolar Disorder.; in people with Disease:Bipolar Disorder
;TACROLIMUS;CYP3A5;CYP3A5 poor metabolizers;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ TACROLIMUS;CYP3A5 poor metabolizer is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 intermediate metabolizer.; in people with Disease:Kidney Transplantation
;MORPHINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased exposure to ⮕ MORPHINE;CYP2D6 poor metabolizer is associated with decreased exposure to morphine in infants as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in infants 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Disease:Breast Neoplasms
;SULFAPYRIDINE;NAT2;NAT2*5;*5/*5;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *5/*5 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ ARIPIPRAZOLE;CYP2D6 poor metabolizer is associated with increased dose-adjusted trough concentrations of aripiprazole in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer.; in people with Disease:Psychotic Disorder
;ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ ATOMOXETINE;CYP2C19 poor metabolizer is associated with increased concentrations of atomoxetine as compared to CYP2C19 normal metabolizer and intermediate metabolizer.;  
;SULFAPYRIDINE;NAT2;NAT2*4, NAT2*6;*6;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *6 is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;decreased dose of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 (assigned as normal metabolizer and intermediate metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7 (assigned as poor metabolizer phenotype) .; in people with Other:Heart transplantation
;ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;Metabolism/PK;slow acetylator decreased clearance of ⮕ ISONIAZID;NAT2 *5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7 (assigned as slow acetylator phenotype) is associated with decreased clearance of isoniazid in children with Tuberculosis as compared to NAT2 *4/*5 + *4/*6 + *4/*39 + *4/*7G + *5/*1 (assigned as intermediate acetylator phenotype) .; in children with Disease:Tuberculosis
;TACROLIMUS;ABCB1;rs1045642;GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Other:Kidney Transplantation
;INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;Efficacy;increased discontinuation of ⮕ INFLIXIMAB;HLA-DQA1 *05 is associated with increased discontinuation of infliximab in people with Crohn Disease.; in people with Efficacy:Crohn Disease
;TACROLIMUS;ABCB1;rs1045642;AA;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;SULFAPYRIDINE;NAT2;NAT2*6;*6/*6;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *6/*6 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;ENZYME INHIBITORS;CYP19A1;rs700518;CC;Other;response to ⮕ ENZYME INHIBITORS;Genotype CC is associated with response to Enzyme inhibitors in women with Breast Neoplasms as compared to genotypes CC + CT.; in women with Disease:Breast Neoplasms
;TACROLIMUS;ABCB1;rs1128503;AA;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;CORTICOSTEROIDS;FCER2;rs28364072;G;Dosage;increased dose of ⮕ CORTICOSTEROIDS;Allele G is associated with increased dose of corticosteroids in children Asthma as compared to allele A.; in children Disease:Asthma
;TACROLIMUS;ABCB1;rs2032582;AA;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype AA is associated with decreased clearance of tacrolimus in people with Kidney Transplantation.; in people with Disease:Kidney Transplantation
;HYDROCHLOROTHIAZIDE, OLMESARTAN;SLC22A1;rs34059508;AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ HYDROCHLOROTHIAZIDE, OLMESARTAN;Genotype AG is associated with increased dose-adjusted trough concentrations of hydrochlorothiazide null olmesartan in healthy individuals as compared to genotype GG.; in healthy individuals 
;TACROLIMUS;ABCB1;rs1045642;AG + GG;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes AG + GG is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype AA.; in people with Disease:Liver transplantation
;HYDRALAZINE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*16 + *4/*6 + *4/*7;Metabolism/PK;rapid acetylator increased metabolism of ⮕ HYDRALAZINE;NAT2 *4/*16 + *4/*6 + *4/*7 (assigned as rapid acetylator phenotype) are associated with increased metabolism of hydralazine in women with Hypertension and Pregnancy as compared to NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 (assigned as slow acetylator phenotype) .; in women with Other:Hypertension, Other:Pregnancy
;HALOPERIDOL;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ HALOPERIDOL;CYP2D6 poor metabolizer is associated with increased dose-adjusted trough concentrations of haloperidol in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer.; in people with Disease:Psychotic Disorder
;ESCITALOPRAM;;rs12154537;G;Efficacy;increased response to ⮕ ESCITALOPRAM;Allele G is associated with increased response to escitalopram in people with Depressive Disorder, Major as compared to allele A.; in people with Other:Major Depressive Disorder
;MORPHINE;ABCB1;rs1128503;AG + GG;Metabolism/PK;decreased concentrations of ⮕ MORPHINE;Genotypes AG + GG are associated with decreased concentrations of morphine as compared to genotype AA.;  
;SULFAPYRIDINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7;Metabolism/PK;slow acetylator increased concentrations of ⮕ SULFAPYRIDINE;NAT2 *16/*16 + *16/*5 + *16/*6 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased concentrations of sulfapyridine in healthy individuals as compared to NAT2 *4/*4.; in healthy individuals 
;ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;*4/*4;Dosage, Metabolism/PK;rapid acetylator increased dose of ⮕ ISONIAZID;NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased dose of isoniazid in people with Tuberculosis as compared to NAT2 *19 + *14 + *16 + *6 + *7 (assigned as slow acetylator phenotype) .; in people with Disease:Tuberculosis
;DOCETAXEL;SLCO1B3;rs11045585;G;Other, Metabolism/PK;decreased clearance of ⮕ DOCETAXEL;Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.; in people with Disease:Nasopharyngeal Neoplasms
;SULFAPYRIDINE;NAT2;NAT2*5, NAT2*7;*5/*7;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *5/*7 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;DOCETAXEL;SLCO1B3;rs7311358;A;Other, Metabolism/PK;decreased clearance of ⮕ DOCETAXEL;Allele A is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.; in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;SLCO1B3;rs4149118;G;Other, Metabolism/PK;decreased clearance of ⮕ DOCETAXEL;Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.; in people with Disease:Nasopharyngeal Neoplasms
;ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;Metabolism/PK;slow acetylator decreased metabolism of ⮕ ISONIAZID;NAT2 *5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7 (assigned as slow acetylator phenotype) is associated with decreased metabolism of isoniazid in children with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .; in children with Disease:Tuberculosis
;SULFAPYRIDINE;NAT2;NAT2*4, NAT2*7;*7;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *7 is associated with decreased metabolism of sulfapyridine in healthy individuals as compared to NAT2 *4.; in healthy individuals 
;WARFARIN;VKORC1;rs9934438;A;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin.;  
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 + *22/*22 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to CYP3A4 rapid metabolizer.; in people with Other:Heart transplantation
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;MIDAZOLAM;VDR;rs1544410;C;Metabolism/PK;increased clearance of ⮕ MIDAZOLAM;Allele C is associated with increased clearance of midazolam as compared to allele T.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;rs1154831;GG;Efficacy;increased clinical benefit to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype GG is associated with increased clinical benefit to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylarthropathy as compared to genotypes GT + TT.; in people with Other:Spondylarthropathies
;DIAZEPAM;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DIAZEPAM;CYP2C19 poor metabolizer is associated with decreased clearance of diazepam in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased dose-adjusted trough concentrations of ⮕ ESCITALOPRAM;CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.; in children with Other:Depression, Other:Anxiety Disorders
;METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Efficacy;ultrarapid metabolizer decreased response to ⮕ METHADONE;CYP2D6 ultrarapid metabolizer is associated with decreased response to methadone in people with Heroin Dependence as compared to CYP2D6 normal metabolizer and poor metabolizer.; in people with Other:Heroin Dependence
;FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Efficacy;ultrarapid metabolizer decreased clinical benefit to ⮕ FLUOXETINE;CYP2D6 ultrarapid metabolizer is associated with decreased clinical benefit to fluoxetine in children with Depressive Disorder, Major or Obsessive-Compulsive Disorder as compared to CYP2D6 intermediate metabolizer and poor metabolizer.; in children with Efficacy:Major Depressive Disorder, Efficacy:Obsessive-Compulsive Disorder
;HYDRALAZINE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;Efficacy;slow acetylator increased response to ⮕ HYDRALAZINE;NAT2 *16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6 (assigned as slow acetylator phenotype) is associated with increased response to hydralazine in people with resistant hypertension.; in people with Other:resistant hypertension
;ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;Metabolism/PK;slow acetylator increased concentrations of ⮕ ISONIAZID;NAT2 *16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) is associated with increased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 *4/*14 + *4/*16 + *4/*6 + *4/*7 (assigned as intermediate acetylator phenotype) .; in people with Other:Tuberculosis
;SULFAPYRIDINE;NAT2;NAT2*5, NAT2*6;*5/*6;Metabolism/PK;decreased metabolism of ⮕ SULFAPYRIDINE;NAT2 *5/*6 is associated with decreased metabolism of sulfapyridine in healthy individuals.; in healthy individuals 
;ACETYLISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;Metabolism/PK;slow acetylator decreased concentrations of ⮕ ACETYLISONIAZID;NAT2 *16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) is associated with decreased concentrations of acetylisoniazid in people with Tuberculosis as compared to NAT2 *4/*14 + *4/*16 + *4/*6 + *4/*7 (assigned as intermediate acetylator phenotype) .; in people with Other:Tuberculosis
;DIPYRONE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;Metabolism/PK;slow acetylator decreased metabolism of ⮕ DIPYRONE;NAT2 *16 + *6 + *7 + *14 (assigned as slow acetylator phenotype) are associated with decreased metabolism of dipyrone in healthy individuals.; in healthy individuals 
;BUPROPION;CYP2B6;CYP2B6*6;*6;Metabolism/PK;increased exposure to ⮕ BUPROPION;CYP2B6 *6 is associated with increased exposure to bupropion in people with Depressive Disorder, Major.; in people with Other:Major Depressive Disorder
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*41;*1xN/*41;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ CODEINE;CYP2D6 *1xN/*41 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;WARFARIN;VKORC1;rs7294;T;Dosage, Metabolism/PK;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin.;  
;PARAMETHOXYMETHAMPHETAMINE;CYP2D6;CYP2D6 normal metabolizer genotype;;Metabolism/PK;normal metabolizer increased metabolism of ⮕ PARAMETHOXYMETHAMPHETAMINE;CYP2D6 normal metabolizer is associated with increased metabolism of paramethoxymethamphetamine in people with Substance-Related Disorders as compared to CYP2D6 poor metabolizer.; in people with Disease:Substance-Related Disorders
;MARAVIROC;CYP3A5;CYP3A5 intermediate metabolizers;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ MARAVIROC;CYP3A5 intermediate metabolizer is associated with increased concentrations of maraviroc in people with HIV Infections as compared to CYP3A5 normal metabolizer.; in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Efficacy;intermediate metabolizer and poor metabolizer decreased response to ⮕ CLOPIDOGREL;CYP2C19 intermediate metabolizer and poor metabolizer are associated with decreased response to clopidogrel as compared to CYP2C19 normal metabolizer.;  
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ CODEINE;CYP2D6 *1/*2xN (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;Efficacy;poor metabolizer decreased response to ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased response to endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in women with Disease:Breast Neoplasms
;CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN, CYP2D6*41;*2xN/*41;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ CODEINE;CYP2D6 *2xN/*41 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*10;*1xN/*10;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ CODEINE;CYP2D6 *1xN/*10 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in women with Disease:Breast Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer decreased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with decreased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) .; in people with Disease:Fungal infectious disease
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;Metabolism/PK;increased exposure to ⮕ CITALOPRAM, ESCITALOPRAM;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;or  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ EFAVIRENZ;Genotype TT (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG (assigned as normal metabolizer phenotype) .; in people with Disease:HIV infectious disease
;NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ NORTRIPTYLINE;CYP2D6 ultrarapid metabolizer is associated with increased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Disease:Major Depressive Disorder
;HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;rs1799978;C;Efficacy;increased resistance to ⮕ HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;Allele C is associated with increased resistance to haloperidol, olanzapine, perphenazine, quetiapine or risperidone in people with Schizophrenia as compared to allele T.;or in people with Other:Schizophrenia
;MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ MARAVIROC;CYP3A5 poor metabolizer is associated with increased concentrations of maraviroc in people with HIV Infections as compared to CYP3A5 normal metabolizer.; in people with Disease:HIV infectious disease
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Metabolism/PK;ultrarapid metabolizer decreased exposure to ⮕ CITALOPRAM, ESCITALOPRAM;CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;or  
;TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;Dosage, Metabolism/PK;normal metabolizer and intermediate metabolizer increased time to response to ⮕ TACROLIMUS;CYP3A5 normal metabolizer and intermediate metabolizer is associated with increased time to response to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 poor metabolizer.; in people with Other:Kidney Transplantation
;NORTRIPTYLINE;CYP2D6;CYP2D6 intermediate metabolizers;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ NORTRIPTYLINE;CYP2D6 intermediate metabolizer is associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;poor metabolizer increased concentrations of ⮕ TACROLIMUS;CYP3A4 *1/*22 (assigned as poor metabolizer phenotype) is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;HYDROCODONE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ HYDROCODONE;CYP2D6 poor metabolizer is associated with decreased metabolism of hydrocodone in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in healthy individuals 
;IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ IMIPRAMINE;CYP2D6 poor metabolizer is associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ ATOMOXETINE;CYP2C19 poor metabolizer is associated with decreased clearance of atomoxetine as compared to CYP2C19 normal metabolizer and intermediate metabolizer.;  
;IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ IMIPRAMINE;CYP2C19 poor metabolizer is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ IMIPRAMINE;CYP2C19 poor metabolizer is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.; in people with Disease:Major Depressive Disorder
;IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ IMIPRAMINE;CYP2C19 poor metabolizer is associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Disease:Breast Neoplasms
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ RISPERIDONE;CYP2D6 poor metabolizer is associated with increased dose-adjusted trough concentrations of risperidone in people with Psychotic Disorders as compared to CYP2D6 normal metabolizer.; in people with Disease:Psychotic Disorder
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;Efficacy, Metabolism/PK;poor metabolizer decreased metabolism of ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .; in people with Disease:Coronary Artery Disease
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.; in healthy individuals 
;TAMOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;Metabolism/PK;intermediate metabolizer increased dose of ⮕ TAMOXIFEN;CYP2D6 intermediate metabolizer is associated with increased dose of tamoxifen in women Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women Disease:Breast Neoplasms
;PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;*1/*5 + *2/*36 + *5/*10 + *5/*5;Metabolism/PK;poor metabolizer increased concentrations of ⮕ PROPAFENONE;CYP2D6 *1/*5 + *2/*36 + *5/*10 + *5/*5 (assigned as poor metabolizer phenotype) is associated with increased concentrations of propafenone in people with Tachycardia as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2 + *1/*10 + *2/*10 + *10/*10 (assigned as normal metabolizer and intermediate metabolizer phenotype) .; in people with Other:Tachycardia
;IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;Dosage;poor metabolizer decreased dose of ⮕ IMIPRAMINE;CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with decreased dose of imipramine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.; in people with Disease:Major Depressive Disorder
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Metabolism/PK;decreased exposure to ⮕ CITALOPRAM, ESCITALOPRAM;CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;or  
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;Efficacy, Metabolism/PK;poor metabolizer decreased response to ⮕ CLOPIDOGREL;CYP2C19 *1/*2 + *1/*8 + *2/*2 (assigned as poor metabolizer phenotype) is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .; in people with Disease:Coronary Artery Disease
;METHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ METHAMPHETAMINE;CYP2D6 *4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36 (assigned as intermediate metabolizer phenotype) are associated with increased concentrations of methamphetamine as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *2/*2 + *2/*4 + *2/*5 + *2/*10 (assigned as normal metabolizer phenotype) .;  
;TOLTERODINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ TOLTERODINE;CYP2D6 poor metabolizer is associated with decreased clearance of tolterodine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased exposure to ⮕ RISPERIDONE;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased exposure to risperidone in people with Psychotic Disorders or Schizophrenia as compared to CYP2D6 normal metabolizer.; in people with Other:Psychotic Disorder, Other:Schizophrenia
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9 *2 + *3 (assigned as poor metabolizer phenotype) are associated with decreased concentrations of 4-hydroxytamoxifen and endoxifen in women with Breast Neoplasms as compared to CYP2C9 *1/*1 (assigned as normal metabolizer phenotype) .;and in women with Disease:Breast Neoplasms
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*5/*10 + *4/*10 + *10/*10 + *10/*41;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *5/*10 + *4/*10 + *10/*10 + *10/*41 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of risperidone in children as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *2/*10 + *1/*4 + *1/*5 + *2/*41 + *1/*41 (assigned as normal metabolizer phenotype) .; in children 
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine as compared to CYP2D6 normal metabolizer.;  
;METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;Dosage;ultrarapid metabolizer increased dose of ⮕ METHADONE;CYP2D6 *1/*2xN + *2/*2xN (assigned as ultrarapid metabolizer phenotype) are associated with increased dose of methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer.; in people with Other:Opioid-Related Disorders
;DESIPRAMINE, IMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;Metabolism/PK;poor metabolizer increased concentrations of ⮕ DESIPRAMINE, IMIPRAMINE;CYP2D6 *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.;and in people with Disease:Major Depressive Disorder
;TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;rs890293;AA + AC;Metabolism/PK;increased concentrations of ⮕ TRANS 4-HYDROXYPRAZIQUANTEL;Genotypes AA + AC is associated with increased concentrations of trans 4-hydroxypraziquantel in children with Schistosomiasis as compared to genotype CC.; in children with Other:Schistosomiasis
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine as compared to CYP2D6 normal metabolizer.;  
;PERPHENAZINE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ PERPHENAZINE;CYP2D6 poor metabolizer is associated with increased concentrations of perphenazine as compared to CYP2D6 normal metabolizer.;  
;TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 +*2/*3;Dosage, Metabolism/PK;intermediate metabolizer and poor metabolizer decreased dose of ⮕ TACROLIMUS;CYP2C19 *1/*2 + *1/*3 + *2/*2 +*2/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with decreased dose of tacrolimus in people with heart transplantation as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Heart transplantation
;VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Toxicity;poor metabolizer increased discontinuation of ⮕ VORTIOXETINE;CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased discontinuation of vortioxetine as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;  
;FENTANYL;;poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ FENTANYL;CYP3A poor metabolizer is associated with decreased metabolism of fentanyl in people with Pain.; in people with Disease:Pain
;ESCITALOPRAM;CYP2C19;CYP2C19 ultrarapid metabolizer phenotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ ESCITALOPRAM;CYP2C19 ultrarapid metabolizer is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;*1/*1;Metabolism/PK;normal metabolizer increased dose of ⮕ WARFARIN;CYP2C9 *1/*1 (assigned as normal metabolizer phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *1/*8 + *2/*3 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) .; in healthy individuals 
;NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ NORTRIPTYLINE;CYP2D6 poor metabolizer is associated with decreased metabolism of nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Disease:Major Depressive Disorder
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;Metabolism/PK;intermediate metabolizer decreased clearance of ⮕ PAROXETINE;CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizer phenotype) are associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ ESCITALOPRAM;CYP2C19 poor metabolizer is associated with decreased metabolism of escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.; in people with Disease:Major Depressive Disorder
;ETHANOL;OPRM1;rs2075572;G;Efficacy;increased response to ⮕ ETHANOL;Allele G is associated with increased response to ethanol as compared to allele C.;  
;PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Efficacy;intermediate metabolizer and poor metabolizer increased clinical benefit to ⮕ PROTON PUMP INHIBITORS;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased clinical benefit to Proton pump inhibitors in people with Helicobacter Infections as compared to CYP2C19 normal metabolizer.; in people with Other:Helicobacter Infections
;TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ TRAMADOL;CYP2D6 ultrarapid metabolizer is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;METOPROLOL;CYP2D6;CYP2D6 poor metabolizers;;Dosage;poor metabolizer decreased dose of ⮕ METOPROLOL;CYP2D6 poor metabolizer is associated with decreased dose of metoprolol.;  
;ETHANOL;OPRM1;rs548646;T;Efficacy;increased response to ⮕ ETHANOL;Allele T is associated with increased response to ethanol as compared to allele C.;  
;GLICLAZIDE;KCNQ1;rs2237892;T;Efficacy;increased clinical benefit to ⮕ GLICLAZIDE;Allele T is associated with increased clinical benefit to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;NICOTINE;DRD2;rs1799732;G/del + del/del;Efficacy;increased response to ⮕ NICOTINE;Genotypes G/del + del/del is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.; in people with Disease:Tobacco Use Disorder
;PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ PAROXETINE;CYP2D6 poor metabolizer is associated with decreased clearance of paroxetine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DESIPRAMINE;CYP2D6 poor metabolizer is associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;LINAGLIPTIN;TCF7L2;rs7903146;CC + CT;Efficacy;increased clinical benefit to ⮕ LINAGLIPTIN;Genotypes CC + CT is associated with increased clinical benefit to linagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.; in people with Other:Diabetes Mellitus, Type 2
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;Efficacy;poor metabolizer increased response to ⮕ CITALOPRAM, ESCITALOPRAM;CYP2C19 poor metabolizer is associated with increased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.;or in people with Disease:Major Depressive Disorder
;ETHANOL;OPRM1;rs681243;T;Efficacy;increased response to ⮕ ETHANOL;Allele T is associated with increased response to ethanol as compared to allele C.;  
;DEXTROMETHORPHAN;CYP2D6;CYP2D6 normal metabolizer genotype;;Metabolism/PK;normal metabolizer increased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 normal metabolizer is associated with increased metabolism of dextromethorphan in children as compared to CYP2D6 poor metabolizer.; in children 
;TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ TRAMADOL;CYP2D6 ultrarapid metabolizer is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer.; in healthy individuals 
;HYDROXYBUPROPION;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased exposure to ⮕ HYDROXYBUPROPION;CYP2B6 intermediate metabolizer and poor metabolizer is associated with decreased exposure to hydroxybupropion in healthy individuals as compared to CYP2B6 normal metabolizer.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 normal metabolizer genotype;;Metabolism/PK;normal metabolizer increased metabolism of ⮕ TRAMADOL;CYP2D6 normal metabolizer is associated with increased metabolism of tramadol in healthy individuals as compared to CYP2D6 poor metabolizer.; in healthy individuals 
;AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;Efficacy;normal metabolizer decreased response to ⮕ AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19 normal metabolizer is associated with decreased response to amoxicillin, clarithromycin and esomeprazole in people with Gastritis as compared to CYP2C19 intermediate metabolizer and poor metabolizer.;and in people with Disease:Gastritis
;DABIGATRAN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DABIGATRAN;CYP2D6 poor metabolizer is associated with decreased clearance of dabigatran in healthy individuals.; in healthy individuals 
;ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ ESCITALOPRAM;CYP2C19 poor metabolizer is associated with decreased metabolism of escitalopram as compared to CYP2C19 normal metabolizer.;  
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;Efficacy;poor metabolizer decreased response to ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased response to venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Efficacy:Major Depressive Disorder
;BUPROPION;COMT;rs4680;AG + GG;Efficacy;increased response to ⮕ BUPROPION;Genotypes AG + GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotype AA.; in people with Other:Major Depressive Disorder
;ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ ARIPIPRAZOLE;CYP2D6 intermediate metabolizer is associated with decreased metabolism of aripiprazole as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .;  
;CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Efficacy;intermediate metabolizer and poor metabolizer decreased response to ⮕ CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6 intermediate metabolizer and poor metabolizer are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizer.;or in people with Other:Neoplasms, Other:Pain
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased metabolism of venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Other:Major Depressive Disorder
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*41;*1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ PAROXETINE;CYP2D6 *1/*5 + *5/*10 + *10/*10 + *10/*14 + *10/*41 (assigned as intermediate metabolizer phenotype) are associated with decreased metabolism of paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*41 + *2/*10 + *2/*14 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;ETHANOL;OPRM1;rs1461773;A;Efficacy;increased response to ⮕ ETHANOL;Allele A is associated with increased response to ethanol as compared to allele G.;  
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;Efficacy;increased response to ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6 *4/*4 + *3/*5 is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to CYP2D6 *4/*10 + *4/*41 + *5/*10 + *5/*41 + *10/*41 + *10/*10 + *4/*9 (assigned as intermediate metabolizer phenotype) .;  
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Disease:Breast Neoplasms
;ETHANOL;OPRM1;rs3778148;T;Efficacy;increased response to ⮕ ETHANOL;Allele T is associated with increased response to ethanol as compared to allele G.;  
;AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;Efficacy;normal metabolizer decreased clinical benefit to ⮕ AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19 normal metabolizer is associated with decreased clinical benefit to amoxicillin, clarithromycin and lansoprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer.;and in people with Efficacy:Helicobacter Infections
;AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;Efficacy;normal metabolizer decreased clinical benefit to ⮕ AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19 normal metabolizer is associated with decreased clinical benefit to amoxicillin, clarithromycin and omeprazole in people with Helicobacter Infections as compared to CYP2C19 poor metabolizer.;and in people with Efficacy:Helicobacter Infections
;MIDAZOLAM;VDR;rs4516035;T;Metabolism/PK;increased clearance of ⮕ MIDAZOLAM;Allele T is associated with increased clearance of midazolam as compared to allele C.;  
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*6;*1xN/*1;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ CODEINE;CYP2D6 *1xN/*1 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of codeine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;OXYCODONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased exposure to ⮕ OXYCODONE;CYP2D6 poor metabolizer is associated with increased exposure to oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;OXYMORPHONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer decreased exposure to ⮕ OXYMORPHONE;CYP2D6 poor metabolizer is associated with decreased exposure to oxymorphone in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;OXYMORPHONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer decreased exposure to ⮕ OXYMORPHONE;CYP2D6 poor metabolizer is associated with decreased exposure to oxymorphone in healthy individuals as compared to CYP2D6 ultrarapid metabolizer.; in healthy individuals 
;NOROXYMORPHONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ NOROXYMORPHONE;CYP2D6 poor metabolizer is associated with decreased concentrations of noroxymorphone in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Efficacy;poor metabolizer decreased response to ⮕ AMITRIPTYLINE;CYP2D6 poor metabolizer is associated with decreased response to amitriptyline in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer.; in people with Other:Phantom limb syndrome
;NOROXYMORPHONE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ NOROXYMORPHONE;CYP2D6 poor metabolizer is associated with decreased concentrations of noroxymorphone in healthy individuals as compared to CYP2D6 ultrarapid metabolizer.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;Efficacy;poor metabolizer increased response to ⮕ TRAMADOL;CYP2D6 poor metabolizer is associated with increased response to tramadol in people with Phantom limb syndrome as compared to CYP2D6 normal metabolizer.; in people with Other:Phantom limb syndrome
;TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer and normal metabolizer;;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased concentrations of ⮕ TAMSULOSIN;CYP2D6 normal metabolizer and intermediate metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizer.; in healthy individuals 
;NOROXYCODONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer decreased exposure to ⮕ NOROXYCODONE;CYP2D6 ultrarapid metabolizer is associated with decreased exposure to noroxycodone in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;MORPHINE;COMT;rs4680;A;Efficacy;increased response to ⮕ MORPHINE;Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G.; in people with Disease:Low Back Pain
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Efficacy;poor metabolizer increased response to ⮕ VORICONAZOLE;CYP2C19 poor metabolizer is associated with increased response to voriconazole as compared to CYP2C19 normal metabolizer.;  
;TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer and normal metabolizer;;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased concentrations of ⮕ TAMSULOSIN;CYP2D6 normal metabolizer and intermediate metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizer.; in healthy individuals 
;ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AC + CC are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.; in people with Disease:Major Depressive Disorder
;TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer and normal metabolizer;;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased concentrations of ⮕ TAMSULOSIN;CYP2D6 normal metabolizer and intermediate metabolizer are associated with decreased concentrations of tamsulosin in healthy individuals as compared to CYP2D6 poor metabolizer.; in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ VENLAFAXINE;CYP2D6 poor metabolizer is associated with decreased clearance of venlafaxine as compared to CYP2D6 normal metabolizer.;  
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 intermediate metabolizer and poor metabolizer are associated with increased trough concentration of voriconazole as compared to CYP2C19 normal metabolizer.;  
;OPIOIDS;COMT;rs4680;GG;Dosage;increased dose of ⮕ OPIOIDS;Genotype GG is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.; in people with Disease:Pain, Postoperative
;ATENOLOL, METOPROLOL;ADRB2;rs1042714;CC;Efficacy;increased response to ⮕ ATENOLOL, METOPROLOL;Genotype CC is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes CG + GG.;or in people with Other:Tachycardia
;TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*5 + *4/*4;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TRIMIPRAMINE;CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN.; in healthy individuals 
;TAMSULOSIN;CYP2D6;CYP2D6 poor metabolizer genotype;;Efficacy;poor metabolizer increased response to ⮕ TAMSULOSIN;CYP2D6 poor metabolizer is associated with increased response to tamsulosin in healthy individuals as compared to CYP2D6 normal metabolizer and intermediate metabolizer.; in healthy individuals 
;GLICLAZIDE;KCNQ1;rs2237895;C;Efficacy;increased clinical benefit to ⮕ GLICLAZIDE;Allele C is associated with increased clinical benefit to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele A.; in people with Other:Diabetes Mellitus, Type 2
;WARFARIN;CYP2C9;CYP2C9 normal metabolizers;;Dosage;normal metabolizer increased dose of ⮕ WARFARIN;CYP2C9 normal metabolizer is associated with increased dose of warfarin as compared to CYP2C9 intermediate metabolizer and poor metabolizer.;  
;SOLANIDINE;CYP2D6;CYP2D6 poor metabolizer genotype;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ SOLANIDINE;CYP2D6 poor metabolizer is associated with decreased metabolism of solanidine in people with Depression.; in people with Other:Depression
;FLECAINIDE;CYP2D6;CYP2D6 normal metabolizer genotype;;Metabolism/PK;normal metabolizer concentrations of ⮕ FLECAINIDE;CYP2D6 normal metabolizer is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 intermediate metabolizer and poor metabolizer.; in people with Disease:Tachycardia, Supraventricular
;TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*5 + *4/*4;Metabolism/PK;poor metabolizer decreased clearance of ⮕ TRIMIPRAMINE;CYP2D6 *3/*3 + *3/*5 + *4/*4 (assigned as poor metabolizer phenotype) are associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN + *1/*1.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ VORICONAZOLE;Genotypes *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of voriconazole in people with Mycoses.; in people with Disease:Fungal infectious disease
;PRIDOPIDINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ PRIDOPIDINE;CYP2D6 poor metabolizer is associated with decreased metabolism of pridopidine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer increased exposure to ⮕ MORPHINE;CYP2D6 ultrarapid metabolizer is associated with increased exposure to morphine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TRAMADOL;CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;RABEPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ RABEPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;BUPROPION;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased metabolism of ⮕ BUPROPION;CYP2C19 *2 + *3 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2C19 *17 (assigned as normal metabolizer phenotype) .; in women with Disease:Pregnancy
;(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*1xN;Metabolism/PK;decreased concentrations of ⮕ (R)-METHADONE, (S)-METHADONE;CYP2D6 *1/*1xN is associated with decreased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer phenotype) .;and in people with Other:Heroin Dependence
;METHADONE;OPRM1;rs1799971;AA;Efficacy;increased clinical benefit to ⮕ METHADONE;Genotype AA is associated with increased clinical benefit to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Other:Opioid-Related Disorders
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17;*1/*2 + *1/*9 + *1/*17;Metabolism/PK;reduced metabolizers decreased metabolism of ⮕ NICOTINE;CYP2A6 *1/*2 + *1/*9 + *1/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of nicotine in healthy individuals as compared to CYP2A6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;METRONIDAZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17;*1/*2 + *1/*9 + *1/*17;Metabolism/PK;reduced metabolizers decreased metabolism of ⮕ METRONIDAZOLE;CYP2A6 *1/*2 + *1/*9 + *1/*17 (assigned as reduced metabolizers phenotype) are associated with decreased metabolism of metronidazole in healthy individuals as compared to CYP2A6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;ARSENIC COMPOUNDS;CBS;rs4920037;AA + AG;Toxicity, Metabolism/PK;increased metabolism of ⮕ ARSENIC COMPOUNDS;Genotypes AA + AG are associated with increased metabolism of Arsenic compounds as compared to genotype GG.;  
;(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*6;Metabolism/PK;increased concentrations of ⮕ (R)-METHADONE, (S)-METHADONE;CYP2D6 *3/*4 + *4/*4 + *4/*6 are associated with increased concentrations of (R)-methadone and (S)-methadone in people with Heroin Dependence as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as normal metabolizer phenotype) .;and in people with Other:Heroin Dependence
;MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Dosage, Efficacy;ultrarapid metabolizer decreased dose of ⮕ MORPHINE;CYP2D6 ultrarapid metabolizer is associated with decreased dose of morphine in women with Pain, Postoperative.; in women with Disease:Pain, Postoperative
;CODEINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ CODEINE;CYP2D6 poor metabolizer is associated with decreased metabolism of codeine.;  
;CLOMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ CLOMIPRAMINE;CYP2C19 poor metabolizer is associated with decreased clearance of clomipramine in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased concentrations of ⮕ O-DESMETHYLTRAMADOL;CYP2D6 intermediate metabolizer and poor metabolizer are associated with decreased concentrations of o-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizer.; in people with Other:Neoplasms, Other:Pain
;(S)-METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer decreased concentrations of ⮕ (S)-METHADONE;CYP2D6 ultrarapid metabolizer is associated with decreased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer and intermediate metabolizer.; in people with Disease:Opioid-Related Disorders
;WARFARIN;VKORC1;rs9934438;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AA + AG.; in people with Other:Heart valve replacement
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Efficacy;intermediate metabolizer and poor metabolizer increased clinical benefit to ⮕ VORICONAZOLE;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased clinical benefit to voriconazole as compared to CYP2C19 normal metabolizer.;  
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;*4/*4;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TRAMADOL;CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of tramadol as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*6 + *1/*9 + *4/*9 (assigned as normal metabolizer phenotype) .;  
;METHOTREXATE;FOXP3;rs3761548;G;Other;decreased response to ⮕ METHOTREXATE;Allele G is associated with decreased response to methotrexate in people with Psoriasis as compared to allele T.; in people with Disease:Psoriasis
;ATENOLOL, METOPROLOL;ADRB2;rs1042713;AA;Efficacy;increased response to ⮕ ATENOLOL, METOPROLOL;Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG.;or in people with Other:Tachycardia
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;poor metabolizer increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 (assigned as poor metabolizer phenotype) are associated with increased trough concentration of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Disease:Fungal infectious disease
;N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ N-DESMETHYLTRAMADOL;CYP2D6 intermediate metabolizer and poor metabolizer are associated with increased concentrations of n-desmethyltramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizer.; in people with Other:Neoplasms, Other:Pain
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.;or in women with Disease:Breast Neoplasms
;GEMCITABINE;NT5C2;rs11598702;TT;Metabolism/PK;decreased clearance of ⮕ GEMCITABINE;Genotype TT is associated with decreased clearance of gemcitabine as compared to genotypes CC + CT.;  
;GEMCITABINE;CDA;rs1048977;TT;Metabolism/PK;decreased metabolism of ⮕ GEMCITABINE;Genotype TT is associated with decreased metabolism of gemcitabine as compared to genotypes CC + CT.;  
;OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;OXYMORPHONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;Metabolism/PK;normal metabolizer increased exposure to ⮕ OXYMORPHONE;CYP2D6 *1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2 (assigned as normal metabolizer phenotype) is associated with increased exposure to oxymorphone in children with as compared to CYP2D6 *1/*4 + *1/*6 + *17/*41 + *2/*4 + *2/*5 + *4/*41 (assigned as intermediate metabolizer and poor metabolizer phenotype) .; in children with 
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;rs7202877;GG + GT;Efficacy;decreased response to ⮕ DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;Genotypes GG + GT is associated with decreased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus, Type 2 as compared to genotype TT.; in people with Other:Diabetes Mellitus, Type 2
;LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Efficacy;intermediate metabolizer and poor metabolizer increased clinical benefit to ⮕ LANSOPRAZOLE, OMEPRAZOLE;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased clinical benefit to lansoprazole or omeprazole in people with Helicobacter Infections as compared to CYP2C19 normal metabolizer.;or in people with Other:Helicobacter Infections
;SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*6 + *6/*9;Metabolism/PK;poor metabolizer increased concentrations of ⮕ SERTRALINE;CYP2B6 *6/*6 + *6/*9 (assigned as poor metabolizer phenotype) are associated with increased concentrations of sertraline as compared to CYP2B6 *1/*1.;  
;OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;Metabolism/PK;poor metabolizer increased exposure to ⮕ OLANZAPINE;CYP2C9 poor metabolizer is associated with increased exposure to olanzapine in healthy individuals as compared to CYP2C9 normal metabolizer and intermediate metabolizer.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;Genotypes *3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to genotypes *1 + *2 + *35 (assigned as normal metabolizer phenotype) .; in women with Disease:Breast Neoplasms
;ARSENIC COMPOUNDS;CBS;rs234709;CT + TT;Toxicity, Metabolism/PK;increased metabolism of ⮕ ARSENIC COMPOUNDS;Genotypes CT + TT are associated with increased metabolism of Arsenic compounds as compared to genotype CC.;  
;3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;*1 + *2;Metabolism/PK;normal metabolizer and intermediate metabolizer increased concentrations of ⮕ 3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6 *1 + *2 (assigned as normal metabolizer and intermediate metabolizer phenotype) is associated with increased concentrations of 3-hydroxycotinine and 3-hydroxycotinine glucuronide in people with Tobacco Use Disorder as compared to CYP2A6 *10 + *9 (assigned as poor metabolizer phenotype) .;and in people with Other:Tobacco Use Disorder
;RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Metabolism/PK;ultrarapid metabolizer increased clearance of ⮕ RISPERIDONE;CYP2D6 ultrarapid metabolizer is associated with increased clearance of risperidone in people with Psychotic Disorders as compared to genotypes *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer phenotype) .; in people with Disease:Psychotic Disorder
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ RISPERIDONE;CYP2D6 poor metabolizer is associated with decreased metabolism of risperidone in children as compared to CYP2D6 normal metabolizer and intermediate metabolizer.; in children 
;SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs2239179;C;Efficacy;decreased response to ⮕ SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T.; in people with Disease:Asthma
;SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs1540339;C;Efficacy;decreased response to ⮕ SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele C is associated with decreased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele T.; in people with Disease:Asthma
;ENDOXIFEN;CYP2C9;CYP2C9 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2C9 poor metabolizer is associated with decreased concentrations of endoxifen as compared to CYP2C9 normal metabolizer.;  
;CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;Dosage, Efficacy;increased response to ⮕ CLOPIDOGREL;Genotypes CT + TT is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.; in people with Disease:Acute coronary syndrome
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer increased trough concentration of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with increased trough concentration of voriconazole in people with Hematologic Diseases and Infection as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .; in people with Disease:Hematologic Disorder, Disease:Infectious disease
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Disease:Breast Neoplasms
;CARISOPRODOL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ CARISOPRODOL;CYP2C19 *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased concentrations of carisoprodol in healthy individuals as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ LANSOPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of lansoprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ IMIPRAMINE;CYP2C19 poor metabolizer is associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.; in people with Disease:Major Depressive Disorder
;GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs3765467;AA + AG;Efficacy;increased clinical benefit to ⮕ GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;Genotypes AA + AG is associated with increased clinical benefit to gemigliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;or in people with Other:Diabetes Mellitus, Type 2
;METHADONE;ABCB1;rs1045642;AA;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.;  
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ FENTANYL;CYP3A5 *1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with decreased clearance of fentanyl in children as compared to CYP3A5 *1/*1 (assigned as normal metabolizer phenotype) .; in children 
;GLICLAZIDE;CYP2C9;CYP2C9 intermediate metabolizers;;Metabolism/PK;intermediate metabolizer decreased clearance of ⮕ GLICLAZIDE;CYP2C9 intermediate metabolizer is associated with decreased clearance of gliclazide in healthy individuals as compared to CYP2C9 normal metabolizer.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;NORQUETIAPINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased exposure to ⮕ NORQUETIAPINE;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased exposure to norquetiapine as compared to CYP2D6 normal metabolizer.;  
;VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ VORICONAZOLE;Genotypes *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with decreased metabolism of voriconazole in people with Mycoses as compared to genotype *1/*1 (assigned as normal metabolizer phenotype) .; in people with Disease:Fungal infectious disease
;TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*2xN;*1/*2xN;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ TROPISETRON;CYP2D6 *1/*2xN (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of tropisetron in healthy individuals as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; in healthy individuals 
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;Metabolism/PK;poor metabolizer increased exposure to ⮕ CITALOPRAM, ESCITALOPRAM;CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizer phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;or  
;INDOMETHACIN;CYP2C9;rs2153628;G;Efficacy;increased response to ⮕ INDOMETHACIN;Allele G is associated with increased response to indomethacin as compared to allele A.;  
;GEMCITABINE;CDA;rs2072671;AA;Metabolism/PK;decreased metabolism of ⮕ GEMCITABINE;Genotype AA is associated with decreased metabolism of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.; in people with Disease:Non-Small Cell Lung Carcinoma
;TACROLIMUS;CYP3A5;CYP3A5 poor metabolizer genotype;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ TACROLIMUS;CYP3A5 poor metabolizer is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to CYP3A5 normal metabolizer and intermediate metabolizer.; in people with Disease:Liver transplantation
;VENLAFAXINE;SLC6A4;rs25531;TT;Efficacy;increased clinical benefit to ⮕ VENLAFAXINE;Genotype TT is associated with increased clinical benefit to venlafaxine in people with Anxiety Disorders as compared to genotypes CC + CT.; in people with Disease:Anxiety Disorders
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 poor metabolizer is associated with decreased concentrations of endoxifen in women Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women Disease:Breast Neoplasms
;OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;NIMODIPINE;CACNA1C;rs2239128;CC;Efficacy;increased response to ⮕ NIMODIPINE;Genotype CC is associated with increased response to nimodipine in healthy individuals as compared to genotype CT.; in healthy individuals 
;ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;Metabolism/PK;intermediate metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 intermediate metabolizer is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.; in women with Disease:Breast Neoplasms
;NIMODIPINE;CACNA1C;rs2239050;CG;Efficacy;increased response to ⮕ NIMODIPINE;Genotype CG is associated with increased response to nimodipine in healthy individuals as compared to genotype CC.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ TRAMADOL;CYP2D6 ultrarapid metabolizer is associated with increased metabolism of tramadol.;  
;OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ OMEPRAZOLE;CYP2C19 poor metabolizer is associated with decreased metabolism of omeprazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ TRAMADOL;CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;Metabolism/PK;poor metabolizer decreased concentrations of ⮕ MARAVIROC;CYP3A5 poor metabolizer is associated with decreased concentrations of maraviroc in people with HIV Infections as compared to CYP3A5 normal metabolizer.; in people with Disease:HIV infectious disease
;VENLAFAXINE;GABRQ;rs3810651;AA + AT;Efficacy;increased response to ⮕ VENLAFAXINE;Genotypes AA + AT are associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;METOPROLOL;CYP2D6;CYP2D6 normal metabolizers;;Metabolism/PK;normal metabolizer increased clearance of ⮕ METOPROLOL;CYP2D6 normal metabolizer is associated with increased clearance of metoprolol in women with Pregnancy as compared to CYP2D6 intermediate metabolizer.; in women with Other:Pregnancy
;CYTARABINE, IDARUBICIN;DCK;rs80143932;G;Efficacy;increased response to ⮕ CYTARABINE, IDARUBICIN;Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.;and in people with Disease:Leukemia, Myeloid, Acute
;FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;Dosage;ultrarapid metabolizer increased dose of ⮕ FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6 ultrarapid metabolizer is associated with increased dose of fentanyl, hydromorphone, opioids, oxycodone or tramadol in women with surgery as compared to CYP2D6 normal metabolizer and intermediate metabolizer and poor metabolizer.;or in women with Other:surgery
;2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;Metabolism/PK;decreased exposure to ⮕ 2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN;UGT1A3 *2 is associated with decreased exposure to 2-hydroxyatorvastatin, 4-hydroxyatorvastatin and atorvastatin in healthy individuals as compared to UGT1A3 *1.;and in healthy individuals 
;CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4 HTTLPR short form (S allele) is associated with decreased concentrations of clozapine and n-desmethylclozapine in people with Schizophrenia as compared to SLC6A4 HTTLPR long form (L allele).;and in people with Other:Schizophrenia
;IBOGAINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ IBOGAINE;CYP2D6 poor metabolizer is associated with decreased clearance of ibogaine in people with Opioid-Related Disorders as compared to CYP2D6 normal metabolizer.; in people with Other:Opioid-Related Disorders
;ATORVASTATIN, ATORVASTATIN LACTONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*22;*2 + *22;Metabolism/PK;intermediate metabolizer increased exposure to ⮕ ATORVASTATIN, ATORVASTATIN LACTONE;CYP3A4 *2 + *22 (assigned as intermediate metabolizer phenotype) is associated with increased exposure to atorvastatin and atorvastatin lactone in healthy individuals as compared to CYP3A4 *1.;and in healthy individuals 
;ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;Metabolism/PK;intermediate metabolizer increased exposure to ⮕ ATOMOXETINE;CYP2D6 *10/*10 (assigned as intermediate metabolizer phenotype) is associated with increased exposure to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.; in children with Other:Attention Deficit Disorder with Hyperactivity
;ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;Efficacy;intermediate metabolizer increased clinical benefit to ⮕ ATOMOXETINE;CYP2D6 *10/*10 (assigned as intermediate metabolizer phenotype) is associated with increased clinical benefit to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.; in children with Other:Attention Deficit Disorder with Hyperactivity
;AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;CYP2D6 poor metabolizer;;Efficacy;poor metabolizer increased clinical benefit to ⮕ AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6 poor metabolizer is associated with increased clinical benefit to amphetamine or lisdexamfetamine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.;or in children with Other:Attention Deficit Disorder with Hyperactivity
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs502434;CC;Efficacy;decreased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Genotype CC is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.;or in people with Disease:Major Depressive Disorder
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*41;*41;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *41 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*39;*39;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;CYP2A6 *39 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.;  
;ISONIAZID;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator increased concentrations of ⮕ ISONIAZID;NAT2 slow acetylator is associated with increased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 intermediate acetylator.; in people with Other:Tuberculosis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Kidney Transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;Efficacy;decreased clinical benefit to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1 *05 is associated with decreased clinical benefit to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases or Inflammation.; in people with Other:Inflammatory Bowel Diseases, Other:Inflammation
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Dosage, Efficacy;dose of ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with dose of clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.; in people with Other:percutaneous coronary intervention
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*95, CYP2D6*97;*10/*87 + *10/*95 + *97/*97;Metabolism/PK;increased exposure to ⮕ METOPROLOL;CYP2D6 *10/*87 + *10/*95 + *97/*97 is associated with increased exposure to metoprolol in healthy individuals as compared to CYP2D6 *1/*1.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 poor metabolizer is associated with increased dose-adjusted trough concentrations of voriconazole in healthy individuals as compared to CYP2C19 normal metabolizer.; in healthy individuals 
;1-HYDROXYMIDAZOLAM, MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;increased concentrations of ⮕ 1-HYDROXYMIDAZOLAM, MIDAZOLAM;CYP3A4 *1/*22 is associated with increased concentrations of 1-hydroxymidazolam and midazolam in healthy individuals as compared to CYP3A4 *1/*1.;and in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Metabolism/PK;ultrarapid metabolizer decreased concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased concentrations of voriconazole as compared to CYP2C19 *1/*1.;  
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.; in people with Disease:Coronary Artery Disease
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761554;TT;Efficacy;decreased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.;or in people with Disease:Major Depressive Disorder
;WARFARIN;CALU;rs339097;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin.;  
;ISONIAZID;NAT2;NAT2 intermediate acetylator;;Metabolism/PK;intermediate acetylator and rapid acetylator increased clearance of ⮕ ISONIAZID;NAT2 intermediate acetylator and rapid acetylator is associated with increased clearance of isoniazid in people with Tuberculosis as compared to NAT2 slow acetylator.; in people with Other:Tuberculosis
;DIHYDROARTEMISININ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*6 + *18/*18 + *1/*6;Metabolism/PK;decreased concentrations of ⮕ DIHYDROARTEMISININ;CYP2B6 *6/*6 + *18/*18 + *1/*6 is associated with decreased concentrations of dihydroartemisinin in people with Malaria, Falciparum as compared to CYP2B6 *1/*1.; in people with Other:Malaria, Falciparum
;DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3;Metabolism/PK;decreased concentrations of ⮕ DESBUTYL LUMEFANTRINE;CYP3A5 *1/*3 is associated with decreased concentrations of desbutyl lumefantrine in people with Malaria, Falciparum as compared to CYP3A5 *1/*1 + *1/*6.; in people with Other:Malaria, Falciparum
;SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Metabolism/PK;decreased clearance of ⮕ SERTRALINE;CYP2D6 *2 is associated with decreased clearance of sertraline in people with Substance-Related Disorders, Depressive Disorder, Major, Anxiety Disorders or Borderline Personality Disorder as compared to CYP2D6 *1/*1.; in people with Other:Substance-Related Disorders, Other:Major Depressive Disorder, Other:Anxiety Disorders, Other:Borderline Personality Disorder
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ SERTRALINE;CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with decreased clearance of sertraline in people with Substance-Related Disorders, Depressive Disorder, Major, Anxiety Disorders or Borderline Personality Disorder as compared to CYP2C19 *1/*1.; in people with Other:Substance-Related Disorders, Other:Major Depressive Disorder, Other:Anxiety Disorders, Other:Borderline Personality Disorder
;TACROLIMUS;ABCC2;rs3740066;TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;LEVONORGESTREL;CYP2B6;CYP2B6 poor metabolizer;;Metabolism/PK;poor metabolizer increased clearance of ⮕ LEVONORGESTREL;CYP2B6 poor metabolizer is associated with increased clearance of levonorgestrel in women with HIV Infections as compared to CYP2B6 normal metabolizer.; in women with Other:HIV infectious disease
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761555;TT;Efficacy;decreased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT.;or in people with Disease:Major Depressive Disorder
;WARFARIN;NKX2-6;rs310279;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Other:Heart valve replacement
;CYTARABINE, IDARUBICIN;DCK;rs2306744;T;Efficacy;increased response to ⮕ CYTARABINE, IDARUBICIN;Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.;and in people with Disease:Leukemia, Myeloid, Acute
;VENLAFAXINE;HTR2A;rs7997012;AG + GG;Efficacy;increased clinical benefit to ⮕ VENLAFAXINE;Genotypes AG + GG are associated with increased clinical benefit to venlafaxine in people with Anxiety Disorders as compared to genotype AA.; in people with Disease:Anxiety Disorders
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased concentrations of voriconazole in people with therapeutic drug monitoring analyses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:therapeutic drug monitoring analyses
;ANTIEPILEPTICS;;rs16935279;CC + CT;Metabolism/PK;decreased metabolism of ⮕ ANTIEPILEPTICS;Genotypes CC + CT are associated with decreased metabolism of antiepileptics in people with Bipolar Disorder and Psychotic Disorders as compared to genotype TT.; in people with Disease:Bipolar Disorder, Disease:Psychotic Disorder
;FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;CC + CT;Dosage;increased dose of ⮕ FOLLITROPIN BETA, UROFOLLITROPIN;Genotypes CC + CT are associated with increased dose of follitropin beta or urofollitropin in women as compared to genotype TT.;or in women 
;PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Metabolism/PK;ultrarapid metabolizer decreased steady-state concentration of ⮕ PAROXETINE;CYP2D6 ultrarapid metabolizer is associated with decreased steady-state concentration of paroxetine in people with Depressive Disorder, Major, Anxiety Disorders or Panic Disorder as compared to CYP2D6 normal metabolizer.; in people with Other:Major Depressive Disorder, Other:Anxiety Disorders, Other:Panic Disorder
;PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Efficacy;ultrarapid metabolizer decreased clinical benefit to ⮕ PAROXETINE;CYP2D6 ultrarapid metabolizer is associated with decreased clinical benefit to paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.; in people with Other:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;increased clearance of ⮕ WARFARIN;CYP2C19 *1/*17 + *17/*17 are associated with increased clearance of warfarin as compared to CYP2C19 *1/*2 + *2/*2.;  
;ATORVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;*2 + *4 + *8;Efficacy;poor metabolizer decreased clinical benefit to ⮕ ATORVASTATIN;CYP2C19 *2 + *4 + *8 (assigned as poor metabolizer phenotype) is associated with decreased clinical benefit to atorvastatin in people with Cardiovascular Diseases as compared to CYP2C19 *1 + *11.; in people with Other:Cardiovascular Disease
;CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;Efficacy;increased response to ⮕ CISPLATIN, IRINOTECAN;Genotype CG is associated with increased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;FRAS1;rs4386623;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype GG.; in people with Other:Heart valve replacement
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to lansoprazole in people with Gastroesophageal Reflux as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Gastroesophageal Reflux
;WARFARIN;FAM201A;rs1890109;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Other:Heart valve replacement
;METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.; in people with Disease:Rheumatoid arthritis
;VALPROIC ACID;SCN1A;rs3812718;T;Efficacy;increased clinical benefit to ⮕ VALPROIC ACID;Allele T is associated with increased clinical benefit to valproic acid in children with Epilepsy as compared to allele C.; in children with Other:Epilepsy
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ PANTOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Ulcer
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ PANTOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to pantoprazole in people with Ulcer as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in people with Disease:Ulcer
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased metabolism of ⮕ RISPERIDONE;CYP2D6 *10 is associated with decreased metabolism of risperidone in healthy individuals as compared to CYP2D6 *1.; in healthy individuals 
;CAPECITABINE;DPYD;rs1801159;CC + CT;Efficacy;increased response to ⮕ CAPECITABINE;Genotypes CC + CT are associated with increased response to capecitabine in people with gastroesophageal cancer as compared to genotype TT.; in people with Disease:Gastroesophageal Cancer
;NICOTINE;DRD2;rs6277;A;Efficacy;increased response to ⮕ NICOTINE;Allele A is associated with increased response to nicotine in men as compared to allele G.; in men 
;CAPTOPRIL;ACE;rs1799752;del/del;Efficacy;increased resistance to ⮕ CAPTOPRIL;Genotype del/del is associated with increased resistance to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Diabetes Mellitus
;APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;Genotype CC is associated with increased concentrations of apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotype CT.;or in people with Other:Thromboembolism
;BUPROPION;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ BUPROPION;SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele) are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; in people with Other:Tobacco Use Disorder
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*5, CYP2C9*6;*1/*5 + *5/*6;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;CYP2C9 *1/*5 + *5/*6 is associated with decreased metabolism of losartan in healthy individuals as compared to CYP2C9 *1/*1.; in healthy individuals 
;ETHANOL;OPRM1;rs648007;A;Efficacy;increased response to ⮕ ETHANOL;Allele A is associated with increased response to ethanol as compared to allele G.;  
;FAMOTIDINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ FAMOTIDINE, OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;and in healthy individuals 
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ ESOMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of esomeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;decreased clearance of ⮕ MIDAZOLAM;CYP3A4 *1/*22 is associated with decreased clearance of midazolam in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Disease:Kidney Transplantation
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;ETHANOL;OPRM1;rs1799971;AG + GG;Efficacy;increased response to ⮕ ETHANOL;Genotypes AG + GG are associated with increased response to ethanol as compared to genotype AA.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;increased exposure to ⮕ TACROLIMUS;Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;Metabolism/PK;increased concentrations of ⮕ PRIMAQUINE;CYP2D6 *4/*41 + *5/*6 are associated with increased concentrations of primaquine in people with Malaria as compared to CYP2D6 *1/*1 + *1/*10 + *1/*4 + *1/*5 + *1/*41.; in people with Disease:Malaria
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;NICOTINE;CHRNA7;rs2337980;CC;Efficacy;increased response to ⮕ NICOTINE;Genotype CC is associated with increased response to nicotine in women as compared to genotypes CT + TT.; in women 
;BUPROPION;DRD2;rs1799732;GG;Efficacy;increased response to ⮕ BUPROPION;Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del.; in people with Disease:Tobacco Use Disorder
;WARFARIN;VKORC1;rs7294;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;concentrations of ⮕ SIMVASTATIN;CYP3A4 *1/*22 + *22/*22 is associated with concentrations of simvastatin as compared to CYP3A4 *1/*1.;  
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ OMEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to omeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;Metabolism/PK;decreased concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*17 is associated with decreased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 + *1/*2 + *2/*17 + *2/*2.; in people with Disease:Fungal infectious disease
;QUETIAPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased concentrations of ⮕ QUETIAPINE;CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of quetiapine in people with Psychotic Disorders as compared to CYP3A4 *1/*1.; in people with Other:Psychotic Disorder
;WARFARIN;EPHX1;rs1131873;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin.;  
;TRIMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased metabolism of ⮕ TRIMIPRAMINE;CYP2C19 *2 is associated with decreased metabolism of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;FAMOTIDINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ FAMOTIDINE, OMEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to famotidine and omeprazole in healthy individuals as compared to CYP2C19 *1/*2 + *1/*3.;and in healthy individuals 
;METFORMIN;SLC2A2;rs8192675;C;Efficacy;increased response to ⮕ METFORMIN;Allele C is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele T.; in people with Disease:Diabetes Mellitus
;WARFARIN;CYP2C9;rs28371686;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele C.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Connective Tissue Diseases as compared to genotype CC.; in people with Disease:Connective Tissue Diseases
;WARFARIN;CYP2C9;rs28371685;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;DULOXETINE;CYP2D6;rs3892097;CC;Efficacy;increased clinical benefit to ⮕ DULOXETINE;Genotype CC is associated with increased clinical benefit to duloxetine in men with Alcoholism and Depressive Disorder as compared to genotype CT.; in men with Other:Alcohol abuse, Other:Depressive Disorder
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Metabolism/PK;increased concentrations of ⮕ SN-38;UGT1A1 *1/*28 + *28/*28 is associated with increased concentrations of SN-38 in people with Neoplasms as compared to UGT1A1 *1/*1.; in people with Disease:Neoplasms
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.; in healthy individuals 
;WARFARIN;CYP2C9;rs9332131;del;Dosage;decreased dose of ⮕ WARFARIN;Allele del is associated with decreased dose of warfarin.;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus as compared to CYP3A5 *1/*1 + *1/*3.;  
;HYDROXYUREA;BCL11A;rs4671393;A;Efficacy;increased response to ⮕ HYDROXYUREA;Allele A is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.; in people with Disease:Beta-thalassemia and related diseases
;WARFARIN;CYP2C9;rs7900194;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Efficacy;decreased response to ⮕ ROSIGLITAZONE;CYP2C8 *3 is associated with decreased response to rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.; in people with Disease:Diabetes Mellitus
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.; in people with Disease:Epilepsy
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased metabolism of ⮕ PANTOPRAZOLE;CYP2C19 *1/*2 is associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;BETA BLOCKING AGENTS;KL;rs36217263;A/del + del/del;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Genotypes A/del + del/del are associated with decreased response to Beta Blocking Agents in people with Hypertension as compared to genotype AA.; in people with Other:Hypertension
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6 + *1/*6;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;CYP2B6 *6/*6 + *1/*6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 *1/*1.; in people with Disease:HIV infectious disease
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *2/*2 + *1/*2 + *1/*3 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased concentrations of voriconazole in people with Mycoses as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Disease:Fungal infectious disease
;GEMCITABINE;RRM1;rs12806698;AC;Efficacy;increased response to ⮕ GEMCITABINE;Genotype AC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.; in people with Disease:Non-Small Cell Lung Carcinoma
;FLUOXETINE, SERTRALINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;Efficacy;increased response to ⮕ FLUOXETINE, SERTRALINE;Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased response to fluoxetine or sertraline in people with Depressive Disorder, Major.;or in people with Disease:Major Depressive Disorder
;BUPROPION;ACE;rs8075924;TT;Efficacy;decreased response to ⮕ BUPROPION;Genotype TT is associated with decreased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CT.; in people with Other:Major Depressive Disorder
;LORAZEPAM, VALPROIC ACID;UGT2B7;rs7438284;A;Efficacy;increased response to ⮕ LORAZEPAM, VALPROIC ACID;Allele A is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele T.;and in healthy individuals 
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.; in healthy individuals 
;LORAZEPAM, VALPROIC ACID;UGT2B7;rs7439366;T;Efficacy;increased response to ⮕ LORAZEPAM, VALPROIC ACID;Allele T is associated with increased response to lorazepam and valproic acid in healthy individuals as compared to allele C.;and in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased response to ⮕ SERTRALINE;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Kidney Transplantation
;SUNITINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;decreased clearance of ⮕ SUNITINIB;CYP3A4 *1/*22 + *22/*22 are associated with decreased clearance of sunitinib as compared to CYP3A4 *1/*1.;  
;HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;Metabolism/PK;decreased concentrations of ⮕ HYDROXYCHLOROQUINE;Genotype CC is associated with decreased concentrations of hydroxychloroquine in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes CT + TT.; in people with Other:Rheumatoid arthritis, Other:Systemic lupus erythematosus
;FLUOROURACIL;XRCC1;rs25487;CC;Efficacy;increased response to ⮕ FLUOROURACIL;Genotype CC is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype CT.; in people with Disease:Rectal Neoplasms
;MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;Metabolism/PK;increased metabolism of ⮕ MIRTAZAPINE;CYP2B6 *6/*6 is associated with increased metabolism of mirtazapine in people with Depression.; in people with Disease:Depression
;CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased response to ⮕ CLOBAZAM;CYP2C19 *1/*2 + *1/*3 is associated with increased response to clobazam in people with Epilepsy as compared to CYP2C19 *1/*1.; in people with Disease:Epilepsy
;GEMCITABINE;RRM1;rs11030918;CT;Efficacy;increased response to ⮕ GEMCITABINE;Genotype CT is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;ROSUVASTATIN;HNF4A;rs3212207;C;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Allele C is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;TACROLIMUS;ABCB1;rs1045642;AG + GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes AG + GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.; in people with Other:Kidney Transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;Metabolism/PK;decreased clearance of ⮕ ACENOCOUMAROL;CYP2C9 *1/*3 + *2/*3 are associated with decreased clearance of acenocoumarol as compared to CYP2C9 *1/*1.;  
;RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;Metabolism/PK;intermediate metabolizer decreased metabolism of ⮕ RISPERIDONE;CYP2D6 intermediate metabolizer is associated with decreased metabolism of risperidone as compared to genotypes *1/*3 + *1/*4 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) .;  
;ROSUVASTATIN;ABCC2;rs8187710;A;Metabolism/PK;decreased exposure to ⮕ ROSUVASTATIN;Allele A is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele G.; in healthy individuals 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Dosage, Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with decreased response to clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.; in people with Other:percutaneous coronary intervention
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to rabeprazole in healthy individuals as compared to CYP2C19 *2 + *3.; in healthy individuals 
;CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased concentrations of ⮕ CYCLOSPORINE;CYP3A5 *1/*3 is associated with decreased concentrations of cyclosporine in men as compared to CYP3A5 *3/*3.; in men 
;CYCLOSPORINE;CYP3A4;rs35599367;A;Metabolism/PK;decreased metabolism of ⮕ CYCLOSPORINE;Allele A is associated with decreased metabolism of cyclosporine in people with Kidney Transplantation as compared to allele G.; in people with Other:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;Metabolism/PK;normal metabolizer decreased concentrations of ⮕ FLUOXETINE;CYP2D6 *1/*1 + *10/*10 + *1/*4 + *1/*10 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2D6 *10/*4 (assigned as intermediate metabolizer phenotype) .; in people with Other:Anxiety Disorders, Other:Depression, Other:Major Depressive Disorder
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;decreased metabolism of ⮕ CODEINE;CYP2D6 *4/*4 is associated with decreased metabolism of codeine in people with Kidney Failure, Chronic as compared to CYP2D6 *1/*1 + *1/*4.; in people with Disease:Chronic Kidney Failure
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;ultrarapid metabolizer increased metabolism of ⮕ VORICONAZOLE;CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased metabolism of voriconazole in patients with decreased concentrations of voriconazole.; in Other:patients with decreased concentrations of voriconazole
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;normal metabolizer and intermediate metabolizer decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT (assigned as intermediate metabolizer and normal metabolizer phenotype) is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC (assigned as poor metabolizer phenotype) .; in people with Other:Kidney Transplantation
;DOCETAXEL, THALIDOMIDE;PPARD;rs3734254;T;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.;and in people with Disease:Prostatic Neoplasms
;ATENOLOL, METOPROLOL;OR10P1;rs17117817;G;PD;decreased response to ⮕ ATENOLOL, METOPROLOL;Allele G is associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to allele T.;or in people with Other:Hypertension
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*41;*5 + *10 + *41;Metabolism/PK;decreased metabolism of ⮕ ARIPIPRAZOLE;CYP2D6 *5 + *10 + *41 is associated with decreased metabolism of aripiprazole in healthy individuals as compared to CYP2D6 *1.; in healthy individuals 
;TRIMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased clearance of ⮕ TRIMIPRAMINE;CYP2C19 *2 is associated with decreased clearance of trimipramine in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;Metabolism/PK;increased concentrations of ⮕ PIOGLITAZONE;CYP2C8 *1/*1 is associated with increased concentrations of pioglitazone in healthy individuals as compared to CYP2C8 *1/*3 + *3/*3.; in healthy individuals 
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;CYP2D6 *3/*3 + *4/*4 are associated with increased concentrations of aripiprazole in healthy individuals as compared to CYP2D6 *1/*1 + *1x2/*4.; in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *1/*2 + *1/*3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 *1/*1.;  
;CARBOPLATIN, GEMCITABINE;RRM1;rs12806698;AC;Efficacy;increased response to ⮕ CARBOPLATIN, GEMCITABINE;Genotype AC is associated with increased response to carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;FAMOTIDINE, LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased response to ⮕ FAMOTIDINE, LANSOPRAZOLE;CYP2C19 *1/*2 + *1/*3 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;and in healthy individuals 
;FAMOTIDINE, LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased response to ⮕ FAMOTIDINE, LANSOPRAZOLE;CYP2C19 *1/*1 is associated with decreased response to famotidine and lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;and in healthy individuals 
;ABATACEPT;HLA-DRB1;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;Efficacy;increased clinical benefit to ⮕ ABATACEPT;HLA-DRB1 *04:01 + *04:04 + *04:05 + *04:10 + *10:01 is associated with increased clinical benefit to abatacept in people with Arthritis, Rheumatoid.; in people with Other:Rheumatoid arthritis
;METHADONE;;rs17180299;AG + GG;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotypes AG + GG are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype AA.; in people with Disease:Opioid-Related Disorders
;WARFARIN;CALU;rs339097;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin.;  
;NOSCAPINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*9;*1/*1 + *1/*9;Metabolism/PK;normal metabolizer increased clearance of ⮕ NOSCAPINE;CYP2C9 *1/*1 + *1/*9 (assigned as normal metabolizer phenotype) is associated with increased clearance of Noscapine in healthy individuals as compared to CYP2C9 *1/*2 + *1/*3 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) .; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Kidney Transplantation
;ATENOLOL, METOPROLOL;SNX9;rs2364349;A;PD;decreased response to ⮕ ATENOLOL, METOPROLOL;Allele A is associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to allele G.;or in people with Other:Hypertension
;TACROLIMUS;;rs11265572;GT + TT;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG.; in people with Disease:Liver transplantation
;WARFARIN;STX4;rs10871454;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;SIROLIMUS, TEMSIROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;decreased concentrations of ⮕ SIROLIMUS, TEMSIROLIMUS;Genotype CT is associated with decreased concentrations of sirolimus and temsirolimus in people with Urinary Bladder Neoplasms as compared to genotype CC.;and in people with Disease:Urinary Bladder Neoplasms
;PERAMPANEL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;;increased dose-adjusted trough concentrations of ⮕ PERAMPANEL;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of perampanel in children with Epilepsy as compared to CYP3A5 *1/*3.; in children with Other:Epilepsy
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;CYP2C19 *2 + *3 is associated with increased concentrations of voriconazole in people with Kidney Transplantation as compared to CYP2C19 *1.; in people with Other:Kidney Transplantation
;ENALAPRIL;ACE;rs1799752;del/del;Efficacy;increased response to ⮕ ENALAPRIL;Genotype del/del is associated with increased response to enalapril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.; in people with Disease:Essential hypertension
;URACIL;DPYD;DPYD c.295_298delTCAT (*7), DPYD Reference;c.295_298delTCAT (*7);Metabolism/PK;increased concentrations of ⮕ URACIL;DPYD c.295_298delTCAT (*7) is associated with increased concentrations of uracil as compared to DPYD Reference.;  
;URACIL;DPYD;DPYD c.2846A>T, DPYD Reference;c.2846A>T;Metabolism/PK;increased concentrations of ⮕ URACIL;DPYD c.2846A>T is associated with increased concentrations of uracil as compared to DPYD Reference.;  
;URACIL;DPYD;DPYD c.1679T>G (*13), DPYD Reference;c.1679T>G (*13);Metabolism/PK;increased concentrations of ⮕ URACIL;DPYD c.1679T>G (*13) is associated with increased concentrations of uracil as compared to DPYD Reference.;  
;URACIL;DPYD;DPYD c.1905+1G>A (*2A), DPYD Reference;c.1905+1G>A (*2A);Metabolism/PK;increased concentrations of ⮕ URACIL;DPYD c.1905+1G>A (*2A) is associated with increased concentrations of uracil as compared to DPYD Reference.;  
;N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;Metabolism/PK;decreased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *2xN/*4 + *1/*1xN + *2/*1xN + *1/*2xN.; in women with Disease:Breast Neoplasms
;N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;Metabolism/PK;decreased metabolism of ⮕ N-DESMETHYLTAMOXIFEN;CYP2D6 *4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 are associated with decreased metabolism of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10.; in women with Disease:Breast Neoplasms
;ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;Efficacy;decreased response to ⮕ ATORVASTATIN;CYP3A5 *3/*3 is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to CYP3A5 *1A/*1A + *1A/*3.; in people with Disease:Hypercholesterolemia
;N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTAMOXIFEN;CYP2D6 *10/*10 + *1/*10 is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.; in women with Disease:Breast Neoplasms
;ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ ESCITALOPRAM;CYP2D6 poor metabolizer is associated with increased concentrations of escitalopram as compared to CYP2D6 normal metabolizer.;  
;ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ ESCITALOPRAM;CYP2D6 intermediate metabolizer is associated with increased concentrations of escitalopram as compared to CYP2D6 normal metabolizer.;  
;EFAVIRENZ;ABCB1;rs3842;CC;Metabolism/PK;increased exposure to ⮕ EFAVIRENZ;Genotype CC is associated with increased exposure to efavirenz in healthy individuals as compared to genotype TT.; in healthy individuals 
;EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;Metabolism/PK;poor metabolizer increased exposure to ⮕ EFAVIRENZ;CYP2B6 poor metabolizer is associated with increased exposure to efavirenz in infants as compared to CYP2B6 normal metabolizer and intermediate metabolizer.; in infants 
;BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;Efficacy;decreased clinical benefit to ⮕ BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A *03:01 is associated with decreased clinical benefit to BCR-ABL tyrosine kinase inhibitors in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;Efficacy;decreased clinical benefit to ⮕ BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A *23:17 is associated with decreased clinical benefit to BCR-ABL tyrosine kinase inhibitors in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;Efficacy;increased clinical benefit to ⮕ BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B *57:03 is associated with increased clinical benefit to BCR-ABL tyrosine kinase inhibitors in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*7;*1/*1 + *1/*3;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*7.; in people with Other:Kidney Transplantation
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*2 + *9 + *10 + *35 + *41;Metabolism/PK;decreased clearance of ⮕ RISPERIDONE;CYP2D6 *2 + *9 + *10 + *35 + *41 is associated with decreased clearance of risperidone as compared to CYP2D6 *1.;  
;ANTIDEPRESSANTS;CYP2C19;CYP2C19 poor metabolizer;;Efficacy;poor metabolizer increased clinical benefit to ⮕ ANTIDEPRESSANTS;CYP2C19 poor metabolizer is associated with increased clinical benefit to antidepressants in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.; in people with Other:Major Depressive Disorder
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6 + *18;Metabolism/PK;poor metabolizer increased concentrations of ⮕ METHADONE;CYP2B6 *6 + *18 (assigned as poor metabolizer phenotype) is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Opioid-Related Disorders
;LAMOTRIGINE;UGT1A4;UGT1A4*3b;*3b;Efficacy;decreased clinical benefit to ⮕ LAMOTRIGINE;UGT1A4 *3b is associated with decreased clinical benefit to lamotrigine.;  
;DOCETAXEL, THALIDOMIDE;PPARD;rs2016520;C;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;and in people with Disease:Prostatic Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.; in children with Other:Liver transplantation
;INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;Efficacy;decreased response to ⮕ INFLIXIMAB;HLA-DQA1 *05 is associated with decreased response to infliximab in people with Crohn Disease.; in people with Other:Crohn Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;Efficacy;decreased response to ⮕ CLOPIDOGREL;CYP2C19 *2 + *4 are associated with decreased response to clopidogrel as compared to CYP2C19 *1 + *17.;  
;DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;and in people with Disease:Prostatic Neoplasms
;PROPOFOL;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Toxicity;decreased response to ⮕ PROPOFOL;CYP2B6 *6 is associated with decreased response to propofol in people with Brain Injuries as compared to CYP2B6 *1.; in people with Other:Brain Injury
;TILDRAKIZUMAB;PDE4D;rs10556657;CT/CT;Efficacy;decreased clinical benefit to ⮕ TILDRAKIZUMAB;Genotype CT/CT is associated with decreased clinical benefit to tildrakizumab in people with Psoriasis as compared to genotypes CT/CTGTCT + CTGTCT/CTGTCT.; in people with Other:Psoriasis
;BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;rs1045642;A;Dosage;decreased dose of ⮕ BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;Allele A is associated with decreased dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to allele G.;or in people with Disease:Pain
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Dosage;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.; in people with Other:Hematopoietic stem cell transplantation
;TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;CYP3A4 *1/*22 is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to CYP3A4 *1/*1.; in people with Other:Kidney Transplantation
;SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;deficiency increased concentrations of ⮕ SIROLIMUS;CYP3A5 *3/*3 (assigned as deficiency phenotype) is associated with increased concentrations of sirolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3 (assigned as non-deficient phenotype) .; in people with Other:Kidney Transplantation
;DOCETAXEL, THALIDOMIDE;PPARD;rs1883322;C;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;and in people with Disease:Prostatic Neoplasms
;PHENYTOIN;CYP2C19;CYP2C19 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ PHENYTOIN;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased concentrations of phenytoin as compared to CYP2C19 normal metabolizer.;  
;VALPROIC ACID;CYP2C19;CYP2C19 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ VALPROIC ACID;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased concentrations of valproic acid as compared to CYP2C19 normal metabolizer.;  
;CARBAMAZEPINE;CYP3A5;CYP3A5 poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ CARBAMAZEPINE;CYP3A5 poor metabolizer is associated with increased concentrations of carbamazepine as compared to CYP3A5 normal metabolizer and intermediate metabolizer.;  
;VALPROIC ACID;CYP2C9;CYP2C9 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ VALPROIC ACID;CYP2C9 intermediate metabolizer is associated with increased concentrations of valproic acid as compared to CYP2C9 normal metabolizer.;  
;VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;Metabolism/PK;decreased concentrations of ⮕ VALPROIC ACID;UGT1A6 *2a is associated with decreased concentrations of valproic acid as compared to UGT1A6 *1a/*1a.;  
;PHENYTOIN;CYP2C9;CYP2C9 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ PHENYTOIN;CYP2C9 intermediate metabolizer is associated with increased concentrations of phenytoin as compared to CYP2C9 normal metabolizer.;  
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;Metabolism/PK;increased concentrations of ⮕ SN-38;UGT1A1 *1/*28 is associated with increased concentrations of SN-38 in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.; in people with Other:Colorectal Neoplasms, Other:Metastatic neoplasm
;DOCETAXEL, THALIDOMIDE;CHST3;rs12418;A;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;and in people with Disease:Prostatic Neoplasms
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28 + *60;Dosage;decreased dose of ⮕ FOLFIRI, IRINOTECAN;UGT1A1 *28 + *60 is associated with decreased dose of FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;or in people with Other:Colorectal Neoplasms
;MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased half-life time of ⮕ MIRABEGRON;CYP2D6 intermediate metabolizer is associated with increased half-life time of mirabegron in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;CYP2C19 *1/*1 is associated with increased metabolism of omeprazole in people with Peptic Ulcer, Gastroesophageal Reflux or Esophagitis as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2.; in people with Other:Peptic Ulcer Disease, Other:Gastroesophageal Reflux, Other:Esophagitis
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*8;*1/*8;Metabolism/PK;decreased metabolism of ⮕ MERCAPTOPURINE;TPMT *1/*8 is associated with decreased metabolism of mercaptopurine as compared to TPMT *1/*1.;  
;WARFARIN;CYP2C9;CYP2C9*1;*1/*1;Dosage;increased dose of ⮕ WARFARIN;CYP2C9 *1/*1 is associated with increased dose of warfarin.;  
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;*2 + *3 + *8;Dosage;decreased dose of ⮕ WARFARIN;CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1.;  
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 are associated with increased concentrations of aripiprazole in healthy individuals as compared to CYP2D6 *1/*1 + *1x2/*4.; in healthy individuals 
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;decreased clearance of ⮕ PANTOPRAZOLE;CYP2C19 *1/*2 is associated with decreased clearance of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1.; in healthy individuals 
;OPIOIDS;OPRM1;rs1799971;GG;Dosage;increased dose of ⮕ OPIOIDS;Genotype GG is associated with increased dose of opioids in women with Caesarian section and Pain as compared to genotypes AA + AG.; in women with Other:Caesarian section, Other:Pain
;DULOXETINE;DRD3;rs963468;GG;Efficacy;decreased response to ⮕ DULOXETINE;Genotype GG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + AG.; in people with Disease:Anxiety Disorders
;METFORMIN;C11orf65;rs11212617;C;Efficacy;increased clinical benefit to ⮕ METFORMIN;Allele C is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.; in people with Disease:Diabetes Mellitus, Type 2
;CYCLOSPORINE;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased dose of ⮕ CYCLOSPORINE;Genotype CC is associated with decreased dose of cyclosporine as compared to genotypes CT + TT.;  
;EFAVIRENZ, NEVIRAPINE;NR1I3;rs2307424;AA + AG;Efficacy;increased response to ⮕ EFAVIRENZ, NEVIRAPINE;Genotypes AA + AG is associated with increased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype GG.;or in people with Efficacy:HIV infectious disease
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*2;Metabolism/PK;normal metabolizer and intermediate metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*1 + *1/*2 (assigned as normal metabolizer and intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Hematologic Neoplasms or hematopoietic stem cell transplantation as compared to CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer and rapid metabolizer phenotype) .; in children with Other:Hematologic Neoplasms, Other:Hematopoietic stem cell transplantation
;ARIPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;poor metabolizer increased concentrations of ⮕ ARIPIPRAZOLE;CYP3A4 *1/*22 + *22/*22 (assigned as poor metabolizer phenotype) is associated with increased concentrations of aripiprazole as compared to CYP3A4 *1/*1 (assigned as normal metabolizer phenotype) .;  
;ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6 poor metabolizer is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to CYP2D6 normal metabolizer and intermediate metabolizer.;and  
;PIMOZIDE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Metabolism/PK;decreased concentrations of ⮕ PIMOZIDE;CYP3A4 *22 is associated with decreased concentrations of pimozide in people with Psychotic Disorders as compared to CYP3A4 *1/*1.; in people with Disease:Psychotic Disorder
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148943;C;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;and in people with Disease:Prostatic Neoplasms
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;and in people with Disease:Prostatic Neoplasms
;GLYBURIDE;ABCB11;rs4148776;G;Efficacy;increased response to ⮕ GLYBURIDE;Allele G is associated with increased response to glibenclamide in people with as compared to allele A.; in people with 
;IMATINIB;SLCO1B3;rs7311358;AA + AG;Efficacy;decreased response to ⮕ IMATINIB;Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;SLCO1B3;rs4149117;GG + GT;Efficacy;decreased response to ⮕ IMATINIB;Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*2 + *1/*3 + *3/*3;Metabolism/PK;increased concentrations of ⮕ PRAZIQUANTEL;CYP2C19 *1/*2 + *2/*2 + *1/*3 + *3/*3 is associated with increased concentrations of praziquantel in children with Schistosomiasis as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; in children with Other:Schistosomiasis
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9;Metabolism/PK;decreased clearance of ⮕ ARIPIPRAZOLE;CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*9 are associated with decreased clearance of aripiprazole in healthy individuals as compared to CYP2D6 *1/*1 + *1x2/*4.; in healthy individuals 
;ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;Metabolism/PK;decreased clearance of ⮕ ARIPIPRAZOLE;CYP2D6 *3/*3 + *4/*4 are associated with decreased clearance of aripiprazole in healthy individuals as compared to CYP2D6 *1/*1 + *1x2/*4.; in healthy individuals 
;FESOTERODINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Metabolism/PK;ultrarapid metabolizer increased clearance of ⮕ FESOTERODINE;CYP2D6 ultrarapid metabolizer is associated with increased clearance of fesoterodine in healthy individuals as compared to CYP2D6 normal metabolizer and intermediate metabolizer and poor metabolizer.; in healthy individuals 
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;intermediate metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma or Leukemia, Myeloid, Acute as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;" in children with ""Other:Acute lymphoblastic leukemia"", ""Other:Lymphoma"", ""Other:Leukemia, Myeloid, Acute"""
;GLYBURIDE;CHST13;rs1054097;C;Efficacy;increased response to ⮕ GLYBURIDE;Allele C is associated with increased response to glibenclamide in people with as compared to allele G.; in people with 
;LACOSAMIDE;CYP2C19;CYP2C19 normal metabolizer;;Metabolism/PK;normal metabolizer decreased exposure to ⮕ LACOSAMIDE;CYP2C19 normal metabolizer is associated with decreased exposure to lacosamide in children with Epilepsy as compared to CYP2C19 intermediate metabolizer and poor metabolizer.; in children with Other:Epilepsy
;FESOTERODINE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased clearance of ⮕ FESOTERODINE;CYP2D6 intermediate metabolizer and poor metabolizer is associated with decreased clearance of fesoterodine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;ROSIGLITAZONE;CYP2C8;rs10509681;C;Dosage, Metabolism/PK;increased metabolism of ⮕ ROSIGLITAZONE;Allele C is associated with increased metabolism of rosiglitazone in healthy individuals as compared to allele T.; in healthy individuals 
;LACOSAMIDE;ABCC2;rs717620;T;Metabolism/PK;decreased exposure to ⮕ LACOSAMIDE;Allele T is associated with decreased exposure to lacosamide in children with Epilepsy as compared to allele C.; in children with Other:Epilepsy
;FESOTERODINE;CYP3A4;CYP3A4 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased clearance of ⮕ FESOTERODINE;CYP3A4 intermediate metabolizer is associated with increased clearance of fesoterodine in healthy individuals as compared to CYP3A4 normal metabolizer.; in healthy individuals 
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;Metabolism/PK;increased concentrations of ⮕ ZUCLOPENTHIXOL;CYP2D6 *1/*3 + *1/*4 is associated with increased concentrations of zuclopenthixol as compared to CYP2D6 *1/*1.;  
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4;Metabolism/PK;increased concentrations of ⮕ ZUCLOPENTHIXOL;CYP2D6 *4/*4 is associated with increased concentrations of zuclopenthixol as compared to CYP2D6 *1/*3 + *1/*4 + *1/*1.;  
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;Metabolism/PK;normal metabolizer decreased concentrations of ⮕ PHENYTOIN;CYP2C9 *1/*1 (assigned as normal metabolizer phenotype) is associated with decreased concentrations of phenytoin in people with surgery as compared to CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) .; in people with Other:surgery
;CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;Dosage;normal metabolizer increased dose of ⮕ CLOZAPINE;CYP2D6 normal metabolizer is associated with increased dose of clozapine in people with Schizophrenia or Psychotic Disorder as compared to CYP2D6 intermediate metabolizer and poor metabolizer.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;EFAVIRENZ;CYP2B6;CYP2B6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ EFAVIRENZ;CYP2B6 intermediate metabolizer and poor metabolizer is associated with increased concentrations of efavirenz in children with HIV infectious disease as compared to CYP2B6 normal metabolizer.; in children with Other:HIV infectious disease
;THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT *3A + *3B + *3C (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased concentrations of thioguanosine diphosphate, thioguanosine monophosphate and thioguanosine triphosphate in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1 (assigned as normal metabolizer phenotype) .;and in people with Other:Inflammatory Bowel Diseases
;METOPROLOL;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ METOPROLOL;CYP2D6 poor metabolizer is associated with decreased metabolism of metoprolol as compared to CYP2D6 ultrarapid metabolizer.;  
;CLOZAPINE;ITIH3;rs2535629;AA;Efficacy;increased response to ⮕ CLOZAPINE;Genotype AA is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AG + GG.; in people with Disease:Schizophrenia
;ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Efficacy;poor metabolizer increased response to ⮕ ATOMOXETINE;CYP2D6 poor metabolizer is associated with increased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;COTININE;CYP2A6;CYP2A6 low activity;;Metabolism/PK;low activity increased metabolism of ⮕ COTININE;CYP2A6 low activity is associated with increased metabolism of cotinine in people with Tobacco Use Disorder as compared to CYP2A6 high activity.; in people with Other:Tobacco Use Disorder
;COTININE;CYP2A6;CYP2A6 low activity;;Metabolism/PK;low activity increased concentrations of ⮕ COTININE;CYP2A6 low activity is associated with increased concentrations of cotinine as compared to CYP2A6 high activity.;  
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;Metabolism/PK;low activity decreased metabolism of ⮕ NICOTINE;CYP2A6 *2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24 (assigned as low activity phenotype) is associated with decreased metabolism of nicotine as compared to CYP2A6 *1/*1 (assigned as normal metabolizer phenotype) .;  
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;decreased response to ⮕ ESCITALOPRAM;SLC6A4 HTTLPR short form (S allele) is associated with decreased response to escitalopram in people with Major Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele).; in people with Other:Major Depressive Disorder
;ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 intermediate metabolizer and poor metabolizer is associated with decreased concentrations of endoxifen in people with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.; in people with Other:Breast Neoplasms
;CAFFEINE;ADORA1;rs10920573;CC;Efficacy;decreased clinical benefit to ⮕ CAFFEINE;Genotype CC is associated with decreased clinical benefit to caffeine in infants with Apnea of prematurity as compared to genotypes CT + TT.; in infants with Other:Apnea of prematurity
;NORQUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ NORQUETIAPINE;CYP3A5 *3/*3 is associated with increased concentrations of norquetiapine as compared to CYP3A5 *1/*1 + *1/*3.;  
;QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased concentrations of ⮕ QUETIAPINE;CYP3A5 *3/*3 is associated with increased concentrations of quetiapine as compared to CYP3A5 *1/*1 + *1/*3.;  
;AMLODIPINE;CACNA1D;rs312481;GG;Efficacy;increased clinical benefit to ⮕ AMLODIPINE;Genotype GG is associated with increased clinical benefit to amlodipine in people with Hypertension as compared to genotypes AA + AG.; in people with Other:Hypertension
;PEGINTERFERON ALFA-2A;ZHX2;rs17289471;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A;Allele C is associated with increased response to peginterferon alfa-2a in people with Hepatitis B virus infection as compared to allele T.; in people with Other:Hepatitis B virus infection
;BERBERINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ BERBERINE;CYP2D6 poor metabolizer is associated with decreased metabolism of berberine in women as compared to CYP2D6 normal metabolizer.; in women 
;CLOPIDOGREL;CYP2C19;rs12248560;T;Efficacy, Other;response to ⮕ CLOPIDOGREL;Allele T is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele C.; in people with Disease:Acute coronary syndrome
;RANIBIZUMAB;VEGFA;rs833069;CC + CT;Efficacy;increased response to ⮕ RANIBIZUMAB;Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT.; in people with Disease:Macular Degeneration
;TACROLIMUS;CYP3A5;rs4646449;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;ONDANSETRON;CYP2D6;CYP2D6 poor metabolizer;;Dosage;poor metabolizer increased dose of ⮕ ONDANSETRON;CYP2D6 poor metabolizer is associated with increased dose of ondansetron in people with surgery as compared to CYP2D6 normal metabolizer.; in people with Other:surgery
;IMATINIB;ABCA3;rs150929;GG + GT;Efficacy;decreased response to ⮕ IMATINIB;Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;METFORMIN;CBARP, STK11;rs2301759;TT;Efficacy;decreased clinical benefit to ⮕ METFORMIN;Genotype TT is associated with decreased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;SLC22A3;rs3127602;T;Efficacy;increased response to ⮕ METFORMIN;Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;PRKAA1;rs11749180;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;SLC29A4;rs10234709;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;PRKAG2;rs4725434;T;Efficacy;increased response to ⮕ METFORMIN;Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;SLC47A1;rs2120274;A;Efficacy;increased response to ⮕ METFORMIN;Allele A is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;STK11;rs2301759;C;Efficacy;increased response to ⮕ METFORMIN;Allele C is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.; in people with Other:Diabetes Mellitus, Type 2
;METFORMIN;SLC47A2;rs4621031;C;Efficacy;decreased response to ⮕ METFORMIN;Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.; in people with Other:Diabetes Mellitus, Type 2
;ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;increased concentrations of ⮕ ALECTINIB;CYP3A4 *1/*22 + *22/*22 is associated with increased concentrations of alectinib in people with Non-Small Cell Lung Carcinoma as compared to CYP3A4 *1/*1.; in people with Other:Non-Small Cell Lung Carcinoma
;METFORMIN;TCF7L2;rs7903146;T;Efficacy;increased response to ⮕ METFORMIN;Allele T is associated with increased response to metformin as compared to allele C.;  
;METHADONE;OPRK1;rs3802279;CC;Dosage;decreased dose of ⮕ METHADONE;Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT.; in people with Other:Heroin Dependence
;LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ LACOSAMIDE;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of lacosamide in children with Epilepsy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in children with Other:Epilepsy
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype AG is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype GG.;and in people with Other:Death
;N,N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;*4/*6 + *4/*5;Metabolism/PK;poor metabolizer increased concentrations of ⮕ N,N-DIDESMETHYLTRAMADOL;CYP2D6 *4/*6 + *4/*5 (assigned as poor metabolizer phenotype) is associated with increased concentrations of n,n-didesmethyltramadol as compared to CYP2D6 *1/*1 + *1/*2 + *2/*17 + *29/*45 + *2/*41 + *2/*10 + *1/*41 (assigned as normal metabolizer phenotype) .;  
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;CYP3A5 *1/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Immunoglobulin A vasculitis as compared to CYP3A5 *3/*3.; in children with Disease:Immunoglobulin A vasculitis
;TOCILIZUMAB;IL6R;rs35717427;AG + GG;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotypes AG + GG is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype AA.; in people with Other:Rheumatoid arthritis
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.;and in people with Other:Death
;TOCILIZUMAB;IL6R;rs6690230;CG + GG;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotypes CG + GG is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype CC.; in people with Other:Rheumatoid arthritis
;TOCILIZUMAB;IL6R;rs11265621;AA + AG;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotypes AA + AG is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype GG.; in people with Other:Rheumatoid arthritis
;TOCILIZUMAB;;rs10108210;AA;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotype AA is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotypes AC + CC.; in people with Other:Rheumatoid arthritis
;TOCILIZUMAB;CLEC2D;rs1560011;GG;Efficacy;increased clinical benefit to ⮕ TOCILIZUMAB;Genotype GG is associated with increased clinical benefit to tocilizumab in people with Rheumatoid arthritis.; in people with Other:Rheumatoid arthritis
;TOCILIZUMAB;KCNMB1;rs703505;AA + AG;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotypes AA + AG is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype GG.; in people with Other:Rheumatoid arthritis
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ ESCITALOPRAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of escitalopram in people with Elderly Adult and Major Depressive Disorder as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; in people with Other:Elderly Adult, Other:Major Depressive Disorder
;MORPHINE;CCL11;rs17809012;AA;Efficacy;decreased clinical benefit to ⮕ MORPHINE;Genotype AA is associated with decreased clinical benefit to morphine in people with Neoplasms and Pain as compared to genotypes AG + GG.; in people with Other:Neoplasms, Other:Pain
;MORPHINE;IL16;rs4778889;TT;Efficacy;increased clinical benefit to ⮕ MORPHINE;Genotype TT is associated with increased clinical benefit to morphine in people with Neoplasms and Pain as compared to genotypes CC + CT.; in people with Other:Neoplasms, Other:Pain
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype CT is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CC.;and in people with Other:Death
;VALPROIC ACID;SLC16A1;rs7169;GG;Efficacy;increased clinical benefit to ⮕ VALPROIC ACID;Genotype GG is associated with increased clinical benefit to valproic acid in children with Epilepsy as compared to genotypes AA + AG.; in children with Other:Epilepsy
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Allele C is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to allele T.;and in people with Other:Death
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype CC is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CT.;and in people with Other:Death
;TENOFOVIR;ABCC4;rs3742106;AC + CC;Toxicity;increased concentrations of ⮕ TENOFOVIR;Genotypes AC + CC are associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.; in people with Other:HIV infectious disease
;ANTIDEPRESSANTS;FKBP5;rs1360780;CT + TT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes CT + TT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype CC.; in people with Disease:Major Depressive Disorder
;ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;Metabolism/PK;increased concentrations of ⮕ ACETAMINOPHEN SULFATE;CYP2E1 *1/*5B is associated with increased concentrations of acetaminophen sulfate in infants with Patent Ductus Arteriosus and Premature Birth as compared to CYP2E1 *1/*1.; in infants with Other:Patent Ductus Arteriosus, Other:Premature Birth
;FENTANYL;ABCC1;rs58572178;(A)14;Metabolism/PK;increased clearance of ⮕ FENTANYL;Allele (A)14 is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele (A)13.; in children with Other:Pain, Other:Premature Birth
;VORICONAZOLE;CYP2C19;CYP2C19*2, CYP2C19*17;*2 + *17;Dosage;dose of ⮕ VORICONAZOLE;CYP2C19 *2 + *17 are associated with dose of voriconazole in children with Hematopoietic stem cell transplantation.; in children with Other:Hematopoietic stem cell transplantation
;ROSUVASTATIN;ABCG2;ABCG2 poor metabolizer;;Metabolism/PK;poor metabolizer and reduced metabolizers increased dose-adjusted trough concentrations of ⮕ ROSUVASTATIN;ABCG2 poor metabolizer and reduced metabolizers is associated with increased dose-adjusted trough concentrations of rosuvastatin in healthy individuals as compared to ABCG2 normal metabolizer.; in healthy individuals 
;ROSUVASTATIN;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator and intermediate acetylator increased dose-adjusted trough concentrations of ⮕ ROSUVASTATIN;NAT2 slow acetylator and intermediate acetylator is associated with increased dose-adjusted trough concentrations of rosuvastatin in healthy individuals as compared to NAT2 rapid acetylator.; in healthy individuals 
;ROSUVASTATIN;TPMT;TPMT intermediate metabolizer;;Metabolism/PK;intermediate metabolizer decreased dose-adjusted trough concentrations of ⮕ ROSUVASTATIN;TPMT intermediate metabolizer is associated with decreased dose-adjusted trough concentrations of rosuvastatin in healthy individuals as compared to TPMT normal metabolizer.; in healthy individuals 
;DOXORUBICIN;CBR1;rs20572;T;Metabolism/PK;increased concentrations of ⮕ DOXORUBICIN;Allele T is associated with increased concentrations of doxorubicin in women with Breast Neoplasms as compared to allele C.; in women with Other:Breast Neoplasms
;SUNITINIB;KDR;rs34231037;AG;Efficacy;increased clinical benefit to ⮕ SUNITINIB;Genotype AG is associated with increased clinical benefit to sunitinib as compared to genotype GG.;  
;ANTIDEPRESSANTS;FKBP5;rs3800373;CC;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AA + AC.; in people with Disease:Depressive Disorder
;GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;rs163184;GT + TT;Efficacy;increased clinical benefit to ⮕ GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;Genotypes GT + TT is associated with increased clinical benefit to gliclazide, glimepiride, glipizide or glyburide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;or in people with Other:Diabetes Mellitus, Type 2
;ISONIAZID;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator increased concentrations of ⮕ ISONIAZID;NAT2 slow acetylator is associated with increased concentrations of isoniazid in people with Tuberculosis as compared to NAT2 rapid acetylator.; in people with Other:Tuberculosis
;RAMIPRIL;SLCO1B1;SLCO1B1 low activity;;Metabolism/PK;low activity increased concentrations of ⮕ RAMIPRIL;SLCO1B1 low activity is associated with increased concentrations of ramipril in healthy individuals as compared to SLCO1B1 high activity.; in healthy individuals 
;RAMIPRIL;ABCG2;ABCG2 poor metabolizer;;Metabolism/PK;poor metabolizer and low activity increased concentrations of ⮕ RAMIPRIL;ABCG2 poor metabolizer and low activity is associated with increased concentrations of ramipril in healthy individuals as compared to ABCG2 normal metabolizer.; in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Kidney Transplantation
;DULOXETINE;DRD3;rs324026;CC + CT;Efficacy;decreased response to ⮕ DULOXETINE;Genotypes CC + CT are associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotype TT.; in people with Disease:Anxiety Disorders
;CYTARABINE, DAUNORUBICIN;RAD50;rs2299014;AA + AC;Efficacy;increased resistance to ⮕ CYTARABINE, DAUNORUBICIN;Genotypes AA + AC is associated with increased resistance to cytarabine and daunorubicin in people with Leukemia, Myeloid, Acute as compared to genotype CC.;and in people with Other:Leukemia, Myeloid, Acute
;TENOFOVIR;ABCC4;rs1751034;TT;Toxicity;increased concentrations of ⮕ TENOFOVIR;Genotype TT is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotypes CC + CT.; in people with Other:HIV infectious disease
;DULOXETINE;DRD3;rs324023;CT;Efficacy;decreased response to ⮕ DULOXETINE;Genotype CT is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes CC + TT.; in people with Disease:Anxiety Disorders
;EFAVIRENZ, NEVIRAPINE;NR1I2;rs1523127;AA + AC;Efficacy;decreased response to ⮕ EFAVIRENZ, NEVIRAPINE;Genotypes AA + AC is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype CC.;or in people with Efficacy:HIV infectious disease
;EZETIMIBE;ABCG8;ABCG8 deficiency;;Efficacy;deficiency increased clinical benefit to ⮕ EZETIMIBE;ABCG8 deficiency is associated with increased clinical benefit to ezetimibe in people with Familial hypercholesterolemia.; in people with Other:Familial hypercholesterolemia
;EZETIMIBE;ABCG5;ABCG5 deficiency;;Efficacy;deficiency increased clinical benefit to ⮕ EZETIMIBE;ABCG5 deficiency is associated with increased clinical benefit to ezetimibe in people with Familial hypercholesterolemia.; in people with Other:Familial hypercholesterolemia
;RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy;intermediate metabolizer and poor metabolizer increased response to ⮕ RABEPRAZOLE;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased response to rabeprazole in people with Helicobacter Infections as compared to CYP2C19 *1/*1.; in people with Disease:Helicobacter Infections
;PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ PANTOPRAZOLE;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with decreased metabolism of pantoprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3.; in healthy individuals 
;DULOXETINE;DRD3;rs167770;AG;Efficacy;decreased response to ⮕ DULOXETINE;Genotype AG is associated with decreased response to duloxetine in people with Anxiety Disorders as compared to genotypes AA + GG.; in people with Disease:Anxiety Disorders
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer increased concentrations of ⮕ RISPERIDONE;CYP2D6 poor metabolizer is associated with increased concentrations of risperidone in people with Bipolar Disorder, Schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer and intermediate metabolizer.; in people with Disease:Bipolar Disorder, Disease:Schizoaffective disorder, Disease:Schizophrenia
;TAMSULOSIN;CYP2D6;CYP2D6*10, CYP2D6*41;*10 + *41;Efficacy;increased clinical benefit to ⮕ TAMSULOSIN;CYP2D6 *10 + *41 is associated with increased clinical benefit to tamsulosin in men with Prostatic Hyperplasia.; in men with Other:Prostatic Hyperplasia
;HYDROXYUREA;HBG2;rs7482144;AA + AG;Efficacy;increased clinical benefit to ⮕ HYDROXYUREA;Genotypes AA + AG is associated with increased clinical benefit to hydroxyurea in children with Beta-thalassemia and related diseases as compared to genotype GG.; in children with Other:Beta-thalassemia and related diseases
;HYDROXYUREA;HBG2;rs7482144;AA;Efficacy;increased clinical benefit to ⮕ HYDROXYUREA;Genotype AA is associated with increased clinical benefit to hydroxyurea in people with Beta-thalassemia and related diseases as compared to genotypes AG + GG.; in people with Other:Beta-thalassemia and related diseases
;HYDROXYUREA;BCL11A;rs766432;C;Efficacy;increased clinical benefit to ⮕ HYDROXYUREA;Allele C is associated with increased clinical benefit to hydroxyurea in people with Beta-thalassemia and related diseases as compared to allele A.; in people with Other:Beta-thalassemia and related diseases
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;A;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.;and in people with Disease:Colorectal Neoplasms
;VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*4 + *4/*10;Metabolism/PK;increased concentrations of ⮕ VORTIOXETINE;CYP2D6 *4/*4 + *4/*10 is associated with increased concentrations of vortioxetine as compared to CYP2D6 *1/*1.;  
;ANTIEPILEPTICS;SCN1A;rs121917953;AA + AT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotypes AA + AT is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype TT.; in people with Other:Epilepsy
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;increased concentrations of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 is associated with increased concentrations of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10.; in healthy individuals 
;METHOTREXATE;ENG;rs1800956;G;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele G is associated with decreased clearance of methotrexate in children with Acute lymphoblastic leukemia as compared to allele C.; in children with Other:Acute lymphoblastic leukemia
;METHOTREXATE;PKD1L2;rs16954698;A;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate in children with Acute lymphoblastic leukemia as compared to allele G.; in children with Other:Acute lymphoblastic leukemia
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;Dosage;decreased dose of ⮕ MERCAPTOPURINE;NUDT15 *1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3 is associated with decreased dose of mercaptopurine in children with Acute lymphoblastic leukemia as compared to NUDT15 *1/*1.; in children with Other:Acute lymphoblastic leukemia
;PREGABALIN;NAT2;NAT2 slow acetylator;;Metabolism/PK;slow acetylator increased exposure to ⮕ PREGABALIN;NAT2 slow acetylator is associated with increased exposure to pregabalin in healthy individuals as compared to NAT2 intermediate acetylator and rapid acetylator.; in healthy individuals 
;ANTIDEPRESSANTS;FKBP5;rs1360780;TT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype TT is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes CC + CT.; in people with Disease:Depressive Disorder
;PITAVASTATIN;CYP2C9;CYP2C9 poor metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased exposure to ⮕ PITAVASTATIN;CYP2C9 intermediate metabolizer and poor metabolizer is associated with increased exposure to pitavastatin in healthy individuals as compared to CYP2C9 normal metabolizer.; in healthy individuals 
;EFAVIRENZ, NEVIRAPINE;NR1I3;rs3003596;AG + GG;Efficacy;decreased response to ⮕ EFAVIRENZ, NEVIRAPINE;Genotypes AG + GG is associated with decreased response to efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.;or in people with Efficacy:HIV infectious disease
;ANTIDEPRESSANTS;FKBP5;rs4713916;AA;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype AA is associated with increased response to antidepressants in people with Depressive Disorder as compared to genotypes AG + GG.; in people with Disease:Depressive Disorder
;ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10 + *2/*10;Metabolism/PK;decreased concentrations of ⮕ ENDOXIFEN;CYP2D6 *10/*10 + *2/*10 is associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.; in women with Other:Breast Neoplasms
;ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer;;Metabolism/PK;normal metabolizer increased concentrations of ⮕ ENDOXIFEN;CYP2D6 normal metabolizer is associated with increased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 intermediate metabolizer.; in women with Other:Breast Neoplasms
;CLOZAPINE;CYP2D6;rs202102799;C;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Allele C is associated with decreased concentrations of clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele T.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;CLOZAPINE;CYP2D6;rs28371726;G;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Allele G is associated with decreased concentrations of clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele A.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;poor metabolizer increased concentrations of ⮕ CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19 *2/*2 (assigned as poor metabolizer phenotype) is associated with increased concentrations of clozapine and n-desmethylclozapine in people with Schizophrenia or Psychotic Disorder as compared to CYP2C19 *1/*1 + *1/*2 (assigned as normal metabolizer and intermediate metabolizer phenotype) .;and in people with Other:Schizophrenia, Other:Psychotic Disorder
;CLOZAPINE;DRD4;rs762502;C;Efficacy;increased clinical benefit to ⮕ CLOZAPINE;Allele C is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele T.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;NIFEDIPINE;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ NIFEDIPINE;Genotypes CT + TT are associated with increased clearance of nifedipine in women with Pregnancy as compared to genotype CC.; in women with Disease:Pregnancy
;CLOZAPINE;DRD4;rs2133251840;del;Efficacy;increased clinical benefit to ⮕ CLOZAPINE;Allele del is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele GA.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;Metabolism/PK;ultrarapid metabolizer decreased concentrations of ⮕ CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2 ultrarapid metabolizer is associated with decreased concentrations of clozapine and n-desmethylclozapine in people with Schizophrenia or Psychotic Disorder as compared to CYP1A2 normal metabolizer.;and in people with Other:Schizophrenia, Other:Psychotic Disorder
;EXENATIDE;SORCS1;rs1416406;GG;Efficacy;increased response to ⮕ EXENATIDE;Genotype GG is associated with increased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.; in people with Other:Diabetes Mellitus, Type 2
;LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;rs2285676;GG;Efficacy;increased clinical benefit to ⮕ LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;Genotype GG is associated with increased clinical benefit to linagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.;or in people with Other:Diabetes Mellitus, Type 2
;LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;rs57803087;G;Efficacy;increased response to ⮕ LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;Allele G is associated with increased response to linagliptin, saxagliptin, sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele A.;or in people with Other:Diabetes Mellitus, Type 2
;MIDAZOLAM;NR1I2;rs2461817;CC;Metabolism/PK;increased concentrations of ⮕ MIDAZOLAM;Genotype CC is associated with increased concentrations of midazolam in people with respiratory failure requiring assisted ventilation as compared to genotypes AA + AC.; in people with Other:respiratory failure requiring assisted ventilation
;METHADONE, R-EDDP, S-EDDP;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer increased concentrations of ⮕ METHADONE, R-EDDP, S-EDDP;CYP2D6 intermediate metabolizer is associated with increased concentrations of methadone, R-EDDP and S-EDDP in people with Death as compared to CYP2D6 normal metabolizer.;and in people with Other:Death
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased metabolism of ⮕ DEXTROMETHORPHAN;CYP2D6 *10/*10 is associated with decreased metabolism of dextromethorphan in healthy individuals as compared to CYP2D6 *1/*10 + *1/*1.; in healthy individuals 
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;G;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T.;and in people with Disease:Colorectal Neoplasms
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Dosage;decreased dose of ⮕ AZATHIOPRINE;Genotypes CT + TT are associated with decreased dose of azathioprine in people with Colitis, Ulcerative, Crohn Disease and Hepatitis, Autoimmune as compared to genotype CC.; in people with Disease:Ulcerative Colitis, Disease:Crohn Disease, Disease:Autoimmune hepatitis
;WARFARIN;CYP2C9;rs1057910;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.; in people with Other:Heart valve replacement
;WARFARIN;APOE;rs7412;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes CT + TT.; in people with Other:Atrial Fibrillation, Other:Pulmonary Embolism, Other:Venous Thrombosis
;METFORMIN;SLC22A1;rs2282143;CC;Metabolism/PK;increased clearance of ⮕ METFORMIN;Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;METFORMIN;SLC22A2;rs316019;CC;Metabolism/PK;increased clearance of ⮕ METFORMIN;Genotype CC is associated with increased clearance of metformin in healthy individuals as compared to genotype AC.; in healthy individuals 
;METHACHOLINE;ADRB2;rs1042713;AA;Efficacy;decreased response to ⮕ METHACHOLINE;Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG.; in people with Disease:Asthma
;ACENOCOUMAROL;VKORC1;rs9923231;CT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;TEMSIROLIMUS;NR1I2;rs3814055;TT;Metabolism/PK;decreased metabolism of ⮕ TEMSIROLIMUS;Genotype TT is associated with decreased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT.; in people with Disease:Urinary Bladder Neoplasms
;TEMSIROLIMUS;ABCB1;rs2032582;CC;Metabolism/PK;increased metabolism of ⮕ TEMSIROLIMUS;Genotype CC is associated with increased metabolism of temsirolimus in people with Urinary Bladder Neoplasms as compared to genotypes AA + AC.; in people with Disease:Urinary Bladder Neoplasms
;TACROLIMUS;CYP3A5;rs776746;TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotype TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;;rs4646457;C;Dosage;dose of ⮕ TACROLIMUS;Allele C is associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele A.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs15524;G;Dosage;dose of ⮕ TACROLIMUS;Allele G is associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele A.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs12333983;A;Dosage;dose of ⮕ TACROLIMUS;Allele A is associated with dose of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT are associated with decreased dose of acenocoumarol in people with Rheumatic Heart Disease as compared to genotype CC.; in people with Disease:Rheumatic Heart Disease
;ATENOLOL, METOPROLOL;;rs294610;A;Efficacy;increased response to ⮕ ATENOLOL, METOPROLOL;Allele A is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.;or in people with Other:Hypertension
;ATENOLOL, METOPROLOL;SLC4A1;rs45545233;CC + CT;Efficacy;decreased response to ⮕ ATENOLOL, METOPROLOL;Genotypes CC + CT are associated with decreased response to atenolol or metoprolol in people with Hypertension as compared to genotype TT.;or in people with Other:Hypertension
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;G;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;Dosage;dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotype CT is associated with dose of capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;or in people with Disease:Colorectal Neoplasms
;DICHLOROACETIC ACID;GSTZ1, POMT2;rs7975;G;Other, Metabolism/PK;increased clearance of ⮕ DICHLOROACETIC ACID;Allele G is associated with increased clearance of dichloroacetic acid in healthy individuals.; in healthy individuals 
;DICHLOROACETIC ACID;GSTZ1, POMT2;rs1046428;C;Other, Metabolism/PK;increased clearance of ⮕ DICHLOROACETIC ACID;Allele C is associated with increased clearance of dichloroacetic acid in healthy individuals.; in healthy individuals 
;DICHLOROACETIC ACID;GSTZ1, POMT2;rs7972;G;Other, Metabolism/PK;increased metabolism of ⮕ DICHLOROACETIC ACID;Allele G is associated with increased metabolism of dichloroacetic acid in healthy individuals.; in healthy individuals 
;SUNITINIB;ABCB1;rs2032582;AA;Efficacy;decreased response to ⮕ SUNITINIB;Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell.; in people with Disease:Renal Cell Carcinoma
;FLUOROURACIL;DPYD;rs17376848;AG + GG;Metabolism/PK;increased concentrations of ⮕ FLUOROURACIL;Genotypes AG + GG is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.; in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;HYDROCHLOROTHIAZIDE;;rs11065987;AA + AG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;METHADONE;ABCB1;rs1128503;AA;Dosage;increased dose of ⮕ METHADONE;Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.; in people with Other:Heroin Dependence
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;CAFFEINE;CYP1A2;rs12720461;CT;Metabolism/PK;decreased metabolism of ⮕ CAFFEINE;Genotype CT is associated with decreased metabolism of caffeine in healthy individuals as compared to genotype CC.; in healthy individuals 
;ETHANOL;OPRM1;rs553202;T;Efficacy;increased response to ⮕ ETHANOL;Allele T is associated with increased response to ethanol as compared to allele C.;  
;ETHANOL;OPRM1;rs524731;A;Efficacy;increased response to ⮕ ETHANOL;Allele A is associated with increased response to ethanol as compared to allele C.;  
;NICOTINE;HINT1;rs3852209;CT + TT;Efficacy;increased response to ⮕ NICOTINE;Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC.; in people with Other:Tobacco Use Disorder
;OPIOIDS;OPRM1;rs1799971;AG;Efficacy;decreased response to ⮕ OPIOIDS;Genotype AG is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotype AA.; in people with Disease:Pain, Postoperative
;PHENPROCOUMON;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.;  
;FLUOXETINE;CYP2D6;rs3892097;CT;Efficacy;increased concentrations of ⮕ FLUOXETINE;Genotype CT is associated with increased concentrations of fluoxetine in men with Alcoholism and Depressive Disorder, Major as compared to genotype CC.; in men with Efficacy:Alcohol abuse, Efficacy:Major Depressive Disorder
;LEVODOPA;DBH;rs1611115;CT + TT;Efficacy;increased response to ⮕ LEVODOPA;Genotypes CT + TT are associated with increased response to levodopa in people with Cocaine-Related Disorders as compared to genotype CC.; in people with Disease:Cocaine dependence
;QUETIAPINE;CYP1A2;rs2069514;AA;Metabolism/PK;increased concentrations of ⮕ QUETIAPINE;Genotype AA is associated with increased concentrations of quetiapine in healthy individuals as compared to genotype GG.; in healthy individuals 
;VENLAFAXINE;COMT;rs4680;GG;Efficacy;increased response to ⮕ VENLAFAXINE;Genotype GG is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes AA + AG.; in people with Disease:Major Depressive Disorder
;AXITINIB;OR2B11;rs35305980;A;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele A is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele del.; in people with Disease:Renal Cell Carcinoma
;SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT;Efficacy;increased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotype CT is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotypes CC + TT.; in people with Disease:Diabetes Mellitus
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.; in people with Disease:Coronary Artery Disease
;SULFONAMIDES, UREA DERIVATIVES;ABCC8;rs757110;AA + CC;Efficacy;increased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotypes AA + CC is associated with increased response to sulfonamides, urea derivatives in people with Diabetes Mellitus as compared to genotype AC.; in people with Disease:Diabetes Mellitus
;TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs9394992;CT + TT;Efficacy;increased response to ⮕ TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.;and in people with Disease:Colorectal Neoplasms
;AXITINIB;UGT1A10, UGT1A8, UGT1A9;rs3832043;del;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele del is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele T.; in people with Disease:Renal Cell Carcinoma
;AXITINIB;UGT1A7;rs17868323;G;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele G is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele T.; in people with Disease:Renal Cell Carcinoma
;RISPERIDONE;HTR2C;rs3813928;A;Efficacy;decreased response to ⮕ RISPERIDONE;Allele A is associated with decreased response to risperidone in children with Autistic Disorder as compared to genotype GG.; in children with Disease:Autism
;METHOTREXATE;MTRR;rs1532268;CT + TT;Metabolism/PK;increased exposure to ⮕ METHOTREXATE;Genotypes CT + TT is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Other:Acute lymphoblastic leukemia
;RISPERIDONE;HTR2A;rs6311;CT + TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes CT + TT are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype CC.; in children with Disease:Autism
;AXITINIB;ABCB1;rs1045642;A;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele A is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele G.; in people with Disease:Renal Cell Carcinoma
;BUTORPHANOL;COMT;rs6269;GG;Efficacy;decreased response to ⮕ BUTORPHANOL;Genotype GG is associated with decreased response to butorphanol in healthy individuals as compared to genotypes AA + AG.; in healthy individuals 
;AXITINIB;ABCG2;rs2231142;T;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele G.; in people with Disease:Renal Cell Carcinoma
;AXITINIB;ABCB1;rs2032582;T;Metabolism/PK;concentrations of ⮕ AXITINIB;Allele T is associated with concentrations of axitinib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;VORICONAZOLE;CYP2C19;rs4244285;AA + AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype GG.; in children 
;ERLOTINIB;EGFR;rs121434568;GT + TT;Efficacy;decreased response to ⮕ ERLOTINIB;Genotypes GT + TT are associated with decreased response to erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;ABCB1;rs1045642;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;CYTARABINE;SLC29A1;rs3734703;A;Efficacy;increased response to ⮕ CYTARABINE;Allele A is associated with increased response to cytarabine in people with Leukemia, Myeloid, Acute as compared to allele C.; in people with Disease:Leukemia, Myeloid, Acute
;BUTORPHANOL;COMT;rs4633;CC;Efficacy;decreased response to ⮕ BUTORPHANOL;Genotype CC is associated with decreased response to butorphanol in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;SUNITINIB;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased clearance of ⮕ SUNITINIB;Genotypes AA + AG is associated with increased clearance of sunitinib in people with Carcinoma, Renal Cell and Neoplasm Metastasis as compared to genotype GG.; in people with Disease:Renal Cell Carcinoma, Disease:Metastatic neoplasm
;METHOTREXATE;SLC19A1;rs1051266;CC + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.; in children with Other:Acute lymphoblastic leukemia
;SN-38;UGT1A9;rs3832043;TT;Dosage;increased metabolism of ⮕ SN-38;Genotype TT is associated with increased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + del/del.; in people with Disease:Non-Small Cell Lung Carcinoma
;EFAVIRENZ;CYP2B6;rs2279345;CC + CT;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotypes CC + CT are associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;RISPERIDONE;ABCB1;rs1128503;AA + AG;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes AA + AG are associated with increased response to risperidone in children with Autistic Disorder as compared to genotype GG.; in children with Disease:Autism
;EFAVIRENZ;CYP2B6;rs2279345;CT;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotype CT is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;GLUCOCORTICOIDS;CRHR1;rs1876828;T;Efficacy;increased response to ⮕ GLUCOCORTICOIDS;Allele T is associated with increased response to glucocorticoids in people with Asthma as compared to allele C.; in people with Disease:Asthma
;ANTIDEPRESSANTS;ERICH3;rs11580409;C;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with increased response to antidepressants as compared to allele A.;  
;SN-38;SLCO1B1;rs4149056;CC + CT;Dosage;increased dose of ⮕ SN-38;Genotypes CC + CT are associated with increased dose of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;SALMETEROL;ADRB2;rs1042713;AA;Efficacy;decreased response to ⮕ SALMETEROL;Genotype AA is associated with decreased response to salmeterol in children with Asthma.; in children with Disease:Asthma
;(S)-METHADONE;CYP3A4;rs2740574;CT;Metabolism/PK;increased concentrations of ⮕ (S)-METHADONE;Genotype CT is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to genotype TT.; in people with Disease:Opioid-Related Disorders
;VORICONAZOLE;CYP2C19;rs4986893;AA + AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of voriconazole in children as compared to genotype GG.; in children 
;METHYLPHENIDATE;GRIN2B;rs2284411;CC;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;FENTANYL;CYP3A4;rs2740574;C;Metabolism/PK;decreased clearance of ⮕ FENTANYL;Allele C is associated with decreased clearance of fentanyl in people with Burns as compared to allele T.; in people with Other:Burns
;SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;Efficacy;decreased response to ⮕ SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.;and in people with Disease:Asthma
;ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs2230806;T;Efficacy;decreased response to ⮕ ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.;or  
;SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;Efficacy;decreased response to ⮕ SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele T is associated with decreased response to salbutamol and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele A.;and in people with Disease:Asthma
;ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;rs3892097;T;Efficacy;decreased response to ⮕ ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;Allele T is associated with decreased response to atorvastatin, rosuvastatin or simvastatin as compared to allele C.;or  
;NICARDIPINE, NIMODIPINE;CACNA1B;rs2739258;AG + GG;Efficacy;increased clinical benefit to ⮕ NICARDIPINE, NIMODIPINE;Genotypes AG + GG is associated with increased clinical benefit to nicardipine or nimodipine in people with Bipolar Disorder as compared to genotype AA.;or in people with Other:Bipolar Disorder
;METHOTREXATE;MTHFR;rs1801131;TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype TT is associated with decreased response to methotrexate in children with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.; in children with Other:Non-Hodgkin Lymphoma, Other:Acute lymphoblastic leukemia
;IMATINIB;CYP3A5;rs776746;C;Efficacy;increased response to ⮕ IMATINIB;Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;SLC22A1;rs683369;CG + GG;Efficacy;decreased response to ⮕ IMATINIB;Genotypes CG + GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;SIMVASTATIN;APOA5;rs662799;AA;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype AA is associated with increased response to simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.; in people with Disease:Dyslipidaemia
;IRBESARTAN;APOB;rs1367117;AG;Efficacy, Metabolism/PK;response to ⮕ IRBESARTAN;Genotype AG is associated with response to irbesartan in people with Hypertension.; in people with Disease:Hypertension
;IRBESARTAN;APOB;rs1367117;GG;Efficacy;response to ⮕ IRBESARTAN;Genotype GG is associated with response to irbesartan in people with Hypertension.; in people with Disease:Hypertension
;ATORVASTATIN;APOA5;rs662799;AA;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype AA is associated with increased response to atorvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.; in people with Disease:Dyslipidaemia
;EFAVIRENZ;CYP2A6;rs28399433;C;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele A.; in people with Disease:HIV infectious disease
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;increased response to ⮕ METHOTREXATE;Genotype AA is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.; in children with Other:Acute lymphoblastic leukemia
;BENAZEPRIL;PRCP;rs2229437;GG + GT;Efficacy;decreased response to ⮕ BENAZEPRIL;Genotypes GG + GT are associated with decreased response to benazepril in people with Hypertension as compared to genotype TT.; in people with Disease:Hypertension
;EFAVIRENZ;UGT2B7;rs28365062;GG;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotypes AA + AG.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.; in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy, Other;response to ⮕ CLOPIDOGREL;Allele A is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele G.; in people with Disease:Acute coronary syndrome
;EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;rs2279343;AG + GG;Efficacy;increased clinical benefit to ⮕ EFAVIRENZ, LAMIVUDINE, TENOFOVIR;Genotypes AG + GG is associated with increased clinical benefit to efavirenz, lamivudine and tenofovir in people with HIV Infections as compared to genotype AA.;and in people with Other:HIV infectious disease
;METHOTREXATE;MTHFR;rs1801131;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.; in children with Other:Acute lymphoblastic leukemia
;CLOPIDOGREL;ABCB1;rs1045642;G;Efficacy, Other;response to ⮕ CLOPIDOGREL;Allele G is associated with response to clopidogrel in people with Acute coronary syndrome as compared to allele A.; in people with Disease:Acute coronary syndrome
;MIDAZOLAM;VDR;rs11568820;CT + TT;Metabolism/PK;increased clearance of ⮕ MIDAZOLAM;Genotypes CT + TT are associated with increased clearance of midazolam as compared to genotype CC.;  
;METHYLDOPA;ARG2;rs3742879;G;Efficacy;increased response to ⮕ METHYLDOPA;Allele G is associated with increased response to Methyldopa in women with Pregnancy and Pre-Eclampsia as compared to allele A.; in women with Other:Pregnancy, Other:Pre-Eclampsia
;FLUOROURACIL;MTHFR;rs1801133;AA + AG;Efficacy;increased response to ⮕ FLUOROURACIL;Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.; in people with Disease:Colorectal Neoplasms
;REPAGLINIDE;CYP2C8;rs10509681;C;Dosage, Metabolism/PK;increased metabolism of ⮕ REPAGLINIDE;Allele C is associated with increased metabolism of repaglinide in healthy individuals as compared to allele T.; in healthy individuals 
;REPAGLINIDE;CYP2C8;rs11572080;T;Dosage, Metabolism/PK;increased metabolism of ⮕ REPAGLINIDE;Allele T is associated with increased metabolism of repaglinide in healthy individuals as compared to allele C.; in healthy individuals 
;ARIPIPRAZOLE;ABCB1;rs1128503;AA;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;Genotype AA is associated with increased concentrations of aripiprazole in people with Depressive Disorder, Major as compared to genotypes AG + GG.; in people with Other:Major Depressive Disorder
;OMEPRAZOLE;CYP2C19;rs12248560;TT;Dosage, Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; in people with Other:no disease
;MEPHENYTOIN;CYP2C19;rs12248560;TT;Dosage, Metabolism/PK;increased metabolism of ⮕ MEPHENYTOIN;Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.; in people with Other:no disease
;OMEPRAZOLE;CYP2C19;rs11188072;TT;Dosage, Metabolism/PK;increased metabolism of ⮕ OMEPRAZOLE;Genotype TT is associated with increased metabolism of omeprazole in people with no disease as compared to genotype CC.; in people with Other:no disease
;MEPHENYTOIN;CYP2C19;rs11188072;TT;Dosage, Metabolism/PK;increased metabolism of ⮕ MEPHENYTOIN;Genotype TT is associated with increased metabolism of mephenytoin in people with no disease as compared to genotype CC.; in people with Other:no disease
;METHADONE;CYP2B6;rs3211371;TT;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype TT is associated with increased concentrations of methadone as compared to genotypes CC + CT.;  
;MERCAPTOPURINE, METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Dosage;decreased dose of ⮕ MERCAPTOPURINE, METHOTREXATE;Genotypes CC + CT is associated with decreased dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;or in children with Disease:Acute lymphoblastic leukemia
;GEMCITABINE;CMPK1;rs1044457;CC;Efficacy;increased response to ⮕ GEMCITABINE;Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.; in people with Disease:Pancreatic Neoplasms
;DEXMEDETOMIDINE;ADRA2A;rs1800035;CG + GG;Efficacy;decreased response to ⮕ DEXMEDETOMIDINE;Genotypes CG + GG are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.; in women with Other:Pain, Postoperative
;BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;rs3024498;CC + CT;Efficacy;decreased clinical benefit to ⮕ BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;Genotypes CC + CT is associated with decreased clinical benefit to budesonide, fluticasone/salmeterol, formoterol or omalizumab in children with Asthma as compared to genotype TT.;or in children with Other:Asthma
;DEXMEDETOMIDINE;ADRA2A;rs775887911;CT + TT;Efficacy;decreased response to ⮕ DEXMEDETOMIDINE;Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.; in women with Other:Pain, Postoperative
;DEXMEDETOMIDINE;ADRA2A;rs201376588;CT + TT;Efficacy;decreased response to ⮕ DEXMEDETOMIDINE;Genotypes CT + TT are associated with decreased response to dexmedetomidine in women with Pain, Postoperative as compared to genotype CC.; in women with Other:Pain, Postoperative
;GEMCITABINE;CMPK1;rs35687416;GG;Efficacy;increased response to ⮕ GEMCITABINE;Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; in people with Disease:Pancreatic Neoplasms
;GEMCITABINE;DCTD;rs12507552;CC;Efficacy;increased response to ⮕ GEMCITABINE;Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.; in people with Disease:Pancreatic Neoplasms
;BETA BLOCKING AGENTS;;rs139945292;T;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Allele T is associated with decreased response to Beta Blocking Agents in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;ROSUVASTATIN;APOA5;rs662799;AA;Efficacy;increased response to ⮕ ROSUVASTATIN;Genotype AA is associated with increased response to rosuvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.; in people with Disease:Dyslipidaemia
;GEMCITABINE;TENT4A;rs274713;GG;Efficacy;increased response to ⮕ GEMCITABINE;Genotype GG is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.; in people with Disease:Pancreatic Neoplasms
;METHOTREXATE;FPGS;rs1544105;CT + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;GEMCITABINE;CDC5L;rs992160;CT + TT;Efficacy;increased response to ⮕ GEMCITABINE;Genotypes CT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.; in people with Disease:Pancreatic Neoplasms
;METHOTREXATE;TYMS;rs2853539;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;rs662799;AA;Other;response to ⮕ ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;Genotype AA is associated with response to atorvastatin, rosuvastatin and simvastatin in people with Dyslipidaemia as compared to genotypes AG + GG.;and in people with Disease:Dyslipidaemia
;BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;rs3819024;AG + GG;Efficacy;decreased clinical benefit to ⮕ BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;Genotypes AG + GG is associated with decreased clinical benefit to budesonide, fluticasone/salmeterol, formoterol or omalizumab in children with Asthma as compared to genotype AA.;or in children with Other:Asthma
;GEMCITABINE;SH2D5;rs10916852;GT + TT;Efficacy;increased response to ⮕ GEMCITABINE;Genotypes GT + TT are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.; in people with Disease:Pancreatic Neoplasms
;ROSUVASTATIN;CETP;rs708272;A;Efficacy;decreased response to ⮕ ROSUVASTATIN;Allele A is associated with decreased response to rosuvastatin as compared to allele G.;  
;ATORVASTATIN;ABCB1;rs1045642;AA;Efficacy;increased clinical benefit to ⮕ ATORVASTATIN;Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.; in people with Other:Coronary Artery Disease
;ATORVASTATIN;SLCO1B1;rs2306283;AA;Efficacy;increased clinical benefit to ⮕ ATORVASTATIN;Genotype AA is associated with increased clinical benefit to atorvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.; in people with Other:Coronary Artery Disease
;REPAGLINIDE;SLCO1B1;rs4149056;CT;Metabolism/PK;increased concentrations of ⮕ REPAGLINIDE;Genotype CT is associated with increased concentrations of repaglinide in healthy individuals as compared to genotype TT.; in healthy individuals 
;PHENPROCOUMON;VKORC1;rs9923231;TT;Dosage, Toxicity;decreased dose of ⮕ PHENPROCOUMON;Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.;  
;AZATHIOPRINE;TPMT;rs1142345;CT;Metabolism/PK;decreased metabolism of ⮕ AZATHIOPRINE;Genotype CT is associated with decreased metabolism of azathioprine in people with Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Inflammatory Bowel Diseases
;AZATHIOPRINE;ITPA;rs1127354;AC;Metabolism/PK;increased metabolism of ⮕ AZATHIOPRINE;Genotype AC is associated with increased metabolism of azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Inflammatory Bowel Diseases
;REPAGLINIDE;SLCO1B1;rs4149056;TT;Metabolism/PK;exposure to ⮕ REPAGLINIDE;Genotype TT is associated with exposure to repaglinide in healthy individuals.; in healthy individuals 
;BUPRENORPHINE;CYP3A4;rs2740574;TT;Efficacy;increased response to ⮕ BUPRENORPHINE;Genotype TT is associated with increased response to buprenorphine in people with Ischemia and Pain as compared to genotype CC.; in people with Disease:Ischemia, Disease:Pain
;PERINDOPRIL;AGTR1;rs5186;AA;Efficacy;decreased response to ⮕ PERINDOPRIL;Genotype AA is associated with decreased response to perindopril in people with Hypertension as compared to genotypes AC + CC.; in people with Disease:Hypertension
;NITRENDIPINE;AGTR1;rs5186;AA;Efficacy;increased response to ⮕ NITRENDIPINE;Genotype AA is associated with increased response to nitrendipine in people with Hypertension as compared to genotypes AC + CC.; in people with Disease:Hypertension
;HYDROMORPHONE;OPRM1;rs1799971;AG + GG;PD;increased response to ⮕ HYDROMORPHONE;Genotypes AG + GG is associated with increased response to hydromorphone in healthy individuals as compared to genotype AA.; in healthy individuals 
;LAMOTRIGINE;HNF4A;rs2071197;AA;Metabolism/PK;decreased concentrations of ⮕ LAMOTRIGINE;Genotype AA is associated with decreased concentrations of lamotrigine in people with Epilepsy as compared to genotypes AG + GG.; in people with Disease:Epilepsy
;LAMOTRIGINE;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotypes GT + TT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;LAMOTRIGINE;ABCG2;rs3114020;CC + CT;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotypes CC + CT are associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;CYCLOSPORINE;TSPYL1;rs3828743;AG + GG;Metabolism/PK;increased clearance of ⮕ CYCLOSPORINE;Genotypes AG + GG is associated with increased clearance of cyclosporine in men with Kidney Transplantation as compared to genotype AA.; in men with Other:Kidney Transplantation
;GEMCITABINE;CMPK1;rs7543016;CC;Efficacy;increased response to ⮕ GEMCITABINE;Genotype CC is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CG + GG.; in people with Disease:Pancreatic Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;GEMCITABINE;ESR2;rs944050;TT;Efficacy;increased response to ⮕ GEMCITABINE;Genotype TT is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.; in people with Disease:Pancreatic Neoplasms
;RISPERIDONE;DRD2;rs1799978;TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT.; in people with Other:Schizophrenia
;IRINOTECAN;ABCC2;rs2273697;AA + AG;Metabolism/PK;increased metabolism of ⮕ IRINOTECAN;Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG.; in people with Disease:Colorectal Neoplasms
;RISPERIDONE;DRD2;rs1799978;T;Other;increased response to ⮕ RISPERIDONE;Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.; in people with Disease:Schizophrenia
;ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;GLUCOSE;SLCO1B1;rs4149056;TT;Metabolism/PK;concentrations of ⮕ GLUCOSE;Genotype TT is associated with concentrations of glucose in healthy individuals.; in healthy individuals 
;WARFARIN;;rs12777823;A;Dosage;dose of ⮕ WARFARIN;Allele A is associated with dose of warfarin as compared to allele G.;  
;METHOTREXATE;SLCO1B1;rs2306283;AA + AG;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotypes AA + AG are associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Disease:Acute lymphoblastic leukemia
;IVACAFTOR;CFTR;rs75527207;AA + AG;Efficacy;increased response to ⮕ IVACAFTOR;Genotypes AA + AG are associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.; in people with Disease:Cystic Fibrosis
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Disease:Acute lymphoblastic leukemia
;CONJUGATED ESTROGENS;SLCO1B1;rs4149056;CT;Efficacy;increased response to ⮕ CONJUGATED ESTROGENS;Genotype CT is associated with increased response to conjugated estrogens in women with Menopause as compared to genotype TT.; in women with Disease:Menopause
;CISPLATIN;ERCC1;rs3212986;A;Efficacy;decreased response to ⮕ CISPLATIN;Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele C.; in women with Other:Ovarian Neoplasms
;ANTIPSYCHOTICS;ABCB1;rs1045642;GG;Dosage, Metabolism/PK;increased dose of ⮕ ANTIPSYCHOTICS;Genotype GG is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;ABCB1;rs2032582;AA;Dosage, Metabolism/PK;increased dose of ⮕ ANTIPSYCHOTICS;Genotype AA is associated with increased dose of antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;DIAZEPAM;CYP2C19;rs4244285;AA + AG;Efficacy;increased clinical benefit to ⮕ DIAZEPAM;Genotypes AA + AG is associated with increased clinical benefit to diazepam in men with Alcoholism as compared to genotype GG.; in men with Other:Alcohol abuse
;ALPRAZOLAM;CYP3A4;rs35599367;AG;Metabolism/PK;increased concentrations of ⮕ ALPRAZOLAM;Genotype AG is associated with increased concentrations of alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.; in men with Other:Alcohol abuse, Other:Anxiety Disorders
;DIAZEPAM;CYP2C19;rs12248560;CT + TT;Efficacy;decreased clinical benefit to ⮕ DIAZEPAM;Genotypes CT + TT is associated with decreased clinical benefit to diazepam in men with Alcoholism as compared to genotype CC.; in men with Other:Alcohol abuse
;CLOZAPINE;POR;rs1057868;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ CLOZAPINE;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder.; in people with Other:Schizophrenia, Other:Tobacco Use Disorder
;SALBUTAMOL;IGF2R;rs8191725;AG;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype AA.; in children with Disease:Asthma
;SALBUTAMOL;SLC24A4;rs77441273;AG;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.; in children with Disease:Asthma
;ALPRAZOLAM;CYP3A4;rs35599367;AG;Efficacy;decreased response to ⮕ ALPRAZOLAM;Genotype AG is associated with decreased response to alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.; in men with Other:Alcohol abuse, Other:Anxiety Disorders
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AG;Efficacy;increased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;Genotype AG is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG.;or in people with Disease:Helicobacter Infections
;LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AA;Efficacy;increased response to ⮕ LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;Genotype AA is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG.;or in people with Disease:Helicobacter Infections
;WARFARIN;VKORC1;rs2359612;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;Efficacy;increased clinical benefit to ⮕ PLATINUM COMPOUNDS;Genotypes AG + GG is associated with increased clinical benefit to Platinum compounds in people with Ovarian Neoplasms, Esophageal Neoplasms or Neoplasms as compared to genotype AA.; in people with Other:Ovarian Neoplasms, Other:Neoplasm of esophagus, Other:Neoplasms
;ULINASTATIN;MMP2;rs243865;T;Efficacy;decreased response to ⮕ ULINASTATIN;Allele T is associated with decreased response to ulinastatin in people with Pancreatitis as compared to allele C.; in people with Other:Pancreatitis
;ANTIPSYCHOTICS;ABCB1;rs1128503;G;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Allele G is associated with increased response to antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;ULINASTATIN;MMP9;rs3918242;T;Efficacy;increased response to ⮕ ULINASTATIN;Allele T is associated with increased response to ulinastatin in people with Pancreatitis as compared to allele C.; in people with Other:Pancreatitis
;TACROLIMUS;CYP3A4;rs35599367;AA + AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes AA + AG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;TACROLIMUS;NR1I2;rs2276707;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ANTIPSYCHOTICS;ABCB1;rs1045642;G;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Allele G is associated with increased response to antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;IRINOTECAN;NR1I2;rs10934498;AA;Toxicity, Metabolism/PK;decreased exposure to ⮕ IRINOTECAN;Genotype AA is associated with decreased exposure to irinotecan in people with Colonic Neoplasms as compared to genotypes AG + GG.; in people with Disease:Colonic Neoplasms
;TACROLIMUS;IL10;rs1800896;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;OLANZAPINE;DRD3;rs324026;C;Efficacy;increased clinical benefit to ⮕ OLANZAPINE;Allele C is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele T.; in people with Other:Schizophrenia
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs6811453;A;Efficacy;increased resistance to ⮕ CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;Allele A is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele G.;and in people with Disease:Leukemia, Myeloid, Acute
;MEASLES VACCINES;TLR3;rs3775291;CT;Efficacy;decreased response to ⮕ MEASLES VACCINES;Genotype CT is associated with decreased response to Measles vaccines as compared to genotype CC.;  
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs1826909;T;Efficacy;increased resistance to ⮕ CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;Allele T is associated with increased resistance to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.;and in people with Disease:Leukemia, Myeloid, Acute
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.;  
;TAMOXIFEN;ABCC2;rs717620;CT;Efficacy;increased response to ⮕ TAMOXIFEN;Genotype CT is associated with increased response to tamoxifen in women Breast Neoplasms as compared to genotype CC.; in women Disease:Breast Neoplasms
;SALBUTAMOL;;rs77149876;CT;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.; in children with Disease:Asthma
;ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;Efficacy;decreased response to ⮕ ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;or in people with Disease:Rheumatoid arthritis
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Dosage;increased dose of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;SALBUTAMOL;PAPPA2;rs77977790;CT;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.; in children with Disease:Asthma
;NORBUPRENORPHINE;OPRD1;rs569356;GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ NORBUPRENORPHINE;Genotype GG is associated with decreased dose-adjusted trough concentrations of norbuprenorphine in people with Opioid-Related Disorders as compared to genotypes AA + AG.; in people with Other:Opioid-Related Disorders
;TACROLIMUS;CYP3A4;rs2740574;CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Disease:Kidney Transplantation
;SALMETEROL;ADRB2;rs1042713;G;Efficacy;increased response to ⮕ SALMETEROL;Allele G is associated with increased response to salmeterol in children Asthma as compared to allele A.; in children Other:Asthma
;SALBUTAMOL;;rs116551936;AG;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.; in children with Disease:Asthma
;SALBUTAMOL;NCOA3;rs115501901;CT;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype CC.; in children with Disease:Asthma
;SALBUTAMOL;;rs74973995;AG;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype AA.; in children with Disease:Asthma
;SALBUTAMOL;CRHR2;rs73294475;CT;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype CT is associated with increased response to salbutamol in children with Asthma as compared to genotype TT.; in children with Disease:Asthma
;PHENPROCOUMON;CYP3A4;rs2740574;C;Dosage;decreased dose of ⮕ PHENPROCOUMON;Allele C is associated with decreased dose of phenprocoumon in children as compared to allele T.; in children 
;SALBUTAMOL;ADCY9;rs144315541;AG;Efficacy;increased response to ⮕ SALBUTAMOL;Genotype AG is associated with increased response to salbutamol in children with Asthma as compared to genotype GG.; in children with Disease:Asthma
;PERPHENAZINE;MCPH1;rs17570753;A;Efficacy;response to ⮕ PERPHENAZINE;Allele A is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;PERPHENAZINE;CDH13;rs2116971;G;Efficacy;response to ⮕ PERPHENAZINE;Allele G is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;PERPHENAZINE;SKOR2;rs9952628;G;Efficacy;response to ⮕ PERPHENAZINE;Allele G is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;METFORMIN;SLC47A2;rs12943590;AA;Efficacy, Metabolism/PK;decreased response to ⮕ METFORMIN;Genotype AA is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotypes AG + GG.; in people with Disease:Diabetes Mellitus
;QUETIAPINE;KCNMA1;rs35793;G;Efficacy;response to ⮕ QUETIAPINE;Allele G is associated with response to quetiapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;PERPHENAZINE;MAML3;rs11100483;A;Efficacy;response to ⮕ PERPHENAZINE;Allele A is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;VALPROIC ACID;UGT2B7;rs7668258;CC + CT;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotypes CC + CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;METHACHOLINE;RUNX1;rs11702779;AA;Other;increased response to ⮕ METHACHOLINE;Genotype AA is associated with increased response to methacholine in children with Asthma as compared to genotypes AG + GG.; in children with Disease:Asthma
;RISPERIDONE;LRP1B;rs874295;G;Efficacy;response to ⮕ RISPERIDONE;Allele G is associated with response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;BEVACIZUMAB;HTRA1;rs11200638;AA;Efficacy;decreased response to ⮕ BEVACIZUMAB;Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.; in people with Disease:Macular Degeneration
;RISPERIDONE;PSMD14;rs9713;A;Efficacy;response to ⮕ RISPERIDONE;Allele A is associated with response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;RISPERIDONE;AGAP1;rs1869295;C;Efficacy;response to ⮕ RISPERIDONE;Allele C is associated with response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;BEVACIZUMAB;ARMS2;rs10490924;TT;Efficacy;decreased response to ⮕ BEVACIZUMAB;Genotype TT is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.; in people with Disease:Macular Degeneration
;VALPROIC ACID;APEH;rs3816877;CC;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotype CC is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CT.; in people with Disease:Epilepsy
;RISPERIDONE;NPAS3;rs1315115;G;Efficacy;response to ⮕ RISPERIDONE;Allele G is associated with response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;RISPERIDONE;TMEFF2;rs3738883;G;Efficacy;response to ⮕ RISPERIDONE;Allele G is associated with response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;METFORMIN;PCK1;rs4810083;CT + TT;Efficacy;increased clinical benefit to ⮕ METFORMIN;Genotypes CT + TT is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Other:Diabetes Mellitus, Type 2
;ZIPRASIDONE;CDH4;rs4925300;A;Efficacy;response to ⮕ ZIPRASIDONE;Allele A is associated with response to ziprasidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;ZIPRASIDONE;LYN;rs1546519;G;Efficacy;response to ⮕ ZIPRASIDONE;Allele G is associated with response to ziprasidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;BEVACIZUMAB;CFH;rs800292;GG;Efficacy;decreased response to ⮕ BEVACIZUMAB;Genotype GG is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype AA.; in people with Disease:Macular Degeneration
;WARFARIN;CYP2C9;rs1799853;CT;Dosage;decreased dose of ⮕ WARFARIN;Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.;  
;ZIPRASIDONE;NALCN;rs9585618;C;Efficacy;response to ⮕ ZIPRASIDONE;Allele C is associated with response to ziprasidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;ZIPRASIDONE;CNTN4;rs17194378;A;Efficacy;response to ⮕ ZIPRASIDONE;Allele A is associated with response to ziprasidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;OPIOIDS;COMT;rs4680;GG;Dosage;increased dose of ⮕ OPIOIDS;Genotype GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotypes AA + AG.; in people with Disease:Neoplasms, Disease:Pain
;IMATINIB;SLCO1A2;rs4148978;CT + TT;Toxicity, Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ IMATINIB;Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.; in people with Other:Gastrointestinal Stromal Tumors
;IMATINIB;SLCO1B3;rs4149117;GG;Toxicity, Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ IMATINIB;Genotype GG is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.; in people with Other:Gastrointestinal Stromal Tumors
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes GT + TT is associated with increased response to hydrochlorothiazide as compared to genotype GG.;  
;WARFARIN;CALU;rs2290228;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.;  
;OLANZAPINE;;rs12610827;T;Efficacy;increased clinical benefit to ⮕ OLANZAPINE;Allele T is associated with increased clinical benefit to olanzapine in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;REMIFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ REMIFENTANIL;Genotypes AG + GG is associated with increased dose of remifentanil in women with surgery as compared to genotype AA.; in women with Other:surgery
;FENOFIBRATE;APOB;rs676210;AA;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype AA is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes AG + GG.; in people with Disease:Hypertriglyceridemia
;METHACHOLINE;RUNX1;rs11702779;AG + GG;Other;increased response to ⮕ METHACHOLINE;Genotypes AG + GG are associated with increased response to methacholine in children with Asthma.; in children with Disease:Asthma
;CITALOPRAM, FLUOXETINE;SERPINE1;rs1799889;G;Efficacy;decreased response to ⮕ CITALOPRAM, FLUOXETINE;Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.;and in people with Disease:Major Depressive Disorder
;METHOTREXATE;MTR;rs1805087;G;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Allele G is associated with increased concentrations of methotrexate in people with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.; in people with Other:Non-Hodgkin Lymphoma, Other:Acute lymphoblastic leukemia
;CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;FKBP5;rs4713916;A;Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.;or in people with Disease:Mood Disorder
;OLANZAPINE;CSMD1;rs17070785;A;Efficacy;response to ⮕ OLANZAPINE;Allele A is associated with response to olanzapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;OLANZAPINE;PLAGL1;rs2247408;C;Efficacy;response to ⮕ OLANZAPINE;Allele C is associated with response to olanzapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;SIROLIMUS;CYP3A5;rs15524;AA;Metabolism/PK;increased trough concentration of ⮕ SIROLIMUS;Genotype AA is associated with increased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Other:Kidney Transplantation
;OLANZAPINE;PLAGL1;rs3819811;A;Efficacy;response to ⮕ OLANZAPINE;Allele A is associated with response to olanzapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;SIROLIMUS;CYP3A5;rs4646453;CC;Metabolism/PK;increased trough concentration of ⮕ SIROLIMUS;Genotype CC is associated with increased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotypes AA + AC.; in people with Other:Kidney Transplantation
;ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ ACETAMINOPHEN;Genotypes AG + GG is associated with increased dose of acetaminophen in women with Pain, Postoperative as compared to genotype AA.; in women with Other:Pain, Postoperative
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;OLANZAPINE;PTPRN2;rs221253;C;Efficacy;response to ⮕ OLANZAPINE;Allele C is associated with response to olanzapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;IMATINIB;SLC22A1;rs628031;AA + AG;Efficacy;decreased response to ⮕ IMATINIB;Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;WARFARIN;NQO1;rs1800566;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with increased dose of warfarin as compared to genotype GG.;  
;PERPHENAZINE;PRKCE;rs2278773;C;Efficacy;response to ⮕ PERPHENAZINE;Allele C is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;PERPHENAZINE;;rs11774231;C;Efficacy;response to ⮕ PERPHENAZINE;Allele C is associated with response to perphenazine in people with Schizophrenia.; in people with Disease:Schizophrenia
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased response to ⮕ CLOPIDOGREL;Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.; in people with Disease:Coronary Artery Disease
;HYDROCHLOROTHIAZIDE;DOT1L;rs2269879;CT + TT;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes CT + TT are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;PAROXETINE;ADM;rs11042725;CC;Efficacy;decreased response to ⮕ PAROXETINE;Genotype CC is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AC.; in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;TILDRAKIZUMAB;ATG5;rs9373839;CT;Efficacy;decreased clinical benefit to ⮕ TILDRAKIZUMAB;Genotype CT is associated with decreased clinical benefit to tildrakizumab in people with Psoriasis as compared to genotypes CC + TT.; in people with Other:Psoriasis
;TILDRAKIZUMAB;IL17RC;rs708567;CC;Efficacy;increased clinical benefit to ⮕ TILDRAKIZUMAB;Genotype CC is associated with increased clinical benefit to tildrakizumab in people with Psoriasis as compared to genotypes CT + TT.; in people with Other:Psoriasis
;CITALOPRAM;BDNF;rs7124442;TT;Efficacy;decreased response to ⮕ CITALOPRAM;Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotypes CC + CT.; in people with Disease:Major Depressive Disorder
;ARIPIPRAZOLE;ABCB1;rs2032582;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ ARIPIPRAZOLE;Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AC + CC.; in children 
;CLOZAPINE;OXT;rs2740204;T;Efficacy;increased response to ⮕ CLOZAPINE;Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotype CT.;  
;DIAZEPAM;CYP3A4;rs35599367;GG;Efficacy;increased clinical benefit to ⮕ DIAZEPAM;Genotype GG is associated with increased clinical benefit to diazepam in men with Alcoholism as compared to genotypes AA + AG.; in men with Other:Alcohol abuse
;METHOTREXATE;MTHFR;rs1801133;G;Efficacy;decreased clinical benefit to ⮕ METHOTREXATE;Allele G is associated with decreased clinical benefit to methotrexate in people with Crohn Disease as compared to allele A.; in people with Other:Crohn Disease
;METHOTREXATE;DHFR;rs408626;C;Efficacy;decreased clinical benefit to ⮕ METHOTREXATE;Allele C is associated with decreased clinical benefit to methotrexate in people with Crohn Disease as compared to allele T.; in people with Other:Crohn Disease
;REPAGLINIDE;NOS1AP;rs10494366;T;Dosage, Efficacy;increased response to ⮕ REPAGLINIDE;Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to allele G.; in people with Disease:Diabetes Mellitus, Type 2
;CITALOPRAM;BDNF;rs7103411;TT;Efficacy;decreased response to ⮕ CITALOPRAM;Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype CC.; in people with Disease:Major Depressive Disorder
;HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;rs1045642;AA + AG;Efficacy;increased resistance to ⮕ HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);Genotypes AA + AG are associated with increased resistance to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CITALOPRAM;BDNF;rs6265;CC;Efficacy;decreased response to ⮕ CITALOPRAM;Genotype CC is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;rs212091;CC + CT;Efficacy;increased resistance to ⮕ LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;Genotypes CC + CT are associated with increased resistance to lamivudine, lopinavir, ritonavir and zidovudine in people with HIV Infections as compared to genotype TT.;and in people with Disease:HIV infectious disease
;FLUOXETINE;BDNF;rs6265;CT;Efficacy;increased clinical benefit to ⮕ FLUOXETINE;Genotype CT is associated with increased clinical benefit to fluoxetine in people with Major Depressive Disorder as compared to genotype CC.; in people with Disease:Major Depressive Disorder
;TILDRAKIZUMAB;TNFAIP3;rs610604;GG;Efficacy;decreased clinical benefit to ⮕ TILDRAKIZUMAB;Genotype GG is associated with decreased clinical benefit to tildrakizumab in people with Psoriasis as compared to genotypes GT + TT.; in people with Other:Psoriasis
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;decreased response to ⮕ CLOPIDOGREL;Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.; in people with Disease:Coronary Artery Disease
;ANTIDEPRESSANTS;ERICH3;rs11580409;CC;Efficacy;increased clinical benefit to ⮕ ANTIDEPRESSANTS;Genotype CC is associated with increased clinical benefit to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AC.; in people with Other:Major Depressive Disorder
;CLOPIDOGREL;CYP2C19;rs12248560;CT;Efficacy;increased response to ⮕ CLOPIDOGREL;Genotype CT is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to genotype CC.; in people with Disease:Coronary Artery Disease
;ARIPIPRAZOLE;ABCB1;rs1045642;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ ARIPIPRAZOLE;Genotype AA is associated with decreased dose-adjusted trough concentrations of aripiprazole in children as compared to genotypes AG + GG.; in children 
;IVACAFTOR;CFTR;rs77932196;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele G.; in people with Disease:Cystic Fibrosis
;PAROXETINE;DRD3;rs6280;CC + CT;Efficacy;increased response to ⮕ PAROXETINE;Genotypes CC + CT are associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;ENTACAPONE;COMT;rs4680;GG;Efficacy;increased response to ⮕ ENTACAPONE;Genotype GG is associated with increased response to entacapone in people with Parkinson Disease as compared to genotype AA.; in people with Disease:Parkinson Disease
;CLOZAPINE;CYP2D6;rs1065852;AA;Metabolism/PK;increased concentrations of ⮕ CLOZAPINE;Genotype AA is associated with increased concentrations of clozapine in people with Schizophrenia as compared to genotypes AG + GG.; in people with Other:Schizophrenia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;TELMISARTAN;SLCO1B3;rs60140950;C;Metabolism/PK;increased concentrations of ⮕ TELMISARTAN;Allele C is associated with increased concentrations of telmisartan in healthy individuals as compared to allele G.; in healthy individuals 
;CLOZAPINE;CYP2D6;rs16947;GG;Metabolism/PK;increased concentrations of ⮕ CLOZAPINE;Genotype GG is associated with increased concentrations of clozapine in people with Schizophrenia as compared to genotypes AA + AG.; in people with Other:Schizophrenia
;ATORVASTATIN, SIMVASTATIN;ABCG8;rs11887534;CC + CG;Efficacy;decreased clinical benefit to ⮕ ATORVASTATIN, SIMVASTATIN;Genotypes CC + CG is associated with decreased clinical benefit to atorvastatin or simvastatin in people with Dyslipidaemia as compared to genotype GG.;or in people with Other:Dyslipidaemia
;IVACAFTOR;CFTR;rs121909011;C;Efficacy;increased response to ⮕ IVACAFTOR;Allele C is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to allele T.; in people with Disease:Cystic Fibrosis
;IMATINIB;ULK3;rs2290573;GG;Efficacy;decreased response to ⮕ IMATINIB;Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;CLOZAPINE;DRD1;rs265976;GT;Efficacy;decreased response to ⮕ CLOZAPINE;Genotype GT is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes GG + TT.; in people with Disease:Schizophrenia
;IVACAFTOR;CFTR;rs75527207;AA + AG;Efficacy;increased response to ⮕ IVACAFTOR;Genotypes AA + AG is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.; in people with Disease:Cystic Fibrosis
;INTERFERONS;STAT3;rs4796793;GG;Efficacy;increased response to ⮕ INTERFERONS;Genotype GG is associated with increased response to interferons in people with Carcinoma, Renal Cell as compared to genotypes CC + CG.; in people with Disease:Renal Cell Carcinoma
;TAMOXIFEN;SLCO2B1;rs12422149;AA + AG;Metabolism/PK;increased concentrations of ⮕ TAMOXIFEN;Genotypes AA + AG is associated with increased concentrations of tamoxifen in women with Breast Neoplasms as compared to genotype GG.; in women with Other:Breast Neoplasms
;WARFARIN;VKORC1;rs2359612;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Dosage, Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;or in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;VKORC1;rs8050894;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.;  
;RISPERIDONE;HRH3;rs3787430;TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;WARFARIN;;rs12777823;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;WARFARIN;VKORC1;rs2884737;AC + CC;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.;  
;WARFARIN;VKORC1;rs7294;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;RISPERIDONE;HRH3;rs3787429;TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;ARIPIPRAZOLE;TAAR6;rs4305746;AA + AG;Efficacy;increased response to ⮕ ARIPIPRAZOLE;Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;PEGINTERFERON ALFA-2A;IL6;rs1800795;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2A;Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.; in people with Disease:Chronic hepatitis C virus infection
;SULFASALAZINE;ABCG2;rs2231142;TT;Metabolism/PK;decreased clearance of ⮕ SULFASALAZINE;Genotype TT is associated with decreased clearance of sulfasalazine in healthy individuals as compared to genotypes GG + GT.; in healthy individuals 
;PEGINTERFERON ALFA-2A;IL6;rs1800796;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2A;Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele C.; in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A;IL6;rs1800797;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2A;Allele G is associated with decreased response to peginterferon alfa-2a in people with Hepatitis C, Chronic as compared to allele A.; in people with Disease:Chronic hepatitis C virus infection
;ROSUVASTATIN;ABCG2;rs2199936;AA + AG;Efficacy;increased response to ⮕ ROSUVASTATIN;Genotypes AA + AG are associated with increased response to rosuvastatin as compared to genotype GG.;  
;ILOPERIDONE;CNTF, ZFP91-CNTF;rs1800169;GG;Efficacy;increased response to ⮕ ILOPERIDONE;Genotype GG is associated with increased response to iloperidone in people with Schizophrenia as compared to genotypes AA + AG.; in people with Disease:Schizophrenia
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;DISULFIRAM;OPRD1;rs678849;CC;Efficacy;increased response to ⮕ DISULFIRAM;Genotype CC is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotypes CT + TT.; in people with Other:Cocaine dependence
;ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;Efficacy;increased resistance to ⮕ ERYTHROPOIETIN;Genotypes AG + GG is associated with increased resistance to erythropoietin in people with Kidney Diseases and Anemia as compared to genotype AA.; in people with Other:Kidney Disorder, Other:Anemia
;LATANOPROST;PTGFR;rs3753380;CC;Efficacy;increased response to ⮕ LATANOPROST;Genotype CC is associated with increased response to latanoprost as compared to genotypes CT + TT.;  
;RANIBIZUMAB;VEGFA;rs699947;AC + CC;Efficacy;increased response to ⮕ RANIBIZUMAB;Genotypes AC + CC are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype AA.; in people with Disease:Macular Degeneration
;FUROSEMIDE;ABCC4;rs17268282;T;Efficacy;increased response to ⮕ FUROSEMIDE;Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G.; in people with Disease:Heart Failure
;METFORMIN;SLC22A1;rs622342;CC;Efficacy;response to ⮕ METFORMIN;Genotype CC is associated with response to metformin in people with genetic variation at rs2289669.; in people with Other:genetic variation at rs2289669
;MORPHINE;COMT;rs737866;T;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.; in people with Disease:Neoplasms
;MORPHINE;COMT;rs2075507;G;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele G is associated with decreased dose of morphine in people with Neoplasms as compared to allele A.; in people with Disease:Neoplasms
;ANTIEPILEPTICS;CYP1A1;rs2606345;AA;Efficacy;decreased response to ⮕ ANTIEPILEPTICS;Genotype AA is associated with decreased response to antiepileptics in women with Epilepsy as compared to genotypes AC + CC.; in women with Disease:Epilepsy
;MORPHINE;COMT;rs5746849;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;MORPHINE;COMT, TXNRD2;rs7287550;C;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele C is associated with decreased dose of morphine in people with Neoplasms as compared to allele T.; in people with Disease:Neoplasms
;MORPHINE;COMT;rs6269;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;CARBAMAZEPINE;CYP3A4;rs2740574;TT;Metabolism/PK;increased clearance of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;MORPHINE;COMT;rs740603;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;MORPHINE;ABCC3;rs4793665;T;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Allele T is associated with decreased clearance of morphine in children as compared to allele C.; in children 
;TACROLIMUS;POR;rs1057868;T;Dosage;increased dose of ⮕ TACROLIMUS;Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype DELT/T is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype TT.;and in people with Other:Death
;N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;rs35599367;AG;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, TRAMADOL;Genotype AG is associated with increased concentrations of n-desmethyltramadol and tramadol in people with Death as compared to genotype GG.;and in people with Other:Death
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype AA is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.; in people with Other:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;rs4986893;AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype AG is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotype GG.; in people with Other:Coronary Artery Disease
;CLOPIDOGREL;ABCC2;rs717620;CC;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype CC is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.; in people with Other:Coronary Artery Disease
;ATAZANAVIR;SORCS2;rs73208473;A;Metabolism/PK;decreased exposure to ⮕ ATAZANAVIR;Allele A is associated with decreased exposure to atazanavir in women with HIV Infections as compared to allele C.; in women with Other:HIV infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;rs9304742;CC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes CT + TT.; in people with Disease:Psoriasis
;CARBAMAZEPINE;UGT2B7;rs28365063;AA;Metabolism/PK;decreased clearance of ⮕ CARBAMAZEPINE;Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.; in people with Disease:Epilepsy
;CARBAMAZEPINE;NR1I2;rs3814055;T;Metabolism/PK;decreased clearance of ⮕ CARBAMAZEPINE;Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C.; in people with Disease:Epilepsy
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;rs2916205;CC + CT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CC + CT are associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Metabolism/PK;increased exposure to ⮕ METHOTREXATE;Genotypes AA + AG are associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1799853;TT;Efficacy;increased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotype TT is associated with increased response to sulfonamides, urea derivatives.;  
;SUMATRIPTAN;GNB3;rs5443;CT;Efficacy;increased response to ⮕ SUMATRIPTAN;Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC.; in people with Disease:Cluster Headache
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs2546890;AG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG are associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1135840;G;Metabolism/PK;decreased concentrations of ⮕ DESETHYL HYDROXYCHLOROQUINE;Allele G is associated with decreased concentrations of desethyl hydroxychloroquine in people with Lupus Erythematosus, Systemic as compared to allele C.; in people with Other:Systemic lupus erythematosus
;CANNABINOIDS;TRPV1;rs8065080;CC;Efficacy;increased clinical benefit to ⮕ CANNABINOIDS;Genotype CC is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotypes CT + TT.; in people with Other:Pain
;CANNABINOIDS;UGT2B7;rs7438135;AA;Efficacy;increased clinical benefit to ⮕ CANNABINOIDS;Genotype AA is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotypes AG + GG.; in people with Other:Pain
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;rs11126740;AA;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.; in people with Disease:Psoriasis
;IMATINIB;ABCG2;rs2231142;GT;Other, Metabolism/PK;decreased metabolism of ⮕ IMATINIB;Genotype GT is associated with decreased metabolism of imatinib in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;Metabolism/PK;decreased concentrations of ⮕ DESETHYL HYDROXYCHLOROQUINE;Genotype AA is associated with decreased concentrations of desethyl hydroxychloroquine in people with Lupus Erythematosus, Systemic as compared to genotypes AG + GG.; in people with Other:Systemic lupus erythematosus
;REPAGLINIDE;KCNJ11;rs5219;T;Efficacy;increased response to ⮕ REPAGLINIDE;Allele T is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;TRAMADOL;OPRM1;rs1799971;AG + GG;Efficacy;increased response to ⮕ TRAMADOL;Genotypes AG + GG are associated with increased response to tramadol in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;REPAGLINIDE;TCF7L2;rs290487;TT;Efficacy;increased response to ⮕ REPAGLINIDE;Genotype TT is associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.; in people with Disease:Diabetes Mellitus, Type 2
;MORPHINE;COMT;rs4680;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;CARBAMAZEPINE;EPHX1;rs1051740;TT;Metabolism/PK;decreased metabolism of ⮕ CARBAMAZEPINE;Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;MORPHINE;COMT;rs4818;C;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele C is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;Efficacy;increased resistance to ⮕ ERYTHROPOIETIN;Genotypes GG + GT is associated with increased resistance to erythropoietin in people with Kidney Diseases and Anemia as compared to genotype TT.; in people with Other:Kidney Disorder, Other:Anemia
;CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;Metabolism/PK;increased clearance of ⮕ CARBAMAZEPINE;Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;MORPHINE;COMT;rs2239393;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G.; in people with Disease:Neoplasms
;MERCAPTOPURINE;NUDT15;rs116855232;CT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Disease:Acute lymphoblastic leukemia
;MORPHINE;ARVCF, COMT;rs165728;T;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.; in people with Disease:Neoplasms
;CARBAMAZEPINE;ABCB1;rs4148740;AG;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;CARBAMAZEPINE;ABCB1;rs4148739;TT;Metabolism/PK;decreased metabolism of ⮕ CARBAMAZEPINE;Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.; in people with Disease:Epilepsy
;MORPHINE;ARVCF, COMT;rs174699;T;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele T is associated with decreased dose of morphine in people with Neoplasms as compared to allele C.; in people with Disease:Neoplasms
;ANTIPSYCHOTICS;DRD2;rs1799732;del;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Allele del is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;HMG COA REDUCTASE INHIBITORS;CETP;rs1532624;AA;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype AA is associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype CC.; in people with Disease:Hyperlipidemias
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;rs6908425;CT + TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;Metabolism/PK;increased clearance of ⮕ CARBAMAZEPINE;Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;HMG COA REDUCTASE INHIBITORS;SIK3;rs533556;AA;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype AA is associated with decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to genotype CC.; in people with Disease:Hyperlipidemias
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;rs12191877;CT + TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;RITODRINE;KCNMB2;rs7624046;TT;Efficacy;decreased response to ⮕ RITODRINE;Genotype TT is associated with decreased response to ritodrine as compared to genotypes CC + CT.;  
;CARBAMAZEPINE;ABCC2;rs4148386;AA + AG;Metabolism/PK;increased clearance of ⮕ CARBAMAZEPINE;Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs61742245;AA + AC;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.;  
;CARBAMAZEPINE;ABCC2;rs3740066;CT + TT;Metabolism/PK;decreased metabolism of ⮕ CARBAMAZEPINE;Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.; in men with Disease:Epilepsy
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;rs96844;AG + GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;RITODRINE;KCNMB2;rs9839376;CC;Efficacy;decreased response to ⮕ RITODRINE;Genotype CC is associated with decreased response to ritodrine as compared to genotypes CT + TT.;  
;WARFARIN;GGCX;rs11676382;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele C.;  
;CARBAMAZEPINE;NR1I2;rs7643645;G;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Allele G is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.; in people with Disease:Epilepsy
;MORPHINE;METTL21A;rs2952768;CC;Dosage;increased dose of ⮕ MORPHINE;Genotype CC is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotypes CT + TT.; in women with Other:Pain, Postoperative
;CARBAMAZEPINE;NR1I2;rs4688040;T;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Allele T is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele G.; in people with Disease:Epilepsy
;CANNABINOIDS;ABCB1;rs1045642;AG + GG;Efficacy;increased clinical benefit to ⮕ CANNABINOIDS;Genotypes AG + GG is associated with increased clinical benefit to cannabinoids in people with Pain as compared to genotype AA.; in people with Other:Pain
;MORPHINE;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ MORPHINE;Genotypes AG + GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.; in women with Other:Pain, Postoperative
;CARBAMAZEPINE;NR1I2;rs2461817;C;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.; in people with Disease:Epilepsy
;METOPROLOL;ADRB1;rs1801252;AA;Efficacy;increased response to ⮕ METOPROLOL;Genotype AA is associated with increased response to metoprolol in people with Hypertension as compared to genotype AG.; in people with Disease:Hypertension
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;VKORC1;rs2884737;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotype AA.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;rs495794;G;Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.;or in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.;  
;CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153560;G;Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.;or in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs8050894;GG;Dosage;decreased dose of ⮕ WARFARIN;Genotype GG is associated with decreased dose of warfarin as compared to genotype CC.;  
;CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153549;A;Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.;or in people with Disease:Major Depressive Disorder
;ATAZANAVIR;ABCB1;rs1045642;AA + AG;Dosage;dose of ⮕ ATAZANAVIR;Genotypes AA + AG is associated with dose of atazanavir in people with HIV Infections.; in people with Disease:HIV infectious disease
;ATAZANAVIR;SLCO1B1;rs4149056;TT;Dosage;dose of ⮕ ATAZANAVIR;Genotype TT is associated with dose of atazanavir in people with HIV Infections.; in people with Disease:HIV infectious disease
;FLUOROURACIL;DPYD;rs3918290;CT;Other, Metabolism/PK;decreased metabolism of ⮕ FLUOROURACIL;Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.; in people with Disease:Neoplasms
;ATAZANAVIR;NR1I2;rs2472677;TT;Dosage;dose of ⮕ ATAZANAVIR;Genotype TT is associated with dose of atazanavir in people with HIV Infections.; in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs61742245;AC;Dosage;increased dose of ⮕ WARFARIN;Genotype AC is associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to genotype CC.; in people with Other:warfarin maintenance treatment
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;ACENOCOUMAROL;VKORC1;rs9923231;CT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs2227310;CG + GG;Efficacy;increased response to ⮕ DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;Genotypes CG + GG are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;or in people with Disease:Non-Small Cell Lung Carcinoma
;DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs4353229;CC + CT;Efficacy;increased response to ⮕ DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;Genotypes CC + CT are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;or in people with Disease:Non-Small Cell Lung Carcinoma
;DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs12415607;AA + AC;Efficacy;increased response to ⮕ DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;Genotypes AA + AC are associated with increased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;or in people with Disease:Non-Small Cell Lung Carcinoma
;DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs7921977;CT;Efficacy;decreased response to ⮕ DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;Genotype CT is associated with decreased response to docetaxel, gemcitabine, paclitaxel, Platinum compounds or vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;or in people with Disease:Non-Small Cell Lung Carcinoma
;OLANZAPINE;SLC26A9;rs11240594;A;Dosage, Efficacy;increased response to ⮕ OLANZAPINE;Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;SOLANIDINE;NFIB;rs28379954;CC + CT;Metabolism/PK;increased metabolism of ⮕ SOLANIDINE;Genotypes CC + CT is associated with increased metabolism of solanidine as compared to genotype TT.;  
;ZIPRASIDONE;EHF;rs286913;A;Dosage, Efficacy;increased response to ⮕ ZIPRASIDONE;Allele A is associated with increased response to ziprasidone in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;CLOZAPINE;SLC6A3;rs2975226;A;Dosage, Efficacy;increased response to ⮕ CLOZAPINE;Allele A is associated with increased response to clozapine in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;OLANZAPINE;IL1A;rs11677416;C;Dosage, Efficacy;increased response to ⮕ OLANZAPINE;Allele C is associated with increased response to olanzapine in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;CYCLOSPORINE;POR;rs1057868;TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ CYCLOSPORINE;Genotype TT is associated with decreased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CC + CT.; in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;EPHX1;rs1051740;C;Dosage, Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T.; in people with Disease:Epilepsy
;FESOTERODINE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs10929302;AA;Metabolism/PK;increased clearance of ⮕ FESOTERODINE;Genotype AA is associated with increased clearance of fesoterodine in healthy individuals as compared to genotype AG.; in healthy individuals 
;PIOGLITAZONE;PTPRD;rs17584499;CC;Efficacy;increased response to ⮕ PIOGLITAZONE;Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.; in people with Other:Diabetes Mellitus, Type 2
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CC + CT;Efficacy;increased dose of ⮕ ACENOCOUMAROL, WARFARIN;Genotypes CC + CT are associated with increased dose of acenocoumarol or warfarin as compared to genotype TT.;or  
;ETHANOL;OPRM1;rs1799971;G;Toxicity;increased response to ⮕ ETHANOL;Allele G is associated with increased response to ethanol in people with Alcoholism as compared to allele A.; in people with Other:Alcohol abuse
;ACAMPROSATE;GRIN2B;rs2058878;A;Efficacy;increased response to ⮕ ACAMPROSATE;Allele A is associated with increased response to acamprosate in people with Alcoholism as compared to allele T.; in people with Disease:Alcohol abuse
;OLANZAPINE;ATP1A2;rs6688363;T;Efficacy;decreased response to ⮕ OLANZAPINE;Allele T is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;RISPERIDONE;;rs8050896;T;Efficacy;increased response to ⮕ RISPERIDONE;Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele A.; in people with Other:Schizophrenia
;RISPERIDONE;TNFRSF11A;rs2980976;A;Efficacy;decreased response to ⮕ RISPERIDONE;Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;RISPERIDONE;PPA2;rs2636697;G;Efficacy;decreased response to ⮕ RISPERIDONE;Allele G is associated with decreased response to risperidone in people with Schizophrenia as compared to allele A.; in people with Other:Schizophrenia
;METHOTREXATE;;rs1232027;A;Efficacy;increased response to ⮕ METHOTREXATE;Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G.; in people with Disease:Arthritis, Psoriatic
;FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;rs1799971;AA;Dosage;increased dose of ⮕ FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;Genotype AA is associated with increased dose of fentanyl, hydromorphone, opioids, oxycodone or tramadol in women with surgery as compared to genotype AG.;or in women with Other:surgery
;RISPERIDONE;PPA2;rs2636719;A;Efficacy;decreased response to ⮕ RISPERIDONE;Allele A is associated with decreased response to risperidone in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;REPAGLINIDE;IGF2BP2;rs4402960;GT + TT;Dosage, Efficacy;increased response to ⮕ REPAGLINIDE;Genotypes GT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;RASAGILINE;COMT;rs4680;AA;Metabolism/PK;decreased concentrations of ⮕ RASAGILINE;Genotype AA is associated with decreased concentrations of rasagiline in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;REPAGLINIDE;IGF2BP2;rs1470579;AC + CC;Dosage, Efficacy;decreased response to ⮕ REPAGLINIDE;Genotypes AC + CC are associated with decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Disease:Diabetes Mellitus, Type 2
;DISULFIRAM;MTHFR;rs1801133;AA + AG;Efficacy;increased response to ⮕ DISULFIRAM;Genotypes AA + AG are associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG.; in people with Disease:Cocaine dependence
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic, Crohn Disease, Psoriasis and Spondylitis, Ankylosing as compared to genotype AA.;" in people with ""Disease:Arthritis, Psoriatic"", ""Disease:Crohn Disease"", ""Disease:Psoriasis"", ""Disease:Spondylitis, Ankylosing"""
;ISONIAZID;NAT2;rs4646244;AT;Toxicity, Metabolism/PK;decreased clearance of ⮕ ISONIAZID;Genotype AT is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype TT.; in people with Disease:Tuberculosis
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotype AA is associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to genotype GG.; in women with Disease:Ovarian Neoplasms
;ISONIAZID;NAT2;rs1799930;AA;Toxicity, Metabolism/PK;decreased clearance of ⮕ ISONIAZID;Genotype AA is associated with decreased clearance of isoniazid in people with Tuberculosis as compared to genotype GG.; in people with Disease:Tuberculosis
;HYDROCHLOROTHIAZIDE;BEST3;rs61747221;AA + AG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;DEFERIPRONE;UGT1A6;rs2070959;AA;Efficacy;increased response to ⮕ DEFERIPRONE;Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes AG + GG.; in people with Disease:Beta-thalassemia and related diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic, Crohn Disease, Psoriasis or Spondylitis, Ankylosing as compared to allele A.;" in people with ""Disease:Arthritis, Psoriatic"", ""Disease:Crohn Disease"", ""Disease:Psoriasis"", ""Disease:Spondylitis, Ankylosing"""
;NIFEDIPINE;ADRA1A;rs1048101;AA + AG;Efficacy;increased response to ⮕ NIFEDIPINE;Genotypes AA + AG are associated with increased response to nifedipine in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;DEFERIPRONE;UGT1A6;rs2070959;AA;Efficacy;increased response to ⮕ DEFERIPRONE;Genotype AA is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotype GG.; in people with Disease:Beta-thalassemia and related diseases
;DEFERIPRONE;UGT1A6;rs6759892;GG;Efficacy;increased response to ⮕ DEFERIPRONE;Genotype GG is associated with increased response to deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.; in people with Disease:Beta-thalassemia and related diseases
;PIOGLITAZONE;PPARG;rs1801282;CG;Efficacy;increased response to ⮕ PIOGLITAZONE;Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Other:Diabetes Mellitus, Type 2
;PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;Efficacy;increased response to ⮕ PACLITAXEL, PLATINUM COMPOUNDS;Genotypes CC + CT are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;and in people with Disease:Non-Small Cell Lung Carcinoma
;OPIOIDS;TNF;rs1800629;GG;Dosage;increased dose of ⮕ OPIOIDS;Genotype GG is associated with increased dose of opioids in children with Neoplasms and Pain as compared to genotype AG.; in children with Other:Neoplasms, Other:Pain
;CARBAMAZEPINE;SCN1A;rs3812718;CT;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;Efficacy;increased response to ⮕ PACLITAXEL, PLATINUM COMPOUNDS;Genotypes CG + GG are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;RISPERIDONE;TJP1;rs813676;T;Efficacy;increased response to ⮕ RISPERIDONE;Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;OPIOIDS;IL6;rs1800797;A;Dosage;decreased dose of ⮕ OPIOIDS;Allele A is associated with decreased dose of opioids in children with Neoplasms and Pain as compared to allele G.; in children with Other:Neoplasms, Other:Pain
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin in people with Myocardial Infarction as compared to genotype GG.; in people with Disease:Myocardial Infarction
;METHYLPHENIDATE;ADGRL3;rs734644;CC + CT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CC + CT are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype TT.; in children Disease:Attention Deficit Disorder with Hyperactivity
;PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;Efficacy;decreased response to ⮕ PACLITAXEL, PLATINUM COMPOUNDS;Genotypes AA + AG are associated with decreased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;FLUTICASONE PROPIONATE, MONTELUKAST;CA10;rs967676;CC + CT;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE, MONTELUKAST;Genotypes CC + CT is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype TT.;or in children with Disease:Asthma
;CARBAMAZEPINE;EPHX1;rs1051740;CT;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;CARBAMAZEPINE;EPHX1;rs1051740;CC;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; in people with Disease:Epilepsy
;GEMCITABINE, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;Efficacy;decreased response to ⮕ GEMCITABINE, PLATINUM COMPOUNDS;Genotypes AA + AG are associated with decreased response to gemcitabine and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;FLUTICASONE PROPIONATE, MONTELUKAST;;rs1786929;AA + AG;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE, MONTELUKAST;Genotypes AA + AG is associated with increased response to fluticasone propionate or montelukast in children with Asthma as compared to genotype GG.;or in children with Disease:Asthma
;TACROLIMUS;ABCB1;rs2032582;AA;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotype AA is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.; in people with Other:Kidney Transplantation
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotypes GT + TT is associated with increased concentrations of rosuvastatin as compared to genotype GG.;  
;METHYLPHENIDATE;ADGRL3;rs1355368;AG + GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes AG + GG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype AA.; in children Disease:Attention Deficit Disorder with Hyperactivity
;METHYLPHENIDATE;ADGRL3;rs6813183;CC + CG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CC + CG are associated with increased response to methylphenidate in children Attention Deficit Disorder with Hyperactivity as compared to genotype GG.; in children Disease:Attention Deficit Disorder with Hyperactivity
;RISPERIDONE;;rs7395555;C;Efficacy;increased response to ⮕ RISPERIDONE;Allele C is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;RANIBIZUMAB;CFH;rs1061170;TT;Efficacy;increased response to ⮕ RANIBIZUMAB;Genotype TT is associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype CC.; in people with Disease:Macular Degeneration
;OLANZAPINE;SPOPL;rs10170310;C;Efficacy;decreased response to ⮕ OLANZAPINE;Allele C is associated with decreased response to olanzapine in people with Schizophrenia as compared to allele A.; in people with Other:Schizophrenia
;QUETIAPINE;PDE4D;rs17382202;T;Efficacy;increased response to ⮕ QUETIAPINE;Allele T is associated with increased response to quetiapine in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;ACENOCOUMAROL;VKORC1;rs9923231;T;Dosage;dose of ⮕ ACENOCOUMAROL;Allele T is associated with dose of acenocoumarol.;  
;QUETIAPINE;PDE4D;rs17742120;G;Efficacy;increased response to ⮕ QUETIAPINE;Allele G is associated with increased response to quetiapine in people with Schizophrenia as compared to allele A.; in people with Other:Schizophrenia
;QUETIAPINE;PDE4D;rs2164660;A;Efficacy;increased response to ⮕ QUETIAPINE;Allele A is associated with increased response to quetiapine in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;ACENOCOUMAROL;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype CC is associated with increased dose of acenocoumarol in people with Atrial Fibrillation or venous thromboembolism as compared to genotypes CT + TT.; in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;PERINDOPRIL;AGTR1;rs5182;CC + CT;Efficacy;decreased response to ⮕ PERINDOPRIL;Genotypes CC + CT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.; in people with Disease:Coronary Artery Disease
;RISPERIDONE;TJP1;rs711355;T;Efficacy;increased response to ⮕ RISPERIDONE;Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;RISPERIDONE;TJP1;rs785423;A;Efficacy;increased response to ⮕ RISPERIDONE;Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;TENOFOVIR ALAFENAMIDE;ABCB1;rs3842;CT;Metabolism/PK;increased concentrations of ⮕ TENOFOVIR ALAFENAMIDE;Genotype CT is associated with increased concentrations of tenofovir alafenamide in people with HIV infectious disease as compared to genotype TT.; in people with Other:HIV infectious disease
;CLOZAPINE;SLC6A4;rs25531;T;Efficacy;response to ⮕ CLOZAPINE;Allele T is associated with response to clozapine in people with Schizophrenia.; in people with Disease:Schizophrenia
;RALOXIFENE;UGT1A8;rs1042597;CC;Efficacy;increased response to ⮕ RALOXIFENE;Genotype CC is associated with increased response to raloxifene in women with Menopause and Schizophrenia as compared to genotype CG.; in women with Disease:Menopause, Disease:Schizophrenia
;ESOMEPRAZOLE;STAT6;rs1059513;CC + CT;Efficacy;increased response to ⮕ ESOMEPRAZOLE;Genotypes CC + CT are associated with increased response to esomeprazole in children with eosinophilic esophagitis as compared to genotype TT.; in children with Other:eosinophilic esophagitis
;RISPERIDONE;WBP2NL;rs5758550;A;Metabolism/PK;decreased clearance of ⮕ RISPERIDONE;Allele A is associated with decreased clearance of risperidone as compared to allele G.;  
;PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;Efficacy;increased response to ⮕ PACLITAXEL, PLATINUM COMPOUNDS;Genotypes AA + AC are associated with increased response to paclitaxel and Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;ADALIMUMAB;CD40LG;rs1126535;T;Efficacy;increased response to ⮕ ADALIMUMAB;Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;RALOXIFENE;ESR1;rs11543791;CC;Efficacy;decreased response to ⮕ RALOXIFENE;Genotype CC is associated with decreased response to raloxifene in women Menopause and Schizophrenia as compared to genotypes CT + TT.; in women Disease:Menopause, Disease:Schizophrenia
;PERINDOPRIL;AGTR1;rs275651;AA + AT;Efficacy;decreased response to ⮕ PERINDOPRIL;Genotypes AA + AT is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype TT.; in people with Disease:Coronary Artery Disease
;LITHIUM;MYO1H;rs7959663;C;Efficacy;decreased response to ⮕ LITHIUM;Allele C is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;INFLIXIMAB;FCGR2A;rs1801274;G;Efficacy;decreased response to ⮕ INFLIXIMAB;Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;LITHIUM;EPHX2;rs59724122;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;LOSARTAN, LOSARTAN E-3174;FBXW12;rs17080138;CT;Metabolism/PK;increased concentrations of ⮕ LOSARTAN, LOSARTAN E-3174;Genotype CT is associated with increased concentrations of losartan and losartan E-3174 in healthy individuals as compared to genotype CC.;and in healthy individuals 
;LITHIUM;GRAMD1B;rs61123830;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;WARFARIN;VKORC1;rs7294;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;LITHIUM;;rs66486766;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs324899;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs1611259;T;Efficacy;decreased response to ⮕ LITHIUM;Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs6942227;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;NEVIRAPINE;CYP2D6;rs28371706;AA + AG;Dosage, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotypes AA + AG are associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotype GG.; in children with Disease:HIV infectious disease
;NEVIRAPINE;CYP2B6;rs3745274;GT + TT;Dosage, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CATECHOLAMINES;ADRB1;rs1801253;CC;Dosage;decreased dose of ⮕ CATECHOLAMINES;Genotype CC is associated with decreased dose of catecholamines in people with Coronary Artery Disease as compared to genotypes CG + GG.; in people with Disease:Coronary Artery Disease
;ACENOCOUMAROL;APOE;rs429358;CC;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype CC is associated with increased dose of acenocoumarol in people with Atrial Fibrillation or venous thromboembolism as compared to genotypes CT + TT.; in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;LOSARTAN, LOSARTAN E-3174;ZNF703;rs79707182;CT;Metabolism/PK;increased concentrations of ⮕ LOSARTAN, LOSARTAN E-3174;Genotype CT is associated with increased concentrations of losartan and losartan E-3174 in healthy individuals as compared to genotype CC.;and in healthy individuals 
;PERINDOPRIL;BDKRB1;rs12050217;AA + AG;Efficacy;decreased response to ⮕ PERINDOPRIL;Genotypes AA + AG is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype GG.; in people with Disease:Coronary Artery Disease
;LOSARTAN, LOSARTAN E-3174;SLC17A4;rs11754288;A;Metabolism/PK;increased concentrations of ⮕ LOSARTAN, LOSARTAN E-3174;Allele A is associated with increased concentrations of losartan and losartan E-3174 in healthy individuals as compared to allele G.;and in healthy individuals 
;WARFARIN;VKORC1;rs17708472;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin as compared to allele G.;  
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;C;Other;increased response to ⮕ DRUGS USED IN NICOTINE DEPENDENCE;Allele C is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; in people with Disease:Tobacco Use Disorder
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;rs3787186;CC + CT;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotypes CC + CT is associated with decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotype TT.;or in people with Other:Rheumatoid arthritis
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;G;Other;increased response to ⮕ DRUGS USED IN NICOTINE DEPENDENCE;Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; in people with Disease:Tobacco Use Disorder
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;T;Other;increased response to ⮕ DRUGS USED IN NICOTINE DEPENDENCE;Allele T is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; in people with Disease:Tobacco Use Disorder
;ALLOPURINOL;ABCG2;rs2231142;T;Efficacy;decreased response to ⮕ ALLOPURINOL;Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.; in people with Other:Gout
;LITHIUM;FAM177A1;rs79403677;T;Efficacy;decreased response to ⮕ LITHIUM;Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;CLOPIDOGREL;;rs2487032;A;Efficacy;decreased response to ⮕ CLOPIDOGREL;Allele A is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele G.; in people with Disease:Coronary Artery Disease
;METOPROLOL;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ METOPROLOL;Genotype CC is associated with increased response to metoprolol in healthy individuals as compared to genotypes CG + GG.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele G.; in people with Other:total knee or hip arthroplasty
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;rs11591741;G;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;LITHIUM;ADCY1;rs1521470;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;WARFARIN;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.;  
;REPAGLINIDE;KCNQ1;rs2237892;CT + TT;Efficacy;increased response to ⮕ REPAGLINIDE;Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;LITHIUM;;rs7588746;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;LITHIUM;FAM178B;rs6728642;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;Efficacy;increased response to ⮕ BETA BLOCKING AGENTS;Genotypes AT + TT are associated with increased response to Beta Blocking Agents in people with Heart Failure as compared to genotype AA.; in people with Other:Heart Failure
;ZILEUTON;PRORP;rs12436663;AA;Efficacy;decreased response to ⮕ ZILEUTON;Genotype AA is associated with decreased response to zileuton in people with Asthma as compared to genotypes AG + GG.; in people with Disease:Asthma
;LOSARTAN, LOSARTAN E-3174;CYP2C9;rs10509680;GT;Metabolism/PK;increased concentrations of ⮕ LOSARTAN, LOSARTAN E-3174;Genotype GT is associated with increased concentrations of losartan and losartan E-3174 in healthy individuals as compared to genotype GG.;and in healthy individuals 
;LITHIUM;ZNF804A;rs62200793;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs1611255;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs209474;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;REPAGLINIDE;KCNQ1;rs2237895;AC + CC;Efficacy;increased response to ⮕ REPAGLINIDE;Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Disease:Diabetes Mellitus, Type 2
;LITHIUM;;rs3919583;A;Efficacy;decreased response to ⮕ LITHIUM;Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;GLATIRAMER ACETATE;TGFB1;rs1800469;A;Efficacy;decreased response to ⮕ GLATIRAMER ACETATE;Allele A is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.; in people with Disease:Multiple Sclerosis
;ANTIEPILEPTICS;ABCC2;rs3740066;CT + TT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;N-DESMETHYLTAMOXIFEN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTAMOXIFEN;Genotypes GT + TT is associated with increased concentrations of n-desmethyltamoxifen in women with Breast Neoplasms as compared to genotype GG.; in women with Other:Breast Neoplasms
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;GLUCOCORTICOIDS;GLCCI1;rs37973;G;Efficacy;increased response to ⮕ GLUCOCORTICOIDS;Allele G is associated with increased response to glucocorticoids in people with Asthma as compared to allele A.; in people with Disease:Asthma
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotypes CT + TT are associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;AMLODIPINE;CYP3A4;rs2246709;AG + GG;Efficacy;increased response to ⮕ AMLODIPINE;Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;TENELIGLIPTIN;FMO3;rs2266780;AG + GG;Metabolism/PK;decreased clearance of ⮕ TENELIGLIPTIN;Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.; in men 
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;A;Other;increased response to ⮕ DRUGS USED IN NICOTINE DEPENDENCE;Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder.; in people with Disease:Tobacco Use Disorder
;QUETIAPINE;COMT;rs4818;C;Efficacy;decreased response to ⮕ QUETIAPINE;Allele C is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;HYDROCHLOROTHIAZIDE;GPR83;rs3758785;GG;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Genotype GG is associated with decreased response to hydrochlorothiazide in people with essential hypertension as compared to genotype AA.; in people with Efficacy:essential hypertension
;QUETIAPINE;COMT;rs5993883;T;Efficacy;decreased response to ⮕ QUETIAPINE;Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;TENELIGLIPTIN;FMO3;rs909530;CT + TT;Metabolism/PK;decreased clearance of ⮕ TENELIGLIPTIN;Genotypes CT + TT is associated with decreased clearance of teneligliptin in men as compared to genotype CC.; in men 
;MENOTROPINS;FSHR;rs6166;CT;;decreased dose of ⮕ MENOTROPINS;Genotype CT is associated with decreased dose of menotropins in women as compared to genotype CC.; in women 
;QUETIAPINE;COMT;rs6269;A;Efficacy;decreased response to ⮕ QUETIAPINE;Allele A is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;CANDESARTAN;GPR83;rs3758785;GG;Efficacy;increased response to ⮕ CANDESARTAN;Genotype GG is associated with increased response to candesartan in people with Essential hypertension as compared to genotype AA.; in people with Disease:Essential hypertension
;TACROLIMUS;IL6;rs1800795;GG;Dosage;increased dose of ⮕ TACROLIMUS;Genotype GG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CG.; in people with Other:Kidney Transplantation
;TENELIGLIPTIN;FMO3;rs2266782;AG + GG;Metabolism/PK;decreased clearance of ⮕ TENELIGLIPTIN;Genotypes AG + GG is associated with decreased clearance of teneligliptin in men as compared to genotype AA.; in men 
;PACLITAXEL;ABCB1;rs2032582;CT;Metabolism/PK;increased metabolism of ⮕ PACLITAXEL;Genotype CT is associated with increased metabolism of paclitaxel in people with Ovarian Neoplasms.; in people with Disease:Ovarian Neoplasms
;HYDROCHLOROTHIAZIDE;HSD3B1;rs7553527;CC + CT;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes CC + CT is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype TT.; in people with Disease:Hypertension
;HYDROCHLOROTHIAZIDE;TTC6;rs177852;CC + CT;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes CC + CT is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype TT.; in people with Disease:Hypertension
;TENELIGLIPTIN;CYP3A4;rs2242480;CT + TT;Metabolism/PK;decreased concentrations of ⮕ TENELIGLIPTIN;Genotypes CT + TT is associated with decreased concentrations of teneligliptin in men as compared to genotype CC.; in men 
;GLATIRAMER ACETATE;IFNAR1;rs1012335;G;Efficacy;decreased response to ⮕ GLATIRAMER ACETATE;Allele G is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele C.; in people with Disease:Multiple Sclerosis
;5-HYDROXYOMEPRAZOLE, OMEPRAZOLE;;rs12777823;A;Metabolism/PK;increased concentrations of ⮕ 5-HYDROXYOMEPRAZOLE, OMEPRAZOLE;Allele A is associated with increased concentrations of 5-hydroxyomeprazole and omeprazole in healthy individuals as compared to allele G.;and in healthy individuals 
;ATORVASTATIN;CYP3A4;rs2740574;CC;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype CC is associated with decreased response to atorvastatin in people with Cardiovascular Disease or Hyperlipidemias as compared to genotypes CT + TT.; in people with Other:Cardiovascular Disease, Other:Hyperlipidemias
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;6-HYDROXY S-WARFARIN;;rs368245720;A;Metabolism/PK;increased concentrations of ⮕ 6-HYDROXY S-WARFARIN;Allele A is associated with increased concentrations of 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele T.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;ATORVASTATIN;CYP3A5;rs776746;CC;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype CC is associated with increased response to atorvastatin in people with Cardiovascular Disease or Hyperlipidemias as compared to genotype CT.; in people with Other:Cardiovascular Disease, Other:Hyperlipidemias
;CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;rs6265;CC;Efficacy;increased clinical benefit to ⮕ CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;Genotype CC is associated with increased clinical benefit to citalopram, escitalopram, fluoxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.;or in people with Other:Major Depressive Disorder
;6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;Metabolism/PK;increased concentrations of ⮕ 6-HYDROXY S-WARFARIN;Allele A is associated with increased concentrations of 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;METOPROLOL;ADRB1;rs1801253;C;Efficacy;increased response to ⮕ METOPROLOL;Allele C is associated with increased response to metoprolol in people with Hypertension as compared to allele G.; in people with Disease:Hypertension
;SALBUTAMOL;ADRB2;rs1042713;AA;PD;decreased response to ⮕ SALBUTAMOL;Genotype AA is associated with decreased response to salbutamol in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;EFAVIRENZ;NR1I3;rs3003596;GG;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotype GG is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;IMATINIB;ABCG2;rs12505410;G;Efficacy;increased response to ⮕ IMATINIB;Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;ABCG2;rs12505410;GG + GT;Efficacy;increased response to ⮕ IMATINIB;Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;TAMOXIFEN;CYP19A1;rs4646;AA + AC;Efficacy;increased response to ⮕ TAMOXIFEN;Genotypes AA + AC are associated with increased response to tamoxifen in women with Breast Neoplasms as compared to genotype CC.; in women with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;Metabolism/PK;increased concentrations of ⮕ 6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;Allele G is associated with increased concentrations of 6-hydroxy r-warfarin and 6-hydroxy s-warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.;and in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;IMATINIB;ABCG2;rs13120400;CC + CT;Efficacy;increased response to ⮕ IMATINIB;Genotypes CC + CT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;METHOTREXATE;SLCO1B1;rs10841753;CT + TT;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Disease:Acute lymphoblastic leukemia
;IMATINIB;ABCG2;rs2725252;AC + CC;Efficacy;increased response to ⮕ IMATINIB;Genotypes AC + CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;rs2238032;TT;Efficacy;increased response to ⮕ LACIDIPINE, NIFEDIPINE, NITRENDIPINE;Genotype TT is associated with increased response to lacidipine, nifedipine or nitrendipine in people with Hypertension as compared to genotypes GG + GT.;or in people with Disease:Hypertension
;LUMEFANTRINE;CYP3A4;rs2740574;C;Metabolism/PK;increased concentrations of ⮕ LUMEFANTRINE;Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.; in women with Disease:Malaria, Other:Pregnancy
;QUETIAPINE;HTR1A;rs10042486;TT;Metabolism/PK;increased concentrations of ⮕ QUETIAPINE;Genotype TT is associated with increased concentrations of quetiapine in men with Schizophrenia as compared to genotype CT.; in men with Other:Schizophrenia
;AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;rs6265;CT + TT;Efficacy;increased clinical benefit to ⮕ AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;Genotypes CT + TT is associated with increased clinical benefit to amitriptyline, clomipramine, duloxetine, imipramine, milnacipran or venlafaxine in people with Major Depressive Disorder as compared to genotype CC.;or in people with Other:Major Depressive Disorder
;CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;rs1415744;C;Efficacy;increased response to ⮕ CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;Allele C is associated with increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone or trifluoperazine in people with Schizophrenia as compared to allele T.;or in people with Disease:Schizophrenia
;AMLODIPINE, FELODIPINE;CACNA1C;rs2239050;GG;Efficacy;increased response to ⮕ AMLODIPINE, FELODIPINE;Genotype GG is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to genotype CG.;and in people with Disease:Hypertension
;WARFARIN;CYP2C18;rs41291550;A;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele T.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;ATORVASTATIN;CYP3A4;rs2740574;TT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotype TT is associated with increased concentrations of atorvastatin in people with Cardiovascular Disease or Hyperlipidemias as compared to genotypes CC + CT.; in people with Other:Cardiovascular Disease, Other:Hyperlipidemias
;CITALOPRAM, FLUOXETINE;GSK3B;rs334558;GG;Efficacy;increased response to ⮕ CITALOPRAM, FLUOXETINE;Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.;and in people with Disease:Major Depressive Disorder
;ETHANOL;SRPRB;rs17376019;CT;Metabolism/PK;decreased concentrations of ⮕ ETHANOL;Genotype CT is associated with decreased concentrations of ethanol in healthy individuals as compared to genotype CC.; in healthy individuals 
;WARFARIN;CYP2C9;rs9332241;T;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele C.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;ETHANOL;ALDH2;rs671;AG;Metabolism/PK;increased concentrations of ⮕ ETHANOL;Genotype AG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype GG.; in healthy individuals 
;LUMEFANTRINE;CYP3A5;rs10264272;T;Metabolism/PK;increased concentrations of ⮕ LUMEFANTRINE;Allele T is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele C.; in women with Disease:Malaria, Other:Pregnancy
;ATORVASTATIN;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotype CC is associated with increased concentrations of atorvastatin in people with Cardiovascular Disease or Hyperlipidemias as compared to genotype CT.; in people with Other:Cardiovascular Disease, Other:Hyperlipidemias
;ETHANOL;PGM1;rs4643;CC;Metabolism/PK;decreased concentrations of ⮕ ETHANOL;Genotype CC is associated with decreased concentrations of ethanol in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;WARFARIN;FPGS;rs7856096;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele A.;  
;ACETALDEHYDE;ADH1A;rs1229976;CT;Metabolism/PK;increased concentrations of ⮕ ACETALDEHYDE;Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype TT.; in healthy individuals 
;WARFARIN;FPGS;rs7856096;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele A.;  
;LUMEFANTRINE;CYP3A5;rs776746;C;Metabolism/PK;increased concentrations of ⮕ LUMEFANTRINE;Allele C is associated with increased concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.; in women with Disease:Malaria, Other:Pregnancy
;ACETALDEHYDE;ALDH2;rs671;AG;Metabolism/PK;increased concentrations of ⮕ ACETALDEHYDE;Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG.; in healthy individuals 
;INFLIXIMAB;FCGR3A;rs396991;A;Efficacy;increased response to ⮕ INFLIXIMAB;Allele A is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;CETUXIMAB;FCGR3A;rs396991;A;Efficacy;increased response to ⮕ CETUXIMAB;Allele A is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to allele C.; in people with Disease:Colorectal Neoplasms
;ACETALDEHYDE;PGM1;rs4643;CC;Metabolism/PK;increased concentrations of ⮕ ACETALDEHYDE;Genotype CC is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;VERAPAMIL;ABCB1;rs1045642;GG;Metabolism/PK;decreased metabolism of ⮕ VERAPAMIL;Genotype GG is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AG.; in healthy individuals 
;ACETALDEHYDE;ADH1B;rs1229984;CT;Metabolism/PK;increased concentrations of ⮕ ACETALDEHYDE;Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes CC + TT.; in healthy individuals 
;NALTREXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased response to ⮕ NALTREXONE;Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.; in people with Disease:Alcohol abuse
;AMLODIPINE, FELODIPINE;CACNA1C;rs2239128;C;Efficacy;increased response to ⮕ AMLODIPINE, FELODIPINE;Allele C is associated with increased response to amlodipine and felodipine in people with Hypertension as compared to allele T.;and in people with Disease:Hypertension
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity, Metabolism/PK;decreased clearance of ⮕ FLUOROURACIL;Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms
;SUNITINIB;CYP3A5;rs776746;T;Dosage;decreased dose of ⮕ SUNITINIB;Allele T is associated with decreased dose of sunitinib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;GT;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLCLOZAPINE;Genotype GT is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to genotype GG.; in people with Other:Schizophrenia
;LUMEFANTRINE;CYP3A4;rs2740574;T;Efficacy;decreased response to ⮕ LUMEFANTRINE;Allele T is associated with decreased response to lumefantrine in women with Malaria and Pregnancy as compared to allele C.; in women with Disease:Malaria, Disease:Pregnancy
;CLOPIDOGREL;N6AMT1;rs2254638;G;Efficacy;decreased response to ⮕ CLOPIDOGREL;Allele G is associated with decreased response to clopidogrel in people with Coronary Artery Disease as compared to allele A.; in people with Disease:Coronary Artery Disease
;VALPROIC ACID;UGT1A6;rs6759892;TT;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotype TT is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotypes GG + GT.; in people with Other:Epilepsy
;FENTANYL;ASTN2;rs7858836;CT + TT;Dosage;decreased dose of ⮕ FENTANYL;Genotypes CT + TT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype CC.; in people with Other:Pain, Postoperative
;BENAZEPRIL, IMIDAPRIL;CYP11B2;rs1799998;AA + AG;Efficacy;increased response to ⮕ BENAZEPRIL, IMIDAPRIL;Genotypes AA + AG are associated with increased response to benazepril or imidapril in people with Essential hypertension as compared to genotype GG.;or in people with Disease:Essential hypertension
;FENTANYL;ASTN2;rs958804;CC + CT;Dosage;decreased dose of ⮕ FENTANYL;Genotypes CC + CT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype TT.; in people with Other:Pain, Postoperative
;VALPROIC ACID;UGT1A6;rs1105879;AA;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotype AA is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotypes AC + CC.; in people with Other:Epilepsy
;VALPROIC ACID;UGT1A6;rs2070959;AA;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotype AA is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotypes AG + GG.; in people with Other:Epilepsy
;TACROLIMUS;CYP3A4;rs35599367;AA + AG;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes AA + AG is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotype GG.; in people with Other:Liver transplantation
;VERAPAMIL;ABCB1;rs2032582;CC;Metabolism/PK;decreased metabolism of ⮕ VERAPAMIL;Genotype CC is associated with decreased metabolism of verapamil in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotypes CC + CT are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;ETIDRONIC ACID;COL1A1;rs1800012;AA + AC;Efficacy;decreased response to ⮕ ETIDRONIC ACID;Genotypes AA + AC are associated with decreased response to etidronic acid in people with Bone Diseases, Metabolic as compared to genotype CC.; in people with Disease:Metabolic Bone Disorder
;VORICONAZOLE;ABCG2;rs13120400;CC;Metabolism/PK;increased trough concentration of ⮕ VORICONAZOLE;Genotype CC is associated with increased trough concentration of voriconazole in children as compared to genotypes CT + TT.; in children 
;MORPHINE, NORTRIPTYLINE;ABCB1;rs1045642;GG;Efficacy;increased response to ⮕ MORPHINE, NORTRIPTYLINE;Genotype GG is associated with increased response to morphine and nortriptyline in people with Pain as compared to genotypes AA + AG.;and in people with Other:Pain
;RISPERIDONE;HTR1A;rs6295;CG + GG;Metabolism/PK;increased concentrations of ⮕ RISPERIDONE;Genotypes CG + GG is associated with increased concentrations of risperidone in men with Schizophrenia as compared to genotype CC.; in men with Other:Schizophrenia
;DULOXETINE;;rs4858478;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;FLUOROURACIL;DPYD;rs67376798;AT;Toxicity, Metabolism/PK;decreased clearance of ⮕ FLUOROURACIL;Genotype AT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; in people with Disease:Colorectal Neoplasms
;VALPROIC ACID;UGT1A6;rs6759892;GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ VALPROIC ACID;Genotype GG is associated with decreased dose-adjusted trough concentrations of valproic acid in people with Epilepsy as compared to genotypes GT + TT.; in people with Other:Epilepsy
;DULOXETINE;ZNF385D;rs13093500;T;Efficacy;increased response to ⮕ DULOXETINE;Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;Efficacy;increased clinical benefit to ⮕ ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;Genotype CC is associated with increased clinical benefit to escitalopram, fluoxetine, paroxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.;or in people with Other:Major Depressive Disorder
;FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;rs1051266;T;Efficacy;increased response to ⮕ FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.;and in people with Disease:Rheumatoid arthritis
;DULOXETINE;ZNF385D;rs4334661;T;Efficacy;increased response to ⮕ DULOXETINE;Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;rs1805087;A;Efficacy;increased response to ⮕ FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;Allele A is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele G.;and in people with Disease:Rheumatoid arthritis
;DULOXETINE;;rs7625956;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs4646453;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AC.; in people with Other:Kidney Transplantation
;TAMOXIFEN;SULT1A1;rs1042028;TT;Efficacy;decreased response to ⮕ TAMOXIFEN;Genotype TT is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to genotypes CC + CT.; in women with Disease:Breast Neoplasms
;DULOXETINE;ZNF385D;rs7616119;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;TERBUTALINE;ADRB2;rs1800888;CT;Efficacy;decreased response to ⮕ TERBUTALINE;Genotype CT is associated with decreased response to terbutaline in healthy individuals as compared to genotype CC.; in healthy individuals 
;DULOXETINE;;rs2933304;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;CT;Dosage;increased dose of ⮕ WARFARIN;Genotype CT is associated with increased dose of warfarin in people with Thromboembolism as compared to genotype TT.; in people with Disease:Thromboembolism
;METHOTREXATE;SLC19A1;rs1051266;T;Efficacy;increased response to ⮕ METHOTREXATE;Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;DULOXETINE;NRXN1;rs4971678;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ZNF385D;rs12630569;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC.; in people with Disease:Thromboembolism
;BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs699947;CC;Efficacy;increased response to ⮕ BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;Genotype CC is associated with increased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AC.;and in people with Disease:Colorectal Neoplasms
;ERYTHROPOIETIN;HFE;rs1800562;A;Dosage, Metabolism/PK;decreased dose of ⮕ ERYTHROPOIETIN;Allele A is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele G.; in people with Other:hemodialysis treatment
;DULOXETINE;;rs6700741;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;ENALAPRIL;ADRB2;rs1042714;CG + GG;Efficacy;increased response to ⮕ ENALAPRIL;Genotypes CG + GG are associated with increased response to enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.; in people with Disease:Hypertrophy, Left Ventricular
;ATENOLOL, ENALAPRIL;ADRB2;rs1042714;CG + GG;Efficacy;increased response to ⮕ ATENOLOL, ENALAPRIL;Genotypes CG + GG are associated with increased response to atenolol and enalapril in people with Hypertrophy, Left Ventricular as compared to genotype CC.;and in people with Disease:Hypertrophy, Left Ventricular
;BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs3025039;TT;Efficacy;decreased response to ⮕ BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;Genotype TT is associated with decreased response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.;and in people with Disease:Colorectal Neoplasms
;ERYTHROPOIETIN;HFE;rs1799945;G;Dosage, Metabolism/PK;decreased dose of ⮕ ERYTHROPOIETIN;Allele G is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele C.; in people with Other:hemodialysis treatment
;DULOXETINE;TEX10;rs6479008;C;Efficacy;increased response to ⮕ DULOXETINE;Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs15524;AA;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype AA is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Other:Kidney Transplantation
;DULOXETINE;TEX10;rs7035619;A;Efficacy;increased response to ⮕ DULOXETINE;Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;TEX10;rs10989064;T;Efficacy;increased response to ⮕ DULOXETINE;Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;DIGOXIN;ABCB1;rs1045642;GG;Metabolism/PK;increased metabolism of ⮕ DIGOXIN;Genotype GG is associated with increased metabolism of digoxin as compared to genotype AA.;  
;DULOXETINE;ATP10A;rs12595802;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;TEX10;rs7472;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs56229625;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DIGOXIN;ABCB1;rs2032582;CC;Metabolism/PK;increased metabolism of ⮕ DIGOXIN;Genotype CC is associated with increased metabolism of digoxin as compared to genotype AA.;  
;DULOXETINE;;rs61692318;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs62319299;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;DULOXETINE;TEX10;rs10124893;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;INVS;rs10123866;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1045642;A;Dosage, Toxicity;decreased dose of ⮕ ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;Allele A is associated with decreased dose of abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to allele G.;or in women with Other:Breast Neoplasms
;AMLODIPINE;CYP3A5;rs776746;CC;Metabolism/PK;increased metabolism of ⮕ AMLODIPINE;Genotype CC is associated with increased metabolism of amlodipine in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;DULOXETINE;;rs10007051;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;increased clinical benefit to ⮕ IVACAFTOR;Allele A is associated with increased clinical benefit to ivacaftor in children with Cystic Fibrosis.; in children with Other:Cystic Fibrosis
;DULOXETINE;ZNF385D;rs9879065;C;Efficacy;increased response to ⮕ DULOXETINE;Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs55881666;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;INFLIXIMAB;;rs2097432;CC + CT;Efficacy;decreased response to ⮕ INFLIXIMAB;Genotypes CC + CT is associated with decreased response to infliximab in people with Crohn Disease as compared to genotype TT.; in people with Other:Crohn Disease
;VALPROIC ACID;CYP2C9;rs4918758;CC + CT;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotypes CC + CT is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotype TT.; in people with Other:Epilepsy
;DULOXETINE;;rs11933890;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;VALPROIC ACID;CYP2C19;rs4244285;AA + AG;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotypes AA + AG is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotype GG.; in people with Other:Epilepsy
;DULOXETINE;ZNF385D;rs9310658;C;Efficacy;increased response to ⮕ DULOXETINE;Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ZNF385D;rs7653345;A;Efficacy;increased response to ⮕ DULOXETINE;Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;VALPROIC ACID;ABAT;rs1731017;GG;Metabolism/PK;increased exposure to ⮕ VALPROIC ACID;Genotype GG is associated with increased exposure to valproic acid in people with Epilepsy as compared to genotype AA.; in people with Other:Epilepsy
;DULOXETINE;ZNF385D;rs9310657;T;Efficacy;increased response to ⮕ DULOXETINE;Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ZNF385D;rs9824595;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ZNF385D;rs9873889;C;Efficacy;increased response to ⮕ DULOXETINE;Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ZNF385D;rs9819548;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;CAPECITABINE;CDA;rs532545;CC;Efficacy;decreased response to ⮕ CAPECITABINE;Genotype CC is associated with decreased response to capecitabine in women with Breast Neoplasms as compared to genotypes CT + TT.; in women with Other:Breast Neoplasms
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;rs1799983;GG;Efficacy;increased clinical benefit to ⮕ HYDRALAZINE / ISOSORBIDE DINITRATE;Genotype GG is associated with increased clinical benefit to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes GT + TT.; in people with Other:Heart Failure
;WARFARIN;CYP2C9;rs56165452;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele T.;  
;TACROLIMUS;ABCB1;rs1045642;AA;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ADALIMUMAB;CRP;rs1130864;AG + GG;Efficacy;increased response to ⮕ ADALIMUMAB;Genotypes AG + GG are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype AA.; in people with Disease:Inflammatory Bowel Diseases
;OLANZAPINE;CYP3A43;rs472660;AA;Dosage, Efficacy, Toxicity, Metabolism/PK;increased clearance of ⮕ OLANZAPINE;Genotype AA is associated with increased clearance of olanzapine in people with Schizophrenia as compared to genotypes AG + GG.; in people with Disease:Schizophrenia
;GLATIRAMER ACETATE;EOMES;rs2371108;T;Efficacy;increased response to ⮕ GLATIRAMER ACETATE;Allele T is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.; in people with Disease:Multiple Sclerosis
;CARVEDILOL;UGT1A1;rs4148323;A;Metabolism/PK;decreased metabolism of ⮕ CARVEDILOL;Allele A is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to allele G.; in people with Disease:Angina Pectoris
;ETOPOSIDE;ABCB1;rs1045642;GG;Metabolism/PK;increased metabolism of ⮕ ETOPOSIDE;Genotype GG is associated with increased metabolism of etoposide in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.; in people with Disease:Acute lymphoblastic leukemia
;ADALIMUMAB;ATG5;rs9373839;CC + CT;Efficacy;increased response to ⮕ ADALIMUMAB;Genotypes CC + CT are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Inflammatory Bowel Diseases
;DULOXETINE;MIEF2;rs56355515;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;MIEF2;rs12603700;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;ADALIMUMAB;ATG5;rs510432;CT + TT;Efficacy;increased response to ⮕ ADALIMUMAB;Genotypes CT + TT are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Inflammatory Bowel Diseases
;TACROLIMUS;ABCB1;rs1045642;GG;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype GG is associated with increased dose of tacrolimus in people with Transplantation as compared to genotypes AA + AG.; in people with Disease:Transplantation
;DULOXETINE;MIEF2;rs3889402;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;AZATHIOPRINE;AOX1;rs55754655;G;Efficacy;decreased response to ⮕ AZATHIOPRINE;Allele G is associated with decreased response to azathioprine in people with Inflammatory Bowel Diseases as compared to allele A.; in people with Disease:Inflammatory Bowel Diseases
;AZATHIOPRINE;AOX1;rs55754655;AG + GG;Dosage;increased dose of ⮕ AZATHIOPRINE;Genotypes AG + GG is associated with increased dose of azathioprine in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;rs1799998;AA;Efficacy;increased clinical benefit to ⮕ HYDRALAZINE / ISOSORBIDE DINITRATE;Genotype AA is associated with increased clinical benefit to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes AG + GG.; in people with Other:Heart Failure
;DULOXETINE;;rs58042962;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A4;rs2740574;C;Dosage;increased dose of ⮕ TACROLIMUS;Allele C is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;DULOXETINE;;rs10771997;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;FENOFIBRATE;LPL;rs320;GG;Efficacy;decreased response to ⮕ FENOFIBRATE;Genotype GG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotypes GT + TT.; in people with Disease:Hypertriglyceridemia
;DULOXETINE;FCN2;rs3124955;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;FENOFIBRATE;APOA1;rs2727786;CG;Efficacy;decreased response to ⮕ FENOFIBRATE;Genotype CG is associated with decreased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;DULOXETINE;FCN2;rs3128624;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs7306991;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;GLATIRAMER ACETATE;CLEC16A;rs6498169;A;Efficacy;increased response to ⮕ GLATIRAMER ACETATE;Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.; in people with Disease:Multiple Sclerosis
;TACROLIMUS;CYP3A4;rs2740574;C;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Allele C is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;DIGOXIN;ABCB1;rs1045642;AA;Metabolism/PK;decreased metabolism of ⮕ DIGOXIN;Genotype AA is associated with decreased metabolism of digoxin as compared to genotype GG.;  
;DULOXETINE;;rs10771999;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs10771998;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;SKIC3;rs12657120;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;ETHOSUXIMIDE;CACNA1H;rs61734410;T;Efficacy;decreased clinical benefit to ⮕ ETHOSUXIMIDE;Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C.; in children with Efficacy:Epilepsy
;DULOXETINE;SKIC3;rs4639250;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;DULOXETINE;;rs4437856;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;ETHOSUXIMIDE;CACNA1I;rs3747178;T;Efficacy;decreased clinical benefit to ⮕ ETHOSUXIMIDE;Allele T is associated with decreased clinical benefit to ethosuximide in children with Epilepsy as compared to allele C.; in children with Efficacy:Epilepsy
;DULOXETINE;TREML4;rs9369266;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;AZATHIOPRINE;MOCOS;rs594445;AA + AC;Dosage;decreased dose of ⮕ AZATHIOPRINE;Genotypes AA + AC is associated with decreased dose of azathioprine in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;DULOXETINE;TREML4;rs13204353;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;LAMOTRIGINE;ABCB1;rs2032582;A;Efficacy;decreased clinical benefit to ⮕ LAMOTRIGINE;Allele A is associated with decreased clinical benefit to lamotrigine in children with Epilepsy as compared to allele C.; in children with Efficacy:Epilepsy
;CYCLOSPORINE;CALM1;rs12885713;T;Efficacy;increased response to ⮕ CYCLOSPORINE;Allele T is associated with increased response to cyclosporine in people with Psoriasis as compared to allele C.; in people with Other:Psoriasis
;IRBESARTAN;AGT;rs699;GG;Efficacy;increased response to ⮕ IRBESARTAN;Genotype GG is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.; in people with Disease:Hypertrophy, Left Ventricular
;DULOXETINE;;rs2419128;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;METHOTREXATE;SLC19A1;rs1051266;T;Efficacy;increased response to ⮕ METHOTREXATE;Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;DULOXETINE;;rs12502866;G;Efficacy;increased response to ⮕ DULOXETINE;Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;METHOTREXATE;GGH;rs3758149;AA + AG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AA + AG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;DULOXETINE;;rs12094644;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;CAPECITABINE;CDA;rs2072671;AA + AC;Efficacy;decreased response to ⮕ CAPECITABINE;Genotypes AA + AC is associated with decreased response to capecitabine in women with Breast Neoplasms as compared to genotype CC.; in women with Other:Breast Neoplasms
;LAMOTRIGINE;CACNA1H;rs2753326;A;Efficacy;increased clinical benefit to ⮕ LAMOTRIGINE;Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G.; in children with Efficacy:Epilepsy
;RIVAROXABAN;ABCB1;rs4728709;GG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ RIVAROXABAN;Genotype GG is associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AG.; in people with Other:Atrial Fibrillation
;ATENOLOL;ADRA2A;rs1800545;GG;Efficacy;increased response to ⮕ ATENOLOL;Genotype GG is associated with increased response to atenolol in people with Hypertrophy, Left Ventricular as compared to genotypes AA + AG.; in people with Disease:Hypertrophy, Left Ventricular
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotypes GT + TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CYCLOSPORINE;;rs2874116;G;Efficacy;increased response to ⮕ CYCLOSPORINE;Allele G is associated with increased response to cyclosporine in people with Psoriasis as compared to allele A.; in people with Other:Psoriasis
;IRBESARTAN;APOB;rs1801701;CC;Efficacy;increased response to ⮕ IRBESARTAN;Genotype CC is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotypes CT + TT.; in people with Disease:Hypertrophy, Left Ventricular
;RIVAROXABAN;ABCB1;rs4148738;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ RIVAROXABAN;Genotype CC is associated with increased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.; in people with Other:Atrial Fibrillation
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.; in people with Disease:HIV infectious disease
;MEPHENYTOIN;CYP2C19;rs183701923;T;Metabolism/PK;decreased clearance of ⮕ MEPHENYTOIN;Allele T is associated with decreased clearance of mephenytoin as compared to allele C.;  
;MEPHENYTOIN;CYP2C19;rs140278421;A;Metabolism/PK;decreased clearance of ⮕ MEPHENYTOIN;Allele A is associated with decreased clearance of mephenytoin as compared to allele G.;  
;EFAVIRENZ;CYP2B6;rs4803419;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.; in people with Disease:HIV infectious disease
;CHLORPROMAZINE;DRD2;rs1799732;GG;Efficacy;increased response to ⮕ CHLORPROMAZINE;Genotype GG is associated with increased response to chlorpromazine in people with Schizophrenia as compared to genotypes G/del + del/del.; in people with Disease:Schizophrenia
;METHOTREXATE;AMPD1;rs17602729;AA + AG;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes AA + AG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;BENAZEPRIL;AGT;rs7079;TT;Efficacy;increased response to ⮕ BENAZEPRIL;Genotype TT is associated with increased response to benazepril in people with Hypertension as compared to genotypes GG + GT.; in people with Disease:Hypertension
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;OMEPRAZOLE;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased concentrations of ⮕ OMEPRAZOLE;Genotypes AA + AG are associated with increased concentrations of omeprazole in infants with Gastroesophageal Reflux as compared to genotype GG.; in infants with Disease:Gastroesophageal Reflux
;OPIOIDS;OPRM1;rs1799971;AA;Dosage, Efficacy;decreased dose of ⮕ OPIOIDS;Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotype GG.; in people with Disease:Pain, Postoperative
;NELFINAVIR;CYP2C19;rs4244285;AA;Metabolism/PK;decreased metabolism of ⮕ NELFINAVIR;Genotype AA is associated with decreased metabolism of nelfinavir in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;TOLBUTAMIDE;CYP2C9;rs771237265;C;Metabolism/PK;decreased clearance of ⮕ TOLBUTAMIDE;Allele C is associated with decreased clearance of tolbutamide as compared to allele A.;  
;METHOTREXATE;SLC19A1;rs1051266;TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; in people with Disease:Rheumatoid arthritis
;TOLBUTAMIDE;CYP2C9;rs762081829;T;Metabolism/PK;decreased clearance of ⮕ TOLBUTAMIDE;Allele T is associated with decreased clearance of tolbutamide as compared to allele C.;  
;METFORMIN;SLC22A1;rs628031;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.; in people with Disease:Diabetes Mellitus, Type 2
;MEPHENYTOIN;CYP2C19;rs145119820;A;Metabolism/PK;decreased clearance of ⮕ MEPHENYTOIN;Allele A is associated with decreased clearance of mephenytoin as compared to allele G.;  
;TOLBUTAMIDE;CYP2C9;rs761895497;C;Metabolism/PK;decreased clearance of ⮕ TOLBUTAMIDE;Allele C is associated with decreased clearance of tolbutamide as compared to allele T.;  
;WARFARIN;F7;rs510317;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.;  
;FLUOXETINE;HTR1A;rs6295;GG;Efficacy;increased response to ⮕ FLUOXETINE;Genotype GG is associated with increased response to fluoxetine in people with Major Depressive Disorder as compared to genotypes CC + CG.; in people with Disease:Major Depressive Disorder
;MEPHENYTOIN;CYP2C19;rs61311738;T;Metabolism/PK;decreased clearance of ⮕ MEPHENYTOIN;Allele T is associated with decreased clearance of mephenytoin as compared to allele C.;  
;SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;TT;Efficacy;decreased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;BENAZEPRIL;AGT;rs4762;G;Efficacy;increased response to ⮕ BENAZEPRIL;Allele G is associated with increased response to benazepril in people with Hypertension.; in people with Disease:Hypertension
;DIGOXIN;ABCB1;rs1045642;AA;Metabolism/PK;decreased clearance of ⮕ DIGOXIN;Genotype AA is associated with decreased clearance of digoxin in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;BENAZEPRIL;AGT;rs699;A;Efficacy;increased response to ⮕ BENAZEPRIL;Allele A is associated with increased response to benazepril in people with Hypertension.; in people with Disease:Hypertension
;FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;Efficacy;increased response to ⮕ FLUOROURACIL, OXALIPLATIN;Genotypes AG + GG are associated with increased response to fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.;and in people with Disease:Colorectal Neoplasms
;ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC.;  
;BENAZEPRIL;AGT;rs7079;T;Efficacy;increased response to ⮕ BENAZEPRIL;Allele T is associated with increased response to benazepril in people with Hypertension.; in people with Disease:Hypertension
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;FENOFIBRATE;APOA5;rs3135506;CG + GG;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes CG + GG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;PRAVASTATIN, SIMVASTATIN;RHOA;rs11716445;A;Efficacy;decreased response to ⮕ PRAVASTATIN, SIMVASTATIN;Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G.;or in people with Disease:Hypercholesterolemia
;EFAVIRENZ;CYP2B6;rs35303484;AG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype AG is associated with increased concentrations of efavirenz in children with HIV infectious disease as compared to genotype AA.; in children with Other:HIV infectious disease
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.;  
;CITALOPRAM;;rs585719;CT;Efficacy;increased response to ⮕ CITALOPRAM;Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC.; in people with Disease:Depression
;WARFARIN;GGCX;rs11676382;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;WARFARIN;;rs12777823;A;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;WARFARIN;CYP2C9;rs7900194;A;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele A is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele G.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;ISONIAZID;CYP2E1;rs6413432;A;Metabolism/PK;increased concentrations of ⮕ ISONIAZID;Allele A is associated with increased concentrations of isoniazid in people with Tuberculosis as compared to allele T (assigned as intermediate acetylator phenotype) .; in people with Other:Tuberculosis
;EFAVIRENZ;CYP2B6;rs4803419;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in children with HIV infectious disease as compared to genotypes CC + CT.; in children with Other:HIV infectious disease
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;WARFARIN;GATA4;rs2645400;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.;  
;WARFARIN;CYP2C9;rs28371685;T;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele C.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;WARFARIN;GATA4;rs4841588;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.;  
;MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7662029;GG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID ACYL GLUCURONIDE;Genotype GG is associated with increased dose-adjusted trough concentrations of mycophenolic acid acyl glucuronide in people with Kidney Transplantation as compared to genotype AG.; in people with Other:Kidney Transplantation
;BUPRENORPHINE;UGT2B7;rs7439366;CC;Metabolism/PK;decreased concentrations of ⮕ BUPRENORPHINE;Genotype CC is associated with decreased concentrations of buprenorphine in people with Opioid-Related Disorders as compared to genotype CT.; in people with Other:Opioid-Related Disorders
;METHOTREXATE;SLCO1B1;rs4149056;CC;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype CC is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.; in children with Disease:Acute lymphoblastic leukemia
;MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7439366;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID ACYL GLUCURONIDE;Genotype CC is associated with increased dose-adjusted trough concentrations of mycophenolic acid acyl glucuronide in people with Kidney Transplantation as compared to genotype CT.; in people with Other:Kidney Transplantation
;METHOTREXATE;SLC19A1;rs2838958;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.; in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.;  
;SILDENAFIL;VEGFA;rs1570360;AA;Efficacy;decreased response to ⮕ SILDENAFIL;Genotype AA is associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotypes AG + GG.; in men with Disease:Erectile Dysfunction
;WARFARIN;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;SILDENAFIL;VEGFA;rs699947;AA + AC;Efficacy;decreased response to ⮕ SILDENAFIL;Genotypes AA + AC are associated with decreased response to sildenafil in men with Erectile Dysfunction as compared to genotype CC.; in men with Disease:Erectile Dysfunction
;WARFARIN;CYP4F2;rs2108622;CT + TT;Metabolism/PK;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC.; in healthy individuals 
;CAPTOPRIL;ACE2;rs2106809;GG;Efficacy;increased response to ⮕ CAPTOPRIL;Genotype GG is associated with increased response to captopril in women with Hypertension as compared to genotypes AA + AG.; in women with Disease:Hypertension
;CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;rs1801274;AA;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;Genotype AA is associated with increased response to cyclophosphamide, doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.;and in women with Disease:Breast Neoplasms
;TRASTUZUMAB;FCGR3A;rs396991;CC;Efficacy;increased response to ⮕ TRASTUZUMAB;Genotype CC is associated with increased response to trastuzumab in people with Breast Neoplasms as compared to genotypes AA + AC.; in people with Disease:Breast Neoplasms
;BUPRENORPHINE;UGT2B7;rs7662029;GG;Metabolism/PK;decreased concentrations of ⮕ BUPRENORPHINE;Genotype GG is associated with decreased concentrations of buprenorphine in people with Opioid-Related Disorders as compared to genotypes AA + AG.; in people with Other:Opioid-Related Disorders
;ECULIZUMAB;CR1;rs2274567;AG + GG;Efficacy;decreased response to ⮕ ECULIZUMAB;Genotypes AG + GG is associated with decreased response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype AA.; in people with Disease:paroxysmal nocturnal hemoglobinuria
;MIRABEGRON;UGT1A4;rs2011425;GT;Metabolism/PK;increased half-life time of ⮕ MIRABEGRON;Genotype GT is associated with increased half-life time of mirabegron in healthy individuals as compared to genotype TT.; in healthy individuals 
;TACROLIMUS;CYP3A4;rs2740574;CT;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype CT is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Other:Kidney Transplantation
;MYCOPHENOLIC ACID;UGT1A1;rs4148323;AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID;Genotype AG is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.; in people with Other:Kidney Transplantation
;MIRABEGRON;UGT1A3;rs2008584;AA;Metabolism/PK;decreased half-life time of ⮕ MIRABEGRON;Genotype AA is associated with decreased half-life time of mirabegron in healthy individuals as compared to genotype AG.; in healthy individuals 
;MIRABEGRON;SLC6A2;rs12708954;CC;Metabolism/PK;increased clearance of ⮕ MIRABEGRON;Genotype CC is associated with increased clearance of mirabegron in healthy individuals as compared to genotype AC.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;PHENPROCOUMON;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CC + CT.;  
;CLOZAPINE;DRD1;rs686;G;Efficacy;increased response to ⮕ CLOZAPINE;Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7438135;AA;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID ACYL GLUCURONIDE;Genotype AA is associated with increased dose-adjusted trough concentrations of mycophenolic acid acyl glucuronide in people with Kidney Transplantation as compared to genotype AG.; in people with Other:Kidney Transplantation
;FLUVASTATIN;CYP2C9;rs1057910;CC;Metabolism/PK;decreased metabolism of ⮕ FLUVASTATIN;Genotype CC is associated with decreased metabolism of fluvastatin in healthy individuals as compared to genotype AA.; in healthy individuals 
;MIRABEGRON;SLC19A1;rs1051266;TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ MIRABEGRON;Genotype TT is associated with decreased dose-adjusted trough concentrations of mirabegron in healthy individuals as compared to genotype CT.; in healthy individuals 
;CLOZAPINE;DRD3;rs6280;TT;Efficacy;increased response to ⮕ CLOZAPINE;Genotype TT is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;MERCAPTOPURINE;TPMT;rs12199316;G;Dosage;increased dose of ⮕ MERCAPTOPURINE;Allele G is associated with increased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; in children with Other:Acute lymphoblastic leukemia
;TICAGRELOR;CYP3A4;rs56324128;CC;Metabolism/PK;decreased concentrations of ⮕ TICAGRELOR;Genotype CC is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.; in people with Disease:Acute coronary syndrome
;CANDESARTAN;AGTR1;rs5186;AA;Efficacy;increased response to ⮕ CANDESARTAN;Genotype AA is associated with increased response to candesartan in people with Heart Failure as compared to genotype AC.; in people with Disease:Heart Failure
;IRBESARTAN;AGTR1;rs5186;AC;Efficacy;increased response to ⮕ IRBESARTAN;Genotype AC is associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype AA.; in people with Other:Hypertrophy, Left Ventricular
;WARFARIN;CYP2C9;rs2256871;G;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele G is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;DOCETAXEL, PACLITAXEL;CYP3A5;rs776746;CC;Efficacy;decreased response to ⮕ DOCETAXEL, PACLITAXEL;Genotype CC is associated with decreased response to docetaxel or paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.;or in people with Disease:Breast Neoplasms
;CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;DPYD;rs1801159;CC + CT;Efficacy;decreased response to ⮕ CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;Genotypes CC + CT are associated with decreased response to capecitabine, fluorouracil or s 1 (combination) in people with Stomach Neoplasms as compared to genotype TT.;or in people with Disease:Stomach Neoplasms
;CANDESARTAN;AGTR1;rs5186;AC;Efficacy;increased response to ⮕ CANDESARTAN;Genotype AC is associated with increased response to candesartan in people with Heart Failure as compared to genotype AA.; in people with Disease:Heart Failure
;TICAGRELOR;SLCO1B1;rs113681054;C;Metabolism/PK;increased concentrations of ⮕ TICAGRELOR;Allele C is associated with increased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele T.; in people with Disease:Acute coronary syndrome
;TICAGRELOR;SLCO1B1;rs4149056;T;Metabolism/PK;decreased concentrations of ⮕ TICAGRELOR;Allele T is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele C.; in people with Disease:Acute coronary syndrome
;GEMCITABINE, PACLITAXEL;SLC29A1;rs760370;A;Efficacy;decreased response to ⮕ GEMCITABINE, PACLITAXEL;Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.;and in women Disease:Breast Neoplasms
;CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;Efficacy;increased clinical benefit to ⮕ CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;Genotype CC is associated with increased clinical benefit to citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Major Depressive Disorder as compared to genotypes CT + TT.;or in people with Other:Major Depressive Disorder
;WARFARIN;CYP2C19;rs11188082;T;Metabolism/PK;decreased metabolism of ⮕ WARFARIN;Allele T is associated with decreased metabolism of warfarin in people with Atrial Fibrillation, venous thromboembolism or Heart Valve Diseases as compared to allele A.; in people with Other:Atrial Fibrillation, Other:Venous thromboembolism, Other:Heart Valve Diseases
;METHYLPHENIDATE;CES1;rs71647871;CT;Dosage, Metabolism/PK;decreased dose of ⮕ METHYLPHENIDATE;Genotype CT is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;TICAGRELOR;UGT2B7;rs61361928;TT;Metabolism/PK;decreased concentrations of ⮕ TICAGRELOR;Genotype TT is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to genotype CT.; in people with Disease:Acute coronary syndrome
;QUETIAPINE;HTR1A;rs6295;GG;Metabolism/PK;increased concentrations of ⮕ QUETIAPINE;Genotype GG is associated with increased concentrations of quetiapine in men with Schizophrenia as compared to genotype CG.; in men with Other:Schizophrenia
;TICAGRELOR;CYP3A43;rs62471956;G;Metabolism/PK;decreased concentrations of ⮕ TICAGRELOR;Allele G is associated with decreased concentrations of ticagrelor in people with Acute coronary syndrome as compared to allele A.; in people with Disease:Acute coronary syndrome
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL, WARFARIN;Genotypes CT + TT is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.;or in people with Other:Heart valve replacement
;SIMVASTATIN;LEPR;rs1137101;GG;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotype GG is associated with decreased response to simvastatin in men with Hyperlipidemias as compared to genotypes AA + AG.; in men with Disease:Hyperlipidemias
;LAMOTRIGINE;ABCG2;rs2231142;T;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Allele T is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to allele G.; in people with Disease:Epilepsy
;ACETAMINOPHEN;SULT1A1;rs1042028;CC;Efficacy;increased response to ⮕ ACETAMINOPHEN;Genotype CC is associated with increased response to acetaminophen in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;OPIOIDS;IL2;rs2069762;AA;Dosage;increased dose of ⮕ OPIOIDS;Genotype AA is associated with increased dose of opioids in people with Pain and Neoplasms as compared to genotypes AC + CC.; in people with Other:Pain, Other:Neoplasms
;OPIOIDS;BDNF;rs6265;CC;Dosage;increased dose of ⮕ OPIOIDS;Genotype CC is associated with increased dose of opioids in people with Pain and Neoplasms as compared to genotypes CT + TT.; in people with Other:Pain, Other:Neoplasms
;ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ ACENOCOUMAROL, WARFARIN;Genotypes CT + TT is associated with increased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype CC.;or in people with Other:Heart valve replacement
;VORICONAZOLE;CYP3A4;rs4646437;AG;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype AG is associated with increased concentrations of voriconazole in people with Mycoses as compared to genotype GG.; in people with Disease:Fungal infectious disease
;OPIOIDS;IL6;rs1800795;CC;Dosage;increased dose of ⮕ OPIOIDS;Genotype CC is associated with increased dose of opioids in people with Pain and Neoplasms as compared to genotypes CG + GG.; in people with Other:Pain, Other:Neoplasms
;ATENOLOL, IRBESARTAN;AGT;rs4762;AG;Efficacy;increased response to ⮕ ATENOLOL, IRBESARTAN;Genotype AG is associated with increased response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype GG.;or in people with Other:Hypertrophy, Left Ventricular
;TENOFOVIR;ABCC4;rs1059751;AA + AG;Metabolism/PK;decreased concentrations of ⮕ TENOFOVIR;Genotypes AA + AG is associated with decreased concentrations of tenofovir in people with Hepatitis B, Chronic as compared to genotype GG.; in people with Other:Hepatitis B, Chronic
;CAFFEINE;CYP1A1;rs2472297;T;Metabolism/PK;increased metabolism of ⮕ CAFFEINE;Allele T is associated with increased metabolism of caffeine as compared to allele C.;  
;DOCETAXEL;VEGFA;rs1570360;GG;Efficacy;decreased response to ⮕ DOCETAXEL;Genotype GG is associated with decreased response to docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG.; in women with Disease:Breast Neoplasms
;OPIOIDS;IL1B;rs1143634;AA + AG;Efficacy;decreased clinical benefit to ⮕ OPIOIDS;Genotypes AA + AG is associated with decreased clinical benefit to opioids in people with Pain and Neoplasms as compared to genotype GG.; in people with Other:Pain, Other:Neoplasms
;FENOFIBRATE;SCARB1;rs4238001;CT + TT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes CT + TT are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;TENOFOVIR;SLC22A6;rs4149170;TT;Metabolism/PK;increased concentrations of ⮕ TENOFOVIR;Genotype TT is associated with increased concentrations of tenofovir in people with Hepatitis B, Chronic as compared to genotypes CC + CT.; in people with Other:Hepatitis B, Chronic
;NEVIRAPINE;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ NEVIRAPINE;Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;OPIOIDS;OPRD1;rs678849;CC;Efficacy;decreased clinical benefit to ⮕ OPIOIDS;Genotype CC is associated with decreased clinical benefit to opioids in people with Pain and Neoplasms as compared to genotypes CT + TT.; in people with Other:Pain, Other:Neoplasms
;ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage;decreased dose of ⮕ ACENOCOUMAROL, WARFARIN;Genotypes AC + CC is associated with decreased dose of acenocoumarol or warfarin in people with heart valve replacement as compared to genotype AA.;or in people with Other:Heart valve replacement
;IRBESARTAN;AGT;rs699;AG + GG;Efficacy;increased response to ⮕ IRBESARTAN;Genotypes AG + GG are associated with increased response to irbesartan in people with Hypertrophy, Left Ventricular as compared to genotype AA.; in people with Other:Hypertrophy, Left Ventricular
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;CXCL10;rs56061981;CT + TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;Genotypes CT + TT are associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotype CC.;or in people with Disease:Chronic hepatitis C virus infection
;ATORVASTATIN;ABCB1;rs2032582;T;Efficacy;increased response to ⮕ ATORVASTATIN;Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele C.; in people with Disease:Hypercholesterolemia
;ATORVASTATIN;ABCB1;rs2032582;T;Efficacy;increased response to ⮕ ATORVASTATIN;Allele T is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to allele A.; in people with Disease:Hypercholesterolemia
;ATALUREN;CFTR;rs113993959;T;Efficacy;response to ⮕ ATALUREN;Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.; in children with Disease:Cystic Fibrosis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;or in people with Disease:Chronic hepatitis C virus infection
;ATALUREN;CFTR;rs75039782;T;Efficacy;response to ⮕ ATALUREN;Allele T is associated with response to ataluren in children with Cystic Fibrosis as compared to allele C.; in children with Disease:Cystic Fibrosis
;ATALUREN;CFTR;rs77010898;A;Efficacy;response to ⮕ ATALUREN;Allele A is associated with response to ataluren in children with Cystic Fibrosis as compared to allele G.; in children with Disease:Cystic Fibrosis
;PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;FENOFIBRATE;APOA5;rs3135506;CC + CG;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes CC + CG are associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype GG.; in people with Disease:Hypertriglyceridemia
;INSULIN RECOMBINANT, ZINC ACETATE;SLC30A8;rs13266634;CT + TT;Efficacy;increased response to ⮕ INSULIN RECOMBINANT, ZINC ACETATE;Genotypes CT + TT is associated with increased response to insulin recombinant and zinc acetate in healthy individuals as compared to genotype CC.;and in healthy individuals 
;METHYLPHENIDATE;DRD1;rs5326;CT + TT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.; in children with Disease:Autism Spectrum Disorder
;METFORMIN;SLC22A1;rs12208357;T;Metabolism/PK;increased exposure to ⮕ METFORMIN;Allele T is associated with increased exposure to metformin in healthy individuals as compared to allele C.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;FENTANYL;ABCB1;rs1045642;GG;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Disease:Pain, Postoperative
;FOLIC ACID, METHOTREXATE;ATIC;rs2372536;CC;Efficacy;increased response to ⮕ FOLIC ACID, METHOTREXATE;Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.;and in people with Disease:Rheumatoid arthritis
;CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;rs2853209;AA;Efficacy;decreased clinical benefit to ⮕ CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Genotype AA is associated with decreased clinical benefit to corticosteroids and selective beta-2-adrenoreceptor agonists in people with Asthma as compared to genotype TT.;and in people with Other:Asthma
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;LITHIUM;GADL1;rs17026688;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Other:Bipolar Disorder
;TACROLIMUS;POR;rs1057868;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;FOLIC ACID, METHOTREXATE;ITPA;rs1127354;CC;Efficacy;increased response to ⮕ FOLIC ACID, METHOTREXATE;Genotype CC is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.;and in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ATIC;rs4673993;C;Efficacy;increased response to ⮕ METHOTREXATE;Allele C is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele T.; in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9923231;TT;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;WARFARIN;GGCX;rs12714145;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele T.;  
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;METHOTREXATE;ADA;rs244076;C;Efficacy;decreased response to ⮕ METHOTREXATE;Allele C is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ADORA2A;rs5751876;T;Efficacy;decreased response to ⮕ METHOTREXATE;Allele T is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;FOLIC ACID, METHOTREXATE;AMPD1;rs17602729;A;Efficacy;increased response to ⮕ FOLIC ACID, METHOTREXATE;Allele A is associated with increased response to folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.;and in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;RITUXIMAB;FCGR3A;rs396991;CC;Efficacy;increased response to ⮕ RITUXIMAB;Genotype CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.; in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;FLUOROURACIL;EGFR;rs2293347;CC;Efficacy;decreased response to ⮕ FLUOROURACIL;Genotype CC is associated with decreased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT.; in people with Disease:Stomach Neoplasms
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;ANTIDEPRESSANTS;TGFBR3;rs12082710;TT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype TT is associated with increased response to antidepressants in people with Depression as compared to genotypes CC + CT.; in people with Disease:Depression
;WARFARIN;VKORC1;rs7294;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele T.;  
;METHOTREXATE;SLC19A1;rs1051266;TT;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotype TT is associated with increased clinical benefit to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; in people with Other:Rheumatoid arthritis
;ALLOPURINOL;ABCG2;rs2231142;T;Dosage;increased dose of ⮕ ALLOPURINOL;Allele T is associated with increased dose of allopurinol in people with Gout as compared to allele G.; in people with Disease:Gout
;WARFARIN;VKORC1;rs2884737;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;WARFARIN;VKORC1;rs2359612;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;RIFAMPIN;AADAC;rs1803155;GG;Metabolism/PK;decreased exposure to ⮕ RIFAMPIN;Genotype GG is associated with decreased exposure to rifampin in people with Tuberculosis as compared to genotypes AA + AG.; in people with Other:Tuberculosis
;ABIRATERONE;SLCO2B1;rs1077858;AA + AG;Metabolism/PK;increased concentrations of ⮕ ABIRATERONE;Genotypes AA + AG is associated with increased concentrations of abiraterone in healthy individuals as compared to genotype GG.; in healthy individuals 
;CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA;Efficacy;increased response to ⮕ CETUXIMAB, PANITUMUMAB;Genotype AA is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AG + GG.;or in people with Disease:Colorectal Neoplasms
;CETUXIMAB, PANITUMUMAB;AREG;rs1353295;GG;Efficacy;increased response to ⮕ CETUXIMAB, PANITUMUMAB;Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.;or in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;" in people with ""Disease:Burkitt Lymphoma"", ""Disease:Lymphoma, T-Cell"", ""Disease:Acute lymphoblastic leukemia"""
;RIFAMPIN;ABCB1;rs3842;CC;Metabolism/PK;increased exposure to ⮕ RIFAMPIN;Genotype CC is associated with increased exposure to rifampin in people with Tuberculosis as compared to genotypes CT + TT.; in people with Other:Tuberculosis
;METHOTREXATE;ABCB1;rs1045642;AA;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype AA is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;" in people with ""Disease:Burkitt Lymphoma"", ""Disease:Lymphoma, T-Cell"", ""Disease:Acute lymphoblastic leukemia"""
;FENTANYL;P2RX7;rs1718125;CT + TT;Dosage;increased dose of ⮕ FENTANYL;Genotypes CT + TT are associated with increased dose of fentanyl in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.;" in people with ""Other:Lung Neoplasms"", ""Other:Pain, Postoperative"""
;METHYLPHENIDATE;DRD1;rs4867798;CC + CT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CC + CT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype TT.; in children with Disease:Autism Spectrum Disorder
;METHYLPHENIDATE;DRD3;rs6280;TT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype TT is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CC + CT.; in children with Disease:Autism Spectrum Disorder
;METHYLPHENIDATE;DRD4;rs11246226;AA;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype AA is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes AC + CC.; in children with Disease:Autism Spectrum Disorder
;PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes CT + TT is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; in people with Disease:Non-Small Cell Lung Carcinoma
;METHYLPHENIDATE;ADRA2A;rs1800544;CC;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype CC is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotypes CG + GG.; in children with Disease:Autism Spectrum Disorder
;METHYLPHENIDATE;COMT;rs4680;AA + AG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes AA + AG is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype GG.; in children with Disease:Autism Spectrum Disorder
;ESTRONE SULFATE;SLCO1B1;rs10841753;C;Efficacy;decreased concentrations of ⮕ ESTRONE SULFATE;Allele C is associated with decreased concentrations of estrone sulfate in women with Breast Neoplasms as compared to allele T.; in women with Other:Breast Neoplasms
;DOBUTAMINE;GNAS;rs62205366;CC + CT;Efficacy;increased response to ⮕ DOBUTAMINE;Genotypes CC + CT are associated with increased response to dobutamine in healthy individuals as compared to genotype TT.; in healthy individuals 
;ESTRONE SULFATE;SLCO1B1;rs10841753;C;Metabolism/PK;decreased  ⮕ ESTRONE SULFATE;Allele C is associated with decreased estrone sulfate in women with Breast Neoplasms as compared to allele T.; in women with Other:Breast Neoplasms
;WARFARIN;GGCX;rs12714145;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotype CC.;  
;NEVIRAPINE;CYP2B6;rs3745274;GT + TT;Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CETUXIMAB, PANITUMUMAB;AREG;rs13104811;GG;Efficacy;increased response to ⮕ CETUXIMAB, PANITUMUMAB;Genotype GG is associated with increased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG.;or in people with Disease:Colorectal Neoplasms
;CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;Efficacy;decreased response to ⮕ CETUXIMAB, PANITUMUMAB;Genotype AA is associated with decreased response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.;or in people with Disease:Colorectal Neoplasms
;ANTIDEPRESSANTS;CRHR1;rs28364032;AA + AG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AA + AG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype GG.; in people with Disease:Major Depressive Disorder
;TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TOPIRAMATE;Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of topiramate in children with Epilepsy as compared to genotype TT.; in children with Other:Epilepsy
;CYCLOSPORINE;POR;rs1057868;T;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Allele T is associated with increased concentrations of cyclosporine in children with Kidney Transplantation as compared to allele C.; in children with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC29A1;rs760370;GG;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.;and in people with Disease:Chronic hepatitis C virus infection
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Genotypes AA + AG is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs760370;AG + GG;Efficacy;increased response to ⮕ TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.;and in people with Disease:Colorectal Neoplasms
;ETHANOL;ADH1B;rs2018417;A;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele A is associated with metabolism of ethanol.;  
;ETHANOL;ADH1B;rs17033;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;ETHANOL;ADH1B;rs1229985;G;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele G is associated with metabolism of ethanol.;  
;PHENPROCOUMON;PPARA;rs4253728;A;Dosage;increased dose of ⮕ PHENPROCOUMON;Allele A is associated with increased dose of phenprocoumon as compared to allele G.;  
;ETHANOL;ADH1A;rs931635;A;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele A is associated with metabolism of ethanol.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;METHADONE;KCNJ6;rs2070995;TT;;increased dose of ⮕ METHADONE;Genotype TT is associated with increased dose of methadone in people with Substance-Related Disorders as compared to genotypes CC + CT.; in people with Disease:Substance-Related Disorders
;ETHANOL;ADH1C;rs283416;A;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele A is associated with metabolism of ethanol.;  
;ROSIGLITAZONE;PPARG;rs1801282;CG;Efficacy;increased response to ⮕ ROSIGLITAZONE;Genotype CG is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;ETHANOL;ADH1C;rs283411;A;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele A is associated with metabolism of ethanol.;  
;ETHANOL;ADH1C;rs1662060;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;TACROLIMUS;SUMO4;rs237025;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.; in people with Disease:Liver transplantation
;ACENOCOUMAROL;VKORC1;rs17878544;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.;  
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.;  
;ACENOCOUMAROL;VKORC1;rs7200749;AA + AG;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotypes AA + AG is associated with increased dose of acenocoumarol as compared to genotype GG.;  
;HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.;  
;ACENOCOUMAROL;VKORC1;rs61742245;AA + AC;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotypes AA + AC is associated with increased dose of acenocoumarol as compared to genotype CC.;  
;WARFARIN;VKORC1;rs7200749;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin as compared to allele G.;  
;ACENOCOUMAROL;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.;  
;WARFARIN;VKORC1;rs7294;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;CITALOPRAM;NEDD4L;rs520210;A;Efficacy;increased response to ⮕ CITALOPRAM;Allele A is associated with increased response to citalopram in people with Depression as compared to allele G.; in people with Disease:Depression
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;HMG COA REDUCTASE INHIBITORS;TOMM40;rs2075650;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.;  
;ACENOCOUMAROL;VKORC1;rs55894764;CT + TT;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC.;  
;VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs28898617;G;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A.; in children with Disease:Epilepsy
;IVACAFTOR;CFTR;rs78655421;AA + AG;Efficacy;response to ⮕ IVACAFTOR;Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;METHYLPHENIDATE;PEBP4;rs17685420;T;Efficacy;increased response to ⮕ METHYLPHENIDATE;Allele T is associated with increased response to methylphenidate in people with Attention Deficit Disorder with Hyperactivity.; in people with Disease:Attention Deficit Disorder with Hyperactivity
;ARIPIPRAZOLE;ABCB1;rs1128503;AA;Metabolism/PK;decreased clearance of ⮕ ARIPIPRAZOLE;Genotype AA is associated with decreased clearance of aripiprazole in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.; in people with Disease:Cardiovascular Disease
;VERAPAMIL;ITGAL;rs2230433;C;Efficacy;increased clinical benefit to ⮕ VERAPAMIL;Allele C is associated with increased clinical benefit to verapamil in people with Migraine NOS as compared to allele G.; in people with Other:Migraine disorder
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotypes CC + CT are associated with increased concentrations of atorvastatin in people with Hypercholesterolemia as compared to genotype TT.; in people with Other:Hypercholesterolemia
;PAZOPANIB;KDR;rs34231037;AG;Efficacy;increased response to ⮕ PAZOPANIB;Genotype AG is associated with increased response to pazopanib in people with Carcinoma, Renal Cell as compared to genotype AA.; in people with Disease:Renal Cell Carcinoma
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;ETHANOL;ADH7;rs1154461;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;HEPATITIS VACCINES;IL4R;rs1805015;C;Efficacy;increased response to ⮕ HEPATITIS VACCINES;Allele C is associated with increased response to Hepatitis vaccines as compared to allele T.;  
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT.;and in Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;ETHANOL;ADH1A;rs1229967;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ETHANOL;ADH1A;rs2276332;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.;and in people with Disease:Chronic hepatitis C virus infection
;BENAZEPRIL, IMIDAPRIL;AGT;rs5051;CC;Efficacy;increased response to ⮕ BENAZEPRIL, IMIDAPRIL;Genotype CC is associated with increased response to benazepril or imidapril in people with Hypertension as compared to genotypes CT + TT.;or in people with Disease:Hypertension
;ETHANOL;ADH1A;rs1229976;C;Toxicity, Metabolism/PK;metabolism of ⮕ ETHANOL;Allele C is associated with metabolism of ethanol.;  
;URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;Efficacy;decreased clinical benefit to ⮕ URSODEOXYCHOLIC ACID;Genotype TT is associated with decreased clinical benefit to ursodeoxycholic acid in people with Cholangitis as compared to genotypes CC + CT.; in people with Other:Cholangitis
;CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;rs4244285;A;Metabolism/PK;exposure to ⮕ CLOPIDOGREL THIOL METABOLITE H4;Allele A is associated with exposure to clopidogrel thiol metabolite H4 as compared to allele G.;  
;HEPATITIS VACCINES;IL13;rs1295686;T;Efficacy;decreased response to ⮕ HEPATITIS VACCINES;Allele T is associated with decreased response to Hepatitis vaccines as compared to allele C.;  
;PHENPROCOUMON;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotypes AA + AG are associated with decreased dose of phenprocoumon as compared to genotype GG.;  
;PHENPROCOUMON;VKORC1;rs7294;CT + TT;Dosage;increased dose of ⮕ PHENPROCOUMON;Genotypes CT + TT are associated with increased dose of phenprocoumon as compared to genotype CC.;  
;TACROLIMUS;ABCB1;rs1045642;AA;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP27B1;rs10877012;GT + TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GT + TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;and in people with Disease:Chronic hepatitis C virus infection
;DABIGATRAN;CES1;rs8192935;AA + AG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ DABIGATRAN;Genotypes AA + AG is associated with decreased dose-adjusted trough concentrations of dabigatran in people with Atrial Fibrillation as compared to genotype GG.; in people with Other:Atrial Fibrillation
;IRINOTECAN;VDR;rs11574077;TT;Metabolism/PK;increased metabolism of ⮕ IRINOTECAN;Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT.; in people with Disease:Colorectal Neoplasms
;METHYLPHENIDATE;ADGRL3;rs1868790;AA;Efficacy;decreased response to ⮕ METHYLPHENIDATE;Genotype AA is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AT + TT.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;METHYLPHENIDATE;SNAP25;rs3746544;GG + GT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes GG + GT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;METHYLPHENIDATE;SLC6A3;rs2550948;CC + CT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CC + CT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;PHENPROCOUMON;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.;  
;ATORVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased exposure to ⮕ ATORVASTATIN;Allele C is associated with increased exposure to atorvastatin as compared to allele T.;  
;INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ INTERFERONS, RIBAVIRIN;Genotype CC is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;MORPHINE;SLC22A1;rs34059508;AA + AG;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotypes AA + AG is associated with decreased clearance of morphine in children as compared to genotype GG.; in children 
;METHYLPHENIDATE;ADRA2A;rs1800544;G;Efficacy;increased response to ⮕ METHYLPHENIDATE;Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in healthy individuals as compared to genotype CC.; in healthy individuals 
;PLATINUM;XRCC1;rs25487;CT + TT;Efficacy;decreased response to ⮕ PLATINUM;Genotypes CT + TT is associated with decreased response to platinum in people with Lung Neoplasms as compared to genotype CC.; in people with Disease:Lung Neoplasms
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;rs10514475;A;Efficacy;increased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G.; in people with Disease:Depression
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;rs6108160;A;Efficacy;increased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G.; in people with Disease:Depression
;WARFARIN;LRP1;rs1800139;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.; in people with Other:Heart valve replacement
;WARFARIN;CYP4F2;rs2108622;T;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;WARFARIN;LRP1;rs1800154;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.; in people with Other:Heart valve replacement
;NICOTINE;CYP2A6;rs56113850;T;Metabolism/PK;decreased clearance of ⮕ NICOTINE;Allele T is associated with decreased clearance of nicotine as compared to allele C.;  
;WARFARIN;VKORC1;rs9923231;TT;Efficacy;increased response to ⮕ WARFARIN;Genotype TT is associated with increased response to warfarin as compared to genotypes CC + CT.;  
;INTERFERONS, RIBAVIRIN;IFNL3;rs8099917;GG;Efficacy;increased response to ⮕ INTERFERONS, RIBAVIRIN;Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.;and in people with Disease:Hepatitis C virus infection
;PHENPROCOUMON;VKORC1;rs2359612;AA + AG;Efficacy;increased response to ⮕ PHENPROCOUMON;Genotypes AA + AG is associated with increased response to phenprocoumon as compared to genotype GG.;  
;WARFARIN;CYP4F2;rs2108622;T;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;PLATINUM COMPOUNDS;XRCC1;rs1799782;G;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Allele G is associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to allele A.; in people with Disease:Lung Neoplasms
;MORPHINE;SLC22A1;rs12208357;TT;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotype TT is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes CC + CT.; in children with Other:adenotonsillectomy
;FLUOROURACIL;LGR5;rs17109924;CC + CT;Efficacy;increased response to ⮕ FLUOROURACIL;Genotypes CC + CT is associated with increased response to fluorouracil in people with Colonic Neoplasms as compared to genotype TT.; in people with Disease:Colonic Neoplasms
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.;  
;MORPHINE;SLC22A1;rs34059508;AA;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotype AA is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes AG + GG.; in children with Other:adenotonsillectomy
;ACETAMINOPHEN;UGT2B15;rs1902023;A;Metabolism/PK;decreased clearance of ⮕ ACETAMINOPHEN;Allele A is associated with decreased clearance of acetaminophen in healthy individuals as compared to allele C.; in healthy individuals 
;MORPHINE;SLC22A1;rs34130495;AA;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotype AA is associated with decreased clearance of morphine in children with adenotonsillectomy as compared to genotypes AG + GG.; in children with Other:adenotonsillectomy
;ACETAMINOPHEN;UGT2B15;rs1902023;AA;Metabolism/PK;increased metabolism of ⮕ ACETAMINOPHEN;Genotype AA is associated with increased metabolism of acetaminophen in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;ATORVASTATIN, PRAVASTATIN;KIF6;rs9462535;AA + AC;Efficacy;increased response to ⮕ ATORVASTATIN, PRAVASTATIN;Genotypes AA + AC are associated with increased response to atorvastatin or pravastatin.;or  
;CAPECITABINE, FLUOROURACIL;MTHFR;rs1801133;AA + AG;Dosage;decreased dose of ⮕ CAPECITABINE, FLUOROURACIL;Genotypes AA + AG is associated with decreased dose of capecitabine or fluorouracil in women with Neoplasms as compared to genotype GG.;or in women with Other:Neoplasms
;PITAVASTATIN, PITAVASTATIN LACTONE;SLCO1B1;rs4363657;A;Metabolism/PK;increased exposure to ⮕ PITAVASTATIN, PITAVASTATIN LACTONE;Allele A is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.;and in healthy individuals 
;ROSUVASTATIN;ABCG2;rs1481012;AG + GG;Efficacy;increased response to ⮕ ROSUVASTATIN;Genotypes AG + GG are associated with increased response to rosuvastatin as compared to genotype AA.;  
;SOMATROPIN RECOMBINANT;CDK4;rs2069502;CC;Efficacy;decreased response to ⮕ SOMATROPIN RECOMBINANT;Genotype CC is associated with decreased response to somatropin recombinant in children with Turner Syndrome as compared to genotypes CT + TT.; in children with Disease:Turner Syndrome
;ATORVASTATIN, PRAVASTATIN;KIF6;rs9471077;AG + GG;Efficacy;increased response to ⮕ ATORVASTATIN, PRAVASTATIN;Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin.;or  
;METFORMIN;FMO5;rs7541245;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele C.; in people with Disease:Diabetes Mellitus
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.; in people with Disease:Acute lymphoblastic leukemia
;ROSUVASTATIN;USP24;rs17111584;CC + CT;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.;  
;PITAVASTATIN, PITAVASTATIN LACTONE;SLCO1B1;rs4149056;C;Metabolism/PK;increased exposure to ⮕ PITAVASTATIN, PITAVASTATIN LACTONE;Allele C is associated with increased exposure to pitavastatin and pitavastatin lactone in healthy individuals as compared to allele T.;and in healthy individuals 
;METHYLPHENIDATE;SLC6A2;rs5569;GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;INTERFERON BETA-1A;RORA;rs4774388;TT;Efficacy;increased response to ⮕ INTERFERON BETA-1A;Genotype TT is associated with increased response to interferon beta-1a in people with Multiple Sclerosis as compared to genotypes CC + CT.; in people with Other:Multiple Sclerosis
;METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;REMIMAZOLAM;CES1;rs71647871;CT + TT;Metabolism/PK;decreased metabolism of ⮕ REMIMAZOLAM;Genotypes CT + TT is associated with decreased metabolism of remimazolam as compared to genotype CC.;  
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;NICOTINE;;rs113288603;T;Metabolism/PK;decreased clearance of ⮕ NICOTINE;Allele T is associated with decreased clearance of nicotine as compared to allele C.;  
;ROSUVASTATIN;APOE;rs71352238;CC + CT;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.;  
;METHYLPHENIDATE;ADRA2A;rs1800544;GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CC + CG.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;NICOTINE;;rs12461964;A;Metabolism/PK;decreased clearance of ⮕ NICOTINE;Allele A is associated with decreased clearance of nicotine as compared to allele G.;  
;ROSUVASTATIN;APOE;rs7412;CT + TT;Efficacy;increased response to ⮕ ROSUVASTATIN;Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC.;  
;METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;IDARUBICIN;NCF4;rs1883112;AA;Efficacy;increased response to ⮕ IDARUBICIN;Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.; in people with Disease:Leukemia, Myeloid, Acute
;SIMVASTATIN;ABCC2;rs717620;CT + TT;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotypes CT + TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotype CC.; in people with Disease:Hypercholesterolemia
;IDARUBICIN;RAC2;rs13058338;AT;Efficacy;increased response to ⮕ IDARUBICIN;Genotype AT is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.; in people with Disease:Leukemia, Myeloid, Acute
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;Genotype CC is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Myeloproliferative Disorders as compared to genotypes CT + TT.;or in people with Disease:Myeloproliferative Disorder
;ROSUVASTATIN;LPA;rs10455872;AG + GG;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotypes AG + GG are associated with decreased response to rosuvastatin as compared to genotype AA.;  
;ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs887829;T;Metabolism/PK;increased metabolism of ⮕ ATORVASTATIN;Allele T is associated with increased metabolism of atorvastatin as compared to allele C.;  
;METHYLPHENIDATE;BDNF;rs6265;CC;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;EFAVIRENZ;CYP2B6;rs3745274;GG + GT;Metabolism/PK;decreased concentrations of ⮕ EFAVIRENZ;Genotypes GG + GT is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.; in people with Other:HIV infectious disease
;IVACAFTOR;CFTR;rs78655421;AA + AG;Efficacy;response to ⮕ IVACAFTOR;Genotypes AA + AG is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ATORVASTATIN;CYP3A7;rs45446698;G;Metabolism/PK;increased metabolism of ⮕ ATORVASTATIN;Allele G is associated with increased metabolism of atorvastatin as compared to allele T.;  
;ATALUREN;CFTR;rs77010898;A;Efficacy;response to ⮕ ATALUREN;Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.; in people with Disease:Cystic Fibrosis
;PRAVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased exposure to ⮕ PRAVASTATIN;Allele C is associated with increased exposure to pravastatin in healthy individuals as compared to allele T.; in healthy individuals 
;CLOZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ CLOZAPINE;Genotype AA is associated with decreased dose-adjusted trough concentrations of clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.; in people with Other:Schizophrenia, Other:Tobacco Use Disorder
;EFAVIRENZ;CYP2B6;rs2279343;G;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.; in people with Other:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs2279345;T;Metabolism/PK;decreased concentrations of ⮕ EFAVIRENZ;Allele T is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to allele C.; in people with Other:HIV infectious disease
;ATORVASTATIN, PRAVASTATIN;KIF6;rs20455;AG + GG;Efficacy;increased response to ⮕ ATORVASTATIN, PRAVASTATIN;Genotypes AG + GG are associated with increased response to atorvastatin or pravastatin as compared to genotype AA.;or  
;ATALUREN;CFTR;rs113993959;T;Efficacy;response to ⮕ ATALUREN;Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.; in people with Disease:Cystic Fibrosis
;METHYLPHENIDATE;COMT;rs4680;GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;EFAVIRENZ;ABCB1;rs1045642;AG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype AG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Other:HIV infectious disease
;SOMATROPIN RECOMBINANT;CDK4;rs2270777;TT;Efficacy;increased response to ⮕ SOMATROPIN RECOMBINANT;Genotype TT is associated with increased response to somatropin recombinant in children with growth hormone deficiency as compared to genotypes CC + CT.; in children with Disease:Growth hormone deficiency
;METHYLPHENIDATE;ADRA2A;rs1800544;G;Efficacy;increased response to ⮕ METHYLPHENIDATE;Allele G is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.;  
;ATALUREN;CFTR;rs75039782;T;Efficacy;response to ⮕ ATALUREN;Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele C.; in people with Disease:Cystic Fibrosis
;ACENOCOUMAROL;VKORC1;rs9923231;CT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype CT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;METFORMIN;PRPF31;rs254271;C;Efficacy;decreased response to ⮕ METFORMIN;Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.; in people with Disease:Diabetes Mellitus, Type 2
;GABAPENTIN;SLC7A5;rs4240803;AG;Dosage;increased dose of ⮕ GABAPENTIN;Genotype AG is associated with increased dose of gabapentin in people with neuropathic pain as compared to genotype GG.; in people with Other:Neuropathic pain
;ATALUREN;CFTR;rs77010898;A;Efficacy;response to ⮕ ATALUREN;Allele A is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.; in people with Disease:Cystic Fibrosis
;METFORMIN;NBEA;rs57081354;C;Efficacy;decreased response to ⮕ METFORMIN;Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.; in people with Disease:Diabetes Mellitus, Type 2
;SUMATRIPTAN;SLC22A1;rs12208357;T;Metabolism/PK;low activity increased exposure to ⮕ SUMATRIPTAN;Allele T (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele C (assigned as high activity phenotype) .; in healthy individuals 
;METFORMIN;SLC22A1;rs628031;AA + AG;Efficacy;increased clinical benefit to ⮕ METFORMIN;Genotypes AA + AG is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Other:Diabetes Mellitus, Type 2
;FENOTEROL;SLC22A1;rs34130495;A;Metabolism/PK;increased exposure to ⮕ FENOTEROL;Allele A are associated with increased exposure to fenoterol in healthy individuals as compared to allele G.; in healthy individuals 
;FENOTEROL;SLC22A1;rs12208357;T;Metabolism/PK;increased exposure to ⮕ FENOTEROL;Allele T are associated with increased exposure to fenoterol in healthy individuals as compared to allele C.; in healthy individuals 
;FENOTEROL;SLC22A1;rs55918055;C;Metabolism/PK;increased exposure to ⮕ FENOTEROL;Allele C are associated with increased exposure to fenoterol in healthy individuals as compared to allele T.; in healthy individuals 
;SUMATRIPTAN;SLC22A1;rs34059508;A;Metabolism/PK;low activity increased exposure to ⮕ SUMATRIPTAN;Allele A (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele G (assigned as high activity phenotype) .; in healthy individuals 
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE;Genotypes GT + TT are associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype GG.; in people with Other:Lupus Nephritis
;SUMATRIPTAN;SLC22A1;rs34130495;A;Metabolism/PK;low activity increased exposure to ⮕ SUMATRIPTAN;Allele A (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele G (assigned as high activity phenotype) .; in healthy individuals 
;DRUGS USED IN DIABETES;IRS1;rs1801278;CT + TT;Efficacy;decreased response to ⮕ DRUGS USED IN DIABETES;Genotypes CT + TT is associated with decreased response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;SUMATRIPTAN;SLC22A1;rs55918055;C;Metabolism/PK;low activity increased exposure to ⮕ SUMATRIPTAN;Allele C (assigned as low activity phenotype) is associated with increased exposure to sumatriptan in healthy individuals as compared to allele T (assigned as high activity phenotype) .; in healthy individuals 
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Genotype CC is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.;and in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTRR;rs1801394;A;Efficacy;decreased response to ⮕ METHOTREXATE;Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;GG;Efficacy;increased response to ⮕ FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Genotype GG is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.;and in people with Disease:Colorectal Neoplasms
;FENOTEROL;SLC22A1;rs34059508;A;Metabolism/PK;increased exposure to ⮕ FENOTEROL;Allele A are associated with increased exposure to fenoterol in healthy individuals as compared to allele G.; in healthy individuals 
;HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;A;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Allele A is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;METFORMIN;SLC22A1;rs622342;AC + CC;Efficacy;increased clinical benefit to ⮕ METFORMIN;Genotypes AC + CC is associated with increased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Other:Diabetes Mellitus, Type 2
;WARFARIN;CYP4F2;rs2108622;CT;Dosage;increased dose of ⮕ WARFARIN;Genotype CT is associated with increased dose of warfarin as compared to genotype CC.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;Genotype AA is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Myeloproliferative Disorders as compared to genotypes AG + GG.;or in people with Disease:Myeloproliferative Disorder
;EMTRICITABINE;ABCC2;rs2273897;TT;Metabolism/PK;increased concentrations of ⮕ EMTRICITABINE;Genotype TT is associated with increased concentrations of emtricitabine in people with HIV Infections and Pregnancy as compared to genotypes CC + CT.; in people with Disease:HIV infectious disease, Other:Pregnancy
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotypes CT + TT.; in children with Disease:Kidney Transplantation
;CYCLOGUANIL;SLC22A1;rs12208357;T;Metabolism/PK;increased concentrations of ⮕ CYCLOGUANIL;Allele T are associated with increased concentrations of cycloguanil in healthy individuals as compared to allele C.; in healthy individuals 
;ATALUREN;CFTR;rs113993959;T;Efficacy;response to ⮕ ATALUREN;Allele T is associated with response to ataluren in people with Cystic Fibrosis as compared to allele G.; in people with Disease:Cystic Fibrosis
;CYCLOGUANIL;SLC22A1;rs34130495;A;Metabolism/PK;increased concentrations of ⮕ CYCLOGUANIL;Allele A are associated with increased concentrations of cycloguanil in healthy individuals as compared to allele G.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;Efficacy;decreased response to ⮕ GABAPENTIN, PREGABALIN;Genotype AG is associated with decreased response to gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.;or in people with Other:Neuropathic pain
;METHOTREXATE;SLC19A1;rs1051266;CT + TT;Toxicity;decreased discontinuation of ⮕ METHOTREXATE;Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;MORPHINE;COMT;rs4680;AA;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Genotype AA is associated with decreased dose of morphine in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Disease:Pain, Postoperative
;METFORMIN;CPA6;rs2162145;T;Efficacy;increased response to ⮕ METFORMIN;Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Disease:Diabetes Mellitus, Type 2
;SALBUTAMOL;DUSP1;rs881152;G;Efficacy;increased response to ⮕ SALBUTAMOL;Allele G is associated with increased response to salbutamol in people with Asthma as compared to allele A.; in people with Disease:Asthma
;IVACAFTOR;CFTR;rs75527207;AA + AG;Efficacy;response to ⮕ IVACAFTOR;Genotypes AA + AG are associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;TACROLIMUS;CYP3A4;rs2242480;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.; in people with Other:Lung transplantation
;WARFARIN;VKORC1;rs61742245;AA + AC;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AC are associated with increased dose of warfarin as compared to genotype CC.;  
;TRAMADOL;SLC22A1;rs34059508;A;Dosage;decreased dose of ⮕ TRAMADOL;Allele A is associated with decreased dose of tramadol in people with Pain as compared to allele G.; in people with Disease:Pain
;TACROLIMUS;SLCO1B3;rs4149117;GG + GT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.; in people with Other:Lung transplantation
;ESCITALOPRAM;IL11;rs1126757;CT + TT;Efficacy;increased response to ⮕ ESCITALOPRAM;Genotypes CT + TT is associated with increased response to escitalopram in people with Depression as compared to genotype CC.; in people with Disease:Depression
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;CLOPIDOGREL;CES1;rs2307240;CT + TT;Efficacy;increased response to ⮕ CLOPIDOGREL;Genotypes CT + TT are associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to genotype CC.; in people with Disease:Acute coronary syndrome
;TACROLIMUS;SLC2A2;rs1499821;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.; in people with Other:Lung transplantation
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.;  
;ABIRATERONE;YBX1;rs10493112;AC + CC;Efficacy;increased clinical benefit to ⮕ ABIRATERONE;Genotypes AC + CC is associated with increased clinical benefit to abiraterone in men with Prostatic Neoplasms as compared to genotype AA.; in men with Other:Prostatic Neoplasms
;TACROLIMUS;NFATC4;rs1955915;CC + CT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + CT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.; in people with Other:Lung transplantation
;GRAZOPREVIR;SLCO1B1;rs4149056;C;PD;increased exposure to ⮕ GRAZOPREVIR;Allele C is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele T.; in people with Other:Chronic hepatitis C virus infection
;BISOPROLOL;CYP2D6;rs1080985;CC;Metabolism/PK;decreased concentrations of ⮕ BISOPROLOL;Genotype CC is associated with decreased concentrations of bisoprolol in people with Cardiovascular Diseases as compared to genotypes CG + GG.; in people with Other:Cardiovascular Disease
;GRAZOPREVIR;SLCO1B1;rs11045819;A;PD;increased exposure to ⮕ GRAZOPREVIR;Allele A is associated with increased exposure to grazoprevir in people with Hepatitis C, Chronic as compared to allele C.; in people with Other:Chronic hepatitis C virus infection
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;WARFARIN;VKORC1;rs9923231;C;Metabolism/PK;increased steady-state concentration of ⮕ WARFARIN;Allele C is associated with increased steady-state concentration of warfarin as compared to allele T.;  
;WARFARIN;VKORC1;rs9923231;C;Metabolism/PK;increased dose of ⮕ WARFARIN;Allele C is associated with increased dose of warfarin as compared to allele T.;  
;WARFARIN;;rs12777823;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;METHADONE;BDNF, BDNF-AS;rs7127507;C;Efficacy;decreased response to ⮕ METHADONE;Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele T.; in people with Disease:Opioid-Related Disorders
;O-DESMETHYLTRAMADOL;SLC22A1;rs12208357;T;Metabolism/PK;increased concentrations of ⮕ O-DESMETHYLTRAMADOL;Allele T is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele C.; in people with Disease:Pain
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;ENALAPRIL;NOS3;rs2070744;CC + CT;Efficacy;increased response to ⮕ ENALAPRIL;Genotypes CC + CT are associated with increased response to enalapril in people with Hypertension as compared to genotype TT.; in people with Disease:Hypertension
;METHADONE;BDNF, BDNF-AS;rs11030118;G;Efficacy;decreased response to ⮕ METHADONE;Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.; in people with Disease:Opioid-Related Disorders
;WARFARIN;VKORC1;rs2359612;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.;  
;WARFARIN;CYP2C9;rs7089580;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in children as compared to allele A.; in children 
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.;  
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AC + CC.;  
;METHADONE;BDNF, BDNF-AS;rs1967554;C;Efficacy;decreased response to ⮕ METHADONE;Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.; in people with Disease:Opioid-Related Disorders
;WARFARIN;VKORC1;rs8050894;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.;  
;BISOPROLOL;CYP2D6;rs1080985;G;Metabolism/PK;increased concentrations of ⮕ BISOPROLOL;Allele G is associated with increased concentrations of bisoprolol in people with Acute coronary syndrome as compared to allele C.; in people with Other:Acute coronary syndrome
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;VKORC1;rs7294;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;METHADONE;BDNF;rs2030324;G;Efficacy;decreased response to ⮕ METHADONE;Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.; in people with Disease:Opioid-Related Disorders
;BISOPROLOL;CYP2D6;rs3892097;CT + TT;Metabolism/PK;increased concentrations of ⮕ BISOPROLOL;Genotypes CT + TT is associated with increased concentrations of bisoprolol in people with Acute coronary syndrome as compared to genotype CC.; in people with Other:Acute coronary syndrome
;BUSULFAN;GSTA1;rs3957357;AA;Metabolism/PK;increased clearance of ⮕ BUSULFAN;Genotype AA is associated with increased clearance of busulfan in children with Transplantation as compared to genotypes AG + GG.; in children with Disease:Transplantation
;O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;A;Metabolism/PK;increased concentrations of ⮕ O-DESMETHYLTRAMADOL;Allele A is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele G (assigned as low activity phenotype) .; in people with Disease:Pain
;O-DESMETHYLTRAMADOL;SLC22A1;rs34059508;A;Metabolism/PK;increased concentrations of ⮕ O-DESMETHYLTRAMADOL;Allele A is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele G.; in people with Disease:Pain
;ENALAPRIL;BDKRB2;rs1799722;TT;Efficacy;decreased response to ⮕ ENALAPRIL;Genotype TT is associated with decreased response to enalapril in people with Hypertension as compared to genotypes CC + CT.; in people with Disease:Hypertension
;METHADONE;BDNF;rs988748;C;Efficacy;decreased response to ⮕ METHADONE;Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele G.; in people with Disease:Opioid-Related Disorders
;O-DESMETHYLTRAMADOL;SLC22A1;rs55918055;C;Metabolism/PK;increased concentrations of ⮕ O-DESMETHYLTRAMADOL;Allele C is associated with increased concentrations of o-desmethyltramadol in people with Pain as compared to allele T.; in people with Disease:Pain
;WARFARIN;VKORC1;rs61742245;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin as compared to allele C.;  
;TRAMADOL;SLC22A1;rs55918055;C;Dosage;decreased dose of ⮕ TRAMADOL;Allele C is associated with decreased dose of tramadol in people with Pain as compared to allele T.; in people with Disease:Pain
;CELECOXIB;CYP2C9;rs1057910;CC;Metabolism/PK;decreased clearance of ⮕ CELECOXIB;Genotype CC is associated with decreased clearance of celecoxib in healthy individuals as compared to genotype AA.; in healthy individuals 
;METHADONE;BDNF;rs11030119;G;Efficacy;decreased response to ⮕ METHADONE;Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A.; in people with Disease:Opioid-Related Disorders
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.; in people with Other:Lung transplantation
;TRAMADOL;SLC22A1;rs12208357;T;Dosage;decreased dose of ⮕ TRAMADOL;Allele T is associated with decreased dose of tramadol in people with Pain as compared to allele C.; in people with Disease:Pain
;FENTANYL;CYP3A4;rs2242480;T;Dosage, Efficacy;decreased dose of ⮕ FENTANYL;Allele T is associated with decreased dose of fentanyl in women with Pain, Postoperative.; in women with Disease:Pain, Postoperative
;CELECOXIB;CYP2C9;rs1057910;CC;Metabolism/PK;decreased metabolism of ⮕ CELECOXIB;Genotype CC is associated with decreased metabolism of celecoxib in children as compared to genotype AA.; in children 
;BISOPROLOL;CYP3A5;rs776746;TT;Metabolism/PK;decreased concentrations of ⮕ BISOPROLOL;Genotype TT is associated with decreased concentrations of bisoprolol in people with Acute coronary syndrome as compared to genotypes CC + CT.; in people with Other:Acute coronary syndrome
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;TRAMADOL;SLC22A1;rs34130495;A;Dosage;decreased dose of ⮕ TRAMADOL;Allele A is associated with decreased dose of tramadol in people with Pain as compared to allele G.; in people with Disease:Pain
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs4149570;AA;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes AC + CC.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;rs5030728;AA + AG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype GG.; in people with Disease:Inflammatory Bowel Diseases
;METFORMIN;SLC47A1;rs8065082;CT + TT;Efficacy;increased response to ⮕ METFORMIN;Genotypes CT + TT is associated with increased response to metformin in people with Glucose Intolerance as compared to genotype CC.; in people with Other:Glucose Intolerance
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;TT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotypes AA + AT.; in people with Disease:Ulcerative Colitis
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2430561;AA + AT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease and Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;TT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease or Inflammatory Bowel Diseases as compared to genotypes CC + CT.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases
;WARFARIN;VKORC1L1;rs4072879;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs3804099;CC + CT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Inflammatory Bowel Diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs1816702;CT + TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype CC.; in people with Disease:Crohn Disease
;TACROLIMUS;CYP3A4;rs35599367;A;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Allele A is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation
;SUFENTANIL;OPRM1;rs1799971;G;Dosage;decreased dose of ⮕ SUFENTANIL;Allele G is associated with decreased dose of sufentanil in women with Pain as compared to allele A.; in women with Disease:Pain
;OPIOIDS;ENPP2;rs2249015;AA;Dosage;increased dose of ⮕ OPIOIDS;Genotype AA is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Other:Pain, Postoperative
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;rs429358;CC + CT;Efficacy;decreased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Genotypes CC + CT is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to genotype TT.;and in people with Disease:Alzheimer Disease
;ROSIGLITAZONE;PAX4;rs6467136;AA + AG;Efficacy;increased response to ⮕ ROSIGLITAZONE;Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;ROSIGLITAZONE;PAX4;rs6467136;AA + AG;Efficacy;increased response to ⮕ ROSIGLITAZONE;Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;ATORVASTATIN;APOE;rs429358;CT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype CT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT.; in people with Disease:Hypercholesterolemia
;OPIOIDS;ABCB1;rs1045642;AA;Dosage, Efficacy;decreased dose of ⮕ OPIOIDS;Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Disease:Pain, Postoperative
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs10499563;CC + CT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Ulcerative Colitis, Disease:Inflammatory Bowel Diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;rs2275913;AA + AG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.; in people with Disease:Ulcerative Colitis, Disease:Inflammatory Bowel Diseases
;LATANOPROST;ABCC4;rs11568658;AC;Efficacy;decreased response to ⮕ LATANOPROST;Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC.; in people with Disease:Open-angle glaucoma
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;rs1061622;GG + GT;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;Genotypes GG + GT are associated with decreased response to adalimumab, etanercept, infliximab or ustekinumab in people with Psoriasis as compared to genotype TT.;or in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;rs1554973;CC + CT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype TT.; in people with Disease:Inflammatory Bowel Diseases
;BOTULINUM TOXIN TYPE A;CALCA;rs3781719;G;Efficacy;decreased response to ⮕ BOTULINUM TOXIN TYPE A;Allele G is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele A.; in women with Other:Migraine disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;rs2569190;AA + AG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.; in people with Disease:Ulcerative Colitis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative or Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Ulcerative Colitis, Disease:Inflammatory Bowel Diseases
;BOTULINUM TOXIN TYPE A;TRPV1;rs222749;A;Efficacy;decreased response to ⮕ BOTULINUM TOXIN TYPE A;Allele A is associated with decreased response to botulinum toxin type a in women with Migraine NOS as compared to allele G.; in women with Other:Migraine disorder
;OPIOIDS;ENPP2;rs7832704;AA;Dosage;increased dose of ⮕ OPIOIDS;Genotype AA is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Other:Pain, Postoperative
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs4848306;AA + AG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG.; in people with Disease:Ulcerative Colitis, Disease:Inflammatory Bowel Diseases
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;rs4251961;CC + CT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CC + CT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.; in people with Disease:Ulcerative Colitis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6927172;CG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Ulcerative Colitis, Disease:Inflammatory Bowel Diseases
;HMG COA REDUCTASE INHIBITORS;APOE;rs429358;CC;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Alzheimer Disease as compared to genotypes CT + TT.; in people with Other:Alzheimer Disease
;LOSARTAN;ABCB1;rs1045642;AA + AG;Efficacy;increased response to ⮕ LOSARTAN;Genotypes AA + AG are associated with increased response to losartan in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;PEMETREXED;FOLR3;rs61734430;CT + TT;Efficacy;decreased response to ⮕ PEMETREXED;Genotypes CT + TT is associated with decreased response to pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype CC.; in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803217;AC + CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotypes AC + CC are associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.;and in people with Disease:Chronic hepatitis C virus infection
;METOPROLOL;GRK4;rs1801058;CT;Efficacy;decreased response to ⮕ METOPROLOL;Genotype CT is associated with decreased response to metoprolol in women with hypertensive nephrosclerosis as compared to genotype CC.; in women with Disease:hypertensive nephrosclerosis
;HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);Genotype CC is associated with increased response to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;FLUOXETINE;HTR2A;rs7997012;GG;Efficacy;increased clinical benefit to ⮕ FLUOXETINE;Genotype GG is associated with increased clinical benefit to fluoxetine in children with Depressive Disorder, Major as compared to genotypes AA + AG.; in children with Other:Major Depressive Disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG.; in people with Disease:Inflammation
;DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;rs8099917;GG + GT;Efficacy;decreased clinical benefit to ⮕ DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;Genotypes GG + GT are associated with decreased clinical benefit to direct acting antivirals, elbasvir / grazoprevir or ledipasvir / sofosbuvir in people with Hepatitis C, Chronic as compared to genotype TT.;or in people with Other:Chronic hepatitis C virus infection
;METOPROLOL;GRK4;rs2960306;GT + TT;Efficacy;decreased response to ⮕ METOPROLOL;Genotypes GT + TT are associated with decreased response to metoprolol in men with hypertensive nephrosclerosis.; in men with Disease:hypertensive nephrosclerosis
;TACROLIMUS;ABCC2;rs3740066;CT + TT;Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;ABCC2;rs3740066;CT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;METHOTREXATE;ABCC2;rs717620;CT + TT;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotypes CT + TT are associated with increased clearance of methotrexate in people with Lymphoma as compared to genotype CC.; in people with Disease:Lymphoma
;TACROLIMUS;ABCC2;rs717620;CT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;METOPROLOL;GRK4;rs1024323;CC;Efficacy;decreased response to ⮕ METOPROLOL;Genotype CC is associated with decreased response to metoprolol in men with hypertensive nephrosclerosis as compared to genotype TT.; in men with Disease:hypertensive nephrosclerosis
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes CT + TT.; in people with Disease:Inflammation
;METHADONE;GAD1;rs3762556;G;Dosage;increased dose of ⮕ METHADONE;Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele C.; in people with Other:Heroin Dependence
;INFLIXIMAB;IL1B;rs1143634;GG;Efficacy;decreased response to ⮕ INFLIXIMAB;Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG.; in people with Disease:Crohn Disease
;METHADONE;GAD1;rs769404;TT;Dosage;decreased dose of ⮕ METHADONE;Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.; in people with Other:Heroin Dependence
;ROCURONIUM;SLCO1A2;rs3834939;T/del + TT;Metabolism/PK;decreased clearance of ⮕ ROCURONIUM;Genotypes T/del + TT are associated with decreased clearance of rocuronium in healthy individuals as compared to genotype del/del.; in healthy individuals 
;CLOZAPINE;CYP1A2;rs762551;AA + AC;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Genotypes AA + AC are associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype CC.; in people with Other:Schizophrenia
;ARIPIPRAZOLE;CYP2D6;rs1058164;GG;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.; in healthy individuals 
;ARIPIPRAZOLE;CYP2D6;rs28371699;AA;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;Genotype AA is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;TICAGRELOR;CYP4F2;rs2074900;AA;Metabolism/PK;decreased clearance of ⮕ TICAGRELOR;Genotype AA is associated with decreased clearance of ticagrelor in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;ACENOCOUMAROL;VKORC1;rs9934438;GG;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype GG is associated with increased dose of acenocoumarol as compared to genotypes AA + AG.;  
;CAPECITABINE;DPYD;rs67376798;AT;Dosage;decreased dose of ⮕ CAPECITABINE;Genotype AT is associated with decreased dose of capecitabine in people with Colorectal Neoplasms as compared to genotype TT.; in people with Disease:Colorectal Neoplasms
;CLOZAPINE;UGT1A4;rs2011404;C;Metabolism/PK;increased concentrations of ⮕ CLOZAPINE;Allele C is associated with increased concentrations of clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele T.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;CAPECITABINE;DPYD;rs3918290;CT;Dosage;decreased dose of ⮕ CAPECITABINE;Genotype CT is associated with decreased dose of capecitabine in people with Colorectal Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms
;URIC ACID;VEGFC;rs1002976;C;Metabolism/PK;increased concentrations of ⮕ URIC ACID;Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.; in people with Disease:Hypertension
;LETERMOVIR;SLCO1B1;rs4149032;TT;Metabolism/PK;decreased exposure to ⮕ LETERMOVIR;Genotype TT is associated with decreased exposure to letermovir as compared to genotypes CC + CT.;  
;CLOZAPINE;UGT1A1;rs34946978;T;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Allele T is associated with decreased concentrations of clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele C.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;METFORMIN;CAPN10;rs3792269;G;Efficacy;decreased response to ⮕ METFORMIN;Allele G is associated with decreased response to metformin in people with Diabetes Mellitus as compared to allele A.; in people with Disease:Diabetes Mellitus
;LETERMOVIR;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased exposure to ⮕ LETERMOVIR;Genotypes CC + CT are associated with increased exposure to letermovir as compared to genotype TT.;  
;LETERMOVIR;UGT1A1;rs4148323;AA + AG;Metabolism/PK;increased exposure to ⮕ LETERMOVIR;Genotypes AA + AG are associated with increased exposure to letermovir as compared to genotype GG.;  
;INTERFERON BETA-1A, INTERFERON BETA-1B;FHIT;rs760316;C;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.;and in people with Disease:Multiple Sclerosis
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;GLYBURIDE;FMO2;rs7512785;T;Efficacy;increased response to ⮕ GLYBURIDE;Allele T is associated with increased response to glibenclamide in people with as compared to allele C.; in people with 
;METHOTREXATE;MTRR;rs1801394;AG + GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA.; in children with Disease:Juvenile Rheumatoid Arthritis
;PROPRANOLOL;ADRB2;rs1042713;GG;Efficacy;increased response to ⮕ PROPRANOLOL;Genotype GG is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype AA.; in people with Disease:Liver Cirrhosis
;METHOTREXATE;ABCB1;rs1128503;AA;Efficacy;increased response to ⮕ METHOTREXATE;Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.; in children with Disease:Juvenile Rheumatoid Arthritis
;METHOTREXATE;ABCB1;rs1045642;AA;Efficacy;increased response to ⮕ METHOTREXATE;Genotype AA is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.; in children with Disease:Juvenile Rheumatoid Arthritis
;CLOZAPINE;ABCB1;rs10248420;G;Efficacy;increased clinical benefit to ⮕ CLOZAPINE;Allele G is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele A.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;METHOTREXATE;SLC16A7;rs3763980;A;Efficacy;decreased response to ⮕ METHOTREXATE;Allele A is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.; in children with Disease:Juvenile Rheumatoid Arthritis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;Allele C is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele T.;or in people with Disease:Hepatitis B, Chronic
;METHOTREXATE;SLC16A7;rs12231740;T;Efficacy;decreased response to ⮕ METHOTREXATE;Allele T is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele C.; in children with Disease:Juvenile Rheumatoid Arthritis
;METHOTREXATE;ARID5B;rs4948496;CC;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype CC is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.; in children with Disease:Acute lymphoblastic leukemia
;CLOZAPINE;UGT1A1;rs4148323;A;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Allele A is associated with decreased concentrations of clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele G.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;FENOFIBRATE;APOE;rs7412;CT + TT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes CT + TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;METHOTREXATE;SLCO1B1;rs4149056;TT;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Disease:Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs8099917;T;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;Allele T is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele G.;or in people with Disease:Hepatitis B, Chronic
;METHADONE;GAD1;rs3762555;G;Dosage;increased dose of ⮕ METHADONE;Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele C.; in people with Other:Heroin Dependence
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG.; in children with Disease:Juvenile Rheumatoid Arthritis
;METHADONE;GAD1;rs3749034;G;Dosage;increased dose of ⮕ METHADONE;Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele A.; in people with Other:Heroin Dependence
;CLOZAPINE;ABCB1;rs7787082;A;Efficacy;increased clinical benefit to ⮕ CLOZAPINE;Allele A is associated with increased clinical benefit to clozapine in people with Schizophrenia or Psychotic Disorder as compared to allele G.; in people with Other:Schizophrenia, Other:Psychotic Disorder
;IGURATIMOD;NAT2;rs1495741;AG + GG;Efficacy;decreased clinical benefit to ⮕ IGURATIMOD;Genotypes AG + GG is associated with decreased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4278350;T;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.;and in people with Disease:Multiple Sclerosis
;ARIPIPRAZOLE;CYP2D6;rs28371702;CC;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;Genotype CC is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;rs163184;GG + GT;Efficacy;decreased clinical benefit to ⮕ SITAGLIPTIN, VILDAGLIPTIN;Genotypes GG + GT is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.;or in people with Other:Diabetes Mellitus, Type 2
;IGURATIMOD;ABCG2;rs2231142;GT + TT;Efficacy;increased clinical benefit to ⮕ IGURATIMOD;Genotypes GT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DESIPRAMINE;CYP2D6 poor metabolizer is associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs2291858;G;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.;and in people with Disease:Multiple Sclerosis
;METHADONE;OPRD1;rs204047;GG;Dosage;increased dose of ⮕ METHADONE;Genotype GG is associated with increased dose of methadone as compared to genotypes GT + TT.;  
;METHADONE;OPRD1;rs797397;AA;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype AA is associated with increased concentrations of methadone as compared to genotypes AG + GG.;  
;METHADONE;OPRD1;rs204047;GG;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype GG is associated with increased concentrations of methadone as compared to genotypes GT + TT.;  
;ANTIPSYCHOTICS;ZNF804A;rs1344706;AA;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Genotype AA is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotypes AC + CC.; in people with Disease:Schizophrenia
;PLATINUM COMPOUNDS;XRCC1;rs25487;CC + CT;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes CC + CT are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10819043;T;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele T is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele C.;and in people with Disease:Multiple Sclerosis
;INTERFERON BETA-1A, INTERFERON BETA-1B;;rs3133084;A;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.;and in people with Disease:Multiple Sclerosis
;CAPECITABINE, DOCETAXEL;CYP1A1;rs1048943;AG + GG;Efficacy;increased response to ⮕ CAPECITABINE, DOCETAXEL;Genotypes AG + GG are associated with increased response to capecitabine and docetaxel in women with Breast Neoplasms as compared to genotype AA.;and in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in healthy individuals as compared to genotype CC.; in healthy individuals 
;GLYBURIDE;CYP51A1;rs7793861;G;Efficacy;increased response to ⮕ GLYBURIDE;Allele G is associated with increased response to glibenclamide in people with as compared to allele C.; in people with 
;INTERFERON BETA-1A, INTERFERON BETA-1B;;rs1448673;G;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele G is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.;and in people with Disease:Multiple Sclerosis
;GLYBURIDE;FMO2;rs7515157;T;Efficacy;increased response to ⮕ GLYBURIDE;Allele T is associated with increased response to glibenclamide in people with as compared to allele C.; in people with 
;ANASTROZOLE;ABCB1;rs2032582;AA;Metabolism/PK;increased concentrations of ⮕ ANASTROZOLE;Genotype AA is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.; in women with Disease:Breast Neoplasms
;AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;rs10042486;TT;Efficacy;increased response to ⮕ AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;Genotype TT is associated with increased response to amisulpride, antipsychotics, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to genotypes CC + CT.;or in people with Disease:Schizophrenia
;URIC ACID;BRINP3;rs950569;T;Metabolism/PK;increased concentrations of ⮕ URIC ACID;Allele T is associated with increased concentrations of uric acid in people with Hypertension as compared to allele G.; in people with Disease:Hypertension
;GLYBURIDE;UGT2B15;rs4148269;G;Efficacy;increased response to ⮕ GLYBURIDE;Allele G is associated with increased response to glibenclamide in people with as compared to allele T.; in people with 
;INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10760397;C;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele C is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele T.;and in people with Disease:Multiple Sclerosis
;URIC ACID;PADI4;rs2477134;G;Metabolism/PK;increased concentrations of ⮕ URIC ACID;Allele G is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.; in people with Disease:Hypertension
;INTERFERON BETA-1A, INTERFERON BETA-1B;ZNF697;rs10494227;A;Efficacy;increased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G.;and in people with Disease:Multiple Sclerosis
;DOXORUBICIN;ABCC5;rs1533682;TT;Metabolism/PK;increased clearance of ⮕ DOXORUBICIN;Genotype TT is associated with increased clearance of doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CT.; in women with Disease:Breast Neoplasms
;PLATINUM COMPOUNDS;XRCC3;rs861539;AA + AG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;GLYBURIDE;MAPK1;rs1803545;A;Efficacy;increased response to ⮕ GLYBURIDE;Allele A is associated with increased response to glibenclamide in people with as compared to allele G.; in people with 
;GLYBURIDE;ABCC5;rs3749442;A;Efficacy;increased response to ⮕ GLYBURIDE;Allele A is associated with increased response to glibenclamide in people with as compared to allele G.; in people with 
;ARIPIPRAZOLE;CYP2D6;rs1135840;GG;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE;Genotype GG is associated with increased concentrations of aripiprazole in healthy individuals as compared to genotypes CC + CG.; in healthy individuals 
;GLYBURIDE;SPINK5;rs2303070;T;Efficacy;increased response to ⮕ GLYBURIDE;Allele T is associated with increased response to glibenclamide in people with as compared to allele G.; in people with 
;GLYBURIDE;BDKRB2;rs5224;A;Efficacy;increased response to ⮕ GLYBURIDE;Allele A is associated with increased response to glibenclamide in people with as compared to allele G.; in people with 
;GLYBURIDE;MAPK1;rs3729910;G;Efficacy;increased response to ⮕ GLYBURIDE;Allele G is associated with increased response to glibenclamide in people with as compared to allele A.; in people with 
;IGURATIMOD;ABCB1;rs2032582;CT + TT;Efficacy;increased clinical benefit to ⮕ IGURATIMOD;Genotypes CT + TT is associated with increased clinical benefit to iguratimod in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;ETHANOL;KLB;rs11940694;A;Toxicity;decreased dose of ⮕ ETHANOL;Allele A is associated with decreased dose of ethanol as compared to allele G.;  
;PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;GLYBURIDE;ESR1;rs2077647;T;Efficacy;increased response to ⮕ GLYBURIDE;Allele T is associated with increased response to glibenclamide in people with as compared to allele C.; in people with 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid, Autoimmune Diseases or Psoriasis as compared to allele A.; in people with Other:Rheumatoid arthritis, Other:Autoimmune Diseases, Other:Psoriasis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;ANTIDEPRESSANTS;BDNF;rs6265;C;Efficacy;increased resistance to ⮕ ANTIDEPRESSANTS;Allele C is associated with increased resistance to antidepressants as compared to allele T.;  
;FLUNISOLIDE;TBXT;rs2305089;TT;Efficacy;increased response to ⮕ FLUNISOLIDE;Genotype TT is associated with increased response to flunisolide in people with Asthma as compared to genotypes CC + CT.; in people with Disease:Asthma
;GRANISETRON, PALONOSETRON;ERCC1;rs3212986;AC + CC;Efficacy;increased response to ⮕ GRANISETRON, PALONOSETRON;Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA.;or in people with Side Effect:Nausea, Side Effect:Vomiting
;TACROLIMUS;IL6;rs1800795;GG;Efficacy;decreased clinical benefit to ⮕ TACROLIMUS;Genotype GG is associated with decreased clinical benefit to tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CG.; in people with Other:Kidney Transplantation
;VALPROIC ACID;CYP2D6;rs3892097;CT + TT;Efficacy;decreased clinical benefit to ⮕ VALPROIC ACID;Genotypes CT + TT is associated with decreased clinical benefit to valproic acid in people with Epilepsy as compared to genotype CC.; in people with Other:Epilepsy
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;T;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele T is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele G.; in people with Other:Psoriasis
;TACROLIMUS;IL6;rs1800795;GG;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype GG is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CG.; in people with Other:Kidney Transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele T.; in people with Other:Psoriasis
;TACROLIMUS;CYP3A4;rs4646437;GG;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Disease:Kidney Transplantation
;RASAGILINE;DRD2;rs1076560;CC;Efficacy;increased response to ⮕ RASAGILINE;Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.; in people with Disease:Parkinson Disease
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2242480;CC;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;RASAGILINE;DRD2;rs2283265;CC;Efficacy;increased response to ⮕ RASAGILINE;Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC.; in people with Disease:Parkinson Disease
;TACROLIMUS;CYP3A4;rs4646437;GG;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CTLA4;rs4553808;AG + GG;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotypes AG + GG is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;ANTIDEPRESSANTS;BDNF-AS;rs10501087;T;Efficacy;increased resistance to ⮕ ANTIDEPRESSANTS;Allele T is associated with increased resistance to antidepressants as compared to allele C.;  
;TACROLIMUS;IL3;rs181781;AA;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DESIPRAMINE;CYP2D6 poor metabolizer is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;LAMOTRIGINE;UGT1A4;rs6755571;CC;Metabolism/PK;decreased concentrations of ⮕ LAMOTRIGINE;Genotype CC is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotype AC.; in women with Other:Epilepsy
;WARFARIN;CYP2C9;rs4917639;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;TELAPREVIR;CYP24A1;rs2585428;C;Metabolism/PK;decreased trough concentration of ⮕ TELAPREVIR;Allele C is associated with decreased trough concentration of telaprevir in people with Hepatitis C as compared to allele T.; in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CTLA4;rs4553808;AA;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype AA is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2242480;CC;Metabolism/PK;increased exposure to ⮕ TACROLIMUS;Genotype CC is associated with increased exposure to tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;VARENICLINE;CHRNA4;rs1044396;GG;Efficacy;decreased response to ⮕ VARENICLINE;Genotype GG is associated with decreased response to varenicline in people with Tobacco Use Disorder as compared to genotypes AA + AG.; in people with Disease:Tobacco Use Disorder
;ESCITALOPRAM;CYP1A2;rs4646425;T;Metabolism/PK;increased metabolism of ⮕ ESCITALOPRAM;Allele T is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP1A2;rs2069526;G;Metabolism/PK;increased metabolism of ⮕ ESCITALOPRAM;Allele G is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP1A2;rs4646427;C;Metabolism/PK;increased metabolism of ⮕ ESCITALOPRAM;Allele C is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;PLATINUM COMPOUNDS;HSPA5;rs430397;TT;Efficacy;increased resistance to ⮕ PLATINUM COMPOUNDS;Genotype TT is associated with increased resistance to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; in people with Disease:Non-Small Cell Lung Carcinoma
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;A;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele A is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.; in people with Other:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylarthropathy as compared to allele A.; in people with Other:Spondylarthropathies
;EFAVIRENZ;CYP2B6;rs2279343;GG;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.; in people with Disease:HIV infectious disease
;MORPHINE;ABCB1;rs1045642;AA;Metabolism/PK;increased metabolism of ⮕ MORPHINE;Genotype AA is associated with increased metabolism of morphine in children as compared to genotypes AG + GG.; in children 
;CLOPIDOGREL;P2RY12;rs6785930;AA + AG;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.;  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;GT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CLOPIDOGREL;P2RY12;rs6809699;AA + AC;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotypes AA + AC is associated with increased resistance to clopidogrel as compared to genotype CC.;  
;EFAVIRENZ;CYP2B6;rs2279343;AG;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype AG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele A.; in people with Other:Psoriasis
;FLUTICASONE PROPIONATE;ORMDL3;rs2872507;AA + AG;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE;Genotypes AA + AG are associated with increased response to fluticasone propionate in children with Asthma as compared to genotype GG.; in children with Disease:Asthma
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;RITUXIMAB;FCGR3A;rs396991;AC + CC;Efficacy;increased response to ⮕ RITUXIMAB;Genotypes AC + CC is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Other:Rheumatoid arthritis
;ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;Efficacy;increased response to ⮕ ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG is associated with increased response to abatacept, rituximab, tocilizumab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype AA.;or in people with Other:Rheumatoid arthritis
;VALPROIC ACID;CYP2C9;rs1057910;AC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ VALPROIC ACID;Genotype AC is associated with increased dose-adjusted trough concentrations of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Other:Epilepsy
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Disease:Kidney Transplantation
;WARFARIN;CALU;rs339097;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin.;  
;ATAZANAVIR / RITONAVIR;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ATAZANAVIR / RITONAVIR;Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;DEFERASIROX;ABCG2;rs13120400;CT + TT;Metabolism/PK;increased exposure to ⮕ DEFERASIROX;Genotypes CT + TT is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype CC.; in children with Disease:Beta-thalassemia and related diseases
;ATAZANAVIR / RITONAVIR;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ ATAZANAVIR / RITONAVIR;Genotype CC is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotypes CT + TT.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;rs10509680;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele G.;  
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;rs7975232;AA + AC;Efficacy;increased clinical benefit to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;Genotypes AA + AC is associated with increased clinical benefit to adalimumab, certolizumab pegol, etanercept, golimumab or infliximab in people with Arthritis, Rheumatoid as compared to genotype CC.;or in people with Other:Rheumatoid arthritis
;ANGIOTENSIN II;AGTR1;rs5186;AA;Efficacy;increased response to ⮕ ANGIOTENSIN II;Genotype AA is associated with increased response to angiotensin II in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased clearance of ⮕ DESIPRAMINE;CYP2D6 poor metabolizer is associated with decreased clearance of desipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;ANTIEPILEPTICS;NR3C1;rs41423247;GG;Efficacy;decreased clinical benefit to ⮕ ANTIEPILEPTICS;Genotype GG is associated with decreased clinical benefit to antiepileptics in children with Epilepsy as compared to genotypes CC + CG.; in children with Other:Epilepsy
;DEFERASIROX;ABCC2;rs2273697;AG;Metabolism/PK;increased exposure to ⮕ DEFERASIROX;Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG.; in children with Disease:Beta-thalassemia and related diseases
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;FLUVASTATIN;APOE;rs7412;CT;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype CT is associated with increased response to fluvastatin as compared to genotype CC.;  
;METFORMIN;SLC47A1;rs2289669;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.; in people with Disease:Diabetes Mellitus, Type 2
;TALINOLOL;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ TALINOLOL;Genotype AA is associated with increased clearance of talinolol in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;LAMOTRIGINE;UGT2B7;rs7439366;TT;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes CC + CT.; in people with Other:Epilepsy
;TACROLIMUS;CYP3A4;rs2740574;CC + CT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CC + CT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Disease:Kidney Transplantation
;RITODRINE;PDE4B;rs598961;AA;Efficacy;decreased clinical benefit to ⮕ RITODRINE;Genotype AA is associated with decreased clinical benefit to ritodrine in women with Premature Birth as compared to genotypes AG + GG.; in women with Other:Premature Birth
;TACROLIMUS;CYP3A4;rs4986910;G;Dosage, Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A.; in people with Disease:Kidney Transplantation
;ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ ACENOCOUMAROL, WARFARIN;Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC.;or  
;LAMOTRIGINE;UGT2B15;rs1902023;AA;Metabolism/PK;decreased concentrations of ⮕ LAMOTRIGINE;Genotype AA is associated with decreased concentrations of lamotrigine in women with Epilepsy as compared to genotypes AC + CC.; in women with Other:Epilepsy
;DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;poor metabolizer decreased metabolism of ⮕ DESIPRAMINE;CYP2D6 poor metabolizer is associated with decreased metabolism of desipramine in healthy individuals as compared to CYP2D6 normal metabolizer.; in healthy individuals 
;PLATINUM COMPOUNDS;XPA;rs1800975;CC;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs2032582;CC;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;Genotype CC is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.;and  
;ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1045642;GG;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.;and  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1128503;GG;Metabolism/PK;increased concentrations of ⮕ ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;Genotype GG is associated with increased concentrations of aripiprazole and dehydroaripiprazole as compared to genotype AA.;and  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;TACROLIMUS;IL10;rs1800871;AA;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype AA is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Other:Kidney Transplantation
;ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;rs3918242;CT;Efficacy;decreased response to ⮕ ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;Genotype CT is associated with decreased response to Antihypertensives, hydralazine, Methyldopa or nifedipine in people with Gestational hypertension as compared to genotype CC.;or in people with Disease:Gestational hypertension
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin in people with Rheumatic Heart Disease, Atrial Fibrillation, Heart Valve Diseases or Coronary Artery Disease.; in people with Other:Rheumatic Heart Disease, Other:Atrial Fibrillation, Other:Heart Valve Diseases, Other:Coronary Artery Disease
;DACLATASVIR;VDR;rs11568820;TT;Metabolism/PK;decreased concentrations of ⮕ DACLATASVIR;Genotype TT is associated with decreased concentrations of daclatasvir in people with Hepatitis C as compared to genotypes CC + CT.; in people with Disease:Hepatitis C virus infection
;MORPHINE;COMT;rs4680;AG + GG;Efficacy;increased dose of ⮕ MORPHINE;Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA.;  
;METHYLDOPA;MMP9;rs3918242;CT + TT;Efficacy;decreased response to ⮕ METHYLDOPA;Genotypes CT + TT are associated with decreased response to Methyldopa in people with Gestational hypertension as compared to genotype CC.; in people with Disease:Gestational hypertension
;DACLATASVIR;CYP24A1;rs2248359;CT + TT;Metabolism/PK;increased concentrations of ⮕ DACLATASVIR;Genotypes CT + TT is associated with increased concentrations of daclatasvir in people with Hepatitis C as compared to genotype CC.; in people with Disease:Hepatitis C virus infection
;TACROLIMUS;ABCB1;rs1045642;AG + GG;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes AG + GG are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;Efficacy;resistance to ⮕ CARBAMAZEPINE, OXCARBAZEPINE;Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.;or in people with Disease:Epilepsy
;METOPROLOL;ADRB1;rs1801252;AA;Efficacy;increased response to ⮕ METOPROLOL;Genotype AA is associated with increased response to metoprolol in people with Essential hypertension as compared to genotype AG.; in people with Disease:Essential hypertension
;METOPROLOL;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ METOPROLOL;Genotype CC is associated with increased response to metoprolol in people with Essential hypertension as compared to genotypes CG + GG.; in people with Disease:Essential hypertension
;CALCIUM CHANNEL BLOCKERS;NUMA1;rs10898815;GG;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;Efficacy;resistance to ⮕ CARBAMAZEPINE, OXCARBAZEPINE;Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.;or in people with Disease:Epilepsy
;CALCIUM CHANNEL BLOCKERS;TANC2;rs2429427;GG;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;SIBUTRAMINE;GNB3;rs5443;CC;Efficacy;increased response to ⮕ SIBUTRAMINE;Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT.; in people with Other:Obesity
;CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;rs2273697;AG;Efficacy;resistance to ⮕ CARBAMAZEPINE, OXCARBAZEPINE;Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.;or in people with Disease:Epilepsy
;BUSULFAN;GSTA1;rs3957356;T;Metabolism/PK;decreased clearance of ⮕ BUSULFAN;Allele T is associated with decreased clearance of busulfan in children with hematopoietic stem cell transplantation as compared to allele C.; in children with Other:Hematopoietic stem cell transplantation
;S-EDDP;CYP2B6;rs8192709;CT;Metabolism/PK;increased concentrations of ⮕ S-EDDP;Genotype CT is associated with increased concentrations of (S)-EDDP as compared to genotype CC.;  
;BUSULFAN;GSTA1;rs3957357;A;Metabolism/PK;decreased clearance of ⮕ BUSULFAN;Allele A is associated with decreased clearance of busulfan in children with hematopoietic stem cell transplantation as compared to allele G.; in children with Other:Hematopoietic stem cell transplantation
;SIMVASTATIN;UGT1A9;rs12052787;T;Efficacy;increased response to ⮕ SIMVASTATIN;Allele T is associated with increased response to simvastatin as compared to allele C.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;SIMVASTATIN;UGT1A9;rs2003569;A;Efficacy;increased response to ⮕ SIMVASTATIN;Allele A is associated with increased response to simvastatin as compared to allele G.;  
;PLATINUM COMPOUNDS;ERCC4;rs1799801;TT;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotype TT is associated with decreased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.; in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;Dosage, Efficacy;decreased dose of ⮕ AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;Genotype TT is associated with decreased dose of amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.;or in people with Disease:Depression
;PLATINUM COMPOUNDS;ERCC3;rs3738948;AG + GG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AG + GG is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.; in people with Disease:Non-Small Cell Lung Carcinoma
;TEGAFUR;CYP2A6;rs8192720;AA + AG;Metabolism/PK;increased metabolism of ⮕ TEGAFUR;Genotypes AA + AG are associated with increased metabolism of tegafur as compared to genotype GG.;  
;DIGOXIN;ABCB1;rs1045642;AA + AG;Metabolism/PK;decreased dose of ⮕ DIGOXIN;Genotypes AA + AG are associated with decreased dose of digoxin in healthy individuals as compared to genotype GG.; in healthy individuals 
;ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;rs1801133;AG;Efficacy;decreased clinical benefit to ⮕ ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;Genotype AG is associated with decreased clinical benefit to antipsychotics, chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine or risperidone in women with Schizophrenia as compared to genotype GG.;or in women with Other:Schizophrenia
;OXYCODONE;UGT2B7;rs7439366;TT;Efficacy;decreased response to ⮕ OXYCODONE;Genotype TT is associated with decreased response to oxycodone in people with Neoplasms and Pain as compared to genotype CC.; in people with Disease:Neoplasms, Disease:Pain
;TERBUTALINE;ADRB2;rs1042714;GG;Metabolism/PK;increased response to ⮕ TERBUTALINE;Genotype GG is associated with increased response to terbutaline in healthy individuals as compared to genotypes CC + CG.; in healthy individuals 
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;BUPROPION;CYP2B6;rs3745274;T;Metabolism/PK;increased exposure to ⮕ BUPROPION;Allele T is associated with increased exposure to bupropion in people with Depressive Disorder, Major as compared to allele G.; in people with Other:Major Depressive Disorder
;RISPERIDONE;HRH4;rs4483927;TT;Efficacy;decreased response to ⮕ RISPERIDONE;Genotype TT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotypes GG + GT.; in people with Disease:Schizophrenia
;ATENOLOL;GRK4;rs2960306;T;Efficacy;decreased response to ⮕ ATENOLOL;Allele T is associated with decreased response to atenolol in people with Hypertension as compared to allele G.; in people with Disease:Hypertension
;ATENOLOL;GRK4;rs1024323;T;Efficacy;decreased response to ⮕ ATENOLOL;Allele T is associated with decreased response to atenolol in people with Hypertension as compared to allele C.; in people with Disease:Hypertension
;CALCIUM CHANNEL BLOCKERS;PICALM;rs588076;GG;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ DELEOBUVIR, FALDAPREVIR;Genotype CC is associated with increased response to deleobuvir and faldaprevir in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in children as compared to allele C.; in children 
;PROPOFOL;GABRA2;rs11503014;CC;Other;decreased response to ⮕ PROPOFOL;Genotype CC is associated with decreased response to propofol as compared to genotypes CG + GG.;  
;WARFARIN;HNF4A;rs3212198;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.; in people with Disease:Heart valve replacement
;CODEINE, TRAMADOL;CYP1B1;rs1056836;C;Efficacy;decreased clinical benefit to ⮕ CODEINE, TRAMADOL;Allele C is associated with decreased clinical benefit to codeine or tramadol in men with Pain as compared to allele G.;or in men with Other:Pain
;ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;Efficacy;decreased response to ⮕ ERLOTINIB, GEFITINIB;Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;or in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;NR1I3;rs2501873;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.; in people with Disease:Heart valve replacement
;VERAPAMIL;PCDHB8;rs3733694;G;Efficacy;decreased clinical benefit to ⮕ VERAPAMIL;Allele G is associated with decreased clinical benefit to verapamil in people with Migraine NOS as compared to allele A.; in people with Other:Migraine disorder
;RIVAROXABAN;POR;rs1057868;TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ RIVAROXABAN;Genotype TT is associated with decreased dose-adjusted trough concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CC + CT.; in people with Other:Atrial Fibrillation
;VERAPAMIL;PCDHB6;rs17844444;A;Efficacy;decreased clinical benefit to ⮕ VERAPAMIL;Allele A is associated with decreased clinical benefit to verapamil in people with Migraine NOS as compared to allele G.; in people with Other:Migraine disorder
;CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;rs61764370;AC;Efficacy;increased response to ⮕ CAPECITABINE, CETUXIMAB, OXALIPLATIN;Genotype AC is associated with increased response to capecitabine, cetuximab and oxaliplatin in people with Rectal Neoplasms as compared to genotype AA.;and in people with Disease:Rectal Neoplasms
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;Metabolism/PK;increased exposure to ⮕ SIMVASTATIN ACID;Genotype CT is associated with increased exposure to simvastatin acid as compared to genotype TT.;  
;ATORVASTATIN;AGTR1;rs5186;AC;Metabolism/PK;increased exposure to ⮕ ATORVASTATIN;Genotype AC is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes AA + CC.; in healthy individuals 
;ATORVASTATIN;BDKRB2;rs1799722;CT;Metabolism/PK;increased exposure to ⮕ ATORVASTATIN;Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT.; in healthy individuals 
;LOSARTAN;AGTR1;rs5186;AA;Efficacy;increased response to ⮕ LOSARTAN;Genotype AA is associated with increased response to losartan in people with Liver Cirrhosis as compared to genotypes AC + CC.; in people with Disease:Liver Cirrhosis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;HEROIN;OPRM1;rs9479757;AG;Dosage;increased dose of ⮕ HEROIN;Genotype AG is associated with increased dose of heroin in people with Heroin Dependence as compared to genotype GG.; in people with Disease:Heroin Dependence
;5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;T;Metabolism/PK;increased concentrations of ⮕ 5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;Allele T is associated with increased concentrations of 5-hydroxyindole-3-acetic acid and serotonin in men with Depressive Disorder, Major as compared to allele C.;and in men with Other:Major Depressive Disorder
;ANTIDEPRESSANTS;GRIK4;rs1954787;CC;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;RIVAROXABAN;ABCB1;rs4148738;CT;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Genotype CT is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.; in people with Other:Atrial Fibrillation
;5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;TT;Metabolism/PK;increased concentrations of ⮕ 5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;Genotype TT is associated with increased concentrations of 5-hydroxyindole-3-acetic acid and serotonin in women with Depressive Disorder, Major as compared to genotype CC.;and in women with Other:Major Depressive Disorder
;APIXABAN;POR;rs1057868;T;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ APIXABAN;Allele T is associated with decreased dose-adjusted trough concentrations of apixaban in people with Atrial Fibrillation as compared to allele C.; in people with Other:Atrial Fibrillation
;OXCARBAZEPINE;UGT1A9;rs2741049;CC;Efficacy;increased response to ⮕ OXCARBAZEPINE;Genotype CC is associated with increased response to oxcarbazepine in people with Seizures as compared to genotypes CT + TT.; in people with Disease:Seizures
;CODEINE, TRAMADOL;CYP1B1;rs1056837;A;Efficacy;decreased clinical benefit to ⮕ CODEINE, TRAMADOL;Allele A is associated with decreased clinical benefit to codeine or tramadol in men with Pain as compared to allele G.;or in men with Other:Pain
;CANDESARTAN;CYP11B2;rs1799998;GG;Efficacy;increased response to ⮕ CANDESARTAN;Genotype GG is associated with increased response to candesartan in people with Hypertension as compared to genotypes AA + AG.; in people with Disease:Hypertension
;3-HYDROXYCOTININE;;rs4105144;CC + CT;Metabolism/PK;increased concentrations of ⮕ 3-HYDROXYCOTININE;Genotypes CC + CT are associated with increased concentrations of 3-hydroxycotinine in people with Tobacco Use Disorder as compared to genotype TT.; in people with Other:Tobacco Use Disorder
;HYDROCODONE, OXYCODONE;CYP2D6;rs35742686;DELT;Efficacy;increased clinical benefit to ⮕ HYDROCODONE, OXYCODONE;Allele DELT is associated with increased clinical benefit to hydrocodone or oxycodone in people with Pain as compared to allele T.;or in people with Other:Pain
;3-HYDROXYCOTININE;EGLN2;rs3733829;AA + AG;Metabolism/PK;decreased concentrations of ⮕ 3-HYDROXYCOTININE;Genotypes AA + AG are associated with decreased concentrations of 3-hydroxycotinine in people with Tobacco Use Disorder as compared to genotype GG.; in people with Other:Tobacco Use Disorder
;HYDROCODONE, OXYCODONE;MACROD2;rs76026520;G;Efficacy;increased clinical benefit to ⮕ HYDROCODONE, OXYCODONE;Allele G is associated with increased clinical benefit to hydrocodone or oxycodone in people with Pain as compared to allele A.;or in people with Other:Pain
;CLONIDINE;GNB3;rs5443;CT + TT;Efficacy;increased response to ⮕ CLONIDINE;Genotypes CT + TT are associated with increased response to clonidine in healthy individuals as compared to genotype CC.; in healthy individuals 
;BENAZEPRIL;MTHFR;rs1801133;AA;Efficacy;increased response to ⮕ BENAZEPRIL;Genotype AA is associated with increased response to benazepril in people with Hypertension as compared to genotypes AG + GG.; in people with Disease:Hypertension
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;DEFERASIROX;CYP1A1;rs2606345;AC + CC;Metabolism/PK;increased trough concentration of ⮕ DEFERASIROX;Genotypes AC + CC is associated with increased trough concentration of deferasirox in children with beta-Thalassemia as compared to genotype AA.; in children with Disease:Beta-thalassemia and related diseases
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PITRAKINRA;IL4R;rs1029489;GG;Efficacy;increased response to ⮕ PITRAKINRA;Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.; in people with Disease:Asthma
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;RADIOTHERAPY;CACNA2D3;rs11130424;AG + GG;Efficacy;increased resistance to ⮕ RADIOTHERAPY;Genotypes AG + GG is associated with increased resistance to radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotype AA.; in people with Other:Nasopharyngeal Neoplasms
;HYDROXYUREA;MAP3K5;rs9483947;CC;Efficacy;increased clinical benefit to ⮕ HYDROXYUREA;Genotype CC is associated with increased clinical benefit to hydroxyurea in people with Beta-thalassemia and related diseases.; in people with Other:Beta-thalassemia and related diseases
;ANTIHYPERTENSIVES;CLNK;rs13144136;G;Efficacy;increased response to ⮕ ANTIHYPERTENSIVES;Allele G is associated with increased response to Antihypertensives in people with Hypertension as compared to allele T.; in people with Disease:Hypertension
;HYDROXYUREA;MAP3K5;rs9376230;CC;Efficacy;increased clinical benefit to ⮕ HYDROXYUREA;Genotype CC is associated with increased clinical benefit to hydroxyurea in people with Beta-thalassemia and related diseases.; in people with Other:Beta-thalassemia and related diseases
;IMATINIB;ABCB1;rs1128503;GG;Efficacy;decreased response to ⮕ IMATINIB;Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;ABCB1;rs1045642;AA;Efficacy;increased response to ⮕ IMATINIB;Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;ATORVASTATIN;ABCC2;rs717620;CT + TT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotypes CT + TT are associated with decreased response to atorvastatin in men with Hypercholesterolemia as compared to genotype CC.; in men with Disease:Hypercholesterolemia
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;LENALIDOMIDE, THALIDOMIDE;FGF2;rs308395;CG + GG;Efficacy;decreased response to ⮕ LENALIDOMIDE, THALIDOMIDE;Genotypes CG + GG is associated with decreased response to lenalidomide or thalidomide in people with Multiple Myeloma as compared to genotype CC.;or in people with Disease:Multiple Myeloma
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;METHOTREXATE;ABCC2;rs717620;CT + TT;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Other:Acute lymphoblastic leukemia
;ANTIDEPRESSANTS;MAOA;rs979605;AA;Metabolism/PK;decreased clinical benefit to ⮕ ANTIDEPRESSANTS;Genotype AA is associated with decreased clinical benefit to antidepressants in people with Depressive Disorder, Major as compared to allele A.; in people with Other:Major Depressive Disorder
;METHOTREXATE;ABCB1;rs1045642;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; in people with Disease:Rheumatoid arthritis
;ANTIDEPRESSANTS;GRIK4;rs1954787;C;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;ETHANOL;ALDH2;rs671;AG;Other;increased exposure to ⮕ ETHANOL;Genotype AG is associated with increased exposure to ethanol in men as compared to genotype GG.; in men 
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Disease:Kidney Transplantation
;HYDROCHLOROTHIAZIDE;NEDD4L;rs292449;CC + CG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes CC + CG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;PITRAKINRA;IL4R;rs8832;GG;Efficacy;increased response to ⮕ PITRAKINRA;Genotype GG is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AA + AG.; in people with Disease:Asthma
;TACROLIMUS;CYP3A5;rs776746;T;Dosage;increased dose of ⮕ TACROLIMUS;Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation
;PITRAKINRA;IL4R;rs3024530;AA;Efficacy;increased response to ⮕ PITRAKINRA;Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.; in people with Disease:Asthma
;PITRAKINRA;IL4R;rs1110470;AA;Efficacy;increased response to ⮕ PITRAKINRA;Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.; in people with Disease:Asthma
;PITRAKINRA;IL4R;rs2239347;AA;Efficacy;increased response to ⮕ PITRAKINRA;Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AC + CC.; in people with Disease:Asthma
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;BENAZEPRIL;MTR;rs1805087;AG + GG;Efficacy;decreased response to ⮕ BENAZEPRIL;Genotypes AG + GG are associated with decreased response to benazepril in people with Essential hypertension as compared to genotype AA.; in people with Disease:Essential hypertension
;PITRAKINRA;IL4R;rs1805010;AA;Efficacy;increased response to ⮕ PITRAKINRA;Genotype AA is associated with increased response to pitrakinra in people with Asthma as compared to genotypes AG + GG.; in people with Disease:Asthma
;VORICONAZOLE;ABCC2;rs717620;CT + TT;Metabolism/PK;increased trough concentration of ⮕ VORICONAZOLE;Genotypes CT + TT is associated with increased trough concentration of voriconazole in children as compared to genotype CC.; in children 
;ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;GG;Dosage, Toxicity;increased dose of ⮕ ACENOCOUMAROL, PHENPROCOUMON;Genotype GG is associated with increased dose of acenocoumarol or phenprocoumon as compared to genotypes AA + AG.;or  
;SULINDAC;FMO3;rs2266782;AA;Metabolism/PK;increased exposure to ⮕ SULINDAC;Genotype AA is associated with increased exposure to sulindac in healthy individuals as compared to genotype GG.; in healthy individuals 
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;A;Metabolism/PK;decreased clearance of ⮕ MYCOPHENOLATE MOFETIL;Allele A is associated with decreased clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation
;SULINDAC;FMO3;rs2266780;GG;Metabolism/PK;increased exposure to ⮕ SULINDAC;Genotype GG is associated with increased exposure to sulindac in healthy individuals as compared to genotype AA.; in healthy individuals 
;MORPHINE;ABCC3;rs4793665;CC;Metabolism/PK;increased metabolism of ⮕ MORPHINE;Genotype CC is associated with increased metabolism of morphine in children as compared to genotypes CT + TT.; in children 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8105790;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;ATORVASTATIN;SLCO1B1;rs4149056;CT;Metabolism/PK;increased exposure to ⮕ ATORVASTATIN;Genotype CT is associated with increased exposure to atorvastatin as compared to genotype TT.;  
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8103142;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;MEMANTINE;NR1I2;rs1523130;CT + TT;Metabolism/PK;decreased clearance of ⮕ MEMANTINE;Genotypes CT + TT are associated with decreased clearance of memantine in people with Dementia as compared to genotype CC.; in people with Disease:Dementia
;BENAZEPRIL;ADRB2;rs1042713;AG + GG;Efficacy;increased response to ⮕ BENAZEPRIL;Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA.; in people with Disease:Essential hypertension
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs11881222;G;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele G is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele A.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs7248668;A;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele A is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;AMISULPRIDE;ANKS1B;rs7968606;CC;Efficacy;increased response to ⮕ AMISULPRIDE;Genotype CC is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CT + TT.; in people with Disease:Schizophrenia
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs28416813;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803219;C;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Allele C is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;MORPHINE;OPRM1;rs1799971;AG;Dosage;increased dose of ⮕ MORPHINE;Genotype AG is associated with increased dose of morphine in people with Neoplasms as compared to genotype AA.; in people with Disease:Neoplasms
;ESCITALOPRAM;;rs2069521;A;Metabolism/PK;increased metabolism of ⮕ ESCITALOPRAM;Allele A is associated with increased metabolism of escitalopram in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;IMATINIB;CYP3A5;rs776746;CC;Metabolism/PK;increased response to ⮕ IMATINIB;Genotype CC is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;ROSUVASTATIN;SCARB1;rs4238001;CC;Efficacy;increased clinical benefit to ⮕ ROSUVASTATIN;Genotype CC is associated with increased clinical benefit to rosuvastatin in people with Myocardial Ischemia as compared to genotypes CT + TT.; in people with Other:Myocardial Ischemia
;IMATINIB;ABCB1;rs1045642;AA;Metabolism/PK;increased response to ⮕ IMATINIB;Genotype AA is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ IMATINIB;Genotype CC is associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CT + TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;LACOSAMIDE;ABCC2;rs2273697;GG;Metabolism/PK;increased concentrations of ⮕ LACOSAMIDE;Genotype GG is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes AA + AG.; in children with Other:Epilepsy
;IMATINIB;ABCB1;rs1045642;AA;Metabolism/PK;increased concentrations of ⮕ IMATINIB;Genotype AA is associated with increased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotypes CC + CT is associated with decreased response to simvastatin in people with Dyslipidaemia as compared to genotype TT.; in people with Disease:Dyslipidaemia
;OLANZAPINE;SV2C;rs11960832;TT;Efficacy;decreased response to ⮕ OLANZAPINE;Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;CORTICOSTEROIDS;TBX21;rs2240017;CG;Efficacy;increased response to ⮕ CORTICOSTEROIDS;Genotype CG is associated with increased response to corticosteroids in children with Asthma as compared to genotype CC.; in children with Disease:Asthma
;METHOTREXATE;ABCC1;rs2238476;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to allele A.; in people with Disease:Psoriasis
;ANTIDEPRESSANTS;HTR2A;rs6314;AG + GG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AG + GG are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.; in people with Disease:Major Depressive Disorder
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs1065852;A;Efficacy;increased response to ⮕ CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;Allele A is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele G.;or in children with Disease:Epilepsy
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2C9;rs9332120;C;Efficacy;increased response to ⮕ CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.;or in children with Disease:Epilepsy
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs3892097;C;Efficacy;increased response to ⮕ CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.;or in children with Disease:Epilepsy
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2740574;C;Efficacy;increased response to ⮕ CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.;or in children with Disease:Epilepsy
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2687116;C;Efficacy;increased response to ⮕ CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.;or in children with Disease:Epilepsy
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.; in children with Disease:Liver transplantation
;DULOXETINE;ANO2;rs61908411;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908409;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908410;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs78615940;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs78482393;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908405;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908406;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;rs2781659;A;Efficacy;increased response to ⮕ SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele A is associated with increased response to selective beta-2-adrenoreceptor agonists in people with Asthma as compared to allele G.; in people with Disease:Asthma
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.; in people with Disease:Acute coronary syndrome
;DULOXETINE;ANO2;rs61908404;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908408;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908407;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs17786412;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;DULOXETINE;ANO2;rs17786400;A;Efficacy;decreased response to ⮕ DULOXETINE;Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;METHADONE;ABCB1;rs9282564;C;Metabolism/PK;decreased concentrations of ⮕ METHADONE;Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T.; in people with Disease:Opioid-Related Disorders
;DULOXETINE;ANO2;rs61908403;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs61908402;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;DOBUTAMINE;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ DOBUTAMINE;Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.; in healthy individuals 
;DULOXETINE;ANO2;rs17724452;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;GLATIRAMER ACETATE;PVT1;rs2114358;A;Efficacy;increased response to ⮕ GLATIRAMER ACETATE;Allele A is associated with increased response to glatiramer acetate in people with Multiple Sclerosis as compared to allele G.; in people with Disease:Multiple Sclerosis
;DULOXETINE;;rs7316769;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs17724494;C;Efficacy;decreased response to ⮕ DULOXETINE;Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;rs56165452;CT;Dosage;decreased dose of ⮕ WARFARIN;Genotype CT is associated with decreased dose of warfarin as compared to genotype TT.;  
;METHADONE;ABCB1;rs1045642;A;Metabolism/PK;decreased concentrations of ⮕ METHADONE;Allele A is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele G.; in people with Disease:Opioid-Related Disorders
;DULOXETINE;ANO2;rs17786394;T;Efficacy;decreased response to ⮕ DULOXETINE;Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;DULOXETINE;ANO2;rs17724464;G;Efficacy;decreased response to ⮕ DULOXETINE;Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;METHADONE;UGT2B7;rs7439366;CT;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype CT is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes CC + TT.; in people with Disease:Opioid-Related Disorders
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;PEMETREXED, PLATINUM COMPOUNDS;CCND1;rs9344;A;Efficacy;increased clinical benefit to ⮕ PEMETREXED, PLATINUM COMPOUNDS;Allele A is associated with increased clinical benefit to pemetrexed and Platinum compounds in people with Lung Neoplasms as compared to allele G.;and in people with Other:Lung Neoplasms
;WARFARIN;VKORC1;rs2359612;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;METOPROLOL;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ METOPROLOL;Genotype CC is associated with increased response to metoprolol in people with Heart Failure as compared to genotypes CG + GG.; in people with Disease:Heart Failure
;WARFARIN;VKORC1;rs7294;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;LIRAGLUTIDE;GLP1R;rs10305420;CT + TT;Efficacy;decreased response to ⮕ LIRAGLUTIDE;Genotypes CT + TT are associated with decreased response to liraglutide in women with Obesity and Polycystic Ovary Syndrome as compared to genotype CC.; in women with Disease:Obesity, Disease:Polycystic Ovary Syndrome
;LAMOTRIGINE;CACNA1H;rs2753325;A;Efficacy;increased clinical benefit to ⮕ LAMOTRIGINE;Allele A is associated with increased clinical benefit to lamotrigine in children with Epilepsy as compared to allele G.; in children with Efficacy:Epilepsy
;AZATHIOPRINE;TPMT;TPMT low activity;;Metabolism/PK;low activity decreased dose of ⮕ AZATHIOPRINE;TPMT low activity is associated with decreased dose of azathioprine as compared to TPMT high activity.;  
;FLUOROURACIL;DPYD;rs3918290;CT;Metabolism/PK;decreased metabolism of ⮕ FLUOROURACIL;Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.; in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs2297595;CC + CT;Metabolism/PK;decreased metabolism of ⮕ FLUOROURACIL;Genotypes CC + CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype TT.; in people with Disease:Neoplasms
;ASPIRIN;GP1BA;rs6065;CT + TT;Efficacy;increased response to ⮕ ASPIRIN;Genotypes CT + TT are associated with increased response to aspirin in men as compared to genotype CC.; in men 
;FLUOROURACIL;DPYD;rs1801160;CT + TT;Metabolism/PK;decreased metabolism of ⮕ FLUOROURACIL;Genotypes CT + TT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC.; in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs1801265;GG;Metabolism/PK;decreased metabolism of ⮕ FLUOROURACIL;Genotype GG is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotypes AA + AG.; in people with Disease:Neoplasms
;LACOSAMIDE;ABCC2;rs717620;CC;Metabolism/PK;increased concentrations of ⮕ LACOSAMIDE;Genotype CC is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes CT + TT.; in children with Other:Epilepsy
;ANASTROZOLE;;rs11648166;G;Metabolism/PK;increased concentrations of ⮕ ANASTROZOLE;Allele G is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to allele A.; in women with Disease:Breast Neoplasms
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in children as compared to genotypes CC + CT.; in children 
;LACOSAMIDE;ABCC2;rs2273697;A;Efficacy;increased resistance to ⮕ LACOSAMIDE;Allele A is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele G.; in children with Other:Epilepsy
;LACOSAMIDE;ABCC2;rs717620;T;Efficacy;increased resistance to ⮕ LACOSAMIDE;Allele T is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele C.; in children with Other:Epilepsy
;ANASTROZOLE;;rs28845026;T;Metabolism/PK;increased concentrations of ⮕ ANASTROZOLE;Allele T is associated with increased concentrations of anastrozole in women with Breast Neoplasms as compared to allele C.; in women with Disease:Breast Neoplasms
;TRAZODONE;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ TRAZODONE;Genotype AA is associated with increased clearance of trazodone in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AC + CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Other:Heart valve replacement
;CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;Allele C is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.; in people with Disease:Lupus erythematosus
;DOBUTAMINE;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ DOBUTAMINE;Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotypes CG + GG.; in healthy individuals 
;SIMVASTATIN ACID;SLCO1B1;rs4149056;C;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Allele C is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.; in healthy individuals 
;METHOTREXATE;ARID5B;rs10994982;A;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Disease:Acute lymphoblastic leukemia
;OXYCODONE;OPRM1;rs1799971;AG + GG;Efficacy;decreased response to ⮕ OXYCODONE;Genotypes AG + GG are associated with decreased response to oxycodone in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;Metabolism/PK;decreased metabolism of ⮕ CYCLOPHOSPHAMIDE;Allele A is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele G.; in people with Disease:Lupus erythematosus
;IMATINIB;ABCB1;rs1045642;AG + GG;Metabolism/PK;increased trough concentration of ⮕ IMATINIB;Genotypes AG + GG is associated with increased trough concentration of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.; in people with Other:Gastrointestinal Stromal Tumors
;FENOFIBRATE;PPARA;rs4253778;GG;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype GG is associated with increased response to fenofibrate in people with Diabetes Mellitus as compared to genotypes CC + CG.; in people with Disease:Diabetes Mellitus
;METHOTREXATE;SLC22A11;rs11231809;AT + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AT + TT are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ABCC1;rs246240;AG + GG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;HMG COA REDUCTASE INHIBITORS;HMGCR;rs3846662;AA;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype AA is associated with decreased response to hmg coa reductase inhibitors in women with familial hypercholesterolemia as compared to allele G.; in women with Disease:Familial hypercholesterolemia
;METHOTREXATE;ABCC1;rs3784864;AG + GG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AG + GG are associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AG + GG;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE;Genotypes AG + GG is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype AA.; in people with Disease:Lupus Nephritis
;4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;rs776746;CC + CT;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYCYCLOPHOSPHAMIDE;Genotypes CC + CT is associated with decreased concentrations of 4-hydroxycyclophosphamide in people with Lupus Nephritis as compared to genotype TT.; in people with Disease:Lupus Nephritis
;CYCLOPHOSPHAMIDE;CYP2B6;rs7254579;C;Metabolism/PK;metabolism of ⮕ CYCLOPHOSPHAMIDE;Allele C is associated with metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.; in people with Disease:Lupus erythematosus
;HMG COA REDUCTASE INHIBITORS;;rs445925;A;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele A is associated with increased response to hmg coa reductase inhibitors as compared to allele G.;  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;GT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A.;  
;FENOFIBRATE;IL6;rs1800795;CC + CG;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes CC + CG are associated with increased response to fenofibrate in patients with a high risk of cardiovascular disease as compared to genotype GG.; in Other:patients with a high risk of cardiovascular disease
;RANIBIZUMAB;NRP1;rs2070296;T;Efficacy;decreased response to ⮕ RANIBIZUMAB;Allele T is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotype CC.; in people with Disease:Macular Degeneration
;ATORVASTATIN;CETP;rs708272;GG;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype GG is associated with increased response to atorvastatin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Disease:Diabetes Mellitus, Type 2
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;MICB;rs3828913;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;and in people with Disease:Chronic hepatitis C virus infection
;METHOTREXATE;ABCG2;rs13120400;CC;Efficacy;increased response to ⮕ METHOTREXATE;Genotype CC is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CT + TT.; in people with Side Effect:Psoriasis
;NICOTINE;DBH;rs77905;GG;Dosage;decreased dose of ⮕ NICOTINE;Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.; in people with Disease:Tobacco Use Disorder
;WARFARIN;VKORC1;rs9923231;CC + CT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype TT.; in people with Other:Heart valve replacement
;NICOTINE;MAOA;rs1137070;TT;Dosage;increased dose of ⮕ NICOTINE;Genotype TT is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes CC + CT.; in people with Disease:Tobacco Use Disorder
;OMEPRAZOLE, PANTOPRAZOLE;ABCB1;rs1045642;AA;Efficacy;increased response to ⮕ OMEPRAZOLE, PANTOPRAZOLE;Genotype AA is associated with increased response to omeprazole or pantoprazole in people with Helicobacter Infections as compared to genotypes AG + GG.;or in people with Disease:Helicobacter Infections
;DEFERASIROX;VDR;rs7975232;AA;Metabolism/PK;metabolism of ⮕ DEFERASIROX;Genotype AA is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to genotypes AC + CC.; in children with Disease:Beta-thalassemia and related diseases
;FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs1364043;TT;Efficacy;increased response to ⮕ FLUVOXAMINE, MILNACIPRAN, PAROXETINE;Genotype TT is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes GG + GT.;and in people with Disease:Major Depressive Disorder
;DEFERASIROX;VDR;rs2228570;G;Metabolism/PK;metabolism of ⮕ DEFERASIROX;Allele G is associated with metabolism of deferasirox in children with beta-Thalassemia as compared to allele A.; in children with Disease:Beta-thalassemia and related diseases
;ANTIPSYCHOTICS;GRM3;rs6465084;AA;Toxicity;increased response to ⮕ ANTIPSYCHOTICS;Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.; in people with Disease:Schizophrenia
;METFORMIN;SLC47A1;rs2289669;AA;Efficacy;increased response to ⮕ METFORMIN;Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.; in people with Disease:Diabetes Mellitus, Type 2
;WARFARIN;CYP4F2;rs2108622;CC + CT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CC + CT are associated with decreased dose of warfarin as compared to genotype TT.;  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;METFORMIN;SLC47A1;rs2289669;AA;Metabolism/PK;decreased clearance of ⮕ METFORMIN;Genotype AA is associated with decreased clearance of metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.; in people with Disease:Diabetes Mellitus, Type 2
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;EFAVIRENZ;NR1I3;rs2307424;G;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Allele G is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;EFAVIRENZ;NR1I3;rs2307424;AG;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;ANTIHYPERTENSIVES;ATP2B1;rs12817819;CT + TT;Efficacy;increased resistance to ⮕ ANTIHYPERTENSIVES;Genotypes CT + TT are associated with increased resistance to Antihypertensives in people with Coronary Artery Disease or Hypertension as compared to genotype CC.; in people with Disease:Coronary Artery Disease, Disease:Hypertension
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;EPHX1;rs1051741;CT;Dosage;decreased dose of ⮕ WARFARIN;Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype AA is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AG.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;ISONIAZID;NAT2;rs1799930;AA;Metabolism/PK;increased exposure to ⮕ ISONIAZID;Genotype AA is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes AG + GG.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;MERCAPTOPURINE;NUDT15;rs73189762;T;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Other:Acute lymphoblastic leukemia
;WARFARIN;PRSS53, VKORC1;rs7294;CT;Dosage;increased dose of ⮕ WARFARIN;Genotype CT is associated with increased dose of warfarin as compared to genotype CC.;  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;ISONIAZID;NR1I2;rs2472677;TT;Metabolism/PK;increased exposure to ⮕ ISONIAZID;Genotype TT is associated with increased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CC + CT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;AMLODIPINE, FELODIPINE;CACNA1C;rs2238032;TT;Efficacy;increased response to ⮕ AMLODIPINE, FELODIPINE;Genotype TT is associated with increased response to amlodipine or felodipine in people with Hypertension as compared to genotypes GG + GT.;or in people with Disease:Hypertension
;ISONIAZID;SLCO1B1;rs4149032;CC;Metabolism/PK;decreased exposure to ⮕ ISONIAZID;Genotype CC is associated with decreased exposure to isoniazid in people with HIV Infections and Tuberculosis as compared to genotypes CT + TT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239128;C;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Allele C is associated with increased response to calcium channel blockers in people with Hypertension as compared to allele T.; in people with Disease:Hypertension
;MORPHINE;OPRM1;rs1799971;AG + GG;Efficacy;increased dose of ⮕ MORPHINE;Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA.;  
;GEFITINIB;EGFR;rs121434568;G;Efficacy;response to ⮕ GEFITINIB;Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung.; in people with Disease:Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;response to ⮕ ERLOTINIB;Allele G is associated with response to erlotinib in people with Carcinoma, Non-Small-Cell Lung.; in people with Disease:Non-Small Cell Lung Carcinoma
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2900478;A;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele A is associated with decreased response to hmg coa reductase inhibitors as compared to allele T.;  
;CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239050;GG;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Genotype GG is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes CC + CG.; in people with Disease:Hypertension
;HMG COA REDUCTASE INHIBITORS;CELSR2;rs646776;C;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele C is associated with increased response to hmg coa reductase inhibitors as compared to allele T.;  
;VALPROIC ACID;UGT2B7;rs12233719;GG;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotype GG is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;EFAVIRENZ;CYP2A6;rs28399454;T;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele C.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;metabolism of ⮕ EFAVIRENZ;Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GT.; in people with Disease:HIV infectious disease
;CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2238032;TT;Efficacy;increased response to ⮕ CALCIUM CHANNEL BLOCKERS;Genotype TT is associated with increased response to calcium channel blockers in people with Hypertension as compared to genotypes GG + GT.; in people with Disease:Hypertension
;EFAVIRENZ;CYP2B6;rs3745274;GT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with venous thromboembolism as compared to genotype CC.; in people with Disease:Venous thromboembolism
;PHENPROCOUMON, WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ PHENPROCOUMON, WARFARIN;Genotype TT is associated with decreased dose of phenprocoumon or warfarin as compared to genotype CC.;or  
;EFAVIRENZ;CYP2B6;rs2279343;GG;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;ATAZANAVIR;ABCB1;rs1045642;GG;Metabolism/PK;increased concentrations of ⮕ ATAZANAVIR;Genotype GG is associated with increased concentrations of atazanavir in people with HIV Infections as compared to genotypes AA + AG.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;CYP2C9;rs7900194;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;EFAVIRENZ;CYP2B6;rs2279343;AG;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;VALPROIC ACID;UGT2B7;rs7668258;CT;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotype CT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;CYP2C9;rs28371686;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele C.;  
;WARFARIN;APOC1, APOE;rs429358;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2.; in people with Other:haplotype epsilon2
;VALPROIC ACID;UGT2B7;rs7668258;TT;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Genotype TT is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;WARFARIN;APOC1, APOE;rs7412;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2.; in people with Other:haplotype epsilon2
;INFLIXIMAB;;rs2097432;CC + CT;Efficacy;increased discontinuation of ⮕ INFLIXIMAB;Genotypes CC + CT are associated with increased discontinuation of infliximab in people with Crohn Disease as compared to genotype TT.; in people with Efficacy:Crohn Disease
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;PHOTODYNAMIC THERAPY;CFH;rs1061170;TT;Efficacy;decreased response to ⮕ PHOTODYNAMIC THERAPY;Genotype TT is associated with decreased response to photodynamic therapy in people with Macular Degeneration as compared to genotypes CC + CT.; in people with Disease:Macular Degeneration
;VALPROIC ACID;UGT2B7;rs7439366;TT;Metabolism/PK;concentrations of ⮕ VALPROIC ACID;Genotype TT is associated with concentrations of valproic acid in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;RISPERIDONE;ABCG2;rs2231142;GT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ RISPERIDONE;Genotypes GT + TT is associated with decreased dose-adjusted trough concentrations of risperidone in children as compared to genotype GG.; in children 
;FLUOXETINE;HTR1B;rs9361233;CC + TT;Efficacy;increased response to ⮕ FLUOXETINE;Genotypes CC + TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT.; in children with Disease:Major Depressive Disorder
;EFAVIRENZ;CYP2B6;rs8192709;CC;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype CC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CT.; in people with Disease:HIV infectious disease
;INFLIXIMAB;;rs73277969;T;Efficacy;increased discontinuation of ⮕ INFLIXIMAB;Allele T is associated with increased discontinuation of infliximab in people with Crohn Disease as compared to allele G.; in people with Efficacy:Crohn Disease
;IVACAFTOR;CFTR;rs121908757;C;Efficacy;response to ⮕ IVACAFTOR;Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;IVACAFTOR;CFTR;rs121909005;G;Efficacy;response to ⮕ IVACAFTOR;Allele G is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.;and in people with Disease:Coronary Artery Disease
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;T;;increased response to ⮕ ASPIRIN, CLOPIDOGREL;Allele T is associated with increased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele C.;and in people with Disease:Coronary Artery Disease
;IVACAFTOR;CFTR;rs121908755;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ASPIRIN, PRASUGREL;PEAR1;rs2768759;AC + CC;Efficacy;decreased response to ⮕ ASPIRIN, PRASUGREL;Genotypes AC + CC are associated with decreased response to aspirin or prasugrel as compared to genotype AA.;or  
;CYCLOSPORINE;ABCB1;rs2032582;AC + CC;Dosage;increased dose of ⮕ CYCLOSPORINE;Genotypes AC + CC is associated with increased dose of cyclosporine in people with Kidney Transplantation as compared to genotypes AA + CT.; in people with Disease:Kidney Transplantation
;ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;rs12041331;AA + AG;Efficacy;increased response to ⮕ ASPIRIN, CLOPIDOGREL, PRASUGREL;Genotypes AA + AG are associated with increased response to aspirin, clopidogrel or prasugrel as compared to genotype GG.;or  
;CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ CYCLOSPORINE;Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;rs5443;TT;Efficacy;increased response to ⮕ HYDRALAZINE / ISOSORBIDE DINITRATE;Genotype TT is associated with increased response to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes CC + CT.; in people with Disease:Heart Failure
;IVACAFTOR;CFTR;rs397508453;C;Efficacy;response to ⮕ IVACAFTOR;Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.; in children with Other:Liver transplantation
;IVACAFTOR;CFTR;rs121909013;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;LOVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ LOVASTATIN ACID;Genotypes CC + CT is associated with increased concentrations of lovastatin acid in healthy individuals as compared to genotype TT.; in healthy individuals 
;SIMVASTATIN;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ SIMVASTATIN;Genotype CC is associated with decreased metabolism of simvastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;IVACAFTOR;CFTR;rs121909041;C;Efficacy;response to ⮕ IVACAFTOR;Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;TACROLIMUS;CYP3A4;rs2242480;T;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Allele T is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype C/C.; in people with Disease:Kidney Transplantation
;SIMVASTATIN;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ SIMVASTATIN;Genotype CC is associated with decreased clearance of simvastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;Allele A is associated with decreased response to aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele G.;and in people with Disease:Coronary Artery Disease
;IVACAFTOR;CFTR;rs74503330;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;LOVASTATIN;PPARA;rs4823613;AG + GG;Metabolism/PK;increased concentrations of ⮕ LOVASTATIN;Genotypes AG + GG is associated with increased concentrations of lovastatin in healthy individuals as compared to genotype AA.; in healthy individuals 
;NEVIRAPINE;CYP1A2;rs762551;CC;Efficacy;increased response to ⮕ NEVIRAPINE;Genotype CC is associated with increased response to nevirapine in people with HIV Infections as compared to genotypes AA + AC.; in people with Disease:HIV infectious disease
;FENTANYL;OPRM1;rs1799971;AG + GG;Efficacy;increased response to ⮕ FENTANYL;Genotypes AG + GG are associated with increased response to fentanyl in women with Pain as compared to genotype AA.; in women with Disease:Pain
;ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;Efficacy;decreased response to ⮕ ANASTROZOLE, LETROZOLE, TAMOXIFEN;Genotype AA is associated with decreased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.;or in women with Disease:Breast Neoplasms, Disease:Menopause
;IVACAFTOR;CFTR;rs267606723;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;SEROTONIN;ERICH3;rs696692;T;Other;decreased concentrations of ⮕ SEROTONIN;Allele T is associated with decreased concentrations of serotonin in people with Depressive Disorder as compared to allele C.; in people with Disease:Depressive Disorder
;IVACAFTOR;CFTR;rs80282562;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;TACROLIMUS;ABCB1;rs1045642;AG + GG;Dosage;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;Efficacy;increased response to ⮕ CYCLOSPORINE;Genotypes AG + GG is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;Efficacy;increased response to ⮕ ANASTROZOLE, LETROZOLE, TAMOXIFEN;Genotype AA is associated with increased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to genotypes AC + CC.;or in women with Disease:Breast Neoplasms
;PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;Efficacy;increased resistance to ⮕ PLATINUM COMPOUNDS;Genotypes CT + TT is associated with increased resistance to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; in people with Other:Non-Small Cell Lung Carcinoma
;SEROTONIN;TSPAN5;rs11947402;G;Other;decreased concentrations of ⮕ SEROTONIN;Allele G is associated with decreased concentrations of serotonin in people with Depressive Disorder as compared to allele A.; in people with Disease:Depressive Disorder
;NEVIRAPINE;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ NEVIRAPINE;Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;rs3761847;G;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;THALIDOMIDE;CTNNB1;rs4533622;AA;Efficacy;increased response to ⮕ THALIDOMIDE;Genotype AA is associated with increased response to thalidomide in people with Multiple Myeloma as compared to genotypes AC + CC.; in people with Disease:Multiple Myeloma
;WARFARIN;VKORC1;rs9934438;AG;Dosage;increased dose of ⮕ WARFARIN;Genotype AG is associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype GG.; in people with Disease:Atrial Fibrillation, Disease:Cardiomyopathies, Disease:Heart valve replacement, Disease:Peripheral Vascular Diseases, Disease:Pulmonary Embolism, Disease:Venous Thrombosis
;FENTANYL;OPRM1;rs1799971;AG + GG;Dosage;decreased dose of ⮕ FENTANYL;Genotypes AG + GG are associated with decreased dose of fentanyl in women with Pain as compared to genotype AA.; in women with Disease:Pain
;IVACAFTOR;CFTR;rs193922525;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;rs4135385;AA;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;Genotype AA is associated with increased response to cyclophosphamide, dexamethasone and thalidomide in people with Multiple Myeloma as compared to genotypes AG + GG.;and in people with Disease:Multiple Myeloma
;OPIOIDS;IL17A;rs2275913;A;Dosage, Efficacy;increased dose of ⮕ OPIOIDS;Allele A is associated with increased dose of opioids in people with Pain, Postoperative as compared to allele G.; in people with Disease:Pain, Postoperative
;PLATINUM COMPOUNDS;CYP1A1;rs1048943;CC + CT;Efficacy;increased resistance to ⮕ PLATINUM COMPOUNDS;Genotypes CC + CT is associated with increased resistance to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.; in people with Other:Non-Small Cell Lung Carcinoma
;WARFARIN;CYP4F2;rs2108622;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele T.; in people with Disease:Venous thromboembolism
;TACROLIMUS;ABCB1;rs2032582;AC + CC;Dosage;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes AC + CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele C.; in people with Disease:Venous thromboembolism
;ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;rs11580409;C;Efficacy;increased response to ⮕ ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;Allele C is associated with increased response to antidepressants, citalopram and escitalopram in people with Depressive Disorder as compared to allele A.;and in people with Disease:Depressive Disorder
;ETHANOL;OPRM1;rs1799971;AG + GG;Other;decreased dose of ⮕ ETHANOL;Genotypes AG + GG are associated with decreased dose of ethanol as compared to genotype AA.;  
;CYCLOSPORINE;ABCB1;rs2032582;AC + CC;Dosage;decreased dose-adjusted trough concentrations of ⮕ CYCLOSPORINE;Genotypes AC + CC is associated with decreased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes AA + CT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A7;rs10211;TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype TT are associated with increased concentrations of tacrolimus in children with null as compared to genotypes CC + CT.; in children with Other:null
;WARFARIN;VKORC1;rs9923231;C;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Allele C is associated with increased dose of warfarin as compared to allele T.;  
;WARFARIN;VKORC1;rs9923231;T;Dosage, Efficacy;increased response to ⮕ WARFARIN;Allele T is associated with increased response to warfarin as compared to allele C.;  
;ACETAMINOPHEN, TRAMADOL;OPRM1;rs1799971;AA;Efficacy;increased response to ⮕ ACETAMINOPHEN, TRAMADOL;Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG.;and in people with Disease:Neuropathic pain
;RITUXIMAB;FCGR2A;rs1801274;AA;Efficacy;increased response to ⮕ RITUXIMAB;Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;METHADONE;CYP2B6;rs3745274;T;Metabolism/PK;decreased clearance of ⮕ METHADONE;Allele T is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to allele G.; in people with Disease:Opioid-Related Disorders
;COTININE;UGT2B10;rs2942857;CC;Metabolism/PK;decreased clearance of ⮕ COTININE;Genotype CC is associated with decreased clearance of cotinine in people with Tobacco Use Disorder as compared to genotypes AA + AC.; in people with Disease:Tobacco Use Disorder
;FENTANYL;;rs6961071;GG;Efficacy;increased response to ⮕ FENTANYL;Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Disease:Pain, Postoperative
;RITUXIMAB;FCGR3A;rs396991;AC + CC;Efficacy;increased response to ⮕ RITUXIMAB;Genotypes AC + CC are associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs2359612;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin as compared to allele A.;  
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AG + GG;Efficacy;increased clinical benefit to ⮕ CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;Genotypes AG + GG is associated with increased clinical benefit to cyclophosphamide, doxorubicin, FEC100 or fluorouracil in people with Breast Neoplasms.;or in people with Other:Breast Neoplasms
;TACROLIMUS;POR;rs1057868;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;METHADONE;ABCB1;rs2032582;CC;Metabolism/PK;decreased clearance of ⮕ METHADONE;Genotype CC is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AC + CT.; in people with Disease:Opioid-Related Disorders
;TOCILIZUMAB;FCGR3A;rs396991;AA;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AC + CC.; in people with Disease:Rheumatoid arthritis
;CARVEDILOL;ADRB2;rs1042714;GG;Efficacy;increased response to ⮕ CARVEDILOL;Genotype GG is associated with increased response to carvedilol in people with Heart Failure as compared to genotypes CC + CG.; in people with Disease:Heart Failure
;FENTANYL;;rs13093031;GG;Efficacy;increased response to ⮕ FENTANYL;Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Disease:Pain, Postoperative
;ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;rs776746;CC;Efficacy;increased response to ⮕ ATORVASTATIN, LOVASTATIN, SIMVASTATIN;Genotype CC is associated with increased response to atorvastatin, lovastatin or simvastatin in people with Arteriosclerosis as compared to genotype CT.;or in people with Disease:Arteriosclerosis
;COTININE;UGT2B10;rs2942857;CC;Metabolism/PK;increased exposure to ⮕ COTININE;Genotype CC is associated with increased exposure to cotinine in people with Tobacco Use Disorder as compared to genotypes AA + AC.; in people with Disease:Tobacco Use Disorder
;CLOPIDOGREL;ABCB1;rs1045642;A;Efficacy;increased response to ⮕ CLOPIDOGREL;Allele A is associated with increased response to clopidogrel in people with Acute coronary syndrome as compared to allele G.; in people with Other:Acute coronary syndrome
;CISPLATIN;ERCC1;rs11615;A;Efficacy;decreased response to ⮕ CISPLATIN;Allele A is associated with decreased response to cisplatin in women with Ovarian Neoplasms as compared to allele G.; in women with Other:Ovarian Neoplasms
;WARFARIN;VKORC1;rs2884737;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;WARFARIN;PRSS53, VKORC1;rs7294;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele C.;  
;PHENOBARBITAL;ABCB1;rs1045642;GG;Efficacy;increased resistance to ⮕ PHENOBARBITAL;Genotype GG is associated with increased resistance to phenobarbital in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;TACROLIMUS;FMO3;rs1800822;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;FENOFIBRATE;CRP;rs1417938;TT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype TT is associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.; in people with Disease:Metabolic Syndrome
;PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ PRAVASTATIN;Genotypes CC + CT is associated with decreased response to pravastatin in people with Dyslipidaemia as compared to genotype TT.; in people with Disease:Dyslipidaemia
;METFORMIN;SLC22A3;rs2076828;G;Efficacy;decreased response to ⮕ METFORMIN;Allele G is associated with decreased response to metformin in healthy individuals as compared to allele C.; in healthy individuals 
;FLUOXETINE;HTR1B;rs9361235;CC + TT;Efficacy;increased response to ⮕ FLUOXETINE;Genotypes CC + TT is associated with increased response to fluoxetine in children with Depressive Disorder, Major as compared to genotype CT.; in children with Disease:Major Depressive Disorder
;N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;T;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLCLOZAPINE;Allele T is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;WARFARIN;NQO1;rs10517;GG;Dosage;decreased dose of ⮕ WARFARIN;Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.;  
;FENOFIBRATE;CRP;rs3091244;AG + GG;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes AG + GG are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.; in people with Disease:Metabolic Syndrome
;PRAVASTATIN;MMP3;rs35068180;A/del + AA;Efficacy;increased response to ⮕ PRAVASTATIN;Genotypes A/del + AA are associated with increased response to pravastatin in men with Coronary Artery Disease.; in men with Disease:Coronary Artery Disease
;N-DESMETHYLCLOZAPINE;UGT1A4;rs2011425;G;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLCLOZAPINE;Allele G is associated with decreased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to allele T.; in people with Other:Schizophrenia
;FENOFIBRATE;CRP;rs3091244;GG + GT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotypes GG + GT are associated with increased response to fenofibrate in people with Metabolic Syndrome as compared to genotypes AA + AT.; in people with Disease:Metabolic Syndrome
;FENTANYL;ABCB1;rs1128503;AA;Efficacy;decreased response to ⮕ FENTANYL;Genotype AA is associated with decreased response to fentanyl in people with Neoplasms and Pain as compared to genotypes AG + GG.; in people with Disease:Neoplasms, Disease:Pain
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.; in people with Disease:Cardiovascular Disease
;CLOZAPINE;CYP2C18;rs1126545;T;Metabolism/PK;decreased metabolism of ⮕ CLOZAPINE;Allele T is associated with decreased metabolism of clozapine in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;SIMVASTATIN;SLCO1B1;rs4149056;C;Efficacy;decreased response to ⮕ SIMVASTATIN;Allele C is associated with decreased response to simvastatin as compared to genotype TT.;  
;DESLORATADINE, MIZOLASTINE;FCER1A;rs2298805;AA;Efficacy;increased response to ⮕ DESLORATADINE, MIZOLASTINE;Genotype AA is associated with increased response to desloratadine and mizolastine in people with Urticaria as compared to genotypes AG + GG.;and in people with Disease:Urticaria
;ATORVASTATIN;CYP3A5;rs17161788;TT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype TT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.; in people with Disease:Hypercholesterolemia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T.;and in people with Disease:Hepatitis C virus infection
;CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;rs3917412;CC;Efficacy;decreased response to ⮕ CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Genotype CC is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele T.;and in people with Disease:Colonic Neoplasms
;ATORVASTATIN;CYP3A5;rs776746;CC;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype CC is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes CT + TT.; in people with Disease:Hypercholesterolemia
;OPIOIDS;;rs2952768;CC;Efficacy;decreased response to ⮕ OPIOIDS;Genotype CC is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotypes CT + TT.; in people with Other:Pain, Postoperative
;HMG COA REDUCTASE INHIBITORS;PCSK9;rs11591147;T;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele T is associated with increased response to hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype GG.; in people with Disease:Hypercholesterolemia
;IMATINIB;CYP3A4;rs28371759;AG;Efficacy;increased response to ⮕ IMATINIB;Genotype AG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype AA.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;DIGOXIN;ABCB1;rs2032582;CC;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype CC is associated with increased clearance of digoxin in people with Heart Failure as compared to genotype AC.; in people with Disease:Heart Failure
;CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;Efficacy;decreased response to ⮕ CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;Genotype AA is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele G.;and in people with Disease:Colonic Neoplasms
;PLATINUM;ERCC5;rs17655;GG;Efficacy;increased response to ⮕ PLATINUM;Genotype GG is associated with increased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.; in people with Disease:Non-Small Cell Lung Carcinoma
;ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs75389940;AG + GG;Efficacy;increased clinical benefit to ⮕ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;Genotypes AG + GG is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor or ivacaftor / tezacaftor in people with Cystic Fibrosis.;or in people with Other:Cystic Fibrosis
;CARVEDILOL;UGT2B7;rs12233719;T;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;Allele T is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele G.; in people with Disease:Heart Diseases
;BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs2036527;AA + AG;Efficacy;increased response to ⮕ BUPROPION, NICOTINE, VARENICLINE;Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.;or in women with Other:Tobacco Use Disorder
;BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs16969968;AA + AG;Efficacy;increased response to ⮕ BUPROPION, NICOTINE, VARENICLINE;Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG.;or in women with Other:Tobacco Use Disorder
;CARVEDILOL;UGT2B7;rs28365063;G;Metabolism/PK;decreased clearance of ⮕ CARVEDILOL;Allele G is associated with decreased clearance of carvedilol in people with Heart Diseases as compared to allele A.; in people with Disease:Heart Diseases
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;TACROLIMUS;FMO3;rs909530;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;DIGOXIN;ABCB1;rs2032582;AA + AT;Metabolism/PK;decreased clearance of ⮕ DIGOXIN;Genotypes AA + AT are associated with decreased clearance of digoxin in people with Heart Failure as compared to genotype AC.; in people with Disease:Heart Failure
;TACROLIMUS;NR1I2;rs3814055;CT + TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased concentrations of tacrolimus in healthy individuals as compared to genotype CC.; in healthy individuals 
;LUMACAFTOR;CFTR;rs121909047;AA;Efficacy;response to ⮕ LUMACAFTOR;Genotype AA is associated with response to lumacaftor.;  
;METHADONE;CDH2;rs8094439;AA;Efficacy;increased response to ⮕ METHADONE;Genotype AA is associated with increased response to methadone as compared to genotypes AG + GG.;  
;PERTUSSIS VACCINES;TLR4;rs4986790;AA;Efficacy;increased response to ⮕ PERTUSSIS VACCINES;Genotype AA is associated with increased response to Pertussis vaccines in children as compared to genotypes AG + GG.; in children 
;TACROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;METHADONE;CDH2;rs17446819;CC;Efficacy;increased response to ⮕ METHADONE;Genotype CC is associated with increased response to methadone as compared to genotypes AA + AC.;  
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;SORAFENIB;ABCG2;rs2231137;CT;Metabolism/PK;concentrations of ⮕ SORAFENIB;Genotype CT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype CC.; in people with Disease:Hepatocellular Carcinoma
;NICOTINE;CYP2A6;rs376817657;CT + TT;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;Genotypes CT + TT is associated with decreased metabolism of nicotine as compared to genotype CC.;  
;SORAFENIB;ABCG2;rs2231142;GT;Metabolism/PK;concentrations of ⮕ SORAFENIB;Genotype GT is associated with concentrations of sorafenib in people with Carcinoma, Hepatocellular as compared to genotype GG.; in people with Disease:Hepatocellular Carcinoma
;IMATINIB;SLC22A1;rs683369;CC;Efficacy;decreased response to ⮕ IMATINIB;Genotype CC is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;ABCB1;rs1045642;GG;Efficacy;decreased response to ⮕ IMATINIB;Genotype GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotypes CC + CT are associated with decreased response to simvastatin.;  
;FENTANYL;OPRM1;rs1799971;GG;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG.; in women with Disease:Pain, Postoperative
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;BILIRUBIN;UGT1A1;rs887829;TT;Metabolism/PK;increased concentrations of ⮕ BILIRUBIN;Genotype TT is associated with increased concentrations of bilirubin in children as compared to genotypes CC + CT.; in children 
;WARFARIN;CYP2C9;rs1799853;CT;Dosage;decreased dose of ⮕ WARFARIN;Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.;  
;METHOTREXATE;GGH;rs3758149;AA + AG;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes AA + AG are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;MERCAPTOPURINE;NUDT15;rs186364861;A;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Allele A is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Disease:Acute lymphoblastic leukemia
;IMIQUIMOD;TLR7;rs179008;A;Efficacy;increased response to ⮕ IMIQUIMOD;Allele A is associated with increased response to imiquimod in people with Carcinoma, Basal Cell as compared to allele T.; in people with Disease:Basal Cell Carcinoma
;MERCAPTOPURINE;NUDT15;rs116855232;T;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; in children with Disease:Acute lymphoblastic leukemia
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;METHOTREXATE;GGH;rs11545077;CC + CT;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes CC + CT are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Other:Acute lymphoblastic leukemia
;WARFARIN;VKORC1;rs9923231;T;Dosage, Other;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;CLONIDINE;GNB3;rs5443;CT + TT;Efficacy;increased response to ⮕ CLONIDINE;Genotypes CT + TT are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype CC.; in people with Disease:Liver Cirrhosis
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;CLOZAPINE;UGT2B10;rs61750900;T;Metabolism/PK;decreased metabolism of ⮕ CLOZAPINE;Allele T is associated with decreased metabolism of clozapine in people with Schizophrenia as compared to allele G.; in people with Other:Schizophrenia
;OPIOIDS;TAOK3;rs1277441;AG + GG;Dosage;increased dose of ⮕ OPIOIDS;Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.; in people with Other:Neoplasms, Other:Pain
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;OPIOIDS;TAOK3;rs795484;TT;Dosage;decreased response to ⮕ OPIOIDS;Genotype TT is associated with decreased response to opioids in people with Neoplasms and Pain as compared to genotypes CC + CT.; in people with Other:Neoplasms, Other:Pain
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;FENTANYL;OPRM1;rs1799971;GG;Dosage;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG.; in women with Disease:Pain, Postoperative
;OPIOIDS;TAOK3;rs795484;CT + TT;Dosage;increased dose of ⮕ OPIOIDS;Genotypes CT + TT are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype CC.; in people with Other:Neoplasms, Other:Pain
;FENTANYL;ABCB1;rs1128503;AA;Dosage;increased dose of ⮕ FENTANYL;Genotype AA is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AG + GG.; in women with Disease:Pain, Postoperative
;TENOFOVIR;ABCC4;rs3742106;AC + CC;Metabolism/PK;increased concentrations of ⮕ TENOFOVIR;Genotypes AC + CC is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;Efficacy;decreased clinical benefit to ⮕ VITAMIN B12 AND FOLIC ACID;Allele A is associated with decreased clinical benefit to vitamin b12 and folic acid in people with Hyperhomocysteinemia and Stroke as compared to allele G.; in people with Other:Hyperhomocysteinemia, Other:Stroke
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity, Metabolism/PK;increased exposure to ⮕ METHOTREXATE;Genotypes AA + AG is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Disease:Acute lymphoblastic leukemia
;CAPTOPRIL;AGTR1;rs5186;AC + CC;Efficacy;increased response to ⮕ CAPTOPRIL;Genotypes AC + CC are associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Disease:Diabetes Mellitus, Type 2
;ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;rs1695;A;Efficacy;increased response to ⮕ ANTHRACYCLINES AND RELATED SUBSTANCES;Allele A is associated with increased response to anthracyclines and related substances in women with Breast Neoplasms as compared to allele G.; in women with Disease:Breast Neoplasms
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotypes CC + CT are associated with decreased response to simvastatin as compared to genotype TT.;  
;DAUNORUBICIN;CBR1;rs25678;CC;Metabolism/PK;decreased exposure to ⮕ DAUNORUBICIN;Genotype CC is associated with decreased exposure to daunorubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CG + GG.; in people with Disease:Leukemia, Myeloid, Acute
;SILIBININ;ABCB1;rs1045642;GG;Metabolism/PK;increased exposure to ⮕ SILIBININ;Genotype GG is associated with increased exposure to silibinin in healthy individuals as compared to genotype AA.; in healthy individuals 
;IVACAFTOR;CFTR;rs78655421;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;MERCAPTOPURINE;TPMT;rs1142345;CC;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype CC is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.; in children with Disease:Acute lymphoblastic leukemia
;CITALOPRAM;CYP2C19;rs4244285;AG;Efficacy;decreased response to ⮕ CITALOPRAM;Genotype AG is associated with decreased response to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.; in men with Other:Alcohol abuse, Other:Major Depressive Disorder
;BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;rs1910167;C;Metabolism/PK;increased concentrations of ⮕ BILIRUBIN;Allele C is associated with increased concentrations of bilirubin in children as compared to allele T.; in children 
;CITALOPRAM;CYP2C19;rs4244285;AG;Metabolism/PK;increased concentrations of ⮕ CITALOPRAM;Genotype AG is associated with increased concentrations of citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.; in men with Other:Alcohol abuse, Other:Major Depressive Disorder
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;ATENOLOL;GNB3;rs5443;CC;Efficacy;increased response to ⮕ ATENOLOL;Genotype CC is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes CT + TT.; in people with Disease:Essential hypertension
;ETANERCEPT;PSORS1C1;rs2233945;C;Efficacy;decreased response to ⮕ ETANERCEPT;Allele C is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;TACROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;MERCAPTOPURINE;ABCC4;rs2274407;AA;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype AA is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.; in children with Disease:Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;DISULFIRAM;TPH2;rs4290270;AA + AT;Efficacy;increased response to ⮕ DISULFIRAM;Genotypes AA + AT is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype TT (assigned as high activity phenotype) .; in people with Other:Cocaine dependence
;ATENOLOL;GNB3;rs11064426;AA;Efficacy;increased response to ⮕ ATENOLOL;Genotype AA is associated with increased response to atenolol in people with Essential hypertension as compared to genotype CC.; in people with Disease:Essential hypertension
;ENALAPRIL;NR3C2;rs5522;TT;Efficacy;increased response to ⮕ ENALAPRIL;Genotype TT is associated with increased response to enalapril in people with Hypertension as compared to genotypes CC + CT.; in people with Disease:Hypertension
;ATENOLOL;GNB3;rs2301339;GG;Efficacy;increased response to ⮕ ATENOLOL;Genotype GG is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes AA + AG.; in people with Disease:Essential hypertension
;ATENOLOL;GNB3;rs5443;CC;Efficacy;increased response to ⮕ ATENOLOL;Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotype TT.; in women with Disease:Essential hypertension
;MERCAPTOPURINE;NUDT15;rs116855232;TT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Disease:Acute lymphoblastic leukemia
;ATENOLOL;GNB3;rs11064426;AA;Efficacy;increased response to ⮕ ATENOLOL;Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotype CC.; in women with Disease:Essential hypertension
;ACENOCOUMAROL;CYP2C9;rs4086116;T;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele T is associated with decreased dose of acenocoumarol as compared to allele C.;  
;ATENOLOL;GNB3;rs11064426;AA;Efficacy;increased response to ⮕ ATENOLOL;Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AC + CC.; in women with Disease:Essential hypertension
;ETANERCEPT;STAT4;rs7574865;T;Efficacy;decreased response to ⮕ ETANERCEPT;Allele T is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;ATENOLOL;GNB3;rs2301339;GG;Efficacy;increased response to ⮕ ATENOLOL;Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AA + AG.; in women with Disease:Essential hypertension
;METHOTREXATE;GGH;rs11545076;AC + CC;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes AC + CC are associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in children with Other:Acute lymphoblastic leukemia
;DIGOXIN;ABCB1;rs1128503;AG;Metabolism/PK;decreased clearance of ⮕ DIGOXIN;Genotype AG is associated with decreased clearance of digoxin in healthy individuals as compared to genotype AA.; in healthy individuals 
;ALLOPURINOL;ABCG2;rs2231142;T;Efficacy;decreased response to ⮕ ALLOPURINOL;Allele T is associated with decreased response to allopurinol in people with Gout as compared to allele G.; in people with Disease:Gout
;PRAVASTATIN;SLCO1B1;rs4149015;AG;Efficacy, Metabolism/PK;decreased response to ⮕ PRAVASTATIN;Genotype AG is associated with decreased response to pravastatin as compared to genotype GG.;  
;DIGOXIN;ABCB1;rs1045642;GG;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype GG is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.; in healthy individuals 
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;DIGOXIN;ABCB1;rs2032582;CC;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype CC is associated with increased clearance of digoxin in healthy individuals as compared to genotype AA.; in healthy individuals 
;IVACAFTOR, TEZACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR, TEZACAFTOR;Allele A is associated with response to ivacaftor and tezacaftor in people with Cystic Fibrosis.;and in people with Disease:Cystic Fibrosis
;ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;Genotypes CC + CT are associated with decreased response to atorvastatin, hmg coa reductase inhibitors, pravastatin or simvastatin in people with Hyperlipidemias as compared to genotype TT.;or in people with Other:Hyperlipidemias
;FENOFIBRATE;ABCA1;rs2230806;CT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype CT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;SERTRALINE;HTR2A;rs6313;AA + AG;Dosage;increased dose of ⮕ SERTRALINE;Genotypes AA + AG is associated with increased dose of sertraline in children with Depression or Anxiety Disorders as compared to genotype GG.; in children with Other:Depression, Other:Anxiety Disorders
;FENOFIBRATE;ABCA1;rs2230808;CC;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype CC is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.; in people with Disease:Hypertriglyceridemia
;PLATINUM COMPOUNDS;NUP107;rs79419059;C;Efficacy;increased resistance to ⮕ PLATINUM COMPOUNDS;Allele C is associated with increased resistance to Platinum compounds in women with Ovarian Neoplasms as compared to allele T.; in women with Disease:Ovarian Neoplasms
;FENOFIBRATE;ABCA1;rs2230806;TT;Efficacy;increased response to ⮕ FENOFIBRATE;Genotype TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC.; in people with Disease:Hypertriglyceridemia
;VENLAFAXINE;COMT;rs4680;AA + AG;Efficacy;increased response to ⮕ VENLAFAXINE;Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG.; in people with Disease:Anxiety Disorders
;WARFARIN;NQO1;rs1800566;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;KETOPROFEN;CYP2C9;rs1799853;CC;Efficacy;increased response to ⮕ KETOPROFEN;Genotype CC is associated with increased response to ketoprofen in people with Pain, Postoperative as compared to genotype CT.; in people with Other:Pain, Postoperative
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased trough concentration of ⮕ TACROLIMUS;Genotype CC is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;ETANERCEPT;TNF;rs1800629;AG + GG;Efficacy;increased response to ⮕ ETANERCEPT;Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;ANTIDEPRESSANTS;CHL1;rs1516338;TT;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype TT is associated with increased response to antidepressants in people with Bipolar Disorder, Depressive Disorder or Depressive Disorder, Major as compared to genotype CC.; in people with Disease:Bipolar Disorder, Disease:Depressive Disorder, Disease:Major Depressive Disorder
;ADALIMUMAB;TANK;rs1267067;CC;Efficacy;increased response to ⮕ ADALIMUMAB;Genotype CC is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;TACROLIMUS;CYP3A5;rs15524;AA;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.; in people with Disease:Liver transplantation
;ADALIMUMAB;VEGFA;rs25648;T;Efficacy;increased response to ⮕ ADALIMUMAB;Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C.; in people with Disease:Rheumatoid arthritis
;CARVEDILOL;ADRB1;rs1801253;GG;Dosage;increased dose of ⮕ CARVEDILOL;Genotype GG is associated with increased dose of carvedilol in people with Heart Failure as compared to genotype CC.; in people with Disease:Heart Failure
;TACROLIMUS;CYP3A5;rs4646450;GG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.; in people with Disease:Liver transplantation
;INFLIXIMAB;TNF;rs361525;GG;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;SLCO1B1;rs11045879;CC + CT;Metabolism/PK;increased exposure to ⮕ METHOTREXATE;Genotypes CC + CT is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Other:Acute lymphoblastic leukemia
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;TACROLIMUS;CYP3A4;rs4646437;GG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.; in people with Disease:Liver transplantation
;HYDROCHLOROTHIAZIDE;VASP;rs10995;AG + GG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;ADALIMUMAB;TNFAIP3;rs2230926;T;Efficacy;increased response to ⮕ ADALIMUMAB;Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;METHOTREXATE;SLC19A1;rs2838958;AA + AG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in people with Other:Acute lymphoblastic leukemia
;SIMVASTATIN, SIMVASTATIN ACID;SLCO1B1;rs4149056;C;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN, SIMVASTATIN ACID;Allele C is associated with increased concentrations of simvastatin and simvastatin acid in people with Hypercholesterolemia as compared to allele T.;and in people with Disease:Hypercholesterolemia
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;IVACAFTOR;CFTR;rs121908757;C;Efficacy;response to ⮕ IVACAFTOR;Allele C is associated with response to ivacaftor in people with Cystic Fibrosis.; in people with Disease:Cystic Fibrosis
;METHOTREXATE;SLC19A1;rs3788200;AG + GG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes AG + GG is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in people with Other:Acute lymphoblastic leukemia
;LITHIUM;NR1D1, THRA;rs2314339;T;Efficacy;decreased response to ⮕ LITHIUM;Allele T is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A.; in people with Disease:Venous thromboembolism
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;ATENOLOL;GNB3;rs2301339;GG;Efficacy;increased response to ⮕ ATENOLOL;Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotype AA.; in women with Disease:Essential hypertension
;BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;rs13181;GG;Efficacy;increased response to ⮕ BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT.;or in people with Disease:Stomach Neoplasms
;ACENOCOUMAROL;APOE;rs429358;C;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele C is associated with decreased dose of acenocoumarol in people with venous thromboembolism as compared to allele T.; in people with Disease:Venous thromboembolism
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;WARFARIN;VKORC1;rs8050894;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;CYP4F2;rs2108622;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotype CT.;  
;WARFARIN;VKORC1;rs2359612;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;ATAZANAVIR;SORCS2;rs73208473;A;Metabolism/PK;decreased exposure to ⮕ ATAZANAVIR;Allele A is associated with decreased exposure to atazanavir in women with HIV Infections as compared to allele C.; in women with Disease:HIV infectious disease
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotypes GT + TT are associated with increased concentrations of rosuvastatin as compared to genotype GG.;  
;BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;rs11615;GG;Efficacy;decreased response to ⮕ BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;Genotype GG is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AA + AG.;or in people with Disease:Stomach Neoplasms
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin.;  
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;rs1801133;AA;Efficacy;decreased response to ⮕ BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG.;or in people with Disease:Stomach Neoplasms
;METHADONE;CNR1;rs806368;CT + TT;Dosage;increased dose of ⮕ METHADONE;Genotypes CT + TT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.; in people with Other:Heroin Dependence
;METHADONE;TPH2;rs1386493;GG;Dosage;increased dose of ⮕ METHADONE;Genotype GG is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype AG.; in people with Other:Heroin Dependence
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;rs5065;GG;Efficacy;decreased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype GG is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.;and in healthy individuals 
;MORPHINE;UGT2B7;rs7439366;CT + TT;Metabolism/PK;decreased concentrations of ⮕ MORPHINE;Genotypes CT + TT are associated with decreased concentrations of morphine in people with Neoplasms and Pain as compared to genotype CC.; in people with Other:Neoplasms, Other:Pain
;ATORVASTATIN, SIMVASTATIN;KIF6;rs20455;GG;Efficacy;decreased response to ⮕ ATORVASTATIN, SIMVASTATIN;Genotype GG is associated with decreased response to atorvastatin or simvastatin in people with Hypercholesterolemia as compared to genotype AA.;or in people with Disease:Hypercholesterolemia
;EFAVIRENZ;CYP2B6;rs35303484;GG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype GG is associated with increased concentrations of efavirenz in children with HIV Infections.; in children with Disease:HIV infectious disease
;METHADONE;CYP2B6;rs16974799;CT;Dosage;increased dose of ⮕ METHADONE;Genotype CT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.; in people with Other:Heroin Dependence
;METHADONE;OPRL1;rs2229205;CT;Dosage;increased dose of ⮕ METHADONE;Genotype CT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.; in people with Other:Heroin Dependence
;ROSUVASTATIN;KIF6;rs20455;GG;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotype GG is associated with decreased response to rosuvastatin in people with Hypercholesterolemia as compared to genotype AA.; in people with Disease:Hypercholesterolemia
;ADRENERGICS, INHALANTS;;rs34548976;T;Efficacy;decreased response to ⮕ ADRENERGICS, INHALANTS;Allele T is associated with decreased response to adrenergics, inhalants in children with Asthma as compared to allele C.; in children with Disease:Asthma
;TOPIRAMATE;GRIK1;rs2832407;AA + AC;Metabolism/PK;increased concentrations of ⮕ TOPIRAMATE;Genotypes AA + AC is associated with increased concentrations of topiramate in people with Alcohol-Related Disorders as compared to genotype CC.; in people with Disease:Alcohol-Related Disorders
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;ADD1;rs4961;TT;Efficacy;increased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.;and in healthy individuals 
;CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;Efficacy;increased response to ⮕ CISPLATIN, GEMCITABINE;Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;TOPIRAMATE;GRIK1;rs2832407;AA + AC;Efficacy;decreased response to ⮕ TOPIRAMATE;Genotypes AA + AC is associated with decreased response to topiramate in people with Alcohol-Related Disorders as compared to genotype CC.; in people with Disease:Alcohol-Related Disorders
;ATORVASTATIN;KIF6;rs20455;GG;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype GG is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.; in people with Disease:Hypercholesterolemia
;CISPLATIN, GEMCITABINE;ERCC1;rs11615;AA;Efficacy;increased response to ⮕ CISPLATIN, GEMCITABINE;Genotype AA is associated with increased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;rs1529927;CC;Efficacy;increased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype CC is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG.;and in healthy individuals 
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in children with HIV Infections.; in children with Disease:HIV infectious disease
;FLUVASTATIN;ABCB1;rs1922242;AA;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype AA is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotype AT.; in people with Disease:Hypercholesterolemia
;GLICLAZIDE;KCNQ1;rs2237897;CT + TT;Efficacy;increased response to ⮕ GLICLAZIDE;Genotypes CT + TT are associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;WARFARIN;CYP4F11;rs1060467;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele A.;  
;CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC + CT;Efficacy;increased response to ⮕ CARBOPLATIN, TAXANES;Genotypes CC + CT are associated with increased response to carboplatin and taxanes in women with as compared to genotype TT.;and in women with 
;DEBRISOQUINE;CYP2D6;rs1080985;C;Metabolism/PK;increased metabolism of ⮕ DEBRISOQUINE;Allele C is associated with increased metabolism of debrisoquine in healthy individuals as compared to allele G.; in healthy individuals 
;TACROLIMUS;CYP3A4;rs35599367;AA + AG;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotypes AA + AG are associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Other:Kidney Transplantation
;EFAVIRENZ;CYP2A6;rs28399433;AC;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype AC is associated with increased concentrations of efavirenz in children with HIV Infections.; in children with Disease:HIV infectious disease
;FLUVASTATIN;CETP;rs4783961;GG;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype GG is associated with increased response to fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.; in people with Disease:Hypercholesterolemia
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;TACROLIMUS;ABCB1;rs9282564;CC + CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Disease:Kidney Transplantation
;METHOTREXATE;MTRR;rs1801394;AG + GG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes AG + GG is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in people with Other:Acute lymphoblastic leukemia
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;TENOFOVIR;IFNL3, IFNL4;rs12979860;C;Metabolism/PK;increased clearance of ⮕ TENOFOVIR;Allele C is associated with increased clearance of tenofovir in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;GLUCOCORTICOIDS;ABCB1;rs1128503;GG;Efficacy;decreased response to ⮕ GLUCOCORTICOIDS;Genotype GG is associated with decreased response to glucocorticoids in people with Crohn Disease.; in people with Disease:Crohn Disease
;METFORMIN;SLC22A1;rs622342;A;Efficacy;increased response to ⮕ METFORMIN;Allele A is associated with increased response to metformin in people with Diabetes Mellitus as compared to allele C.; in people with Efficacy:Diabetes Mellitus
;GLUCOCORTICOIDS;ABCB1;rs1045642;GG;Efficacy;decreased response to ⮕ GLUCOCORTICOIDS;Genotype GG is associated with decreased response to glucocorticoids in people with Crohn Disease.; in people with Disease:Crohn Disease
;HYDROXYUREA;BCL11A;rs1427407;T;Efficacy;increased response to ⮕ HYDROXYUREA;Allele T is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele G.; in people with Disease:Beta-thalassemia and related diseases
;HYDROXYUREA;BCL11A;rs766432;C;Efficacy;increased response to ⮕ HYDROXYUREA;Allele C is associated with increased response to hydroxyurea in people with beta-Thalassemia as compared to allele A.; in people with Disease:Beta-thalassemia and related diseases
;WARFARIN;CYP2C9;rs2860905;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;FENTANYL;UGT2B7;rs7439366;TT;Efficacy;decreased response to ⮕ FENTANYL;Genotype TT is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.; in people with Disease:Pain, Postoperative
;WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.; in men 
;TIOTROPIUM;ADRB2;rs1042713;AA;Efficacy;increased response to ⮕ TIOTROPIUM;Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG.; in people with Disease:Asthma
;LUMEFANTRINE;ABCC2;rs8187710;AA;Metabolism/PK;increased concentrations of ⮕ LUMEFANTRINE;Genotype AA is associated with increased concentrations of lumefantrine in children with Malaria as compared to genotypes AG + GG.; in children with Other:Malaria
;ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;Efficacy;increased clinical benefit to ⮕ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;Allele G is associated with increased clinical benefit to elexacaftor / tezacaftor / ivacaftor in people with Cystic Fibrosis as compared to allele C.; in people with Other:Cystic Fibrosis
;ATORVASTATIN;APOE;rs7412;CT;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype CT is associated with increased response to atorvastatin as compared to genotype CC.;  
;METHADONE;ABCB1;rs1045642;AG;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.; in men with Disease:Opioid-Related Disorders
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;rs5065;GG;Efficacy;increased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype GG is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype AA.;and in healthy individuals 
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;CLOPIDOGREL;ABCB1;rs1045642;GG;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotype GG is associated with increased resistance to clopidogrel in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;GNB3;rs5443;TT;Efficacy;decreased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.;and in healthy individuals 
;MORPHINE;UGT2B7;rs7439366;CT + TT;Efficacy;decreased response to ⮕ MORPHINE;Genotypes CT + TT are associated with decreased response to morphine in people with Neoplasms and Pain as compared to genotype CC.; in people with Other:Neoplasms, Other:Pain
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;NPPA-AS1;rs5063;TT;Efficacy;decreased response to ⮕ BUMETANIDE, FUROSEMIDE, TORASEMIDE;Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC.;and in healthy individuals 
;VALPROIC ACID;UGT1A6;rs2070959;AG + GG;Metabolism/PK;decreased concentrations of ⮕ VALPROIC ACID;Genotypes AG + GG is associated with decreased concentrations of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Other:Epilepsy
;VALPROIC ACID;UGT1A6;rs1105879;AC + CC;Metabolism/PK;decreased concentrations of ⮕ VALPROIC ACID;Genotypes AC + CC is associated with decreased concentrations of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Other:Epilepsy
;CLOZAPINE;HTR2A;rs6314;AA + AG;Efficacy;increased clinical benefit to ⮕ CLOZAPINE;Genotypes AA + AG is associated with increased clinical benefit to clozapine in people with Schizophrenia as compared to genotype GG.; in people with Other:Schizophrenia
;FLUVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype TT is associated with increased response to fluvastatin as compared to genotypes CC + CT.;  
;PRAVASTATIN;ACE;rs4341;CG + GG;Efficacy;increased response to ⮕ PRAVASTATIN;Genotypes CG + GG are associated with increased response to pravastatin as compared to genotype CC.;  
;PRAVASTATIN;LPL;rs328;GG;Efficacy;increased response to ⮕ PRAVASTATIN;Genotype GG is associated with increased response to pravastatin as compared to genotypes CC + CG.;  
;LOVASTATIN;CETP;rs708272;AG;Efficacy;increased response to ⮕ LOVASTATIN;Genotype AG is associated with increased response to lovastatin as compared to genotype GG.;  
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;FENTANYL;UGT2B7;rs10028494;CC;Efficacy;decreased response to ⮕ FENTANYL;Genotype CC is associated with decreased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AC.; in people with Disease:Pain, Postoperative
;METHOTREXATE;MTHFR;rs1801133;AA;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype AA is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.; in people with Disease:Acute lymphoblastic leukemia
;NICOTINE;CHRNA3;rs1051730;A;Metabolism/PK;increased dose of ⮕ NICOTINE;Allele A is associated with increased dose of nicotine as compared to allele G.;  
;FLUVASTATIN;LIPC;rs1800588;CC + CT;Efficacy;increased response to ⮕ FLUVASTATIN;Genotypes CC + CT are associated with increased response to fluvastatin as compared to genotype TT.;  
;CLOZAPINE;CYP1A1;rs2472297;T;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Allele T is associated with decreased concentrations of clozapine in people with Schizophrenia as compared to allele C.; in people with Other:Schizophrenia
;METHYLPHENIDATE;CES1;rs114119971;CG;Dosage;decreased dose of ⮕ METHYLPHENIDATE;Genotype CG is associated with decreased dose of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.; in children with Other:Attention Deficit Disorder with Hyperactivity
;SIMVASTATIN;LIPC;rs1800588;CT;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype CT is associated with increased response to simvastatin as compared to genotype TT.;  
;CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;rs25648;CT + TT;Efficacy;decreased response to ⮕ CISPLATIN, FLUOROURACIL, OXALIPLATIN;Genotypes CT + TT are associated with decreased response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC.;and in people with Disease:Stomach Neoplasms
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C.; in people with Disease:Cardiovascular Disease
;ATORVASTATIN;ABCB1;rs2032582;CC;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype CC is associated with increased response to atorvastatin as compared to genotype AA.;  
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.; in children with Disease:Cystic Fibrosis
;ATORVASTATIN;SLCO1B1;rs4149036;AC + CC;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes AC + CC are associated with increased response to atorvastatin as compared to genotype AA.;  
;ATORVASTATIN;CYP3A5;rs776746;CC + CT;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes CC + CT are associated with increased response to atorvastatin as compared to genotype TT.;  
;PERTUSSIS VACCINES;TLR4;rs2770150;GG;Efficacy;decreased response to ⮕ PERTUSSIS VACCINES;Genotype GG is associated with decreased response to Pertussis vaccines in children as compared to genotype AG.; in children 
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6025211;CC + TT;Efficacy;increased response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Genotypes CC + TT are associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Liver Neoplasms as compared to genotype CT.;and in people with Other:Liver cancer
;TACROLIMUS;ABCB1;rs2032582;AA + TT;Efficacy;increased response to ⮕ TACROLIMUS;Genotypes AA + TT is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes CC + CT.; in people with Disease:Nephrotic Syndrome
;LOVASTATIN;SLCO1B1;rs2291073;GT + TT;Efficacy;increased response to ⮕ LOVASTATIN;Genotypes GT + TT are associated with increased response to lovastatin as compared to genotype GG.;  
;TACROLIMUS;ABCB1;rs1128503;AA;Efficacy;increased response to ⮕ TACROLIMUS;Genotype AA is associated with increased response to tacrolimus in people with Nephrotic Syndrome as compared to genotypes AG + GG.; in people with Disease:Nephrotic Syndrome
;CATECHOLAMINES, METFORMIN;SLC22A3;rs8187725;T;Other, Metabolism/PK;decreased metabolism of ⮕ CATECHOLAMINES, METFORMIN;Allele T is associated with decreased metabolism of catecholamines and metformin as compared to allele C.;and  
;LOVASTATIN;LDLR;rs688;TT;Efficacy;increased response to ⮕ LOVASTATIN;Genotype TT is associated with increased response to lovastatin as compared to genotype CT.;  
;AMLODIPINE;CACNA1C;rs2239050;GG;Efficacy;increased clinical benefit to ⮕ AMLODIPINE;Genotype GG is associated with increased clinical benefit to amlodipine in people with Hypertension as compared to genotypes CC + CG.; in people with Other:Hypertension
;FLUVASTATIN;CYP3A4;rs4986910;AG;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype AG is associated with increased response to fluvastatin as compared to genotype AA.;  
;NALTREXONE;ADH1C;rs698;C;Efficacy;increased response to ⮕ NALTREXONE;Allele C is associated with increased response to naltrexone in men with Alcoholism as compared to allele T.; in men with Other:Alcohol abuse
;NALTREXONE;ADH1B;rs2066702;A;Efficacy;decreased response to ⮕ NALTREXONE;Allele A is associated with decreased response to naltrexone in men with Alcoholism as compared to allele G.; in men with Other:Alcohol abuse
;LOVASTATIN;LDLR;rs5925;CC;Efficacy;increased response to ⮕ LOVASTATIN;Genotype CC is associated with increased response to lovastatin as compared to genotype CT.;  
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;Efficacy;increased response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Liver Neoplasms as compared to genotypes GG + GT.;and in people with Other:Liver cancer
;FLUOXETINE;HTR2A;rs6313;GG;Efficacy;decreased time to response to ⮕ FLUOXETINE;Genotype GG is associated with decreased time to response to fluoxetine in children with Depression and Anxiety Disorders as compared to genotypes AA + AG.; in children with Other:Depression, Other:Anxiety Disorders
;NALTREXONE;ALDH2;rs671;G;Efficacy;increased response to ⮕ NALTREXONE;Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.; in men with Other:Alcohol abuse
;VARENICLINE;CYP2B6;rs8109525;AG + GG;Efficacy;increased response to ⮕ VARENICLINE;Genotypes AG + GG is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to genotype AA.; in people with Other:Tobacco Use Disorder
;TACROLIMUS;ABCB1;rs1128503;AG;Dosage;increased dose of ⮕ TACROLIMUS;Genotype AG is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;rs7089580;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin.;  
;CLOPIDOGREL;P2RY12;rs2046934;AA;Efficacy;increased response to ⮕ CLOPIDOGREL;Genotype AA is associated with increased response to clopidogrel in people with Coronary Disease as compared to genotypes AG + GG.; in people with Disease:Coronary Disease
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in children with null as compared to genotypes CT + TT.; in children with Other:null
;TACROLIMUS;ABCB1;rs1045642;AA;Dosage;increased dose of ⮕ TACROLIMUS;Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype AG.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C19;rs3814637;C;Dosage;dose of ⮕ WARFARIN;Allele C is associated with dose of warfarin.;  
;TACROLIMUS;ABCB1;rs2032582;AA;Dosage;increased dose of ⮕ TACROLIMUS;Genotype AA is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes AC + CC.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;rs4917639;A;Dosage;dose of ⮕ WARFARIN;Allele A is associated with dose of warfarin.;  
;WARFARIN;VKORC1;rs2359612;A;Dosage;dose of ⮕ WARFARIN;Allele A is associated with dose of warfarin.;  
;TACROLIMUS;CYP3A7;rs2257401;CG + GG;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotypes CG + GG are associated with decreased concentrations of tacrolimus in children with null as compared to genotype CC.; in children with Other:null
;CLOPIDOGREL;P2RY12;rs3732759;GG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype GG is associated with decreased response to clopidogrel in people with Coronary Disease as compared to genotypes AA + AG.; in people with Disease:Coronary Disease
;ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;rs1045642;AA;Efficacy;decreased clinical benefit to ⮕ ANTIBIOTICS, ESOMEPRAZOLE;Genotype AA is associated with decreased clinical benefit to Antibiotics and esomeprazole in children with Helicobacter Infections as compared to genotypes AG + GG.;and in children with Other:Helicobacter Infections
;CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;rs833061;CT + TT;Efficacy;increased response to ⮕ CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.;and in people with Disease:Multiple Myeloma
;DOLUTEGRAVIR;ABCG2;rs2231142;TT;Metabolism/PK;increased concentrations of ⮕ DOLUTEGRAVIR;Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;QUETIAPINE;DRD3;rs6280;TT;Metabolism/PK;increased clearance of ⮕ QUETIAPINE;Genotype TT is associated with increased clearance of quetiapine in healthy individuals as compared to genotypes CC + CT.; in healthy individuals 
;CLOPIDOGREL;ABCB1;rs1128503;AA + AG;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotypes AA + AG is associated with increased resistance to clopidogrel as compared to genotype GG.;  
;CISPLATIN, FLUOROURACIL;GALNT14;rs9679162;GG;Efficacy;increased response to ⮕ CISPLATIN, FLUOROURACIL;Genotype GG is associated with increased response to cisplatin and fluorouracil in people with Liver Neoplasms as compared to genotypes GT + TT.;and in people with Other:Liver cancer
;CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs2305948;CT + TT;Efficacy;increased response to ⮕ CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.;and in people with Disease:Multiple Myeloma
;CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs1870377;AT + TT;Efficacy;increased response to ⮕ CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;Genotypes AT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype AA.;and in people with Disease:Multiple Myeloma
;MORPHINE;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ MORPHINE;Genotypes AG + GG are associated with increased dose of morphine in people with Liver Neoplasms and Pain as compared to genotype AA.; in people with Other:Liver cancer, Other:Pain
;SORAFENIB;GALNT14;rs9679162;GG;Efficacy;increased response to ⮕ SORAFENIB;Genotype GG is associated with increased response to sorafenib in people with Hepatitis C and Liver Neoplasms as compared to genotypes GT + TT.; in people with Other:Hepatitis C virus infection, Other:Liver cancer
;MYCOPHENOLIC ACID;ABCC2;rs2273697;A;Metabolism/PK;decreased exposure to ⮕ MYCOPHENOLIC ACID;Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in children with liver transplantation as compared to genotypes CT + TT.; in children with Other:Liver transplantation
;MYCOPHENOLIC ACID;ABCC2;rs717620;T;Metabolism/PK;exposure to ⮕ MYCOPHENOLIC ACID;Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.; in people with Other:Kidney Transplantation
;FENTANYL;ATF2;rs7583431;A;Efficacy;increased response to ⮕ FENTANYL;Allele A is associated with increased response to fentanyl in people with Pain, Postoperative as compared to allele C.; in people with Disease:Pain, Postoperative
;MYCOPHENOLIC ACID;ABCC2;rs717620;T;Metabolism/PK;exposure to ⮕ MYCOPHENOLIC ACID;Allele T is associated with exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele C.; in people with Other:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;TACROLIMUS;NR1I2;rs3814055;CT + TT;Dosage;decreased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;AFLIBERCEPT, RANIBIZUMAB;ANO2;rs2110166;TT;Efficacy;increased clinical benefit to ⮕ AFLIBERCEPT, RANIBIZUMAB;Genotype TT is associated with increased clinical benefit to aflibercept or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CT.;or in people with Other:Macular Degeneration
;TACROLIMUS;NR1I2;rs3814055;CT + TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;VENLAFAXINE;SLC6A2;rs2242446;CC;Efficacy;increased response to ⮕ VENLAFAXINE;Genotype CC is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Disease:Major Depressive Disorder
;MYCOPHENOLIC ACID;ABCC2;rs2273697;A;Metabolism/PK;decreased exposure to ⮕ MYCOPHENOLIC ACID;Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G.; in people with Other:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;C;Efficacy;increased response to ⮕ BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.;or in people with Disease:Chronic hepatitis C virus infection
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; in people with Disease:Rheumatoid arthritis
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;rs6494223;T;Efficacy;increased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.;and in people with Disease:Alzheimer Disease
;ADALIMUMAB;FCGR2A;rs1801274;A;Efficacy;increased response to ⮕ ADALIMUMAB;Allele A is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;FLUOROURACIL;ENOSF1;rs2612091;CC;Efficacy;increased response to ⮕ FLUOROURACIL;Genotype CC is associated with increased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT.; in people with Other:Stomach Neoplasms
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotype CT is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.; in healthy individuals 
;DOBUTAMINE;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ DOBUTAMINE;Genotype CC is associated with increased response to dobutamine in healthy individuals as compared to genotype GG.; in healthy individuals 
;DACLATASVIR, SOFOSBUVIR;HINT1;rs7728773;CT + TT;Efficacy;increased clinical benefit to ⮕ DACLATASVIR, SOFOSBUVIR;Genotypes CT + TT is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.; in people with Other:Chronic hepatitis C virus infection
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Disease:Acute lymphoblastic leukemia
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;rs1800795;G;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele C.;or in people with Disease:Rheumatoid arthritis
;LITHIUM;;rs78015114;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;BUPRENORPHINE;OPRD1;rs678849;CC;Efficacy;decreased response to ⮕ BUPRENORPHINE;Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.; in people with Disease:Opioid-Related Disorders
;CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;Efficacy;resistance to ⮕ CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.;or  
;QUETIAPINE;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ QUETIAPINE;Genotype CC is associated with decreased metabolism of quetiapine in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;LITHIUM;;rs79663003;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C.; in people with Disease:Bipolar Disorder
;APREMILAST;CYP3A4, TMEM130;rs1203844;C;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele C is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele T.; in people with Other:Psoriasis
;APREMILAST;CYP3A4;rs35599367;A;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele A is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele G.; in people with Other:Psoriasis
;ATORVASTATIN;MYLIP;rs9370867;AA;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.; in people with Disease:Hypercholesterolemia
;LITHIUM;;rs75222709;T;Efficacy;increased response to ⮕ LITHIUM;Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele G.; in people with Disease:Bipolar Disorder
;LITHIUM;;rs74795342;G;Efficacy;increased response to ⮕ LITHIUM;Allele G is associated with increased response to lithium in people with Bipolar Disorder as compared to allele A.; in people with Disease:Bipolar Disorder
;APREMILAST;PDE4D;rs295943;T;Efficacy;decreased clinical benefit to ⮕ APREMILAST;Allele T is associated with decreased clinical benefit to apremilast in people with Psoriasis as compared to allele C.; in people with Other:Psoriasis
;METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes CG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;SIMVASTATIN;SCAP;rs12487736;TT;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotype TT is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.; in people with Disease:Hypercholesterolemia
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A.; in people with Other:total knee or hip arthroplasty
;CAFFEINE;CYP1A2;rs2069514;AA + AG;Other, Metabolism/PK;decreased metabolism of ⮕ CAFFEINE;Genotypes AA + AG are associated with decreased metabolism of caffeine as compared to genotype GG.;  
;APREMILAST;CDKN2B, CDKN2B-AS1;rs1063192;G;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele G is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele A.; in people with Other:Psoriasis
;PRAVASTATIN;LIPC;rs1800588;CT + TT;Efficacy;increased response to ⮕ PRAVASTATIN;Genotypes CT + TT are associated with increased response to pravastatin in people with Hypercholesterolemia as compared to genotype CC.; in people with Disease:Hypercholesterolemia
;WARFARIN;CYP2C9;rs1799853;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C.; in people with Other:total knee or hip arthroplasty
;EFAVIRENZ;CYP2B6;rs28399499;CT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.; in children with Disease:HIV infectious disease
;LOSARTAN;AGTR1;rs5186;AC + CC;Efficacy;increased response to ⮕ LOSARTAN;Genotypes AC + CC are associated with increased response to losartan in healthy individuals as compared to genotype AA.; in healthy individuals 
;(R)-METHADONE;NR1I3;rs2307424;GG;Metabolism/PK;increased clearance of ⮕ (R)-METHADONE;Genotype GG is associated with increased clearance of (R)-methadone in people with HIV Infections.; in people with Other:HIV infectious disease
;OLANZAPINE;HTR2A;rs6314;GG;Efficacy;increased response to ⮕ OLANZAPINE;Genotype GG is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes AA + AG.; in people with Disease:Schizophrenia
;SIMVASTATIN;ABCB1;rs1128503;GG;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotype GG is associated with decreased response to simvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.; in people with Disease:Hypercholesterolemia
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;Toxicity;increased discontinuation of ⮕ AZATHIOPRINE, MERCAPTOPURINE;Genotype CT is associated with increased discontinuation of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.;or in people with Disease:Inflammatory Bowel Diseases
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;(R)-METHADONE;NR1I3;rs3003596;GG;Metabolism/PK;increased clearance of ⮕ (R)-METHADONE;Genotype GG is associated with increased clearance of (R)-methadone in people with HIV Infections.; in people with Other:HIV infectious disease
;BEVACIZUMAB;CFH;rs1061170;CT;Dosage;increased dose of ⮕ BEVACIZUMAB;Genotype CT is associated with increased dose of bevacizumab in people with Macular Degeneration as compared to genotype TT.; in people with Disease:Macular Degeneration
;METHADONE;OPRD1;rs678849;CC;Efficacy;increased response to ⮕ METHADONE;Genotype CC is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.; in people with Disease:Opioid-Related Disorders
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;Dosage;decreased dose of ⮕ AZATHIOPRINE, MERCAPTOPURINE;Genotype CT is associated with decreased dose of azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.;and in people with Disease:Inflammatory Bowel Diseases
;BEVACIZUMAB;ARMS2;rs10490924;GT + TT;Efficacy;increased response to ⮕ BEVACIZUMAB;Genotypes GT + TT are associated with increased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.; in people with Disease:Macular Degeneration
;PRAVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;decreased clearance of ⮕ PRAVASTATIN;Allele C is associated with decreased clearance of pravastatin in healthy individuals as compared to allele T.; in healthy individuals 
;SIMVASTATIN;ABCB1;rs2032582;CC;Efficacy;decreased response to ⮕ SIMVASTATIN;Genotype CC is associated with decreased response to simvastatin in people with Hypercholesterolemia.; in people with Disease:Hypercholesterolemia
;WARFARIN;NQO1;rs1800566;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.;  
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotypes CC + CT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotypes CC + CT are associated with increased concentrations of atorvastatin as compared to genotype TT.;  
;DEFERASIROX;ABCC2;rs2273697;AG;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG.; in people with Disease:Beta-thalassemia and related diseases
;BUDESONIDE;;rs2392165;AG + GG;Efficacy;increased response to ⮕ BUDESONIDE;Genotypes AG + GG are associated with increased response to budesonide in children with Asthma as compared to genotype AA.; in children with Other:Asthma
;THIORIDAZINE;CYP2D6;rs1080985;CC + CG;Metabolism/PK;decreased metabolism of ⮕ THIORIDAZINE;Genotypes CC + CG is associated with decreased metabolism of thioridazine as compared to genotype GG.;  
;PRAVASTATIN;SLCO1B1;rs2306283;G;Metabolism/PK;decreased clearance of ⮕ PRAVASTATIN;Allele G is associated with decreased clearance of pravastatin in healthy individuals as compared to allele A.; in healthy individuals 
;DEFERASIROX;CYP1A2;rs2470890;CC + CT;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotypes CC + CT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype TT.; in people with Disease:Beta-thalassemia and related diseases
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotypes CT + TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Disease:Acute lymphoblastic leukemia
;DEFERASIROX;CYP1A2;rs762551;AC + CC;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.; in people with Disease:Beta-thalassemia and related diseases
;ATORVASTATIN;ABCC2;rs2273697;AG;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype AG is associated with decreased response to atorvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;OLANZAPINE;DRD2;rs1076560;AA + AC;Efficacy;increased response to ⮕ OLANZAPINE;Genotypes AA + AC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;DEFERASIROX;CYP1A1;rs2606345;AC + CC;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA.; in people with Disease:Beta-thalassemia and related diseases
;DEFERASIROX;UGT1A1;rs887829;TT;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotype TT is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.; in people with Disease:Beta-thalassemia and related diseases
;PRAVASTATIN;SLC10A1;rs2296651;A;Metabolism/PK;increased clearance of ⮕ PRAVASTATIN;Allele A is associated with increased clearance of pravastatin in healthy individuals as compared to allele G.; in healthy individuals 
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;rs1801274;GG;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG.;or in people with Disease:Psoriasis
;CAPECITABINE;MTHFR;rs1801133;GG;Metabolism/PK;increased exposure to ⮕ CAPECITABINE;Genotype GG is associated with increased exposure to capecitabine in people with Neoplasms as compared to genotypes AA + AG.; in people with Disease:Neoplasms
;DACLATASVIR, SOFOSBUVIR;IFNL3;rs12979860;CC;Efficacy;increased clinical benefit to ⮕ DACLATASVIR, SOFOSBUVIR;Genotype CC is associated with increased clinical benefit to daclatasvir null sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.; in people with Other:Chronic hepatitis C virus infection
;BUPRENORPHINE;;rs6973474;T;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.; in people with Other:Opioid-Related Disorders
;BUPRENORPHINE;;rs13169373;T;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.; in people with Other:Opioid-Related Disorders
;HALOPERIDOL;CYP2D6;rs3892097;CC;Efficacy;decreased response to ⮕ HALOPERIDOL;Genotype CC is associated with decreased response to haloperidol in men with Alcohol-Related Disorders, Alcoholic psychosis NOS and Alcoholism as compared to genotype CT.; in men with Disease:Alcoholic psychosis, Disease:Alcohol abuse, Disease:Alcohol-Related Disorders
;NEVIRAPINE;CYP2B6;rs28399499;C;Metabolism/PK;increased concentrations of ⮕ NEVIRAPINE;Allele C is associated with increased concentrations of nevirapine in women as compared to allele T.; in women 
;IMATINIB;SLC22A1;rs628031;GG;Metabolism/PK;decreased clearance of ⮕ IMATINIB;Genotype GG is associated with decreased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;NICOTINE;CHRNA5;rs16969968;A;Dosage;increased dose of ⮕ NICOTINE;Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G.; in people with Disease:Tobacco Use Disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in children with liver transplantation as compared to genotype CC.; in children with Disease:Liver transplantation
;BUPRENORPHINE;;rs62368105;G;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele G is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele A.; in people with Other:Opioid-Related Disorders
;BUPRENORPHINE;;rs11782370;T;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.; in people with Other:Opioid-Related Disorders
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;rs396991;AA;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype AA is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AC + CC.;or in people with Disease:Psoriasis
;BUPRENORPHINE;;rs7205113;T;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele T is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.; in people with Other:Opioid-Related Disorders
;ETANERCEPT;IL10;rs1800896;CC;Efficacy;increased response to ⮕ ETANERCEPT;Genotype CC is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;BUPRENORPHINE;ADAMTSL2;rs756770;A;Efficacy;increased response to ⮕ BUPRENORPHINE;Allele A is associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to allele C.; in people with Other:Opioid-Related Disorders
;(R)-METHADONE;ABCB1;rs2032582;AA;Metabolism/PK;decreased clearance of ⮕ (R)-METHADONE;Genotype AA is associated with decreased clearance of (R)-methadone in people with HIV Infections as compared to genotypes AT + TT.; in people with Other:HIV infectious disease
;ETANERCEPT;TGFB1;rs1800471;CG;Efficacy;decreased response to ⮕ ETANERCEPT;Genotype CG is associated with decreased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;ATORVASTATIN;SLCO1B1;rs2306283;AG + GG;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes AG + GG is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype AA.; in people with Disease:Hypercholesterolemia
;EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;rs3745274;T;Efficacy;increased response to ⮕ EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;Allele T is associated with increased response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype GG.;or in women with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs2279345;CC + CT;Metabolism/PK;increased clearance of ⮕ EFAVIRENZ;Genotypes CC + CT are associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Efficacy;increased response to ⮕ EFAVIRENZ;Genotype TT is associated with increased response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;METHOTREXATE;SLCO1B1;rs4149056;TT;Metabolism/PK;increased exposure to ⮕ METHOTREXATE;Genotype TT is associated with increased exposure to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in people with Other:Acute lymphoblastic leukemia
;XK469;AOX1;rs10931910;G;Metabolism/PK;decreased clearance of ⮕ XK469;Allele G is associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.; in people with Disease:Neoplasms
;SIMVASTATIN;PON1;rs662;CC;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype CC is associated with increased response to simvastatin in people with Coronary Disease as compared to genotype TT.; in people with Disease:Coronary Disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;MERCAPTOPURINE;NUDT15;rs116855232;T;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; in children with Disease:Acute lymphoblastic leukemia
;ETANERCEPT;TNF;rs1800629;GG;Efficacy;increased response to ⮕ ETANERCEPT;Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; in people with Disease:Rheumatoid arthritis
;MERCAPTOPURINE;TPMT;rs1142345;CT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Disease:Acute lymphoblastic leukemia
;NEVIRAPINE;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ NEVIRAPINE;Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.; in women 
;BUCINDOLOL;ADRB1;rs1801253;CC;Efficacy;increased response to ⮕ BUCINDOLOL;Genotype CC is associated with increased response to bucindolol in people with Heart Failure as compared to genotypes CG + GG.; in people with Disease:Heart Failure
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A4;rs4986907;CT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CT is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;NEVIRAPINE;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ NEVIRAPINE;Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;PHENPROCOUMON;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ PHENPROCOUMON;Genotype CC is associated with increased dose of phenprocoumon as compared to genotypes CT + TT.;  
;WARFARIN;CYP4F2;rs2189784;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Disease:Heart valve replacement
;PHENPROCOUMON;EPHX1;rs1051740;CC;Dosage, Metabolism/PK;decreased dose of ⮕ PHENPROCOUMON;Genotype CC is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT.;  
;ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;rs1800629;A;Efficacy;decreased clinical benefit to ⮕ ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;Allele A is associated with decreased clinical benefit to aspirin, diclofenac, ibuprofen, indomethacin, ketorolac or naproxen in people with Migraine without Aura as compared to allele G.;or in people with Other:Migraine without Aura
;PHENPROCOUMON;PROC;rs1799808;CC;Dosage, Metabolism/PK;increased dose of ⮕ PHENPROCOUMON;Genotype CC is associated with increased dose of phenprocoumon as compared to genotypes CT + TT.;  
;LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;Metabolism/PK;increased steady-state concentration of ⮕ LAMOTRIGINE;Genotypes CT + TT are associated with increased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;INFLIXIMAB;TNF;rs1800629;GG;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; in people with Disease:Rheumatoid arthritis
;IMATINIB;SLC22A4;rs1050152;TT;Efficacy;decreased response to ⮕ IMATINIB;Genotype TT is associated with decreased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.; in people with Disease:Gastrointestinal Stromal Tumors
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CC.; in people with Disease:Heart valve replacement
;ATORVASTATIN;TNF;rs1800629;AA + AG;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotypes AA + AG are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;IMATINIB;SLC22A5;rs2631367;CG + GG;Efficacy;increased response to ⮕ IMATINIB;Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.; in people with Disease:Gastrointestinal Stromal Tumors
;IMATINIB;SLC22A5;rs2631372;CG + GG;Efficacy;increased response to ⮕ IMATINIB;Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.; in people with Disease:Gastrointestinal Stromal Tumors
;METFORMIN;SP1;rs784888;G;Metabolism/PK;decreased clearance of ⮕ METFORMIN;Allele G is associated with decreased clearance of metformin in healthy individuals as compared to allele C.; in healthy individuals 
;ETANERCEPT;TNF;rs1799724;CT + TT;Efficacy;increased response to ⮕ ETANERCEPT;Genotypes CT + TT is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;WARFARIN;EPHX1;rs2260863;CG;Dosage;increased dose of ⮕ WARFARIN;Genotype CG is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype CC.; in people with Disease:Heart valve replacement
;WARFARIN;APOE;rs7412;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CT.; in people with Disease:Heart valve replacement
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE;Genotypes AG + GG are associated with decreased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to genotype AA.; in people with Disease:Non-Hodgkin Lymphoma
;WARFARIN;CYP3A4;rs28371759;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AG.; in people with Disease:Heart valve replacement
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype AA is associated with decreased response to clopidogrel as compared to genotypes AG + GG.;  
;WARFARIN;CYP1A2;rs2069514;GG;Dosage;decreased dose of ⮕ WARFARIN;Genotype GG are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Disease:Heart valve replacement
;IMATINIB;ABCC4;rs9561765;AG;Efficacy;increased response to ⮕ IMATINIB;Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.; in people with Disease:Gastrointestinal Stromal Tumors
;WARFARIN;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in children as compared to genotypes CT + TT.; in children 
;ATORVASTATIN;DRD3;rs6280;TT;Metabolism/PK;increased concentrations of ⮕ ATORVASTATIN;Genotype TT are associated with increased concentrations of atorvastatin in healthy individuals as compared to genotypes CC + CT.; in healthy individuals 
;WARFARIN;SLC15A2;rs1143671;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;ATORVASTATIN;MTHFR;rs1801133;AA + AG;Metabolism/PK;decreased concentrations of ⮕ ATORVASTATIN;Genotypes AA + AG are associated with decreased concentrations of atorvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;LAMOTRIGINE;UGT1A4;rs2011425;GG + GT;Metabolism/PK;decreased steady-state concentration of ⮕ LAMOTRIGINE;Genotypes GG + GT are associated with decreased steady-state concentration of lamotrigine in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;WARFARIN;EPHX1;rs2260863;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype CG.; in people with Other:Atrial Fibrillation
;RITONAVIR;NR1I2;rs1523130;CC + CT;Metabolism/PK;increased concentrations of ⮕ RITONAVIR;Genotypes CC + CT are associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;L-TRYPTOPHAN;SLC22A2;rs316019;CC;Metabolism/PK;increased clearance of ⮕ L-TRYPTOPHAN;Genotype CC is associated with increased clearance of l-tryptophan as compared to genotypes AA + AC.;  
;WARFARIN;VKORC1;rs9923231;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.; in people with Other:Atrial Fibrillation
;PHENPROCOUMON;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ PHENPROCOUMON;Allele A is associated with decreased dose of phenprocoumon in children as compared to allele G.; in children 
;RITONAVIR;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ RITONAVIR;Genotypes CC + CT is associated with increased concentrations of ritonavir in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;RITONAVIR;ABCB1;rs2032582;AC + CC;Metabolism/PK;concentrations of ⮕ RITONAVIR;Genotypes AC + CC is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;ERENUMAB;RAMP1;rs13386048;A;Efficacy;decreased clinical benefit to ⮕ ERENUMAB;Allele A is associated with decreased clinical benefit to erenumab in people with Migraine with Aura or Migraine without Aura as compared to allele G.; in people with Other:Migraine with Aura, Other:Migraine without Aura
;ADALIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;Efficacy;increased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotype GG is associated with increased response to adalimumab or infliximab in people with Spondylitis, Ankylosing as compared to genotype AG.;or in people with Other:Spondylitis, Ankylosing
;ERLOTINIB;CYP1A2;rs2472304;AA + AG;Metabolism/PK;increased concentrations of ⮕ ERLOTINIB;Genotypes AA + AG is associated with increased concentrations of erlotinib in healthy individuals as compared to genotype GG.; in healthy individuals 
;SIROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;decreased trough concentration of ⮕ SIROLIMUS;Genotypes CT + TT are associated with decreased trough concentration of sirolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.; in people with Other:Atrial Fibrillation
;OLANZAPINE;BDNF;rs6265;CC;Efficacy;increased response to ⮕ OLANZAPINE;Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT.; in people with Disease:Schizophrenia
;RITONAVIR;NR1I2;rs6785049;AA + AG;Metabolism/PK;concentrations of ⮕ RITONAVIR;Genotypes AA + AG is associated with concentrations of ritonavir in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;ERENUMAB;RAMP1;rs6431564;G;Efficacy;increased clinical benefit to ⮕ ERENUMAB;Allele G is associated with increased clinical benefit to erenumab in people with Migraine with Aura or Migraine without Aura as compared to allele A.; in people with Other:Migraine with Aura, Other:Migraine without Aura
;INFLIXIMAB;TNF;rs1800629;GG;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG.; in people with Disease:Rheumatoid arthritis
;LOSARTAN;SLC22A12;rs1529909;CC + CT;Efficacy;decreased response to ⮕ LOSARTAN;Genotypes CC + CT is associated with decreased response to losartan in people with Hypertension and Hyperuricemia as compared to genotype TT.; in people with Disease:Hypertension, Disease:Hyperuricemia
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;ERENUMAB;RAMP1;rs12465864;G;Efficacy;decreased clinical benefit to ⮕ ERENUMAB;Allele G is associated with decreased clinical benefit to erenumab in people with Migraine with Aura or Migraine without Aura as compared to allele A.; in people with Other:Migraine with Aura, Other:Migraine without Aura
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;GG;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.;or in people with Disease:Rheumatoid arthritis
;LOSARTAN;SLC22A12;rs3825016;CT + TT;Efficacy;decreased response to ⮕ LOSARTAN;Genotypes CT + TT is associated with decreased response to losartan in people with Hypertension and Hyperuricemia as compared to genotype CC.; in people with Disease:Hypertension, Disease:Hyperuricemia
;ETHANOL;OPRM1;rs1799971;AG + GG;Metabolism/PK;increased concentrations of ⮕ ETHANOL;Genotypes AG + GG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype AA.; in healthy individuals 
;ADALIMUMAB;TNF;rs1800629;GG;Efficacy;increased response to ⮕ ADALIMUMAB;Genotype GG is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotype AG.; in people with Disease:Rheumatoid arthritis
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;SIROLIMUS;IL10;rs1800896;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ SIROLIMUS;Genotype CC are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;CYCLOSPORINE;ABCB1;rs9282564;CT;Toxicity, Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Genotype CT is associated with increased concentrations of cyclosporine in people with heart transplantation as compared to genotype TT.; in people with Other:Heart transplantation
;CLADRIBINE, CYTARABINE;RRM1;rs1042919;AT;Efficacy;decreased response to ⮕ CLADRIBINE, CYTARABINE;Genotype AT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.;and in children with Disease:Leukemia, Myeloid, Acute
;CLADRIBINE, CYTARABINE;RRM2B;rs1265138;AA;Efficacy;increased response to ⮕ CLADRIBINE, CYTARABINE;Genotype AA is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.;and in children with Disease:Leukemia, Myeloid, Acute
;FLUOROURACIL;DPYD;rs1801265;AA;Efficacy;increased response to ⮕ FLUOROURACIL;Genotype AA is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Disease:Acute lymphoblastic leukemia
;CLADRIBINE, CYTARABINE;RRM1;rs2898950;AC + CC;Efficacy;increased response to ⮕ CLADRIBINE, CYTARABINE;Genotypes AC + CC is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype AA.;and in children with Disease:Leukemia, Myeloid, Acute
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;rs12979860;CC;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;BUPROPION;CYP2B6;rs2279343;AA;Efficacy;increased response to ⮕ BUPROPION;Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.; in people with Disease:Tobacco Use Disorder
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;rs8099917;TT;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;CLADRIBINE, CYTARABINE;RRM1;rs1561876;GG;Efficacy;decreased response to ⮕ CLADRIBINE, CYTARABINE;Genotype GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;and in children with Disease:Leukemia, Myeloid, Acute
;COTININE;PSMA4;rs57064725;A;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele C.; in people with Disease:Tobacco Use Disorder
;METHOTREXATE;ATIC;rs16853826;GG;Toxicity;increased discontinuation of ⮕ METHOTREXATE;Genotype GG is associated with increased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ABCC1;rs35592;TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotype TT is associated with increased response to methotrexate in people with Psoriasis as compared to genotypes CC + CT.; in people with Disease:Psoriasis
;COTININE;CHRNA5;rs16969968;A;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.; in people with Disease:Tobacco Use Disorder
;INFLIXIMAB;TNFRSF10A;rs20575;CC;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype CC is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.; in people with Disease:Rheumatoid arthritis
;CLADRIBINE, CYTARABINE;RRM2;rs1130609;GT + TT;Efficacy;decreased response to ⮕ CLADRIBINE, CYTARABINE;Genotypes GT + TT is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype GG.;and in children with Disease:Leukemia, Myeloid, Acute
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";FTO;rs9939609;AA + AT;Efficacy;"decreased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection, Disease:HIV infectious disease
;COTININE;;rs77107237;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele A.; in people with Disease:Tobacco Use Disorder
;CLOZAPINE;DTNBP1;rs742105;CT + TT;Efficacy;increased response to ⮕ CLOZAPINE;Genotypes CT + TT are associated with increased response to clozapine in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;CLADRIBINE, CYTARABINE;RRM2;rs5030743;CG + GG;Efficacy;decreased response to ⮕ CLADRIBINE, CYTARABINE;Genotypes CG + GG is associated with decreased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotype CC.;and in children with Disease:Leukemia, Myeloid, Acute
;COTININE;CHRNB4;rs10851907;A;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.; in people with Disease:Tobacco Use Disorder
;SIROLIMUS;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ SIROLIMUS;Genotypes AA + AG are associated with increased dose-adjusted trough concentrations of sirolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;WARFARIN;SLCO1B3;rs7311358;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;WARFARIN;SLC15A2;rs1143672;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotype GG.;  
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3, IFNL4;rs12979860;CC;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";Genotype CC is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;SLCO1B3;rs4149117;GG;Dosage;decreased dose of ⮕ WARFARIN;Genotype GG is associated with decreased dose of warfarin as compared to genotypes GT + TT.;  
;ETANERCEPT;TNF;rs1800629;GG;Efficacy;increased response to ⮕ ETANERCEPT;Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG.; in people with Disease:Rheumatoid arthritis
;COTININE;CHRNA3;rs7170068;A;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G.; in people with Disease:Tobacco Use Disorder
;SUNITINIB;ABCB1;rs1045642;AA;Efficacy;decreased response to ⮕ SUNITINIB;Genotype AA is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.; in people with Disease:Renal Cell Carcinoma
;WARFARIN;CYP4F2;rs2108622;CC;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.;  
;"""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";IFNL3;rs8099917;TT;Efficacy;"increased response to ⮕ ""INTERFERON ALFA-2A, RECOMBINANT"", ""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;FLUPENTHIXOL;NFKB1;rs230504;CT + TT;Efficacy;increased response to ⮕ FLUPENTHIXOL;Genotypes CT + TT is associated with increased response to flupenthixol in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;MONTELUKAST;SLCO2B1;rs12422149;AG;Efficacy, Metabolism/PK;decreased response to ⮕ MONTELUKAST;Genotype AG is associated with decreased response to montelukast in people with Asthma as compared to genotype GG.; in people with Disease:Asthma
;DEFERASIROX;CYP24A1;rs927650;CT + TT;Metabolism/PK;decreased metabolism of ⮕ DEFERASIROX;Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.; in people with Disease:Beta-thalassemia and related diseases
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;DEFERASIROX;CYP24A1;rs2585428;CT + TT;Metabolism/PK;decreased metabolism of ⮕ DEFERASIROX;Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.; in people with Disease:Beta-thalassemia and related diseases
;FLUPENTHIXOL;NFKB1;rs3774959;AG;Efficacy;increased response to ⮕ FLUPENTHIXOL;Genotype AG is associated with increased response to flupenthixol in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;ANTIDEPRESSANTS;TPH2;rs10879346;C;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT.; in people with Disease:Major Depressive Disorder
;METHOTREXATE POLYGLUTAMATE;IMPDH1;rs4731448;GG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE POLYGLUTAMATE;Genotype GG is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AG.; in children with Other:Acute lymphoblastic leukemia
;CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;Efficacy;increased response to ⮕ CARBOPLATIN, CISPLATIN;Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE POLYGLUTAMATE;CEP72;rs924607;TT;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE POLYGLUTAMATE;Genotype TT is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;IL10;rs1800896;TT;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype TT is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotype CT.; in people with Disease:Liver transplantation
;MIRTAZAPINE, VENLAFAXINE;TPH2;rs1487278;C;Efficacy;increased response to ⮕ MIRTAZAPINE, VENLAFAXINE;Allele C is associated with increased response to mirtazapine and venlafaxine in people with Depression as compared to genotype TT.;and in people with Disease:Depression
;TACROLIMUS;ABCB1;rs1045642;GG;Dosage;increased dose of ⮕ TACROLIMUS;Genotype GG is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotypes AA + AG.; in people with Disease:Liver transplantation
;BILIRUBIN;UGT1A1;rs4124874;GG + GT;Metabolism/PK;increased concentrations of ⮕ BILIRUBIN;Genotypes GG + GT is associated with increased concentrations of bilirubin in people with Neoplasms as compared to genotype TT.; in people with Disease:Neoplasms
;CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;Efficacy;increased response to ⮕ CARBOPLATIN, CISPLATIN;Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Lung Neoplasms as compared to genotype GG.;and in people with Disease:Lung Neoplasms
;DEFERASIROX;CYP24A1;rs2248359;CT + TT;Metabolism/PK;decreased metabolism of ⮕ DEFERASIROX;Genotypes CT + TT is associated with decreased metabolism of deferasirox in people with beta-Thalassemia as compared to genotype CC.; in people with Disease:Beta-thalassemia and related diseases
;FLUPENTHIXOL;NFKB1;rs230493;AT;Efficacy;increased response to ⮕ FLUPENTHIXOL;Genotype AT is associated with increased response to flupenthixol in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;METHOTREXATE POLYGLUTAMATE;SLCO1B3;rs7311358;AA + AG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE POLYGLUTAMATE;Genotypes AA + AG is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;NICOTINE;FMO3;rs2266780;AA;Metabolism/PK;increased metabolism of ⮕ NICOTINE;Genotype AA is associated with increased metabolism of nicotine as compared to genotypes AG + GG.;  
;PAZOPANIB;VEGFA;rs699947;A;Efficacy;decreased response to ⮕ PAZOPANIB;Allele A is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;METHOTREXATE POLYGLUTAMATE;FSTL5;rs3749598;AA + AC;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE POLYGLUTAMATE;Genotypes AA + AC is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in children with Other:Acute lymphoblastic leukemia
;METHOTREXATE POLYGLUTAMATE;ATG16L1;rs2241880;AG + GG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE POLYGLUTAMATE;Genotypes AG + GG is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in children with Other:Acute lymphoblastic leukemia
;FLUOROURACIL;DPYD;rs3918290;CC;Efficacy;increased response to ⮕ FLUOROURACIL;Genotype CC is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.; in children with Disease:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;THEOPHYLLINE;CYP1A2;rs2069514;AA + AG;Other, Metabolism/PK;decreased metabolism of ⮕ THEOPHYLLINE;Genotypes AA + AG are associated with decreased metabolism of theophylline in people with Asthma as compared to genotype GG.; in people with Disease:Asthma
;INFLIXIMAB;TNFRSF10A;rs20575;CC;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype CC is associated with increased response to infliximab in people with Arthritis, Psoriatic as compared to genotypes CG + GG.; in people with Disease:Arthritis, Psoriatic
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype TT is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Psoriatic as compared to genotypes CC + CT.;and in people with Disease:Arthritis, Psoriatic
;PAZOPANIB;VEGFA;rs2010963;G;Efficacy;decreased response to ⮕ PAZOPANIB;Allele G is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;rs20575;CC;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype CC is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CG + GG.;and in people with Disease:Rheumatoid arthritis
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotype TT is associated with decreased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;and in people with Disease:Rheumatoid arthritis
;PAZOPANIB;VEGFA;rs833061;T;Efficacy;decreased response to ⮕ PAZOPANIB;Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;ETANERCEPT;PTTG1;rs2431697;CC + CT;Efficacy;decreased response to ⮕ ETANERCEPT;Genotypes CC + CT is associated with decreased response to etanercept in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;CISPLATIN, GEMCITABINE;CMPK1;rs4492666;CC;Efficacy;decreased response to ⮕ CISPLATIN, GEMCITABINE;Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs503464;A;Efficacy;increased response to ⮕ BUPROPION, NICOTINE, VARENICLINE;Allele A is associated with increased response to bupropion, nicotine and varenicline in people with Tobacco Use Disorder as compared to allele T.;and in people with Disease:Tobacco Use Disorder
;VORICONAZOLE;NR1I2;rs6785049;GG;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.;  
;ETANERCEPT;HLA-B;rs13437088;TT;Efficacy;decreased response to ⮕ ETANERCEPT;Genotype TT is associated with decreased response to etanercept in people with Psoriasis as compared to genotypes CC + CT.; in people with Disease:Psoriasis
;ETANERCEPT;MAP3K1;rs96844;AG + GG;Efficacy;increased response to ⮕ ETANERCEPT;Genotypes AG + GG is associated with increased response to etanercept in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;CLOZAPINE;COMT;rs4680;GG;Efficacy;increased response to ⮕ CLOZAPINE;Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AA + AG.; in people with Disease:Schizophrenia
;CLOZAPINE;HTR1A;rs6295;GG;Efficacy;increased response to ⮕ CLOZAPINE;Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes CC + CG.; in people with Disease:Schizophrenia
;ETANERCEPT;GBP6;rs928655;AG + GG;Efficacy;increased response to ⮕ ETANERCEPT;Genotypes AG + GG is associated with increased response to etanercept in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;CELIPROLOL;ABCB1;rs1045642;G;Metabolism/PK;decreased concentrations of ⮕ CELIPROLOL;Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele A.; in healthy individuals 
;ATORVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype TT is associated with decreased response to atorvastatin as compared to genotypes CC + CT.;  
;CELIPROLOL;SLCO1A2;rs11568563;G;Metabolism/PK;decreased concentrations of ⮕ CELIPROLOL;Allele G is associated with decreased concentrations of Celiprolol in healthy individuals as compared to allele T.; in healthy individuals 
;ETANERCEPT;IL12B;rs2546890;AG + GG;Efficacy;decreased response to ⮕ ETANERCEPT;Genotypes AG + GG is associated with decreased response to etanercept in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;TEMOZOLOMIDE;ABCB1;rs1128503;AA + AG;Metabolism/PK;decreased concentrations of ⮕ TEMOZOLOMIDE;Genotypes AA + AG are associated with decreased concentrations of temozolomide in people with Glioma as compared to genotype GG.; in people with Other:Glioma
;IVACAFTOR;SLC26A9;rs7512462;CC + CT;Efficacy;increased response to ⮕ IVACAFTOR;Genotypes CC + CT is associated with increased response to ivacaftor in children with Cystic Fibrosis as compared to genotype TT.; in children with Disease:Cystic Fibrosis
;GEMCITABINE;DCK;rs66878317;AG + GG;Metabolism/PK;increased clearance of ⮕ GEMCITABINE;Genotypes AG + GG are associated with increased clearance of gemcitabine as compared to genotype AA.;  
;VORICONAZOLE;NR1I2;rs3814057;CC;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype CC is associated with increased concentrations of voriconazole as compared to genotypes AA + AC.;  
;NICOTINE;COMT;rs4680;GG;Efficacy;increased response to ⮕ NICOTINE;Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.; in people with Disease:Tobacco Use Disorder
;MILNACIPRAN;ADRA2A;rs1800544;CC + CG;Efficacy;increased response to ⮕ MILNACIPRAN;Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.; in people with Disease:Depressive Disorder
;PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;rs4244809;GG;Efficacy;decreased resistance to ⮕ PLATINUM COMPOUNDS;Genotype GG is associated with decreased resistance to Platinum compounds in women with Ovarian Neoplasms as compared to genotypes AA + AG.; in women with Disease:Ovarian Neoplasms
;VORICONAZOLE;FMO3;rs2266780;AA;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG.;  
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;GG;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype GG is associated with increased response to hmg coa reductase inhibitors as compared to genotype AA.;  
;FLUVOXAMINE;FGF2;rs1449683;CC + CT;Efficacy;decreased response to ⮕ FLUVOXAMINE;Genotypes CC + CT are associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to genotype TT.; in people with Disease:Depressive Disorder
;VORICONAZOLE;POR;rs10954732;GG;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.;  
;PLATINUM COMPOUNDS;INS-IGF2;rs3842761;GG;Efficacy;decreased resistance to ⮕ PLATINUM COMPOUNDS;Genotype GG is associated with decreased resistance to Platinum compounds in women with Ovarian Neoplasms.; in women with Disease:Ovarian Neoplasms
;MILNACIPRAN;HTR1A;rs6295;CC + CG;Efficacy;increased response to ⮕ MILNACIPRAN;Genotypes CC + CG are associated with increased response to milnacipran in people with Depressive Disorder as compared to genotype GG.; in people with Disease:Depressive Disorder
;VALPROIC ACID;SCN2A;rs17183814;AA + AG;Efficacy;increased resistance to ⮕ VALPROIC ACID;Genotypes AA + AG is associated with increased resistance to valproic acid in children with Epilepsy as compared to genotype GG.; in children with Other:Epilepsy
;VALPROIC ACID;SCN1A;rs2298771;TT;Efficacy;increased clinical benefit to ⮕ VALPROIC ACID;Genotype TT is associated with increased clinical benefit to valproic acid in children with Epilepsy as compared to genotypes CC + CT.; in children with Other:Epilepsy
;VORICONAZOLE;NR1I2;rs2461817;AA;Metabolism/PK;decreased concentrations of ⮕ VORICONAZOLE;Genotype AA is associated with decreased concentrations of voriconazole as compared to genotype AC.;  
;VORICONAZOLE;NR1I2;rs3732359;GG;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA.;  
;METHOTREXATE;ABCC2;rs3740066;TT;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotype TT is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotypes CC + CT.; in children with Disease:Osteosarcoma
;CISPLATIN, GEMCITABINE;RRM1;rs720106;TT;Efficacy;decreased response to ⮕ CISPLATIN, GEMCITABINE;Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;and in people with Disease:Non-Small Cell Lung Carcinoma
;VORICONAZOLE;NR1I2;rs7643645;AA;Metabolism/PK;increased concentrations of ⮕ VORICONAZOLE;Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG.;  
;SIMVASTATIN;SLCO1B1;rs2306283;AA;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype AA is associated with increased response to simvastatin as compared to genotype GG.;  
;CISPLATIN, GEMCITABINE;RRM1;rs232043;AA;Efficacy;decreased response to ⮕ CISPLATIN, GEMCITABINE;Genotype AA is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;and in people with Disease:Non-Small Cell Lung Carcinoma
;CISPLATIN, GEMCITABINE;CMPK1;rs11211524;CC;Efficacy;decreased response to ⮕ CISPLATIN, GEMCITABINE;Genotype CC is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;and in people with Disease:Non-Small Cell Lung Carcinoma
;SIMVASTATIN;SLCO1B1;rs2306283;GG;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype GG is associated with increased response to simvastatin as compared to genotype AA.;  
;CISPLATIN, GEMCITABINE;RRM1;rs2284449;TT;Efficacy;decreased response to ⮕ CISPLATIN, GEMCITABINE;Genotype TT is associated with decreased response to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung.;and in people with Disease:Non-Small Cell Lung Carcinoma
;ACENOCOUMAROL;GGCX;rs11676382;G;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele G is associated with decreased dose of acenocoumarol as compared to allele C.;  
;ACENOCOUMAROL;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ ACENOCOUMAROL;Allele T is associated with increased dose of acenocoumarol as compared to allele C.;  
;ACENOCOUMAROL;VKORC1;rs7294;T;Dosage;increased dose of ⮕ ACENOCOUMAROL;Allele T is associated with increased dose of acenocoumarol as compared to allele C.;  
;METHOTREXATE;NR1I2;rs6785049;G;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Allele G is associated with increased concentrations of methotrexate in children with Osteosarcoma as compared to allele A.; in children with Disease:Osteosarcoma
;RITUXIMAB;TGFB1;rs1800470;AG;Efficacy;increased response to ⮕ RITUXIMAB;Genotype AG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Disease:Rheumatoid arthritis
;RITUXIMAB;TGFB1;rs1800471;CG;Efficacy;increased response to ⮕ RITUXIMAB;Genotype CG is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;A;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.;and in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G.;and in people with Disease:Hepatitis C virus infection
;SIMVASTATIN;CYP3A4;rs35599367;A;Efficacy;increased response to ⮕ SIMVASTATIN;Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype GG.; in people with Other:Hypercholesterolemia
;PIOGLITAZONE;ADIPOQ;rs2241766;GT;Efficacy;increased response to ⮕ PIOGLITAZONE;Genotype GT is associated with increased response to pioglitazone in people with Diabetes Mellitus as compared to genotype TT.; in people with Disease:Diabetes Mellitus
;MORPHINE;OPRM1;rs1799971;GG;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Genotype GG is associated with increased dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Disease:Pain, Postoperative
;MORPHINE;OPRM1;rs1799971;GG;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.; in women with Disease:Pain, Postoperative
;ACENOCOUMAROL;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele T is associated with decreased dose of acenocoumarol as compared to allele C.;  
;ROSUVASTATIN;CYP3A5;rs776746;C;Efficacy;increased response to ⮕ ROSUVASTATIN;Allele C is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele T.; in people with Disease:Myocardial Infarction
;METHOTREXATE;GSK3B;rs3732361;A;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Allele A is associated with increased concentrations of methotrexate in children with Osteosarcoma as compared to allele G.; in children with Disease:Osteosarcoma
;NALOXONE;OPRM1;rs1799971;AG + GG;Other;increased response to ⮕ NALOXONE;Genotypes AG + GG is associated with increased response to naloxone as compared to genotype AA.;  
;TIPIFARNIB;ABCB1;rs1128503;AA;Other, Metabolism/PK;decreased metabolism of ⮕ TIPIFARNIB;Genotype AA is associated with decreased metabolism of tipifarnib as compared to genotypes AG + GG.;  
;ETANERCEPT;ZNF816;rs9304742;CC;Efficacy;decreased response to ⮕ ETANERCEPT;Genotype CC is associated with decreased response to etanercept in people with Psoriasis as compared to genotypes CT + TT.; in people with Disease:Psoriasis
;ROSUVASTATIN;ABCG2;rs2231142;T;Efficacy;increased response to ⮕ ROSUVASTATIN;Allele T is associated with increased response to rosuvastatin in people with Myocardial Infarction as compared to allele G.; in people with Disease:Myocardial Infarction
;NALTREXONE;OPRM1;rs1799971;G;Efficacy;increased response to ⮕ NALTREXONE;Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A.; in men with Disease:Alcohol abuse
;ANTIPSYCHOTICS;NRG1;rs13250975;G;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Allele G is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin in children with Heart Diseases as compared to genotypes AG + GG.; in children with Disease:Heart Diseases
;METHOTREXATE;SLCO1A2;rs4149009;CC + CT;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Genotypes CC + CT are associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.; in children with Other:Acute lymphoblastic leukemia
;ANTIPSYCHOTICS;;rs2513265;A;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Allele A is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;ADCY2;rs1544938;C;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Allele C is associated with increased response to antipsychotics in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;NRG1;rs17716295;A;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Allele A is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele C.; in people with Disease:Schizophrenia
;NICOTINE;CHRNA5;rs16969968;GG;Other;decreased dose of ⮕ NICOTINE;Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.; in people with Disease:Tobacco Use Disorder
;METHADONE;DAO;rs55944529;TT;Dosage;increased dose of ⮕ METHADONE;Genotype TT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.; in people with Other:Heroin Dependence
;ANTIPSYCHOTICS;CCL2;rs4795893;G;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Allele G is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;CCL2;rs4586;T;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Allele T is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele C.; in people with Disease:Schizophrenia
;METHADONE;DAO;rs55944529;TT;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype TT is associated with increased concentrations of methadone in people with Heroin Dependence as compared to genotypes CC + CT.; in people with Other:Heroin Dependence
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CT.; in people with Disease:Kidney Transplantation
;ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;rs3803189;GG + GT;Efficacy;increased response to ⮕ ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;Genotypes GG + GT are associated with increased response to escitalopram, fluoxetine, fluvoxamine or sertraline in people with Depressive Disorder, Major as compared to genotype TT.;or in people with Other:Major Depressive Disorder
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.; in women Other:HIV infectious disease, Other:Malaria
;IVACAFTOR;CFTR;rs121908755;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;METHADONE;DRD1;rs5326;TT;Dosage;increased dose of ⮕ METHADONE;Genotype TT is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes CC + CT.; in people with Other:Heroin Dependence
;IVACAFTOR;CFTR;rs121908757;C;Efficacy;increased response to ⮕ IVACAFTOR;Allele C is associated with increased response to ivacaftor.;  
;IVACAFTOR;CFTR;rs80282562;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;RIFAMPIN;SLCO1B1;rs4149056;CT;Metabolism/PK;increased concentrations of ⮕ RIFAMPIN;Genotype CT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype TT.; in people with Disease:Tuberculosis
;METHYLPHENIDATE;CYP2D6;rs1065852;GG;Efficacy;increased clinical benefit to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased clinical benefit to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AG.; in children with Other:Attention Deficit Disorder with Hyperactivity
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs11045819;CC;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype CC is associated with decreased response to hmg coa reductase inhibitors as compared to genotypes AA + AC.;  
;METHYLPHENIDATE;CYP2D6;rs1135840;CG;Efficacy;increased clinical benefit to ⮕ METHYLPHENIDATE;Genotype CG is associated with increased clinical benefit to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.; in children with Other:Attention Deficit Disorder with Hyperactivity
;IVACAFTOR;CFTR;rs121909041;C;Efficacy;increased response to ⮕ IVACAFTOR;Allele C is associated with increased response to ivacaftor.;  
;PRAVASTATIN;SLCO1B1;rs2306283;GG;Efficacy;decreased response to ⮕ PRAVASTATIN;Genotype GG is associated with decreased response to pravastatin as compared to genotype AA.;  
;WARFARIN;CYP2C9;rs1057910;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC.;  
;IVACAFTOR;CFTR;rs193922525;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;WARFARIN;VKORC1;rs7196161;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.;  
;IVACAFTOR;CFTR;rs267606723;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;IVACAFTOR;CFTR;rs74503330;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;IVACAFTOR;CFTR;rs121909005;G;Efficacy;increased response to ⮕ IVACAFTOR;Allele G is associated with increased response to ivacaftor.;  
;IVACAFTOR;CFTR;rs121909013;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;SUNITINIB;GLP1R;rs6923761;A;Metabolism/PK;decreased concentrations of ⮕ SUNITINIB;Allele A is associated with decreased concentrations of sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to allele G.; in people with Other:Renal Cell Carcinoma, Other:Gastrointestinal Stromal Tumors
;DOXORUBICIN;ABCB1;rs1128503;AA;Metabolism/PK;decreased metabolism of ⮕ DOXORUBICIN;Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.; in people with Disease:Breast Neoplasms
;ATOMOXETINE;CYP2D6;rs1135840;CC;Efficacy;increased clinical benefit to ⮕ ATOMOXETINE;Genotype CC is associated with increased clinical benefit to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to genotype CG.; in children with Other:Attention Deficit Disorder with Hyperactivity
;BETA BLOCKING AGENTS;GRK5;rs3740563;A;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele C.; in people with Other:Coronary Artery Disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2069705;G;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.; in people with Disease:Rheumatoid arthritis
;MONTELUKAST;MLLT3;rs6475448;AA;Efficacy;increased response to ⮕ MONTELUKAST;Genotype AA is associated with increased response to montelukast in people with Asthma as compared to genotype GG.; in people with Disease:Asthma
;BETA BLOCKING AGENTS;GRK5;rs10787959;A;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.; in people with Other:Coronary Artery Disease
;BUPROPION;;rs1908557;C;Efficacy;decreased response to ⮕ BUPROPION;Allele C is associated with decreased response to bupropion in people with Depression as compared to allele T.; in people with Disease:Depression
;BETA BLOCKING AGENTS;GRK5;rs11198893;A;Efficacy;decreased response to ⮕ BETA BLOCKING AGENTS;Allele A is associated with decreased response to Beta Blocking Agents in people with Coronary Artery Disease as compared to allele G.; in people with Other:Coronary Artery Disease
;RIFAMPIN;CYP27B1;rs4646536;AG + GG;Metabolism/PK;increased concentrations of ⮕ RIFAMPIN;Genotypes AG + GG is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotype AA.; in people with Disease:Tuberculosis
;CORTICOSTEROIDS;ST13;rs138335;G;Efficacy;decreased response to ⮕ CORTICOSTEROIDS;Allele G is associated with decreased response to corticosteroids in children with Asthma as compared to allele C.; in children with Disease:Asthma
;RIFAMPIN;VDR;rs1544410;TT;Metabolism/PK;increased concentrations of ⮕ RIFAMPIN;Genotype TT is associated with increased concentrations of rifampin in people with Tuberculosis as compared to genotypes CC + CT.; in people with Disease:Tuberculosis
;DOCETAXEL;CYP3A4;rs2740574;C;Metabolism/PK;increased clearance of ⮕ DOCETAXEL;Allele C is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele T.; in people with Disease:Neoplasms
;METHADONE;CYP2B6;rs3745274;GG + GT;Dosage;increased dose of ⮕ METHADONE;Genotypes GG + GT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT.; in people with Disease:Heroin Dependence
;DOCETAXEL;CYP3A5;rs776746;T;Metabolism/PK;increased clearance of ⮕ DOCETAXEL;Allele T is associated with increased clearance of docetaxel in people with Neoplasms as compared to allele C.; in people with Disease:Neoplasms
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele C is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.; in people with Disease:Cardiovascular Disease
;RAMIPRIL;ADRB2;rs2053044;AA + AG;Efficacy;increased response to ⮕ RAMIPRIL;Genotypes AA + AG is associated with increased response to ramipril in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;OPIOIDS;COMT;rs4680;GG;Dosage;increased dose of ⮕ OPIOIDS;Genotype GG is associated with increased dose of opioids in women with Breast Neoplasms and Pain, Postoperative as compared to genotypes AA + AG.;" in women with ""Other:Breast Neoplasms"", ""Other:Pain, Postoperative"""
;METHADONE;NGF;rs2239622;AA;Dosage;decreased dose of ⮕ METHADONE;Genotype AA is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Disease:Opioid-Related Disorders
;NICOTINE;CYP1A2;rs35694136;T/del + del/del;Efficacy;increased exposure to ⮕ NICOTINE;Genotypes T/del + del/del is associated with increased exposure to nicotine in men Urinary Bladder Neoplasms as compared to genotype TT.; in men Other:Urinary Bladder Neoplasms
;METHADONE;CYP2B6;rs2279343;AA + AG;Dosage;increased dose of ⮕ METHADONE;Genotypes AA + AG are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.; in people with Disease:Heroin Dependence
;GEMCITABINE;NT5C3A;rs3750117;AA;Other, Metabolism/PK;increased clearance of ⮕ GEMCITABINE;Genotype AA is associated with increased clearance of gemcitabine in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;GEMCITABINE;NT5C2;rs11598702;TT;Other, Metabolism/PK;decreased clearance of ⮕ GEMCITABINE;Genotype TT is associated with decreased clearance of gemcitabine in people with Neoplasms as compared to genotypes CC + CT.; in people with Disease:Neoplasms
;FENTANYL, REMIFENTANIL;PGAP6;rs199670311;T;Efficacy;increased dose of ⮕ FENTANYL, REMIFENTANIL;Allele T is associated with increased dose of fentanyl or remifentanil in people with Pain as compared to allele C.;or in people with Disease:Pain
;OLANZAPINE;UGT1A4;rs2011425;GT;Metabolism/PK;decreased concentrations of ⮕ OLANZAPINE;Genotype GT is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;ANTIDEPRESSANTS;ADCY9;rs2230739;CC;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype CC is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Other:Major Depressive Disorder
;DABIGATRAN;CES1;rs2244613;GG + GT;Metabolism/PK;decreased concentrations of ⮕ DABIGATRAN;Genotypes GG + GT is associated with decreased concentrations of dabigatran in people with Stroke as compared to genotype TT.; in people with Other:Stroke
;ANTIPSYCHOTICS;PI4KA;rs165854;AG + GG;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Genotypes AG + GG is associated with decreased response to antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;GRM3;rs1468412;AA + AT;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Genotypes AA + AT is associated with decreased response to antipsychotics in people with Schizophrenia.; in people with Disease:Schizophrenia
;BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;ZNF432;rs3752120;TT;Efficacy;decreased response to ⮕ BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;Genotype TT is associated with decreased response to budesonide, corticosteroids, fluticasone propionate or fluticasone/salmeterol in people with Asthma.;or in people with Disease:Asthma
;AZATHIOPRINE;ITPA;rs1127354;AA + AC;Efficacy;increased response to ⮕ AZATHIOPRINE;Genotypes AA + AC is associated with increased response to azathioprine in people with Lupus Erythematosus, Systemic as compared to genotype CC.; in people with Disease:Systemic lupus erythematosus
;CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;rs1136201;G;Efficacy;decreased response to ⮕ CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;Allele G is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.;and in women with Disease:Breast Neoplasms
;ANTIPSYCHOTICS;SLC1A3;rs1529461;AA + AG;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Genotypes AA + AG is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;GRM3;rs2299214;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.; in people with Disease:Schizophrenia
;CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;rs2284922;A;Efficacy;increased response to ⮕ CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;Allele A is associated with increased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.;and in women with Disease:Breast Neoplasms
;ANTIPSYCHOTICS;GRM3;rs6465084;AG + GG;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotypes AG + GG is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;rs2070096;A;Efficacy;decreased response to ⮕ CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.;and in women with Disease:Breast Neoplasms
;GEMCITABINE;CDA;rs1048977;CC;Efficacy;increased response to ⮕ GEMCITABINE;Genotype CC is associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs2229046;C;Efficacy;decreased response to ⮕ CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;Allele C is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.;and in women with Disease:Breast Neoplasms
;CORTICOSTEROIDS;ST13;rs138337;G;Efficacy;decreased response to ⮕ CORTICOSTEROIDS;Allele G is associated with decreased response to corticosteroids in children with Asthma as compared to allele A.; in children with Disease:Asthma
;CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs773123;A;Efficacy;decreased response to ⮕ CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;Allele A is associated with decreased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms.;and in women with Disease:Breast Neoplasms
;ANTIPSYCHOTICS;SLC1A4;rs10211524;AA;Efficacy;decreased response to ⮕ ANTIPSYCHOTICS;Genotype AA is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.; in people with Disease:Schizophrenia
;RISPERIDONE;GRM3;rs2299214;CC + CT;Efficacy;decreased response to ⮕ RISPERIDONE;Genotypes CC + CT is associated with decreased response to risperidone in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ PRAVASTATIN;Genotypes CC + CT are associated with decreased response to pravastatin as compared to genotype TT.;  
;SUFENTANIL;COMT;rs4680;AA;Dosage, Efficacy;decreased dose of ⮕ SUFENTANIL;Genotype AA is associated with decreased dose of sufentanil in children as compared to genotypes AG + GG.; in children 
;FLUINDIONE;VKORC1;rs9923231;TT;Metabolism/PK;dose of ⮕ FLUINDIONE;Genotype TT is associated with dose of fluindione in children as compared to genotype CC.; in children 
;APREMILAST;LEPR, LEPROT;rs1045895;AA + AG;Efficacy;decreased clinical benefit to ⮕ APREMILAST;Genotypes AA + AG is associated with decreased clinical benefit to apremilast in people with Psoriasis as compared to genotype GG.; in people with Other:Psoriasis
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.;  
;OPIOIDS;ABCB1;rs1045642;AA;Dosage, Efficacy;decreased dose of ⮕ OPIOIDS;Genotype AA is associated with decreased dose of opioids in people with Neoplasms and Pain as compared to genotypes AG + GG.; in people with Disease:Neoplasms, Disease:Pain
;CARBOPLATIN, CISPLATIN;AKT1;rs2494752;AG;Efficacy;decreased response to ⮕ CARBOPLATIN, CISPLATIN;Genotype AG is associated with decreased response to carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + GG.;or in people with Disease:Non-Small Cell Lung Carcinoma
;QUINAPRIL;AGT;rs699;GG;Efficacy;increased response to ⮕ QUINAPRIL;Genotype GG is associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotypes AA + AG.; in people with Disease:Coronary Artery Disease
;OPIOIDS;KCNJ6;rs6517442;CC;Dosage;increased dose of ⮕ OPIOIDS;Genotype CC is associated with increased dose of opioids in people with Low Back Pain as compared to genotypes CT + TT.; in people with Other:Low Back Pain
;OLANZAPINE;CYP1A2;rs35694136;T/del;Metabolism/PK;increased concentrations of ⮕ OLANZAPINE;Genotype T/del is associated with increased concentrations of olanzapine in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage, Efficacy;increased dose of ⮕ OPIOIDS;Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA.; in people with Disease:Neoplasms, Disease:Pain
;OLANZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;decreased concentrations of ⮕ OLANZAPINE;Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC.; in people with Disease:Schizophrenia
;FENTANYL;OPRM1;rs1799971;GG;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotype AA.; in people with Disease:Pain, Postoperative
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Genotypes GT + TT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;PHENPROCOUMON;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ PHENPROCOUMON;Genotype TT is associated with increased dose of phenprocoumon as compared to genotypes CC + CT.;  
;CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;rs183205964;C;Toxicity;increased discontinuation of ⮕ CAPECITABINE, FLUOROURACIL, TEGAFUR;Allele C is associated with increased discontinuation of capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to allele G.;or in people with Disease:Neoplasms
;KETOPROFEN;CYP2C9;rs1057910;AC;Efficacy;increased response to ⮕ KETOPROFEN;Genotype AC is associated with increased response to ketoprofen in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;ATORVASTATIN;ABCB1;rs1045642;GG;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotype GG is associated with decreased response to atorvastatin in people with Coronary Artery Disease as compared to genotypes AA + AG.; in people with Disease:Coronary Artery Disease
;IMATINIB;SLC22A1;rs683369;CC;Metabolism/PK;increased clearance of ⮕ IMATINIB;Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;CAFFEINE;CYP1A2;rs762551;AA;Other, Metabolism/PK;increased metabolism of ⮕ CAFFEINE;Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC.;  
;IMATINIB;SLC22A1;rs683369;CC;Metabolism/PK;decreased concentrations of ⮕ IMATINIB;Genotype CC is associated with decreased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;ETANERCEPT;TNFRSF1B;rs1061622;GT;Efficacy;decreased response to ⮕ ETANERCEPT;Genotype GT is associated with decreased response to etanercept in people with Spondylitis, Ankylosing as compared to genotypes GG + TT.; in people with Disease:Spondylitis, Ankylosing
;FENTANYL, REMIFENTANIL;SLC9A9;rs4839603;GG;Efficacy;decreased dose of ⮕ FENTANYL, REMIFENTANIL;Genotype GG is associated with decreased dose of fentanyl or remifentanil in people with Pain as compared to genotypes AA + AG.;or in people with Disease:Pain
;EFAVIRENZ;CYP2B6;rs3745274;T;Efficacy;decreased clearance of ⮕ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz in children with HIV Infections as compared to allele G.; in children with Disease:HIV infectious disease
;APREMILAST;PDE4B;rs12745871;T;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele T is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele C.; in people with Other:Psoriasis
;ATORVASTATIN;SCARB1;rs5888;AA;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.; in people with Disease:Hypercholesterolemia
;APREMILAST;TSPAN16;rs322144;C;Efficacy;decreased clinical benefit to ⮕ APREMILAST;Allele C is associated with decreased clinical benefit to apremilast in people with Psoriasis as compared to allele G.; in people with Other:Psoriasis
;PRAVASTATIN;FCAR;rs11666735;AA + AG;Efficacy;increased response to ⮕ PRAVASTATIN;Genotypes AA + AG are associated with increased response to pravastatin in men with Myocardial Infarction as compared to genotype GG.; in men with Disease:Myocardial Infarction
;CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE, EPIRUBICIN;Genotypes AA + AG are associated with increased response to cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.;and in women with Disease:Breast Neoplasms
;FENOFIBRATE;APOA1;rs964184;G;Efficacy;increased response to ⮕ FENOFIBRATE;Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C.; in people with Disease:Hypertriglyceridemia
;ANTIEPILEPTICS;SCN1A;rs10188577;CT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotype CT is associated with increased resistance to antiepileptics in people with Epilepsy.; in people with Disease:Epilepsy
;APREMILAST;DOCK6;rs12979813;G;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele G is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele A.; in people with Other:Psoriasis
;DAPTOMYCIN;ABCB1;rs1045642;AA;Metabolism/PK;increased concentrations of ⮕ DAPTOMYCIN;Genotype AA is associated with increased concentrations of daptomycin as compared to genotypes AG + GG.;  
;NALTREXONE;DBH;rs1611115;CT + TT;Efficacy;increased response to ⮕ NALTREXONE;Genotypes CT + TT is associated with increased response to naltrexone in men with Alcoholism as compared to genotype CC.; in men with Disease:Alcohol abuse
;GEMCITABINE;SLC28A2;rs11854484;CC;Efficacy;decreased response to ⮕ GEMCITABINE;Genotype CC is associated with decreased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;ANTINEOPLASTIC AGENTS;ABCG2;rs2231142;GG;Efficacy;decreased response to ⮕ ANTINEOPLASTIC AGENTS;Genotype GG is associated with decreased response to antineoplastic agents in people with Colorectal Neoplasms as compared to genotypes GT + TT.; in people with Disease:Colorectal Neoplasms
;GEMCITABINE;SLC28A2;rs1060896;CC;Efficacy;decreased response to ⮕ GEMCITABINE;Genotype CC is associated with decreased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.; in people with Disease:Non-Small Cell Lung Carcinoma
;APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;rs2305795;G;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele G is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele A.; in people with Other:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs767455;TT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with decreased dose of acenocoumarol as compared to genotypes CC + CT.;  
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.; in people with Disease:Osteosarcoma
;DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;GG;Efficacy;increased resistance to ⮕ DRUGS FOR TREATMENT OF TUBERCULOSIS;Genotype GG is associated with increased resistance to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotypes AA + AG.; in people with Other:Tuberculosis
;METHOTREXATE;SLCO1B1;rs11045879;CC + CT;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes CC + CT is associated with increased concentrations of methotrexate in people with Osteosarcoma as compared to genotype TT.; in people with Disease:Osteosarcoma
;SUFENTANIL;OPRM1;rs1799971;AG;Dosage;increased dose of ⮕ SUFENTANIL;Genotype AG is associated with increased dose of sufentanil in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;APREMILAST;ILF3;rs76966440;T;Efficacy;increased clinical benefit to ⮕ APREMILAST;Allele T is associated with increased clinical benefit to apremilast in people with Psoriasis as compared to allele C.; in people with Other:Psoriasis
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.;  
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;rs1695;A;Efficacy;increased response to ⮕ CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;Allele A is associated with increased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;and in women with Disease:Breast Neoplasms
;SULFASALAZINE;ABCG2;rs2231142;GT + TT;Efficacy;increased response to ⮕ SULFASALAZINE;Genotypes GT + TT are associated with increased response to sulfasalazine in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.; in children 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G.;and in children with Disease:Hepatitis C virus infection
;WARFARIN;VKORC1;rs9923231;CC + CT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with increased dose of warfarin as compared to genotype TT.;  
;TACROLIMUS;ABCB1;rs1128503;AG + GG;Efficacy;increased response to ⮕ TACROLIMUS;Genotypes AG + GG are associated with increased response to tacrolimus in people with Colitis, Ulcerative as compared to genotype AA.; in people with Disease:Ulcerative Colitis
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotype CC.;  
;ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased exposure to ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B;Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.; in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;PRSS53, VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;A;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;NORTRIPTYLINE;NOS3;rs1799983;TT;Efficacy;increased response to ⮕ NORTRIPTYLINE;Genotype TT is associated with increased response to nortriptyline in people with Migraine without Aura or Migraine with Aura as compared to genotypes GG + GT.; in people with Other:Migraine without Aura, Other:Migraine with Aura
;ALLOPURINOL;GREM2;rs1934341;T;Efficacy;increased response to ⮕ ALLOPURINOL;Allele T is associated with increased response to allopurinol.;  
;COTININE;NAT1;rs13253389;AG + GG;Metabolism/PK;increased concentrations of ⮕ COTININE;Genotypes AG + GG is associated with increased concentrations of cotinine in children as compared to genotype AA.; in children 
;ALLOPURINOL;GREM2;rs77567654;G;Efficacy;increased response to ⮕ ALLOPURINOL;Allele G is associated with increased response to allopurinol as compared to allele A.;  
;TACROLIMUS;ABCB1;rs2032582;CC;Dosage;increased dose of ⮕ TACROLIMUS;Genotype CC is associated with increased dose of tacrolimus in people with Kidney Transplantation.; in people with Disease:Kidney Transplantation
;ALLOPURINOL;ABCG2;rs45499402;C;Efficacy;decreased response to ⮕ ALLOPURINOL;Allele C is associated with decreased response to allopurinol.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;ALLOPURINOL;ABCG2;rs2231142;T;Efficacy;decreased response to ⮕ ALLOPURINOL;Allele T is associated with decreased response to allopurinol as compared to allele G.;  
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;EXENATIDE;GLP1R;rs10305420;T;Efficacy;decreased response to ⮕ EXENATIDE;Allele T is associated with decreased response to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Disease:Diabetes Mellitus, Type 2
;TOPIRAMATE;ABCB1;rs1045642;AA;Efficacy;increased response to ⮕ TOPIRAMATE;Genotype AA is associated with increased response to topiramate in people with Migraine without Aura or Migraine with Aura as compared to genotypes AG + GG.; in people with Other:Migraine without Aura, Other:Migraine with Aura
;LAMOTRIGINE;UGT2B7;rs7668258;TT;Metabolism/PK;decreased clearance of ⮕ LAMOTRIGINE;Genotype TT is associated with decreased clearance of lamotrigine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs7294;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;BENAZEPRIL;AGT;rs4762;GG;Efficacy;response to ⮕ BENAZEPRIL;Genotype GG is associated with response to benazepril in men with Hypertension as compared to genotype AA.; in men with Disease:Hypertension
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection, Disease:HIV infectious disease
;IMATINIB;ABCB1;rs1128503;GG;Efficacy;increased response to ⮕ IMATINIB;Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;LAMOTRIGINE;UGT2B7;rs28365063;GG;Metabolism/PK;increased clearance of ⮕ LAMOTRIGINE;Genotype GG is associated with increased clearance of lamotrigine in people with Epilepsy as compared to genotypes AA + AG.; in people with Disease:Epilepsy
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;Genotype TT is associated with increased concentrations of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to genotype GG.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;METHOTREXATE;ABCC4;rs7317112;GG;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotype GG is associated with increased clearance of methotrexate in children with Acute lymphoblastic leukemia as compared to genotypes AA + AG.; in children with Other:Acute lymphoblastic leukemia
;BENAZEPRIL;AGTR1;rs2640543;GG;Efficacy;response to ⮕ BENAZEPRIL;Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype AA.; in women with Disease:Hypertension
;ALENDRONATE;MVK;rs10161126;GG;Efficacy;increased response to ⮕ ALENDRONATE;Genotype GG is associated with increased response to alendronate in women with Bone Diseases as compared to genotypes AA + AG.; in women with Disease:Bone Diseases
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.;and in people with Disease:Hepatitis C virus infection
;SARILUMAB;IL6R;rs11265618;CC;Efficacy;increased response to ⮕ SARILUMAB;Genotype CC is associated with increased response to sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Other:Rheumatoid arthritis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;LDLR;rs14158;GG;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotypes AA + AG.;and in people with Disease:Chronic hepatitis C virus infection, Disease:HIV infectious disease
;BENAZEPRIL;SPTA1;rs2106089;G;Efficacy;response to ⮕ BENAZEPRIL;Allele G is associated with response to benazepril in men with Hypertension as compared to allele A.; in men with Disease:Hypertension
;IMATINIB;ABCB1;rs1045642;GG;Efficacy;increased response to ⮕ IMATINIB;Genotype GG is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A5;rs776746;TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;SARILUMAB;IL6R;rs4329505;TT;Efficacy;increased response to ⮕ SARILUMAB;Genotype TT is associated with increased response to sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.; in people with Other:Rheumatoid arthritis
;LOSARTAN;CYP2C9;rs1934969;AT + TT;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;Genotypes AT + TT are associated with decreased metabolism of losartan in healthy individuals as compared to genotype AA.; in healthy individuals 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CT.;and in people with Disease:Hepatitis C virus infection
;IMATINIB;ABCB1;rs2032582;C;Efficacy;decreased response to ⮕ IMATINIB;Allele C is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;BUPRENORPHINE;OPRD1;rs678849;CC;Efficacy;decreased response to ⮕ BUPRENORPHINE;Genotype CC is associated with decreased response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes CT + TT.; in people with Disease:Opioid-Related Disorders
;PHENPROCOUMON;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotypes CT + TT are associated with decreased dose of phenprocoumon as compared to genotype CC.;  
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;rs1052248;AT + TT;Efficacy;increased clinical benefit to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AT + TT is associated with increased clinical benefit to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype AA.;or in people with Other:Rheumatoid arthritis
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;SALBUTAMOL;COL2A1;rs3809324;GT + TT;PD;decreased response to ⮕ SALBUTAMOL;Genotypes GT + TT is associated with decreased response to salbutamol in children with Asthma as compared to genotype GG.; in children with Other:Asthma
;ANTIPSYCHOTICS;CACNA1C;rs2238087;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;rs4791040;T;Efficacy;"decreased response to ⮕ ""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";Allele T is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.;or in people with Disease:Hypertension
;ANTIPSYCHOTICS;CACNA1B;rs2229949;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;ACENOCOUMAROL;STX4;rs10871454;T;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele T is associated with decreased dose of acenocoumarol as compared to allele C.;  
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC.;  
;WARFARIN;;rs12777823;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;CORTICOSTEROIDS;GLCCI1;rs37973;GG;Efficacy;decreased clinical benefit to ⮕ CORTICOSTEROIDS;Genotype GG is associated with decreased clinical benefit to corticosteroids in people with Rhinitis as compared to genotypes AA + AG.; in people with Other:Rhinitis
;DEFERASIROX;GC;rs7041;AA;Efficacy;increased response to ⮕ DEFERASIROX;Genotype AA is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AC + CC.; in people with Other:Beta-thalassemia and related diseases
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT are associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes AA + AG are associated with decreased dose of acenocoumarol as compared to genotype GG.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CC + CT;Efficacy;decreased response to ⮕ ASPIRIN, CLOPIDOGREL;Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.;and in people with Disease:Acute coronary syndrome
;ACENOCOUMAROL;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ ACENOCOUMAROL;Allele T is associated with increased dose of acenocoumarol as compared to allele C.;  
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype GG.; in people with Disease:Cardiovascular Disease
;METHYLPHENIDATE;CES1;rs71647871;T;Metabolism/PK;decreased metabolism of ⮕ METHYLPHENIDATE;Allele T is associated with decreased metabolism of methylphenidate in healthy individuals as compared to allele C.; in healthy individuals 
;WARFARIN;VKORC1;rs7294;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to genotype CC.; in people with Disease:Cardiovascular Disease
;INTERFERON BETA-1A, INTERFERON BETA-1B;CD58;rs12044852;CC;Efficacy;decreased response to ⮕ INTERFERON BETA-1A, INTERFERON BETA-1B;Genotype CC is associated with decreased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to genotypes AA + AC.;and in people with Disease:Multiple Sclerosis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes GG + GT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotype TT.;" in people with ""Other:Arthritis, Psoriatic"", ""Other:Psoriasis"""
;MORPHINE;OPRM1;rs1799971;AG + GG;Efficacy;decreased response to ⮕ MORPHINE;Genotypes AG + GG is associated with decreased response to morphine in children as compared to genotype AA.; in children 
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotypes CC + CT.; in people with Disease:Cardiovascular Disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotypes AG + GG.;" in people with ""Other:Arthritis, Psoriatic"", ""Other:Psoriasis"""
;WARFARIN;CYP4F2;rs2108622;CC + CT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype TT.; in people with Disease:Cardiovascular Disease
;ANTIPSYCHOTICS;CACNB2;rs12245847;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CT.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A7;rs2257401;C;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele C is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;DEFERASIROX;UGT1A1;rs887829;CC;Efficacy;decreased response to ⮕ DEFERASIROX;Genotype CC is associated with decreased response to deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.; in people with Other:Beta-thalassemia and related diseases
;ANTIPSYCHOTICS;CACNG3;rs1859204;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele C is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;DEFERASIROX;UGT1A3;rs1983023;TT;Efficacy;increased response to ⮕ DEFERASIROX;Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.; in people with Other:Beta-thalassemia and related diseases
;DEFERASIROX;CYP27B1;rs10877012;GG;Efficacy;increased response to ⮕ DEFERASIROX;Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes GT + TT.; in people with Other:Beta-thalassemia and related diseases
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CYP3A4;rs4646437;A;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;ADALIMUMAB;ATG16L1;rs10210302;CT + TT;Efficacy;increased response to ⮕ ADALIMUMAB;Genotypes CT + TT is associated with increased response to adalimumab in people with Crohn Disease as compared to genotype CC.; in people with Disease:Crohn Disease
;ANTIPSYCHOTICS;CACNB2;rs982003;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CYP3A4;rs2242480;T;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele T is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;DEFERASIROX;VDR;rs731236;GG;Efficacy;increased response to ⮕ DEFERASIROX;Genotype GG is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes AA + AG.; in people with Other:Beta-thalassemia and related diseases
;DEFERASIROX;VDR;rs1544410;TT;Efficacy;increased response to ⮕ DEFERASIROX;Genotype TT is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CC + CT.; in people with Other:Beta-thalassemia and related diseases
;TACROLIMUS;CYP3A5;rs41303343;A;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele del.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;rs1051266;CC;Efficacy;increased response to ⮕ CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.;or in people with Disease:Colorectal Neoplasms
;CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;rs2306283;AA + AG;Efficacy;increased response to ⮕ CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;Genotypes AA + AG are associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;or in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;rs4646450;A;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotypes CC + CT are associated with increased concentrations of simvastatin acid in children as compared to genotype TT.; in children 
;"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;rs2776546;A;Efficacy;"increased response to ⮕ ""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.;or in people with Disease:Hypertension
;WARFARIN;CYP2C9;rs28371686;CG;Dosage;decreased dose of ⮕ WARFARIN;Genotype CG is associated with decreased dose of warfarin as compared to genotype CC.;  
;ANTIPSYCHOTICS;CACNB2;rs10741058;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;ATAZANAVIR;UGT1A1;rs887829;TT;Toxicity;increased discontinuation of ⮕ ATAZANAVIR;Genotype TT is associated with increased discontinuation of atazanavir in people with HIV Infections as compared to genotypes CC + CT.; in people with Disease:HIV infectious disease
;"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;rs238;A;Efficacy;"decreased response to ⮕ ""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";Allele A is associated with decreased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.;or in people with Disease:Hypertension
;ANTIPSYCHOTICS;CACNA2D3;rs4505744;AA;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";;rs4815273;T;Efficacy;"increased response to ⮕ ""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";Allele T is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C.;or in people with Disease:Hypertension
;IBUPROFEN;CYP2C9;rs1057910;AC;Efficacy;decreased time to response to ⮕ IBUPROFEN;Genotype AC is associated with decreased time to response to ibuprofen in infants with Patent Ductus Arteriosus as compared to genotype AA.; in infants with Other:Patent Ductus Arteriosus
;ANTIPSYCHOTICS;CACNA1E;rs12060765;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;CORTICOSTEROIDS;TAAR6;rs7772821;GG;Efficacy;increased response to ⮕ CORTICOSTEROIDS;Genotype GG is associated with increased response to corticosteroids in people with Asthma as compared to genotypes GT + TT.; in people with Disease:Asthma
;SALBUTAMOL;VEGFA;rs3025039;CT + TT;PD;decreased response to ⮕ SALBUTAMOL;Genotypes CT + TT is associated with decreased response to salbutamol in children with Asthma as compared to genotype CC.; in children with Other:Asthma
;BEVACIZUMAB, RANIBIZUMAB;CFH;rs1061170;CC;Efficacy;decreased response to ⮕ BEVACIZUMAB, RANIBIZUMAB;Genotype CC is associated with decreased response to bevacizumab and ranibizumab in people with Macular Degeneration as compared to genotypes CT + TT.;and in people with Disease:Macular Degeneration
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;MORPHINE;TAOK3;rs795484;TT;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Genotype TT is associated with increased dose of morphine in children with Pain, Postoperative as compared to genotypes CC + CT.; in children with Disease:Pain, Postoperative
;PREDNISONE;NR3C1;rs6196;G;Efficacy;decreased resistance to ⮕ PREDNISONE;Allele G is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele A.; in people with Disease:Nephrotic Syndrome
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;SN-38;UGT1A1;rs4148323;AA;Metabolism/PK;decreased metabolism of ⮕ SN-38;Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;DOCETAXEL;;rs4842198;G;Metabolism/PK;increased metabolism of ⮕ DOCETAXEL;Allele G is associated with increased metabolism of docetaxel in people with Nasopharyngeal Neoplasms.; in people with Disease:Nasopharyngeal Neoplasms
;FLUVOXAMINE;HTR2A;rs6311;CC;Efficacy;increased response to ⮕ FLUVOXAMINE;Genotype CC is associated with increased response to fluvoxamine in people with Depressive Disorder, Major as compared to genotypes CT + TT.; in people with Disease:Major Depressive Disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;Dosage, Efficacy;decreased dose of ⮕ ACENOCOUMAROL;Genotypes AA + AG is associated with decreased dose of acenocoumarol as compared to genotype GG.;  
;PREDNISONE;NR3C1;rs258751;A;Efficacy;decreased resistance to ⮕ PREDNISONE;Allele A is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele G.; in people with Disease:Nephrotic Syndrome
;LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ LEDIPASVIR, SOFOSBUVIR;Genotype CC is associated with increased response to ledipasvir and sofosbuvir in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;SN-38;UGT1A9;rs3832043;del/del;Metabolism/PK;decreased metabolism of ⮕ SN-38;Genotype del/del is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;PHENYTOIN;CYP2C9;rs28371686;G;Other, Metabolism/PK;decreased metabolism of ⮕ PHENYTOIN;Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC.; in people with Other:no disease
;IMATINIB;ABCG2;rs2231137;CT + TT;Dosage;decreased dose of ⮕ IMATINIB;Genotypes CT + TT are associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.; in people with Other:Gastrointestinal Stromal Tumors
;PREDNISONE;NR3C1;rs10052957;A;Efficacy;decreased resistance to ⮕ PREDNISONE;Allele A is associated with decreased resistance to prednisone in people with Nephrotic Syndrome as compared to allele G.; in people with Disease:Nephrotic Syndrome
;IMATINIB;CYP1A2;rs762551;CC;Dosage;decreased dose of ⮕ IMATINIB;Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC.; in people with Other:Gastrointestinal Stromal Tumors
;PHENYTOIN;CYP2C9;rs7900194;A;Other, Metabolism/PK;decreased metabolism of ⮕ PHENYTOIN;Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG.; in people with Other:no disease
;LURASIDONE;HTR1A;rs6295;CG + GG;Efficacy;decreased response to ⮕ LURASIDONE;Genotypes CG + GG are associated with decreased response to lurasidone in people with Schizophrenia as compared to genotype CC.; in people with Other:Schizophrenia
;PHENYTOIN;CYP2C9;rs28371685;T;Other, Metabolism/PK;increased metabolism of ⮕ PHENYTOIN;Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC.; in people with PK:no disease
;PHENYTOIN;CYP2C9;rs9332131;del;Other, Metabolism/PK;decreased metabolism of ⮕ PHENYTOIN;Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.; in people with PK:no disease
;DOCETAXEL;RXRA;rs3132291;A;Metabolism/PK;increased metabolism of ⮕ DOCETAXEL;Allele A is associated with increased metabolism of docetaxel in people with Nasopharyngeal Neoplasms as compared to allele G.; in people with Disease:Nasopharyngeal Neoplasms
;INFLIXIMAB;TNFRSF1B;rs1061622;G;Efficacy;decreased response to ⮕ INFLIXIMAB;Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele T.; in people with Disease:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;METFORMIN;SLC22A1;rs12208357;TT;Metabolism/PK;decreased exposure to ⮕ METFORMIN;Genotype TT is associated with decreased exposure to metformin in healthy individuals as compared to genotype CC.; in healthy individuals 
;CODEINE;OPRM1;rs1799971;AA;Dosage;decreased dose of ⮕ CODEINE;Genotype AA is associated with decreased dose of codeine in women as compared to genotype AG.; in women 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;CODEINE;UGT2B7;rs7439366;TT;Dosage;decreased dose of ⮕ CODEINE;Genotype TT is associated with decreased dose of codeine in women as compared to genotype CC.; in women 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B;Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT.; in people with Disease:Chronic hepatitis C virus infection
;ANTIPSYCHOTICS;CACNB2;rs4237348;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CT.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A4;rs2740574;T;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele T is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ANTIPSYCHOTICS;CACNB4;rs3768652;AA + AC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotypes AA + AC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A4;rs35599367;A;Metabolism/PK;trough concentration of ⮕ TACROLIMUS;Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.; in people with Disease:Kidney Transplantation, Disease:Transplantation
;ANTIPSYCHOTICS;CACNA2D3;rs7427395;CC;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;CACNB2;rs1277733;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;SOFOSBUVIR;CES1;rs4513095;A;Efficacy;decreased response to ⮕ SOFOSBUVIR;Allele A is associated with decreased response to sofosbuvir in people with Hepatitis C, Chronic as compared to allele C.; in people with Other:Chronic hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PROPOFOL;SCN9A;rs6746030;AA + AG;Other;increased response to ⮕ PROPOFOL;Genotypes AA + AG are associated with increased response to propofol as compared to genotype GG.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in children with Transplantation as compared to genotypes CT + TT.; in children with Disease:Transplantation
;SALBUTAMOL;PRKG1;rs7081864;A;Efficacy;decreased clinical benefit to ⮕ SALBUTAMOL;Allele A is associated with decreased clinical benefit to salbutamol in children with Asthma as compared to allele G.; in children with Other:Asthma
;TACROLIMUS;CYP3A5;rs776746;C;Dosage;decreased dose of ⮕ TACROLIMUS;Allele C is associated with decreased dose of tacrolimus in people with liver transplantation as compared to allele T.; in people with Disease:Liver transplantation
;TOCILIZUMAB;IL6R;rs12083537;AA;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;ANTIPSYCHOTICS;BDNF;rs11030104;AG + GG;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Genotypes AG + GG is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;SUNITINIB;ABCB1;rs1045642;GG;Metabolism/PK;increased exposure to ⮕ SUNITINIB;Genotype GG is associated with increased exposure to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.; in people with Disease:Renal Cell Carcinoma
;PROPOFOL;HTR2A;rs6313;AA;Dosage;decreased dose of ⮕ PROPOFOL;Genotype AA is associated with decreased dose of propofol as compared to genotypes AG + GG.;  
;ANTIPSYCHOTICS;BDNF-AS;rs10501087;CC + CT;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Genotypes CC + CT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;PROPOFOL;GABRA1;rs2279020;GG;Other;increased response to ⮕ PROPOFOL;Genotype GG is associated with increased response to propofol as compared to genotypes AA + AG.;  
;SUNITINIB;ABCB1;rs1045642;GG;Efficacy;decreased response to ⮕ SUNITINIB;Genotype GG is associated with decreased response to sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.; in people with Disease:Renal Cell Carcinoma
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.; in children with Disease:Kidney Transplantation
;OPIOIDS;COMT;rs4680;AA + AG;Efficacy;increased response to ⮕ OPIOIDS;Genotypes AA + AG are associated with increased response to opioids in children as compared to genotype GG.; in children 
;TACROLIMUS;CYP3A5;rs776746;CT;Dosage;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;Efficacy;decreased resistance to ⮕ DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;Genotype AA is associated with decreased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;and in children with Disease:Acute lymphoblastic leukemia
;ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype CC.; in people with Disease:Schizophrenia
;OPIOIDS;COMT;rs4680;AG;Dosage;decreased dose of ⮕ OPIOIDS;Genotype AG is associated with decreased dose of opioids in children as compared to genotype GG.; in children 
;"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";ABCC8, KCNJ11;rs5219;CT + TT;Efficacy;"increased clinical benefit to ⮕ ""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";Genotypes CT + TT is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;and in people with Other:Diabetes Mellitus, Type 2
;PALIPERIDONE, RISPERIDONE;NFIB;rs28379954;CT;Metabolism/PK;increased concentrations of ⮕ PALIPERIDONE, RISPERIDONE;Genotype CT is associated with increased concentrations of paliperidone and risperidone as compared to genotype TT.;and  
;REMIFENTANIL, SEVOFLURANE;ABCB1;rs1128503;GG;Efficacy;increased response to ⮕ REMIFENTANIL, SEVOFLURANE;Genotype GG is associated with increased response to remifentanil and sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.;and in children with Other:tonsillectomy
;MORPHINE;TAOK3;rs1277441;GG;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Genotype GG is associated with increased dose of morphine in children with Pain, Postoperative as compared to genotypes AA + AG.; in children with Disease:Pain, Postoperative
;DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs2229109;CT;Efficacy;increased resistance to ⮕ DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;and in children with Disease:Acute lymphoblastic leukemia
;HYDROXYUREA;KLF4;rs2236599;C;Efficacy;increased response to ⮕ HYDROXYUREA;Allele C is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele T.;" in people with ""Other:Anemia, Sickle Cell"", ""Other:Beta-thalassemia and related diseases"""
;OXYCODONE;OPRM1;rs1799971;GG;Dosage;increased dose of ⮕ OXYCODONE;Genotype GG is associated with increased dose of oxycodone in women with Pain, Postoperative as compared to genotypes AA + AG.; in women with Other:Pain, Postoperative
;TACROLIMUS;CYP3A4;rs2242480;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in people with heart transplantation as compared to genotype CC.; in people with Other:Heart transplantation
;METHOTREXATE;SLCO1B1;rs11045821;A;Efficacy, Toxicity, Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Disease:Acute lymphoblastic leukemia
;METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes AT + TT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;BILIRUBIN;UGT1A;rs11563250;AG + GG;Metabolism/PK;decreased concentrations of ⮕ BILIRUBIN;Genotypes AG + GG is associated with decreased concentrations of bilirubin in people with Colorectal Neoplasms as compared to genotype AA.; in people with Disease:Colorectal Neoplasms
;DEFERASIROX;UGT1A3;rs1983023;CT + TT;Metabolism/PK;decreased concentrations of ⮕ DEFERASIROX;Genotypes CT + TT is associated with decreased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype CC.; in people with Disease:Beta-thalassemia and related diseases
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;Efficacy;increased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele A is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;or in people with Other:Rheumatoid arthritis
;MORPHINE;SLC22A1;rs12208357;CT + TT;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotypes CT + TT is associated with decreased clearance of morphine in children as compared to genotype CC.; in children 
;MIDAZOLAM;CYP3A4;rs35599367;AG;Metabolism/PK;decreased metabolism of ⮕ MIDAZOLAM;Genotype AG is associated with decreased metabolism of midazolam in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;MORPHINE;SLC22A1;rs55918055;CC + CT;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotypes CC + CT is associated with decreased clearance of morphine in children as compared to genotype TT.; in children 
;BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;rs4803381;T;Efficacy;increased response to ⮕ BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;Allele T is associated with increased response to bupropion and Drugs used in nicotine dependence in people with Tobacco Use Disorder as compared to allele C.;and in people with Disease:Tobacco Use Disorder
;METFORMIN;SRR;rs391300;CC + CT;Efficacy;increased response to ⮕ METFORMIN;Genotypes CC + CT are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype TT.; in people with Disease:Diabetes Mellitus, Type 2
;METHYLPHENIDATE;SLC6A2;rs5569;AG + GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;ERYTHROMYCIN;CYP3A4;rs35599367;AG;Metabolism/PK;decreased metabolism of ⮕ ERYTHROMYCIN;Genotype AG is associated with decreased metabolism of erythromycin in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;NICOTINE;CYP2A6;rs4803381;T;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;Allele T is associated with decreased metabolism of nicotine as compared to allele C.;  
;CLOZAPINE;ABCB1;rs7787082;G;Efficacy;decreased response to ⮕ CLOZAPINE;Allele G is associated with decreased response to clozapine in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;CAFFEINE;CYP1A2;rs762551;AA + AC;Metabolism/PK;increased metabolism of ⮕ CAFFEINE;Genotypes AA + AC is associated with increased metabolism of caffeine as compared to genotype CC.;  
;ATENOLOL;;rs12346562;AA + AC;Efficacy;increased response to ⮕ ATENOLOL;Genotypes AA + AC is associated with increased response to atenolol in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;HYDROCHLOROTHIAZIDE;;rs12346562;AA + AC;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AA + AC is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;ATENOLOL;;rs1104514;AA + AG;Efficacy;increased response to ⮕ ATENOLOL;Genotypes AA + AG are associated with increased response to atenolol in people with Hypertension as compared to genotype GG.; in people with Disease:Hypertension
;MORPHINE;SLC22A1;rs34130495;AA + AG;Metabolism/PK;decreased clearance of ⮕ MORPHINE;Genotypes AA + AG is associated with decreased clearance of morphine in children as compared to genotype GG.; in children 
;ATENOLOL;;rs10739150;GG + GT;Efficacy;increased response to ⮕ ATENOLOL;Genotypes GG + GT are associated with increased response to atenolol in people with Hypertension as compared to genotype TT.; in people with Disease:Hypertension
;CLOZAPINE;ABCB1;rs10248420;A;Efficacy;decreased response to ⮕ CLOZAPINE;Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;DEFERASIROX;UGT1A3;rs3806596;CC;Efficacy, Metabolism/PK;increased response to ⮕ DEFERASIROX;Genotype CC is associated with increased response to deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.; in people with Disease:Beta-thalassemia and related diseases
;TRANDOLAPRIL, VERAPAMIL;PTPRD;rs4742610;T;Efficacy;resistance to ⮕ TRANDOLAPRIL, VERAPAMIL;Allele T is associated with resistance to trandolapril and verapamil in people with Hypertension as compared to allele C.;and in people with Disease:Hypertension
;DEFERASIROX;ABCG2;rs13120400;CC;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.; in people with Disease:Beta-thalassemia and related diseases
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC47A1;rs2289669;A;Efficacy;"increased clinical benefit to ⮕ ""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";Allele A is associated with increased clinical benefit to metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele G.;and in people with Other:Diabetes Mellitus, Type 2
;SUNITINIB;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased exposure to ⮕ SUNITINIB;Genotypes GT + TT is associated with increased exposure to sunitinib in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;WARFARIN;VDR;rs11168292;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotypes CC + CG.;  
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1136703;AA;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;Genotype AA are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to genotypes AG + GG.;or in women with Disease:Breast Neoplasms
;ARA-CTP;SLC28A3;rs17343066;AA;Metabolism/PK;increased concentrations of ⮕ ARA-CTP;Genotype AA is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG.; in children with Disease:Leukemia, Myeloid, Acute
;WARFARIN;VDR;rs4760658;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.;  
;WARFARIN;VDR;rs11168293;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes GG + GT.;  
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;rs885814;T;Efficacy;decreased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele T is associated with decreased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.;or in people with Other:Rheumatoid arthritis
;ETOPOSIDE;SLIT1;rs2784917;AA;Metabolism/PK;decreased inhibition of ⮕ ETOPOSIDE;Genotype AA is associated with decreased inhibition of etoposide as compared to genotypes AG + GG.;  
;METHOTREXATE;SLCO1B1;rs4149056;C;Efficacy, Toxicity, Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.; in children with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;SLCO1B1;rs2306283;A;Efficacy, Toxicity, Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Disease:Acute lymphoblastic leukemia
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs1350948;A;Efficacy;increased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele A is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;or in people with Other:Rheumatoid arthritis
;4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1059491;TT;Metabolism/PK;decreased concentrations of ⮕ 4-HYDROXYTAMOXIFEN, ENDOXIFEN;Genotype TT are associated with decreased concentrations of 4-hydroxytamoxifen or endoxifen in women with Breast Neoplasms as compared to genotypes GG + GT.;or in women with Disease:Breast Neoplasms
;METHOTREXATE;SLCO1B1;rs4149081;A;Efficacy, Toxicity, Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Disease:Acute lymphoblastic leukemia
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;rs17301249;C;Efficacy;decreased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with decreased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;or in people with Other:Rheumatoid arthritis
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.;  
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs12081765;G;Efficacy;increased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.;or in people with Other:Rheumatoid arthritis
;METHOTREXATE;SLCO1B1;rs11045879;C;Efficacy, Toxicity, Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Allele C is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.; in children with Disease:Acute lymphoblastic leukemia
;PHENYLEPHRINE;ADRB2;rs1042713;AA;Dosage;increased dose of ⮕ PHENYLEPHRINE;Genotype AA is associated with increased dose of phenylephrine in women as compared to genotype GG.; in women 
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.; in people with Other:mechanical heart valve replacement
;ANASTROZOLE;CSMD1;rs6990851;G;Efficacy;increased response to ⮕ ANASTROZOLE;Allele G is associated with increased response to anastrozole in women with Breast Neoplasms as compared to allele A.; in women with Other:Breast Neoplasms
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype AA is associated with increased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes AG + GG.;and in people with Other:Death
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs6806020;C;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;NICOTINE;CYP2A6;rs28399433;C;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;Allele C is associated with decreased metabolism of nicotine.;  
;ATORVASTATIN;ABCB1;rs2032582;AA + AC;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes AA + AC are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.; in people with Disease:Hypercholesterolemia
;WARFARIN;VKORC1;rs7294;CT + TT;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC.; in people with Other:mechanical heart valve replacement
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs1931704;A;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;ACAMPROSATE;CHDH, IL17RB;rs6801605;A;Efficacy;increased clinical benefit to ⮕ ACAMPROSATE;Allele A is associated with increased clinical benefit to acamprosate in people with Alcoholism as compared to allele G.; in people with Other:Alcohol abuse
;WARFARIN;VKORC1;rs9923231;TT;Dosage, Efficacy;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to genotypes CC + CT.; in people with Other:mechanical heart valve replacement
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;Efficacy;increased clinical benefit to ⮕ CYCLOPHOSPHAMIDE;Genotype GG is associated with increased clinical benefit to cyclophosphamide in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotypes GT + TT.; in people with Other:Leukemia, Lymphocytic, Chronic, B-Cell
;FENTANYL;ABCB1;rs1128503;AG;Metabolism/PK;decreased exposure to ⮕ FENTANYL;Genotype AG is associated with decreased exposure to fentanyl in healthy individuals as compared to genotypes AA + GG.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG are associated with decreased dose of warfarin as compared to genotype GG.;  
;COUMARIN;CYP2A6;rs28399433;C;Metabolism/PK;decreased metabolism of ⮕ COUMARIN;Allele C is associated with decreased metabolism of coumarin.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IL21R;rs3093390;C;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;Efficacy;decreased response to ⮕ BEVACIZUMAB, IRINOTECAN;Genotype GG is associated with decreased response to bevacizumab and irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.;and in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7512595;A;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1792774;C;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C19;rs3814637;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.;  
;WARFARIN;CYP2C9;rs1057910;AA + AC;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC.;  
;N-DESMETHYLTRAMADOL;ABCC2;rs3740066;TT;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLTRAMADOL;Genotype TT is associated with increased concentrations of n-desmethyltramadol in people with Death as compared to genotypes CC + CT.; in people with Other:Death
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7750468;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.;and in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;GGCX;rs699664;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC.;  
;ATORVASTATIN;SLCO1B1;rs2306283;AA;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype AA is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes AG + GG.; in people with Disease:Hypercholesterolemia
;FENTANYL;ABCC3;rs11079921;C;Metabolism/PK;increased clearance of ⮕ FENTANYL;Allele C is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele T.; in children with Other:Pain, Other:Premature Birth
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1503391;A;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs557905;T;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele T is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs2066911;A;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele G.;and in people with Disease:Chronic hepatitis C virus infection
;HMG COA REDUCTASE INHIBITORS;CFAP44;rs13064411;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to genotype AA.;  
;ATORVASTATIN;CYP7A1;rs3808607;TT;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotypes GG + GT.; in people with Disease:Hypercholesterolemia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs568910;A;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele A is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;and in people with Disease:Chronic hepatitis C virus infection
;NICOTINE;CHRNB2;rs2072658;AG;Other;increased response to ⮕ NICOTINE;Genotype AG is associated with increased response to nicotine in people with daily smoking as compared to genotype GG.; in people with Other:daily smoking
;METFORMIN;SLC22A1;rs622342;AC + CC;Efficacy;decreased response to ⮕ METFORMIN;Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype AA.; in people with Disease:Diabetes Mellitus, Type 2
;N-DESMETHYLTRAMADOL;UGT1A8;rs8330;CC;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLTRAMADOL;Genotype CC is associated with decreased concentrations of n-desmethyltramadol in people with Death as compared to genotypes CG + GG.; in people with Other:Death
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes CC + CT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;NICOTINE;CHRNA4;rs2229959;C;Other;increased response to ⮕ NICOTINE;Allele C is associated with increased response to nicotine in people with daily smoking as compared to allele A.; in people with Other:daily smoking
;PEGINTERFERON ALFA-2B, RIBAVIRIN;TUT7;rs17461620;C;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;ACETYLCYSTEINE;TOLLIP;rs3750920;TT;Efficacy;increased response to ⮕ ACETYLCYSTEINE;Genotype TT is associated with increased response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CC + CT.; in people with Disease:Pulmonary Fibrosis
;OXCARBAZEPINE;ABCB1;rs1045642;A;Efficacy;decreased response to ⮕ OXCARBAZEPINE;Allele A is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele G.; in people with Disease:Epilepsy
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype CC is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;OXCARBAZEPINE;UGT2B7;rs7439366;C;Efficacy;decreased response to ⮕ OXCARBAZEPINE;Allele C is associated with decreased response to oxcarbazepine in people with Epilepsy as compared to allele T.; in people with Disease:Epilepsy
;ARA-CTP;CDA;rs12404655;AG + GG;Metabolism/PK;increased concentrations of ⮕ ARA-CTP;Genotypes AG + GG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype AA.; in children with Disease:Leukemia, Myeloid, Acute
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ARA-CTP;RRM1;rs11030918;CT + TT;Metabolism/PK;decreased concentrations of ⮕ ARA-CTP;Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC.; in children with Disease:Leukemia, Myeloid, Acute
;CLOZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;increased concentrations of ⮕ CLOZAPINE;Genotype AA is associated with increased concentrations of clozapine in people with Schizophrenia as compared to genotypes AC + CC.; in people with Other:Schizophrenia
;CLOPIDOGREL;CYP3A5;rs776746;CC + CT;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotypes CC + CT are associated with increased resistance to clopidogrel in people with Stroke as compared to genotype TT.; in people with Disease:Stroke
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;ARA-CTP;CTPS1;rs11577910;AG;Metabolism/PK;increased concentrations of ⮕ ARA-CTP;Genotype AG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype GG.; in children with Disease:Leukemia, Myeloid, Acute
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ARA-CTP;CTPS1;rs12067645;AA + AG;Metabolism/PK;increased concentrations of ⮕ ARA-CTP;Genotypes AA + AG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype GG.; in children with Disease:Leukemia, Myeloid, Acute
;ARA-CTP;CTPS1;rs4364871;CT + TT;Metabolism/PK;decreased concentrations of ⮕ ARA-CTP;Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC.; in children with Disease:Leukemia, Myeloid, Acute
;N-DESMETHYLTRAMADOL;UGT1A8;rs10929303;CC;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLTRAMADOL;Genotype CC is associated with decreased concentrations of n-desmethyltramadol in people with Death as compared to genotypes CT + TT.; in people with Other:Death
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT are associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype CC is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotype CT.;and in people with Other:Death
;ARA-CTP;SLC28A1;rs11853372;TT;Metabolism/PK;decreased concentrations of ⮕ ARA-CTP;Genotype TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes GG + GT.; in children with Disease:Leukemia, Myeloid, Acute
;ARA-CTP;DCTD;rs4742;GG;Metabolism/PK;decreased concentrations of ⮕ ARA-CTP;Genotype GG is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.; in children with Disease:Leukemia, Myeloid, Acute
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ALLOPURINOL;ABCG2;rs2231142;GT + TT;Efficacy;decreased response to ⮕ ALLOPURINOL;Genotypes GT + TT are associated with decreased response to allopurinol in people with Gout as compared to genotype GG.; in people with Disease:Gout
;OXCARBAZEPINE;ABCB1;rs1045642;GG;Metabolism/PK;increased concentrations of ⮕ OXCARBAZEPINE;Genotype GG is associated with increased concentrations of oxcarbazepine in people with Epilepsy as compared to genotypes AA + AG.; in people with Disease:Epilepsy
;AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;Dosage, Efficacy;increased dose of ⮕ AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;Allele C is associated with increased dose of amantadine, Anticholinergics, levodopa or selegiline in people with Parkinson Disease.;or in people with Disease:Parkinson Disease
;ARA-CTP;DCK;rs4643786;CC + CT;Metabolism/PK;decreased concentrations of ⮕ ARA-CTP;Genotypes CC + CT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype TT.; in children with Disease:Leukemia, Myeloid, Acute
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype AA is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;rs4793665;CC;Metabolism/PK;increased concentrations of ⮕ MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;Genotype CC is associated with increased concentrations of morphine-3-glucuronide and morphine-6-glucuronide in children with Scoliosis or tonsillectomy as compared to genotypes CT + TT.;and in children with Disease:Scoliosis, Disease:tonsillectomy
;TACROLIMUS;ABCB1;rs1128503;GG;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotype GG is associated with decreased concentrations of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.; in children with Disease:Liver transplantation
;MORPHINE-3-GLUCURONIDE;ABCC3;rs4148412;TT;Metabolism/PK;increased concentrations of ⮕ MORPHINE-3-GLUCURONIDE;Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT.; in children with Disease:tonsillectomy
;GLUCOSE;CRTC2;rs8450;AA + AG;Toxicity;increased concentrations of ⮕ GLUCOSE;Genotypes AA + AG are associated with increased concentrations of glucose in people with Transplantation as compared to genotype GG.; in people with Disease:Transplantation
;ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotypes CT + TT are associated with increased dose of acenocoumarol as compared to genotype CC.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic as compared to genotype AA.; in people with Disease:Arthritis, Psoriatic
;TACROLIMUS;ABCB1;rs1128503;GG;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype GG is associated with increased dose of tacrolimus in children with liver transplantation as compared to genotypes AA + AG.; in children with Disease:Liver transplantation
;SERTRALINE;GNB3;rs5441;GG;Efficacy;increased response to ⮕ SERTRALINE;Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG.; in people with Other:Major Depressive Disorder
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.; in children with Disease:HIV infectious disease
;FENTANYL;CYP3A4;rs2242480;TT;Efficacy;increased response to ⮕ FENTANYL;Genotype TT is associated with increased response to fentanyl in women with Pain, Postoperative as compared to genotypes CC + CT.; in women with Other:Pain, Postoperative
;SUFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ SUFENTANIL;Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA.;" in people with ""Other:Lung Neoplasms"", ""Other:Pain, Postoperative"""
;SUFENTANIL;OPRM1;rs1323040;AG + GG;Dosage;increased dose of ⮕ SUFENTANIL;Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA.;" in people with ""Other:Lung Neoplasms"", ""Other:Pain, Postoperative"""
;SUFENTANIL;ABCB1;rs1128503;AA + AG;Dosage;increased dose of ⮕ SUFENTANIL;Genotypes AA + AG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype GG.;" in people with ""Other:Lung Neoplasms"", ""Other:Pain, Postoperative"""
;CYCLOSPORINE;ABCB1;rs1045642;A;Efficacy;decreased response to ⮕ CYCLOSPORINE;Allele A is associated with decreased response to cyclosporine in people with Psoriasis as compared to allele G.; in people with Disease:Psoriasis
;SUFENTANIL;ABCB1;rs2032582;AA + AC;Dosage;increased dose of ⮕ SUFENTANIL;Genotypes AA + AC are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype CC.;" in people with ""Other:Lung Neoplasms"", ""Other:Pain, Postoperative"""
;MORPHINE;OPRM1;rs1799971;GG;Dosage;increased dose of ⮕ MORPHINE;Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotypes AA + AG.; in women with Other:Pain, Postoperative
;HDL CHOLESTEROL;CRTC2;rs8450;AA;Toxicity;decreased concentrations of ⮕ HDL CHOLESTEROL;Genotype AA is associated with decreased concentrations of hdl cholesterol in people with Transplantation as compared to genotypes AG + GG.; in people with Disease:Transplantation
;O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;GG;Metabolism/PK;decreased concentrations of ⮕ O-DESMETHYLTRAMADOL;Genotype GG is associated with decreased concentrations of o-desmethyltramadol in people with Death as compared to genotype AG.; in people with Other:Death
;MYCOPHENOLIC ACID;ABCC2;rs717620;TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID;Genotype TT is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to genotypes CC + CT.; in people with Disease:Kidney Transplantation
;METHYLPHENIDATE;COMT;rs4680;GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;Metabolism/PK;decreased concentrations of ⮕ N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;Genotype TT is associated with decreased concentrations of n-desmethyltramadol and o-desmethyltramadol in people with Death as compared to genotypes CC + CT.;and in people with Other:Death
;PHENYTOIN;CYP2C9;rs12782374;AA + AG;Dosage, Metabolism/PK;decreased dose of ⮕ PHENYTOIN;Genotypes AA + AG are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;WARFARIN;CYP2C9;rs1057910;C;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;FENTANYL;ABCC3;rs8077268;T;Metabolism/PK;increased clearance of ⮕ FENTANYL;Allele T is associated with increased clearance of fentanyl in children with Pain and Premature Birth as compared to allele C.; in children with Other:Pain, Other:Premature Birth
;METHYLPHENIDATE;COMT;rs4680;G;Efficacy;increased clearance of ⮕ METHYLPHENIDATE;Allele G is associated with increased clearance of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;WARFARIN;CYP2C9;rs1799853;T;Dosage, Metabolism/PK;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;PLATINUM COMPOUNDS;XRCC1;rs25487;CC;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.; in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;CYCLOSPORINE;ABCB1;rs1045642;GG;Metabolism/PK;decreased concentrations of ⮕ CYCLOSPORINE;Genotype GG is associated with decreased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;NICOTINE;CYP1A2;rs35694136;T/del + del/del;Efficacy;decreased exposure to ⮕ NICOTINE;Genotypes T/del + del/del is associated with decreased exposure to nicotine in men as compared to genotype TT.; in men 
;SIROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased metabolism of ⮕ SIROLIMUS;Genotype CC is associated with decreased metabolism of sirolimus in people with Transplantation as compared to genotypes CT + TT.; in people with Disease:Transplantation
;PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.; in people with Disease:Non-Small Cell Lung Carcinoma
;MYCOPHENOLIC ACID;UGT2B7;rs7662029;G;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID;Allele G is associated with increased dose-adjusted trough concentrations of mycophenolic acid in people with Kidney Transplantation as compared to allele A.; in people with Disease:Kidney Transplantation
;METHYLPHENIDATE;TH;rs2070762;GG;Efficacy;decreased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with decreased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotypes CC + CT is associated with decreased response to atorvastatin as compared to genotype TT.;  
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;IL18;rs5744247;CC + CG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype GG.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;SIROLIMUS;CYP3A4;rs2740574;CC + CT;Dosage, Metabolism/PK;increased dose of ⮕ SIROLIMUS;Genotypes CC + CT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Disease:Kidney Transplantation
;SIROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ SIROLIMUS;Genotypes CT + TT are associated with increased dose of sirolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;CETUXIMAB;FCGR2A;rs1801274;AA;Efficacy;increased response to ⮕ CETUXIMAB;Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.; in people with Disease:Colorectal Neoplasms
;CARBAMAZEPINE;CYP3A4;rs2242480;CC;Metabolism/PK;increased concentrations of ⮕ CARBAMAZEPINE;Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; in people with Disease:Epilepsy
;RISPERIDONE;HTR2C;rs518147;CC;Efficacy;increased response to ⮕ RISPERIDONE;Genotype CC is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CG + GG.; in women with Disease:Schizophrenia
;CARBAMAZEPINE;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ CARBAMAZEPINE;Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; in people with Disease:Epilepsy
;SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;Efficacy;decreased clinical benefit to ⮕ SITAGLIPTIN, VILDAGLIPTIN;Genotype AA is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.;or in people with Other:Diabetes Mellitus, Type 2
;DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs7910936;C;Metabolism/PK;increased concentrations of ⮕ DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;Allele C is associated with increased concentrations of desethylchloroquine or hydroxychloroquine in people with Lupus Erythematosus, Systemic as compared to allele T.;or in people with Other:Systemic lupus erythematosus
;CARBAMAZEPINE;ABCB1;rs1045642;GG;Metabolism/PK;increased concentrations of ⮕ CARBAMAZEPINE;Genotype GG is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotype AG.; in people with Disease:Epilepsy
;CARBAMAZEPINE;EPHX1;rs3738046;CG;Metabolism/PK;concentrations of ⮕ CARBAMAZEPINE;Genotype CG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.; in children with Other:Hypercholesterolemia
;PHENYTOIN;CYP2C9;rs1799853;CT;Metabolism/PK;decreased metabolism of ⮕ PHENYTOIN;Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CC;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotype TT.; in healthy individuals 
;PHENYTOIN;CYP2C19;rs4244285;AG;Other, Metabolism/PK;decreased metabolism of ⮕ PHENYTOIN;Genotype AG is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;CLOZAPINE;HTR2C;rs6318;C;Efficacy;increased response to ⮕ CLOZAPINE;Allele C is associated with increased response to clozapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;CARBAMAZEPINE;EPHX1;rs2234922;AG + GG;Metabolism/PK;concentrations of ⮕ CARBAMAZEPINE;Genotypes AG + GG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;CARBAMAZEPINE;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ CARBAMAZEPINE;Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs12255372;TT;Efficacy;decreased response to ⮕ SULFONAMIDES, UREA DERIVATIVES;Genotype TT is associated with decreased response to sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;SIMVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.; in people with Other:Hypercholesterolemia
;CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;rs25487;T;Efficacy;decreased response to ⮕ CARBOPLATIN, CISPLATIN, FLUOROURACIL;Allele T is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele C.;and in people with Disease:Uterine Cervical Neoplasm
;TRAMADOL;ABCB1;rs2032582;AA;Metabolism/PK;increased exposure to ⮕ TRAMADOL;Genotype AA is associated with increased exposure to tramadol as compared to genotype CC.;  
;TRAMADOL;ABCB1;rs1045642;AA;Metabolism/PK;increased exposure to ⮕ TRAMADOL;Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.;  
;CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;rs12659;A;Efficacy;decreased response to ⮕ CARBOPLATIN, CISPLATIN, FLUOROURACIL;Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.;and in people with Disease:Uterine Cervical Neoplasm
;TRAMADOL;ABCB1;rs1128503;AA;Metabolism/PK;increased exposure to ⮕ TRAMADOL;Genotype AA is associated with increased exposure to tramadol as compared to genotype GG.;  
;TOCILIZUMAB;IL6R;rs12083537;AA;Efficacy;decreased response to ⮕ TOCILIZUMAB;Genotype AA is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype AG.; in people with Disease:Rheumatoid arthritis
;CAFFEINE;ADORA1;rs16851030;CC;Efficacy;increased response to ⮕ CAFFEINE;Genotype CC is associated with increased response to caffeine in infants with apnea of prematurity as compared to genotypes CT + TT.; in infants with Other:Apnea of prematurity
;TOCILIZUMAB;IL6R;rs4329505;CC + CT;Efficacy;decreased response to ⮕ TOCILIZUMAB;Genotypes CC + CT is associated with decreased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotype TT.; in people with Disease:Rheumatoid arthritis
;RISPERIDONE;HTR2C;rs1023574;CC;Efficacy;increased response to ⮕ RISPERIDONE;Genotype CC is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CG + GG.; in women with Disease:Schizophrenia
;RISPERIDONE;HTR2C;rs9698290;TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype TT is associated with increased response to risperidone in women with Schizophrenia as compared to genotypes CC + CT.; in women with Disease:Schizophrenia
;"""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";PRKCA;rs16960228;A;Efficacy;"increased response to ⮕ ""DIURETICS"", ""HYDROCHLOROTHIAZIDE"", ""THIAZIDES, PLAIN""";Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele G.;or in people with Disease:Hypertension
;ANTIDEPRESSANTS;RGS17;rs672170;A;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;rs7089580;AT;Dosage;increased dose of ⮕ WARFARIN;Genotype AT is associated with increased dose of warfarin as compared to genotype AA.;  
;WARFARIN;CYP2C9;rs7089580;AT;Dosage;increased clearance of ⮕ WARFARIN;Genotype AT is associated with increased clearance of warfarin as compared to genotype AA.;  
;VORICONAZOLE;SLCO1B3;rs4149117;GT + TT;Metabolism/PK;decreased trough concentration of ⮕ VORICONAZOLE;Genotypes GT + TT is associated with decreased trough concentration of voriconazole in children as compared to genotype GG.; in children 
;OXALIPLATIN;TP53;rs1042522;CG + GG;Efficacy;decreased response to ⮕ OXALIPLATIN;Genotypes CG + GG is associated with decreased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms
;ANTIDEPRESSANTS;NBEA;rs9315310;T;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;ANTIDEPRESSANTS;CRH;rs4737771;C;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;ANTIDEPRESSANTS;FHIT;rs49411;C;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;ANTIDEPRESSANTS;PARP11;rs2532560;G;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;ANTIDEPRESSANTS;;rs2831440;T;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;SILDENAFIL;GNB3;rs5443;TT;Efficacy;increased response to ⮕ SILDENAFIL;Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT.; in people with Disease:Erectile Dysfunction
;ANTIDEPRESSANTS;MTRF1L;rs766127;G;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;ATORVASTATIN;POR;rs1057868;CT + TT;Efficacy;decreased response to ⮕ ATORVASTATIN;Genotypes CT + TT is associated with decreased response to atorvastatin in children with familial hypercholesterolemia as compared to genotype CC.; in children with Disease:Familial hypercholesterolemia
;TACROLIMUS;HSD11B1;rs846908;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;SARILUMAB;IL6R;rs4845625;CC;Efficacy;decreased response to ⮕ SARILUMAB;Genotype CC is associated with decreased response to sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Other:Rheumatoid arthritis
;SALVIANOLIC ACID B;NOS3;rs1799983;GG;Efficacy;increased response to ⮕ SALVIANOLIC ACID B;Genotype GG is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes GT + TT.; in people with Disease:Coronary Disease
;BUPROPION;COMT;rs165599;AA + AG;Efficacy;increased response to ⮕ BUPROPION;Genotypes AA + AG are associated with increased response to bupropion in smokers as compared to genotype GG.; in Other:smokers
;BUPROPION;COMT;rs737865;AA;Efficacy;decreased response to ⮕ BUPROPION;Genotype AA is associated with decreased response to bupropion in smokers as compared to genotypes AG + GG.; in Other:smokers
;SALBUTAMOL;CRHR2;rs2267715;G;Efficacy;decreased response to ⮕ SALBUTAMOL;Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.; in people with Disease:Asthma
;DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs10882521;T;Metabolism/PK;decreased concentrations of ⮕ DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;Allele T is associated with decreased concentrations of desethylchloroquine or hydroxychloroquine in people with Lupus Erythematosus, Systemic as compared to allele G.;or in people with Other:Systemic lupus erythematosus
;SALMETEROL;ADRB2;rs1042713;AA;Efficacy;decreased response to ⮕ SALMETEROL;Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG.; in people with Disease:Asthma
;WARFARIN;STX1B;rs4889606;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.;  
;ADALIMUMAB;HFE;rs2071303;CC + CT;Efficacy;increased response to ⮕ ADALIMUMAB;Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT.; in people with Disease:Crohn Disease
;ROSIGLITAZONE;LPIN1;rs10192566;G;Efficacy;increased response to ⮕ ROSIGLITAZONE;Allele G is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Disease:Diabetes Mellitus, Type 2
;TACROLIMUS;HSD11B1;rs4844880;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AT + TT.; in people with Disease:Kidney Transplantation
;DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;Metabolism/PK;decreased concentrations of ⮕ DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;Genotype AA is associated with decreased concentrations of desethylchloroquine and hydroxychloroquine in people with Lupus Erythematosus, Systemic as compared to genotypes AG + GG.;and in people with Other:Systemic lupus erythematosus
;TACROLIMUS;HSD11B1;rs846910;AA;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype AA is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.; in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;ACENOCOUMAROL;GATA4;rs3735814;AG + GG;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotypes AG + GG are associated with decreased dose of acenocoumarol as compared to genotype AA.;  
;"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;rs4149601;AG + GG;Efficacy;"increased response to ⮕ ""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";Genotypes AG + GG are associated with increased response to Beta blocking agents, selective or diuretics in people with Hypertension as compared to genotype AA.;or in people with Disease:Hypertension
;ANTIDEPRESSANTS;CTNNA3;rs10997242;C;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;ALDOSTERONE ANTAGONISTS, AMILORIDE;NEDD4L;rs4149601;G;Efficacy;increased response to ⮕ ALDOSTERONE ANTAGONISTS, AMILORIDE;Allele G is associated with increased response to Aldosterone antagonists or amiloride in people with Hypertension as compared to allele A.;or in people with Disease:Hypertension
;ANTIDEPRESSANTS;HTR2A;rs7997012;AG + GG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AG + GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype AA.; in people with Disease:Major Depressive Disorder
;SALBUTAMOL;CRHR2;rs255100;A;Efficacy;decreased response to ⮕ SALBUTAMOL;Allele A is associated with decreased response to salbutamol in people with Asthma as compared to allele T.; in people with Disease:Asthma
;ANTIDEPRESSANTS;HTR2A;rs6313;GG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.; in people with Disease:Major Depressive Disorder
;ANTIDEPRESSANTS;CACNA1A;rs2112460;A;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;SALBUTAMOL;CRHR2;rs2284220;G;Efficacy;decreased response to ⮕ SALBUTAMOL;Allele G is associated with decreased response to salbutamol in people with Asthma as compared to allele A.; in people with Disease:Asthma
;WARFARIN;ORM1;rs17650;AG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AG + GG is associated with decreased dose of warfarin as compared to genotype AA.;  
;ANTIDEPRESSANTS;;rs521093;T;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele T is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;MORPHINE;UGT2B7;rs7439366;CC;Dosage;decreased dose of ⮕ MORPHINE;Genotype CC is associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT.; in women with Disease:Pain, Postoperative
;WARFARIN;VKORC1;rs7294;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele T.;  
;ANTIDEPRESSANTS;RAPGEF5;rs16873129;C;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T.; in people with Disease:Major Depressive Disorder
;VALPROIC ACID;ABCB1;rs1128503;AA;Efficacy;decreased clinical benefit to ⮕ VALPROIC ACID;Genotype AA is associated with decreased clinical benefit to valproic acid in children with Epilepsy as compared to genotypes AG + GG.; in children with Other:Epilepsy
;ANTIDEPRESSANTS;PON2;rs2299267;G;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Allele G is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Allele C is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;CISPLATIN;GALNT18;rs7937567;GG;Efficacy;increased response to ⮕ CISPLATIN;Genotype GG is associated with increased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotypes AA + AG.; in people with Disease:Urinary Bladder Neoplasms
;EFAVIRENZ;CYP2B6;rs2279343;AG + GG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes AG + GG are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype AA.; in children with Disease:HIV infectious disease
;RITUXIMAB;;rs3759467;CC;Efficacy;decreased response to ⮕ RITUXIMAB;Genotype CC is associated with decreased response to rituximab in people with Vasculitis as compared to genotypes CT + TT.; in people with Disease:Vasculitis
;ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;rs680055;CG;Efficacy;increased response to ⮕ ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;Genotype CG is associated with increased response to antipsychotics, aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to genotype CC.;or in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased steady-state concentration of ⮕ TACROLIMUS;Genotype CC is associated with increased steady-state concentration of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;CORTICOSTEROIDS;HDAC1;rs1741981;CC;Efficacy;decreased response to ⮕ CORTICOSTEROIDS;Genotype CC is associated with decreased response to corticosteroids in children with Asthma as compared to genotypes CT + TT.; in children with Disease:Asthma
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;VINCRISTINE;MTNR1B;rs8192552;AG;Metabolism/PK;increased exposure to ⮕ VINCRISTINE;Genotype AG is associated with increased exposure to vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia, Other:Hodgkin Disease, Other:Rhabdomyosarcoma, Other:Medulloblastoma, Other:Glioma
;MORPHINE;TLR2;rs3804100;CC + CT;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Genotypes CC + CT are associated with decreased dose of morphine in women with Pain, Postoperative as compared to genotype TT.; in women with Disease:Pain, Postoperative
;TACROLIMUS;CYP3A5;rs776746;CT;Other, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotype CT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148947;T;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele T is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.;and in people with Disease:Prostatic Neoplasms
;MORPHINE;IL1B;rs1143634;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in women with Pain, Postoperative as compared to allele G.; in women with Disease:Pain, Postoperative
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.; in children with Disease:HIV infectious disease
;CISPLATIN;MLLT3;rs10964552;AA + AC;Efficacy;decreased response to ⮕ CISPLATIN;Genotypes AA + AC are associated with decreased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotype CC.; in people with Disease:Urinary Bladder Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;T;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Allele T is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation
;MORPHINE;IL1B;rs1143634;A;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Allele A is associated with increased dose of morphine in women with Pain, Postoperative as compared to allele G.; in women with Disease:Pain, Postoperative
;EFAVIRENZ;CYP2B6;rs28399499;CT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.; in children with Disease:HIV infectious disease
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele A is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;and in people with Disease:Prostatic Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;TT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;ATORVASTATIN;MTTP;rs1800591;TT;Efficacy;increased response to ⮕ ATORVASTATIN;Genotype TT is associated with increased response to atorvastatin in men with Hyperlipoproteinemia Type II.; in men with Disease:Hyperlipoproteinemia Type II
;NITROGLYCERIN;ALDH2;rs671;AA + AG;Efficacy;decreased response to ⮕ NITROGLYCERIN;Genotypes AA + AG is associated with decreased response to nitroglycerin in children with Heart Defects, Congenital as compared to genotype GG.; in children with Disease:Congenital Heart Defects
;TOCILIZUMAB;GALNT18;rs4910008;CC;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CISPLATIN;RARS1;rs244898;TT;Efficacy;increased response to ⮕ CISPLATIN;Genotype TT is associated with increased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotypes CC + CT.; in people with Disease:Urinary Bladder Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in children with Kidney Transplantation as compared to genotype CT.; in children with Disease:Kidney Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;RISPERIDONE;ABCB1;rs2235048;AG + GG;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes AG + GG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in children with heart transplantation as compared to genotype CC.; in children with Other:heart transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;NITROGLYCERIN;ALDH2;rs671;AA + AG;Metabolism/PK;increased concentrations of ⮕ NITROGLYCERIN;Genotypes AA + AG are associated with increased concentrations of nitroglycerin in children with Heart Defects, Congenital and Hypertension, Pulmonary as compared to genotype GG.; in children with Disease:Congenital Heart Defects, Disease:Pulmonary Hypertension
;DIGOXIN;ABCB1;rs2032582;AT;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype AT is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TOCILIZUMAB;CD69;rs11052877;A;Efficacy;increased response to ⮕ TOCILIZUMAB;Allele A is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to allele G.; in people with Disease:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PHENAZEPAM;CYP2C19;rs12248560;CC + CT;Efficacy;increased response to ⮕ PHENAZEPAM;Genotypes CC + CT are associated with increased response to phenazepam in men with Alcohol-Related Disorders as compared to genotype TT.; in men with Disease:Alcohol-Related Disorders
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;VINCRISTINE;SNU13;rs6519270;G;Metabolism/PK;increased concentrations of ⮕ VINCRISTINE;Allele G is associated with increased concentrations of vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to allele A.; in children with Other:Acute lymphoblastic leukemia, Other:Hodgkin Disease, Other:Rhabdomyosarcoma, Other:Medulloblastoma, Other:Glioma
;ATENOLOL;;rs7184292;A;Efficacy;increased response to ⮕ ATENOLOL;Allele A is associated with increased response to atenolol in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;ATENOLOL;XIRP2;rs7606603;C;Efficacy;decreased response to ⮕ ATENOLOL;Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;CYCLOSPORINE;CYP3A7;rs10211;TT;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Genotype TT is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CC + CT.; in people with Disease:Kidney Transplantation
;CYCLOSPORINE;CYP3A7;rs2257401;CC;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CG + GG.; in people with Disease:Kidney Transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;rs12343867;CC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.; in people with Disease:Ulcerative Colitis
;NILOTINIB;GSTP1;rs1695;A;Efficacy;increased response to ⮕ NILOTINIB;Allele A is associated with increased response to nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;HYDROCHLOROTHIAZIDE;;rs16872401;C;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Allele C is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Inflammatory Bowel Diseases
;CYCLOSPORINE;CYP3A4;rs4646437;GG;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Genotype GG is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype AA.; in people with Disease:Kidney Transplantation
;CARVEDILOL;ADRB1;rs1801252;G;Efficacy;increased response to ⮕ CARVEDILOL;Allele G is associated with increased response to carvedilol in healthy individuals as compared to allele A.; in healthy individuals 
;PAROXETINE;ABCB1;rs2032582;CC + CT;Efficacy;decreased response to ⮕ PAROXETINE;Genotypes CC + CT are associated with decreased response to paroxetine in people with Depression as compared to genotypes AA + AT.; in people with Disease:Depression
;NILOTINIB;CYP1A1;rs1048943;CT + TT;Efficacy;increased response to ⮕ NILOTINIB;Genotypes CT + TT is associated with increased response to nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;rs10754558;CG + GG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype CC.; in people with Disease:Inflammatory Bowel Diseases
;ATENOLOL;;rs7184292;GG;Dosage;decreased dose of ⮕ ATENOLOL;Genotype GG is associated with decreased dose of atenolol in people with Hypertension as compared to genotypes AA + AG.; in people with Other:Hypertension
;ATORVASTATIN;SLCO1B1;rs2306283;GG;Efficacy;decreased clinical benefit to ⮕ ATORVASTATIN;Genotype GG is associated with decreased clinical benefit to atorvastatin in people with Hyperlipidemias as compared to genotype AA.; in people with Other:Hyperlipidemias
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;rs1946518;GT + TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes GT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype GG.; in people with Disease:Ulcerative Colitis
;CARVEDILOL;ADRB1;rs1801253;C;Efficacy;increased response to ⮕ CARVEDILOL;Allele C is associated with increased response to carvedilol in healthy individuals as compared to allele G.; in healthy individuals 
;RISPERIDONE;AKT1;rs3803300;CT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;RISPERIDONE;AKT1;rs2494732;TT;Efficacy;increased response to ⮕ RISPERIDONE;Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased exposure to ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype GG.; in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype AA.; in people with Disease:Ulcerative Colitis
;IMATINIB;CYP2B6;rs3745274;GG + TT;Efficacy;increased resistance to ⮕ IMATINIB;Genotypes GG + TT is associated with increased resistance to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;WARFARIN;CYP2C19;rs4986893;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.;  
;CYCLOSPORINE;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE;Genotype CC is associated with increased concentrations of cyclosporine in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C19;rs3814637;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin as compared to genotype CC.;  
;CANNABIDIOL;AOC1;rs12539;CT + TT;Efficacy;increased response to ⮕ CANNABIDIOL;Genotypes CT + TT are associated with increased response to cannabidiol in people with Epilepsy as compared to genotype CC.; in people with Other:Epilepsy
;EFAVIRENZ;CYP2B6;rs3211371;CT + TT;Metabolism/PK;decreased exposure to ⮕ EFAVIRENZ;Genotypes CT + TT are associated with decreased exposure to efavirenz in healthy individuals as compared to genotype CC.; in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;rs17250932;CC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT.; in people with Disease:Ulcerative Colitis
;VINCRISTINE;RAB7A;rs4548;CT;Metabolism/PK;increased exposure to ⮕ VINCRISTINE;Genotype CT is associated with increased exposure to vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to genotype CC.; in children with Other:Acute lymphoblastic leukemia, Other:Hodgkin Disease, Other:Rhabdomyosarcoma, Other:Medulloblastoma, Other:Glioma
;DOCETAXEL, THALIDOMIDE;CHST3;rs730720;C;Efficacy;increased response to ⮕ DOCETAXEL, THALIDOMIDE;Allele C is associated with increased response to docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;and in people with Disease:Prostatic Neoplasms
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;rs8126756;CC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype TT.; in people with Disease:Crohn Disease
;CANNABIDIOL;SLC15A1;rs1339067;TT;Efficacy;decreased response to ⮕ CANNABIDIOL;Genotype TT is associated with decreased response to cannabidiol in people with Epilepsy as compared to genotypes AA + AT.; in people with Other:Epilepsy
;WARFARIN;;rs12772169;T;Dosage;dose of ⮕ WARFARIN;Allele T is associated with dose of warfarin as compared to allele C.;  
;ROSIGLITAZONE;SLCO1B1;rs4149056;C;Efficacy;increased response to ⮕ ROSIGLITAZONE;Allele C is associated with increased response to rosiglitazone in people with Diabetes Mellitus as compared to allele T.; in people with Disease:Diabetes Mellitus
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;CG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype CC.; in people with Disease:Crohn Disease
;CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;rs1741981;CC;Efficacy;decreased response to ⮕ CORTICOSTEROIDS FOR SYSTEMIC USE;Genotype CC is associated with decreased response to Corticosteroids For Systemic Use in people with Asthma as compared to genotypes CT + TT.; in people with Disease:Asthma
;RISPERIDONE;COMT;rs165599;G;Efficacy;increased response to ⮕ RISPERIDONE;Allele G is associated with increased response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;RISPERIDONE;GRM3;rs724226;G;Efficacy;increased response to ⮕ RISPERIDONE;Allele G is associated with increased response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;rs5744174;AG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease as compared to genotype AA.; in people with Disease:Crohn Disease
;MORPHINE;KCNJ6;rs6517442;CC;Efficacy;increased response to ⮕ MORPHINE;Genotype CC is associated with increased response to morphine in infants with Pain as compared to genotypes CT + TT.; in infants with Disease:Pain
;METHOTREXATE;ABCG2;rs2231142;GT;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype GT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;decreased trough concentration of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;MORPHINE, REMIFENTANIL;KCNJ6;rs6517442;TT;Efficacy;decreased response to ⮕ MORPHINE, REMIFENTANIL;Genotype TT is associated with decreased response to morphine or remifentanil in infants with Pain as compared to genotypes CC + CT.;or in infants with Disease:Pain
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;LOW DENSITY LIPOPROTEIN;SH2B1;rs3888190;CC;Other;increased concentrations of ⮕ LOW DENSITY LIPOPROTEIN;Genotype CC is associated with increased concentrations of low density lipoprotein in people with Bipolar Disorder, Depressive Disorder, Psychotic Disorders or schizoaffective disorder as compared to genotypes AA + AC.; in people with Disease:Bipolar Disorder, Disease:Depressive Disorder, Disease:Psychotic Disorder, Disease:Schizoaffective disorder
;TACROLIMUS;CYP3A5;rs776746;T;Dosage;increased dose of ⮕ TACROLIMUS;Allele T is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation
;ENALAPRIL;VEGFA;rs699947;AA + AC;Efficacy;increased response to ⮕ ENALAPRIL;Genotypes AA + AC are associated with increased response to enalapril in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;LITHIUM;CACNG2;rs2284018;TT;Efficacy;decreased response to ⮕ LITHIUM;Genotype TT is associated with decreased response to lithium in people with Bipolar Disorder as compared to genotypes CC + CT.; in people with Disease:Bipolar Disorder
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;EFAVIRENZ;ABCB1;rs1045642;GG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz as compared to genotype GG.;  
;ANASTROZOLE;;rs1437153;T;Efficacy;decreased response to ⮕ ANASTROZOLE;Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele G.; in women with Other:Breast Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;DOCETAXEL;ORM2;rs2250242;AA;Metabolism/PK;increased clearance of ⮕ DOCETAXEL;Genotype AA is associated with increased clearance of docetaxel in men with Prostatic Neoplasms as compared to genotypes AG + GG.; in men with Disease:Prostatic Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;ETANERCEPT, INFLIXIMAB;CARD8;rs2043211;TT;Efficacy;decreased response to ⮕ ETANERCEPT, INFLIXIMAB;Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.;or in people with Other:Rheumatoid arthritis
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;METHOTREXATE;ABCB1;rs1045642;AA + AG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AA + AG are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammatory Bowel Diseases as compared to genotype AA.; in people with Disease:Inflammatory Bowel Diseases
;ETANERCEPT, INFLIXIMAB;NLRP3;rs4612666;TT;Efficacy;decreased response to ⮕ ETANERCEPT, INFLIXIMAB;Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;or in people with Other:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ANASTROZOLE;DLG2;rs2449598;T;Efficacy;decreased response to ⮕ ANASTROZOLE;Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele G.; in women with Other:Breast Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Nephrotic Syndrome as compared to genotypes CT + TT.; in children with Other:Nephrotic Syndrome
;EFAVIRENZ;CYP2B6;rs2279343;GG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CC.; in children 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2242480;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in children with Nephrotic Syndrome as compared to genotype CT.; in children with Other:Nephrotic Syndrome
;DIGOXIN;ABCB1;rs2032582;AA;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype CC.; in healthy individuals 
;METHOTREXATE;MTHFR;rs1801133;AA;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype AA is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2B;HLA-DPA1;rs3077;GG;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B;Genotype GG is associated with increased response to peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to genotypes AA + AG.; in people with Disease:Hepatitis B, Chronic
;RIVASTIGMINE;BCHE;rs1803274;CC;Efficacy;increased response to ⮕ RIVASTIGMINE;Genotype CC is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CT + TT.; in people with Disease:Alzheimer Disease
;DIGOXIN;ABCB1;rs1045642;AG;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype AG is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.; in healthy individuals 
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;WARFARIN;CYP4F2;rs2108622;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.;  
;METHOTREXATE;ABCB1;rs1045642;AG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype AG is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;Efficacy;decreased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;or in people with Disease:Rheumatoid arthritis
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;CANNABIDIOL;ABCC5;rs3749442;AA + AG;Efficacy;decreased response to ⮕ CANNABIDIOL;Genotypes AA + AG are associated with decreased response to cannabidiol in people with Epilepsy as compared to genotype GG.; in people with Other:Epilepsy
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AA + AC.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.; in Disease:Liver transplantation
;EFAVIRENZ;CYP2B6;rs3181842;CC + CT;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotypes CC + CT are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype TT.; in healthy individuals 
;EFAVIRENZ;CYP2B6;rs707265;AA + AG;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotypes AA + AG are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype GG.; in healthy individuals 
;EFAVIRENZ;CYP2B6;rs7246465;CT + TT;Metabolism/PK;increased metabolism of ⮕ EFAVIRENZ;Genotypes CT + TT are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype CC.; in healthy individuals 
;SUFENTANIL;NFKBIA;rs696;TT;Dosage;increased dose of ⮕ SUFENTANIL;Genotype TT is associated with increased dose of sufentanil in people with Pain, Postoperative as compared to genotypes CC + CT.; in people with Other:Pain, Postoperative
;EFAVIRENZ;CYP2B6;rs1042389;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype CC.; in healthy individuals 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AG + GG.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;GLUCOSE;RABEP1;rs1000940;AG + GG;Other;decreased concentrations of ⮕ GLUCOSE;Genotypes AG + GG is associated with decreased concentrations of glucose in people with Bipolar Disorder, Depressive Disorder, Psychotic Disorders and schizoaffective disorder as compared to genotype AA.; in people with Disease:Bipolar Disorder, Disease:Depressive Disorder, Disease:Psychotic Disorder, Disease:Schizoaffective disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;PAROXETINE;BDNF;rs6265;TT;Efficacy;decreased response to ⮕ PAROXETINE;Genotype TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.; in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;REMIFENTANIL;COMT;rs4680;AA;Efficacy;increased response to ⮕ REMIFENTANIL;Genotype AA is associated with increased response to remifentanil in infants with Pain as compared to genotypes AG + GG.; in infants with Disease:Pain
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in liver transplantation as compared to genotype CC.; in Disease:Liver transplantation
;MORPHINE;COMT;rs4680;GG;Efficacy;decreased response to ⮕ MORPHINE;Genotype GG is associated with decreased response to morphine in infants with Pain as compared to genotypes AA + AG.; in infants with Disease:Pain
;MORPHINE, REMIFENTANIL;COMT;rs4680;AA + AG;Efficacy;increased response to ⮕ MORPHINE, REMIFENTANIL;Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG.;or in infants with Disease:Pain
;TACROLIMUS;CYP3A5;rs776746;CT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;ANTIPSYCHOTICS;ABCB1;rs2032582;CC;Dosage, Metabolism/PK;increased dose of ⮕ ANTIPSYCHOTICS;Genotype CC is associated with increased dose of antipsychotics in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;ADALIMUMAB, INFLIXIMAB;TLR2;rs3804099;T;Efficacy;decreased response to ⮕ ADALIMUMAB, INFLIXIMAB;Allele T is associated with decreased response to adalimumab or infliximab in people with Crohn Disease as compared to allele C.;or in people with Other:Crohn Disease
;INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;MORPHINE;COMT;rs4680;G;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A.;" in people with ""Other:Coronary Artery Disease"", ""Efficacy:Pain, Postoperative"""
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased exposure to ⮕ EFAVIRENZ;Genotype TT is associated with increased exposure to efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CC + CT.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased clearance of tacrolimus in people with HSCT as compared to genotype CC.; in people with Other:HSCT
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CG + GG.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with kidney disease as compared to genotype CC.; in people with Other:kidney disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;IMATINIB;ABCG2;rs2231142;GT;Efficacy;increased clinical benefit to ⮕ IMATINIB;Genotype GT is associated with increased clinical benefit to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.; in people with Other:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs8113007;AA;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype AA is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes AT + TT.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C and HIV Infections as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection, Disease:HIV infectious disease
;CLOZAPINE;CHRM1;rs2075748;CC;Dosage;decreased dose of ⮕ CLOZAPINE;Genotype CC is associated with decreased dose of clozapine in people with Schizophrenia as compared to genotypes CT + TT.; in people with Other:Schizophrenia
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;Genotype CC is associated with decreased response to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.;and in women with Disease:Breast Neoplasms
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased exposure to ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased exposure to efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;G;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele G is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.;and in people with Disease:Hepatitis C virus infection
;INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;;rs12615320;G;Efficacy;decreased response to ⮕ ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;Allele G is associated with decreased response to erenumab, fremanezumab or galcanezumab in people with Migraine without Aura or Migraine with Aura as compared to allele A.;or in people with Other:Migraine without Aura, Other:Migraine with Aura
;ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotypes CC + CT are associated with decreased response to rosuvastatin as compared to genotype TT.;  
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;HYDROXYUREA;ASS1;rs10901080;T;Efficacy;increased response to ⮕ HYDROXYUREA;Allele T is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele G.;" in people with ""Disease:Anemia, Sickle Cell"", ""Disease:Beta-thalassemia and related diseases"""
;ANASTROZOLE;CSMD1;rs6981827;T;Efficacy;decreased response to ⮕ ANASTROZOLE;Allele T is associated with decreased response to anastrozole in women with Breast Neoplasms as compared to allele C.; in women with Other:Breast Neoplasms
;HYDROXYUREA;ASS1;rs10793902;T;Efficacy;increased response to ⮕ HYDROXYUREA;Allele T is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele C.;" in people with ""Disease:Anemia, Sickle Cell"", ""Disease:Beta-thalassemia and related diseases"""
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C.;and in people with Disease:Hepatitis C virus infection
;DOXORUBICIN;ABCB1;rs2032582;AA;Metabolism/PK;decreased metabolism of ⮕ DOXORUBICIN;Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype CC.; in people with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT.;and in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;T;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.;and in people with Disease:Hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT;Dosage;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;EPIRUBICIN;NQO1;rs1800566;AA;Efficacy, Toxicity;decreased response to ⮕ EPIRUBICIN;Genotype AA is associated with decreased response to epirubicin in Breast Cancer Cell Lines as compared to genotype GG.; in Other:Breast Cancer Cell Lines
;DOCETAXEL, EPIRUBICIN;MDM4;rs1563828;AA;Efficacy;increased response to ⮕ DOCETAXEL, EPIRUBICIN;Genotype AA is associated with increased response to docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes AG + GG.;and in women with Disease:Breast Neoplasms
;GEMCITABINE;CDA;rs2072671;C;Metabolism/PK;decreased clearance of ⮕ GEMCITABINE;Allele C is associated with decreased clearance of gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.; in people with Disease:Non-Small Cell Lung Carcinoma
;HYDROCHLOROTHIAZIDE;NEDD4L;rs75982813;AG + GG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;GLICLAZIDE;KCNJ11;rs5219;TT;Efficacy;increased response to ⮕ GLICLAZIDE;Genotype TT is associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes CC + CT.; in people with Disease:Diabetes Mellitus, Type 2
;WARFARIN;;rs12777823;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin as compared to genotype GG.;  
;DOXORUBICIN;ABCB1;rs1045642;AA;Metabolism/PK;decreased metabolism of ⮕ DOXORUBICIN;Genotype AA is associated with decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to genotype GG.; in people with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;ARIPIPRAZOLE;DRD2;rs6277;GG;Efficacy;decreased response to ⮕ ARIPIPRAZOLE;Genotype GG is associated with decreased response to aripiprazole in people with Schizophrenia as compared to genotype AA.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;DIGOXIN;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ DIGOXIN;Genotype AA is associated with increased clearance of digoxin in healthy individuals as compared to genotype GG.; in healthy individuals 
;CAPECITABINE, RADIOTHERAPY;AREG;rs11942466;AA + AC;Efficacy;decreased response to ⮕ CAPECITABINE, RADIOTHERAPY;Genotypes AA + AC is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype CC.;and in people with Disease:Rectal Neoplasms
;(S)-METHADONE;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ (S)-METHADONE;Genotypes GT + TT are associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to genotype GG.; in people with Disease:Opioid-Related Disorders
;(R)-METHADONE;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ (R)-METHADONE;Genotypes GT + TT are associated with increased concentrations of (R)-methadone in people with Opioid-Related Disorders as compared to genotype GG.; in people with Disease:Opioid-Related Disorders
;CAPECITABINE, RADIOTHERAPY;ERCC1;rs11615;AG + GG;Efficacy;decreased response to ⮕ CAPECITABINE, RADIOTHERAPY;Genotypes AG + GG is associated with decreased response to capecitabine and radiotherapy in people with Rectal Neoplasms as compared to genotype AA.;and in people with Disease:Rectal Neoplasms
;CAPECITABINE, OXALIPLATIN;VEGFA;rs2010963;CG;Efficacy;decreased response to ⮕ CAPECITABINE, OXALIPLATIN;Genotype CG is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + GG.;and in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;ACETAMINOPHEN;UGT2B15;rs1902023;AA;Efficacy;increased response to ⮕ ACETAMINOPHEN;Genotype AA is associated with increased response to acetaminophen in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;ARIPIPRAZOLE;ANKK1;rs1800497;AA + AG;Efficacy;increased response to ⮕ ARIPIPRAZOLE;Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;MORPHINE;COMT;rs4633;C;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Allele C is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele T.;" in people with ""Other:Coronary Artery Disease"", ""Efficacy:Pain, Postoperative"""
;ACETAMINOPHEN;TRPV1;rs224534;AA + AG;Efficacy;increased response to ⮕ ACETAMINOPHEN;Genotypes AA + AG is associated with increased response to acetaminophen in healthy individuals as compared to genotype GG.; in healthy individuals 
;CLOZAPINE;HTR3A;rs1150226;G;Efficacy;increased response to ⮕ CLOZAPINE;Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;RISPERIDONE;GRM7;rs2069062;CC;Efficacy;increased response to ⮕ RISPERIDONE;Genotype CC is associated with increased response to risperidone in people with as compared to genotypes CG + GG.; in people with 
;CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.; in people with Disease:Acute coronary syndrome
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;CLOZAPINE;HTR3A;rs2276302;A;Efficacy;increased response to ⮕ CLOZAPINE;Allele A is associated with increased response to clozapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;GLUCOSE;COMT;rs4680;AA + AG;Toxicity;increased concentrations of ⮕ GLUCOSE;Genotypes AA + AG is associated with increased concentrations of glucose in children as compared to genotype GG.; in children 
;CLOZAPINE;HTR3A;rs1062613;C;Efficacy;increased response to ⮕ CLOZAPINE;Allele C is associated with increased response to clozapine in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;Genotypes AA + AG are associated with decreased metabolism of clopidogrel in people with Acute coronary syndrome as compared to genotype GG.; in people with Disease:Acute coronary syndrome
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;rs10919563;G;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Allele G is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to allele A.;or in people with Disease:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased discontinuation of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased discontinuation of tacrolimus in people with Kidney Diseases as compared to genotype CC.; in people with Disease:Kidney Disorder
;RISPERIDONE;GRID2;rs1875705;GG;Efficacy;increased response to ⮕ RISPERIDONE;Genotype GG is associated with increased response to risperidone in people with as compared to genotypes AA + AG.; in people with 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in healthy individuals as compared to genotype CC.; in healthy individuals 
;CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotypes AA + AG are associated with decreased response to clopidogrel in people with Acute coronary syndrome as compared to genotype GG.; in people with Disease:Acute coronary syndrome
;PACLITAXEL;ABCB1;rs2032582;CC;Efficacy;decreased response to ⮕ PACLITAXEL;Genotype CC is associated with decreased response to paclitaxel in women with Breast Neoplasms.; in women with Disease:Breast Neoplasms
;TACROLIMUS;NR1I2;rs2276707;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.; in people with Other:Hematopoietic stem cell transplantation
;TACROLIMUS;CYP3A5;rs776746;CT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotype CT is associated with increased clearance of tacrolimus in Kidney Transplantation as compared to genotype CC.; in Disease:Kidney Transplantation
;CAPECITABINE, OXALIPLATIN;VEGFA;rs699947;AC;Efficacy;decreased response to ⮕ CAPECITABINE, OXALIPLATIN;Genotype AC is associated with decreased response to capecitabine and oxaliplatin in people with Colorectal Neoplasms.;and in people with Disease:Colorectal Neoplasms
;WARFARIN;PRSS53, VKORC1;rs17886199;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;rs12422149;AG;Metabolism/PK;increased concentrations of ⮕ 4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;Genotype AG is associated with increased concentrations of 4-hydroxyatorvastatin and 4-hydroxyatorvastatin lactone in people with Coronary Disease as compared to genotype GG.;and in people with Other:Coronary Disease
;PACLITAXEL;ABCB1;rs2032582;AA + AT;Efficacy;increased response to ⮕ PACLITAXEL;Genotypes AA + AT are associated with increased response to paclitaxel in women with Ovarian Neoplasms as compared to genotypes AC + CC.; in women with Disease:Ovarian Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AG + GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.;and in people with Disease:Chronic hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Other, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased metabolism of tacrolimus in healthy individuals as compared to genotype CC.; in healthy individuals 
;2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;UGT1A1;rs887829;CC;Metabolism/PK;decreased concentrations of ⮕ 2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;Genotype CC is associated with decreased concentrations of 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin lactone and atorvastatin lactone in people with Coronary Disease as compared to genotypes CT + TT.;and in people with Other:Coronary Disease
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs1056515;TT;Efficacy;increased response to ⮕ BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;Genotype TT is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes GG + GT.;and in people with Disease:Colorectal Neoplasms
;SN-38;UGT1A1;rs4148323;AA;Dosage;decreased metabolism of ⮕ SN-38;Genotype AA is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to genotype GG.; in people with Disease:Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8105790;CC + CT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes CC + CT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AG + GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes AG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype AA.;and in people with Disease:Chronic hepatitis C virus infection
;VALPROIC ACID;GABRA1;rs10068980;AA + AG;Efficacy;increased clinical benefit to ⮕ VALPROIC ACID;Genotypes AA + AG is associated with increased clinical benefit to valproic acid in children with Epilepsy as compared to genotype GG.; in children with Other:Epilepsy
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes CT + TT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;and in people with Disease:Chronic hepatitis C virus infection
;CLOZAPINE;CHRM1;rs1942499;GG;Dosage;decreased dose of ⮕ CLOZAPINE;Genotype GG is associated with decreased dose of clozapine in people with Schizophrenia as compared to genotypes AA + AG.; in people with Other:Schizophrenia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ROSUVASTATIN;SCAP;rs12487736;C;Efficacy;increased response to ⮕ ROSUVASTATIN;Allele C is associated with increased response to rosuvastatin in people with Metabolic Syndrome as compared to allele T.; in people with Disease:Metabolic Syndrome
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803219;CT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;and in people with Disease:Chronic hepatitis C virus infection
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;rs329007;GG;Efficacy;decreased response to ⮕ BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.;and in people with Disease:Colorectal Neoplasms
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;response to ⮕ IVACAFTOR;Allele A is associated with response to ivacaftor in children with Cystic Fibrosis.; in children with Disease:Cystic Fibrosis
;ROCURONIUM;ABCB1;rs1128503;AA;Efficacy;decreased response to ⮕ ROCURONIUM;Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.;  
;MYCOPHENOLIC ACID;UGT1A9;rs6714486;AA + AT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ MYCOPHENOLIC ACID;Genotypes AA + AT is associated with decreased dose-adjusted trough concentrations of mycophenolic acid in children with Kidney Transplantation as compared to genotype TT.; in children with Other:Kidney Transplantation
;ACENOCOUMAROL;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele T is associated with decreased dose of acenocoumarol as compared to allele C.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;ROCURONIUM;SLCO1B1;rs2306283;AA;Efficacy;decreased response to ⮕ ROCURONIUM;Genotype AA is associated with decreased response to rocuronium as compared to genotypes AG + GG.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;and in people with Disease:Chronic hepatitis C virus infection
;PERAMPANEL;CYP3A5, ZSCAN25;rs776746;C;Metabolism/PK;increased concentrations of ⮕ PERAMPANEL;Allele C is associated with increased concentrations of perampanel in children with Epilepsy as compared to allele T.; in children with Other:Epilepsy
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.; in children with Disease:Liver transplantation
;MORPHINE;UGT2B7;rs7438135;AA + AG;Metabolism/PK;decreased concentrations of ⮕ MORPHINE;Genotypes AA + AG is associated with decreased concentrations of morphine in infants as compared to genotype GG.; in infants 
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotype CC is associated with decreased clearance of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GT;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs7248668;AA + AG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes AA + AG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;and in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;and in people with Disease:Chronic hepatitis C virus infection
;PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ PRAVASTATIN;Genotypes CC + CT are associated with increased concentrations of pravastatin in children with Hypercholesterolemia as compared to genotype TT.; in children with Other:Hypercholesterolemia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;CG + GG;Efficacy;decreased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotypes CG + GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;and in people with Disease:Chronic hepatitis C virus infection
;ACENOCOUMAROL;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with increased dose of acenocoumarol as compared to genotype CT.;  
;IMATINIB;ABCG2;rs2725252;C;Efficacy;increased response to ⮕ IMATINIB;Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;PHENPROCOUMON;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ PHENPROCOUMON;Allele T is associated with increased dose of phenprocoumon maintenance dosage by 1.5 mg/week as compared to allele C.;  Other:maintenance dosage by 1.5 mg/week
;ATENOLOL, IRBESARTAN;EDN1;rs5370;GT;Efficacy;increased response to ⮕ ATENOLOL, IRBESARTAN;Genotype GT is associated with increased response to atenolol and irbesartan in men with Essential hypertension as compared to genotype GG.;and in men with Disease:Essential hypertension
;PAROXETINE;HTR2A;rs6311;CC;Efficacy;increased response to ⮕ PAROXETINE;Genotype CC is associated with increased response to paroxetine in people with Obsessive-Compulsive Disorder as compared to genotypes CT + TT.; in people with Other:Obsessive-Compulsive Disorder
;PHENPROCOUMON;CYP2C9;rs4086116;T;Dosage;decreased dose of ⮕ PHENPROCOUMON;Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 2.2 mg/week as compared to allele C.;  Other:maintenance dosage by 2.2 mg/week
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;rs7412;C;Efficacy;decreased response to ⮕ ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T.;or in people with Disease:Hyperlipidemias
;IMATINIB;ABCG2;rs2725252;C;Efficacy;increased response to ⮕ IMATINIB;Allele C is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele A.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;ATAZANAVIR;NR1I2;rs2472677;CT;Metabolism/PK;deficiency decreased concentrations of ⮕ ATAZANAVIR;Genotype CT (assigned as deficiency phenotype) is associated with decreased concentrations of atazanavir in people with HIV Infections as compared to genotypes CC + TT.; in people with Disease:HIV infectious disease
;PRAVASTATIN;SLCO1B1;rs4149015;AG;Metabolism/PK;increased metabolism of ⮕ PRAVASTATIN;Genotype AG is associated with increased metabolism of pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.; in children with Disease:Hyperlipoproteinemia Type II
;APIXABAN;CYP3A5;rs776746;CC + CT;Metabolism/PK;increased concentrations of ⮕ APIXABAN;Genotypes CC + CT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype TT.; in people with Disease:Atrial Fibrillation
;IMATINIB;ABCG2;rs12505410;G;Efficacy;increased response to ⮕ IMATINIB;Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;NIACIN;HCAR2;rs2454727;CT + TT;Efficacy;decreased response to ⮕ NIACIN;Genotypes CT + TT is associated with decreased response to niacin as compared to genotype CC.;  
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;rs12003906;C;Efficacy;decreased response to ⮕ ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele G.;or in people with Disease:Hyperlipidemias
;CEFTRIAXONE;ABCG2;rs13120400;TT;Metabolism/PK;concentrations of ⮕ CEFTRIAXONE;Genotype TT is associated with concentrations of ceftriaxone in people with Central Nervous System Infections as compared to genotypes CC + CT.; in people with Disease:Central Nervous System Infectious Disorder
;RIBAVIRIN;ITPA;rs1127354;CC;Dosage;decreased dose of ⮕ RIBAVIRIN;Genotype CC is associated with decreased dose of ribavirin.;  
;TACROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;decreased exposure to ⮕ TACROLIMUS;Genotype CT is associated with decreased exposure to tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;PRAVASTATIN;SLCO1B1;rs4149015;AG;Metabolism/PK;increased response to ⮕ PRAVASTATIN;Genotype AG is associated with increased response to pravastatin in children with Hyperlipoproteinemia Type II as compared to genotype GG.; in children with Disease:Hyperlipoproteinemia Type II
;CREATINE;MOBP;rs616147;AA + AG;Efficacy;increased response to ⮕ CREATINE;Genotypes AA + AG are associated with increased response to creatine in people with Amyotrophic Lateral Sclerosis as compared to genotype GG.; in people with Other:Amyotrophic Lateral Sclerosis
;PEMETREXED;EXO1;rs1047840;AA + AG;Efficacy;decreased clinical benefit to ⮕ PEMETREXED;Genotypes AA + AG is associated with decreased clinical benefit to pemetrexed in people with Lung Neoplasms as compared to genotype GG.; in people with Other:Lung Neoplasms
;PRAVASTATIN;SLCO1B1;rs4149056;CT;Efficacy;increased response to ⮕ PRAVASTATIN;Genotype CT is associated with increased response to pravastatin in children with Transplantation as compared to genotype TT.; in children with Disease:Transplantation
;PHENPROCOUMON;STX4;rs10871454;T;Dosage;decreased dose of ⮕ PHENPROCOUMON;Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 4.8 mg/week as compared to allele C.;  Other:maintenance dosage by 4.8 mg/week
;PRAVASTATIN;SLCO1B1;rs4149056;CT;Metabolism/PK;increased metabolism of ⮕ PRAVASTATIN;Genotype CT is associated with increased metabolism of pravastatin in children with Transplantation as compared to genotype TT.; in children with Disease:Transplantation
;PROPOFOL;CYP2B6;rs3745274;GT + TT;Dosage;decreased dose of ⮕ PROPOFOL;Genotypes GT + TT are associated with decreased dose of propofol as compared to genotype GG.;  
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CT + TT is associated with increased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype CC.;or in people with Other:Rheumatoid arthritis
;VALPROIC ACID;CYP2C19;rs4244285;AA + AG;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotypes AA + AG are associated with increased dose of valproic acid in people with Myelodysplastic Syndromes as compared to genotype GG.; in people with Disease:Myelodysplastic Syndromes
;APIXABAN;ABCG2;rs2231142;TT;Metabolism/PK;increased concentrations of ⮕ APIXABAN;Genotype TT is associated with increased concentrations of apixaban in people with Atrial Fibrillation as compared to genotype GG.; in people with Disease:Atrial Fibrillation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in people with Disease:Chronic hepatitis C virus infection
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs2242446;TT;Other;decreased response to ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;Genotype TT are associated with decreased response to 3,4-methylenedioxymethamphetamine as compared to genotypes CC + CT.;  
;ATENOLOL;AGT;rs699;AG + GG;Efficacy;increased response to ⮕ ATENOLOL;Genotypes AG + GG are associated with increased response to atenolol in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;IRBESARTAN;CYP2C9;rs1057910;AC;Metabolism/PK;decreased clearance of ⮕ IRBESARTAN;Genotype AC is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype AA.; in healthy individuals 
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs1861647;GG;Other;increased response to ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;Genotype GG is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AA + AG.;  
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs36029;AA;Other;increased response to ⮕ 3,4-METHYLENEDIOXYMETHAMPHETAMINE;Genotype AA is associated with increased response to 3,4-methylenedioxymethamphetamine as compared to genotypes AG + GG.;  
;ATENOLOL;AGT;rs5051;CT + TT;Efficacy;increased response to ⮕ ATENOLOL;Genotypes CT + TT are associated with increased response to atenolol in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;IRBESARTAN;CYP2C9;rs1057910;AC;Metabolism/PK;decreased metabolism of ⮕ IRBESARTAN;Genotype AC is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype AA.; in healthy individuals 
;IRBESARTAN;CYP2C9;rs72558187;CT;Metabolism/PK;decreased metabolism of ⮕ IRBESARTAN;Genotype CT is associated with decreased metabolism of irbesartan in healthy individuals as compared to genotype TT.; in healthy individuals 
;IRBESARTAN;CYP2C9;rs1057910;AC;Metabolism/PK;increased concentrations of ⮕ IRBESARTAN;Genotype AC is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype AA.; in healthy individuals 
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;rs1264457;AA;Efficacy;increased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;Genotype AA is associated with increased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.;or in women with Disease:Rheumatoid arthritis
;REPAGLINIDE;SLC30A8;rs13266634;CT + TT;Efficacy;increased response to ⮕ REPAGLINIDE;Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;DISULFIRAM;ADRA1A;rs1048101;AA + AG;Efficacy;increased response to ⮕ DISULFIRAM;Genotypes AA + AG is associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG.; in people with Other:Cocaine dependence
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;rs1059150;GG;Efficacy;decreased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;Genotype GG is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in women with Arthritis, Rheumatoid as compared to genotype TT.;or in women with Disease:Rheumatoid arthritis
;SIROLIMUS;ABCB1;rs1045642;AG;Metabolism/PK;increased concentrations of ⮕ SIROLIMUS;Genotype AG is associated with increased concentrations of sirolimus as compared to genotypes AA + GG.;  
;MERCAPTOPURINE;NUDT15;rs116855232;TT;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;FELODIPINE;ABCG2;rs2231142;TT;Metabolism/PK;increased exposure to ⮕ FELODIPINE;Genotype TT is associated with increased exposure to felodipine in healthy individuals as compared to genotypes GG + GT.; in healthy individuals 
;DEXMEDETOMIDINE;CYP2A6;rs28399433;C;Metabolism/PK;decreased clearance of ⮕ DEXMEDETOMIDINE;Allele C is associated with decreased clearance of dexmedetomidine in women as compared to allele A.; in women 
;IRBESARTAN;CYP2C9;rs1799853;CT;Efficacy;increased response to ⮕ IRBESARTAN;Genotype CT is associated with increased response to irbesartan in people with Hypertension as compared to genotype CC.; in people with Disease:Hypertension
;FENTANYL;CALCA;rs145837941;GG;Dosage;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Other:Pain, Postoperative
;NITRIC OXIDE;NAMPT;rs1319501;TT;Efficacy;increased concentrations of ⮕ NITRIC OXIDE;Genotype TT is associated with increased concentrations of nitric oxide in women with Pre-Eclampsia as compared to genotypes CC + CT.; in women with Other:Pre-Eclampsia
;TOCILIZUMAB;GALNT18;rs4910008;CC + CT;Efficacy;increased clinical benefit to ⮕ TOCILIZUMAB;Genotypes CC + CT is associated with increased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype TT.; in people with Other:Rheumatoid arthritis
;BUPRENORPHINE;OPRD1;rs529520;AA;Efficacy;decreased response to ⮕ BUPRENORPHINE;Genotype AA is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype CC.; in women with Disease:Opioid-Related Disorders
;NICOTINE;;rs12459249;C;Metabolism/PK;decreased metabolism of ⮕ NICOTINE;Allele C is associated with decreased metabolism of nicotine as compared to allele T.;  
;WARFARIN;GGCX;rs2592551;AA + AG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype GG.; in people with Disease:Atrial Fibrillation
;ARSENIC COMPOUNDS;AS3MT;rs11191439;C;Toxicity, Metabolism/PK;increased metabolism of ⮕ ARSENIC COMPOUNDS;Allele C is associated with increased metabolism of Arsenic compounds in healthy individuals as compared to allele T.; in healthy individuals 
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors in people with Depression as compared to genotypes GG + GT.; in people with Disease:Depression
;ESCITALOPRAM;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ ESCITALOPRAM;Genotype TT is associated with decreased response to escitalopram in people with Depression as compared to genotypes GG + GT.; in people with Disease:Depression
;ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Genotype TT is associated with decreased response to atomoxetine, desvenlafaxine, duloxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Depression as compared to genotypes GG + GT.;or in people with Disease:Depression
;IRBESARTAN;CYP2C9;rs72558187;CT;Metabolism/PK;decreased clearance of ⮕ IRBESARTAN;Genotype CT is associated with decreased clearance of irbesartan in healthy individuals as compared to genotype TT.; in healthy individuals 
;TOCILIZUMAB;IL6;rs2069840;CC;Efficacy;decreased clinical benefit to ⮕ TOCILIZUMAB;Genotype CC is associated with decreased clinical benefit to tocilizumab in people with Rheumatoid arthritis as compared to genotype CG.; in people with Other:Rheumatoid arthritis
;ANTIDEPRESSANTS;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS;Genotype TT is associated with decreased response to antidepressants in people with Depression as compared to genotypes GG + GT.; in people with Disease:Depression
;IRBESARTAN;CYP2C9;rs72558187;CT;Metabolism/PK;increased concentrations of ⮕ IRBESARTAN;Genotype CT is associated with increased concentrations of irbesartan in healthy individuals as compared to genotype TT.; in healthy individuals 
;BENAZEPRIL;MTHFR;rs1801131;G;Efficacy;decreased response to ⮕ BENAZEPRIL;Allele G is associated with decreased response to benazepril in people with Hypertension.; in people with Disease:Hypertension
;FLUOXETINE, PAROXETINE;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ FLUOXETINE, PAROXETINE;Genotype TT is associated with decreased response to fluoxetine or paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.;or in people with Disease:Bipolar Disorder
;BENAZEPRIL;MTHFR;rs1801133;G;Efficacy;decreased response to ⮕ BENAZEPRIL;Allele G is associated with decreased response to benazepril in people with Hypertension.; in people with Disease:Hypertension
;TRAMADOL;CYP2B6;rs3745274;TT;Metabolism/PK;increased exposure to ⮕ TRAMADOL;Genotype TT is associated with increased exposure to tramadol in healthy individuals as compared to genotypes GG + GT.; in healthy individuals 
;IRBESARTAN;CYP2C9;rs1057910;AC;Metabolism/PK;increased concentrations of ⮕ IRBESARTAN;Genotype AC is associated with increased concentrations of irbesartan in people with Essential hypertension as compared to genotype AA.; in people with Disease:Essential hypertension
;PAROXETINE;HTR7;rs7905446;TT;Efficacy;decreased response to ⮕ PAROXETINE;Genotype TT is associated with decreased response to paroxetine in people with Bipolar Disorder as compared to genotypes GG + GT.; in people with Disease:Bipolar Disorder
;FENTANYL;CALCA;rs145837941;AG + GG;Dosage;increased dose of ⮕ FENTANYL;Genotypes AG + GG is associated with increased dose of fentanyl in women with Pain, Postoperative and cesarean section as compared to genotype AA.;" in women with ""Other:Pain, Postoperative"", ""Other:Caesarian section"""
;PEMETREXED;CAMKK2;rs1653586;GT;Efficacy;decreased clinical benefit to ⮕ PEMETREXED;Genotype GT is associated with decreased clinical benefit to pemetrexed in people with Lung Neoplasms as compared to genotype GG.; in people with Other:Lung Neoplasms
;ABIRATERONE;SRD5A2;rs523349;CC;Efficacy;increased response to ⮕ ABIRATERONE;Genotype CC is associated with increased response to abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG.; in men with Other:Prostatic Neoplasms
;BUPRENORPHINE;OPRD1;rs581111;AA + AG;Efficacy;decreased response to ⮕ BUPRENORPHINE;Genotypes AA + AG is associated with decreased response to buprenorphine in women with Opioid-Related Disorders as compared to genotype GG.; in women with Disease:Opioid-Related Disorders
;CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;rs11623866;GG;Efficacy;response to ⮕ CARBOPLATIN, LONAFARNIB, PACLITAXEL;Genotype GG is associated with response to carboplatin, lonafarnib and paclitaxel in women with Ovarian Neoplasms.;and in women with Disease:Ovarian Neoplasms
;METHOTREXATE;ABCG2;rs12505410;GG;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT.; in people with Disease:Osteosarcoma
;ESCITALOPRAM;BMP5;rs41271330;A;Efficacy;decreased response to ⮕ ESCITALOPRAM;Allele A is associated with decreased response to escitalopram in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;ENALAPRIL;CES1;rs71647871;CT;Metabolism/PK;decreased metabolism of ⮕ ENALAPRIL;Genotype CT is associated with decreased metabolism of enalapril in healthy individuals as compared to genotype CC.; in healthy individuals 
;METHOTREXATE;ABCG2;rs13137622;GT + TT;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotypes GT + TT are associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotype GG.; in people with Disease:Osteosarcoma
;METHOTREXATE;ABCG2;rs13120400;CC;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotype CC is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes CT + TT.; in people with Disease:Osteosarcoma
;AMLODIPINE;CYP3A4;rs2740574;CT + TT;Efficacy;increased response to ⮕ AMLODIPINE;Genotypes CT + TT are associated with increased response to amlodipine in women with Hypertension as compared to genotype CC.; in women with Disease:Hypertension
;TACROLIMUS;IL18;rs1946518;GG + GT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.; in people with Disease:Lung transplantation
;TACROLIMUS;IL10;rs1800896;TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype CT.; in people with Disease:Lung transplantation
;RIVASTIGMINE;BCHE;rs1803274;CT + TT;Efficacy;decreased response to ⮕ RIVASTIGMINE;Genotypes CT + TT is associated with decreased response to rivastigmine in people with Alzheimer Disease as compared to genotype CC.; in people with Disease:Alzheimer Disease
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT is associated with concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs35303484;G;Metabolism/PK;concentrations of ⮕ EFAVIRENZ;Allele G is associated with concentrations of efavirenz in people with HIV Infections as compared to allele A.; in people with Disease:HIV infectious disease
;VALPROIC ACID;CYP2C9;rs1057910;C;Metabolism/PK;increased concentrations of ⮕ VALPROIC ACID;Allele C is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A.; in children with Other:Epilepsy
;METHOTREXATE;MTHFR;rs1801133;AG + GG;Metabolism/PK;increased steady-state concentration of ⮕ METHOTREXATE;Genotypes AG + GG are associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in children with Other:Acute lymphoblastic leukemia
;AZATHIOPRINE;NUDT15;rs116855232;TT;Toxicity;decreased dose of ⮕ AZATHIOPRINE;Genotype TT is associated with decreased dose of azathioprine in people with Leukopenia as compared to genotype CC.; in people with Disease:Leukopenia
;CELECOXIB;PTGS2;rs689466;CC;Efficacy;increased response to ⮕ CELECOXIB;Genotype CC is associated with increased response to celecoxib in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;CLOZAPINE;NFIB;rs28379954;CT;Metabolism/PK;decreased concentrations of ⮕ CLOZAPINE;Genotype CT is associated with decreased concentrations of clozapine in people with Schizophrenia as compared to genotype TT.; in people with Other:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotypes CT + TT.; in people with Disease:Lung transplantation
;METFORMIN;SLC22A1;rs594709;AA + AG;Efficacy;increased response to ⮕ METFORMIN;Genotypes AA + AG are associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;IRINOTECAN;TDP1;rs2401863;GG;Efficacy;increased response to ⮕ IRINOTECAN;Genotype GG is associated with increased response to irinotecan in people with Colorectal Neoplasms as compared to genotypes GT + TT.; in people with Disease:Colorectal Neoplasms
;LOSARTAN;CYP2C9;rs1934969;AA;Metabolism/PK;decreased metabolism of ⮕ LOSARTAN;Genotype AA is associated with decreased metabolism of losartan in healthy individuals as compared to genotype TT.; in healthy individuals 
;METFORMIN;SLC47A1;rs2289669;GG;Efficacy;increased response to ⮕ METFORMIN;Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.; in people with Disease:Diabetes Mellitus, Type 2
;TACROLIMUS;IL18;rs5744247;CC + CG;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + CG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.; in people with Disease:Lung transplantation
;METHOTREXATE;SLC19A1;rs1051266;TT;Metabolism/PK;increased steady-state concentration of ⮕ METHOTREXATE;Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;DEXMEDETOMIDINE;CYP2D6;rs16947;GG;Dosage;increased dose of ⮕ DEXMEDETOMIDINE;Genotype GG is associated with increased dose of dexmedetomidine in people with surgery as compared to genotypes AA + AG.; in people with Other:surgery
;CARBAMAZEPINE;CYP1A2;rs762551;AA;Metabolism/PK;increased clearance of ⮕ CARBAMAZEPINE;Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC.; in children with Disease:Epilepsy
;RIVAROXABAN;CYP3A4;rs2242480;T;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Allele T is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.; in people with Other:Atrial Fibrillation
;CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;increased concentrations of ⮕ CYCLOSPORINE, TACROLIMUS;Genotype CC is associated with increased concentrations of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.;or in people with Other:Liver transplantation
;METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;Metabolism/PK;decreased clearance of ⮕ METHOTREXATE;Genotypes GG + GT are associated with decreased clearance of methotrexate in people with Osteosarcoma as compared to genotype TT.; in people with Disease:Osteosarcoma
;EFAVIRENZ;ABCB1;rs3842;C;Metabolism/PK;concentrations of ⮕ EFAVIRENZ;Allele C is associated with concentrations of efavirenz in people with HIV Infections as compared to allele T.; in people with Disease:HIV infectious disease
;CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;Dosage, Metabolism/PK;decreased dose of ⮕ CYCLOSPORINE, TACROLIMUS;Genotype CC is associated with decreased dose of cyclosporine or tacrolimus in people with liver transplantation as compared to genotypes CT + TT.;or in people with Other:Liver transplantation
;DEXMEDETOMIDINE;WBP2NL;rs5758550;AG + GG;Toxicity;increased response to ⮕ DEXMEDETOMIDINE;Genotypes AG + GG is associated with increased response to dexmedetomidine in people with surgery as compared to genotype AA.; in people with Other:surgery
;MEMANTINE, RIVASTIGMINE;BCHE;rs1803274;CT + TT;Efficacy;decreased response to ⮕ MEMANTINE, RIVASTIGMINE;Genotypes CT + TT is associated with decreased response to memantine and rivastigmine in people with Alzheimer Disease as compared to genotype CC.;and in people with Disease:Alzheimer Disease
;WARFARIN;CYP4F2;rs2108622;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotype TT.;  
;WARFARIN;GGCX;rs699664;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.;  
;METHOTREXATE;MTHFR;rs1801131;GT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype GT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.; in people with Disease:Rheumatoid arthritis
;CLOPIDOGREL;ABCB1;rs1045642;AA;Metabolism/PK;decreased exposure to ⮕ CLOPIDOGREL;Genotype AA is associated with decreased exposure to clopidogrel as compared to genotypes AG + GG.;  
;TACROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9934438;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotype AA.;  
;RIVASTIGMINE;BCHE;rs1803274;CT;Efficacy;increased response to ⮕ RIVASTIGMINE;Genotype CT is associated with increased response to rivastigmine in people with Lewy Body Disease as compared to genotype TT.; in people with Disease:Lewy Body Disease
;FENTANYL;CALCA;rs145837941;GG;Dosage;increased dose of ⮕ FENTANYL;Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG.; in people with Other:Pain, Postoperative
;APIXABAN;ABCG2;rs2231142;G;Metabolism/PK;decreased concentrations of ⮕ APIXABAN;Allele G is associated with decreased concentrations of apixaban in people with Atrial Fibrillation as compared to allele T.; in people with Other:Atrial Fibrillation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.; in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;CC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;AMLODIPINE;ABCB1;rs1045642;GG;Metabolism/PK;decreased clearance of ⮕ AMLODIPINE;Genotype GG is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AG.; in healthy individuals 
;LATANOPROST;PTGFR;rs3766355;CC;Efficacy;increased response to ⮕ LATANOPROST;Genotype CC is associated with increased response to latanoprost in people with Glaucoma or Ocular Hypertension as compared to genotypes AA + AC.; in people with Disease:Glaucoma, Disease:Ocular Hypertension
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061631;AA;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;MTHFR;rs1801133;AG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + GG.; in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;C;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.; in people with Disease:Rheumatoid arthritis
;AMLODIPINE;ABCB1;rs2032582;CC;Metabolism/PK;decreased clearance of ⮕ AMLODIPINE;Genotype CC is associated with decreased clearance of amlodipine in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;METHADONE;NECTIN4;rs11265549;AA;Metabolism/PK;decreased concentrations of ⮕ METHADONE;Genotype AA is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Other:Opioid-Related Disorders
;OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;OPRM1;rs1799971;GG;Efficacy;increased response to ⮕ OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;Genotype GG is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes AA + AG.;or  
;OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;ABCG2;rs2231142;TT;Efficacy;increased response to ⮕ OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;Genotype TT is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes GG + GT.;or  
;METHADONE;NECTIN4;rs11265549;AA;Dosage;decreased dose of ⮕ METHADONE;Genotype AA is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Other:Opioid-Related Disorders
;DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;Dosage;decreased dose of ⮕ DEXMEDETOMIDINE;Genotypes AA + AG is associated with decreased dose of dexmedetomidine in people with surgery as compared to genotype GG.; in people with Other:surgery
;DABIGATRAN;CES1;rs2244613;GG + GT;Metabolism/PK;decreased concentrations of ⮕ DABIGATRAN;Genotypes GG + GT is associated with decreased concentrations of dabigatran in people with Atrial Fibrillation as compared to genotype TT.; in people with Other:Atrial Fibrillation
;ATORVASTATIN;ABCG8;rs11887534;CC + CG;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes CC + CG are associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype GG.; in people with Disease:Hypercholesterolemia
;DEXMEDETOMIDINE;ADRA2A;rs1800544;GG;Dosage;decreased dose of ⮕ DEXMEDETOMIDINE;Genotype GG is associated with decreased dose of dexmedetomidine in people with surgery as compared to genotypes CC + CG.; in people with Other:surgery
;TAMOXIFEN-N-GLUCURONIDE;UGT1A4;rs2011425;GG + GT;Metabolism/PK;increased concentrations of ⮕ TAMOXIFEN-N-GLUCURONIDE;Genotypes GG + GT are associated with increased concentrations of tamoxifen-n-glucuronide in women with Breast Neoplasms as compared to genotype TT.; in women with Disease:Breast Neoplasms
;IMATINIB;CYP2B6;rs3745274;GG + GT;Efficacy;increased response to ⮕ IMATINIB;Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;METHOTREXATE;ATIC;rs4673993;CC;Efficacy;increased response to ⮕ METHOTREXATE;Genotype CC is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Other:Rheumatoid arthritis
;BENAZEPRIL;AGT;rs7079;GG;Efficacy;response to ⮕ BENAZEPRIL;Genotype GG is associated with response to benazepril in women with Hypertension as compared to genotype TT.; in women with Disease:Hypertension
;WARFARIN;CYP2C9;rs9332098;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotype AG.;  
;CANNABIDIOL;;rs6729738;CC;Efficacy;increased response to ⮕ CANNABIDIOL;Genotype CC is associated with increased response to cannabidiol in people with Epilepsy as compared to genotypes AA + AC.; in people with Other:Epilepsy
;METHOTREXATE;MTHFR;rs1801133;AG + GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.; in people with Other:Rheumatoid arthritis
;DEXMEDETOMIDINE;ADRB2;rs1042713;AA;Efficacy;increased response to ⮕ DEXMEDETOMIDINE;Genotype AA is associated with increased response to dexmedetomidine in people with surgery as compared to genotypes AG + GG.; in people with Other:surgery
;WARFARIN;CYP2C9;rs9332092;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotype CT.;  
;HYDROCHLOROTHIAZIDE;TXNDC11;rs3784921;G;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele G is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;WARFARIN;CYP2C9;rs1057910;CC;Metabolism/PK;decreased clearance of ⮕ WARFARIN;Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.;  
;PAROXETINE;CYP1A2;rs762551;A;Metabolism/PK;increased dose of ⮕ PAROXETINE;Allele A is associated with increased dose of paroxetine in people with Depressive Disorder, Major as compared to allele C.; in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;rs1799853;TT;Metabolism/PK;decreased clearance of ⮕ WARFARIN;Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.;  
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;Toxicity;increased response to ⮕ DEXMEDETOMIDINE;Genotypes AA + AG is associated with increased response to dexmedetomidine in people with surgery as compared to genotype GG.; in people with Other:surgery
;TOPOTECAN;ABCG2;rs4148157;AA + AG;Metabolism/PK;increased concentrations of ⮕ TOPOTECAN;Genotypes AA + AG is associated with increased concentrations of topotecan in children with Brain Neoplasms as compared to genotype GG.; in children with Disease:Brain Neoplasms
;EFAVIRENZ;CYP2B6;rs28399499;CC + CT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes CC + CT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.; in people with Disease:HIV infectious disease
;RIVAROXABAN;CYP3A4;rs2246709;G;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Allele G is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele A.; in people with Other:Atrial Fibrillation
;DULOXETINE;KMT2E;rs117986340;GG;Efficacy;increased response to ⮕ DULOXETINE;Genotype GG is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotype GT.; in people with Disease:Major Depressive Disorder
;RIVASTIGMINE;ACHE;rs2571598;TT;Efficacy;increased response to ⮕ RIVASTIGMINE;Genotype TT is associated with increased response to rivastigmine in people with Alzheimer Disease as compared to genotypes CC + CT.; in people with Disease:Alzheimer Disease
;MORPHINE;OPRM1;rs1799971;AG + GG;Dosage, Efficacy;increased dose of ⮕ MORPHINE;Genotypes AG + GG are associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA.; in women with Disease:Pain, Postoperative
;DULOXETINE;NCAM1;rs2303377;TT;Efficacy;increased response to ⮕ DULOXETINE;Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.; in people with Disease:Major Depressive Disorder
;RIVAROXABAN;CYP3A5;rs776746;T;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Allele T is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.; in people with Other:Atrial Fibrillation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.; in people with Disease:Heart transplantation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;DULOXETINE;ZNF385D;rs4261893;TT;Efficacy;increased response to ⮕ DULOXETINE;Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.; in people with Disease:Major Depressive Disorder
;EFAVIRENZ;CYP2B6;rs2279343;AG + GG;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes AG + GG are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype AA.; in people with Disease:HIV infectious disease
;RIVAROXABAN;CYP3A4;rs3735451;C;Metabolism/PK;increased concentrations of ⮕ RIVAROXABAN;Allele C is associated with increased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele T.; in people with Other:Atrial Fibrillation
;WARFARIN;VKORC1;rs2359612;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.;  
;WARFARIN;VKORC1;rs7294;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotype CC.;  
;DEXMEDETOMIDINE;;rs141294036;CC;Toxicity;increased response to ⮕ DEXMEDETOMIDINE;Genotype CC is associated with increased response to dexmedetomidine in people with surgery as compared to genotypes CT + TT.; in people with Other:surgery
;AMPHETAMINE;CDH13;rs3784943;AG + GG;Efficacy;increased response to ⮕ AMPHETAMINE;Genotypes AG + GG is associated with increased response to amphetamine as compared to genotype AA.;  
;EVEROLIMUS;CYP3A4;rs35599367;AG;Metabolism/PK;increased concentrations of ⮕ EVEROLIMUS;Genotype AG is associated with increased concentrations of everolimus in women with Breast Neoplasms as compared to genotype GG.; in women with Disease:Breast Neoplasms
;PRAVASTATIN;SLCO1B1;rs4149056;CT;Efficacy;decreased response to ⮕ PRAVASTATIN;Genotype CT is associated with decreased response to pravastatin in people with Coronary Stenosis as compared to genotype TT.; in people with Disease:Coronary Stenosis
;DEXMEDETOMIDINE;KCNMB1;rs11739136;CC + CT;Efficacy;increased response to ⮕ DEXMEDETOMIDINE;Genotypes CC + CT is associated with increased response to dexmedetomidine in people with surgery as compared to genotype TT.; in people with Other:surgery
;MORPHINE;UGT2B7;rs7668282;CC + CT;Metabolism/PK;decreased metabolism of ⮕ MORPHINE;Genotypes CC + CT is associated with decreased metabolism of morphine in people with Anemia, Sickle Cell as compared to genotype TT.; in people with Disease:Anemia, Sickle Cell
;EFAVIRENZ;CYP2A7P1, CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in women with Pregnancy as compared to allele G.; in women with Other:Pregnancy
;DABIGATRAN;CES1;rs8192935;GG;Metabolism/PK;increased concentrations of ⮕ DABIGATRAN;Genotype GG is associated with increased concentrations of dabigatran in people with Atrial Fibrillation as compared to genotypes AA + AG.; in people with Other:Atrial Fibrillation
;ETHANOL;OPRM1;rs1799971;AG + GG;Dosage;decreased dose of ⮕ ETHANOL;Genotypes AG + GG are associated with decreased dose of ethanol in women as compared to genotype AA.; in women 
;METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;MTR;rs1805087;AA;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;RANIBIZUMAB;CXCL8;rs4073;AA;Efficacy;decreased response to ⮕ RANIBIZUMAB;Genotype AA is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotypes AT + TT.; in people with Disease:Macular Degeneration
;ETHANOL;OPRM1;rs10485057;AA;Dosage;increased dose of ⮕ ETHANOL;Genotype AA is associated with increased dose of ethanol as compared to genotype AG.;  
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;OPIOIDS;COMT;rs4680;AA + AG;Dosage;decreased dose of ⮕ OPIOIDS;Genotypes AA + AG is associated with decreased dose of opioids in people with Pain and Neoplasms as compared to genotype GG.; in people with Other:Pain, Other:Neoplasms
;METHOTREXATE;BIRC5;rs9904341;CG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype CG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;ACENOCOUMAROL;VKORC1;rs9934438;GG;Efficacy;decreased response to ⮕ ACENOCOUMAROL;Genotype GG is associated with decreased response to acenocoumarol as compared to genotypes AA + AG.;  
;SALBUTAMOL;;rs17834628;A;Efficacy;increased response to ⮕ SALBUTAMOL;Allele A is associated with increased response to salbutamol in children with as compared to allele G.; in children with 
;NICOTINE;CHRNA3;rs1051730;A;Dosage;decreased dose of ⮕ NICOTINE;Allele A is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to allele G.; in people with Other:Tobacco Use Disorder
;ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;A;Efficacy;decreased response to ⮕ ABIRATERONE, PREDNISOLONE;Allele A is associated with decreased response to abiraterone and prednisolone in people with Prostatic Neoplasms as compared to allele G.;and in people with Disease:Prostatic Neoplasms
;PLATINUM;RICTOR;rs6878291;GG;Efficacy;decreased response to ⮕ PLATINUM;Genotype GG is associated with decreased response to platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.; in people with Disease:Non-Small Cell Lung Carcinoma
;EFAVIRENZ;CYP2B6;rs3745274;GT;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;CLOZAPINE;DRD2;rs2514218;T;Efficacy;increased response to ⮕ CLOZAPINE;Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.; in people with Disease:Schizophrenia
;METHOTREXATE;FASTKD3, MTRR;rs1801394;AA + AG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;RANIBIZUMAB;KDR;rs2071559;AA + AG;Efficacy;decreased response to ⮕ RANIBIZUMAB;Genotypes AA + AG is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotype GG.; in people with Disease:Macular Degeneration
;ETHANOL;OPRM1;rs1799971;AG;Other;increased response to ⮕ ETHANOL;Genotype AG is associated with increased response to ethanol in people with Alcoholism as compared to genotype AA.; in people with Other:Alcohol abuse
;BUSULFAN;GSTA1;rs3957356;CT;Metabolism/PK;decreased clearance of ⮕ BUSULFAN;Genotype CT is associated with decreased clearance of busulfan in people with hematopoietic stem cell transplantation as compared to genotype CC.; in people with Other:Hematopoietic stem cell transplantation
;METHOTREXATE;ATIC;rs12995526;CT + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;CLOZAPINE;HTR3A;rs1062613;T;Efficacy;increased response to ⮕ CLOZAPINE;Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C.; in people with Disease:Schizophrenia
;METHOTREXATE;ATIC;rs7563206;CT + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;WARFARIN;CYP4F2;rs2108622;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.;  
;METHOTREXATE;ATIC;rs2372536;CC + CG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CC + CG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ATIC;rs4673993;CT + TT;Efficacy;decreased response to ⮕ METHOTREXATE;Genotypes CT + TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;CANDESARTAN;KCNK3;rs1275988;C;Efficacy;increased response to ⮕ CANDESARTAN;Allele C is associated with increased response to candesartan in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;RISPERIDONE;NR1I2;rs1523130;CC;Metabolism/PK;decreased clearance of ⮕ RISPERIDONE;Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression or Substance-Related Disorders as compared to genotypes CT + TT.; in people with Disease:Bipolar Disorder, Disease:Depression, Disease:Substance-Related Disorders
;SUFENTANIL;ABCB1;rs1045642;GG;Dosage;increased dose of ⮕ SUFENTANIL;Genotype GG is associated with increased dose of sufentanil in children with Pain, Postoperative as compared to genotypes AA + AG.; in children with Other:Pain, Postoperative
;ADALIMUMAB;IL17F;rs763780;TT;Efficacy;increased response to ⮕ ADALIMUMAB;Genotype TT is associated with increased response to adalimumab in people with as compared to genotype CT.; in people with 
;IMMUNOGLOBULINS;CASP3, PRIMPOL;rs113420705;CT + TT;Efficacy;decreased response to ⮕ IMMUNOGLOBULINS;Genotypes CT + TT are associated with decreased response to Immunoglobulins in children with Mucocutaneous Lymph Node Syndrome as compared to genotype CC.; in children with Disease:Mucocutaneous Lymph Node Syndrome
;SUFENTANIL;COMT;rs4680;AA;Dosage;increased dose of ⮕ SUFENTANIL;Genotype AA is associated with increased dose of sufentanil in children with Pain, Postoperative as compared to genotypes AG + GG.; in children with Other:Pain, Postoperative
;WARFARIN;VKORC1;rs7294;CC;Dosage;decreased concentrations of ⮕ WARFARIN;Genotype CC is associated with decreased concentrations of warfarin in people with heart valve replacement as compared to genotypes CT + TT.; in people with Other:Heart valve replacement
;IMMUNOGLOBULINS;COQ8B, ITPKC;rs28493229;CC + CG;Efficacy;decreased response to ⮕ IMMUNOGLOBULINS;Genotypes CC + CG are associated with decreased response to Immunoglobulins in children with Mucocutaneous Lymph Node Syndrome as compared to genotype GG.; in children with Disease:Mucocutaneous Lymph Node Syndrome
;USTEKINUMAB;IL17F;rs763780;TT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotype TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CT.; in people with Disease:Psoriasis
;WARFARIN;CYP2C9;rs1057910;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.; in people with Other:Heart valve replacement
;INFLIXIMAB;IL17F;rs763780;CT;Efficacy;increased response to ⮕ INFLIXIMAB;Genotype CT is associated with increased response to infliximab in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;HYDROCHLOROTHIAZIDE;CSK;rs1378942;C;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele A.; in people with Other:Hypertension
;SALBUTAMOL;;rs35661809;G;Efficacy;increased response to ⮕ SALBUTAMOL;Allele G is associated with increased response to salbutamol in children with as compared to allele A.; in children with 
;ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Mood Disorders or Schizophrenia as compared to genotype CC.; in people with Other:Mood Disorder, Other:Schizophrenia
;HYDROCHLOROTHIAZIDE;PDE3A;rs12579720;C;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Allele C is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;CANDESARTAN;SULT1C3;rs6722745;T;Efficacy;decreased response to ⮕ CANDESARTAN;Allele T is associated with decreased response to candesartan in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;ATENOLOL;STN1;rs4387287;A;Efficacy;decreased response to ⮕ ATENOLOL;Allele A is associated with decreased response to atenolol in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;METFORMIN;;rs10783050;TT;Efficacy;increased response to ⮕ METFORMIN;Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT.; in people with Disease:Diabetes Mellitus
;METFORMIN;IL1B;rs1143623;GG;Efficacy;increased response to ⮕ METFORMIN;Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CG.; in people with Disease:Diabetes Mellitus
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with as compared to genotype CT.; in people with 
;WARFARIN;VKORC1;rs9923231;TT;Metabolism/PK;decreased concentrations of ⮕ WARFARIN;Genotype TT is associated with decreased concentrations of warfarin in people with as compared to genotype CT.; in people with 
;CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;Efficacy;decreased response to ⮕ CISPLATIN, PACLITAXEL;Genotypes CG + GG are associated with decreased response to cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.;and in people with Disease:Stomach Neoplasms
;RIFAPENTINE;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased clearance of ⮕ RIFAPENTINE;Genotypes AA + AG is associated with increased clearance of rifapentine as compared to genotype GG.;  
;BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;Efficacy;decreased response to ⮕ BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;Genotype CC is associated with decreased response to bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.;or in people with Disease:Choroidal Neovascularization
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;rs1800566;AA + AG;Efficacy;decreased response to ⮕ EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;Genotypes AA + AG are associated with decreased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotype GG.;and in people with Disease:Metastatic neoplasm, Disease:Stomach Neoplasms
;WARFARIN;VKORC1;rs9923231;CT;Efficacy;increased dose of ⮕ WARFARIN;Genotype CT is associated with increased dose of warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.; in people with Other:Left Ventricular Dysfunction
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;rs662;CC;Efficacy;increased response to ⮕ EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;Genotype CC is associated with increased response to epirubicin, fluorouracil and oxaliplatin in people with Neoplasm Metastasis and Stomach Neoplasms as compared to genotypes CT + TT.;and in people with Disease:Metastatic neoplasm, Disease:Stomach Neoplasms
;RISPERIDONE;NR1I2;rs2276707;CC;Metabolism/PK;decreased clearance of ⮕ RISPERIDONE;Genotype CC is associated with decreased clearance of risperidone in people with Bipolar Disorder, Depression and Substance-Related Disorders as compared to genotypes CT + TT.; in people with Disease:Bipolar Disorder, Disease:Depression, Disease:Substance-Related Disorders
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;WARFARIN;VKORC1;rs9923231;CT;Efficacy;decreased response to ⮕ WARFARIN;Genotype CT is associated with decreased response to warfarin in people with Ventricular Dysfunction, Left as compared to genotype TT.; in people with Other:Left Ventricular Dysfunction
;RITUXIMAB;FCGR3A;rs396991;C;Efficacy;increased response to ⮕ RITUXIMAB;Allele C is associated with increased response to rituximab in people with Autoimmune Diseases as compared to allele A.; in people with Other:Autoimmune Diseases
;NICOTINE;CHRNA3, CHRNA5;rs16969968;AA + AG;Efficacy;increased response to ⮕ NICOTINE;Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG.; in people with Other:Tobacco Use Disorder
;CLOZAPINE;HTR3A;rs2276302;G;Efficacy;increased response to ⮕ CLOZAPINE;Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A.; in people with Disease:Schizophrenia
;IMATINIB;ABCB1;rs2032582;AT + TT;Efficacy;decreased response to ⮕ IMATINIB;Genotypes AT + TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;ABCG2;rs2231142;T;Efficacy;decreased response to ⮕ IMATINIB;Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele G.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;TELMISARTAN;GNB3;rs5443;TT;Efficacy;decreased response to ⮕ TELMISARTAN;Genotype TT is associated with decreased response to telmisartan in people with Essential hypertension as compared to genotypes CC + CT.; in people with Disease:Essential hypertension
;EFAVIRENZ;CYP2B6;rs8192719;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.; in people with Other:HIV infectious disease
;LITHIUM, VALPROIC ACID;;rs2769605;CC;Efficacy;decreased response to ⮕ LITHIUM, VALPROIC ACID;Genotype CC is associated with decreased response to lithium or valproic acid in people with Bipolar Disorder as compared to genotypes CT + TT.;or in people with Disease:Bipolar Disorder
;CISPLATIN, FLUOROURACIL;GNAS;rs7121;CC;Efficacy;increased response to ⮕ CISPLATIN, FLUOROURACIL;Genotype CC is associated with increased response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT.;and in people with Disease:Neoplasm of esophagus
;ATENOLOL, METOPROLOL;ZMAT4;rs1367094;T;Efficacy;increased response to ⮕ ATENOLOL, METOPROLOL;Allele T is associated with increased response to atenolol or metoprolol in people with Hypertension as compared to allele C.;or in people with Disease:Hypertension
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.; in people with Other:HIV infectious disease
;ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;rs11313667;del;Efficacy;increased response to ⮕ ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;Allele del is associated with increased response to atenolol, hydrochlorothiazide or metoprolol in people with Hypertension as compared to allele C.;or in people with Disease:Hypertension
;ONDANSETRON;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ ONDANSETRON;Genotype CC is associated with decreased metabolism of ondansetron as compared to genotypes CT + TT.;  
;LITHIUM, OLANZAPINE;DRD2;rs1800497;GG;Efficacy;increased clinical benefit to ⮕ LITHIUM, OLANZAPINE;Genotype GG is associated with increased clinical benefit to lithium and olanzapine in people with Bipolar Disorder as compared to genotypes AA + AG.;and in people with Other:Bipolar Disorder
;HMG COA REDUCTASE INHIBITORS;;rs247616;T;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele T is associated with increased response to hmg coa reductase inhibitors as compared to allele C.;  
;BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.;or in people with Disease:Hepatitis C virus infection
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;rs7301582;CC;Efficacy;decreased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;Genotype CC is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;or in people with Disease:Rheumatoid arthritis
;HYDROCHLOROTHIAZIDE;PRKAG2;rs10224002;A;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Allele A is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;ABCB1;rs1045642;GG;Efficacy;increased response to ⮕ AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;Genotype GG is associated with increased response to agomelatine, Melatonin receptor agonists, Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder as compared to genotypes AA + AG.;or in people with Disease:Depressive Disorder
;ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;rs2302489;TT;Efficacy;decreased response to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;Genotype TT is associated with decreased response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AT.;or in people with Disease:Rheumatoid arthritis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C, Chronic as compared to genotypes CT + TT.;and in children with Disease:Chronic hepatitis C virus infection
;HYDROCHLOROTHIAZIDE;PLCE1;rs932764;A;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele A is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT.;or in people with Disease:Hepatitis C virus infection
;METOPROLOL;;rs1446468;T;Efficacy;increased response to ⮕ METOPROLOL;Allele T is associated with increased response to metoprolol in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;ATENOLOL;RRP1B;rs9306160;T;Efficacy;increased response to ⮕ ATENOLOL;Allele T is associated with increased response to atenolol in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;ATENOLOL;TBX2;rs8068318;C;Efficacy;decreased response to ⮕ ATENOLOL;Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;AMISULPRIDE;DRD2;rs1079597;C;Efficacy;increased response to ⮕ AMISULPRIDE;Allele C is associated with increased response to amisulpride in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;USTEKINUMAB;NFKBIA;rs2145623;CC;Efficacy;decreased response to ⮕ USTEKINUMAB;Genotype CC is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotypes CG + GG.; in people with Disease:Psoriasis
;HYDROCHLOROTHIAZIDE;ADO;rs10995311;C;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;PLATINUM COMPOUNDS;XBP1;rs2269577;CC;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Disease:Non-Small Cell Lung Carcinoma
;CANDESARTAN;DOT1L, PLEKHJ1;rs740406;A;Efficacy;decreased response to ⮕ CANDESARTAN;Allele A is associated with decreased response to candesartan in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;USTEKINUMAB;ADAM33;rs2787094;CC;Efficacy;decreased response to ⮕ USTEKINUMAB;Genotype CC is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotypes CG + GG.; in people with Disease:Psoriasis
;HYDROCHLOROTHIAZIDE;NUCB2;rs757081;C;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele C is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;USTEKINUMAB;;rs1975974;AG + GG;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;and in people with Disease:Hepatitis C virus infection
;EXENATIDE;KCNQ1;rs163184;G;Efficacy;decreased clinical benefit to ⮕ EXENATIDE;Allele G is associated with decreased clinical benefit to exenatide in people with Diabetes Mellitus, Type 2 as compared to allele T.; in people with Other:Diabetes Mellitus, Type 2
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease, Disease:Tuberculosis
;USTEKINUMAB;AGBL4;rs191190;CC + CT;Efficacy;decreased response to ⮕ USTEKINUMAB;Genotypes CC + CT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;NORTRIPTYLINE;SLC39A14;rs17060812;C;Efficacy;increased response to ⮕ NORTRIPTYLINE;Allele C is associated with increased response to nortriptyline in people with Depression as compared to allele T.; in people with Disease:Depression
;ACENOCOUMAROL;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ ACENOCOUMAROL;Genotype CC is associated with increased dose of acenocoumarol as compared to genotypes CT + TT.;  
;USTEKINUMAB;CHUK;rs11591741;CC + CG;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes CC + CG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG.; in people with Disease:Psoriasis
;USTEKINUMAB;HTR2A;rs6311;CT + TT;Efficacy;decreased response to ⮕ USTEKINUMAB;Genotypes CT + TT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;WARFARIN;VKORC1;rs9923231;CC + CT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with increased dose of warfarin as compared to genotype TT.;  
;HYDROCHLOROTHIAZIDE;C5orf56;rs12521868;G;Efficacy;decreased response to ⮕ HYDROCHLOROTHIAZIDE;Allele G is associated with decreased response to hydrochlorothiazide in people with Hypertension as compared to allele T.; in people with Other:Hypertension
;PITAVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ PITAVASTATIN;Genotypes CC + CT are associated with increased concentrations of pitavastatin in healthy individuals as compared to genotype TT.; in healthy individuals 
;CANDESARTAN;SH2B3;rs3184504;T;Efficacy;increased response to ⮕ CANDESARTAN;Allele T is associated with increased response to candesartan in people with Hypertension as compared to allele C.; in people with Other:Hypertension
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;CARBAMAZEPINE;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ CARBAMAZEPINE;Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; in people with Disease:Epilepsy
;2-HYDROXYATORVASTATIN, 2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN, ATORVASTATIN LACTONE;SLCO1B1;rs4149056;C;Metabolism/PK;increased exposure to ⮕ 2-HYDROXYATORVASTATIN, 2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN, ATORVASTATIN LACTONE;Allele C is associated with increased exposure to 2-hydroxyatorvastatin, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin, 4-hydroxyatorvastatin lactone, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele T.;and in healthy individuals 
;CARBAMAZEPINE;CYP3A5;rs15524;AA;Metabolism/PK;increased concentrations of ⮕ CARBAMAZEPINE;Genotype AA is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.; in people with Disease:Epilepsy
;PAROXETINE;COMT;rs4680;A;Efficacy;increased response to ⮕ PAROXETINE;Allele A is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to allele G.; in people with Disease:Major Depressive Disorder
;CAPECITABINE, PACLITAXEL;TP53;rs1042522;GG;Efficacy;decreased response to ⮕ CAPECITABINE, PACLITAXEL;Genotype GG is associated with decreased response to capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotype CC.;and in people with Disease:Stomach Neoplasms
;SUFENTANIL;CYP3A4;rs2242480;CC;Dosage;increased dose of ⮕ SUFENTANIL;Genotype CC is associated with increased dose of sufentanil in women with Pain, Postoperative as compared to genotypes CT + TT.; in women with Other:Pain, Postoperative
;TRIGLYCERIDES;CYP19A1;rs749292;A;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.; in women with Disease:Breast Neoplasms, Disease:Menopause
;HDL CHOLESTEROL;CYP19A1;rs1062033;G;Other;increased concentrations of ⮕ HDL CHOLESTEROL;Allele G is associated with increased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.; in women with Disease:Breast Neoplasms, Disease:Menopause
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;WARFARIN;CYP2C9;rs1057910;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC.; in people with Disease:Heart Valve Diseases
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.; in people with Other:heart valve replacement
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.; in people with Disease:HIV infectious disease
;NORTRIPTYLINE;PPM1A;rs2273623;AA;Efficacy;decreased response to ⮕ NORTRIPTYLINE;Genotype AA is associated with decreased response to nortriptyline in people with Depression as compared to genotypes AG + GG.; in people with Disease:Depression
;AMILORIDE, SPIRONOLACTONE;CYP4A11;rs1126742;GG;Efficacy;decreased response to ⮕ AMILORIDE, SPIRONOLACTONE;Genotype GG is associated with decreased response to amiloride or spironolactone in people with Hypertension as compared to genotypes AA + AG.;or in people with Other:Hypertension
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;Dosage;decreased dose of ⮕ AZATHIOPRINE, MERCAPTOPURINE;Genotype TT is associated with decreased dose of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.;or in people with Disease:Inflammatory Bowel Diseases
;DEFERASIROX;UGT1A3;rs3806596;CC;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.; in people with Disease:Beta-thalassemia and related diseases
;LOPINAVIR;CYP3A5;rs776746;C;Metabolism/PK;increased trough concentration of ⮕ LOPINAVIR;Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;PROPOFOL;CYP2B6;rs2279343;AA + AG;Metabolism/PK;decreased clearance of ⮕ PROPOFOL;Genotypes AA + AG is associated with decreased clearance of propofol as compared to genotype GG.;  
;SPIRONOLACTONE;CYP4A11;rs3890011;CC;Efficacy;decreased response to ⮕ SPIRONOLACTONE;Genotype CC is associated with decreased response to spironolactone in people with Hypertension as compared to genotypes CG + GG.; in people with Other:Hypertension
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage, Efficacy;increased dose of ⮕ OPIOIDS;Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;ATAZANAVIR;NR1I2;rs2472677;TT;Metabolism/PK;increased metabolism of ⮕ ATAZANAVIR;Genotype TT is associated with increased metabolism of atazanavir in people with HIV Infections as compared to genotypes CC + CT.; in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased concentrations of tacrolimus in people with Liver transplantation as compared to genotype CC.; in people with Other:Liver transplantation
;RIFAMPIN;AADAC;rs1803155;AA;Metabolism/PK;decreased clearance of ⮕ RIFAMPIN;Genotype AA is associated with decreased clearance of rifampin in people with Tuberculosis as compared to genotypes AG + GG.; in people with Other:Tuberculosis
;APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs1934968;GG;Metabolism/PK;increased exposure to ⮕ APATINIB, APATINIB METABOLITE M1-1;Genotype GG is associated with increased exposure to apatinib and apatinib metabolite m1-1 in people with Neoplasms as compared to genotypes AA + AG.;and in people with Other:Neoplasms
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs11075995;AT + TT;Efficacy;increased clinical benefit to ⮕ PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;Genotypes AT + TT is associated with increased clinical benefit to PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to genotype AA.; in people with Other:Neoplasms
;AMPRENAVIR;SLCO1B1;rs4149056;C;Metabolism/PK;decreased trough concentration of ⮕ AMPRENAVIR;Allele C is associated with decreased trough concentration of amprenavir in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;ACAMPROSATE;;rs77583603;G;Efficacy;decreased response to ⮕ ACAMPROSATE;Allele G is associated with decreased response to acamprosate in people with Alcoholism as compared to allele A.; in people with Other:Alcohol abuse
;EVEROLIMUS;CYP3A5;rs776746;CC + CT;Metabolism/PK;decreased clearance of ⮕ EVEROLIMUS;Genotypes CC + CT is associated with decreased clearance of everolimus in people with heart transplantation as compared to genotype TT.; in people with Disease:Heart transplantation
;NALTREXONE;;rs12749274;A;Efficacy;decreased response to ⮕ NALTREXONE;Allele A is associated with decreased response to naltrexone in people with Alcoholism as compared to allele G.; in people with Other:Alcohol abuse
;DEFERASIROX;ABCG2;rs13120400;CC;Metabolism/PK;increased concentrations of ⮕ DEFERASIROX;Genotype CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotypes CT + TT.; in people with Disease:Beta-thalassemia and related diseases
;FLUVASTATIN;SLCO1B1;rs4149056;CC + CT;Efficacy;increased clinical benefit to ⮕ FLUVASTATIN;Genotypes CC + CT is associated with increased clinical benefit to fluvastatin as compared to genotype TT.;  
;RITONAVIR;ABCB1;rs1128503;AA;Metabolism/PK;increased clearance of ⮕ RITONAVIR;Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;RITONAVIR;ABCB1;rs2032582;AA;Metabolism/PK;increased clearance of ⮕ RITONAVIR;Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;FLUVASTATIN;APOE;rs429358;CC;Efficacy;increased clinical benefit to ⮕ FLUVASTATIN;Genotype CC is associated with increased clinical benefit to fluvastatin as compared to genotype TT.;  
;RITONAVIR;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ RITONAVIR;Genotype AA is associated with increased clearance of ritonavir in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;DOXORUBICIN;CBR1;rs20572;CC;Metabolism/PK;increased clearance of ⮕ DOXORUBICIN;Genotype CC is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype CT.; in people with Disease:Breast Neoplasms
;DEHYDROARIPIPRAZOLE;CYP1A2;rs762551;AA;Metabolism/PK;decreased concentrations of ⮕ DEHYDROARIPIPRAZOLE;Genotype AA is associated with decreased concentrations of dehydroaripiprazole in people with Schizophrenia.; in people with Other:Schizophrenia
;CLOZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;decreased exposure to ⮕ CLOZAPINE;Genotype AA is associated with decreased exposure to clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.; in people with Other:Schizophrenia, Other:Tobacco Use Disorder
;ETHANOL;OPRM1;rs1799971;AA;Dosage;increased dose of ⮕ ETHANOL;Genotype AA is associated with increased dose of ethanol in children as compared to genotypes AG + GG.; in children 
;PREDNISOLONE;GATA3;rs3824662;AA;Efficacy;decreased clinical benefit to ⮕ PREDNISOLONE;Genotype AA is associated with decreased clinical benefit to prednisolone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;GSTM3;rs7483;TT;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Genotype TT is associated with decreased concentrations of tacrolimus in people with Liver transplantation as compared to genotypes CC + CT.; in people with Other:Liver transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + GG.; in people with Other:Rheumatoid arthritis
;ADALIMUMAB;TNF;rs1799724;CC;Efficacy;decreased response to ⮕ ADALIMUMAB;Genotype CC is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.; in people with Other:Rheumatoid arthritis
;FLUOXETINE;HTR1B;rs130058;AA + TT;Efficacy;increased response to ⮕ FLUOXETINE;Genotypes AA + TT are associated with increased response to fluoxetine in children with Mental Disorders as compared to genotype AT.; in children with Disease:Mental Disorders
;ADALIMUMAB;TNF;rs1800629;GG;Efficacy;decreased response to ⮕ ADALIMUMAB;Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;CLOZAPINE;CYP1A2;rs762551;AA;Efficacy;decreased clinical benefit to ⮕ CLOZAPINE;Genotype AA is associated with decreased clinical benefit to clozapine in people with Schizophrenia as compared to genotypes AC + CC.; in people with Other:Schizophrenia
;FLUVASTATIN;APOE;rs7412;TT;Efficacy;increased clinical benefit to ⮕ FLUVASTATIN;Genotype TT is associated with increased clinical benefit to fluvastatin as compared to genotype CC.;  
;ADALIMUMAB;TNF;rs361525;GG;Efficacy;decreased response to ⮕ ADALIMUMAB;Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid.; in people with Disease:Rheumatoid arthritis
;MORPHINE;SLC6A4;rs1042173;CC;Dosage;decreased dose of ⮕ MORPHINE;Genotype CC is associated with decreased dose of morphine in people with Lung Neoplasms and Pain as compared to genotypes AA + AC.; in people with Other:Lung Neoplasms, Other:Pain
;FLUOXETINE;TPH2;rs4570625;TT;Efficacy;increased response to ⮕ FLUOXETINE;Genotype TT is associated with increased response to fluoxetine in children with Mental Disorders as compared to genotypes GG + GT.; in children with Disease:Mental Disorders
;METHOTREXATE;ADORA2A-AS1;rs17004921;CT + TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes CT + TT are associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Other:Rheumatoid arthritis
;ANTIEPILEPTICS;ABCB1;rs2032582;AA;Efficacy;increased clinical benefit to ⮕ ANTIEPILEPTICS;Genotype AA is associated with increased clinical benefit to antiepileptics in children with Epilepsy as compared to genotypes AC + CC.; in children with Other:Epilepsy
;ANTIEPILEPTICS;ABCB1;rs1045642;AA;Efficacy;increased clinical benefit to ⮕ ANTIEPILEPTICS;Genotype AA is associated with increased clinical benefit to antiepileptics in children with Epilepsy as compared to genotypes AG + GG.; in children with Other:Epilepsy
;ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;rs261316;T;Efficacy;decreased response to ⮕ ATENOLOL, HYDROCHLOROTHIAZIDE;Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C.;and in people with Disease:Hypertension
;CISPLATIN;REV3L;rs462779;AG + GG;Efficacy;decreased response to ⮕ CISPLATIN;Genotypes AG + GG are associated with decreased response to cisplatin in people with Osteosarcoma as compared to genotype AA.; in people with Disease:Osteosarcoma
;CISPLATIN;REV1;rs3087403;CT + TT;Efficacy;increased response to ⮕ CISPLATIN;Genotypes CT + TT are associated with increased response to cisplatin in people with Osteosarcoma as compared to genotype CC.; in people with Disease:Osteosarcoma
;ANTIEPILEPTICS;SCN1A;rs2298771;CC + CT;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotypes CC + CT is associated with increased resistance to antiepileptics in children with Epilepsy as compared to genotype TT.; in children with Other:Epilepsy
;AZITHROMYCIN;ABCB1;rs2032582;AA;Metabolism/PK;decreased concentrations of ⮕ AZITHROMYCIN;Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype CC.; in healthy individuals 
;AZITHROMYCIN;ABCB1;rs1045642;AA;Metabolism/PK;decreased concentrations of ⮕ AZITHROMYCIN;Genotype AA is associated with decreased concentrations of azithromycin in healthy individuals as compared to genotype GG.; in healthy individuals 
;LOPINAVIR;SLCO1B1;rs4149056;C;Metabolism/PK;increased trough concentration of ⮕ LOPINAVIR;Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;FENTANYL;OPRM1;rs9384179;AA;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Side Effect:Pain, Postoperative
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;FLUVASTATIN;CYP2C9;rs1057910;AC;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;Genotype AC is associated with increased concentrations of fluvastatin as compared to genotype AA.;  
;FENTANYL;KCNJ6;rs2835859;TT;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype TT is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CC + CT.; in people with Side Effect:Pain, Postoperative
;ABIRATERONE;HSD3B1;rs1047303;AC;Metabolism/PK;increased metabolism of ⮕ ABIRATERONE;Genotype AC is associated with increased metabolism of abiraterone in men with Prostatic Neoplasms as compared to genotype AA.; in men with Other:Prostatic Neoplasms
;FENTANYL;;rs2952768;CC;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype CC is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes CT + TT.; in people with Side Effect:Pain, Postoperative
;FENTANYL;;rs11959113;AA;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.; in people with Side Effect:Pain, Postoperative
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with heart transplantation as compared to genotype CC.; in people with Disease:Heart transplantation
;CYCLOPHOSPHAMIDE;GSTA1;rs3957356;CT;Efficacy, Toxicity, Metabolism/PK;decreased response to ⮕ CYCLOPHOSPHAMIDE;Genotype CT is associated with decreased response to cyclophosphamide in people with Lupus Nephritis as compared to genotype CC.; in people with Disease:Lupus Nephritis
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;BILIRUBIN;SOD2;rs4880;GG;Toxicity;increased concentrations of ⮕ BILIRUBIN;Genotype GG is associated with increased concentrations of bilirubin in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.; in people with Disease:Heart transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CC.; in children with Disease:Kidney Transplantation
;ETHANOL;OPRM1;rs1799971;AG + GG;Other;increased exposure to ⮕ ETHANOL;Genotypes AG + GG are associated with increased exposure to ethanol in healthy individuals as compared to genotype AA.; in healthy individuals 
;METHYLPHENIDATE;SLC6A2;rs5569;GG;Efficacy;increased response to ⮕ METHYLPHENIDATE;Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;TACROLIMUS;POR;rs1057868;CT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with heart transplantation as compared to genotype CC.; in people with Disease:Heart transplantation
;MONTELUKAST;UGT1A3;rs7604115;T;Metabolism/PK;decreased concentrations of ⮕ MONTELUKAST;Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.; in healthy individuals 
;MONTELUKAST;ABCC9;rs704212;T;Metabolism/PK;decreased concentrations of ⮕ MONTELUKAST;Allele T is associated with decreased concentrations of montelukast in healthy individuals as compared to allele C.; in healthy individuals 
;IVACAFTOR;CFTR;rs77010898;AA;Efficacy;increased response to ⮕ IVACAFTOR;Genotype AA is associated with increased response to ivacaftor in people with Cystic Fibrosis as compared to genotype GG.; in people with Disease:Cystic Fibrosis
;DOCETAXEL, DOXORUBICIN;AKR1C3;rs1937840;GG;Efficacy;increased response to ⮕ DOCETAXEL, DOXORUBICIN;Genotype GG is associated with increased response to docetaxel and doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.;and in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;rs4244285;AA + AG;Efficacy;decreased response to ⮕ CYCLOPHOSPHAMIDE, DOXORUBICIN;Genotypes AA + AG are associated with decreased response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype GG.;and in women with Disease:Breast Neoplasms
;ANTIDEPRESSANTS;GRIK4;rs1954787;TT;Efficacy;decreased clinical benefit to ⮕ ANTIDEPRESSANTS;Genotype TT is associated with decreased clinical benefit to antidepressants in people with Major Depressive Disorder as compared to genotypes CC + CT.; in people with Other:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Hematopoietic stem cell transplantation as compared to genotype CC.; in people with Other:Hematopoietic stem cell transplantation
;ANTIDEPRESSANTS;GRIK4;rs1954787;C;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele C is associated with increased response to antidepressants in people with Major Depressive Disorder as compared to allele T.; in people with Other:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased dose of ⮕ WARFARIN;Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.; in people with Other:an international normalized ratio (INR) of 2.0-3.0
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs7294;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.; in people with Disease:Heart valve replacement
;WARFARIN;CYP2C9;rs1057910;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.; in people with Disease:Heart valve replacement
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.;  
;BUPRENORPHINE;OPRM1;rs2075572;CC + CG;Metabolism/PK;increased concentrations of ⮕ BUPRENORPHINE;Genotypes CC + CG is associated with increased concentrations of buprenorphine in people with Opioid-Related Disorders as compared to genotype GG.; in people with Other:Opioid-Related Disorders
;SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;Efficacy;increased response to ⮕ SELECTIVE SEROTONIN (5HT1) AGONISTS;Allele C is associated with increased response to Selective serotonin (5HT1) agonists in people with Migraine with Aura or Migraine without Aura as compared to allele T.; in people with Other:Migraine with Aura, Other:Migraine without Aura
;AFATINIB;NR1I2;rs6785049;AA + AG;Metabolism/PK;decreased clearance of ⮕ AFATINIB;Genotypes AA + AG is associated with decreased clearance of afatinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; in people with Other:Non-Small Cell Lung Carcinoma
;WARFARIN;CYP2C9;rs4917639;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele A.; in people with Disease:Heart valve replacement
;RIVAROXABAN;ABCG2;rs2231142;TT;Metabolism/PK;increased half-life time of ⮕ RIVAROXABAN;Genotype TT is associated with increased half-life time of rivaroxaban in healthy individuals as compared to genotypes GG + GT.; in healthy individuals 
;LOPINAVIR;SLCO1B1;rs4149056;CT;Metabolism/PK;increased exposure to ⮕ LOPINAVIR;Genotype CT is associated with increased exposure to lopinavir in children with HIV Infections as compared to genotype TT.; in children with Other:HIV infectious disease
;NALTREXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased response to ⮕ NALTREXONE;Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA.; in people with Disease:Alcohol abuse
;ATAZANAVIR;ABCB1;rs1128503;AG + GG;Metabolism/PK;decreased clearance of ⮕ ATAZANAVIR;Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.; in healthy individuals 
;ANTIDEPRESSANTS;ABCB1;rs1128503;A;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Allele A is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele G.; in people with Other:Major Depressive Disorder
;METHADONE;COMT;rs933271;CC + CT;Efficacy;increased response to ⮕ METHADONE;Genotypes CC + CT are associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotype TT.; in people with Other:Opioid-Related Disorders
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;AG;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype AG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;ATAZANAVIR;ABCB1;rs2032582;AC + CC;Metabolism/PK;decreased clearance of ⮕ ATAZANAVIR;Genotypes AC + CC is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.; in healthy individuals 
;ATAZANAVIR;ABCB1;rs1045642;AG + GG;Metabolism/PK;decreased clearance of ⮕ ATAZANAVIR;Genotypes AG + GG is associated with decreased clearance of atazanavir in healthy individuals as compared to genotype AA.; in healthy individuals 
;METHOTREXATE;MTHFR;rs1801131;GT + TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.; in people with Disease:Rheumatoid arthritis
;VALPROIC ACID;GRIN2B;rs1019385;AC;Dosage, Metabolism/PK;decreased dose of ⮕ VALPROIC ACID;Genotype AC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;VALPROIC ACID;GRIN2B;rs1019385;CC;Dosage, Metabolism/PK;decreased dose of ⮕ VALPROIC ACID;Genotype CC is associated with decreased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.; in people with Disease:Epilepsy
;METHOTREXATE;SLC19A1;rs1051266;CT + TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.; in people with Disease:Rheumatoid arthritis
;CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;SCN1A;rs2298771;C;Efficacy;increased response to ⮕ CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T.;or in children with Disease:Epilepsy
;LOPINAVIR;SLCO1B1;rs4149056;C;Metabolism/PK;increased trough concentration of ⮕ LOPINAVIR;Allele C is associated with increased trough concentration of lopinavir in people with HIV Infections as compared to allele T.; in people with Other:HIV infectious disease
;VALPROIC ACID;UGT1A6;rs1105879;AC;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype AC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;FLUVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ FLUVASTATIN;Genotype TT is associated with increased response to fluvastatin as compared to genotypes CC + CT.;  
;EVEROLIMUS;CYP3A5;rs776746;CT;Metabolism/PK;decreased trough concentration of ⮕ EVEROLIMUS;Genotype CT is associated with decreased trough concentration of everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to genotype CC.; in people with Other:Breast Neoplasms, Other:Kidney Neoplasms, Other:Neuroendocrine Tumors
;WARFARIN;CYP4F2;rs2108622;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele T.; in people with Disease:Heart valve replacement
;AMISULPRIDE;SNAP25;rs8636;CT;Efficacy;increased response to ⮕ AMISULPRIDE;Genotype CT is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CC + TT.; in people with Disease:Schizophrenia
;CLOPIDOGREL;ABCA1;rs2487032;A;Metabolism/PK;increased metabolism of ⮕ CLOPIDOGREL;Allele A is associated with increased metabolism of clopidogrel as compared to genotype GG.;  
;CLOPIDOGREL;N6AMT1;rs2254638;G;Metabolism/PK;decreased metabolism of ⮕ CLOPIDOGREL;Allele G is associated with decreased metabolism of clopidogrel as compared to genotype AA.;  
;TENOFOVIR;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased concentrations of ⮕ TENOFOVIR;Genotypes GT + TT are associated with increased concentrations of tenofovir in women with HIV Infections as compared to genotype GG.; in women with Disease:HIV infectious disease
;SIROLIMUS;ABCB1;rs2032582;A;Metabolism/PK;increased concentrations of ⮕ SIROLIMUS;Allele A is associated with increased concentrations of sirolimus in people with hematopoietic stem cell transplantation.; in people with Disease:Hematopoietic stem cell transplantation
;ANTIPSYCHOTICS;NRXN1;rs12467557;AA;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype AA is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.; in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;NRXN1;rs10490162;TT;Efficacy;increased response to ⮕ ANTIPSYCHOTICS;Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotypes CC + CT.; in people with Disease:Schizophrenia
;CLOPIDOGREL;CYP2C19;rs4986893;AA;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype AA is associated with decreased response to clopidogrel.;  
;DABIGATRAN;CES1;rs8192935;GG;Metabolism/PK;increased concentrations of ⮕ DABIGATRAN;Genotype GG is associated with increased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotypes AA + AG.; in people with Disease:Atrial Fibrillation
;ATAZANAVIR;ABCB1;rs2032582;AA;Metabolism/PK;increased clearance of ⮕ ATAZANAVIR;Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;Efficacy;increased clinical benefit to ⮕ ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;Genotype GG is associated with increased clinical benefit to adalimumab, certolizumab pegol, golimumab or infliximab in people with Behcet Syndrome as compared to genotype AG.;or in people with Other:Behcet Syndrome
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Efficacy;decreased response to ⮕ CLOPIDOGREL;Genotype AA is associated with decreased response to clopidogrel.;  
;TACROLIMUS;CYP3A5;rs776746;CC;Other, Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;ATAZANAVIR;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ ATAZANAVIR;Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.; in children with Disease:HIV infectious disease
;BEVACIZUMAB;CFH;rs1061170;CC;Efficacy;decreased response to ⮕ BEVACIZUMAB;Genotype CC is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes CT + TT.; in people with Disease:Macular Degeneration
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;GG;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AG.; in people with Disease:Epilepsy
;CISPLATIN, FLUOROURACIL;DPYD;rs3918290;CT;Efficacy;decreased response to ⮕ CISPLATIN, FLUOROURACIL;Genotype CT is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms as compared to genotype CC.;and in men with Disease:Head and Neck Neoplasms
;CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;rs861539;AA;Efficacy;decreased response to ⮕ CISPLATIN, DOCETAXEL, IRINOTECAN;Genotype AA is associated with decreased response to cisplatin, docetaxel and irinotecan in people with Stomach Neoplasms as compared to genotypes AG + GG.;and in people with Disease:Stomach Neoplasms
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GG;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype GG is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes GT + TT.; in people with Disease:Epilepsy
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GT;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype GT is associated with increased dose of valproic acid in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;VALPROIC ACID;UGT1A6;rs1105879;CC;Dosage, Metabolism/PK;increased dose of ⮕ VALPROIC ACID;Genotype CC is associated with increased dose of valproic acid in people with Epilepsy as compared to genotypes AA + AC.; in people with Disease:Epilepsy
;10-MONOHYDROXY OXCARBAZEPINE;INSR;rs2396185;C;Metabolism/PK;decreased clearance of ⮕ 10-MONOHYDROXY OXCARBAZEPINE;Allele C is associated with decreased clearance of 10-monohydroxy oxcarbazepine in children with Epilepsy as compared to allele A.; in children with Other:Epilepsy
;ATAZANAVIR;ABCB1;rs1128503;AA;Metabolism/PK;increased clearance of ⮕ ATAZANAVIR;Genotype AA is associated with increased clearance of atazanavir in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;RISPERIDONE;HTR1A;rs6295;GG;Dosage, Efficacy;increased response to ⮕ RISPERIDONE;Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.; in people with Disease:Schizophrenia
;FENTANYL;CACNA1E;rs3845446;CC + CT;Dosage;decreased dose of ⮕ FENTANYL;Genotypes CC + CT are associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype TT.; in people with Other:Pain, Postoperative
;FENTANYL;LAMB3;rs2076222;G;Dosage, Efficacy;increased dose of ⮕ FENTANYL;Allele G is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to allele T.; in people with Disease:Pain, Postoperative
;CETUXIMAB;VEGFA;rs833061;TT;Efficacy;increased response to ⮕ CETUXIMAB;Genotype TT is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes CC + CT.; in people with Disease:Colorectal Neoplasms
;CETUXIMAB;VEGFA;rs1570360;GG;Efficacy;increased response to ⮕ CETUXIMAB;Genotype GG is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG.; in people with Disease:Colorectal Neoplasms
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734791;A;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734787;A;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs17435;A;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;VORICONAZOLE;CYP3A4;rs2242480;CT;Metabolism/PK;poor metabolizer increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Genotype CT (assigned as poor metabolizer phenotype) is associated with increased dose-adjusted trough concentrations of voriconazole in healthy individuals as compared to genotype CC (assigned as normal metabolizer phenotype) .; in healthy individuals 
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5906072;T;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.;and in people with Disease:Hepatocellular Carcinoma
;PROCHLORPERAZINE;ANKK1, DRD2;rs1800497;AA + AG;Efficacy;decreased response to ⮕ PROCHLORPERAZINE;Genotypes AA + AG are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype GG.; in people with Other:Nausea
;PROCHLORPERAZINE;DRD2;rs1079597;CT + TT;Efficacy;decreased response to ⮕ PROCHLORPERAZINE;Genotypes CT + TT are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype CC.; in people with Other:Nausea
;METFORMIN;ATM;rs11212617;AC;Efficacy;increased response to ⮕ METFORMIN;Genotype AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + CC.; in people with Other:Diabetes Mellitus, Type 2
;MORPHINE;OPRK1;rs1051660;A;Dosage, Efficacy;decreased dose of ⮕ MORPHINE;Allele A is associated with decreased dose of morphine in people with Pain as compared to allele C.; in people with Disease:Pain
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12613732;G;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele G is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs5009910;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;ATORVASTATIN;HMGCR;rs17671591;CT + TT;Efficacy;increased response to ⮕ ATORVASTATIN;Genotypes CT + TT is associated with increased response to atorvastatin in people with Hypercholesterolemia as compared to genotype CC.; in people with Disease:Hypercholesterolemia
;ESCITALOPRAM;TPH1;rs1800532;GT + TT;Efficacy;decreased response to ⮕ ESCITALOPRAM;Genotypes GT + TT are associated with decreased response to escitalopram in people with Depression as compared to genotype GG.; in people with Other:Depression
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs6752303;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;TENOFOVIR ALAFENAMIDE;CYP3A4;rs35599367;AG;Metabolism/PK;decreased concentrations of ⮕ TENOFOVIR ALAFENAMIDE;Genotype AG is associated with decreased concentrations of tenofovir alafenamide in healthy individuals as compared to genotype GG.; in healthy individuals 
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs10209881;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;DABIGATRAN;CES1;rs2244613;GG;Metabolism/PK;decreased concentrations of ⮕ DABIGATRAN;Genotype GG is associated with decreased concentrations of Dabigatran in people with Atrial Fibrillation as compared to genotype TT.; in people with Disease:Atrial Fibrillation
;CLOPIDOGREL;CYP2C19;rs4244285;A;Metabolism/PK;poor metabolizer increased dose of ⮕ CLOPIDOGREL;Allele A (assigned as poor metabolizer phenotype) is associated with increased dose of clopidogrel in healthy individuals as compared to allele G (assigned as normal metabolizer phenotype) .; in healthy individuals 
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12999804;A;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele A is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;TACROLIMUS;CYP3A4;rs2740574;TT;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype TT is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs34532201;TT;Metabolism/PK;increased exposure to ⮕ APATINIB, APATINIB METABOLITE M1-1;Genotype TT is associated with increased exposure to apatinib and apatinib metabolite m1-1 in people with Neoplasms as compared to genotypes CC + CT.;and in people with Other:Neoplasms
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5934731;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs715171;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs4932551;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele G.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs7170769;T;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele T is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele C.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6458232;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele A.;and in people with Disease:Hepatocellular Carcinoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs7608731;C;Efficacy;response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T.;and in people with Disease:Hepatocellular Carcinoma
;ALLOPURINOL, FEBUXOSTAT;AOX1;rs3731722;G;Dosage;dose of ⮕ ALLOPURINOL, FEBUXOSTAT;Allele G is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele A.;or in people with Disease:Gout
;PAZOPANIB;CYP3A4;rs35599367;AG;Metabolism/PK;decreased clearance of ⮕ PAZOPANIB;Genotype AG is associated with decreased clearance of pazopanib in people with Neoplasms as compared to genotype GG.; in people with Other:Neoplasms
;RITUXIMAB;IL2;rs6822844;GG;Efficacy;increased response to ⮕ RITUXIMAB;Genotype GG is associated with increased response to rituximab in people with Autoimmune Diseases as compared to genotype GT.; in people with Disease:Autoimmune Diseases
;RITUXIMAB;IL2;rs6822844;GG;Efficacy;increased response to ⮕ RITUXIMAB;Genotype GG is associated with increased response to rituximab in people with Lupus Erythematosus, Systemic as compared to genotype GT.; in people with Disease:Systemic lupus erythematosus
;ALLOPURINOL, FEBUXOSTAT;AOX1;rs11678615;T;Dosage;dose of ⮕ ALLOPURINOL, FEBUXOSTAT;Allele T is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele C.;or in people with Disease:Gout
;METHOTREXATE;MTHFR;rs1801131;GG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GT + TT.; in people with Disease:Rheumatoid arthritis
;DIAZEPAM;ABCB1;rs1128503;AA;Metabolism/PK;increased exposure to ⮕ DIAZEPAM;Genotype AA is associated with increased exposure to diazepam in healthy individuals as compared to genotype GG (assigned as normal metabolizer phenotype) .; in healthy individuals 
;ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs34650714;T;Dosage;decreased dose of ⮕ ALLOPURINOL, FEBUXOSTAT;Allele T is associated with decreased dose of allopurinol or febuxostat in people with Gout as compared to allele C.;or in people with Disease:Gout
;ALLOPURINOL, FEBUXOSTAT;XDH;rs1884725;G;Dosage;decreased dose of ⮕ ALLOPURINOL, FEBUXOSTAT;Allele G is associated with decreased dose of allopurinol or febuxostat in people with Gout as compared to allele A.;or in people with Disease:Gout
;ALLOPURINOL, FEBUXOSTAT;AOX1;rs75995567;T;Dosage;increased dose of ⮕ ALLOPURINOL, FEBUXOSTAT;Allele T is associated with increased dose of allopurinol or febuxostat in people with Gout as compared to allele C.;or in people with Disease:Gout
;METFORMIN;SLC22A1;rs622342;AC;Efficacy;increased response to ⮕ METFORMIN;Genotype AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + CC.; in people with Other:Diabetes Mellitus, Type 2
;PROPOFOL, REMIFENTANIL;ABCB1;rs1128503;GG;Efficacy;increased response to ⮕ PROPOFOL, REMIFENTANIL;Genotype GG is associated with increased response to propofol and remifentanil in children as compared to genotypes AA + AG.;and in children 
;METHOTREXATE;ABCC3;rs4148416;TT;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotype TT is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A4;rs2740574;TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype TT is associated with increased concentrations of tacrolimus in children with Kidney Transplantation as compared to genotype CT.; in children with Disease:Kidney Transplantation
;METHOTREXATE;SLC19A1;rs17004785;CG;Metabolism/PK;increased clearance of ⮕ METHOTREXATE;Genotype CG is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;DONEPEZIL;BCHE;rs1803274;T;Efficacy;increased response to ⮕ DONEPEZIL;Allele T is associated with increased response to donepezil in women with Alzheimer Disease as compared to allele C.; in women with Disease:Alzheimer Disease
;CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;rs2236225;AA + AG;Efficacy;increased response to ⮕ CISPLATIN, DOXORUBICIN, METHOTREXATE;Genotypes AA + AG is associated with increased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.;and in people with Other:Osteosarcoma
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;Efficacy;increased response to ⮕ CISPLATIN, FLUOROURACIL, MITOXANTRONE;Genotype TT is associated with increased response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.;and in people with Disease:Hepatocellular Carcinoma
;PAROXETINE;GDNF;rs2973049;CT + TT;Efficacy;decreased response to ⮕ PAROXETINE;Genotypes CT + TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotype CC.; in people with Disease:Major Depressive Disorder
;PAROXETINE;GDNF;rs2216711;AA + AG;Efficacy;decreased response to ⮕ PAROXETINE;Genotypes AA + AG is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype GG.; in women with Disease:Major Depressive Disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;rs4819554;AA;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotype AA is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.; in people with Disease:Psoriasis
;ATOMOXETINE;SLC6A2;rs3785143;T;Efficacy;decreased response to ⮕ ATOMOXETINE;Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C.; in children with Disease:Attention Deficit Disorder with Hyperactivity
;PAROXETINE;BDNF;rs6265;CC + CT;Efficacy;decreased response to ⮕ PAROXETINE;Genotypes CC + CT is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype TT.; in women with Disease:Major Depressive Disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;AC + CC;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AC + CC is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;ROSUVASTATIN;CETP;rs5882;G;Efficacy;increased response to ⮕ ROSUVASTATIN;Allele G is associated with increased response to rosuvastatin as compared to allele A.;  
;FLUOXETINE;CYP2D6;rs28371703;GT;Metabolism/PK;increased half-life time of ⮕ FLUOXETINE;Genotype GT is associated with increased half-life time of fluoxetine in healthy individuals as compared to genotype GG.; in healthy individuals 
;FLUOXETINE;CYP2D6;rs1135840;C;Metabolism/PK;increased concentrations of ⮕ FLUOXETINE;Allele C is associated with increased concentrations of fluoxetine in healthy individuals as compared to allele G.; in healthy individuals 
;DISULFIRAM;DBH;rs1611115;CC;Efficacy;increased response to ⮕ DISULFIRAM;Genotype CC is associated with increased response to disulfiram in men with Alcoholism as compared to genotypes CT + TT.; in men with Disease:Alcohol abuse
;FLUOXETINE;CYP2D6;rs1065852;A;Metabolism/PK;increased half-life time of ⮕ FLUOXETINE;Allele A is associated with increased half-life time of fluoxetine in healthy individuals as compared to allele G.; in healthy individuals 
;RIVAROXABAN;CYP3A5;rs776746;TT;Metabolism/PK;increased steady-state concentration of ⮕ RIVAROXABAN;Genotype TT is associated with increased steady-state concentration of rivaroxaban in people with Atrial Fibrillation as compared to genotypes CC + CT.; in people with Other:Atrial Fibrillation
;RISPERIDONE;COMT;rs9606186;GG;Efficacy;increased response to ⮕ RISPERIDONE;Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.; in people with Disease:Schizophrenia
;RIVAROXABAN;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased clearance of ⮕ RIVAROXABAN;Genotypes AA + AG are associated with increased clearance of rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.; in people with Other:Atrial Fibrillation
;TACROLIMUS;C6;rs10052999;CC + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CT.; in people with Disease:Liver transplantation
;WARFARIN;VKORC1;rs9934438;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin in children as compared to genotypes AA + AG.; in children 
;TACROLIMUS;C6;rs9200;CC + CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CC + CT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype TT.; in people with Disease:Liver transplantation
;CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;rs717620;CT + TT;Efficacy;decreased response to ⮕ CISPLATIN, DOXORUBICIN, METHOTREXATE;Genotypes CT + TT is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype CC.;and in people with Other:Osteosarcoma
;RISPERIDONE;RGS4;rs2661319;C;Efficacy;decreased response to ⮕ RISPERIDONE;Allele C is associated with decreased response to risperidone in people with Schizophrenia as compared to allele T.; in people with Disease:Schizophrenia
;LAMOTRIGINE;SLC22A1;rs628031;AA + AG;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotypes AA + AG is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;RISPERIDONE;ANKK1;rs1800497;A;Efficacy;increased response to ⮕ RISPERIDONE;Allele A is associated with increased response to risperidone in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A4;rs2740574;CT;Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotype CT is associated with increased dose of tacrolimus in people with Transplantation as compared to genotype TT.; in people with Other:Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;Efficacy;decreased response to ⮕ CISPLATIN, DOXORUBICIN, METHOTREXATE;Genotypes AG + GG is associated with decreased response to cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.;and in people with Other:Osteosarcoma
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Genotype CC is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CC.; in people with Disease:Liver transplantation
;PHENYTOIN;CYP2C9;rs1057910;C;Dosage, Metabolism/PK;increased dose of ⮕ PHENYTOIN;Allele C is associated with increased dose of phenytoin in people with Epilepsy as compared to allele A.; in people with Disease:Epilepsy
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Dosage;increased dose of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;PHENYTOIN;SCN1A;rs3812718;T;Dosage;increased dose of ⮕ PHENYTOIN;Allele T is associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.; in people with Disease:Epilepsy
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Genotype TT is associated with decreased dose of acenocoumarol as compared to genotype CC.;  
;TACROLIMUS;ABCB1;rs2032582;T;Metabolism/PK;decreased metabolism of ⮕ TACROLIMUS;Allele T is associated with decreased metabolism of tacrolimus in people with Kidney Transplantation.; in people with Disease:Kidney Transplantation
;ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs28371738;A;Metabolism/PK;increased concentrations of ⮕ ALPHA-HYDROXYMETOPROLOL;Allele A is associated with increased concentrations of alpha-hydroxymetoprolol as compared to allele G.;  
;RIVAROXABAN;ABCB1;rs1128503;AG + GG;Metabolism/PK;decreased concentrations of ⮕ RIVAROXABAN;Genotypes AG + GG is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AA.; in people with Other:Atrial Fibrillation
;FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs6295;GG;Efficacy;increased response to ⮕ FLUVOXAMINE, MILNACIPRAN, PAROXETINE;Genotype GG is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CG.;and in people with Disease:Major Depressive Disorder
;LANSOPRAZOLE;ABCB1;rs1045642;G;Other, Metabolism/PK;increased metabolism of ⮕ LANSOPRAZOLE;Allele G is associated with increased metabolism of lansoprazole as compared to genotype AA.;  
;FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs10042486;CC;Efficacy;increased response to ⮕ FLUVOXAMINE, MILNACIPRAN, PAROXETINE;Genotype CC is associated with increased response to fluvoxamine, milnacipran and paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.;and in people with Disease:Major Depressive Disorder
;LAMOTRIGINE;ABCG2;rs2231142;TT;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.; in people with Disease:Epilepsy
;RIVAROXABAN;ABCB1;rs1045642;AG + GG;Metabolism/PK;decreased concentrations of ⮕ RIVAROXABAN;Genotypes AG + GG is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to genotype AA.; in people with Other:Atrial Fibrillation
;RIVAROXABAN;ABCB1;rs4148738;T;Metabolism/PK;decreased concentrations of ⮕ RIVAROXABAN;Allele T is associated with decreased concentrations of rivaroxaban in people with Atrial Fibrillation as compared to allele C.; in people with Other:Atrial Fibrillation
;PHENYTOIN;CYP2C9;rs1934969;AT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ PHENYTOIN;Genotypes AT + TT is associated with increased dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.; in people with Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis
;HMG COA REDUCTASE INHIBITORS;APOC1;rs4420638;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases or Hypercholesterolemia as compared to allele A.; in people with Disease:Cardiovascular Disease, Disease:Hypercholesterolemia
;WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.; in people with Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis
;PHOTODYNAMIC THERAPY;F13A1;rs5985;AA + AC;Efficacy;decreased response to ⮕ PHOTODYNAMIC THERAPY;Genotypes AA + AC are associated with decreased response to photodynamic therapy in people with Choroidal Neovascularization as compared to genotype CC.; in people with Disease:Choroidal Neovascularization
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.; in people with Disease:Atrial Fibrillation, Disease:Heart valve replacement, Disease:Pulmonary Hypertension, Disease:Pulmonary Embolism, Disease:Venous Thrombosis
;CITALOPRAM;TPH1;rs1800532;GT + TT;Efficacy;decreased response to ⮕ CITALOPRAM;Genotypes GT + TT are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.; in people with Disease:Major Depressive Disorder
;HMG COA REDUCTASE INHIBITORS;NPC1L1;rs2072183;G;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases and Hypercholesterolemia as compared to allele C.; in people with Disease:Cardiovascular Disease, Disease:Hypercholesterolemia
;HMG COA REDUCTASE INHIBITORS;SORT1;rs629301;T;Efficacy;decreased response to ⮕ HMG COA REDUCTASE INHIBITORS;Allele T is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases and Hypercholesterolemia as compared to allele G.; in people with Disease:Cardiovascular Disease, Disease:Hypercholesterolemia
;MYCOPHENOLIC ACID;UGT1A9;rs3832043;del;Metabolism/PK;decreased metabolism of ⮕ MYCOPHENOLIC ACID;Allele del is associated with decreased metabolism of mycophenolic acid in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;BISOPROLOL;ACY3;rs2514036;T;Efficacy;increased response to ⮕ BISOPROLOL;Allele T is associated with increased response to bisoprolol in men with Hypertension as compared to allele C.; in men with Disease:Hypertension
;MYCOPHENOLIC ACID;SLCO1B1;rs2306283;AA + AG;Metabolism/PK;decreased clearance of ⮕ MYCOPHENOLIC ACID;Genotypes AA + AG is associated with decreased clearance of mycophenolic acid in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;IMATINIB;BCL2L11;rs724710;T;Efficacy;decreased response to ⮕ IMATINIB;Allele T is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele C.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;FLUOROURACIL;DPYD;rs3918290;CT;Metabolism/PK;decreased clearance of ⮕ FLUOROURACIL;Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms
;ITOPRIDE;FMO3;rs2266782;AA;Metabolism/PK;decreased metabolism of ⮕ ITOPRIDE;Genotype AA is associated with decreased metabolism of itopride in healthy individuals as compared to genotype GG.; in healthy individuals 
;METOPROLOL;SEPTIN3;rs56234624;G;Metabolism/PK;increased concentrations of ⮕ METOPROLOL;Allele G is associated with increased concentrations of metoprolol as compared to allele A.;  
;ITOPRIDE;FMO3;rs2266780;GG;Metabolism/PK;decreased metabolism of ⮕ ITOPRIDE;Genotype GG is associated with decreased metabolism of itopride in healthy individuals as compared to genotype AA.; in healthy individuals 
;ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;rs1801157;CT + TT;Efficacy;decreased response to ⮕ ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;Genotypes CT + TT are associated with decreased response to alemtuzumab, chlorambucil, cyclophosphamide, fludarabine, prednisone, rituximab or vincristine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype CC.;or in people with Disease:Leukemia, Lymphocytic, Chronic, B-Cell
;MYCOPHENOLIC ACID;ABCC2;rs3740066;CT;Metabolism/PK;decreased concentrations of ⮕ MYCOPHENOLIC ACID;Genotype CT is associated with decreased concentrations of mycophenolic acid in people with lung transplantation as compared to genotypes CC + TT.; in people with Disease:Lung transplantation
;GEMCITABINE;RRM1;rs9937;AA;Efficacy;decreased response to ⮕ GEMCITABINE;Genotype AA is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.; in people with Disease:Pancreatic Neoplasms
;TACROLIMUS;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes AA + AG are associated with increased concentrations of tacrolimus in people with lung transplantation as compared to genotype GG.; in people with Disease:Lung transplantation
;BEVACIZUMAB;CXCL8;rs4073;AA;Efficacy;decreased response to ⮕ BEVACIZUMAB;Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes AT + TT.; in people with Disease:Macular Degeneration
;GEMCITABINE;RRM1;rs183484;AC;Efficacy, Toxicity;decreased response to ⮕ GEMCITABINE;Genotype AC is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + CC.; in people with Disease:Pancreatic Neoplasms
;HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;AG + GG;Efficacy;increased response to ⮕ HYDROCHLOROTHIAZIDE;Genotypes AG + GG are associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype AA.; in people with Disease:Hypertension
;SN-38;UGT1A1;rs4148323;AA;Dosage;increased concentrations of ⮕ SN-38;Genotype AA is associated with increased concentrations of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.; in people with Other:Non-Small Cell Lung Carcinoma
;COTININE GLUCURONIDE;UGT1A9;rs12471326;CT;Metabolism/PK;increased concentrations of ⮕ COTININE GLUCURONIDE;Genotype CT is associated with increased concentrations of cotinine glucuronide as compared to genotype TT.;  
;NICOTINE;CYP2A6;rs145014075;GT;Metabolism/PK;increased concentrations of ⮕ NICOTINE;Genotype GT is associated with increased concentrations of nicotine as compared to genotype GG.;  
;BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;Efficacy;increased response to ⮕ BEVACIZUMAB, RANIBIZUMAB;Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.;or in people with Disease:Macular Degeneration
;CYCLOSPORINE;CYP3A5;rs776746;CC + CT;Metabolism/PK;increased metabolism of ⮕ CYCLOSPORINE;Genotypes CC + CT are associated with increased metabolism of cyclosporine in healthy individuals as compared to genotype TT.; in healthy individuals 
;GRANISETRON;ABCB1;rs1045642;AA;Efficacy;increased response to ⮕ GRANISETRON;Genotype AA is associated with increased response to granisetron in people with Nausea and Vomiting as compared to genotypes AG + GG.; in people with Side Effect:Nausea, Side Effect:Vomiting
;WARFARIN;VKORC1;rs9923231;CC + CT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with increased dose of warfarin in people with Heart Failure as compared to genotype TT.; in people with Other:Heart Failure
;CARBAMAZEPINE;SCN1A;rs3812718;CC + CT;Efficacy;increased response to ⮕ CARBAMAZEPINE;Genotypes CC + CT are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype TT.; in people with Disease:Epilepsy
;BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;Efficacy;increased response to ⮕ BEVACIZUMAB, RANIBIZUMAB;Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC.;or in people with Disease:Macular Degeneration
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Dosage;increased dose of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Disease:Epilepsy
;ETANERCEPT;CD84;rs6427528;AG;Efficacy;increased response to ⮕ ETANERCEPT;Genotype AG is associated with increased response to etanercept in people with Psoriasis as compared to genotype GG.; in people with Disease:Psoriasis
;LOPINAVIR;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased trough concentration of ⮕ LOPINAVIR;Genotypes CC + CT are associated with increased trough concentration of lopinavir in men with HIV Infections as compared to genotype TT.; in men with Other:HIV infectious disease
;CARBAMAZEPINE;SCN1A;rs2298771;TT;Efficacy;increased response to ⮕ CARBAMAZEPINE;Genotype TT is associated with increased response to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;METHADONE;OPRM1;rs10485058;AA;Efficacy;increased response to ⮕ METHADONE;Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Disease:Opioid-Related Disorders
;CARBAMAZEPINE;GABRA1;rs2290732;AA + AG;Efficacy;increased response to ⮕ CARBAMAZEPINE;Genotypes AA + AG are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC.;  
;USTEKINUMAB;IL12B;rs3213094;CT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotype CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;GEMCITABINE;CDA;rs2072671;AA;Efficacy;increased response to ⮕ GEMCITABINE;Genotype AA is associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AC + CC.; in people with Disease:Pancreatic Neoplasms
;TOCILIZUMAB;IL6R;rs11265618;CC;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.; in people with Disease:Rheumatoid arthritis
;TOCILIZUMAB;IL6R;rs12083537;AA;Efficacy;increased response to ⮕ TOCILIZUMAB;Genotype AA is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in people with Disease:Rheumatoid arthritis
;EFAVIRENZ;ABCB1;rs2032582;AA;Metabolism/PK;decreased concentrations of ⮕ EFAVIRENZ;Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AC + CC.; in people with Disease:HIV infectious disease
;ALFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ ALFENTANIL;Genotypes AG + GG are associated with increased dose of alfentanil in people with Pain as compared to genotype AA.; in people with Disease:Pain
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.; in people with Disease:HIV infectious disease
;EFAVIRENZ;ABCB1;rs1045642;AA;Metabolism/PK;decreased concentrations of ⮕ EFAVIRENZ;Genotype AA is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.; in people with Disease:HIV infectious disease
;CETUXIMAB;FCGR3A;rs396991;AA;Efficacy;increased response to ⮕ CETUXIMAB;Genotype AA is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AC + CC.; in people with Disease:Head and Neck Neoplasms
;CETUXIMAB;FCGR2A;rs1801274;GG;Efficacy;increased response to ⮕ CETUXIMAB;Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG.; in people with Disease:Head and Neck Neoplasms
;EFAVIRENZ;HNF4A;rs1884613;CC;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CG + GG.; in people with Disease:HIV infectious disease
;METHADONE;ALDH5A1;rs2760118;CT + TT;Efficacy;decreased response to ⮕ METHADONE;Genotypes CT + TT is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to genotype CC.; in people with Disease:Opioid-Related Disorders
;ATAZANAVIR;UGT1A1;rs887829;TT;Toxicity;increased discontinuation of ⮕ ATAZANAVIR;Genotype TT is associated with increased discontinuation of atazanavir as compared to genotype CC.;  
;PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotypes CT + TT is associated with decreased response to Platinum compounds in people with Colorectal Neoplasms and Stomach Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms, Disease:Stomach Neoplasms
;OLANZAPINE;CHAT;rs1880676;A;Dosage, Efficacy;increased response to ⮕ OLANZAPINE;Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.; in people with Disease:Schizophrenia
;PRAVASTATIN;ABCC2;rs113646094;CG;Metabolism/PK;increased clearance of ⮕ PRAVASTATIN;Genotype CG is associated with increased clearance of pravastatin in healthy individuals as compared to genotype CC.; in healthy individuals 
;RAMIPRIL;ACE;rs4359;CC + TT;Efficacy;increased response to ⮕ RAMIPRIL;Genotypes CC + TT are associated with increased response to ramipril in people with Hypertension as compared to genotype CT.; in people with Disease:Hypertension
;RAMIPRIL;ACE;rs4344;AA + GG;Efficacy;increased response to ⮕ RAMIPRIL;Genotypes AA + GG are associated with increased response to ramipril in people with Hypertension as compared to genotype AG.; in people with Disease:Hypertension
;WARFARIN;CYP4F2;rs2108622;T;Dosage;dose of ⮕ WARFARIN;Allele T is associated with dose of warfarin as compared to allele C.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy;decreased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Glomerulonephritis, Membranous as compared to genotype CC.; in people with Other:Glomerulonephritis, Membranous
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;or in people with Disease:Chronic hepatitis C virus infection
;OXYCODONE;OPRD1;rs581111;AA + AG;Efficacy;decreased response to ⮕ OXYCODONE;Genotypes AA + AG are associated with decreased response to oxycodone as compared to genotype GG.;  
;PEGINTERFERON ALFA-2B, RIBAVIRIN;KLRK1;rs1049174;GG;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype GG is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;and in people with Disease:Chronic hepatitis C virus infection
;CITALOPRAM;CRHR2;rs2270007;CC + CG;Efficacy;decreased response to ⮕ CITALOPRAM;Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.; in people with Disease:Major Depressive Disorder
;RIFAMPIN;NR1I2;rs3732357;AA + AG;Metabolism/PK;decreased exposure to ⮕ RIFAMPIN;Genotypes AA + AG is associated with decreased exposure to rifampin in people with Tuberculosis as compared to genotype GG.; in people with Other:Tuberculosis
;METHOTREXATE;SLC19A1;rs1051266;CT + TT;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.; in children with Other:Osteosarcoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;or in people with Disease:Chronic hepatitis C virus infection
;OXYCODONE;;rs6848893;CT;Efficacy;decreased response to ⮕ OXYCODONE;Genotype CT is associated with decreased response to oxycodone as compared to genotype TT.;  
;PLATINUM COMPOUNDS;ATP7B;rs9535826;G;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Allele G is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele T.; in people with Disease:Lung Neoplasms
;DEXAMETHASONE;NR3C1;rs6198;CC;Efficacy;increased time to response to ⮕ DEXAMETHASONE;Genotype CC is associated with increased time to response to dexamethasone in people with COVID-19 as compared to genotypes CT + TT.; in people with Other:COVID-19
;ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotypes AA + AG is associated with increased response to antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype GG.; in people with Other:Bipolar Disorder, Other:Depression, Other:Major Depressive Disorder
;PLATINUM COMPOUNDS;ATP7B;rs9535828;A;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Allele A is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to allele G.; in people with Disease:Lung Neoplasms
;DEXAMETHASONE;NR3C1;rs33388;AA;Efficacy;increased time to response to ⮕ DEXAMETHASONE;Genotype AA is associated with increased time to response to dexamethasone in people with COVID-19 as compared to genotypes AT + TT.; in people with Other:COVID-19
;RISPERIDONE;CCL2;rs4795893;AA + AG;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.; in people with Disease:Schizophrenia
;RISPERIDONE;CCL2;rs4586;CC + CT;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes CC + CT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype TT.; in people with Disease:Schizophrenia
;ETHANOL;OPRM1;rs1799971;AG + GG;Toxicity;decreased exposure to ⮕ ETHANOL;Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA.; in healthy individuals 
;METHOTREXATE;FPGS;rs1544105;TT;Efficacy;increased response to ⮕ METHOTREXATE;Genotype TT is associated with increased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;ACENOCOUMAROL;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ ACENOCOUMAROL;Allele T is associated with decreased dose of acenocoumarol as compared to allele C.;  
;METHOTREXATE;FPGS;rs1544105;TT;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotype TT is associated with increased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;DEXAMETHASONE;NR3C1;rs33389;TT;Efficacy;increased time to response to ⮕ DEXAMETHASONE;Genotype TT is associated with increased time to response to dexamethasone in people with COVID-19 as compared to genotypes CC + CT.; in people with Other:COVID-19
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs769705621;AAAA;Efficacy;decreased response to ⮕ ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;Allele AAAA is associated with decreased response to atorvastatin, rosuvastatin or simvastatin in people with familial hypercholesterolemia as compared to genotypes A/AA + A/del.;or in people with Other:Familial hypercholesterolemia
;CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;rs1042713;A;Efficacy;decreased response to ⮕ CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG.;and in children with Disease:Asthma
;RISPERIDONE;CCL2;rs2857657;GG;Efficacy;increased response to ⮕ RISPERIDONE;Genotype GG is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CG.; in people with Disease:Schizophrenia
;LAMOTRIGINE;UGT1A4;rs2011425;TT;Efficacy;increased response to ⮕ LAMOTRIGINE;Genotype TT is associated with increased response to lamotrigine in people with Epilepsy as compared to genotypes GG + GT.; in people with Disease:Epilepsy
;MERCAPTOPURINE;ITPA;rs1127354;A;Metabolism/PK;metabolism of ⮕ MERCAPTOPURINE;Allele A is associated with metabolism of mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.; in people with Disease:Acute lymphoblastic leukemia
;LAMOTRIGINE;UGT1A4;rs2011425;TT;Metabolism/PK;increased concentrations of ⮕ LAMOTRIGINE;Genotype TT is associated with increased concentrations of lamotrigine in people with Epilepsy as compared to genotypes GG + GT.; in people with Disease:Epilepsy
;WARFARIN;CYP2C9;rs1057910;C;Dosage;decreased dose of ⮕ WARFARIN;Allele C is associated with decreased dose of warfarin as compared to allele A.;  
;OLANZAPINE;SLC22A1;rs34059508;AG;Metabolism/PK;increased exposure to ⮕ OLANZAPINE;Genotype AG is associated with increased exposure to olanzapine in healthy individuals as compared to genotype GG.; in healthy individuals 
;EFAVIRENZ;CYP2B6;rs28399499;CC;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.; in people with Disease:HIV infectious disease
;NICOTINE;CHRNB3;rs4950;G;Efficacy, Other;increased response to ⮕ NICOTINE;Allele G is associated with increased response to nicotine in smokers as compared to allele A.; in Other:smokers
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;decreased clearance of ⮕ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;PLATINUM COMPOUNDS;HMGB1;rs1412125;CC;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype CC is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotypes CT + TT.; in people with Disease:Lung Neoplasms
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CT + TT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;NICOTINE;CHRNB3;rs13280604;G;Efficacy, Other;increased response to ⮕ NICOTINE;Allele G is associated with increased response to nicotine in smokers as compared to allele A.; in Other:smokers
;WARFARIN;VKORC1;rs749671;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin as compared to allele A.;  
;DEXAMETHASONE;CYP3A4;rs35599367;AG;Efficacy;increased time to response to ⮕ DEXAMETHASONE;Genotype AG is associated with increased time to response to dexamethasone in people with COVID-19 as compared to genotype GG.; in people with Other:COVID-19
;OLANZAPINE;ABCB1;rs3842;T;Metabolism/PK;increased clearance of ⮕ OLANZAPINE;Allele T is associated with increased clearance of olanzapine in healthy individuals as compared to allele C.; in healthy individuals 
;PLATINUM COMPOUNDS;HMGB1;rs2249825;GG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotype GG is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotypes CC + CG.; in people with Disease:Lung Neoplasms
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs2279343;G;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.; in people with Disease:HIV infectious disease
;CISPLATIN, RADIOTHERAPY;XRCC1;rs25487;TT;Efficacy;decreased response to ⮕ CISPLATIN, RADIOTHERAPY;Genotype TT is associated with decreased response to cisplatin and radiotherapy in people with Nasopharyngeal Neoplasms and Tobacco Use Disorder as compared to genotypes CC + CT.;and in people with Disease:Nasopharyngeal Neoplasms, Disease:Tobacco Use Disorder
;LOSARTAN;ACE;rs4291;AT + TT;Efficacy;increased clinical benefit to ⮕ LOSARTAN;Genotypes AT + TT is associated with increased clinical benefit to losartan in people with Hypertension as compared to genotype AA.; in people with Other:Hypertension
;VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;rs699947;AC + CC;Efficacy;increased response to ⮕ VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;Genotypes AC + CC is associated with increased response to VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors in people with Macular Degeneration as compared to genotype AA.; in people with Other:Macular Degeneration
;OXYCODONE;COMT;rs4680;AA + AG;Efficacy;increased response to ⮕ OXYCODONE;Genotypes AA + AG are associated with increased response to oxycodone as compared to genotype GG.;  
;ADALIMUMAB, INFLIXIMAB;IL12B;rs2546890;AA + AG;Efficacy;increased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotypes AA + AG is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype GG.;or in people with Disease:Psoriasis
;TACROLIMUS;CYP3A4;rs2740574;T;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Allele T is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation
;ADALIMUMAB, INFLIXIMAB;IVL;rs6661932;CT + TT;Efficacy;decreased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotypes CT + TT is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype CC.;or in people with Disease:Psoriasis
;OPIOIDS;COMT;rs4680;AA + AG;Dosage;increased dose of ⮕ OPIOIDS;Genotypes AA + AG is associated with increased dose of opioids in people with Pain as compared to genotype GG.; in people with Other:Pain
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin as compared to allele C.;  
;USTEKINUMAB;TIRAP;rs8177374;CT + TT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes CT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;NICOTINE;OPRM1;rs1799971;AG + GG;Other;increased exposure to ⮕ NICOTINE;Genotypes AG + GG are associated with increased exposure to nicotine in people with Schizophrenia as compared to genotype AA.; in people with Other:Schizophrenia
;USTEKINUMAB;TLR5;rs5744174;AG + GG;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;rs11465996;CG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;RIVAROXABAN;BRD3;rs467387;AA;PD;increased response to ⮕ RIVAROXABAN;Genotype AA is associated with increased response to rivaroxaban in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;AT + TT;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AT + TT is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.; in people with Disease:Psoriasis
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Allele C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143623;CG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype CC.;or in people with Disease:Psoriasis
;WARFARIN;ABCB1;rs1045642;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin as compared to allele G.;  
;WARFARIN;APOE;rs429358;CC + CT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT.;  
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143627;AG + GG;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA.;or in people with Disease:Psoriasis
;REPAGLINIDE;NR1I2;rs2276706;GG;Metabolism/PK;decreased metabolism of ⮕ REPAGLINIDE;Genotype GG is associated with decreased metabolism of repaglinide in men as compared to genotype AA.; in men 
;COTININE;OPRM1;rs510769;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;RISPERIDONE;COMT;rs9606186;C;Efficacy;decreased response to ⮕ RISPERIDONE;Allele C is associated with decreased response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;REPAGLINIDE;NR1I2;rs3814058;CC;Metabolism/PK;decreased metabolism of ⮕ REPAGLINIDE;Genotype CC is associated with decreased metabolism of repaglinide in men as compared to genotype TT.; in men 
;ATEZOLIZUMAB, BEVACIZUMAB;IL7;rs16906115;AA;Efficacy;decreased clinical benefit to ⮕ ATEZOLIZUMAB, BEVACIZUMAB;Genotype AA is associated with decreased clinical benefit to atezolizumab and bevacizumab in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.;and in people with Other:Hepatocellular Carcinoma
;COTININE;OPRM1;rs12209447;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;RISPERIDONE;COMT;rs2020917;C;Efficacy;decreased response to ⮕ RISPERIDONE;Allele C is associated with decreased response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;COTININE;OPRM1;rs3798676;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;WARFARIN;VKORC1;rs2359612;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin as compared to allele G.;  
;FENTANYL;ABCB1;rs1045642;AA;Dosage;decreased dose of ⮕ FENTANYL;Genotype AA is associated with decreased dose of fentanyl in children as compared to genotypes AG + GG.; in children 
;RISPERIDONE;COMT;rs933271;C;Efficacy;decreased response to ⮕ RISPERIDONE;Allele C is associated with decreased response to risperidone in people with Schizophrenia.; in people with Disease:Schizophrenia
;COTININE;OPRM1;rs553202;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs1074287;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.; in people with Disease:Heroin Dependence
;METHADONE;OPRD1;rs529520;AA + AC;Dosage;increased dose of ⮕ METHADONE;Genotypes AA + AC is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC.; in people with Disease:Heroin Dependence
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype CC is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;and in people with Disease:Hepatitis C virus infection
;COTININE;OPRM1;rs1799971;A;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele A is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs6912029;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G.; in people with Disease:Heroin Dependence
;PREDNISONE;EDNRA;rs5333;CC + CT;Efficacy;increased resistance to ⮕ PREDNISONE;Genotypes CC + CT is associated with increased resistance to prednisone in children with Nephrotic Syndrome as compared to genotype TT.; in children with Disease:Nephrotic Syndrome
;REPAGLINIDE;NR1I2;rs3814058;CC;Metabolism/PK;increased metabolism of ⮕ REPAGLINIDE;Genotype CC is associated with increased metabolism of repaglinide in men as compared to genotype TT.; in men 
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;TLR4;rs1927907;CC;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.; in people with Disease:Liver transplantation
;PAZOPANIB;NR1I2;rs3814055;T;Efficacy;decreased response to ⮕ PAZOPANIB;Allele T is associated with decreased response to pazopanib in people with Carcinoma, Renal Cell as compared to allele C.; in people with Disease:Renal Cell Carcinoma
;ACENOCOUMAROL;CYP4F2;rs2108622;T;Dosage;increased dose of ⮕ ACENOCOUMAROL;Allele T is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele C.; in people with Disease:Atrial Fibrillation
;ADALIMUMAB, INFLIXIMAB;ZNF816;rs9304742;CC + CT;Efficacy;increased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotypes CC + CT is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype TT.;or in people with Disease:Psoriasis
;ACENOCOUMAROL;CALU;rs1043550;G;Dosage;increased dose of ⮕ ACENOCOUMAROL;Allele G is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele A.; in people with Disease:Atrial Fibrillation
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.; in children with Disease:HIV infectious disease
;TACROLIMUS;IL18;rs1946518;GG + GT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes GG + GT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Disease:Kidney Transplantation
;ADALIMUMAB, INFLIXIMAB;NFKBIA;rs2145623;CC + CG;Efficacy;decreased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotypes CC + CG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype GG.;or in people with Disease:Psoriasis
;ADALIMUMAB, INFLIXIMAB;TNFRSF1B;rs1061624;AG + GG;Efficacy;decreased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotypes AG + GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotype AA.;or in people with Disease:Psoriasis
;REPAGLINIDE;NR1I2;rs2276706;GG;Metabolism/PK;increased metabolism of ⮕ REPAGLINIDE;Genotype GG is associated with increased metabolism of repaglinide in men as compared to genotype AA.; in men 
;ADALIMUMAB, INFLIXIMAB;SLC9A8;rs645544;GG;Efficacy;decreased response to ⮕ ADALIMUMAB, INFLIXIMAB;Genotype GG is associated with decreased response to adalimumab or infliximab in people with Psoriasis as compared to genotypes AA + AG.;or in people with Disease:Psoriasis
;FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs10040363;G;Efficacy;decreased response to ⮕ FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;Allele G is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele A.;and in people with Disease:Stomach Neoplasms
;FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs2075685;T;Efficacy;decreased response to ⮕ FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;Allele T is associated with decreased response to fluorouracil, Platinum compounds and radiotherapy in people with Stomach Neoplasms as compared to allele G.;and in people with Disease:Stomach Neoplasms
;MYCOPHENOLIC ACID;SLCO1B1;rs4149056;TT;Metabolism/PK;increased exposure to ⮕ MYCOPHENOLIC ACID;Genotype TT is associated with increased exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotype CT.; in people with Other:Kidney Transplantation
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ HMG COA REDUCTASE INHIBITORS;Genotype TT is associated with increased response to hmg coa reductase inhibitors as compared to genotypes CC + CT.;  
;FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;ERCC1;rs2298881;A;Efficacy;increased response to ⮕ FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;Allele A is associated with increased response to fluorouracil, Platinum compounds or radiotherapy in people with Stomach Neoplasms as compared to allele C.;or in people with Disease:Stomach Neoplasms
;COTININE;OPRM1;rs563649;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs2075572;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;SIMVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ SIMVASTATIN;Genotype TT is associated with increased response to simvastatin as compared to genotype CT.;  
;COTININE;OPRM1;rs7748401;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele T.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs495491;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs10457090;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.; in people with Disease:Heroin Dependence
;COTININE;OPRM1;rs3778152;G;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A.; in people with Disease:Heroin Dependence
;PRAVASTATIN;SLCO1B1;rs4149056;TT;Efficacy;increased response to ⮕ PRAVASTATIN;Genotype TT is associated with increased response to pravastatin as compared to genotype CC.;  
;COTININE;OPRM1;rs589046;T;Metabolism/PK;increased concentrations of ⮕ COTININE;Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C.; in people with Disease:Heroin Dependence
;METHOTREXATE;NR1I2;rs3814055;T;Metabolism/PK;decreased metabolism of ⮕ METHOTREXATE;Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele C.; in children with Disease:Osteosarcoma
;METHOTREXATE;SLCO1B1;rs2306283;AA + AG;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotypes AA + AG are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.; in children with Other:Acute lymphoblastic leukemia
;METHOTREXATE;ABCC3;rs4793665;C;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Allele C is associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to allele T.; in children with Disease:Osteosarcoma
;METHOTREXATE;NR1I2;rs7643038;G;Metabolism/PK;decreased metabolism of ⮕ METHOTREXATE;Allele G is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele A.; in children with Disease:Osteosarcoma
;METHOTREXATE;ABCB1;rs9282564;C;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T.; in children with 
;METHOTREXATE;ABCG2;rs2231142;T;Metabolism/PK;decreased metabolism of ⮕ METHOTREXATE;Allele T is associated with decreased metabolism of methotrexate in children with Osteosarcoma as compared to allele G.; in children with Disease:Osteosarcoma
;GLUCOCORTICOIDS;;rs17446593;AA;Efficacy;increased clinical benefit to ⮕ GLUCOCORTICOIDS;Genotype AA is associated with increased clinical benefit to glucocorticoids in children with Thrombocytopenia as compared to genotypes AG + GG.; in children with Other:Thrombocytopenia
;DABIGATRAN GLUCURONIDE;UGT2B15;rs1902023;AA;Metabolism/PK;decreased concentrations of ⮕ DABIGATRAN GLUCURONIDE;Genotype AA is associated with decreased concentrations of dabigatran glucuronide in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;SUNITINIB;CYP3A5;rs776746;CC;Metabolism/PK;decreased clearance of ⮕ SUNITINIB;Genotype CC is associated with decreased clearance of sunitinib as compared to genotypes CT + TT.;  
;CLOZAPINE;NTRK2;rs10465180;CC;Efficacy;decreased response to ⮕ CLOZAPINE;Genotype CC is associated with decreased response to clozapine in people with Schizophrenia as compared to genotypes CT + TT.; in people with Disease:Schizophrenia
;WARFARIN;CYP2C9;rs9332238;G;Dosage;increased dose of ⮕ WARFARIN;Allele G is associated with increased dose of warfarin as compared to allele A.;  
;CLOPIDOGREL;P2RY12;rs6809699;AA + AC;Efficacy;increased resistance to ⮕ CLOPIDOGREL;Genotypes AA + AC is associated with increased resistance to clopidogrel in people with Coronary Disease as compared to genotype CC.; in people with Other:Coronary Disease
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased concentrations of ⮕ EFAVIRENZ;Allele T is associated with increased concentrations of efavirenz in women with HIV Infections as compared to allele G.; in women with Other:HIV infectious disease
;DOXORUBICIN;CBR1;rs20572;CC;Metabolism/PK;decreased concentrations of ⮕ DOXORUBICIN;Genotype CC is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype CT.; in people with Disease:Breast Neoplasms
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;rs1800544;CG;Efficacy;increased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Genotype CG is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CC + GG.; in people with Disease:Major Depressive Disorder
;ERLOTINIB;ABCB1;rs1045642;AA;Toxicity, Metabolism/PK;decreased clearance of ⮕ ERLOTINIB;Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.; in people with Disease:Non-Small Cell Lung Carcinoma
;ERLOTINIB;ABCB1;rs1128503;AA;Toxicity, Metabolism/PK;decreased clearance of ⮕ ERLOTINIB;Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.; in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;ABCC1;rs28364006;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.; in people with Disease:Psoriasis
;DOLUTEGRAVIR;NR1I2;rs2472677;TT;Metabolism/PK;increased concentrations of ⮕ DOLUTEGRAVIR;Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes CC + CT.; in people with Other:HIV infectious disease
;ERLOTINIB;ABCB1;rs2032582;AA;Toxicity, Metabolism/PK;decreased clearance of ⮕ ERLOTINIB;Genotype AA is associated with decreased clearance of erlotinib in people with Carcinoma, Non-Small-Cell Lung.; in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;LOSARTAN;AGTR1;rs5186;CC;Efficacy;decreased response to ⮕ LOSARTAN;Genotype CC is associated with decreased response to losartan in people with Essential hypertension as compared to genotype AA.; in people with Disease:Essential hypertension
;CLOPIDOGREL;KDR;rs2305948;T;Efficacy;decreased response to ⮕ CLOPIDOGREL;Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C.; in people with Disease:Coronary Disease
;LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;Dosage;increased dose of ⮕ LAMOTRIGINE;Genotypes CT + TT are associated with increased dose of lamotrigine in people with Epilepsy as compared to genotype CC.; in people with Other:Epilepsy
;MERCAPTOPURINE;NUDT15;rs73189762;T;Dosage;decreased dose of ⮕ MERCAPTOPURINE;Allele T is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.; in children with Other:Acute lymphoblastic leukemia
;METFORMIN;ARFGEF3;rs143276236;AC;Efficacy;decreased clinical benefit to ⮕ METFORMIN;Genotype AC is associated with decreased clinical benefit to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Other:Diabetes Mellitus, Type 2
;TRASTUZUMAB;ERBB2;rs1136201;G;Toxicity;response to ⮕ TRASTUZUMAB;Allele G is associated with response to trastuzumab.;  
;DOXORUBICIN;CBR1;rs9024;GG;Metabolism/PK;increased clearance of ⮕ DOXORUBICIN;Genotype GG is associated with increased clearance of doxorubicin in people with Breast Neoplasms as compared to genotype AG.; in people with Disease:Breast Neoplasms
;METFORMIN;PRKAB2;rs7541245;A;Efficacy;decreased response to ⮕ METFORMIN;Allele A is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.; in people with Other:Diabetes Mellitus, Type 2
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Dosage;decreased dose of ⮕ AZATHIOPRINE;Genotypes CT + TT are associated with decreased dose of azathioprine in people with Inflammatory Bowel Diseases and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.; in people with Disease:Inflammatory Bowel Diseases, Disease:Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ TACROLIMUS;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;TACROLIMUS;POR;rs1057868;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;DOXORUBICIN;CBR1;rs9024;GG;Metabolism/PK;decreased concentrations of ⮕ DOXORUBICIN;Genotype GG is associated with decreased concentrations of doxorubicin in people with Breast Neoplasms as compared to genotype AG.; in people with Disease:Breast Neoplasms
;DOXORUBICIN;CBR1;rs9024;GG;Metabolism/PK;decreased exposure to ⮕ DOXORUBICIN;Genotype GG is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype AG.; in people with Disease:Breast Neoplasms
;PRAMIPEXOLE;DRD3;rs6280;T;Efficacy;increased response to ⮕ PRAMIPEXOLE;Allele T is associated with increased response to pramipexole.;  
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT.;  
;WARFARIN;VKORC1;rs7196161;GG;Dosage;decreased dose of ⮕ WARFARIN;Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG.;  
;ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;rs948854;C;Efficacy;decreased response to ⮕ ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Allele C is associated with decreased response to antidepressants, benzodiazepine derivatives, mirtazapine or Selective serotonin reuptake inhibitors in women Depressive Disorder, Major as compared to allele T.;or in women Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;decreased dose of ⮕ TACROLIMUS;Genotype CC is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9934438;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.;  
;SUFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ SUFENTANIL;Genotypes AG + GG is associated with increased dose of sufentanil in people with Pregnancy as compared to genotype AA.; in people with Other:Pregnancy
;WARFARIN;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin as compared to genotypes CT + TT.;  
;TACROLIMUS;CYP3A5;rs41303343;A;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Allele A is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele del.; in people with Disease:Kidney Transplantation
;METFORMIN;SLC22A1;rs628031;GG;Efficacy;increased response to ⮕ METFORMIN;Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.; in people with Other:Diabetes Mellitus, Type 2
;TACROLIMUS;CYP3A5;rs10264272;T;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Allele T is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele C.; in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs2884737;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin as compared to genotype AC.;  
;WARFARIN;VKORC1;rs61742245;A;Dosage;increased dose of ⮕ WARFARIN;Allele A is associated with increased dose of warfarin as compared to allele C.;  
;TACROLIMUS;CYP3A5;rs776746;C;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Allele C is associated with decreased clearance of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Disease:Kidney Transplantation
;MYCOPHENOLIC ACID;ABCC2;rs717620;CC;Metabolism/PK;increased exposure to ⮕ MYCOPHENOLIC ACID;Genotype CC is associated with increased exposure to mycophenolic acid in people with Kidney Transplantation as compared to genotypes CT + TT.; in people with Other:Kidney Transplantation
;WARFARIN;PRSS53, VKORC1;rs2359612;A;Dosage;decreased dose of ⮕ WARFARIN;Allele A is associated with decreased dose of warfarin.;  
;CAFFEINE;CYP1A2;rs762551;AA;Other, Metabolism/PK;increased metabolism of ⮕ CAFFEINE;Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC.; in people with Disease:Tobacco Use Disorder
;DOXORUBICIN;CBR1;rs20572;CC;Metabolism/PK;decreased exposure to ⮕ DOXORUBICIN;Genotype CC is associated with decreased exposure to doxorubicin in people with Breast Neoplasms as compared to genotype CT.; in people with Disease:Breast Neoplasms
;WARFARIN;GGCX;rs11676382;CG;Dosage;decreased dose of ⮕ WARFARIN;Genotype CG is associated with decreased dose of warfarin as compared to genotype CC.;  
;CAFFEINE;CYP1A2;rs762551;AA;Other, Metabolism/PK;increased metabolism of ⮕ CAFFEINE;Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC.; in people with Other:heavy coffee consumption
;TICAGRELOR;PEAR1;rs4661012;GT + TT;Efficacy;decreased response to ⮕ TICAGRELOR;Genotypes GT + TT is associated with decreased response to ticagrelor in healthy individuals as compared to genotype GG.; in healthy individuals 
;METHOTREXATE;ATIC;rs2372536;GG;Efficacy;decreased response to ⮕ METHOTREXATE;Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.; in people with Other:Rheumatoid arthritis
;TACROLIMUS;CYP3A4;rs35599367;AA + AG;Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotypes AA + AG is associated with decreased clearance of tacrolimus in children with liver transplantation as compared to genotype GG.; in children with Other:Liver transplantation
;TICAGRELOR;PEAR1;rs12566888;TT;Efficacy;increased response to ⮕ TICAGRELOR;Genotype TT is associated with increased response to ticagrelor in healthy individuals as compared to genotype GT.; in healthy individuals 
;TACROLIMUS;CYP3A4;rs2740574;C;Metabolism/PK;decreased concentrations of ⮕ TACROLIMUS;Allele C is associated with decreased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele T.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs35599367;A;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Allele A is associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to allele G.; in people with Other:Kidney Transplantation
;TICAGRELOR;PEAR1;rs12041331;AA;Efficacy;increased response to ⮕ TICAGRELOR;Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotype GG.; in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased clearance of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased clearance of tacrolimus in children with liver transplantation as compared to genotype CC.; in children with Other:Liver transplantation
;TICAGRELOR;PEAR1;rs12041331;AA;Efficacy;increased response to ⮕ TICAGRELOR;Genotype AA is associated with increased response to ticagrelor in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin.;  
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;increased concentrations of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;WARFARIN;PRSS53, VKORC1;rs7294;T;Dosage;increased dose of ⮕ WARFARIN;Allele T is associated with increased dose of warfarin as compared to allele C.;  
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotype GG.; in people with Other:Spondylitis, Ankylosing
;RITUXIMAB;FCGR3A;rs396991;AA;Efficacy;decreased response to ⮕ RITUXIMAB;Genotype AA is associated with decreased response to rituximab in people with Neuromyelitis Optica as compared to genotype CC.; in people with Disease:Neuromyelitis Optica
;PREDNISOLONE;CD40;rs1883832;CC;Efficacy;decreased clinical benefit to ⮕ PREDNISOLONE;Genotype CC is associated with decreased clinical benefit to prednisolone in children with Thrombocytopenia as compared to genotypes CT + TT.; in children with Other:Thrombocytopenia
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased metabolism of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased metabolism of tacrolimus in children with liver transplantation as compared to genotype CC.; in children with Other:Liver transplantation
;METFORMIN;SLC47A1;rs2289669;AA;Efficacy;increased response to ⮕ METFORMIN;Genotype AA is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AG + GG.; in people with Disease:Diabetes Mellitus, Type 2
;ERENUMAB;CALCRL;rs6710852;G;Efficacy;increased clinical benefit to ⮕ ERENUMAB;Allele G is associated with increased clinical benefit to erenumab in people with Migraine with Aura or Migraine without Aura as compared to allele T.; in people with Other:Migraine with Aura, Other:Migraine without Aura
;TACROLIMUS;ABCB1;rs2032582;AA + TT;Dosage, Metabolism/PK;decreased clearance of ⮕ TACROLIMUS;Genotypes AA + TT is associated with decreased clearance of tacrolimus in children with liver transplantation.; in children with Other:Liver transplantation
;WARFARIN;VKORC1;rs7294;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT.;  
;HALOTHANE;RYR1;rs118192161;T;Other;increased response to ⮕ HALOTHANE;Allele T is associated with increased response to halothane as compared to allele C.;  
;WARFARIN;VKORC1;rs8050894;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin as compared to genotypes CG + GG.;  
;WARFARIN;VKORC1;rs2359612;GG;Dosage;increased dose of ⮕ WARFARIN;Genotype GG is associated with increased dose of warfarin as compared to genotypes AA + AG.;  
;2-HYDROXYATORVASTATIN;CYP3A4;rs35599367;AG;Metabolism/PK;decreased concentrations of ⮕ 2-HYDROXYATORVASTATIN;Genotype AG is associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Spondylitis, Ankylosing as compared to genotype GG.; in people with Other:Spondylitis, Ankylosing
;BETA BLOCKING AGENTS, SELECTIVE;BST1;rs28404156;A;Efficacy;increased response to ⮕ BETA BLOCKING AGENTS, SELECTIVE;Allele A is associated with increased response to Beta blocking agents, selective in people with Hypertension as compared to allele G.; in people with Other:Hypertension
;TAMOXIFEN;CYP19A1;rs4646;AA;Efficacy;decreased response to ⮕ TAMOXIFEN;Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.; in women with Disease:Breast Neoplasms, Disease:Menopause
;BISPHOSPHONATES;FDPS;rs2297480;T;Efficacy;increased response to ⮕ BISPHOSPHONATES;Allele T is associated with increased response to Bisphosphonates in people with Osteoporosis as compared to allele G.; in people with Disease:Osteoporosis
;SIMVASTATIN;CETP;rs5882;A;Efficacy;increased response to ⮕ SIMVASTATIN;Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to allele G.; in people with Disease:Hypercholesterolemia
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;rs405509;TT;Efficacy;increased response to ⮕ SELECTIVE SEROTONIN REUPTAKE INHIBITORS;Genotype TT is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes GG + GT.; in people with Other:Major Depressive Disorder
;METHOTREXATE;ABCG2;rs17731538;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in people with Psoriasis as compared to genotype AG.; in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele C is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele T.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases, Disease:Psoriasis, Disease:Spondylarthropathies
;CYCLOSPORINE;UMOD;rs12917707;GT + TT;Efficacy;increased response to ⮕ CYCLOSPORINE;Genotypes GT + TT is associated with increased response to cyclosporine in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;MODAFINIL;ABCB1;rs2032582;AC + CT;Efficacy;increased response to ⮕ MODAFINIL;Genotypes AC + CT is associated with increased response to modafinil in people with Narcolepsy as compared to genotype CC.; in people with Disease:Narcolepsy
;MODAFINIL;ABCB1;rs1045642;AG;Efficacy;increased response to ⮕ MODAFINIL;Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.; in people with Disease:Narcolepsy
;WARFARIN;MYC;rs4645962;CT;Dosage;decreased dose of ⮕ WARFARIN;Genotype CT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.; in people with Disease:Heart valve replacement
;WARFARIN;MYC;rs4645943;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype CC.; in people with Disease:Heart valve replacement
;CARBAMAZEPINE;EPHX1;rs2234922;G;Dosage, Metabolism/PK;decreased metabolism of ⮕ CARBAMAZEPINE;Allele G is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to allele A.; in people with Disease:Epilepsy
;MODAFINIL;ABCB1;rs1128503;AG;Efficacy;increased response to ⮕ MODAFINIL;Genotype AG is associated with increased response to modafinil in people with Narcolepsy as compared to genotypes AA + GG.; in people with Disease:Narcolepsy
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis and Spondylarthropathies as compared to allele A.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases, Disease:Psoriasis, Disease:Spondylarthropathies
;BISPHOSPHONATES;FDPS;rs11264359;A;Efficacy;increased response to ⮕ BISPHOSPHONATES;Allele A is associated with increased response to Bisphosphonates in people with Osteoporosis as compared to allele G.; in people with Disease:Osteoporosis
;WARFARIN;MYC;rs4645974;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.; in people with Disease:Heart valve replacement
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;Efficacy;increased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A.; in people with Disease:Crohn Disease, Disease:Inflammatory Bowel Diseases, Disease:Psoriasis, Disease:Spondylarthropathies
;ATORVASTATIN, SIMVASTATIN;ABCC2;rs717620;T;Efficacy;decreased dose of ⮕ ATORVASTATIN, SIMVASTATIN;Allele T is associated with decreased dose of atorvastatin and simvastatin.;and  
;LEFLUNOMIDE;DHODH;rs3213422;CC;Efficacy;increased clinical benefit to ⮕ LEFLUNOMIDE;Genotype CC is associated with increased clinical benefit to leflunomide in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.; in people with Other:Rheumatoid arthritis
;ANTIPSYCHOTICS;DRD2;rs1799732;G;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Allele G is associated with increased resistance to antipsychotics in people with Mood Disorders or Schizophrenia as compared to allele del.; in people with Other:Mood Disorder, Other:Schizophrenia
;IMATINIB;SLC22A4;rs1050152;TT;Efficacy;decreased response to ⮕ IMATINIB;Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;RISPERIDONE;HTR2A;rs6313;AA + AG;Efficacy;increased response to ⮕ RISPERIDONE;Genotypes AA + AG are associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG.; in people with Other:Schizophrenia
;ANTIPSYCHOTICS;HTR2A;rs7997012;AG;Efficacy;increased resistance to ⮕ ANTIPSYCHOTICS;Genotype AG is associated with increased resistance to antipsychotics in people with Mood Disorders or Schizophrenia as compared to genotypes AA + GG.; in people with Other:Mood Disorder, Other:Schizophrenia
;METHADONE;CYP2B6;rs3745274;TT;Dosage, Metabolism/PK;decreased dose of ⮕ METHADONE;Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.; in people with Disease:Heroin Dependence
;METHADONE;ABCB1;rs1045642;AA + AG;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotypes AA + AG is associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype GG (assigned as normal metabolizer phenotype) .; in people with Other:Opioid-Related Disorders
;OLANZAPINE;HTR2A;rs6313;AG + GG;Efficacy;increased response to ⮕ OLANZAPINE;Genotypes AG + GG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype AA.; in people with Other:Schizophrenia
;OLANZAPINE;HTR2A;rs6313;AA + AG;Efficacy;increased response to ⮕ OLANZAPINE;Genotypes AA + AG are associated with increased response to olanzapine in people with Schizophrenia as compared to genotype GG.; in people with Other:Schizophrenia
;CARBAMAZEPINE;EPHX1;rs1051740;CC;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.; in people with Disease:Epilepsy
;EFAVIRENZ;CYP2B6;rs3745274;GG;Metabolism/PK;increased clearance of ⮕ EFAVIRENZ;Genotype GG is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotypes GT + TT.; in people with Disease:HIV infectious disease
;CARBAMAZEPINE;EPHX1;rs2234922;GG;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.; in people with Disease:Epilepsy
;AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;Toxicity, Metabolism/PK;increased metabolism of ⮕ AZATHIOPRINE, MERCAPTOPURINE;Genotypes AC + CC is associated with increased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;or in people with Disease:Inflammatory Bowel Diseases, Disease:Acute lymphoblastic leukemia
;IMATINIB;ABCB1;rs1045642;AA + AG;Efficacy;decreased response to ⮕ IMATINIB;Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;IMATINIB;SLC22A4;rs1050152;TT;Efficacy;decreased response to ⮕ IMATINIB;Genotype TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.; in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage, Metabolism/PK;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT are associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype CC.; in people with Disease:Kidney Transplantation
;ETHANOL;OPRM1;rs3778150;CC + CT;;decreased response to ⮕ ETHANOL;Genotypes CC + CT are associated with decreased response to ethanol as compared to genotype TT.;  
;CARBAMAZEPINE;ABCB1;rs1045642;AG;Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype AG is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.; in people with Disease:Epilepsy
;ANTIEPILEPTICS;ABCB1;rs1045642;AG;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotype AG is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;RALOXIFENE;COMT;rs737865;AG;Efficacy;increased clinical benefit to ⮕ RALOXIFENE;Genotype AG is associated with increased clinical benefit to raloxifene in men with Schizophrenia or Schizoaffective disorder as compared to genotype AA.; in men with Other:Schizophrenia, Other:Schizoaffective disorder
;PACLITAXEL;ABCC2;rs717620;CT;Toxicity;decreased dose of ⮕ PACLITAXEL;Genotype CT is associated with decreased dose of paclitaxel in people with Peripheral Nervous System Diseases as compared to genotype CC.; in people with Side Effect:Peripheral Nervous System Diseases
;RALOXIFENE;COMT;rs737865;AA;Efficacy;increased clinical benefit to ⮕ RALOXIFENE;Genotype AA is associated with increased clinical benefit to raloxifene in men with Schizophrenia or Schizoaffective disorder as compared to genotype AG.; in men with Other:Schizophrenia, Other:Schizoaffective disorder
;BUPRENORPHINE;OPRD1;rs678849;CT + TT;Efficacy;increased response to ⮕ BUPRENORPHINE;Genotypes CT + TT are associated with increased response to buprenorphine in people with Opioid-Related Disorders as compared to genotype CC.; in people with Other:Opioid-Related Disorders
;METHADONE;ABCB1;rs2032582;AC;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype AC is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + CC.; in men with Disease:Opioid-Related Disorders
;ETHANOL;OPRM1;rs1799971;AG + GG;Other;increased exposure to ⮕ ETHANOL;Genotypes AG + GG are associated with increased exposure to ethanol as compared to genotype AA.;  
;ANTIEPILEPTICS;ABCB1;rs1045642;AA;Efficacy;increased resistance to ⮕ ANTIEPILEPTICS;Genotype AA is associated with increased resistance to antiepileptics in people with Epilepsy as compared to genotype GG.; in people with Disease:Epilepsy
;RISPERIDONE;TNIK;rs7627954;CC;Efficacy;increased response to ⮕ RISPERIDONE;Genotype CC is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CT + TT.; in people with Other:Schizophrenia
;RALOXIFENE;COMT;rs4818;CG;Efficacy;increased clinical benefit to ⮕ RALOXIFENE;Genotype CG is associated with increased clinical benefit to raloxifene in people with Schizophrenia or Schizoaffective disorder as compared to genotype CC.; in people with Other:Schizophrenia, Other:Schizoaffective disorder
;METHADONE;CYP3A4;rs35599367;AG;Metabolism/PK;decreased clearance of ⮕ METHADONE;Genotype AG is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to genotype GG.; in people with Disease:Opioid-Related Disorders
;SUNITINIB;ABCB1;rs2032582;AA + AT;Dosage, Toxicity;increased dose of ⮕ SUNITINIB;Genotypes AA + AT is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.; in people with Disease:Renal Cell Carcinoma
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CT + TT is associated with increased dose of tacrolimus in people with Lupus Erythematosus, Systemic as compared to genotype CC.; in people with Other:Systemic lupus erythematosus
;ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;AG + GG;Efficacy;increased response to ⮕ ADALIMUMAB, ETANERCEPT, INFLIXIMAB;Genotypes AG + GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotype AA.;or in people with Disease:Rheumatoid arthritis
;SUNITINIB;ABCB1;rs1128503;AA;Dosage, Toxicity;increased dose of ⮕ SUNITINIB;Genotype AA is associated with increased dose of sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.; in people with Disease:Renal Cell Carcinoma
;METHADONE;ABCB1;rs1045642;AA;Metabolism/PK;increased clearance of ⮕ METHADONE;Genotype AA is associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Disease:Opioid-Related Disorders
;METHADONE;ABCB1;rs1128503;AG;Metabolism/PK;increased concentrations of ⮕ METHADONE;Genotype AG is associated with increased concentrations of methadone in men with Opioid-Related Disorders as compared to genotypes AA + GG.; in men with Disease:Opioid-Related Disorders
;METHADONE;POR;rs1057868;CT + TT;Metabolism/PK;increased clearance of ⮕ METHADONE;Genotypes CT + TT are associated with increased clearance of methadone in people with Opioid-Related Disorders as compared to genotype CC.; in people with Disease:Opioid-Related Disorders
;METHADONE;CYP2B6;rs2279343;AA;Dosage;increased dose of ⮕ METHADONE;Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG.; in people with Other:Heroin Dependence
;DOLUTEGRAVIR;ABCG2;rs2231142;TT;Metabolism/PK;increased concentrations of ⮕ DOLUTEGRAVIR;Genotype TT is associated with increased concentrations of dolutegravir in people with HIV Infections as compared to genotypes GG + GT.; in people with Other:HIV infectious disease
;METHADONE;CYP2B6;rs3745274;GG;Dosage;increased dose of ⮕ METHADONE;Genotype GG is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes GT + TT.; in people with Other:Heroin Dependence
;PREDNISOLONE;TLR4;rs4986791;T;Efficacy;decreased clinical benefit to ⮕ PREDNISOLONE;Allele T is associated with decreased clinical benefit to prednisolone in children with Thrombocytopenia as compared to allele C.; in children with Other:Thrombocytopenia
;PERAMPANEL;CYP3A4;rs4986908;CG;Efficacy;decreased clinical benefit to ⮕ PERAMPANEL;Genotype CG is associated with decreased clinical benefit to perampanel in children with Epilepsy as compared to genotype CC.; in children with Other:Epilepsy
;TELBIVUDINE;TK2;rs3826160;CC + CT;Metabolism/PK;increased concentrations of ⮕ TELBIVUDINE;Genotypes CC + CT is associated with increased concentrations of telbivudine in people with Hepatitis B, Chronic as compared to genotype TT.; in people with Other:Hepatitis B, Chronic
;WARFARIN;EPHX1;rs1877724;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin as compared to genotypes CC + CT.;  
;NEVIRAPINE;CYP2B6;rs3745274;TT;Toxicity, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotype TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;ETHANOL;OPRM1;rs3778150;CC + CT;Dosage;increased dose of ⮕ ETHANOL;Genotypes CC + CT are associated with increased dose of ethanol as compared to genotype TT.;  
;OLANZAPINE;GSTP1;rs1695;AA;Metabolism/PK;increased clearance of ⮕ OLANZAPINE;Genotype AA is associated with increased clearance of olanzapine in healthy individuals as compared to genotypes AG + GG.; in healthy individuals 
;CEFOTAXIME;SLC22A8;rs11568482;AT;Metabolism/PK;decreased clearance of ⮕ CEFOTAXIME;Genotype AT is associated with decreased clearance of cefotaxime in healthy individuals as compared to genotype TT.; in healthy individuals 
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in children as compared to genotype CT.; in children 
;ESCITALOPRAM;CYP2C18;rs11188059;G;Metabolism/PK;decreased concentrations of ⮕ ESCITALOPRAM;Allele G is associated with decreased concentrations of escitalopram as compared to allele A.;  
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;rs6720975;T;Efficacy;increased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.;and in people with Other:Alzheimer Disease
;ESCITALOPRAM;CYP2C18;rs2860840;T;Metabolism/PK;decreased concentrations of ⮕ ESCITALOPRAM;Allele T is associated with decreased concentrations of escitalopram as compared to allele C.;  
;EFAVIRENZ;CYP2B6;rs2279345;TT;Metabolism/PK;decreased metabolism of ⮕ EFAVIRENZ;Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CC.; in people with Disease:HIV infectious disease
;PERAMPANEL;CYP3A4;rs2242480;CT + TT;Efficacy;decreased clinical benefit to ⮕ PERAMPANEL;Genotypes CT + TT is associated with decreased clinical benefit to perampanel in children with Epilepsy as compared to genotype CC.; in children with Other:Epilepsy
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;;rs17798800;T;Efficacy;decreased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C.;and in people with Disease:Alzheimer Disease
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased dose of ⮕ WARFARIN;Allele T is associated with decreased dose of warfarin in children as compared to allele C.; in children 
;PREDNISOLONE;TLR4;rs4986790;G;Efficacy;decreased clinical benefit to ⮕ PREDNISOLONE;Allele G is associated with decreased clinical benefit to prednisolone in children with Thrombocytopenia as compared to allele A.; in children with Other:Thrombocytopenia
;METHADONE;ABCB1;rs2032582;CC;Dosage;decreased dose of ⮕ METHADONE;Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC.; in people with Other:Heroin Dependence
;METHADONE;ABCB1;rs1045642;AA;Dosage, Metabolism/PK;increased dose of ⮕ METHADONE;Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.; in people with Disease:Heroin Dependence
;SN-38;ABCB1;rs12720066;AC + CC;Metabolism/PK;decreased exposure to ⮕ SN-38;Genotypes AC + CC are associated with decreased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.; in people with Disease:Colorectal Neoplasms
;ANTIPSYCHOTICS;GABRB1;rs4627835;T;Dosage;increased dose of ⮕ ANTIPSYCHOTICS;Allele T is associated with increased dose of antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to allele A.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;ANTIPSYCHOTICS;GABRB1;rs16860087;A;Dosage;increased dose of ⮕ ANTIPSYCHOTICS;Allele A is associated with increased dose of antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to allele C.; in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;WARFARIN;VKORC1;rs9923231;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to genotype TT.; in people with Other:a stable international normalized ratio of between two and three
;SN-38;ABCC1;rs35621;CT + TT;Metabolism/PK;increased exposure to ⮕ SN-38;Genotypes CT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype CC.; in people with Disease:Colorectal Neoplasms
;CARBAMAZEPINE;ABCB1;rs1045642;AA;Dosage;increased dose of ⮕ CARBAMAZEPINE;Genotype AA is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.; in people with Other:Epilepsy
;LITHIUM;ASIC2;rs11869731;CC;Efficacy;increased response to ⮕ LITHIUM;Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG.; in people with Disease:Bipolar Disorder
;SN-38;ABCC1;rs6498588;AT + TT;Metabolism/PK;increased exposure to ⮕ SN-38;Genotypes AT + TT are associated with increased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA.; in people with Disease:Colorectal Neoplasms
;CAPECITABINE, FLUOROURACIL;HLA-G;rs9380142;GG;Efficacy;decreased response to ⮕ CAPECITABINE, FLUOROURACIL;Genotype GG is associated with decreased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotypes AA + AG.;or in people with Disease:Colorectal Neoplasms
;ANTIDEPRESSANTS;MAPK1;rs8136867;AG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype AG is associated with increased response to antidepressants in people with Mental Disorders.; in people with Disease:Mental Disorders
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased dose of ⮕ WARFARIN;Allele G is associated with decreased dose of warfarin as compared to allele C.;  
;CAPECITABINE, FLUOROURACIL;HLA-G;rs17179108;CT;Efficacy;increased response to ⮕ CAPECITABINE, FLUOROURACIL;Genotype CT is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;or in people with Disease:Colorectal Neoplasms
;WARFARIN;VKORC1;rs9923231;CC;Dosage, Efficacy;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in children with Heart Diseases as compared to genotype TT.; in children with Disease:Heart Diseases
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs3793790;G;Efficacy;increased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Allele G is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.;or in people with Disease:Alzheimer Disease
;FLUVOXAMINE;COMT;rs4680;GG;Efficacy;decreased response to ⮕ FLUVOXAMINE;Genotype GG is associated with decreased response to fluvoxamine in people with Depressive Disorder, Major as compared to allele A.; in people with Disease:Major Depressive Disorder
;2-HYDROXYATORVASTATIN;PPARA;rs4253728;AA + AG;Metabolism/PK;decreased concentrations of ⮕ 2-HYDROXYATORVASTATIN;Genotypes AA + AG is associated with decreased concentrations of 2-hydroxyatorvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;LITHIUM;OR52E2;rs16909440;TT;Efficacy;increased response to ⮕ LITHIUM;Genotype TT is associated with increased response to lithium in people with Bipolar Disorder as compared to genotype CC.; in people with Disease:Bipolar Disorder
;LITHIUM;OR52J3;rs2499984;GG;Efficacy;increased response to ⮕ LITHIUM;Genotype GG is associated with increased response to lithium in people with Bipolar Disorder as compared to genotype AA.; in people with Disease:Bipolar Disorder
;ANTIDEPRESSANTS;CREB1;rs889895;GG;Efficacy;increased response to ⮕ ANTIDEPRESSANTS;Genotype GG is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.; in people with Disease:Major Depressive Disorder
;LITHIUM;;rs16973410;CC;Efficacy;increased response to ⮕ LITHIUM;Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CT + TT.; in people with Disease:Bipolar Disorder
;MERCAPTOPURINE;TPMT;rs1142345;C;Efficacy;exposure to ⮕ MERCAPTOPURINE;Allele C is associated with exposure to mercaptopurine in children with Leukemia as compared to allele T.; in children with Disease:Leukemia
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;increased response to ⮕ IVACAFTOR;Allele A is associated with increased response to ivacaftor.;  
;DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs2177370;A;Efficacy;increased response to ⮕ DONEPEZIL, GALANTAMINE, RIVASTIGMINE;Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.;or in people with Disease:Alzheimer Disease
;METHOTREXATE;ATIC;rs2372536;GG;Efficacy;increased response to ⮕ METHOTREXATE;Genotype GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.; in people with Disease:Rheumatoid arthritis
;ZIDOVUDINE;UGT2B7;rs28365062;G;Metabolism/PK;increased metabolism of ⮕ ZIDOVUDINE;Allele G is associated with increased metabolism of zidovudine as compared to allele A.;  
;ROSUVASTATIN;ABCG2;rs2231142;CT;Efficacy;increased response to ⮕ ROSUVASTATIN;Genotype CT is associated with increased response to rosuvastatin in healthy individuals as compared to genotype CC.; in healthy individuals 
;CHOLESTEROL;APOE;rs429358;TT;Toxicity;increased concentrations of ⮕ CHOLESTEROL;Genotype TT is associated with increased concentrations of cholesterol in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.; in children with Other:Acute lymphoblastic leukemia
;METHADONE;DRD2;rs6275;AA;Dosage, Metabolism/PK;decreased dose of ⮕ METHADONE;Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.; in people with Disease:Heroin Dependence
;METFORMIN;SLC47A2;rs12943590;AA + AG;Efficacy;increased response to ⮕ METFORMIN;Genotypes AA + AG is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.; in people with Disease:Diabetes Mellitus, Type 2
;ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;rs1801253;CG + GG;Efficacy;increased response to ⮕ ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;Genotypes CG + GG are associated with increased response to atenolol, carvedilol, diltiazem, metoprolol or verapamil in people with Atrial Fibrillation as compared to genotype CC.;or in people with Disease:Atrial Fibrillation
;METHADONE;DRD2;rs1799978;CC;Dosage, Metabolism/PK;decreased dose of ⮕ METHADONE;Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT.; in people with Disease:Heroin Dependence
;METFORMIN;SLC22A2;rs316019;AA + AC;Efficacy;increased response to ⮕ METFORMIN;Genotypes AA + AC is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to genotype CC.; in people with Disease:Diabetes Mellitus, Type 2
;CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;Efficacy;decreased clinical benefit to ⮕ CARBAMAZEPINE;Genotypes AA + AG is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Other:Epilepsy
;CARBAMAZEPINE;ABCB1;rs2032582;AA + AC;Efficacy;decreased clinical benefit to ⮕ CARBAMAZEPINE;Genotypes AA + AC is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype CC.; in people with Other:Epilepsy
;ERYTHROMYCIN;ABCC2;rs717620;TT;Other, Metabolism/PK;increased metabolism of ⮕ ERYTHROMYCIN;Genotype TT is associated with increased metabolism of erythromycin as compared to genotypes CC + CT.;  
;WARFARIN;GGCX;rs11676382;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG are associated with decreased dose of warfarin as compared to genotype CC.;  
;CARBAMAZEPINE;ABCB1;rs1045642;AA + AG;Efficacy;decreased clinical benefit to ⮕ CARBAMAZEPINE;Genotypes AA + AG is associated with decreased clinical benefit to carbamazepine in people with Epilepsy as compared to genotype GG.; in people with Other:Epilepsy
;ABIRATERONE, DUTASTERIDE;HSD3B1;rs1047303;AC;Efficacy;decreased response to ⮕ ABIRATERONE, DUTASTERIDE;Genotype AC is associated with decreased response to abiraterone and dutasteride in men with Prostatic Neoplasms as compared to genotype AA.;and in men with Other:Prostatic Neoplasms
;AZATHIOPRINE;PACSIN2;rs2413739;CT + TT;Efficacy;decreased response to ⮕ AZATHIOPRINE;Genotypes CT + TT is associated with decreased response to azathioprine in children with Irritable Bowel Syndrome as compared to genotype CC.; in children with Other:Irritable Bowel Syndrome
;ROSUVASTATIN;SLCO2B1;rs12422149;AA + AG;Efficacy;decreased response to ⮕ ROSUVASTATIN;Genotypes AA + AG are associated with decreased response to rosuvastatin in healthy individuals as compared to genotype GG.; in healthy individuals 
;GEFITINIB;CYP3A5;rs776746;CC;Metabolism/PK;increased concentrations of ⮕ GEFITINIB;Genotype CC is associated with increased concentrations of gefitinib in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;SILDENAFIL;NOS3;rs2070744;CC + CT;Efficacy;increased response to ⮕ SILDENAFIL;Genotypes CC + CT are associated with increased response to sildenafil in men with Erectile Dysfunction as compared to genotype TT.; in men with Disease:Erectile Dysfunction
;NEVIRAPINE;CYP2B6;rs3745274;TT;Toxicity, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotype TT is associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotypes GG + GT.; in children with Disease:HIV infectious disease
;ABIRATERONE;SRD5A2;rs523349;CC;Metabolism/PK;increased metabolism of ⮕ ABIRATERONE;Genotype CC is associated with increased metabolism of abiraterone in men with Prostatic Neoplasms as compared to genotypes CG + GG.; in men with Other:Prostatic Neoplasms
;GEFITINIB;CYP2C9;rs1057910;AC;Metabolism/PK;increased concentrations of ⮕ GEFITINIB;Genotype AC is associated with increased concentrations of gefitinib in healthy individuals as compared to genotype AA.; in healthy individuals 
;TRIGLYCERIDES;CYP19A1;rs10046;A;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.; in women with Disease:Breast Neoplasms, Disease:Menopause
;TRIGLYCERIDES;CYP19A1;rs3759811;C;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.; in women with Disease:Breast Neoplasms, Disease:Menopause
;HDL CHOLESTEROL;CYP19A1;rs1008805;G;Other;decreased concentrations of ⮕ HDL CHOLESTEROL;Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.; in women with Disease:Breast Neoplasms, Disease:Menopause
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage;increased dose of ⮕ OPIOIDS;Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;TRIGLYCERIDES;CYP19A1;rs2289105;C;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.; in women with Disease:Breast Neoplasms, Disease:Menopause
;METHOTREXATE;SLC19A1;rs1051296;AC + CC;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.; in children with Other:Acute lymphoblastic leukemia
;HDL CHOLESTEROL;CYP19A1;rs10046;G;Other;decreased concentrations of ⮕ HDL CHOLESTEROL;Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.; in women with Disease:Breast Neoplasms, Disease:Menopause
;FENTANYL;CYP3A4;rs2242480;T;Dosage;decreased dose of ⮕ FENTANYL;Allele T is associated with decreased dose of fentanyl in people with Pain, Postoperative as compared to genotype C/C.; in people with Other:Pain, Postoperative
;HDL CHOLESTEROL;CYP19A1;rs2289105;T;Other;decreased concentrations of ⮕ HDL CHOLESTEROL;Allele T is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.; in women with Disease:Breast Neoplasms, Disease:Menopause
;LEFLUNOMIDE;ESR1;rs2234693;TT;Efficacy;increased response to ⮕ LEFLUNOMIDE;Genotype TT is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotype CC.; in women with Disease:Rheumatoid arthritis
;NEVIRAPINE;CYP2B6;rs3745274;GT;Toxicity, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Genotype GT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.; in people with Disease:HIV infectious disease
;LEFLUNOMIDE;ESR1;rs9340799;AA;Efficacy;increased response to ⮕ LEFLUNOMIDE;Genotype AA is associated with increased response to leflunomide in women with Arthritis, Rheumatoid as compared to genotypes AG + GG.; in women with Disease:Rheumatoid arthritis
;2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN, ATORVASTATIN LACTONE;LPP;rs1975991;A;Metabolism/PK;decreased exposure to ⮕ 2-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN, ATORVASTATIN, ATORVASTATIN LACTONE;Allele A is associated with decreased exposure to 2-hydroxyatorvastatin, 4-hydroxyatorvastatin, atorvastatin and atorvastatin lactone in healthy individuals as compared to allele G.;and in healthy individuals 
;USTEKINUMAB;C9orf72;rs774359;CC + CT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes CC + CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;METHOTREXATE;GGH;rs3758149;GG;Metabolism/PK;decreased concentrations of ⮕ METHOTREXATE;Genotype GG is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.; in children with Other:Acute lymphoblastic leukemia
;HDL CHOLESTEROL;CYP19A1;rs4646;A;Other;decreased concentrations of ⮕ HDL CHOLESTEROL;Allele A is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.; in women with Disease:Breast Neoplasms, Disease:Menopause
;USTEKINUMAB;IL13;rs848;AA + AC;Efficacy;decreased response to ⮕ USTEKINUMAB;Genotypes AA + AC is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;TRIGLYCERIDES;CYP19A1;rs700518;C;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele A.; in women with Disease:Breast Neoplasms, Disease:Menopause
;USTEKINUMAB;ZNF816;rs9304742;CC + CT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes CC + CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype TT.; in people with Disease:Psoriasis
;TRIGLYCERIDES;CYP19A1;rs4775936;C;Other;decreased concentrations of ⮕ TRIGLYCERIDES;Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.; in women with Disease:Breast Neoplasms, Disease:Menopause
;WARFARIN;GGCX;rs11676382;CG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CG + GG is associated with decreased dose of warfarin as compared to genotype CC.;  
;USTEKINUMAB;STAT4;rs7574865;GT + TT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotypes GT + TT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype GG.; in people with Disease:Psoriasis
;USTEKINUMAB;SLC22A4;rs1050152;CT;Efficacy;increased response to ⮕ USTEKINUMAB;Genotype CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype CC.; in people with Disease:Psoriasis
;NICOTINE;CHRNA5;rs16969968;GG;Efficacy;increased response to ⮕ NICOTINE;Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder.; in people with Other:Tobacco Use Disorder
;WARFARIN;STX1B;rs72800847;AA + AG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AA + AG is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype GG.; in people with Disease:Heart valve replacement
;WARFARIN;CYP1A1;rs3826041;CC;Dosage;increased dose of ⮕ WARFARIN;Genotype CC is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AA + AC.; in people with Disease:Heart valve replacement
;VARENICLINE;CHRNA5;rs16969968;AA + AG;Efficacy;increased response to ⮕ VARENICLINE;Genotypes AA + AG are associated with increased response to varenicline in people with Tobacco Use Disorder.; in people with Other:Tobacco Use Disorder
;WARFARIN;DNMT3A;rs2304429;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT.; in people with Disease:Heart valve replacement
;WARFARIN;NQO1;rs10517;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG.; in people with Disease:Heart valve replacement
;RALOXIFENE;ESR1;rs2234693;TT;Efficacy;increased clinical benefit to ⮕ RALOXIFENE;Genotype TT is associated with increased clinical benefit to raloxifene in people with Schizophrenia or Schizoaffective disorder as compared to genotypes CC + CT.; in people with Other:Schizophrenia, Other:Schizoaffective disorder
;ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;AA + AG;Dosage;decreased dose of ⮕ ACENOCOUMAROL, PHENPROCOUMON;Genotypes AA + AG are associated with decreased dose of acenocoumarol or phenprocoumon as compared to genotype GG.;or  
;FENTANYL;DRD1;rs966775;AG + GG;Efficacy;increased concentrations of ⮕ FENTANYL;Genotypes AG + GG is associated with increased concentrations of fentanyl in people with Pain, Postoperative as compared to genotype AA.; in people with Other:Pain, Postoperative
;FLUTICASONE / SALMETEROL;CHRM2;rs8191992;A;Efficacy;response to ⮕ FLUTICASONE / SALMETEROL;Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.; in people with Disease:Asthma
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Metabolism/PK;increased concentrations of ⮕ METHOTREXATE;Genotypes AA + AG are associated with increased concentrations of methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.; in children with Other:Non-Hodgkin Lymphoma
;PHENPROCOUMON;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ PHENPROCOUMON;Genotype TT is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT.;  
;WARFARIN;CYP2C9;rs1057910;AA;Dosage;increased dose of ⮕ WARFARIN;Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.; in people with Disease:Heart valve replacement
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA.; in people with Disease:Heart valve replacement
;ARIPIPRAZOLE, RISPERIDONE;DRD2;rs2514218;CC;Efficacy;increased response to ⮕ ARIPIPRAZOLE, RISPERIDONE;Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.;or in people with Other:Psychotic Disorder, Other:Schizoaffective disorder, Other:Schizophrenia
;VORICONAZOLE;ABCG2;rs2231142;GT + TT;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Genotypes GT + TT is associated with increased dose-adjusted trough concentrations of voriconazole in people with Leukemia, Lymphoma or Myelodysplastic Syndromes as compared to genotype GG.; in people with Other:Leukemia, Other:Lymphoma, Other:Myelodysplastic Syndromes
;WARFARIN;STX1B;rs4889606;AG + GG;Dosage;decreased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with decreased dose of warfarin as compared to genotype AA.;  
;WARFARIN;UGT1A1;rs887829;CC;Dosage;decreased dose of ⮕ WARFARIN;Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT.; in people with Disease:Heart valve replacement
;WARFARIN;CYP4F2;rs2108622;CC + CT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CC + CT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT.; in people with Disease:Heart valve replacement
;AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs1127354;AA + AC;Metabolism/PK;decreased metabolism of ⮕ AZATHIOPRINE, MERCAPTOPURINE;Genotypes AA + AC is associated with decreased metabolism of azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.;or in people with Disease:Inflammatory Bowel Diseases
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased dose of ⮕ WARFARIN;Genotype TT is associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement or Pulmonary Embolism as compared to genotypes CC + CT.; in people with Other:Atrial Fibrillation, Other:Heart valve replacement, Other:Pulmonary Embolism
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;Efficacy;increased response to ⮕ BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;Allele A is associated with increased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.;and in people with Disease:Colorectal Neoplasms
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs1800795;G;Efficacy;decreased response to ⮕ TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele C.; in people with Disease:Psoriasis
;WARFARIN;CYP2C9;rs1057910;AC + CC;Dosage;increased dose of ⮕ WARFARIN;Genotypes AC + CC is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement or Pulmonary Embolism as compared to genotype AA.; in people with Other:Atrial Fibrillation, Other:Heart valve replacement, Other:Pulmonary Embolism
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;increased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement or Pulmonary Embolism as compared to genotype CC.; in people with Other:Atrial Fibrillation, Other:Heart valve replacement, Other:Pulmonary Embolism
;PLATINUM COMPOUNDS;;rs6983267;GG + GT;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes GG + GT are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype TT.; in people with Disease:Lung Neoplasms
;FLUVASTATIN;CYP2C9;rs77760615;G;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;Allele G is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele A.; in healthy individuals 
;METFORMIN;SLC22A2;rs316009;TT;Efficacy;increased response to ⮕ METFORMIN;Genotype TT is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CT.; in people with Disease:Diabetes Mellitus
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage, Efficacy;increased dose of ⮕ OPIOIDS;Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA.;" in people with ""Other:Pain"", ""Other:Pain, Postoperative"""
;FLUVASTATIN;SLCO1B1;rs58310495;T;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;Allele T is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele C.; in healthy individuals 
;ATORVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased dose-adjusted trough concentrations of ⮕ ATORVASTATIN;Allele C is associated with increased dose-adjusted trough concentrations of atorvastatin in children with Hypercholesterolemia as compared to allele T.; in children with Other:Hypercholesterolemia
;CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;Toxicity, Metabolism/PK;decreased clearance of ⮕ CYCLOSPORINE;Genotypes AA + AG are associated with decreased clearance of cyclosporine in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;FLUVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased concentrations of ⮕ FLUVASTATIN;Allele C is associated with increased concentrations of fluvastatin in healthy individuals as compared to allele T.; in healthy individuals 
;PLATINUM COMPOUNDS;MALAT1;rs619586;AG + GG;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotypes AG + GG are associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to genotype AA.; in people with Disease:Lung Neoplasms
;PLATINUM COMPOUNDS;HOTAIR;rs7958904;CC + CG;Efficacy;decreased response to ⮕ PLATINUM COMPOUNDS;Genotypes CC + CG are associated with decreased response to Platinum compounds in people with Lung Neoplasms as compared to genotype GG.; in people with Disease:Lung Neoplasms
;PLATINUM COMPOUNDS;H19;rs2839698;AA + AG;Efficacy;increased response to ⮕ PLATINUM COMPOUNDS;Genotypes AA + AG are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype GG.; in people with Disease:Lung Neoplasms
;TACROLIMUS;CYP3A4;rs35599367;AG;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;EPHX1;rs1051740;C;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.; in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.;  
;FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;Efficacy;response to ⮕ FLUTICASONE / SALMETEROL;Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.; in people with Disease:Asthma
;NICOTINE;OPRM1;rs1799971;AG + GG;Other;increased exposure to ⮕ NICOTINE;Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG.;  
;BETA BLOCKING AGENTS;ADRB1;rs1801253;C;Efficacy;increased response to ⮕ BETA BLOCKING AGENTS;Allele C is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele G.; in children with Other:Cardiomyopathy, Dilated
;SIMVASTATIN ACID;SLCO1B1;rs4149056;CC;Metabolism/PK;increased concentrations of ⮕ SIMVASTATIN ACID;Genotype CC is associated with increased concentrations of simvastatin acid in healthy individuals as compared to genotypes CT + TT.; in healthy individuals 
;BETA BLOCKING AGENTS;ADRB2;rs1042713;A;Efficacy;increased response to ⮕ BETA BLOCKING AGENTS;Allele A is associated with increased response to Beta Blocking Agents in children with Cardiomyopathy, Dilated as compared to allele G.; in children with Other:Cardiomyopathy, Dilated
;FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;Efficacy;response to ⮕ FLUTICASONE / SALMETEROL;Allele A is associated with response to fluticasone/salmeterol in people with Asthma as compared to allele T.; in people with Disease:Asthma
;CARBAMAZEPINE;EPHX1;rs2234922;G;Dosage, Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Allele G is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.; in people with Disease:Epilepsy
;FLUTICASONE PROPIONATE;CRHR1;rs1876831;T;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE;Allele T is associated with increased response to fluticasone propionate in people with Asthma as compared to allele C.; in people with Disease:Asthma
;RISPERIDONE;TNIK;rs2088885;AA;Efficacy;increased response to ⮕ RISPERIDONE;Genotype AA is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes AC + CC.; in people with Other:Schizophrenia
;FLUTICASONE PROPIONATE;CRHR1;rs1876828;T;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE;Allele T is associated with increased response to fluticasone propionate in people with Asthma as compared to allele C.; in people with Disease:Asthma
;METFORMIN;CSMD1;rs2617102;AC + CC;Efficacy;decreased response to ⮕ METFORMIN;Genotypes AC + CC is associated with decreased response to metformin in people with Diabetes Mellitus as compared to genotype AA.; in people with Disease:Diabetes Mellitus
;FLUTICASONE PROPIONATE;CRHR1;rs1876829;C;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE;Allele C is associated with increased response to fluticasone propionate in people with Asthma as compared to allele T.; in people with Disease:Asthma
;FLUTICASONE PROPIONATE;CRHR1;rs739645;G;Efficacy;increased response to ⮕ FLUTICASONE PROPIONATE;Allele G is associated with increased response to fluticasone propionate in people with Asthma as compared to allele T.; in people with Disease:Asthma
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;dose of ⮕ WARFARIN;Genotypes CT + TT are associated with dose of warfarin.;  
;NEVIRAPINE;CYP2B6;rs3745274;T;Toxicity, Metabolism/PK;decreased clearance of ⮕ NEVIRAPINE;Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.; in people with Disease:HIV infectious disease
;NICOTINE;POR;rs1057868;CT + TT;Metabolism/PK;increased metabolism of ⮕ NICOTINE;Genotypes CT + TT is associated with increased metabolism of nicotine in CYP2A6 normal, but not reduced, metabolizers as compared to genotype CC.; in PK:CYP2A6 normal, but not reduced, metabolizers
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Metabolism/PK;increased metabolism of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;WARFARIN;CYP4F2;rs2108622;TT;Dosage;increased dose of ⮕ WARFARIN;Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes CC + CT.; in people with Disease:Atrial Fibrillation
;VORICONAZOLE;CYP2C18;rs2860840;T;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Allele T is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Leukemia, Lymphoma or Myelodysplastic Syndromes as compared to allele C.; in people with Other:Leukemia, Other:Lymphoma, Other:Myelodysplastic Syndromes
;VORICONAZOLE;CYP2C18;rs11188059;G;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ VORICONAZOLE;Allele G is associated with decreased dose-adjusted trough concentrations of voriconazole in people with Leukemia, Lymphoma or Myelodysplastic Syndromes as compared to allele A.; in people with Other:Leukemia, Other:Lymphoma, Other:Myelodysplastic Syndromes
;REMIFENTANIL;ABCB1;rs1045642;GG;Dosage;increased dose of ⮕ REMIFENTANIL;Genotype GG is associated with increased dose of remifentanil as compared to genotype AA.;  
;WARFARIN;GGCX;rs12714145;CT + TT;Dosage;decreased dose of ⮕ WARFARIN;Genotypes CT + TT is associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement or Pulmonary Embolism as compared to genotype CC.; in people with Other:Atrial Fibrillation, Other:Heart valve replacement, Other:Pulmonary Embolism
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased dose of ⮕ WARFARIN;Genotypes AG + GG are associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.; in people with Disease:Atrial Fibrillation
;REMIFENTANIL;ABCB1;rs1045642;GG;Efficacy;decreased response to ⮕ REMIFENTANIL;Genotype GG is associated with decreased response to remifentanil as compared to genotype AA.;  
;FLUOROURACIL;DPYD;rs1801159;CC + CT;Metabolism/PK;increased concentrations of ⮕ FLUOROURACIL;Genotypes CC + CT is associated with increased concentrations of fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.; in people with Disease:Colorectal Neoplasms
;WARFARIN;VKORC1;rs9934438;AA;Dosage;decreased dose of ⮕ WARFARIN;Genotype AA is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotypes AG + GG.; in people with Disease:Atrial Fibrillation
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased response to ⮕ PEGINTERFERON ALFA-2B, RIBAVIRIN;Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;and in people with Disease:Chronic hepatitis C virus infection
;CLOPIDOGREL;CES1;rs71647871;CT + TT;Metabolism/PK;increased exposure to ⮕ CLOPIDOGREL;Genotypes CT + TT are associated with increased exposure to clopidogrel in healthy individuals as compared to genotype CC.; in healthy individuals 
;CLOPIDOGREL;CES1;rs71647871;CT + TT;Efficacy;increased response to ⮕ CLOPIDOGREL;Genotypes CT + TT are associated with increased response to clopidogrel in healthy individuals as compared to genotype CC.; in healthy individuals 
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Metabolism/PK;increased dose of ⮕ CARBAMAZEPINE;Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.; in people with Disease:Epilepsy
;NALTREXONE;OPRM1;rs1799971;AA;Efficacy;increased clinical benefit to ⮕ NALTREXONE;Genotype AA is associated with increased clinical benefit to naltrexone in people with Opioid-Related Disorders as compared to genotypes AG + GG.; in people with Other:Opioid-Related Disorders
;ASPIRIN;P2RY1;rs1371097;T;Efficacy;decreased clinical benefit to ⮕ ASPIRIN;Allele T is associated with decreased clinical benefit to aspirin in people with Stroke as compared to allele C.; in people with Other:Stroke
;GEMCITABINE;CMPK1;rs1044457;TT;Efficacy;decreased clinical benefit to ⮕ GEMCITABINE;Genotype TT is associated with decreased clinical benefit to gemcitabine in people with Non-Small Cell Lung Carcinoma as compared to genotypes CC + CT.; in people with Other:Non-Small Cell Lung Carcinoma
;MERCAPTOPURINE;NUDT15;rs55713253;CC;Dosage;increased dose of ⮕ MERCAPTOPURINE;Genotype CC is associated with increased dose of mercaptopurine in children with Acute lymphoblastic leukemia as compared to genotypes CT + TT.; in children with Other:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;rs145008610;AA;Efficacy;decreased clinical benefit to ⮕ CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;Genotype AA is associated with decreased clinical benefit to cyclophosphamide, doxorubicin and paclitaxel in people with Breast Neoplasms as compared to genotypes AC + CC.;and in people with Other:Breast Neoplasms
;DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;Metabolism/PK;increased concentrations of ⮕ DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;Genotype CT is associated with increased concentrations of deoxy-thioguanosine triphosphate and thioguanosine triphosphate in children with Inflammatory Bowel Diseases as compared to genotype TT.;and in children with Other:Inflammatory Bowel Diseases
;AZATHIOPRINE;PACSIN2;rs2413739;CC + CT;Efficacy;increased clinical benefit to ⮕ AZATHIOPRINE;Genotypes CC + CT is associated with increased clinical benefit to azathioprine in children with Inflammatory Bowel Diseases as compared to genotype TT.; in children with Other:Inflammatory Bowel Diseases
;CLOPIDOGREL CARBOXYLIC ACID;ABCB1;rs1045642;AA + AG;Metabolism/PK;decreased concentrations of ⮕ CLOPIDOGREL CARBOXYLIC ACID;Genotypes AA + AG is associated with decreased concentrations of clopidogrel carboxylic acid in people with Cardiovascular Disease as compared to genotype GG.; in people with Other:Cardiovascular Disease
;THIORIDAZINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;Metabolism/PK;increased concentrations of ⮕ THIORIDAZINE;CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 are associated with increased concentrations of thioridazine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*5 + *1/*6.; in people with Other:Mental Disorders
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;Efficacy;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ PRIMAQUINE;CYP2D6 *4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased concentrations of primaquine in people with Malaria, Vivax as compared to CYP2D6 *2/*41 + *1/*41 + *2/*17 + *2/*29 + *1/*29 + *1/*1 + *1/*2 + *2/*2 + *1/*39 + *1/*34 + *2/*34 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .; in people with Other:Malaria, Vivax
;CYCLOSPORINE;CYP3A5;rs776746;CT;Metabolism/PK;decreased dose-adjusted trough concentrations of ⮕ CYCLOSPORINE;Genotype CT is associated with decreased dose-adjusted trough concentrations of cyclosporine in people with Kidney Transplantation as compared to genotype CC.; in people with Other:Kidney Transplantation
;CLOZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;decreased clearance of ⮕ CLOZAPINE;Genotype AA is associated with decreased clearance of clozapine in healthy individuals as compared to genotypes AC + CC.; in healthy individuals 
;N-DESMETHYLCLOZAPINE;ABCB1;rs2032582;CC;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLCLOZAPINE;Genotype CC is associated with increased concentrations of n-desmethylclozapine in healthy individuals as compared to genotypes AA + AC.; in healthy individuals 
;DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;rs6923761;GG;Efficacy;increased clinical benefit to ⮕ DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;Genotype GG is associated with increased clinical benefit to dulaglutide, liraglutide or semaglutide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AG.;or in people with Other:Diabetes Mellitus, Type 2
;N-DESMETHYLCLOZAPINE;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased concentrations of ⮕ N-DESMETHYLCLOZAPINE;Genotypes CC + CT is associated with increased concentrations of n-desmethylclozapine in people with Schizophrenia as compared to genotype TT.; in people with Other:Schizophrenia
;NORCLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;poor metabolizer decreased clearance of ⮕ NORCLOBAZAM;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased clearance of norclobazam in children with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 + *2/*17 + *3/*17 (assigned as normal metabolizer and intermediate metabolizer phenotype) .; in children with Other:Epilepsy
;ARTEMETHER, LUMEFANTRINE;CYP2B6;rs3745274;GT;Efficacy;decreased clinical benefit to ⮕ ARTEMETHER, LUMEFANTRINE;Genotype GT is associated with decreased clinical benefit to artemether and lumefantrine in people with Malaria as compared to genotypes GG + TT.;and in people with Other:Malaria
;4-ENE VALPROIC ACID;CPT1A;rs2228502;GG;Metabolism/PK;increased concentrations of ⮕ 4-ENE VALPROIC ACID;Genotype GG is associated with increased concentrations of 4-ene valproic acid in people with Epilepsy as compared to genotypes AA + AG.; in people with Other:Epilepsy
;METHOTREXATE;ATIC;rs4673991;CC + CT;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotypes CC + CT is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotype TT.; in people with Other:Rheumatoid arthritis
;METHOTREXATE;ATIC;rs4673993;CT + TT;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotypes CT + TT is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotype CC.; in people with Other:Rheumatoid arthritis
;METHOTREXATE;ADA;rs2057638;GT + TT;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotypes GT + TT is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotype GG.; in people with Other:Rheumatoid arthritis
;METHOTREXATE;ATIC;rs2372536;CC + CG;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotypes CC + CG is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotype GG.; in people with Other:Rheumatoid arthritis
;METHOTREXATE;ADA;rs6017375;CG + GG;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotypes CG + GG is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotype CC.; in people with Other:Rheumatoid arthritis
;METHOTREXATE;ADA;rs371927;AA;Efficacy;increased clinical benefit to ⮕ METHOTREXATE;Genotype AA is associated with increased clinical benefit to methotrexate in people with Rheumatoid arthritis as compared to genotypes AG + GG.; in people with Other:Rheumatoid arthritis
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;;increased clinical benefit to ⮕ LOSARTAN;CYP2C9 *1/*1 is associated with increased clinical benefit to losartan as compared to CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.;  
;CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;Efficacy;poor metabolizer decreased clinical benefit to ⮕ CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6 poor metabolizer is associated with decreased clinical benefit to codeine, hydrocodone, oxycodone or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.;or in people with Other:Pain
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6 normal metabolizer;;Metabolism/PK;normal metabolizer and ultrarapid metabolizer decreased dose-adjusted trough concentrations of ⮕ ZUCLOPENTHIXOL;CYP2D6 normal metabolizer and ultrarapid metabolizer is associated with decreased dose-adjusted trough concentrations of zuclopenthixol as compared to CYP2D6 intermediate metabolizer and poor metabolizer.;  
;SITAGLIPTIN;GLP1R;rs6923761;GG;Efficacy;increased clinical benefit to ⮕ SITAGLIPTIN;Genotype GG is associated with increased clinical benefit to sitagliptin in people with Hypertension and Diabetes Mellitus as compared to genotypes AA + AG.; in people with Other:Hypertension, Other:Diabetes Mellitus
;SALBUTAMOL;ADRB2;rs1042717;AA;Efficacy;decreased clinical benefit to ⮕ SALBUTAMOL;Genotype AA is associated with decreased clinical benefit to salbutamol in people with Asthma as compared to genotypes AG + GG.; in people with Other:Asthma
;SALBUTAMOL;ADRB2;rs1042714;GG;Efficacy;decreased clinical benefit to ⮕ SALBUTAMOL;Genotype GG is associated with decreased clinical benefit to salbutamol in people with Asthma as compared to genotypes CC + CG.; in people with Other:Asthma
;ZUCLOPENTHIXOL;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ ZUCLOPENTHIXOL;CYP2D6 intermediate metabolizer and poor metabolizer are associated with increased concentrations of zuclopenthixol in people with Mental Disorders as compared to CYP2D6 normal metabolizer.; in people with Other:Mental Disorders
;PERPHENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;Metabolism/PK;intermediate metabolizer and poor metabolizer increased concentrations of ⮕ PERPHENAZINE;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased concentrations of perphenazine in people with Mental Disorders as compared to CYP2D6 normal metabolizer.; in people with Other:Mental Disorders
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7754840;CC;Efficacy;increased response to ⮕ DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;Genotype CC is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to genotypes CG + GG.; in people with Disease:Diabetes Mellitus
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7756992;GG;Efficacy;increased response to ⮕ DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;Genotype GG is associated with increased response to Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to genotypes AA + AG.; in people with Disease:Diabetes Mellitus
;SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;Efficacy;decreased response to ⮕ SITAGLIPTIN, VILDAGLIPTIN;Genotype AA is associated with decreased response to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;or in people with Disease:Diabetes Mellitus, Type 2
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;Metabolism/PK;increased concentrations of ⮕ NORTRIPTYLINE;CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased concentrations of nortriptyline in people with Major Depressive Disorder as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.; in people with Disease:Major Depressive Disorder
;ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;Efficacy;increased resistance to ⮕ ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19 *17 is associated with increased resistance to antidepressants or antipsychotics in people with Schizophrenia, Mental Disorders, Neurotic Disorder or Personality Disorder.;or in people with Other:Schizophrenia, Other:Mental Disorders, Other:Neurotic Disorder, Other:Personality Disorder
;ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;Efficacy;increased resistance to ⮕ ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6 *3 is associated with increased resistance to antidepressants or antipsychotics in people with Schizophrenia, Mental Disorders, Neurotic Disorder or Personality Disorder.;or in people with Other:Schizophrenia, Other:Mental Disorders, Other:Neurotic Disorder, Other:Personality Disorder
;ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;Efficacy;increased resistance to ⮕ ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2 *30 is associated with increased resistance to antidepressants or antipsychotics in people with Schizophrenia, Mental Disorders, Neurotic Disorder or Personality Disorder.;or in people with Other:Schizophrenia, Other:Mental Disorders, Other:Neurotic Disorder, Other:Personality Disorder
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased dose of tacrolimus in people with Liver transplantation as compared to CYP3A5 *3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7.; in people with Other:Liver transplantation
;TACROLIMUS;CYP3A4;rs35599367;AG;Dosage;decreased dose of ⮕ TACROLIMUS;Genotype AG is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to genotype GG.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Dosage;increased dose of ⮕ TACROLIMUS;CYP3A5 *1/*1 + *1/*3 is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.; in people with Other:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2740574;CC + CT;Dosage;increased dose of ⮕ TACROLIMUS;Genotypes CC + CT is associated with increased dose of tacrolimus in people with Kidney Transplantation as compared to genotype TT.; in people with Other:Kidney Transplantation
;ANTIDEPRESSANTS;SLC22A3;rs2292334;AG + GG;Dosage;increased dose of ⮕ ANTIDEPRESSANTS;Genotypes AG + GG is associated with increased dose of antidepressants in people with Depression as compared to genotype AA.; in people with Other:Depression
;KETANSERIN;HTR1B;rs130060;C;PD;decreased affinity to HTR1B with  ➔ KETANSERIN;Allele C is associated with decreased affinity to HTR1B with ketanserin in COS-7 cells as compared to allele G.;
;THIOXANTHINE;XDH;rs2295474;T;Metabolism/PK;decreased clearance of XDH with  ➔ THIOXANTHINE;Allele T is associated with decreased clearance of XDH with thioxanthine as compared to allele C.;
;PAROMOMYCIN;MT-RNR1;rs267606617;G;PD;decreased activity  of MT-RNR1 with  ➔ PAROMOMYCIN;Allele G is associated with decreased activity of MT-RNR1 with paromomycin.;
;THIOXANTHINE;XDH;rs45442092;T;Metabolism/PK;decreased clearance of XDH with  ➔ THIOXANTHINE;Allele T is associated with decreased clearance of XDH with thioxanthine as compared to allele C.;
;DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;rs130060;C;PD;increased affinity to HTR1B with  ➔ DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;Allele C is associated with increased affinity to HTR1B with dihydroergotamine, methysergide or sumatriptan in COS-7 cells as compared to allele G.;
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Metabolism/PK;increased  expression of TYMS when treated  with  ➔ FLUOROURACIL;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased expression of TYMS when treated with fluorouracil in colonic mucosa of colorectal cancer patients as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;
;CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;Metabolism/PK;increased  expression of SAE1 when treated  with  ➔ CISPLATIN, IRINOTECAN;Genotype CG is associated with increased expression of SAE1 when treated with cisplatin and irinotecan non-small-cell lung cancer tumors.;
;METHOTREXATE;SHMT1;rs1979277;AA;Metabolism/PK;increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;Genotype AA is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.;
;IVACAFTOR;CFTR;rs113993960;del;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele del is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508139;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;FLUOROURACIL;DPYD;rs1335150891;C;Metabolism/PK;decreasedcatalytic  activity  of DPYD when treated  with  ➔ FLUOROURACIL;Allele C is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele T.;
;IVACAFTOR;CFTR;rs141033578;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs121909011;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs77409459;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508510;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;PHENYTOIN;CYP2C9;rs12782374;A;;decreased expression of CYP2C9 when treated  with  ➔ PHENYTOIN;Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.;
;IVACAFTOR;CFTR;rs397508435;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs77010898;A;Efficacy;increased  activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with increased activity of CFTR when treated with ivacaftor as compared to allele G.;
;ESTRADIOL;TCL1A;rs7158782;G;Other;increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.;
;IVACAFTOR;CFTR;rs397508328;G;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs77932196;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;NIMESULIDE;PTGS2;rs5272;C;Metabolism/PK;increased enzyme  activity  of PTGS2 when treated  with  ➔ NIMESULIDE;Allele C is associated with increased enzyme activity of PTGS2 when treated with nimesulide.;
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;protein stability of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with protein stability of CFTR when treated with ivacaftor.;
;IVACAFTOR;CFTR;rs1800111;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs74551128;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs186045772;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs78769542;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508537;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508256;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs121908751;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Other;increased  expression of TLR4 when treated  with  ➔ CISPLATIN;TPMT *3A is associated with increased expression of TLR4 when treated with cisplatin in HEI-OC1 cells as compared to TPMT *1.;
;IVACAFTOR;CFTR;rs368505753;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;NIMESULIDE;PTGS2;rs5273;G;Metabolism/PK;increased enzyme  activity  of PTGS2 when treated  with  ➔ NIMESULIDE;Allele G is associated with increased enzyme activity of PTGS2 when treated with nimesulide.;
;IVACAFTOR;CFTR;rs115545701;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;SACUBITRIL;CES1;rs71647871;CT;Efficacy;decreasedcatalytic  activity  of CES1 when treated  with  ➔ SACUBITRIL;Genotype CT is associated with decreased catalytic activity of CES1 when treated with sacubitril as compared to genotype CC.;
;IVACAFTOR;CFTR;rs1800100;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;ESTRADIOL;TCL1A;rs7158782;A;Other;increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7158782;G;Other;increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.;
;ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AG;Other;activity  of CYP19A1 when treated  with  ➔ ANASTROZOLE, EXEMESTANE, LETROZOLE;Genotype AG is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole.;
;ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs7176005;CT;Other;activity  of CYP19A1 when treated  with  ➔ ANASTROZOLE, EXEMESTANE, LETROZOLE;Genotype CT is associated with activity of CYP19A1 when treated with anastrozole, exemestane and letrozole as compared to genotype CC.;
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;Metabolism/PK;decreased activity  of TPMT when treated  with  ➔ MERCAPTOPURINE, THIOGUANINE;TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34 are associated with decreased activity of TPMT when treated with mercaptopurine or thioguanine as compared to TPMT *1/*1.;
;SITAGLIPTIN;DPP4;rs759717;CC;PD;increased  activity  of DPP4 when treated  with  ➔ SITAGLIPTIN;Genotype CC is associated with increased activity of DPP4 when treated with sitagliptin as compared to genotypes CG + GG.;
;SITAGLIPTIN;DPP4;rs2909451;TT;PD;increased  activity  of DPP4 when treated  with  ➔ SITAGLIPTIN;Genotype TT is associated with increased activity of DPP4 when treated with sitagliptin as compared to genotypes CC + CT.;
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;Efficacy;increased  expression of MKI67 when treated  with  ➔ TAMOXIFEN;CYP2D6 *5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41 is associated with increased expression of MKI67 when treated with tamoxifen in tumor biopsy tissue as compared to CYP2D6 *1/*1 + *1/*5 + *1/*10 + *1/*14 + *1/*18 + *1/*21 + *1/*41.;
;ESTRADIOL;TCL1A;rs7158782;A;Other;increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7158782;A;Other;increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7159713;A;Other;increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7159713;A;Other;increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7159713;A;Other;increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.;
;ESTRADIOL;TCL1A;rs7159713;G;Other;increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.;
;IVACAFTOR;CFTR;rs78655421;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508759;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs150212784;G;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs34911792;G;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508513;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;ESTRADIOL;TCL1A;rs7159713;G;Other;increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.;
;METHOXSALEN;CYP2A6;CYP2A6*15, CYP2A6*21, CYP2A6*22;*15 + *21 + *22;Other;decreasedenzyme  activity  of CYP2A6 when treated  with  ➔ METHOXSALEN;CYP2A6 *15 + *21 + *22 are associated with decreased enzyme activity of CYP2A6 when treated with methoxsalen in E. coli membrane fractions from cells expressing human CYP2A6 *15, *21 or *22.;
;ATORVASTATIN;SCAP;rs12487736;TT;Other;decreasedtranscription of SCAP when treated  with  ➔ ATORVASTATIN;Genotype TT is associated with decreased transcription of SCAP when treated with atorvastatin in PBMCs.;
;IVACAFTOR;CFTR;rs202179988;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Other;decreased activity  of CYP2D6 when treated  with  ➔ TAMOXIFEN;CYP2D6 *2 is associated with decreased activity of CYP2D6 when treated with tamoxifen as compared to CYP2D6 *1.;
;VITAMIN E;CYP4F2;rs3093105;C;Metabolism/PK;increased catalytic  activity  of CYP4F2 when treated  with  ➔ VITAMIN E;Allele C is associated with increased catalytic activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2 as compared to allele A.;
;ESTRADIOL;;rs11849538;C;Other;increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Allele C is associated with increased expression of IL17A when treated with estradiol as compared to allele G.;
;ESTRADIOL;;rs11849538;C;Other;increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Allele C is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.;
;IVACAFTOR / LUMACAFTOR;CFTR;rs78655421;A;Efficacy;increased  activity  of CFTR when treated  with  ➔ IVACAFTOR / LUMACAFTOR;Allele A is associated with increased activity of CFTR when treated with ivacaftor / lumacaftor as compared to allele G.;
;IVACAFTOR, NPPB;CFTR;rs75527207;A;Efficacy;increased  activity  of CFTR when treated  with  ➔ IVACAFTOR, NPPB;Allele A is associated with increased activity of CFTR when treated with ivacaftor and nppb Chinese hamster ovary cells as compared to allele G.;
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6;Metabolism/PK;increased  activity  of CYP3A4 when treated  with  ➔ EFAVIRENZ;CYP2B6 *6 is associated with increased activity of CYP3A4 when treated with efavirenz.;
;FLUOROURACIL;DPYD;rs56005131;T;Metabolism/PK;decreasedcatalytic  activity  of DPYD when treated  with  ➔ FLUOROURACIL;Allele T is associated with decreased catalytic activity of DPYD when treated with fluorouracil in 293FT cells as compared to allele G.;
;ESTRADIOL;;rs2369049;G;Other;increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele A.;
;ESTRADIOL;;rs2369049;A;Other;increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.;
;ESTRADIOL;;rs2369049;A;Other;increased  expression of IL17A when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL17A when treated with estradiol as compared to allele G.;
;ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;PD;increased  activity  of CFTR when treated  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;Genotype CG is associated with increased activity of CFTR when treated with elexacaftor / tezacaftor / ivacaftor in intestinal organoid.;
;CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;Efficacy;increased  activity  of CFTR when treated  with  ➔ CORR-4A, IVACAFTOR, LUMACAFTOR;Genotype del/del is associated with increased activity of CFTR when treated with corr-4a, ivacaftor and lumacaftor as compared to genotype CTT/CTT.;
;ESTRADIOL;;rs2369049;A;Other;increased  expression of IL1R2 when treated  with  ➔ ESTRADIOL;Allele A is associated with increased expression of IL1R2 when treated with estradiol as compared to allele G.;
;IVACAFTOR;CFTR;rs397508288;G;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs75541969;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;ESCITALOPRAM;IL11;rs1126757;CT + TT;Other;decreased expression of IL11 when treated  with  ➔ ESCITALOPRAM;Genotypes CT + TT is associated with decreased expression of IL11 when treated with escitalopram as compared to genotype CC.;
;ESTRADIOL;;rs11849538;G;Other;increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele C.;
;METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;;increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;Genotypes AG + GG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.;
;ESTRADIOL;;rs11849538;G;Other;increased  expression of IL17RA when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of IL17RA when treated with estradiol as compared to allele C.;
;ESTRADIOL;;rs11849538;C;Other;increased  expression of IL12RB2 when treated  with  ➔ ESTRADIOL;Allele C is associated with increased expression of IL12RB2 when treated with estradiol as compared to allele G.;
;IVACAFTOR;CFTR;rs11971167;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;ESTRADIOL;;rs2369049;G;Other;increased  expression of TCL1A when treated  with  ➔ ESTRADIOL;Allele G is associated with increased expression of TCL1A when treated with estradiol as compared to allele A.;
;IVACAFTOR;CFTR;rs121909019;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs121908753;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;PHENYTOIN;CYP2C9;rs71486745;del;;decreased expression of CYP2C9 when treated  with  ➔ PHENYTOIN;Allele del is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.;
;METHOTREXATE;MTHFR;rs1801131;GT;;increased catalytic  activity  of TYMS when treated  with  ➔ METHOTREXATE;Genotype GT is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.;
;IVACAFTOR;CFTR;rs77834169;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs397508442;T;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs121909047;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in BHK cells.;
;GLYBURIDE;KCNJ11;rs5219;T;Metabolism/PK;decreased activity  of KCNJ11 when treated  with  ➔ GLYBURIDE;Allele T is associated with decreased activity of KCNJ11 when treated with glibenclamide pancreatic islet cells.;
;HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;Metabolism/PK;decreased expression of YEATS4 when treated  with  ➔ HYDROCHLOROTHIAZIDE;Genotype CC is associated with decreased expression of YEATS4 when treated with hydrochlorothiazide in whole blood RNA.;
;IVACAFTOR;CFTR;rs121908752;G;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele G is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;increased  activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with increased activity of CFTR when treated with ivacaftor in transfected CHO cells.;
;VITAMIN E;CYP4F2;rs2108622;T;Other;decreasedenzyme  activity  of CYP4F2 when treated  with  ➔ VITAMIN E;Allele T is associated with decreased enzyme activity of CYP4F2 when treated with vitamin e in Sf9 insect cells transfected with CYP4F2.;
;IVACAFTOR;CFTR;rs121909020;A;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele A is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;IVACAFTOR;CFTR;rs113993958;C;Efficacy;activity  of CFTR when treated  with  ➔ IVACAFTOR;Allele C is associated with activity of CFTR when treated with ivacaftor in FRT cell lines.;
;DISOPYRAMIDE;KCNH2;rs104894021;T;Efficacy;decreasedinhibition of KCNH2 when exposed to  ➔ DISOPYRAMIDE;Allele T is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.;
;QUINIDINE;KCNH2;rs104894021;T;Efficacy;decreasedinhibition of KCNH2 when exposed to  ➔ QUINIDINE;Allele T is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.;
;CHLOROCRESOL;RYR1;rs193922803;T;Other;increased  activity  of RYR1 when exposed to  ➔ CHLOROCRESOL;Allele T is associated with increased activity of RYR1 when exposed to chlorocresol in lymphoblastoid cell lines as compared to allele C.;
;TAMOXIFEN;NCOA1;rs1804645;T;;decreased activity  of NCOA1 when exposed to  ➔ TAMOXIFEN;Allele T is associated with decreased activity of NCOA1 when exposed to tamoxifen.;
;CYTARABINE;CDA;rs60369023;AA + AG;Metabolism/PK;decreasedcatalytic  activity  of CDA when exposed to  ➔ CYTARABINE;Genotypes AA + AG are associated with decreased catalytic activity of CDA when exposed to cytarabine as compared to genotype GG.;
;GENTAMICIN;MT-RNR1;rs267606619;T;PD;decreased activity  of MT-RNR1 when exposed to  ➔ GENTAMICIN;Allele T is associated with decreased activity of MT-RNR1 when exposed to gentamicin.;
;QUINIDINE;KCNH2;rs104894021;C;Efficacy;decreasedinhibition of KCNH2 when exposed to  ➔ QUINIDINE;Allele C is associated with decreased inhibition of KCNH2 when exposed to quinidine as compared to allele G.;
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;Other;decreased activity  of CYP2B6 when exposed to  ➔ BUPROPION;CYP2B6 *1/*30 is associated with decreased activity of CYP2B6 when exposed to bupropion as compared to CYP2B6 *1/*1.;
;GEMCITABINE;DCTD;rs35932500;C;Metabolism/PK;decreasedenzyme  activity  of DCTD when exposed to  ➔ GEMCITABINE;Allele C is associated with decreased enzyme activity of DCTD when exposed to gemcitabine in transfected cells as compared to allele T.;
;BUPROPION;POR;rs2868177;AG + GG;Metabolism/PK;increased  activity  of CYP2B6 when exposed to  ➔ BUPROPION;Genotypes AG + GG are associated with increased activity of CYP2B6 when exposed to bupropion as compared to genotype AA.;
;GEMCITABINE;CDA;rs2072671;C;Metabolism/PK;decreasedenzyme  activity  of CDA when exposed to  ➔ GEMCITABINE;Allele C is associated with decreased enzyme activity of CDA when exposed to gemcitabine in transfected cells as compared to allele A.;
;ADALIMUMAB;TNF;rs1800629;AG;Metabolism/PK;decreasedsteady-state level of TNF when exposed to  ➔ ADALIMUMAB;Genotype AG is associated with decreased steady-state level of TNF when exposed to adalimumab as compared to genotype GG.;
;PAROMOMYCIN;MT-RNR1;rs267606617;G;PD;decreased activity  of MT-RNR1 when exposed to  ➔ PAROMOMYCIN;Allele G is associated with decreased activity of MT-RNR1 when exposed to paromomycin.;
;SIMVASTATIN;HLA-G;rs1063320;GG;Other;increased  expression of HLA-G when exposed to  ➔ SIMVASTATIN;Genotype GG is associated with increased expression of HLA-G when exposed to simvastatin in lymphoblastoid cell lines.;
;ACETAMINOPHEN;CYP2E1;rs2515641;T;Other;increased  expression of CYP2E1 when exposed to  ➔ ACETAMINOPHEN;Allele T is associated with increased expression of CYP2E1 when exposed to acetaminophen as compared to allele C.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Other;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *19 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in yeast microsomes heterologously expressing CYP2C19*19 as compared to CYP2C19 *1.;
;BUPRENORPHINE;OPRM1;rs1799971;G;Efficacy;decreased activity  of OPRM1 when exposed to  ➔ BUPRENORPHINE;Allele G is associated with decreased activity of OPRM1 when exposed to buprenorphine in COS cells as compared to allele A.;
;TAMOXIFEN;UGT1A4;rs8330;CC;Metabolism/PK;decreased activity  of UGT1A4 when exposed to  ➔ TAMOXIFEN;Genotype CC is associated with decreased activity of UGT1A4 when exposed to tamoxifen in human liver microsomes as compared to genotypes CG + GG.;
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;increased catalytic  activity  of CYP2C19 when exposed to  ➔ OMEPRAZOLE;CYP2C19 *19 is associated with increased catalytic activity of CYP2C19 when exposed to omeprazole as compared to CYP2C19 *1.;
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;Metabolism/PK;increased catalytic  activity  of CYP2C19 when exposed to  ➔ CLOPIDOGREL;CYP2C19 *28 is associated with increased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.;
;GEMCITABINE;FKBP5;rs73748206;CT;Other;increased  expression of FKBP5 when exposed to  ➔ GEMCITABINE;Genotype CT is associated with increased expression of FKBP5 when exposed to gemcitabine as compared to genotype CC.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.;
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ CLOPIDOGREL;CYP2C19 *10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26 are associated with decreased catalytic activity of CYP2C19 when exposed to clopidogrel in cos-7 cells as compared to CYP2C19 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *26 is associated with decreased catalytic activity of CYP2C19 when exposed to mephenytoin and omeprazole as compared to CYP2C19 *1.;
;ACETAMINOPHEN;UGT1A;rs8330;CC;Metabolism/PK;decreased activity  of UGT1A when exposed to  ➔ ACETAMINOPHEN;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.;
;ETHANOL;ADH1B;rs1229984;CT + TT;Metabolism/PK;increased enzyme  activity  of ADH1B when exposed to  ➔ ETHANOL;Genotypes CT + TT are associated with increased enzyme activity of ADH1B when exposed to ethanol as compared to genotype CC.;
;ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;Other;increased transport of CFTR when exposed to  ➔ ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;Genotype del/del are associated with increased transport of CFTR when exposed to elexacaftor, ivacaftor and tezacaftor.;
;ACETAMINOPHEN;UGT1A;rs10929303;CC;Metabolism/PK;decreased activity  of UGT1A when exposed to  ➔ ACETAMINOPHEN;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CT + TT.;
;XENOBIOTICS;AHR;rs2066853;A;Metabolism/PK;increased  expression of CYP1A1 when exposed to  ➔ XENOBIOTICS;Allele A is associated with increased expression of CYP1A1 when exposed to xenobiotics in lymphocytes.;
;OMEPRAZOLE, XENOBIOTICS;AHR;rs75519181;G;Metabolism/PK;decreased expression of CYP1A1 when exposed to  ➔ OMEPRAZOLE, XENOBIOTICS;Allele G is associated with decreased expression of CYP1A1 when exposed to omeprazole and xenobiotics in HeLa cells.;
;ACETAMINOPHEN;UGT1A;rs1042640;CC;Metabolism/PK;decreased activity  of UGT1A when exposed to  ➔ ACETAMINOPHEN;Genotype CC is associated with decreased activity of UGT1A when exposed to acetaminophen in human liver microsomes as compared to genotypes CG + GG.;
;GEMCITABINE;FKBP5;rs73748206;CT;Other;increased  expression of NR3C1 when exposed to  ➔ GEMCITABINE;Genotype CT is associated with increased expression of NR3C1 when exposed to gemcitabine as compared to genotype CC.;
;ESTRADIOL;;rs3802201;GG;Other;increased  expression of MIR2052 when exposed to  ➔ ESTRADIOL;Genotype GG is associated with increased expression of MIR2052 when exposed to estradiol in lymphoblastoid cell lines as compared to genotype CC.;
;ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;rs34241435;A;Other;increased transcription of SCNN1B when exposed to  ➔ ALDOSTERONE, INSULIN RECOMBINANT;Allele A is associated with increased transcription of SCNN1B when exposed to aldosterone and insulin recombinant in COS cells.;
;ESTRADIOL;;rs4476990;CC;Other;increased  expression of MIR2052 when exposed to  ➔ ESTRADIOL;Genotype CC is associated with increased expression of MIR2052 when exposed to estradiol in lymphoblastoid cell lines as compared to genotype GG.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Metabolism/PK;decreased activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *9 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreased activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *10 is associated with decreased activity of CYP2C19 when exposed to mephenytoin as compared to CYP2C19 *1.;
;BERBERINE, COPTISINE;CYP2D6;CYP2D6*1;*1/*1;Metabolism/PK;increased inhibition of CYP2D6 when exposed to  ➔ BERBERINE, COPTISINE;CYP2D6 *1/*1 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.;
;3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*10;*8 + *10;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when exposed to  ➔ 3-CYANO-7-ETHOXYCOUMARIN;CYP2C19 *8 + *10 are associated with decreased catalytic activity of CYP2C19 when exposed to 3-cyano-7-ethoxycoumarin as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Metabolism/PK;increased catalytic  activity  of CYP2C19 when exposed to  ➔ MEPHENYTOIN;CYP2C19 *23 is associated with increased catalytic activity of CYP2C19 when exposed to mephenytoin in cos-7 cells as compared to CYP2C19 *1.;
;BERBERINE, COPTISINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;Metabolism/PK;increased inhibition of CYP2D6 when exposed to  ➔ BERBERINE, COPTISINE;CYP2D6 *1/*10 is associated with increased inhibition of CYP2D6 when exposed to berberine and coptisine.;
;DISOPYRAMIDE;KCNH2;rs104894021;C;Efficacy;decreasedinhibition of KCNH2 when exposed to  ➔ DISOPYRAMIDE;Allele C is associated with decreased inhibition of KCNH2 when exposed to disopyramide as compared to allele G.;
;IVACAFTOR;CFTR;rs74503330;A;Other;increased  activity  of CFTR when exposed to  ➔ IVACAFTOR;Allele A is associated with increased activity of CFTR when exposed to ivacaftor.;
;FLUOROURACIL;DPYD;rs372307932;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;MIDAZOLAM;CYP3A4;rs35599367;AG;Metabolism/PK;decreased activity  of CYP3A4 when assayed  with  ➔ MIDAZOLAM;Genotype AG is associated with decreased activity of CYP3A4 when assayed with midazolam in human liver microsomes as compared to genotype GG.;
;DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;Metabolism/PK;decreased activity  of CYP3A4 when assayed  with  ➔ DEXTROMETHORPHAN;Genotype AG is associated with decreased activity of CYP3A4 when assayed with dextromethorphan in human liver microsomes as compared to genotype GG.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *16 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;CYP2C19 *19 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;CYP2C19 *18 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.;
;FLUOROURACIL;DPYD;rs376073289;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs374527058;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;FLUOROURACIL;DPYD;rs538336580;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *9 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.;
;FLUOROURACIL;DPYD;rs568367673;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs558354142;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs770829708;A;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs374825099;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs199654337;T;Metabolism/PK;decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele C.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;*9 + *10 + *16;Metabolism/PK;decreased clearance of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *9 + *10 + *16 are associated with decreased clearance of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.;
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;decreased clearance of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;CYP2C19 *19 are associated with decreased clearance of CYP2C19 when assayed with omeprazole in yeast microsomes as compared to CYP2C19 *1.;
;ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1009122956;C;Metabolism/PK;decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Allele C is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele G.;
;ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1621378;T;Metabolism/PK;decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE, ROSUVASTATIN;Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate or rosuvastatin HEK293 cells expressing OATP2B1 variants as compared to allele C.;
;ESTRONE SULFATE;SLCO2B1;rs2306168;T;Metabolism/PK;decreasedtransport of SLCO2B1 when assayed  with  ➔ ESTRONE SULFATE;Allele T is associated with decreased transport of SLCO2B1 when assayed with estrone sulfate HEK293 cells expressing OATP2B1 variants as compared to allele C.;
;FLUOROURACIL;DPYD;rs548783838;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;Efficacy;increased  activity  of CYP2B6 when assayed  with  ➔ ;CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with as compared to CYP2B6 *6/*6.;
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;Efficacy;increased  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;CYP2B6 *1/*1 is associated with increased activity of CYP2B6 when assayed with bupropion as compared to CYP2B6 *1/*6.;
;FLUOROURACIL;DPYD;rs140989814;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *8 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in yeast microsomes as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;CYP2C19 *13 is associated with decreased activity of CYP2C19 when assayed with mephenytoin in yeast microsomes as compared to CYP2C19 *1.;
;BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*29;*29;Metabolism/PK;increased  activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;CYP3A4 *29 is associated with increased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.;
;TESTOSTERONE;CYP3A4;rs35599367;AG;Metabolism/PK;decreased activity  of CYP3A4 when assayed  with  ➔ TESTOSTERONE;Genotype AG is associated with decreased activity of CYP3A4 when assayed with testosterone in human liver microsomes as compared to genotype GG.;
;ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;*2 + *3 + *11 + *29 + *33;Metabolism/PK;increased catalytic  activity  of CYP3A4 when assayed  with  ➔ ACALABRUTINIB;CYP3A4 *2 + *3 + *11 + *29 + *33 is associated with increased catalytic activity of CYP3A4 when assayed with acalabrutinib as compared to CYP3A4 *1.;
;ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;Metabolism/PK;decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ ACALABRUTINIB;CYP3A4 *9 + *14 + *16 + *19 + *23 + *24 + *28 + *32 is associated with decreased catalytic activity of CYP3A4 when assayed with acalabrutinib as compared to CYP3A4 *1.;
;VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;Metabolism/PK;increased clearance of CYP3A4 when assayed  with  ➔ VANDETANIB;CYP3A4 *2 + *3 + *9 + *15 + *16 + *29 + *32 + *33 is associated with increased clearance of CYP3A4 when assayed with vandetanib as compared to CYP3A4 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *10 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.;
;FLUOROURACIL;DPYD;rs1801266;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;DEXTROMETHORPHAN;SEPTIN3, WBP2NL;rs1062753;G;Metabolism/PK;increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Allele G is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to allele A.;
;BUMETANIDE;SLC17A3;rs34376145;A;Metabolism/PK;decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.;
;BUMETANIDE;SLC17A3;rs34902660;A;Metabolism/PK;decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.;
;BUMETANIDE;SLC17A3;rs11966370;A;Metabolism/PK;decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Allele A is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele G.;
;BUMETANIDE;SLC17A3;rs56027330;T;Metabolism/PK;decreasedtransport of SLC17A3 when assayed  with  ➔ BUMETANIDE;Allele T is associated with decreased transport of SLC17A3 when assayed with bumetanide in Xenopus oocytes as compared to allele C.;
;OMEPRAZOLE;CYP2C19;rs148247410;G;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele C.;
;FLUOROURACIL;DPYD;rs528152707;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs570122671;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs201268750;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs527580106;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;FLUOROURACIL;DPYD;rs55886062;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs550527959;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele A.;
;FLUOROURACIL;DPYD;rs538703919;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;IBUPROFEN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;Other;decreased clearance of CYP3A4 when assayed  with  ➔ IBUPROFEN;CYP3A4 *4 + *5 + *18 + *23 + *32 + *34 + *28 + *29 + *31 + *33 is associated with decreased clearance of CYP3A4 when assayed with ibuprofen as compared to CYP3A4 *1.;
;BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*20;*20;Metabolism/PK;decreased activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;CYP3A4 *20 is associated with decreased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs763625282;A;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.;
;BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;Metabolism/PK;decreased activity  of CYP3A4 when assayed  with  ➔ BLONANSERIN;CYP3A4 *4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34 is associated with decreased activity of CYP3A4 when assayed with blonanserin as compared to CYP3A4 *1.;
;REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*20;*20;Metabolism/PK;decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ REGORAFENIB;CYP3A4 *20 is associated with decreased catalytic activity of CYP3A4 when assayed with regorafenib as compared to CYP3A4 *1.;
;FLUOROURACIL;DPYD;rs72549307;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;OMEPRAZOLE;CYP2C19;rs1431015009;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele A.;
;BUFURALOL;CYP2D6;rs1058171;T;Metabolism/PK;decreased activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Allele T is associated with decreased activity of CYP2D6 when assayed with bufuralol in HEK293 as compared to allele C.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*72;*72;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *72 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;SUMATRIPTAN;HTR1B;rs130060;C;PD;increased concentrations of cAMP when assayed  with  ➔ SUMATRIPTAN;Allele C is associated with increased concentrations of cAMP when assayed with sumatriptan in stably transfected C6 cells as compared to allele G.;
;BUFURALOL;CYP2D6;rs1230912765;A;Metabolism/PK;decreased activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;Allele A is associated with decreased activity of CYP2D6 when assayed with bufuralol in HEK293 as compared to allele G.;
;PURINE ANALOGUES;PACSIN2;rs2413739;C;Other, Metabolism/PK;increased  activity  of TPMT when assayed  with  ➔ PURINE ANALOGUES;Allele C is associated with increased activity of TPMT when assayed with purine analogues erythrocytes as compared to allele T.;
;L-PHENYLALANINE;PAH;rs76394784;A;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Allele A is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.;
;CARBOCISTEINE;PAH;rs62516101;T;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.;
;CARBOCISTEINE;PAH;rs75193786;G;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Allele G is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele A.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*75;*75;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ LOSARTAN;CYP2C9 *75 is associated with decreased enzyme activity of CYP2C9 when assayed with losartan as compared to CYP2C9 *1.;
;L-PHENYLALANINE;PAH;rs62516101;T;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.;
;CARBOCISTEINE;PAH;rs5030860;C;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Allele C is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.;
;L-PHENYLALANINE;PAH;rs5030849;T;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Allele T is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele C.;
;CARBOCISTEINE;PAH;rs76394784;A;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Allele A is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele T.;
;DICLOFENAC;CYP2C9;CYP2C9*3;*3;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *3 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ WARFARIN;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with warfarin as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*37;*37;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *37 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*46;*46;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *46 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;CARBOCISTEINE;PAH;rs5030849;T;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ CARBOCISTEINE;Allele T is associated with decreased activity of PAH when assayed with carbocisteine as compared to allele C.;
;L-PHENYLALANINE;PAH;rs5030860;C;Metabolism/PK;decreased activity  of PAH when assayed  with  ➔ L-PHENYLALANINE;Allele C is associated with decreased activity of PAH when assayed with l-phenylalanine as compared to allele T.;
;DICLOFENAC;CYP2C9;CYP2C9*54;*54;Metabolism/PK;increased catalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *54 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*74;*74;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *74 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;TOLBUTAMIDE;CYP2C9;rs9332239;T;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with tolbutamide.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*49, CYP2D6*55;*49 + *55;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *49 + *55 are associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;TOLTERODINE;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;Metabolism/PK;decreased activity  of CYP2D6 when assayed  with  ➔ TOLTERODINE;CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 when assayed with tolterodine.;
;GEFITINIB;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ GEFITINIB;CYP2D6 *92 + *96 are associated with decreased catalytic activity of CYP2D6 when assayed with gefitinib.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;CYP2D6 *10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114 are associated with decreased enzyme activity of CYP2D6 when assayed with dextromethorphan in COS-7 cells as compared to CYP2D6 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*18;*18;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *18 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*4/*5 + *4/*6;Other;increased  activity  of NAT2 when assayed  with  ➔ HYDRALAZINE;NAT2 *4/*5 + *4/*6 are associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *5/*5 + *5/*6 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) .;
;HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6;*4/*4;Other;increased  activity  of NAT2 when assayed  with  ➔ HYDRALAZINE;NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased activity of NAT2 when assayed with hydralazine as compared to NAT2 *4/*5 + *4/*6 (assigned as intermediate acetylator phenotype) .;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *36 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;DICLOFENAC, LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*73;*73;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC, LOSARTAN;CYP2C9 *73 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac or losartan as compared to CYP2C9 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *36 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;FLUOXETINE;CYP2D6;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ FLUOXETINE;CYP2D6 *10 + *92 + *93 + *96 + *87 + *2 is associated with decreased catalytic activity of CYP2D6 when assayed with fluoxetine.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *2 + *10 + *89 + *92 + *93 + *96 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol in 293 FT cells as compared to CYP2D6 *1.;
;TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with tolbutamide as compared to CYP2C9 *1.;
;TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ TOLBUTAMIDE;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with tolbutamide as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*60;*60;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *60 is associated with decreased enzyme activity of CYP2C9 when assayed with diclofenac as compared to CYP2C9 *1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in 293 FT cells as compared to CYP2D6 *1.;
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreasedenzyme  activity  of CYP2C9 when assayed  with  ➔ WARFARIN;CYP2C9 *3 is associated with decreased enzyme activity of CYP2C9 when assayed with warfarin as compared to CYP2C9 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*50;*50;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *50 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*44;*44;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *44 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*42;*42;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *42 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*40;*40;Metabolism/PK;increased catalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *40 is associated with increased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200346442;A;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200150287;G;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele G is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs150152656;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.;
;BUPROPION;POR;rs2868177;AA;Other, Metabolism/PK;decreasedenzyme  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Genotype AA is associated with decreased enzyme activity of CYP2B6 when assayed with bupropion as compared to genotype AG.;
;BUPROPION;POR;rs2868177;GG;Other, Metabolism/PK;increased  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Genotype GG is associated with increased activity of CYP2B6 when assayed with bupropion.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*51;*51;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *51 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN;CYP2C19 *32 is associated with decreased activity of CYP2C19 when assayed with mephenytoin as compared to CYP2C19 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;*29 + *30 + *31 + *33;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *29 + *30 + *31 + *33 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.;
;;POR;rs2868177;AA;Other, Metabolism/PK;decreased activity  of CYP2B6 when assayed  with  ➔ ;Genotype AA is associated with decreased activity of CYP2B6 when assayed with as compared to genotype GG.;
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ CLOPIDOGREL;CYP2C19 *10 is associated with decreased catalytic activity of CYP2C19 when assayed with clopidogrel in E. coli DH5alpha as compared to CYP2C19 *1.;
;OMEPRAZOLE;CYP2C19;rs140278421;A;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Genotype A is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele G.;
;OMEPRAZOLE;CYP2C19;rs1361528097;G;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele T.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *3 is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole as compared to CYP2C19 *1.;
;FLUOROURACIL;DPYD;rs536577604;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEBRISOQUINE;CYP2D6 *10 is associated with decreased catalytic activity of CYP2D6 when assayed with debrisoquine in yeast microsomes as compared to CYP2D6 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1267723490;C;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele C is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*54;*54;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *54 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;BUFURALOL, DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL, DEBRISOQUINE;CYP2D6 *29 is associated with decreased catalytic activity of CYP2D6 when assayed with bufuralol or debrisoquine in COS-1 cells as compared to CYP2D6 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*47;*47;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *47 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs764137538;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele C.;
;IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*3, CYP2C19*35;*3 + *35;Other;decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ IBUPROFEN;CYP2C19 *3 + *35 is associated with decreased catalytic activity of CYP2C19 when assayed with ibuprofen as compared to CYP2C19 *1.;
;IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*33 + *30 + *31 + *32;Other;decreasedcatalytic  activity  of CYP2C19 when assayed  with  ➔ IBUPROFEN;CYP2C19 *33 + *30 + *31 + *32 is associated with decreased catalytic activity of CYP2C19 when assayed with ibuprofen as compared to CYP2C19 *1.;
;DEXTROMETHORPHAN;PHETA2, SMDT1;rs1807493;G;Metabolism/PK;increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Allele G is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to allele C.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreasedenzyme  activity  of CYP2D6 when assayed  with  ➔ BUFURALOL;CYP2D6 *10 is associated with decreased enzyme activity of CYP2D6 when assayed with bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*52;*52;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *52 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*43;*43;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *43 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*45;*45;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *45 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*36;*36;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *36 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*55;*55;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *55 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*39;*39;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *39 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*50;*50;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *50 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*47;*47;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *47 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*53;*53;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *53 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*38;*38;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *38 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*48;*48;Metabolism/PK;decreasedcatalytic  activity  of CYP2C9 when assayed  with  ➔ DICLOFENAC;CYP2C9 *48 is associated with decreased catalytic activity of CYP2C9 when assayed with diclofenac expressed in COS-7 cells as compared to CYP2C9 *1.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1463550071;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele A.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1349931378;A;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele A is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele G.;
;DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*75;*75;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEBRISOQUINE;CYP2D6 *75 is associated with decreased catalytic activity of CYP2D6 when assayed with debrisoquine in yeast microsomes as compared to CYP2D6 *1.;
;OMEPRAZOLE;CYP2C19;rs1393133490;T;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Allele T is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele C.;
;OMEPRAZOLE;CYP2C19;rs1466428833;G;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ OMEPRAZOLE;Allele G is associated with decreased activity of CYP2C19 when assayed with omeprazole in HEK293 as compared to allele T.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs749678783;C;Metabolism/PK;decreased activity  of CYP2C19 when assayed  with  ➔ MEPHENYTOIN, OMEPRAZOLE;Allele C is associated with decreased activity of CYP2C19 when assayed with mephenytoin or omeprazole in 293FT cells as compared to allele T.;
;IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;Metabolism/PK;decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ IBRUTINIB;CYP3A4 *17 + *24 is associated with decreased catalytic activity of CYP3A4 when assayed with ibrutinib as compared to CYP3A4 *1.;
;EFAVIRENZ;CYP2B6;rs58871670;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs72547601;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;BUPROPION;CYP2B6;rs201500445;C;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele C is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele T.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B;*1/*3A + *1/*3B;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*3A + *1/*3B is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.;
;FLUOROURACIL;DPYD;rs188052243;C;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*3A is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in red blood cells as compared to TPMT *1/*1.;
;DAUNORUBICIN, DOXORUBICIN;AKR7A2;rs1043657;T;Metabolism/PK;decreasedenzyme  activity  of AKR7A2 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Allele T is associated with decreased enzyme activity of AKR7A2 when assayed with daunorubicin or doxorubicin as compared to allele C.;
;DAUNORUBICIN;AKR1C4;rs17134592;G;Metabolism/PK;decreasedenzyme  activity  of AKR1C4 when assayed  with  ➔ DAUNORUBICIN;Allele G is associated with decreased enzyme activity of AKR1C4 when assayed with daunorubicin as compared to allele C.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*1;Metabolism/PK;increased enzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*1 is associated with increased enzyme activity of TPMT when assayed with mercaptopurine in red blood cell lysates as compared to TPMT *1/*3A + *1/*3C.;
;MERCAPTOPURINE;TPMT;rs3931660;AT;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Genotype AT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype AA.;
;MERCAPTOPURINE;TPMT;rs1142345;CT;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;Genotype CT is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocytes as compared to genotype TT.;
;DAUNORUBICIN;AKR1C3;rs4987102;A;Metabolism/PK;decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN;Allele A is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin as compared to allele G.;
;DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs35575889;T;Metabolism/PK;decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Allele T is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin or doxorubicin as compared to allele C.;
;DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs34186955;T;Metabolism/PK;decreasedenzyme  activity  of AKR1C3 when assayed  with  ➔ DAUNORUBICIN, DOXORUBICIN;Allele T is associated with decreased enzyme activity of AKR1C3 when assayed with daunorubicin or doxorubicin as compared to allele C.;
;;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;Metabolism/PK;decreased expression of TPMT when assayed  with  ➔ ;TPMT *2 + *3A + *5 + *12 + *14 + *18 + *22 is associated with decreased expression of TPMT when assayed with in COS-7 cells as compared to TPMT *1.;
;FLUOROURACIL;DPYD;rs72549306;A;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.;
;SN-38;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*1/*28 + *28/*28 + *1/*37;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;UGT1A1 *1/*28 + *28/*28 + *1/*37 are associated with decreased enzyme activity of UGT1A1 when assayed with SN-38 in human livers as compared to UGT1A1 *1/*1.;
;SN-38;UGT1A1;rs4148323;A;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.;
;FLUOROURACIL;DPYD;rs137999090;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs145773863;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;Metabolism/PK;decreasedcatalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Allele T is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Metabolism/PK;decreased activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*2 + *1/*3A + *1/*3C is associated with decreased activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.;
;FLUOROURACIL;DPYD;rs59086055;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B/*3C;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *3B/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.;
;PURINE ANALOGUES;TPMT;rs1142345;CT;Other, Metabolism/PK;decreased activity  of TPMT when assayed  with  ➔ PURINE ANALOGUES;Genotype CT is associated with decreased activity of TPMT when assayed with purine analogues as compared to genotype TT.;
;ELEXACAFTOR, TEZACAFTOR;CFTR;rs1792306355;T;Efficacy;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.;
;ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs186089140;CT;PD;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;Genotype CT is associated with increased activity of CFTR when assayed with elexacaftor / tezacaftor / ivacaftor in immortalized bronchial epithelial cells as compared to genotype CC.;
;ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs35516286;A;PD;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;Allele A is associated with increased activity of CFTR when assayed with elexacaftor / tezacaftor / ivacaftor or ivacaftor / tezacaftor intestinal organoids as compared to allele T.;
;CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs143718310;G;Metabolism/PK;decreasedmetabolism of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Allele G is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.;
;ENALAPRIL;CES1;rs202121317;C;Metabolism/PK;decreasedenzyme  activity  of  when assayed  with  ➔ ENALAPRIL;Allele C is associated with decreased enzyme activity of when assayed with enalapril in HEK cells as compared to allele A.;
;REMIMAZOLAM;CES1;rs2307240;T;Metabolism/PK;increased catalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Allele T is associated with increased catalytic activity of CES1 when assayed with remimazolam as compared to allele C.;
;CLOPIDOGREL;CES1;rs202001817;A;Metabolism/PK;decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL;Allele A is associated with decreased enzyme activity of when assayed with clopidogrel in HEK cells as compared to allele G.;
;REMIMAZOLAM;CES1;rs71647871;T;Metabolism/PK;decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Allele T is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele C.;
;REMIMAZOLAM;CES1;rs151291296;C;Metabolism/PK;decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Allele C is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele A.;
;CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs151291296;C;Metabolism/PK;decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele A.;
;CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs146456965;A;Metabolism/PK;decreasedmetabolism of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Allele A is associated with decreased metabolism of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele C.;
;REMIMAZOLAM;CES1;rs143718310;G;Metabolism/PK;decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Allele G is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele T.;
;CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs200707504;C;Metabolism/PK;decreasedenzyme  activity  of  when assayed  with  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Allele C is associated with decreased enzyme activity of when assayed with clopidogrel, enalapril and sacubitril in HEK cells as compared to allele T.;
;ENALAPRIL;CES1;rs2307243;T;Metabolism/PK;decreasedenzyme  activity  of  when assayed  with  ➔ ENALAPRIL;Allele T is associated with decreased enzyme activity of when assayed with enalapril in HEK cells as compared to allele C.;
;REMIMAZOLAM;CES1;rs200707504;C;Metabolism/PK;decreasedcatalytic  activity  of CES1 when assayed  with  ➔ REMIMAZOLAM;Allele C is associated with decreased catalytic activity of CES1 when assayed with remimazolam as compared to allele T.;
;BUPROPION;CYP2B6;rs58871670;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs755692084;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13 are associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in COS-1 cells as compared to TPMT *1.;
;THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ THIOGUANINE;TPMT *2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30 are associated with decreased enzyme activity of TPMT when assayed with thioguanine in COS-7 cells as compared to TPMT *1.;
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;Metabolism/PK;decreasedenzyme  activity  of TPMT when assayed  with  ➔ MERCAPTOPURINE;TPMT *1/*3A + *1/*3B + *1/*3C is associated with decreased enzyme activity of TPMT when assayed with mercaptopurine in erythrocyte lysates as compared to TPMT *1/*1.;
;ELEXACAFTOR, TEZACAFTOR;CFTR;rs758900656;T;Efficacy;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.;
;17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;Metabolism/PK;increased catalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.;
;FLUOROURACIL;DPYD;rs183385770;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;Metabolism/PK;increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele A is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele G.;
;ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;Metabolism/PK;increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele A is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele G.;
;ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;Metabolism/PK;decreasedcatalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele C is associated with decreased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele T.;
;FLUOROURACIL;DPYD;rs114096998;T;Metabolism/PK;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs60139309;C;Metabolism/PK;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;FLUOROURACIL;DPYD;rs143986398;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;SN-38;UGT1A9;rs11692021;C;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Allele C is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.;
;SN-38;UGT1A9;rs72551344;G;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.;
;SN-38;UGT1A9;rs34993780;G;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Allele G is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.;
;FLUOROURACIL;DPYD;rs72549308;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;FLUOROURACIL;DPYD;rs1184321568;del;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele del is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele T.;
;FLUOROURACIL;DPYD;rs143879757;A;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs59086055;A;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs148994843;T;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.;
;DEXTROMETHORPHAN;;rs729559;GG;Metabolism/PK;increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Genotype GG is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to genotypes AA + AG.;
;FLUOROURACIL;DPYD;rs748620513;G;Metabolism/PK;decreasedcatalytic  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased catalytic activity of DPYD when assayed with fluorouracil in 293FT cells as compared to allele C.;
;DEXTROMETHORPHAN;;rs4073010;TT;Metabolism/PK;increased enzyme  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;Genotype TT is associated with increased enzyme activity of CYP2D6 when assayed with dextromethorphan in human liver s9 fractions as compared to genotypes CC + CT.;
;FLUOROURACIL;DPYD;rs72549304;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs200687447;T;Metabolism/PK;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;Metabolism/PK;increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele G is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele A.;
;FLUOROURACIL;DPYD;rs146356975;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;Metabolism/PK;increased catalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele G is associated with increased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele C.;
;FLUOROURACIL;DPYD;rs2297595;C;Metabolism/PK;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with increased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;FLUOROURACIL;DPYD;rs183105782;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;FLUOROURACIL;DPYD;rs190577302;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;Metabolism/PK;decreasedcatalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Allele A is associated with decreased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele G.;
;17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;Metabolism/PK;increased catalytic  activity  of ABCC4 when assayed  with  ➔ 17BETA-ESTRADIOL GLUCURONIDE;Allele T is associated with increased catalytic activity of ABCC4 when assayed with 17beta-estradiol glucuronide as compared to allele C.;
;FLUOROURACIL;DPYD;rs186169810;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;FLUOROURACIL;DPYD;rs143154602;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs368146607;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;FLUOROURACIL;DPYD;rs371258350;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs575853463;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs569661196;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;FLUOROURACIL;DPYD;rs138616379;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;rs2229109;T;Metabolism/PK;decreasedtransport of ABCB1 when assayed  with  ➔ AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C.;
;FLUOROURACIL;DPYD;rs115232898;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;CLOZAPINE;UGT1A4;rs2011425;G;Metabolism/PK;increased catalytic  activity  of UGT1A4 when assayed  with  ➔ CLOZAPINE;Allele G is associated with increased catalytic activity of UGT1A4 when assayed with clozapine as compared to allele T.;
;FLUOROURACIL;DPYD;rs111858276;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;Metabolism/PK;increased  activity  of UGT1A6 when assayed  with  ➔ ACETAMINOPHEN;UGT1A6 *2a is associated with increased activity of UGT1A6 when assayed with acetaminophen in HEK cells as compared to UGT1A6 *1a.;
;FLUOROURACIL;DPYD;rs140039091;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs187713395;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;SN-38;UGT1A9;rs35350960;A;Metabolism/PK;decreasedenzyme  activity  of UGT1A1 when assayed  with  ➔ SN-38;Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38.;
;ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;Metabolism/PK;decreasedcatalytic  activity  of AADAC when assayed  with  ➔ ESLICARBAZEPINE ACETATE;Allele T is associated with decreased catalytic activity of AADAC when assayed with eslicarbazepine acetate as compared to allele A.;
;ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508139;A;Efficacy;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Allele A is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.;
;FLUOROURACIL;MIR27A;rs895819;C;Metabolism/PK;decreasedenzyme  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased enzyme activity of DPYD when assayed with fluorouracil in peripheral blood mononuclear cells as compared to allele T.;
;ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508609;A;Efficacy;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Allele A is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.;
;FLUOROURACIL;DPYD;rs141044036;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;ARACHIDONIC ACID;CYP4F2;rs753169154;G;PD;decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;Allele G is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs201500445;C;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele C is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele T.;
;BUPROPION;CYP2B6;rs535039125;T;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele T is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele C.;
;EFAVIRENZ;CYP2B6;rs117872433;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;BUPROPION;CYP2B6;rs200238771;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele T.;
;ARACHIDONIC ACID;CYP4F2;rs114396708;A;PD;decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;Allele A is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele G.;
;COUMARIN, NICOTINE, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*19;*7 + *19;Metabolism/PK;decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ COUMARIN, NICOTINE, TEGAFUR;CYP2A6 *7 + *19 are associated with decreased catalytic activity of CYP2A6 when assayed with coumarin, nicotine or tegafur as compared to CYP2A6 *1.;
;BUPROPION;CYP2B6;CYP2B6*47;*47;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;CYP2B6 *47 is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells.;
;NICOTINE;CYP2A6;rs4803381;CC + CT;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.;
;EFAVIRENZ;CYP2B6;CYP2B6*47;*47;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;CYP2B6 *47 is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells.;
;NICOTINE;CYP2A6;rs57837628;AG + GG;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotypes AG + GG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype AA.;
;COUMARIN, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*18;*18;Metabolism/PK;decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ COUMARIN, TEGAFUR;CYP2A6 *18 is associated with decreased catalytic activity of CYP2A6 when assayed with coumarin or tegafur as compared to CYP2A6 *1.;
;FLUOROURACIL;DPYD;rs67376798;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;EFAVIRENZ;CYP2B6;CYP2B6*46;*46;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;CYP2B6 *46 is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells.;
;NICOTINE;CYP2A6;rs72549435;C;Metabolism/PK;decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Allele C is associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs535039125;T;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele T is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele C.;
;PREGNENOLONE;SULT2B1;rs746398875;T;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.;
;PREGNENOLONE;SULT2B1;rs762765702;A;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele A is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.;
;COUMARIN;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;Metabolism/PK;decreasedenzyme  activity  of CYP2A6 when assayed  with  ➔ COUMARIN;CYP2A6 *4/*9 is associated with decreased enzyme activity of CYP2A6 when assayed with coumarin.;
;BUPROPION;CYP2B6;rs374099483;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;BUPROPION;CYP2B6;rs764288403;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;BUPROPION;CYP2B6;CYP2B6*46;*46;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;CYP2B6 *46 is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells.;
;EFAVIRENZ;CYP2B6;rs374099483;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;BUPROPION;CYP2B6;rs117872433;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;FLUOROURACIL;DPYD;rs112766203;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;FLUOROURACIL;DPYD;rs1801158;TT;Other;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Genotype TT is associated with increased activity of DPYD when assayed with fluorouracil as compared to genotype CC.;
;FLUOROURACIL;DPYD;rs188052243;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;PREGNENOLONE;SULT2B1;rs527454384;T;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele C.;
;FLUOROURACIL;DPYD;rs61757362;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele G.;
;ARACHIDONIC ACID;CYP4F2;rs2108622;T;PD;decreasedcatalytic  activity  of CYP4F2 when assayed  with  ➔ ARACHIDONIC ACID;Allele T is associated with decreased catalytic activity of CYP4F2 when assayed with arachidonic acid as compared to allele C.;
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*17, CYP2A6*35;*17 + *35;Metabolism/PK;decreasedcatalytic  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;CYP2A6 *17 + *35 are associated with decreased catalytic activity of CYP2A6 when assayed with nicotine as compared to CYP2A6 *1.;
;BUPROPION;CYP2B6;rs148009906;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508293;T;Efficacy;increased  activity  of CFTR when assayed  with  ➔ ELEXACAFTOR, TEZACAFTOR;Allele T is associated with increased activity of CFTR when assayed with elexacaftor and tezacaftor.;
;FLUOROURACIL;DPYD;rs1801268;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;BUPROPION;CYP2B6;rs200458614;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ BUPROPION;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with bupropion by recombinant protein expressed in Sf21 cells as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs764288403;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs200238771;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele T.;
;FLUOROURACIL;DPYD;rs367619008;C;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele C is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele T.;
;EFAVIRENZ;CYP2B6;rs200458614;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;NICOTINE;CYP2A6;rs56113850;CC + CT;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.;
;FLUOROURACIL;DPYD;rs758649719;T;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele T is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;NICOTINE;CYP2A6;rs7259706;TT;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotype TT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype CC.;
;FLUOROURACIL;DPYD;rs369103276;G;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele G is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele A.;
;VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*30;*6 + *30;Metabolism/PK;decreasedcatalytic  activity  of CYP3A4 when assayed  with  ➔ VANDETANIB;CYP3A4 *6 + *30 is associated with decreased catalytic activity of CYP3A4 when assayed with vandetanib as compared to CYP3A4 *1.;
;NICOTINE;CYP2A6;rs28399453;AA + AG;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotypes AA + AG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype GG.;
;NICOTINE;CYP2A6;rs8192733;CC + CG;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotypes CC + CG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype GG.;
;EFAVIRENZ;CYP2B6;rs148009906;A;Metabolism/PK;decreasedcatalytic  activity  of CYP2B6 when assayed  with  ➔ EFAVIRENZ;Allele A is associated with decreased catalytic activity of CYP2B6 when assayed with efavirenz by recombinant protein expressed in Sf21 cells as compared to allele G.;
;PREGNENOLONE;SULT2B1;rs777924668;G;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele G is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele C.;
;FLUOROURACIL;DPYD;rs55674432;A;Metabolism/PK;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Allele A is associated with decreased activity of DPYD when assayed with fluorouracil as compared to allele C.;
;FLUOROURACIL;DPYD;rs55886062;CC;Other;decreased activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Genotype CC is associated with decreased activity of DPYD when assayed with fluorouracil as compared to genotype AA.;
;LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;Metabolism/PK;decreasedenzyme  activity  of CYP2A6 when assayed  with  ➔ LETROZOLE;CYP2A6 *1/*4 + *1/*7 + *4/*4 + *4/*9 are associated with decreased enzyme activity of CYP2A6 when assayed with letrozole in human liver microsome samples as compared to CYP2A6 *1/*1.;
;NICOTINE;CYP2A6;rs7260629;GG;Metabolism/PK;increased  activity  of CYP2A6 when assayed  with  ➔ NICOTINE;Genotype GG are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT.;
;FLUOROURACIL;DPYD;rs1801265;GG;Other;increased  activity  of DPYD when assayed  with  ➔ FLUOROURACIL;Genotype GG is associated with increased activity of DPYD when assayed with fluorouracil as compared to genotype AA.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*89 + *92 + *93 + *96;Metabolism/PK;decreasedcatalytic  activity  of CYP2D6 when assayed  with  ➔ DEXTROMETHORPHAN;CYP2D6 *89 + *92 + *93 + *96 are associated with decreased catalytic activity of CYP2D6 when assayed with dextromethorphan in 293 FT cells as compared to CYP2D6 *1.;
;PREGNENOLONE;SULT2B1;rs777140014;A;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele A is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.;
;TESTOSTERONE;CYP3A5;rs55817950;A;Metabolism/PK;decreasedenzyme  activity  of CYP3A5 when assayed  with  ➔ TESTOSTERONE;Allele A is associated with decreased enzyme activity of CYP3A5 when assayed with testosterone as compared to allele G.;
;NIFEDIPINE;CYP3A5;rs72552791;C;Metabolism/PK;decreasedenzyme  activity  of CYP3A5 when assayed  with  ➔ NIFEDIPINE;Allele C is associated with decreased enzyme activity of CYP3A5 when assayed with nifedipine as compared to allele T.;
;PREGNENOLONE;SULT2B1;rs774212320;T;Metabolism/PK;decreasedenzyme  activity  of SULT2B1 when assayed  with  ➔ PREGNENOLONE;Allele T is associated with decreased enzyme activity of SULT2B1 when assayed with pregnenolone as compared to allele G.;
;;CYP2C9;rs762081829;T;Other;decreased expression of CYP2C9protein ➔ ;Allele T is associated with decreased expression of CYP2C9 protein as compared to allele C.;
;;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;Other;increased  expression of SLCO1B1protein ➔ ;SLCO1B1 *14 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1.;
;;VDR;rs11568820;T;Other;increased steady-state level of CYP3A4protein ➔ ;Allele T is associated with increased steady-state level of CYP3A4 protein as compared to allele C.;
;;A2M;rs669;T;Metabolism/PK;increased steady-state level of A2Mprotein ➔ ;Allele T is associated with increased steady-state level of A2M protein as compared to allele C.;
;;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37;Other;increased  expression of SLCO1B1protein ➔ ;SLCO1B1 *37 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1.;
;;NAMPT;rs1319501;CC + CT;Other;decreasedsteady-state level of NAMPTprotein ➔ ;Genotypes CC + CT is associated with decreased steady-state level of NAMPT protein as compared to genotype TT.;
;;DPYD;rs1801160;T;Other;increased  expression of DPYDprotein ➔ ;Allele T is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.;
;;NAMPT;rs3801266;CC + CT;Other;increased steady-state level of NAMPTprotein ➔ ;Genotypes CC + CT is associated with increased steady-state level of NAMPT protein as compared to genotype TT.;
;;SLCO1B1;SLCO1B1*1, SLCO1B1*20;*20;Other;increased  expression of SLCO1B1protein ➔ ;SLCO1B1 *20 is associated with increased expression of SLCO1B1 protein as compared to SLCO1B1 *1/*1.;
;;ABCC11;rs17822471;AA + AG;Other;decreased expression of ABCC11protein ➔ ;Genotypes AA + AG are associated with decreased expression of ABCC11 protein in liver samples as compared to genotype GG.;
;;CYP2C9;rs771237265;C;Other;decreased expression of CYP2C9protein ➔ ;Allele C is associated with decreased expression of CYP2C9 protein as compared to allele A.;
;;CYP2C9;rs761895497;C;Other;decreased expression of CYP2C9protein ➔ ;Allele C is associated with decreased expression of CYP2C9 protein as compared to allele T.;
;;CYP2C19;rs183701923;T;Other;decreased expression of CYP2C19protein ➔ ;Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.;
;;DPYD;rs748620513;G;Other;increased  expression of DPYDprotein ➔ ;Allele G is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.;
;;CYP2C19;rs61311738;T;Other;decreased expression of CYP2C19protein ➔ ;Allele T is associated with decreased expression of CYP2C19 protein as compared to allele C.;
;;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;;decreasedenzyme  activity  of TPMTprotein ➔ ;TPMT *1/*2 + *1/*3A + *1/*3C is associated with decreased enzyme activity of TPMT protein as compared to TPMT *1/*1.;
;;DPYD;rs143879757;A;Other;increased  expression of DPYDprotein ➔ ;Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele G.;
;;DPYD;rs1212037891;T;Other;increased  expression of DPYDprotein ➔ ;Allele T is associated with increased expression of DPYD protein in 293FT cells as compared to allele A.;
;;DPYD;rs72549306;A;Other;increased  expression of DPYDprotein ➔ ;Allele A is associated with increased expression of DPYD protein in 293FT cells as compared to allele C.;
;;CYP2C19;rs140278421;A;Other;decreased expression of CYP2C19protein ➔ ;Allele A is associated with decreased expression of CYP2C19 protein as compared to allele G.;
;DOXORUBICIN;CBR1;rs9024;GG;Metabolism/PK;increased catalytic  activity  of CBR1of  ➔ DOXORUBICIN;Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.;
;DOXORUBICIN;CBR1;rs9024;GG;Metabolism/PK;increased catalytic  activity  of CBR1of  ➔ DOXORUBICIN;Genotype GG is associated with increased catalytic activity of CBR1 of doxorubicin.;
;;ADRB2;rs1042713;G;Other;decreased activity  of ADRB2of  ➔ ;Allele G is associated with decreased activity of ADRB2 of peripheral lymphocytes as compared to allele A.;
;;NOS3;rs1799983;GT + TT;;decreased expression of NOS3mRNA ➔ ;Genotypes GT + TT is associated with decreased expression of NOS3 mRNA as compared to genotype GG.;
;;IL18;rs5744247;CC + CG;Other;increased  expression of IL18mRNA ➔ ;Genotypes CC + CG is associated with increased expression of IL18 mRNA as compared to genotype GG.;
;;IL18;rs1946518;GG + GT;Other;increased  expression of IL18mRNA ➔ ;Genotypes GG + GT is associated with increased expression of IL18 mRNA as compared to genotype TT.;
;;CYP3A5;rs776746;CC;Other;decreased expression of CYP3A5mRNA ➔ ;Genotype CC is associated with decreased expression of CYP3A5 mRNA as compared to genotypes CT + TT.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;PD;decreased expression of HDAC2mRNA ➔ ;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of HDAC2 mRNA as compared to CYP3A5 *3/*3.;
;;CYP3A5;rs776746;TT;Other;increased  expression of CYP3A5mRNA ➔ ;Genotype TT is associated with increased expression of CYP3A5 mRNA in liver samples as compared to genotypes CC + CT.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;PD;decreased expression of FKBP5mRNA ➔ ;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of FKBP5 mRNA as compared to CYP3A5 *3/*3.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;PD;decreased expression of NR3C1mRNA ➔ ;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of NR3C1 mRNA as compared to CYP3A5 *3/*3.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;PD;decreased expression of GLCCI1mRNA ➔ ;CYP3A5 *1/*1 + *1/*3 is associated with decreased expression of GLCCI1 mRNA as compared to CYP3A5 *3/*3.;
;;ERCC1;rs2298881;A;Other;decreased expression of ERCC1mRNA ➔ ;Allele A is associated with decreased expression of ERCC1 mRNA in whole blood and gastric cells as compared to allele C.;
;;HSPA5;rs430397;TT;Other;increased  expression of HSPA5mRNA ➔ ;Genotype TT is associated with increased expression of HSPA5 mRNA in NSCLC tissue samples as compared to genotype CC.;
;;CCND1;rs9344;AA + AG;Other;increased transcription of CCND1mRNA ➔ ;Genotypes AA + AG is associated with increased transcription of CCND1 mRNA as compared to genotype GG.;
;;ABCC2;rs113646094;CG;Other;increased  expression of ABCC2mRNA ➔ ;Genotype CG is associated with increased expression of ABCC2 mRNA in human liver samples as compared to genotype CC.;
;;ABCB1;rs1128503;GG;;increased  expression of ABCB1mRNA ➔ ;Genotype GG is associated with increased expression of ABCB1 mRNA as compared to genotype AA.;
;;XRCC4;rs2075685;T;Other;increased  expression of XRCC4mRNA ➔ ;Allele T is associated with increased expression of XRCC4 mRNA in gastric cells as compared to allele G.;
;;XRCC4;rs10040363;G;Other;increased  expression of ERCC1mRNA ➔ ;Allele G is associated with increased expression of ERCC1 mRNA in whole blood but not gastric cells as compared to allele A.;
;;GCLC;rs761142;CC;Other;decreased expression of GCLCmRNA ➔ ;Genotype CC is associated with decreased expression of GCLC mRNA in liver tissue and B-lymphocytes as compared to genotype AA.;
;;BCL2L11;rs724710;T;Other;decreased expression of BCL2L11mRNA ➔ ;Allele T is associated with decreased expression of BCL2L11 mRNA as compared to allele C.;
;;EPO;rs1617640;AA;Other;increased  expression of EPOmRNA ➔ ;Genotype AA is associated with increased expression of EPO mRNA as compared to genotype AC.;
;;KDR;rs34231037;G;Other;decreasedsteady-state level of KDR ➔ ;Allele G is associated with decreased steady-state level of KDR as compared to allele A.;
;METHOTREXATE;GGH;rs11545078;A;Metabolism/PK;decreased clearance of  ➔ METHOTREXATE;Allele A is associated with decreased clearance of methotrexate.;
;;DPYD;rs1801265;G;Metabolism/PK;increased  activity  of DPYD ➔ ;Allele G is associated with increased activity of DPYD.;
;;FCER2;rs28364072;GG;;decreased expression of FCER2 ➔ ;Genotype GG is associated with decreased expression of FCER2.;
;;DPYD;rs114096998;T;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele T is associated with decreased catalytic activity of DPYD as compared to allele G.;
;;DPYD;rs55886062;AC;Other;decreased activity  of DPYD ➔ ;Genotype AC is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype AA.;
;;MGMT;rs4751104;G;Metabolism/PK;increased transcription of MGMT ➔ ;Allele G is associated with increased transcription of MGMT in human liver samples as compared to allele A.;
;;ERCC2;rs1799793;TT;;increased  expression of ERCC2 ➔ ;Genotype TT is associated with increased expression of ERCC2 in diagnostic FFPE tumor samples as compared to genotypes CC + CT.;
;CISPLATIN;ERCC2;rs13181;GG;Toxicity;decreasedsensitivity to  ➔ CISPLATIN;Genotype GG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype TT.;
;;ERCC2;rs13181;GG;;increased  expression of ERCC2 ➔ ;Genotype GG is associated with increased expression of ERCC2 in diagnostic FFPE tumor samples as compared to genotypes GT + TT.;
;;GSTT1;rs1007888;T;Metabolism/PK;increased transcription of GSTT1 ➔ ;Allele T is associated with increased transcription of GSTT1 in human liver samples as compared to allele C.;
;;KCNQ3;rs7818112;AA;Other;increased transcription of ABCB1 ➔ ;Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AC + CC.;
;;GSK3B;rs334558;A;;increased transcription of GSK3B ➔ ;Allele A is associated with increased transcription of GSK3B.;
;CISPLATIN;GSTP1;rs1695;AG;Toxicity;decreasedsensitivity to  ➔ CISPLATIN;Genotype AG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype AA.;
;BUSULFAN;GSTM1;rs3754446;C;Metabolism/PK;increased clearance of  ➔ BUSULFAN;Allele C is associated with increased clearance of busulfan as compared to allele A.;
;;DPYD;rs780025995;A;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.;
;;F12;rs1801020;G;Metabolism/PK;increased enzyme  activity  of F12 ➔ ;Allele G is associated with increased enzyme activity of F12 as compared to allele A.;
;;ERCC1;rs11615;GG;;increased  expression of ERCC1 ➔ ;Genotype GG is associated with increased expression of ERCC1 in diagnostic FFPE tumor samples as compared to genotypes AA + AG.;
;;IL7;rs16906115;AA + AG;Other;increased  expression of IL7 ➔ ;Genotypes AA + AG is associated with increased expression of IL7 in B-cells from Melanoma patient as compared to genotype GG.;
;;F3;rs841698;T;;increased  expression of ABCD3 ➔ ;Allele T is associated with increased expression of ABCD3 in HapMap cells.;
;;DPYD;rs56038477;CT + TT;Metabolism/PK;decreased activity  of DPYD ➔ ;Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.;
;;DPYD;rs2297595;C;Other;decreased activity  of DPYD ➔ ;Allele C is associated with decreased activity of DPYD.;
;;DPYD;rs1801160;CT + TT;Metabolism/PK;decreased activity  of DPYD ➔ ;Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC.;
;;DPYD;rs2297595;CC + CT;Metabolism/PK;decreased activity  of DPYD ➔ ;Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT.;
;;HPR;rs2000999;G;Other;increased  expression of HP ➔ ;Allele G is associated with increased expression of HP as compared to allele A.;
;FLUOROURACIL;DPYD;rs4294451;A;Toxicity;increased sensitivity to  ➔ FLUOROURACIL;Allele A is associated with increased sensitivity to fluorouracil as compared to allele A.;
;;DPYD;rs115232898;CT;Other;decreased activity  of DPYD ➔ ;Genotype CT is associated with decreased activity of DPYD as compared to genotype TT.;
;;DPYD;rs4294451;T;Other;increased  expression of DPYD ➔ ;Allele T is associated with increased expression of DPYD as compared to allele A.;
;TAMOXIFEN;E2F7;rs310786;CC;Other;increased sensitivity to  ➔ TAMOXIFEN;Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.;
;;ECHDC1;rs6569487;AA;Other;increased transcription of ABCB1 ➔ ;Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.;
;;EGFR;rs712829;TT;;increased  expression of EGFR ➔ ;Genotype TT is associated with increased expression of EGFR NCI60 cell lines.;
;;HLA-G;rs1063320;C;Other;increased  expression of HLA-G ➔ ;Allele C is associated with increased expression of HLA-G in lymphoblastoid cell lines as compared to allele G.;
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Other;increased sensitivity to  ➔ CARBAMAZEPINE;HLA-DRB1 *07:01 is associated with increased sensitivity to carbamazepine.;
;;DPYD;rs3918290;CT;Other;decreased activity  of DPYD ➔ ;Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.;
;;IFNL3;rs4803217;C;Other;increased  expression of IFNL3 ➔ ;Allele C is associated with increased expression of IFNL3 as compared to allele A.;
;;DPYD;rs3918290;CT;Other;decreased activity  of DPYD ➔ ;Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC.;
;CISPLATIN;ERCC1;rs11615;GG;Toxicity;decreasedsensitivity to  ➔ CISPLATIN;Genotype GG is associated with decreased sensitivity to cisplatin High-grade osteosarcoma cells as compared to genotype AA.;
;;DPYD;rs748639205;G;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele G is associated with decreased catalytic activity of DPYD as compared to allele A.;
;;DPYD;rs75017182;CG;Other;decreased activity  of DPYD ➔ ;Genotype CG is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype GG.;
;FLUOROURACIL;DPYD;rs3918290;CT;Other;decreased clearance of  ➔ FLUOROURACIL;Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC.;
;;IFNL4;rs11322783;TT/TT;Other;increased  expression of IFNAR1 ➔ ;Genotype TT/TT is associated with increased expression of IFNAR1 as compared to genotypes G/TT + GG.;
;;DPYD;rs75017182;C;Metabolism/PK;decreased activity  of DPYD ➔ ;Allele C is associated with decreased activity of DPYD.;
;;IMPDH2;rs121434586;A;Other;decreasedenzyme  activity  of IMPDH2 ➔ ;Allele A is associated with decreased enzyme activity of IMPDH2 as compared to allele G.;
;;DPYD;rs67376798;A;Other;decreased activity  of DPYD ➔ ;Allele A is associated with decreased activity of DPYD.;
;CALCIUM;RYR1;rs118192167;AG;Other;increased steady-state level of  ➔ CALCIUM;Genotype AG is associated with increased steady-state level of calcium as compared to genotype AA.;
;;MIR6076;rs1463411;G;Other;decreased expression of P2RY12 ➔ ;Allele G is associated with decreased expression of P2RY12 as compared to allele T.;
;DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;Metabolism/PK;increased sulfation of  ➔ DESMETHYLNAPROXEN;Allele G is associated with increased sulfation of desmethylnaproxen as compared to allele A.;
;ACETAMINOPHEN;SULT1A1;rs28374453;G;Metabolism/PK;increased sulfation of  ➔ ACETAMINOPHEN;Allele G is associated with increased sulfation of acetaminophen as compared to allele A.;
;DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.;
;ACETAMINOPHEN;SULT1A1;rs1042008;A;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.;
;DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele A.;
;DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele C is associated with decreased sulfation of desmethylnaproxen as compared to allele A.;
;ACETAMINOPHEN;SULT1A1;rs72547527;T;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.;
;TAPENTADOL;SULT1A1;rs1042008;A;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele A is associated with decreased sulfation of tapentadol as compared to allele G.;
;ACETAMINOPHEN;SULT1A1;rs767487725;C;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele C is associated with decreased sulfation of acetaminophen as compared to allele A.;
;DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.;
;ACETAMINOPHEN;SULT1A1;rs544820732;A;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele A is associated with decreased sulfation of acetaminophen as compared to allele G.;
;;TBXAS1;rs6962291;AA;Other;decreasedsteady-state level of TBX2 ➔ ;Genotype AA is associated with decreased steady-state level of TBX2 in plasma.;
;;TBXAS1;rs6962291;AA;Other;decreased expression of TBXAS1 ➔ ;Genotype AA is associated with decreased expression of TBXAS1 in PBMCs.;
;;TMPRSS11E;rs2168047;T;;increased  expression of UGT2B4 ➔ ;Allele T is associated with increased expression of UGT2B4 in normal breast tissue.;
;;TNF;rs1800629;AA + AG;Metabolism/PK;increased  activity  of TNF ➔ ;Genotypes AA + AG is associated with increased activity of TNF as compared to genotype GG.;
;;TPH2;rs7305115;AA;Other;increased  expression of TPH2 ➔ ;Genotype AA is associated with increased expression of TPH2 in human brain samples as compared to genotypes AG + GG.;
;;TPH2;rs4290270;T;Other;increased  expression of TPH2 ➔ ;Allele T is associated with increased expression of TPH2 in human brain samples as compared to allele A.;
;THIOGUANINE;TPMT;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;*7 + *10 + *12 + *13;Metabolism/PK;decreased clearance of  ➔ THIOGUANINE;TPMT *7 + *10 + *12 + *13 are associated with decreased clearance of thioguanine in yeast cells as compared to TPMT *1.;
;;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;Other;decreased activity  of TPMT ➔ ;TPMT *3A + *3C are associated with decreased activity of TPMT as compared to TPMT *1/*1.;
;ACETAMINOPHEN;SULT1A1;rs765399160;T;Metabolism/PK;increased sulfation of  ➔ ACETAMINOPHEN;Allele T is associated with increased sulfation of acetaminophen as compared to allele C.;
;;TPMT;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;*3A + *3C + *24;Other;decreased expression of TPMT ➔ ;TPMT *3A + *3C + *24 is associated with decreased expression of TPMT as compared to TPMT *1/*1.;
;ACETAMINOPHEN;SULT1A1;rs552524124;G;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele G is associated with decreased sulfation of acetaminophen as compared to allele T.;
;TAPENTADOL;SULT1A1;rs1042028;T;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele T is associated with decreased sulfation of tapentadol as compared to allele C.;
;ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Metabolism/PK;decreaseduptake of  ➔ ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1 *15 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.;
;PACLITAXEL;SLCO1B3;rs7311358;A;Other;decreasedtransport of  ➔ PACLITAXEL;Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.;
;ROSUVASTATIN;SLCO2B1;rs2306168;T;Metabolism/PK;decreaseduptake of  ➔ ROSUVASTATIN;Allele T is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele C.;
;ROSUVASTATIN;SLCO2B1;rs142693902;A;Metabolism/PK;decreaseduptake of  ➔ ROSUVASTATIN;Allele A is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele G.;
;ROSUVASTATIN;SLCO2B1;rs35199625;A;Metabolism/PK;decreaseduptake of  ➔ ROSUVASTATIN;Allele A is associated with decreased uptake of rosuvastatin in transfected HEK293T cells as compared to allele G.;
;METHOTREXATE;SOD2;rs4880;G;Toxicity;decreasedsensitivity to  ➔ METHOTREXATE;Allele G is associated with decreased sensitivity to methotrexate in peripheral blood mononuclear cells as compared to allele A.;
;;SPAG16;rs35945601;CC;Other;increased transcription of ABCB1 ➔ ;Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.;
;;SQSTM1;rs10277;C;Metabolism/PK;increased transcription of SQSTM1 ➔ ;Allele C is associated with increased transcription of SQSTM1 in human liver samples as compared to allele T.;
;;STXBP4;rs9303363;AA;Other;increased transcription of ABCB1 ➔ ;Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.;
;DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele G is associated with decreased sulfation of desmethylnaproxen as compared to allele T.;
;TAPENTADOL;SULT1A1;rs758145522;T;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele T is associated with decreased sulfation of tapentadol as compared to allele A.;
;TAPENTADOL;SULT1A1;rs72547527;T;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele T is associated with decreased sulfation of tapentadol as compared to allele C.;
;TAPENTADOL;SULT1A1;rs544820732;A;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele A is associated with decreased sulfation of tapentadol as compared to allele G.;
;TAPENTADOL;SULT1A1;rs767487725;C;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele C is associated with decreased sulfation of tapentadol as compared to allele A.;
;DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele A is associated with decreased sulfation of desmethylnaproxen as compared to allele G.;
;ACETAMINOPHEN;SULT1A1;rs1042028;T;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele T is associated with decreased sulfation of acetaminophen as compared to allele C.;
;DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;Metabolism/PK;decreasedsulfation of  ➔ DESMETHYLNAPROXEN;Allele T is associated with decreased sulfation of desmethylnaproxen as compared to allele C.;
;TAPENTADOL;SULT1A1;rs552524124;G;Metabolism/PK;decreasedsulfation of  ➔ TAPENTADOL;Allele G is associated with decreased sulfation of tapentadol as compared to allele T.;
;TAPENTADOL;SULT1A1;rs28374453;G;Metabolism/PK;increased sulfation of  ➔ TAPENTADOL;Allele G is associated with increased sulfation of tapentadol as compared to allele A.;
;ACETAMINOPHEN;SULT1A1;rs758145522;T;Metabolism/PK;decreasedsulfation of  ➔ ACETAMINOPHEN;Allele T is associated with decreased sulfation of acetaminophen as compared to allele A.;
;ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;Metabolism/PK;decreaseduptake of  ➔ ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1 *5 is associated with decreased uptake of atorvastatin, cerivastatin and pravastatin as compared to SLCO1B1 *1/*1.;
;MERCAPTOPURINE;TPMT;TPMT deficiency;;Toxicity, Metabolism/PK;increased concentrations of  ➔ MERCAPTOPURINE;TPMT deficiency is associated with increased concentrations of mercaptopurine in mice.;
;CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Toxicity;increased sensitivity to  ➔ CISPLATIN;TPMT *3A is associated with increased sensitivity to cisplatin in UB/OC1 cells as compared to TPMT *1.;
;SN-38;UGT1A9;rs2741049;CT + TT;Metabolism/PK;increased clearance of  ➔ SN-38;Genotypes CT + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype CC.;
;;UGT1A9;rs3832043;T/del + TT;Metabolism/PK;increased formation of UGT1A9 ➔ ;Genotypes T/del + TT is associated with increased formation of UGT1A9 in human liver microsomes as compared to genotype del/del.;
;;UGT1A9;rs2741049;TT;Metabolism/PK;increased formation of UGT1A1 ➔ ;Genotype TT is associated with increased formation of UGT1A1 in human liver microsomes as compared to genotype CC.;
;SN-38;UGT1A9;rs3806598;AA;Metabolism/PK;increased clearance of  ➔ SN-38;Genotype AA is associated with increased clearance of SN-38 in human liver microsomes as compared to genotypes AC + CC.;
;;UGT1A9;rs3832043;T/del + TT;Metabolism/PK;increased formation of UGT1A1 ➔ ;Genotypes T/del + TT is associated with increased formation of UGT1A1 in human liver microsomes as compared to genotype del/del.;
;SN-38;UGT1A9;rs3832043;T/del + TT;Metabolism/PK;increased clearance of  ➔ SN-38;Genotypes T/del + TT is associated with increased clearance of SN-38 in human liver microsomes as compared to genotype del/del.;
;;UGT1A9;rs2741049;CT + TT;Metabolism/PK;increased formation of UGT1A9 ➔ ;Genotypes CT + TT is associated with increased formation of UGT1A9 in human liver microsomes as compared to genotype CC.;
;OLANZAPINE;UGT2B10;rs61750900;GT + TT;Metabolism/PK;decreasedglucuronidation of  ➔ OLANZAPINE;Genotypes GT + TT is associated with decreased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to genotype GG.;
;LORAZEPAM;UGT2B15;rs1902023;AA;Metabolism/PK;decreased clearance of  ➔ LORAZEPAM;Genotype AA is associated with decreased clearance of lorazepam.;
;OXAZEPAM;UGT2B15;rs1902023;A;Other;decreasedglucuronidation of  ➔ OXAZEPAM;Allele A is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele C.;
;;UGT2B17;rs6817882;C;Other;increased  expression of UGT2B17 ➔ ;Allele C is associated with increased expression of UGT2B17 in human livers as compared to allele T.;
;;UGT2B4;rs4557343;T;;increased  expression of UGT2B15 ➔ ;Allele T is associated with increased expression of UGT2B15 in normal breast tissue.;
;BUPRENORPHINE;UGT2B7;rs7438135;A;Metabolism/PK;increased glucuronidation of  ➔ BUPRENORPHINE;Allele A is associated with increased glucuronidation of buprenorphine as compared to allele G.;
;;UMPS;rs1801019;C;Metabolism/PK;increased  expression of UMPS ➔ ;Allele C is associated with increased expression of UMPS in normal colon mucosa cells.;
;;VKORC1;rs56314408;C;Other;increased transcription of VKORC1 ➔ ;Allele C is associated with increased transcription of VKORC1 in HepG2 cells as compared to allele T.;
;;VKORC1;rs9923231;T;;decreased expression of VKORC1 ➔ ;Allele T is associated with decreased expression of VKORC1.;
;;WBP2NL;rs5758550;AG + GG;Other;increased  expression of CYP2D6 ➔ ;Genotypes AG + GG are associated with increased expression of CYP2D6 in human liver cells as compared to genotype AA.;
;;YAP1;rs1820453;C;;decreasedtranscription of YAP1 ➔ ;Allele C is associated with decreased transcription of YAP1 H446 cells.;
;;YEATS4;rs7297610;CC;Metabolism/PK;increased  expression of YEATS4 ➔ ;Genotype CC is associated with increased expression of YEATS4 in whole blood RNA.;
;RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2;*2/*2;Metabolism/PK;increased clearance of  ➔ RALOXIFENE;UGT1A8 *2/*2 is associated with increased clearance of raloxifene in human jejunum homogenates as compared to UGT1A8 *1a/*1a + *1a/*2.;
;THIOGUANINE;TPMT;TPMT*1, TPMT*16;*16;Metabolism/PK;decreased clearance of  ➔ THIOGUANINE;TPMT *16 is associated with decreased clearance of thioguanine in artificial constructs expressed in yeast cells as compared to TPMT *1.;
;VALPROIC ACID;UGT1A6;rs1105879;C;Metabolism/PK;increased glucuronidation of  ➔ VALPROIC ACID;Allele C is associated with increased glucuronidation of valproic acid in HEK 293 cells..;
;CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;Metabolism/PK;increased formation of  ➔ CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;Allele G is associated with increased formation of clozapine 5-N-glucuronide and desmethylclozapine glucuronide in human liver microsomes as compared to allele T.;
;CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;Toxicity;increased sensitivity to  ➔ CISPLATIN;TPMT *3A is associated with increased sensitivity to cisplatin in HEI-OC1 cells as compared to TPMT *1.;
;;TXLNB;rs9495425;CC;Other;increased transcription of ABCB1 ➔ ;Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.;
;;UGT1A1;rs4124874;GG + GT;Metabolism/PK;decreasedformation of UGT1A1 ➔ ;Genotypes GG + GT is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype TT.;
;SN-38;UGT1A1;rs4124874;GG + GT;Metabolism/PK;decreased clearance of  ➔ SN-38;Genotypes GG + GT is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype TT.;
;OXAZEPAM;UGT1A1;rs10929302;A;Other;decreasedglucuronidation of  ➔ OXAZEPAM;Allele A is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele G.;
;;UGT1A1;rs10929302;A;Other;decreasedconcentrations of UGT1A1 ➔ ;Allele A is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele G.;
;;UGT1A1;rs28967009;A;Other;increased  expression of UGT1A1 ➔ ;Allele A is associated with increased expression of UGT1A1 as compared to allele T.;
;SN-38;UGT1A1;rs4148323;AG;Metabolism/PK;decreased clearance of  ➔ SN-38;Genotype AG is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype GG.;
;;UGT1A1;rs4148323;AG;Metabolism/PK;decreasedformation of UGT1A1 ➔ ;Genotype AG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype GG.;
;OXAZEPAM;UGT1A1;rs887829;T;Other;decreasedglucuronidation of  ➔ OXAZEPAM;Allele T is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele C.;
;OXAZEPAM;UGT1A1;rs4124874;G;Other;glucuronidation of  ➔ OXAZEPAM;Allele G is associated with glucuronidation of oxazepam in human liver microsomes as compared to allele T.;
;;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Other;decreasedconcentrations of UGT1A1 ➔ ;UGT1A1 *28 is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to UGT1A1 *1.;
;CLOZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Metabolism/PK;decreasedmetabolism of  ➔ CLOZAPINE;UGT1A1 *28/*28 is associated with decreased metabolism of clozapine in human liver microsomes as compared to UGT1A1 *1/*1 + *1/*28.;
;BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Metabolism/PK;decreasedmetabolism of  ➔ BELINOSTAT;UGT1A1 *28 is associated with decreased metabolism of belinostat in human liver microsomes as compared to UGT1A1 *1.;
;;UGT1A1;rs887829;T;Other;decreasedconcentrations of UGT1A1 ➔ ;Allele T is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele C.;
;;UGT1A1;rs4124874;G;Other;decreasedconcentrations of UGT1A1 ➔ ;Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele T.;
;RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Metabolism/PK;decreasedformation of  ➔ RALOXIFENE 6-GLUCURONIDE;UGT1A1 *28 is associated with decreased formation of raloxifene 6-glucuronide in human liver microsomes as compared to UGT1A1 *1.;
;;UGT1A1;rs11568319;CG;Metabolism/PK;decreasedformation of UGT1A1 ➔ ;Genotype CG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype CC.;
;;UGT1A3;rs7604115;T;Other;increased  expression of UGT1A3 ➔ ;Allele T is associated with increased expression of UGT1A3 as compared to allele C.;
;OLANZAPINE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;Metabolism/PK;increased glucuronidation of  ➔ OLANZAPINE;UGT1A4 *3a is associated with increased glucuronidation of olanzapine in experiments with expressed proteins and HLMs as compared to UGT1A4 *1a.;
;;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Other;decreased expression of SLCO1B1 ➔ ;SLCO1B1 *15 is associated with decreased expression of SLCO1B1 as compared to SLCO1B1 *1/*1.;
;ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;Metabolism/PK;decreasedtransport of  ➔ ATRASENTAN;SLCO1B1 *14 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.;
;ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;*9;Metabolism/PK;decreasedtransport of  ➔ ATRASENTAN;SLCO1B1 *9 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.;
;;PACSIN2;rs2413739;CT + TT;Metabolism/PK;decreased activity  of TPMT ➔ ;Genotypes CT + TT are associated with decreased activity of TPMT as compared to genotype CC.;
;;PHETA2, SMDT1;rs1807493;G;Metabolism/PK;increased  expression of CYP2D6 ➔ ;Allele G is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to allele C.;
;;PITPNM2;rs12425009;C;;decreased expression of ABCB9 ➔ ;Allele C is associated with decreased expression of ABCB9 in HapMap cells.;
;;PKNOX1;rs2839629;A;Other;increased  expression of PKNOX1 ➔ ;Allele A is associated with increased expression of PKNOX1 as compared to allele G.;
;;PKNOX1;rs2839629;A;Other;increased  expression of CBS ➔ ;Allele A is associated with increased expression of CBS as compared to allele G.;
;;PLG;rs783145;G;Metabolism/PK;decreasedtranscription of PRSS55 ➔ ;Allele G is associated with decreased transcription of PRSS55 in human liver samples as compared to allele A.;
;;PLG;rs783145;G;Metabolism/PK;increased transcription of PLG ➔ ;Allele G is associated with increased transcription of PLG in human liver samples as compared to allele A.;
;;PLXNB3;rs4898439;A;;increased  expression of ABCD1 ➔ ;Allele A is associated with increased expression of ABCD1 in HapMap cells.;
;;POR;rs2868177;AG;Efficacy;increased enzyme  activity  of CYP2B6 ➔ ;Genotype AG is associated with increased enzyme activity of CYP2B6 as compared to genotype AA.;
;;PPARA;rs4253728;AA;Metabolism/PK;decreasedconcentrations of CYP3A4 ➔ ;Genotype AA is associated with decreased concentrations of CYP3A4 protein in human liver microsomes as compared to genotypes AG + GG.;
;;PROM1;rs2286455;CC;;decreased expression of PROM1 ➔ ;Genotype CC is associated with decreased expression of PROM1 primary tumor tissue.;
;;PSMB8, TAP1, TAP2;rs2071543;T;;increased  expression of TAP2 ➔ ;Allele T is associated with increased expression of TAP2 in HapMap cells.;
;;PSMB8, TAP2;rs9357155;A;;increased  expression of TAP2 ➔ ;Allele A is associated with increased expression of TAP2 in HapMap cells.;
;;RALGAPA2;rs3827963;GG;Other;increased transcription of ABCB1 ➔ ;Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.;
;DOXORUBICIN;RARG;rs2229774;A;Toxicity;increased sensitivity to  ➔ DOXORUBICIN;Allele A is associated with increased sensitivity to doxorubicin in induced pluripotent stem cell derived cardiomyocytes as compared to allele G.;
;;RARG;rs2229774;A;Other;decreasedprotein stability of RARG ➔ ;Allele A is associated with decreased protein stability of RARG as compared to allele G.;
;;REDIC1;rs10783969;T;;increased  expression of ABCD2 ➔ ;Allele T is associated with increased expression of ABCD2 in HapMap cells.;
;;RGMA;rs7165938;GG;Other;increased transcription of ABCB1 ➔ ;Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.;
;CAFFEINE;RYR1;rs193922753;T;Other;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.;
;;ORMDL3;rs2872507;AG + GG;Metabolism/PK;increased  expression of ORMDL3 ➔ ;Genotypes AG + GG are associated with increased expression of ORMDL3 in before-treatment blood samples from pediatric asthma patients as compared to genotype AA.;
;CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs118204423;C;Other;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL, HALOTHANE;Allele C is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.;
;ETHANOL;OPRM1;rs1799971;GG;Efficacy;decreasedsensitivity to  ➔ ETHANOL;Genotype GG is associated with decreased sensitivity to ethanol in iPS-derived neurons as compared to genotype AA.;
;;NT5C2;rs11191612;GG;Metabolism/PK;increased transcription of NT5C2 ➔ ;Genotype GG is associated with increased transcription of NT5C2 as compared to genotypes AA + AG.;
;PAROMOMYCIN;MT-RNR1;rs267606619;T;PD;increased sensitivity to  ➔ PAROMOMYCIN;Allele T is associated with increased sensitivity to paromomycin in cybrid lines.;
;GEMCITABINE;MTHFR;rs1801131;GG + GT;Toxicity;increased sensitivity to  ➔ GEMCITABINE;Genotypes GG + GT is associated with increased sensitivity to gemcitabine as compared to genotype TT.;
;;NAF1;rs17571991;AA;Other;increased transcription of ABCC1 ➔ ;Genotype AA is associated with increased transcription of ABCC1 as compared to genotypes AG + GG.;
;SOLITHROMYCIN;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*4;Metabolism/PK;increased metabolism of  ➔ SOLITHROMYCIN;NAT2 *4 is associated with increased metabolism of solithromycin in yeast expressed recombinant proteins and human hepatocytes as compared to NAT2 *5 + *6 + *7 + *14.;
;;NAT2;rs4646244;A;Other;decreasedtranscription of NAT2 ➔ ;Allele A is associated with decreased transcription of NAT2 (as determined in luciferase reporter assays) as compared to allele T.;
;;NCOA1;rs1804645;T;;increased half-life of NCOA1 ➔ ;Allele T is associated with increased half-life of NCOA1.;
;;NFATC2;rs6021191;T;Other;increased  expression of NFATC2 ➔ ;Allele T is associated with increased expression of NFATC2 as compared to allele A.;
;;NHLH1;rs11265375;T;Other;increased luciferase  activity  ➔ ;Allele T is associated with increased luciferase activity in H446 lung cancer cells.;
;;NQO1;rs1800566;AA;;decreasedenzyme  activity  of NQO1 ➔ ;Genotype AA is associated with decreased enzyme activity of NQO1.;
;;NQO1;rs1800566;A;;decreased expression of NQO1 ➔ ;Allele A is associated with decreased expression of NQO1.;
;MIDAZOLAM;NR1I2;rs1464602;G;Metabolism/PK;increased clearance of  ➔ MIDAZOLAM;Allele G is associated with increased clearance of midazolam.;
;MIDAZOLAM;NR1I2;rs1464603;G;Metabolism/PK;increased clearance of  ➔ MIDAZOLAM;Allele G is associated with increased clearance of midazolam liver.;
;;NRP2;rs10932125;C;;increased  expression of CYP1B1 ➔ ;Allele C is associated with increased expression of CYP1B1 in CEU and YRI cell lines.;
;CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs201045130;G;Other;decreasedsensitivity to  ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Allele G is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele A.;
;CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs370457585;T;Other;decreasedsensitivity to  ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Allele T is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele C.;
;CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs374150125;A;Other;decreasedsensitivity to  ➔ CLADRIBINE, FLUOROURACIL, GEMCITABINE;Allele A is associated with decreased sensitivity to cladribine, fluorouracil or gemcitabine in HEK 293 cells as compared to allele G.;
;CYTARABINE;NT5C2;rs1163075;G;Efficacy;decreasedsensitivity to  ➔ CYTARABINE;Allele G is associated with decreased sensitivity to cytarabine as compared to allele A.;
;;NT5C2;rs1163075;G;Metabolism/PK;increased transcription of NT5C2 ➔ ;Allele G is associated with increased transcription of NT5C2 as compared to allele A.;
;CYTARABINE;NT5C2;rs11191612;GG;Efficacy;decreasedsensitivity to  ➔ CYTARABINE;Genotype GG is associated with decreased sensitivity to cytarabine as compared to genotypes AA + AG.;
;;NT5E;rs9450278;A;;decreased expression of NT5E ➔ ;Allele A is associated with decreased expression of NT5E.;
;CHLOROCRESOL;RYR1;rs121918596;del;Other;increased sensitivity to  ➔ CHLOROCRESOL;Allele del is associated with increased sensitivity to chlorocresol in HEK293T cells transfected with RYR1 as compared to allele GAG.;
;CAFFEINE;RYR1;rs193922843;T;Dosage;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine as compared to allele G.;
;CAFFEINE;RYR1;rs193922816;T;Other;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele C.;
;CAFFEINE;RYR1;rs118192176;A;Other;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.;
;;SEMA6A;rs3806915;A;Other;increased luciferase  activity  ➔ ;Allele A is associated with increased luciferase activity in H446 lung cancer cells as compared to allele C.;
;;SEPTIN3, WBP2NL;rs1062753;G;Metabolism/PK;increased  expression of CYP2D6 ➔ ;Allele G is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to allele A.;
;RANITIDINE;SLC22A1;rs12208357;T;Metabolism/PK;decreasedtransport of  ➔ RANITIDINE;Allele T is associated with decreased transport of ranitidine as compared to allele C.;
;RANITIDINE;SLC22A1;rs72552763;del;Metabolism/PK;decreasedtransport of  ➔ RANITIDINE;Allele del is associated with decreased transport of ranitidine as compared to allele GAT.;
;RANITIDINE;SLC22A1;rs34130495;A;Metabolism/PK;decreasedtransport of  ➔ RANITIDINE;Allele A is associated with decreased transport of ranitidine as compared to allele G.;
;;SLC22A3;rs2076828;G;Other;decreased expression of SLC22A3 ➔ ;Allele G is associated with decreased expression of SLC22A3 as compared to allele C.;
;;SLC22A3;rs884742;C;Metabolism/PK;increased transcription of SLC22A3 ➔ ;Allele C is associated with increased transcription of SLC22A3 in human liver samples as compared to allele A.;
;;SLC22A3;rs555754;AA;;increased  expression of SLC22A3 ➔ ;Genotype AA is associated with increased expression of SLC22A3 human liver tissue.;
;ADEFOVIR DIPIVOXIL;SLC22A6;rs11568634;T;Other;decreaseduptake of  ➔ ADEFOVIR DIPIVOXIL;Allele T is associated with decreased uptake of adefovir dipivoxil as compared to allele C.;
;CEFOTAXIME;SLC22A8;rs11568482;A;Metabolism/PK;decreasedtransport of  ➔ CEFOTAXIME;Allele A is associated with decreased transport of cefotaxime as compared to allele T.;
;GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;Metabolism/PK;increased formation of  ➔ GEMCITABINE TRIPHOSPHATE;Genotype CC is associated with increased formation of gemcitabine triphosphate.;
;DOXORUBICIN;SLC28A3;rs11140490;AA;Toxicity;increased sensitivity to  ➔ DOXORUBICIN;Genotype AA is associated with increased sensitivity to doxorubicin in Peripheral blood mononuclear cells from pediatric patients reprogramed to hiPSCs (cardiomyocytes) as compared to genotype AG.;
;;SLC29A1;rs731780;G;Other;increased  expression of SLC29A1 ➔ ;Allele G is associated with increased expression of SLC29A1 as compared to allele C.;
;;SLC29A1;rs70914;A;;increased  expression of SLC29A1 ➔ ;Allele A is associated with increased expression of SLC29A1 as compared to allele G.;
;;SLCO1A2;rs4148981;T;;decreased expression of SLCO1A2 ➔ ;Allele T is associated with decreased expression of SLCO1A2.;
;ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;Metabolism/PK;decreasedtransport of  ➔ ATRASENTAN;SLCO1B1 *15 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.;
;;SLCO1B1;rs4149056;C;Other;decreased expression of SLCO1B1 ➔ ;Allele C is associated with decreased expression of SLCO1B1 as compared to allele T.;
;ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;Metabolism/PK;decreasedtransport of  ➔ ATRASENTAN;SLCO1B1 *5 is associated with decreased transport of atrasentan as compared to SLCO1B1 *1 + *37.;
;CAFFEINE, HALOTHANE;RYR1;rs28933397;CT;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.;
;CAFFEINE, CHLOROCRESOL;RYR1;rs186983396;T;Metabolism/PK;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL;Allele T is associated with increased sensitivity to caffeine and chlorocresol in HEK 293 cells and myotubes as compared to allele C.;
;CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;T;Other;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL;Allele T is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele C.;
;CHLOROCRESOL;RYR1;rs118192124;T;Other;increased sensitivity to  ➔ CHLOROCRESOL;Allele T is associated with increased sensitivity to chlorocresol as compared to allele C.;
;CAFFEINE;RYR1;rs118192167;G;Other;increased sensitivity to  ➔ CAFFEINE;Allele G is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele A.;
;CAFFEINE;RYR1;rs193922803;T;Dosage;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine as compared to allele C.;
;CAFFEINE;RYR1;rs118192122;A;Other;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.;
;CAFFEINE;RYR1;rs193922809;A;Other;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele G.;
;CAFFEINE;RYR1;rs118192168;A;Dosage;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine as compared to allele G.;
;CAFFEINE;RYR1;rs193922832;A;Dosage;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine as compared to allele G.;
;CAFFEINE;RYR1;rs112563513;A;Dosage;increased sensitivity to  ➔ CAFFEINE;Allele A is associated with increased sensitivity to caffeine as compared to allele G.;
;CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs121918594;A;Other;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL, HALOTHANE;Allele A is associated with increased sensitivity to caffeine, chlorocresol or halothane in differentiated muscle cells as compared to allele G.;
;CAFFEINE;RYR1;rs193922878;G;Other;increased sensitivity to  ➔ CAFFEINE;Allele G is associated with increased sensitivity to caffeine in CHO cells as compared to allele C.;
;;MIR27A;rs895819;CC;Other;increased  expression of MIR27A ➔ ;Genotype CC is associated with increased expression of MIR27A in lymphoblastoid cell lines as compared to genotype TT.;
;CAFFEINE;RYR1;rs118192161;T;Other;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine in myotubes as compared to allele C.;
;CAFFEINE;RYR1;rs118192177;T;Other;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells as compared to allele C.;
;CAFFEINE;RYR1;rs118192167;AG;Other;increased sensitivity to  ➔ CAFFEINE;Genotype AG is associated with increased sensitivity to caffeine as compared to genotype AA.;
;CAFFEINE, HALOTHANE;RYR1;rs118192172;CT;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.;
;CAFFEINE, HALOTHANE;RYR1;rs193922772;GT;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype GT is associated with sensitivity to caffeine or halothane in muscle.;
;CAFFEINE, HALOTHANE;RYR1;rs118192175;CT;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.;
;CAFFEINE, HALOTHANE;RYR1;rs193922747;CT;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype CT is associated with sensitivity to caffeine or halothane in muscle.;
;CAFFEINE, HALOTHANE;RYR1;rs118192176;AG;Other;sensitivity to  ➔ CAFFEINE, HALOTHANE;Genotype AG is associated with sensitivity to caffeine or halothane in muscle.;
;CHLOROCRESOL;RYR1;rs118192124;T;Other;increased sensitivity to  ➔ CHLOROCRESOL;Allele T is associated with increased sensitivity to chlorocresol as compared to allele C.;
;CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;G;Other;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL;Allele G is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele C.;
;CAFFEINE, CHLOROCRESOL;RYR1;rs193922818;A;Other;increased sensitivity to  ➔ CAFFEINE, CHLOROCRESOL;Allele A is associated with increased sensitivity to caffeine and chlorocresol in HEK-293 cells as compared to allele G.;
;;;rs2000068;G;;increased  expression of ABCA1 ➔ ;Allele G is associated with increased expression of ABCA1 in HapMap cells.;
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;*17 + *18 + *35 + *39 + *53;Metabolism/PK;decreased clearance of  ➔ PRIMAQUINE;CYP2D6 *17 + *18 + *35 + *39 + *53 is associated with decreased clearance of primaquine in 293FT cells as compared to CYP2D6 *1.;
;;DPYD;rs1801158;T;Other;decreased activity  of DPYD ➔ ;Allele T is associated with decreased activity of DPYD as compared to allele C.;
;EFAVIRENZ;CYP2B6;rs142421637;T;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz as compared to allele C.;
;EFAVIRENZ;CYP2B6;rs373442191;A;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele A is associated with increased clearance of efavirenz as compared to allele G.;
;PROPOFOL;CYP2B6;rs752695347;T;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele T is associated with decreased clearance of propofol as compared to allele C.;
;PROPOFOL;CYP2B6;rs142421637;T;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele T is associated with decreased clearance of propofol as compared to allele C.;
;PROPOFOL;CYP2B6;rs1282926098;T;Metabolism/PK;increased clearance of  ➔ PROPOFOL;Allele T is associated with increased clearance of propofol as compared to allele C.;
;PROPOFOL;CYP2B6;rs1969136524;C;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele C is associated with decreased clearance of propofol as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs773494867;C;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele C is associated with decreased clearance of efavirenz as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs1969376664;T;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz as compared to allele A.;
;PROPOFOL;CYP2B6;rs138264188;T;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele T is associated with decreased clearance of propofol as compared to allele C.;
;PROPOFOL;CYP2B6;rs373442191;A;Metabolism/PK;increased clearance of  ➔ PROPOFOL;Allele A is associated with increased clearance of propofol as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs1969255598;T;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele T is associated with increased clearance of efavirenz as compared to allele C.;
;EFAVIRENZ;CYP2B6;rs1248477767;G;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele G is associated with increased clearance of efavirenz as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs750671397;G;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele G is associated with increased clearance of efavirenz as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs141666881;A;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele A is associated with increased clearance of efavirenz as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs1968919352;G;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele G is associated with increased clearance of efavirenz as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs1282926098;T;Metabolism/PK;increased clearance of  ➔ EFAVIRENZ;Allele T is associated with increased clearance of efavirenz as compared to allele C.;
;R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*4;*4;Metabolism/PK;increased formation of  ➔ R-EDDP, S-EDDP;CYP2B6 *4 is associated with increased formation of R-EDDP and S-EDDP as compared to CYP2B6 *1.;
;R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;Metabolism/PK;decreasedformation of  ➔ R-EDDP, S-EDDP;CYP2B6 *5+ *17 + *6+ *7 + *9+ *19 + *26 + *18 is associated with decreased formation of R-EDDP and S-EDDP as compared to CYP2B6 *1.;
;;CYP2B6;rs70950385;CA/CA;Other;decreased activity  of CYP2B6 ➔ ;Genotype CA/CA is associated with decreased activity of CYP2B6 as compared to genotype AG/AG.;
;EFAVIRENZ;CYP2B6;rs1969136524;C;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele C is associated with decreased clearance of efavirenz as compared to allele A.;
;EFAVIRENZ;CYP2B6;rs772413158;A;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele A is associated with decreased clearance of efavirenz as compared to allele G.;
;EFAVIRENZ;CYP2B6;rs752695347;T;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz as compared to allele C.;
;EFAVIRENZ;CYP2B6;rs553968231;T;Metabolism/PK;decreased clearance of  ➔ EFAVIRENZ;Allele T is associated with decreased clearance of efavirenz as compared to allele G.;
;;CYP1A2;rs762551;A;;increased  activity  of CYP1A2 ➔ ;Allele A is associated with increased activity of CYP1A2.;
;;CYP1A2;rs35694136;del;;decreased activity  of CYP1A2 ➔ ;Allele del is associated with decreased activity of CYP1A2.;
;DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*11;*11;Metabolism/PK;decreased clearance of  ➔ DACARBAZINE;CYP1A2 *11 is associated with decreased clearance of dacarbazine as compared to CYP1A2 *1.;
;;CYP1A2;rs762551;AA + AC;Metabolism/PK;increased transcription of CYP1A2 ➔ ;Genotypes AA + AC is associated with increased transcription of CYP1A2 as compared to genotype CC.;
;DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*3;*3;Metabolism/PK;decreased clearance of  ➔ DACARBAZINE;CYP1A2 *3 is associated with decreased clearance of dacarbazine as compared to CYP1A2 *1.;
;;CYP2A6;rs8192720;AA + AG;;increased  expression of CYP2A6 ➔ ;Genotypes AA + AG are associated with increased expression of CYP2A6 in human liver samples.;
;;CYP2A6;rs8192725;AG + GG;;increased  expression of CYP2A6 ➔ ;Genotypes AG + GG are associated with increased expression of CYP2A6 in human liver samples.;
;;CYP2A6;rs28399433;AC + CC;;decreased expression of CYP2A6 ➔ ;Genotypes AC + CC are associated with decreased expression of CYP2A6 in human liver samples.;
;;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;;decreased expression of CYP2A6 ➔ ;CYP2A6 *4/*9 is associated with decreased expression of CYP2A6.;
;;CYP2B6;CYP2B6*1, CYP2B6*27;*27;;decreased expression of CYP2B6 ➔ ;CYP2B6 *27 is associated with decreased expression of CYP2B6 as compared to CYP2B6 *1.;
;COUMARIN;CYP2A6;rs28399454;T;Metabolism/PK;decreasedmetabolism of  ➔ COUMARIN;Allele T is associated with decreased metabolism of coumarin as compared to allele C.;
;COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4;*1/*4;Metabolism/PK;decreased clearance of  ➔ COUMARIN;CYP2A6 *1/*4 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.;
;COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*9;*1/*9;Metabolism/PK;decreased clearance of  ➔ COUMARIN;CYP2A6 *1/*9 is associated with decreased clearance of coumarin as compared to CYP2A6 *1/*1.;
;;CYP2A6;CYP2A6*46;*46;;increased  expression of CYP2A6 ➔ ;CYP2A6 *46 is associated with increased expression of CYP2A6 in human liver samples.;
;;CYP2A6;CYP2A6*1, CYP2A6*4;*4;;decreased expression of CYP2A6 ➔ ;CYP2A6 *4 is associated with decreased expression of CYP2A6 in human liver samples.;
;;CYP2A6;CYP2A6*46;*46;;increased transcription of CYP2A6 ➔ ;CYP2A6 *46 is associated with increased transcription of CYP2A6.;
;;CYP2B6;rs3745274;TT;Other;decreased expression of CYP2B6 ➔ ;Genotype TT is associated with decreased expression of CYP2B6 as compared to genotypes GG + GT.;
;PROPOFOL;CYP2B6;rs553968231;T;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele T is associated with decreased clearance of propofol as compared to allele G.;
;PROPOFOL;CYP2B6;rs1969376664;T;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele T is associated with decreased clearance of propofol as compared to allele A.;
;PROPOFOL;CYP2B6;rs773494867;C;Metabolism/PK;decreased clearance of  ➔ PROPOFOL;Allele C is associated with decreased clearance of propofol as compared to allele A.;
;;CYP2A6;CYP2A6*46;*46;;increased  expression of CYP2A6 ➔ ;CYP2A6 *46 is associated with increased expression of CYP2A6.;
;3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;*8 + *9 + *10 + *16 + *19;Metabolism/PK;decreased clearance of  ➔ 3-CYANO-7-ETHOXYCOUMARIN;CYP2C19 *8 + *9 + *10 + *16 + *19 are associated with decreased clearance of 3-cyano-7-ethoxycoumarin as compared to CYP2C19 *1.;
;NEBIVOLOL;CYP2C19;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;Metabolism/PK;decreased clearance of  ➔ NEBIVOLOL;CYP2C19 *30 + *31 + *32 + *33 + *6 + *18 are associated with decreased clearance of nebivolol in Sf21 insect cells as compared to CYP2C19 *1.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;Metabolism/PK;decreased clearance of  ➔ MEPHENYTOIN;CYP2C19 *10 + *14 + *19 + *25 + *26 are associated with decreased clearance of mephenytoin in cos-7 cells as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*6;*6;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *6 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;rs550527959;T;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.;
;METHADONE;CYP2C19;rs1463550071;T;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele T is associated with decreased clearance of methadone as compared to allele A.;
;FLUOXETINE;CYP2C19;rs200346442;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;FLUOXETINE;CYP2C19;rs200150287;G;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.;
;FLUOXETINE;CYP2C19;rs118203756;C;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;Metabolism/PK;increased sensitivity to  ➔ FLUVOXAMINE, OMEPRAZOLE;CYP2C19 *15 is associated with increased sensitivity to fluvoxamine and omeprazole as compared to CYP2C19 *1.;
;FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Metabolism/PK;increased sensitivity to  ➔ FLUVOXAMINE, OMEPRAZOLE;CYP2C19 *18 is associated with increased sensitivity to fluvoxamine and omeprazole as compared to CYP2C19 *1.;
;CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Metabolism/PK;decreasedsensitivity to  ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19 *18 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole and ticlopidine as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;rs778258371;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;CELECOXIB;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;increased sensitivity to  ➔ CELECOXIB;CYP2C19 *19 is associated with increased sensitivity to celecoxib as compared to CYP2C19 *1.;
;CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Metabolism/PK;decreasedsensitivity to  ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19 *16 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and ticlopidine as compared to CYP2C19 *1.;
;FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19 *19 is associated with decreased sensitivity to fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine and tranylcypromine as compared to CYP2C19 *1.;
;;CYP2C19;CYP2C19*1, CYP2C19*16;*16;Other;decreasedformation of CYP2C19 ➔ ;CYP2C19 *16 is associated with decreased formation of CYP2C19 in yeast microsomes as compared to CYP2C19 *1.;
;FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*11;*11;Metabolism/PK;increased sensitivity to  ➔ FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19 *11 is associated with increased sensitivity to fluconazole, fluvoxamine and sertraline as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE;CYP2C19 *10 is associated with decreased sensitivity to fluoxetine as compared to CYP2C19 *1.;
;CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Metabolism/PK;decreasedsensitivity to  ➔ CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19 *9 is associated with decreased sensitivity to celecoxib, fluoxetine, ketoconazole, sertraline and troglitazone as compared to CYP2C19 *1.;
;FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;Metabolism/PK;increased sensitivity to  ➔ FLUCONAZOLE, FLUVOXAMINE;CYP2C19 *9 is associated with increased sensitivity to fluconazole and fluvoxamine as compared to CYP2C19 *1.;
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;Metabolism/PK;decreased clearance of  ➔ OMEPRAZOLE;CYP2C19 *10 is associated with decreased clearance of omeprazole as compared to CYP2C19 *1.;
;FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;Metabolism/PK;decreasedsensitivity to  ➔ FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19 *8 is associated with decreased sensitivity to fluconazole, fluoxetine, fluvoxamine, ketoconazole, omeprazole, sertraline, ticlopidine, tranylcypromine and troglitazone as compared to CYP2C19 *1.;
;FLUOXETINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE, TRANYLCYPROMINE;CYP2C19 *15 is associated with decreased sensitivity to fluoxetine and tranylcypromine as compared to CYP2C19 *1.;
;;CYP1A2;rs2069514;A;;decreased activity  of CYP1A2 ➔ ;Allele A is associated with decreased activity of CYP1A2.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;Metabolism/PK;decreased clearance of  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *26 is associated with decreased clearance of mephenytoin and omeprazole as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *23 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;Metabolism/PK;decreased clearance of  ➔ CLOPIDOGREL;CYP2C19 *10 + *14 + *19 + *23 + *25 + *26 are associated with decreased clearance of clopidogrel in cos-7 cell as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;rs370803989;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;FLUOXETINE;CYP2C19;rs145328984;T;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.;
;FLUOXETINE;CYP2C19;rs763625282;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.;
;FLUOXETINE;CYP2C19;rs147255955;T;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.;
;FLUOXETINE;CYP2C19;rs3758581;G;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele G is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.;
;FLUOXETINE;CYP2C19;rs559628884;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.;
;FLUOXETINE;CYP2C19;rs764137538;T;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele C.;
;FLUOXETINE;CYP2C19;rs1349931378;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*33;*33;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *33 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;rs1463550071;T;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele T is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele A.;
;METHADONE;CYP2C19;rs778258371;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *18 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;METHADONE;CYP2C19;rs72552267;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;METHADONE;CYP2C19;rs118203756;C;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele C is associated with decreased clearance of methadone as compared to allele G.;
;METHADONE;CYP2C19;rs764137538;T;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele T is associated with decreased clearance of methadone as compared to allele C.;
;METHADONE;CYP2C19;rs550527959;T;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele T is associated with decreased clearance of methadone as compared to allele A.;
;METHADONE;CYP2C19;rs1349931378;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;FLUOXETINE;CYP2C19;rs770829708;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;METHADONE;CYP2C19;rs1267723490;C;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele C is associated with decreased clearance of methadone as compared to allele T.;
;FLUOXETINE;CYP2C19;rs1267723490;C;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.;
;DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*2C;*2C;Metabolism/PK;decreased clearance of  ➔ DACARBAZINE;CYP1A1 *2C is associated with decreased clearance of dacarbazine as compared to CYP1A1 *1.;
;DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*4;*4;Metabolism/PK;decreased clearance of  ➔ DACARBAZINE;CYP1A1 *4 is associated with decreased clearance of dacarbazine as compared to CYP1A1 *1.;
;;CHD2;rs28458425;TT;Other;increased transcription of ABCB1 ➔ ;Genotype TT is associated with increased transcription of ABCB1 as compared to genotypes AA + AT.;
;OXAZEPAM;;rs1976391;G;Other;decreasedglucuronidation of  ➔ OXAZEPAM;Allele G is associated with decreased glucuronidation of oxazepam in human liver microsomes as compared to allele A.;
;;;rs247616;T;Other;decreased expression of CETP ➔ ;Allele T is associated with decreased expression of CETP in HepG2 cells as compared to allele C.;
;;ABCA1;rs2515629;G;;increased  expression of ABCA1 ➔ ;Allele G is associated with increased expression of ABCA1 in HapMap cells.;
;;ABCA1;rs4149297;G;;increased  expression of ABCA1 ➔ ;Allele G is associated with increased expression of ABCA1 in HapMap cells.;
;;ABCA1;rs2472507;C;;increased  expression of ABCA1 ➔ ;Allele C is associated with increased expression of ABCA1 in HapMap cells.;
;;ABCA12;rs10182702;C;;increased  expression of ABCA12 ➔ ;Allele C is associated with increased expression of ABCA12 in HapMap cells.;
;;ABCA12;rs2888327;A;;increased  expression of ABCA12 ➔ ;Allele A is associated with increased expression of ABCA12 in HapMap cells.;
;;ABCA8;rs11656365;T;;decreased expression of ABCA8 ➔ ;Allele T is associated with decreased expression of ABCA8 in HapMap cells.;
;;ABCB1;rs1045642;AG + GG;Metabolism/PK;increased  activity  of ABCB1 ➔ ;Genotypes AG + GG are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.;
;;;rs1976391;G;Other;decreasedconcentrations of UGT1A1 ➔ ;Allele G is associated with decreased concentrations of UGT1A1 in human liver microsomes as compared to allele A.;
;;ABCB1;rs1128503;AG + GG;Metabolism/PK;increased  activity  of ABCB1 ➔ ;Genotypes AG + GG are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.;
;;ABCB1;rs1045642;AA;Other;decreased expression of ABCB1 ➔ ;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AG + GG.;
;;ABCB1;rs1128503;AA;Other;decreased expression of ABCB1 ➔ ;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AG + GG.;
;;ABCB1;rs2032582;AA;Other;decreased expression of ABCB1 ➔ ;Genotype AA is associated with decreased expression of ABCB1 as compared to genotypes AC + CC.;
;;ABCB9;rs4148866;T;;increased  expression of ABCB9 ➔ ;Allele T is associated with increased expression of ABCB9 in HapMap cells.;
;;ABCC10;rs2185631;A;;decreased expression of ABCC10 ➔ ;Allele A is associated with decreased expression of ABCC10 in HapMap cells.;
;DOCETAXEL;ABCC10;rs2125739;TT;Toxicity;increased sensitivity to  ➔ DOCETAXEL;Genotype TT is associated with increased sensitivity to docetaxel in 18 NSCLC cell lines as compared to genotypes CC + CT.;
;;ABCC10;rs9394952;G;;decreased expression of ABCC10 ➔ ;Allele G is associated with decreased expression of ABCC10 in HapMap cells.;
;;ABCC10;rs2487663;A;;decreased expression of ABCC10 ➔ ;Allele A is associated with decreased expression of ABCC10 in HapMap cells.;
;;ABCC11;rs11861379;C;Metabolism/PK;increased transcription of ABCC11 ➔ ;Allele C is associated with increased transcription of ABCC11 in human liver samples as compared to allele T.;
;;ABCB1;rs2032582;AC + CC;Metabolism/PK;increased  activity  of ABCB1 ➔ ;Genotypes AC + CC are associated with increased activity of ABCB1 in peripheral blood mononuclear cells as compared to genotype AA.;
;;ABCC2;rs717620;T;;increased transcription of ABCC2 ➔ ;Allele T is associated with increased transcription of ABCC2 HepG2 liver cell line.;
;;;rs6822259;CC;;increased  expression of UGT2B17 ➔ ;Genotype CC is associated with increased expression of UGT2B17 in normal breast tissue.;
;;;rs729559;GG;Metabolism/PK;increased  expression of CYP2D6 ➔ ;Genotype GG is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to genotypes AA + AG.;
;;;rs6539870;GG;Other;increased  expression of IL1B ➔ ;Genotype GG is associated with increased expression of IL1B as compared to genotypes AA + AG.;
;;;rs478437;CC;Other;increased  expression of USP7 ➔ ;Genotype CC is associated with increased expression of USP7 in lymphoblastoid cell lines as compared to genotypes CT + TT.;
;;;rs9999111;C;Other;decreased expression of ABCG2 ➔ ;Allele C is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.;
;;;rs149713212;A;Other;decreased expression of ABCG2 ➔ ;Allele A is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele G.;
;;;rs12508471;G;Other;decreased expression of ABCG2 ➔ ;Allele G is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.;
;ENDOXIFEN;;rs4386686;C;Toxicity;increased sensitivity to  ➔ ENDOXIFEN;Allele C is associated with increased sensitivity to endoxifen HapMal LCLs as compared to allele G.;
;;;rs4073010;TT;Metabolism/PK;increased  expression of CYP2D6 ➔ ;Genotype TT is associated with increased expression of CYP2D6 in human liver s9 fractions as compared to genotypes CC + CT.;
;;;rs35283911;G;Other;increased  expression of HP ➔ ;Allele G is associated with increased expression of HP as compared to allele del.;
;;;rs4386686;C;Toxicity, Other;increased  expression of MIRLET7I ➔ ;Allele C is associated with increased expression of MIRLET7I in HapMap LCLs as compared to allele G.;
;TAMOXIFEN;;rs478437;CC;Other;increased sensitivity to  ➔ TAMOXIFEN;Genotype CC is associated with increased sensitivity to tamoxifen in lymphoblastoid cell lines as compared to genotypes CT + TT.;
;;;rs2784917;AA;Other;increased  expression of WNT5B ➔ ;Genotype AA is associated with increased expression of WNT5B as compared to genotypes AG + GG.;
;;;rs9999111;C;Other;decreased expression of ABCG2 ➔ ;Allele C is associated with decreased expression of ABCG2 in human umbilical cord and T cells as compared to allele A.;
;;;rs10242455;AG;Metabolism/PK;increased transcription of CYP3A5 ➔ ;Genotype AG is associated with increased transcription of CYP3A5 in human liver samples as compared to genotype AA.;
;;;rs446112;AA;Other;increased  expression of AGPAT2 ➔ ;Genotype AA is associated with increased expression of AGPAT2 as compared to genotypes AG + GG.;
;;;rs10871454;C;Metabolism/PK;increased transcription of VKORC1 ➔ ;Allele C is associated with increased transcription of VKORC1 in human liver samples as compared to allele T.;
;;;rs2487030;T;;increased  expression of ABCA1 ➔ ;Allele T is associated with increased expression of ABCA1 in HapMap cells.;
;;;rs4355801;G;;increased  expression of TNFRSF11B ➔ ;Allele G is associated with increased expression of TNFRSF11B lymphoblast cell lines.;
;;;rs4285917;G;;decreased expression of ABCD2 ➔ ;Allele G is associated with decreased expression of ABCD2 in HapMap cells.;
;;;rs12195350;G;;decreased expression of ABCC10 ➔ ;Allele G is associated with decreased expression of ABCC10 in HapMap cells.;
;;;rs4898437;C;;increased  expression of ABCD1 ➔ ;Allele C is associated with increased expression of ABCD1 in HapMap cells.;
;;;rs4386686;C;Toxicity, Other;decreased expression of TRAF1 ➔ ;Allele C is associated with decreased expression of TRAF1 in HapMap LCLs as compared to allele G.;
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;Metabolism/PK;increased clearance of  ➔ CLOPIDOGREL;CYP2C19 *28 is associated with increased clearance of clopidogrel in cos-7 cells as compared to CYP2C19 *1.;
;;ABCC4;rs11568658;A;Metabolism/PK;increased catalytic  activity  of ABCC4 ➔ ;Allele A is associated with increased catalytic activity of ABCC4 as compared to allele C.;
;MERCAPTOPURINE;ABCC4;rs3765534;TT;Toxicity, Metabolism/PK;increased sensitivity to  ➔ MERCAPTOPURINE;Genotype TT is associated with increased sensitivity to mercaptopurine in NA18967 cells as compared to genotype CC.;
;;CACNA1S;rs1800559;T;Other;increased  activity  of CACNA1S ➔ ;Allele T is associated with increased activity of CACNA1S in HEK-293 cells and dysgenic myotubes as compared to allele C.;
;CAFFEINE;CACNA1S;rs1800559;T;Other;increased sensitivity to  ➔ CAFFEINE;Allele T is associated with increased sensitivity to caffeine in HEK-293 cells and dysgenic myotubes as compared to allele C.;
;HALOTHANE, ISOFLURANE;CACNA1S;rs772226819;A;Other;increased sensitivity to  ➔ HALOTHANE, ISOFLURANE;Allele A is associated with increased sensitivity to halothane and isoflurane as compared to allele G.;
;;CBR3;rs8133052;A;;decreased expression of CBR3 ➔ ;Allele A is associated with decreased expression of CBR3 in breast tissue.;
;;CBR3;rs1056892;A;;increased  expression of CBR3 ➔ ;Allele A is associated with increased expression of CBR3 in breast tissue.;
;;CBS;rs915854;C;Other;increased  expression of PKNOX1 ➔ ;Allele C is associated with increased expression of PKNOX1 as compared to allele T.;
;;CD38;rs1130169;T;;decreased expression of CD38 ➔ ;Allele T is associated with decreased expression of CD38.;
;;CDA;rs3215400;C/del + del/del;Other;increased  expression of CDA ➔ ;Genotypes C/del + del/del are associated with increased expression of CDA in PBMCs.;
;;CDA;rs2072671;CC;Other;increased  expression of CDA ➔ ;Genotype CC is associated with increased expression of CDA in PBMCs.;
;DEXAMETHASONE;BCL2L11;rs2241843;AA;Toxicity;increased sensitivity to  ➔ DEXAMETHASONE;Genotype AA is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes AC + CC.;
;;CDA;rs532545;CC;Other;decreased activity  of CDA ➔ ;Genotype CC is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes CT + TT.;
;;CDA;rs2072671;AA;Other;decreased activity  of CDA ➔ ;Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AC + CC.;
;;CDA;rs1048977;TT;Other;increased  expression of CDA ➔ ;Genotype TT is associated with increased expression of CDA in PBMCs.;
;;CDA;rs602950;AA;Other;decreased activity  of CDA ➔ ;Genotype AA is associated with decreased activity of CDA in whole blood from healthy volunteers as compared to genotypes AG + GG.;
;;CDA;rs602950;GG;Other;increased  expression of CDA ➔ ;Genotype GG is associated with increased expression of CDA in PBMCs.;
;;CDA;rs3215400;del/del;;increased  expression of CDA ➔ ;Genotype del/del is associated with increased expression of CDA in CEPH cell lines.;
;PALBOCICLIB;CDKN2A;rs759922342;C;Efficacy;increased sensitivity to  ➔ PALBOCICLIB;Allele C is associated with increased sensitivity to palbociclib in Nalm6 cells as compared to allele T.;
;REMIMAZOLAM;CES1;rs71647871;T;Metabolism/PK;decreasedmetabolism of  ➔ REMIMAZOLAM;Allele T is associated with decreased metabolism of remimazolam as compared to allele C.;
;CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs201065375;A;Metabolism/PK;decreasedmetabolism of  ➔ CLOPIDOGREL, ENALAPRIL, SACUBITRIL;Allele A is associated with decreased metabolism of clopidogrel, enalapril and sacubitril in HEK cells as compared to allele G.;
;;CETP;rs708272;GG;Other;increased  expression of CETP ➔ ;Genotype GG is associated with increased expression of CETP in plasma as compared to genotype AA.;
;;CDA;rs532545;TT;Other;increased  expression of CDA ➔ ;Genotype TT is associated with increased expression of CDA in PBMCs.;
;MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;Toxicity, Metabolism/PK;increased concentrations of  ➔ MERCAPTOPURINE;ABCC4 deficiency is associated with increased concentrations of mercaptopurine in mice.;
;DEXAMETHASONE;BCL2L11;rs724710;CC;Toxicity;increased sensitivity to  ➔ DEXAMETHASONE;Genotype CC is associated with increased sensitivity to dexamethasone in lymphoblastic cell lines as compared to genotypes CT + TT.;
;;ARNT;rs2134688;GG;Metabolism/PK;decreasedconcentrations of CYP3A4 ➔ ;Genotype GG is associated with decreased concentrations of CYP3A4 protein in human liver microsomes as compared to genotypes AA + AG.;
;;ABCC4;rs11568684;C;Metabolism/PK;increased catalytic  activity  of ABCC4 ➔ ;Allele C is associated with increased catalytic activity of ABCC4 as compared to allele T.;
;;ABCC4;rs4773866;T;;increased  expression of ABCC4 ➔ ;Allele T is associated with increased expression of ABCC4 in HapMap cells.;
;;ABCC9;rs704212;T;Other;increased  expression of ABCC9 ➔ ;Allele T is associated with increased expression of ABCC9 as compared to allele C.;
;;ABCD1, BCAP31;rs17091297;C;;increased  expression of ABCD1 ➔ ;Allele C is associated with increased expression of ABCD1 in HapMap cells.;
;;ABCD2;rs4284427;C;;decreased expression of ABCD2 ➔ ;Allele C is associated with decreased expression of ABCD2 in HapMap cells.;
;;ABCG2;rs2725263;C;Other;increased  expression of ABCG2 ➔ ;Allele C is associated with increased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A.;
;;ACE;rs1799752;del;;increased enzyme  activity  of ACE ➔ ;Allele del is associated with increased enzyme activity of ACE.;
;;ADCYAP1;rs304400;AA;Other;increased transcription of ABCB1 ➔ ;Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG.;
;LOSARTAN;AGTR1;rs12721226;A;Other;decreased affinity to  ➔ LOSARTAN;Allele A is associated with decreased affinity to losartan in COS-1 cells.;
;;ATP2B1;rs12817819;CT + TT;;decreased expression of ATP2B1 ➔ ;Genotypes CT + TT are associated with decreased expression of ATP2B1 as compared to genotype CC.;
;DOXORUBICINOL;AKR1A1;rs2229540;G;Metabolism/PK;decreasedformation of  ➔ DOXORUBICINOL;Allele G is associated with decreased formation of doxorubicinol as compared to allele A.;
;DAUNORUBICINOL;AKR1A1;rs6690497;C;Metabolism/PK;decreasedformation of  ➔ DAUNORUBICINOL;Allele C is associated with decreased formation of daunorubicinol as compared to allele G.;
;DAUNORUBICINOL;AKR1A1;rs2229540;G;Metabolism/PK;decreasedformation of  ➔ DAUNORUBICINOL;Allele G is associated with decreased formation of daunorubicinol as compared to allele A.;
;EXEMESTANE;AKR1C3;rs62621365;T;Metabolism/PK;decreased affinity to  ➔ EXEMESTANE;Allele T is associated with decreased affinity to exemestane in human liver cytosol as compared to allele C.;
;DOXORUBICIN;AKR1C3;rs62621365;T;Metabolism/PK;decreased clearance of  ➔ DOXORUBICIN;Allele T is associated with decreased clearance of doxorubicin as compared to allele C.;
;DOXORUBICIN;AKR1C3;rs34186955;T;Metabolism/PK;decreased clearance of  ➔ DOXORUBICIN;Allele T is associated with decreased clearance of doxorubicin as compared to allele C.;
;DOXORUBICIN;AKR1C3;rs28943579;A;Metabolism/PK;decreased clearance of  ➔ DOXORUBICIN;Allele A is associated with decreased clearance of doxorubicin as compared to allele G.;
;EXEMESTANE;AKR1C4;rs11253043;A;Metabolism/PK;decreased affinity to  ➔ EXEMESTANE;Allele A is associated with decreased affinity to exemestane in human liver cytosol as compared to allele G.;
;;ALDH1A2;rs12915901;AA + AG;Other;decreased expression of ALDH1A2 ➔ ;Genotypes AA + AG is associated with decreased expression of ALDH1A2 as compared to allele G.;
;;AMPH;rs12701634;CC;Other;increased transcription of ABCB1 ➔ ;Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT.;
;DOXORUBICINOL;AKR1A1;rs6690497;C;Metabolism/PK;decreasedformation of  ➔ DOXORUBICINOL;Allele C is associated with decreased formation of doxorubicinol as compared to allele G.;
;;DPYD;rs2297595;C;Metabolism/PK;decreased activity  of DPYD ➔ ;Allele C is associated with decreased activity of DPYD.;
;;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Other;decreased expression of CYP2C19 ➔ ;CYP2C19 *19 is associated with decreased expression of CYP2C19 as compared to CYP2C19 *1.;
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Metabolism/PK;decreasedsensitivity to  ➔ SERTRALINE;CYP2C19 *13 is associated with decreased sensitivity to sertraline as compared to CYP2C19 *1.;
;EBASTINE, TERFENADINE;CYP2J2;rs201379188;A;Metabolism/PK;decreased clearance of  ➔ EBASTINE, TERFENADINE;Allele A is associated with decreased clearance of ebastine or terfenadine as compared to allele G.;
;TERFENADINE;CYP2J2;rs199717190;A;Metabolism/PK;decreased clearance of  ➔ TERFENADINE;Allele A is associated with decreased clearance of terfenadine as compared to allele T.;
;OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ OXYCODONE;CYP3A4 *2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.;
;OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;Metabolism/PK;decreased clearance of  ➔ OXYCODONE;CYP3A4 *6 + *17 + *20 + *21 + *26 + *30 are associated with decreased clearance of oxycodone as compared to CYP3A4 *1.;
;SIROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;Metabolism/PK;decreased clearance of  ➔ SIROLIMUS;CYP3A4 *1/*22 + *22/*22 are associated with decreased clearance of sirolimus in human liver microsomes as compared to CYP3A4 *1/*1.;
;SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;*3 + *10 + *14 + *32;Metabolism/PK;increased clearance of  ➔ SILDENAFIL;CYP3A4 *3 + *10 + *14 + *32 is associated with increased clearance of sildenafil as compared to CYP3A4 *1.;
;IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;Metabolism/PK;decreased clearance of  ➔ IBRUTINIB;CYP3A4 *2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32 is associated with decreased clearance of ibrutinib as compared to CYP3A4 *1.;
;;CYP3A4;rs2242480;TT;Metabolism/PK;decreased activity  of CYP3A4 ➔ ;Genotype TT is associated with decreased activity of CYP3A4 as compared to genotypes CC + CT.;
;TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;*2 + *3 + *11 + *15 + *31;Metabolism/PK;increased clearance of  ➔ TESTOSTERONE;CYP3A4 *2 + *3 + *11 + *15 + *31 is associated with increased clearance of testosterone as compared to CYP3A4 *1.;
;TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ TESTOSTERONE;CYP3A4 *5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34 is associated with decreased clearance of testosterone as compared to CYP3A4 *1.;
;LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;*2 + *5 + *9 + *16 + *24;Metabolism/PK;decreased clearance of  ➔ LIDOCAINE;CYP3A4 *2 + *5 + *9 + *16 + *24 is associated with decreased clearance of lidocaine as compared to CYP3A4 *1.;
;MIDAZOLAM;CYP3A4;rs12721627;C;Metabolism/PK;decreased clearance of  ➔ MIDAZOLAM;Allele C is associated with decreased clearance of midazolam.;
;FENTANYL;CYP3A4;rs2242480;T/T;Metabolism/PK;decreasedmetabolism of  ➔ FENTANYL;Genotype T/T is associated with decreased metabolism of fentanyl in human liver microsomes as compared to genotypes C/C + C/T.;
;REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ REGORAFENIB;CYP3A4 *2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34 is associated with decreased clearance of regorafenib as compared to CYP3A4 *1.;
;TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;*11 + *18 + *33;Metabolism/PK;increased clearance of  ➔ TICAGRELOR;CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1.;
;TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;Metabolism/PK;decreased clearance of  ➔ TICAGRELOR;CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.;
;LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*12;*12;Metabolism/PK;decreased clearance of  ➔ LURASIDONE;CYP3A4 *12 is associated with decreased clearance of lurasidone as compared to CYP3A4 *1.;
;LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;Metabolism/PK;increased clearance of  ➔ LURASIDONE;CYP3A4 *15 + *19 + *23 + *24 + *28 + *29 + *32 + *33 is associated with increased clearance of lurasidone as compared to CYP3A4 *1.;
;SAXAGLIPTIN;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;Metabolism/PK;decreased clearance of  ➔ SAXAGLIPTIN;CYP3A4 *2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34 is associated with decreased clearance of saxagliptin as compared to CYP3A4 *1.;
;EBASTINE, TERFENADINE;CYP2J2;rs759510111;A;Metabolism/PK;increased clearance of  ➔ EBASTINE, TERFENADINE;Allele A is associated with increased clearance of ebastine or terfenadine as compared to allele G.;
;EBASTINE;CYP2J2;rs757528200;(CTC)1;Metabolism/PK;decreased clearance of  ➔ EBASTINE;Allele (CTC)1 is associated with decreased clearance of ebastine as compared to allele CTCCTC.;
;;CYP2E1;CYP2E1*7A, CYP2E1*7B;*7B;Metabolism/PK;increased transcription of CYP2E1 ➔ ;CYP2E1 *7B is associated with increased transcription of CYP2E1 in HepG2 cells as compared to CYP2E1 *7A.;
;;CYP2E1;CYP2E1*7, CYP2E1*7A;*7A;Metabolism/PK;increased transcription of CYP2E1 ➔ ;CYP2E1 *7A is associated with increased transcription of CYP2E1.;
;N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;Metabolism/PK;decreasedmetabolism of  ➔ N-DESMETHYLTAMOXIFEN;CYP2D6 *2 + *28 + *35 is associated with decreased metabolism of N-desmethyltamoxifen in HEK293 cells as compared to CYP2D6 *1.;
;BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6 *17 is associated with decreased clearance of bufuralol, debrisoquine or dextromethorphan in microsomes from baculovirus-transfected cells as compared to CYP2D6 *1.;
;;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Metabolism/PK;decreased expression of CYP2D6 ➔ ;CYP2D6 *1/*4 is associated with decreased expression of CYP2D6 as compared to CYP2D6 *1/*1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*169;*169;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *169 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.;
;DEXTROMETHORPHAN;CYP2D6;rs76187628;G;Metabolism/PK;increased clearance of  ➔ DEXTROMETHORPHAN;Allele G is associated with increased clearance of dextromethorphan as compared to allele A.;
;;CYP2D6;CYP2D6*1, CYP2D6*169;*169;Metabolism/PK;decreased expression of CYP2D6 ➔ ;CYP2D6 *169 is associated with decreased expression of CYP2D6 as compared to CYP2D6 *1.;
;;CYP2D6;rs76187628;G;Metabolism/PK;increased  expression of CYP2D6 ➔ ;Allele G is associated with increased expression of CYP2D6 as compared to allele A.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *2 is associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *10 is associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.;
;IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;*3 + *4 + *9 + *19 +*34;Metabolism/PK;increased clearance of  ➔ IBRUTINIB;CYP3A4 *3 + *4 + *9 + *19 +*34 is associated with increased clearance of ibrutinib as compared to CYP3A4 *1.;
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;Metabolism/PK;decreasedmetabolism of  ➔ RISPERIDONE;CYP2D6 *2 + *28 + *35 is associated with decreased metabolism of risperidone in HEK293 cells as compared to CYP2D6 *1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*26;*26;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *26 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs750996195;T;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;CYP2D6 *17 is associated with decreased clearance of bufuralol or dextromethorphan in COS-7 cells as compared to CYP2D6 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*14;*14;Metabolism/PK;decreased clearance of  ➔ BUFURALOL;CYP2D6 *14 is associated with decreased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*53;*53;Metabolism/PK;increased clearance of  ➔ N-DESMETHYLTAMOXIFEN;CYP2D6 *53 is associated with increased clearance of n-desmethyltamoxifen in COS-7 microsomes as compared to CYP2D6 *1.;
;DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;Metabolism/PK;decreased clearance of  ➔ DAPOXETINE;CYP2D6 *2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98 is associated with decreased clearance of dapoxetine as compared to CYP2D6 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*53;*53;Metabolism/PK;increased clearance of  ➔ BUFURALOL;CYP2D6 *53 is associated with increased clearance of bufuralol in COS-7 cells as compared to CYP2D6 *1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *10/*10 is associated with decreased clearance of dextromethorphan as compared to CYP2D6 *1/*1.;
;;CYP2E1;rs2515641;T;Other;decreased expression of CYP2E1 ➔ ;Allele T is associated with decreased expression of CYP2E1 as compared to allele C.;
;;ZBED5;rs10840501;GG;Other;increased transcription of ABCB1 ➔ ;Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.;
;REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;*14 + *15 + *28 + *31;Metabolism/PK;increased clearance of  ➔ REGORAFENIB;CYP3A4 *14 + *15 + *28 + *31 is associated with increased clearance of regorafenib as compared to CYP3A4 *1.;
;LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;Metabolism/PK;increased clearance of  ➔ LIDOCAINE;CYP3A4 *11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34 is associated with increased clearance of lidocaine as compared to CYP3A4 *1.;
;CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;Metabolism/PK;increased clearance of  ➔ CABOZANTINIB;CYP3A4 *14 + *15 is associated with increased clearance of cabozantinib as compared to CYP3A4 *1.;
;VITAMIN E;CYP4F2;rs2108622;T;Metabolism/PK;increased steady-state level of  ➔ VITAMIN E;Allele T is associated with increased steady-state level of vitamin e as compared to allele C.;
;;CYP4F2;rs2189784;A;Other;increased  expression of CYP4F2 ➔ ;Allele A is associated with increased expression of CYP4F2 as compared to allele G.;
;;CYP4F2;rs2189784;A;Other;decreased expression of CYP4F12 ➔ ;Allele A is associated with decreased expression of CYP4F12 as compared to allele G.;
;;CYP4F2;rs2108622;CT;Other;increased concentrations of CYP4F2 ➔ ;Genotype CT is associated with increased concentrations of CYP4F2 as compared to genotype CC.;
;VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;Other, Metabolism/PK;increased concentrations of  ➔ VITAMIN K AND ANALOGUES;Genotypes CT + TT is associated with increased concentrations of Vitamin K as compared to genotype CC.;
;;CYP4F2;rs2108622;T;Other;increased  expression of CYP4F2 ➔ ;Allele T is associated with increased expression of CYP4F2 as compared to allele C.;
;;CYP4F2;rs2108622;T;Other;increased  expression of CYP4F11 ➔ ;Allele T is associated with increased expression of CYP4F11 as compared to allele C.;
;;DCK;rs2306744;T;Other;increased  expression of DCK ➔ ;Allele T is associated with increased expression of DCK as compared to allele C.;
;;DHRS4L1;rs10147475;GG;Other;increased transcription of ABCB1 ➔ ;Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes AA + AG.;
;VITAMIN E;CYP4F2;rs2108622;T;Metabolism/PK;increased steady-state level of  ➔ VITAMIN E;Allele T is associated with increased steady-state level of vitamin e as compared to allele C.;
;;DISP1;rs61840266;TT;Other;increased transcription of ABCC1 ➔ ;Genotype TT is associated with increased transcription of ABCC1 as compared to genotypes AA + AT.;
;;DPYD;rs568132506;A;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.;
;;DPYD;rs760663364;A;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.;
;FLUOROURACIL;DPYD;rs1801159;CC;Toxicity, Metabolism/PK;decreased clearance of  ➔ FLUOROURACIL;Genotype CC is associated with decreased clearance of fluorouracil as compared to genotype TT.;
;;DPYD;rs3918290;CT;Other;decreased activity  of DPYD ➔ ;Genotype CT is associated with decreased activity of DPYD as compared to genotype CC.;
;;DPYD;rs1801158;CT;Other;decreasedcatalytic  activity  of DPYD ➔ ;Genotype CT is associated with decreased catalytic activity of DPYD as compared to genotype CC.;
;;DPYD;rs547099198;A;Other;decreasedcatalytic  activity  of DPYD ➔ ;Allele A is associated with decreased catalytic activity of DPYD as compared to allele G.;
;;DPYD;rs67376798;AT;Other;decreasedcatalytic  activity  of DPYD ➔ ;Genotype AT is associated with decreased catalytic activity of DPYD in peripheral blood mononuclear cells.;
;;DPYD;rs1801265;G;Other;decreased activity  of DPYD ➔ ;Allele G is associated with decreased activity of DPYD as compared to allele A.;
;;DPYD;rs1801160;T;Other;decreased activity  of DPYD ➔ ;Allele T is associated with decreased activity of DPYD as compared to allele C.;
;;DISP1;rs17535305;GG;Other;increased transcription of ABCB1 ➔ ;Genotype GG is associated with increased transcription of ABCB1 as compared to genotypes CC + CG.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs777560972;A;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Allele A is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele G.;
;;CYP4F11;rs1060467;A;Other;increased  expression of CYP4F2 ➔ ;Allele A is associated with increased expression of CYP4F2 as compared to allele G.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Other;decreased expression of CYP3A5 ➔ ;CYP3A5 *3/*3 is associated with decreased expression of CYP3A5 graft liver cell as compared to CYP3A5 *1.;
;BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;Metabolism/PK;increased clearance of  ➔ BREXPIPRAZOLE;CYP3A4 *14 + *15 is associated with increased clearance of brexpiprazole as compared to CYP3A4 *1.;
;ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;Metabolism/PK;decreasedmetabolism of  ➔ ALECTINIB;CYP3A4 *4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24 (assigned as poor metabolizer phenotype) is associated with decreased metabolism of alectinib as compared to CYP3A4 *1.;
;METHADONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;Metabolism/PK;decreased clearance of  ➔ METHADONE;CYP3A4 *2 + *3 + *5 + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31 is associated with decreased clearance of methadone as compared to CYP3A4 *1/*1.;
;METHADONE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;*11 + *32 + *34;Metabolism/PK;increased clearance of  ➔ METHADONE;CYP3A4 *11 + *32 + *34 is associated with increased clearance of methadone as compared to CYP3A4 *1/*1.;
;;CYP3A4;rs35599367;A;Other;decreased expression of CYP3A4 ➔ ;Allele A is associated with decreased expression of CYP3A4 as compared to genotype GG.;
;MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;Metabolism/PK;decreased clearance of  ➔ MIDAZOLAM;CYP3A4 *39 + *40 + *41 + *42 + *43 + *44 + *46 is associated with decreased clearance of midazolam by recombinant protein expressed in yeast as compared to CYP3A4 *1.;
;MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;Metabolism/PK;increased clearance of  ➔ MACITENTAN;CYP3A4 *3 + *4 + *5 + *10 +*15 + *16 is associated with increased clearance of macitentan as compared to CYP3A4 *1.;
;;CYP3A4;rs4986909;A;;decreasedsteady-state level of CYP3A4 ➔ ;Allele A is associated with decreased steady-state level of CYP3A4.;
;VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;Metabolism/PK;decreased clearance of  ➔ VANDETANIB;CYP3A4 *5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34 is associated with decreased clearance of vandetanib as compared to CYP3A4 *1.;
;;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Other;decreased expression of CYP3A5 ➔ ;CYP3A5 *3/*3 is associated with decreased expression of CYP3A5 intestinal cell as compared to CYP3A5 *1.;
;CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ CABOZANTINIB;CYP3A4 *2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34 is associated with decreased clearance of cabozantinib as compared to CYP3A4 *1.;
;AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;Metabolism/PK;increased clearance of  ➔ AMIODARONE;CYP3A4 *2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34 is associated with increased clearance of amiodarone as compared to CYP3A4 *1.;
;SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;*2 + *5 + *24 + *28 + *29;Metabolism/PK;decreased clearance of  ➔ SILDENAFIL;CYP3A4 *2 + *5 + *24 + *28 + *29 is associated with decreased clearance of sildenafil as compared to CYP3A4 *1.;
;;CYP3A4;CYP3A4*8;*8;;decreasedsteady-state level of CYP3A4 ➔ ;CYP3A4 *8 is associated with decreased steady-state level of CYP3A4.;
;BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ BREXPIPRAZOLE;CYP3A4 *3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34 is associated with decreased clearance of brexpiprazole as compared to CYP3A4 *1.;
;;CYP3A4;CYP3A4*12;*12;;decreasedenzyme  activity  of CYP3A4 ➔ ;CYP3A4 *12 is associated with decreased enzyme activity of CYP3A4.;
;BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;*2 + *7 + *8 + *17 + *20;Metabolism/PK;decreased clearance of  ➔ BREXPIPRAZOLE;CYP3A4 *2 + *7 + *8 + *17 + *20 is associated with decreased clearance of brexpiprazole as compared to CYP3A4 *1.;
;;CYP3A4;CYP3A4*11;*11;;decreasedsteady-state level of CYP3A4 ➔ ;CYP3A4 *11 is associated with decreased steady-state level of CYP3A4.;
;AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;Metabolism/PK;decreased clearance of  ➔ AMIODARONE;CYP3A4 *17 + *24 is associated with decreased clearance of amiodarone as compared to CYP3A4 *1.;
;MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;increased metabolism of  ➔ MIDAZOLAM;CYP3A5 *1/*1 is associated with increased metabolism of midazolam in fetal liver microsomes as compared to CYP3A5 *3/*3.;
;MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;Metabolism/PK;decreased clearance of  ➔ MACITENTAN;CYP3A4 *9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34 is associated with decreased clearance of macitentan as compared to CYP3A4 *1.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs138417770;T;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs371793722;G;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Allele G is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele A.;
;;CYP2D6;rs1058164;G;Other;decreased expression of CYP2D6 ➔ ;Allele G is associated with decreased expression of CYP2D6 as compared to allele C.;
;METHADONE;CYP2C19;rs181297724;C;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele C is associated with decreased clearance of methadone as compared to allele G.;
;METHADONE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*29 + *30 + *31 + *32 + *33;Metabolism/PK;decreased clearance of  ➔ METHADONE;CYP2C19 *29 + *30 + *31 + *32 + *33 is associated with decreased clearance of methadone as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;rs778258371;A;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele A is associated with decreased clearance of voriconazole in insect microsomes as compared to allele G.;
;FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;CYP2C19 *32 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *2 is associated with decreased clearance of voriconazole in insect microsomes as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *3 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;METHADONE;CYP2C19;rs138142612;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*24;*24;Metabolism/PK;decreased clearance of  ➔ MEPHENYTOIN, OMEPRAZOLE;CYP2C19 *24 is associated with decreased clearance of mephenytoin and omeprazole in E.coli as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *32 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;CYP2C19 *31 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.;
;16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*11, CYP2C19*23;*11 + *23;Metabolism/PK;increased formation of  ➔ 16ALPHA-HYDROXYTESTOSTERONE;CYP2C19 *11 + *23 is associated with increased formation of 16alpha-hydroxytestosterone as compared to CYP2C19 *1.;
;11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;Metabolism/PK;increased formation of  ➔ 11ALPHA-HYDROXYTESTOSTERONE;CYP2C19 *9 + *11 + *23 is associated with increased formation of 11alpha-hydroxytestosterone as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *29 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;CYP2C19 *29 is associated with decreased clearance of fluoxetine in insect microsomes as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *31 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*30;*30;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;CYP2C19 *30 is associated with decreased clearance of voriconazole as compared to CYP2C19 *1.;
;SIPONIMOD;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3/*3 + *2/*2;Metabolism/PK;decreasedmetabolism of  ➔ SIPONIMOD;CYP2C9 *3/*3 + *2/*2 are associated with decreased metabolism of siponimod as compared to CYP2C9 *1/*1.;
;DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*13;*13;Metabolism/PK;decreased clearance of  ➔ DICLOFENAC;CYP2C9 *13 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.;
;DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreased clearance of  ➔ DICLOFENAC;CYP2C9 *3 is associated with decreased clearance of diclofenac in yeast expression system as compared to CYP2C9 *1.;
;TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased clearance of  ➔ TOLBUTAMIDE;CYP2C9 *1/*3 is associated with decreased clearance of tolbutamide as compared to CYP2C9 *1/*1.;
;ANDROSTENEDIONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;Metabolism/PK;increased formation of  ➔ ANDROSTENEDIONE;CYP2C19 *9 + *11 + *23 is associated with increased formation of androstenedione as compared to CYP2C19 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*52;*52;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *52 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;METHADONE;CYP2C19;rs749678783;C;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele C is associated with decreased clearance of methadone as compared to allele T.;
;METHADONE;CYP2C19;rs770829708;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;FLUOXETINE;CYP2C19;rs72552267;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;METHADONE;CYP2C19;rs200150287;G;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele G is associated with decreased clearance of methadone as compared to allele C.;
;FLUOXETINE;CYP2C19;rs749678783;C;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele T.;
;FLUOXETINE;CYP2C19;rs138142612;A;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele A is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;FLUOXETINE;CYP2C19;rs181297724;C;Metabolism/PK;decreased clearance of  ➔ FLUOXETINE;Allele C is associated with decreased clearance of fluoxetine in insect microsomes as compared to allele G.;
;FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;rs181297724;C;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;Allele C is associated with decreased sensitivity to fluoxetine, ketoconazole, sertraline or ticlopidine as compared to allele G.;
;FLUVOXAMINE, OMEPRAZOLE;CYP2C19;rs181297724;C;Metabolism/PK;increased sensitivity to  ➔ FLUVOXAMINE, OMEPRAZOLE;Allele C is associated with increased sensitivity to fluvoxamine or omeprazole as compared to allele G.;
;FLUOXETINE;CYP2C19;rs17878459;C;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE;Allele C is associated with decreased sensitivity to fluoxetine as compared to allele G.;
;CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;rs17878459;C;Metabolism/PK;increased sensitivity to  ➔ CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;Allele C is associated with increased sensitivity to celecoxib, fluconazole or fluvoxamine as compared to allele G.;
;MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;Metabolism/PK;increased clearance of  ➔ MEPHENYTOIN;CYP2C19 *23 is associated with increased clearance of mephenytoin in cos-7 cell as compared to CYP2C19 *1.;
;FLUVOXAMINE;CYP2C19;rs3758581;G;Metabolism/PK;increased sensitivity to  ➔ FLUVOXAMINE;Allele G is associated with increased sensitivity to fluvoxamine as compared to allele A.;
;VORICONAZOLE;CYP2C19;rs763625282;A;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele A is associated with decreased clearance of voriconazole in insect microsomes as compared to allele T.;
;VORICONAZOLE;CYP2C19;rs3758581;G;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele G is associated with decreased clearance of voriconazole in insect microsomes as compared to allele A.;
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;Metabolism/PK;decreased affinity to  ➔ OMEPRAZOLE;CYP2C19 *19 is associated with decreased affinity to omeprazole as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;rs770829708;A;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele A is associated with decreased clearance of voriconazole n insect microsomes as compared to allele G.;
;CELECOXIB, FLUCONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;Metabolism/PK;increased sensitivity to  ➔ CELECOXIB, FLUCONAZOLE;CYP2C19 *14 is associated with increased sensitivity to celecoxib and fluconazole as compared to CYP2C19 *1.;
;FLUOXETINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;Metabolism/PK;decreasedsensitivity to  ➔ FLUOXETINE, SERTRALINE;CYP2C19 *14 is associated with decreased sensitivity to fluoxetine and sertraline as compared to CYP2C19 *1.;
;FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;Metabolism/PK;increased sensitivity to  ➔ FLUCONAZOLE, FLUVOXAMINE;CYP2C19 *13 is associated with increased sensitivity to fluconazole and fluvoxamine as compared to CYP2C19 *1.;
;VORICONAZOLE;CYP2C19;rs181297724;C;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele C is associated with decreased clearance of voriconazole in insect microsomes as compared to allele G.;
;METHADONE;CYP2C19;rs200346442;A;Metabolism/PK;decreased clearance of  ➔ METHADONE;Allele A is associated with decreased clearance of methadone as compared to allele G.;
;VORICONAZOLE;CYP2C19;rs550527959;T;Metabolism/PK;decreased clearance of  ➔ VORICONAZOLE;Allele T is associated with decreased clearance of voriconazole in insect microsomes as compared to allele A.;
;;CYP2C19;rs7902257;A;Other;decreased expression of CYP2C19 ➔ ;Allele A is associated with decreased expression of CYP2C19 in HepG2 cells as compared to allele G.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*51;*51;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *51 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;;CYP2C9;rs4918758;C;Other;decreasedtranscription of CYP2C9 ➔ ;Allele C is associated with decreased transcription of CYP2C9 as compared to allele T.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*33;*33;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *33 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*13;*13;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *13 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*16;*16;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *16 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*45;*45;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *45 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;;CYP2D6;rs16947;AA + AG;Other;decreased expression of CYP2D6 ➔ ;Genotypes AA + AG are associated with decreased expression of CYP2D6 in human liver cells as compared to genotype GG.;
;PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;*22 + *48;Metabolism/PK;increased clearance of  ➔ PRIMAQUINE;CYP2D6 *22 + *48 are associated with increased clearance of primaquine in 293FT cells as compared to CYP2D6 *1.;
;METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;Metabolism/PK;decreased clearance of  ➔ METHADONE;CYP2D6 *2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98 are associated with decreased clearance of methadone as compared to CYP2D6 *1.;
;;CYP2D6;CYP2D6*1, CYP2D6*92, CYP2D6*96;*92 + *96;Metabolism/PK;decreased activity  of CYP2D6 ➔ ;CYP2D6 *92 + *96 are associated with decreased activity of CYP2D6 as compared to CYP2D6 *1.;
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Metabolism/PK;decreased clearance of  ➔ VENLAFAXINE;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of venlafaxine as compared to CYP2D6 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*36;*36;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *36 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;Metabolism/PK;decreased clearance of  ➔ GEFITINIB;CYP2D6 *10 + *87 + *90 + *93 + *95 + *98 are associated with decreased clearance of gefitinib as compared to CYP2D6 *1.;
;BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;Metabolism/PK;decreased clearance of  ➔ BUFURALOL;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153 are associated with decreased clearance of bufuralol in insect microsomes as compared to CYP2D6 *1.;
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Metabolism/PK;decreased clearance of  ➔ RISPERIDONE;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of risperidone as compared to CYP2D6 *1.;
;CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;Metabolism/PK;decreased clearance of  ➔ CITALOPRAM;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98 are associated with decreased clearance of citalopram as compared to CYP2D6 *1.;
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;Metabolism/PK;decreased clearance of  ➔ ATOMOXETINE;CYP2D6 *90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10 are associated with decreased clearance of atomoxetine as compared to CYP2D6 *1.;
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;Metabolism/PK;decreased clearance of  ➔ TAMOXIFEN;CYP2D6 *2 + *10 + *87 + *90 + *91 + *93 + *95 + *98 are associated with decreased clearance of tamoxifen as compared to CYP2D6 *1.;
;TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;*10 + *93 + *94 + *95;Metabolism/PK;decreased clearance of  ➔ TOLTERODINE;CYP2D6 *10 + *93 + *94 + *95 are associated with decreased clearance of tolterodine as compared to CYP2D6 *1.;
;DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;Metabolism/PK;decreased clearance of  ➔ DEXTROMETHORPHAN;CYP2D6 *87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153 are associated with decreased clearance of dextromethorphan in insect microsomes as compared to CYP2D6 *1.;
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;Metabolism/PK;decreased clearance of  ➔ AMITRIPTYLINE;CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 are associated with decreased clearance of amitriptyline as compared to CYP2D6 *1.;
;BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs745746329;T;Metabolism/PK;decreased clearance of  ➔ BUFURALOL, DEXTROMETHORPHAN;Allele T is associated with decreased clearance of bufuralol or dextromethorphan in insect microsomes as compared to allele C.;
;OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;Metabolism/PK;decreased clearance of  ➔ OLANZAPINE;CYP2D6 *10 + *87 + *88 + *90 + *91 + *93 + *95 + *97 are associated with decreased clearance of olanzapine as compared to CYP2D6 *1.;
;;CYP2C9;rs9332094;C;Other;decreasedtranscription of CYP2C9 ➔ ;Allele C is associated with decreased transcription of CYP2C9 as compared to allele T.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*37;*37;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *37 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*42;*42;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *42 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;;CYP2C9;rs7089580;AT + TT;Other;increased  expression of CYP2C9 ➔ ;Genotypes AT + TT is associated with increased expression of CYP2C9 as compared to genotype AA.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*55;*55;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *55 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*56;*56;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *56 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*53;*53;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *53 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*50;*50;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *50 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*54;*54;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *54 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*19;*19;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *19 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*31;*31;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *31 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;LOSARTAN;CYP2C9;rs1057910;C;Metabolism/PK;decreased clearance of  ➔ LOSARTAN;Allele C is associated with decreased clearance of losartan.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*41;*41;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *41 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*27;*27;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *27 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*14;*14;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *14 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*62;*62;Metabolism/PK;decreased clearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *62 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Metabolism/PK;decreased clearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *2 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreased clearance of  ➔ DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9 *3 is associated with decreased clearance of diclofenac, losartan or tolbutamide as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*47;*47;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *47 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*49;*49;Metabolism/PK;increased clearance of  ➔ PHENYTOIN;CYP2C9 *49 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *3 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*43;*43;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *43 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*39;*39;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *39 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;Metabolism/PK;decreased clearance of  ➔ PHENYTOIN;CYP2C9 *8 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.;
;;ZNF890P;rs62442010;AA;Other;increased transcription of ABCB1 ➔ ;Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AC + CC.;
;NICOTINE;CYP2A6;rs1801272;AA + AT;Toxicity;decreased risk of Other:Tobacco Use Disorder;Genotypes AA + AT are associated with decreased risk of Tobacco Use Disorder due to nicotine as compared to genotype TT.; 
;SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with sacituzumab govitecan in people with Breast Neoplasms as compared to UGT1A1 *1/*1.;in people with Breast Neoplasms
;TACROLIMUS;CYP3A4;rs2740574;T;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele T is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele C.; 
;ARIPIPRAZOLE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2D6 ultrarapid metabolizer is associated with increased likelihood of adverse events when treated with aripiprazole in people with Schizophrenia, Schizoaffective disorder, Bipolar Disorder or Psychotic Disorder as compared to CYP2D6 normal metabolizer.;in people with Schizophrenia, Schizoaffective disorder, Bipolar Disorder, Psychotic Disorder
;SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799930;A;Toxicity;increased  risk of Side Effect:adverse reactions;Allele A is associated with increased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia.;in children with Disease:Pneumonia
;ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*04:06;*04:06;Toxicity;increased  risk of Side Effect:Muscular Diseases;HLA-DRB1 *04:06 is associated with increased risk of Muscular Diseases when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pitavastatin, pravastatin, rosuvastatin or simvastatin as compared to HLA-DRB1 *01:01.; 
;ETHANOL;CHRNA5;rs615470;T;Toxicity, Other;decreased likelihood of Disease:Alcohol abuse;Allele T is associated with decreased likelihood of Alcoholism due to ethanol as compared to allele C.; 
;LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting, Side Effect:Diarrhea, Side Effect:Gastrointestinal toxicity;Genotypes AT + TT is associated with increased likelihood of Nausea, Vomiting, Diarrhea or Gastrointestinal toxicity when treated with liraglutide in people with Diabetes Mellitus, Type 2 as compared to genotype AA.;in people with Diabetes Mellitus, Type 2
;PEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1041983;T;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele T is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.;in people with Tuberculosis
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;A;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele A is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.;in people with Tuberculosis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted AUC24;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted AUC24 of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Kidney Transplantation
;GEFITINIB;ABCG2;rs2231142;GG;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotype GG is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.;in people with Non-Small Cell Lung Carcinoma
;LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting, Side Effect:Diarrhea, Side Effect:Gastrointestinal toxicity;Genotypes AA + AG is associated with increased likelihood of Nausea, Vomiting, Diarrhea or Gastrointestinal toxicity when treated with liraglutide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Diabetes Mellitus, Type 2
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  likelihood of Disease:Hemorrhage;Genotype TT is associated with increased likelihood of Hemorrhage when treated with warfarin as compared to genotype CC.; 
;TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;rs2276307;G;Toxicity;increased  risk of Disease:Myalgia;Allele G is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele A.;in people with Disease:Hypercholesterolemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased  likelihood of PK:achieving optimal trough level;CYP3A5 *3/*3 is associated with increased likelihood of achieving optimal trough level of tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Ulcerative Colitis
;NORTRIPTYLINE;UST;rs2500535;A;Efficacy;decreased  Efficacy:improvement of depression symptoms;Allele A is associated with decreased improvement of depression symptoms when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotype GG.;in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A4;rs1851426;G;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele G is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;Efficacy:time to therapeutic inr;CYP2C9 *2 + *3 are associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to CYP2C9 *1.;in people with Disease:Atrial Fibrillation
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased likelihood of over-anticoagulation when treated with warfarin as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Toxicity;increased  risk of Side Effect:bleeding;CYP2C19 *17 is associated with increased risk of bleeding when treated with clopidogrel as compared to CYP2C19 *1.; 
;OSIMERTINIB;IL6;rs1800796;CG + GG;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes CG + GG is associated with decreased likelihood of overall survival when treated with osimertinib in people with Non-Small Cell Lung Carcinoma as compared to genotype CC.;in people with Non-Small Cell Lung Carcinoma
;FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *03:03 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;RISPERIDONE;HTR2A;rs6311;CT + TT;Toxicity;increased  severity of Side Effect:Weight gain;Genotypes CT + TT is associated with increased severity of Weight gain when treated with risperidone in people with Schizophrenia as compared to genotype CC.;in people with Schizophrenia
;TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*6;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *6/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*5;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *5/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  severity of Other:interstitial inflammatory cell infiltration;CYP3A5 *3/*3 is associated with increased severity of interstitial inflammatory cell infiltration when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.;in people with Disease:Kidney Transplantation
;RISPERIDONE;HTR2A;rs6313;AA + AG;Toxicity;increased  severity of Side Effect:Weight gain;Genotypes AA + AG is associated with increased severity of Weight gain when treated with risperidone in people with Schizophrenia as compared to genotype GG.;in people with Schizophrenia
;OXAZEPAM;UGT2B15;rs1902023;AA;Metabolism/PK;decreased  PK:S-oxazepam glucuronidation in human liver microsomes;Genotype AA is associated with decreased S-oxazepam glucuronidation in human liver microsomes when exposed to oxazepam as compared to genotype CC.; 
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.;in children with Disease:Juvenile Rheumatoid Arthritis
;OXAZEPAM;UGT2B15;rs1902023;AA;Metabolism/PK;decreased  PK:oxazepam oral clearance;Genotype AA is associated with decreased oxazepam oral clearance when exposed to oxazepam as compared to genotype CC.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Hypercholesterolemia;CYP2B6 poor metabolizer is associated with increased likelihood of Hypercholesterolemia when treated with efavirenz and isoniazid in people with HIV infectious disease as compared to CYP2B6 normal metabolizer.;in people with HIV infectious disease
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Toxicity;increased  risk of Disease:Drug Reaction with Eosinophilia and Systemic Symptoms;CYP2C9 *3 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.; 
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.; 
;TACROLIMUS;PPARA;rs4823613;GG;Toxicity;decreased likelihood of Side Effect:Acute cellular rejection;Genotype GG is associated with decreased likelihood of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.;in people with Liver transplantation
;MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased  likelihood of Disease:Drug Toxicity, Disease:Infectious disease, Disease:Stomatitis;TPMT *1/*3A is associated with increased likelihood of Drug Toxicity, Infection and Stomatitis when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;NITROUS OXIDE;MTHFR;rs1801133;AA;Toxicity;increased   Side Effect:plasma total homocysteine concentrations;Genotype AA is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype GG.;in people with surgery
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;Efficacy;increased  likelihood of Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) .;in people with Stroke
;RISPERIDONE;DRD3;rs167771;G;Toxicity;increased  risk of Side Effect:extrapyramidal symptoms;Allele G is associated with increased risk of extrapyramidal symptoms when treated with risperidone in people with Bipolar Disorder or Schizophrenia as compared to allele A.;in people with Disease:Bipolar Disorder, Disease:Schizophrenia
;ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;Toxicity;increased  risk of Side Effect:Tardive Dyskinesia;CYP2D6 *1/*10 + *10/*10 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in men with Schizophrenia as compared to CYP2D6 *1/*1.;in men with Disease:Schizophrenia
;FLUCLOXACILLIN;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQA1 *02:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;FLUCLOXACILLIN;HLA-A;HLA-A*01:01;*01:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-A *01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;AMOXICILLIN;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *58:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin.; 
;CISPLATIN, PACLITAXEL;GGT1;rs5751901;CC;Toxicity;decreased likelihood of Side Effect:Neutropenia, Side Effect:Leukopenia;Genotype CC is associated with decreased likelihood of Neutropenia or Leukopenia when treated with cisplatin and paclitaxel in people with Breast Neoplasms as compared to genotypes CT + TT.;in people with Breast Neoplasms
;ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *27:05 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations.; 
;FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *07:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;BUSULFAN;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*9;*1/*1 + *1/*5 + *1/*9;Efficacy;increased   Efficacy:event-free survival;CYP2B6 *1/*1 + *1/*5 + *1/*9 is associated with increased event-free survival when treated with busulfan in children with hemopoietic stem cell transplant as compared to CYP2B6 *5/*5 + *9/*9 + *5/*9.;in children with Disease:hemopoietic stem cell transplant
;TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;increased  risk of Side Effect:Uterine disorder, Side Effect:Leiomyoma, Side Effect:Endometrial Hyperplasia, Side Effect:Polyps;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased risk of Uterine disorder, Leiomyoma, Endometrial Hyperplasia or Polyps when treated with tamoxifen in people with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;in people with Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:time above therapeutic range;CYP2C9 *2 + *3 are associated with increased risk of time above therapeutic range when treated with warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.;in people with Disease:Venous thromboembolism
;CAPECITABINE, FLUOROURACIL;ABCC11;rs17822471;AA + AG;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes AA + AG is associated with increased risk of Leukopenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;Toxicity;increased  risk of Side Effect:Tardive Dyskinesia;CYP2D6 *1/*4 + *1/*5 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1/*1.;in people with Disease:Schizophrenia
;FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5 + *10/*10 + *5/*10;Metabolism/PK;PK:differences in the fluvoxamine plasma level at 50 mg/day;CYP2D6 *1/*10 + *1/*5 + *10/*10 + *5/*10 are associated with differences in the fluvoxamine plasma level at 50 mg/day when treated with fluvoxamine in people with as compared to CYP2D6 *1/*1.;in people with 
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;Toxicity;increased  likelihood of Side Effect:Bullous Pemphigoid;HLA-DQA1 *05 is associated with increased likelihood of Bullous Pemphigoid when treated with Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus.;in people with Diabetes Mellitus
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IDO1;rs9657182;CC;Toxicity;increased   Side Effect:Depression;Genotype CC is associated with increased Depression when treated with peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;rs3129763;AA + AG;Toxicity;increased  likelihood of Side Effect:Bullous Pemphigoid;Genotypes AA + AG is associated with increased likelihood of Bullous Pemphigoid when treated with Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus as compared to genotype GG.;in people with Diabetes Mellitus
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;Toxicity;increased  likelihood of Side Effect:Bullous Pemphigoid;HLA-DQB1 *03:01 is associated with increased likelihood of Bullous Pemphigoid when treated with Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus.;in people with Diabetes Mellitus
;NITROUS OXIDE;MTHFR;rs1801131;GG;Toxicity;increased   Side Effect:plasma total homocysteine concentrations;Genotype GG is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype TT.;in people with surgery
;CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-B *57:01 is associated with increased likelihood of Drug-induced liver injury when treated with ciprofloxacin, levofloxacin or moxifloxacin.; 
;OMEPRAZOLE;CYP2C19;rs11188072;TT;Dosage, Metabolism/PK;decreased  PK:AUC;Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.;in people with no disease
;METHADONE;CYP3A4;rs3735451;C;Toxicity;increased  severity of Side Effect:side effects;Allele C is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele T.;in people with Disease:Heroin Dependence
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Efficacy:high on-treatment platelet reactivity;CYP2C19 *2 is associated with increased high on-treatment platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;CARBOPLATIN, PACLITAXEL;ABCB1;rs2032582;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AC + CC.;in people with Ovarian Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *1/*1 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.;in women with Disease:Breast Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *1/*6 + *6/*6 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfamethoxazole / trimethoprim.; 
;ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Toxicity;risk of Side Effect:Tardive Dyskinesia;CYP2D6 *10 is associated with risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.;in people with Disease:Schizophrenia
;ANTIDEPRESSANTS;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;Efficacy;increased  risk of Efficacy:non-response;CYP2D6 *2/*2xN (assigned as ultrarapid metabolizer phenotype) is associated with increased risk of non-response when treated with antidepressants in people with Depressive Disorder, Major.;in people with Disease:Major Depressive Disorder
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ASPARAGINASE;ATL2;rs59569490;T;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;Allele T is associated with increased likelihood of Drug Hypersensitivity when treated with asparaginase in children with Neoplasms as compared to allele C.;in children with Neoplasms
;AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Pancreatitis;HLA-DQA1 *02:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.;in people with Disease:Inflammatory Bowel Diseases
;ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;Metabolism/PK;increased   Efficacy:maximal platelet aggregation;CYP2C19 *2/*3 is associated with increased maximal platelet aggregation when treated with aspirin, cilostazol and clopidogrel in high risk patients (acute myocaridal infarction, diabetes e.g.) as compared to CYP2C19 *1/*1.;in high risk patients (acute myocaridal infarction, diabetes e.g.)
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:stent thrombosis (ST) after 1 year;CYP2C19 *2 is associated with increased risk of stent thrombosis (ST) after 1 year when treated with clopidogrel as compared to CYP2C19 *1.; 
;ESCITALOPRAM;CYP2C19;rs4986893;A;Dosage, Metabolism/PK;increased   PK:serum concentration;Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.;in people with Disease:Mental Disorders
;PLATINUM COMPOUNDS;RETN;rs1862513;GG;Toxicity;increased  severity of Side Effect:Gastrointestinal toxicity;Genotype GG is associated with increased severity of Gastrointestinal toxicity when treated with Platinum compounds in people with Lung Neoplasms as compared to genotypes CC + CG.;in people with Lung Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;decreased  Efficacy:event-free survival, Efficacy:Recurrence free survival;CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *1/*6 + *6/*6 is associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Colorectal Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4 + *1/*4;Efficacy;decreased  Efficacy:event-free survival, Efficacy:Recurrence free survival;CYP2D6 *4/*4 + *1/*4 are associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *6/*6 + *6/*28 is associated with increased risk of Hyperbilirubinemia when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*6 + *1/*28 + *27/*28.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;PRIMAQUINE;MAOA;rs1137070;CC + CT;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotypes CC + CT is associated with increased likelihood of Recurrence when treated with primaquine in people with Malaria as compared to genotype TT.;in people with Malaria
;OMEPRAZOLE;CYP2C19;rs12248560;TT;Dosage, Metabolism/PK;decreased  PK:AUC;Genotype TT is associated with decreased AUC of omeprazole in people with no disease as compared to genotype CC.;in people with no disease
;PRIMAQUINE;CYP2D6;CYP2D6 normal metabolizer;;Efficacy;decreased likelihood of Efficacy:Recurrence;CYP2D6 normal metabolizer is associated with decreased likelihood of Recurrence when treated with primaquine in people with Malaria.;in people with Malaria
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;Toxicity;increased  severity of Side Effect:Leukopenia;Allele GGAGTC is associated with increased severity of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele del.;in people with Disease:Inflammatory Bowel Diseases
;PRIMAQUINE;CYP2D6;CYP2D6*4;*4;Efficacy;increased  likelihood of Efficacy:Recurrence;CYP2D6 *4 is associated with increased likelihood of Recurrence when treated with primaquine in people with Malaria.;in people with Malaria
;ESCITALOPRAM;CYP2C19;rs11188072;TT;Dosage, Metabolism/PK;decreased  PK:serum concentration;Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.;in people with Disease:Mental Disorders
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:concentration/dose ratio;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased  PK:concentration/dose ratio;CYP3A5 *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Kidney Transplantation
;TENOFOVIR;ABCC10;rs2125739;C;Toxicity;increased   Side Effect:kidney tubular dysfunction;Allele C is associated with increased kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Metabolism/PK;increased   PK:blood concentration/dosage ratio;CYP3A5 *1/*3 + *3/*3 is associated with increased blood concentration/dosage ratio of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:concentration/dose ratio;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.;in children with heart transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;Toxicity;increased  risk of Side Effect:cardiovascular events;CYP2C19 *5 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;CYP2B6 poor metabolizer is associated with increased likelihood of Toxic liver disease when treated with efavirenz and isoniazid in people with HIV infectious disease and Pregnancy as compared to CYP2B6 normal metabolizer and intermediate metabolizer.;in people with HIV infectious disease, Pregnancy
;ROSUVASTATIN;ABCG2;rs2231142;GT + TT;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Genotypes GT + TT is associated with increased likelihood of Elevated liver enzymes when treated with rosuvastatin in people with Acute coronary syndrome, Dyslipidaemia, Diabetes Mellitus or Cardiovascular Disease as compared to genotype GG.;in people with Acute coronary syndrome, Dyslipidaemia, Diabetes Mellitus, Cardiovascular Disease
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Toxicity;increased  likelihood of Side Effect:haematological toxicity or hepatotoxicity;TPMT *1/*3A + *1/*3C is associated with increased likelihood of haematological toxicity or hepatotoxicity when treated with azathioprine in people with neurological problems as compared to TPMT *1/*1.;in people with neurological problems
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotypes CC + CT is associated with increased likelihood of statin-related myopathy when treated with atorvastatin in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome or Dyslipidaemia as compared to genotype TT.;in people with Cardiovascular Disease, Diabetes Mellitus, Acute coronary syndrome, Dyslipidaemia
;TACROLIMUS;CYP3A4;rs2687116;A;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele A is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus.; 
;CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;Toxicity;increased  risk of Side Effect:Nausea;Genotypes AG + GG is associated with increased risk of Nausea when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;Toxicity;increased  risk of Side Effect:Vomiting;Genotypes AG + GG is associated with increased risk of Vomiting when treated with carboplatin and paclitaxel in people with Non-Small Cell Lung Carcinoma as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;ESCITALOPRAM;CYP2C19;rs4244285;A;Dosage, Metabolism/PK;increased   PK:serum concentration;Allele A is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to allele G.;in people with Disease:Mental Disorders
;;IFNL4;rs11322783;TT/TT;Other;increased   Other:spontaneous HCV clearance;Genotype TT/TT is associated with increased spontaneous HCV clearance in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;MERCAPTOPURINE;SLC22A1;rs72552763;del;Toxicity;increased  severity of Side Effect:Infectious disease;Allele del is associated with increased severity of Infection when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele GAT.;in children with Acute lymphoblastic leukemia
;CARBOPLATIN, CISPLATIN;;rs6856089;AA + AG;Toxicity;decreased likelihood of Side Effect:Myelosuppression;Genotypes AA + AG is associated with decreased likelihood of Myelosuppression when treated with carboplatin or cisplatin in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.;in people with Non-Small Cell Lung Carcinoma
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Metabolism/PK;decreased  PK:6-MMPN levels;TPMT *1/*2 + *1/*3A + *1/*3C is associated with decreased 6-MMPN levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;;SOD1;rs36232792;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;Other;decreased likelihood of Other:Opioid-Related Disorders;Genotypes GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del is associated with decreased likelihood of Opioid-Related Disorders as compared to genotype GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG.; 
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;Toxicity;increased  likelihood of Side Effect:Bone Marrow toxicity;TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of Bone Marrow toxicity when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;NAT2 *5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 *1/*1 + *1/*5 + *1/*6 + *1/*7 (assigned as intermediate acetylator and rapid acetylator phenotype) .;in people with Tuberculosis
;LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Efficacy, Toxicity;increased  likelihood of Efficacy:Discontinuation;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased likelihood of Discontinuation lacosamide in people with Epilepsy as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 (assigned as normal metabolizer and intermediate metabolizer phenotype) .;in people with Epilepsy
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;Toxicity;increased  likelihood of Side Effect:overall ADRs;TPMT *1/*3A + *3A/*3A + *1/*3C + *3C/*3C is associated with increased likelihood of overall ADRs when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Other;increased  likelihood of Other:Decreased glomerular filtration rate;CYP3A5 *1/*3 + *3/*3 is associated with increased likelihood of Decreased glomerular filtration rate in people with Kidney Disorder as compared to CYP3A5 *1/*1.;in people with Kidney Disorder
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;increased  likelihood of Other:Discontinuation, Other:Treatment modification;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Discontinuation and Treatment modification when treated with escitalopram in people with Depressive Disorder as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Depressive Disorder
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Exanthema;CYP2C9 *3 is associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C9 *1/*1.; 
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;Metabolism/PK;increased  likelihood of Other:Discontinuation, Other:Treatment modification;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Discontinuation and Treatment modification when treated with sertraline in people with Depressive Disorder as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Depressive Disorder
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;Toxicity;decreased  Side Effect:hematological indices;TPMT *1/*3A + *1/*3B + *1/*3C is associated with decreased hematological indices when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.;in people with Disease:Kidney Transplantation
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.;in women with Side Effect:Breast Neoplasms
;CYCLOSPORINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;Toxicity;increased   PK:plasma levels;TPMT *1/*3A + *1/*3B + *1/*3C is associated with increased plasma levels of cyclosporine in people with Kidney Transplantation as compared to TPMT *1/*1.;in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1;Genotype TT/TT is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;CISPLATIN, PEMETREXED;MTHFR;rs1801131;GG + GT;Efficacy;decreased  Efficacy:overall survival;Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT.;in people with Disease:Stomach Neoplasms
;ESCITALOPRAM;CYP2C19;rs12248560;TT;Dosage, Metabolism/PK;decreased  PK:serum concentration;Genotype TT is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to genotype CC.;in people with Disease:Mental Disorders
;PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *13:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.; 
;SUFENTANIL;ADRB1;rs1801253;GG;Efficacy;decreased severity of Efficacy:Pain, Postoperative;Genotype GG is associated with decreased severity of Pain, Postoperative when treated with sufentanil in children with Surgical procedure as compared to genotype CC.;in children with surgery
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;*10/*5 + *10/*10 + *10/*41;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *10/*5 + *10/*10 + *10/*41 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*36 + *1/*41 + *2/*2 + *2/*4 + *2/*10 + *10/*35.;in women with Side Effect:Breast Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;TENOFOVIR;ABCC10;rs9349256;G;Toxicity;increased   Side Effect:kidney tubular dysfunction;Allele G is associated with increased kidney tubular dysfunction when exposed to tenofovir as compared to allele A.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Toxicity;increased  risk of Side Effect:mortality;CYP2C19 *17 is associated with increased risk of mortality when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Disease:Myocardial Infarction;CYP2C19 *2 + *3 are associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;IMATINIB;ABCB1;rs1045642;A;Toxicity;increased  severity of Side Effect:Myelosuppression;Allele A is associated with increased severity of Myelosuppression when treated with imatinib in people with Chronic myelomonocytic leukemia as compared to allele G.;in people with Chronic myelomonocytic leukemia
;IMATINIB;NR1I2;rs3814055;TT;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotype TT is associated with increased severity of Myelosuppression when treated with imatinib in people with Chronic myelomonocytic leukemia as compared to genotypes CC + CT.;in people with Chronic myelomonocytic leukemia
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy, Toxicity;increased  risk of Side Effect:adverse clinical events;CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;rs6295;C;Efficacy;increased  likelihood of Efficacy:Treatment failure;Allele C is associated with increased likelihood of Treatment failure when treated with Selective serotonin reuptake inhibitors in people with Anxiety Disorders or Depressive Disorder as compared to allele G.;in people with Anxiety Disorders, Depressive Disorder
;FLUOROURACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;Metabolism/PK;decreased  PK:area under the plasma concentration-time curve;CYP2A6 *1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9 is associated with decreased area under the plasma concentration-time curve of fluorouracil in people with Neoplasms as compared to CYP2A6 *1/*1.;in people with Disease:Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;METHOTREXATE;MTRR;rs1801394;G;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele G is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A.;in children with Disease:Juvenile Rheumatoid Arthritis
;TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;Efficacy;decreased  Efficacy:Progression-free survival, Efficacy:Overall survival;CYP2A6 *4 + *7 + *9 + *10 are associated with decreased progression-free survival or overall survival when treated with tegafur / gimeracil / oteracil in people with Stomach Neoplasms as compared to CYP2A6 *1/*4 + *1/*7 + *1/*9 + *1/*10 + *1/*1.;in people with Disease:Stomach Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:adverse clinical events;CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL, ROSUVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Other;increased   Other:P2Y12 reaction unit(PRU) values;CYP2C19 *2 + *3 are associated with increased P2Y12 reaction unit(PRU) values when treated with clopidogrel and rosuvastatin in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.;in patients undergoing percutaneous coronary intervention
;METHADONE;CYP3A4;rs4646437;A;Toxicity;increased  severity of Side Effect:side effects;Allele A is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele G.;in people with Disease:Heroin Dependence
;TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;Metabolism/PK;increased   PK:area under the plasma concentration-time curve;CYP2A6 *1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9 is associated with increased area under the plasma concentration-time curve of tegafur in people with Neoplasms as compared to CYP2A6 *1/*1.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Toxicity;decreased risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *17/*17 is associated with decreased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;*3 + *4 + *5 + *6 + *7 + *14;Toxicity;increased  risk of Side Effect:Tardive Dyskinesia;CYP2D6 *3 + *4 + *5 + *6 + *7 + *14 is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.;in people with Disease:Schizophrenia
;AZATHIOPRINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Neutropenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to allele CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3.;in children with Disease:Inflammatory Bowel Diseases
;LAMOTRIGINE;HLA-C;HLA-C*07:18;*07:18;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-C *07:18 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.; 
;LAMOTRIGINE;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.; 
;RIVAROXABAN;ABCB1;rs4148738;CC;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype CC is associated with increased risk of Hemorrhage when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotypes CT + TT.;in people with Atrial Fibrillation
;LAMOTRIGINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-DQB1 *06:09 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.; 
;RIVAROXABAN;ABCB1;rs1045642;AA;Efficacy;increased  risk of Side Effect:Thromboembolism;Genotype AA is associated with increased risk of Thromboembolism when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.;in people with Atrial Fibrillation
;TAMOXIFEN;CYP2D6;CYP2D6*10;*10;Toxicity;increased  likelihood of Side Effect:Endometrial Hyperplasia;CYP2D6 *10 is associated with increased likelihood of Endometrial Hyperplasia when treated with tamoxifen in people with Breast Neoplasms.;in people with Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:clopidogrel resistance;CYP2C19 *2/*2 + *2/*3 + *3/*3 are associated with increased risk of clopidogrel resistance when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Disease
;METHOTREXATE;MTHFD1;rs2236225;A;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Allele A is associated with decreased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele G.;in children with Disease:Juvenile Rheumatoid Arthritis
;METHADONE;CYP3A4;rs2242480;T;Toxicity;increased  severity of Side Effect:side effects;Allele T is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele C.;in people with Disease:Heroin Dependence
;CARBOPLATIN, CISPLATIN;CD274;rs2297136;AG + GG;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotypes AG + GG is associated with increased likelihood of Progression-free survival when treated with carboplatin or cisplatin in people with Small cell carcinoma as compared to genotype AA.;in people with Small cell carcinoma
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Toxicity;increased  risk of Side Effect:bleeding events;CYP2C19 *17/*17 is associated with increased risk of bleeding events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;CARBOPLATIN, CISPLATIN;CD274;rs822336;CC + CG;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotypes CC + CG is associated with increased likelihood of Progression-free survival when treated with carboplatin or cisplatin in people with Small cell carcinoma as compared to genotype GG.;in people with Small cell carcinoma
;CARBOPLATIN, CISPLATIN;CD274;rs2282055;GT + TT;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotypes GT + TT is associated with increased likelihood of Progression-free survival when treated with carboplatin or cisplatin in people with Small cell carcinoma as compared to genotype GG.;in people with Small cell carcinoma
;HYDROMORPHONE, MORPHINE;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:Pruritus;Genotype AA is associated with increased likelihood of Pruritus when treated with hydromorphone or morphine as compared to genotypes AG + GG.; 
;ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*2;*2;Toxicity;increased  likelihood of Side Effect:extrapyramidal symptoms;CYP2D6 *2 is associated with increased likelihood of extrapyramidal symptoms when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 *1.;in people with Disease:Schizophrenia
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic, severe cutaneous adverse reactions and Stevens-Johnson Syndrome when treated with phenytoin.; 
;DOXORUBICIN;NCF4;rs1883112;AA + AG;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Genotypes AA + AG is associated with decreased likelihood of Cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*1/*2 + *1/*3;Toxicity;increased  risk of Side Effect:Discontinuation, Side Effect:Myelosuppression;NUDT15 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased risk of discontinuation and Myelosuppression when treated with azathioprine in people with Inflammation as compared to NUDT15 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Inflammation
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;Toxicity;increased  risk of Side Effect:Discontinuation, Side Effect:Myelosuppression;TPMT *1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of discontinuation and Myelosuppression when treated with azathioprine in people with Inflammation as compared to TPMT *1/*1 (assigned as normal metabolizer phenotype) .;in people with Inflammation
;DOXORUBICIN;CBR1;rs3787728;CT + TT;Efficacy;decreased likelihood of Efficacy:Progression-free survival, Efficacy:Overall survival;Genotypes CT + TT is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC.;in people with Hepatocellular Carcinoma
;INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:04;*04:04;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *04:04 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;DOXORUBICIN;CBR1;rs1005695;CG + GG;Efficacy;decreased likelihood of Efficacy:Progression-free survival, Efficacy:Overall survival;Genotypes CG + GG is associated with decreased likelihood of Progression-free survival and overall survival when treated with doxorubicin in people with Hepatocellular Carcinoma as compared to genotype CC.;in people with Hepatocellular Carcinoma
;ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*1/*5 + *5/*5;Toxicity;increased  risk of Side Effect:Discontinuation, Side Effect:statin-related myopathy;SLCO1B1 *1/*5 + *5/*5 is associated with increased risk of discontinuation and statin-related myopathy when treated with atorvastatin as compared to SLCO1B1 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Other;increased   Other:platelet reactivity by P2Y12 reaction units;CYP2C19 *2 is associated with increased platelet reactivity by P2Y12 reaction units when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2C19 *1/*1.;in patients undergoing percutaneous coronary intervention
;DABIGATRAN;CES1;rs2244613;GG + GT;Toxicity;decreased likelihood of Side Effect:Hemorrhage;Genotypes GG + GT is associated with decreased likelihood of Hemorrhage when treated with dabigatran in people with Atrial Fibrillation as compared to genotype TT.;in people with Atrial Fibrillation
;OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Toxicity;increased  risk of Disease:Dizziness;SLC6A4 HTTLPR long form (L allele) is associated with increased risk of Dizziness when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;in healthy individuals 
;RIVAROXABAN;ABCB1;rs1045642;AA + AG;Toxicity;decreased likelihood of Side Effect:Thromboembolism;Genotypes AA + AG is associated with decreased likelihood of Thromboembolism when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotype GG.;in people with Atrial Fibrillation
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;CAPECITABINE, PLATINUM;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased progression-free survival when treated with capecitabine and platinum in people with Colorectal Neoplasms or gastroesophageal cancer as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.;in people with Disease:Colorectal Neoplasms, Disease:Gastroesophageal Cancer
;ONDANSETRON;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased   Other:percentage of days abstinent and lower number of drinks per drinking day;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased percentage of days abstinent and lower number of drinks per drinking day when treated with ondansetron in people with Alcoholism as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).;in people with Disease:Alcohol abuse
;CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotypes AA + AG is associated with increased likelihood of Cardiotoxicity when treated with CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.;in people with Non-Hodgkin Lymphoma
;LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.; 
;CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotypes AA + AG is associated with increased likelihood of Cardiotoxicity when treated with CHOP and rituximab in people with Non-Hodgkin Lymphoma as compared to genotype GG.;in people with Non-Hodgkin Lymphoma
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;decreased  Efficacy:Overall survival;Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with decreased overall survival when treated with fluorouracil in people with Stomach Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Stomach Neoplasms
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6;*5/*6;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2B6 *5/*6 is associated with decreased Recurrence free survival when treated with cyclophosphamide in women with Breast Neoplasms as compared to CYP2B6 *1/*1.;in women with Disease:Breast Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;T;Efficacy;Efficacy:worse prognoses;Allele T is associated with worse prognoses when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Toxicity;increased  risk of Side Effect:sexual dysfunction;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased risk of sexual dysfunction when treated with Selective serotonin reuptake inhibitors as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;Efficacy;increased   Efficacy:international normalized ratio variability (inr-var);CYP2C9 *1/*11 is associated with increased international normalized ratio variability (inr-var) warfarin in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3C;*1/*3C;Toxicity;increased  risk of Side Effect:leukopenia;TPMT *1/*3C is associated with increased risk of leukopenia when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs1042927;C;Efficacy;decreased  Efficacy:overall survival probability;Allele C is associated with decreased overall survival probability when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele A.;in people with Disease:Mesothelioma
;METHOTREXATE;SLC19A1;rs1051266;CC;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CC is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;in people with Disease:Rheumatoid arthritis
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;Toxicity;decreased likelihood of Side Effect:Tremor, Side Effect:Diarrhea;Genotypes CC + TT are associated with decreased likelihood of Tremor or Diarrhea when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotype CT.;in people with Major Depressive Disorder
;AMOXICILLIN, CLAVULANATE;HLA-B;HLA-B*15:18;*15:18;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-B *15:18 is associated with increased likelihood of Drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28 + *28/*37;Toxicity;increased  severity of Side Effect:Asthenia, Side Effect:Diarrhea, Side Effect:Neutropenia;UGT1A1 *28/*28 + *28/*37 is associated with increased severity of Asthenia, Diarrhea and Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE, PACLITAXEL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Efficacy;decreased  Efficacy:Overall survival;Genotype TTAAAGTTA/TTAAAGTTA is associated with decreased overall survival when treated with capecitabine and paclitaxel in people with Stomach Neoplasms as compared to genotypes TTAAAGTTA/del + del/del.;in people with Disease:Stomach Neoplasms
;AZATHIOPRINE, MERCAPTOPURINE;PTPN2;rs11664064;C;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele C is associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases, Lupus erythematosus or Autoimmune Diseases as compared to allele T.;in people with Inflammatory Bowel Diseases, Lupus erythematosus, Autoimmune Diseases
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;Efficacy;decreased  Efficacy:Overall survival;CYP2D6 *3/*4 + *4/*4 + *4/*5 are associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4 + *1/*41 + *41/*41.;in women with Disease:Breast Neoplasms
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;Efficacy;increased   Efficacy:progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034);Allele A is associated with increased progression-free survival (PFS) (P=0.00004) and overall survival (OS) (P=0.034) when treated with bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFD1;rs2236225;AA;Toxicity;increased  severity of Side Effect:Gastrointestinal toxicity;Genotype AA is associated with increased severity of Gastrointestinal toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma or Sarcoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma, Sarcoma
;TAMOXIFEN;CYP2D6;rs3892097;CT + TT;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes CT + TT is associated with decreased likelihood of overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype CC.;in women with Breast Neoplasms
;METHOTREXATE;ABCB1;rs1045642;GG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;GSTP1;rs1695;AA;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotype AA is associated with increased severity of Myelosuppression when treated with methotrexate in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma or Sarcoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma, Sarcoma
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotypes AA + AG is associated with increased severity of Myelosuppression when treated with methotrexate in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma or Sarcoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia, Osteosarcoma, Non-Hodgkin Lymphoma, Sarcoma
;MERCAPTOPURINE, METHOTREXATE;TPMT;rs1142345;C;Toxicity;increased   Side Effect:GI toxicity;Allele C is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.;in children with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;SLCO1B1;rs11045879;T;Toxicity;increased  risk of Disease:Mucositis;Allele T is associated with increased risk of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in people with Disease:Acute lymphoblastic leukemia
;AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-DRB1 *15:01 is associated with increased likelihood of Drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-A *02:01 is associated with increased likelihood of Drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;rs1363907;G;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele G is associated with increased likelihood of Drug-induced liver injury when treated with amoxicillin and clavulanate as compared to allele A.; 
;CYCLOPHOSPHAMIDE;GSTT1;GSTT1 non-null, GSTT1 null;;Toxicity;increased  likelihood of Side Effect:Graft vs Host Disease;GSTT1 null is associated with increased likelihood of Graft vs Host Disease when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to GSTT1 non-null.;in people with Hematopoietic stem cell transplantation
;AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele A is associated with increased likelihood of Drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null, GSTM1 null;;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;GSTM1 null is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to GSTM1 non-null.;in people with Hematopoietic stem cell transplantation
;CAPECITABINE;TYMS;rs3786362;G;Toxicity;decreased likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A.;in people with Colorectal Neoplasms
;CAPECITABINE;TYMS;rs699517;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.;in people with Colorectal Neoplasms
;CAPECITABINE;ENOSF1, TYMS;rs11280056;TTAAAGTTA;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele TTAAAGTTA is associated with increased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele TTA.;in people with Colorectal Neoplasms
;CAPECITABINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;CAPECITABINE;ENOSF1, TYMS;rs2790;G;Toxicity;decreased likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with decreased likelihood of Hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele A.;in people with Colorectal Neoplasms
;;NME1, NME1-NME2;rs2302254;TT;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Recurrence free survival;Genotype TT is associated with decreased likelihood of overall survival or Recurrence free survival in people with Colorectal Neoplasms as compared to genotypes CC + CT.;in people with Colorectal Neoplasms
;IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:Diarrhea;UGT1A7 *1a/*3 + *2/*3 + *3/*3 is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A7 *1a/*1a.;in people with Stomach Neoplasms
;RIVAROXABAN;SUSD3;rs76292544;TT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype TT is associated with increased likelihood of Hemorrhage when treated with rivaroxaban in people with Venous thromboembolism as compared to genotypes AA + AT.;in people with Venous thromboembolism
;;CYP3A5, ZSCAN25;rs776746;CC;;Side Effect:Drug Toxicity;Genotype CC is associated with Drug Toxicity.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  likelihood of Side Effect:Diarrhea;UGT1A1 *1/*6 + *6/*6 is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1/*1.;in people with Stomach Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  likelihood of Side Effect:Neutropenia;UGT1A1 *1/*6 + *6/*6 is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1/*1.;in people with Stomach Neoplasms
;IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:Neutropenia;UGT1A7 *1a/*3 + *2/*3 + *3/*3 is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A7 *1a/*1a.;in people with Stomach Neoplasms
;METHOTREXATE;SLCO1B1;rs4149081;G;Toxicity;increased  risk of Side Effect:GI toxicity;Allele G is associated with increased risk of GI toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in people with Disease:Acute lymphoblastic leukemia
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;Toxicity;increased  likelihood of Side Effect:Exanthema, Side Effect:Drug Hypersensitivity;HLA-A *02:07 is associated with increased likelihood of Exanthema and Drug Hypersensitivity when treated with sulfamethoxazole / trimethoprim.; 
;ASPIRIN;FCER1G;rs11587213;AA;Toxicity;increased  risk of Side Effect:aspirin-intolerant asthma;Genotype AA is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AG + GG.;in people with Disease:Asthma
;LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Efficacy;increased  risk of Efficacy:Transplant rejection;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.;in people with Disease:Kidney Transplantation
;LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in people with Breast Neoplasms.;in people with Breast Neoplasms
;TACROLIMUS;CYP3A5;rs776746;C;Metabolism/PK;increased   PK:tacrolimus concentration to dose ratio (C/D ratio);Allele C is associated with increased tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele T.; 
;LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *07:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in people with Breast Neoplasms.;in people with Breast Neoplasms
;;MS4A2;rs569108;AG + GG;Toxicity;increased  likelihood of Other:atopy in patients with aspirin-intolerant chronic urticaria;Genotypes AG + GG are associated with increased likelihood of atopy in patients with aspirin-intolerant chronic urticaria as compared to genotype AA.; 
;LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *07:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;PACLITAXEL;ABCB1;rs2032582;AA;Efficacy;increased   Efficacy:chance of positive response to paclitaxel;Genotype AA is associated with increased chance of positive response to paclitaxel when treated with paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.;in people with Disease:Ovarian Neoplasms
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;rs536560;CC;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype CC is associated with increased likelihood of Drug-induced liver injury when treated with ethambutol null isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotypes CT + TT.;in people with Tuberculosis
;;FCER1G;rs11587213;AG + GG;Toxicity;increased  likelihood of Other:atopy in patients with aspirin-intolerant chronic urticaria;Genotypes AG + GG are associated with increased likelihood of atopy in patients with aspirin-intolerant chronic urticaria as compared to genotype AA.; 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:Drug Toxicity;CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CISPLATIN, RADIOTHERAPY;EPHX1;rs1051740;CT + TT;Toxicity;increased  likelihood of Side Effect:Nephrotoxicity;Genotypes CT + TT is associated with increased likelihood of Nephrotoxicity when treated with cisplatin null radiotherapy in people with Head and Neck Neoplasms as compared to genotype CC.;in people with Head and Neck Neoplasms
;CISPLATIN, RADIOTHERAPY;ERCC2;rs13181;GG + GT;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes GG + GT is associated with decreased likelihood of overall survival when treated with cisplatin null radiotherapy in people with Head and Neck Neoplasms, Lung Neoplasms or Neoplasm of esophagus as compared to genotype TT.;in people with Head and Neck Neoplasms, Lung Neoplasms, Neoplasm of esophagus
;CISPLATIN, RADIOTHERAPY;ERCC2;rs1799793;CT + TT;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes CT + TT is associated with decreased likelihood of overall survival when treated with cisplatin null radiotherapy in people with Head and Neck Neoplasms, Lung Neoplasms or Neoplasm of esophagus as compared to genotype CC.;in people with Head and Neck Neoplasms, Lung Neoplasms, Neoplasm of esophagus
;GEMCITABINE, PLATINUM COMPOUNDS;CDA;rs2072671;C;Toxicity;increased  likelihood of Disease:Nausea;Allele C is associated with increased likelihood of Nausea when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele A.;in people with Disease:Mesothelioma
;;CYP2A6;CYP2A6*4;*4/*4;Other;increased  likelihood of Other:Smoking Cessation;CYP2A6 *4/*4 is associated with increased likelihood of cessation in people with Tobacco Use Disorder.;in people with Tobacco Use Disorder
;ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;rs4646450;AA;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotype AA is associated with increased likelihood of Cardiotoxicity when exposed to anthracyclines and related substances in children with Acute lymphoblastic leukemia or Osteosarcoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia, Osteosarcoma
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;*1/*2 + *1/*3 + *1/*6 + *2/*2;Toxicity;increased   Side Effect:Neutropenia;NUDT15 *1/*2 + *1/*3 + *1/*6 + *2/*2 is associated with increased Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.;in children with Acute lymphoblastic leukemia
;ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;AA;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotype AA is associated with increased likelihood of Cardiotoxicity when exposed to anthracyclines and related substances in children with Acute lymphoblastic leukemia as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Toxicity;increased  likelihood of Side Effect:myelosuppression;TPMT *1/*3C is associated with increased likelihood of myelosuppression when treated with azathioprine in people with Kidney Transplantation as compared to TPMT *1/*1.;in people with Disease:Kidney Transplantation
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;Efficacy;decreased  Disease:Gastric pH;CYP2C19 *1/*1 + *1/*2 + *1/*3 are associated with decreased intragastric ph when treated with omeprazole in people with Helicobacter Infections as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;in people with Disease:Helicobacter Infections
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased likelihood of Drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 intermediate acetylator and rapid acetylator.;in people with Tuberculosis
;PHENPROCOUMON;VKORC1;rs9923231;TT;Dosage, Other;increased  risk of Side Effect:adverse events;Genotype TT is associated with increased risk of adverse events due to phenprocoumon as compared to genotypes CC + CT.; 
;METHOTREXATE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype TTAAAGTTA/TTAAAGTTA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes TTAAAGTTA/del + del/del.;in people with Disease:Rheumatoid arthritis
;CARBOPLATIN, GEMCITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Toxicity;increased  likelihood of Disease:Thrombocytopenia;Genotype TTAAAGTTA/TTAAAGTTA is associated with increased likelihood of Thrombocytopenia when treated with carboplatin and gemcitabine in women Breast Neoplasms as compared to allele del.;in women Disease:Breast Neoplasms
;METHOTREXATE;SLCO1B1;rs4149056;C;Other, Metabolism/PK;decreased  PK:clearance;Allele C is associated with decreased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in people with Disease:Acute lymphoblastic leukemia
;ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased   Side Effect:Drug Hypersensitivity;HLA-DRB1 *07:01 is associated with increased Drug Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in children with Acute lymphoblastic leukemia
;ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased  likelihood of Disease:Chronic Kidney Failure;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased likelihood of Kidney Failure, Chronic when treated with enalapril in people with Glomerulonephritis, IGA as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.;in people with Disease:Glomerulonephritis, IGA
;SUCCINYLCHOLINE, VOLATILE ANESTHETICS;RYR1;rs193922752;G;Toxicity;increased  risk of Side Effect:Malignant Hyperthermia;Allele G is associated with increased risk of Malignant Hyperthermia when exposed to succinylcholine null volatile anesthetics as compared to allele A.; 
;EGFR INHIBITORS;EGFR;rs2227983;GG;Toxicity;increased  likelihood of Disease:Exanthema;Genotype GG is associated with increased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to genotypes AA + AG.;in people with Disease:Neoplasms
;GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs12806698;A;Toxicity;decreased likelihood of Disease:Nausea;Allele A is associated with decreased likelihood of Nausea when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele C.;in people with Disease:Mesothelioma
;GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs11030918;C;Toxicity;decreased likelihood of Disease:Nausea;Allele C is associated with decreased likelihood of Nausea when treated with gemcitabine and Platinum compounds in people with Mesothelioma as compared to allele T.;in people with Disease:Mesothelioma
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.;in children 
;VERAPAMIL;ADRB1;rs1801252;AA + AG;Efficacy;increased  risk of Disease:Death;Genotypes AA + AG are associated with increased risk of Death when treated with verapamil in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;HEROIN;DRD2;rs12364283;G;Toxicity;increased  risk of Side Effect:Heroin Dependence;Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.; 
;REPAGLINIDE;CYP2C8;CYP2C8*3;*3;Metabolism/PK;decreased  PK:repaglinide AUC;CYP2C8 *3 is associated with decreased repaglinide AUC when exposed to repaglinide in healthy individuals as compared to CYP2C8 *1A.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Toxicity;increased  likelihood of Side Effect:haematopoietic toxicity;TPMT *1/*3C is associated with increased likelihood of haematopoietic toxicity when treated with azathioprine in people with Kidney Transplantation.;in people with Disease:Kidney Transplantation
;SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased risk of drug-induced liver injury when treated with sulfamethoxazole / trimethoprim.; 
;AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*3/*3;Toxicity;increased  risk of Side Effect:Leukopenia;NUDT15 *3/*3 is associated with increased risk of Leukopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to NUDT15 *1/*1 + *1/*2 + *1/*3 + *1/*5 + *1/*6.;in children with Disease:Inflammatory Bowel Diseases
;TACROLIMUS;CYP3A7;rs2257401;C;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele C is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele G.; 
;SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  likelihood of Side Effect:Muscular Diseases;CYP3A5 *3/*3 is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to CYP3A5 *1/*1 + *1/*3.;in people with Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;PHENYTOIN;CYP2C19;rs4986893;A;Toxicity;increased  likelihood of Disease:Drug Reaction with Eosinophilia and Systemic Symptoms;Allele A is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele G.; 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;Dosage, Efficacy;increased  risk of Efficacy:non-response and required higher dose;CYP2D6 *3/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:cardiovascular events;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Dosage, Efficacy;increased  risk of Efficacy:non-response and required higher dose;CYP2D6 *4/*4 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.; 
;TACROLIMUS;CYP3A4;rs4646437;G;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele G is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele A.; 
;ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;Toxicity, Metabolism/PK;decreased likelihood of Disease:Toxic liver disease;NAT2 *4 is associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ASPARAGINASE;SOD2;rs4880;GG;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotype GG is associated with increased risk of Toxic liver disease when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in people with Disease:Acute lymphoblastic leukemia
;;CYP1A2;rs762551;AC + CC;Other;increased  risk of Disease:Myocardial Infarction;Genotypes AC + CC are associated with increased risk of Myocardial Infarction in people with increased coffee intake.;in people with increased coffee intake
;ANTITHYROID PREPARATIONS;HLA-B;HLA-B*39:01;*39:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *39:01 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.;in people with Graves Disease
;TRASTUZUMAB;ERBB2;rs1136201;AG + GG;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Genotypes AG + GG is associated with increased risk of cardiotoxicity when treated with trastuzumab in women with Breast Neoplasms as compared to genotype AA.;in women with Disease:Breast Neoplasms
;SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;CYP3A5 *3/*3 is associated with increased likelihood of drug-induced liver injury when treated with simvastatin in people with Coronary Artery Disease as compared to CYP3A5 *1/*1 + *1/*3.;in people with Coronary Artery Disease
;PHENYTOIN;CYP2C9;rs1799853;T;Toxicity;increased  likelihood of Disease:Stevens-Johnson Syndrome;Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele C.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;BETA BLOCKING AGENTS;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;Efficacy;increased  risk of Efficacy:Death;Genotype GGGGCGGGGCCG/GGGGCGGGGCCG is associated with increased risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes GGGGCGGGGCCG/del + del/del.;in people with Acute coronary syndrome
;PACLITAXEL;FZD3;rs7001034;A;Toxicity;decreased risk of Side Effect:sensory peripheral neuropathy;Allele A is associated with decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women Breast Neoplasms as compared to allele G.;in women Disease:Breast Neoplasms
;CAPECITABINE, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype TTA/TTA is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.; 
;SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Toxicity;increased  likelihood of Side Effect:Physiological sexual disorder;SLC6A4 HTTLPR long form (L allele) is associated with increased likelihood of Sexual Dysfunctions, Psychological due to sertraline in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).;in people with Major Depressive Disorder
;CLOZAPINE;HLA-DRB1;HLA-DRB1*04:02;*04:02;Toxicity;increased  likelihood of Side Effect:Agranulocytosis;HLA-DRB1 *04:02 is associated with increased likelihood of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Schizophrenia
;DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;rs12979860;TT;Toxicity;increased  likelihood of Side Effect:Hepatocellular Carcinoma;Genotype TT is associated with increased likelihood of Carcinoma, Hepatocellular when treated with direct acting antivirals in people with Hepatitis C, Chronic as compared to genotypes CC + CT.;in people with Chronic hepatitis C virus infection
;GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Other;increased  risk of Disease:Hypoglycemia;CYP2C9 *2 + *3 is associated with increased risk of Hypoglycemia when treated with glibenclamide, gliclazide, glimepiride, glipizide and gliquidone in people with Diabetes Mellitus as compared to CYP2C9 *1.;in people with Disease:Diabetes Mellitus
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5/*5;Dosage, Efficacy;increased  risk of Efficacy:non-response and required higher dose;CYP2D6 *5/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.; 
;ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;NOS3;rs1799983;T;Other;increased  risk of Other:in-stent restenosis;Allele T is associated with increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors in men with Coronary Artery Disease as compared to allele G.;in men with Disease:Coronary Artery Disease
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTHRACYCLINES AND RELATED SUBSTANCES, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;decreased  Efficacy:Progression-free survival;CYP2D6 *4/*4 is associated with decreased progression-free survival when treated with anthracyclines and related substances and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.;in women with Disease:Breast Neoplasms
;ASPIRIN, CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;Efficacy;increased  risk of Side Effect:stent thrombosis;Genotypes AC + CC is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to genotype AA.;in people with percutaneous coronary interventions
;TACROLIMUS;CYP3A4;rs6956344;C;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele C is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele T.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;decreased  Efficacy:event-free survival, Efficacy:Recurrence free survival;CYP2D6 *4/*4 is associated with decreased event-free survival and Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.;in women with Disease:Breast Neoplasms
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *1/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:21 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy, Mood Disorders or neuropathic pain.;in people with Epilepsy, Mood Disorder, Neuropathic pain
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *28/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;PACLITAXEL;ABCB1;rs1045642;AG;Efficacy;decreased  Efficacy:disease control rate and lower overall survival rate;Genotype AG is associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in people with metastatic breast cancer as compared to genotype GG.;in people with metastatic breast cancer
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Metabolism/PK;decreased  PK:clopidogrel active metabolite level;CYP2C19 *2 is associated with decreased clopidogrel active metabolite level when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.;in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased  likelihood of PK:achieving target concentrations;CYP3A5 *3/*3 is associated with increased likelihood of achieving target concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in children with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Efficacy;increased   Efficacy:post-treatment ADP-stimulated platelet aggregation;CYP2C19 *2 is associated with increased post-treatment ADP-stimulated platelet aggregation when treated with clopidogrel in healthy individuals as compared to CYP2C19 *1.;in healthy individuals 
;PACLITAXEL;CYP3A5;rs776746;C;Toxicity;decreased risk of Disease:Neurotoxicity Syndromes;Allele C is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Toxicity;decreased risk of Side Effect:Hot Flashes;CYP2D6 *4/*4 is associated with decreased risk of Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*4 + *1/*1.;in women with Disease:Breast Neoplasms
;INFLIXIMAB;HLA-DQB1;HLA-DQB1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *02:01 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;INFLIXIMAB;HLA-DPB1;HLA-DPB1*10:01;*10:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DPB1 *10:01 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;INFLIXIMAB;HLA-DRB1;HLA-DRB1*03:01;*03:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *03:01 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;;HLA-DPB1;HLA-DPB1*03:01;*03:01;Toxicity;increased  risk of Disease:Aspirin-induced asthma;HLA-DPB1 *03:01 is associated with increased risk of aspirin-induced asthma.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*4 + *4/*5 + *4/*10;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *4/*4 + *4/*5 + *4/*10 are associated with increased risk of Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*4.;in women with Disease:Breast Neoplasms
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*6;*6/*6;Dosage, Efficacy;increased  risk of Efficacy:non-response and required higher dose;CYP2D6 *6/*6 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.; 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;Dosage, Efficacy;increased  risk of Efficacy:non-response and required higher dose;CYP2D6 *4/*5 is associated with increased risk of non-response and required higher dose when treated with tramadol as compared to CYP2D6 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;Efficacy;decreased  Efficacy:antiplatelet response and reduced clopidogrel active metabolite formation;CYP2C19 *2/*2 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.;in people with Disease:Arthritis, Gouty
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;rs12283870;T;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Allele T is associated with increased likelihood of elevated liver enzymes when treated with cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mercaptopurine, methotrexate, pegaspargase, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Toxicity;increased  risk of Side Effect:Thrombocytopenia;UGT1A1 *28 is associated with increased risk of Thrombocytopenia when treated with FOLFIRINOX in people with Pancreatic Neoplasms as compared to UGT1A1 *1.;in people with Pancreatic Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*4 + *5 + *10 + *14 + *21 + *36 + *41;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *4 + *5 + *10 + *14 + *21 + *36 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:dose-adjusted blood levels;CYP3A5 *3/*3 is associated with increased dose-adjusted blood levels of tacrolimus in people with lung transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with lung transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:dose-adjusted trough concentration;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:trough concentration;CYP3A5 *3/*3 is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2242480;C;Metabolism/PK;PK:tacrolimus concentration to dose ratio (C/D ratio);Allele C is associated with tacrolimus concentration to dose ratio (C/D ratio) when treated with tacrolimus as compared to allele T.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *10/*10 is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.;in women with Disease:Breast Neoplasms
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;Toxicity;increased  risk of Side Effect:Leukopenia;TPMT *1/*2 + *1/*3A are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *01:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:response rate to pegIFN-alpha/RBV treatment at week 20/24;Genotype TT/TT is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Other;increased   Other:creatinine clearance;CYP3A5 *1/*1 is associated with increased creatinine clearance when treated with tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Kidney Transplantation
;FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*4 + *5 + *10 + *21 + *36;Metabolism/PK;increased   PK:age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias;CYP2D6 *4 + *5 + *10 + *21 + *36 are associated with increased age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias when treated with flecainide as compared to CYP2D6 *1.; 
;TRANILAST;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with tranilast in people with Myocardial Ischemia as compared to UGT1A1 *1/*1 + *1/*28.;in people with Myocardial Ischemia
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;Metabolism/PK;increased   PK:mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication;CYP2D6 *3 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*5/*36 + *10/*10 + *10/*36 + *21/*36;Metabolism/PK;decreased  PK:oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia;CYP2D6 *5/*36 + *10/*10 + *10/*36 + *21/*36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 *1/*1 + *1/*2.; 
;ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DRB1 *08:03 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.;in people with Graves Disease
;ANTITHYROID PREPARATIONS;HLA-DQA1;HLA-DQA1*01:03;*01:03;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DQA1 *01:03 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.;in people with Graves Disease
;ANTITHYROID PREPARATIONS;HLA-DQB1;HLA-DQB1*06:01;*06:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DQB1 *06:01 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations in people with Graves Disease.;in people with Graves Disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *1/*3 is associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*4 + *4/*41 + *1/*5 + *2/*5 are associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *3/*4 + *4/*9 + *9/*10 + *9/*41 + *41/*41 + *1/*4 + *1/*6 + *2/*4 + *2/*20 + *35/*4 + *1/*10 + *1/*9 + *1/*41 + *35/*10 + *2/*9 + *2/*41 + *35/*41 + *35/*9 + *1/*1 + *2/*2 + *1/*2 + *1/*35 + *1xN/*2.;in people with Disease:Breast Neoplasms
;CAPECITABINE;DPYD;rs67376798;AT;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype AT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity, Side Effect:Leukopenia, Side Effect:Toxic liver disease;Genotype AA is associated with increased risk of gastrointestinal toxicity, Leukopenia and Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in people with Disease:Acute lymphoblastic leukemia
;CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;Efficacy;increased  likelihood of Efficacy:3 year event free survival;Genotype CC is associated with increased likelihood of 3 year event free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.;in people with Disease:Leukemia, Myeloid, Acute
;CLOPIDOGREL;CYP1A2;rs2069514;A;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele A is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;OPIOIDS;OPRM1;rs548646;T;Toxicity;decreased risk of Other:Opioid-Related Disorders;Allele T is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele C.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentrations of tacrolimus in children with heart transplantation as compared to CYP3A5 *3/*3.;in children with heart transplantation
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10;Metabolism/PK;increased   PK:nortriptyline concentrations corrected for dose and weight;CYP2D6 *10 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.;in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;Toxicity;increased  risk of Disease:Acute cellular rejection;Genotypes C/T + T/T is associated with increased risk of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to genotype C/C.;in people with Disease:Liver transplantation
;RHODAMINE 123;ABCB1;rs1045642;GG;Metabolism/PK;increased   PK:efflux of rhodamine from CD56+ natural killer cells;Genotype GG is associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Side Effect:stent thrombosis;Genotypes AA + AG is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to genotype GG.;in people with percutaneous coronary interventions
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;Side Effect:Neutropenia, Side Effect:Thrombocytopenia;TPMT *1/*3A is associated with Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs2768759;AC;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype AC is associated with increased risk of Hemorrhage when treated with aspirin, clopidogrel or ticagrelor in people with Stroke as compared to genotype AA.;in people with Stroke
;LAMOTRIGINE;HLA-A;HLA-A*68:01;*68:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *68:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.; 
;CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;decreased  Efficacy:Pain;CYP2C9 *1/*3 is associated with decreased Pain when treated with celecoxib in children as compared to CYP2C9 *1/*1.;in children 
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;*2 + *3 + *4 + *5 + *6;Toxicity;increased  likelihood of Side Effect:Leukopenia;NUDT15 *2 + *3 + *4 + *5 + *6 are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to NUDT15 *1.;in people with Disease:Inflammatory Bowel Diseases
;CARBAMAZEPINE;HLA-A;HLA-A*01:01;*01:01;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema;HLA-A *01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;TETANUS ANTITOXIN;HLA-A;HLA-A*02:06;*02:06;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-A *02:06 is associated with increased likelihood of Drug Hypersensitivity when treated with tetanus antitoxin.; 
;CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-A *11:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.; 
;ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;Toxicity;decreased likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-A *24:02 is associated with decreased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.; 
;CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *24:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;INFLIXIMAB;HLA-B;HLA-B*08:01;*08:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *08:01 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-A *31:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *32:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to vancomycin.; 
;PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *38:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;NEVIRAPINE;HLA-B;HLA-B*14:02;*14:02;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *14:02 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;PHENYTOIN;HLA-B;HLA-B*15:01;*15:01;Toxicity;increased  risk of Side Effect:Exanthema;HLA-B *15:01 is associated with increased risk of Exanthema when treated with phenytoin.; 
;ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema;HLA-B *15:02 is associated with increased risk of Maculopapular Exanthema when treated with antiepileptics in people with Epilepsy.;in people with Epilepsy
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.;in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:11 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:13 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Neutropenia;TPMT *3A + *3C is associated with increased likelihood of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;Toxicity;increased  risk of Side Effect:Leukopenia;NUDT15 *1/*2 + *1/*3 + *1/*4 + *1/*6 are associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;CLINDAMYCIN;HLA-B;HLA-B*15:27;*15:27;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-B *15:27 is associated with increased risk of Drug Toxicity when treated with clindamycin.; 
;NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *35:01 is associated with increased risk of severe cutaneous adverse reactions when treated with nevirapine.; 
;CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *38:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with schizoaffective disorder or Schizophrenia.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *38:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *38:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;INFLIXIMAB;HLA-B;HLA-B*39:01;*39:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *39:01 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;Toxicity;decreased risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *40:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;OXCARBAZEPINE;HLA-B;HLA-B*40:02;*40:02;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema;HLA-B *40:02 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;*3/*4 + *4/*6;Metabolism/PK;increased   PK:S-mirtazapine plasma levels in non-smokers at day 14 of treatment;CYP2D6 *3/*4 + *4/*6 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 *1/*1.;in people with Disease:Depression
;PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *51:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.; 
;CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-B *51:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.; 
;NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with nilotinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to UGT1A1 *1/*1 + *1/*28.;in people with Chronic myelogenous leukemia, BCR-ABL1 positive
;CLINDAMYCIN;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-B *51:01 is associated with increased risk of Drug Toxicity when treated with clindamycin.; 
;PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *51:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.; 
;PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *51:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;ISONIAZID;HLA-B;HLA-B*52:01;*52:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *52:01 is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis.;in people with Tuberculosis
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:hypersensitivity;HLA-B *57:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *59:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.; 
;METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *59:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.; 
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;Metabolism/PK;increased   PK:serum concentrations of S(+)-mirtazapine,  mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine;CYP2D6 *4 + *5 are associated with increased serum concentrations of S(+)-mirtazapine, mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine when treated with mirtazapine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;OPIOIDS;OPRM1;rs609148;A;Toxicity;decreased risk of Other:Opioid-Related Disorders;Allele A is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele G.; 
;ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *1/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to UGT1A1 *1/*1.;in people with Disease:HIV infectious disease
;METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-C *01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.; 
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1 + *1/*18;Metabolism/PK;increased   PK:trough concentrations;CYP3A4 *1/*1 + *1/*18 is associated with increased trough concentrations of cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *18/*18.;in people with Disease:Kidney Transplantation
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *07:27 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;NEVIRAPINE;HLA-C;HLA-C*08:02;*08:02;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-C *08:02 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;INFLIXIMAB;HLA-C;HLA-C*12:03;*12:03;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-C *12:03 is associated with increased risk of drug-induced liver injury due to infliximab.; 
;;HLA-DPB1;HLA-DPB1*03:01;*03:01;Toxicity;increased  risk of Disease:Aspirin-induced asthma;HLA-DPB1 *03:01 is associated with increased risk of aspirin-induced asthma.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with Kidney Transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Kidney Transplantation
;PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;TACROLIMUS;CYP2J2;rs890293;AA + AC;Toxicity;increased  risk of Disease:Nausea, Disease:Vomiting;Genotypes AA + AC is associated with increased risk of Nausea and Vomiting when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;HLA-DQB1;HLA-DQB1*03:03;*03:03;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-DQB1 *03:03 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;ABACAVIR;HLA-DQB1;HLA-DQB1*03:03;*03:03;Toxicity;increased  risk of Side Effect:hypersensitivity;HLA-DQB1 *03:03 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *05:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;FLUPIRTINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *05:02 is associated with increased risk of drug-induced liver injury when treated with flupirtine.; 
;AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;increased  risk of Side Effect:Hepatitis;HLA-DQB1 *06:02 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.;in people with Disease:Infectious disease
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-DRB1 *01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *01:01 is associated with increased risk of Toxic liver disease when treated with nevirapine.; 
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:02;*01:02;Toxicity;increased  risk of Disease:Toxic liver disease;HLA-DRB1 *01:02 is associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;HYDRALAZINE;HLA-DRB1;HLA-DRB1*04:01;*04:01;Toxicity;increased  likelihood of Side Effect:drug-induced lupus erythematosus due to hydralazine;HLA-DRB1 *04:01 is associated with increased likelihood of drug-induced lupus erythematosus due to hydralazine when treated with hydralazine in people with Hypertension.;in people with Hypertension
;OXCARBAZEPINE;HLA-DRB1;HLA-DRB1*04:03;*04:03;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema;HLA-DRB1 *04:03 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;ABACAVIR;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:hypersensitivity;HLA-DRB1 *07:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  likelihood of Side Effect:Hypersensitivity;HLA-DRB1 *07:01 is associated with increased likelihood of Hypersensitivity when exposed to asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in people with Disease:Acute lymphoblastic leukemia
;LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *07:01 is associated with increased risk of drug-induced liver injury when treated with lapatinib.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4969170;AA;Toxicity;decreased risk of Disease:Thrombocytopenia;Genotype AA is associated with decreased risk of Thrombocytopenia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype GG.; 
;PRAVASTATIN;LDLR;rs2738466;G;Efficacy;increased  risk of Disease:Coronary Disease;Allele G is associated with increased risk of Coronary Disease when treated with pravastatin in men.;in men 
;LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-DRB1 *13:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.; 
;FLUPIRTINE;HLA-DRB1;HLA-DRB1*16:01;*16:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *16:01 is associated with increased risk of drug-induced liver injury when treated with flupirtine.; 
;THALIDOMIDE;GSTT1;rs4630;AA;Toxicity;increased  likelihood of Side Effect:Neurotoxicity;Genotype AA is associated with increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to genotype AG.;in people with Disease:Multiple Myeloma
;MINOCYCLINE;HLA-B;HLA-B*35:02;*35:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *35:02 is associated with increased risk of drug-induced liver injury when treated with minocycline in people with.;in people with 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Metabolism/PK;decreased  PK:dose;CYP2C9 *1/*2 + *1/*3 are associated with decreased dose when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.;in Disease:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;increased   Efficacy:prothrombin time (PT) at induction;CYP2C9 *3 is associated with increased prothrombin time (PT) at induction when treated with warfarin as compared to CYP2C9 *1.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.;in people with Disease:Hyperuricemia
;ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Toxicity;decreased  Side Effect:Weight gain;CYP2C8 *3 is associated with decreased Weight gain when treated with rosiglitazone in people with Diabetes Mellitus as compared to CYP2C8 *1/*1.;in people with Disease:Diabetes Mellitus
;TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Toxicity;increased  risk of Disease:Kidney Disorder;CYP2C8 *3 is associated with increased risk of Kidney Diseases when treated with tacrolimus in people with liver transplantation as compared to CYP2C8 *1.;in people with Disease:Liver transplantation
;CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Toxicity;increased  risk of Disease:Kidney Disorder;CYP2C8 *3 is associated with increased risk of Kidney Diseases when treated with Calcineurin inhibitors, cyclosporine or tacrolimus in people with liver transplantation as compared to CYP2C8 *1.;in people with Disease:Liver transplantation
;ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;Metabolism/PK;increased   Efficacy:high on-treatment platelet reactivity;CYP2C19 *2/*3 is associated with increased high on-treatment platelet reactivity when treated with aspirin, cilostazol and clopidogrel in high risk patients (acute myocaridal infarction, diabetes e.g.) as compared to CYP2C19 *1/*1.;in high risk patients (acute myocaridal infarction, diabetes e.g.)
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy, Toxicity;increased  risk of Side Effect:Hemorrhage, Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Hemorrhage and over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to CYP2C9 *1/*1 + *1/*3.;in men 
;PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with paclitaxel and Platinum compounds in people with Lung Neoplasms as compared to genotype GG.;in people with Lung Neoplasms
;CAFFEINE;CYP1A2;CYP1A2 low activity;;Other;increased   Other:intake;CYP1A2 low activity phenotype is associated with increased intake of caffeine in women with Pregnancy as compared to CYP1A2 high activity phenotype.;in women with Disease:Pregnancy
;HMG COA REDUCTASE INHIBITORS;GNB3;rs5443;CT + TT;Efficacy;decreased risk of Disease:Myocardial Infarction;Genotypes CT + TT are associated with decreased risk of Myocardial Infarction when treated with hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype CC.;in people with Disease:Hypercholesterolemia
;;HMGCR;rs3846662;AA;Other;decreased  Other:HMGCRv_1 expression and an increase in the expression of the full-length transcript;Genotype AA is associated with decreased HMGCRv_1 expression and an increase in the expression of the full-length transcript as compared to genotypes AG + GG.; 
;ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;Metabolism/PK;Disease:Hyperbilirubinemia;UGT1A1 *28 is associated with Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV.;in people with Disease:HIV infectious disease
;ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;Efficacy;increased  likelihood of Efficacy:primary graft failure;NUDT15 *2/*2 +*2/*3 +*3/*3 + *5/*5 (assigned as poor metabolizer phenotype) are associated with increased likelihood of primary graft failure when treated with aciclovir in people with hematopoietic stem cell transplantation as compared to NUDT15 *1/*1 + *1/*2 + *1/*3 + *1/*4 + *1/*5 (assigned as intermediate metabolizer and normal metabolizer phenotype) .;in people with Hematopoietic stem cell transplantation
;METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;Toxicity;increased  likelihood of Side Effect:Nausea;SLCO1B1 *15 is associated with increased likelihood of Nausea when treated with methotrexate in children with Inflammatory Bowel Diseases.;in children with Inflammatory Bowel Diseases
;CAFFEINE;ADORA2A;rs35320474;T/del + TT;Efficacy;increased  likelihood of Efficacy:Bronchopulmonary dysplasia;Genotypes T/del + TT is associated with increased likelihood of Bronchopulmonary dysplasia of newborn when treated with caffeine in infants with apnea of prematurity and Premature Birth as compared to genotype del/del.;in infants with Apnea of prematurity, Premature Birth
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;Efficacy:higher mean peak INR during week 1 of warfarin therapy;CYP2C9 *2 is associated with higher mean peak INR during week 1 of warfarin therapy when treated with warfarin in children as compared to CYP2C9 *1.;in children 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;Efficacy:higher mean peak INR during week 1 of warfarin therapy;CYP2C9 *3 is associated with higher mean peak INR during week 1 of warfarin therapy when treated with warfarin in children as compared to CYP2C9 *1.;in children 
;;DHFR;rs70991108;del/del;Other;increased   Other:serum and red blood cell folate concentrations;Genotype del/del is associated with increased serum and red blood cell folate concentrations.; 
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;Toxicity;increased   Disease:Neutropenia;Genotype AA is associated with increased Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;Efficacy;decreased severity of Efficacy:Depression;CYP2C19 *1/*17 + *17/*17 is associated with decreased severity of Depression when treated with fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizer phenotype) .;in people with Anxiety Disorders, Depression, Major Depressive Disorder
;FLUOXETINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;decreased severity of Efficacy:Anxiety Disorders;CYP3A5 *1/*1 + *1/*3 is associated with decreased severity of Anxiety Disorders when treated with fluoxetine in people with Anxiety Disorders, Depression or Depressive Disorder, Major as compared to CYP3A5 *3/*3 (assigned as intermediate metabolizer phenotype) .;in people with Anxiety Disorders, Depression, Major Depressive Disorder
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;*20 + *26 + *24+ *9 + *27 + *17;Other, Metabolism/PK;decreased  PK:metabolism;CYP2A6 *20 + *26 + *24+ *9 + *27 + *17 is associated with decreased metabolism of nicotine as compared to CYP2A6 *1.; 
;COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3823010;A;Toxicity;increased  risk of Other:Alcohol abuse, Other:Cocaine dependence, Other:Opioid-Related Disorders;Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele G.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:11 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased likelihood of adverse events when treated with capecitabine, fluorouracil, FOLFOX or XELOX in women with Breast Neoplasms, Colorectal Neoplasms or Neoplasms.;in women with Breast Neoplasms, Colorectal Neoplasms, Neoplasms
;COCAINE, ETHANOL, OPIOIDS;OPRM1;rs495491;G;Toxicity;increased  risk of Other:Alcohol abuse, Other:Cocaine dependence, Other:Opioid-Related Disorders;Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.; 
;INTERFERON BETA-1A, INTERFERON BETA-1B;HLA-DQA1;rs9272105;G;Efficacy;increased   Efficacy:anti-IFN-beta antibodies;Allele G is associated with increased anti-IFN-beta antibodies when treated with interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.;in people with Disease:Multiple Sclerosis
;CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Discontinuation;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of discontinuation when treated with capecitabine, fluorouracil, FOLFOX or XELOX in women with Breast Neoplasms, Colorectal Neoplasms or Neoplasms.;in women with Breast Neoplasms, Colorectal Neoplasms, Neoplasms
;REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;*37/*37;Metabolism/PK;decreased  PK:repaglinide exposure (decreased AUC and increased  clearance);SLCO1B1 *37/*37 is associated with decreased repaglinide exposure (decreased AUC and increased clearance) when exposed to repaglinide in healthy individuals as compared to SLCO1B1 *15/*1 + *5/*1.;in healthy individuals 
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-C *04:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;EGFR INHIBITORS;EGFR;rs2227983;A;Efficacy;Efficacy:cytotoxicity;Allele A is associated with cytotoxicity of egfr inhibitors.; 
;ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 + *1/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV as compared to UGT1A1 *1/*1.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-C *08:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4961252;G;Efficacy;increased   Efficacy:anti-IFN-beta antibodies;Allele G is associated with increased anti-IFN-beta antibodies when treated with interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele A.;in people with Disease:Multiple Sclerosis
;METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 are associated with decreased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2.;in children with Acute lymphoblastic leukemia
;PEGASPARGASE;HLA-DRB1;HLA-DRB1*16:02;*16:02;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *16:02 is associated with increased likelihood of Drug Hypersensitivity when treated with pegaspargase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in children with Acute lymphoblastic leukemia
;ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;increased  risk of Efficacy:CNS relapse, Efficacy:hematologic relapse;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased risk of CNS relapse or hematologic relapse when treated with asparaginase, cytarabine, daunorubicin, etoposide, mercaptopurine, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in children with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased  Efficacy:event free survival;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Disease:Acute lymphoblastic leukemia
;GEMCITABINE;RRM1;rs9937;G;Toxicity;decreased risk of Disease:Neutropenia;Allele G is associated with decreased risk of Neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;;ACE;rs1799752;del/del;Other;increased  severity of Other:COVID-19;Genotype del/del is associated with increased severity of COVID-19 in people with COVID-19 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;in people with COVID-19
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;PD;decreased likelihood of Other:time to therapeutic inr;CYP2C9 *1/*3 + *3/*3 is associated with decreased likelihood of time to therapeutic inr in people not taking warfarin in people with as compared to CYP2C9 *1/*1.;in people with 
;ETHANOL;OPRM1;rs1381376;T;Toxicity;increased  risk of Other:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *35:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;PEGASPARGASE;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.; 
;PEGASPARGASE;HLA-DQB1;HLA-DQB1*02:02;*02:02;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase.; 
;PEGASPARGASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase.; 
;METHOTREXATE;DHFR, MSH3;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;Toxicity;increased  severity of Side Effect:Leukopenia;Genotype TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT is associated with increased severity of Leukopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TGGCGCGTCCCGCCCAGGT/del + del/del.;in children with Acute lymphoblastic leukemia
;METHOTREXATE;ENOSF1, TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotypes TTA/TTA + TTA/TTAAAGTTA are associated with increased risk of Neutropenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TTAAAGTTA/TTAAAGTTA.;in children with Acute lymphoblastic leukemia
;;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Other;decreased likelihood of Other:COVID-19;Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased likelihood of COVID-19 as compared to allele del.; 
;CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;GG;Efficacy;increased  risk of Efficacy:Transplant rejection;Genotype GG is associated with increased risk of transplant rejection when treated with cyclosporine or tacrolimus in people with liver transplantation as compared to genotype AA.;in people with Disease:Liver transplantation
;;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Other;decreased severity of Other:COVID-19;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased severity of COVID-19 in people with COVID-19.;in people with COVID-19
;AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;Efficacy;increased  risk of Efficacy:treatment emergent mania;CYP2C19 *2/*2 + *2/*1 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of treatment emergent mania when treated with amitriptyline or clomipramine in people with Bipolar Disorder as compared to CYP2C19 *1/*17 + *17/*17 (assigned as rapid and ultrarapid metabolizers phenotype) .;in people with Bipolar Disorder
;;ACE;rs1799752;del;Other;increased  likelihood of Other:COVID-19;Allele del is associated with increased likelihood of COVID-19 in people with as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in people with 
;ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;;rs1050450;A;Other;increased  risk of Other:in-stent restenosis;Allele A is associated with increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors in men with Coronary Artery Disease as compared to allele G.;in men with Disease:Coronary Artery Disease
;;ACE;rs1799752;del/del;Other;increased  risk of Other:Death;Genotype del/del is associated with increased risk of Death in people with COVID-19 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;in people with COVID-19
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;Efficacy;increased  risk of Efficacy:treatment emergent mania;CYP2C19 *2/*2 + *2/*1 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased risk of treatment emergent mania when treated with sertraline in people with Bipolar Disorder as compared to CYP2C19 *1/*17 + *17/*17 (assigned as rapid and ultrarapid metabolizers phenotype) .;in people with Bipolar Disorder
;MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;Toxicity;increased  likelihood of Side Effect:Neutropenia;NUDT15 *1/*2 + *1/*3 + *1/*5 + *1/*6 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to NUDT15 *1/*1 (assigned as normal metabolizer phenotype) .;in children with Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;Toxicity;decreased  Side Effect:Hemorrhage;CYP2C19 poor metabolizers and intermediate metabolizers is associated with decreased Hemorrhage when treated with clopidogrel as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer.; 
;LEFLUNOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;Toxicity;decreased likelihood of Side Effect:Discontinuation;CYP2C19 *1/*17 + *17/*17 is associated with decreased likelihood of discontinuation when treated with leflunomide in people with Arthritis, Rheumatoid as compared to CYP2C19 *1/*1 + *1/*2.;in people with Rheumatoid arthritis
;ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  likelihood of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-DRB1 *15:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when treated with anakinra, canakinumab, rilonacept or tocilizumab in people with Arthritis, Juvenile Rheumatoid or Still's Disease, Adult-Onset.;in people with Juvenile Rheumatoid Arthritis, Adult-onset Still disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;Efficacy;increased  risk of Efficacy:treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients;Genotype GG is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype TT/TT.; 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;Metabolism/PK;increased   PK: apparent terminal elimination half-life;CYP2D6 *3 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;FLUCLOXACILLIN;HLA-B;HLA-B*57:03;*57:03;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *57:03 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;CISPLATIN;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B + *3C;Toxicity;increased  risk of Side Effect:Ototoxicity;TPMT *3B + *3C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to TPMT *1.;in children with Neoplasms
;PREDNISONE, TACROLIMUS;ABCB1;rs1045642;GG;Efficacy;increased  risk of Other:remaining on steroids at 1 year after transplantation;Genotype GG is associated with increased risk of remaining on steroids at 1 year after transplantation when treated with prednisone and tacrolimus in people with heart transplantation as compared to genotypes AA + AG.;in people with heart transplantation
;CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-A *11:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *57:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *1/*1;Metabolism/PK;increased   PK:oral clearance (CL) of atazanavir;CYP3A5 *1/*3 + *1/*1 are associated with increased oral clearance (CL) of atazanavir when treated with atazanavir in people with HIV as compared to CYP3A5 *3/*3.;in people with Disease:HIV infectious disease
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *1/*2;Toxicity;increased  likelihood of Side Effect:Febrile neutropenia;TPMT *1/*3A + *1/*3B + *1/*3C + *1/*2 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of febrile neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Acute lymphoblastic leukemia
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CYP2C9;CYP2C9*3;*3;Toxicity;increased  likelihood of Side Effect:Gastrointestinal Hemorrhage;CYP2C9 *3 is associated with increased likelihood of Gastrointestinal Hemorrhage when treated with Antiinflammatory agents, non-steroids.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;EGFR INHIBITORS;EGFR;rs712829;T;Toxicity;Efficacy:cytotoxicity;Allele T is associated with cytotoxicity of egfr inhibitors.; 
;ANTINEOPLASTIC AGENTS;TYMS;rs11280056;TTA;Toxicity;decreased likelihood of Side Effect:Gastrointestinal toxicity;Allele TTA is associated with decreased likelihood of gastrointestinal toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele TTAAAGTTA.;in children with Acute lymphoblastic leukemia
;CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *74:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*24:07;*24:07;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *24:07 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *24:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*3A;Toxicity;increased  risk of Side Effect:low leukocyte counts;TPMT *1/*3A is associated with increased risk of low leukocyte counts when treated with azathioprine in people with Rheumatic Diseases as compared to TPMT *1/*1.;in people with Disease:Rheumatic Diseases
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*1;Efficacy;increased   Efficacy:treatment duration;TPMT *1/*1 is associated with increased treatment duration when treated with azathioprine in people with Rheumatic Diseases as compared to TPMT *1/*3A.;in people with Disease:Rheumatic Diseases
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *31:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*4;*4;Toxicity;increased  risk of Side Effect:cardiovascular events;CYP2C19 *4 is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;ATAZANAVIR;UGT1A1;UGT1A1*28;*28;Toxicity;increased  risk of Disease:Hyperbilirubinemia;UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV.;in people with Disease:HIV infectious disease
;ATORVASTATIN, PRAVASTATIN;APOE;rs429358;CC + CT;Efficacy;increased   Efficacy:reduction in C-reactive protein (CRP);Genotypes CC + CT is associated with increased reduction in C-reactive protein (CRP) when treated with atorvastatin or pravastatin in people with Acute coronary syndrome.;in people with Disease:Acute coronary syndrome
;CLOZAPINE;GSTM1;GSTM1 non-null, GSTM1 null;null/null;Toxicity;decreased risk of Side Effect:Neutropenia;GSTM1 null/null is associated with decreased risk of Neutropenia when treated with clozapine as compared to GSTM1 non-null/non-null + non-null/null.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;Efficacy;increased  likelihood of Efficacy:Thrombotic disease, Efficacy:Sudden cardiac death, Efficacy:Myocardial Infarction;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased likelihood of Thrombosis, Death, Sudden, Cardiac or Myocardial Infarction when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizers and rapid metabolizers phenotype) .;in people with Acute coronary syndrome
;OPIOIDS;OPRM1;rs1799971;AA;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Genotype AA is associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes AG + GG.;in men 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*7;*4/*7;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;Efficacy, Metabolism/PK;decreased  Efficacy:metabolism of tramadol and decreased response to tramadol;CYP2D6 poor metabolizer is associated with decreased metabolism of tramadol and decreased response to tramadol when treated with tramadol as compared to CYP2D6 normal metabolizer.; 
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotypes CC + CT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype TT.;in people with Disease:Non-Hodgkin Lymphoma
;TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-DRB1 *07:01 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when exposed to carbamazepine.; 
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-DRB1 *12:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when exposed to carbamazepine.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;Toxicity;decreased likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-DRB1 *04:05 is associated with decreased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when exposed to carbamazepine.; 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased   Other:intragastric pH;CYP2C19 *1/*2 is associated with increased intragastric pH when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.;in people with Disease:Ulcer
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *31:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-B *46:01 is associated with increased likelihood of Drug Hypersensitivity when treated with carbamazepine in people with Epilepsy.;in people with Epilepsy
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;Metabolism/PK;increased   PK:apparent terminal elimination half-life;CYP2D6 *5 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*09:01;*09:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *09:01 is associated with increased likelihood of Drug Hypersensitivity when treated with carbamazepine in people with Epilepsy.;in people with Epilepsy
;CARBAMAZEPINE;HLA-DQA1;HLA-DQA1*03:02;*03:02;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DQA1 *03:02 is associated with increased likelihood of Drug Hypersensitivity when treated with carbamazepine in people with Epilepsy.;in people with Epilepsy
;TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Efficacy;increased   Efficacy:platelet aggregation inhibition;CYP3A4 *1/*22 is associated with increased platelet aggregation inhibition when exposed to ticagrelor in healthy individuals as compared to CYP3A4 *1/*1.;in healthy individuals 
;EFAVIRENZ;HLA-DRB1;HLA-DRB1*08:03;*08:03;Toxicity;decreased likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *08:03 is associated with decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections.;in people with HIV infectious disease
;EFAVIRENZ;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-C *01:02 is associated with increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections.;in people with HIV infectious disease
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *04:05 is associated with increased likelihood of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with HIV infectious disease
;TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*11;*4/*11;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*11 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE;ABCB1;rs1128503;AA;Dosage, Metabolism/PK;increased   PK:trough blood concentration;Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype GG.;in people with Disease:Myasthenia Gravis
;;TMPRSS2;rs383510;CC;Other;increased  likelihood of Other:COVID-19;Genotype CC is associated with increased likelihood of COVID-19 as compared to genotypes CT + TT.; 
;LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *07:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in people with Breast Neoplasms.;in people with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *3/*4 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2C9 *2 + *3 are associated with increased likelihood of adverse events when treated with fluvastatin in people with Kidney Transplantation as compared to CYP2C9 *1/*1.;in people with Kidney Transplantation
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Metabolism/PK;increased   PK:apparent terminal elimination half-life;CYP2D6 *4 is associated with increased apparent terminal elimination half-life when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *3/*5 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.;in people with HIV infectious disease
;CYCLOSPORINE;ABCB1;rs2032582;AA;Dosage, Metabolism/PK;increased   PK:trough blood concentration;Genotype AA is associated with increased trough blood concentration of cyclosporine in people with Myasthenia Gravis as compared to genotype CC.;in people with Disease:Myasthenia Gravis
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;Metabolism/PK;increased   PK:mean serum concentrations of sertraline and N-desmethyl sertraline;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 are associated with increased mean serum concentrations of sertraline and N-desmethyl sertraline when treated with sertraline in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Dosage, Efficacy;increased   Efficacy:time to achieve stable dose;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.; 
;METHADONE;CYP3A4;rs2246709;G;Toxicity;increased  severity of Side Effect:side effects;Allele G is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele A.;in people with Disease:Heroin Dependence
;FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;increased   PK:fluvoxamine plasma concentrations;CYP2D6 *10/*10 + *5/*10 are associated with increased fluvoxamine plasma concentrations when treated with fluvoxamine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*2/*2 + *2/*4;Metabolism/PK;increased   PK:area under the time-plasma concentration curve (AUC(0-24));CYP2C19 *2/*2 + *2/*4 (assigned as poor metabolizer phenotype) is associated with increased area under the time-plasma concentration curve (AUC(0-24)) when treated with escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; 
;PRAVASTATIN;KIF6;rs20455;AG + GG;Efficacy;decreased risk of Disease:Coronary Disease;Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *55:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.; 
;METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *59:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.; 
;ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;CYP2D6*1;*1/*1;Efficacy, Metabolism/PK;PK:inhibition of metabolism;CYP2D6 *1/*1 is associated with inhibition of metabolism when treated with acetaminophen, codeine and levomepromazine in people with Back Pain.;in people with Disease:Back Pain
;LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when exposed to lamotrigine.; 
;METHADONE;CYP3A4;rs2242480;T;Other;increased  severity of Side Effect:opioid withdrawal symptoms;Allele T is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele C.;in people with Disease:Heroin Dependence
;DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;rs12960;G;Toxicity;increased  risk of Side Effect:toxicity;Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.;in people with Disease:Prostatic Neoplasms
;DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;Toxicity;increased  risk of Side Effect:toxicity;Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;in people with Disease:Prostatic Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);CYP2C19 *1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Acute coronary syndrome
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;increased   PK:metabolic ratio CIT/DCIT values and mean citalopram dose;CYP2C19 *2/*2 is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to CYP2C19 *1/*1.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Toxicity;decreased risk of Disease:Depression;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with decreased risk of Depression when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele).;in people with Disease:Chronic hepatitis C virus infection
;METHADONE;CYP3A4;rs4646440;A;Other;increased  severity of Side Effect:opioid withdrawal symptoms;Allele A is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G.;in people with Disease:Heroin Dependence
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *1/*17;Efficacy;increased  likelihood of Efficacy:adverse cardiovascular events;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *1/*17 (assigned as normal metabolizer phenotype) is associated with increased likelihood of adverse cardiovascular events when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.;in people with Cardiovascular Disease
;CARBAMAZEPINE;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;ETHANOL, OPIOIDS;OPRM1;rs511435;T;Toxicity;increased  risk of Other:Alcohol abuse, Other:Opioid-Related Disorders;Allele T is associated with increased risk of Alcoholism or Opioid-Related Disorders due to ethanol or opioids as compared to allele C.; 
;DOCETAXEL, THALIDOMIDE;NAT2;rs1799931;G;Toxicity;increased  risk of Side Effect:toxicity;Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele A.;in people with Disease:Prostatic Neoplasms
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Metabolism/PK;decreased  PK:mean logarithm escitalopram concentration;CYP2C19 *1/*17 is associated with decreased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;DOCETAXEL, THALIDOMIDE;CYP4B1;rs4646487;T;Toxicity;increased  risk of Side Effect:toxicity;Allele T is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.;in people with Disease:Prostatic Neoplasms
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*07:02;*07:02;Toxicity;increased  risk of Side Effect:Respiratory Insufficiency;HLA-B *07:02 is associated with increased risk of Respiratory Insufficiency when treated with sulfamethoxazole / trimethoprim.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:02;*07:02;Toxicity;increased  risk of Side Effect:Respiratory Insufficiency;HLA-C *07:02 is associated with increased risk of Respiratory Insufficiency when treated with sulfamethoxazole / trimethoprim.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;GSTM1 null;null/null;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;GSTM1 null/null is associated with increased risk of severe cutaneous adverse reactions when treated with sulfamethoxazole / trimethoprim in people with Acquired Immunodeficiency Syndrome.;in people with Disease:Acquired Immunodeficiency Syndrome
;CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-DRB1 *07:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;OLANZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  likelihood of Disease:Fatigue;UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to UGT1A1 *1/*1.;in healthy individuals 
;FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;Toxicity;increased  likelihood of Side Effect:Febrile neutropenia;UGT1A1 *1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) is associated with increased likelihood of febrile neutropenia when treated with FOLFIRINOX in people with Pancreatic Neoplasms as compared to UGT1A1 *1/*1.;in people with Pancreatic Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.; 
;METHOTREXATE;DHFR;rs3045983;GGGAGCTGG/del + del/del;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotypes GGGAGCTGG/del + del/del is associated with decreased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GGGAGCTGG/GGGAGCTGG.;in people with Disease:Rheumatoid arthritis
;OPIOIDS;OPRM1;rs589046;CC;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Genotype CC is associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CT + TT.;in men 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *31:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased   PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole, R-5-hydroxyomeprazole and S-5-hydroxyomeprazole;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole, R-5-hydroxyomeprazole and S-5-hydroxyomeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *17/*17.;in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Toxicity;increased  risk of Side Effect:Graft vs Host Disease;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Graft vs Host Disease when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Hematopoietic stem cell transplantation
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Toxicity;decreased  Side Effect:leukocytes and neutrophils;TPMT *1/*3A + *1/*3C is associated with decreased leukocytes and neutrophils when treated with azathioprine in people with heart transplantation as compared to TPMT *1/*1.;in people with Disease:Heart transplantation
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased   PK:metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole and R-5-hydroxyomeprazole;CYP2C19 *1/*2 + *1/*3 is associated with increased metabolic ratio (defined as ratio of omeprazole to its metabolites) of 5-hydroxyomeprazole and R-5-hydroxyomeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.;in healthy individuals 
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;increased   PK:amitriptyline/nortriptyline ratio corrected for dose and weight;CYP2C19 *1/*2 + *2/*2 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;Efficacy;increased  risk of Side Effect:adverse events;CYP3A4 low activity is associated with increased risk of adverse events when treated with alprazolam in men with Alcoholism and Anxiety Disorders as compared to CYP3A4 high activity.;in men with Alcohol abuse, Anxiety Disorders
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;CYP2C19 *1/*2 + *1/*3 + *2/*2 is associated with increased likelihood of high on-treatment platelet reactivity when treated with aspirin null clopidogrel as compared to CYP2C19 *1/*1.; 
;PACLITAXEL;CYP3A4;CYP3A4*1, CYP3A4*8, CYP3A4*20;*1/*8 + *1/*20;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases, Side Effect:Treatment modification;CYP3A4 *1/*8 + *1/*20 are associated with increased risk of Peripheral Nervous System Diseases and treatment modification when treated with paclitaxel in people with Breast Neoplasms and Ovarian Neoplasms as compared to CYP3A4 *1/*1.;in people with Disease:Breast Neoplasms, Disease:Ovarian Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;DOCETAXEL;VEGFA;rs144854329;del/del;Efficacy;decreased  Efficacy:progression-free survival;Genotype del/del is associated with decreased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype GGTCCCACTCTTCCCACA/GGTCCCACTCTTCCCACA.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*3/*3 + *3/*2 + *2/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *3/*3 + *3/*2 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation.;in people with Disease:Atrial Fibrillation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased  PK:unbound oral clearance for S-warfarin;CYP2C9 *1/*3 is associated with decreased unbound oral clearance for S-warfarin when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;Toxicity;decreased  Side Effect:adverse effect burden;SLC6A4 L allele-rs25531T/L allele-rs25531T is associated with decreased adverse effect burden when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C.;in people with Disease:Major Depressive Disorder
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*3, NUDT15*6;*1/*3 + *3/*3 + *1/*6;Toxicity;increased  likelihood of Side Effect:Leukopenia;NUDT15 *1/*3 + *3/*3 + *1/*6 is associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to NUDT15 *1/*1.;in people with Inflammatory Bowel Diseases
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Toxicity;increased  risk of Side Effect:side effects;SLC6A4 HTTLPR short form (S allele) is associated with increased risk of side effects when treated with antidepressants in people with Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Depressive Disorder
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Adenocarcinoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Adenocarcinoma
;WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3 + *2/*2;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2/*3 + *3/*3 + *2/*2 are associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation.;in people with Disease:Atrial Fibrillation
;HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;CYP2D6 *1/*4 is associated with increased likelihood of Drug Toxicity when treated with haloperidol in men with Alcoholic psychosis NOS as compared to CYP2D6 *1/*1.;in men with Alcoholic psychosis
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotype CC is associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;;HLA-DPB1;HLA-DPB1*04:01;*04:01;Toxicity;decreased risk of Disease:Aspirin-induced asthma;HLA-DPB1 *04:01 is associated with decreased risk of aspirin-induced asthma.; 
;CARBOPLATIN, CISPLATIN;DPYD;DPYD Reference;Reference;Efficacy;increased   Efficacy:Progression-free survival, Efficacy:Overall survival;DPYD Reference is associated with increased progression-free survival and overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung.;in people with Non-Small Cell Lung Carcinoma
;METHAMPHETAMINE;DAOA;rs947267;T;Toxicity;increased  likelihood of Disease:Psychotic Disorder;Allele T is associated with increased likelihood of Psychotic Disorders due to methamphetamine.; 
;CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.;in children with Disease:Epilepsy
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*36;*10/*10 + *5/*10 + *36;Efficacy;increased  severity of Efficacy:Pain;CYP2D6 *10/*10 + *5/*10 + *36 (assigned as intermediate metabolizer phenotype) is associated with increased severity of Pain when treated with tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10 + *1/*2 + *1/*5 + *2/*10 + *2/*2 + *1/*10x2 (assigned as normal metabolizer phenotype) .;in people with Pain, Postoperative
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased   PK:area under curve (AUC) of omeprazole racemate, omeprazole sulfone, R-omeprazole and S-omeprazole;CYP2C19 *1/*2 + *1/*3 is associated with increased area under curve (AUC) of omeprazole racemate, omeprazole sulfone, R-omeprazole and S-omeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.;in healthy individuals 
;TACROLIMUS;CYP3A5;rs776746;TT;Dosage, Metabolism/PK;Other:higher stable dose levels;Genotype TT is associated with higher stable dose levels of tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.;in people with Disease:Kidney Transplantation
;METHAMPHETAMINE;OPRM1;rs2075572;C;Toxicity;decreased risk of Other:Methamphetamine dependence;Allele C is associated with decreased risk of methamphetamine dependence due to methamphetamine as compared to allele G.; 
;ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *13:01 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.; 
;ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-A *02:06 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.; 
;ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *44:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.; 
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;increased   PK:area under curve (AUC) of omeprazole racemate, omeprazole sulfone, R-omeprazole and S-omeprazole;CYP2C19 *1/*2 + *1/*3 is associated with increased area under curve (AUC) of omeprazole racemate, omeprazole sulfone, R-omeprazole and S-omeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *17/*17.;in healthy individuals 
;ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-C *14:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Disease:Thrombotic disease;CYP2C19 *2 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Toxicity;increased  risk of Disease:Thrombotic disease;CYP2C19 *3 is associated with increased risk of Thrombosis when treated with clopidogrel as compared to CYP2C19 *1.; 
;CARBAMAZEPINE, LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine or lamotrigine.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10 + *1/*41.;in women with Disease:Breast Neoplasms
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;Toxicity;increased  risk of Side Effect:Neutropenia, Side Effect:Thrombocytopenia;TPMT *1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34 are associated with increased risk of Neutropenia and Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;METHADONE;CYP3A4;rs2246709;A;Other;decreased severity of Side Effect:opioid withdrawal symptoms;Allele A is associated with decreased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G.;in people with Disease:Heroin Dependence
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:clopi-H4 concentrations after 300 or 900 mg clopidogrel loading dose;Allele A is associated with decreased clopi-H4 concentrations after 300 or 900 mg clopidogrel loading dose when treated with clopidogrel in men with Myocardial Infarction as compared to genotype GG.;in men with Disease:Myocardial Infarction
;ATORVASTATIN, PRAVASTATIN;APOE;rs7412;CT + TT;Efficacy;increased   Efficacy:percent reduction in LDL-cholesterol;Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;Toxicity;increased  risk of Side Effect:Drug Toxicity;SLCO1B1 *5 is associated with increased risk of Drug Toxicity when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to SLCO1B1 *1.;in people with Disease:Hypercholesterolemia
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Toxicity;increased  risk of Disease:Maculopapular Exanthema;CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.; 
;ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28 is associated with increased likelihood of Hyperbilirubinemia when treated with Antivirals for treatment of HIV infections, combinations in people with HIV as compared to UGT1A1 *1.;in people with Disease:HIV infectious disease
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.; 
;ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;rs2230345;AT + TT;Other;decreased risk of Other:adverse cardiovascular outcomes;Genotypes AT + TT are associated with decreased risk of adverse cardiovascular outcomes when treated with atenolol, hydrochlorothiazide, trandolapril and verapamil in people with Hypertension and Coronary Artery Disease as compared to genotype AA.;in people with Hypertension and Coronary Artery Disease
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *13:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.;in people with Disease:Leprosy
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:major cardiovascular events;Allele A is associated with increased risk of major cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;METHAMPHETAMINE;BDNF;rs6265;CC;Toxicity;decreased severity of Other:Methamphetamine dependence;Genotype CC is associated with decreased severity of methamphetamine dependence due to methamphetamine as compared to genotypes CT + TT.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.; 
;TACROLIMUS;ABCB1;rs1045642;GG;Efficacy, Metabolism/PK;increased  likelihood of Disease:delayed graft function;Genotype GG is associated with increased likelihood of delayed graft function when treated with tacrolimus in people with as compared to genotypes AA + AG.;in people with 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;Toxicity;decreased risk of Side Effect:Toxic liver disease;NAT2 *4 is associated with decreased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;ANTICHOLINERGIC AGENTS;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;increased   PK:Serum anticholinergic activity;CYP2D6 poor metabolizer is associated with increased serum anticholinergic activity when treated with Anticholinergic Agents as compared to CYP2D6 normal metabolizer.; 
;ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with antiepileptics.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased   PK:formation of metabolites;CYP3A5 *1/*3 is associated with increased formation of metabolites of tacrolimus in human liver microsomes as compared to CYP3A5 *3/*3.;in human liver microsomes
;AZATHIOPRINE;NUDT15;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*2 + *3 + *5 + *6;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Drug Toxicity;NUDT15 *2 + *3 + *5 + *6 is associated with increased likelihood of Leukopenia and Drug Toxicity when treated with azathioprine in people with Inflammatory Bowel Diseases.;in people with Inflammatory Bowel Diseases
;;GSTT1;GSTT1 non-null, GSTT1 null;;Other;increased  likelihood of Other:Asthma;GSTT1 null is associated with increased likelihood of Asthma in children as compared to GSTT1 non-null.;in children 
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-C *04:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.; 
;;GSTM1;GSTM1 non-null, GSTM1 null;;Other;increased  likelihood of Other:Asthma;GSTM1 null is associated with increased likelihood of Asthma in children as compared to GSTM1 non-null.;in children 
;METHAMPHETAMINE;DAOA;rs2391191;A;Toxicity;decreased likelihood of Disease:Psychotic Disorder;Allele A is associated with decreased likelihood of Psychotic Disorders due to methamphetamine.; 
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*6 + *6/*6 + *4/*6 + *5/*6;Toxicity;decreased severity of Side Effect:Elevated liver enzymes;CYP2B6 *1/*6 + *6/*6 + *4/*6 + *5/*6 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) is associated with decreased severity of elevated liver enzymes when treated with cyclophosphamide in children with Neuroblastoma as compared to CYP2B6 *1/*1 + *1/*5 + *1/*4 + *1/*22 (assigned as normal metabolizers and rapid metabolizers phenotype) .;in children with Neuroblastoma
;CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*1 + *1/*5 + *1/*4 + *1/*22;Toxicity;increased  severity of Side Effect:Myelosuppression;CYP2B6 *1/*1 + *1/*5 + *1/*4 + *1/*22 (assigned as normal metabolizers and rapid metabolizers phenotype) is associated with increased severity of Myelosuppression when treated with cyclophosphamide in children with Neuroblastoma as compared to CYP2B6 *1/*6 + *6/*6 + *4/*6 + *5/*6 (assigned as poor metabolizer and intermediate metabolizer genotypes phenotype) .;in children with Neuroblastoma
;IRINOTECAN;HLA-DQB3;rs2859101;C;Toxicity;decreased severity of Side Effect:Neutropenia;Allele C is associated with decreased severity of Neutropenia when treated with irinotecan as compared to allele T.; 
;CYCLOSPORINE, METHOTREXATE;MTHFR;rs3737967;GG;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype GG is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype AG.;in people with Hematopoietic stem cell transplantation
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-DRB1 *01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.; 
;ANTIDEPRESSANTS;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Metabolism/PK;decreased  PK:plasma concentrations;CYP2C19 *1/*1 is associated with decreased plasma concentrations when treated with antidepressants in people with Depressive Disorder, Major as compared to CYP2C19 *1/*2 + *2/*2.;in people with Disease:Major Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs55633228;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Toxicity;increased  risk of Side Effect:stent thrombosis;Genotype AA is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;UGT1A1*6;*6;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;UGT1A1 *6 is associated with increased overall survival and progression-free survival when treated with carboplatin, dexamethasone, etoposide and irinotecan in people with Lymphoma, Large B-Cell, Diffuse.;in people with Disease:Lymphoma, Large B-Cell, Diffuse
;SULFASALAZINE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.; 
;ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 *1/*1.; 
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;Toxicity;increased  risk of Side Effect:Pancytopenia, Side Effect:Thrombocytopenia;Allele GGAGTC is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele del.;in people with Autoimmune Diseases, Inflammatory Bowel Diseases
;CYCLOSPORINE, METHOTREXATE;MTHFR;rs2274976;CC;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype CC is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype CT.;in people with Hematopoietic stem cell transplantation
;;G6PD;rs1050828;T;;increased   Other:protection against severe malaria;Allele T is associated with increased protection against severe malaria.; 
;TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;Efficacy;increased  likelihood of Disease:Breast Neoplasms;CYP2D6 *4/*4 is associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.;in women 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs117101815;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;Toxicity;increased  likelihood of Side Effect:Myelosuppression;TPMT *3A + *3B + *3C is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;CISPLATIN;ERCC1;rs11615;GG;Toxicity;decreased likelihood of Disease:Nephrotoxicity;Genotype GG is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AA + AG.;in people with Disease:Neoplasms
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;Toxicity;increased  likelihood of Side Effect:Jaundice;UGT1A1 *28/*28 is associated with increased likelihood of Jaundice when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 +*1/*36 + *36/*36.;in people with HIV infectious disease
;PRAVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC);SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.;in healthy individuals 
;CAPECITABINE, FLUOROURACIL;DPYD;DPYD low activity;;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Treatment modification;DPYD low activity is associated with increased likelihood of Drug Toxicity or treatment modification when treated with capecitabine or fluorouracil in people with Neoplasms as compared to DPYD high activity.;in people with Neoplasms
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;increased   Efficacy:time to achieve stable dose;CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CISPLATIN, RADIOTHERAPY;GSTM1;GSTM1 non-null, GSTM1 null;null/null;Efficacy;decreased likelihood of Other:Death, Other:Recurrence;GSTM1 null/null is associated with decreased likelihood of Death and Recurrence when exposed to cisplatin and radiotherapy in women with Uterine Cervical Neoplasms as compared to GSTM1 non-null/non-null.;in women with Disease:Uterine Cervical Neoplasm
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*3 + *1/*3 + *2/*17;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *1/*2 + *2/*3 + *1/*3 + *2/*17 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Efficacy;decreased  Efficacy:time in therapeutic range;CYP2C9 *1/*3 + *3/*3 are associated with decreased time in therapeutic range when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Other;decreased  Other:use;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased use of antidepressants, antiepileptics, Beta Blocking Agents or calcium channel blockers in people with chronic migraine as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.;in people with chronic migraine
;ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Other;decreased  Other:use;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with decreased use of antidepressants, antiepileptics, Beta Blocking Agents or calcium channel blockers in people with Migraine with Aura as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.;in people with Disease:Migraine with Aura
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Metabolism/PK;decreased  PK:C/D ratio;CYP3A5 *1/*1 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;Efficacy;increased  risk of Efficacy:acute cellular rejection;CYP3A5 *1 is associated with increased risk of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;IRINOTECAN;DPYD;rs1042482;T;Toxicity;increased  severity of Side Effect:Neutropenia;Allele T is associated with increased severity of Neutropenia when treated with irinotecan as compared to allele C.; 
;PAZOPANIB;UGT1A1;UGT1A1*6, UGT1A1*28, UGT1A1*37;*28 + *37 + *6;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *28 + *37 + *6 (assigned as reduced metabolisers phenotype) are associated with increased risk of Hyperbilirubinemia when treated with pazopanib in people with Carcinoma, Renal Cell as compared to UGT1A1 normal metabolizer.;in people with Disease:Renal Cell Carcinoma
;METHADONE;CYP3A4;rs4646440;A;Toxicity;increased  severity of Side Effect:side effects;Allele A is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele G.;in people with Disease:Heroin Dependence
;WARFARIN;VKORC1;rs9923231;CC;Other;increased  likelihood of Other:having warfarin Dose greater than 7.5 mg/day;Genotype CC is associated with increased likelihood of having warfarin Dose greater than 7.5 mg/day when treated with warfarin as compared to genotypes CT + TT.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Efficacy:time to achieve stable dose;CYP2C9 *2 + *3 are associated with decreased time to achieve stable dose when treated with phenprocoumon as compared to CYP2C9 *1/*1.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;rs3805945;C;Toxicity;increased  risk of Side Effect:Neutropenia;Allele C is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased  risk of Efficacy:Stroke;CYP2C19 *2 is associated with increased risk of Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Cerebrovascular Disorders
;ATAZANAVIR / RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;Toxicity;decreased severity of Side Effect:Hyperbilirubinemia;UGT1A1 *1/*36 + *28/*36 + *36/*37 + *1/*1 are associated with decreased severity of Hyperbilirubinemia when treated with atazanavir / ritonavir, lamivudine and zidovudine in women with HIV Infections and Pregnancy as compared to UGT1A1 *1/*28 + *1/*37 + *28/*28 + *28/*37.;in women with HIV infectious disease, Pregnancy
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;rs77769901;G;Toxicity;decreased risk of Side Effect:Neutropenia;Allele G is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;SCN1A;rs3812718;TT;Efficacy;increased  risk of Efficacy:Discontinuation;Genotype TT is associated with increased risk of discontinuation when treated with carbamazepine in people with Epilepsy as compared to genotypes CC + CT.;in people with Epilepsy
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Side Effect:major but not minor hemorrhage;CYP2C9 *2 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;;CHRNB2;rs2072661;GG;;increased  likelihood of Other:smoking cessation;Genotype GG is associated with increased likelihood of smoking cessation as compared to genotypes AA + AG.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:major but not minor hemorrhage;CYP2C9 *3 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *28/*28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;ROSIGLITAZONE;PLIN1;rs894160;CT + TT;Toxicity;decreased  Side Effect:Weight gain;Genotypes CT + TT are associated with decreased Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Diabetes Mellitus, Type 2
;PLATINUM;;rs836554;T;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele T is associated with increased likelihood of Drug Toxicity when treated with platinum in people with Lung Neoplasms as compared to allele C.;in people with Disease:Lung Neoplasms
;CYCLOSPORINE, METHOTREXATE;ABCC1;rs17264736;GG + GT;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotypes GG + GT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype TT.;in people with Hematopoietic stem cell transplantation
;METHADONE;CYP2B6;CYP2B6*6;*6;Toxicity;increased  severity of Disease:Pain;CYP2B6 *6 is associated with increased severity of Pain when treated with methadone in men with Opioid-Related Disorders.;in men with Disease:Opioid-Related Disorders
;OXCARBAZEPINE;HLA-B;HLA-B*15:01;*15:01;Toxicity;decreased risk of Side Effect:Maculopapular Exanthema;HLA-B *15:01 is associated with decreased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;;LRP5;rs3736228;T;;increased  risk of Other:osteoporotic fracture;Allele T is associated with increased risk of osteoporotic fracture as compared to allele C.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs118129530;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Metabolism/PK;increased   PK:AUC of citalopram;CYP2D6 *1/*4 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148013902;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;DRUGS USED IN NICOTINE DEPENDENCE;COMT;rs4680;AA;Efficacy;increased  likelihood of Efficacy:Smoking Cessation;Genotype AA is associated with increased likelihood of cessation when treated with Drugs used in nicotine dependence in people with as compared to genotypes AG + GG.;in people with 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Efficacy;decreased risk of Efficacy:Transplant rejection;CYP3A5 *1/*3 + *3/*3 is associated with decreased risk of transplant rejection when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1.;in people with Disease:Hematopoietic stem cell transplantation
;NICOTINE;ANKK1;rs1800497;AA + AG;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotypes AA + AG is associated with increased likelihood of smoking cessation when treated with nicotine in people with female gender as compared to genotype GG.;in people with female gender
;VALGANCICLOVIR;ABCC4;rs11568658;AC;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AC is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *2 + *3 are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs145623321;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE, METHOTREXATE;NFATC1;rs1017860;CC;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype CC is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.;in people with Hematopoietic stem cell transplantation
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;rs117458836;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;PRASUGREL;PEAR1;rs822442;AA;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AC + CC.;in healthy individuals 
;TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;Efficacy;decreased likelihood of Efficacy:delayed graft function;CYP2C8 *3 is associated with decreased likelihood of delayed graft function when treated with tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*1.;in people with Kidney Transplantation
;CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*15:21;*15:21;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-B *15:21 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine as compared to HLA-B *07:02.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;NICOTINE;COMT;rs4680;G;Toxicity, Other;decreased risk of Disease:Tobacco Use Disorder;Allele G is associated with decreased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele A.;in smokers
;FLUOROURACIL;DPYD;DPYD deficiency;;Toxicity;Side Effect:Drug Toxicity;DPYD deficiency is associated with Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *15:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Toxicity;increased  risk of Side Effect:adverse events;CYP2D6 *4/*4 is associated with increased risk of adverse events when treated with risperidone as compared to CYP2D6 *1/*1.; 
;RISPERIDONE;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *4/*5 + *4/*6;Efficacy;decreased  Efficacy:reduction in psychotic symptoms;CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizer phenotype) is associated with decreased reduction in psychotic symptoms when treated with risperidone in people with Schizophrenia as compared to CYP2D6 normal metabolizer.;in people with Disease:Schizophrenia
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to CYP2C9 *1/*1.;in people with Disease:Venous thromboembolism
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-A *31:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *2/*2 + *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with phenprocoumon as compared to CYP2C9 *1/*1.; 
;PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-A *02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.; 
;LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased likelihood of Maculopapular Exanthema or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.;in people with Side Effect:Epilepsy
;BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Metabolism/PK;decreased  PK:Bosentan metabolism in vitro;CYP2C9 *3 is associated with decreased Bosentan metabolism in vitro when exposed to bosentan as compared to CYP2C9 *1.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;CYP2C19 *2 is associated with increased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to CYP2C19 *1/*1.;in people with Disease:Schizophrenia
;BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Metabolism/PK;decreased  PK:Bosentan metabolism in vitro;CYP2C9 *2 is associated with decreased Bosentan metabolism in vitro when exposed to bosentan as compared to CYP2C9 *1.; 
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased   Side Effect:Drug Toxicity;Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased   Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 are associated with increased Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.; 
;ATORVASTATIN;TNF;rs1800629;GG;Efficacy;increased   Efficacy:bone marrow density in the lumbar spine;Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome.;in people with Disease:Acute coronary syndrome
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Efficacy:time in therapeutic range;CYP2C9 *2 + *3 are associated with decreased time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;Toxicity;increased  likelihood of Side Effect:Hemorrhage;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 are associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;LAMOTRIGINE;HLA-B;HLA-B*44:03;*44:03;Toxicity;increased  likelihood of Side Effect:Maculopapular Exanthema;HLA-B *44:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.;in people with Disease:Epilepsy
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:11 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G/TT + GG;Efficacy;increased  risk of Efficacy:treatment failure in Japanese patients with with chronic genotype 1 HCV infection;Genotypes G/TT + GG are associated with increased risk of treatment failure in Japanese patients with with chronic genotype 1 HCV infection when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:response (SVR rate) to HCV triple therapy (telaprevir (TVR), peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy);Genotype TT/TT is associated with increased response (SVR rate) to HCV triple therapy (telaprevir (TVR), peg-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1.;in people with Colorectal Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome;HLA-A *02:07 is associated with increased risk of Maculopapular Exanthema, severe cutaneous adverse reactions or Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.;in people with Disease:Epilepsy
;FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-C *06:02 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;NICOTINE;CYP2A6;CYP2A6 low activity;;Toxicity;decreased risk of Other:Recurrence;CYP2A6 low activity is associated with decreased risk of Recurrence in people not taking nicotine in people with Tobacco Use Disorder as compared to CYP2A6 high activity.;in people with Tobacco Use Disorder
;FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Efficacy;increased   Efficacy:improvement based on HAM-D score percentage reduction;SLC6A4 HTTLPR long form (L allele) is associated with increased improvement based on HAM-D score percentage reduction when treated with fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;NICOTINE;CYP2A6;CYP2A6 low activity;;Toxicity;decreased risk of Disease:Tobacco Use Disorder;CYP2A6 low activity is associated with decreased risk of Tobacco Use Disorder due to nicotine.; 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions;CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with phenytoin as compared to CYP2C9 *1/*1.; 
;METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.; 
;METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *59:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with methazolamide.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*6;Toxicity;increased  risk of Side Effect:major  but not minor hemorrhage;CYP2C9 *6 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;METHOTREXATE;SLCO1B1;rs11045879;T;Other, Metabolism/PK;increased   PK:clearance;Allele T is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in people with Disease:Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*17/*17;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C19 *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*11;Toxicity;increased  risk of Side Effect:major  but not minor hemorrhage;CYP2C9 *11 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*5;Toxicity;increased  risk of Side Effect:major but not minor hemorrhage;CYP2C9 *5 is associated with increased risk of major but not minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;Efficacy;increased  likelihood of Disease:Pain;CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.;in people with Disease:Pain
;BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Disease:Drug-induced liver injury;CYP2C9 *2 is associated with increased risk of drug-induced liver injury when treated with bosentan as compared to CYP2C9 *1.; 
;TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;Toxicity;increased  risk of Disease:Diarrhea;CYP3A5 *3/*3 is associated with increased risk of Diarrhea when treated with tacrolimus in people with Kidney Transplantation.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Toxicity;increased  severity of Other:tubular vacuolar degeneration;CYP3A5 *1/*3 + *3/*3 is associated with increased severity of tubular vacuolar degeneration when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough levels;CYP3A5 *1/*3 is associated with decreased dose-adjusted trough levels of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  severity of Disease:interstitial fibrosis;CYP3A5 *3/*3 is associated with increased severity of interstitial fibrosis when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:concentration/dose ratio;CYP3A5 *1/*1 + *1/*3 is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;decreased  PK:C/D ratio;CYP3A5 *1/*3 is associated with decreased C/D ratio when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;CLOPIDOGREL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Efficacy;increased   Efficacy:Platelet reactivity after 9month of treatment;CYP3A5 *3/*3 is associated with increased Platelet reactivity after 9month of treatment when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Coronary Artery Disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Toxicity;increased  risk of PK:acute rejection;CYP3A5 *1/*1 is associated with increased risk of acute rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3 + *3/*3.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;Efficacy;increased  risk of Efficacy:delayed graft function;CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7 is associated with increased risk of delayed graft function when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;Metabolism/PK;increased   PK:blood concentrations;CYP3A5 *1/*3 + *3/*3 is associated with increased blood concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  risk of Side Effect:Nephrotoxicity;CYP3A5 *3/*3 is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Hematopoietic stem cell transplantation
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3 + *1/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *2/*2 + *2/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;ACE INHIBITORS, PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;Toxicity;increased  likelihood of Side Effect:Angioedema, Side Effect:Cough;Genotypes (GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC is associated with increased likelihood of Angioedema or Cough when treated with Ace Inhibitors, Plain as compared to genotype GGTGGGGACGGTGGGGACGGTGGGGAC/GGTGGGGACGGTGGGGACGGTGGGGAC.; 
;CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;Efficacy, Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Discontinuation;CYP2D6 poor and ultrarapid metabolizers is associated with increased likelihood of discontinuation when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.;in people with Disease:Pain
;;KCNE1;rs727957;T;Other;increased   Other:QT interval;Allele T is associated with increased QT interval as compared to allele G.; 
;AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *07:01 is associated with decreased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;OXCARBAZEPINE;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *38:02 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine.; 
;HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;Efficacy;increased   Efficacy:reduction in systolic blood pressure;Genotype del/del is associated with increased reduction in systolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;in people with Disease:Essential hypertension
;METHOTREXATE;TYMS;rs11280056;del/del;Toxicity;increased  severity of Side Effect:Mucositis;Genotype del/del is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype TTAAAGTTA/TTAAAGTTA.;in people with Hematopoietic stem cell transplantation
;PERINDOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Toxicity;increased  likelihood of Side Effect:ACEI-related cough;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased likelihood of ACEI-related cough due to perindopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.;in people with Disease:Diabetes Mellitus, Type 2
;METHOTREXATE;TYMS;rs11280056;del/del;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype del/del is associated with decreased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes TTAAAGTTA/TTAAAGTTA + TTAAAGTTA/del.;in people with Disease:Rheumatoid arthritis
;;RGS2;rs34717272;TC/del + del/del;Other;increased  risk of Disease:Hypertension;Genotypes TC/del + del/del are associated with increased risk of Hypertension as compared to genotype TC/TC.; 
;CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-A *02:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Myelosuppression when treated with methotrexate in people with Arthritis, Rheumatoid.;in people with Disease:Rheumatoid arthritis
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*14:05;*14:05;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-DRB1 *14:05 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs74743371;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;Toxicity;decreased risk of Disease:Maculopapular Exanthema;HLA-B *58:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  risk of Disease:Stomatitis;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased risk of Stomatitis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in children with Disease:Acute lymphoblastic leukemia
;LAMOTRIGINE;HLA-A;HLA-A*30:01;*30:01;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-A *30:01 is associated with increased risk of Maculopapular Exanthema when treated with lamotrigine.; 
;CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;Toxicity;decreased risk of Disease:Maculopapular Exanthema;HLA-DRB1 *03:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;OXCARBAZEPINE;HLA-B;HLA-B*13:02;*13:02;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *13:02 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;OXCARBAZEPINE;HLA-B;HLA-B*15:27;*15:27;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *15:27 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;OXCARBAZEPINE;HLA-B;HLA-B*15:19;*15:19;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *15:19 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;OXCARBAZEPINE;HLA-B;HLA-B*48:04;*48:04;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *48:04 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;RALOXIFENE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Efficacy;increased   Efficacy:bone mineral density;UGT1A1 *28/*28 is associated with increased bone mineral density when treated with raloxifene in women with Osteoporosis as compared to UGT1A1 *1/*1 + *1/*28.;in women with Disease:Osteoporosis
;ASPIRIN;HLA-DQB1;HLA-DQB1*03:02;*03:02;Efficacy, Toxicity;decreased severity of Disease:Aspirin-induced asthma;HLA-DQB1 *03:02 is associated with decreased severity of aspirin-induced asthma when treated with aspirin in people with aspirin-induced asthma.;in people with Side Effect:Aspirin-induced asthma
;OXCARBAZEPINE;HLA-B;HLA-B*27:09;*27:09;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *27:09 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;NEVIRAPINE;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Toxic liver disease;HLA-B *58:01 is associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV.;in people with Disease:HIV infectious disease
;TAMOXIFEN;ABCB1;rs1045642;AG;Other;increased  risk of Other:disease recurrence;Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes AA + GG.;in women with Disease:Breast Neoplasms
;NEVIRAPINE;HLA-B;HLA-B*58:02;*58:02;Toxicity;decreased risk of Disease:Toxic liver disease;HLA-B *58:02 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV.;in people with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12979860;CC;Efficacy;Efficacy:higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients;Genotype CC is associated with higher mean baseline HCV RNA level and steeper 1st phase HCV RNA decline in genotype 2 and 3 HCV infected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;PRASUGREL;PEAR1;rs3737224;TT;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype TT is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CC + CT.;in healthy individuals 
;NEVIRAPINE;HLA-C;HLA-C*02:10;*02:10;Toxicity;decreased risk of Disease:Toxic liver disease;HLA-C *02:10 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV.;in people with Disease:HIV infectious disease
;CYCLOSPORINE, METHOTREXATE;ABCC1;rs4781712;AA + AG;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotypes AA + AG is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype GG.;in people with Hematopoietic stem cell transplantation
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema due to carbamazepine.; 
;CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype CT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + TT.;in people with Neoplasms
;OLANZAPINE;ABCB1;rs4728709;GG;Toxicity;increased  likelihood of Side Effect:Asthenia;Genotype GG is associated with increased likelihood of Asthenia due to olanzapine in healthy individuals as compared to genotypes AA + AG.;in healthy individuals 
;BUPROPION;CYP2B6;rs3211371;TT;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype TT is associated with increased likelihood of smoking cessation when treated with bupropion in people with female gender as compared to genotype CC.;in people with female gender
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;rs118088833;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;ASPIRIN, SULFASALAZINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5;*3 + *4;Dosage, Toxicity;increased  likelihood of Disease:Brain Neoplasms;CYP2D6 *3 + *4 is associated with increased likelihood of Brain Neoplasms when exposed to aspirin or sulfasalazine in children with russitis as compared to CYP2D6 *5/*3.;in children with Side Effect:russitis
;PRASUGREL;PEAR1;rs41273215;TT;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype TT is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CC + CT.;in healthy individuals 
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;increased   Efficacy:time to improve (based on mean reductions from baseline in HRSD);SLC6A4 HTTLPR short form (S allele) is associated with increased time to improve (based on mean reductions from baseline in HRSD) when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;TAMOXIFEN;ABCB1;rs1045642;AG;Other;increased  risk of Other:disease recurrence;Genotype AG is associated with increased risk of disease recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;rs112242273;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Dosage;Other:significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy;CYP2D6 *10/*10 is associated with significantly higher tramadol consumption in Chinese gastric cancer patients recovering from gastrectomy when treated with tramadol as compared to CYP2D6 *1/*1 + *1/*10.; 
;PRASUGREL;PEAR1;rs822441;CC;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype CC is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes CG + GG.;in healthy individuals 
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity, Metabolism/PK;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Toxicity;increased  risk of Disease:Carcinoma, Squamous Cell;CYP2C19 *1/*17 + *17/*17 is associated with increased risk of Carcinoma, Squamous Cell when treated with voriconazole in people with lung transplantation.;in people with Disease:Lung transplantation
;CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Side Effect:adverse cardiovascular events;CYP2C9 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *1/*2 + *1/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;Efficacy;increased  likelihood of Efficacy:complete remission;Genotype CC is associated with increased likelihood of complete remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute.;in people with Disease:Leukemia, Myeloid, Acute
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:non-response;SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-response when treated with antidepressants in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Mood Disorder
;CAFFEINE;CYP1A2;CYP1A2 high activity;;Toxicity;increased  risk of Disease:Abortion, Spontaneous;CYP1A2 high activity phenotype is associated with increased risk of Abortion, Spontaneous when exposed to caffeine in women with Pregnancy as compared to CYP1A2 low activity phenotype.;in women with Disease:Pregnancy
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased  Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy;CYP2C9 *1/*3 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:non-response;SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-response when treated with antidepressants in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Mood Disorder
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:non-response;SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-response when treated with antidepressants in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Mood Disorder
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.;in children 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;rs181501757;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;LAMOTRIGINE;HLA-B;HLA-B*13:02;*13:02;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *13:02 is associated with increased risk of Maculopapular Exanthema when treated with lamotrigine.; 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased  likelihood of Efficacy:remission after second treatment switch;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased likelihood of remission after second treatment switch when treated with antidepressants in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;Toxicity;decreased risk of Disease:Maculopapular Exanthema;HLA-A *33:03 is associated with decreased risk of Maculopapular Exanthema when treated with lamotrigine.; 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:improved second treatment switch response;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with improved second treatment switch response when treated with antidepressants in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;Toxicity;increased  risk of Side Effect:Thrombocytopenia;UGT1A1 *1/*60 + *60/*60 is associated with increased risk of Thrombocytopenia when treated with Belinostat in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased  likelihood of Efficacy:response;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased likelihood of response when treated with antidepressants in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9402944;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:non-remission;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-remission when treated with antidepressants in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).;in people with Disease:Mood Disorder
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;OAS1;rs2660;AG;Toxicity;decreased risk of Disease:Anemia;Genotype AG is associated with decreased risk of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype AA.; 
;ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;Efficacy:non-response;SLC6A4 HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with non-response when treated with antidepressants in people with Mood Disorders as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Mood Disorder
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;;VDR;rs731236;A;;increased  risk of Disease:Asthma;Allele A is associated with increased risk of Asthma.; 
;OLANZAPINE;ABCB1;rs3842;CC;Toxicity;increased  likelihood of Side Effect:Cardiac rhythm disease;Genotype CC is associated with increased likelihood of Arrhythmias, Cardiac due to olanzapine in healthy individuals as compared to genotypes CT + TT.;in healthy individuals 
;IRINOTECAN;UGT1A1;rs10929302;A;Toxicity;increased  severity of Side Effect:Neutropenia;Allele A is associated with increased severity of Neutropenia when treated with irinotecan as compared to allele G.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs112783657;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;BUPROPION;GALR1;rs2717162;CC + CT;Efficacy;decreased likelihood of Other:smoking cessation;Genotypes CC + CT are associated with decreased likelihood of smoking cessation when treated with bupropion as compared to genotype TT.; 
;CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;Toxicity;decreased risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *46:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;HEROIN;OPRM1;rs1799971;AG;Toxicity;increased  risk of Other:Heroin Dependence;Genotype AG is associated with increased risk of Heroin Dependence due to heroin as compared to genotype AA.; 
;CYCLOSPORINE, METHOTREXATE;NFATC1;rs8090560;GG;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype GG is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AA + AG.;in people with Hematopoietic stem cell transplantation
;VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;CYP3A5 *1/*3 is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to CYP3A5 *3/*3.;in children with Disease:Acute lymphoblastic leukemia
;ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased  likelihood of Side Effect:nausea and vomiting;TPMT *1/*3A is associated with increased likelihood of nausea and vomiting when treated with azathioprine in people with Arthritis, Rheumatoid as compared to TPMT *1/*1.;in people with Disease:Rheumatoid arthritis
;RISPERIDONE;LEP;rs7799039;A;Toxicity;increased  likelihood of Side Effect:Weight gain;Allele A is associated with increased likelihood of Weight gain when treated with risperidone in children as compared to genotype GG.;in children 
;BUPROPION;GALR1;rs2717162;CC + CT;Efficacy;increased  risk of Efficacy:Recurrence;Genotypes CC + CT are associated with increased risk of Recurrence when treated with bupropion in people with Tobacco Use Disorder as compared to genotype TT.;in people with Disease:Tobacco Use Disorder
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;AG;Toxicity;decreased risk of Disease:Anemia;Genotype AG is associated with decreased risk of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype GG.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;rs149212925;G;Toxicity;decreased risk of Side Effect:Neutropenia;Allele G is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE, METHOTREXATE;DHFR;rs34965641;GG;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotype GG is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AA + AG.;in people with Hematopoietic stem cell transplantation
;ETRAVIRINE;CYP2C19;rs4244285;AA + AG;Metabolism/PK;decreased  PK:etravirine clearance;Genotypes AA + AG are associated with decreased etravirine clearance when treated with etravirine in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;CISPLATIN;ERCC1;rs3212986;A;Efficacy;increased   Efficacy:overall survival and progression-free survival;Allele A is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C.;in people with Disease:Neoplasm of esophagus
;ROSUVASTATIN;ABCG2;rs2231142;T;Efficacy;increased   Efficacy:reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner,;Allele T is associated with increased reduction in low-density lipoprotein cholesterol (LDL-C) level, in a gene-dose-dependent manner, when treated with rosuvastatin in people with Hypercholesterolemia as compared to allele G.;in people with Disease:Hypercholesterolemia
;FLUOROURACIL;MTHFR;rs1801131;TT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT.;in people with Disease:Rectal Neoplasms
;FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased   Efficacy:improvement based on change of HAM-D score after antidepressant medication;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased improvement based on change of HAM-D score after antidepressant medication when treated with fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs58695150;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;PEMETREXED;GGH;rs11545078;A;Toxicity;decreased risk of Side Effect:Drug Toxicity;Allele A is associated with decreased risk of Drug Toxicity when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;METFORMIN;SLC22A1;rs72552763;GAT/del;Other, Metabolism/PK;decreased  Efficacy:trough metformin steady-state concentration;Genotype GAT/del is associated with decreased trough metformin steady-state concentration when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.;in people with Disease:Diabetes Mellitus, Type 2
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.;in people with Disease:Neuropathic pain
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased   Side Effect:Drug Toxicity;CYP2C19 *2 is associated with increased Drug Toxicity when treated with phenazepam in men with Alcoholism and Anxiety Disorders as compared to CYP2C19 *1.;in men with Alcohol abuse, Anxiety Disorders
;CAPECITABINE;CDA;rs602950;AG + GG;Toxicity;increased  risk of Disease:Dehydration;Genotypes AG + GG are associated with increased risk of Dehydration when treated with capecitabine in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Efficacy;decreased  Efficacy:progression free survival;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased progression free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in children with Acute lymphoblastic leukemia
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;DPYD low activity;;Toxicity;increased  risk of Side Effect:Drug Toxicity;DPYD low activity is associated with increased risk of Drug Toxicity when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema;HLA-C *08:01 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.; 
;FLUOROURACIL;DPYD;DPYD deficiency;;Toxicity;Side Effect:Drug Toxicity;DPYD deficiency is associated with Drug Toxicity when treated with fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs150688309;G;Toxicity;increased  risk of Side Effect:Neutropenia;Allele G is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CAPECITABINE;CDA;rs602950;AG + GG;Toxicity;increased  risk of Disease:Diarrhea;Genotypes AG + GG are associated with increased risk of Diarrhea when treated with capecitabine in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;TAMOXIFEN;CYP2D6;CYP2D6*2;*2;Efficacy;decreased likelihood of Disease:Breast Neoplasms;CYP2D6 *2 is associated with decreased likelihood of Breast Neoplasms when treated with tamoxifen in women.;in women 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.; 
;TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;Toxicity;decreased  Side Effect:Hot Flashes;CYP3A4 *22 is associated with decreased Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP3A4 *1/*1.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *74:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:total hemorrhage and major hemorrhage;CYP2C9 *3 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased  likelihood of Efficacy:Coronary Restenosis;CYP2C19 *2 is associated with increased likelihood of Coronary Restenosis when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to CYP2C19 *1/*1.;in people with Disease:Peripheral Vascular Diseases
;CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;Toxicity;decreased risk of Side Effect:Drug Toxicity;HLA-A *02:01 is associated with decreased risk of Drug Toxicity when treated with carbamazepine.; 
;CODEINE;SLC22A1;SLC22A1 low activity;;Toxicity;increased  likelihood of Side Effect:Dizziness, Side Effect:Drug Toxicity, Side Effect:Headache, Side Effect:Nausea, Side Effect:sedation;SLC22A1 low activity is associated with increased likelihood of Dizziness, Drug Toxicity, Headache, Nausea and sedation when exposed to codeine in healthy individuals as compared to SLC22A1 high activity.;in healthy individuals 
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to dapsone in people with Skin Diseases.;in people with Disease:Skin Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  likelihood of Side Effect:over anti-coagulation;CYP2C9 *3 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.; 
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;Toxicity;increased  risk of Disease:Leukopenia;TPMT *1/*3A + *1/*3C + *3A/*3A is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-B *15:02 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.;in people with Disease:Epilepsy
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;ETHANOL;OPRM1;rs1799971;G;;increased   Other:alcohol response, consumption, and preference;Allele G is associated with increased alcohol response, consumption, and preference when exposed to ethanol.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;Toxicity;increased  risk of Disease:Diarrhea;UGT1A1 *6/*6 is associated with increased risk of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Toxicity;increased  risk of Disease:Transplant rejection;TPMT *1/*2 + *1/*3A + *1/*3C are associated with increased risk of transplant rejection when treated with azathioprine in heart transplantation as compared to TPMT *1/*1.;in Disease:Heart transplantation
;VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:venlafaxine levels;CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299293;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;EXEMESTANE;;rs934635;AA;Toxicity;Side Effect:a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients;Genotype AA is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9389568;C;Toxicity;decreased risk of Side Effect:Neutropenia;Allele C is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 + *3 is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Disease
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;rs144991623;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *1/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;PRASUGREL;PEAR1;rs12407843;AA;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;DIGOXIN;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Sudden cardiac death;Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AG + GG.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;PRASUGREL;PEAR1;rs77235035;AA;Efficacy;decreased  Efficacy:inhibition of ADP-induced platelet aggregation;Genotype AA is associated with decreased inhibition of ADP-induced platelet aggregation when treated with prasugrel in healthy individuals as compared to genotypes AC + CC.;in healthy individuals 
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:venlafaxine levels;CYP2D6 *4/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.;in people with Disease:Obsessive-Compulsive Disorder
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Metabolism/PK;increased   PK:venlafaxine levels;CYP2D6 *1/*4 is associated with increased venlafaxine levels when treated with venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.;in people with Disease:Obsessive-Compulsive Disorder
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *2/*2 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;Efficacy;increased   Efficacy:platelet aggregation inhibition;CYP2C19 *17/*17 + *1/*17 are associated with increased platelet aggregation inhibition when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;DIGOXIN;ABCB1;rs2032582;AA;Toxicity;increased  likelihood of Side Effect:Sudden cardiac death;Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AC + CC.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:Cardiovascular Disease;CYP2C19 *2 + *3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;Toxicity;risk of Disease:Neutropenia;UGT1A1 *6 + *28 is associated with risk of Neutropenia when treated with irinotecan in people with Neoplasms.;in people with Disease:Neoplasms
;DIGOXIN;ABCB1;rs1128503;AA;Toxicity;increased  likelihood of Side Effect:Sudden cardiac death;Genotype AA is associated with increased likelihood of Death, Sudden, Cardiac when treated with digoxin as compared to genotypes AG + GG.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Metabolism/PK;decreased  PK:Cmax and AUC of thiol metabolite;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with decreased Cmax and AUC of thiol metabolite when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .;in healthy individuals 
;CAPECITABINE;MTHFR;rs1801131;GG;Toxicity;increased  risk of Disease:Hand-foot syndrome;Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Neoplasms.;in people with Disease:Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:all and minor hemorrhage;CYP2C9 *3 is associated with increased risk of all and minor hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *1/*6 + *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs8110364;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;OLANZAPINE;ABCB1;rs10248420;G;Toxicity;increased  likelihood of Side Effect:Somnolence;Allele G is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to allele A.;in healthy individuals 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28 + *1/*1.;in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs56293913;AG + GG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AG + GG are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype AA.;in people with Disease:Breast Neoplasms, Disease:Gastroesophageal Cancer
;FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA;Efficacy;increased   Efficacy:PC20;Genotype AA is associated with increased PC20 when treated with fluticasone propionate in children with Asthma as compared to genotypes AG + GG.;in children with Disease:Asthma
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117341846;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose requirement;CYP2C9 *3 is associated with decreased warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;Efficacy;Efficacy:significantly delayed time to inhibition of platelet aggregation (IPA);CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .;in healthy individuals 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:complete early virological response;Genotype TT/TT is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased  likelihood of Efficacy:remission;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with escitalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;rs115457081;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;Toxicity;decreased risk of Disease:Stevens-Johnson Syndrome;HLA-B *40:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.;in people with Disease:Epilepsy
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Efficacy;Efficacy:significantly delayed time to inhibition of platelet aggregation (IPA);CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with significantly delayed time to inhibition of platelet aggregation (IPA) when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17 (assigned as normal metabolizer phenotype) .;in healthy individuals 
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.;in people with Disease:Epilepsy
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Efficacy;increased  risk of Efficacy:Treatment failure;CYP2C19 *1/*17 + *17/*17 are associated with increased risk of treatment failure when treated with escitalopram as compared to CYP2C19 *1/*1.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs142244113;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased  likelihood of Efficacy:remission;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Major Depressive Disorder as compared to SLC6A4 HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;ASPIRIN, CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Efficacy;increased  risk of Side Effect:stent thrombosis;CYP2C9 *1/*3 + *3/*3 is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to CYP2C9 *1/*1.;in people with percutaneous coronary interventions
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;Toxicity;increased  risk of Side Effect:major adverse cardiac and cerebrovascular events;CYP2C19 *2/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;METHOTREXATE;ATIC;rs2372536;GG;Efficacy;decreased  Efficacy:disease activity as assessed by the physician;Genotype GG is associated with decreased disease activity as assessed by the physician when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.;in people with Disease:Rheumatoid arthritis
;DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;Metabolism/PK;decreased  PK:median oral clearance of doxepin;CYP2D6 *4/*4 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs79430272;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;Toxicity;increased   Disease:Weight gain;CYP2D6 *1/*3 + *1/*4 are associated with increased Weight gain when treated with olanzapine in men with Schizophrenia as compared to CYP2D6 *1/*1.;in men with Disease:Schizophrenia
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;rs4968187;T;Toxicity;decreased risk of Side Effect:Neutropenia;Allele T is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased  likelihood of Efficacy:remission;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;CISPLATIN;ERCC1;rs3212986;AA;Toxicity;decreased likelihood of Disease:Nephrotoxicity;Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC.;in people with Disease:Neoplasms
;PALBOCICLIB;ABCG2;rs2231137;CT;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotype CT is associated with increased likelihood of Neutropenia when treated with palbociclib in people with Breast Neoplasms as compared to genotype CC.;in people with Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117951771;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *2/*2 + *2/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;Efficacy;increased  risk of Efficacy:Treatment failure;CYP2C19 *2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4 are associated with increased risk of treatment failure when treated with escitalopram as compared to CYP2C19 *1/*1.; 
;EXEMESTANE;;rs934635;AA;Toxicity;Side Effect:a significantly higher odds of Musculoskeletal adverse events (MSAEs) in postmenopausal hormone receptor (HR)-positive breast cancer patients;Genotype AA is associated with a significantly higher odds of Musculoskeletal adverse events (MSAEs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;PRIMAQUINE;G6PD;G6PD deficiency;;Toxicity;increased  likelihood of Side Effect:decreased hemocrit levels;G6PD deficiency is associated with increased likelihood of decreased hemocrit levels when treated with primaquine in people with Malaria, Vivax.;in people with Disease:Malaria, Vivax
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148235907;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;METHAMPHETAMINE;DAOA;rs3916965;C;Toxicity;decreased likelihood of Disease:Psychotic Disorder;Allele C is associated with decreased likelihood of Psychotic Disorders due to methamphetamine.; 
;;UGT1A1;rs34993780;G;Other;increased  likelihood of Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome;Allele G is associated with increased likelihood of Gilbert's syndrome or Crigler-Najjar Syndrome as compared to allele T.; 
;CYCLOPHOSPHAMIDE;CYP2C9;CYP2C9 poor metabolizer;*2 + *3;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes *2 + *3 (assigned as poor metabolizer phenotype) is associated with increased likelihood of Leukopenia when treated with cyclophosphamide in people with Vasculitis and Wegener Granulomatosis as compared to genotype *1/*1.;in people with Disease:Vasculitis, Disease:Wegener Granulomatosis
;CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Gastrointestinal Neoplasms.;in people with Disease:Gastrointestinal Neoplasms
;DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;increased   PK:desipramine/2-hydroxy-desipramine ratio;CYP2D6 *10/*10 + *5/*10 is associated with increased desipramine/2-hydroxy-desipramine ratio when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.;in people with Disease:Mental Disorders
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;increased   PK:the intrinsic metabolic activity (V(max)/K(m));CYP2C9 *1/*1 is associated with increased the intrinsic metabolic activity (V(max)/K(m)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.;in children Disease:Epilepsy
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;increased   PK:the mean maximal elimination rates (V(max));CYP2C9 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.;in children Disease:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;Other;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir and ritonavir in healthy individuals.;in healthy individuals 
;ATAZANAVIR;UGT1A1;UGT1A1*28;*28;Other;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in healthy individuals.;in healthy individuals 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *1/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in Colorectal Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in Disease:Colorectal Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;PALBOCICLIB;SULT2A1;rs182420;CC;Toxicity;increased  likelihood of Side Effect:Dose reduction, Side Effect:Discontinuation;Genotype CC is associated with increased likelihood of dose reduction or discontinuation when treated with palbociclib in people with Breast Neoplasms as compared to genotypes CT + TT.;in people with Breast Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in Disease:Colorectal Neoplasms
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;Efficacy;increased   Efficacy:Recurrence free survival;CYP2D6 *1/*4 + *4/*4 are associated with increased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Metabolism/PK;decreased  PK:dose-corrected plasma concentrations;CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to CYP2C19 *1/*1.;in people with Disease:Depressive Disorder
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299313;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;PRIMAQUINE;G6PD;G6PD deficiency;;Other;increased   Other:reductions in glutathione levels;G6PD deficiency is associated with increased reductions in glutathione levels when treated with primaquine as compared to G6PD non-deficient.; 
;SULFANILAMIDE;G6PD;G6PD deficiency;;Other;increased   Other:reductions in glutathione levels;G6PD deficiency is associated with increased reductions in glutathione levels when treated with sulfanilamide as compared to G6PD non-deficient.; 
;CHLORAMPHENICOL;G6PD;G6PD deficiency;;Other;increased   Other:reductions in glutathione levels;G6PD deficiency is associated with increased reductions in glutathione levels when treated with chloramphenicol as compared to G6PD non-deficient.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *1/*3 + *2/*3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;Toxicity;increased  likelihood of Side Effect:Neutropenia;UGT1A1 *28/*28 + *6/*6 + *1/*6 + *1/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI or irinotecan in people with biliary tract neoplasms or Pancreatic Neoplasms as compared to UGT1A1 *1/*1.;in people with Biliary tract neoplasm, Pancreatic Neoplasms
;CODEINE, MORPHINE, TRAMADOL;UGT2B7;rs73823859;A;Efficacy;increased   Efficacy:Pain;Allele A is associated with increased Pain when treated with codeine, morphine or tramadol in children with Anemia, Sickle Cell as compared to allele G.;in children with Anemia, Sickle Cell
;CISPLATIN, DOCETAXEL;ALDH2;rs671;AA + AG;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotypes AA + AG is associated with increased likelihood of Nausea and Vomiting when treated with cisplatin and docetaxel in people with Neoplasms as compared to genotype GG.;in people with Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299314;C;Toxicity;increased  risk of Side Effect:Neutropenia;Allele C is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;Metabolism/PK;decreased  PK:in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein;CYP2C9 *8 is associated with decreased in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein when treated with warfarin as compared to CYP2C9 *1/*1.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Drug Toxicity;UGT1A1 *28 is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1.;in people with Neoplasms
;ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;G;Toxicity;increased  risk of Disease:Heart Failure;Allele G is associated with increased risk of Heart Failure when treated with anthracyclines and related substances as compared to allele A.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in Colorectal Neoplasms
;CISPLATIN;ERCC2;rs13181;G;Efficacy;increased   Efficacy:overall survival and progression-free survival;Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T.;in people with Disease:Neoplasm of esophagus
;ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-A *33:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with allopurinol in people with Drug Hypersensitivity.;in people with Disease:Drug Hypersensitivity
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *03:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.;in people with Disease:Drug Hypersensitivity
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2C19 *1/*2 + *2/*2 are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1.;in people with Disease:Stroke
;ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  likelihood of Disease:Stevens-Johnson Syndrome;HLA-C *08:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.;in people with Disease:Drug Hypersensitivity
;ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;rs10836235;CC;Toxicity;increased  risk of Side Effect:cardiac damage;Genotype CC is associated with increased risk of cardiac damage when treated with anthracyclines and related substances in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in people with Disease:Acute lymphoblastic leukemia
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;EXEMESTANE;UGT2B17;UGT2B17 deficiency;;Toxicity;increased  severity of Side Effect:Fatigue;UGT2B17 deficiency is associated with increased severity of Fatigue when treated with exemestane in women with Breast Neoplasms as compared to UGT2B17 non-deficient.;in women with Breast Neoplasms
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;Toxicity;increased   Side Effect:bleeding time;SLC6A4 HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T is associated with increased bleeding time when treated with paroxetine in people with Mood Disorders as compared to SLC6A4 L allele-rs25531T/L allele-rs25531T.;in people with Disease:Mood Disorder
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 + *2/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;VALPROIC ACID;XBP1;rs2269577;G;Efficacy;increased  likelihood of Efficacy:prophylactic treatment response;Allele G is associated with increased likelihood of prophylactic treatment response when treated with valproic acid in people with Bipolar Disorder as compared to allele C.;in people with Disease:Bipolar Disorder
;ACE INHIBITORS, PLAIN;ACE;rs1799752;del;Toxicity;increased   Side Effect:major cardiovascular events (MACE) rate;Allele del is associated with increased major cardiovascular events (MACE) rate when treated with Ace Inhibitors, Plain in people with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in people with Disease:Coronary Artery Disease
;PACLITAXEL;CYP1B1;rs1056836;GG;Efficacy;increased   Efficacy:Progression-free survival;Genotype GG is associated with increased progression-free survival when treated with paclitaxel in people with Breast Neoplasms as compared to genotypes CC + CG.;in people with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;*10/*10 + *4/*10 + *5/*10;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *10/*10 + *4/*10 + *5/*10 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;DOCETAXEL;CYP1B1;rs1056836;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with docetaxel in people with Prostatic Neoplasms as compared to genotypes CG + GG.;in people with Disease:Prostatic Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;Dosage, Metabolism/PK;decreased  PK:unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio;CYP2C9 *8 is associated with decreased unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;rs9561778;T;Toxicity, Metabolism/PK;increased  risk of Side Effect:ADR;Allele T is associated with increased risk of ADR when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;Toxicity, Metabolism/PK;increased  severity of Disease:Neutropenia;Allele T is associated with increased severity of Neutropenia when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;Toxicity, Metabolism/PK;increased  risk of Side Effect:gastrointestinal toxicity;Allele T is associated with increased risk of gastrointestinal toxicity when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3;Efficacy;increased   Efficacy:ADP-induced platelet aggregation (PA);CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*2.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;Efficacy;increased   Efficacy:ADP-induced platelet aggregation (PA);CYP2C19 *1/*3 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased   Efficacy:ADP-induced platelet aggregation (PA);CYP2C19 *1/*2 is associated with increased ADP-induced platelet aggregation (PA) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Other;increased   Other:hydrochlorothiazide induced potassium excretion;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased hydrochlorothiazide induced potassium excretion when treated with hydrochlorothiazide in men with Hypertension as compared to genotype del/del.;in men with Disease:Hypertension
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;Toxicity;increased  likelihood of Side Effect:Venous thromboembolism;Allele T is associated with increased likelihood of venous thromboembolism when treated with hormonal contraceptives for systemic use as compared to allele C.; 
;ENALAPRIL;ACE;rs1799752;del/del;Efficacy;increased   Efficacy:bone mineral density response;Genotype del/del is associated with increased bone mineral density response when treated with enalapril in women with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;in women with Disease:Hypertension
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;increased  risk of Efficacy:Death;CYP2D6 *4/*4 is associated with increased risk of Death when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *38:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;decreased  PK:paroxetine serum concentration;CYP2D6 *1/*1xN is associated with decreased paroxetine serum concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Disease:Drug-induced liver injury;HLA-B *57:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Disease:Drug-induced liver injury;HLA-B *57:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;NAT2 *4 is associated with decreased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;CAPECITABINE;ANK3;rs143414470;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;*10/*10 + *5/*10;Toxicity;increased  risk of Side Effect:Toxic liver disease;CYP2D6 *10/*10 + *5/*10 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*5 + *1/*10 + *1/*14 + *2/*5 + *2/*10.;in people with Disease:Non-Small Cell Lung Carcinoma
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;Other;increased  risk of Disease:Respiratory Tract Infections;CYP2C19 *2 + *3 + *8 + *9 (assigned as poor metabolizer phenotype) is associated with increased risk of Respiratory Tract Infections when treated with lansoprazole in children with Asthma.;in children with Disease:Asthma
;NEVIRAPINE;CCHCR1;rs130072;T;Toxicity;increased  risk of Side Effect:Nevirapine-induced rash;Allele T is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;Toxicity;increased  risk of Disease:Exanthema;HLA-B *35:05 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;RITONAVIR;APOC3;rs5128;G;Toxicity;increased   Side Effect:triglyceride levels;Allele G is associated with increased triglyceride levels when treated with ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;T;Toxicity, Metabolism/PK;increased   PK:plasma concentration;Allele T is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;METFORMIN;BDNF;rs6265;C;Efficacy;increased  likelihood of Other:weight regain after intentional weight loss;Allele C is associated with increased likelihood of weight regain after intentional weight loss when treated with metformin as compared to allele T.; 
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;Metabolism/PK;increased   PK:plasma efavirenz levels;CYP2B6 *1/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;LUMIRACOXIB;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*15:01;*15:01;Toxicity;increased  risk of Disease:Toxic liver disease;HLA-DRB1 *15:01 is associated with increased risk of Toxic liver disease when treated with lumiracoxib as compared to HLA-DRB1 *01:01.; 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased   PK:trough ( R , S )-methadone plasma concentrations;CYP2B6 *6/*6 is associated with increased trough ( R , S )-methadone plasma concentrations when treated with methadone as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .; 
;MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*12;*12;Toxicity;increased  severity of Disease:Drug Toxicity;TPMT *12 is associated with increased severity of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1.;in children with Disease:Acute lymphoblastic leukemia
;MYCOPHENOLATE MOFETIL;IMPDH1;rs2278293;CT + TT;Toxicity;decreased risk of Side Effect:biopsy-proven acute rejection;Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with Transplantation as compared to genotype CC.;in people with Disease:Transplantation
;MITOXANTRONE;ABCB1;rs2032582;AA;Other;increased   Other:sensitivity in vitro;Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone as compared to genotypes AC + CC.; 
;LUMIRACOXIB;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;increased  risk of Disease:Toxic liver disease;HLA-DQB1 *06:02 is associated with increased risk of Toxic liver disease when treated with lumiracoxib.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;Metabolism/PK;increased  risk of Other:overanticoagulation;CYP2C9 *3 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;decreased  Efficacy:relative inhibition of ADP-induced platelet aggregation;Genotypes CT + TT is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.;in people with Disease:Angina Pectoris
;ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;Metabolism/PK;increased  risk of Other:overanticoagulation;CYP2C9 *2 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *1/*3 is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to CYP2C9 *1/*1.;in children 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity;increased  risk of Side Effect:prolonged QTc;CYP2B6 *6/*6 is associated with increased risk of prolonged QTc when treated with methadone as compared to CYP2B6 *1/*1 (assigned as normal metabolizer phenotype) .; 
;METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Metabolism/PK;increased   PK:(S)-methadone plasma levels;CYP2B6 *6/*6 is associated with increased (S)-methadone plasma levels when treated with methadone as compared to CYP2B6 *1/*1 + *1/*6.; 
;TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4 + *3/*5 + *3/*3;Toxicity;increased   Side Effect:sedation;CYP2D6 *4/*4 + *3/*5 + *3/*3 are associated with increased sedation when treated with trimipramine in healthy individuals as compared to CYP2D6 *1/*2xN + *1/*1.;in healthy individuals 
;CLOPIDOGREL;ABCB1;rs1045642;A;Other;increased  risk of Side Effect:Hemorrhage;Allele A is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Disease as compared to allele G.;in people with Disease:Coronary Disease
;NEVIRAPINE;HLA-C;rs9461684;T;Toxicity;increased  risk of Side Effect:Nevirapine-induced rash;Allele T is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;ASPIRIN;IL1B;rs1143627;A;Toxicity;Disease:Peptic Ulcer Disease;Allele A is associated with Peptic Ulcer when treated with aspirin in people with Cardiovascular Diseases as compared to allele G.;in people with Disease:Cardiovascular Disease
;PACLITAXEL;CYP3A4;rs35599367;AA + AG;Toxicity;increased  severity of Side Effect:Neurotoxicity Syndromes;Genotypes AA + AG is associated with increased severity of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;CC + CT;Toxicity;decreased likelihood of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotypes CC + CT is associated with decreased likelihood of Leukopenia or Neutropenia when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype TT.;in women with Breast Neoplasms
;PHENYTOIN;EPHX1;rs2234922;G;Toxicity;increased  risk of Disease:Disorder of facial skeleton;Allele G is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele A.;in people with first trimester pregnancy
;PHENYTOIN;EPHX1;rs1051740;T;Toxicity;increased  risk of Disease:Disorder of facial skeleton;Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C.;in people with first trimester pregnancy
;NEVIRAPINE;TCF19;rs2073724;T;Toxicity;increased  risk of Side Effect:Exanthema;Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Toxicity;increased  severity of Side Effect:weight gain;CYP2D6 *10 is associated with increased severity of weight gain due to risperidone in people with Schizophrenia as compared to CYP2D6 *1.;in people with Disease:Schizophrenia
;CARBOPLATIN, PACLITAXEL;NRG3;rs1649942;G;Efficacy;decreased  Efficacy:Progression-free survival;Allele G is associated with decreased progression-free survival when treated with carboplatin and paclitaxel in women with Ovarian Neoplasms as compared to allele A.;in women with Ovarian Neoplasms
;PHENPROCOUMON;EPHX1;rs1051740;CC;Toxicity;increased  likelihood of Side Effect:being overanticoagulated;Genotype CC is associated with increased likelihood of being overanticoagulated due to phenprocoumon as compared to genotypes CT + TT.; 
;;SLCO1B1;rs4149056;C;Metabolism/PK;increased   PK:sterol/bile acid metabolites;Allele C is associated with increased sterol/bile acid metabolites in people with Hypercholesterolemia as compared to allele T.;in people with Disease:Hypercholesterolemia
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;Metabolism/PK;increased   PK:plasma efavirenz levels;CYP2B6 *6/*6 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;increased   Efficacy:non-responsiveness;CYP2C19 *1/*2 + *2/*2 is associated with increased non-responsiveness when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.;in people with Disease:Angina Pectoris
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in women with Disease:Breast Neoplasms
;CAFFEINE;ADORA2A;rs5751876;TT;Toxicity;increased   Disease:Anxiety Disorders;Genotype TT is associated with increased Anxiety Disorders when exposed to caffeine.; 
;PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1208;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with paclitaxel and Platinum compounds in people with Lung Neoplasms as compared to genotype AA.;in people with Lung Neoplasms
;DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;*05:01 + *05:02 + *05:03;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *05:01 + *05:02 + *05:03 is associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *6/*6 + *6/*4;Toxicity, Metabolism/PK;increased  risk of Side Effect:side effects;CYP2D6 *5/*4 + *6/*6 + *6/*4 are associated with increased risk of side effects when treated with venlafaxine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*5 + *10/*10 + *5/*10;Toxicity;increased  risk of Side Effect:gastrointestinal side effects;CYP2D6 *1/*5 + *10/*10 + *5/*10 are associated with increased risk of gastrointestinal side effects when treated with fluvoxamine in people with Depressive Disorder as compared to CYP2D6 *1/*1 + *1/*10.;in people with Disease:Depressive Disorder
;NEMONAPRIDE;ANKK1;rs1800497;A;Toxicity;increased   Side Effect:prolactin concentrations;Allele A is associated with increased prolactin concentrations when exposed to nemonapride in women with schizophrenia as compared to allele G.;in women with schizophrenia
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;Efficacy;increased  likelihood of Efficacy:Recurrence;CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.;in women with Disease:Breast Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;TT;Other, Metabolism/PK;increased   PK:methotrexate polyglutamate (MTXPG3-5) levels;Genotype TT is associated with increased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Disease:Rheumatoid arthritis
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;FLUVOXAMINE;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;increased   PK:areas under the serum concentration-time curve;CYP2D6 poor metabolizer is associated with increased areas under the serum concentration-time curve when treated with fluvoxamine in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;METHOTREXATE;GGH;rs3758149;AA;Metabolism/PK;decreased  PK:methotrexate polyglutamate (MTXPG3-5) levels;Genotype AA is associated with decreased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + AG.;in people with Disease:Rheumatoid arthritis
;RISPERIDONE;DRD2;rs1799978;C;Toxicity;increased  risk of Disease:Hyperprolactinemia;Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:Death, Side Effect:Myocardial Infarction, Side Effect:Stroke;CYP2C19 *2 + *3 are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;RISPERIDONE;ANKK1;rs1800497;AA + AG;Toxicity;increased  risk of Disease:Hyperprolactinemia;Genotypes AA + AG are associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to genotype GG.; 
;MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;G;Other;increased   Other:inosine monophosphate dehydrogenase activity;Allele G is associated with increased inosine monophosphate dehydrogenase activity when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.;in people with Disease:Kidney Transplantation
;MERCAPTOPURINE;XDH;rs2281547;CC + CT;Toxicity;increased  severity of Side Effect:Treatment interruption;Genotypes CC + CT is associated with increased severity of treatment interruptions when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;Efficacy;increased   Efficacy: ADP-induced on treatment platelet aggregation (OTPR);CYP2C19 *2/*2 + *1/*2 is associated with increased ADP-induced on treatment platelet aggregation (OTPR) when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.;in people with Disease:Angina Pectoris
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;G;Metabolism/PK;decreased  PK:dose-normalized  Cmax and dose-normalized  AUC0to12 h;Allele G is associated with decreased dose-normalized Cmax and dose-normalized AUC0to12 h when treated with mycophenolate mofetil in people with kidney transplants as compared to allele T.;in people with kidney transplants
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;decreased  Efficacy:relative inhibition of ADP-induced platelet aggregation;CYP2C19 *2/*2 is associated with decreased relative inhibition of ADP-induced platelet aggregation when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to CYP2C19 *1/*1.;in people with Disease:Angina Pectoris
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased   Efficacy:on-clopidogrel platelet reactivity (HPR);CYP2C19 *2 + *3 is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *6/*28 is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV Infections as compared to UGT1A1 *1/*1.;in people with HIV infectious disease
;ANASTROZOLE;ABCB1;rs1045642;AA;Other;decreased likelihood of Side Effect:Arthralgia;Genotype AA is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;METHOTREXATE;MTHFR;rs1801131;GG;Efficacy;decreased  Other:event-free survival;Genotype GG is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;increased  likelihood of Efficacy:having INR above target range in week 1;CYP2C9 *2 is associated with increased likelihood of having INR above target range in week 1 when treated with warfarin in children as compared to CYP2C9 *1.;in children 
;;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Other:Substance-Related Disorders;Genotypes AG + GG are associated with increased risk of Substance-Related Disorders in men as compared to genotype AA.;in men 
;MERCAPTOPURINE;ITPA;rs1127354;AC;Toxicity;increased  severity of Side Effect:Febrile neutropenia;Genotype AC is associated with increased severity of febrile neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Toxicity;increased  risk of Side Effect:Drug Toxicity, Side Effect:Nephrotoxicity;CYP3A5 *1/*1 + *1/*3 are associated with increased risk of Drug Toxicity and nephrotoxicity when treated with tacrolimus in people with Colitis, Ulcerative as compared to CYP3A5 *3/*3.;in people with Disease:Ulcerative Colitis
;FLECAINIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:systemic exposure (AUC) and lower oral clearance of flecainide;CYP3A5 *3/*3 is associated with increased systemic exposure (AUC) and lower oral clearance of flecainide when exposed to flecainide in healthy individuals as compared to CYP3A5 *1/*1 + *1/*3.;in healthy individuals 
;ETHANOL;ALDH2;rs671;GG;Toxicity;increased  risk of Other:Alcohol abuse;Genotype GG is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AA + AG.; 
;DIDANOSINE;XDH;rs1429376;AA;Toxicity;increased  risk of Disease:Hypertension, Portal;Genotype AA is associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotypes AC + CC.;in people with Disease:HIV infectious disease
;DAUNORUBICIN;SZRD1;rs6603859;T;Other, Metabolism/PK;decreased  PK:IC50;Allele T is associated with decreased IC50 of daunorubicin as compared to allele G.; 
;DIDANOSINE;NT5C2;rs11598702;CC + CT;Toxicity;increased  risk of Disease:Hypertension, Portal;Genotypes CC + CT are associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;Efficacy;increased   Other:platelet reactivity;CYP2C19 *1/*2 + *2/*2 are associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.;in people with Disease:Coronary Artery Disease
;DIDANOSINE;XDH;rs1594160;AA;Toxicity;increased  risk of Disease:Hypertension, Portal;Genotype AA is associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotypes AC + CC.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*6;*6;Toxicity;increased  risk of Side Effect:ischaemic events;CYP2C19 *6 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;DAUNORUBICIN;;rs7929521;GG;Other, Metabolism/PK;increased   PK:IC50;Genotype GG is associated with increased IC50 of daunorubicin.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28 + *1/*37.;in people with Neoplasms
;AZACITIDINE;TYMS;rs11280056;del/del;Efficacy;decreased  Efficacy:Overall survival;Genotype del/del is associated with decreased overall survival when treated with azacitidine in people with Myelodysplastic Syndromes as compared to genotypes AAGTTA/AAGTTA + AAGTTA/del.;in people with Disease:Myelodysplastic Syndromes
;DAUNORUBICIN;MAN1B1;rs3750518;T;Other, Metabolism/PK;increased   PK:IC50;Allele T is associated with increased IC50 of daunorubicin as compared to allele C.; 
;OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;Metabolism/PK;decreased  PK:Mean oxymorphone/oxycodone ratios;CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7 (assigned as poor metabolizer phenotype) is associated with decreased Mean oxymorphone/oxycodone ratios when treated with oxycodone as compared to CYP2D6 *1/*1xN + *2/*2xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype) .; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;DIDANOSINE;NT5C2;rs11191561;CG + GG;Toxicity;increased  risk of Disease:Hypertension, Portal;Genotypes CG + GG are associated with increased risk of Hypertension, Portal when treated with didanosine in people with HIV Infections as compared to genotype CC.;in people with Disease:HIV infectious disease
;DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;HLA-DQA1*01:02;*01:02;Toxicity;decreased likelihood of Disease:Toxic liver disease;HLA-DQA1 *01:02 is associated with decreased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;IGURATIMOD;CYP2C19;rs4244285;A;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when treated with iguratimod in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;Efficacy;increased  risk of Efficacy:Transplant rejection;CYP3A4 *1/*22 is associated with increased risk of transplant rejection when treated with cyclosporine in people with liver transplantation as compared to CYP3A4 *1/*1.;in people with Disease:Liver transplantation
;PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *14:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.; 
;PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *56:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.; 
;NICOTINE;CYP2A6;rs1801272;AT + TT;Toxicity;increased  severity of Other:Tobacco Use Disorder;Genotypes AT + TT are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype AA.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.; 
;OLANZAPINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;*1/*3 + *2/*3 + *3/*6;Toxicity;increased  likelihood of Disease:Hypotensive disorder;CYP2C9 *1/*3 + *2/*3 + *3/*6 is associated with increased likelihood of Hypotension when exposed to olanzapine in healthy individuals as compared to CYP2C9 *1/*1 + *1/*2 + *2/*2.;in healthy individuals 
;DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;increased   PK:steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight;CYP2D6 *10/*10 + *5/*10 is associated with increased steady-state plasma concentrations of desipramine/daily dose of desipramine/body weight when treated with desipramine in people with Mental Disorders as compared to CYP2D6 *1/*1 + *1/*2.;in people with Disease:Mental Disorders
;GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Genotype (CA)16/(CA)16 is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes (CA)16/(CA)17 + (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Toxicity;increased  likelihood of Disease:Fatigue;TPMT *1/*3A + *1/*3C is associated with increased likelihood of Fatigue when exposed to olanzapine in healthy individuals as compared to TPMT *1/*1.;in healthy individuals 
;;NAT1;NAT1*4, NAT1*11B;*11B/*4;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *11B/*4 is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*3C;Efficacy;decreased  Efficacy:event-free survival;TPMT *1/*3C is associated with decreased event-free survival when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1 + *1/*3A + *1/*2 + *1/*21 + *1/*9 + *1/*32 + *1/*33 + *1/*34.;in children with Disease:Acute lymphoblastic leukemia
;OLANZAPINE;GSTM3;rs1799735;CCT/CCT;Metabolism/PK;decreased  PK:area under the curve;Genotype CCT/CCT is associated with decreased area under the curve when exposed to olanzapine in healthy individuals as compared to genotypes CCT/del + del/del.;in healthy individuals 
;OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased   PK:area under the curve;CYP3A5 *1/*1 + *1/*3 is associated with increased area under the curve when exposed to olanzapine in healthy individuals as compared to CYP3A5 *3/*3.;in healthy individuals 
;MERCAPTOPURINE;XDH;rs2281547;CC + CT;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes CC + CT is associated with increased severity of Neutropenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ANASTROZOLE;CYP19A1;rs727479;AA;Efficacy;increased   Other:Recurrence free survival;Genotype AA is associated with increased Recurrence free survival when treated with anastrozole in women with Breast Neoplasms as compared to genotypes AC + CC.;in women with Disease:Breast Neoplasms
;OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;Metabolism/PK;decreased  PK:serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios;CYP2D6 *4/*4 + *4/*6 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.;in people with Disease:Neoplasms
;FLUVASTATIN;SLCO1B1;rs11045819;CC;Efficacy;decreased  Efficacy:LDL-C reduction;Genotype CC is associated with decreased LDL-C reduction when treated with fluvastatin in people with Hypercholesterolemia as compared to genotypes AA + AC.;in people with Disease:Hypercholesterolemia
;OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;Metabolism/PK;decreased  PK:serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios;CYP2D6 *4/*4 + *3/*4 are associated with decreased serum concentrations of oxymorphone and noroxymorphone and oxymorphone/oxycodone ratios when treated with oxycodone in people with Neoplasms as compared to CYP2D6 *1/*1 + *2/*2.;in people with Disease:Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6*18;*18/*18;Metabolism/PK;increased   PK:plasma efavirenz levels;CYP2B6 *18/*18 is associated with increased plasma efavirenz levels when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;rs1143684;C;Efficacy;Efficacy:worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative;Allele C is associated with worse prognosis (overall survival and progression-free survival) in patients who were ER-ve/PR-ve negative when treated with cyclophosphamide and doxorubicin in people with Breast Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms
;PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2 + *2/*2;Metabolism/PK;decreased  PK:M-III:pioglitazone AUC0-48 ratio and M-III:M-IV AUC0-48 ratio in healthy African-American volunteers;CYP2C8 *1/*2 + *2/*2 is associated with decreased M-III:pioglitazone AUC0-48 ratio and M-III:M-IV AUC0-48 ratio in healthy African-American volunteers when exposed to pioglitazone in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin as compared to CYP2C9 *1.; 
;DICLOFENAC;UGT2B7;rs7668258;T;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele T is associated with increased likelihood of Toxic liver disease when treated with diclofenac as compared to allele C.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;increased  likelihood of Efficacy:sustained virological response (SVR);Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT.;in people with Disease:Hepatitis
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Toxicity;increased  risk of Disease:Hemorrhage;CYP2C19 *1/*17 + *17/*17 is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;Efficacy;decreased risk of Other:non-fatal myocardial infarction,stroke, revascularization or death;CYP2C19 *1/*17 + *17/*17 is associated with decreased risk of non-fatal myocardial infarction,stroke, revascularization or death when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2;Metabolism/PK;increased   PK:R-ibuprofen metabolism;CYP2C8 *1/*2 is associated with increased R-ibuprofen metabolism when exposed to ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;Toxicity;decreased risk of Side Effect:Anemia;Genotype TCCTC/TCCTC is associated with decreased risk of Anemia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.;in people with Disease:Ovarian Neoplasms
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;Side Effect:higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up;Allele A is associated with higher composite har outcome (cardiac death, non fatal myocardial infarction and stent thrombosis) up to 12 months' follow up when treated with aspirin and clopidogrel in people with drug-eluting stents as compared to allele G.;in people with drug-eluting stents
;;IRS1;rs1801123;C;Other;Other:lymph node involvement;Allele C is associated with lymph node involvement when treated with in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;ESTRADIOL;;rs1864729;A;Other;increased   Other:plasma level;Allele A is associated with increased plasma level of estradiol in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;Efficacy;increased   Efficacy:median survival time;Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased median survival time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Hemorrhage, Side Effect:Stroke;CYP2C9 *3 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.;in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;Efficacy;increased   Efficacy:response rate (RR);Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased response rate (RR) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;HLA-DRB1*08:03;*08:03;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DRB1 *08:03 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.;in people with Disease:Graves Disease
;ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null, GSTM1 null;;Toxicity;increased  likelihood of Side Effect:Cardiomyopathies;GSTM1 null is associated with increased likelihood of Cardiomyopathies when treated with anthracyclines and related substances in children with Neoplasms as compared to GSTM1 non-null.;in children with Neoplasms
;;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;;increased   Efficacy:progression-free survival (PFS) time;Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased progression-free survival (PFS) time in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased likelihood of drug-induced liver injury due to ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 intermediate and rapid acetylators.;in people with Tuberculosis
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Metabolism/PK;decreased  PK:citalopram oral clearances of citalopram;CYP2C19 *2 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;DICLOFENAC;ABCC2;rs717620;T;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele T is associated with increased likelihood of Toxic liver disease when treated with diclofenac as compared to allele C.; 
;ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GG;Efficacy;increased  likelihood of Efficacy:successful rhythm control;Genotype GG is associated with increased likelihood of successful rhythm control when treated with antiarrhythmics, class i and iii in people with Atrial Fibrillation as compared to genotypes GT + TT.;in people with Disease:Atrial Fibrillation
;CARBIMAZOLE, METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *38:02 is associated with increased risk of Agranulocytosis when treated with carbimazole or methimazole in people with Graves Disease.;in people with Disease:Graves Disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *1/*2 + *1/*3 + *2/*3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.; 
;GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;Efficacy;increased   Efficacy:survival time;Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased survival time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;HYDRALAZINE;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:adverse events;NAT2 slow acetylator is associated with increased likelihood of adverse events when treated with hydralazine in people with Hypertension as compared to NAT2 rapid acetylator.;in people with Hypertension
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;Efficacy:more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation;CYP2C19 *3 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.; 
;GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;Efficacy;increased   Efficacy:better clinical response;Genotypes (CA)16/(CA)16 + (CA)16/(CA)17 are associated with increased better clinical response when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotype (CA)17/(CA)17.;in Efficacy:advanced non-small-cell lung cancer patients
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased  PK:Unbound oral clearance for S-warfarin;CYP2C9 *1/*3 is associated with decreased Unbound oral clearance for S-warfarin when treated with warfarin in children as compared to CYP2C9 *1/*1.;in children 
;RIFAMPIN;SLCO1B1;SLCO1B1*15;*15;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;SLCO1B1 *15 is associated with increased risk of drug-induced liver injury due to rifampin.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;Efficacy:more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation;CYP2C19 *2 is associated with more frequent high platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stent implantation when treated with clopidogrel as compared to CYP2C19 *1.; 
;FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;Efficacy;decreased  Efficacy:HAM-D score changes in fluvoxamine-treated patients compared to paroxetine-treated patients;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C is associated with decreased HAM-D score changes in fluvoxamine-treated patients compared to paroxetine-treated patients when treated with fluvoxamine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531T + L allele-rs25531T/L allele-rs25531C + L allele-rs25531T/L allele-rs25531T.;in people with Disease:Major Depressive Disorder
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;Other;decreased  Other:wakefulness activity level;CYP2D6 *4/*5 + *4/*6 + *3/*4 + *4/*4 (assigned as poor metabolizer phenotype) is associated with decreased wakefulness activity level when treated with risperidone in healthy individuals as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .;in healthy individuals 
;;IGFBP3;rs2854744;T;Other;Other:tumor size;Allele T is associated with tumor size when treated with in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine.; 
;IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *6 + *28 are associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms.;in people with Disease:Neoplasms
;CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;Toxicity;decreased risk of Side Effect:Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions;HLA-A *24:02 is associated with decreased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  risk of Side Effect:Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions;HLA-B *15:11 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.; 
;NEVIRAPINE;GSTM1;GSTM1 non-null, GSTM1 null;;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;GSTM1 null is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV as compared to GSTM1 non-null.;in women with Disease:HIV infectious disease
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;Toxicity;decreased risk of Side Effect:Thrombocytopenia;Genotype TCCTC/TCCTC is associated with decreased risk of Thrombocytopenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.;in people with Disease:Ovarian Neoplasms
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions;HLA-B *15:02 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;Toxicity;decreased risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *40:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;Toxicity;decreased risk of Side Effect:Neurotoxicity Syndromes;Genotype TCCTC/TCCTC is associated with decreased risk of Neurotoxicity Syndromes when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes TC/TC + TC/TCCTC.;in people with Disease:Ovarian Neoplasms
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;Metabolism/PK;increased   PK:paroxetine plasma concentration;CYP2D6 *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;;GSTM3;rs36120609;TC/TC + TC/TCCTC;Other;increased  likelihood of Other:Metastatic neoplasm;Genotypes TC/TC + TC/TCCTC is associated with increased likelihood of Neoplasm Metastasis in children with Osteosarcoma as compared to genotype TCCTC/TCCTC.;in children with Osteosarcoma
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;Metabolism/PK;increased   PK:fluoxetine/(S)-norfluoxetine ratio;CYP2D6 *5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6 are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .;in children with Disease:Depressive Disorder
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;Other;Side Effect:requirement for earlier dose reduction of ribavirin;Genotype CC is associated with requirement for earlier dose reduction of ribavirin when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes AA + AC.;in people with Disease:Hepatitis
;CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;Toxicity;increased  severity of Disease:Drug Toxicity;Genotype CTGGTGAGGAGAGAACC/del is associated with increased severity of Drug Toxicity when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype CTGGTGAGGAGAGAACC/CTGGTGAGGAGAGAACC.;in people with Disease:Neoplasms
;ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;Toxicity;increased  likelihood of Disease:Agranulocytosis;HLA-B *27:05 is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;increased  risk of Efficacy:high platelet reactivity;CYP2C19 *1/*2 + *2/*2 is associated with increased risk of high platelet reactivity when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to CYP2C19 *1/*1.;in people with percutaneous coronary intervention
;;IFNL3;rs8099917;TT;;increased   Other:baseline viral load;Genotype TT is associated with increased baseline viral load in people with Hepatitis as compared to genotypes GG + GT.;in people with Disease:Hepatitis
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *6/*28;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;UGT1A1 *1/*28 + *6/*28 are associated with increased risk of Leukopenia or Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Lung Neoplasms
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;Metabolism/PK;increased   PK:paroxetine plasma concentrations increased  during the course of pregnancy;CYP2D6 *1/*4 + *1/*5 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.;in women 
;DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;Metabolism/PK;increased   PK:diclofenac/5-hydroxydiclofenac urinary concentration ratio;CYP2C8 *1/*3 + *3/*3 is associated with increased diclofenac/5-hydroxydiclofenac urinary concentration ratio when exposed to diclofenac in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;Metabolism/PK;increased   PK:paroxetine plasma concentration;CYP2D6 *3/*4 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;HEPARIN;HLA-DRB3;HLA-DRB3*01:01;*01:01;Toxicity;increased  likelihood of Side Effect:Heparin-induced thrombocytopenia;HLA-DRB3 *01:01 is associated with increased likelihood of heparin-induced thrombocytopenia when treated with heparin.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-A *31:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *2/*2 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *6 + *28 are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;Toxicity;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Efficacy;increased  risk of Efficacy:non-remission;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of non-remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin in children as compared to CYP2C9 *1/*1.;in children 
;IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;decreased  PK:racemic, S-ibuprofen and R-ibuprofen metabolism, with increase of AUC(0-infinity) and reduction of clearance;CYP2C9 *1/*3 is associated with decreased racemic, S-ibuprofen and R-ibuprofen metabolism, with increase of AUC(0-infinity) and reduction of clearance when exposed to ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Metabolism/PK;increased   PK:exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance;CYP2C9 *1/*2 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *2 is associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.; 
;TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased   PK:exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance;CYP2C9 *1/*3 is associated with increased exposure (area under the plasma concentration-time curve (AUC)) and decreased oral clearance when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;increased   PK:plasma 4beta-OHC/Chol ratio;CYP2B6 *6 is associated with increased plasma 4beta-OHC/Chol ratio when treated with efavirenz, lamivudine, stavudine and zidovudine in people with HIV as compared to CYP2B6 *1.;in people with Disease:HIV infectious disease
;TAMOXIFEN;CYP2D6;CYP2D6 low activity;;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 low activity is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 high activity.;in women with Disease:Breast Neoplasms
;PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;increased   Efficacy:inhibitory effect on cyclooxygenase 1 activity;CYP2C9 *1/*3 is associated with increased inhibitory effect on cyclooxygenase 1 activity when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;*4 + *10 + *9;Metabolism/PK;decreased  PK:plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT);CYP2A6 *4 + *10 + *9 is associated with decreased plasma and urinary ratio of metabolites trans-3'-hydroxycotinine to cotinine (3HC/COT) when exposed to nicotine in healthy individuals as compared to CYP2A6 *1.;in healthy individuals 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Efficacy;decreased  Efficacy:platelet reactivity;CYP2C19 *17 is associated with decreased platelet reactivity when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.; 
;LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:01, HLA-DQA1*01:02;*01:02;Toxicity;increased  risk of Disease:Toxic liver disease;HLA-DQA1 *01:02 is associated with increased risk of Toxic liver disease when treated with lumiracoxib as compared to HLA-DQA1 *01:01.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.; 
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:paroxetine levels;CYP2D6 *4/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.;in people with Disease:Obsessive-Compulsive Disorder
;IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Other;decreased  Other:iNOS expression;CYP2C9 *1/*2 is associated with decreased iNOS expression when exposed to ibuprofen in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;IRINOTECAN;UGT1A6;rs2070959;A;Toxicity;increased  risk of Disease:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;Metabolism/PK;increased   PK:R-ibuprofen metabolism;CYP2C8 *1/*3 is associated with increased R-ibuprofen metabolism when exposed to ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;increased   Efficacy:Overall survival;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Colorectal Neoplasms
;IMATINIB;EGFR;rs2072454;CC;Toxicity;increased  likelihood of Side Effect:periorbital edema;Genotype CC is associated with increased likelihood of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CT + TT.;in people with Gastrointestinal Stromal Tumors
;FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;Toxicity;decreased severity of Side Effect:side effects;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 is associated with decreased severity of side effects when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Disease:Colorectal Neoplasms
;KETOPROFEN, TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;Toxicity;increased  risk of Side Effect:sedation;CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41 (assigned as intermediate metabolizer phenotype) are associated with increased risk of sedation when treated with ketoprofen and tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*2 + *1/*9 + *1/*10 + *1/*17 + *1/*41 + *2/*2 (assigned as normal metabolizer phenotype) .;in people with Pain, Postoperative
;PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Efficacy;increased   Efficacy:inhibitory effect on cyclooxygenase 1 activity;CYP2C9 *1/*2 is associated with increased inhibitory effect on cyclooxygenase 1 activity when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased   PK:Piroxicam's area under the plasma concentration-time curve and decreased oral clearance;CYP2C9 *1/*3 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;Metabolism/PK;increased   PK:Piroxicam's area under the plasma concentration-time curve and decreased oral clearance;CYP2C9 *1/*2 is associated with increased Piroxicam's area under the plasma concentration-time curve and decreased oral clearance when exposed to piroxicam in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;*10/*10;Toxicity;increased  risk of Side Effect:Exanthema;CYP2D6 *10/*10 is associated with increased risk of Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP2D6 *1/*1 + *1/*2 + *1/*10 + *1/*114 + *2/*2 + *2/*10.;in people with Disease:Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele TT.;in people with Disease:Chronic hepatitis C virus infection
;CITALOPRAM, ESCITALOPRAM;CYP2D6;rs1065852;A;Other;Other:plasma concentration of S-didesmethyl-citalopram;Allele A is associated with plasma concentration of S-didesmethyl-citalopram when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;Efficacy;increased   Efficacy:reduction in blood pressure;Genotype del/del is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in men with Essential hypertension as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in men with Disease:Essential hypertension
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;Efficacy;decreased  Efficacy:platelet aggregation;CYP2C19 *1/*1 is associated with decreased platelet aggregation when treated with aspirin and clopidogrel in people with Acute coronary syndrome and Myocardial Infarction as compared to CYP2C19 *1/*2 + *2/*2.;in people with Disease:Acute coronary syndrome, Disease:Myocardial Infarction
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.; 
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;increased   PK:clearance of S(+) mirtazapine;CYP2D6 *1/*1xN is associated with increased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;Toxicity;increased  risk of Side Effect:Drug Toxicity;CYP3A5 *3/*3 is associated with increased risk of Drug Toxicity when treated with tacrolimus in people with Myasthenia Gravis.;in people with Disease:Myasthenia Gravis
;;CYP2D6;CYP2D6*2xN;*2xN;Other;increased  risk of Disease:Suicide;CYP2D6 *2xN is associated with increased risk of suicide in people with gene duplication/multiduplication.;in people with gene duplication/multiduplication
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Efficacy;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.;in children with Disease:Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Toxicity;increased  risk of Side Effect:Drug Toxicity;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Drug Toxicity when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Efficacy:time in therapeutic range;CYP2C9 *2 + *3 are associated with decreased time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;increased   Side Effect:time above therapeutic range;CYP2C9 *2 + *3 are associated with increased time above therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.; 
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;decreased  PK:total clearance of racemic mirtazapine;CYP2D6 *4/*4 is associated with decreased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Other;decreased severity of Disease:Depression;CYP2C19 *2/*2 is associated with decreased severity of Depression as compared to CYP2C19 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *2 + *3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.; 
;IRINOTECAN;UGT1A9;rs11692021;C;Toxicity;increased  risk of Disease:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to allele T.;in people with Disease:Colorectal Neoplasms
;METOPROLOL;ADRB2;rs1042714;CG;Toxicity;increased   Side Effect:triglycerides;Genotype CG is associated with increased triglycerides due to metoprolol in people with Hypertension.;in people with Disease:Hypertension
;LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  likelihood of Disease:Maculopapular Exanthema;HLA-A *33:03 is associated with increased likelihood of Maculopapular Exanthema when exposed to lamotrigine in people with Epilepsy.;in people with Disease:Epilepsy
;TAMOXIFEN;IGF1R;rs2016347;GG;Efficacy;increased  risk of Disease:Recurrence;Genotype GG is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes GT + TT.;in women with Disease:Breast Neoplasms
;IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 are associated with increased risk of Diarrhea when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *1/*2 + *1/*3 are associated with decreased time to therapeutic inr when treated with warfarin in children with Neoplasms as compared to CYP2C9 *1/*1.;in children with Disease:Neoplasms
;;CYP2D6;CYP2D6*1xN;*1xN;Other;increased  risk of Disease:Suicide;CYP2D6 *1xN is associated with increased risk of suicide in people with gene duplication/multiduplication.;in people with gene duplication/multiduplication
;ALLOPURINOL;HLA-B;HLA-B*48:01;*48:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *48:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.;in people with Disease:Hematologic Neoplasms
;PACLITAXEL;CYP2C8;rs10509681;C;Toxicity;increased  risk of Disease:Peripheral Nervous System Diseases;Allele C is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Vomiting;UGT1A1 *1/*28 + *28/*28 are associated with increased risk of Vomiting when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;PAZOPANIB;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;HLA-B *57:01 is associated with increased likelihood of Toxic liver disease when treated with pazopanib in people with Carcinoma, Renal Cell, Ovarian Neoplasms, Sarcoma or Soft Tissue Neoplasms.;in people with Disease:Renal Cell Carcinoma, Disease:Ovarian Neoplasms, Disease:Sarcoma, Disease:Soft Tissue Neoplasms
;IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Asthenia;UGT1A1 *1/*28 + *28/*28 are associated with increased risk of Asthenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:trough concentrations;CYP3A5 *3/*3 is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.;in people with Disease:Kidney Transplantation
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased   Side Effect:intolerance;CYP2C19 *2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;CYP3A5 *3/*3 is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*3.;in people with Disease:Kidney Transplantation
;QUETIAPINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*2 + *2/*2 + *2/*4;Metabolism/PK;increased  severity of Side Effect:Hyperprolactinemia;CYP2C19 *1/*2 + *2/*2 + *2/*4 are associated with increased severity of Hyperprolactinemia when treated with quetiapine in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;CAFFEINE;ADORA2A;rs35060421;TTTTTTT/TTTTTTT;Toxicity;increased   Side Effect:anxiety;Genotype TTTTTTT/TTTTTTT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes TTTTTT/TTTTTT + TTTTTT/TTTTTTT.;in healthy individuals 
;ALLOPURINOL;HLA-DRB1;HLA-DRB1*14:01;*14:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-DRB1 *14:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.;in people with Disease:Hematologic Neoplasms
;ALLOPURINOL;HLA-DRB1;HLA-DRB1*09:01;*09:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-DRB1 *09:01 is associated with increased risk of Drug Hypersensitivity when exposed to allopurinol in people with Hematologic Neoplasms.;in people with Disease:Hematologic Neoplasms
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Disease:Tuberculosis
;ZONISAMIDE;HLA-A;HLA-A*02:07;*02:07;Toxicity;Disease:Stevens-Johnson Syndrome;HLA-A *02:07 is associated with Stevens-Johnson Syndrome when treated with zonisamide.; 
;PHENOBARBITAL;HLA-B;HLA-B*51:01;*51:01;Toxicity;Disease:Stevens-Johnson Syndrome;HLA-B *51:01 is associated with Stevens-Johnson Syndrome when treated with phenobarbital.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Colorectal Neoplasms
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Metabolism/PK;decreased  PK:mean logarithm escitalopram concentration and higher mean metabolic ratio;CYP2C19 *17/*17 is associated with decreased mean logarithm escitalopram concentration and higher mean metabolic ratio when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;increased  severity of Other:Pain;CYP2D6 *10/*10 is associated with increased severity of Pain when treated with tramadol in people with Pain, Postoperative as compared to CYP2D6 *1/*1 + *1/*10.;in people with Pain, Postoperative
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*35:05;*35:05;Toxicity;Side Effect:Exanthema;HLA-B *35:05 is associated with Exanthema when treated with lamivudine, nevirapine and stavudine in people with HIV Infections.;in people with Disease:HIV infectious disease
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased   PK:time to achieve therapeutic window;CYP3A5 *1/*1 + *1/*3 is associated with increased time to achieve therapeutic window of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased   Side Effect:Death;UGT1A1 *1/*28 + *28/*28 are associated with increased Death when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;METHOTREXATE;ABCC2;rs3740065;AG + GG;Metabolism/PK;increased   PK:plasma level;Genotypes AG + GG are associated with increased plasma level when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.;in people with Disease:Hyperuricemia
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;METOPROLOL;ADRB2;rs1042714;CC;Toxicity;decreased  Side Effect:total cholesterol;Genotype CC is associated with decreased total cholesterol due to metoprolol in people with Hypertension.;in people with Disease:Hypertension
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;METHOTREXATE;ABCC4;rs9516519;GG + GT;Metabolism/PK;decreased  PK:plasma level;Genotypes GG + GT are associated with decreased plasma level when exposed to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.;in people with Disease:Chronic Kidney Failure
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased dose-adjusted trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;rs746071566;del;Toxicity;increased  risk of Side Effect:Myelosuppression;Allele del is associated with increased risk of Myelosuppression when treated with azathioprine, mercaptopurine or thioguanine in people with Inflammatory Bowel Diseases as compared to allele GGAGTC.;in people with Disease:Inflammatory Bowel Diseases
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;decreased  PK:trough concentrations;CYP3A5 *1/*1 + *1/*3 is associated with decreased trough concentrations of tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotypes AA + AG are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel as compared to genotype GG.; 
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased   PK:S-CIT serum concentrations;CYP2C19 *2/*2 + *2/*3 is associated with increased S-CIT serum concentrations when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1 + *1/*2.;in people with Disease:Major Depressive Disorder
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.; 
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased   PK:mean escitalopram concentration;CYP2C19 *2/*2 + *2/*3 are associated with increased mean escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;decreased  Efficacy:response when measured by the Geriatric Depression Scale at day 7 and day 28;SLC6A4 HTTLPR short form (S allele) is associated with decreased response when measured by the Geriatric Depression Scale at day 7 and day 28 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Toxicity;increased  risk of Side Effect:side effects;SLC6A4 HTTLPR short form (S allele) is associated with increased risk of side effects when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Toxicity;increased  risk of Side Effect:lower final daily dose, decreased dosing compliance and lower plasma levels at day 28;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of lower final daily dose, decreased dosing compliance and lower plasma levels at day 28 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;Dosage, Metabolism/PK;decreased  PK:serum concentration;CYP2C19 *17/*17 is associated with decreased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:Cardiovascular Disease;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);Toxicity;increased  risk of Side Effect:side effects;SLC6A4 HTTLPR long form (L allele) is associated with increased risk of side effects when treated with mirtazapine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Dosage, Metabolism/PK;increased   PK:serum concentration;CYP2C19 *3 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;LISINOPRIL;MMP3;rs35068180;del/del;Efficacy;decreased risk of Side Effect:Stroke;Genotype del/del is associated with decreased risk of Stroke when treated with lisinopril in people with Hypertension.;in people with Disease:Hypertension
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased  risk of Disease:Infectious disease;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Infection when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Metabolism/PK;increased  risk of Disease:Toxic liver disease;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Toxic liver disease when treated with tacrolimus in children with liver transplantation as compared to CYP3A5 *3/*3.;in children with Disease:Liver transplantation
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;Efficacy:positive correlation of paroxetine concentration with improvement in HAMD scores at week 2;SLC6A4 HTTLPR short form (S allele) is associated with positive correlation of paroxetine concentration with improvement in HAMD scores at week 2 when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Side Effect:Hemorrhage, Side Effect:Stroke;CYP2C9 *2 is associated with increased risk of Hemorrhage and Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation and venous thromboembolism as compared to CYP2C9 *1.;in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*4/*41;Metabolism/PK;increased   PK:mean logarithm escitalopram concentration;CYP2D6 *4/*41 is associated with increased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;Toxicity;increased   Efficacy:risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients;CYP2C19 *1/*3 + *2/*3 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Toxicity;increased   Efficacy:risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients;CYP2C19 *1/*2 + *2/*2 is associated with increased risk of recurrent cardiovascular (CV) events 1 year after PCI in Chinese patients when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  risk of Side Effect:adverse events;CYP3A5 *3/*3 is associated with increased risk of adverse events due to fentanyl in people with Neoplasms and Pain as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Neoplasms, Disease:Pain
;DIRECT ACTING ANTIVIRALS, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased likelihood of sustained virological response (svr) when treated with direct acting antivirals or sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Maculopapular Exanthema;HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.;in children 
;ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2;Dosage, Metabolism/PK;increased   PK:serum concentration;CYP2C19 *2 is associated with increased serum concentration of escitalopram in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  likelihood of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 are associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;CITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;Metabolism/PK;decreased  PK:demethylation clearance of desmethylcitalopram;CYP2D6 poor metabolizer is associated with decreased demethylation clearance of desmethylcitalopram when treated with citalopram in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.;in people with Disease:Chronic Kidney Failure
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Toxicity;increased  risk of Side Effect:Toxic liver disease;CYP2B6 *6 is associated with increased risk of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity;increased  risk of Side Effect:Long QT Syndrome;CYP2B6 *6/*6 is associated with increased risk of Long QT Syndrome when exposed to efavirenz in healthy individuals as compared to CYP2B6 *1/*1.;in healthy individuals 
;ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.;in people with Disease:Chronic Kidney Failure
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Side Effect:Exanthema;HLA-C *03:02 is associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.;in people with Disease:Chronic Kidney Failure
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  likelihood of Disease:Neutropenia;UGT1A1 *28/*28 is associated with increased likelihood of Neutropenia when treated with FOLFIRI in people with Colonic Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Colonic Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9;Efficacy;increased  likelihood of Efficacy:Discontinuation;CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel in people with Angina Pectoris.;in people with Disease:Angina Pectoris
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;UGT1A6*2a;*2a;Toxicity;increased  likelihood of Disease:Vomiting;UGT1A6 *2a is associated with increased likelihood of Vomiting when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;Toxicity;increased  risk of Side Effect:Drug Toxicity;UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*6 + *1/*28.;in people with Disease:Neoplasms
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*28;*28;Efficacy;decreased  Efficacy:overall survival;UGT1A1 *28 is associated with decreased overall survival when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;FOLFOX;TYMS;rs11280056;TTA/TTA;Toxicity;increased  severity of Side Effect:Neurotoxicity Syndromes;Genotype TTA/TTA is associated with increased severity of Neurotoxicity Syndromes when treated with FOLFOX in people with Neoplasms as compared to genotypes TTA/TTAAAGTTA + TTAAAGTTA/TTAAAGTTA.;in people with Neoplasms
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;Efficacy;decreased  Efficacy:overall survival;UGT1A1 *60 is associated with decreased overall survival when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *10/*10 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *1/*1.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *2 + *3 are associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-C *04:01 is associated with increased risk of Drug Hypersensitivity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;Toxicity, Metabolism/PK;decreased likelihood of Disease:Toxic liver disease;NAT2 *4 is associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;METHOTREXATE;TYMS;rs11280056;TTA/TTA;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TTA/TTA is associated with increased likelihood of gastrointestinal toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TTA/TTAAAGTTA + TTAAAGTTA/TTAAAGTTA.;in children with Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9 + *1/*9;Efficacy;increased  risk of Efficacy:Discontinuation;CYP2B6 *9/*9 + *1/*9 are associated with increased risk of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;Efficacy;increased  risk of Efficacy:Stroke;CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke when treated with clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.;in people with Disease:Transient Ischemic Attack, Disease:Stroke
;FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  severity of Side Effect:Anemia;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased severity of Anemia when treated with FOLFOX in people with Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Neoplasms
;MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;Toxicity;increased  risk of Side Effect:leukopenia;TPMT *1/*2 + *1/*3A + *3A/*3B is associated with increased risk of leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;EGFR INHIBITORS;HLA-A;HLA-A*02:01;*02:01;Toxicity;decreased risk of Side Effect:Exanthema;HLA-A *02:01 is associated with decreased risk of Exanthema when treated with egfr inhibitors in people with Neoplasms.;in people with Disease:Neoplasms
;CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Toxicity;decreased risk of Disease:Drug Toxicity;CYP2B6 *1/*6 + *6/*6 is associated with decreased risk of Drug Toxicity when treated with cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 *1/*1.;in people with Disease:Leukemia, Lymphocytic, Chronic, B-Cell
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2 + *1/*2;Efficacy;increased   Efficacy:event-free survival;UGT2B15 *2/*2 + *1/*2 is associated with increased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to UGT2B15 *1/*1.;in women with Disease:Breast Neoplasms
;EGFR INHIBITORS;HLA-A;HLA-A*03:01;*03:01;Toxicity;decreased risk of Side Effect:Exanthema;HLA-A *03:01 is associated with decreased risk of Exanthema when treated with egfr inhibitors in people with Neoplasms.;in people with Disease:Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased   Side Effect:Asthenia;UGT1A1 *1/*28 + *28/*28 are associated with increased Asthenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Colorectal Neoplasms
;DOCETAXEL;SLCO1B3;rs3834935;A;Other, Metabolism/PK;increased   PK:AUC;Allele A is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.;in people with Disease:Nasopharyngeal Neoplasms
;CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;GG;Efficacy;Efficacy:drug-resistant phenotype;Genotype GG is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to genotype AA.;in people with Disease:Epilepsy
;PACLITAXEL;CYP2C8;CYP2C8*2, CYP2C8*3, CYP2C8*4;*2 + *3 + *4;Toxicity;increased  risk of Disease:Peripheral Nervous System Diseases;CYP2C8 *2 + *3 + *4 (assigned as poor metabolizer phenotype) is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to CYP2C8 normal metabolizer.;in women with Disease:Breast Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  risk of Side Effect:Nephrotoxicity;CYP3A5 *3/*3 is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Kidney Transplantation
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;CYP2B6 *6/*6 is associated with decreased risk of drug-induced liver injury when treated with ethambutol, isoniazid, pyrazinamide and rifampin in men with Tuberculosis as compared to CYP2B6 *1/*1.;in men with Disease:Tuberculosis
;AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*30:02;*30:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-A *30:02 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;CITALOPRAM, ESCITALOPRAM;;rs1074145;A;Other;Other:concentrations of S-citalopram and metabolic ratio of of S-desmethylcitalopram/citalopram;Allele A is associated with concentrations of S-citalopram and metabolic ratio of of S-desmethylcitalopram/citalopram when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;decreased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-DQB1 *06:02 is associated with decreased risk of drug reaction with eosinophilia and systemic symptoms when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:03;*06:03;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *06:03 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;decreased  Efficacy:event-free survival;CYP2C19 *2/*2 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1 + *1/*2.;in women with Disease:Breast Neoplasms
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *06:02 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:03;*15:03;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *15:03 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *06:09 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;Toxicity;decreased risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *02:01 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;IMATINIB;CYP1A2;rs11636419;AA;Toxicity;increased  likelihood of Side Effect:periorbital edema;Genotype AA is associated with increased likelihood of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AG + GG.;in people with Gastrointestinal Stromal Tumors
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1.; 
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *02:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;Toxicity;decreased risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-DQB1 *03:02 is associated with decreased risk of drug reaction with eosinophilia and systemic symptoms when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *06:02 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DQB1 *03:02 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *04:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-C *04:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;ETHANOL;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Toxicity;increased  risk of Side Effect:Alcohol abuse;SLC6A4 HTTLPR short form (S allele) is associated with increased risk of Alcoholism due to ethanol as compared to SLC6A4 HTTLPR long form (L allele).; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Efficacy;increased   Efficacy:platelet aggregation inhibition;CYP2C19 *1/*17 is associated with increased platelet aggregation inhibition when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;Toxicity;decreased risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-DQB1 *05:01 is associated with decreased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;G;Efficacy;Efficacy:drug-resistant phenotype;Allele G is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele A.;in people with Disease:Epilepsy
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;Other;Other:greater heart rate (HR) reduction;CYP2D6 *3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17 are associated with greater heart rate (HR) reduction when treated with metoprolol as compared to CYP2D6 *1/*1.; 
;BUCILLAMINE;HLA-DRB1;HLA-DRB1*08:02;*08:02;Toxicity;increased  risk of Side Effect:Proteinuria;HLA-DRB1 *08:02 is associated with increased risk of Proteinuria when treated with bucillamine in people with Arthritis, Rheumatoid.;in people with Disease:Rheumatoid arthritis
;MERCAPTOPURINE;TPMT;TPMT deficiency;;Toxicity;increased  risk of Side Effect:Death;TPMT deficiency is associated with increased risk of Death when treated with mercaptopurine.; 
;AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Toxicity;increased  likelihood of Side Effect:leukopenia;TPMT *1/*2 + *1/*3A + *1/*3C is associated with increased likelihood of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation as compared to TPMT *1/*1.;in people with Disease:Kidney Transplantation
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;BUCILLAMINE;HLA-DQB1;HLA-DQB1*04:02;*04:02;Toxicity;increased  risk of Side Effect:Proteinuria;HLA-DQB1 *04:02 is associated with increased risk of Proteinuria when treated with bucillamine in people with Arthritis, Rheumatoid.;in people with Disease:Rheumatoid arthritis
;CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;Efficacy;increased   Efficacy:Recurrence;Genotype CT is associated with increased Recurrence when treated with cyclophosphamide in people with Lymphoma as compared to genotype CC.;in people with Disease:Lymphoma
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;Efficacy;increased   Efficacy:platelet aggregation;CYP2C19 *1/*2 + *2/*2 + *2/*17 (assigned as poor metabolizers and intermediate metabolizers phenotype) are associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultra-metabolizer phenotype) .; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 + *5 + *6 + *11 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *06:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome;HLA-B *13:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with dapsone.; 
;DAPSONE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with dapsone.; 
;LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;DAPSONE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with dapsone.; 
;LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *07:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with dapsone.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of;CYP2C19 *2 is associated with increased risk of when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;Toxicity;increased  risk of Side Effect:Death;ABCC4 deficiency is associated with increased risk of Death when treated with mercaptopurine.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;Other:High Platelet Reactivity (HPR);Allele A is associated with High Platelet Reactivity (HPR) when treated with clopidogrel as compared to allele G.; 
;AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *06:02 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.; 
;CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DQB1 *05:02 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;CYP2C19 *2 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.;in patients undergoing PCI
;ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;Toxicity;increased  risk of Side Effect:Urticaria;HLA-DQB1 *06:09 is associated with increased risk of Urticaria when treated with aspirin.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;CYP2C19 *3 is associated with increased risk of high on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.;in patients undergoing PCI
;ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;Toxicity;increased  risk of Side Effect:Urticaria;HLA-DRB1 *13:02 is associated with increased risk of Urticaria when treated with aspirin.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole / trimethoprim.; 
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with FOLFIRI or irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Neoplasms
;CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DQB1 *05:02 is associated with increased risk of Agranulocytosis when exposed to clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;CLOZAPINE;HLA-DPB1;HLA-DPB1*04:01;*04:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DPB1 *04:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;CLOZAPINE;HLA-DRB5;HLA-DRB5*02:02;*02:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DRB5 *02:02 is associated with increased risk of Agranulocytosis when exposed to clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.; 
;ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;Efficacy;decreased likelihood of Disease:Inflammation;CYP2C19 *17/*17 + *1/*17 is associated with decreased likelihood of Inflammation when treated with aspirin, clopidogrel and prasugrel in people with Tobacco Use Disorder as compared to CYP2C19 *1/*1.;in people with Disease:Tobacco Use Disorder
;OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased likelihood of severe cutaneous adverse reactions when treated with oxcarbazepine.; 
;AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  risk of Side Effect:Jaundice;HLA-DRB1 *15:01 is associated with increased risk of Jaundice when treated with amoxicillin and clavulanate.; 
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;Other;Other:a correlation of brain SERT occupancy was associated with larger proportional HDRS17 decreases;SLC6A4 L allele-rs25531T/L allele-rs25531T is associated with a correlation of brain SERT occupancy was associated with larger proportional HDRS17 decreases when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele) + L allele-rs25531C.;in people with Disease:Major Depressive Disorder
;AMOXICILLIN, CLAVULANATE;HLA-DRB5;HLA-DRB5*01:01;*01:01;Toxicity;increased  risk of Side Effect:Hepatitis;HLA-DRB5 *01:01 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.;in people with Disease:Infectious disease
;SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with sorafenib as compared to UGT1A1 *1/*1.; 
;SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  likelihood of Side Effect:Treatment interruption;UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of treatment interruptions when treated with sorafenib as compared to UGT1A1 *1/*1.; 
;AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  risk of Side Effect:Hepatitis;HLA-DRB1 *15:01 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.;in people with Disease:Infectious disease
;SUNITINIB;ABCB1;rs1128503;AA + AG;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes AA + AG are associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;TICLOPIDINE;HLA-DRB1;HLA-DRB1*13:02;*13:02;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DRB1 *13:02 is associated with increased risk of Toxic liver disease when treated with ticlopidine.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased  Efficacy:efficacy;CYP2C19 *2 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.;in patients that had undergone coronary angiography or had an uneventful PCI
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;decreased  Efficacy:efficacy;CYP2C19 *3 is associated with decreased efficacy when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.;in patients that had undergone coronary angiography or had an uneventful PCI
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*41;*41;Other, Metabolism/PK;increased   PK:plasma nortriptyline;CYP2D6 *41 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.;in people with Disease:Mental Disorders
;TICLOPIDINE;HLA-C;HLA-C*14:03;*14:03;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-C *14:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.; 
;CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;Efficacy;decreased  Efficacy:Overall survival;Genotype CT is associated with decreased overall survival when treated with cyclophosphamide in people with Lymphoma as compared to genotype CC.;in people with Disease:Lymphoma
;ATORVASTATIN;LEPR;rs1805094;GG;Other;increased   Other:bone marrow density in the lumbar spine;Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome.;in people with Disease:Acute coronary syndrome
;TICLOPIDINE;HLA-DQB1;HLA-DQB1*06:04;*06:04;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-DQB1 *06:04 is associated with increased risk of Toxic liver disease when treated with ticlopidine.; 
;TICLOPIDINE;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-A *33:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in people with Disease:Neoplasms
;BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;rs4148405;G;Efficacy, Toxicity;decreased  Other:Disease-Free Survival;Allele G is associated with decreased Disease-Free Survival when treated with busulfan, cytarabine and etoposide in people with Leukemia, Myeloid, Acute as compared to allele T.;in people with Disease:Leukemia, Myeloid, Acute
;TICLOPIDINE;HLA-B;HLA-B*44:03;*44:03;Toxicity;increased  risk of Side Effect:Toxic liver disease;HLA-B *44:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.; 
;COCAINE, ETHANOL, NICOTINE;OPRM1;rs1799972;TT;Toxicity;increased  risk of Disease:Substance-Related Disorders;Genotype TT is associated with increased risk of Substance-Related Disorders due to cocaine, ethanol or nicotine in women as compared to genotypes CC + CT.;in women 
;NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Hypersensitivity;HLA-C *08:01 is associated with increased risk of Hypersensitivity when treated with nevirapine in people with HIV.;in people with Disease:HIV infectious disease
;ANTIPSYCHOTICS;COMT;rs4680;A;Other;increased   Other:methylation at sites 1 and 2 in the COMT promoter;Allele A is associated with increased methylation at sites 1 and 2 in the COMT promoter when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;ISONIAZID;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with isoniazid in people with Tuberculosis as compared to NAT2 intermediate and rapid acetylators.;in people with Disease:Tuberculosis
;ASPIRIN;HLA-DRB1;HLA-DRB1*09:01;*09:01;Toxicity;decreased risk of Side Effect:Urticaria;HLA-DRB1 *09:01 is associated with decreased risk of Urticaria when treated with aspirin.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;decreased  Efficacy:time to therapeutic inr;CYP2C9 *3 is associated with decreased time to therapeutic inr when treated with warfarin as compared to CYP2C9 *1/*1.; 
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;CYP2B6 *6/*6 is associated with increased likelihood of Toxic liver disease when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;ASPIRIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;Toxicity;decreased risk of Side Effect:Urticaria;HLA-DPB1 *05:01 is associated with decreased risk of Urticaria when treated with aspirin.; 
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 poor metabolizer and intermediate metabolizer genotypes are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A, CYP2E1*5B;*1A/*5B;Toxicity;increased  risk of Side Effect:Toxic liver disease;CYP2E1 *1A/*5B is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to CYP2E1 *1A/*1A.;in people with Disease:Tuberculosis
;ASPIRIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;Toxicity;decreased risk of Side Effect:Urticaria;HLA-DQB1 *03:03 is associated with decreased risk of Urticaria when treated with aspirin.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Disease:Tuberculosis
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;Toxicity;increased  risk of Side Effect:Urticaria;HLA-DRB1 *13:02 is associated with increased risk of Urticaria when treated with aspirin.; 
;MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Toxicity;Side Effect:Thrombocytopenia;TPMT *1/*3C is associated with Thrombocytopenia when treated with mercaptopurine or thioguanine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;Toxicity;increased  risk of Side Effect:Urticaria;HLA-DQB1 *06:09 is associated with increased risk of Urticaria when treated with aspirin.; 
;FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA + AG;Other;decreased  Efficacy:FEV1/FVC ratio;Genotypes AA + AG are associated with decreased FEV1/FVC ratio when treated with fluticasone propionate in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;Toxicity;decreased risk of Disease:Drug Toxicity;GSTM1 non-null/non-null is associated with decreased risk of Drug Toxicity when treated with bleomycin, dacarbazine, doxorubicin and vinblastine in people with Hodgkin Disease as compared to GSTM1 non-null/null + null/null.;in people with Disease:Hodgkin Disease
;EFAVIRENZ, NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Side Effect:Exanthema;HLA-DRB1 *01:01 is associated with increased risk of Exanthema when treated with efavirenz or nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;HLA-DRB1 *15:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;ETHANOL;ADH1B;rs1229984;T;Toxicity;decreased risk of Other:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-C *04:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *28/*28 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in people with Disease:Neoplasms
;ISONIAZID, RIFAMPIN;GSTT1;GSTT1 null;;Metabolism/PK;decreased  PK:serum hydrazine concentrations;GSTT1 null is associated with decreased serum hydrazine concentrations when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs56038477;T;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.;in people with Disease:Neoplasms
;ISONIAZID, RIFAMPIN;GSTM1;GSTM1 null;;Metabolism/PK;increased   PK:serum hydrazine concentrations;GSTM1 null is associated with increased serum hydrazine concentrations when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-DQB1 *05:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.;in people with Disease:Drug Hypersensitivity
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;GSTM1 null;;Toxicity;increased  likelihood of Disease:Toxic liver disease;GSTM1 null is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased  risk of Side Effect:Hematologic Disorder;TPMT *1/*3A is associated with increased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased  likelihood of Side Effect:Dose reduction;TPMT *1/*3A is associated with increased likelihood of dose reduction when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.; 
;METHADONE;CYP3A4;rs3735451;C;Other;increased  severity of Side Effect:opioid withdrawal symptoms;Allele C is associated with increased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele T.;in people with Disease:Heroin Dependence
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*27;*1/*27;Toxicity;increased  severity of Side Effect:Leukopenia;UGT1A1 *1/*27 is associated with increased severity of Leukopenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Lung Neoplasms
;CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;Toxicity;decreased likelihood of Side Effect:Diabetes Mellitus;CYP2C19 *17/*17 is associated with decreased likelihood of Diabetes Mellitus when treated with clozapine in people with schizoaffective disorder and Schizophrenia.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;CLOZAPINE;HLA-B;HLA-B*59:01;*59:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *59:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;Toxicity;increased  severity of Side Effect:Leukopenia;UGT1A1 *1/*6 is associated with increased severity of Leukopenia when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *1/*1.;in people with Disease:Lung Neoplasms
;NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;PHENYTOIN;HLA-B;HLA-B*07:02, HLA-B*13:01;*13:01;Toxicity;increased  likelihood of Disease:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to HLA-B *07:02.; 
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;PK:significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations;CYP2D6 *4/*4 is associated with significantly higher (S)-fluoxetine and lower and (S)-norfluoxetine concentrations when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;;TRPA1;rs920829;CT + TT;Other;increased  likelihood of Disease:Pain;Genotypes CT + TT is associated with increased likelihood of Pain in people with Anemia, Sickle Cell as compared to genotype CC.;in people with Disease:Anemia, Sickle Cell
;ETHANOL;ALDH2;rs671;A;Toxicity;decreased risk of Other:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;;NAT2;NAT2 deficiency;;Other;Disease:Insulin Resistance;NAT2 deficiency is associated with Insulin Resistance.; 
;FLUOXETINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Metabolism/PK;increased   PK:dose-corrected plasma concentrations of fluoxetine and the active moiety in patients with two functional CYP2D6 alleles;CYP2C9 *1/*2 + *1/*3 is associated with increased dose-corrected plasma concentrations of fluoxetine and the active moiety in patients with two functional CYP2D6 alleles when treated with fluoxetine in people with Mental Disorders as compared to CYP2C9 *1/*1.;in people with Disease:Mental Disorders
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;Metabolism/PK;decreased  PK:concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio;CYP2D6 *1/*4 + *1/*5 is associated with decreased concentrations of 10-OH-nortriptyline and higher nortriptyline/10-OH-nortriptyline ratio when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;RITODRINE;CACNA1C;rs10774053;AA + AG;Other;decreased likelihood of Side Effect:adverse events;Genotypes AA + AG are associated with decreased likelihood of adverse events when treated with ritodrine in women with Premature Birth as compared to genotype GG.;in women with Disease:Premature Birth
;SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;Efficacy;Efficacy:improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume;Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype del/del.;in people with chronic heart failure
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C.;in people with Disease:Hepatitis C virus infection
;WARFARIN;APOE;rs429358;TT;Efficacy;increased   Efficacy:time to achieve stable dose;Genotype TT is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CC + CT.; 
;WARFARIN;APOE;rs7412;CC;Efficacy;increased   Efficacy:time to achieve stable dose;Genotype CC is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CT + TT.; 
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *06:02 is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin.; 
;ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;Efficacy;decreased  Efficacy:reduction in D-dimer levels;Genotype del/del is associated with decreased reduction in D-dimer levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in men with Disease:Coronary Artery Disease
;TIMOLOL;CYP2D6;CYP2D6 poor metabolizer;;Efficacy, Metabolism/PK;increased   PK:plasma timolol concentration and excerice heart rate reduction;CYP2D6 poor metabolizer is associated with increased plasma timolol concentration and excerice heart rate reduction when exposed to timolol in men as compared to CYP2D6 normal metabolizer.;in men 
;LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;Metabolism/PK;decreased  Other:Gastric pH;CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizers and intermediate metabolizers.;in healthy individuals 
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-C *06:02 is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin.; 
;RABEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;Efficacy;decreased  Other:Gastric pH;CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to rabeprazole in healthy individuals as compared to CYP2C19 poor metabolizer.;in healthy individuals 
;;AREG;rs1615111;A;Other;decreased  Other:Overall survival;Allele A is associated with decreased overall survival in people with Adenocarcinoma as compared to genotype GG.;in people with Disease:Adenocarcinoma
;CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Efficacy;increased   Efficacy:Overall survival;Genotype (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased overall survival when treated with cisplatin, epirubicin and fluorouracil in people with Esophageal Neoplasms or Stomach Neoplasms as compared to genotypes (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Disease:Neoplasm of esophagus, Disease:Stomach Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);CYP2C19 *2 + *3 are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;Efficacy;decreased  Efficacy:reduction in IL-6 levels;Genotype del/del is associated with decreased reduction in IL-6 levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in men with Disease:Coronary Artery Disease
;ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;Efficacy;increased   Efficacy:reduction in CRP levels;Genotype del/del is associated with increased reduction in CRP levels when treated with atorvastatin and quinapril in men with Coronary Artery Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.;in men with Disease:Coronary Artery Disease
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-B *57:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin.; 
;CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;Efficacy;increased   Efficacy:platelet aggregation;CYP2C9 *2/*2 is associated with increased platelet aggregation when treated with clopidogrel as compared to CYP2C9 *1/*1.; 
;VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Toxicity;decreased  Side Effect:average cumulative neurotoxicity grade;CYP3A5 *1/*3 is associated with decreased average cumulative neurotoxicity grade when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to CYP3A5 *3/*3.;in children with Disease:Acute lymphoblastic leukemia
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;Efficacy;increased   Efficacy:platelet aggregation;CYP2C19 *2 is associated with increased platelet aggregation when treated with aspirin and clopidogrel as compared to CYP2C19 *1 + *17.; 
;ETHANOL;CYP2E1;rs2031920;T;Toxicity;increased  risk of Other:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;CISPLATIN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Diarrhea when treated with cisplatin and irinotecan in women with Ovarian Neoplasms as compared to UGT1A1 *1/*1.;in women with Disease:Ovarian Neoplasms
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Other;increased  likelihood of Other:Blood Coagulation Disorders;CYP2C9 *3 is associated with increased likelihood of Blood Coagulation Disorders when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 *1.;in people with Disease:Atrial Fibrillation, Disease:Atrial Flutter, Disease:Venous Thrombosis
;TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;Metabolism/PK;increased   PK:tolterodine exposure and increased  active metabolite (5-HM) concentrations;CYP2D6 *10/*10 + *5/*10 is associated with increased tolterodine exposure and increased active metabolite (5-HM) concentrations when exposed to tolterodine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*10.;in healthy individuals 
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DQB1 *03:03 is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin.; 
;PHENYTOIN;CYP2C9;CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions due to phenytoin in children with Epilepsy.;in children with Disease:Epilepsy
;ANASTROZOLE;CYP19A1;rs1008805;GG;Other;decreased likelihood of Side Effect:Arthralgia;Genotype GG is associated with decreased likelihood of Arthralgia when exposed to anastrozole in women with Breast Neoplasms as compared to genotypes AA + AG.;in women with Disease:Breast Neoplasms
;ACE INHIBITORS, PLAIN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Toxicity;increased  likelihood of Side Effect:Cough;Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele del.; 
;OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Toxicity;increased  likelihood of Side Effect:Somnolence;CYP3A5 *1/*1 is associated with increased likelihood of somnolence due to olanzapine in healthy individuals as compared to CYP3A5 *1/*3 + *3/*3.;in healthy individuals 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs41412545;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE, METHOTREXATE;ATIC;rs2177735;AA;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AG + GG.;in people with Hematopoietic stem cell transplantation
;LEVETIRACETAM;HLA-A;HLA-A*11:01;*11:01;Toxicity;increased  risk of Side Effect:adverse events;HLA-A *11:01 is associated with increased risk of adverse events due to levetiracetam in people with Epilepsy.;in people with Disease:Epilepsy
;ALLOPURINOL;HLA-DRB1;HLA-DRB1*03:01;*03:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs56022120;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;G;Dosage, Metabolism/PK;increased   PK:glucuronidation;Allele G is associated with increased glucuronidation of valproic acid.; 
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;G;Dosage, Metabolism/PK;increased   PK:glucuronidation;Allele G is associated with increased glucuronidation of valproic acid.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs138602176;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-A *02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.; 
;NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-DRB1 *01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;MED12L, P2RY12;rs5853517;T/del;Efficacy;decreased  Efficacy:platelet aggregation;Genotype T/del is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype del/del.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;increased   Efficacy:platelet reactivity;CYP2C19 *2/*2 is associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2.; 
;PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-A *24:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.; 
;EXEMESTANE;;rs16964189;TT;Toxicity;Side Effect:a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients;Genotype TT is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs78428806;A;Toxicity;decreased risk of Side Effect:Neutropenia;Allele A is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;increased  likelihood of Disease:Inflammation;CYP2C9 *2 is associated with increased likelihood of Inflammation when treated with aspirin, clopidogrel and prasugrel in people with Tobacco Use Disorder as compared to CYP2C9 *1.;in people with Disease:Tobacco Use Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;increased   Efficacy:time to achieve stable dose;CYP2C9 *2 + *3 are associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 *1/*1.; 
;FLUOROURACIL;DPYD;DPYD deficiency;;Toxicity;increased  risk of Side Effect:Drug Toxicity;DPYD deficiency is associated with increased risk of Drug Toxicity when treated with fluorouracil.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2 + *3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ANTIPSYCHOTICS;INSIG2;rs11123469;CC;Efficacy;increased  likelihood of Disease:Metabolic Syndrome;Genotype CC is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:adverse cardiovascular events;CYP2C19 *2 is associated with increased risk of adverse cardiovascular events when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;HLA-A*33:01;*33:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-A *33:01 is associated with increased risk of drug-induced liver injury when treated with fenofibrate, sertraline, terbinafine or ticlopidine.; 
;CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;ABCB1;rs2032582;T;Efficacy;Efficacy:drug-resistant phenotype;Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.;in people with Disease:Epilepsy
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;Efficacy;increased   Efficacy:progression-free survival;Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype 33.;in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;Efficacy;Efficacy:time to therapeutic inr;CYP4F2 *3 is associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to CYP4F2 *1.;in people with Disease:Atrial Fibrillation
;ASPIRIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased  risk of Side Effect:Gastritis;CYP2C9 *1/*3 is associated with increased risk of Gastritis when treated with aspirin in people with Cardiovascular Diseases as compared to CYP2C9 *1/*1.;in people with Disease:Cardiovascular Disease
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.;in people with Disease:Neoplasms
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;Metabolism/PK;increased   PK:plasma metoprolol concentrations;CYP2D6 *1/*4 + *4/*4 are associated with increased plasma metoprolol concentrations when treated with metoprolol as compared to CYP2D6 *1/*1.; 
;FLUOROURACIL;DPYD;DPYD deficiency;;Toxicity;increased  risk of Side Effect:Neutropenia;DPYD deficiency is associated with increased risk of Neutropenia when treated with fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Other;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV as compared to UGT1A1 *1.;in people with Disease:HIV infectious disease
;;ACE2;rs2285666;C;Other;increased  severity of Other:COVID-19;Allele C is associated with increased severity of COVID-19 as compared to allele T.; 
;"""ACE INHIBITORS, PLAIN"", ""BETA BLOCKING AGENTS"", ""CALCIUM CHANNEL BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;rs1799752;del;Efficacy;increased   Efficacy:mortality;Allele del is associated with increased mortality when treated with Ace Inhibitors, Plain, Beta Blocking Agents, calcium channel blockers, digoxin or diuretics in people with Heart Failure as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.;in people with Disease:Heart Failure
;IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;Other;decreased  Side Effect:Cystic fibrosis pulmonary exacerbation;Genotype del/del is associated with decreased cystic fibrosis pulmonary exacerbation when treated with ivacaftor and tezacaftor in people with Cystic Fibrosis.;in people with Disease:Cystic Fibrosis
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;Toxicity;increased  risk of Side Effect:severe leukopenia;TPMT *1/*3C is associated with increased risk of severe leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*1;Metabolism/PK;decreased  PK:metabolic ratios of desipamine;CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4/*4 + *4/*5.;in healthy individuals 
;PAMAQUINE;G6PD;G6PD deficiency;;Toxicity;Disease:Hemolysis;G6PD deficiency is associated with Hemolysis when treated with pamaquine in G6PD deficient mice.;in G6PD deficient mice
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;Efficacy, Other;increased   Other:heart rate (HR) and diastolic blood pressure (DBP) reductions during early titration;CYP2D6 *1/*4 + *4/*4 are associated with increased heart rate (HR) and diastolic blood pressure (DBP) reductions during early titration when treated with metoprolol as compared to CYP2D6 *1/*1.; 
;PRIMAQUINE;G6PD;G6PD deficiency;;Toxicity;Disease:Hemolysis;G6PD deficiency is associated with Hemolysis when treated with primaquine in G6PD deficient mice.;in G6PD deficient mice
;ITRACONAZOLE, KETOCONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Other, Metabolism/PK;decreased severity of Other:inhibition of CYP3A-catalyzed metabolism of midazolam or testosterone;CYP3A5 *1/*1 + *1/*3 are associated with decreased severity of inhibition of CYP3A-catalyzed metabolism of midazolam or testosterone when treated with itraconazole or ketoconazole in Human Liver Microsomes as compared to CYP3A5 *3/*3.;in Human Liver Microsomes
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:stent thrombosis;CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Disease
;HMG COA REDUCTASE INHIBITORS;;rs3764261;A;Efficacy;decreased  Efficacy:protection against myocardial infarction;Allele A is associated with decreased protection against myocardial infarction when treated with hmg coa reductase inhibitors.; 
;CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;Toxicity;increased  likelihood of Side Effect:Diarrhea, Side Effect:Drug Toxicity, Side Effect:Hand-foot syndrome;Allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 is associated with increased likelihood of Diarrhea, Drug Toxicity or hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased  risk of Efficacy:on-treatment platelet activity;CYP2C19 *2 + *3 are associated with increased risk of on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Disease
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Efficacy;decreased  Side Effect:time below therapeutic range;CYP2C9 *2 + *3 are associated with decreased time below therapeutic range when treated with phenprocoumon as compared to CYP2C9 *1/*1.; 
;OSIMERTINIB;CYP2A6;rs28399433;CC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;in people with Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;CYP2C19 *3 is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;AMITRIPTYLINE, FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *2/*2xN;Toxicity;increased  likelihood of Side Effect:Discontinuation;CYP2D6 *1/*1xN + *2/*2xN are associated with increased likelihood of discontinuation when treated with amitriptyline or fluoxetine in people with Depressive Disorder, Major.;in people with Disease:Major Depressive Disorder
;PAZOPANIB, PEMETREXED;VEGFA;rs833061;CC + CT;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes CC + CT is associated with increased severity of Neutropenia when treated with pazopanib and pemetrexed in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *3/*3 + *1/*3 are associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PENICILLIN G, PENICILLIN V;HLA-B;HLA-B*55:01;*55:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-B *55:01 is associated with increased risk of Drug Hypersensitivity due to penicillin g or penicillin v.; 
;ETHANOL;GHSR;rs2948694;AG;Other;Other:weight;Genotype AG is associated with weight when exposed to ethanol.; 
;OPIOIDS;OPRM1;rs495491;AG + GG;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.;in men 
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;;increased   Other:cigarettes per day;CYP2A6 *46/*46 is associated with increased cigarettes per day due to nicotine as compared to CYP2A6 *1/*1.; 
;OPIOIDS;OPRM1;rs10457090;AA + AG;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Genotypes AA + AG are associated with decreased risk of Opioid-Related Disorders due to opioids in men as compared to genotype GG.;in men 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased   PK:steady state concentration per dosage;CYP2C9 *1/*3 is associated with increased steady state concentration per dosage when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.;in Disease:Epilepsy
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01/*58:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.;in people with Disease:Arthritis, Gouty
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.;in Disease:Epilepsy
;CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;Efficacy;Efficacy:non-response;Allele A is associated with non-response when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.;in people with Disease:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*2;*2;Efficacy;Efficacy:shorter time to the first INR of more than 4;CYP2C9 *2 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.; 
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;rs1935349;T;Toxicity;increased  risk of Disease:Myalgia;Allele T is associated with increased risk of Myalgia unspecified when treated with atorvastatin, pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele C.;in people with Disease:Hypercholesterolemia
;METHOTREXATE;TYMS;rs45445694;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC is associated with increased risk of Drug Toxicity when exposed to methotrexate in people with Psoriasis.;in people with Disease:Psoriasis
;NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*18;Toxicity, Metabolism/PK;increased  likelihood of PK:elevated plasma concentrations;CYP2B6 *6/*18 is associated with increased likelihood of elevated plasma concentrations when treated with nevirapine in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;DOCETAXEL, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;Efficacy;decreased likelihood of Efficacy:efficacy;CYP2A6 *4/*4 is associated with decreased likelihood of efficacy when treated with docetaxel and tegafur in people with Stomach Neoplasms as compared to CYP2A6 *1/*1.;in people with Disease:Stomach Neoplasms
;CISPLATIN;ERCC2;rs1799793;T;Efficacy;increased   Efficacy:overall survival and progression-free survival;Allele T is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C.;in people with Disease:Neoplasm of esophagus
;CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;Toxicity;decreased likelihood of Disease:Stevens-Johnson Syndrome;HLA-B *40:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;COCAINE;SLC6A3;rs3836790;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;Toxicity;increased  risk of Disease:Death;Genotype CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to genotypes CACATACCATGCAACATACACACTCAGACA/del + del/del.;in people with Disease:Cocaine dependence
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Dosage;Efficacy:lower warfarin dose requirement;CYP2C9 *2 is associated with lower warfarin dose requirement when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.;in people with Disease:Epilepsy
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI);CYP2C19 *2 is associated with increased risk of stent thrombosis in Taiwanese patients receiving clopidogrel after percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.; 
;PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;Toxicity;increased  risk of Side Effect:Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome;HLA-DRB1 *16:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.;in Disease:Epilepsy
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*1/*4;Metabolism/PK;increased   PK:paroxetine serum concentrations (Cmin);CYP2D6 *1/*4 is associated with increased paroxetine serum concentrations (Cmin) when treated with paroxetine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*41.;in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased  likelihood of Side Effect:diphenylhydantoin-induced skin rash;CYP2C9 *1/*3 is associated with increased likelihood of diphenylhydantoin-induced skin rash when exposed to phenytoin in neurological patients as compared to CYP2C9 *1/*1.;in Side Effect:neurological patients
;IBUPROFEN;CYP2C9;CYP2C9*3;*3;Efficacy;increased   Efficacy:duration of inhibition of prostanoids;CYP2C9 *3 is associated with increased duration of inhibition of prostanoids when treated with ibuprofen in healthy individuals as compared to CYP2C9 *1.;in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;decreased  PK:plasma concentration;CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *2/*2.;in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;increased   PK:the maximal elimination rate (Vmax);CYP2C9 *1/*1 is associated with increased the maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*3.;in Disease:Epilepsy
;ACETAMINOPHEN;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;Metabolism/PK;increased   PK:elimination rate;CYP2E1 *1/*5B is associated with increased elimination rate of acetaminophen in people with Liver Diseases, Alcoholic as compared to CYP2E1 *1/*1.;in people with Disease:Alcoholic Liver Diseases
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased   PK:plasma methylmercaptopurine nucleotides levels;TPMT *1/*3A is associated with increased plasma methylmercaptopurine nucleotides levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*3C.;in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Dosage;decreased  Other:warfarin dose in Japanese patients;CYP2C9 *1/*3 + *3/*3 are associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage, Efficacy;Efficacy:decreased warfarin dose and increased  risk of over-anticoagulation;CYP2C9 *2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased   Efficacy:ADP-induced maximum platelet aggregation;CYP2C19 *1/*2 is associated with increased ADP-induced maximum platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*4;*1/*3 + *1/*4;Dosage;decreased  Other:warfarin dose;CYP2C9 *1/*3 + *1/*4 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.; 
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;MERCAPTOPURINE;CYP2A7;rs73032311;C;Toxicity;increased  risk of Side Effect:Leukopenia;Allele C is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.;in children with Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;decreased  Efficacy:response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke;CYP2C19 *1/*2 + *2/*2 are associated with decreased response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;BUPROPION;CYP2B6;CYP2B6*18;*18;Metabolism/PK;decreased  PK:hydroxybupropion concentrations;CYP2B6 *18 is associated with decreased hydroxybupropion concentrations when exposed to bupropion in healthy individuals.;in healthy individuals 
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;decreased  PK:plasma concentration;CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*2.;in healthy individuals 
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;Metabolism/PK;decreased  PK:plasma concentration;CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*3.;in healthy individuals 
;ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:cutaneous reactions;HLA-B *15:02 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.;in Disease:Epilepsy
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;Metabolism/PK;increased   PK:mean amitriptyline concentrations corrected for dose and weight;CYP2C19 *2/*3 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome;HLA-B *13:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.;in Disease:Epilepsy
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Toxicity;increased  risk of Side Effect:stent thrombosis;CYP2C19 *3 is associated with increased risk of stent thrombosis when treated with clopidogrel as compared to CYP2C19 *1.; 
;;NAT1;NAT1*10, NAT1*11A;*10/*11A;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *10/*11A is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased  Other:warfarin dose;CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;;NAT1;NAT1*4, NAT1*10;*10/*4;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *10/*4 is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;GSTT1 null;;Toxicity;increased  likelihood of Disease:Toxic liver disease;GSTT1 null is associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;*5;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype *5 (assigned as slow acetylator phenotype) is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Disease:Tuberculosis
;PACLITAXEL;CYP2C8;CYP2C8*3;*3;Metabolism/PK;decreased  PK:clerance of paclitaxel;CYP2C8 *3 is associated with decreased clerance of paclitaxel when treated with paclitaxel in women with Ovarian Neoplasms as compared to CYP2C8 *1A.;in women with Disease:Ovarian Neoplasms
;BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6;Metabolism/PK;decreased  PK:hydroxybupropion concentrations and hydroxybupropion/bupropion ratio;CYP2B6 *6 is associated with decreased hydroxybupropion concentrations and hydroxybupropion/bupropion ratio when exposed to bupropion in healthy individuals as compared to CYP2B6 *1/*1.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Efficacy;Efficacy:ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention;CYP2C19 *2 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.; 
;IRINOTECAN, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;Toxicity;decreased risk of Disease:Asthenia;Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with decreased risk of Asthenia when treated with irinotecan and raltitrexed in people with Colorectal Neoplasms as compared to genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;Efficacy;Efficacy:ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention;CYP2C19 *3 is associated with ADP-induced maximum platelet aggregation (MPA) in clopidogrel-treated patients undergoing pe rcutaneous coronary intervention when treated with clopidogrel as compared to CYP2C19 *1.; 
;TEMSIROLIMUS;NR1I2;rs6785049;AG + GG;Toxicity;decreased likelihood of Side Effect:adverse events;Genotypes AG + GG is associated with decreased likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to genotype AA.;in people with Disease:Urinary Bladder Neoplasms
;TACROLIMUS;CYP3A4;rs2242480;C/C;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;Genotype C/C is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes C/T + T/T.;in people with Disease:Kidney Transplantation
;;NAT1;NAT1*3, NAT1*11B;*11B/*3;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *11B/*3 is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;;NAT1;NAT1*10;*10/*10;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *10/*10 is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine in Epilepsy.;in Disease:Epilepsy
;CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*3;*3;Toxicity;increased  risk of Side Effect:Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors;CYP2C8 *3 is associated with increased risk of Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors when treated with Calcineurin inhibitors, cyclosporine or tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1A.;in people with Disease:Kidney Transplantation
;DAUNORUBICIN;NRP2;rs10932125;C;Dosage, Metabolism/PK;increased   PK:IC50;Allele C is associated with increased IC50 of daunorubicin as compared to allele G.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;Toxicity, Metabolism/PK;decreased risk of Disease:Thrombocytopenia;Genotype CCT/CCT is associated with decreased risk of Thrombocytopenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.;in people with Disease:Ovarian Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;Toxicity, Metabolism/PK;decreased risk of Disease:Anemia;Genotype CCT/CCT is associated with decreased risk of Anemia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.;in people with Disease:Ovarian Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;Toxicity, Metabolism/PK;decreased risk of Disease:Peripheral Nervous System Diseases;Genotype CCT/CCT is associated with decreased risk of Peripheral Nervous System Diseases when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CCT/DEL + DEL/DEL.;in people with Disease:Ovarian Neoplasms
;METOPROLOL;CYP2D6;rs5030655;del/del;Other;increased   PK:plasma concentrations of metoprolol;Genotype del/del is associated with increased plasma concentrations of metoprolol when treated with metoprolol.; 
;ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;;Efficacy:lack of remission and lack of response;Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with lack of remission and lack of response when treated with antidepressants in people with Depression.;in people with Disease:Depression
;ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;Toxicity;increased  risk of Side Effect:adverse drug reaction after the second switch in treatment;Genotype (CCCACCCGA)12/(CCCACCCGA)12 is associated with increased risk of adverse drug reaction after the second switch in treatment when treated with antidepressants in people with Depression.;in people with Disease:Depression
;VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs1105879;C;Metabolism/PK;increased   PK:glucuronidation;Allele C is associated with increased glucuronidation of valproic acid.; 
;NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity, Metabolism/PK;increased  likelihood of PK:elevated plasma concentrations;CYP2B6 *6/*6 is associated with increased likelihood of elevated plasma concentrations when treated with nevirapine in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;ISONIAZID, PYRIDOXAL PHOSPHATE;CYP2E1;CYP2E1*1A;*1A/*1A;Toxicity;increased  likelihood of Disease:Toxic liver disease;CYP2E1 *1A/*1A is associated with increased likelihood of Toxic liver disease when treated with isoniazid and pyridoxal phosphate in people with Tuberculosis.;in people with Disease:Tuberculosis
;ATENOLOL;ADRB1;rs1801253;CC;Efficacy;increased   Efficacy:reduction in blood pressure;Genotype CC is associated with increased reduction in blood pressure when treated with atenolol in healthy individuals as compared to genotype GG.;in healthy individuals 
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:amitriptyline/(E)-10- OH-AT ratio;CYP2D6 *4/*4 is associated with increased amitriptyline/(E)-10- OH-AT ratio when treated with amitriptyline as compared to CYP2D6 *1.; 
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:nortriptyline/(E)-10-OH-NT ratio;CYP2D6 *4/*4 is associated with increased nortriptyline/(E)-10-OH-NT ratio when treated with amitriptyline as compared to CYP2D6 *1.; 
;REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37/*37;Metabolism/PK;decreased  PK:repaglinide exposure (decreased AUC and increased  clearance);SLCO1B1 *37/*37 is associated with decreased repaglinide exposure (decreased AUC and increased clearance) when exposed to repaglinide in healthy individuals as compared to SLCO1B1 *1/*1 + *1/*37.;in healthy individuals 
;PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Side Effect:Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome;HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.;in Disease:Epilepsy
;BENZENE;NQO1;rs1800566;AA;Toxicity;increased  risk of Side Effect:hematotoxicity;Genotype AA is associated with increased risk of hematotoxicity when exposed to benzene.; 
;ATAZANAVIR, EFAVIRENZ;TPH2;rs4570625;TT;Toxicity;increased  severity of Side Effect:Depression;Genotype TT is associated with increased severity of Depression when treated with atazanavir or efavirenz in men with HIV infectious disease as compared to genotypes GG + GT.;in men with HIV infectious disease
;METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;Toxicity;increased  risk of Disease:Thrombocytopenia;Genotype TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes TGGCGCGTCCCGCCCAGGT/del + del/del.;in people with Disease:Acute lymphoblastic leukemia
;ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;EFAVIRENZ;CYP2B6;CYP2B6*1;*1;Efficacy, Metabolism/PK;decreased  PK:plasma concentration of efavirenz;CYP2B6 *1 is associated with decreased plasma concentration of efavirenz when treated with efavirenz in people with HIV.;in people with Disease:HIV infectious disease
;ANTITHYROID PREPARATIONS;HLA-B;HLA-B*08:01;*08:01;Toxicity;increased  likelihood of Disease:Agranulocytosis;HLA-B *08:01 is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations.; 
;TEGAFUR;CYP2A6;CYP2A6*1;*1;Other, Metabolism/PK;increased   PK:plasma fluorouracil;CYP2A6 *1 is associated with increased plasma fluorouracil when treated with tegafur in people with Neoplasms.;in people with Disease:Neoplasms
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;Toxicity;increased   Side Effect:adverse drug reactions;CYP2C9 *1/*2 + *1/*3 is associated with increased adverse drug reactions when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.;in Disease:Epilepsy
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;Toxicity;increased  risk of Disease:Neutropenia;UGT1A1 *6/*6 is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1 + *1/*6.;in people with Disease:Neoplasms
;CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;Toxicity;increased  risk of Side Effect:liver injury;CYP3A4 *1/*1 is associated with increased risk of liver injury when treated with cyclosporine in people with Kidney Transplantation as compared to CYP3A4 *1/*18 + *18/*18.;in people with Disease:Kidney Transplantation
;ANTIEPILEPTICS;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;decreased likelihood of Disease:Drug Resistance;CYP2C9 *1/*3 is associated with decreased likelihood of Drug Resistance when exposed to antiepileptics in people with Epilepsy as compared to CYP2C9 *1/*1.;in people with Disease:Epilepsy
;ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2/*2;Efficacy, Metabolism/PK;increased   PK:atorvastatin lactonization;UGT1A3 *2/*2 is associated with increased atorvastatin lactonization when exposed to atorvastatin in healthy individuals as compared to UGT1A3 *1/*1.;in healthy individuals 
;ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;Efficacy, Metabolism/PK;decreased  Efficacy:total and the low-density lipoprotein cholesterol maximum percent decreases from baseline;UGT1A3 *2 is associated with decreased total and the low-density lipoprotein cholesterol maximum percent decreases from baseline when exposed to atorvastatin in healthy individuals as compared to UGT1A3 *1.;in healthy individuals 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;DOXEPIN;CYP2C9;CYP2C9*3;*3/*3;Metabolism/PK;decreased  PK:median oral clearance of doxepin;CYP2C9 *3/*3 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;decreased  PK:oral clearance (CL/F) of omeprazole racemate, 5-hydroxyomeprazole, R-omeprazole and S-omeprazole;CYP2C19 *1/*2 + *1/*3 is associated with decreased oral clearance (CL/F) of omeprazole racemate, 5-hydroxyomeprazole, R-omeprazole and S-omeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *17/*17.;in healthy individuals 
;TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;Other;increased   Other:hospital stay;CYP2C19 *2/*2 is associated with increased hospital stay when treated with tacrolimus in people with Kidney Transplantation as compared to CYP2C19 *1/*1 + *1/*2.;in people with Disease:Kidney Transplantation
;MERCAPTOPURINE;COMT;rs4680;A;Toxicity;increased  risk of Side Effect:Toxic liver disease;Allele A is associated with increased risk of Toxic liver disease when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia
;ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;Efficacy;decreased  Efficacy:mean absolute difference in HbA1c;CYP2C8 *3 is associated with decreased mean absolute difference in HbA1c when treated with rosiglitazone in people with Diabetes Mellitus, Type 2.;in people with Disease:Diabetes Mellitus, Type 2
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2xN;*1/*2xN;Metabolism/PK;increased   PK:maximum plasma concentration of 10-hydroxy nortriptyline;CYP2D6 *1/*2xN is associated with increased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;Metabolism/PK;increased   PK:relative bioavailability of pravastatin;SLCO1B1 *15 is associated with increased relative bioavailability of pravastatin when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1.;in healthy individuals 
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;increased  likelihood of Disease:Drug Hypersensitivity;HLA-B *57:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;Efficacy;decreased  Efficacy:antiplatelet response and reduced clopidogrel active metabolite formation;CYP2C19 *1/*3 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Metabolism/PK;increased   PK:mean amitriptyline concentrations corrected for dose and weight;CYP2C19 *2/*2 is associated with increased mean amitriptyline concentrations corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;decreased  Efficacy:clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI);CYP2C19 *3 is associated with decreased clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;decreased  Efficacy:clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI);CYP2C19 *2 is associated with decreased clopidogrel response in Chinese patients undergoing percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1.; 
;;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Other;risk of Disease:Peptic Ulcer Disease;CYP2C19 *17 is associated with risk of Peptic Ulcer as compared to CYP2C19 *1.; 
;CAFFEINE;ADORA2A;rs5751876;TT;Other;increased   Side Effect:anxiety;Genotype TT is associated with increased anxiety when exposed to caffeine in healthy individuals as compared to genotypes CC + CT.;in healthy individuals 
;METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;Efficacy;increased  severity of Disease:Rheumatoid arthritis;Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)3 is associated with increased severity of Arthritis, Rheumatoid when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2.;in people with Disease:Rheumatoid arthritis
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Toxicity;increased  risk of Side Effect:composite ischemic events;CYP2C19 *3 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.;in patients that had undergone coronary angiography or had an uneventful PCI
;EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;Toxicity, Metabolism/PK;increased   PK:plasma concentration;CYP2B6 *6/*6 is associated with increased plasma concentration when treated with efavirenz in people with HIV.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:composite ischemic events;CYP2C19 *2 is associated with increased risk of composite ischemic events when treated with clopidogrel in patients that had undergone coronary angiography or had an uneventful PCI as compared to CYP2C19 *1.;in patients that had undergone coronary angiography or had an uneventful PCI
;ATORVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased   Side Effect:serum creatine kinase levels (increased  risk of myalgia and greater degree of muscle damage);CYP3A5 *3/*3 is associated with increased serum creatine kinase levels (increased risk of myalgia and greater degree of muscle damage) when treated with atorvastatin as compared to CYP3A5 *1/*3.; 
;NEVIRAPINE;ABCC10;rs2125739;CC;Efficacy, Metabolism/PK;increased  likelihood of PK:lower nevirapine plasma concentrations;Genotype CC is associated with increased likelihood of lower nevirapine plasma concentrations when treated with nevirapine in people with HIV Infections as compared to genotypes CT + TT.;in people with Disease:HIV infectious disease
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:carbamazepine-induced hypersensitivity;HLA-A *31:01 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN);HLA-B *15:02 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.; 
;METFORMIN;SLC22A1;rs36056065;GTAAGTTG;Toxicity, Metabolism/PK;Side Effect:gastrointestinal side effects;Allele GTAAGTTG is associated with gastrointestinal side effects when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele del.;in people with Disease:Diabetes Mellitus, Type 2
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*1A;Toxicity;increased  likelihood of Disease:Toxic liver disease;CYP2E1 *1A/*1A is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Carbamazepine-induced hypersensitivity syndrome;HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.;in children 
;CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;Efficacy;Efficacy:enhanced response to clopidogrel (as measured by inhibition of ADP-induced platelet aggregation);CYP2C19 *17 is associated with enhanced response to clopidogrel (as measured by inhibition of ADP-induced platelet aggregation) when treated with clopidogrel as compared to CYP2C19 *1.; 
;PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Toxicity;increased  risk of Side Effect:phenytoin toxicity;CYP2C9 *1/*3 is associated with increased risk of phenytoin toxicity when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.;in Disease:Epilepsy
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;decreased  Efficacy:antiplatelet response and reduced clopidogrel active metabolite formation;CYP2C19 *1/*2 is associated with decreased antiplatelet response and reduced clopidogrel active metabolite formation when exposed to clopidogrel in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;;NAT1;NAT1*10, NAT1*11B;*10/*11B;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *10/*11B is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Metabolism/PK;decreased  PK:oral clearance (CL/F) of omeprazole racemate, 5-hydroxyomeprazole, R-omeprazole and S-omeprazole;CYP2C19 *1/*2 + *1/*3 is associated with decreased oral clearance (CL/F) of omeprazole racemate, 5-hydroxyomeprazole, R-omeprazole and S-omeprazole when treated with efavirenz and omeprazole in healthy individuals as compared to CYP2C19 *1/*1 + *1/*17.;in healthy individuals 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*02:01;*02:01;Toxicity;increased  likelihood of Disease:Toxic liver disease;HLA-DQB1 *02:01 is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;;NAT1;NAT1*4, NAT1*11A;*11A/*4;Other;increased  risk of Other:adenomatous and hyperplastic polyps;NAT1 *11A/*4 is associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA.;in people with a NAT1 rapid acetylator genotype and high meat consumption and rs2066853 genotype AA or GA
;WARFARIN;CYP2C9;CYP2C9*3;*3;Efficacy;Efficacy:shorter time to the first INR of more than 4;CYP2C9 *3 is associated with shorter time to the first INR of more than 4 when treated with warfarin as compared to CYP2C9 *1.; 
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;Toxicity;increased   PK:plasma thioguanine nucleotides metabolites;TPMT *1/*3A is associated with increased plasma thioguanine nucleotides metabolites when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*3C.;in children with Disease:Acute lymphoblastic leukemia
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*1/*15;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC) and Cmax;SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *37/*37.;in healthy individuals 
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC) and Cmax;SLCO1B1 *1/*15 is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.;in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Dosage;decreased  Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy;CYP2C9 *1/*13 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Dosage, Toxicity;increased  risk of Other:complications;CYP2C9 *2 + *3 are associated with increased risk of complications due to phenprocoumon as compared to CYP2C9 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;Efficacy;increased   Efficacy:ADP-induced maximum platelet aggregation;CYP2C19 *1/*3 is associated with increased ADP-induced maximum platelet aggregation when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;METOPROLOL;CYP2D6;CYP2D6*4;*4;Dosage, Toxicity;increased  risk of Disease:Bradycardia;CYP2D6 *4 is associated with increased risk of Bradycardia due to metoprolol as compared to CYP2D6 *1.; 
;PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC);SLCO1B1 *15/*15 is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to SLCO1B1 *1/*1.;in healthy individuals 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;Toxicity;decreased severity of Disease:Drug Toxicity;GSTM1 null is associated with decreased severity of Drug Toxicity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to GSTM1 non-null.;in people with Disease:Tuberculosis
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Efficacy;increased  risk of Efficacy:High on-treatment platelet reactivity;CYP2C19 *2 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.;in patients undergoing PCI
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;Efficacy;increased  risk of Efficacy:High on-treatment platelet reactivity;CYP2C19 *3 is associated with increased risk of High on-treatment platelet reactivity when treated with aspirin and clopidogrel in patients undergoing PCI as compared to CYP2C19 *1/*1.;in patients undergoing PCI
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose after adjustment for VKORC1*1173;CYP2C9 *3 is associated with decreased warfarin dose after adjustment for VKORC1*1173 when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *1/*3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1/*1.; 
;DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;Metabolism/PK;decreased  PK:median oral clearance of doxepin;CYP2D6 *3/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;HALOPERIDOL;COMT;rs4680;AG;Toxicity;increased  likelihood of Side Effect:extrapyramidal symptoms;Genotype AG is associated with increased likelihood of extrapyramidal symptoms when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG.;in men with Disease:Schizophrenia
;ATORVASTATIN;CYP2D6;CYP2D6*4;*4;Toxicity;increased  likelihood of Side Effect:muscle effects;CYP2D6 *4 is associated with increased likelihood of muscle effects when treated with atorvastatin.; 
;DOXEPIN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;Metabolism/PK;decreased  PK:median oral clearance of doxepin;CYP2D6 *4/*5 is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;Efficacy;Efficacy:delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5;CYP2C9 *1/*13 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage, Efficacy;Efficacy:decreased warfarin dose and increased  risk of over-anticoagulation;CYP2C9 *3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased  Other:warfarin dose;CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased  Other:warfarin dose;CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;Dosage;decreased  Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy;CYP2C9 *1/*14 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased  Other:warfarin dose;CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;increased   Efficacy:mean INR values in patients with heart valve replacement;CYP2C9 *1/*3 is associated with increased mean INR values in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CLOPIDOGREL;CYP2B6;CYP2B6*5;*5;Efficacy;Efficacy:high on-treatment platelet reactivity in CYP2C19*1/*1 carriers;CYP2B6 *5 is associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to CYP2B6 *1.;in patients undergoing percutaneous coronary intervention
;VENLAFAXINE;CYP2D6;CYP2D6*10;*10/*10;Metabolism/PK;increased   PK:Cmax and AUC of venlafaxine;CYP2D6 *10/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;Efficacy;increased   Efficacy:mean INR value;CYP2C9 *2/*3 is associated with increased mean INR value when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*2;*2;Dosage;decreased  Other:warfarin dose;CYP2C9 *2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;WARFARIN;CYP2C9;CYP2C9*3;*3;Dosage;decreased  Other:warfarin dose;CYP2C9 *3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 *1.; 
;VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;Metabolism/PK;increased   PK:Cmax and AUC of venlafaxine;CYP2D6 *1/*10 is associated with increased Cmax and AUC of venlafaxine when treated with venlafaxine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;Efficacy;Efficacy:delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5;CYP2C9 *1/*14 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Efficacy;Efficacy:delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5;CYP2C9 *1/*3 is associated with delayed time to reach stable dose and and tended to have high risk for the first INR greater than 3.5 when treated with warfarin as compared to CYP2C9 *1/*1.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *3 is associated with increased risk of Hemorrhage due to phenprocoumon as compared to CYP2C9 *1.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;Efficacy;increased  likelihood of Efficacy:achieving a stable dose;CYP2C9 *3 is associated with increased likelihood of achieving a stable dose of phenprocoumon as compared to CYP2C9 *1.; 
;PHENPROCOUMON;CYP2C9;CYP2C9*2;*2;Efficacy;increased  likelihood of Efficacy:achieving a stable dose;CYP2C9 *2 is associated with increased likelihood of achieving a stable dose of phenprocoumon as compared to CYP2C9 *1.; 
;ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*10;Efficacy;increased   Efficacy:frequency of remitters;CYP2D6 *4/*10 is associated with increased frequency of remitters when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased  Other:intragastric pH;CYP2C19 *1/*1 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;in healthy individuals 
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;decreased  Other:intragastric pH;CYP2C19 *1/*2 + *1/*3 is associated with decreased intragastric pH when treated with lansoprazole in healthy individuals as compared to CYP2C19 *2/*2 + *2/*3 + *3/*3.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Efficacy:On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI);CYP2C19 *2 is associated with increased On-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Metabolism/PK;decreased  PK:tramadol clearance in Chinese volunteers;CYP2D6 *10/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy, Metabolism/PK;decreased  Efficacy:tramadol metabolism and response;CYP2D6 *4/*4 is associated with decreased tramadol metabolism and response when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased   Other:meal-stimulated plasma gastrin concentrations;CYP2C19 *1/*2 is associated with increased meal-stimulated plasma gastrin concentrations when treated with omeprazole in people with Ulcer as compared to CYP2C19 *1/*1.;in people with Disease:Ulcer
;PAROXETINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;Metabolism/PK;increased   PK:paroxetine plasma concentrations increased  during the course of pregnancy;CYP2D6 *4/*4 + *3/*4 is associated with increased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.;in women 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Dosage, Efficacy;decreased  Efficacy:metabolism and decreased response to tramadol;CYP2D6 *4/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3 + *3/*3;Efficacy;decreased  Efficacy:response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke;CYP2C19 *1/*3 + *3/*3 are associated with decreased response to clopidogrel and poorer outcomes in Chinese patients with acute ischemic stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;TAMOXIFEN;CYP2D6;CYP2D6*6, CYP2D6*7;*6/*7;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *6/*7 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;Efficacy;increased   Efficacy:frequency of remitters;CYP2D6 *5/*10 is associated with increased frequency of remitters when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*6;*3/*6;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *3/*6 is associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;Dosage, Efficacy;decreased  Efficacy:metabolism and decreased response to tramadol;CYP2D6 *3/*4 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.; 
;CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Efficacy:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine;CYP2C19 *2 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Metabolism/PK;increased   PK:mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication;CYP2D6 *4 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;Metabolism/PK;PK:mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio;CYP2D6 *4/*4 + *3/*4 is associated with mean plasma concentration of oxymorphone and lower mean oxymorphone/oxycodone ratio when treated with oxycodone as compared to CYP2D6 *1/*1.; 
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*41;*1/*1 + *1/*41;Metabolism/PK;decreased  PK:paroxetine plasma concentrations increased  during the course of pregnancy;CYP2D6 *1/*1 + *1/*41 is associated with decreased paroxetine plasma concentrations increased during the course of pregnancy when treated with paroxetine in women.;in women 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;Metabolism/PK;increased   PK:mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication;CYP2D6 *5/*10 is associated with increased mean nortriptyline concentrations and nortriptyline concentrations per unit dose of the medication when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.;in people with Disease:Major Depressive Disorder
;DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*1;Metabolism/PK;decreased  PK:metabolic ratios of desipamine;CYP2D6 *1/*1 is associated with decreased metabolic ratios of desipamine when exposed to desipramine in healthy individuals as compared to CYP2D6 *4 + *3.;in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*2/*10;Metabolism/PK;decreased  PK:tramadol clearance in Chinese volunteers;CYP2D6 *2/*10 is associated with decreased tramadol clearance in Chinese volunteers when treated with tramadol in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;Dosage, Efficacy;decreased  Efficacy:metabolism and decreased response to tramadol;CYP2D6 *3/*5 is associated with decreased metabolism and decreased response to tramadol when treated with tramadol as compared to CYP2D6 *1.; 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5;*5;Metabolism/PK;increased   PK:nortriptyline concentrations corrected for dose and weight;CYP2D6 *5 is associated with increased nortriptyline concentrations corrected for dose and weight when treated with nortriptyline in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 + *1/*2.;in people with Disease:Major Depressive Disorder
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5;Metabolism/PK;increased   PK:paroxetine plasma concentration at an administered dose of 30mg/day;CYP2D6 *1/*10 + *1/*5 is associated with increased paroxetine plasma concentration at an administered dose of 30mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;COTININE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;*1/*1;Metabolism/PK;PK:shorter continin half-life;CYP2A6 *1/*1 is associated with shorter continin half-life when exposed to cotinine in children as compared to CYP2A6 *17/*17 + *1/*17 + *1/*2 + *1/*20 + *1/*9 + *9/*9.;in children 
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;decreased  PK:clearance of S(+) mirtazapine;CYP2D6 *4/*4 is associated with decreased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;Metabolism/PK;increased   PK:paroxetine levels;CYP2D6 *1/*4 is associated with increased paroxetine levels when treated with paroxetine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1.;in people with Disease:Obsessive-Compulsive Disorder
;CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;increased   Efficacy:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine;CYP2C19 *3 is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;decreased  PK:oral clearance of citalopram;CYP2C19 *2/*2 + *2/*3 is associated with decreased oral clearance of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.;in healthy individuals 
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;Metabolism/PK;increased   PK: plasma paroxetine concentrations at administered dose of 10mg/day;CYP2D6 *10/*10 + *1/*10 are associated with increased plasma paroxetine concentrations at administered dose of 10mg/day when treated with paroxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;increased   PK:total clearance of racemic mirtazapine;CYP2D6 *1/*1xN is associated with increased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*36;*36;Metabolism/PK;decreased  PK:codeine metabolism and morphine and glucuronides formation;CYP2D6 *36 is associated with decreased codeine metabolism and morphine and glucuronides formation when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;Metabolism/PK;increased   PK:plasma level of morphine;CYP2D6 *1/*1 + *1/*4 is associated with increased plasma level of morphine when treated with codeine in healthy individuals as compared to CYP2D6 *3/*4 + *4/*4 + *5/*5.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;increased   Efficacy:on-treatment platelet aggregation;CYP2C19 *1/*2 + *2/*2 is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of over-anticoagulation when treated with warfarin.; 
;;UGT1A1;rs34946978;T;Other;increased  likelihood of Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome;Allele T is associated with increased likelihood of Gilbert's syndrome or Crigler-Najjar Syndrome as compared to allele C.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;Metabolism/PK;increased   PK:AUC, higher half-life and lower flurbiprofen clearance;CYP2C9 *1/*3 is associated with increased AUC, higher half-life and lower flurbiprofen clearance when treated with flurbiprofen in healthy individuals as compared to CYP2C9 *1/*1.;in healthy individuals 
;DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*4;*1/*4 + *4/*4;Metabolism/PK;increased   PK:diclofenac/5-hydroxydiclofenac urinary concentration ratio;CYP2C8 *1/*4 + *4/*4 is associated with increased diclofenac/5-hydroxydiclofenac urinary concentration ratio when exposed to diclofenac in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:major adverse cardiac and cerebrovascular events;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.;in people with Disease:Myocardial Infarction
;PYRIMIDINE ANALOGUES;MIR27A;rs895819;CC + CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CC + CT is associated with increased risk of Drug Toxicity when treated with Pyrimidine analogues in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:major adverse cardiac and cerebrovascular events;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1 + *1/*17 + *1/*2 + *1/*3 + *2/*17 + *3/*17.;in people with Disease:Myocardial Infarction
;CITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;Metabolism/PK;increased   PK:plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT);CYP2C19 poor metabolizer is associated with increased plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.;in people with Disease:Major Depressive Disorder
;TIMOLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;Metabolism/PK;increased   PK:exposure to timolol (higher area-under-curve, longer elimination half-lives );CYP2D6 *3/*3 + *3/*4 + *4/*4 + *5/*4 is associated with increased exposure to timolol (higher area-under-curve, longer elimination half-lives ) when exposed to timolol in healthy individuals as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.;in healthy individuals 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Disease:Epilepsy
;CLOPIDOGREL;PON1;rs662;C;Efficacy;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);Allele C is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele T.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Side Effect:total hemorrhage and major hemorrhage;CYP2C9 *2 is associated with increased risk of total hemorrhage and major hemorrhage when treated with warfarin as compared to CYP2C9 *1.; 
;TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3;Metabolism/PK;increased   PK:AUC and half-life time (t1/2);CYP2C9 *3 is associated with increased AUC and half-life time (t1/2) when exposed to tenoxicam in healthy individuals as compared to CYP2C9 *1 + *2.;in healthy individuals 
;IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;Toxicity;decreased  Side Effect:iNOS expression and fewer adverse events;CYP2C8 *1/*3 is associated with decreased iNOS expression and fewer adverse events when exposed to ibuprofen in healthy individuals as compared to CYP2C8 *1/*1.;in healthy individuals 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CLOPIDOGREL;P2RY12;rs2046934;A;Efficacy;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele G.; 
;ANTIEPILEPTICS;HLA-B;HLA-B*58:01;*58:01;Toxicity;decreased risk of Disease:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;ASPIRIN;HLA-DPB1;HLA-DPB1*03:01;*03:01;Toxicity;increased  risk of Side Effect:Asthma;HLA-DPB1 *03:01 is associated with increased risk of Asthma when treated with aspirin.; 
;SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;CC;Efficacy;increased   Efficacy:response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels);Genotype CC is associated with increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.;in people with Disease:Diabetes Mellitus, Type 2
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;LUMACAFTOR;CFTR;rs113993960;del/del;Toxicity;increased   Efficacy:change in sweat chloride;Genotype del/del is associated with increased change in sweat chloride when treated with lumacaftor in people with Cystic Fibrosis.;in people with Disease:Cystic Fibrosis
;CAFFEINE;CYP1A2;rs762551;AA;Toxicity;increased  likelihood of Disease:Abortion, Spontaneous;Genotype AA is associated with increased likelihood of Abortion, Spontaneous when exposed to caffeine in women as compared to genotypes AC + CC.;in women 
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *13:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.;in people with Disease:Leprosy
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;Dosage;decreased  Efficacy:acenocoumarol dose;CYP2C9 *2/*2 + *2/*3 + *3/*3 is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to CYP2C9 *1/*1.;in people with Disease:Atrial Fibrillation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Efficacy;increased   Efficacy:on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI);CYP2C19 *3 is associated with increased on-clopidogrel platelet aggregation (PA) and higher platelet reactivity index (PRI) in patients undergoing elective percutaneous coronary intervention (PCI) when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;Metabolism/PK;decreased  PK:plasma levels of morphine, M3G and M6G levels but not those of codeine;CYP2D6 *1/*10 + *10/*10 is associated with decreased plasma levels of morphine, M3G and M6G levels but not those of codeine when treated with codeine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;Toxicity;increased  risk of Disease:Transplant rejection;TPMT *1/*2 + *1/*3A + *1/*3C are associated with increased risk of transplant rejection when treated with azathioprine in heart transplantation as compared to TPMT *1/*1.;in Disease:Heart transplantation
;BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  risk of Disease:Drug-induced liver injury;CYP2C9 *2 is associated with increased risk of drug-induced liver injury when treated with bosentan as compared to CYP2C9 *1.; 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;Other;increased   Other:oroceccal transit time;CYP2D6 *1/*1 + *1/*4 is associated with increased oroceccal transit time when treated with codeine in healthy individuals.;in healthy individuals 
;;CYP1B1;rs1056836;CC + CG;;decreased  Efficacy:event-free survival, Efficacy:Overall survival;Genotypes CC + CG is associated with decreased event-free survival and overall survival in people with Esophageal Neoplasms as compared to genotype GG.;in people with Disease:Neoplasm of esophagus
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Toxicity;increased  risk of Side Effect:major adverse cardiac and cerebrovascular events;CYP2C19 *2/*2 is associated with increased risk of major adverse cardiac and cerebrovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;TETRABENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;Efficacy;Efficacy:less robust treatment response;CYP2D6 intermediate metabolizer is associated with less robust treatment response when treated with tetrabenazine as compared to CYP2D6 normal metabolizer.; 
;WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;Toxicity;decreased risk of Side Effect:Hemorrhage;CYP4F2 *3 is associated with decreased risk of Hemorrhage when treated with warfarin as compared to CYP4F2 *1.; 
;CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;Toxicity;increased  likelihood of Side Effect:side effects;SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to SLC6A4 L allele-rs25531T.;in people with Disease:Dementia
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;Metabolism/PK;decreased  PK:metabolic ratio CIT/DCIT values;CYP2C19 *1/*17 is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to CYP2C19 *1/*1.; 
;CLOPIDOGREL;PTGS1;rs1330344;T;Efficacy;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel as compared to allele C.; 
;CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Toxicity;increased   Side Effect:clomipramine-induced prolactin release;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased clomipramine-induced prolactin release when exposed to clomipramine in healthy individuals as compared to SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele).;in healthy individuals 
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Metabolism/PK;increased   PK:AUC of citalopram;CYP2C19 *1/*2 + *2/*2 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);Efficacy;increased   Efficacy:presentation in the non-reponder group;SLC6A4 HTTLPR short form (S allele) is associated with increased presentation in the non-reponder group when treated with paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;PHENOBARBITAL;CYP2C19;CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:severe cutaneous adverse drug reactions;CYP2C19 *2 is associated with increased risk of severe cutaneous adverse drug reactions when treated with phenobarbital in children as compared to CYP2C19 *1.;in children 
;OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Toxicity;increased  likelihood of Disease:Dizziness;TPMT *1/*3A + *1/*3C is associated with increased likelihood of Dizziness when exposed to olanzapine in healthy individuals as compared to TPMT *1/*1.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:ischaemic stroke;CYP2C19 *2 + *3 are associated with increased risk of ischaemic stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;Efficacy;increased   Efficacy:PRU;CYP2C19 *2/*2 is associated with increased PRU when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*2.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;Toxicity;increased  likelihood of Side Effect:major adverse cardiovascular events;CYP2C19 *2/*2 + *1/*2 is associated with increased likelihood of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*08:01;*07:02;Toxicity;decreased risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *07:02 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01.; 
;TRICHLOROETHYLENE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *13:01 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Toxicity;increased  risk of Side Effect:stent thrombosis;CYP2C19 *2 + *3 are associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy, Toxicity;increased  risk of Side Effect:adverse clinical events;CYP2C19 *2 + *3 are associated with increased risk of adverse clinical events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;Toxicity;severity of Side Effect:leukopenia;TPMT *3A/*3C is associated with severity of leukopenia when treated with azathioprine, cyclosporine and prednisone in people with Kidney Transplantation.;in people with Disease:Kidney Transplantation
;ALLOPURINOL;HLA-A;HLA-A*02:01;*02:01;Toxicity;decreased risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *02:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *3 is associated with increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 *1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Efficacy;increased  risk of Efficacy:cardiovascular event occurrence;CYP2C19 *2/*2 + *2/*3 is associated with increased risk of cardiovascular event occurrence when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 *1/*1.;in people with Disease:Myocardial Infarction
;ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-C *08:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.;in people with Disease:Hematologic Neoplasms
;IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;UGT1A7*3;*3;Toxicity;increased  likelihood of Disease:Vomiting;UGT1A7 *3 is associated with increased likelihood of Vomiting when treated with irinotecan, oxaliplatin and s 1 (combination) in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;Efficacy;increased  risk of Side Effect:stent thrombosis;CYP2C19 *1/*2 + *2/*2 is associated with increased risk of stent thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary interventions as compared to CYP2C19 *1/*1.;in people with percutaneous coronary interventions
;OSIMERTINIB;CYP2C9;rs1057910;CC;Toxicity;increased  likelihood of Side Effect:adverse events, Side Effect:Exanthema;Genotype CC is associated with increased likelihood of adverse events or Exanthema when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;in people with Non-Small Cell Lung Carcinoma
;CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);Efficacy;increased  likelihood of Efficacy:remission;SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).;in people with Disease:Major Depressive Disorder
;MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;CC;Toxicity;decreased risk of Disease:Leukopenia;Genotype CC is associated with decreased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CT.;in people with Disease:Kidney Transplantation
;ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.; 
;CLOZAPINE;HLA-DRB3;HLA-DRB3*02:02;*02:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DRB3 *02:02 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;MERCAPTOPURINE;TPMT;rs1142345;C;Toxicity;increased  risk of Side Effect:Leukopenia;Allele C is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.;in children with Acute lymphoblastic leukemia
;MYCOPHENOLATE MOFETIL;UGT2B7;rs7438135;G;Toxicity;increased  risk of Disease:Anemia;Allele G is associated with increased risk of Anemia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele A.;in people with Disease:Kidney Transplantation
;CLOZAPINE;HLA-C;HLA-C*07:01;*07:01;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-C *07:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;CLOZAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;Toxicity;decreased risk of Side Effect:Agranulocytosis;HLA-DRB1 *01:01 is associated with decreased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  risk of Side Effect:Pancreatitis;HLA-DRB1 *07:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.;in people with Disease:Inflammatory Bowel Diseases
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2 is associated with increased platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *39:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.; 
;METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  risk of Disease:Toxic Epidermal Necrolysis, Disease:Stevens-Johnson Syndrome;HLA-C *01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.; 
;CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *38:02 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.;in people with Disease:Graves Disease
;PLATINUM COMPOUNDS, PYRIMIDINE ANALOGUES;DPYD;rs1801265;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AG + GG is associated with increased likelihood of Drug Toxicity when treated with Platinum compounds null Pyrimidine analogues in people with Stomach Neoplasms as compared to genotype AA.;in people with Stomach Neoplasms
;CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;decreased  Efficacy:platelet reactivity;CYP2C19 *2 + *3 are associated with decreased platelet reactivity when treated with cilostazol and clopidogrel in healthy individuals as compared to CYP2C19 *1.;in healthy individuals 
;PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.;in people with Disease:Epilepsy
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;Efficacy;increased   Efficacy:time to achieve stable dose;CYP2C9 *3 is associated with increased time to achieve stable dose when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C9 *2 + *3 are associated with increased risk of Hemorrhage when treated with warfarin as compared to CYP2C9 *1/*1.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Exanthema, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.;in people with Disease:Bipolar Disorder, Disease:Epilepsy
;CAPECITABINE, FLUOROURACIL;DPYD;DPYD deficiency;;Toxicity;increased  risk of Side Effect:Neutropenia;DPYD deficiency is associated with increased risk of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;DOLASETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Efficacy;increased  likelihood of Side Effect:Vomiting;CYP2D6 *1/*1xN is associated with increased likelihood of Vomiting when treated with dolasetron in people with Postoperative Nausea and Vomiting.;in people with Disease:Postoperative Nausea and Vomiting
;CYCLOSPORINE, METHOTREXATE;NFATC2;rs6123048;AA;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype AG.;in people with Hematopoietic stem cell transplantation
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*4;*4;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;CYP2C8 *4 is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to CYP2C8 *1.;in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Efficacy;increased   Efficacy:Overall survival;CYP2C19 *1/*2 is associated with increased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1/*1.;in women with Disease:Breast Neoplasms
;ABACAVIR;HLA-B;HLA-B*57:01;*57:01;Toxicity;Side Effect:Drug Hypersensitivity;HLA-B *57:01 is associated with Drug Hypersensitivity when treated with abacavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;IFOSFAMIDE;ALDH1A1;rs3764435;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with ifosfamide in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes AC + CC.;in people with Soft Tissue Neoplasms, Sarcoma
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;Toxicity;decreased risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *17 is associated with decreased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.; 
;DAPSONE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *13:01 is associated with increased risk of severe cutaneous adverse reactions when treated with dapsone.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;CLOZAPINE;GSTT1;GSTT1 non-null, GSTT1 null;null/null;Toxicity;increased  risk of Side Effect:Neutropenia;GSTT1 null/null is associated with increased risk of Neutropenia when treated with clozapine as compared to GSTT1 non-null/non-null + non-null/null.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *3 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1.;in people with Disease:Coronary Artery Disease
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;Efficacy;increased  likelihood of Efficacy:achieving SVR in older patients with genotype 1b chronic hepatitis C;Genotype TT/TT is associated with increased likelihood of achieving SVR in older patients with genotype 1b chronic hepatitis C when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype TT/TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;del;Toxicity;increased  risk of Side Effect:Pancytopenia, Side Effect:Thrombocytopenia;Allele del is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele GGAGTC.;in people with Autoimmune Diseases, Inflammatory Bowel Diseases
;HMG COA REDUCTASE INHIBITORS;ADAMTS1;rs402007;CC;Efficacy;Efficacy:the most benefit from statin treatment in reducing the risk of myocardial infarction;Genotype CC is associated with the most benefit from statin treatment in reducing the risk of myocardial infarction when treated with hmg coa reductase inhibitors as compared to genotype GG.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-A *31:01 is associated with increased risk of drug-induced liver injury when treated with carbamazepine.; 
;NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;Toxicity;increased  severity of Other:Tobacco Use Disorder;CYP2B6 *1/*4 + *4/*4 is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to CYP2B6 *1/*1.; 
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*1;Toxicity;decreased risk of Other:Tobacco Use Disorder;CYP2A6 *1/*1 is associated with decreased risk of Tobacco Use Disorder due to nicotine as compared to CYP2A6 *1/*12 + *12/*12.; 
;ANTITHYROID PREPARATIONS;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-B *38:02 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations.; 
;ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;Toxicity;increased  risk of Side Effect:Agranulocytosis;HLA-DRB1 *08:03 is associated with increased risk of Agranulocytosis when treated with Antithyroid Preparations.; 
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;HLA-DRB1 *15:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Toxicity;increased  risk of Disease:Virus Diseases;CYP3A5 *1/*3 is associated with increased risk of Virus Diseases when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Toxicity;increased  risk of Disease:Infectious disease;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of Infection when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;GEFITINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  risk of Side Effect:Toxic liver disease;CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) is associated with increased risk of Toxic liver disease when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Non-Small Cell Lung Carcinoma
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Efficacy;decreased risk of Efficacy:allograft rejection;CYP3A5 *3/*3 is associated with decreased risk of allograft rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Disease:Kidney Transplantation
;CARBOPLATIN, PACLITAXEL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;CYP3A5 *1/*3 is associated with increased risk of Leukopenia or Neutropenia when treated with carboplatin and paclitaxel in women with Ovarian Neoplasms as compared to CYP3A5 *3/*3.;in women with Disease:Ovarian Neoplasms
;LAMOTRIGINE;SCN1A;rs3812718;C;Efficacy;increased   Efficacy:tonic block of Na(V) 1.1 channels;Allele C is associated with increased tonic block of Na(V) 1.1 channels when treated with lamotrigine as compared to allele T.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Metabolism/PK;increased   PK:formation of metabolites;CYP3A5 *1/*3 is associated with increased formation of metabolites of tacrolimus in human kidney microsomes as compared to CYP3A5 *3/*3.;in human kidney microsomes
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  risk of Efficacy:Transplant rejection;CYP3A5 *1/*1 + *1/*3 is associated with increased risk of transplant rejection when treated with tacrolimus in people with liver transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Liver transplantation
;PEMETREXED;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TTAAAGTTA/TTAAAGTTA is associated with decreased progression-free survival when treated with pemetrexed in people with Mesothelioma as compared to genotypes TTAAAGTTA/del + del/del.;in people with Disease:Mesothelioma
;METHOTREXATE;TYMS;rs11280056;del;Toxicity;increased  risk of Disease:Toxic liver disease;Allele del is associated with increased risk of Toxic liver disease when exposed to methotrexate in people with Psoriasis.;in people with Disease:Psoriasis
;;SLCO1B1;rs4149056;C;Other;decreased  Other:erythromycin transport;Allele C is associated with decreased erythromycin transport as compared to allele T.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  likelihood of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *31:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.;in people with Epilepsy
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  likelihood of Side Effect:Maculopapular Exanthema;HLA-A *31:01 is associated with increased likelihood of Maculopapular Exanthema when treated with carbamazepine.; 
;LEVOFLOXACIN;HLA-B;HLA-B*13:01, HLA-B*13:02;*13:01 + *13:02;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *13:01 + *13:02 is associated with increased likelihood of severe cutaneous adverse reactions when treated with levofloxacin.; 
;PHENYTOIN;HLA-A;HLA-A*03:01;*03:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-A *03:01 is associated with increased likelihood of drug-induced liver injury when treated with phenytoin.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;Efficacy;increased  risk of Side Effect:Thrombotic disease;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with as compared to CYP2C19 normal metabolizer.;in people with 
;BETA-LACTAM ANTIBACTERIALS, PENICILLINS;HLA-DRB1;HLA-DRB1*10:01;*10:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *10:01 is associated with increased likelihood of Drug Hypersensitivity when treated with beta-lactam antibacterials, penicillins.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;Toxicity;increased  likelihood of Side Effect:adverse cardiovascular events;CYP2C19 *2 + *3 + *8 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultrarapid metabolizer and rapid metabolizer phenotype) .;in people with Coronary Artery Disease
;CLOPIDOGREL, PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;Toxicity;increased  likelihood of Side Effect:adverse cardiovascular events;CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultrarapid metabolizer and rapid metabolizer phenotype) is associated with increased likelihood of adverse cardiovascular events when treated with clopidogrel and Proton pump inhibitors in people with Coronary Artery Disease.;in people with Coronary Artery Disease
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10  + *1/*10;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *10/*10 + *1/*10 is associated with decreased Recurrence free survival when treated with tamoxifen in people with Breast Neoplasms as compared to CYP2D6 *1/*1.;in people with Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;Toxicity;decreased risk of Side Effect:Hemorrhage;CYP2C19 *1/*1 + *1/*17 + *17/*17 is associated with decreased risk of Hemorrhage when treated with clopidogrel.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;Efficacy;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 poor metabolizer is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with high on-treatment platelet reactivity.;in people with high on-treatment platelet reactivity
;CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4818789;TT;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes GG + GT.;in people with Hematopoietic stem cell transplantation
;ATENOLOL, METOPROLOL;ADRB2;rs1042714;GG;Toxicity;increased  risk of Disease:Hypertriglyceridemia;Genotype GG is associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes CC + CG.;in people with Disease:Hypertension
;ZOLEDRONATE;;rs1152003;CC;Toxicity;increased  risk of Disease:Osteonecrosis;Genotype CC is associated with increased risk of Osteonecrosis when treated with zoledronate in people with Multiple Myeloma as compared to genotypes CG + GG.;in people with Disease:Multiple Myeloma
;CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.; 
;ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19 intermediate metabolizer;;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Nausea and Vomiting when treated with antidepressants or antipsychotics in people with drug-drug pharmacokinetic interaction as compared to CYP2C19 normal metabolizer and ultrarapid metabolizer.;in people with drug-drug pharmacokinetic interaction
;ATORVASTATIN;HMGCR;rs17671591;T;Efficacy;Efficacy:LDL-C response;Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.;in people with Disease:Coronary Disease
;ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6 intermediate metabolizer;;Toxicity;increased  likelihood of Side Effect:Depression;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Depression when treated with antidepressants or antipsychotics in people with drug-drug pharmacokinetic interaction as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;in people with drug-drug pharmacokinetic interaction
;TACROLIMUS, VORICONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Metabolism/PK;increased  severity of Side Effect:drug-drug pharmacokinetic interaction;CYP3A5 *3/*3 is associated with increased severity of drug-drug pharmacokinetic interaction when treated with tacrolimus null voriconazole in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Kidney Transplantation
;CARBOPLATIN, PACLITAXEL;LIG3;rs1052536;T;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with increased likelihood of Neurotoxicity Syndromes when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to allele C.;in people with Ovarian Neoplasms
;CLOPIDOGREL;CYP1A2;rs2069514;A;Toxicity;increased  risk of Side Effect:Death;Allele A is associated with increased risk of Death when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4819128;TT;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CC + CT.;in people with Hematopoietic stem cell transplantation
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 intermediate acetylator and rapid acetylator.;in people with Tuberculosis
;ATORVASTATIN;HMGCR;rs10474433;T;Efficacy;Efficacy:LDL-C response;Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.;in people with Disease:Coronary Disease
;VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Drug-induced liver injury;HLA-A *32:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and drug-induced liver injury when exposed to vancomycin.; 
;MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Side Effect:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;ATORVASTATIN;PCSK9;rs11591147;T;Efficacy;Efficacy:LDL-C response;Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.;in people with Disease:Coronary Disease
;"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*02:07;*02:07;Toxicity;decreased likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *02:07 is associated with decreased likelihood of severe cutaneous adverse reactions when treated with beta-lactam antibacterials, penicillins or other beta-lactam antibacterials.; 
;"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*01:01;*01:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-A *01:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with beta-lactam antibacterials, penicillins or other beta-lactam antibacterials.; 
;"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;HLA-C*06:02;*06:02;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *06:02 is associated with increased likelihood of severe cutaneous adverse reactions when treated with beta-lactam antibacterials, penicillins or other beta-lactam antibacterials.; 
;"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-DRB1 *15:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with beta-lactam antibacterials, penicillins or other beta-lactam antibacterials.; 
;"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-DQB1 *03:02 is associated with increased likelihood of severe cutaneous adverse reactions when treated with beta-lactam antibacterials, penicillins or other beta-lactam antibacterials.; 
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer;;Efficacy;increased  likelihood of Efficacy:Recurrence;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Myocardial Infarction as compared to CYP2C19 normal metabolizer and rapid metabolizer.;in people with Myocardial Infarction
;VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2C9 *1/*3 + *3/*3 is associated with increased likelihood of adverse events when treated with valproic acid in people with Epilepsy as compared to CYP2C9 *1/*1.;in people with Epilepsy
;ATORVASTATIN;APOE;rs429358;T;Efficacy;Efficacy:LDL-C response;Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.;in people with Disease:Coronary Disease
;ENALAPRIL;;rs495828;TT;Toxicity;increased  risk of Disease:Cough;Genotype TT is associated with increased risk of Cough when treated with enalapril in women with Hypertension as compared to genotypes GG + GT.;in women with Disease:Hypertension
;RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;AC;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype AC is associated with increased likelihood of sustained virological response (svr) when treated with ribavirin and sofosbuvir in people with Hepatitis C as compared to genotype CC.;in people with Hepatitis C virus infection
;ENALAPRIL;;rs495828;TT;Toxicity;increased  risk of Disease:Cough;Genotype TT is associated with increased risk of Cough when treated with enalapril in people with Hypertension as compared to genotypes GG + GT.;in people with Disease:Hypertension
;ATORVASTATIN;APOE;rs7412;T;Efficacy;Efficacy:LDL-C response;Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease.;in people with Disease:Coronary Disease
;;GSTT1;GSTT1 non-null, GSTT1 null;;Efficacy, Toxicity;increased  likelihood of Side Effect:Transplant rejection;GSTT1 null is associated with increased likelihood of transplant rejection in people with Kidney Transplantation as compared to GSTT1 non-null.;in people with Kidney Transplantation
;SIMVASTATIN;ABCG2;rs2231142;TT;Metabolism/PK;increased   PK:exposure to drug;Genotype TT is associated with increased exposure to drug when treated with simvastatin in healthy individuals as compared to genotypes GG + GT.;in healthy individuals 
;CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;Toxicity;increased  severity of Side Effect:Hyponatremia;Genotype TTA/TTA is associated with increased severity of Hyponatremia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotypes TTA/TTAAAGTTA + TTAAAGTTA/TTAAAGTTA.;"in people with ""Carcinoma, Squamous Cell"", ""Adenocarcinoma"", ""Adenosquamous Carcinoma"", ""Neoplasm of esophagus"""
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Maculopapular Exanthema, Side Effect:Drug Hypersensitivity, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Erythema multiforme;HLA-A *31:01 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic, Maculopapular Exanthema, Drug Hypersensitivity, drug reaction with eosinophilia and systemic symptoms or Erythema multiforme NOS when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *15:11 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with carbamazepine.; 
;;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased  likelihood of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *2 + *3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of major adverse cardiac events (mace) in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Acute coronary syndrome
;EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;Toxicity;increased  severity of Side Effect:Weight gain;CYP2B6 poor metabolizer is associated with increased severity of Weight gain with efavirenz in people with discontinuation and HIV Infections as compared to CYP2B6 normal metabolizer.;in people with Discontinuation, HIV infectious disease
;CAPECITABINE, FLUOROURACIL;DPYS;rs143004875;(T)7/(T)8;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype (T)7/(T)8 is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype (T)7/(T)7.;in people with Neoplasms
;FLUVASTATIN;ABCG2;rs2231142;TT;Metabolism/PK;increased   PK:exposure to drug;Genotype TT is associated with increased exposure to drug when treated with fluvastatin in healthy individuals as compared to genotypes GG + GT.;in healthy individuals 
;CAPECITABINE, FLUOROURACIL;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);Toxicity;increased  severity of Side Effect:Drug Toxicity;DPYD c.1129-5923C>G, c.1236G>A (HapB3) is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.;in people with Neoplasms
;OSIMERTINIB;CYP2A6;CYP2A6*4;*4;Toxicity;increased  likelihood of Side Effect:Diarrhea;CYP2A6 *4 is associated with increased likelihood of Diarrhea when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung.;in people with Non-Small Cell Lung Carcinoma
;OSIMERTINIB;ABCG2;rs2622604;TT;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotype TT is associated with increased likelihood of Diarrhea when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Non-Small Cell Lung Carcinoma
;L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7;Toxicity;increased  likelihood of Side Effect:Mucositis;CYP3A5 *3/*3 + *3/*6 + *3/*7 is associated with increased likelihood of mucositis when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to CYP3A5 *1/*1 + *1/*3.;in children with Acute lymphoblastic leukemia
;L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotype (GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3 is associated with increased likelihood of mucositis when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in children with Acute lymphoblastic leukemia
;PRAVASTATIN;NPC1L1;rs17655652;CC;Efficacy;decreased  Efficacy:reduction in LDL-C;Genotype CC is associated with decreased reduction in LDL-C when treated with pravastatin in women as compared to genotypes CT + TT.;in women 
;PRAVASTATIN;NPC1L1;rs17655652;CC;Efficacy;increased   Efficacy:reduction in LDL-C;Genotype CC is associated with increased reduction in LDL-C when treated with pravastatin in men as compared to genotypes CT + TT.;in men 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased risk of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 intermediate acetylator and rapid acetylator.;in people with Tuberculosis
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:high on-treatment platelet reactivity;CYP2C19 *2 is associated with increased risk of high on-treatment platelet reactivity due to clopidogrel in people with Cardiovascular Disease.;in people with Cardiovascular Disease
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Toxicity;decreased risk of Side Effect:Hemorrhage;CYP2C19 *2 is associated with decreased risk of Hemorrhage when treated with clopidogrel.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *2 is associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;Toxicity;decreased risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 *17 is associated with decreased risk of major adverse cardiac events (mace) when treated with clopidogrel.; 
;TRAMADOL;CYP2B6;CYP2B6 poor metabolizer;;Efficacy;decreased severity of Efficacy:Pain, Postoperative;CYP2B6 poor metabolizer is associated with decreased severity of Pain, Postoperative when treated with tramadol in people with Pain, Postoperative as compared to CYP2B6 normal metabolizer and intermediate metabolizer and rapid metabolizer.;in people with Pain, Postoperative
;TRAMADOL;CYP3A4;CYP3A4 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Dizziness, Side Effect:Somnolence;CYP3A4 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Dizziness or somnolence when treated with tramadol in people with Pain, Postoperative as compared to CYP3A4 normal metabolizer.;in people with Pain, Postoperative
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2C19 poor metabolizer is associated with increased likelihood of adverse events when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.;in people with Major Depressive Disorder
;IRINOTECAN;HLA-B;rs9266271;C;Toxicity;decreased severity of Side Effect:Neutropenia;Allele C is associated with decreased severity of Neutropenia when treated with irinotecan as compared to allele T.; 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-A *02:01 is associated with increased likelihood of Drug Hypersensitivity when exposed to Antiinflammatory agents, non-steroids.; 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*34:01;*34:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-A *34:01 is associated with increased likelihood of Drug Hypersensitivity when exposed to Antiinflammatory agents, non-steroids.; 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*16:02;*16:02;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *16:02 is associated with increased likelihood of Drug Hypersensitivity when exposed to Antiinflammatory agents, non-steroids.; 
;ATORVASTATIN;HMGCR;rs3846662;GG;Efficacy;increased   Efficacy:low-density lipoprotein cholesterol level in basal state and possibly in response to atorvastatin.;Genotype GG is associated with increased low-density lipoprotein cholesterol level in basal state and possibly in response to atorvastatin. when treated with atorvastatin in healthy individuals as compared to genotype AA.;in healthy individuals 
;CLOPIDOGREL;ABCB1;rs1128503;GG;Efficacy;decreased  Efficacy:platelet reactivity;Genotype GG is associated with decreased platelet reactivity when treated with clopidogrel in people with Stroke as compared to genotypes AA + AG.;in people with Stroke
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Toxicity;increased  likelihood of Side Effect:Nephrotoxicity, Side Effect:Tremor, Side Effect:Diabetes Mellitus;CYP3A5 *3/*3 is associated with increased likelihood of nephrotoxicity, Tremor or Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Kidney Transplantation
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6;*6;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;NAT2 *6 is associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 *4.;in people with Disease:Tuberculosis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  likelihood of Efficacy:Acute cellular rejection;CYP3A5 *1/*1 + *1/*3 is associated with increased likelihood of acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Kidney Transplantation
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CT + TT are associated with increased risk of Leukopenia when treated with azathioprine in people with Colitis, Ulcerative, Crohn Disease or Hepatitis, Autoimmune as compared to genotype CC.;in people with Disease:Ulcerative Colitis, Disease:Crohn Disease, Disease:Autoimmune hepatitis
;BETA BLOCKING AGENTS, METOPROLOL;ADRB1;rs1801252;AG + GG;Efficacy;increased   Efficacy:improvement in left ventricular(LV) remodeling;Genotypes AG + GG are associated with increased improvement in left ventricular(LV) remodeling when treated with Beta Blocking Agents and metoprolol in people with Heart Failure as compared to genotype AA.;in people with Disease:Heart Failure
;LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:Nephrotoxicity;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased likelihood of nephrotoxicity when treated with lansoprazole as compared to CYP2C19 *1/*1 + *1/*2 + *1/*3 + *1/*17 + *2/*17 + *3/*17 (assigned as normal metabolizer and intermediate metabolizer phenotype) .; 
;FOLFIRI, FOLFOX, XELOX;TYMS;rs11280056;del/del;Efficacy;decreased  Efficacy:Overall survival;Genotype del/del is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes TTAAAGTTA/del + TTAAAGTTAAAGTTA/TTAAAGTTAAAGTTA.;in people with Colorectal Neoplasms
;IRINOTECAN;ALOX5;rs1051713;T;Toxicity;increased  severity of Side Effect:Neutropenia;Allele T is associated with increased severity of Neutropenia when treated with irinotecan as compared to allele C.; 
;ETOPOSIDE;;rs6539870;GG;Other;increased   Other:sensitivity to etoposide;Genotype GG is associated with increased sensitivity to etoposide when exposed to etoposide as compared to genotypes AA + AG.; 
;"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;Efficacy;decreased  Efficacy:frequency of patients who received at least the recommended 80% of scheduled ribavirin;Genotype CC is associated with decreased frequency of patients who received at least the recommended 80% of scheduled ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;Efficacy;increased  risk of Efficacy:Stroke;CYP2C19 *2 + *3 are associated with increased risk of Stroke when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;Efficacy;Efficacy:cumulative reduction of ribavirin;Genotype CC is associated with cumulative reduction of ribavirin when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;ASPARAGINASE;F5;rs6025;CT;Toxicity;increased  risk of Side Effect:Venous thromboembolism;Genotype CT is associated with increased risk of venous thromboembolism when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;DABIGATRAN;CES1;rs2244613;GG + GT;Metabolism/PK;decreased  PK:adjusted trough concentrations;Genotypes GG + GT are associated with decreased adjusted trough concentrations when treated with Dabigatran in people with Atrial Fibrillation as compared to genotype TT.;in people with Disease:Atrial Fibrillation
;DESIPRAMINE;MC1R;rs2228478;G;Efficacy;increased  likelihood of Efficacy:remission;Allele G is associated with increased likelihood of remission when treated with desipramine in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;;ABCB1;rs1045642;A;;increased   Other:level of apolipoprotein A1;Allele A is associated with increased level of apolipoprotein A1.; 
;ACENOCOUMAROL;VKORC1;rs9934438;AA;Dosage, Efficacy, Toxicity;decreased  Efficacy:dose requirement;Genotype AA is associated with decreased dose requirement of acenocoumarol as compared to genotypes AG + GG.; 
;DESIPRAMINE;MC1R;rs2228479;A;Efficacy;increased  likelihood of Efficacy:remission;Allele A is associated with increased likelihood of remission when treated with desipramine in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*7, NAT2*16;*16/*7;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;NAT2 *16/*7 is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Disease:Tuberculosis
;CARBAMAZEPINE;LTA, TNF;rs1800629;A;Toxicity;increased  likelihood of Side Effect:serious hypersensitivity;Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G.; 
;ASPARAGINASE;IL16;rs11556218;GG + GT;Toxicity;increased  risk of Side Effect:Thrombotic disease;Genotypes GG + GT is associated with increased risk of Thrombosis when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;MERCAPTOPURINE;PACSIN2;rs2413739;TT;Toxicity;increased  risk of Side Effect:Hematologic Disorder;Genotype TT is associated with increased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Disease:Acute lymphoblastic leukemia
;GEMCITABINE;SLC29A1;rs9394992;CT + TT;Toxicity;increased  risk of Side Effect:neutropenia;Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.;in people with Disease:Pancreatic Neoplasms
;DOCETAXEL, THALIDOMIDE;SPG7;rs2292954;A;Toxicity;increased  risk of Side Effect:toxicity;Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;in people with Disease:Prostatic Neoplasms
;ANTINEOPLASTIC AGENTS;CTH;rs648743;CC;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with decreased likelihood of Drug Toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in children with Acute lymphoblastic leukemia
;DOCETAXEL, THALIDOMIDE;ABCC6;rs2238472;C;Toxicity;increased  risk of Side Effect:toxicity;Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;in people with Disease:Prostatic Neoplasms
;DOCETAXEL, THALIDOMIDE;ATP7A;rs2227291;G;Toxicity;increased  risk of Side Effect:toxicity;Allele G is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele C.;in people with Disease:Prostatic Neoplasms
;MERCAPTOPURINE;GNMT;rs10948059;CT + TT;Toxicity;decreased risk of Side Effect:Hematologic Disorder;Genotypes CT + TT is associated with decreased risk of Hematologic Diseases when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;ACENOCOUMAROL;CYP4F2;rs2108622;CC;Other, Metabolism/PK;decreased  Other:levels of vitamin K-dependent proteins;Genotype CC is associated with decreased levels of vitamin K-dependent proteins when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes CT + TT.;in people with Disease:Atrial Fibrillation
;ACENOCOUMAROL;CYP4F2;rs2108622;CT;Other, Metabolism/PK;decreased  Other:levels of vitamin K-dependent proteins;Genotype CT is associated with decreased levels of vitamin K-dependent proteins when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotype TT.;in people with Disease:Atrial Fibrillation
;DABIGATRAN;CES1;rs2244613;GG + GT;Toxicity;decreased risk of Side Effect:bleeding events;Genotypes GG + GT are associated with decreased risk of bleeding events when treated with Dabigatran in people with Atrial Fibrillation as compared to genotype TT.;in people with Disease:Atrial Fibrillation
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:cardiovascular event;Allele A is associated with increased risk of cardiovascular event when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.;in people with Disease:Myocardial Infarction
;ACENOCOUMAROL;CYP4F2;rs2108622;CC;Dosage, Efficacy, Toxicity;decreased  Efficacy:dosage requirement;Genotype CC is associated with decreased dosage requirement when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotypes CT + TT.;in people with Disease:Atrial Fibrillation
;CLOPIDOGREL;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:cardiovascular events;Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3 are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;IRINOTECAN;SLCO1B1;rs4149015;AA + AG;Toxicity;increased   Disease:Neutropenia;Genotypes AA + AG are associated with increased Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;;CHRM3;rs2165870;AA + AG;;increased  risk of Disease:Postoperative Nausea and Vomiting;Genotypes AA + AG is associated with increased risk of Postoperative Nausea and Vomiting as compared to genotype GG.; 
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*16;Toxicity;increased  likelihood of Side Effect:a mild increase of liver enzymes;NAT2 *16/*16 is associated with increased likelihood of a mild increase of liver enzymes when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Disease:Tuberculosis
;SALBUTAMOL, SALMETEROL;ADRB2;rs1042713;AA;Efficacy;increased  risk of Efficacy:asthma exacerbations;Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;IRINOTECAN;UGT1A9;rs3832043;del/del;Toxicity;increased  risk of Disease:Diarrhea;Genotype del/del is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes T/del + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs1414334;C;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, aripiprazole, clozapine, olanzapine, quetiapine or risperidone in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;CISPLATIN;SLC16A5;rs4788863;T;Toxicity;decreased likelihood of Side Effect:Ototoxicity;Allele T is associated with decreased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele C.;in men with Disease:Testicular Neoplasms
;ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;Toxicity;increased  likelihood of Side Effect:adverse reactions;NAT2 *5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30 is associated with increased likelihood of adverse reactions when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4 + *1 (assigned as rapid acetylator phenotype) .;in people with Tuberculosis
;IRINOTECAN;ABCC2;rs3740066;CC;Toxicity;increased  risk of Disease:Diarrhea;Genotype CC is associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*6/*6 + *6/*7 + *7/*7;Toxicity;increased  severity of Side Effect:Drug-induced liver injury;NAT2 *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased severity of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*16 + *4/*6 + *4/*7 (assigned as intermediate acetylator and rapid acetylator phenotype) .;in people with Tuberculosis
;ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;rs1799722;CT + TT;Toxicity;increased  risk of Disease:Cough;Genotypes CT + TT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC.;in people with Disease:Essential hypertension
;IRINOTECAN;ABCG2;rs2231137;CT + TT;Toxicity;increased  risk of Disease:Diarrhea;Genotypes CT + TT are associated with increased risk of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOZAPINE, RISPERIDONE;HTR2C;rs1414334;C;Toxicity;increased  risk of Side Effect:Metabolic Syndrome;Allele C is associated with increased risk of Metabolic Syndrome when treated with clozapine and risperidone in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;HMG COA REDUCTASE INHIBITORS;SREBF1;rs11868035;AA + AG;Other;increased   Other:total cholesterol;Genotypes AA + AG is associated with increased total cholesterol when treated with hmg coa reductase inhibitors in people with Schizophrenia as compared to genotype GG.;in people with Disease:Schizophrenia
;OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;Dosage;increased   PK:Oxycodone consumption up to the 12(th) hour in postoperative patients;CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7 (assigned as poor metabolizer phenotype) is associated with increased Oxycodone consumption up to the 12(th) hour in postoperative patients when treated with oxycodone as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .; 
;CISPLATIN;GSTP1;rs1695;G;Toxicity;increased  likelihood of Side Effect:Ototoxicity;Allele G is associated with increased likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele A.;in men with Disease:Testicular Neoplasms
;ACE INHIBITORS, PLAIN;BDKRB2;rs1799722;T;Toxicity;increased  risk of Disease:Cough;Allele T is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;ATORVASTATIN;ABCG2;rs2231142;TT;Dosage, Metabolism/PK;increased   PK:AUC;Genotype TT is associated with increased AUC of atorvastatin in people with no disease as compared to genotypes GG + GT.;in people with no disease
;LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;Metabolism/PK;decreased  Other:Gastric pH;CYP2C19 intermediate metabolizer is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizer.;in healthy individuals 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;NAT2 *5/*7 + *6/*6 + *6/*7 + *7/*7 are associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;Toxicity;increased  risk of Disease:Toxic liver disease;NAT2 *6/*7 is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;IRBESARTAN;AGTR1;rs5186;AC + CC;Efficacy;increased   Efficacy:blood pressure response;Genotypes AC + CC are associated with increased blood pressure response when treated with irbesartan in people with Hypertension as compared to genotype AA.;in people with Disease:Hypertension
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;Toxicity;increased  risk of Disease:Toxic liver disease;NAT2 *6/*6 is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;OPIOIDS;PDE3A;rs12305038;A;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Allele A is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.;in people with Neoplasms, Pain
;ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;NAT2 *5/*7 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) is associated with increased risk of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*1 (assigned as rapid acetylator phenotype) .;in people with Disease:Tuberculosis
;DEXMEDETOMIDINE;ADRA2A;rs1800544;G;Efficacy;increased   Efficacy:Bispectral Index and Ramsay Sedation Scores, indicating a longer period for falling asleep;Allele G is associated with increased Bispectral Index and Ramsay Sedation Scores, indicating a longer period for falling asleep when exposed to dexmedetomidine as compared to genotype CC.; 
;PACLITAXEL;CYP2C8;rs1113129;G;Toxicity;decreased risk of Disease:Neurotoxicity Syndromes;Allele G is associated with decreased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;OPIOIDS;MUC16;rs11882256;T;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Allele T is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele C.;in people with Neoplasms, Pain
;ISONIAZID, RIFAMPIN;NAT2;NAT2*6;*6;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;NAT2 *6 is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ROSUVASTATIN;ABCG2;rs2231142;TT;Dosage, Metabolism/PK;increased   PK:AUC;Genotype TT is associated with increased AUC of rosuvastatin in people with no disease as compared to genotypes GG + GT.;in people with no disease
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;NAT2 *6/*6 is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;NAT2 *16 + *5 + *6 + *6 + *7 + *7 + *14 + *14 (assigned as slow acetylator phenotype) are associated with increased risk of severe cutaneous adverse reactions when treated with sulfamethoxazole / trimethoprim in people with Acquired Immunodeficiency Syndrome.;in people with Disease:Acquired Immunodeficiency Syndrome
;IRINOTECAN;UGT1A1;rs4148323;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ROSUVASTATIN;ABCG2;rs2231142;GG;Dosage, Metabolism/PK;decreased  PK:AUC;Genotype GG is associated with decreased AUC of rosuvastatin in people with no disease as compared to genotypes GT + TT.;in people with no disease
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 *6 is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;ISONIAZID, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;NAT2 *6/*7 is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;SORAFENIB;TNF;rs1800629;GG;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype GG is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotype AG.;in people with Disease:Hepatocellular Carcinoma
;OPIOIDS;PDE3A;rs12305038;A;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Allele A is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.;in people with Neoplasms, Pain
;IRINOTECAN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Disease:Neutropenia;Genotypes CC + CT are associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;ALFENTANIL;OPRM1;rs1799971;AG + GG;Efficacy;increased  risk of Disease:Pain;Genotypes AG + GG are associated with increased risk of Pain when treated with alfentanil in people with Extracorporeal shock wave lithotripsy (ESWL) as compared to genotype AA.;in people with Extracorporeal shock wave lithotripsy (ESWL)
;ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;Toxicity;increased  risk of Disease:Drug-induced liver injury;NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased risk of drug-induced liver injury when exposed to isoniazid as compared to NAT2 *4/*4 + *4/*16 + *4/*6 + *4/*7 (assigned as rapid acetylator phenotype) .; 
;"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;Toxicity;decreased  Side Effect:hemoglobin levels;Genotype CC is associated with decreased hemoglobin levels when treated with interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 *6 is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ALFENTANIL;OPRM1;rs1799971;AG + GG;Metabolism/PK;increased   PK:plasma concentration;Genotypes AG + GG are associated with increased plasma concentration when treated with alfentanil in people with Pain as compared to genotype AA.;in people with Disease:Pain
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;Toxicity;increased  likelihood of Disease:Toxic liver disease;NAT2 *16 + *6 + *7 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .;in people with Disease:Tuberculosis
;SALMETEROL;ADRB2;rs1042713;AA;Efficacy;increased  risk of Other:asthma exacerbations;Genotype AA is associated with increased risk of asthma exacerbations when exposed to salmeterol in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;rs6051702;C;Toxicity;decreased severity of Side Effect:Anemia;Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.;in people with Disease:Chronic hepatitis C virus infection
;CLOPIDOGREL;MIR6076;rs1463411;GG + GT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes GG + GT is associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype TT.;in people with Acute coronary syndrome
;LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;Metabolism/PK;decreased  Other:Gastric pH;CYP2C19 intermediate metabolizer is associated with decreased intragastric ph when exposed to lansoprazole in healthy individuals as compared to CYP2C19 poor metabolizer.;in healthy individuals 
;TAMOXIFEN;LRMDA;rs10509373;C;Efficacy;decreased  Other:recurrence-free survival;Allele C is associated with decreased recurrence-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;OPIOIDS;CRYBG2;rs36024412;T;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Allele T is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.;in people with Neoplasms, Pain
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;G;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele G is associated with increased likelihood of Toxic liver disease when treated with ethambutol null isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to allele A.;in people with Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;NAT2 *6/*7 is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;OPIOIDS;CLCC1;rs168107;T;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Allele T is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.;in people with Neoplasms, Pain
;CAPECITABINE;CDA;rs1048977;CT + TT;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotypes CT + TT are associated with increased likelihood of Hyperbilirubinemia when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Genotype AC is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;OPIOIDS;POM121L2;rs41269255;T;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Allele T is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele C.;in people with Neoplasms, Pain
;"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;Toxicity, Metabolism/PK;increased  risk of Disease:Drug-induced liver injury;NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to NAT2 *4/*4 + *4/*1 + *1/*1 + *4/*16 + *4/*6 + *16/*1 + *6/*1 (assigned as rapid acetylator phenotype) .;in people with HIV and tuberculosis co-infection
;DIPYRONE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;Toxicity;increased  risk of Side Effect:Hypersensitivity;NAT2 *16 + *6 + *7 + *14 (assigned as slow acetylator phenotype) are associated with increased risk of Hypersensitivity when exposed to dipyrone as compared to NAT2 rapid acetylator.; 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;NAT2 *16 + *6 + *7 + *14 (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;METHOTREXATE;ABCC2;rs3740065;AG + GG;Toxicity;increased  risk of Side Effect:toxicity;Genotypes AG + GG are associated with increased risk of toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;IRINOTECAN;NR3C1;rs61754806;A;Toxicity;decreased severity of Side Effect:Neutropenia;Allele A is associated with decreased severity of Neutropenia when treated with irinotecan as compared to allele G.; 
;IRINOTECAN;VKORC1;rs7294;T;Toxicity;increased  severity of Side Effect:Neutropenia;Allele T is associated with increased severity of Neutropenia when treated with irinotecan as compared to allele C.; 
;PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;Toxicity;decreased severity of Side Effect:Drug Toxicity;Genotype AA is associated with decreased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;OPIOIDS;ZNF165;rs9393888;C;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Allele C is associated with decreased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele G.;in people with Neoplasms, Pain
;CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;rs1142345;CT;Efficacy;decreased  Efficacy:progression-free survival;Genotype CT is associated with decreased progression-free survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.;in women with Disease:Ovarian Neoplasms
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;SLCO1B1*5;*5;Toxicity;decreased risk of Side Effect:Cataract;SLCO1B1 *5 is associated with decreased risk of Cataract when treated with hmg coa reductase inhibitors in people with cardio-metabolic conditions.;in people with cardio-metabolic conditions
;GEMCITABINE;RRM1;rs9937;AA;Toxicity;increased  risk of Side Effect:neutropenia;Genotype AA is associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Pancreatic Neoplasms
;OLANZAPINE, RISPERIDONE;DRD2;rs1799978;C;Efficacy;decreased  Efficacy:time until response;Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT.;in people with Disease:Schizophrenia
;PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;Efficacy;increased  likelihood of Efficacy:Overall survival;Genotype AA is associated with increased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;Toxicity;increased  risk of Side Effect:bleeding events;Genotypes CT + TT are associated with increased risk of bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 *16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis.;in people with Tuberculosis
;METHOTREXATE;ABCC4;rs9516519;GG + GT;Toxicity;decreased risk of Side Effect:toxicity;Genotypes GG + GT are associated with decreased risk of toxicity when exposed to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Psychomotor Agitation, Side Effect:Hyperkinesis, Side Effect:Impulse control disorder;CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer.;in children with Depression, Anxiety Disorders
;RISPERIDONE;CYP2D6;CYP2D6 normal metabolizer;;Efficacy;increased  likelihood of Efficacy:Discontinuation;CYP2D6 normal metabolizer and ultrarapid metabolizer is associated with increased likelihood of discontinuation when treated with risperidone in children as compared to CYP2D6 intermediate metabolizer and poor metabolizer.;in children 
;PALIPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Discontinuation, Side Effect:Weight gain;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased likelihood of discontinuation and Weight gain when treated with paliperidone in children as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;in children 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 *6/*6 + *6/*7 + *7/*7 is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Tuberculosis
;TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2D6 *10/*10 is associated with increased likelihood of adverse events when treated with tramadol in people with Pain.;in people with Pain
;CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;Efficacy;decreased  Efficacy:magnitude of platelet reactivity;Genotypes CT + TT are associated with decreased magnitude of platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;ISONIAZID;NAT2;NAT2*6, NAT2*7;*6 + *7;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;NAT2 *6 + *7 (assigned as slow acetylator phenotype) are associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis.;in people with Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6 + *7;Toxicity;increased  likelihood of Disease:Toxic liver disease;NAT2 *6 + *7 (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 (assigned as rapid acetylator phenotype) .;in people with Disease:Tuberculosis
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;Toxicity;increased  risk of Side Effect:hepatotoxicity;NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*16;*16;Toxicity;increased  likelihood of Disease:Toxic liver disease;NAT2 *16 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*6 + *6/*7;Toxicity, Metabolism/PK;increased  risk of Disease:Hepatitis;NAT2 *6/*6 + *6/*7 (assigned as slow acetylator phenotype) are associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Disease:Tuberculosis
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*04:03;*04:03;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-DRB1 *04:03 is associated with increased likelihood of drug-induced liver injury when exposed to Antiinflammatory agents, non-steroids.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:on-treatment platelet reactivity;Genotypes AA + AG are associated with increased risk of on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*4;Toxicity, Metabolism/PK;decreased likelihood of Disease:Toxic liver disease;NAT2 *16/*4 is associated with decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Disease:Tuberculosis
;PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CAPECITABINE;CDA;rs2072671;AC + CC;Toxicity;decreased likelihood of Side Effect:Drug Toxicity, Disease:Hand-foot syndrome;Genotypes AC + CC are associated with decreased likelihood of hand-foot syndrome and Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*7 + *6/*7;Toxicity;increased  risk of Side Effect:hepatotoxicity;NAT2 *16/*7 + *6/*7 (assigned as slow acetylator phenotype) is associated with increased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*16 + *4/*7.;in people with Disease:Tuberculosis
;ISONIAZID;NAT2;NAT2*16;*16;Toxicity;decreased likelihood of Side Effect:Drug-induced liver injury;NAT2 *16 is associated with decreased likelihood of drug-induced liver injury when treated with isoniazid in people with Tuberculosis.;in people with Tuberculosis
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;Toxicity;increased  likelihood of Disease:Toxic liver disease;NAT2 *16 + *6 + *7 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 *4.;in people with Disease:Tuberculosis
;OLANZAPINE, RISPERIDONE;DRD2;rs1799732;del;Efficacy;increased   Efficacy:time to respond;Allele del is associated with increased time to respond when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype GG.;in people with Disease:Schizophrenia
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;NAT2 *5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) are associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 *4/*4.;in people with Disease:Tuberculosis
;OPIOIDS;CYP2A7P1, CYP2B6;rs3745274;GG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype GG is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes GT + TT.;in men 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to NAT2 *4/*4 + *4/*16 + *4/*6 + *4/*7 (assigned as intermediate acetylator and rapid acetylator phenotype) .;in people with Tuberculosis
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-B;HLA-B*35:03;*35:03;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-B *35:03 is associated with increased likelihood of drug-induced liver injury when exposed to Antiinflammatory agents, non-steroids.; 
;PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;;CHRNA3;rs1051730;A;Other;increased  likelihood of Other:Tobacco Use Disorder;Allele A is associated with increased likelihood of Tobacco Use Disorder in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;CC;Toxicity;increased  likelihood of Side Effect:Hemolytic Anemia;Genotype CC is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin and sofosbuvir in people with Hepatitis C as compared to genotype AC.;in people with Hepatitis C virus infection
;PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;Toxicity;decreased risk of Side Effect:Infectious disease;CYP2C19 ultrarapid metabolizer and rapid metabolizer are associated with decreased risk of Infection due to Proton pump inhibitors in children as compared to CYP2C19 normal metabolizer.;in children 
;ANTINEOPLASTIC AGENTS;TYMS;rs2853539;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AG + GG is associated with increased likelihood of Drug Toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;rs2279343;AG + GG;Efficacy;increased   Efficacy:event-free survival;Genotypes AG + GG are associated with increased event-free survival when treated with cyclophosphamide, dactinomycin and vincristine in children with Rhabdomyosarcoma as compared to genotype AA.;in children with Disease:Rhabdomyosarcoma
;ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:Tardive Dyskinesia;CYP2D6 poor metabolizer is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer and intermediate metabolizer.;in people with Schizoaffective disorder, Schizophrenia
;OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizers;;Metabolism/PK;decreased  Other:Gastric pH;CYP2C19 normal metabolizer is associated with decreased intragastric ph when exposed to omeprazole in healthy individuals as compared to CYP2C19 intermediate metabolizer and poor metabolizer.;in healthy individuals 
;TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Efficacy, Toxicity;increased  risk of Side Effect:Hot Flashes;CYP2D6 intermediate metabolizer and poor metabolizer are associated with increased risk of Hot Flashes when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer.;in women with Disease:Breast Neoplasms
;ANTINEOPLASTIC AGENTS;AKR1C3;rs1937840;G;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Allele G is associated with decreased likelihood of Drug Toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;ANTIHYPERTENSIVES;ADIPOQ;rs266729;CG + GG;Efficacy;increased  severity of Efficacy:Hypertension;Genotypes CG + GG is associated with increased severity of Hypertension when treated with Antihypertensives in people with Hypertension as compared to genotype CC.;in people with Hypertension
;MYCOPHENOLIC ACID, TACROLIMUS;IMPDH1;rs2278293;T;Efficacy;decreased likelihood of Other:subclinical acute rejection;Allele T is associated with decreased likelihood of subclinical acute rejection when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;GEMCITABINE;CDA;rs2072671;AA;Toxicity;decreased risk of Side Effect:neutropenia;Genotype AA is associated with decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms.;in people with Disease:Pancreatic Neoplasms
;ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;Toxicity;increased  risk of Side Effect:Dry mouth, Side Effect:Erectile Dysfunction, Side Effect:Hyperhidrosis, Side Effect:Insomnia, Side Effect:Urinary Retention;CYP2D6 *3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5 (assigned as poor metabolizer phenotype) are associated with increased risk of dry mouth, Erectile Dysfunction, Hyperhidrosis, insomnia and Urinary Retention when treated with atomoxetine in people with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 *1/*3 + *1/*4 + *1/*5 + *1/*6 + *1/*7 + *1/*1xN + *1/*1 + *1/*10 + *1/*17 + *3/*10 + *4/*10 + *4/*17 + *5/*10 + *5/*17 + *6/*10 + *10/*10 + *10/*17 + *17/*17.;in people with Disease:Attention Deficit Disorder with Hyperactivity
;CODEINE;CYP2D6;CYP2D6 poor metabolizers;;Toxicity;decreased risk of Side Effect:adverse events;CYP2D6 poor metabolizer is associated with decreased risk of adverse events due to codeine in children with Pain, Postoperative as compared to CYP2D6 normal metabolizer and intermediate metabolizer.;in children with Pain, Postoperative
;NICOTINE;CYP2D6;CYP2D6*2xN, CYP2D6*4, CYP2D6*5;*2xN;Toxicity;increased  risk of Side Effect:Tobacco Use Disorder;CYP2D6 *2xN is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to CYP2D6 *4/*5 + *4/*4 (assigned as poor metabolizer phenotype) .; 
;GEMCITABINE;DCK;rs4694362;TT;Toxicity;increased  risk of Side Effect:neutropenia;Genotype TT is associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.;in people with Disease:Pancreatic Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;rs141084494;A;Toxicity;decreased risk of Side Effect:Neutropenia;Allele A is associated with decreased risk of Neutropenia due to cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1801280;T;Toxicity;decreased likelihood of Side Effect:Toxic liver disease;Allele T is associated with decreased likelihood of Toxic liver disease when treated with ethambutol null isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to allele C.;in people with Tuberculosis
;PLATINUM COMPOUNDS;SLC31A1;rs4978536;AG + GG;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Genotypes AG + GG is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;OPIOIDS;BDNF-AS;rs11030096;CC + CT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype TT.;in women 
;IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799930;AA;Efficacy;increased   Efficacy:Overall survival;Genotype AA is associated with increased overall survival when treated with irinotecan and Platinum compounds in people with Lung Neoplasms as compared to genotype GG.;in people with Lung Neoplasms
;PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;Toxicity;increased  severity of Side Effect:Drug Toxicity, Side Effect:Hematologic Disorder, Side Effect:Leukopenia, Side Effect:Thrombocytopenia;Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2C19 poor metabolizer is associated with increased likelihood of adverse events when treated with voriconazole as compared to CYP2C19 normal metabolizer and intermediate metabolizer.; 
;PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Genotype AC is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;COCAINE;SYT1;rs2251214;G;Toxicity;increased  risk of Side Effect:Cocaine dependence;Allele G is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele A.; 
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC.;in people with Autoimmune hepatitis
;VALGANCICLOVIR;ABCB1;rs2229109;CT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;increased   PK:fluoxetine plasma concentration;CYP2D6 *4/*4 is associated with increased fluoxetine plasma concentration when treated with fluoxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.;in people with Disease:Major Depressive Disorder
;TETRABENAZINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Efficacy;Other:longer titration to achieve optimal benefit;CYP2D6 ultrarapid metabolizer is associated with longer titration to achieve optimal benefit when treated with tetrabenazine as compared to CYP2D6 poor metabolizer.; 
;MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;Metabolism/PK;increased   PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid;Allele T is associated with increased dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype del/del.;in people with Disease:Kidney Transplantation
;OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;Toxicity;increased  likelihood of Side Effect:Dizziness;CYP2C9 poor metabolizer is associated with increased likelihood of Dizziness due to olanzapine in healthy individuals as compared to CYP2C9 normal metabolizer and intermediate metabolizer.;in healthy individuals 
;"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTRR;rs1801394;AA + AG;Efficacy;decreased severity of Disease:Pain;Genotypes AA + AG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype GG.;in women with Disease:Migraine with Aura
;NICOTINE;HTR3B;rs3758987;TT;Toxicity;increased  severity of Other:Tobacco Use Disorder;Genotype TT is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotypes CC + CT.; 
;CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;Toxicity;increased  severity of Side Effect:Diarrhea, Side Effect:Drug Toxicity, Side Effect:Hand-foot syndrome;Allele TTAAAGTTA is associated with increased severity of Diarrhea, Drug Toxicity and hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele del.;in people with Colorectal Neoplasms
;CAPECITABINE;DPYD;rs67376798;AT;Toxicity;increased  severity of Side Effect:Diarrhea;Genotype AT is associated with increased severity of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype TT.;in people with Disease:Gastroesophageal Cancer
;ANTIDEPRESSANTS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;Metabolism/PK;increased   PK:plasma concentrations;CYP2D6 *3/*4 + *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizer phenotype) is associated with increased plasma concentrations when treated with antidepressants in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Disease:Major Depressive Disorder
;ENALAPRIL;PCGF3;rs1044147;A;Toxicity;increased  likelihood of Side Effect:Cough;Allele A is associated with increased likelihood of Cough when treated with enalapril in people with Hypertension as compared to allele G.;in people with Hypertension
;TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;Metabolism/PK;increased   PK:paroxetine plasma concentration;CYP2D6 *3/*4 + *4/*4 + *4/*5 is associated with increased paroxetine plasma concentration when treated with paroxetine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.;in people with Disease:Major Depressive Disorder
;TRAMADOL;COMT;rs4680;AA + AG;Toxicity;increased  severity of Side Effect:sedation;Genotypes AA + AG is associated with increased severity of sedation when treated with tramadol in people with surgery as compared to genotype GG.;in people with surgery
;ANTICHOLINERGIC AGENTS;CYP2C19;CYP2C19 poor metabolizers;;Metabolism/PK;increased   PK:Serum anticholinergic activity;CYP2C19 poor metabolizer is associated with increased serum anticholinergic activity when treated with Anticholinergic Agents as compared to CYP2C19 normal metabolizer.; 
;VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;Toxicity;increased  risk of Side Effect:side effects;CYP2D6 normal metabolizer is associated with increased risk of side effects when treated with venlafaxine in people with Obsessive-Compulsive Disorder.;in people with Disease:Obsessive-Compulsive Disorder
;ANTINEOPLASTIC AGENTS;ABCG2;rs2231164;CC + CT;Efficacy;increased   Efficacy:survival;Genotypes CC + CT are associated with increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype TT.;in people with Disease:Pancreatic Neoplasms
;CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;Efficacy;decreased  Efficacy:number of failed medication trails;CYP2D6 normal metabolizer is associated with decreased number of failed medication trails when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder.;in people with Disease:Obsessive-Compulsive Disorder
;MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;Metabolism/PK;increased   PK:dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid-7-O-glucuronide;Allele T is associated with increased dose-adjusted area under the concentration versus time curve (AUC6-12) level of mycophenolic acid-7-O-glucuronide when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype del/del.;in people with Disease:Kidney Transplantation
;MYCOPHENOLATE MOFETIL;ABCC2;rs2273697;AG;Metabolism/PK;increased   PK: area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid;Genotype AG is associated with increased area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;CAPECITABINE;DPYD;rs2297595;CT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CT is associated with decreased progression-free survival when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;OPRM1;rs1799971;GG;Toxicity;decreased  Side Effect:Nausea, Side Effect:Vomiting;Genotype GG is associated with decreased Nausea and Vomiting due to opioids in people with Pain as compared to genotypes AA + AG.;in people with Pain
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;Efficacy;increased  likelihood of Efficacy:Recurrence;CYP2C19 *1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Stroke
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;Toxicity;increased  risk of Side Effect:Hemorrhage;CYP2C19 *1/*17 + *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with increased risk of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1 + *1/*2 + *2/*2 + *2/*17 (assigned as normal metabolizer and intermediate metabolizer phenotype) .; 
;ATENOLOL;PAH;rs2245360;AA;Toxicity;increased  likelihood of Side Effect:Insulin Resistance;Genotype AA is associated with increased likelihood of Insulin Resistance when treated with atenolol in people with Hypertension as compared to genotypes AG + GG.;in people with Hypertension
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;Efficacy;increased  likelihood of Disease:Breast Neoplasms;CYP2D6 *3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7 (assigned as poor metabolizer phenotype) are associated with increased likelihood of Breast Neoplasms when treated with tamoxifen in women.;in women 
;ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Genotypes CT + TT is associated with increased likelihood of high on-treatment platelet reactivity when treated with aspirin null clopidogrel as compared to genotype CC.; 
;OPIOIDS;DRD2;rs1125394;CC + CT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype TT.;in women 
;OPIOIDS;OPRM1;rs1799971;G;Toxicity;decreased  Side Effect:adverse events;Allele G is associated with decreased adverse events due to opioids in people with Pain as compared to allele A.;in people with Pain
;SORAFENIB;VEGFA;rs3025040;CC;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype CC is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;Efficacy;decreased  Efficacy:Overall survival;CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;OPIOIDS;DRD2;rs1079596;CT + TT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes CT + TT are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype CC.;in women 
;TRAMADOL;COMT;rs4680;AA + AG;Toxicity;increased  severity of Side Effect:Postoperative Nausea and Vomiting;Genotypes AA + AG is associated with increased severity of Postoperative Nausea and Vomiting when treated with tramadol in people with surgery as compared to genotype GG.;in people with surgery
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;Efficacy;decreased  Efficacy:Overall survival;CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased overall survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;Other;increased  risk of Side Effect:Suicide;CYP2B6 intermediate metabolizer and poor metabolizer are associated with increased risk of suicide when treated with efavirenz in people with HIV Infections as compared to CYP2B6 normal metabolizer.;in people with Disease:HIV infectious disease
;ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;Toxicity;increased  likelihood of Side Effect:Febrile neutropenia;Genotype TT is associated with increased likelihood of febrile neutropenia when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes CC + CT.;in people with Soft Tissue Neoplasms, Sarcoma
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT intermediate metabolizers;;Toxicity;increased  likelihood of Side Effect:adverse events;TPMT intermediate metabolizer is associated with increased likelihood of adverse events when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;FLUOROURACIL;TYMS;rs2847153;AG + GG;Efficacy;decreased likelihood of Efficacy:survival;Genotypes AG + GG are associated with decreased likelihood of survival when treated with fluorouracil in people with Pancreatic Neoplasms as compared to genotype AA.;in people with Disease:Pancreatic Neoplasms
;MORPHINE;ABCC3;rs4148412;T;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele T is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele C.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;SORAFENIB;UGT1A9;rs7574296;AA;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype AA is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.;in people with Disease:Hepatocellular Carcinoma
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;Toxicity;decreased likelihood of Side Effect:Diarrhea;UGT1A1 *1/*1 + *1/*28 is associated with decreased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.;in people with Lung Neoplasms
;SORAFENIB;KDR;rs2071559;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;Dosage;increased  likelihood of Other:drug dosage altered;CYP3A5 normal metabolizer and intermediate metabolizer is associated with increased likelihood of drug dosage altered when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 poor metabolizer.;in people with Kidney Transplantation
;TRAMADOL;COMT;rs4680;GG;Efficacy;increased  severity of Efficacy:Pain, Postoperative;Genotype GG is associated with increased severity of Pain, Postoperative when treated with tramadol in people with surgery as compared to genotypes AA + AG.;in people with surgery
;"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;Efficacy;Efficacy:greater reduction in homocysteine;Genotypes AG + GG are associated with greater reduction in homocysteine when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA.;in women with Disease:Migraine with Aura
;AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;increased   PK:antidepressant serum levels;CYP2D6 poor metabolizer is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizer.;in people with Disease:Mental Disorders
;SORAFENIB;SLC15A2;rs2257212;CC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;FLUOROURACIL;CCND1;rs9344;AA;Efficacy;decreased  Efficacy:time-to-tumor recurrence;Genotype AA is associated with decreased time-to-tumor recurrence when treated with fluorouracil in Colonic Neoplasms as compared to genotypes AG + GG.;in Disease:Colonic Neoplasms
;AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:adverse effects;TPMT intermediate metabolizer is associated with increased likelihood of adverse effects when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;CAPECITABINE;UMPS;rs2279199;CC + CT;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotypes CC + CT are associated with decreased likelihood of Nausea and Vomiting when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;METFORMIN;;rs578427;TT;Metabolism/PK;increased   PK:renal clearance and secretion clearance of metformin;Genotype TT is associated with increased renal clearance and secretion clearance of metformin when exposed to metformin in healthy individuals as compared to genotype CC.;in healthy individuals 
;CAPECITABINE;TYMS;rs2853741;CT + TT;Toxicity;decreased likelihood of Side Effect:Diarrhea;Genotypes CT + TT are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;Toxicity;increased  likelihood of Side Effect:Hemorrhage;CYP2C19 ultrarapid metabolizer and rapid metabolizer is associated with increased likelihood of Hemorrhage when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 normal metabolizer.;in people with Cardiovascular Disease
;CAPECITABINE;SLC22A7;rs4149178;AG + GG;Toxicity;decreased likelihood of Side Effect:Diarrhea;Genotypes AG + GG are associated with decreased likelihood of Diarrhea when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;CISPLATIN;ABCC3;rs1051640;G;Toxicity;increased  risk of Disease:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;Metabolism/PK;increased   PK:dose-adjusted plasma levels;CYP2D6 *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*1 + *1/*41 + *4/*1xN (assigned as normal metabolizer phenotype) .;in people with Disease:Dementia
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizer phenotype) are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19 normal metabolizers;;Other;decreased risk of Other:major adverse cardiac events;CYP2C19 normal metabolizer is associated with decreased risk of major adverse cardiac events when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 intermediate metabolizer and poor metabolizer.;in people with Disease:Coronary Artery Disease
;METHOTREXATE;SLC19A1;rs1051266;T;Toxicity;increased   Disease:Drug-induced liver injury;Allele T is associated with increased drug-induced liver injury when treated with methotrexate in people with Psoriasis as compared to allele C.;in people with Disease:Psoriasis
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Efficacy;increased  likelihood of Efficacy:Major Adverse Cardiac Events (MACE);CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 normal metabolizer.;in people with Cardiovascular Disease
;ABT-751;UGT1A4;rs6755571;AC;Metabolism/PK;decreased  PK:plasma predose concentration (Ctrough);Genotype AC is associated with decreased plasma predose concentration (Ctrough) when treated with ABT-751 in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;CAPECITABINE;UMPS;rs4678145;CC + CG;Toxicity;increased  likelihood of Side Effect:Asthenia;Genotypes CC + CG are associated with increased likelihood of Asthenia when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ABT-751;UGT1A8;rs6431558;CC + CT;Metabolism/PK;increased   PK:glucuronidation metabolic ratios;Genotypes CC + CT are associated with increased glucuronidation metabolic ratios when treated with ABT-751 in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;increased   PK:mean area under the plasma concentration-time curve (AUC) of desipramine;CYP2D6 poor metabolizer is associated with increased mean area under the plasma concentration-time curve (AUC) of desipramine when treated with imipramine in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;ANTINEOPLASTIC AGENTS;DPYD;rs1760217;AA + AG;Efficacy;decreased  Efficacy:survival;Genotypes AA + AG are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype GG.;in people with Disease:Pancreatic Neoplasms
;AZATHIOPRINE;TPMT;rs1142345;CC + CT;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotypes CC + CT (assigned as poor metabolizers and intermediate metabolizers phenotype) is associated with increased risk of Toxic liver disease when treated with azathioprine as compared to genotype TT (assigned as normal metabolizer phenotype) .; 
;ANTINEOPLASTIC AGENTS;SERPINA3;rs17091162;AC + CC;Efficacy;decreased  Efficacy:survival;Genotypes AC + CC are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype AA.;in people with Disease:Pancreatic Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;Metabolism/PK;decreased  PK:mean peak plasma concentration of H4;CYP2C19 *1/*2 + *2/*17 (assigned as intermediate metabolizer phenotype) is associated with decreased mean peak plasma concentration of H4 when treated with clopidogrel in people with Cardiovascular Diseases as compared to CYP2C19 *1/*1.;in people with Disease:Cardiovascular Disease
;VALPROIC ACID;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;Toxicity;increased  risk of Side Effect:Weight gain;CYP2C19 intermediate metabolizer and poor metabolizer is associated with increased risk of Weight gain when treated with valproic acid in women with Epilepsy as compared to CYP2C19 normal metabolizer.;in women with Disease:Epilepsy
;ASPIRIN, CLOPIDOGREL;PTGS1;rs10306114;AG + GG;Toxicity;increased  risk of Side Effect:cardiovascular events;Genotypes AG + GG are associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotype AA.;in people with ST-segment elevation myocardial infarction (STEMI)
;METFORMIN;SLC47A2;rs12943590;AA;Metabolism/PK;increased   PK:renal clearance and secretion clearance of metformin;Genotype AA is associated with increased renal clearance and secretion clearance of metformin when exposed to metformin in healthy individuals as compared to genotype GG.;in healthy individuals 
;TAMOXIFEN;NCOA1;rs1804645;CT;Other;increased  severity of Side Effect:change in Lumbar Bone Mineral Density;Genotype CT is associated with increased severity of change in Lumbar Bone Mineral Density when treated with tamoxifen as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;Efficacy;increased  risk of Other:cardiovascular death,myocardial infarction or stroke;CYP2C19 intermediate metabolizer is associated with increased risk of cardiovascular death,myocardial infarction or stroke when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer.;in people with percutaneous coronary intervention (most of the patients)
;CITALOPRAM, ESCITALOPRAM;;rs352428;A;Efficacy;Efficacy:poor response at 8 week of treatment;Allele A is associated with poor response at 8 week of treatment when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;Efficacy;increased  risk of Disease:Thrombotic disease;CYP2C19 intermediate metabolizer is associated with increased risk of Thrombosis when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer.;in people with percutaneous coronary intervention (most of the patients)
;CITALOPRAM;;rs352428;A;Efficacy;Efficacy:poor response at 6 week of treatment;Allele A is associated with poor response at 6 week of treatment when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;Efficacy;increased  risk of Other:cardiovascular death,myocardial infarction or stroke;CYP2C19 poor metabolizer is associated with increased risk of cardiovascular death,myocardial infarction or stroke when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer.;in people with percutaneous coronary intervention (most of the patients)
;MIDAZOLAM;POR;rs1057868;CT;Metabolism/PK;decreased  PK:midazolam metabolic ratios by 45%;Genotype CT is associated with decreased midazolam metabolic ratios by 45% when exposed to midazolam as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;Efficacy;increased  risk of Disease:Thrombotic disease;CYP2C19 poor metabolizer is associated with increased risk of Thrombosis when treated with clopidogrel in people with percutaneous coronary intervention (most of the patients) as compared to CYP2C19 normal metabolizer.;in people with percutaneous coronary intervention (most of the patients)
;LENVATINIB;ABCG2;rs2231142;GG;Toxicity;increased  severity of Side Effect:Dry mouth, Side Effect:Mucositis;Genotype GG is associated with increased severity of dry mouth and mucositis when treated with lenvatinib in people with Thyroid Neoplasms as compared to genotype GT.;in people with Thyroid tumor
;NICOTINE;CHRNA3;rs578776;G;Metabolism/PK;increased   PK:plasma level;Allele G is associated with increased plasma level of nicotine in tobacco users as compared to allele A.;in tobacco users
;GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;Metabolism/PK;increased   PK:dose-adjusted plasma levels;CYP2D6 *3/*4 + *4/*4 + *4/*5 (assigned as poor metabolizer phenotype) are associated with increased dose-adjusted plasma levels of galantamine in people with Dementia as compared to CYP2D6 *1/*4 + *4/*41 + *5/*41 + *6/*41.;in people with Disease:Dementia
;TRAZODONE;CYP2D6;CYP2D6 normal metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:Dizziness;CYP2D6 normal metabolizer is associated with increased likelihood of Dizziness when treated with trazodone in healthy individuals as compared to CYP2D6 intermediate metabolizer and poor metabolizer.;in healthy individuals 
;CAPECITABINE;DPYD;rs17376848;AG;Toxicity;increased  severity of Side Effect:Stomatitis;Genotype AG is associated with increased severity of Stomatitis when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.;in people with Disease:Gastroesophageal Cancer
;RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Toxicity;decreased severity of Side Effect:Weight gain;CYP2D6 ultrarapid metabolizer is associated with decreased severity of Weight gain when treated with risperidone in children with Autistic Disorder as compared to CYP2D6 normal metabolizer.;in children with Disease:Autism
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA;Toxicity;increased  risk of Side Effect:cardiovascular events;Genotype AA is associated with increased risk of cardiovascular events when treated with aspirin and clopidogrel in people with ST-segment elevation myocardial infarction (STEMI) as compared to genotypes AG + GG.;in people with ST-segment elevation myocardial infarction (STEMI)
;LENVATINIB;CYP3A4;rs2242480;C;Toxicity;increased  severity of Side Effect:Diarrhea;Allele C is associated with increased severity of Diarrhea when treated with lenvatinib in people with Thyroid Neoplasms as compared to allele T.;in people with Thyroid tumor
;LENVATINIB;CYP3A5;rs776746;C;Toxicity;increased  severity of Side Effect:Diarrhea;Allele C is associated with increased severity of Diarrhea when treated with lenvatinib in people with Thyroid Neoplasms as compared to allele T.;in people with Thyroid tumor
;CAPECITABINE;ENOSF1, TYMS;rs699517;TT;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotype TT is associated with increased likelihood of Nausea and Vomiting when treated with capecitabine in people with as compared to genotypes CC + CT.;in people with 
;HEROIN;OPRK1;rs6473797;C;Toxicity;decreased risk of Other:Heroin Dependence;Allele C is associated with decreased risk of Heroin Dependence due to heroin as compared to allele T.; 
;HEROIN;CSNK1E;rs1534891;T;Toxicity;decreased risk of Other:Heroin Dependence;Allele T is associated with decreased risk of Heroin Dependence due to heroin as compared to allele C.; 
;CAPECITABINE;DPYD;rs12119882;AG;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotype AG is associated with increased likelihood of Hyperbilirubinemia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ETHANOL;CHRNA5;rs16969968;G;Toxicity;increased  likelihood of Disease:Alcohol abuse;Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A.; 
;HEROIN;GAL;rs694066;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;Efficacy;increased   Other:platelet reactivity;CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizer phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; 
;HEROIN;OPRD1;rs2236861;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.; 
;CAPECITABINE;SLC22A7;rs2270860;TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype TT is associated with increased likelihood of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotypes CC + CT.;in people with Disease:Colorectal Neoplasms
;HEROIN;OPRD1;rs3766951;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;METHADONE;CRHBP;rs1500;G;Other;decreased  Other:Recurrence;Allele G is associated with decreased Recurrence in people not taking methadone in people with Heroin Dependence as compared to allele C.;in people with Disease:Heroin Dependence
;METHAMPHETAMINE;FAAH;rs324420;A;Other;increased  likelihood of Other:dependence;Allele A is associated with increased likelihood of dependence with methamphetamine in men as compared to allele C.;in men 
;ETHANOL;CHRNA3;rs1051730;G;Toxicity;increased  likelihood of Disease:Alcohol abuse;Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A.; 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;Efficacy;increased  risk of Efficacy:Recurrence;CYP2D6 *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7 (assigned as poor metabolizer phenotype) are associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *1/*35 + *2/*2 + *2/*35 + *35/*35 + *1/*1xN + *2/*1xN + *1/*2xN.;in women with Disease:Breast Neoplasms
;HEROIN;OPRD1;rs2236857;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;NALOXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased   Efficacy:peak cortisol response;Genotypes AG + GG are associated with increased peak cortisol response when treated with naloxone as compared to genotype AA.; 
;TAMOXIFEN;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;Toxicity;increased  risk of Side Effect:Weight gain;CYP2D6 ultrarapid metabolizer is associated with increased risk of Weight gain when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;CAPECITABINE;ENOSF1, TYMS;rs699517;CT + TT;Toxicity;decreased likelihood of Side Effect:Asthenia;Genotypes CT + TT are associated with decreased likelihood of Asthenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1 + *1/*10;Toxicity;increased  likelihood of Side Effect:Leiomyoma, Side Effect:Liver Disorder, Side Effect:Ovarian Cysts;CYP2D6 *1/*1 + *1/*10 (assigned as normal metabolizer phenotype) is associated with increased likelihood of Leiomyoma, Liver Diseases or Ovarian Cysts when treated with tamoxifen in women with Breast Neoplasms.;in women with Breast Neoplasms
;HEROIN;HTR3B;rs3758987;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;METOPROLOL;CYP2D6;CYP2D6 poor metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:Bradycardia;CYP2D6 poor metabolizer is associated with increased likelihood of Bradycardia when treated with metoprolol as compared to CYP2D6 normal metabolizer.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Toxicity;increased  risk of Side Effect:Cardiovascular Disease;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; 
;OSIMERTINIB;ABCG2;rs2231142;GG;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotype GG is associated with increased likelihood of Diarrhea when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.;in people with Non-Small Cell Lung Carcinoma
;TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;Efficacy;increased   Efficacy:Recurrence free survival;CYP2D6 normal metabolizer is associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CT.;in people with Disease:Chronic hepatitis C virus infection
;ESCITALOPRAM;HTR2C;rs6318;C;Efficacy;decreased  Disease:Pain;Allele C is associated with decreased Pain when treated with escitalopram in men with neuropathic pain as compared to allele G.;in men with Disease:Neuropathic pain
;OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Metabolism/PK;decreased  PK:plasma oxymorphone/oxycodone ratio;CYP2D6 poor metabolizer is associated with decreased plasma oxymorphone/oxycodone ratio when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Efficacy;decreased  Efficacy:reduction in pain AUC;CYP2D6 poor metabolizer is associated with decreased reduction in pain AUC when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;MERCAPTOPURINE;GNMT;rs10948059;CT + TT;Toxicity;decreased likelihood of Side Effect:Dose reduction;Genotypes CT + TT is associated with decreased likelihood of dose reduction when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;NICOTINE;CHRNA5;rs16969968;A;Toxicity;increased  likelihood of Disease:Tobacco Use Disorder;Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.; 
;OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;Efficacy;decreased  PK:plasma oxymorphone/oxycodone ratio;CYP2D6 poor metabolizer is associated with decreased plasma oxymorphone/oxycodone ratio when treated with oxycodone in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;NICOTINE;CHRNA3;rs1051730;A;Toxicity;increased  likelihood of Disease:Tobacco Use Disorder;Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G.; 
;PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;Other;increased   Other:metabolic ratio DEM/DOR;CYP2D6 normal metabolizer is associated with increased metabolic ratio DEM/DOR when treated with paroxetine in people with Anxiety Disorders.;in people with Disease:Anxiety Disorders
;IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with irinotecan and Platinum compounds in people with Lung Neoplasms as compared to genotype GG.;in people with Lung Neoplasms
;PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;Toxicity;increased  risk of Side Effect:sexual dysfunction;CYP2D6 poor metabolizer is associated with increased risk of sexual dysfunction when treated with paroxetine in women with Mental Disorders as compared to CYP2D6 normal metabolizer.;in women with Disease:Mental Disorders
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;Efficacy;increased   Other:platelet reactivity;CYP2C19 *1/*2 + *1/*3 (assigned as intermediate metabolizer phenotype) are associated with increased platelet reactivity when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; 
;HEROIN;OPRM1;rs3778151;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizers;;Metabolism/PK;increased   PK:mean logarithm escitalopram concentration;CYP2D6 intermediate metabolizer is associated with increased mean logarithm escitalopram concentration when treated with escitalopram in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.;in people with Disease:Major Depressive Disorder
;PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;Metabolism/PK;increased   PK:median AUC, plasma half-life and steady-state plasma concentrations of paroxetine;CYP2D6 poor metabolizer is associated with increased median AUC, plasma half-life and steady-state plasma concentrations of paroxetine when exposed to paroxetine in healthy individuals as compared to CYP2D6 normal metabolizer.;in healthy individuals 
;CAPECITABINE;DPYD;rs1801265;AG + GG;Toxicity;increased  risk of Disease:Hand-foot syndrome;Genotypes AG + GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;Toxicity;increased  risk of Side Effect:sexual dysfunction;CYP2D6 poor metabolizer is associated with increased risk of sexual dysfunction when treated with paroxetine in people with Depressive Disorder as compared to CYP2D6 normal metabolizer.;in people with Disease:Depressive Disorder
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;Metabolism/PK;increased   PK:fluoxetine/(S)-norfluoxetine ratio;CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) are associated with increased fluoxetine/(S)-norfluoxetine ratio when treated with fluoxetine in children with Depressive Disorder as compared to CYP2D6 *1/*1xN (assigned as ultrarapid metabolizer phenotype) .;in children with Disease:Depressive Disorder
;CAPECITABINE;DPYD;rs1801265;AG + GG;Toxicity;increased  risk of Side Effect:Diarrhea;Genotypes AG + GG is associated with increased risk of Diarrhea when treated with capecitabine in people with gastroesophageal cancer as compared to genotype AA.;in people with Disease:Gastroesophageal Cancer
;ALKYLATING AGENTS, CISPLATIN;ESR1;rs2207396;A;Toxicity;increased  risk of Disease:Oligospermia;Allele A is associated with increased risk of Oligospermia when treated with Alkylating Agents and cisplatin in people with childhood cancer as compared to genotype GG.;in people with childhood cancer
;HEROIN;OPRM1;rs510769;T;Toxicity;increased  risk of Other:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;Toxicity;increased  risk of Side Effect:Cardiovascular Disease;CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizer phenotype) are associated with increased risk of Cardiovascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .; 
;ANTIDEPRESSANTS;CYP2D6;CYP2D6 poor metabolizers;;Toxicity;increased  risk of Side Effect:side effects;CYP2D6 poor metabolizer is associated with increased risk of side effects when treated with antidepressants in people with Depressive Disorder, Major.;in people with Disease:Major Depressive Disorder
;CITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;Efficacy;increased  likelihood of Efficacy:remission if tolerant to citalopram treatment;CYP2C19 poor metabolizer is associated with increased likelihood of remission if tolerant to citalopram treatment when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.;in people with Disease:Major Depressive Disorder
;TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;Efficacy;increased   Efficacy:event-free survival, Efficacy:Overall survival;Genotype *1/*1 (assigned as normal metabolizer phenotype) is associated with increased event-free survival and overall survival when treated with tamoxifen in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;Toxicity;increased  likelihood of Side Effect:Discontinuation;CYP2D6 normal metabolizer is associated with increased likelihood of discontinuation when treated with tamoxifen in women as compared to CYP2D6 poor metabolizer.;in women 
;ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Toxicity;increased  risk of Side Effect:Parkinsonian Disorder, Side Effect:Tardive Dyskinesia;CYP2D6 intermediate metabolizer and poor metabolizer are associated with increased risk of Parkinsonian Disorders and tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to CYP2D6 normal metabolizer.;in people with Disease:Schizophrenia
;OSIMERTINIB;STAT3;rs4796793;GG;Toxicity;increased  likelihood of Side Effect:Nail disorder;Genotype GG is associated with increased likelihood of Nail disease NOS when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CG.;in people with Non-Small Cell Lung Carcinoma
;ESCITALOPRAM;CYP2D6;rs1065852;AA;Efficacy;decreased  Efficacy:response and remission rate;Genotype AA is associated with decreased response and remission rate when treated with escitalopram in people with Depressive Disorder as compared to genotypes AG + GG.;in people with Disease:Depressive Disorder
;3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 poor metabolizer genotype;;Toxicity;increased  severity of Side Effect:Hypertension;CYP2C19 poor metabolizer is associated with increased severity of Hypertension when exposed to 3,4-methylenedioxymethamphetamine in healthy individuals as compared to CYP2C19 normal metabolizer and intermediate metabolizer.;in healthy individuals 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;rs4149014;GG + GT;Toxicity;decreased likelihood of Side Effect:Drug-induced liver injury;Genotypes GG + GT is associated with decreased likelihood of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype TT.;in people with Tuberculosis
;DOCETAXEL, EPIRUBICIN;;poor metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;CYP3A poor metabolizer is associated with increased likelihood of Drug Toxicity when treated with docetaxel and epirubicin in people with Breast Neoplasms as compared to CYP3A normal metabolizer and intermediate metabolizer.;in people with Disease:Breast Neoplasms
;;;rs6968865;T;Dosage;increased   Other:coffee consumption;Allele T is associated with increased coffee consumption.; 
;SULFAMETHOXAZOLE;GCLC;rs761142;AA;Toxicity;decreased risk of Disease:Drug Hypersensitivity;Genotype AA is associated with decreased risk of Drug Hypersensitivity when treated with sulfamethoxazole in people with HIV Infections as compared to genotypes AC + CC.;in people with Disease:HIV infectious disease
;AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer genotype;;Efficacy, Toxicity, Metabolism/PK;increased   PK:6-TG levels;TPMT intermediate metabolizer is associated with increased 6-TG levels when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:Death, Side Effect:Myocardial Infarction, Side Effect:Stroke;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) are associated with increased risk of Death, Myocardial Infarction and Stroke when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Disease:Coronary Artery Disease
;;CYP1A1;rs2472297;T;Dosage;increased   Other:coffee consumption;Allele T is associated with increased coffee consumption.; 
;SULFAMETHOXAZOLE;GCLC;rs761142;A;Toxicity;decreased risk of Disease:Drug Hypersensitivity;Allele A is associated with decreased risk of Drug Hypersensitivity when treated with sulfamethoxazole in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;rs2244613;GT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes GT + TT is associated with increased risk of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban in people with Thromboembolism as compared to genotype GG.;in people with Thromboembolism
;TRAMADOL;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;Toxicity;increased  severity of Side Effect:Toxic liver disease;CYP2D6 normal metabolizer and ultrarapid metabolizer is associated with increased severity of Toxic liver disease due to tramadol in people with Low Back Pain or Osteoarthritis as compared to CYP2D6 poor metabolizer.;in people with Disease:Low Back Pain, Disease:Osteoarthritis
;ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs2273697;AG + GG;Efficacy;increased   Efficacy:Recurrence free survival;Genotypes AG + GG is associated with increased Recurrence free survival when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotype AA.;in people with Soft Tissue Neoplasms, Sarcoma
;SORAFENIB;KDR;rs1870377;TT;Efficacy;increased   Efficacy:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AT.;in people with Disease:Hepatocellular Carcinoma
;TACROLIMUS;CYP3A4;rs35599367;AG;Other;increased   PK:creatinine clearance;Genotype AG is associated with increased creatinine clearance when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with anthracyclines and related substances in people with Soft Tissue Neoplasms and Sarcoma as compared to genotypes CC + CT.;in people with Soft Tissue Neoplasms, Sarcoma
;CLOPIDOGREL;PON1;rs662;CC;Efficacy;decreased  Efficacy:on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI);Genotype CC is associated with decreased on-clopidogrel platelet reactivity (PR) at 1 month and at 6 months after percutaneous coronary intervention (PCI) when treated with clopidogrel in people with Myocardial Ischemia as compared to genotypes CT + TT.;in people with Disease:Myocardial Ischemia
;ANTIPSYCHOTICS;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;Toxicity;increased  likelihood of Side Effect:Tardive Dyskinesia;CYP2D6 ultrarapid metabolizer is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with schizoaffective disorder or Schizophrenia as compared to CYP2D6 normal metabolizer and intermediate metabolizer.;in people with Schizoaffective disorder, Schizophrenia
;ISONIAZID;ASTN2;rs117491755;C;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele C is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.;in people with Tuberculosis
;ALECTINIB;PPARA;rs4253728;AA + AG;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased severity of Drug Toxicity when treated with alectinib in people with Non-Small Cell Lung Carcinoma as compared to genotype GG.;in people with Non-Small Cell Lung Carcinoma
;VALPROIC ACID;SCN1A;rs2298771;TT;Efficacy;decreased likelihood of Side Effect:Weight gain;Genotype TT is associated with decreased likelihood of Weight gain when treated with valproic acid in children with Epilepsy as compared to genotypes CC + CT.;in children with Epilepsy
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or drug reaction with eosinophilia and systemic symptoms when treated with sulfamethoxazole / trimethoprim.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Diarrhea;UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.;in people with Stomach Neoplasms
;ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;Efficacy;increased  likelihood of Side Effect:Gastrointestinal toxicity;CYP2D6 *10/*10 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of gastrointestinal toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.;in children with Attention Deficit Disorder with Hyperactivity
;CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;;Toxicity;increased  likelihood of Side Effect:Ototoxicity;GSTT1 null is associated with increased likelihood of Ototoxicity when treated with cisplatin in people with Head and Neck Neoplasms as compared to GSTT1 non-null.;in people with Head and Neck Neoplasms
;CISPLATIN;GSTM1;GSTM1 non-null, GSTM1 null;;Toxicity;decreased likelihood of Side Effect:Ototoxicity;GSTM1 null is associated with decreased likelihood of Ototoxicity when treated with cisplatin in people with Head and Neck Neoplasms as compared to GSTM1 non-null.;in people with Head and Neck Neoplasms
;ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2D6 *1/*4 + *4/*4 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of adverse events when treated with aripiprazole, olanzapine or risperidone in children with Schizophrenia as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in children with Schizophrenia
;CODEINE;ABCB1;rs2032582;AA;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:CNS depression in breast-feeding infants;Genotype AA is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain.;in women with Disease:Pain
;ETHANOL;CRHBP;rs10055255;TT;Toxicity;increased  severity of Other:Alcohol abuse;Genotype TT is associated with increased severity of Alcoholism due to ethanol as compared to genotypes AA + AT.; 
;SUNITINIB;NR1I2;rs2276707;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;ANTIPSYCHOTICS;DRD2;rs1799732;del;Toxicity;decreased likelihood of Side Effect:sexual dysfunction;Allele del is associated with decreased likelihood of sexual dysfunction when treated with antipsychotics in men with Schizophrenia as compared to allele G.;in men with Disease:Schizophrenia
;LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *15:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.; 
;OXALIPLATIN;HLA-DRB1;HLA-DRB1*12:01;*12:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *12:01 is associated with increased likelihood of Drug Hypersensitivity when treated with oxaliplatin.; 
;TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;CYP2A6 *4 + *7 + *9 + *10 is associated with decreased likelihood of overall survival or progression-free survival when treated with tegafur / gimeracil / oteracil in people with Stomach Neoplasms as compared to CYP2A6 *1.;in people with Stomach Neoplasms
;CEFACLOR;HLA-DRB1;HLA-DRB1*14:54;*14:54;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *14:54 is associated with increased likelihood of Drug Hypersensitivity when exposed to cefaclor.; 
;ETHANOL;OPRM1;rs1799971;AG + GG;Toxicity;increased  severity of Other:Alcohol abuse;Genotypes AG + GG is associated with increased severity of Alcoholism due to ethanol as compared to genotype AA.; 
;SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *11:01 is associated with increased likelihood of severe cutaneous adverse reactions or drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.; 
;SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *39:01 is associated with increased likelihood of severe cutaneous adverse reactions or drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.; 
;SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *56:03 is associated with increased likelihood of severe cutaneous adverse reactions or drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.; 
;METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2;*1/*2;Efficacy;decreased  Efficacy:heart rate;CYP2D6 *1/*2 is associated with decreased heart rate when treated with metoprolol in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;METHAMPHETAMINE;DAOA;rs778293;C;Toxicity;increased  likelihood of Disease:Psychotic Disorder;Allele C is associated with increased likelihood of Psychotic Disorders due to methamphetamine as compared to allele T.; 
;CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;Toxicity;increased  likelihood of Side Effect:Anaphylaxis;HLA-DRB1 *04:03 is associated with increased likelihood of Anaphylaxis when exposed to cefaclor.; 
;CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DRB1 *04:03 is associated with increased likelihood of Drug Hypersensitivity when exposed to cefaclor.; 
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  severity of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *58:01 is associated with increased severity of severe cutaneous adverse reactions when exposed to allopurinol.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;Efficacy, Toxicity;increased  likelihood of Side Effect:Discontinuation;SLCO1B1 *15 is associated with increased likelihood of discontinuation when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*20;*20;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;SLCO1B1 *20 is associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;Efficacy;decreased likelihood of Efficacy:Myocardial Infarction, Efficacy:Angina Pectoris;SLCO1B1 *37 is associated with decreased likelihood of Myocardial Infarction or Angina Pectoris when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;Efficacy;increased  severity of Efficacy:Hypercholesterolemia;SLCO1B1 *5 is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;Efficacy;increased  severity of Efficacy:Hypercholesterolemia;SLCO1B1 *15 is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;Efficacy, Toxicity;increased  likelihood of Side Effect:Discontinuation;SLCO1B1 *5 is associated with increased likelihood of discontinuation when treated with atorvastatin or simvastatin.; 
;SORAFENIB;KDR;rs2071559;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AG.;in people with Disease:Hepatocellular Carcinoma
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;SLCO1B1 *15 is associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*14;*14;Efficacy;decreased severity of Efficacy:Hypercholesterolemia;SLCO1B1 *14 is associated with decreased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin.; 
;TACROLIMUS;ABCB1;rs1045642;AG;Efficacy;increased  risk of Disease:Hypokalemia;Genotype AG is associated with increased risk of Hypokalemia when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.;in children with Disease:Kidney Transplantation
;RISPERIDONE;ADRB2;rs1042713;G;Toxicity;increased  likelihood of Side Effect:Sexual adverse events;Allele G is associated with increased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia as compared to allele A.;in people with Disease:Schizophrenia
;BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE PROPIONATE, MOMETASONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  likelihood of Efficacy:Status asthmaticus;CYP3A5 *1/*1 + *1/*3 is associated with increased likelihood of exacerbation of asthma when treated with beclomethasone, budesonide, fluticasone, fluticasone propionate or mometasone in people with Asthma as compared to CYP3A5 *3/*3.;in people with Asthma
;NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*1x2;*1/*1x2;Toxicity;increased  severity of Other:Tobacco Use Disorder;CYP2A6 *1/*1x2 is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to CYP2A6 *1/*1.; 
;CYTARABINE;GLI1;rs2228224;AA;Efficacy;decreased  Efficacy:Recurrence free survival;Genotype AA is associated with decreased Recurrence free survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Leukemia, Myeloid, Acute
;CYTARABINE;ARHGAP9, GLI1;rs2229300;GT + TT;Efficacy;decreased  Efficacy:Recurrence free survival, Efficacy:Overall survival;Genotypes GT + TT is associated with decreased Recurrence free survival and overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Leukemia, Myeloid, Acute
;CODEINE;ABCB1;rs1128503;A;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:CNS depression in breast-feeding infants;Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.;in women with Disease:Pain
;CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;SORAFENIB;KDR;rs1870377;TT;Efficacy;increased   Efficacy:Overall survival;Genotype TT is associated with increased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AT.;in people with Disease:Hepatocellular Carcinoma
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.;in people with Disease:Drug Hypersensitivity
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.;in people with Disease:Hyperuricemia
;CODEINE;ABCB1;rs2032582;AA;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:CNS depression;Genotype AA is associated with increased likelihood of CNS depression when treated with codeine in women with Pain.;in women with Disease:Pain
;CODEINE;ABCB1;rs1045642;A;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:CNS depression in breast-feeding infants;Allele A is associated with increased likelihood of CNS depression in breast-feeding infants when treated with codeine in women with Pain as compared to allele G.;in women with Disease:Pain
;CLOPIDOGREL, RESPIRATORY SYSTEM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy;increased  likelihood of Efficacy:Major Adverse Cardiac Events (MACE);CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel and Respiratory System in people with Elderly Adult and Cardiovascular Diseases as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Elderly Adult, Cardiovascular Disease
;;CELSR2, PSRC1;rs602633;T;Metabolism/PK;PK:baseline LDL cholesterol;Allele T is associated with baseline LDL cholesterol in people with Vascular Diseases.;in people with Disease:Vascular Diseases
;COCAINE, ETHANOL, OPIOIDS;OPRM1;rs524731;A;Toxicity;increased  risk of Other:Alcohol abuse, Other:Cocaine dependence, Other:Opioid-Related Disorders;Allele A is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele C.; 
;ATAZANAVIR, INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir or indinavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28.;in people with HIV infectious disease
;ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;Toxicity;increased  risk of Side Effect:over-anticoagulation;CYP2C9 *1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3 are associated with increased risk of over-anticoagulation when treated with phenprocoumon as compared to CYP2C9 *1/*1.; 
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;UGT1A1 *1/*28 + *28/*28 is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.;in people with HIV infectious disease
;METHOTREXATE;SLCO1B1;rs4149081;G;Other, Metabolism/PK;increased   PK:clearance;Allele G is associated with increased clearance of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in people with Disease:Acute lymphoblastic leukemia
;BETA BLOCKING AGENTS;GRK5;rs2230345;AA;Efficacy;decreased risk of Efficacy:Death;Genotype AA is associated with decreased risk of Death when treated with Beta Blocking Agents in people with Heart Failure as compared to genotypes AT + TT.;in people with Heart Failure
;VALPROIC ACID;SCN1A;rs10167228;AA;Efficacy;decreased likelihood of Side Effect:Weight gain;Genotype AA is associated with decreased likelihood of Weight gain when treated with valproic acid in children with Epilepsy as compared to genotypes AT + TT.;in children with Epilepsy
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  likelihood of Efficacy:Graft vs Host Disease;CYP3A5 *1/*1 + *1/*3 (assigned as normal metabolizer and intermediate metabolizer phenotype) is associated with increased likelihood of Graft vs Host Disease when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *3/*3 (assigned as poor metabolizer phenotype) .;in people with Hematopoietic stem cell transplantation
;TACROLIMUS;ABCB1;rs1045642;AG;Efficacy;increased  risk of Disease:Transplant rejection;Genotype AG is associated with increased risk of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotypes AA + GG.;in children with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;Toxicity;increased  risk of Disease:Death;CYP2C19 *5 is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;Metabolism/PK;increased   PK:dose/weight adjusted AUC for mirtazapine;CYP2D6 *4/*4 + *4/*6 is associated with increased dose/weight adjusted AUC for mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;TROGLITAZONE;;rs10811661;C;Efficacy;increased   Efficacy:beta cell function;Allele C is associated with increased beta cell function when treated with troglitazone in people with high risk for type 2 diabetes as compared to allele T.;in people with high risk for type 2 diabetes
;PLATINUM COMPOUNDS;ERCC2;rs1799793;CC + CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CC + CT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;NEVIRAPINE;CYP2B6;rs3745274;T;Metabolism/PK;increased   Other:plasma level;Allele T is associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;Metabolism/PK;decreased  PK:citalopram oral clearances of citalopram;CYP2C19 *3 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;METHAMPHETAMINE;PICK1;rs713729;T;Toxicity;increased  likelihood of Disease:Substance-Related Disorders;Allele T is associated with increased likelihood of Substance-Related Disorders due to methamphetamine as compared to allele A.; 
;IMATINIB;ABCG2;rs2231142;T;Toxicity;increased  severity of Side Effect:Exanthema;Allele T is associated with increased severity of Exanthema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.;in people with Gastrointestinal Stromal Tumors
;CAFFEINE;DRD2;rs1110976;GG;Other;decreased  Side Effect:anxiety;Genotype GG is associated with decreased anxiety when exposed to caffeine in people with no disease.;in people with no disease
;OPIOIDS;;rs4530637;AG + GG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.;in men 
;NEVIRAPINE;ABCB1;rs1045642;A;Toxicity;decreased risk of Disease:Toxic liver disease;Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3778156;G;Toxicity;increased  risk of Other:Alcohol abuse, Other:Cocaine dependence, Other:Opioid-Related Disorders;Allele G is associated with increased risk of Alcoholism, Cocaine-Related Disorders or Opioid-Related Disorders due to cocaine, ethanol or opioids as compared to allele A.; 
;;;rs1111875;C;Metabolism/PK;decreased  PK:insulin secretion at baseline;Allele C is associated with decreased insulin secretion at baseline in people with high risk of type 2 diabetes as compared to allele T.;in people with high risk of type 2 diabetes
;CISPLATIN;COMT;rs9332377;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children as compared to allele C.;in children 
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4 + *6;Metabolism/PK;increased   PK:dose-corrected plasma concentrations of fluoxetine;CYP2D6 *4 + *6 is associated with increased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;OPIOIDS;TACR3;rs1384401;AG + GG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype AA.;in men 
;CISPLATIN;COMT;rs4646316;C;Toxicity;increased  risk of Disease:Ototoxicity;Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.;in children with Disease:Neoplasms
;FOLFIRI;ABCC2;rs2273697;GG;Toxicity;decreased severity of Side Effect:Diarrhea;Genotype GG is associated with decreased severity of Diarrhea when treated with FOLFIRI in people with Pancreatic Neoplasms as compared to genotypes AA + AG.;in people with Pancreatic Neoplasms
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased   PK:citalopram AUC and terminal elimination half-life;CYP2C19 *2/*2 + *2/*3 is associated with increased citalopram AUC and terminal elimination half-life when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.;in healthy individuals 
;PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;Efficacy;increased   Efficacy:Progression-free survival, Efficacy:Overall survival;Genotypes CT + TT is associated with increased progression-free survival and overall survival when treated with Platinum compounds in people with Lung Neoplasms and Tobacco Use Disorder as compared to genotype CC.;in people with Lung Neoplasms, Tobacco Use Disorder
;METHOTREXATE;ABCC2;rs717620;T;Toxicity;increased  risk of Disease:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Efficacy;increased   Efficacy:Recurrence free survival;CYP2D6 *4/*4 is associated with increased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*4.;in women with Disease:Breast Neoplasms
;METHAMPHETAMINE;PICK1;rs713729;T;Other;increased  likelihood of Side Effect:Recurrence;Allele T is associated with increased likelihood of Recurrence due to methamphetamine in people with Substance-Related Disorders as compared to allele A.;in people with Disease:Substance-Related Disorders
;OPIOIDS;CYP2D6;rs1065852;AA;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes AG + GG.;in men 
;FOLFIRI;ABCC2;rs1885301;AA;Toxicity;increased  severity of Side Effect:Nausea;Genotype AA is associated with increased severity of Nausea when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Colorectal Neoplasms
;CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Metabolism/PK;increased   PK:median concentration/dose ratio and median parent drug/metabolite ratio;CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.;in people with Disease:Major Depressive Disorder
;OPIOIDS;DRD3;rs6280;CC + CT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype TT.;in men 
;HYDROCHLOROTHIAZIDE;;rs17137967;CC + CT;Toxicity;increased   Side Effect:fasting glucose;Genotypes CC + CT are associated with increased fasting glucose when treated with hydrochlorothiazide in people with Hypertension as compared to genotype TT.;in people with Disease:Hypertension
;;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;Other;decreased severity of Other:Tobacco Use Disorder;CYP2A6 *4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9 are associated with decreased severity of Tobacco Use Disorder as compared to CYP2A6 *1/*1.; 
;OPIOIDS;DRD3;rs324029;AA + AG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotype GG.;in men 
;TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;Toxicity;decreased severity of Disease:Breast tenderness, Disease:Vaginal dryness, Disease:Vomiting;CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased severity of breast tenderness, vaginal dryness and Vomiting when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 normal metabolizer and ultra-metabolizer.;in women with Disease:Breast Neoplasms
;OPIOIDS;EXOC4;rs718656;TT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype TT is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CC + CT.;in men 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs4646244;A;Toxicity, Metabolism/PK;increased  risk of Disease:Hepatitis;Allele A is associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Toxicity;increased  risk of Side Effect:extrapyramidal symptoms;CYP2D6 *4/*4 (assigned as poor metabolizer phenotype) is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Schizophrenia, Bipolar Disorder, Personality Disorder, Psychotic Disorder, Obsessive-Compulsive Disorder
;NICOTINE;CHRNB2;rs2072660;T;Other;increased  severity of Disease:Tobacco Use Disorder;Allele T is associated with increased severity of Tobacco Use Disorder due to nicotine in smokers as compared to allele C.;in smokers
;DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;GG;Efficacy;decreased  Efficacy:Sustained virological response (SVR);Genotype GG is associated with decreased sustained virological response (svr) when treated with direct acting antivirals in people with Hepatitis C, Chronic as compared to genotypes G/TT + TT/TT.;in people with Disease:Chronic hepatitis C virus infection
;PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes CCGG/CCGG + CCGG/del is associated with decreased overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype del/del.;in people with Disease:Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;GG;Efficacy;Efficacy:lack of treatment response;Genotype GG is associated with lack of treatment response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes GT + TT.;in people with Disease:Hepatitis C virus infection
;ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;UGT1A1 *1/*28 + *28/*28 is associated with increased risk of Hyperbilirubinemia when treated with atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.;in people with HIV infectious disease
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;PLATINUM COMPOUNDS;ERCC2;rs50872;GG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;ABCG2;rs1448784;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotypes AA + AG.;in people with Lung Neoplasms
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;Toxicity, Metabolism/PK;increased  risk of Disease:Hepatitis;Allele A is associated with increased risk of Hepatitis when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;NICOTINE;CHRNB2;rs2072661;A;Other;increased  severity of Disease:Tobacco Use Disorder;Allele A is associated with increased severity of Tobacco Use Disorder due to nicotine in smokers as compared to allele G.;in smokers
;CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;CYP2D6 *3/*3 + *4/*4 are associated with decreased risk of Opioid-Related Disorders due to codeine, hydrocodone or oxycodone as compared to CYP2D6 *1/*1 + *1/*3 + *1/*4.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;Toxicity;decreased severity of Side Effect:Diarrhea;UGT1A1 *1/*1 + *1/*28 is associated with decreased severity of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to UGT1A1 *28/*28.;in people with Lung Neoplasms
;BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AA + AG are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;HLA-B *15:11 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.; 
;HYDROXYCHLOROQUINE;CYP2C8;rs10882526;GG;Toxicity;increased  risk of Side Effect:adverse events;Genotype GG is associated with increased risk of adverse events when treated with hydroxychloroquine in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes AA + AG.;in people with Rheumatoid arthritis, Systemic lupus erythematosus
;OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs660652;GG;Toxicity;increased   Disease:Tobacco Use Disorder;Genotype GG is associated with increased Tobacco Use Disorder when treated with Opium alkaloids and derivatives in people with Pain as compared to genotypes AA + AG.;in people with Disease:Pain
;METHAMPHETAMINE;;rs1421292;T;Toxicity;increased  likelihood of Disease:Psychotic Disorder;Allele T is associated with increased likelihood of Psychotic Disorders due to methamphetamine.; 
;ACE INHIBITORS, PLAIN;ABO;rs495828;GT + TT;Toxicity;Disease:Cough;Genotypes GT + TT are associated with Cough when treated with Ace Inhibitors, Plain as compared to genotype GG.; 
;AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Toxicity;increased  risk of Side Effect:Side Effects;CYP2D6 *4/*4 is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or Opipramol in people with Depression as compared to CYP2D6 *1/*1.;in people with Disease:Depression
;GLICLAZIDE;KCNJ11;rs5219;CT + TT;Efficacy;increased   Efficacy:efficacy as measured by decrease in HbA1c;Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c when treated with gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Disease:Diabetes Mellitus, Type 2
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1 + *17;Efficacy;decreased  Other:platelet reactivity;CYP2C19 *1 + *17 are associated with decreased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to CYP2C19 *2.;in people with Disease:Coronary Artery Disease
;PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;Toxicity;increased  risk of Side Effect:Toxic liver disease;NAT2 slow acetylator is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Disease:Tuberculosis
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  risk of Side Effect:Cardiovascular Disease;CYP2C19 *2/*2 + *2/*3 + *3/*3 is associated with increased risk of Cardiovascular Diseases when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;OPIOIDS;ZNF804A;rs7597593;CC;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes CT + TT.;in women 
;NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;Metabolism/PK;decreased  PK:maximum plasma concentration of 10-hydroxy nortriptyline;CYP2D6 *4/*4 is associated with decreased maximum plasma concentration of 10-hydroxy nortriptyline when exposed to nortriptyline in healthy individuals as compared to CYP2D6 *1/*1.;in healthy individuals 
;OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;rs1051730;AA;Toxicity;increased  severity of Disease:Substance-Related Disorders;Genotype AA is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to genotypes AG + GG.;in people with Disease:Pain
;HYDROXYCHLOROQUINE;CYP3A5;rs776746;TT;Toxicity;increased  risk of Side Effect:adverse events;Genotype TT is associated with increased risk of adverse events when treated with hydroxychloroquine in people with Arthritis, Rheumatoid or Lupus Erythematosus, Systemic as compared to genotypes CC + CT.;in people with Rheumatoid arthritis, Systemic lupus erythematosus
;PLATINUM COMPOUNDS;IL16;rs7170924;GT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes GT + TT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;INDOMETHACIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;increased  likelihood of Efficacy:Treatment failure;CYP2C9 *2 is associated with increased likelihood of treatment failure when treated with indomethacin in infants with Ductus Arteriosus, Patent as compared to CYP2C9 *1.;in infants with Patent Ductus Arteriosus
;;CHRNA3;rs1051730;AA + AG;Other;increased  likelihood of Other:Non-Small Cell Lung Carcinoma;Genotypes AA + AG is associated with increased likelihood of Carcinoma, Non-Small-Cell Lung as compared to genotype GG.; 
;NEVIRAPINE;HLA-B;HLA-B*15:10;*15:10;Toxicity;decreased risk of Disease:Toxic liver disease;HLA-B *15:10 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;CYP2C9 *1/*3 + *3/*3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 *1/*1.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;Efficacy;increased  risk of Efficacy:Stroke, Efficacy:Myocardial Infarction, Efficacy:Death;CYP2C19 *2 + *3 + *8 are associated with increased risk of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Ischemic Attack, Transient and Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17.;in people with Transient Ischemic Attack, Stroke
;ASPIRIN;TBXA2R;rs1131882;A;Efficacy, Toxicity;increased  risk of Side Effect:Death;Allele A is associated with increased risk of Death when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to allele G.;in people with Disease:Diabetes Mellitus, Type 2
;OPIOIDS;CNR1;rs2023239;TT;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype TT is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CC + CT.;in men 
;;NQO1;rs1800566;AA;Other;Other:significantly shorter survival;Genotype AA is associated with significantly shorter survival in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;BUSULFAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;Metabolism/PK;increased   PK:metabolic ratio;CYP2C9 *2 + *3 is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to CYP2C9 *1/*1.;in children with Disease:hemopoietic stem cell transplant
;PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;METFORMIN;SLC29A4;rs3889348;G;Toxicity;increased  severity of Side Effect:Gastrointestinal toxicity;Allele G is associated with increased severity of gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.;in people with Diabetes Mellitus, Type 2
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 are associated with increased severity of Diarrhea when treated with irinotecan in people with Neoplasms as compared to UGT1A1 *1/*1.;in people with Neoplasms
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Diarrhea when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;;NQO1;rs1800566;A;Toxicity;increased  risk of Disease:Leukemia;Allele A is associated with increased risk of Leukemia.; 
;HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;Efficacy;increased   Efficacy:reduction in blood pressure;Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in women with Essential hypertension as compared to genotype del/del.;in women with Disease:Essential hypertension
;DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;Toxicity;increased  risk of Side Effect:Toxic liver disease;GSTM1 null is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;GSTT1 null;;Toxicity;increased  risk of Side Effect:Toxic liver disease;GSTT1 null is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.;in people with Disease:Tuberculosis
;OPIOIDS;CNR1;rs6928499;CC;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to genotypes CG + GG.;in men 
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*10 + *10/*10 + *1/*5 + *2/*10 (assigned as intermediate metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;NEVIRAPINE;CYP2B6;rs58425034;CC + CG;Other;increased  likelihood of Side Effect:Elevated liver enzymes;Genotypes CC + CG is associated with increased likelihood of Elevated liver enzymes when treated with nevirapine in people with HIV infectious disease as compared to genotype GG.;in people with Disease:HIV infectious disease
;FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Efficacy;decreased  Disease:event-free survival, Disease:Overall survival;Genotype TTAAAGTTA/TTAAAGTTA is associated with decreased event-free survival and overall survival when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes TTAAAGTTA/del + del/del.;in people with Disease:Rectal Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;Efficacy;increased  risk of Side Effect:Death, Side Effect:Myocardial Infarction;CYP2C19 *2/*2 is associated with increased risk of Death and Myocardial Infarction when treated with clopidogrel in people with Angina Pectoris.;in people with Disease:Angina Pectoris
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;Toxicity;increased  risk of Side Effect:toxicity;Allele C is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele T.;in people with Disease:Prostatic Neoplasms
;"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;Efficacy;decreased severity of Disease:Pain;Genotypes AG + GG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA.;in women with Disease:Migraine with Aura
;CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;Toxicity;increased  risk of Disease:Drug Hypersensitivity;HLA-B *51:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.; 
;DOCETAXEL, THALIDOMIDE;SLC10A2;rs2301159;A;Toxicity;increased  risk of Side Effect:toxicity;Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;in people with Disease:Prostatic Neoplasms
;AXITINIB, SORAFENIB;HIF1A;rs11549465;CT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CT is associated with decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;Efficacy;increased  risk of Efficacy:Disease Progression;Genotype TTAAAGTTA/TTAAAGTTA is associated with increased risk of Disease Progression when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes TTAAAGTTA/del + del/del.;in people with Disease:Colorectal Neoplasms
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;Toxicity, Metabolism/PK;increased  risk of Side Effect:drug-induced liver injury;CYP2B6 *6/*6 is associated with increased risk of drug-induced liver injury when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1.;in people with Disease:HIV infectious disease
;METHOTREXATE;SLC19A1;rs1051266;CC + CT;Efficacy;increased  severity of Disease:Rheumatoid arthritis;Genotypes CC + CT are associated with increased severity of Arthritis, Rheumatoid when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;SORAFENIB;KDR;rs2071559;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;decreased  Efficacy:time in therapeutic range;CYP2C9 *2 is associated with decreased time in therapeutic range when treated with warfarin as compared to CYP2C9 *1/*1.; 
;NICOTINE;DBH;rs77905;AA + AG;Efficacy;increased  likelihood of Efficacy:Smoking Cessation;Genotypes AA + AG is associated with increased likelihood of cessation when treated with nicotine in people with Tobacco Use Disorder as compared to genotype GG.;in people with Disease:Tobacco Use Disorder
;METHOTREXATE;ADORA2A;rs2298383;GG;Toxicity;increased  risk of Side Effect:Neurotoxicity Syndromes;Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with methotrexate in children with Hematologic Neoplasms as compared to genotypes AA + AG.;in children with Disease:Hematologic Neoplasms
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *5/*10 (assigned as poor metabolizer phenotype) is associated with decreased Recurrence free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;Other;increased   Other:platelet aggregation with ADP;CYP2C19 *1/*2 is associated with increased platelet aggregation with ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;RISPERIDONE;CYP2D6;rs3892097;CT + TT;Toxicity;increased  likelihood of Side Effect:extrapyramidal symptoms, Side Effect:Tremor, Side Effect:Muscle Rigidity;Genotypes CT + TT is associated with increased likelihood of extrapyramidal symptoms, Tremor or Muscle Rigidity when treated with risperidone in people with Schizophrenia or schizoaffective disorder as compared to genotype CC.;in people with Schizophrenia, Schizoaffective disorder
;;CYP2B6;rs3211371;TT;Other;increased  likelihood of Other:smoking cessation;Genotype TT is associated with increased likelihood of smoking cessation in people with rs1800497 GG genotypes as compared to genotype CC.;in people with rs1800497 GG genotypes
;;CYP2B6;rs3211371;CT;Other;increased  likelihood of Other:smoking cessation;Genotype CT is associated with increased likelihood of smoking cessation in people with rs1800497 GG genotypes as compared to genotype CC.;in people with rs1800497 GG genotypes
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *3 + *4 + *5 + *10 + *41 are associated with decreased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 (assigned as normal metabolizer phenotype) .;in women with Disease:Breast Neoplasms
;FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);Toxicity;increased  risk of Side Effect:Psychomotor Agitation, Side Effect:Insomnia;SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of Psychomotor Agitation or insomnia when treated with fluoxetine in people with Major Depressive Disorder as compared to SLC6A4 HTTLPR long form (L allele).;in people with Disease:Major Depressive Disorder
;IRINOTECAN;UGT1A1;rs4124874;G;Toxicity;increased  risk of Disease:Neutropenia;Allele G is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;;CYP24A1;rs2762939;C;Other;decreased risk of Disease:Coronary Artery Disease;Allele C is associated with decreased risk of Coronary Artery Disease as compared to allele G.; 
;OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs16969968;A;Toxicity;increased  severity of Disease:Substance-Related Disorders;Allele A is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to allele G.;in people with Disease:Pain
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;Toxicity;increased  risk of Side Effect:adverse outcome;CYP2C9 *1/*2 + *1/*3 + *2/*3 is associated with increased risk of adverse outcome when treated with warfarin in orthopedic patients as compared to CYP2C9 *1/*1.;in orthopedic patients
;MORPHINE;ABCC3;rs739923;G;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele A.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;CITALOPRAM;PAPLN;rs11628713;T;Toxicity;increased  risk of Side Effect:suicidal ideation;Allele T is associated with increased risk of suicidal ideation when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Toxicity;increased  likelihood of Side Effect:over anti-coagulation;CYP2C9 *2 is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to CYP2C9 *1.; 
;SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;Efficacy;increased   Efficacy:efficacy as measured by decrease in HbA1c after 6-month treatment;Genotypes CT + TT are associated with increased efficacy as measured by decrease in HbA1c after 6-month treatment when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Disease:Diabetes Mellitus, Type 2
;FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;Metabolism/PK;decreased  PK:dose-corrected plasma concentrations of fluoxetine;CYP2D6 *1/*1xN is associated with decreased dose-corrected plasma concentrations of fluoxetine when treated with fluoxetine in people with Mental Disorders as compared to CYP2D6 *1/*1.;in people with Disease:Mental Disorders
;IMATINIB;SLC22A1;rs1867351;TT;Toxicity;increased  likelihood of Side Effect:periorbital edema;Genotype TT is associated with increased likelihood of periorbital edema when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.;in people with Gastrointestinal Stromal Tumors
;FLUOROURACIL, LEUCOVORIN;ERCC2;rs13181;GG + GT;Efficacy;increased  risk of Efficacy:Recurrence;Genotypes GG + GT are associated with increased risk of Recurrence when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;VERAPAMIL;KCNIP1, KCNMB1;rs11739136;CT + TT;Efficacy;Efficacy:earlier achievement of blood pressure control;Genotypes CT + TT are associated with earlier achievement of blood pressure control when treated with verapamil in people with Hypertension as compared to genotype CC.;in people with Disease:Hypertension
;OPIOIDS;DRD3;rs9288993;AG + GG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.;in women 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype TT/TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes G/TT + GG.;in people with Disease:Chronic hepatitis C virus infection
;OSIMERTINIB;CYP2C9;rs1057910;AC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AC is associated with decreased progression-free survival when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;OPIOIDS;DRD3;rs2654754;AG + GG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotype AA.;in women 
;OPIOIDS;ZNF568;rs10405238;G;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Allele G is associated with increased severity of Nausea and Vomiting due to opioids in people with Neoplasms and Pain as compared to allele T.;in people with Neoplasms, Pain
;ANTIEPILEPTICS;HLA-B;HLA-B*53:01;*53:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-B *53:01 is associated with increased likelihood of drug-induced liver injury when treated with antiepileptics.; 
;SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.; 
;PENICILLIN G;HLA-DPB1;HLA-DPB1*05:01;*05:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DPB1 *05:01 is associated with increased likelihood of Drug Hypersensitivity when treated with penicillin g.; 
;SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.; 
;SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis, Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim.; 
;APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs3842;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype CC is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotypes CT + TT.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Efficacy;increased  likelihood of Efficacy:Coronary Restenosis, Side Effect:Thrombotic disease;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Coronary Restenosis or Thrombosis when treated with clopidogrel in people with Cerebrovascular Disorders and Carotid Stenosis as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Cerebrovascular Disorders, Carotid Stenosis
;METFORMIN;AMHR2;rs784892;G;Metabolism/PK;decreased  PK:metformin secretory clearance;Allele G is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele A.;in healthy individuals 
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;Metabolism/PK;increased   PK:dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA);Genotype GG is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.;in people with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer;;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);CYP2C19 intermediate metabolizer and poor metabolizer are associated with increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with percutaneous coronary intervention.;in people with percutaneous coronary intervention
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE), Efficacy:Death, Efficacy:Myocardial Infarction, Efficacy:Stroke, Side Effect:Unstable Angina;CYP2C19 *1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased risk of major adverse cardiac events (mace), Death, Myocardial Infarction, Stroke or Angina, Unstable when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer and ultrarapid metabolizer and rapid metabolizer phenotype) .;in people with Acute coronary syndrome
;ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;increased  likelihood of Efficacy:Thrombotic disease;Genotypes CT + TT is associated with increased likelihood of Thrombosis when treated with aspirin null clopidogrel as compared to genotype CC.; 
;OPIOIDS;OPRM1;rs1799971;AA;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AG + GG.;in women 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;Other;increased  risk of Disease:Myocardial Infarction;CYP2C19 *2 + *4 are associated with increased risk of Myocardial Infarction when treated with clopidogrel as compared to CYP2C19 *1 + *17.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*8;*8;Toxicity;increased  risk of Side Effect:ischaemic events;CYP2C19 *8 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;Toxicity;increased  risk of Side Effect:ischaemic events;CYP2C19 *5 is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Disease:Acute coronary syndrome
;ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;Efficacy;increased  likelihood of Efficacy:international normalized ratio variability (inr-var);CYP2C9 *2 is associated with increased likelihood of international normalized ratio variability (inr-var) when treated with acenocoumarol in people with Stroke as compared to CYP2C9 *1/*1.;in people with Stroke
;ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;Toxicity;increased  likelihood of Side Effect:Thyrotoxicosis, Side Effect:Hypothyroidism;HLA-A *26:01 is associated with increased likelihood of Thyrotoxicosis or Hypothyroidism when treated with atezolizumab, durvalumab, ipilimumab, nivolumab or pembrolizumab in people with Lung Neoplasms, Urologic Neoplasms, Melanoma, Breast Neoplasms or Head and Neck Neoplasms.;in people with Lung Neoplasms, Urologic Neoplasms, Melanoma, Breast Neoplasms, Head and Neck Neoplasms
;CARBOPLATIN, GEMCITABINE;RRM1;rs9937;GG;Toxicity;risk of Disease:Hematologic Disorder;Genotype GG is associated with risk of Hematologic Diseases when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;ETHANOL;OPRM1;rs1799971;AA;Toxicity;increased  severity of Other:Alcohol abuse;Genotype AA is associated with increased severity of Alcoholism due to ethanol as compared to genotypes AG + GG.; 
;METFORMIN;SLC22A1;rs628031;A;Toxicity, Metabolism/PK;Side Effect:Gastrointestinal toxicity;Allele A is associated with gastrointestinal toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele G.;in people with Disease:Diabetes Mellitus, Type 2
;OPIOIDS;GABRB3;rs4906902;AA;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype AA are associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AG + GG.;in women 
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;Other, Metabolism/PK;increased   PK:plasma nortriptyline;CYP2D6 *4 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.;in people with Disease:Mental Disorders
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;Other, Metabolism/PK;increased   PK:plasma nortriptyline;CYP2D6 *10 is associated with increased plasma nortriptyline when treated with amitriptyline in people with Mental Disorders as compared to CYP2D6 *1.;in people with Disease:Mental Disorders
;BECLOMETHASONE DIPROPIONATE, FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  likelihood of Efficacy:Status asthmaticus, Efficacy:Emergencies;CYP3A5 *1/*1 + *1/*3 is associated with increased likelihood of exacerbation of asthma or Emergencies when treated with beclomethasone dipropionate or fluticasone propionate in children with Asthma as compared to CYP3A5 *3/*3.;in children with Asthma
;AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;Metabolism/PK;increased   PK:amitriptyline/nortriptyline ratio corrected for dose and weight;CYP2C19 *1/*3 + *2/*3 are associated with increased amitriptyline/nortriptyline ratio corrected for dose and weight when treated with amitriptyline in people with Mental Disorders as compared to CYP2C19 *1/*1.;in people with Disease:Mental Disorders
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;AA;Metabolism/PK;increased   PK:dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA);Genotype AA is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Genotype TT is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and sofosbuvir in people with Hepatitis C as compared to genotypes CC + CT.;in people with Hepatitis C virus infection
;ISONIAZID, RIFAMPIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;HLA-DPB1 *05:01 is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Tuberculosis
;ISONIAZID, RIFAMPIN;HLA-A;HLA-A*11:01;*11:01;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-A *11:01 is associated with increased likelihood of Drug Hypersensitivity when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Tuberculosis
;ETHANOL;DRD2;rs1799732;GG;Toxicity;increased  severity of Other:Alcohol abuse;Genotype GG is associated with increased severity of Alcoholism due to ethanol as compared to genotypes G/del + del/del.; 
;SALBUTAMOL;THRB;rs892940;A;Efficacy;increased   Efficacy:bronchodilator response (BDR);Allele A is associated with increased bronchodilator response (BDR) when treated with salbutamol in children with Asthma as compared to allele G.;in children with Disease:Asthma
;OPIOIDS;TACR1;rs735668;AA;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype AA is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes AC + CC.;in women 
;TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;Efficacy;decreased  Efficacy:Recurrence free survival;CYP2D6 *3 + *4 + *5 + *6 + *7 + *9 + *10 + *41 are associated with decreased Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*1xN + *1/*35 + *2/*2.;in women with Disease:Breast Neoplasms
;ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Genotypes AA + AG is associated with increased likelihood of high on-treatment platelet reactivity when treated with aspirin null clopidogrel as compared to genotype GG.; 
;ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Efficacy;increased  likelihood of Efficacy:Thrombotic disease;Genotypes AA + AG is associated with increased likelihood of Thrombosis when treated with aspirin null clopidogrel as compared to genotype GG.; 
;APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;rs13306198;AA + AG;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes AA + AG is associated with increased likelihood of Hemorrhage when treated with apixaban, dabigatran, edoxaban or rivaroxaban as compared to genotype GG.; 
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;Efficacy;increased  risk of Efficacy:Death, Efficacy:Recurrence;CYP2D6 *1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5 are associated with increased risk of Death and Recurrence when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1xN/*4 + *1/*1xN + *1/*1 + *1/*41 + *1/*10.;in women with Disease:Breast Neoplasms
;ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;Efficacy;decreased  Efficacy:event-free survival;CYP2D6 *10/*10 is associated with decreased event-free survival when treated with antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.;in women with Disease:Breast Neoplasms
;OPIOIDS;OPRM1;rs510769;CC;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotype CC is associated with increased risk of Opioid-Related Disorders due to opioids in women as compared to genotypes CT + TT.;in women 
;ETHANOL;OPRM1;rs1799971;G;Toxicity;increased  risk of Other:Alcohol abuse;Allele G is associated with increased risk of Alcoholism due to ethanol in children as compared to allele A.;in children 
;FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-B *55:02 is associated with increased likelihood of Drug Hypersensitivity when treated with First-generation cephalosporins, Fourth-generation cephalosporins, Other cephalosporins or Third-generation cephalosporins.; 
;AMOXICILLIN;HLA-B;HLA-B*15:01;*15:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *15:01 is associated with increased likelihood of severe cutaneous adverse reactions when exposed to amoxicillin.; 
;"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs72552763;GAT/del;Efficacy;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype GAT/del is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GAT/GAT.;in people with Diabetes Mellitus, Type 2
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4;*4;Toxicity;decreased risk of Side Effect:hepatotoxicity;NAT2 *4 (assigned as rapid acetylator phenotype) is associated with decreased risk of hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;NAT2 *16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7 are associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;Toxicity;increased  severity of Side Effect:Drug Hypersensitivity;HLA-C *01:02 is associated with increased severity of Drug Hypersensitivity when treated with First-generation cephalosporins, Fourth-generation cephalosporins, Other cephalosporins or Third-generation cephalosporins.; 
;FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;HLA-DQB1 *06:09 is associated with increased likelihood of Drug Hypersensitivity when treated with First-generation cephalosporins, Fourth-generation cephalosporins, Other cephalosporins or Third-generation cephalosporins.; 
;INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;Efficacy;increased  likelihood of Efficacy:Discontinuation;HLA-DQA1 *05 is associated with increased likelihood of discontinuation when treated with infliximab in people with Crohn Disease.;in people with Crohn Disease
;NICOTINE;CYP2A13;rs72552266;CT;Toxicity;increased  severity of Other:Tobacco Use Disorder;Genotype CT is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;Efficacy;decreased  Efficacy:platelet reactivity;CYP2C19 *1/*1 is associated with decreased platelet reactivity when treated with clopidogrel in people with as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3.;in people with 
;CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6;Toxicity;increased  severity of Side Effect:Cystitis;CYP3A5 *1/*3 + *1/*6 + *3/*3 + *3/*6 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased severity of Cystitis when treated with cyclophosphamide in children with Rhabdomyosarcoma as compared to CYP3A5 *1/*1 (assigned as normal metabolizer phenotype) .;in children with Rhabdomyosarcoma
;;UGT1A1;UGT1A1*28;*28;Other;increased  likelihood of Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome;UGT1A1 *28 is associated with increased likelihood of Gilbert's syndrome or Crigler-Najjar Syndrome.; 
;DOXORUBICIN;GSTT1;GSTT1 non-null, GSTT1 null;;Toxicity;increased  likelihood of Side Effect:Neutropenia;GSTT1 null is associated with increased likelihood of Neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to GSTT1 non-null.;in women with Breast Neoplasms
;DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;Toxicity;increased  likelihood of Side Effect:Bullous Pemphigoid;HLA-DQB1 *03:01 is associated with increased likelihood of Pemphigoid, Bullous when treated with Dipeptidyl peptidase 4 (DPP-4) inhibitors in people with Diabetes Mellitus, Type 2.;in people with Diabetes Mellitus, Type 2
;IRINOTECAN;UGT1A1;rs4148323;AA + AG;Toxicity;increased  likelihood of Side Effect:Diarrhea, Side Effect:Neutropenia;Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG.;in people with Disease:Lung Neoplasms
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;Efficacy;increased  likelihood of Efficacy:Graft vs Host Disease;CYP3A5 *1/*1 is associated with increased likelihood of Graft vs Host Disease when treated with tacrolimus in people with hematopoietic stem cell transplantation as compared to CYP3A5 *1/*3 + *3/*3.;in people with Hematopoietic stem cell transplantation
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*6 + *6/*6 is associated with increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *28/*28 + *6/*6 + *6/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;Toxicity;increased  severity of Side Effect:Myelosuppression;UGT1A1 *1/*6 + *6/*6 is associated with increased severity of Myelosuppression when treated with FOLFIRI in people with Neoplasm Metastasis and Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Metastatic neoplasm, Colorectal Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  severity of Side Effect:Myelosuppression;UGT1A1 *28/*28 is associated with increased severity of Myelosuppression when treated with FOLFIRI as compared to UGT1A1 *1/*1.; 
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Efficacy;increased  likelihood of Efficacy:Acute cellular rejection;CYP3A5 *1/*1 + *1/*3 is associated with increased likelihood of acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Kidney Transplantation
;SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  likelihood of Side Effect:Discontinuation, Side Effect:Drug Toxicity, Side Effect:Neutropenia, Side Effect:Diarrhea;UGT1A1 *28/*28 is associated with increased likelihood of discontinuation, Drug Toxicity, Neutropenia or Diarrhea when treated with sacituzumab govitecan in people with Breast Neoplasms as compared to UGT1A1 *1/*1.;in people with Breast Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *28/*28 + *6/*6 + *6/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms, Metastatic neoplasm
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Febrile neutropenia, Side Effect:Leukopenia;UGT1A1 *28/*28 is associated with increased severity of Neutropenia, febrile neutropenia or Leukopenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1 + *1/*28.;in people with Colorectal Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 is associated with increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *28/*28 + *1/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms, Metastatic neoplasm
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;Toxicity;increased  likelihood of Side Effect:Diarrhea;UGT1A1 *28/*28 + *1/*28 is associated with increased likelihood of Diarrhea when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms, Metastatic neoplasm
;SUNITINIB;KDR;rs1870377;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AT.;in people with Disease:Renal Cell Carcinoma
;IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*28 + *6;Toxicity;increased  likelihood of Side Effect:Neutropenia;UGT1A1 *28 + *6 is associated with increased likelihood of Neutropenia when treated with irinotecan.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;Toxicity;increased  likelihood of Side Effect:Diarrhea;UGT1A1 *28 is associated with increased likelihood of Diarrhea when treated with irinotecan as compared to UGT1A1 *1/*1.; 
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;Toxicity;increased  likelihood of Side Effect:Diarrhea;UGT1A1 *6/*6 is associated with increased likelihood of Diarrhea when treated with irinotecan as compared to UGT1A1 *1/*1 + *1/*6.; 
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28 is associated with increased severity of Diarrhea when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;MIRABEGRON;CYP2D6;CYP2D6 intermediate metabolizer;;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Headache, Side Effect:Insomnia, Side Effect:Drug Toxicity;CYP2D6 intermediate metabolizer is associated with increased likelihood of Nausea, Headache, insomnia or Drug Toxicity when exposed to mirabegron in healthy individuals as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;in healthy individuals 
;MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Headache, Side Effect:Insomnia, Side Effect:Drug Toxicity;SLCO1B1 deficiency is associated with increased likelihood of Nausea, Headache, insomnia or Drug Toxicity when exposed to mirabegron in healthy individuals as compared to SLCO1B1 non-deficient.;in healthy individuals 
;TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;Efficacy;decreased severity of Efficacy:Pain;CYP2D6 ultrarapid metabolizer is associated with decreased severity of Pain when treated with tramadol in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer and intermediate metabolizer.;in people with Pain, Postoperative
;METHOTREXATE;MTR;rs3768142;GG;Toxicity;increased  risk of Side Effect:Agranulocytosis;Genotype GG is associated with increased risk of Agranulocytosis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.;in children with Disease:Acute lymphoblastic leukemia
;CARBAMAZEPINE;HLA-B;HLA-B*13:01;*13:01;Toxicity;increased  likelihood of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *13:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *15:01 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with carbamazepine.; 
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  likelihood of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-A *31:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.; 
;AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3C;Toxicity, Metabolism/PK;increased   PK:levels of erythrocyte 6-thioguanine nucleotide metabolites;TPMT *1/*3A + *3A/*3C is associated with increased levels of erythrocyte 6-thioguanine nucleotide metabolites when treated with azathioprine, mercaptopurine or purine analogues in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Disease:Inflammatory Bowel Diseases
;CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;non-null;Toxicity;increased  risk of Side Effect:Hearing Loss;GSTT1 non-null is associated with increased risk of Hearing Loss when treated with cisplatin in children with Neoplasms as compared to GSTT1 null.;in children with Disease:Neoplasms
;SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4;Toxicity;decreased risk of Side Effect:adverse reactions;NAT2 *4 is associated with decreased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia as compared to NAT2 *16 + *5 + *6 + *7.;in children with Disease:Pneumonia
;MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;Dosage;increased  likelihood of Side Effect:Dose reduction;TPMT *1/*3A + *1/*3C + *3A/*3A are associated with increased likelihood of Dose reduction of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT *1/*1.;in children with Disease:Acute lymphoblastic leukemia
;ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;*2 + *3 + *8;Efficacy;decreased risk of Efficacy:Transient Ischemic Attack, Efficacy:Death, Efficacy:Stroke, Efficacy:Myocardial Infarction;CYP2C19 *2 + *3 + *8 are associated with decreased risk of Ischemic Attack, Transient, Death, Stroke or Myocardial Infarction when treated with aspirin and clopidogrel as compared to CYP2C19 *1/*1.; 
;TACROLIMUS;CYP3A4;rs4646437;AG + GG;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;Genotypes AG + GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype AA.;in people with Disease:Kidney Transplantation
;DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;Efficacy;increased  risk of Efficacy:Heart Failure, Efficacy:Myocardial Infarction, Efficacy:Angina Pectoris;Genotype TT is associated with increased risk of Heart Failure, Myocardial Infarction or Angina Pectoris when treated with Dihydropyridine derivatives in people with Coronary Disease as compared to genotype CC.;in people with Coronary Disease
;;CYP4A11;rs1126742;AG + GG;Metabolism/PK;decreased  PK:HDL-C concentration;Genotypes AG + GG are associated with decreased HDL-C concentration in women as compared to genotype AA.;in women 
;CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*2, CYP2D6*2x2, CYP2D6*2xN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;Other;increased  likelihood of Side Effect:Opioid-Related Disorders;CYP2D6 *1/*1x2 + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) is associated with increased likelihood of Opioid-Related Disorders when exposed to codeine.; 
;TICAGRELOR;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;Toxicity;increased  likelihood of Side Effect:Hemorrhage;CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of Hemorrhage when treated with ticagrelor.; 
;PEMETREXED;SLC19A1;rs914232;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;Toxicity;increased  severity of Side Effect:Diarrhea;UGT1A1 *6 + *28 is associated with increased severity of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms or Lung Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms, Lung Neoplasms
;FLUOROURACIL, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *6/*6;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *1/*28 + *28/*28 + *6/*6 is associated with increased severity of Neutropenia when treated with fluorouracil and irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;FLUOROURACIL, IRINOTECAN;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);Toxicity;increased  severity of Side Effect:Diarrhea;DPYD c.1627A>G (*5) is associated with increased severity of Diarrhea when treated with fluorouracil and irinotecan in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;Metabolism/PK;increased   PK:AUC of the S-enantiomer of citalopram (no effect on R-CT);CYP2C19 *2/*2 + *2/*3 are associated with increased AUC of the S-enantiomer of citalopram (no effect on R-CT) when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.;in healthy individuals 
;PEMETREXED;SLC19A1;rs1051298;AA + AG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;RISPERIDONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*1 + *1/*2;Toxicity;increased  likelihood of Side Effect:Headache, Side Effect:Muscle spasm, Side Effect:Somnolence, Side Effect:Dizziness;CYP2C19 *1/*1 + *1/*2 is associated with increased likelihood of Headache, Muscle Cramp, Somnolence or Dizziness when treated with risperidone in healthy individuals as compared to CYP2C19 *2/*2 + *2/*4.;in healthy individuals 
;CETUXIMAB;FCGR2A;rs1801274;GG;Efficacy;increased   Efficacy:overall survival;Genotype GG is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;HLA-A *02:01 is associated with increased risk of Drug Hypersensitivity when treated with amoxicillin, ampicillin or bacampicillin.; 
;METHAMPHETAMINE;DRD3;rs6280;CC + CT;Toxicity;increased  risk of Side Effect:Cognitive disorder;Genotypes CC + CT are associated with increased risk of Cognitive disorder when exposed to methamphetamine in men with HIV Infections as compared to genotype TT.;in men with Disease:HIV infectious disease
;NICOTINE;CYP2A6;CYP2A6 low activity;;Other;decreased risk of Disease:Lung Neoplasms;CYP2A6 low activity is associated with decreased risk of Lung Neoplasms when exposed to nicotine in men with Tobacco Use Disorder as compared to CYP2A6 high activity.;in men with Disease:Tobacco Use Disorder
;VINCRISTINE;ACTN1;rs2268979;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;Toxicity;increased  severity of Side Effect:mucositis;Genotype GG is associated with increased severity of mucositis when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.;in people with Disease:Neoplasms
;PEMETREXED;MTHFR;rs1801133;AA + AG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);Toxicity;increased  likelihood of Side Effect:Neutropenia, Side Effect:Diarrhea, Side Effect:Stomatitis, Side Effect:Leukopenia, Side Effect:Nausea, Side Effect:Vomiting;DPYD c.2194G>A (*6) is associated with increased likelihood of Neutropenia, Diarrhea, Stomatitis, Leukopenia, Nausea or Vomiting when treated with capecitabine, fluorouracil, FOLFIRI, FOLFIRINOX or FOLFOX in people with Colorectal Neoplasms, Breast Neoplasms or Stomach Neoplasms.;in people with Colorectal Neoplasms, Breast Neoplasms, Stomach Neoplasms
;VINCRISTINE;PAPPA;rs12235805;A;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele A is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele G.;in children with Neoplasms
;CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;Toxicity;decreased severity of Disease:Diarrhea;Genotype GG is associated with decreased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CG.;in people with Disease:Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;Toxicity;increased  risk of Side Effect:Diarrhea;Genotypes AA + AG is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Gastrointestinal Neoplasms as compared to genotype GG.;in people with Disease:Gastrointestinal Neoplasms
;PEMETREXED;SLC19A1;rs3788189;GG + GT;Efficacy;decreased  Efficacy:Overall survival;Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;CYP2C19 *1/*2 + *1/*3 + *2/*2 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in children with Mucocutaneous Lymph Node Syndrome as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in children with Mucocutaneous Lymph Node Syndrome
;NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;Toxicity;decreased severity of Other:Tobacco Use Disorder;Genotypes AA + AG is associated with decreased severity of Tobacco Use Disorder due to nicotine as compared to genotype GG.; 
;CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);Toxicity;increased  risk of Side Effect:Death;DPYD c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13) (assigned as deficiency phenotype) is associated with increased risk of Death when treated with capecitabine, fluorouracil or FOLFOX in people with Colorectal Neoplasms, Breast Neoplasms or Neoplasms.;in people with Colorectal Neoplasms, Breast Neoplasms, Neoplasms
;AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;Toxicity;increased  risk of Side Effect:Drug Toxicity;CYP2D6 *3 + *4 + *5 + *6 is associated with increased risk of Drug Toxicity when treated with amitriptyline, antidepressants, clomipramine, desipramine, fluoxetine, imipramine, nortriptyline, paroxetine or venlafaxine in people with Depression.;in people with Disease:Depression
;SIROLIMUS;ABCB1;rs1045642;AA + AG;Toxicity;increased   Side Effect:total cholesterol;Genotypes AA + AG are associated with increased total cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;Toxicity;increased  severity of Side Effect:Neutropenia;UGT1A1 *28/*28 + *1/*28 + *1/*6 + *6/*28 is associated with increased severity of Neutropenia when treated with FOLFIRI or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*1;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Diarrhea;UGT1A1 *1/*1 is associated with decreased severity of Neutropenia or Diarrhea when treated with FOLFIRI in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*28 + *1/*6 + *6/*6.;in people with Colorectal Neoplasms, Metastatic neoplasm
;ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;CYP2D6 poor metabolizer is associated with increased likelihood of Drug Toxicity when treated with atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to CYP2D6 normal metabolizer.;in children with Disease:Attention Deficit Disorder with Hyperactivity
;VINCRISTINE;NRG3;rs12253008;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;Efficacy;decreased  Efficacy:Overall survival;UGT1A1 *28/*28 + *6/*6 + *6/*28 is associated with decreased overall survival when treated with irinotecan in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1 + *1/*6 + *1/*28.;in people with Colorectal Neoplasms, Metastatic neoplasm
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Myelosuppression;TPMT *1/*3A + *1/*3B + *1/*3C + *3A/*3B is associated with increased likelihood of Leukopenia or Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Inflammatory Bowel Diseases
;MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT intermediate metabolizer;;Toxicity;increased  likelihood of Side Effect:Discontinuation;TPMT intermediate metabolizer is associated with increased likelihood of Discontinuation when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT normal metabolizer.;in children with Disease:Acute lymphoblastic leukemia
;VINCRISTINE;LRRTM3;rs10997459;G;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele T.;in children with Neoplasms
;AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;Toxicity;increased  severity of Side Effect:Drug Toxicity;TPMT *1/*3A + *1/*3C (assigned as intermediate metabolizer phenotype) is associated with increased severity of Drug Toxicity when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1 (assigned as normal metabolizer phenotype) .;in people with Inflammatory Bowel Diseases
;VINCRISTINE;ARHGAP5;rs8006511;G;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele A.;in children with Neoplasms
;MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT normal metabolizer;;Efficacy;increased  risk of Efficacy:Recurrence;TPMT normal metabolizer is associated with increased risk of Recurrence when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to TPMT intermediate metabolizer and poor metabolizer.;in children with Disease:Acute lymphoblastic leukemia
;NICOTINE;CYP2A6;rs28399433;CC;Toxicity;decreased severity of Other:Tobacco Use Disorder;Genotype CC is associated with decreased severity of Tobacco Use Disorder due to nicotine as compared to genotypes AA + AC.; 
;VINCRISTINE;METTL8;rs79802223;G;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele A.;in children with Neoplasms
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;Efficacy;increased  likelihood of Efficacy:Death, Efficacy:Stroke, Efficacy:Heart Failure, Efficacy:Myocardial Infarction;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 is associated with increased likelihood of Death, Stroke, Heart Failure or Myocardial Infarction when treated with clopidogrel in people with Acute coronary syndrome as compared to CYP2C19 *1/*1.;in people with Acute coronary syndrome
;;UGT1A1;rs4148325;CT;Metabolism/PK;decreased likelihood of Other:Neonatal hyperbilirubinemia;Genotype CT is associated with decreased likelihood of Jaundice, Neonatal in infants as compared to genotype CC.;in infants 
;;UGT1A1;rs11888492;G;Metabolism/PK;decreased likelihood of Other:Neonatal hyperbilirubinemia;Allele G is associated with decreased likelihood of Jaundice, Neonatal in infants as compared to allele C.;in infants 
;NALOXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased   Efficacy:cortisol response;Genotypes AG + GG are associated with increased cortisol response when treated with naloxone as compared to genotype AA.; 
;CISPLATIN;CERS6;rs13022792;T;Toxicity;increased  likelihood of Side Effect:Ototoxicity;Allele T is associated with increased likelihood of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.;in children with Neoplasms
;CISPLATIN;TLR4;rs10759932;C;Toxicity;decreased likelihood of Side Effect:Ototoxicity;Allele C is associated with decreased likelihood of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.;in children with Neoplasms
;VINCRISTINE;NFIB;rs10961381;G;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele G is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele A.;in children with Neoplasms
;ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GT + TT;Efficacy;increased   Efficacy:recurrence;Genotypes GT + TT are associated with increased recurrence when treated with antiarrhythmics, class i and iii in people with Atrial Fibrillation as compared to genotype GG.;in people with Disease:Atrial Fibrillation
;VINCRISTINE;MCM3AP;rs1815857;T;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with increased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;VINCRISTINE;SPDYA;rs12474420;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;VINCRISTINE;PDE4D;rs12658429;C;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele C is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele T.;in children with Neoplasms
;VINCRISTINE;FBN2;rs12656510;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;VINCRISTINE;VTI1A;rs17129858;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele C.;in children with Neoplasms
;VINCRISTINE;ZFAND3;rs200858088;C;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele C is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Neoplasms as compared to allele A.;in children with Neoplasms
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*11:01;*11:01;Toxicity;increased  risk of Side Effect:Anaphylaxis;HLA-DRB1 *11:01 is associated with increased risk of Anaphylaxis when treated with Antiinflammatory agents, non-steroids.; 
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;Toxicity;increased  risk of Efficacy:Peripheral Vascular Diseases;CYP2C19 *2 is associated with increased risk of Peripheral Vascular Diseases when treated with clopidogrel as compared to CYP2C19 *1/*1.; 
;MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;Other;increased  likelihood of Side Effect:Virus Diseases;CYP3A5 *1/*1 + *1/*3 is associated with increased likelihood of Virus Diseases when treated with mycophenolate mofetil, prednisone and tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Kidney Transplantation
;SIROLIMUS;ABCB1;rs1045642;AA + AG;Toxicity;increased   Side Effect:low-density lipoprotein cholesterol;Genotypes AA + AG are associated with increased low-density lipoprotein cholesterol when treated with sirolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;ACETAMINOPHEN / CODEINE;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;decreased severity of Side Effect:Constipation;CYP2D6 poor metabolizer is associated with decreased severity of Constipation when treated with acetaminophen / codeine in people with Pain, Postoperative as compared to CYP2D6 normal metabolizer.;in people with Pain, Postoperative
;RASBURICASE;G6PD;G6PD deficiency;;Toxicity;increased  likelihood of Side Effect:Hemolytic Anemia;G6PD deficiency is associated with increased likelihood of Anemia, Hemolytic when treated with rasburicase in people with Hyperuricemia.;in people with Hyperuricemia
;NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Toxicity;decreased likelihood of Side Effect:Drug-induced liver injury;CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.;in people with HIV infectious disease
;EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1.;in people with HIV infectious disease
;SIROLIMUS;ABCB1;rs1128503;AA;Toxicity;increased   Side Effect:triglycerides;Genotype AA is associated with increased triglycerides when treated with sirolimus in people with Kidney Transplantation as compared to genotypes AG + GG.;in people with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:Atrial Fibrillation;CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Atrial Fibrillation when treated with clopidogrel in people with Coronary Disease and surgery as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in people with Coronary Disease, surgery
;RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2D6 poor metabolizer is associated with increased likelihood of adverse events when treated with risperidone in children as compared to CYP2D6 normal metabolizer.;in children 
;ISONIAZID;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *5/*6 + *6/*6;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 *5/*7 + *5/*6 + *6/*6 (assigned as slow acetylator phenotype) is associated with increased likelihood of Drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to NAT2 intermediate acetylator and rapid acetylator.;in people with Tuberculosis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;Toxicity;increased  likelihood of Side Effect:Decreased glomerular filtration rate;CYP3A5 *1/*3 is associated with increased likelihood of Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *3/*3.;in people with Disease:Kidney Transplantation
;ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR / GIMERACIL / OTERACIL, TRASTUZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;Toxicity;increased  risk of Side Effect:Interstitial Lung Diseases;HLA-DRB1 *04:05 is associated with increased risk of Interstitial Lung Diseases when exposed to adalimumab, amiodarone, bevacizumab, bicalutamide, carboplatin, cyclophosphamide, docetaxel, erlotinib, everolimus, fluorouracil, gefitinib, gemcitabine, irinotecan, leucovorin, methotrexate, oxaliplatin, paclitaxel, pembrolizumab, sitagliptin, tegafur / gimeracil / oteracil or trastuzumab.; 
;TAMSULOSIN;CYP2D6;CYP2D6 intermediate metabolizer;;Toxicity;increased  likelihood of Side Effect:Interstitial Lung Diseases;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Interstitial Lung Diseases when treated with tamsulosin in men.;in men 
;ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;rs79048288;CT + TT;Toxicity;decreased likelihood of Side Effect:Musculoskeletal pain;Genotypes CT + TT is associated with decreased likelihood of musculoskeletal pain when treated with anastrozole, exemestane or letrozole in women with Breast Neoplasms as compared to genotype CC.;in women with Breast Neoplasms
;ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome, Side Effect:Erythema multiforme;HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome or Erythema multiforme when treated with allopurinol in people with Hyperuricemia.;in people with Disease:Hyperuricemia
;PEMETREXED;DHFR;rs1650697;AA + AG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma, Disease:Mesothelioma
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;Efficacy;Efficacy:Decreased glomerular filtration rate;CYP3A5 *3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7 is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to CYP3A5 *1/*1 + *1/*3 + *1/*6 + *1/*7.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;Efficacy;Efficacy:Decreased glomerular filtration rate;CYP2C8 *1/*1 is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to CYP2C8 *1/*3 + *3/*3.;in people with Disease:Kidney Transplantation
;FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);Toxicity;increased  likelihood of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia;DPYD c.85T>C (*9A)/c.85T>C (*9A) is associated with increased likelihood of Neutropenia, Leukopenia or Thrombocytopenia when treated with fluorouracil, FOLFIRI or FOLFOX in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;Toxicity;increased  likelihood of Side Effect:Somnolence, Side Effect:Dizziness, Side Effect:Drug Toxicity;CYP2C19 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is associated with increased likelihood of Somnolence, Dizziness or Drug Toxicity when treated with lacosamide in children with Epilepsy as compared to CYP2C19 *1/*1 (assigned as normal metabolizer phenotype) .;in children with Epilepsy
;FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);Toxicity;decreased likelihood of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia;DPYD c.1627A>G (*5)/c.1627A>G (*5) is associated with decreased likelihood of Neutropenia, Leukopenia or Thrombocytopenia when treated with fluorouracil, FOLFIRI or FOLFOX in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;Toxicity;increased  risk of Side Effect:Drug Toxicity;HLA-A *31:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.; 
;ASPIRIN;PTGS2;rs12042763;GG;Efficacy;decreased risk of Disease:Prostatic Neoplasms;Genotype GG is associated with decreased risk of Prostatic Neoplasms when exposed to aspirin as compared to genotypes GT + TT.; 
;METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*37/*37 + *37/*15;Toxicity;decreased likelihood of Side Effect:Drug-induced liver injury;SLCO1B1 *37/*37 + *37/*15 is associated with decreased likelihood of Drug-induced liver injury when treated with methotrexate in people with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Osteosarcoma or Non-Hodgkin Lymphoma as compared to SLCO1B1 *1/*1.;in people with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Osteosarcoma, Non-Hodgkin Lymphoma
;;CYP2A6;rs56267346;G;Other;decreased likelihood of Other:Smoking Cessation;Allele G is associated with decreased likelihood of Smoking Cessation in women with Tobacco Use Disorder as compared to allele A.;in women with Tobacco Use Disorder
;;DBH;rs6479643;C;Other;decreased likelihood of Other:Smoking Cessation;Allele C is associated with decreased likelihood of Smoking Cessation in women with Tobacco Use Disorder as compared to allele G.;in women with Tobacco Use Disorder
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;Toxicity, Metabolism/PK;increased  risk of Side Effect:Toxic liver disease;NAT2 *16 + *6 + *7 are associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;NAT2 *16 + *6 + *7 (assigned as slow acetylator phenotype) are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to NAT2 *4 (assigned as rapid acetylator phenotype) .;in people with Disease:Tuberculosis
;ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *7 + *14;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;NAT2 *16 + *5 + *6 + *7 + *14 (assigned as slow acetylator phenotype) is associated with increased likelihood of Toxic liver disease when treated with isoniazid in people with Tuberculosis as compared to NAT2 *4 + *1.;in people with Disease:Tuberculosis
;FLURBIPROFEN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*36;*1/*36;Efficacy;decreased  Efficacy:Overall survival;UGT1A1 *1/*36 is associated with decreased overall survival when treated with flurbiprofen or irinotecan in people with Colorectal Neoplasms as compared to UGT1A1 *1/*1.;in people with Colorectal Neoplasms
;ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 *5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7 (assigned as slow acetylator phenotype) is associated with increased likelihood of Drug-induced liver injury when treated with isoniazid and rifampin in people with Tuberculosis as compared to NAT2 *1/*1 + *1/*5 + *1/*6 + *1/*7 (assigned as intermediate acetylator and rapid acetylator phenotype) .;in people with Tuberculosis
;TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;Efficacy;decreased likelihood of Efficacy:Graft vs Host Disease;CYP3A5 *3/*3 is associated with decreased likelihood of Graft vs Host Disease when treated with tacrolimus in people with Hematopoietic stem cell transplantation as compared to CYP3A5 *1/*1 + *1/*3.;in people with Hematopoietic stem cell transplantation
;IRINOTECAN;UGT1A1;rs4148323;A;Toxicity;increased  likelihood of Side Effect:Diarrhea;Allele A is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to allele G.;in people with Disease:Lung Neoplasms
;;CASP9;rs1052576;T;Efficacy;increased  severity of Efficacy:Leukocytosis;Allele T is associated with increased severity of Leukocytosis in children with Acute lymphoblastic leukemia as compared to allele C.;in children with Acute lymphoblastic leukemia
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;Toxicity;decreased  Side Effect:Drug Toxicity;Genotypes AA + AG is associated with decreased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;IRINOTECAN;UGT1A1;rs4148323;A;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele A is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to allele G.;in people with Disease:Lung Neoplasms
;CYCLOSPORINE, METHOTREXATE;SLC19A1;rs1051266;CC;Efficacy;decreased risk of Side Effect:Graft vs Host Disease;Genotype CC is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.;in people with Hematopoietic stem cell transplantation
;CYCLOSPORINE, METHOTREXATE;ATIC;rs17514110;CC;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype CC is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.;in people with Hematopoietic stem cell transplantation
;CYCLOSPORINE, METHOTREXATE;NFATC2;rs3787186;TT;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype TT is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CC + CT.;in people with Hematopoietic stem cell transplantation
;CYCLOSPORINE, METHOTREXATE;ABCC2;rs3740065;AA;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotype AG.;in people with Hematopoietic stem cell transplantation
;CETUXIMAB;FCGR3A;rs396991;CC;Efficacy;increased   Efficacy:antibody-dependent cellular cytotoxicity;Genotype CC is associated with increased antibody-dependent cellular cytotoxicity when exposed to cetuximab as compared to genotypes AA + AC.; 
;CYCLOSPORINE, METHOTREXATE;ABCC1;rs8058040;AA;Efficacy;increased  risk of Side Effect:Graft vs Host Disease;Genotype AA is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes AG + GG.;in people with Hematopoietic stem cell transplantation
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-A *24:02 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with carbamazepine, lamotrigine or phenytoin.; 
;ATAZANAVIR, EFAVIRENZ;TPH2;rs7305115;GG;Toxicity;increased  severity of Side Effect:Depression;Genotype GG is associated with increased severity of Depression when treated with atazanavir or efavirenz in men with HIV infectious disease as compared to genotypes AA + AG.;in men with HIV infectious disease
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*01:02;*01:02;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis;HLA-A *01:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*52:01;*52:01;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis;HLA-B *52:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*03:01;*03:01;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis;HLA-DRB1 *03:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic when treated with carbamazepine, lamotrigine or phenytoin.; 
;ATAZANAVIR, EFAVIRENZ;TPH2;rs1386493;GG;Toxicity;increased  severity of Side Effect:Depression;Genotype GG is associated with increased severity of Depression when treated with atazanavir or efavirenz in men with HIV infectious disease as compared to genotypes AA + AG.;in men with HIV infectious disease
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*13:01;*13:01;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-DRB1 *13:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.; 
;CAPECITABINE;ENOSF1;rs2612091;TT;Efficacy;increased   Efficacy:Recurrence free survival;Genotype TT is associated with increased Recurrence free survival when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes CC + CT.;in people with Colorectal Neoplasms
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;Toxicity;decreased likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-A *02:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*40:02;*40:02;Toxicity;increased  likelihood of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms;HLA-B *40:02 is associated with increased likelihood of Drug Reaction with Eosinophilia and Systemic Symptoms when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*31:03;*31:03;Toxicity;decreased likelihood of Side Effect:Stevens-Johnson Syndrome;HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.; 
;CARBOPLATIN, PACLITAXEL;OPRM1;rs544093;GG + GT;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes GG + GT is associated with decreased progression-free survival when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotype TT.;in people with Ovarian Neoplasms
;MYCOPHENOLATE MOFETIL;IMPDH1;rs2228075;T;Efficacy, Toxicity;increased  likelihood of Side Effect:GI intolerance;Allele T is associated with increased likelihood of GI intolerance when treated with mycophenolate mofetil in children with Organ Transplantation as compared to allele C.;in children with Disease:Organ Transplantation
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity, Side Effect:Neutropenia;Genotypes CT + TT are associated with increased risk of Drug Toxicity and Neutropenia when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;ISONIAZID;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;NAT2 slow acetylator and intermediate acetylator is associated with increased likelihood of Toxic liver disease when treated with isoniazid in people with Tuberculosis as compared to NAT2 rapid acetylator.;in people with Tuberculosis
;ERLOTINIB, GEFITINIB;USP36;rs3744797;CC;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotype CC is associated with increased likelihood of Progression-free survival when treated with erlotinib or gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotype AC.;in people with Non-Small Cell Lung Carcinoma
;OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;Toxicity;increased  likelihood of Side Effect:Stevens-Johnson Syndrome, Side Effect:Toxic Epidermal Necrolysis;HLA-B *51:02 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with osimertinib in people with Lung Neoplasms.;in people with Lung Neoplasms
;DEXMEDETOMIDINE;CACNB2;rs10764319;CT;Toxicity;decreased likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotype CT is associated with decreased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotypes CC + TT.;in children with surgery
;DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;Toxicity;decreased likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotype AA is associated with decreased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotypes AG + GG.;in children with surgery
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2 slow acetylator;;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;NAT2 slow acetylator is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to NAT2 intermediate acetylator and rapid acetylator.; 
;DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;Toxicity;decreased likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotype AA is associated with decreased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotypes AG + GG.;in children with surgery
;DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;Toxicity;increased  likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotypes AA + CC is associated with increased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotype AC.;in children with surgery
;METHYLPHENIDATE;CES1;rs2307227;T;Toxicity;increased  likelihood of Side Effect:adverse events;Allele T is associated with increased likelihood of adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele G.;in children with Attention Deficit Disorder with Hyperactivity
;PURINE ANALOGUES;NUDT15;NUDT15*1, NUDT15*3;*1/*3;Toxicity;increased  risk of Side Effect:Myelosuppression;NUDT15 *1/*3 is associated with increased risk of Myelosuppression when treated with purine analogues in people with Inflammatory Bowel Diseases as compared to NUDT15 *1/*1.;in people with Inflammatory Bowel Diseases
;CLOPIDOGREL;THSD7A;rs7807369;G;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Allele G is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel as compared to allele C.; 
;CLOPIDOGREL;;rs1149515;C;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity, Efficacy:Major Adverse Cardiac Events (MACE);Allele C is associated with increased likelihood of high on-treatment platelet reactivity or Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to allele T.; 
;ONDANSETRON;CYP2D6;CYP2D6 normal metabolizer;;Efficacy;increased  likelihood of Efficacy:Postoperative Nausea and Vomiting;CYP2D6 normal metabolizer is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron as compared to CYP2D6 intermediate metabolizer and poor metabolizer.; 
;;ERAP2;rs17524572;TT;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype TT is associated with increased likelihood of Drug-induced liver injury in people with Tuberculosis as compared to genotypes CC + CT.;in people with Tuberculosis
;MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;Toxicity;increased  risk of Disease:Diarrhea;Genotype CC is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes CG + GG.;in people with Disease:Kidney Transplantation
;PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*13:01;*13:01;Efficacy;decreased likelihood of Efficacy:Progression-free survival;HLA-DRB1 *13:01 is associated with decreased likelihood of Progression-free survival when treated with pembrolizumab in people with Adenocarcinoma, Non-Small Cell Lung Carcinoma, Carcinoma, Squamous Cell or Neuroendocrine Carcinoma.;"in people with ""Adenocarcinoma"", ""Non-Small Cell Lung Carcinoma"", ""Carcinoma, Squamous Cell"", ""Neuroendocrine Carcinoma"""
;PEMBROLIZUMAB;HLA-DPB1;HLA-DPB1*02:02;*02:02;Toxicity;increased  likelihood of Side Effect:Pneumonitis;HLA-DPB1 *02:02 is associated with increased likelihood of Pneumonitis when treated with pembrolizumab in people with Adenocarcinoma, Non-Small Cell Lung Carcinoma, Carcinoma, Squamous Cell or Neuroendocrine Carcinoma.;"in people with ""Adenocarcinoma"", ""Non-Small Cell Lung Carcinoma"", ""Carcinoma, Squamous Cell"", ""Neuroendocrine Carcinoma"""
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;MORPHINE;SLC22A1;rs72552763;del/del;Toxicity;increased  likelihood of Side Effect:Hypoventilation;Genotype del/del is associated with increased likelihood of Hypoventilation when treated with morphine in children as compared to genotypes GAT/GAT + GAT/del.;in children 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 non-null, GSTM1 null;;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;GSTM1 null is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to GSTM1 non-null.; 
;;CASP9;rs4661636;C;Efficacy;increased  severity of Efficacy:Leukocytosis;Allele C is associated with increased severity of Leukocytosis in children with Acute lymphoblastic leukemia as compared to allele T.;in children with Acute lymphoblastic leukemia
;;CASP8;rs6736233;G;Efficacy;increased  likelihood of Efficacy:Recurrence;Allele G is associated with increased likelihood of Recurrence in children with Acute lymphoblastic leukemia as compared to allele C.;in children with Acute lymphoblastic leukemia
;CLOZAPINE;LEPR;rs6657868;AG + GG;Toxicity;increased  risk of Side Effect:Pneumonia;Genotypes AG + GG is associated with increased risk of Pneumonia when treated with clozapine in people with Schizophrenia or Schizoaffective disorder as compared to genotype AA.;in people with Schizophrenia, Schizoaffective disorder
;CLOZAPINE;CYP1A2;rs762551;AA;Toxicity;increased  risk of Disease:Seizures;Genotype AA is associated with increased risk of Seizures when treated with clozapine in people with Schizophrenia as compared to genotypes AC + CC.;in people with Disease:Schizophrenia
;CISPLATIN, PACLITAXEL;GGT1;rs2017869;CC;Toxicity;decreased likelihood of Side Effect:Neutropenia, Side Effect:Leukopenia;Genotype CC is associated with decreased likelihood of Neutropenia or Leukopenia when treated with cisplatin and paclitaxel in people with Breast Neoplasms as compared to genotypes CG + GG.;in people with Breast Neoplasms
;CISPLATIN;TPMT;rs12201199;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;;UGT1A1;rs4148323;A;Other;increased  likelihood of Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome;Allele A is associated with increased likelihood of Gilbert's syndrome or Crigler-Najjar Syndrome as compared to allele G.; 
;CLOZAPINE;LEPR, LEPROT;rs1137101;AA;Toxicity;increased  risk of Side Effect:Pneumonia;Genotype AA is associated with increased risk of Pneumonia when treated with clozapine in people with Schizophrenia or Schizoaffective disorder as compared to genotypes AG + GG.;in people with Schizophrenia, Schizoaffective disorder
;DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;Toxicity;decreased likelihood of Side Effect:Discontinuation, Side Effect:adverse events;Genotypes CT + TT is associated with decreased likelihood of Discontinuation and adverse events when treated with dolutegravir in people with HIV infectious disease as compared to genotype CC.;in people with HIV infectious disease
;CISPLATIN;TPMT;rs1800460;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.;in children with Disease:Neoplasms
;CLOZAPINE;LEPR;rs1805096;GG;Toxicity;increased  risk of Side Effect:Pneumonia;Genotype GG is associated with increased risk of Pneumonia when treated with clozapine in people with Schizophrenia or Schizoaffective disorder as compared to genotypes AA + AG.;in people with Schizophrenia, Schizoaffective disorder
;CLOZAPINE;LEPR;rs9436746;AC + CC;Toxicity;increased  risk of Side Effect:Pneumonia;Genotypes AC + CC is associated with increased risk of Pneumonia when treated with clozapine in people with Schizophrenia or Schizoaffective disorder as compared to genotype AA.;in people with Schizophrenia, Schizoaffective disorder
;RISPERIDONE;DRD2;rs1800497;AA + AG;Toxicity;increased  severity of Side Effect:Weight gain;Genotypes AA + AG is associated with increased severity of Weight gain when treated with risperidone in people with Psychotic Disorder as compared to genotype GG.;in people with Psychotic Disorder
;;UGT1A1;rs35350960;A;Other;increased  likelihood of Other:Gilbert syndrome, Other:Crigler-Najjar Syndrome;Allele A is associated with increased likelihood of Gilbert's syndrome or Crigler-Najjar Syndrome as compared to allele C.; 
;CISPLATIN;TPMT;rs1142345;C;Toxicity;increased  risk of Disease:Ototoxicity;Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.;in children with Disease:Neoplasms
;WARFARIN;ASPH;rs4379440;T;Efficacy;decreased  Efficacy:time in therapeutic range;Allele T is associated with decreased time in therapeutic range when treated with warfarin as compared to allele G.; 
;CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with decreased likelihood of Drug Toxicity when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AG + GG.;in people with Ovarian Neoplasms
;ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs12041331;AA + AG;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes AA + AG is associated with increased risk of Hemorrhage when treated with aspirin, clopidogrel or ticagrelor in people with Stroke as compared to genotype GG.;in people with Stroke
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased   Side Effect:Drug Toxicity;Genotype AT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801131;G;Toxicity;increased  likelihood of Side Effect:neurotoxicity;Allele G is associated with increased likelihood of neurotoxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;Toxicity;increased  risk of Side Effect:gastrointestinal disturbances in HCV-HIV coinfected patients;Genotype AC is associated with increased risk of gastrointestinal disturbances in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype CC.; 
;HMG COA REDUCTASE INHIBITORS;CETP;rs3764261;A;Efficacy, Metabolism/PK;increased   Other:HDL cholesterol;Allele A is associated with increased HDL cholesterol when treated with hmg coa reductase inhibitors.; 
;PYRIMIDINE ANALOGUES;MTHFR;rs1801133;AA + AC;;increased   Efficacy:Progression-free survival;Genotypes AA + AC are associated with increased progression-free survival when treated with Pyrimidine analogues in people with Colorectal Neoplasms as compared to genotype CC.;in people with Colorectal Neoplasms
;METHOTREXATE;ITPA;rs1127354;A;Toxicity;Side Effect:gastrointestinal toxicities;Allele A is associated with gastrointestinal toxicities when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;GEFITINIB;ABCB1;rs1128503;AA;Toxicity;increased  likelihood of Side Effect:Exanthema;Genotype AA is associated with increased likelihood of Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;A;Efficacy;increased   Efficacy:rapid virological response (RVR) in HCV-HIV coinfected patients;Allele A is associated with increased rapid virological response (RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G.; 
;CAFFEINE;;rs4410790;T;Other;Other:habitual consumption;Allele T is associated with habitual consumption of caffeine as compared to allele C.; 
;LIRAGLUTIDE;GLP1R;rs6923761;AA + AG;Efficacy;increased  likelihood of Efficacy:weight loss;Genotypes AA + AG is associated with increased likelihood of weight loss when treated with liraglutide in people with Diabetes Mellitus, Type 2 and Obesity as compared to genotype GG.;"in people with ""Diabetes Mellitus, Type 2"", ""Obesity"""
;METHAMPHETAMINE;ESR1;rs2234693;CC;Toxicity;increased  likelihood of Disease:Psychotic Disorder;Genotype CC is associated with increased likelihood of Psychotic Disorders due to methamphetamine in men as compared to genotypes CT + TT.;in men 
;;ABCG8;rs11887534;CG;Other;increased  risk of Disease:Coronary Artery Disease;Genotype CG is associated with increased risk of Coronary Artery Disease as compared to genotype GG.; 
;PLATINUM;ERCC5;rs17655;GG;Efficacy;increased   Efficacy:survival;Genotype GG is associated with increased survival when treated with platinum in women with Ovarian Neoplasms as compared to genotypes CC + CG.;in women with Disease:Ovarian Neoplasms
;PLATINUM;ERCC5;rs17655;GG;Efficacy;decreased  Efficacy:survival;Genotype GG is associated with decreased survival when treated with platinum in women with Ovarian Neoplasms as compared to genotypes CC + CG.;in women with Disease:Ovarian Neoplasms
;RISPERIDONE;HTR2C;rs3813929;T;Toxicity;decreased likelihood of Side Effect:Weight gain;Allele T is associated with decreased likelihood of Weight gain when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.;in children with Disease:Autism Spectrum Disorder
;PACLITAXEL;FGD4;rs10771973;A;Toxicity;increased  risk of Side Effect:sensory peripheral neuropathy;Allele A is associated with increased risk of sensory peripheral neuropathy when treated with paclitaxel in women Breast Neoplasms as compared to allele G.;in women Disease:Breast Neoplasms
;CAFFEINE;CYP1A1;rs2470893;T;Other;Other:habitual consumption;Allele T is associated with habitual consumption of caffeine as compared to allele C.; 
;CITALOPRAM;SLC6A4;rs25531;C;Toxicity;increased  likelihood of Side Effect:side effects;Allele C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to allele T.;in people with Disease:Dementia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SOCS3;rs4969170;AG;Toxicity;decreased risk of Side Effect:Neutropenia in HCV-HIV coinfected patients;Genotype AG is associated with decreased risk of Neutropenia in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype GG.; 
;MIDAZOLAM;POR;rs1057868;TT;Other, Metabolism/PK;increased   PK:metabolic ratio of midazolam;Genotype TT is associated with increased metabolic ratio of midazolam when exposed to midazolam as compared to allele C.; 
;ENALAPRIL;PNPT1;rs13009649;G;Toxicity;decreased likelihood of Side Effect:Cough;Allele G is associated with decreased likelihood of Cough when treated with enalapril in people with Hypertension as compared to allele A.;in people with Hypertension
;METHOTREXATE;ITPA;rs1127354;A;Efficacy;Efficacy:response to methotrexate;Allele A is associated with response to methotrexate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;NICOTINE;HTR3B;rs11606194;CT + TT;Toxicity;increased  severity of Other:Tobacco Use Disorder;Genotypes CT + TT are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype CC.; 
;ASPIRIN;SLC6A12;rs499368;A;Toxicity;increased  likelihood of Disease:Asthma;Allele A is associated with increased likelihood of Asthma when treated with aspirin in people with Asthma as compared to allele T.;in people with Disease:Asthma
;GEFITINIB;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotype AA is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Non-Small Cell Lung Carcinoma
;WARFARIN;CYP4F2;rs2189784;GG;Efficacy;decreased  Efficacy:time to therapeutic inr;Genotype GG is associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype AA.; 
;ASPIRIN;SLC6A12;rs557881;G;Toxicity;increased  likelihood of Disease:Asthma;Allele G is associated with increased likelihood of Asthma when treated with aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;PLATINUM COMPOUNDS;WIF1;rs10878232;GG + GT;Efficacy;decreased  Efficacy:Overall survival;Genotypes GG + GT is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIEPILEPTICS;ABCB1;rs1045642;G;Efficacy;increased  likelihood of Efficacy:non-response;Allele G is associated with increased likelihood of non-response when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;AG;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Genotype AG is associated with increased risk of cardiotoxicity when treated with anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;PLATINUM COMPOUNDS;WNT5B;rs12819505;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;AXIN2;rs4541111;AA + AC;Efficacy;increased   Efficacy:Overall survival;Genotypes AA + AC is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;T;Toxicity;increased   Side Effect:GI toxicity;Allele T is associated with increased GI toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE;SLCO1B1;rs11045879;T;Toxicity;increased   Side Effect:GI toxicity;Allele T is associated with increased GI toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;Efficacy;increased   Efficacy:event free survival;Genotype CC is associated with increased event free survival when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.;in children with Disease:Acute lymphoblastic leukemia
;PLATINUM COMPOUNDS;CXXC4;rs4413407;AA + AG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AG is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ENALAPRIL;PNPT1;rs13015243;C;Toxicity;decreased likelihood of Side Effect:Cough;Allele C is associated with decreased likelihood of Cough when treated with enalapril in people with Hypertension as compared to allele T.;in people with Hypertension
;AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;;rs11969064;T;Toxicity;increased  risk of Side Effect:Myelosuppression;Allele T is associated with increased risk of Myelosuppression when treated with azathioprine, mercaptopurine or thioguanine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;Efficacy;increased   Efficacy:response (SVR and RVR) in HCV-HIV coinfected patients;Allele T is associated with increased response (SVR and RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G.; 
;PLATINUM COMPOUNDS;ERCC2;rs13181;GG;Toxicity;increased  likelihood of Disease:Pneumonitis;Genotype GG is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;Toxicity;increased  likelihood of Disease:Pneumonitis;Genotypes CT + TT is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;DOXORUBICIN;NCF4;rs1883112;AA + AG;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Genotypes AA + AG is associated with increased risk of cardiotoxicity when treated with doxorubicin in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;AMPHETAMINE;DRD2;rs12364283;AA;Efficacy;decreased  Other:stop reaction time;Genotype AA is associated with decreased stop reaction time when treated with amphetamine in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;ANTIEPILEPTICS;ABCB1;rs1045642;AA;Efficacy;increased  likelihood of Efficacy:drug-resistance;Genotype AA is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;ANTIEPILEPTICS;ABCB1;rs1045642;GG;Efficacy;increased  likelihood of Efficacy:drug-resistance;Genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics in people with Epilepsy as compared to genotype AA.;in people with Disease:Epilepsy
;PAROXETINE;HTR2A;rs6313;GG;Toxicity;increased  risk of Side Effect:discontinuations due to adverse events and greater severity of side effects;Genotype GG is associated with increased risk of discontinuations due to adverse events and greater severity of side effects when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.;in people with Disease:Major Depressive Disorder
;CLOPIDOGREL;CD80;rs34394661;AA;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.;in people with Acute coronary syndrome
;MYCOPHENOLATE MOFETIL;UGT1A9;rs6714486;A;Metabolism/PK;PK:changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day);Allele A is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.;in people with Disease:Kidney Transplantation
;CARBAMAZEPINE;;rs1633021;TT;Toxicity;increased  likelihood of Disease:Severe Cutaneous Adverse Reactions;Genotype TT is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine as compared to genotypes CC + CT.; 
;PLATINUM COMPOUNDS;AXIN2;rs11868547;CC + CG;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CG is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;MYCOPHENOLATE MOFETIL;UGT1A9;rs17868320;T;Metabolism/PK;PK:changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day);Allele T is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;MORPHINE;ABCB1;rs1045642;GG;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotype GG is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative as compared to genotypes AA + AG.;in people with Disease:Pain, Postoperative
;CYCLOSPORINE, MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;Toxicity;increased  risk of Disease:Diarrhea;Genotype CC is associated with increased risk of Diarrhea when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes CG + GG.;in people with Disease:Kidney Transplantation
;TACROLIMUS;IL10;rs1800871;AA;Metabolism/PK;increased  likelihood of PK:achieving target concentrations;Genotype AA is associated with increased likelihood of achieving target concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.;in people with Disease:Kidney Transplantation
;METHOTREXATE;ARID5B;rs4948496;CC + CT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CC + CT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;;CYP2B6;rs3760657;AA;Other;decreased likelihood of Other:Smoking Cessation;Genotype AA is associated with decreased likelihood of cessation in people with Tobacco Use Disorder as compared to genotypes AG + GG.;in people with Tobacco Use Disorder
;FOLLITROPIN BETA, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;T;Efficacy, Metabolism/PK;Efficacy:good response to controlled ovarian hyperstimulation;Allele T is associated with good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to allele C.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy, Other;increased  risk of Disease:Thrombotic disease;Genotypes AA + AG is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype GG.;in people with percutaneous coronary intervention
;;UGT2B10;rs11726322;CC;Other;increased  likelihood of Other:Smoking Cessation;Genotype CC is associated with increased likelihood of cessation in people with Tobacco Use Disorder as compared to genotypes CG + GG.;in people with Tobacco Use Disorder
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;Toxicity;increased  risk of Side Effect:Venous thromboembolism;Allele T is associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to allele C.;in women 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;Efficacy, Other;decreased risk of Disease:Thrombotic disease;Genotypes CT + TT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype CC.;in people with percutaneous coronary intervention
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;Toxicity;increased  risk of Side Effect:Venous thromboembolism;Allele A is associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to allele G.;in women 
;CLOPIDOGREL;ABCB1;rs1045642;AG;Efficacy;increased   Efficacy:platelet reactivity;Genotype AG is associated with increased platelet reactivity when treated with clopidogrel as compared to genotypes AA + GG.; 
;CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP4F2;rs2108622;CT + TT;Metabolism/PK;increased   PK:plasma MK-4 concentration;Genotypes CT + TT is associated with increased plasma MK-4 concentration when treated with warfarin in children as compared to genotype CC.;in children 
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ALENDRONATE;VDR;rs1544410;CC;Efficacy;increased   Efficacy:Bone Mineral Density;Genotype CC is associated with increased Bone Mineral Density when treated with alendronate in people with Osteoporosis as compared to genotype TT.;in people with Disease:Osteoporosis
;FENOFIBRATE;PPARA;rs135543;TT;Efficacy;increased   Efficacy:reduction in fasting LDL-C;Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT.; 
;FENOFIBRATE;PPARA;rs9626730;CC + CT;Efficacy;decreased  Efficacy:reduction in fasting IL-2;Genotypes CC + CT are associated with decreased reduction in fasting IL-2 when treated with fenofibrate as compared to genotype TT.; 
;WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;decreased  Other:warfarin sensitivity index (INR/Cpss);Genotypes CT + TT is associated with decreased warfarin sensitivity index (INR/Cpss) when treated with warfarin in children as compared to genotype CC.;in children 
;;VDR;rs1544410;CC;;decreased  Efficacy:Bone Mineral Density;Genotype CC is associated with decreased Bone Mineral Density in people with as compared to genotype TT.;in people with 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Other:major adverse cardiovascular events;Genotypes AA + AG is associated with increased risk of major adverse cardiovascular events when treated with clopidogrel as compared to genotype GG.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Disease:Death;Genotypes AA + AG is associated with increased risk of Death when treated with clopidogrel as compared to genotype GG.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Disease:Thrombotic disease;Genotypes AA + AG is associated with increased risk of Thrombosis when treated with clopidogrel as compared to genotype GG.; 
;FENOFIBRATE;PPARA;rs135550;TT;Efficacy;increased   Efficacy:reduction in fasting LDL-C;Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT.; 
;ALENDRONATE;VDR;rs1544410;CC;Efficacy;decreased  Efficacy:urinary DPD/Cr levels;Genotype CC is associated with decreased urinary DPD/Cr levels when treated with alendronate in people with Osteoporosis as compared to genotype TT.;in people with Disease:Osteoporosis
;EXEMESTANE;CYP19A1;rs7176005;TT;Toxicity;Side Effect:a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients;Genotype TT is associated with a significantly higher odds of Vasomotor symptoms in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;TACROLIMUS;PPARA;rs4253728;GG;Toxicity;decreased likelihood of Side Effect:Acute cellular rejection;Genotype GG is associated with decreased likelihood of acute cellular rejection when treated with tacrolimus in people with liver transplantation as compared to genotypes AA + AG.;in people with Liver transplantation
;VINCRISTINE;SLC5A7;rs1013940;AG + GG;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotypes AG + GG are associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to genotype AA.; 
;ETHANOL;ADH1B;rs1229984;T;Toxicity;increased  likelihood of Side Effect:Hyperuricemia;Allele T is associated with increased likelihood of Hyperuricemia when exposed to ethanol.; 
;VINCRISTINE;NKAIN3;rs10504361;A;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Allele A are associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to allele G.; 
;SIMVASTATIN;SLCO1B1;rs4149056;C;Toxicity;increased  likelihood of Side Effect:Muscular Diseases;Allele C is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Coronary Artery Disease as compared to allele T.;in people with Coronary Artery Disease
;ATENOLOL;PROX1;rs340874;C;Toxicity;increased   Side Effect:glucose elevation;Allele C is associated with increased glucose elevation when treated with atenolol in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;TACROLIMUS;CYP3A4;rs35599367;AA + AG;Toxicity;increased  likelihood of Side Effect:Sepsis, Side Effect:Seizures, Side Effect:Nephrotoxicity;Genotypes AA + AG is associated with increased likelihood of Sepsis, Seizures or nephrotoxicity when treated with tacrolimus in people with liver transplantation as compared to genotype GG.;in people with Liver transplantation
;ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1128503;AA;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotype AA is associated with increased likelihood of Neutropenia when treated with abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Breast Neoplasms
;SIMVASTATIN;ABCG2;rs2231142;GT;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype GT is associated with increased likelihood of drug-induced liver injury when treated with simvastatin in people with Coronary Artery Disease as compared to genotype TT.;in people with Coronary Artery Disease
;VINCRISTINE;ABCC1;rs3784867;T;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to allele C.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AG;Efficacy;increased  risk of Efficacy:significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily;Genotype AG is associated with increased risk of significantly higher on-treatment platelet reactivity with a maintenance dose of 75 mg daily when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.;in people with Disease:Cardiovascular Disease
;OPIOIDS;COMT;rs4680;AA + AG;Toxicity;decreased likelihood of Side Effect:Somnolence, Side Effect:Nausea, Side Effect:adverse events;Genotypes AA + AG is associated with decreased likelihood of somnolence, Nausea or adverse events when treated with opioids in people with Pain and Neoplasms as compared to genotype GG.;in people with Pain, Neoplasms
;OPIOIDS;IL6;rs1800795;CG + GG;Toxicity;decreased likelihood of Side Effect:Somnolence, Side Effect:Nausea, Side Effect:adverse events;Genotypes CG + GG is associated with decreased likelihood of somnolence, Nausea or adverse events when treated with opioids in people with Pain and Neoplasms as compared to genotype CC.;in people with Pain, Neoplasms
;FLUOROURACIL;DPYD;rs67376798;A;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil.; 
;SUNITINIB;CYP3A5;rs776746;CT + TT;Efficacy;increased   Efficacy:Progression-free survival;Genotypes CT + TT is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;rs35599367;AG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Treatment interruption;Genotype AG is associated with increased likelihood of Drug Toxicity and treatment interruptions when treated with abemaciclib, palbociclib or ribociclib in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to genotypes CC + CT.; 
;METOPROLOL;CYP2D6;rs1065852;GG;Efficacy;decreased  Efficacy:heart rate;Genotype GG is associated with decreased heart rate when treated with metoprolol in people with as compared to genotypes AA + AG.;in people with 
;CONJUGATED ESTROGENS, MEDROXYPROGESTERONE;VDR;rs1544410;TT;Efficacy;increased   Other:spine Bone Mineral Density;Genotype TT is associated with increased spine Bone Mineral Density when treated with conjugated estrogens and medroxyprogesterone as compared to genotype CC.; 
;VERAPAMIL;CACNB2;rs2357928;GG;Efficacy, Toxicity;increased  risk of Efficacy:adverse outcome;Genotype GG is associated with increased risk of adverse outcome when treated with verapamil in people with Hypertension and Coronary Artery Disease.;in people with Hypertension and Coronary Artery Disease
;METFORMIN;SLC47A1;rs2252281;CC;Efficacy;increased   Efficacy:response to metformin;Genotype CC is associated with increased response to metformin when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.;in people with Disease:Diabetes Mellitus, Type 2
;TACROLIMUS;CYP3A5;rs4646450;A;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele A is associated with increased likelihood of discontinuation when treated with tacrolimus in people with liver transplantation as compared to allele G.;in people with Liver transplantation
;METFORMIN;SLC47A1;rs2252281;CC;Efficacy;increased   Efficacy:response to metformin;Genotype CC is associated with increased response to metformin when exposed to metformin in healthy individuals as compared to genotypes CT + TT.;in healthy individuals 
;TRAZODONE;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Prolonged QTc interval;Genotype AA is associated with increased likelihood of electrocardiogram qt prolonged when treated with trazodone in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;INTERFERONS, RIBAVIRIN;BCL2;rs1800477;T;Efficacy;increased   Efficacy:frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4);Allele T is associated with increased frequency (about double) in non-responder patients compared with responder patients (HCV genotype 4) when treated with interferons and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;in people with Disease:Chronic hepatitis C virus infection
;CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;rs112445441;T;Efficacy;increased   Efficacy:Progression-free survival;Allele T is associated with increased progression-free survival when treated with cetuximab, fluorouracil, irinotecan and oxaliplatin in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;rs3136228;GG;Toxicity;increased  severity of Disease:Neutropenia;Genotype GG is associated with increased severity of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;rs1799794;CC;Toxicity;increased  severity of Disease:Drug Toxicity;Genotype CC is associated with increased severity of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colorectal Neoplasms
;;NR1I2;rs7643645;GG;Other;increased  risk of Other:Death;Genotype GG is associated with increased risk of Death in people with Fatty Liver as compared to genotypes AA + AG.;in people with Fatty liver disease
;PLATINUM COMPOUNDS;CCND1;rs9344;AA;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Genotype AA is associated with increased severity of Nausea and Vomiting when treated with Platinum compounds in people with Lung Neoplasms as compared to genotypes AG + GG.;in people with Lung Neoplasms
;VERAPAMIL;CACNB2;rs11014166;AT + TT;Efficacy, Toxicity;increased  risk of Efficacy:adverse outcome;Genotypes AT + TT are associated with increased risk of adverse outcome when treated with verapamil in people with Hypertension and Coronary Artery Disease.;in people with Hypertension and Coronary Artery Disease
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;rs2074087;C;Toxicity;decreased severity of Disease:Neurotoxicity Syndromes;Allele C is associated with decreased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL;;rs2960436;AA;Efficacy;Other:better survival outcome;Genotype AA is associated with better survival outcome when treated with fluorouracil in people with Stomach Neoplasms as compared to genotype GG.;in people with Disease:Stomach Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs1885301;AA;Toxicity;increased  severity of Disease:Neurotoxicity Syndromes;Genotype AA is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL;IGFBP3;rs2854744;TT;Efficacy;Other:better survival outcome;Genotype TT is associated with better survival outcome when treated with fluorouracil in people with Stomach Neoplasms as compared to genotype GG.;in people with Disease:Stomach Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;TT;Toxicity;increased  severity of Disease:Neurotoxicity Syndromes;Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs3740066;TT;Toxicity;increased  severity of Disease:Neurotoxicity Syndromes;Genotype TT is associated with increased severity of Neurotoxicity Syndromes when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes CC + CT.;in people with Disease:Colorectal Neoplasms
;COCAINE;DRD2;rs1125394;C;Toxicity;increased  risk of Disease:Cocaine dependence;Allele C is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele T.; 
;COCAINE;DRD2;rs1076560;A;Toxicity;increased  risk of Disease:Cocaine dependence;Allele A is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.; 
;COCAINE;DRD2;rs2283265;A;Toxicity;increased  risk of Disease:Cocaine dependence;Allele A is associated with increased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.; 
;MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149015;A;Toxicity;increased  risk of Side Effect:adverse drug reactions;Allele A is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs4646453;CC;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype CC is associated with increased likelihood of adverse events when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AC.;in people with Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Efficacy;increased  risk of Efficacy:Transplant rejection;Genotype CC is associated with increased risk of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Kidney Transplantation
;MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;TT;Toxicity, Metabolism/PK;increased  risk of Side Effect:adverse drug reaction;Genotype TT is associated with increased risk of adverse drug reaction when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;OPIOIDS;COMT;rs4633;CC;Toxicity;increased  likelihood of Side Effect:Physiological sexual disorder;Genotype CC is associated with increased likelihood of Sexual Dysfunctions, Psychological due to opioids in women with Pain as compared to genotypes CT + TT.;in women with Pain
;MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;C;Toxicity, Metabolism/PK;decreased risk of Side Effect:adverse drug reactions;Allele C is associated with decreased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.;in people with Disease:Kidney Transplantation
;ACETAMINOPHEN / TRAMADOL;OPRM1;rs1799971;AG + GG;Toxicity;increased  likelihood of Side Effect:Constipation;Genotypes AG + GG is associated with increased likelihood of Constipation when treated with acetaminophen / tramadol in people with Pain, Postoperative as compared to genotype AA.;in people with Pain, Postoperative
;;VDR;rs2228570;AA + AG;;decreased  Efficacy:Bone Mineral Density;Genotypes AA + AG are associated with decreased Bone Mineral Density as compared to genotype GG.; 
;OPIOIDS;COMT;rs4633;CT;Toxicity;increased  likelihood of Side Effect:Dizziness;Genotype CT is associated with increased likelihood of Dizziness due to opioids in people with Pain as compared to genotypes CC + TT.;in people with Pain
;CAPECITABINE;ABCB1;rs1128503;AA;Toxicity;decreased risk of Side Effect:Hand-foot syndrome, Side Effect:Neutropenia;Genotype AA is associated with decreased risk of hand-foot syndrome and Neutropenia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;OPRM1;rs1799971;G;Toxicity;decreased likelihood of Disease:Opioid-Related Disorders;Allele G is associated with decreased likelihood of Opioid-Related Disorders due to opioids as compared to allele A.; 
;CAPECITABINE;ABCB1;rs2032582;CC;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype CC is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;OPRM1;rs1799971;AG + GG;Toxicity;increased  likelihood of Side Effect:Erectile Dysfunction, Side Effect:Insomnia, Side Effect:sedation, Side Effect:Physiological sexual disorder, Side Effect:Vomiting;Genotypes AG + GG are associated with increased likelihood of Erectile Dysfunction, insomnia, sedation, Sexual Dysfunctions, Psychological or Vomiting due to opioids in people with Pain as compared to genotype AA.;in people with Pain
;FLUOROURACIL;ABCB1;rs1045642;GG;Toxicity;decreased risk of Disease:Diarrhea;Genotype GG is associated with decreased risk of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;ABCB1;rs1045642;GG;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP2C9;rs7900194;A;Dosage, Metabolism/PK;Other:warfarin variability;Allele A is associated with warfarin variability when treated with warfarin as compared to allele G.; 
;SUNITINIB;NR1I2;rs3814055;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;AMPHETAMINE;OPRM1;rs510769;TT;Other;decreased  Other:Stimulation and Euphoria scores after amphetamine;Genotype TT is associated with decreased Stimulation and Euphoria scores after amphetamine when exposed to amphetamine in healthy individuals as compared to genotypes CC + CT.;in healthy individuals 
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Disease:Muscular Diseases;Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin in people with Hyperlipidemias as compared to genotype TT.;in people with Disease:Hyperlipidemias
;SUNITINIB;ABCG2;rs2231137;CT;Efficacy;increased   Efficacy:Progression-free survival;Genotype CT is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;;LRP5;rs3736228;T;;decreased  Other:Bone Mineral Density;Allele T is associated with decreased Bone Mineral Density as compared to allele C.; 
;CISPLATIN;NHLH1;rs11265375;CT + TT;Efficacy;increased   Efficacy:Overall survival;Genotypes CT + TT is associated with increased overall survival when treated with cisplatin in people with Carcinoma, Small Cell and Lung Neoplasms as compared to genotype CC.;in people with Small cell carcinoma, Lung Neoplasms
;;;rs4355801;A;;decreased  Other:lumbar spine Bone Mineral Density;Allele A is associated with decreased lumbar spine Bone Mineral Density as compared to allele G.; 
;;;rs4355801;A;;increased  risk of Disease:Osteoporosis;Allele A is associated with increased risk of Osteoporosis as compared to allele G.; 
;;LRP5;rs3736228;T;;increased  risk of Disease:Osteoporosis;Allele T is associated with increased risk of Osteoporosis.; 
;BORTEZOMIB;CBS;rs915854;TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases, Side Effect:Pain, Side Effect:Neuropathic pain;Genotype TT is associated with increased likelihood of Peripheral Nervous System Diseases, Pain and neuropathic pain when treated with bortezomib in people with Multiple Myeloma as compared to genotypes CC + CT.;in people with Multiple Myeloma
;;UGT2B15;rs3100;AA;Other;increased  likelihood of Other:Smoking Cessation;Genotype AA is associated with increased likelihood of cessation in people with Tobacco Use Disorder as compared to genotypes AG + GG.;in people with Tobacco Use Disorder
;AMPHETAMINE;OPRM1;rs2281617;CC;Other;increased   Other:Euphoric and Energetic after amphetamine (10 mg);Genotype CC is associated with increased Euphoric and Energetic after amphetamine (10 mg) when exposed to amphetamine in healthy individuals as compared to genotypes CT + TT.;in healthy individuals 
;WARFARIN;HNF4A;rs6130615;CC;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CT + TT.; 
;CISPLATIN;SEMA6A;rs3806915;A;Efficacy;increased   Efficacy:Overall survival;Allele A is associated with increased overall survival when treated with cisplatin in people with Carcinoma, Small Cell and Lung Neoplasms as compared to allele C.;in people with Small cell carcinoma, Lung Neoplasms
;ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy, Other;increased  risk of Disease:Thrombotic disease;Genotype AA is associated with increased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotypes AG + GG.;in people with percutaneous coronary intervention
;WARFARIN;HNF4A;rs1884613;GG;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype GG is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CC + CG.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;ASPIRIN, CLOPIDOGREL;ITGB3;rs5918;CC + CT;Efficacy, Other;decreased risk of Disease:Thrombotic disease;Genotypes CC + CT is associated with decreased risk of Thrombosis when treated with aspirin and clopidogrel in people with percutaneous coronary intervention as compared to genotype TT.;in people with percutaneous coronary intervention
;WARFARIN;HNF4A;rs3212191;TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CC + CT.; 
;ONDANSETRON;SLC6A4;rs1042173;AA;Efficacy;increased   Efficacy:treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype;Genotype AA is associated with increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype when treated with ondansetron in people with Alcoholism as compared to allele C.;in people with Disease:Alcohol abuse
;WARFARIN;;rs61162043;G;Other;increased  likelihood of Other:having warfarin Dose greater than 7.5 mg/day;Allele G is associated with increased likelihood of having warfarin Dose greater than 7.5 mg/day when treated with warfarin as compared to allele A.; 
;RISPERIDONE;HTR2A;rs6313;GG;Toxicity;decreased severity of Side Effect:weight gain;Genotype GG is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotypes AA + AG.;in people with Disease:Schizophrenia
;HEROIN;OPRM1;rs2075572;G;Toxicity;increased  risk of Disease:Heroin Dependence;Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;RISPERIDONE;;rs1805054;TT;Toxicity;decreased severity of Side Effect:weight gain;Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotypes CC + CT.;in people with Disease:Schizophrenia
;ANTIHYPERTENSIVES;NEDD4L;rs4149601;AA;Efficacy;increased  likelihood of Efficacy:resistant hypertension;Genotype AA is associated with increased likelihood of resistant hypertension when treated with Antihypertensives in people with Hypertension as compared to genotypes AG + GG.;in people with Hypertension
;ANTIHYPERTENSIVES;ADRB1;rs1801252;GG;Efficacy;increased  likelihood of Efficacy:resistant hypertension;Genotype GG is associated with increased likelihood of resistant hypertension when treated with Antihypertensives in people with Hypertension as compared to genotypes AA + AG.;in people with Hypertension
;FLUOROURACIL;MTHFR;rs1801133;AA + AG;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;RISPERIDONE;HTR2C;rs3813929;CT + TT;Toxicity;decreased severity of Side Effect:Weight gain;Genotypes CT + TT is associated with decreased severity of Weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.;in people with Disease:Schizophrenia
;HEROIN;OPRM1;rs1799971;G;Toxicity;increased  risk of Disease:Heroin Dependence;Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.; 
;BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;rs2229109;CT;Toxicity;increased  risk of Side Effect:Diarrhea, Side Effect:Vomiting;Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC.;in people with Disease:Non-Hodgkin Lymphoma
;CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;Toxicity;decreased risk of Side Effect:Gastrointestinal toxicity, Side Effect:Leukopenia;Allele C is associated with decreased risk of gastrointestinal toxicity and Leukopenia when exposed to cyclophosphamide in people with Lupus erythematosus as compared to allele T.;in people with Disease:Lupus erythematosus
;ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;rs776746;CC;Efficacy;decreased likelihood of Efficacy:resistant hypertension;Genotype CC is associated with decreased likelihood of resistant hypertension when treated with Antihypertensives in people with Hypertension as compared to genotypes CT + TT.;in people with Hypertension
;CISPLATIN;XPC;rs2228001;GG + GT;Toxicity;increased  risk of Disease:Neutropenia;Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.;in people with Disease:Urinary Bladder Neoplasms
;METHADONE;OPRM1;rs1799971;G;Other;decreased likelihood of Disease:Recurrence;Allele G is associated with decreased likelihood of Recurrence in people not taking methadone in people with Heroin Dependence as compared to allele A.;in people with Disease:Heroin Dependence
;;CYP2C9;rs1057910;C;;decreased risk of Disease:Coronary Artery Disease;Allele C is associated with decreased risk of Coronary Artery Disease as compared to allele A.; 
;;CYP2C9;rs1057910;C;;increased  risk of Disease:Myocardial Infarction;Allele C is associated with increased risk of Myocardial Infarction as compared to allele A.; 
;SUFENTANIL;CYP3A4;rs2242480;TT;Toxicity;increased  likelihood of Side Effect:Hypoventilation;Genotype TT is associated with increased likelihood of Hypoventilation due to sufentanil in people with Pain, Postoperative as compared to genotypes CC + CT.;in people with Pain, Postoperative
;;ADRA2A;rs3750625;A;Other;increased  likelihood of Disease:Diabetes, Gestational;Allele A is associated with increased likelihood of Diabetes, Gestational in women with Pregnancy as compared to allele C.;in women with Pregnancy
;;ADRA2A;rs11195418;G;Other;decreased likelihood of Disease:Diabetes, Gestational;Allele G is associated with decreased likelihood of Diabetes, Gestational in women with Pregnancy as compared to allele A.;in women with Pregnancy
;MURAGLITAZAR;REN;rs2368564;TT;Toxicity;decreased risk of Disease:Edema;Genotype TT is associated with decreased risk of Edema when treated with muraglitazar in people with Diabetes Mellitus as compared to genotype CC.;in people with Disease:Diabetes Mellitus
;CHLOROQUINE, PRIMAQUINE;SLCO2B1;rs12422149;GG;Efficacy;increased  severity of Efficacy:Parasitemia;Genotype GG is associated with increased severity of Parasitemia when treated with chloroquine and primaquine in people with Malaria as compared to genotypes AA + AG.;in people with Disease:Malaria
;ASPIRIN;IL4;rs2243250;TT;Other;decreased  Side Effect:Aspirin-induced asthma;Genotype TT is associated with decreased aspirin-induced asthma when treated with aspirin in people with Asthma as compared to genotypes CC + CT.;in people with Disease:Asthma
;ANTIPSYCHOTICS;CNR1;rs806374;CC;Toxicity;increased  likelihood of Disease:Tardive Dyskinesia;Genotype CC is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;WARFARIN;CYP2C9;rs1057910;AC + CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes AC + CC is associated with increased likelihood of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to genotype AA.;in people with Heart valve replacement
;METHOTREXATE;SLC16A7;rs3763980;A;Efficacy;increased  risk of Efficacy:non-response to methotrexate;Allele A is associated with increased risk of non-response to methotrexate when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.;in children with Disease:Juvenile Rheumatoid Arthritis
;METFORMIN;AMHR2;rs784892;G;Efficacy;decreased  Efficacy:post-HbA1c levels;Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.;in people with Disease:Diabetes Mellitus, Type 2
;ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLA2G4A;rs12746200;G;Toxicity;increased  risk of Side Effect:Urticaria;Allele G is associated with increased risk of Urticaria when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones as compared to genotype AA.; 
;ANTIPSYCHOTICS;CNR1;rs806374;CC;Toxicity;increased  severity of Disease:Tardive Dyskinesia;Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;WARFARIN;VKORC1;rs9923231;TT;Efficacy;Efficacy:shorter time to first therapeutic INR and time to first INR>4;Genotype TT is associated with shorter time to first therapeutic INR and time to first INR>4 when treated with warfarin in children as compared to genotypes CC + CT.;in children 
;FLUOROURACIL;DPYD;rs75017182;C;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele C is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;ETHANOL;OPRM1;rs1799971;AA;Toxicity;increased  risk of Disease:Alcohol abuse;Genotype AA is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AG + GG.; 
;NEVIRAPINE;CYCSP5;rs3099844;A;Toxicity, Other;increased  risk of Disease:Stevens-Johnson Syndrome;Allele A is associated with increased risk of Stevens-Johnson Syndrome when exposed to nevirapine in women with Acquired Immunodeficiency Syndrome as compared to allele C.;in women with Disease:Acquired Immunodeficiency Syndrome
;ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLCG1;rs2228246;G;Toxicity;increased  risk of Side Effect:Angioedema;Allele G is associated with increased risk of Angioedema when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives and Pyrazolones as compared to genotype AA.; 
;ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;TNFRSF11A;rs1805034;C;Toxicity;increased  risk of Side Effect:Angioedema, Side Effect:Urticaria;Allele C is associated with increased risk of Angioedema and Urticaria when treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives and Pyrazolones as compared to genotype TT.; 
;ANTIHYPERTENSIVES;NOS3;rs1799983;G;Efficacy;increased  likelihood of Efficacy:response;Allele G is associated with increased likelihood of response when treated with Antihypertensives in people with Pre-Eclampsia.;in people with Disease:Pre-Eclampsia
;ANTIHYPERTENSIVES;NOS3;rs2070744;C;Efficacy;increased  likelihood of Efficacy:response;Allele C is associated with increased likelihood of response when treated with Antihypertensives in people with Pre-Eclampsia as compared to allele T.;in people with Disease:Pre-Eclampsia
;METHOTREXATE;ABCB1;rs1045642;AG;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype AG is associated with increased likelihood of gastrointestinal toxicity when exposed to methotrexate in people with Arthritis, Rheumatoid.;in people with Disease:Rheumatoid arthritis
;;ADRA2A;rs1800038;A;Other;increased  likelihood of Disease:Diabetes, Gestational;Allele A is associated with increased likelihood of Diabetes, Gestational in women with Pregnancy as compared to allele C.;in women with Pregnancy
;TACROLIMUS;CYP3A5;rs776746;T;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele T is associated with increased likelihood of discontinuation when treated with tacrolimus in people with liver transplantation as compared to allele C.;in people with Liver transplantation
;CISPLATIN;SLC22A1;rs683369;CG + GG;Efficacy;increased   Efficacy:Overall survival;Genotypes CG + GG is associated with increased overall survival when treated with cisplatin in people with Esophageal Neoplasms as compared to genotype CC.;in people with Neoplasm of esophagus
;NICOTINE;;rs4887074;G;Toxicity;decreased risk of Disease:Tobacco Use Disorder;Allele G is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele C.; 
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs10937158;T;Toxicity;decreased risk of Side Effect:Diarrhea;Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs3749438;A;Toxicity;increased  risk of Side Effect:Diarrhea;Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;rs225440;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;PON1;rs854552;CC;Efficacy;increased   Efficacy:platelet reactivity;Genotype CC is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.;in people with Coronary Artery Disease
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;;rs2292997;A;Toxicity;increased  risk of Side Effect:Neutropenia;Allele A is associated with increased risk of Neutropenia when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;CISPLATIN;PPARD;rs2038067;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with cisplatin in people with Esophageal Neoplasms as compared to genotype AA.;in people with Neoplasm of esophagus
;TACROLIMUS;CYP3A5;rs6977165;C;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele C is associated with increased likelihood of discontinuation when treated with tacrolimus in people with liver transplantation as compared to allele T.;in people with Liver transplantation
;CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;Toxicity;decreased risk of Side Effect:Gastrointestinal toxicity, Side Effect:Leukopenia;Allele A is associated with decreased risk of gastrointestinal toxicity and Leukopenia when exposed to cyclophosphamide in people with Lupus erythematosus as compared to allele G.;in people with Disease:Lupus erythematosus
;WARFARIN;VKORC1;rs9923231;CT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype CT is associated with increased risk of Hemorrhage when treated with warfarin in children as compared to genotype CC.;in children 
;WARFARIN;VKORC1;rs9923231;T;Efficacy;increased   Efficacy:propertion of the first 6 months' treatment time spent within the target INR range (PTIR);Allele T is associated with increased propertion of the first 6 months' treatment time spent within the target INR range (PTIR) when treated with warfarin in children as compared to allele C.;in children 
;FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  severity of Disease:Myelosuppression;Genotypes CT + TT is associated with increased severity of Myelosuppression when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;;OPRM1;rs1799971;AA;Toxicity;increased  severity of Disease:Substance-Related Disorders;Genotype AA is associated with increased severity of Substance-Related Disorders as compared to genotypes AG + GG.; 
;FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  severity of Disease:Hand-foot syndrome;Genotypes CT + TT is associated with increased severity of hand-foot syndrome when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  severity of Disease:Diarrhea;Genotypes CT + TT is associated with increased severity of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL;DPYD;rs17376848;G;Toxicity;increased  risk of Disease:Neutropenia;Allele G is associated with increased risk of Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele A.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;CYP3A5;rs776746;CC + CT;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes CC + CT are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype TT.; 
;ACETAMINOPHEN / TRAMADOL;MIR107;rs2296616;AA + AG;Toxicity;decreased likelihood of Side Effect:Nausea;Genotypes AA + AG is associated with decreased likelihood of Nausea when treated with acetaminophen / tramadol in people with Pain, Postoperative as compared to genotype GG.;in people with Pain, Postoperative
;LITHIUM;GSK3B;rs334558;AA;Efficacy;decreased  Efficacy:response;Genotype AA is associated with decreased response when treated with lithium in people with Bipolar Disorder as compared to genotypes AG + GG.;in people with Disease:Bipolar Disorder
;CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;rs1800566;AA;Toxicity;decreased risk of Side Effect:Anemia, Side Effect:Drug Toxicity;Genotype AA is associated with decreased risk of Anemia and Drug Toxicity when treated with cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate in women Breast Neoplasms as compared to genotype GG.;in women Disease:Breast Neoplasms
;ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;GG;Toxicity;increased  likelihood of Side Effect:Nausea;Genotype GG is associated with increased likelihood of Nausea when treated with acetaminophen / tramadol in people with Pain, Postoperative as compared to genotypes CC + CG.;in people with Pain, Postoperative
;ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;CG + GG;Efficacy;increased  likelihood of Efficacy:Neuropathic pain;Genotypes CG + GG is associated with increased likelihood of neuropathic pain when treated with acetaminophen / tramadol in people with Pain, Postoperative as compared to genotype CC.;in people with Pain, Postoperative
;OPIOIDS;CYP1A2;rs2069514;AA + AG;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Genotypes AA + AG are associated with decreased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.; 
;OPIOIDS;DRD3;rs2654754;AA + AG;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.; 
;SIMVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotype CC is associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.; 
;OPIOIDS;DRD3;rs324029;AG + GG;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes AG + GG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype AA.; 
;METHAMPHETAMINE;FAAH;rs324420;A;Toxicity;increased  risk of Side Effect:Methamphetamine dependence;Allele A are associated with increased risk of methamphetamine dependence due to methamphetamine as compared to allele C.; 
;OPIOIDS;CYP3A4;rs2740574;CC + CT;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Genotypes CC + CT are associated with decreased risk of Opioid-Related Disorders due to opioids as compared to genotype TT.; 
;RISPERIDONE;ABCG2;rs2231142;GT + TT;Toxicity;increased  risk of Side Effect:adverse events;Genotypes GT + TT is associated with increased risk of adverse events when treated with risperidone in children as compared to genotype GG.;in children 
;ASPIRIN;UGT1A6;rs1105879;AC + CC;Efficacy;increased  risk of Disease:Colonic Neoplasms;Genotypes AC + CC is associated with increased risk of Colonic Neoplasms in people not taking aspirin as compared to genotype AA.; 
;ACETAMINOPHEN / TRAMADOL;OPRM1;rs677830;CT + TT;Toxicity;increased  likelihood of Side Effect:Constipation;Genotypes CT + TT is associated with increased likelihood of Constipation when treated with acetaminophen / tramadol in people with Pain, Postoperative as compared to genotype CC.;in people with Pain, Postoperative
;OPIOIDS;CYP3A5;rs15524;AA + AG;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.; 
;REGORAFENIB;KDR;rs4864950;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with regorafenib in people with Neoplasms as compared to allele T.;in people with Neoplasms
;EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;Toxicity;increased  likelihood of Side Effect:Death;Genotype TT is associated with increased likelihood of Death when treated with efavirenz, ethambutol, isoniazid and rifampin in people with HIV Infections and Tuberculosis as compared to genotypes CC + CT.;in people with Disease:HIV infectious disease, Disease:Tuberculosis
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:time above therapeutic range;Genotype TT are associated with increased risk of time above therapeutic range when treated with warfarin in people with venous thromboembolism as compared to genotype CC.;in people with Disease:Venous thromboembolism
;EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased severity of Peripheral Nervous System Diseases when treated with efavirenz, ethambutol, isoniazid and rifampin in people with HIV Infections and Tuberculosis as compared to genotypes CC + CT.;in people with Disease:HIV infectious disease, Disease:Tuberculosis
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AA + TT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotypes AA + TT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.;in women Disease:Breast Neoplasms
;TAXANES;NR1I3;rs11584174;CC;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype CC is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with taxanes in women with Breast Neoplasms as compared to genotype CT.;in women with Disease:Breast Neoplasms
;ATAZANAVIR, RITONAVIR;UGT1A1;rs8330;G;Other;increased  risk of Side Effect:Nephrolithiasis;Allele G is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AC + CT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotypes AC + CT are associated with increased risk of Neutropenia when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to genotype CC.;in women Disease:Breast Neoplasms
;EFAVIRENZ;CYP2B6;rs28399499;TT;Toxicity;increased  risk of Disease:Central Nervous System Disorder;Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections.;in people with Disease:HIV infectious disease
;NEVIRAPINE;ABCB1;rs10276036;TT;Toxicity;increased  risk of Disease:Drug Hypersensitivity;Genotype TT is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;TAXANES;UGT2B7;rs7438284;AA;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with taxanes in women with Breast Neoplasms as compared to genotypes AT + TT.;in women with Disease:Breast Neoplasms
;ATAZANAVIR, RITONAVIR;UGT1A1;rs10929303;T;Other;increased  risk of Side Effect:Nephrolithiasis;Allele T is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;TAXANES;UGT2B7;rs7439366;TT;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with taxanes in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;ATAZANAVIR, RITONAVIR;UGT1A1;rs1042640;G;Other;increased  risk of Side Effect:Nephrolithiasis;Allele G is associated with increased risk of nephrolithiasis when treated with atazanavir and ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;TAXANES;UGT2B7;rs7662029;AA;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with taxanes in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;TAXANES;UGT2B7;rs7668258;TT;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with taxanes in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity;increased  risk of Disease:Central Nervous System Disorder;Genotype TT is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in men with HIV Infections.;in men with Disease:HIV infectious disease
;ANTIPSYCHOTICS;GRM3;rs1468412;TT;Toxicity;increased  risk of Side Effect:Memory impairment;Genotype TT is associated with increased risk of Memory Disorders when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AT.;in people with Disease:Schizophrenia
;ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;increased   Efficacy:non-responsiveness;Genotypes CT + TT is associated with increased non-responsiveness when treated with aspirin and clopidogrel in people with Angina Pectoris as compared to genotype CC.;in people with Disease:Angina Pectoris
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with venous thromboembolism as compared to genotype CC.;in people with Disease:Venous thromboembolism
;RISPERIDONE;BDNF;rs6265;TT;Toxicity;decreased severity of Side Effect:weight gain;Genotype TT is associated with decreased severity of weight gain due to risperidone in people with Schizophrenia as compared to genotype CC.;in people with Disease:Schizophrenia
;CORTICOSTEROIDS;FCER2;rs28364072;G;Efficacy;increased  likelihood of Side Effect:Asthma-related ER visit or hospitalization;Allele G is associated with increased likelihood of Asthma-related ER visit or hospitalization when treated with corticosteroids in children with Asthma as compared to allele A.;in children with Disease:Asthma
;FLUOROURACIL, RADIOTHERAPY;CXCL8;rs4073;AA;Efficacy;decreased risk of Side Effect:Drug Toxicity;Genotype AA is associated with decreased risk of Drug Toxicity when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to genotypes AT + TT.;in people with Disease:Rectal Neoplasms
;METHOTREXATE;ABCB1;rs1045642;AA + AG;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;FLUOROURACIL, RADIOTHERAPY;KDR;rs1870377;AA;Toxicity;risk of Side Effect:Mucositis;Genotype AA is associated with risk of mucositis when treated with fluorouracil and radiotherapy in people with Rectal Neoplasms as compared to genotypes AT + TT.;in people with Disease:Rectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;Toxicity;decreased risk of Disease:Depression;Genotype CC is associated with decreased risk of Depression when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CG + GG.;in people with Disease:Chronic hepatitis C virus infection
;ATORVASTATIN;CYP7A1;rs3808607;TT;Efficacy;increased   Efficacy:mean percentage reduction of triglycerides level;Genotype TT is associated with increased mean percentage reduction of triglycerides level when treated with atorvastatin in people with Hyperlipidemias as compared to genotypes GG + GT.;in people with Disease:Hyperlipidemias
;CANGRELOR;P2RY12;rs6787801;G;Other;Other:5% lower ADP-induced peak platelet aggregation in-vitro;Allele G is associated with 5% lower ADP-induced peak platelet aggregation in-vitro when exposed to cangrelor as compared to genotype AA.; 
;;APOC1, APOE;rs445925;A;Metabolism/PK;PK:baseline LDL cholesterol;Allele A is associated with baseline LDL cholesterol in people with Vascular Diseases.;in people with Disease:Vascular Diseases
;SUNITINIB;FGFR2;rs2981582;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799931;A;Toxicity;increased  risk of Side Effect:adverse reactions;Allele A is associated with increased risk of adverse reactions when treated with sulfamethoxazole / trimethoprim in children with Pneumonia.;in children with Disease:Pneumonia
;SUNITINIB;FLT4;rs307826;CC + CT;Efficacy;decreased  Disease:Overall survival;Genotypes CC + CT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.;in people with Disease:Renal Cell Carcinoma
;HEROIN;OPRM1;rs1799971;AG + GG;Toxicity;decreased risk of Disease:Heroin Dependence;Genotypes AG + GG are associated with decreased risk of Heroin Dependence when exposed to heroin as compared to genotype AA.; 
;SUNITINIB;NR1I3;rs2307424;AA + AG;Efficacy;decreased  Disease:Overall survival;Genotypes AA + AG is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;;FADS1, FEN1, MIR611, TMEM258;rs174541;T;Metabolism/PK;PK:baseline LDL cholesterol;Allele T is associated with baseline LDL cholesterol in people with Vascular Diseases.;in people with Disease:Vascular Diseases
;;;rs258494;C;Metabolism/PK;PK:baseline LDL cholesterol;Allele C is associated with baseline LDL cholesterol in people with Vascular Diseases.;in people with Disease:Vascular Diseases
;;LDLR;rs6511720;T;Other;PK:baseline LDL cholesterol;Allele T is associated with baseline LDL cholesterol in people with Vascular Diseases.;in people with Disease:Vascular Diseases
;;PNMT;rs2934965;T;Other;decreased risk of Other:Sickle cell pain crisis;Allele T is associated with decreased risk of pain crisis in people with Anemia, Sickle Cell as compared to allele G.;in people with Anemia, Sickle Cell
;FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;rs1695;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with fluorouracil, leucovorin, levamisole or radiotherapy in people with Rectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Rectal Neoplasms
;DEXAMETHASONE, LENALIDOMIDE;ABCB1;rs2229109;CT;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC.;in people with Disease:Multiple Myeloma
;AZATHIOPRINE;DDRGK1, ITPA;rs1127354;AC;Efficacy;increased  likelihood of Efficacy:non-response;Genotype AC is associated with increased likelihood of non-response when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Disease:Inflammatory Bowel Diseases
;;PNMT;rs2941523;GG;Other;decreased risk of Other:Sickle cell pain crisis;Genotype GG is associated with decreased risk of pain crisis in people with Anemia, Sickle Cell as compared to genotypes CC + CG.;in people with Anemia, Sickle Cell
;MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;Efficacy;increased  risk of Other:Chronic lung allograft dysfunction;Genotypes GT + TT are associated with increased risk of chronic lung allograft dysfunction when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.;in people with Lung transplantation
;;PNMT;rs876493;AA + AG;Other;decreased risk of Other:Sickle cell pain crisis;Genotypes AA + AG is associated with decreased risk of pain crisis in women with Anemia, Sickle Cell as compared to genotype GG.;in women with Anemia, Sickle Cell
;ATENOLOL, BISOPROLOL;ACY3;rs2514036;C;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure, Efficacy:Elevated systolic blood pressure;Allele C is associated with decreased severity of Elevated diastolic blood pressure and Elevated systolic blood pressure when treated with atenolol or bisoprolol in men with Hypertension as compared to allele T.;in men with Disease:Hypertension
;LOSARTAN;KIRREL2, NPHS1;rs3814995;T;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele T is associated with decreased severity of Elevated diastolic blood pressure when treated with losartan in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;ASPIRIN;ADORA1;rs16851030;TT;Toxicity;increased  risk of Side Effect:aspirin-intolerant asthma;Genotype TT is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes CC + CT.;in people with Disease:Asthma
;ANTINEOPLASTIC AGENTS;FPGS;rs1544105;TT;Toxicity;decreased likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with decreased likelihood of gastrointestinal toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;SUNITINIB;NR1I3;rs4073054;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.;in people with Disease:Renal Cell Carcinoma
;SUNITINIB;FLT4;rs307821;AA + AC;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AC is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;ALPRAZOLAM;CYP3A4;rs35599367;AG;Toxicity;increased  risk of Side Effect:adverse events;Genotype AG is associated with increased risk of adverse events when treated with alprazolam in men with Alcoholism and Anxiety Disorders as compared to genotype GG.;in men with Alcohol abuse, Anxiety Disorders
;MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;Efficacy;increased  risk of Other:Transplant rejection;Genotypes AG + GG are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.;in people with Lung transplantation
;MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;Efficacy;decreased likelihood of Other:Overall survival;Genotypes AG + GG are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.;in people with Lung transplantation
;SUNITINIB;ABCB1;rs1128503;AG + GG;Efficacy;increased   Efficacy:Progression-free survival;Genotypes AG + GG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.;in people with Disease:Renal Cell Carcinoma
;OLANZAPINE;CYP1A1;rs2472297;T;Metabolism/PK;PK:25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio;Allele T is associated with 25% higher mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.;in people with Disease:Psychotic Disorder
;MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;Efficacy;increased  risk of Other:Transplant rejection;Genotypes GT + TT are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.;in people with Lung transplantation
;BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;rs885036;G;Efficacy;increased   Disease:Progression-free survival;Allele G is associated with increased progression-free survival when treated with bevacizumab, capecitabine, cetuximab and oxaliplatin in people with Colorectal Neoplasms as compared to allele A.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;ADGRV1;rs2366929;C;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Allele C is associated with increased risk of Opioid-Related Disorders due to opioids in men as compared to allele T.;in men 
;BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;rs885036;G;Efficacy;decreased  Disease:Progression-free survival;Allele G is associated with decreased progression-free survival when treated with bevacizumab, capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to allele A.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;FMO3;rs1736557;AA;Efficacy;decreased risk of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with decreased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AG + GG.;in people with Efficacy:Coronary Artery Disease
;MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;Efficacy;decreased likelihood of Other:Overall survival;Genotypes GT + TT are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.;in people with Lung transplantation
;IRINOTECAN;UGT1A1;rs10929302;AA;Toxicity;increased  risk of Disease:Diarrhea;Genotype AA is associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ASPIRIN, CLOPIDOGREL;PEAR1;rs2644592;G;Efficacy;Efficacy:high on-treatment platelet reactivity;Allele G is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele A.; 
;ASPIRIN, CLOPIDOGREL;PEAR1;rs11264580;C;Efficacy;Efficacy:high on-treatment platelet reactivity;Allele C is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele T.; 
;BUPROPION, NICOTINE;APOE;rs429358;CC + CT;Other;increased  likelihood of Disease:Recurrence;Genotypes CC + CT is associated with increased likelihood of Recurrence when treated with bupropion or nicotine in people with Tobacco Use Disorder as compared to genotype TT.;in people with Disease:Tobacco Use Disorder
;ASPIRIN, CLOPIDOGREL;PEAR1;rs57731889;TT;Efficacy;Efficacy:low on-treatment platelet reactivity;Genotype TT is associated with low on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to genotypes CC + CT.; 
;ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;rs932658;A;Toxicity;decreased likelihood of Side Effect:Osteonecrosis of the jaw;Allele A is associated with decreased likelihood of osteonecrosis of jaw caused by drug when treated with alendronate, ibandronate, risedronate or zoledronate in people with Neoplasms as compared to allele C.;in people with Neoplasms
;VALPROIC ACID;LEPR;rs1137101;AG + GG;Toxicity;increased  severity of Side Effect:Weight gain;Genotypes AG + GG is associated with increased severity of Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype AA.;in people with Epilepsy
;ANTINEOPLASTIC AGENTS;GSTM5;rs3754446;C;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Allele C is associated with increased likelihood of gastrointestinal toxicity when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Acute lymphoblastic leukemia
;ATORVASTATIN, BEZAFIBRATE;APOE;rs449647;AT + TT;Efficacy;increased   Efficacy:lipid-lowering effect;Genotypes AT + TT is associated with increased lipid-lowering effect when treated with atorvastatin or bezafibrate in people with Hyperlipidemias as compared to genotype AA.;in people with Disease:Hyperlipidemias
;HALOPERIDOL;SLC6A5;rs2298826;AA;Toxicity;Side Effect:motor side effects;Genotype AA is associated with motor side effects when treated with haloperidol in people with Schizophrenia as compared to genotypes AG + GG.;in people with Disease:Schizophrenia
;OLANZAPINE;AHR;rs4410790;T;Metabolism/PK;PK:29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio;Allele T is associated with 29% lower mean 4'-desmethyl OLA/olanzapine (OLA) ratio when treated with olanzapine in people with Psychotic Disorders as compared to genotype CC.;in people with Disease:Psychotic Disorder
;CLOPIDOGREL;P2RY12;rs6785930;AA + AG;Toxicity;increased  risk of Side Effect:adverse events;Genotypes AA + AG is associated with increased risk of adverse events when treated with clopidogrel as compared to genotype GG.; 
;ASPIRIN, CLOPIDOGREL;PEAR1;rs3737224;T;Efficacy;Efficacy:high on-treatment platelet reactivity;Allele T is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele C.; 
;ASPIRIN, CLOPIDOGREL;CYP4F2;rs3093135;T;Efficacy;increased  likelihood of Side Effect:Epistaxis, Side Effect:Gastrointestinal Hemorrhage, Side Effect:Hematoma, Side Effect:Hematuria, Side Effect:Thrombotic disease;Allele T is associated with increased likelihood of Epistaxis, Gastrointestinal Hemorrhage, Hematoma, Hematuria and Thrombosis when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;ETHANOL;OPRM1;rs1799971;G;Toxicity;increased  severity of Disease:Alcohol abuse;Allele G is associated with increased severity of Alcoholism due to ethanol as compared to allele A.; 
;VENLAFAXINE;CYP2D6;rs5030655;del;Metabolism/PK;PK:impaired metabolic activity;Allele del is associated with impaired metabolic activity when treated with venlafaxine in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;T;Efficacy;increased  likelihood of Side Effect:Epistaxis, Side Effect:Gastrointestinal Hemorrhage, Side Effect:Hematoma, Side Effect:Hematuria, Side Effect:Thrombotic disease;Allele T is associated with increased likelihood of Epistaxis, Gastrointestinal Hemorrhage, Hematoma, Hematuria and Thrombosis when treated with aspirin and ticagrelor in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;P2RY12;rs6809699;AA + AC;Toxicity;increased  risk of Side Effect:adverse events;Genotypes AA + AC is associated with increased risk of adverse events when treated with clopidogrel as compared to genotype CC.; 
;CISPLATIN, DOXORUBICIN;CASP3;rs2720376;C;Efficacy;increased   Efficacy:Progression-free survival;Allele C is associated with increased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele T.;in people with Disease:Osteosarcoma
;ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;Toxicity;increased  likelihood of Side Effect:Angioedema;Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain in men as compared to allele C.;in men 
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs59502379;C;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Allele C is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to allele G.; 
;CAPECITABINE;CES1;rs2244613;GG + GT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes GG + GT is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to genotype TT.;in people with Neoplasms
;NEVIRAPINE;CCHCR1;rs1265112;C;Toxicity;increased  risk of Side Effect:Nevirapine-induced rash;Allele C is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;CISPLATIN, DOXORUBICIN;CYP3A4;rs4646437;A;Efficacy;increased   Efficacy:Progression-free survival;Allele A is associated with increased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele G.;in people with Disease:Osteosarcoma
;;GLI1;rs2228226;CC;Efficacy;decreased  Efficacy:Recurrence free survival;Genotype CC is associated with decreased Recurrence free survival in people with Colonic Neoplasms as compared to genotypes CG + GG.;in people with Disease:Colonic Neoplasms
;NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;Toxicity;increased  severity of Disease:Tobacco Use Disorder;Genotypes AA + AG are associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype GG.; 
;VALPROIC ACID;UGT1A6;rs2070959;AG + GG;Toxicity;increased  likelihood of Side Effect:Tremor;Genotypes AG + GG is associated with increased likelihood of Tremor when treated with valproic acid in people with Epilepsy as compared to genotype AA.;in people with Epilepsy
;ESCITALOPRAM;CYP1A2;rs4646425;T;Toxicity;increased   Disease:Fatigue;Allele T is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major.;in people with Disease:Major Depressive Disorder
;CLOZAPINE;ACKR1;rs2814778;CC;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotype CC is associated with increased likelihood of Neutropenia when treated with clozapine in people with Schizophrenia as compared to genotypes CT + TT.;in people with Schizophrenia
;ESCITALOPRAM;;rs2069521;A;Toxicity;increased   Disease:Fatigue;Allele A is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;Efficacy;Efficacy:high on-treatment platelet reactivity;Allele T is associated with high on-treatment platelet reactivity when treated with aspirin and clopidogrel as compared to allele C.; 
;ESCITALOPRAM;CYP1A2;rs4646427;C;Toxicity;increased   Disease:Fatigue;Allele C is associated with increased Fatigue when treated with escitalopram in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;;rs2069521;A;Toxicity;increased   Side Effect:nausea/vomiting;Allele A is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP1A2;rs4646425;T;Toxicity;increased   Side Effect:nausea/vomiting;Allele T is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;CYP1A2;rs4646427;C;Toxicity;increased   Side Effect:nausea/vomiting;Allele C is associated with increased nausea/vomiting when treated with escitalopram in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;ALLOPURINOL;CYCSP5;rs3099844;AA + AC;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Stevens-Johnson Syndrome;Genotypes AA + AC are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype CC.; 
;CLOPIDOGREL;CYP1A2;rs762551;AA + AC;Efficacy, Metabolism/PK;decreased  Efficacy:on-treatment platelet reactivity;Genotypes AA + AC are associated with decreased on-treatment platelet reactivity when treated with clopidogrel in people with cigarette smokers as compared to genotype CC.;in people with cigarette smokers
;ETHANOL;OPRK1;rs6473797;CC + CT;Toxicity;increased  severity of Side Effect:Alcohol abuse;Genotypes CC + CT are associated with increased severity of Alcoholism due to ethanol in men as compared to genotype TT.;in men 
;CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;rs1800566;A;Efficacy;Efficacy:worse outcome (overall survival and progression-free survival);Allele A is associated with worse outcome (overall survival and progression-free survival) when treated with cyclophosphamide and doxorubicin in people with Breast Neoplasms as compared to genotype GG.;in people with Disease:Breast Neoplasms
;HEROIN;GRM3;rs274618;T;Other;increased  risk of Disease:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele A.; 
;THIAZOLIDINEDIONES;AQP2;rs296766;T;Toxicity;increased  risk of Disease:Edema;Allele T is associated with increased risk of Edema when treated with thiazolidinediones in people with Diabetes Mellitus, Type 2 as compared to allele C.;in people with Disease:Diabetes Mellitus, Type 2
;ETHANOL;CHRNA3;rs578776;G;Toxicity, Other;decreased likelihood of Disease:Alcohol abuse;Allele G is associated with decreased likelihood of Alcoholism due to ethanol as compared to allele A.; 
;CISPLATIN, DOXORUBICIN;ABCC5;rs939338;G;Efficacy;decreased  Efficacy:Progression-free survival;Allele G is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele A.;in people with Disease:Osteosarcoma
;CISPLATIN, DOXORUBICIN;FASLG;rs763110;T;Efficacy;decreased  Efficacy:Progression-free survival;Allele T is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele C.;in people with Disease:Osteosarcoma
;CISPLATIN, DOXORUBICIN;MSH2;rs4638843;C;Efficacy;decreased  Efficacy:Progression-free survival;Allele C is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele G.;in people with Disease:Osteosarcoma
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;rs3087879;C;Efficacy;increased  severity of Efficacy:pharmacological resistance;Allele C is associated with increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors in people with Obsessive-Compulsive Disorder as compared to allele G.;in people with Disease:Obsessive-Compulsive Disorder
;COCAINE;CHRNA5;rs684513;G;Other;increased  likelihood of Disease:Cocaine dependence;Allele G is associated with increased likelihood of Cocaine-Related Disorders due to cocaine as compared to allele C.; 
;ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;Toxicity;increased  likelihood of Side Effect:Angioedema;Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.; 
;ALLOPURINOL;;rs2734583;AG + GG;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Stevens-Johnson Syndrome;Genotypes AG + GG are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype AA.; 
;METHOTREXATE;ABCC2;rs717620;CT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CT + TT are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;Toxicity;increased  risk of Side Effect:Drug Reaction with Eosinophilia and Systemic Symptoms, Side Effect:Stevens-Johnson Syndrome;Genotypes AA + AG are associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol as compared to genotype GG.; 
;FEXOFENADINE;SLCO2B1;rs2306168;T;Metabolism/PK;decreased  PK: area under the plasma concentration-time curve;Allele T is associated with decreased area under the plasma concentration-time curve when treated with fexofenadine in healthy individuals as compared to genotype CC.;in healthy individuals 
;ANTINEOPLASTIC AGENTS;SLC28A3;rs17343066;AA;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Genotype AA is associated with decreased likelihood of Neurotoxicity Syndromes when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma concentration (p<0.001);Genotype TT is associated with increased plasma concentration (p<0.001) of efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;CLOZAPINE;TRAT1;rs116982346;C;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele C is associated with increased likelihood of Neutropenia when treated with clozapine in people with Schizophrenia as compared to allele G.;in people with Schizophrenia
;MERCAPTOPURINE;NUDT15;rs116855232;CT;Toxicity;increased  likelihood of Side Effect:Anemia, Side Effect:Neutropenia, Side Effect:Pancytopenia, Side Effect:Thrombocytopenia;Genotype CT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2A6;rs8192726;AC + CC;Metabolism/PK;increased   PK:plasma concentration (p=0.028);Genotypes AC + CC are associated with increased plasma concentration (p=0.028) of efavirenz in people with HIV Infections as compared to genotype AA.;in people with Disease:HIV infectious disease
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CC;Efficacy;decreased  Efficacy:disease free survival;Genotype CC is associated with decreased disease free survival when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to genotype TT.;in people with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CT;Efficacy;decreased  Efficacy:disease free survival;Genotype CT is associated with decreased disease free survival when treated with cyclophosphamide, doxorubicin and fluorouracil in people with Breast Neoplasms as compared to genotype TT.;in people with Disease:Breast Neoplasms
;;ADH1B;rs1789891;A;Other;increased   Disease:Alcohol abuse;Allele A is associated with increased Alcoholism.; 
;ANTINEOPLASTIC AGENTS;DCTD;rs12067645;AA;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Genotype AA is associated with increased likelihood of Neurotoxicity Syndromes when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;EFAVIRENZ;UGT2B7;rs7439366;CC + CT;Metabolism/PK;increased   PK:plasma concentration;Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;MERCAPTOPURINE;SLC19A1;rs1051266;TT;Toxicity;increased  likelihood of Side Effect:Anemia, Side Effect:Neutropenia, Side Effect:Pancytopenia, Side Effect:Thrombocytopenia;Genotype TT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;rs13181;G;Toxicity;increased  risk of Disease:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;CLOZAPINE;TRAC;rs377360;A;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele A is associated with increased likelihood of Leukopenia when treated with clozapine in people with Schizophrenia as compared to allele T.;in people with Schizophrenia
;NEVIRAPINE;CCHCR1;rs746647;G;Toxicity;increased  risk of Side Effect:Exanthema;Allele G is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele A.;in people with Disease:HIV infectious disease
;;FGFBP1;rs2245964;CC;Other;increased   Other:bone mineral density;Genotype CC is associated with increased bone mineral density as compared to genotypes CG + GG.; 
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Efficacy;increased  risk of Side Effect:Death, Disease:Gastrointestinal Hemorrhage;Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to genotype CC.;in people with Disease:Cardiovascular Disease
;;FGFBP1;rs16892645;TT;Other;increased   Other:bone mineral density;Genotype TT is associated with increased bone mineral density as compared to genotypes CC + CT.; 
;ATORVASTATIN;SLCO1B1;rs2306283;GG;Efficacy;increased   Efficacy:reduction in LDL;Genotype GG is associated with increased reduction in LDL when treated with atorvastatin in people with Hypercholesterolemia as compared to genotypes AA + AG.;in people with Disease:Hypercholesterolemia
;;;rs2824292;G;Other;increased  risk of Disease:Ventricular Fibrillation;Allele G is associated with increased risk of Ventricular Fibrillation in people with Myocardial Infarction as compared to allele A.;in people with Disease:Myocardial Infarction
;NEVIRAPINE;;rs6545803;G;Toxicity;increased  risk of Side Effect:Nevirapine-induced rash;Allele G is associated with increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;NICOTINE;FMO1;rs10912675;C;Other;increased  severity of Other:Tobacco Use Disorder;Allele C is associated with increased severity of Tobacco Use Disorder when exposed to nicotine as compared to allele T.; 
;NEVIRAPINE;POLR3G;rs2562519;T;Toxicity;increased  risk of Side Effect:Exanthema;Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;NICOTINE;FMO1;rs7877;T;Other;increased  severity of Other:Tobacco Use Disorder;Allele T is associated with increased severity of Tobacco Use Disorder when exposed to nicotine as compared to allele C.; 
;ASPARAGINASE;GRIA1;rs4958381;T;Toxicity;increased  risk of;Allele T is associated with increased risk of when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in people with Disease:Acute lymphoblastic leukemia
;PACLITAXEL;CYP17A1;rs743572;AG + GG;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Genotypes AG + GG is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype AA.;in women with Breast Neoplasms
;ACENOCOUMAROL;CYP2C9;rs1057910;C;Efficacy;increased  risk of Side Effect:Death, Disease:Gastrointestinal Hemorrhage;Allele C is associated with increased risk of Gastrointestinal Hemorrhage and Death when treated with acenocoumarol in people with Cardiovascular Diseases as compared to allele A.;in people with Disease:Cardiovascular Disease
;CISPLATIN, FLUOROURACIL;ERCC1;rs3212986;AA + AC;Efficacy;increased   Efficacy:overall survival;Genotypes AA + AC are associated with increased overall survival when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype CC.;in people with Disease:Neoplasm of esophagus
;DOXORUBICIN;CYP2C19;rs4244285;AA + AG;Toxicity;increased  severity of Side Effect:Nausea, Side Effect:Vomiting;Genotypes AA + AG is associated with increased severity of Nausea and Vomiting when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;Toxicity;increased  likelihood of Disease:Metabolic Bone Disorder, Disease:Osteoporosis;Genotype CC is associated with increased likelihood of Bone Diseases, Metabolic and Osteoporosis when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.;in women with Breast Neoplasms
;CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;rs139887;CG;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes;Genotype CG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + GG.;in women with Disease:Ovarian Neoplasms
;ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;Toxicity;increased  likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Side Effect:Pain;Genotype CC is associated with increased likelihood of Musculoskeletal pain, Arthritis or Pain when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.;in women with Disease:Breast Neoplasms
;ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;Toxicity;increased  likelihood of Disease:Metabolic Bone Disorder, Disease:Osteoporosis;Genotype CC is associated with increased likelihood of Bone Diseases, Metabolic and Osteoporosis when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.;in women with Disease:Breast Neoplasms
;ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Allele A is associated with increased likelihood of Neurotoxicity Syndromes when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia
;DOXORUBICIN;CYP2C19;rs4244285;AA + AG;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AG is associated with increased severity of Peripheral Nervous System Diseases when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Allele A is associated with increased likelihood of Myelosuppression when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia
;CAPECITABINE;CES2;rs11075646;CG + GG;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Genotypes CG + GG is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype CC.;in people with Neoplasms
;WARFARIN;VKORC1;rs9923231;T;Efficacy;Efficacy:time to therapeutic inr;Allele T is associated with time to therapeutic inr when treated with warfarin in people with Atrial Fibrillation as compared to allele C.;in people with Disease:Atrial Fibrillation
;ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;Toxicity;increased  likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Side Effect:Pain;Genotype CC is associated with increased likelihood of Musculoskeletal pain, Arthritis or Pain when treated with anastrozole or letrozole in women with Breast Neoplasms as compared to genotypes CG + GG.;in women with Disease:Breast Neoplasms
;DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;rs4880;AG + GG;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotypes AG + GG are associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis as compared to genotype AA.; 
;"""ANALGESICS AND ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS FOR SYSTEMIC USE"", ""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID PREPARATIONS""";SOD2;rs4880;AG + GG;Toxicity;increased  risk of Side Effect:drug-induced liver injury;Genotypes AG + GG are associated with increased risk of drug-induced liver injury when treated with Analgesics and anesthetics, Antibiotics, antiepileptics, Antifungals For Systemic Use, antiinflammatory and antirheumatic products, non-steroids, Antimycobacterials and Antithyroid Preparations.; 
;DOXORUBICIN;CYP2C19;rs4244285;AA + AG;Toxicity;increased  severity of Side Effect:Anemia, Side Effect:Thrombocytopenia, Side Effect:Neutropenia;Genotypes AA + AG is associated with increased severity of Anemia, Thrombocytopenia or Neutropenia when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;METFORMIN;PPARG;rs1801282;G;Other;increased  likelihood of Other:short and long-term weight loss;Allele G is associated with increased likelihood of short and long-term weight loss when treated with metformin as compared to allele C.; 
;MITOTANE;CYP2B6;rs3745274;GT + TT;Metabolism/PK;PK:being a predictor of mitotane plasma concentrations of at least 14 ï¿½g/ml after 3 months of treatment;Genotypes GT + TT are associated with being a predictor of mitotane plasma concentrations of at least 14 ï¿½g/ml after 3 months of treatment when treated with mitotane in people with Adrenocortical Carcinoma as compared to genotype GG.;in people with Disease:Adrenocortical Carcinoma
;BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;rs4553808;GG;Toxicity;Side Effect:earlier onset of bortezomib-induced peripheral neuropathy;Genotype GG is associated with earlier onset of bortezomib-induced peripheral neuropathy when treated with bortezomib, melphalan and prednisone in people with Multiple Myeloma as compared to genotypes AA + AG.;in people with Disease:Multiple Myeloma
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased   PK:PBMC-associated drug concentrations;Genotypes GT + TT are associated with increased PBMC-associated drug concentrations of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;;CRHR1;rs1876828;TT;Metabolism/PK;decreased  PK:baseline cortisol levels;Genotype TT is associated with decreased baseline cortisol levels in children with Asthma as compared to genotype CC.;in children with Disease:Asthma
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity, Metabolism/PK;increased   PK:intracellular PBMC exposure;Genotype TT is associated with increased intracellular PBMC exposure of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;VALPROIC ACID;SOD2;rs4880;AG + GG;Toxicity;decreased likelihood of Side Effect:Alopecia;Genotypes AG + GG is associated with decreased likelihood of Alopecia when treated with valproic acid in people with Epilepsy as compared to genotype AA.;in people with Epilepsy
;;ABCB1;rs1045642;AA;Other;increased  likelihood of Other:Helicobacter pylori infection;Genotype AA is associated with increased likelihood of Helicobacter pylori infection as compared to genotype GG.; 
;VALPROIC ACID;LEPR;rs1137101;AG + GG;Toxicity;increased  likelihood of Side Effect:Alopecia;Genotypes AG + GG is associated with increased likelihood of Alopecia when treated with valproic acid in people with Epilepsy as compared to genotype AA.;in people with Epilepsy
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Other:ADP-stimulated platelet aggregation;Allele A is associated with increased ADP-stimulated platelet aggregation when treated with clopidogrel as compared to allele G.; 
;CAPECITABINE;CDA;rs10916825;AG + GG;Toxicity;increased  severity of Side Effect:Hand-foot syndrome;Genotypes AG + GG is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype AA.;in people with Neoplasms
;ANTINEOPLASTIC AGENTS;ABCB1;rs4148737;CC + CT;Toxicity;decreased likelihood of Side Effect:Myelosuppression;Genotypes CC + CT is associated with decreased likelihood of Myelosuppression when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Allele C is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to allele T.; 
;CLOPIDOGREL, TICAGRELOR;CYP4F2;rs3093135;TT;Efficacy;increased  likelihood of Efficacy:Myocardial Infarction, Efficacy:Recurrence;Genotype TT is associated with increased likelihood of Myocardial Infarction and Recurrence when treated with clopidogrel or ticagrelor in people with Coronary Artery Disease as compared to genotypes AA + AT.;in people with Disease:Coronary Artery Disease
;EFAVIRENZ;CYP2B6;rs28399499;CT;Metabolism/PK;increased   PK:minimum plasma concentrations;Genotype CT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;DEFERASIROX;UGT1A3;rs3806596;CC;Efficacy;decreased risk of Efficacy:Iron Overload;Genotype CC is associated with decreased risk of Iron Overload when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotypes CT + TT.;in children with Beta-thalassemia and related diseases
;CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;Efficacy;decreased  Efficacy:overall survival;Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.;in people with Disease:Pancreatic Neoplasms
;DEFERASIROX;UGT1A1;rs887829;TT;Efficacy;decreased risk of Disease:Iron Overload;Genotype TT is associated with decreased risk of Iron Overload when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotypes CC + CT.;in children with Beta-thalassemia and related diseases
;METFORMIN;SLC47A2;rs12943590;AA + AG;Metabolism/PK;increased   PK:renal and secretory clearance of metformin;Genotypes AA + AG are associated with increased renal and secretory clearance of metformin when exposed to metformin in healthy individuals as compared to genotype GG.;in healthy individuals 
;METFORMIN;SLC47A2;rs12943590;AA;Efficacy;decreased  Efficacy:response to metformin;Genotype AA is associated with decreased response to metformin when exposed to metformin in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;CAPECITABINE;CES1;rs2244613;GG + GT;Toxicity;increased  severity of Side Effect:Hand-foot syndrome;Genotypes GG + GT is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype TT.;in people with Neoplasms
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;decreased  PK:oral clearance of atorvastatin;Genotypes CC + CT are associated with decreased oral clearance of atorvastatin when exposed to atorvastatin in people with Obesity as compared to genotype TT.;in people with Disease:Obesity
;CAPECITABINE;CES1;rs2244613;GG + GT;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotypes GG + GT is associated with increased likelihood of Diarrhea when treated with capecitabine in people with Neoplasms as compared to genotype TT.;in people with Neoplasms
;DEFERASIROX;CYP1A2;rs762551;AA;Efficacy;decreased risk of Efficacy:Iron Overload;Genotype AA is associated with decreased risk of Iron Overload when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotypes AC + CC.;in children with Beta-thalassemia and related diseases
;ANTINEOPLASTIC AGENTS;CYP3A5;rs776746;T;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Allele T is associated with increased likelihood of Myelosuppression when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;Efficacy;decreased  Efficacy:progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT.;in people with Disease:Pancreatic Neoplasms
;DEFERASIROX;CYP1A1;rs2606345;CC;Efficacy;decreased risk of Efficacy:Iron Overload;Genotype CC is associated with decreased risk of Iron Overload when treated with deferasirox in children with Beta-thalassemia and related diseases as compared to genotypes AA + AC.;in children with Beta-thalassemia and related diseases
;HEROIN;GRM3;rs274622;C;Other;increased  risk of Disease:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele T.; 
;EFAVIRENZ;ABCB1;rs3842;CC + CT;Metabolism/PK;increased   PK:accumulation of drug in PBMCs;Genotypes CC + CT are associated with increased accumulation of drug in PBMCs of efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;ETHANOL;CHRNA4;rs1044394;G;Toxicity;decreased risk of Other:Alcohol abuse;Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.; 
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;AG;Toxicity;increased  risk of Disease:Venous Thrombosis;Genotype AG is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype GG.;in women 
;OPIOIDS;ENPP2;rs2249015;AA;Efficacy;increased  severity of Efficacy:Pain;Genotype AA is associated with increased severity of Pain when treated with opioids in people with Neoplasms as compared to genotypes AG + GG.;in people with Neoplasms
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;Toxicity;increased  risk of Disease:Venous Thrombosis;Genotype CT is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.;in women 
;CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;rs25487;CT + TT;Efficacy;decreased  Efficacy:overall survival;Genotypes CT + TT are associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.;in people with Disease:Pancreatic Neoplasms
;ASPIRIN;ADORA1;rs2228079;GG + GT;Toxicity;decreased risk of Side Effect:aspirin-intolerant asthma;Genotypes GG + GT are associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype TT.;in people with Disease:Asthma
;LOVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotype CC is associated with increased risk of statin-related myopathy when treated with lovastatin as compared to genotype TT.; 
;METHOTREXATE;MTHFR;rs1801131;GG + GT;Toxicity;decreased risk of Side Effect:Skin Disorder;Genotypes GG + GT are associated with decreased risk of Skin Disorder due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotypes AG + GG are associated with increased likelihood of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in people with Disease:Acute lymphoblastic leukemia
;FLUOROURACIL;DPYD;rs56038477;T;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Thrombocytopenia;Genotypes AA + AG are associated with increased risk of Thrombocytopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;PROPRANOLOL;CYP2D6;rs1065852;AA;Metabolism/PK;increased   PK:area under plasma concentration of propranolol;Genotype AA is associated with increased area under plasma concentration of propranolol when treated with propranolol in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;CAPECITABINE, FLUOROURACIL;DPYD;rs6668296;T;Toxicity;increased  severity of Disease:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;CLOZAPINE;HLA-DQB1;rs113332494;G;Toxicity;increased  likelihood of Side Effect:Agranulocytosis;Allele G is associated with increased likelihood of Agranulocytosis when treated with clozapine in people with Schizophrenia as compared to allele C.;in people with Schizophrenia
;CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs1799793;CC;Efficacy;increased   Efficacy:overall survival;Genotype CC is associated with increased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.;in people with Disease:Pancreatic Neoplasms
;;APOE;rs7412;CT + TT;Other;increased   Other:Hyperuricemia;Genotypes CT + TT is associated with increased Hyperuricemia in people with Coronary Disease or Hypertension as compared to genotype CC.;in people with Coronary Disease, Hypertension
;CAPECITABINE, FLUOROURACIL;DPYD;rs115349832;C;Toxicity;increased  severity of Disease:Drug Toxicity;Allele C is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;METFORMIN;PPARG;rs1801282;G;Other;increased  likelihood of Other:weight regain after intentional weight loss;Allele G is associated with increased likelihood of weight regain after intentional weight loss when treated with metformin as compared to allele C.; 
;;APOE;rs429358;CC + CT;Other;increased   Other:Hypertriglyceridemia;Genotypes CC + CT is associated with increased Hypertriglyceridemia in people with Coronary Disease or Hypertension as compared to genotype TT.;in people with Coronary Disease, Hypertension
;CLOZAPINE;HLA-DQB1;rs113332494;G;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele G is associated with increased likelihood of Neutropenia when treated with clozapine in people with Schizophrenia as compared to allele C.;in people with Schizophrenia
;SIMVASTATIN;APOE;rs429358;C;Efficacy;increased  risk of Other:mortality after myocardial infarction, however this can be eliminated;Allele C is associated with increased risk of mortality after myocardial infarction, however this can be eliminated when treated with simvastatin as compared to allele T.; 
;CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;G;Other;increased  likelihood of Disease:Weight gain;Allele G is associated with increased likelihood of Weight gain when treated with clozapine, haloperidol, olanzapine and risperidone in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;rs3813929;C;Other;increased  risk of Disease:Weight gain;Allele C is associated with increased risk of Weight gain when treated with amisulpride, clozapine, haloperidol, iloperidone, olanzapine, quetiapine, risperidone and ziprasidone as compared to allele T.; 
;HEROIN;SOD2;rs5746136;TT;Toxicity;increased  risk of Disease:Heroin Dependence;Genotype TT is associated with increased risk of Heroin Dependence due to heroin as compared to genotype CC.; 
;OPIOIDS;ENPP2;rs7832704;A;Efficacy;increased  severity of Efficacy:Pain;Allele A is associated with increased severity of Pain when treated with opioids in people with Neoplasms as compared to allele G.;in people with Neoplasms
;CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;rs2849380;TT;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes;Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Ovarian Neoplasms
;CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;rs544093;TT;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes;Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes GG + GT.;in women with Disease:Ovarian Neoplasms
;CARBOPLATIN, DOCETAXEL, PACLITAXEL;;rs879207;AG;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes;Genotype AG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes AA + GG.;in women with Disease:Ovarian Neoplasms
;TOLCAPONE;;rs4680;GG;Efficacy;increased   Efficacy:reaction time;Genotype GG is associated with increased reaction time when treated with tolcapone in abstinent smokers.;in abstinent smokers
;DOLASETRON, GRANISETRON;NOS1AP;rs10494366;GT + TT;Toxicity;increased  risk of Side Effect:QTc prolongation;Genotypes GT + TT are associated with increased risk of QTc prolongation when exposed to dolasetron or granisetron in people with surgery as part of anesthetic management as compared to genotype GG.;in people with surgery as part of anesthetic management
;SUNITINIB;ABCB1;rs2032582;A;Toxicity;decreased risk of Side Effect:Neutropenia;Allele A is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell.;in people with Disease:Renal Cell Carcinoma
;CAPECITABINE, FLUOROURACIL;DPYD;rs56276561;T;Toxicity;increased  severity of Disease:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;CLOZAPINE;ELAVL2;rs73482673;A;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele A is associated with increased likelihood of Neutropenia when treated with clozapine in people with Schizophrenia as compared to allele G.;in people with Schizophrenia
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:mid-dose plasma concentrations;Genotype TT is associated with increased mid-dose plasma concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;FLUOROURACIL;DPYD;rs2297595;CC + CT;Toxicity;decreased likelihood of Side Effect:Neutropenia;Genotypes CC + CT are associated with decreased likelihood of Neutropenia when treated with fluorouracil in women with Neoplasms as compared to genotype TT.;in women with Disease:Neoplasms
;DOCETAXEL;SLCO1B3;rs4149118;G;Other, Metabolism/PK;increased   PK:AUC;Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.;in people with Disease:Nasopharyngeal Neoplasms
;NEVIRAPINE;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma exposure;Genotype TT is associated with increased plasma exposure of nevirapine in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;TOLCAPONE;COMT;rs4680;AG;Efficacy;decreased  Efficacy:reaction time;Genotype AG is associated with decreased reaction time when treated with tolcapone in abstinent smokers.;in abstinent smokers
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma exposure;Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;HEROIN;SOD2;rs2758339;AC + CC;Toxicity;decreased risk of Disease:Heroin Dependence;Genotypes AC + CC are associated with decreased risk of Heroin Dependence due to heroin as compared to genotype AA.; 
;DOCETAXEL;SLCO1B3;rs11045585;G;Other, Metabolism/PK;increased   PK:AUC;Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.;in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;SLCO1B3;rs7311358;A;Other, Metabolism/PK;increased   PK:AUC;Allele A is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.;in people with Disease:Nasopharyngeal Neoplasms
;IRINOTECAN;TOP1;rs6072262;GG;Toxicity;decreased severity of Disease:Neutropenia;Genotype GG is associated with decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;WARFARIN;APOB;rs679899;G;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele G is associated with increased risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.;in people with Heart valve replacement
;ERLOTINIB;EGFR;rs712829;GG;Toxicity;increased  severity of Disease:Diarrhea;Genotype GG is associated with increased severity of Diarrhea when treated with erlotinib in people with Neoplasms as compared to genotypes GT + TT.;in people with Disease:Neoplasms
;ERLOTINIB;ABCG2;rs2622604;CC;Other, Metabolism/PK;decreased  PK:mean AUC;Genotype CC is associated with decreased mean AUC of erlotinib as compared to genotypes CT + TT.; 
;WARFARIN;APOB;rs1367117;G;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele G is associated with increased risk of Hemorrhage when treated with warfarin in people with heart valve replacement as compared to allele A.;in people with Heart valve replacement
;CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;MORPHINE;OPRM1;rs1799971;AA;Efficacy;increased   Efficacy:reduction in pain;Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.;in people with Disease:Neoplasms
;MORPHINE;ABCB1;rs1045642;AA;Efficacy;increased   Efficacy:reduction in pain;Genotype AA is associated with increased reduction in pain when treated with morphine in people with Neoplasms as compared to genotypes AG + GG.;in people with Disease:Neoplasms
;PHENYTOIN;ABCB1;rs1045642;G;Efficacy;increased  likelihood of Efficacy:drug resistance;Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.;in people with Disease:Epilepsy
;ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;C;Toxicity;Side Effect:all statin-induced myopathy and severe myopathy;Allele C is associated with all statin-induced myopathy and severe myopathy when treated with atorvastatin, fluvastatin, hmg coa reductase inhibitors, pravastatin, rosuvastatin or simvastatin as compared to allele T.; 
;ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;Efficacy;decreased  Efficacy:platelet reactivity;Genotypes CT + TT is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;LEFLUNOMIDE;CYB5A;rs1790834;AA + AG;Efficacy;decreased  Efficacy:Disease activity score 28 in rheumatoid arthritis;Genotypes AA + AG is associated with decreased disease activity score 28 joint in rheumatoid arthritis when treated with leflunomide in women with Arthritis, Rheumatoid as compared to genotype GG.;in women with Rheumatoid arthritis
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;Toxicity;increased  risk of Disease:Stroke;Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC.;in women 
;NEVIRAPINE;CYP2B6;rs28399499;CT;Metabolism/PK;increased   PK:plasma concentration;Genotype CT is associated with increased plasma concentration of nevirapine in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;NEVIRAPINE;CYP2B6;rs3745274;T;Metabolism/PK;increased   PK:plasma concentration;Allele T is associated with increased plasma concentration of nevirapine in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;C;Efficacy;Efficacy:nonresponse to anti-EGFR-based treatment;Allele C is associated with nonresponse to anti-EGFR-based treatment when treated with cetuximab and panitumumab in people with Adenocarcinoma as compared to genotype AA.;in people with Disease:Adenocarcinoma
;EDOXABAN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype TT.; 
;CYCLOSPORINE;ABCB1;rs1045642;GG;Efficacy, Metabolism/PK;decreased  PK:intracellular and blood concentration;Genotype GG is associated with decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes AA + AG.;in people with Disease:Transplantation
;BLEOMYCIN;BLMH;rs1050565;CC;Efficacy;decreased  Efficacy:survival;Genotype CC is associated with decreased survival when treated with bleomycin in men with Testicular Neoplasms as compared to genotypes CT + TT.;in men with Disease:Testicular Neoplasms
;CISPLATIN;GSTP1;rs1695;AA + AG;Toxicity;increased  risk of Side Effect:severe hearing impairment;Genotypes AA + AG are associated with increased risk of severe hearing impairment when treated with cisplatin in men with Testicular Neoplasms as compared to genotype GG.;in men with Disease:Testicular Neoplasms
;CITALOPRAM;FKBP5;rs4713916;A;Efficacy;increased  likelihood of Efficacy:remission;Allele A is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;OPIOIDS;TH;rs10770141;AA + AG;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes AA + AG is associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.; 
;DISULFIRAM;DBH;rs1611115;CC;Efficacy;decreased severity of Efficacy:Cocaine dependence;Genotype CC is associated with decreased severity of Cocaine-Related Disorders when treated with disulfiram in people with Cocaine-Related Disorders and Substance-Related Disorders as compared to genotypes CT + TT.;in people with Cocaine dependence, Substance-Related Disorders
;OPIOIDS;COMT;rs4680;AA;Toxicity;decreased risk of Other:Death;Genotype AA is associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Opioid-Related Disorders
;;VEGFA;rs2010963;CC + CG;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CG is associated with increased overall survival in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;rs12979860;CT + TT;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotypes CT + TT are associated with increased likelihood of Recurrence when treated with sofosbuvir, velpatasvir and voxilaprevir in people with Hepatitis C, Chronic as compared to genotype CC.;in people with Disease:Chronic hepatitis C virus infection
;OPIOIDS;TH;rs10770140;CT + TT;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Genotypes CT + TT are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype CC.; 
;PHENYTOIN;ABCB1;rs1128503;A;Other, Metabolism/PK;increased   PK:plasma drug levels;Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.;in people with no disease
;PHENYTOIN;ABCB1;rs1045642;A;Other, Metabolism/PK;increased   PK:plasma drug levels;Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.;in people with no disease
;ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;GG;Toxicity;increased  risk of Disease:Cardiomyopathies;Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.;in people with Disease:Neoplasms
;DEXMEDETOMIDINE;PRKCB;rs9922316;T;Other;increased   Other:dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction;Allele T is associated with increased dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction when exposed to dexmedetomidine in healthy individuals as compared to allele G.;in healthy individuals 
;PRASUGREL;CYP2C19;rs12248560;T;Efficacy;decreased  Efficacy:platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment;Allele T is associated with decreased platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment when treated with prasugrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;CYCLOSPORINE;ABCB1;rs2229109;CC;Efficacy, Metabolism/PK;increased   PK:intracellular and blood concentration;Genotype CC is associated with increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes CT + TT.;in people with Disease:Transplantation
;PRASUGREL;CYP2C19;rs12248560;T;Efficacy;decreased  Efficacy: rate of high on-treatment platelet reactivity (HTPR) at 1 month of treatment;Allele T is associated with decreased rate of high on-treatment platelet reactivity (HTPR) at 1 month of treatment when treated with prasugrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;Toxicity;increased  risk of Side Effect:Coronary Disease;Allele G is associated with increased risk of Coronary Disease when treated with hmg coa reductase inhibitors as compared to allele A.; 
;EFAVIRENZ;CYP2B6;rs28399499;C;Toxicity, Metabolism/PK;increased   PK:plasma concentration;Allele C is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;PRASUGREL;CYP2C19;rs12248560;T;Toxicity;increased  risk of Side Effect:bleeding complications;Allele T is associated with increased risk of bleeding complications when treated with prasugrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;NICOTINE;DRD1;rs686;A;Efficacy, Toxicity, Other;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele G.;in smokers
;PRASUGREL;CYP2C19;rs12248560;T;Efficacy;increased   Efficacy: rate of hyper-response at 1 month of treatment;Allele T is associated with increased rate of hyper-response at 1 month of treatment when treated with prasugrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;ANTIPSYCHOTICS;DRD2;rs1799732;del;Toxicity;increased  risk of Disease:Weight gain;Allele del is associated with increased risk of Weight gain when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;MITOTANE;CYP2B6;rs3745274;GT + TT;Metabolism/PK;increased   PK:mitotane plasma concentrations;Genotypes GT + TT are associated with increased mitotane plasma concentrations when treated with mitotane in people with Adrenocortical Carcinoma as compared to genotype GG.;in people with Disease:Adrenocortical Carcinoma
;NICOTINE;DRD1;rs4532;T;Efficacy, Toxicity, Other;increased  risk of Disease:Tobacco Use Disorder;Allele T is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele C.;in smokers
;REPAGLINIDE;SLC30A8;rs16889462;AG;Efficacy;increased   Efficacy:efficacy;Genotype AG is associated with increased efficacy when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Disease:Diabetes Mellitus, Type 2
;ATAZANAVIR, RITONAVIR;UGT1A7;rs17863778;AA;Toxicity, Other;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotype AA is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;BEVACIZUMAB;EDN1;rs5370;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with bevacizumab in women with Breast Neoplasms as compared to genotypes GG + GT.;in women with Disease:Breast Neoplasms
;;G6PD, IKBKG;rs5030868;A;;Other:protection from Plasmodium vivax malaria infection;Allele A is associated with protection from Plasmodium vivax malaria infection.; 
;MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;Efficacy;decreased risk of Disease:Transplant rejection;Allele T is associated with decreased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;ATAZANAVIR, RITONAVIR;UGT1A3;rs3806596;CC;Toxicity, Other;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotype CC is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;GEFITINIB;ABCB1;rs1128503;AA;Toxicity;increased  risk of Side Effect:Diarrhea, Side Effect:Exanthema;Genotype AA is associated with increased risk of Diarrhea and Exanthema when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;Toxicity;increased  risk of Disease:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;ATAZANAVIR, RITONAVIR;UGT1A7;rs7586110;GG;Toxicity, Other;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotype GG is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;OXALIPLATIN;ERCC2, KLC3;rs13181;GG + GT;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes GG + GT is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;APREPITANT, OLANZAPINE;HTR3C;rs6766410;CC;Efficacy;increased  likelihood of Efficacy:Nausea, Efficacy:Vomiting;Genotype CC is associated with increased likelihood of Nausea and Vomiting when treated with aprepitant or olanzapine in people with Neoplasms as compared to genotypes AA + AC.;in people with Neoplasms
;ATAZANAVIR, RITONAVIR;UGT1A7;rs17868323;GG;Toxicity, Other;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotype GG is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir and ritonavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;BEVACIZUMAB;VEGFA;rs3025039;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with bevacizumab in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;APREPITANT, OLANZAPINE;MTHFR;rs1801131;TT;Efficacy;decreased likelihood of Efficacy:Nausea, Efficacy:Vomiting;Genotype TT is associated with decreased likelihood of Nausea and Vomiting when treated with aprepitant or olanzapine in people with Neoplasms as compared to genotypes GG + GT.;in people with Neoplasms
;APREPITANT, OLANZAPINE;HTR3B;rs7943062;GG;Efficacy;decreased likelihood of Efficacy:Nausea, Efficacy:Vomiting;Genotype GG is associated with decreased likelihood of Nausea and Vomiting when treated with aprepitant or olanzapine in people with Neoplasms as compared to genotypes AA + AG.;in people with Neoplasms
;TAFENOQUINE;;rs62103056;A;Efficacy;increased  likelihood of Efficacy:Recurrence;Allele A is associated with increased likelihood of Recurrence when treated with tafenoquine in people with Malaria, Vivax as compared to allele G.;in people with Malaria, Vivax
;METHOTREXATE;GGH;rs719235;CC;Efficacy, Toxicity;increased  risk of Side Effect:bone marrow toxicity;Genotype CC is associated with increased risk of bone marrow toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AC.;in people with Disease:Rheumatoid arthritis
;TIMOLOL;ADRB1;rs1801252;AA;Other;increased   Other:systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol;Genotype AA is associated with increased systolic (SAP) and diastolic (DAP) arterial pressure responses to timolol when exposed to timolol in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;CISPLATIN;LRP2;rs2228171;G;Toxicity;increased  risk of Disease:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms.;in children with Disease:Neoplasms
;DISULFIRAM;DBH;rs1611115;CT + TT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes CT + TT is associated with increased likelihood of adverse events disulfiram in people with Alcoholism as compared to genotype CC.;in people with Alcohol abuse
;FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;rs1042718;AA;Toxicity;increased  severity of Side Effect:Hypotensive disorder;Genotype AA is associated with increased severity of Hypotension when treated with fentanyl, propofol, remifentanil or sevoflurane as compared to genotype CC.; 
;ROSUVASTATIN;ABCG2;rs2231142;T;Efficacy;severity of Efficacy:Hypercholesterolemia;Allele T is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.; 
;;SLC30A8;rs13266634;C;Other;increased  risk of Disease:Diabetes Mellitus, Type 2;Allele C is associated with increased risk of Diabetes Mellitus, Type 2 as compared to allele T.; 
;THIAZIDES, PLAIN;SLCO2A1;rs34550074;T;Toxicity;increased  likelihood of Side Effect:Hyponatremia;Allele T is associated with increased likelihood of Hyponatremia when treated with Thiazides, plain in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;ROSUVASTATIN;FMO3;rs1736557;A;Efficacy;severity of Efficacy:Hypercholesterolemia;Allele A is associated with severity of Hypercholesterolemia when treated with rosuvastatin as compared to allele G.; 
;WARFARIN;GGCX;rs699664;C;Efficacy;increased   Efficacy:international normalized ratio variability (inr-var);Allele C is associated with increased international normalized ratio variability (inr-var) when treated with warfarin as compared to allele T.; 
;CISPLATIN;GSTP1;rs1695;AG + GG;Toxicity;increased  risk of Disease:Ototoxicity;Genotypes AG + GG are associated with increased risk of Ototoxicity when treated with cisplatin in children with Medulloblastoma as compared to genotype AA.;in children with Disease:Medulloblastoma
;WARFARIN;GGCX;rs11676382;G;Efficacy;decreased  Efficacy:time in therapeutic range;Allele G is associated with decreased time in therapeutic range when treated with warfarin as compared to allele C.; 
;METHYLPHENIDATE;COMT;rs4680;A;Toxicity;increased  likelihood of Side Effect:adverse events;Allele A is associated with increased likelihood of adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity and Fetal Alcohol Syndrome as compared to allele G.;in children with Attention Deficit Disorder with Hyperactivity, Fetal Alcohol Syndrome
;ANTIEPILEPTICS;SCN2A;rs2304016;A;Efficacy;Efficacy:drug resistance;Allele A is associated with drug resistance when treated with antiepileptics in people with Epilepsy as compared to allele G.;in people with Disease:Epilepsy
;WARFARIN;GGCX;rs11676382;G;Efficacy;increased   Efficacy:international normalized ratio variability (inr-var);Allele G is associated with increased international normalized ratio variability (inr-var) when treated with warfarin as compared to allele C.; 
;WARFARIN;NQO1;rs1800566;AA + AG;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes AA + AG are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype GG.; 
;;G6PD;rs1050828;T;;increased   Other:protection against severe (p=0.006) and mild malaria (p=0.027);Allele T is associated with increased protection against severe (p=0.006) and mild malaria (p=0.027).; 
;ANTITHYROID PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;rs2734565;C;Toxicity;increased  likelihood of Side Effect:Agranulocytosis;Allele C is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations, methimazole or propylthiouracil in people with Graves Disease as compared to allele T.;in people with Graves Disease
;OXALIPLATIN;ERCC1;rs11615;AA;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype AA is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;FLUOROURACIL;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Diarrhea, Side Effect:Mucositis, Side Effect:Neutropenia;Genotypes AA + AG is associated with increased risk of Diarrhea, mucositis and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ACE INHIBITORS, PLAIN;;rs4267385;CC + CT;Other;Other:same protective properties against angiotensin-converting enzyme inhibitors-induced cough;Genotypes CC + CT are associated with same protective properties against angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain in people with homozygous GG genotype for rs4343 as compared to genotype TT.;in people with homozygous GG genotype for rs4343
;ACE INHIBITORS, PLAIN;;rs4459610;AA + AT;Other;Other:same protective properties against angiotensin-converting enzyme inhibitors-induced cough;Genotypes AA + AT are associated with same protective properties against angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain in people with homozygous GG genotype for rs4343 as compared to genotype TT.;in people with homozygous GG genotype for rs4343
;;G6PD;rs1050828;T;;increased   Other:protection against developing severe malaria;Allele T is associated with increased protection against developing severe malaria in people with Malaria as compared to allele C.;in people with Disease:Malaria
;METHOTREXATE;MTHFR;rs1801133;AG;Toxicity;increased  risk of Disease:Alopecia;Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;ACE INHIBITORS, PLAIN;BDKRB2;rs8016905;AG;Toxicity;Disease:Cough;Genotype AG is associated with Cough when treated with Ace Inhibitors, Plain as compared to genotypes AA + GG.; 
;;F5;rs6025;C;Other;increased  likelihood of Other:Recurrent pregnancy loss;Allele C is associated with increased likelihood of Abortion, Habitual as compared to allele T.; 
;CARBOPLATIN, PACLITAXEL;TRIM5;rs7950311;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with carboplatin and paclitaxel in women with Ovarian Neoplasms as compared to allele T.;in women with Disease:Ovarian Neoplasms
;;MTHFR;rs1801131;G;Other;increased  likelihood of Other:Recurrent pregnancy loss;Allele G is associated with increased likelihood of Abortion, Habitual as compared to allele T.; 
;ANTINEOPLASTIC AGENTS;;rs6674079;G;Efficacy;decreased  Efficacy:Overall survival;Allele G is associated with decreased overall survival when treated with antineoplastic agents in women with Ovarian Neoplasms as compared to allele A.;in women with Disease:Ovarian Neoplasms
;;MTHFR;rs1801133;G;Other;increased  likelihood of Other:Recurrent pregnancy loss;Allele G is associated with increased likelihood of Abortion, Habitual as compared to allele A.; 
;CARBOPLATIN, PACLITAXEL;;rs2549714;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with carboplatin and paclitaxel in women with Ovarian Neoplasms as compared to allele A.;in women with Disease:Ovarian Neoplasms
;;SERPINE1;rs2227631;A;Other;increased  likelihood of Other:Recurrent pregnancy loss;Allele A is associated with increased likelihood of Abortion, Habitual as compared to allele G.; 
;ANTINEOPLASTIC AGENTS;;rs4910232;G;Efficacy;decreased  Efficacy:Progression-free survival;Allele G is associated with decreased progression-free survival when treated with antineoplastic agents in women with Ovarian Neoplasms.;in women with Disease:Ovarian Neoplasms
;WARFARIN;CYP4F2;rs2108622;CT + TT;Efficacy;decreased  Efficacy:international normalized ratio variability (inr-var);Genotypes CT + TT are associated with decreased international normalized ratio variability (inr-var) when treated with warfarin as compared to genotype CC.; 
;ASPIRIN;PPARG;rs3856806;TT;Toxicity;increased  risk of Side Effect:aspirin hypersensitivity;Genotype TT is associated with increased risk of aspirin hypersensitivity when treated with aspirin in people with Asthma as compared to genotypes CC + CT.;in people with Disease:Asthma
;CYCLOSPORINE;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:nephrotoxicity;Genotype AA is associated with increased risk of nephrotoxicity when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AG + GG.;in people with Disease:Kidney Transplantation
;ANTINEOPLASTIC AGENTS;ZNF100;rs3795247;C;Efficacy;decreased  Efficacy:Progression-free survival;Allele C is associated with decreased progression-free survival when treated with antineoplastic agents in women with Ovarian Neoplasms as compared to allele T.;in women with Disease:Ovarian Neoplasms
;WARFARIN;VKORC1;rs9923231;T;Efficacy;increased   Efficacy:mean INR during 3-month daily observation period in patients with mechanical heart valve replacement;Allele T is associated with increased mean INR during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.; 
;ASPIRIN;PTGIR;rs1126510;AG + GG;Other;decreased risk of Other:aspirin-intolerant asthma;Genotypes AG + GG are associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype AA.;in people with Disease:Asthma
;WARFARIN;VKORC1;rs9923231;CT + TT;Efficacy;increased   Efficacy:number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement;Genotypes CT + TT is associated with increased number of examinations above the therapeutic range during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to genotype CC.; 
;ASPIRIN;TBXA2R;rs1131882;GG;Toxicity;increased  risk of Side Effect:aspirin-intolerant asthma;Genotype GG is associated with increased risk of aspirin-intolerant asthma when treated with aspirin in people with Asthma as compared to genotypes AA + AG.;in people with Disease:Asthma
;ASPIRIN;PTGER3;rs7551789;A;Other;increased  risk of Other:aspirin-intolerant asthma;Allele A is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to allele T.;in people with Disease:Asthma
;WARFARIN;VKORC1;rs9923231;CT + TT;Efficacy;decreased  Efficacy:time to therapeutic INR>=2;Genotypes CT + TT is associated with decreased time to therapeutic INR>=2 when treated with warfarin as compared to genotype CC.; 
;ASPIRIN;PTGER2;rs1353411;GG;Other;increased  risk of Other:aspirin-intolerant asthma;Genotype GG is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AA + AG.;in people with Disease:Asthma
;ASPIRIN;PTGER2;rs2075797;G;Other;decreased risk of Other:aspirin-intolerant asthma;Allele G is associated with decreased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to allele C.;in people with Disease:Asthma
;DOCETAXEL, PACLITAXEL;CYP3A4;rs2740574;CC;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype CC is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Disease:Breast Neoplasms
;DOXORUBICIN;ABCB1;rs1045642;AA + AG;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Genotypes AA + AG is associated with decreased severity of Nausea and Vomiting when treated with doxorubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased  Other:stable warfarin dose;Genotypes CT + TT is associated with decreased stable warfarin dose when treated with warfarin as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;Efficacy;increased   Efficacy: VASP index;Genotypes AG + GG are associated with increased VASP index when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;ASPIRIN;PPARG;rs3856806;TT;Toxicity;increased   Side Effect:decline in FEV 1 after aspirin provocation;Genotype TT is associated with increased decline in FEV 1 after aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes CC + CT.;in people with Disease:Asthma
;CLOPIDOGREL;CYP2C19;rs4986893;AG + GG;Efficacy;Efficacy:high post-clopidogrel platelet reactivity;Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.;in undergoing scheduled percutaneous coronary intervention
;ASPIRIN, CLOPIDOGREL;NECAB1;rs74569896;G;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;Efficacy;Efficacy:high post-clopidogrel platelet reactivity;Genotypes AG + GG are associated with high post-clopidogrel platelet reactivity when treated with clopidogrel in undergoing scheduled percutaneous coronary intervention as compared to genotype AA.;in undergoing scheduled percutaneous coronary intervention
;WARFARIN;VKORC1;rs9923231;T;Toxicity;increased  risk of Side Effect:atherothrombotic events during the 6-year follow up in patients with mechanical heart valve replacement;Allele T is associated with increased risk of atherothrombotic events during the 6-year follow up in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.; 
;WARFARIN;CYP2C9;rs1799853;T;Efficacy, Toxicity;increased   Side Effect:Blood Coagulation Disorders;Allele T is associated with increased Blood Coagulation Disorders when treated with warfarin as compared to allele C.; 
;ASPIRIN, CLOPIDOGREL;EFR3A;rs4736529;G;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Acute coronary syndrome
;DOCETAXEL, PACLITAXEL;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel and paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;GEMCITABINE;SLC28A1;rs2242046;GG;Toxicity;decreased risk of Side Effect:hematologic toxicity;Genotype GG is associated with decreased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.;in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement;Allele T is associated with decreased warfarin dose during 3-month daily observation period in patients with mechanical heart valve replacement when treated with warfarin as compared to allele C.; 
;WARFARIN;CYP2C9;rs1057910;C;Efficacy, Toxicity;increased   Side Effect:Blood Coagulation Disorders;Allele C is associated with increased Blood Coagulation Disorders when treated with warfarin as compared to allele A.; 
;GEMCITABINE;CDA;rs1048977;CC + CT;Other, Metabolism/PK;increased   PK:elimination clearance of dFdU and formation clearance of dFdCTP;Genotypes CC + CT are associated with increased elimination clearance of dFdU and formation clearance of dFdCTP when treated with gemcitabine in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;PACLITAXEL;ABCB1;rs1045642;AA + AG;Toxicity;decreased severity of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AG is associated with decreased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG.;in women with Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;Toxicity;increased  risk of Disease:Coronary Artery Disease;Genotypes AG + GG are associated with increased risk of Coronary Artery Disease when treated with hmg coa reductase inhibitors as compared to genotype AA.; 
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;Toxicity;increased  risk of Disease:Coronary Artery Disease;Genotypes AG + GG are associated with increased risk of Coronary Artery Disease when treated with hmg coa reductase inhibitors as compared to genotype AA.; 
;CYTARABINE;ABCB1;rs1128503;GG;Efficacy;decreased  Efficacy:survival;Genotype GG is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in people with Disease:Leukemia, Myeloid, Acute
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;Efficacy;Efficacy:poorer reduction in low-density lipoprotein cholesterol (LDLc);Genotypes AG + GG are associated with poorer reduction in low-density lipoprotein cholesterol (LDLc) when treated with hmg coa reductase inhibitors as compared to genotype AA.; 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;AA;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype AA is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotypes AG + GG.;in people with Tuberculosis
;HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;Efficacy;Efficacy:poorer reduction in low-density lipoprotein cholesterol (LDLc);Genotypes AG + GG are associated with poorer reduction in low-density lipoprotein cholesterol (LDLc) when treated with hmg coa reductase inhibitors as compared to genotype AA.; 
;PRAVASTATIN;ABCB1;rs2032582;CC;Efficacy;increased   Efficacy:percent reduction in LDL-cholesterol;Genotype CC is associated with increased percent reduction in LDL-cholesterol when treated with pravastatin in people with Acute coronary syndrome.;in people with Disease:Acute coronary syndrome
;GEMCITABINE;CMPK1;rs1044457;CC;Other, Metabolism/PK;decreased  PK:formation clearance of dFdCTP;Genotype CC is associated with decreased formation clearance of dFdCTP when treated with gemcitabine in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;ASPIRIN, CLOPIDOGREL;WDR24;rs11640115;G;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele G is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Acute coronary syndrome
;GEMCITABINE;CDA;rs4655226;CC;Other, Metabolism/PK;increased   PK:elimination clearance of dFdU;Genotype CC is associated with increased elimination clearance of dFdU when treated with gemcitabine in people with Neoplasms as compared to genotype CT.;in people with Disease:Neoplasms
;CARBOPLATIN, PACLITAXEL;MAD1L1;rs1801368;CT + TT;Other;decreased  Other:biochemical response, optimal cytoreduction, and sensitivity to the induction chemotherapy treatment;Genotypes CT + TT are associated with decreased biochemical response, optimal cytoreduction, and sensitivity to the induction chemotherapy treatment when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotype CC.;in people with Disease:Ovarian Neoplasms
;VARENICLINE;ICAM5;rs901886;T;Toxicity;increased  likelihood of Side Effect:Sleep Disorders;Allele T is associated with increased likelihood of Sleep Disorder when treated with varenicline in people with Tobacco Use Disorder and Smoking Cessation as compared to allele C.;in people with Tobacco Use Disorder, Smoking Cessation
;METHOTREXATE;ABCC1;rs2238476;AG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype AG is associated with increased likelihood of adverse events when treated with methotrexate in people with Psoriasis as compared to genotype GG.;in people with Psoriasis
;MITOXANTRONE;ABCB1;rs1128503;AA;Other;increased   Other:sensitivity in vitro;Genotype AA is associated with increased sensitivity in vitro when treated with mitoxantrone.; 
;MERCAPTOPURINE, METHOTREXATE;FOLH1;rs61886492;A;Toxicity;increased  risk of Disease:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;CYTARABINE;ABCB1;rs2032582;CC;Efficacy;decreased  Efficacy:survival;Genotype CC is associated with decreased survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.;in people with Disease:Leukemia, Myeloid, Acute
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1041983;TT;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype TT is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotypes CC + CT.;in people with Tuberculosis
;NEVIRAPINE;CYP2B6;rs28399499;C;Toxicity;increased  risk of Side Effect:Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic;Allele C is associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;;PPARA;rs135561;AA + AG;Other;decreased risk of Other:all-cause mortality;Genotypes AA + AG are associated with decreased risk of all-cause mortality in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;CLOZAPINE;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Agranulocytosis, Side Effect:Neutropenia;Genotype AA is associated with increased risk of Agranulocytosis and Neutropenia when treated with clozapine as compared to genotypes AG + GG.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;Toxicity;decreased  Side Effect:mean cumulative doses of isoniazid before the development of abnormal liver-function tests (ALFTs);Genotype AA is associated with decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests (ALFTs) when treated with Drugs For Treatment Of Tuberculosis and isoniazid in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;METHOTREXATE;ATIC;rs4673993;C;Efficacy;decreased risk of Efficacy:Disease Activity;Allele C is associated with decreased risk of Disease Activity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;Toxicity;decreased  Side Effect:mean cumulative doses of isoniazid before the development of antituberculosis drug-induced hepatotoxicity (ATDIH);Genotype AA is associated with decreased mean cumulative doses of isoniazid before the development of antituberculosis drug-induced hepatotoxicity (ATDIH) when treated with Drugs For Treatment Of Tuberculosis and isoniazid in people with Tuberculosis as compared to genotype AG.;in people with Disease:Tuberculosis
;ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOC3;rs5128;CG + GG;Toxicity;increased  likelihood of Side Effect:Hyperlipidemias;Genotypes CG + GG is associated with increased likelihood of Hyperlipidemias when treated with Antivirals for treatment of HIV infections, combinations in people with HIV Infections as compared to genotype CC.;in people with HIV infectious disease
;FLUTICASONE PROPIONATE;CYP3A4;rs35599367;AA + AG;Efficacy;Efficacy:improved asthma control (as measured by decrease in average asthma control score);Genotypes AA + AG are associated with improved asthma control (as measured by decrease in average asthma control score) when treated with fluticasone propionate in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;ALLOPURINOL;CCHCR1;rs9263745;A;Toxicity;increased  severity of Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with increased severity of severe cutaneous adverse reactions when exposed to allopurinol as compared to allele G.; 
;LETROZOLE;;rs74418677;C;Toxicity;increased  likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Other:Discontinuation;Allele C is associated with increased likelihood of Musculoskeletal pain, Arthritis and Discontinuation when treated with letrozole in women with Breast Neoplasms as compared to allele G.;in women with Breast Neoplasms
;ACE INHIBITORS, PLAIN;AGTR1;rs5186;C;Toxicity;increased   Side Effect:major cardiovascular events (MACE) rate;Allele C is associated with increased major cardiovascular events (MACE) rate when treated with Ace Inhibitors, Plain in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;Efficacy;increased   Efficacy:event-free survival, Efficacy:Overall survival;Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC.;in children with Disease:Leukemia, Myeloid, Acute
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:trough blood concentration normalized for the daily dose (C) per kilogram body weight (D) (C/D, ng/ml/mg/kg/day) ratio during the first month after transplantation;Genotype CC is associated with increased trough blood concentration normalized for the daily dose (C) per kilogram body weight (D) (C/D, ng/ml/mg/kg/day) ratio during the first month after transplantation when treated with tacrolimus as compared to genotypes CT + TT.; 
;CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;Toxicity;increased  risk of Side Effect:delayed graft function;Genotypes AA + AG are associated with increased risk of delayed graft function when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;ALLOPURINOL;CYCSP5;rs3099844;A;Toxicity;increased  severity of Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with increased severity of severe cutaneous adverse reactions when exposed to allopurinol as compared to allele C.; 
;METHOTREXATE;FOXP3;rs3761548;GT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype GT is associated with increased likelihood of adverse events when treated with methotrexate in people with Psoriasis as compared to genotypes GG + TT.;in people with Psoriasis
;;CHAT;rs1880676;G;Other;increased  risk of Disease:Schizophrenia;Allele G is associated with increased risk of Schizophrenia as compared to allele A.; 
;ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;SIK3;rs139961185;AA + AG;Toxicity;increased  likelihood of Side Effect:Hyperlipidemias;Genotypes AA + AG is associated with increased likelihood of Hyperlipidemias when treated with Antivirals for treatment of HIV infections, combinations in people with HIV Infections as compared to genotype GG.;in people with HIV infectious disease
;OXALIPLATIN;XRCC1;rs25487;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;Toxicity;decreased  Side Effect:renal function (lower creatinine clearance) at 3 months of follow-up;Genotypes AA + AG are associated with decreased renal function (lower creatinine clearance) at 3 months of follow-up when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;METFORMIN;SLC22A1;rs622342;AA;Metabolism/PK;decreased  PK:CL renal reference and lower and CL sec reference;Genotype AA is associated with decreased CL renal reference and lower and CL sec reference when exposed to metformin in healthy individuals as compared to genotype CC.;in healthy individuals 
;ALLOPURINOL;PSORS1C2;rs9263733;T;Toxicity;increased  severity of Side Effect:Severe Cutaneous Adverse Reactions;Allele T is associated with increased severity of severe cutaneous adverse reactions when exposed to allopurinol as compared to allele C.; 
;CYCLOSPORINE;ABCB1;rs1045642;AA + AG;Toxicity;decreased risk of Side Effect:delayed graft function;Genotypes AA + AG are associated with decreased risk of delayed graft function when treated with cyclosporine in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;METHOTREXATE;ABCG2;rs13120400;CT + TT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased severity of Drug Toxicity when treated with methotrexate in people with Psoriasis as compared to genotype CC.;in people with Psoriasis
;ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;Toxicity;increased  severity of Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with increased severity of severe cutaneous adverse reactions when exposed to allopurinol as compared to allele G.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype AA is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;EXEMESTANE, LETROZOLE;;rs912571;G;Toxicity;decreased likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Other:Discontinuation;Allele G is associated with decreased likelihood of Musculoskeletal pain, Arthritis and Discontinuation when exposed to exemestane or letrozole in women with Breast Neoplasms as compared to allele C.;in women with Breast Neoplasms
;ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOA5;rs964184;CG + GG;Toxicity;increased  likelihood of Side Effect:Hyperlipidemias;Genotypes CG + GG is associated with increased likelihood of Hyperlipidemias when treated with Antivirals for treatment of HIV infections, combinations in people with HIV Infections as compared to genotype CC.;in people with HIV infectious disease
;VALPROIC ACID;POLG;rs2307441;C;Toxicity;increased  risk of Side Effect:Toxic liver disease;Allele C is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele T.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;rs698;CT;Efficacy;decreased likelihood of Efficacy:complete response;Genotype CT is associated with decreased likelihood of complete response when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + TT.;in women with Disease:Ovarian Neoplasms
;EXEMESTANE, LETROZOLE;CCDC148;rs79048288;T;Toxicity;increased  likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Other:Discontinuation;Allele T is associated with increased likelihood of Musculoskeletal pain, Arthritis and Discontinuation when treated with exemestane or letrozole in women with Breast Neoplasms as compared to allele C.;in women with Breast Neoplasms
;OXALIPLATIN;GSTP1;rs1695;GG;Efficacy;increased   Efficacy:Overall survival;Genotype GG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;;DRD2;rs6277;G;;increased  risk of Disease:Alcohol abuse;Allele G is associated with increased risk of Alcoholism.; 
;ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;rs35599367;AA + AG;Dosage, Metabolism/PK;decreased  Other:statin doses for optimal lipid control;Genotypes AA + AG are associated with decreased statin doses for optimal lipid control when treated with atorvastatin, lovastatin or simvastatin as compared to genotype GG.; 
;;DRD2;rs1799732;G;;increased  risk of Disease:Alcohol abuse;Allele G is associated with increased risk of Alcoholism.; 
;VALPROIC ACID;POLG;rs3087374;A;Toxicity;increased  risk of Side Effect:Toxic liver disease;Allele A is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele C.; 
;EDOXABAN;SLCO1B1;rs2306283;GG;Toxicity;decreased likelihood of Side Effect:Hemorrhage;Genotype GG is associated with decreased likelihood of Hemorrhage when treated with edoxaban as compared to genotypes AA + AG.; 
;EDOXABAN;ABCB1;rs3842;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype CC is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotypes CT + TT.; 
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;TT;Other;increased   Other:hydrochlorothiazide induced calcium retention;Genotype TT is associated with increased hydrochlorothiazide induced calcium retention when treated with hydrochlorothiazide in men with Hypertension as compared to genotype GG.;in men with Disease:Hypertension
;EDOXABAN;SLCO1B1;rs999278;AA + AC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes AA + AC is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype CC.; 
;LEVODOPA;DRD3;rs6280;TT;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased risk of gastrointestinal toxicity when treated with levodopa in people with Parkinson Disease as compared to genotypes CC + CT.;in people with Disease:Parkinson Disease
;LEVODOPA;DRD2;rs1799732;GG;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity;Genotype GG is associated with increased risk of gastrointestinal toxicity when treated with levodopa in people with Parkinson Disease as compared to genotypes G/del + del/del.;in people with Side Effect:Parkinson Disease
;BUSULFAN, CYCLOPHOSPHAMIDE;CTH;rs1021737;TT;Toxicity;increased  risk of Disease:Hepatic Veno-Occlusive Disease;Genotype TT is associated with increased risk of Hepatic Veno-Occlusive Disease when treated with busulfan and cyclophosphamide in children with Hematopoietic stem cell transplantation as compared to genotypes GG + GT.;in children with Hematopoietic stem cell transplantation
;FUROSEMIDE, SPIRONOLACTONE;CYP11B2;rs1799998;AA + AG;Efficacy;increased  likelihood of Efficacy:diuretic unresponsiveness;Genotypes AA + AG are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.;in people with Disease:Liver Cirrhosis
;EDOXABAN;SLCO1B1;rs4149057;CC + CT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with edoxaban as compared to genotype TT.; 
;SIMVASTATIN;ABCB1;rs2032582;AA;Efficacy;increased   Efficacy:reduction in total cholesterol;Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.; 
;SIMVASTATIN;ABCB1;rs2032582;AC;Efficacy;increased   Efficacy:reduction in total cholesterol;Genotype AC is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype CC.; 
;FUROSEMIDE, SPIRONOLACTONE;ACE;rs4341;CG + GG;Efficacy;increased  likelihood of Efficacy:diuretic unresponsiveness;Genotypes CG + GG are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype CC.;in people with Disease:Liver Cirrhosis
;SIMVASTATIN;ABCB1;rs1045642;AA;Efficacy;increased   Efficacy:reduction in total cholesterol;Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.; 
;ATORVASTATIN;NOS3;rs2070744;CC;Efficacy;increased   Efficacy:anti-inflammatory effects;Genotype CC is associated with increased anti-inflammatory effects of atorvastatin in healthy individuals.;in healthy individuals 
;ATORVASTATIN;NOS3;rs2070744;CC;Other;increased   Other:whole blood nitrite;Genotype CC is associated with increased whole blood nitrite when treated with atorvastatin in healthy individuals.;in healthy individuals 
;PAROXETINE;CYP1A2;rs2472304;A;Efficacy;increased  likelihood of Efficacy:remission;Allele A is associated with increased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;FUROSEMIDE, SPIRONOLACTONE;ADD1;rs4961;GT + TT;Efficacy;increased  likelihood of Efficacy:diuretic unresponsiveness;Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG.;in people with Disease:Liver Cirrhosis
;PAROXETINE;CYP1A2;rs4646425;T;Efficacy;decreased likelihood of Efficacy:remission;Allele T is associated with decreased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;ATORVASTATIN;ABCB1;rs2032582;AA;Other, Metabolism/PK;increased   PK:AUC;Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype CC.;in healthy individuals 
;CISPLATIN, DOXORUBICIN;ERCC1;rs11615;AA;Toxicity;decreased risk of Side Effect:Mucositis;Genotype AA is associated with decreased risk of mucositis when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to genotype GG.;in people with Osteosarcoma
;METHAMPHETAMINE;ARRB2;rs4790694;C;Other;increased  likelihood of Disease:Substance-Related Disorders;Allele C is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele A.; 
;METHOTREXATE;ABCG2;rs2231142;GT;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotype GT is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.;in people with Osteosarcoma
;PAROXETINE;CYP1A2;rs2470890;T;Efficacy;increased  likelihood of Efficacy:remission;Allele T is associated with increased likelihood of remission when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;PEGINTERFERON ALFA-2A, RIBAVIRIN;SCARB1;rs10846744;GG;Efficacy;decreased  Efficacy:Sustained virological response (SVR);Genotype GG is associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;in people with Disease:Chronic hepatitis C virus infection
;PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1829346;AA;Toxicity;increased  risk of Side Effect:Dermatitis;Genotype AA is associated with increased risk of Dermatitis when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AC + CC.;in people with Disease:Nasopharyngeal Neoplasms
;CISPLATIN, DOXORUBICIN;CYBA;rs4673;AA + AG;Toxicity;decreased risk of Side Effect:Anemia, Side Effect:Mucositis;Genotypes AA + AG are associated with decreased risk of Anemia or mucositis when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to genotype GG.;in people with Osteosarcoma
;ATORVASTATIN;ABCB1;rs1128503;AA;Other, Metabolism/PK;increased   PK:AUC;Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.;in healthy individuals 
;CLOZAPINE;CYP2C19;rs4244285;AA;Other, Metabolism/PK;increased   PK:plasma concentrations;Genotype AA is associated with increased plasma concentrations of clozapine as compared to genotype GG.; 
;ATORVASTATIN;ABCB1;rs1045642;AA;Other, Metabolism/PK;increased   PK:AUC;Genotype AA is associated with increased AUC of atorvastatin in healthy individuals as compared to genotype GG.;in healthy individuals 
;PRASUGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with prasugrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;IRINOTECAN;SLCO1B1;rs2306283;GG;Toxicity;increased  risk of Disease:Neutropenia;Genotype GG is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;PLATINUM COMPOUNDS, RADIOTHERAPY;;rs2027701;AG + GG;Toxicity;decreased risk of Side Effect:Neutropenia;Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;SIMVASTATIN;ABCB1;rs1128503;AA;Other, Metabolism/PK;increased   PK:AUC simvastatin acid;Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype GG.;in healthy individuals 
;PRASUGREL;CYP2C19;rs4244285;A;Efficacy;Efficacy:higher platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment;Allele A is associated with higher platelet reactivity index (PRI) vasodilator-stimulated phosphoprotein (VASP) at 1 month of treatment when treated with prasugrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;ANTIPSYCHOTICS;SLC18A2;rs363341;TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT.;in people with Disease:Psychotic Disorder
;PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1059698;CC;Toxicity;decreased risk of Side Effect:Myelosuppression;Genotype CC is associated with decreased risk of Myelosuppression when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AC.;in people with Disease:Nasopharyngeal Neoplasms
;ANTIPSYCHOTICS;GRIK3;rs1334802;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype TT.;in people with Disease:Psychotic Disorder
;PLATINUM COMPOUNDS, RADIOTHERAPY;;rs73594404;AA + AG;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Neutropenia;Genotypes AA + AG are associated with increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotype GG.;in people with Disease:Nasopharyngeal Neoplasms
;PAROXETINE;CYP1A2;rs4646427;TT;Efficacy;Efficacy:slower response time;Genotype TT is associated with slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.;in people with Disease:Major Depressive Disorder
;METHOTREXATE;SHMT1;rs1979277;AG + GG;Toxicity;increased  likelihood of Side Effect:Abdominal Pain;Genotypes AG + GG is associated with increased likelihood of Abdominal Pain when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA.;in people with Disease:Rheumatoid arthritis
;PAROXETINE;CYP1A2;rs762551;A;Toxicity;increased  risk of Disease:Fatigue;Allele A is associated with increased risk of Fatigue when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;ANTIPSYCHOTICS;HTR2A;rs9567733;AG + GG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AG + GG are associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype AA.;in people with Disease:Psychotic Disorder
;PLATINUM COMPOUNDS, RADIOTHERAPY;;rs36080650;CC;Toxicity;increased  risk of Side Effect:Dermatitis;Genotype CC is associated with increased risk of Dermatitis when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Nasopharyngeal Neoplasms
;METHOTREXATE;ABCB1;rs1045642;AG + GG;Toxicity;increased  risk of Side Effect:Mucositis;Genotypes AG + GG are associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma.;in people with Osteosarcoma
;ANTIPSYCHOTICS;DRD2;rs1124491;AA + AG;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotype GG.;in people with Disease:Psychotic Disorder
;PLATINUM COMPOUNDS, RADIOTHERAPY;MEG3;rs10132552;CC;Toxicity;increased  risk of Side Effect:Anemia;Genotype CC is associated with increased risk of Anemia when treated with Platinum compounds and radiotherapy in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Nasopharyngeal Neoplasms
;WARFARIN;CYP4F2;rs2108622;CT + TT;Metabolism/PK;increased   PK: serum R -warfarin concentration;Genotypes CT + TT is associated with increased serum R -warfarin concentration when treated with warfarin as compared to genotype CC.; 
;MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;Toxicity;Side Effect:diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment;Allele C is associated with diminished estimated glomerular filtration rate (eGFR) during the first year after engraftment when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.;in people with Disease:Kidney Transplantation
;METHOTREXATE;ABCC2;rs17222723;AT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes AT + TT are associated with increased risk of Leukopenia when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.;in people with Osteosarcoma
;METHAMPHETAMINE;SLC6A9;rs2486001;T;Toxicity, Other;increased  risk of Disease:Substance-Related Disorders;Allele T is associated with increased risk of Substance-Related Disorders due to methamphetamine as compared to allele C.; 
;MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;Toxicity;increased  risk of Disease:Proteinuria;Allele C is associated with increased risk of Proteinuria when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.;in people with Disease:Kidney Transplantation
;ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Allele C is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;;KCNH2;rs1805123;T;Other;increased  likelihood of Disease:Atrial Fibrillation;Allele T is associated with increased likelihood of Atrial Fibrillation.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT.;in people with Disease:Chronic hepatitis C virus infection
;METHAMPHETAMINE;ARRB2;rs2036657;A;Other;increased  likelihood of Disease:Substance-Related Disorders;Allele A is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele G.; 
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Efficacy;decreased  Efficacy:survival;Genotypes AA + AG is associated with decreased survival when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.;in children with Disease:Non-Hodgkin Lymphoma
;ASPIRIN;P2RY1;rs1065776;CT;Efficacy;increased  risk of Efficacy: aspirin-resistant phenotype;Genotype CT is associated with increased risk of aspirin-resistant phenotype when treated with aspirin as compared to genotype TT.; 
;ROSUVASTATIN;SLCO1B1;rs4149056;C;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Allele C is associated with increased likelihood of statin-related myopathy when treated with rosuvastatin in people with Coronary Artery Disease as compared to allele T.;in people with Disease:Coronary Artery Disease
;;CRHR1;rs110402;AA;Other;increased  risk of Disease:Major Depressive Disorder;Genotype AA is associated with increased risk of Depressive Disorder, Major as compared to genotypes AG + GG.; 
;NICOTINE;ARRB2;rs4790694;A;Other;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C.; 
;WARFARIN;CYP2C9;rs7900194;A;Dosage;decreased  Efficacy:median weekly warfarin dose requirements;Allele A is associated with decreased median weekly warfarin dose requirements when treated with warfarin as compared to allele G.; 
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:hematological toxicity;Genotypes AA + AG is associated with increased risk of hematological toxicity when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.;in children with Disease:Non-Hodgkin Lymphoma
;ATORVASTATIN;ABCB1;rs1045642;A;Toxicity;increased  likelihood of Side Effect:myalgia;Allele A is associated with increased likelihood of myalgia when treated with atorvastatin in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;CAPECITABINE;MTHFR;rs1801133;GG;Toxicity;increased  likelihood of Side Effect:Treatment interruption;Genotype GG is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;CARVEDILOL;ADRB2;rs1042714;C;Efficacy;increased   Efficacy:reduction in resting blood pressure;Allele C is associated with increased reduction in resting blood pressure when treated with carvedilol in healthy individuals as compared to allele G.;in healthy individuals 
;CLOPIDOGREL;PON1;rs662;CC + CT;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Genotypes CC + CT is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in children with Mucocutaneous Lymph Node Syndrome as compared to genotype TT.;in children with Mucocutaneous Lymph Node Syndrome
;ANTIDEPRESSANTS;NTRK2;rs1439050;G;Toxicity;increased  risk of Disease:Suicide;Allele G is associated with increased risk of suicide when treated with antidepressants in people with Depressive Disorder as compared to allele T.;in people with Disease:Depressive Disorder
;IRINOTECAN;UGT1A1;rs10929302;AA;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.;in people with Disease:Colonic Neoplasms
;BEVACIZUMAB;;rs1478947;CT + TT;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity;Genotypes CT + TT are associated with increased risk of gastrointestinal toxicity when treated with bevacizumab in people with Prostatic Neoplasms as compared to genotype CC.;in people with Prostatic Neoplasms
;ASPIRIN;TBXA2R;rs4523;AA;Toxicity;increased  risk of Side Effect:aspirin resistance;Genotype AA is associated with increased risk of aspirin resistance when treated with aspirin in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;METHAMPHETAMINE;ARRB2;rs1045280;T;Other;increased  likelihood of Disease:Substance-Related Disorders;Allele T is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele C.; 
;ASPIRIN;GP1BA;rs6065;CC;Toxicity;increased  risk of Side Effect:aspirin resistance;Genotype CC is associated with increased risk of aspirin resistance when treated with aspirin in healthy individuals as compared to genotypes CT + TT.;in healthy individuals 
;OLANZAPINE;PMCH;rs7973796;G;Other;increased  likelihood of Side Effect:obesity;Allele G is associated with increased likelihood of obesity when treated with olanzapine in people with Schizophrenia as compared to allele A.;in people with Disease:Schizophrenia
;IRINOTECAN;UGT1A1;rs10929302;AA;Toxicity;increased   Disease:Neutropenia;Genotype AA is associated with increased Neutropenia when treated with irinotecan in people with Colonic Neoplasms as compared to genotype GG.;in people with Disease:Colonic Neoplasms
;WARFARIN;VKORC1;rs9934438;AA;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype AA is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotypes AG + GG.; 
;ASPIRIN;TGFB1;rs1800469;AA + AG;Toxicity;increased  risk of Side Effect:aspirin-intolerant chronic urticaria;Genotypes AA + AG are associated with increased risk of aspirin-intolerant chronic urticaria when exposed to aspirin as compared to genotype GG.; 
;WARFARIN;F7;rs6046;AA;Efficacy;increased   Efficacy:sen sitivity to warfarin during induction;Genotype AA is associated with increased sen sitivity to warfarin during induction when treated with warfarin as compared to genotypes AG + GG.; 
;WARFARIN;F7;rs6046;AA;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype AA is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotypes AG + GG.; 
;CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;rs1801133;AA;Efficacy;increased  likelihood of Efficacy:response to chemotherapy;Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;rs201441480;A;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Acute coronary syndrome
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Treatment modification;Genotype CT is associated with increased likelihood of Drug Toxicity or treatment modification when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Neoplasms
;METHOTREXATE;MTHFD1;rs2236225;AA + AG;Toxicity;increased  risk of Side Effect:Anemia;Genotypes AA + AG are associated with increased risk of Anemia when treated with methotrexate in people with Osteosarcoma as compared to genotype GG.;in people with Osteosarcoma
;PACLITAXEL;ABCB1;rs1128503;AA;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Breast Neoplasms
;METHOTREXATE;MTHFR;rs1801131;GT + TT;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Drug Toxicity;Genotypes GT + TT are associated with increased risk of Anemia or Drug Toxicity when treated with methotrexate in people with Osteosarcoma.;in people with Osteosarcoma
;ATORVASTATIN;NOS3;rs2070744;CC;Other;decreased  Other:erythrocyte plasma membrane fluidity;Genotype CC is associated with decreased erythrocyte plasma membrane fluidity when treated with atorvastatin in healthy individuals.;in healthy individuals 
;WARFARIN;CYP2C9;rs7900194;A;Metabolism/PK;decreased  PK:S-warfarin clearance;Allele A is associated with decreased S-warfarin clearance when treated with warfarin as compared to allele G.; 
;ASPIRIN, CLOPIDOGREL;ECHS1;rs140410716;T;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele T is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Acute coronary syndrome
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;rs12050587;G;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Neutropenia;Allele G is associated with increased likelihood of Leukopenia and Neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149035;CT + TT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotypes CT + TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype CC.; 
;ASPIRIN, CLOPIDOGREL;AGAP3;rs75750968;A;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele T.;in people with Acute coronary syndrome
;ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs11045818;AA + AG;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotype GG.; 
;GEMCITABINE;SLC28A2;rs11854484;CC;Toxicity;decreased risk of Side Effect:hematologic toxicity;Genotype CC is associated with decreased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;SIMVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:Discontinuation;Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.; 
;ACETAMINOPHEN;TLR4;rs1927911;AA + AG;Toxicity;increased  likelihood of Side Effect:Asthma;Genotypes AA + AG is associated with increased likelihood of Asthma when treated with acetaminophen in children as compared to genotype GG.;in children 
;TIMOLOL;;rs16947;AA + AG;Toxicity;increased  risk of Disease:Bradycardia;Genotypes AA + AG are associated with increased risk of Bradycardia when treated with timolol in people with Glaucoma, Open-Angle as compared to genotype GG.;in people with Disease:Open-angle glaucoma
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;;rs11636687;C;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Neutropenia;Allele C is associated with increased likelihood of Leukopenia and Neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;GEMCITABINE;SLC28A2;rs1060896;CC;Toxicity;decreased risk of Side Effect:hematologic toxicity;Genotype CC is associated with decreased risk of hematologic toxicity when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;in people with Disease:Non-Small Cell Lung Carcinoma
;ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;rs2622629;TT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with atorvastatin, fluvastatin, lovastatin, pitavastatin or simvastatin as compared to genotypes CC + CT.; 
;PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:Discontinuation;Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT.; 
;ASPIRIN, CLOPIDOGREL;ZDHHC3;rs3749187;A;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Allele A is associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Acute coronary syndrome
;VENLAFAXINE;CYP2D6;rs3892097;CT + TT;Metabolism/PK;increased   PK:venlafaxine concentration per unit dose;Genotypes CT + TT are associated with increased venlafaxine concentration per unit dose when treated with venlafaxine in people with Depressive Disorder, Major as compared to genotype CC.;in people with Disease:Major Depressive Disorder
;;ADORA2A;rs5996696;AC + CC;Other;decreased risk of Disease:Parkinson Disease;Genotypes AC + CC are associated with decreased risk of Parkinson Disease as compared to genotype AA.; 
;;ADORA2A;rs71651683;CT;Other;decreased risk of Disease:Parkinson Disease;Genotype CT is associated with decreased risk of Parkinson Disease as compared to genotype CC.; 
;;IFITM3;rs12252;GG;Other;increased  severity of Other:COVID-19;Genotype GG is associated with increased severity of COVID-19 in people with COVID-19 as compared to genotypes AA + AG.;in people with COVID-19
;METHOTREXATE;ABCB1;rs1128503;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes AG + GG is associated with increased likelihood of Drug-induced liver injury when treated with methotrexate in people with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Osteosarcoma or Non-Hodgkin Lymphoma as compared to genotype AA.;in people with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Osteosarcoma, Non-Hodgkin Lymphoma
;CAFFEINE;CYP1A2;rs762551;CC;Other;decreased risk of Disease:Parkinson Disease;Genotype CC is associated with decreased risk of Parkinson Disease when exposed to caffeine in people with coffee consumption as compared to genotype AA.;in people with coffee consumption
;CAFFEINE;CYP1A2;rs2470890;CC;Other;decreased risk of Disease:Parkinson Disease;Genotype CC is associated with decreased risk of Parkinson Disease when exposed to caffeine in people with coffee consumption as compared to genotype TT.;in people with coffee consumption
;CLOZAPINE;ABCB1;rs1045642;AA;Metabolism/PK;increased   PK:plasma concentrations;Genotype AA is associated with increased plasma concentrations of clozapine as compared to genotype GG.; 
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotype CC is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotypes CT + TT.; 
;WARFARIN;VKORC1;rs9934438;AA;Efficacy;increased   Efficacy:mean AUC (area under curve) prothrombin time;Genotype AA is associated with increased mean AUC (area under curve) prothrombin time when exposed to warfarin in men as compared to genotype GG.;in men 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;CC;Efficacy;increased  likelihood of Side Effect:Anemia;Genotype CC is associated with increased likelihood of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;;KCNJ11;rs5219;TT;;increased  likelihood of Disease:Diabetes Mellitus, Type 2;Genotype TT is associated with increased likelihood of Diabetes Mellitus, Type 2 as compared to genotype CC.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs374113543;A;Efficacy;increased  severity of Efficacy:Hypercholesterolemia;Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.; 
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs373327528;A;Efficacy;increased  severity of Efficacy:Hypercholesterolemia;Allele A is associated with increased severity of Hypercholesterolemia when treated with atorvastatin or simvastatin as compared to allele G.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9;rs6051702;AA;Efficacy;decreased likelihood of Side Effect:Thrombocytopenia;Genotype AA is associated with decreased likelihood of Thrombocytopenia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AC + CC.;in people with Disease:Chronic hepatitis C virus infection
;DEXAMETHASONE;SERPINE1;rs6092;AA + AG;Toxicity;increased  risk of Disease:Osteonecrosis;Genotypes AA + AG are associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;GEMCITABINE;CDA;rs2072671;AA + AC;Toxicity;increased  severity of Disease:Drug Toxicity;Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC.;in people with Disease:Pancreatic Neoplasms
;NICOTINE;CHRNB2;rs2072661;GG;Efficacy, Toxicity, Other;increased   Other:abstinence;Genotype GG is associated with increased abstinence due to nicotine in smokers as compared to genotypes AA + AG.;in smokers
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis D, Chronic as compared to genotypes CT + TT.;in people with Disease:Hepatitis D virus infection
;ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;Toxicity;decreased likelihood of Side Effect:cardiotoxicity;Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to allele G.;in children with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;CLOZAPINE;CYP1A2;rs2069514;A;Other;increased  likelihood of Side Effect:elevated insulin levels;Allele A is associated with increased likelihood of elevated insulin levels when treated with clozapine in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Nephrotoxicity;Genotypes AA + AG are associated with increased risk of nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype GG.;in people with Osteosarcoma
;CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Genotypes AG + GG are associated with increased risk of cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype AA.;in people with Osteosarcoma
;EVEROLIMUS;MTOR;rs2024627;C;Efficacy;decreased likelihood of Efficacy:Progression-free survival;Allele C is associated with decreased likelihood of progression-free survival when treated with everolimus in people with Breast Neoplasms, Kidney Neoplasms or Neuroendocrine Tumors as compared to allele T.;in people with Breast Neoplasms, Kidney Neoplasms, Neuroendocrine Tumors
;CAPECITABINE;DPYD;rs3918290;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;rs13181;GG + GT;Toxicity;increased  risk of Side Effect:Nephrotoxicity;Genotypes GG + GT are associated with increased risk of nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate in people with Osteosarcoma as compared to genotype TT.;in people with Osteosarcoma
;NICOTINE;CHRM2;rs324650;T;Toxicity, Other;increased  risk of Disease:Tobacco Use Disorder;Allele T is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele A.; 
;CETUXIMAB, PANITUMUMAB;EGFR;rs712829;GT + TT;Efficacy;increased   Efficacy:survival;Genotypes GT + TT is associated with increased survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;;VDR;rs1544410;C;;increased  risk of Disease:Asthma;Allele C is associated with increased risk of Asthma.; 
;CLOZAPINE;CYP1A2;rs35694136;del;Other;increased  likelihood of Side Effect:elevated insulin levels;Allele del is associated with increased likelihood of elevated insulin levels when treated with clozapine in people with Schizophrenia as compared to allele T.;in people with Disease:Schizophrenia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA + AG;Efficacy;increased   Efficacy:overall survival;Genotypes AA + AG is associated with increased overall survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;Efficacy;decreased  Efficacy:overall survival;Genotype GG is associated with decreased overall survival when treated with bevacizumab and irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;PON1;rs662;CT + TT;Other;increased   Other:small-dense LDL levels;Genotypes CT + TT are associated with increased small-dense LDL levels when treated with clopidogrel as compared to genotype CC.; 
;PROTON PUMP INHIBITORS;TRPM6;rs3750425;T;Toxicity;increased  risk of Side Effect:hypomagnesemia primary;Allele T is associated with increased risk of hypomagnesemia primary when treated with Proton pump inhibitors as compared to allele C.; 
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype CC.;in people with Disease:Colonic Neoplasms
;;FKBP5;rs1360780;CC + CT;Efficacy;increased  likelihood of;Genotypes CC + CT are associated with increased likelihood of in people with Depressive Disorder as compared to genotype TT.;in people with Disease:Depressive Disorder
;CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;rs12836771;GG;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Genotype GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders and Schizophrenia as compared to genotypes AA + AG.;in people with Disease:Psychotic Disorder, Disease:Schizophrenia
;METHOTREXATE;GGH;rs3758149;AA;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype AA is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.;in people with Disease:Rheumatoid arthritis
;HALOTHANE, SUCCINYLCHOLINE;RYR1;rs193922803;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to halothane and succinylcholine as compared to allele C.; 
;CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;Efficacy;decreased  Efficacy:survival;Genotype AA is associated with decreased survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AC + CC.;in people with Disease:Colorectal Neoplasms
;SIMVASTATIN;ABCB1;rs1045642;AA;Other, Metabolism/PK;increased   PK:AUC simvastatin acid;Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype GG.;in healthy individuals 
;PROTON PUMP INHIBITORS;TRPM6;rs2274924;C;Toxicity;increased  risk of Side Effect:hypomagnesemia primary;Allele C is associated with increased risk of hypomagnesemia primary when treated with Proton pump inhibitors as compared to allele T.; 
;DOXORUBICIN;GSTP1;rs1695;AG + GG;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes AG + GG are associated with increased risk of Leukopenia when treated with doxorubicin in people with Osteosarcoma as compared to genotype AA.;in people with Osteosarcoma
;DOXORUBICIN;ERCC1;rs3212986;AA + AC;Toxicity;decreased risk of Side Effect:Infectious disease, Side Effect:Leukopenia;Genotypes AA + AC are associated with decreased risk of Infection or Leukopenia when treated with doxorubicin in people with Osteosarcoma as compared to genotype CC.;in people with Osteosarcoma
;CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs518147;CC;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Genotype CC is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine, quetiapine or risperidone in people with Psychotic Disorders or Schizophrenia as compared to genotypes CG + GG.;in people with Disease:Psychotic Disorder, Disease:Schizophrenia
;SIMVASTATIN;ABCB1;rs2032582;AA;Other, Metabolism/PK;increased   PK:AUC simvastatin acid;Genotype AA is associated with increased AUC simvastatin acid when treated with simvastatin in healthy individuals as compared to genotype CC.;in healthy individuals 
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192172;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.; 
;NEVIRAPINE;CYP2B6;rs2054675;C;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;ASUNAPREVIR, DACLATASVIR, DIRECT ACTING ANTIVIRALS, LEDIPASVIR / SOFOSBUVIR, OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;rs8099917;GG + GT;Toxicity;increased  risk of Side Effect:Hypercholesterolemia;Genotypes GG + GT are associated with increased risk of Hypercholesterolemia when treated with asunaprevir, daclatasvir, direct acting antivirals, ledipasvir / sofosbuvir or ombitasvir / paritaprevir / ritonavir in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192176;A;Other;increased  risk of Disease:Malignant Hyperthermia;Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192177;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.; 
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918593;A;Other;increased  risk of Disease:Malignant Hyperthermia;Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;NEVIRAPINE;CYP2B6;rs3786547;C;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections.;in people with Disease:HIV infectious disease
;CAPECITABINE;DPYD;rs1801160;CC + CT;Toxicity;increased  likelihood of Side Effect:Treatment interruption;Genotypes CC + CT is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918592;A;Other;increased  risk of Disease:Malignant Hyperthermia;Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;CAPECITABINE;DPYD;rs1801159;C;Toxicity;increased  risk of Side Effect:Diarrhea;Allele C is associated with increased risk of Diarrhea due to capecitabine in women with Breast Neoplasms as compared to allele T.;in women with Breast Neoplasms
;METHYLPHENIDATE;DRD3;rs6280;CT + TT;Toxicity;increased   Side Effect:intolerability;Genotypes CT + TT is associated with increased intolerability of methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC.;in children with Disease:Autism Spectrum Disorder
;CISPLATIN;ACYP2;rs1872328;AA + AG;Toxicity;increased  risk of Side Effect:Ototoxicity;Genotypes AA + AG is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to genotype GG.;in children with Disease:Neoplasms
;CLOPIDOGREL;PON1;rs662;CT + TT;Toxicity;increased  risk of Side Effect:cardiovascular events (composite of cardiac death, MI, stent thrombosis) in Korean patients after PCI;Genotypes CT + TT are associated with increased risk of cardiovascular events (composite of cardiac death, MI, stent thrombosis) in Korean patients after PCI when treated with clopidogrel as compared to genotype CC.; 
;DOXORUBICIN;XPC;rs2228001;GG + GT;Toxicity;decreased risk of Side Effect:Infectious disease;Genotypes GG + GT are associated with decreased risk of Infection when treated with doxorubicin in people with Osteosarcoma as compared to genotype TT.;in people with Osteosarcoma
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;HEROIN;OPRM1;rs9479757;GG;Toxicity;increased  severity of Other:Heroin Dependence;Genotype GG is associated with increased severity of Heroin Dependence due to heroin as compared to genotypes AA + AG.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;in people with Disease:Hepatitis C virus infection
;NALTREXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased   Efficacy:blunting of alcohol craving;Genotypes AG + GG are associated with increased blunting of alcohol craving when treated with naltrexone in healthy individuals as compared to genotype AA.;in healthy individuals 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;Efficacy:higher rate of sustained virological response (SVR);Genotype TT is associated with higher rate of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs1125338;CC;Efficacy;increased  likelihood of Efficacy:Overall survival;Genotype CC is associated with increased likelihood of overall survival when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to genotypes CT + TT.;in people with Neoplasms
;BETA-LACTAM ANTIBACTERIALS, PENICILLINS;;rs71542416;T;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;Allele T is associated with increased likelihood of Drug Hypersensitivity when treated with beta-lactam antibacterials, penicillins as compared to allele G.; 
;IRINOTECAN;ABCG1;rs425215;GG;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype GG is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes CC + CG.;in people with Disease:Colorectal Neoplasms
;XELOX;ABCA2;rs2271862;AA;Toxicity;decreased likelihood of Side Effect:Neutropenia;Genotype AA is associated with decreased likelihood of Neutropenia when treated with XELOX in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to genotypes AG + GG.;in people with Colorectal Neoplasms, Metastatic neoplasm
;IRINOTECAN;ABCC5;rs562;CC;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colorectal Neoplasms
;OPIOIDS;TACR1;rs6715729;AG + GG;Toxicity;decreased likelihood of Side Effect:Overdose;Genotypes AG + GG is associated with decreased likelihood of Overdose with opioids.; 
;OPIOIDS;DRD2;rs4436578;CT + TT;Toxicity;increased  likelihood of Side Effect:Overdose;Genotypes CT + TT is associated with increased likelihood of Overdose with opioids as compared to genotype CC.; 
;OPIOIDS;CYP3A5;rs776746;CC + CT;Toxicity;increased  likelihood of Side Effect:Overdose;Genotypes CC + CT is associated with increased likelihood of Overdose with opioids as compared to genotype TT.; 
;IRINOTECAN;SLCO1B1;rs2306283;AG;Toxicity;decreased likelihood of Disease:Drug Toxicity;Genotype AG is associated with decreased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;TRAMADOL;ABCB1;rs1045642;AA;Toxicity;decreased risk of Other:Opioid-Related Disorders;Genotype AA is associated with decreased risk of Opioid-Related Disorders due to tramadol as compared to genotypes AG + GG.; 
;;ABCB1;rs2032582;CC + TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes CC + TT is associated with decreased progression-free survival as compared to genotypes AA + AC.; 
;CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;Toxicity;increased  risk of Side Effect:Anemia;Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;FPGS;rs10106;CC + CT;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotypes CC + CT is associated with decreased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  likelihood of Side Effect:Alopecia, Side Effect:Leukopenia;Allele T is associated with increased likelihood of Alopecia and Leukopenia when exposed to azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;;HIF1A;rs11549467;AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AG is associated with decreased progression-free survival as compared to genotype GG.; 
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;Efficacy;increased  likelihood of Efficacy:Progression-free survival, Efficacy:Overall survival;Genotype GG is associated with increased likelihood of progression-free survival or overall survival when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to genotypes AA + AG.;in people with Neoplasms
;COUMARIN, NICOTINE;CYP2A6;rs28399433;C;Other, Metabolism/PK;decreased  Other:expression of enzyme contributing to the metabolism;Allele C is associated with decreased expression of enzyme contributing to the metabolism of coumarin and nicotine.; 
;SUNITINIB;ABCG2;rs2231142;TT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype TT is associated with increased risk of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;;PEMT;rs7946;T;;increased  risk of Disease:Fatty liver disease;Allele T is associated with increased risk of Fatty Liver as compared to allele C.; 
;ANTIBIOTICS;LGALS3;rs11125;AT + TT;Toxicity;increased  risk of Side Effect:Hypersensitivity;Genotypes AT + TT is associated with increased risk of Hypersensitivity when treated with Antibiotics in people with Infection as compared to genotype AA.;in people with Disease:Infectious disease
;SUNITINIB;ABCG2;rs2231142;TT;Toxicity;increased  risk of Disease:Thrombocytopenia;Genotype TT is associated with increased risk of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CG + GG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes CG + GG is associated with increased likelihood of adverse events when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to genotype CC.;in people with Neoplasms
;SUNITINIB;ABCG2;rs2231142;TT;Toxicity;increased  risk of Disease:Neutropenia;Genotype TT is associated with increased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;;VKORC1;rs9934438;AA + AG;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes AA + AG are associated with increased risk of over-anticoagulation as compared to genotype GG.; 
;SUNITINIB;ABCG2;rs2231142;TT;Toxicity;increased  risk of Disease:Hand-foot syndrome;Genotype TT is associated with increased risk of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;METHOTREXATE;DHFR;rs1650723;T;Toxicity;increased  severity of Side Effect:Mucositis;Allele T is associated with increased severity of mucositis when treated with methotrexate in people with Osteosarcoma as compared to allele C.;in people with Disease:Osteosarcoma
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CC;Efficacy;increased  likelihood of Efficacy:Progression-free survival, Efficacy:Overall survival;Genotype CC is associated with increased likelihood of progression-free survival or overall survival when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to genotypes CG + GG.;in people with Neoplasms
;METHOTREXATE;ABCG2;rs2231135;AG;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AG is associated with increased risk of mucositis when treated with methotrexate in people with Osteosarcoma as compared to genotype AA.;in people with Disease:Osteosarcoma
;NICOTINE;HINT1;rs3852209;CC;Other;increased  likelihood of Other:Smoking Cessation;Genotype CC is associated with increased likelihood of cessation of nicotine in men with Tobacco Use Disorder as compared to genotypes CT + TT.;in men with Tobacco Use Disorder
;METHOTREXATE;SLC19A1;rs1051266;TT;Efficacy;increased  risk of Efficacy:Metastatic neoplasm;Genotype TT is associated with increased risk of Neoplasm Metastasis when treated with methotrexate in people with Osteosarcoma as compared to genotypes CC + CT.;in people with Disease:Osteosarcoma
;;VDR;rs1544410;CC;Other;decreased likelihood of Other:Pre-Eclampsia;Genotype CC is associated with decreased likelihood of Pre-Eclampsia in women with Pregnancy as compared to genotypes CT + TT.;in women with Pregnancy
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;rs352139;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes AA + AG is associated with increased likelihood of Drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotype GG.;in people with Tuberculosis
;RISPERIDONE;SLC6A4;rs3813034;AA;Other;increased  likelihood of Side Effect:Weight gain;Genotype AA is associated with increased likelihood of Weight gain when treated with risperidone in people with Schizophrenia as compared to genotypes AC + CC.;in people with Disease:Schizophrenia
;ISONIAZID, RIFAMPIN;GSTP1;rs1695;AA;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype AA is associated with increased likelihood of drug-induced liver injury when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AG + GG.;in people with Disease:Tuberculosis
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs3764435;A;Toxicity;increased  risk of Disease:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs168351;A;Toxicity;increased  risk of Disease:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;METHOTREXATE;MTHFR;rs1801133;A;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GG;Toxicity;increased  risk of Side Effect:Anemia;Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs117648444;AA + AG;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;ETHANOL, NALTREXONE;OPRM1;rs1799971;AG + GG;Efficacy;increased  severity of Efficacy:intoxication;Genotypes AG + GG are associated with increased severity of intoxication when exposed to ethanol and naltrexone in healthy individuals as compared to genotype AA.;in healthy individuals 
;ISONIAZID, RIFAMPIN;NAT2;rs1799929;TT;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;OPIOIDS;COMT;rs4680;AG;Toxicity;increased  likelihood of Side Effect:Hyperalgesia;Genotype AG is associated with increased likelihood of Hyperalgesia due to opioids in people with Pain as compared to genotypes AA + GG.;in people with Pain
;ISONIAZID, RIFAMPIN;NAT2;rs1799930;AA;Toxicity, Metabolism/PK;increased  likelihood of Disease:Toxic liver disease;Genotype AA is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;METHOTREXATE;SLC19A1;rs1051266;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with methotrexate in people with Osteosarcoma as compared to genotype TT.;in people with Disease:Osteosarcoma
;METHOTREXATE;DHFR;rs1053129;CC;Toxicity;increased  risk of Efficacy:Metastatic neoplasm;Genotype CC is associated with increased risk of Neoplasm Metastasis when treated with methotrexate in people with Osteosarcoma as compared to genotype AC.;in people with Disease:Osteosarcoma
;METHOTREXATE;MTHFR;rs1801133;GG;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotype GG is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Osteosarcoma as compared to genotypes AA + AG.;in people with Disease:Osteosarcoma
;TAMOXIFEN;HS6ST3;rs118042719;A;Efficacy;decreased risk of Efficacy:Recurrence free survival;Allele A is associated with decreased risk of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele G.;in women with Breast Neoplasms
;PHENYTOIN;ABCB1;rs2229107;A;Other, Metabolism/PK;increased   PK:plasma drug levels;Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype TT.;in people with no disease
;"""3,4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;rs1799971;AG;Toxicity;increased  risk of Other:Substance-Related Disorders;Genotype AG is associated with increased risk of Substance-Related Disorders due to 3,4-methylenedioxymethamphetamine, cocaine, ethanol or opioids as compared to genotype AA.; 
;TRASTUZUMAB;FCGR3A;rs396991;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with trastuzumab in women Breast Neoplasms as compared to genotypes AA + AC.;in women Disease:Breast Neoplasms
;MYCOPHENOLIC ACID, TACROLIMUS;ABCC2;rs717620;C;Efficacy;"increased  likelihood of ""Efficacy:primary graft failure"", ""Efficacy:Kidney Tubular Necrosis, Acute""";Allele C is associated with increased likelihood of primary graft failure or Kidney Tubular Necrosis, Acute when treated with mycophenolic acid and tacrolimus in people with Kidney Transplantation as compared to allele T.;in people with Kidney Transplantation
;METHADONE;CYP2B6;rs1038376;TT;Toxicity;increased  likelihood of Side Effect:Postoperative Nausea and Vomiting;Genotype TT is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with methadone in children with Pain, Postoperative and Scoliosis as compared to genotypes AA + AT.;"in children with ""Pain, Postoperative"", ""Scoliosis"""
;TRASTUZUMAB;FCGR2A;rs1801274;AA;Efficacy;increased   Efficacy:Progression-free survival;Genotype AA is associated with increased progression-free survival when treated with trastuzumab in women Breast Neoplasms as compared to genotype GG.;in women Disease:Breast Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;CC + CT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes CC + CT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;SUCCINYLCHOLINE;BCHE;rs1799807;C;Metabolism/PK;Side Effect:Butyrylcholinesterase deficiency;Allele C is associated with Butyrylcholinesterase deficiency when exposed to succinylcholine as compared to allele T.; 
;SUCCINYLCHOLINE;BCHE;rs1803274;T;Metabolism/PK;Side Effect:Butyrylcholinesterase deficiency;Allele T is associated with Butyrylcholinesterase deficiency when exposed to succinylcholine as compared to allele C.; 
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  likelihood of Disease:Thrombocytopenia;Genotype CT is associated with increased likelihood of Thrombocytopenia when treated with fluorouracil in women with Neoplasms as compared to genotype CC.;in women with Disease:Neoplasms
;CLOPIDOGREL;CYP2C18;rs1042192;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.;in people with Cardiovascular Disease
;CLOZAPINE;HNMT;rs2737385;GG;Toxicity;decreased severity of Side Effect:sedation;Genotype GG is associated with decreased severity of sedation when treated with clozapine in people with schizoaffective disorder or Schizophrenia as compared to genotypes GT + TT.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;FLUOROURACIL;DPYD;rs1801160;CT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.;in people with Cardiovascular Disease
;METHADONE;CYP2B6;rs2279343;AG + GG;Toxicity;increased  likelihood of Side Effect:Postoperative Nausea and Vomiting;Genotypes AG + GG is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with methadone in children with Pain, Postoperative and Scoliosis as compared to genotype AA.;"in children with ""Pain, Postoperative"", ""Scoliosis"""
;CLOPIDOGREL;NOC3L;rs12572897;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.;in people with Cardiovascular Disease
;TAMOXIFEN;LPP;rs6790761;A;Efficacy;decreased risk of Efficacy:Recurrence free survival;Allele A is associated with decreased risk of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele G.;in women with Breast Neoplasms
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;Toxicity;decreased severity of Side Effect:Drug Toxicity;Allele T is associated with decreased severity of Drug Toxicity when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to allele C.;in people with Tuberculosis
;SUNITINIB;ABCB1;rs1128503;AA + AG;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Genotypes AA + AG is associated with increased likelihood of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;NICOTINE;CHRNA5;rs16969968;A;Toxicity, Other;increased  likelihood of Disease:Tobacco Use Disorder;Allele A is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;CLOPIDOGREL;CYP2C8;rs1058932;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to allele G.;in people with Cardiovascular Disease
;SUNITINIB;ABCB1;rs2032582;AA + AC;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Genotypes AA + AC is associated with increased likelihood of hand-foot syndrome when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;NICOTINE;CHRNA3;rs578776;A;Toxicity, Other;decreased likelihood of Disease:Tobacco Use Disorder;Allele A is associated with decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;TAMOXIFEN;LPP;rs77693286;A;Efficacy;decreased risk of Efficacy:Recurrence free survival;Allele A is associated with decreased risk of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele T.;in women with Breast Neoplasms
;ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;rs17863783;T;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele T is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia, Sarcoma, Neuroblastoma, Osteosarcoma, Lymphoma
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy;increased  risk of Disease:Transplant rejection;Genotypes CT + TT is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;RIFAMPIN;RIPOR2;rs10946739;C;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele C is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele T.;in people with Disease:Tuberculosis
;ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia, Sarcoma, Neuroblastoma, Osteosarcoma, Lymphoma
;;EGFR;rs763317;AA;Efficacy;increased  risk of Efficacy:Death;Genotype AA is associated with increased risk of Death in people with Lung Neoplasms as compared to genotypes AG + GG.;in people with Lung Neoplasms
;;GAL;rs948854;C;Other;increased  severity of Disease:Anxiety Disorders;Allele C is associated with increased severity of Anxiety Disorders in women with Anxiety Disorders as compared to allele T.;in women with Disease:Anxiety Disorders
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Genotypes AG + GG is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine as compared to genotype AA.; 
;ATAZANAVIR;ABCB1;rs2032582;AA;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AC + CC.;in healthy individuals 
;HMG COA REDUCTASE INHIBITORS;EYS;rs1337512;G;Toxicity;increased  likelihood of Disease:Rhabdomyolysis;Allele G is associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele T.;in people with Disease:Cardiovascular Disease
;RIFAMPIN;AGBL4;rs393994;A;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.;in people with Disease:Tuberculosis
;ATAZANAVIR;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;PHENYTOIN;CYP2C9;rs1799853;T;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele T is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele C.;in people with Disease:Epilepsy
;HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs9342288;A;Toxicity;increased  likelihood of Disease:Rhabdomyolysis;Allele A is associated with increased likelihood of Rhabdomyolysis when treated with HMG CoA reductase inhibitors, other combinations in people with Cardiovascular Diseases as compared to allele G.;in people with Disease:Cardiovascular Disease
;ASPIRIN;SLC30A9;rs1047626;A;Toxicity, Other;decreased risk of Side Effect:Aspirin-induced asthma;Allele A is associated with decreased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.;in people with Disease:Asthma
;ESCITALOPRAM, NORTRIPTYLINE;BDNF;rs962369;C;Efficacy, Toxicity;increased  likelihood of Side Effect:suicidal ideation;Allele C is associated with increased likelihood of suicidal ideation when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;ACE INHIBITORS, PLAIN;KCNMA1;rs2253201;G;Toxicity;increased  risk of Side Effect:Angioedema;Allele G is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain as compared to allele A.; 
;HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs3857532;A;Toxicity;increased  likelihood of Disease:Rhabdomyolysis;Allele A is associated with increased likelihood of Rhabdomyolysis when treated with HMG CoA reductase inhibitors, other combinations in people with Cardiovascular Diseases as compared to allele G.;in people with Disease:Cardiovascular Disease
;ASPIRIN;TSC1;rs7862221;C;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele T.;in people with Disease:Asthma
;RIFAMPIN;AGBL4;rs320003;G;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele G is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele A.;in people with Disease:Tuberculosis
;ASPIRIN;THRA;rs11819745;G;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele G is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;RIFAMPIN;CUX2;rs7958375;G;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele G is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele A.;in people with Disease:Tuberculosis
;ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele A is associated with decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sarcoma, Neuroblastoma, Osteosarcoma or Lymphoma as compared to allele G.;in children with Acute lymphoblastic leukemia, Sarcoma, Neuroblastoma, Osteosarcoma, Lymphoma
;HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;Toxicity;decreased likelihood of Side Effect:statin-related myopathy;Allele A is associated with decreased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to allele G.;in people with Disease:Cardiovascular Disease
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.;in people with Disease:Cardiovascular Disease
;ASPIRIN;CHIA;rs3818822;A;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele A is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.;in people with Disease:Asthma
;ATAZANAVIR;ABCB1;rs1128503;AA;Toxicity;increased  risk of Side Effect:Hyperbilirubinemia;Genotype AA is associated with increased risk of Hyperbilirubinemia when exposed to atazanavir in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;ASPIRIN;;rs1074373;C;Toxicity, Other;decreased risk of Side Effect:Aspirin-induced asthma;Allele C is associated with decreased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;PHENYTOIN;CYP2C9;rs1799853;T;Toxicity, Metabolism/PK;increased   PK:plasma free phenytoin concentration;Allele T is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to genotype CC.;in people with Disease:Epilepsy
;PHENYTOIN;CYP2C9;rs1057910;C;Toxicity, Metabolism/PK;increased   PK:plasma free phenytoin concentration;Allele C is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to allele A.;in people with Disease:Epilepsy
;HEROIN;GRM3;rs1990040;A;Other;increased  risk of Disease:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele G.; 
;ASPIRIN;ZBTB22;rs3130100;C;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele T.;in people with Disease:Asthma
;CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;rs7903146;T;Toxicity;increased  likelihood of Disease:Diabetes Mellitus;Allele T is associated with increased likelihood of Diabetes Mellitus when treated with cyclosporine, sirolimus or tacrolimus in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Disease:Rhabdomyolysis;Genotypes CC + CT are associated with increased likelihood of Rhabdomyolysis when treated with hmg coa reductase inhibitors in people with Cardiovascular Diseases as compared to genotype TT.;in people with Disease:Cardiovascular Disease
;PHENYTOIN;CYP2C9;rs1057910;C;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele C is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele A.;in people with Disease:Epilepsy
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy, Toxicity;increased  risk of Side Effect:stent thrombosis;Genotypes AA + AG are associated with increased risk of stent thrombosis when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype GG.;in patients undergoing percutaneous coronary intervention
;ASPIRIN;HLA-DPB1;rs3097671;C;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele G.;in people with Disease:Asthma
;ASPIRIN;HLA-DPB2;rs3129294;C;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;ASPIRIN;HLA-DPB1;rs1042151;G;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele G is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;ASPIRIN;HLA-DPB1;rs1042136;C;Toxicity, Other;increased  risk of Side Effect:Aspirin-induced asthma;Allele C is associated with increased risk of aspirin-induced asthma when exposed to aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased likelihood of statin-related myopathy when treated with atorvastatin or simvastatin as compared to genotype TT.; 
;RIFAMPIN;RIPOR2;rs10946737;A;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.;in people with Disease:Tuberculosis
;PREDNISOLONE;GATA3;rs3824662;AA;PD;increased  risk of Side Effect:Sepsis;Genotype AA is associated with increased risk of Sepsis when treated with prednisolone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.;in children with Acute lymphoblastic leukemia
;RIFAMPIN;AGBL4;rs319952;A;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele A is associated with increased risk of drug-induced liver injury when treated with rifampin in people with Tuberculosis as compared to allele G.;in people with Disease:Tuberculosis
;NICOTINE;OPRM1;rs10485057;AA;Toxicity;increased  risk of Other:Tobacco Use Disorder;Genotype AA is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to genotypes AG + GG.; 
;ETHANOL;DPP6;rs2533200;C;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;rs1051740;CT;Toxicity;increased  risk of Side Effect:nephrotoxicity grades 1-4;Genotype CT is associated with increased risk of nephrotoxicity grades 1-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.;in women with Disease:Ovarian Neoplasms
;CARBAMAZEPINE;;rs192543598;G;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;Allele G is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to allele A.; 
;ETHANOL;;rs7900002;T;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;;rs2582405;T;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;rs1801280;CT;Toxicity;increased  risk of Disease:Anemia;Genotype CT is associated with increased risk of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.;in women with Disease:Ovarian Neoplasms
;ETHANOL;;rs56722963;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;rs3219484;CT;Toxicity;decreased risk of Side Effect:neutropenia grade 3-4;Genotype CT is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.;in women with Disease:Ovarian Neoplasms
;CARBAMAZEPINE;ALK;rs187926838;G;Toxicity;increased  risk of Side Effect:Severe Cutaneous Adverse Reactions;Allele G is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to allele A.; 
;ETHANOL;MED19, TMX2;rs576859;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;METHOTREXATE;ATIC;rs7563206;CC;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;in people with Disease:Rheumatoid arthritis
;ENZYMES;A2M;rs669;TT;Toxicity;increased  risk of Side Effect:hemorrhagic transformation;Genotype TT is associated with increased risk of hemorrhagic transformation when treated with Enzymes in people with Stroke as compared to genotypes CC + CT.;in people with Disease:Stroke
;METHOTREXATE;ATIC;rs3821353;GT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes GT + TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;CHOP, RITUXIMAB;NCF4;rs1883112;AA;Efficacy;decreased  Efficacy:Progression-free survival, Efficacy:Overall survival;Genotype AA is associated with decreased progression-free survival and overall survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes AG + GG.;in people with Lymphoma, Large B-Cell, Diffuse
;ENZYMES;F12;rs1801020;GG;Toxicity;increased  risk of Disease:Death;Genotype GG is associated with increased risk of Death when treated with Enzymes in people with Stroke as compared to genotypes AA + AG.;in people with Disease:Stroke
;SUNITINIB;ABCB1;rs1128503;A;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Allele A is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Disease:Renal Cell Carcinoma
;METHOTREXATE;ATIC;rs2372536;CG + GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes CG + GG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.;in people with Disease:Rheumatoid arthritis
;ETHANOL;;rs6589386;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;ETHANOL;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Other:Alcohol abuse;Genotypes AG + GG are associated with increased risk of Alcoholism due to ethanol in men as compared to genotype AA.;in men 
;ETHANOL;ADH1C;rs13125415;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;METHOTREXATE;ATIC;rs12995526;CC;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;in people with Disease:Rheumatoid arthritis
;CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;rs11226;AG;Toxicity;decreased risk of Side Effect:neutropenia grade 3-4;Genotype AG is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.;in women with Disease:Ovarian Neoplasms
;ETHANOL;SLC39A8;rs13135092;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;rs1052536;CC;Toxicity;increased  risk of Side Effect:neutropenia grade 3-4;Genotype CC is associated with increased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT.;in women with Disease:Ovarian Neoplasms
;ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with abiraterone and prednisolone in people with Prostatic Neoplasms as compared to genotype GG.;in people with Disease:Prostatic Neoplasms
;OPIOIDS;COMT;rs4680;AA + AG;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotypes AA + AG is associated with increased likelihood of Nausea, Fatigue and Depression when treated with opioids in people with Pain and Neoplasms as compared to genotype GG.;in people with Pain, Neoplasms
;CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;rs1799782;AA + AG;Efficacy;increased  likelihood of Efficacy:Overall survival;Genotypes AA + AG is associated with increased likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotype GG.;in men with Carcinoma, Squamous Cell
;INDINAVIR;UGT1A1;rs4148323;AG;Toxicity;increased  risk of Disease:Hyperbilirubinemia;Genotype AG is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV as compared to genotype GG.;in people with HIV
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;ETHANOL;ADH1B;rs1229984;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;METHOTREXATE;FPGS;rs10760502;AA;Efficacy, Toxicity, Other;decreased likelihood of Other:Discontinuation;Genotype AA is associated with decreased likelihood of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;FPGS;rs10106;TT;Efficacy, Toxicity, Other;decreased likelihood of Other:Discontinuation;Genotype TT is associated with decreased likelihood of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Disease:Rheumatoid arthritis
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs55886062;AC + CC;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AC + CC are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;METHOTREXATE;FPGS;rs10106;TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Disease:Rheumatoid arthritis
;ETHANOL;;rs9679319;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;;rs1402398;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;THSD7B;rs13382553;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype GG is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;METHOTREXATE;ABCB1;rs868755;TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.;in people with Disease:Rheumatoid arthritis
;ETHANOL;;rs2673136;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;;rs13129401;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;METHOTREXATE;ABCB1;rs10280623;TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype TT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Disease:Rheumatoid arthritis
;ETHANOL;CADM2;rs62250713;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;ADH1B;rs75967634;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;rs1139130;AA + AG;Toxicity;increased  likelihood of Side Effect:Fever, Side Effect:Mucositis;Genotypes AA + AG is associated with increased likelihood of Fever or Mucositis when treated with carboplatin, cyclophosphamide, etoposide, lomustine, methotrexate and vincristine in children with Medulloblastoma, Glioblastoma, Astrocytoma or Brain Neoplasms as compared to genotype GG.;in children with Medulloblastoma, Glioblastoma, Astrocytoma, Brain Neoplasms
;HEROIN;OPRM1;rs1799971;AG + GG;Toxicity;increased  severity of Other:Heroin Dependence;Genotypes AG + GG are associated with increased severity of Heroin Dependence due to heroin in men as compared to genotype AA.;in men 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4273729;GG;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype GG is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;in people with Disease:Chronic hepatitis C virus infection
;;CYP2A6;rs56113850;T;Other;decreased likelihood of Other:Smoking Cessation;Allele T is associated with decreased likelihood of Smoking Cessation in women with Tobacco Use Disorder as compared to allele C.;in women with Tobacco Use Disorder
;ETHANOL;PDE4B;rs6421482;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;;rs61767420;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;GCKR;rs1260326;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;ETHANOL;;rs494904;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;;CHRNA5;rs503464;AA + AT;Other;increased  likelihood of Other:Smoking Cessation;Genotypes AA + AT is associated with increased likelihood of Smoking Cessation in women with Tobacco Use Disorder as compared to genotype TT.;in women with Tobacco Use Disorder
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes CT + TT.;in people with 
;METHOTREXATE;SPATA9;rs72783407;A;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Allele A is associated with increased likelihood of elevated liver enzymes when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.;in people with Rheumatoid arthritis
;METHOTREXATE;BIRC5;rs9904341;GG;Efficacy;increased   Efficacy:Disease activity score 28 in rheumatoid arthritis;Genotype GG is associated with increased disease activity score 28 joint in rheumatoid arthritis when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.;in people with Disease:Rheumatoid arthritis
;PROTEIN KINASE INHIBITORS;STAT6;rs324011;TT;Toxicity;increased  severity of Side Effect:adverse events;Genotype TT is associated with increased severity of adverse events when treated with Protein kinase inhibitors in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes GG + GT.;in people with 
;FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;OPIOIDS;ANKK1, DRD2;rs1800497;AA + AG;Toxicity;increased  risk of Other:Opioid-Related Disorders;Genotypes AA + AG are associated with increased risk of Opioid-Related Disorders due to opioids as compared to genotype GG.; 
;TAMOXIFEN;C1QTNF6;rs114557570;C;Efficacy;decreased risk of Efficacy:Recurrence free survival;Allele C is associated with decreased risk of Recurrence free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele T.;in women with Breast Neoplasms
;;CHRNA5;rs637137;AA + AT;Other;increased  likelihood of Other:Smoking Cessation;Genotypes AA + AT is associated with increased likelihood of Smoking Cessation in women with Tobacco Use Disorder as compared to genotype TT.;in women with Tobacco Use Disorder
;DOCETAXEL;VEGFA;rs833061;CC;Efficacy;increased   Efficacy:overall survival;Genotype CC is associated with increased overall survival when treated with docetaxel in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Disease:Breast Neoplasms
;DOCETAXEL;VEGFA;rs13207351;GG;Efficacy;decreased  Efficacy:progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AG.;in women with Disease:Breast Neoplasms
;DOCETAXEL;VEGFA;rs35864111;GG;Efficacy;increased   Efficacy:progression-free survival;Genotype GG is associated with increased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype del/del.;in women with Disease:Breast Neoplasms
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;Efficacy;increased  likelihood of Efficacy:relapse;Allele A is associated with increased likelihood of relapse when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;Efficacy;increased   Efficacy:minimal residual disease;Allele A is associated with increased minimal residual disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;DOCETAXEL;VEGFA;rs699947;AA;Efficacy;increased   Efficacy:progression-free survival;Genotype AA is associated with increased progression-free survival when treated with docetaxel in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;EXEMESTANE;;rs62293499;C;Efficacy;decreased risk of Efficacy:Recurrence;Allele C is associated with decreased risk of Recurrence when treated with exemestane in people with Breast Neoplasms as compared to allele A.;in people with Breast Neoplasms
;ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CT;Other;increased   Other:platelet aggregation with epinephrine;Genotype CT is associated with increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotypes CC + TT.;in people with Disease:Acute coronary syndrome
;FLUOROURACIL;DPYD;rs4294451;AT + TT;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes AT + TT is associated with decreased likelihood of overall survival when treated with fluorouracil as compared to genotype AA.; 
;CITALOPRAM;COL26A1;rs17135437;T;Toxicity;increased   Side Effect:hearing and vision-related side-effects;Allele T is associated with increased hearing and vision-related side-effects when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;CITALOPRAM;;rs16965962;A;Toxicity;increased   Side Effect:general side-effect burden;Allele A is associated with increased general side-effect burden when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.; 
;ASPIRIN;ACE;rs4292;CC + CT;Toxicity;increased  risk of Side Effect:aspirin intolerance;Genotypes CC + CT are associated with increased risk of aspirin intolerance when exposed to aspirin in people with Asthma as compared to genotype TT.;in people with Disease:Asthma
;CLOPIDOGREL;P2RY12;rs6809699;AA;Efficacy;Efficacy:stronger aggreagtion;Genotype AA is associated with stronger aggreagtion when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.;in people with Disease:Coronary Artery Disease
;ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;rs4982753;T;Toxicity;decreased risk of Side Effect:Cardiotoxicity;Allele T is associated with decreased risk of Cardiotoxicity when exposed to anthracyclines and related substances in people with Hodgkin Disease or Sarcoma as compared to allele C.;in people with Hodgkin Disease, Sarcoma
;TACROLIMUS;CYP3A5;rs776746;T;Toxicity;increased  likelihood of Side Effect:Diabetes Mellitus;Allele T is associated with increased likelihood of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.;in people with Kidney Transplantation
;FLUOROURACIL;DPYD;rs4294451;AT + TT;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotypes AT + TT is associated with decreased likelihood of Drug Toxicity when treated with fluorouracil as compared to genotype AA.; 
;;ACE2;rs2074192;T;Other;increased  severity of Other:COVID-19;Allele T is associated with increased severity of COVID-19 in people with COVID-19 as compared to allele C.;in people with COVID-19
;CLOPIDOGREL;P2RY12;rs6809699;AA;Efficacy;increased  risk of Efficacy:clopidogrel resistance;Genotype AA is associated with increased risk of clopidogrel resistance when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.;in people with Disease:Coronary Artery Disease
;ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;Efficacy;decreased  Efficacy:platelet reactivity;Allele T is associated with decreased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele A.;in people with Transient Ischemic Attack, Stroke
;CLOPIDOGREL;P2RY12;rs6809699;AA;Efficacy;increased  risk of Efficacy:non-response;Genotype AA is associated with increased risk of non-response when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes AC + CC.;in people with Disease:Coronary Artery Disease
;ASPIRIN;P2RY1;rs1065776;CT;Efficacy;increased   Efficacy:net decrease in AA-induced platelet aggregation after aspirin treatment;Genotype CT is associated with increased net decrease in AA-induced platelet aggregation after aspirin treatment when treated with aspirin in healthy individuals as compared to genotype CC.;in healthy individuals 
;MERCAPTOPURINE;ITPA;rs1127354;AC;Metabolism/PK;increased   PK:6-MMPN levels;Genotype AC is associated with increased 6-MMPN levels when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;;FGFR2;rs1219648;G;Toxicity, Other;increased  risk of Disease:Breast Neoplasms;Allele G is associated with increased risk of Breast Neoplasms in women Hodgkin Disease as compared to allele A.;in women Disease:Hodgkin Disease
;ANASTROZOLE;;rs6735923;T;Efficacy;increased  risk of Efficacy:Recurrence;Allele T is associated with increased risk of Recurrence when treated with anastrozole in people with Breast Neoplasms as compared to allele T.;in people with Breast Neoplasms
;ACENOCOUMAROL;CYP2C9;rs1799853;CT + TT;Toxicity;increased  risk of Disease:Gastrointestinal Hemorrhage;Genotypes CT + TT are associated with increased risk of Gastrointestinal Hemorrhage when treated with acenocoumarol as compared to genotype CC.; 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Ischemic Attack, Transient or Stroke as compared to allele G.;in people with Transient Ischemic Attack, Stroke
;ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;rs7319981;A;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Allele A is associated with increased risk of Cardiotoxicity when exposed to anthracyclines and related substances in people with Hodgkin Disease or Sarcoma as compared to allele G.;in people with Hodgkin Disease, Sarcoma
;;AGT;rs699;AG;Other;increased  likelihood of Other:COVID-19;Genotype AG is associated with increased likelihood of COVID-19 as compared to genotype AA.; 
;ANASTROZOLE;;rs1877193;C;Efficacy;increased  risk of Efficacy:Recurrence;Allele C is associated with increased risk of Recurrence when treated with anastrozole in people with Breast Neoplasms as compared to allele T.;in people with Breast Neoplasms
;CAPECITABINE;DPYD;rs2786783;A;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine as compared to allele G.; 
;;COMT;rs4818;CC + CG;Other;increased  severity of Other:Pain;Genotypes CC + CG is associated with increased severity of Pain in children with Dental Caries, Tooth Diseases or Toothache as compared to genotype GG.;in children with Dental Caries, Tooth disorder, Toothache
;DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7662029;G;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele G is associated with increased likelihood of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to allele A.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7439366;C;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele C is associated with increased likelihood of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to allele T.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy, Toxicity;increased   Side Effect:Major Adverse Cardiac Events (MACE);Genotypes AA + AG are associated with increased major adverse cardiac events (mace) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;CEFACLOR;LIMD1;rs62242178;C;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;Allele C is associated with increased likelihood of Drug Hypersensitivity when exposed to cefaclor as compared to allele G.; 
;WARFARIN;VKORC1;rs9923231;TT;Dosage;decreased  Other:warfarin dose;Genotype TT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CT.; 
;CEFACLOR;LIMD1;rs62242177;G;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;Allele G is associated with increased likelihood of Drug Hypersensitivity when exposed to cefaclor as compared to allele T.; 
;REPAGLINIDE;SLCO1B1;rs4149056;CC;Other, Metabolism/PK;increased   PK:mean plasma AUC;Genotype CC is associated with increased mean plasma AUC of repaglinide as compared to genotypes CT + TT.; 
;DIHYDROPYRIDINE DERIVATIVES;ADRA1A;rs1048101;AG + GG;Efficacy;decreased risk of Efficacy:Kidney Disorder;Genotypes AG + GG is associated with decreased risk of Kidney Diseases when treated with Dihydropyridine derivatives as compared to genotype AA.; 
;THALIDOMIDE;XRCC5;rs1051685;AG;Efficacy;increased   Efficacy:overall survival;Genotype AG is associated with increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to genotype AA.;in people with Disease:Multiple Myeloma
;THALIDOMIDE;ERCC1;rs735482;AC + CC;Efficacy;increased   Efficacy:Overall survival;Genotypes AC + CC are associated with increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to genotype AA.;in people with Disease:Multiple Myeloma
;CLOZAPINE, OLANZAPINE;GCG;rs13429709;C;Other;increased   Disease:Weight gain;Allele C is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;CLOZAPINE, OLANZAPINE;GLP1R;rs2268639;T;Other;increased   Disease:Weight gain;Allele T is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;NICOTINE;OPRM1;rs1799971;AA + AG;Dosage;increased   Other:smoking;Genotypes AA + AG are associated with increased smoking due to nicotine in children as compared to genotype GG.;in children 
;NICOTINE;OPRM1;rs1799971;AG + GG;Dosage;increased   Other:smoking;Genotypes AG + GG is associated with increased smoking due to nicotine in children as compared to genotype AA.;in children 
;TOLCAPONE;COMT;rs4680;AA;Efficacy;increased  severity of Efficacy:Alcohol abuse;Genotype AA is associated with increased severity of Alcoholism tolcapone in people with Alcohol-Related Disorders as compared to genotype GG.;in people with Alcohol-Related Disorders
;NICOTINE;UGT2B10;rs112561475;AG + GG;Metabolism/PK;increased   PK:glucuronidation of nicotine;Genotypes AG + GG is associated with increased glucuronidation of nicotine when exposed to nicotine as compared to genotype AA.; 
;NICOTINE;UGT2B10;rs61750900;T;Metabolism/PK;decreased  PK:nicotine glucuronidation;Allele T is associated with decreased nicotine glucuronidation when exposed to nicotine as compared to genotype GG.; 
;CLOZAPINE, OLANZAPINE;GCG;rs13429709;CC;Other;increased   Disease:Weight gain;Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotype TT.;in people with Disease:Schizophrenia
;DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;Efficacy;increased  risk of Efficacy:Kidney Disorder;Genotype TT is associated with increased risk of Kidney Diseases when treated with Dihydropyridine derivatives as compared to genotypes CC + CT.; 
;METHAMPHETAMINE;HTR1A;rs878567;A;Toxicity, Other;Disease:Psychotic Disorder;Allele A is associated with Psychotic Disorders when exposed to methamphetamine in people with Substance-Related Disorders as compared to allele G.;in people with Disease:Substance-Related Disorders
;METHOTREXATE;MTHFR;rs1801133;A;Toxicity;increased  risk of Side Effect:Mucositis;Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Lymphoma, Osteosarcoma, Acute lymphoblastic leukemia
;CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;Efficacy;increased  likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype TT is associated with increased likelihood of overall survival or progression-free survival when treated with cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.;in people with Disease:Hepatocellular Carcinoma
;CAPTOPRIL;ACE;rs4291;AA;Efficacy;decreased severity of Disease:Kidney Failure;Genotype AA is associated with decreased severity of Kidney Failure when treated with captopril in people with Alzheimer Disease as compared to genotypes AT + TT.;in people with Disease:Alzheimer Disease
;ANTIEPILEPTICS;;rs4471527;T;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele T is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with antiepileptics as compared to allele C.; 
;ANTIPSYCHOTICS;LEPR;rs1137101;G;Other;increased  likelihood of Disease:Obesity;Allele G is associated with increased likelihood of Obesity when treated with antipsychotics in women as compared to allele A.;in women 
;ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;A;Toxicity;decreased risk of Side Effect:Cardiotoxicity;Allele A is associated with decreased risk of Cardiotoxicity when exposed to anthracyclines and related substances in people with Hodgkin Disease or Sarcoma.;in people with Hodgkin Disease, Sarcoma
;ETHANOL;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Other:Alcohol abuse;Genotypes AG + GG are associated with increased risk of Alcoholism due to ethanol in children as compared to genotype AA.;in children 
;ANTIEPILEPTICS;;rs77542827;T;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele T is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with antiepileptics as compared to allele G.; 
;STAVUDINE;SAMHD1;rs8124728;A;Toxicity;decreased risk of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with decreased risk of Peripheral Nervous System Diseases due to stavudine in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;CARVEDILOL;ADRB1;rs1801253;CC;Efficacy;decreased  Efficacy:response (heart-rate lowering);Genotype CC is associated with decreased response (heart-rate lowering) when treated with carvedilol in people with Heart Failure as compared to genotypes CG + GG.;in people with Disease:Heart Failure
;IRINOTECAN;TGFB1;rs1800469;AG + GG;Toxicity;increased  risk of Side Effect:Diarrhea;Genotypes AG + GG are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Allele A is associated with increased risk of Cardiotoxicity when exposed to anthracyclines and related substances in people with Hodgkin Disease or Sarcoma as compared to allele G.;in people with Hodgkin Disease, Sarcoma
;CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;rs4643786;CT;Efficacy;increased   Efficacy:Overall survival;Genotype CT is associated with increased overall survival when treated with cytarabine, daunorubicin or mitoxantrone in people with Leukemia, Myeloid, Acute as compared to genotype TT.;in people with Disease:Leukemia, Myeloid, Acute
;ANTIEPILEPTICS;NIPAL2;rs199755581;A;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele A is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with antiepileptics as compared to allele del.; 
;OXALIPLATIN, PACLITAXEL;ABCB1;rs1045642;AA + AG;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with oxaliplatin or paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotype GG.;in people with Breast Neoplasms, Colorectal Neoplasms
;AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;rs4291;AA + AT;Other;decreased  Side Effect:fasting glucose;Genotypes AA + AT are associated with decreased fasting glucose when treated with amlodipine, chlorthalidone or lisinopril in people with Hypertension as compared to genotype TT.;in people with Disease:Hypertension
;SORAFENIB;KDR;rs1870377;T;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Allele T is associated with increased risk of hand-foot syndrome when treated with sorafenib as compared to genotype AA.; 
;IRINOTECAN;TGFBR2;rs3087465;GG;Toxicity;increased  risk of Side Effect:Diarrhea;Genotype GG are associated with increased risk of Diarrhea when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;SORAFENIB;KDR;rs1870377;T;Toxicity;increased  risk of Side Effect:Hypertension;Allele T is associated with increased risk of Hypertension when treated with sorafenib as compared to genotype AA.; 
;SUNITINIB;FLT4;rs307826;CT;Efficacy;Efficacy:reduced progression-free survival;Genotype CT is associated with reduced progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.;in people with Disease:Renal Cell Carcinoma
;SUNITINIB;CYP3A5;rs776746;TT;Toxicity;increased  risk of Side Effect:dose reductions due to toxicity;Genotype TT is associated with increased risk of dose reductions due to toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Disease:Renal Cell Carcinoma
;RITODRINE;PDE4B;rs17128809;AA;Toxicity;increased  risk of Side Effect:adverse events;Genotype AA is associated with increased risk of adverse events when treated with ritodrine as compared to genotypes AT + TT.; 
;CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;rs246221;CC;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype CC is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Breast Neoplasms
;SUNITINIB;FLT4;rs307821;AC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AC is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;Efficacy;increased  risk of Efficacy:Heart transplantation, Efficacy:Death;Genotypes AG + GG is associated with increased risk of heart transplantation or Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotype AA.;in people with Heart Failure
;SALBUTAMOL;;rs9552679;C;Efficacy;decreased  Efficacy:bronchodilator response (FEV1);Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T.;in Disease:Asthma
;SALBUTAMOL;COL22A1;rs6988229;T;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;SALBUTAMOL;;rs17495520;T;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;ASPIRIN, CLOPIDOGREL;CDH15;rs72819363;C;Efficacy;increased  likelihood of Efficacy:Coronary Restenosis, Efficacy:Disease Progression;Allele C is associated with increased likelihood of Coronary Restenosis or Disease Progression when treated with aspirin and clopidogrel in people with Coronary Disease as compared to allele A.;in people with Coronary Disease
;ANTIEPILEPTICS;DDX12P;rs77491650;C;Toxicity;decreased likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with decreased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with antiepileptics as compared to allele G.; 
;SALBUTAMOL;;rs1663332;T;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;SALBUTAMOL;;rs1663330;G;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele G is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele A.;in Disease:Asthma
;SALBUTAMOL;;rs17701271;A;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;SALBUTAMOL;;rs518350;T;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;SALBUTAMOL;;rs10511905;G;Efficacy;decreased  Efficacy:bronchodilator response (FEV1);Allele G is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele A.;in Disease:Asthma
;SORAFENIB;ABCC2;rs717620;CC;Toxicity;increased  risk of Side Effect:Exanthema;Genotype CC is associated with increased risk of Exanthema when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CT.;in people with Disease:Renal Cell Carcinoma
;SALBUTAMOL;CLOCK;rs1522113;A;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.;in Disease:Asthma
;SALBUTAMOL;;rs1423515;A;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.;in Disease:Asthma
;SALBUTAMOL;;rs1419555;T;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele T is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele C.;in Disease:Asthma
;SALBUTAMOL;;rs6002674;C;Efficacy;decreased  Efficacy:bronchodilator response (FEV1);Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T.;in Disease:Asthma
;;ACE2;rs2106809;A;Other;increased  likelihood of Other:COVID-19;Allele A is associated with increased likelihood of COVID-19 in men with COVID-19 as compared to allele G.;in men with COVID-19
;DOXORUBICIN;GSTP1;rs1695;AG + GG;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotypes AG + GG is associated with increased likelihood of mucositis when treated with doxorubicin in women with Breast Neoplasms as compared to genotype AA.;in women with Breast Neoplasms
;METHOTREXATE;ABCB1;rs1045642;A;Toxicity;increased  risk of Side Effect:Mucositis;Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Lymphoma, Osteosarcoma, Acute lymphoblastic leukemia
;ASPIRIN, CLOPIDOGREL;CDH13;rs11859453;AA + AG;Efficacy;decreased likelihood of Efficacy:Coronary Restenosis, Efficacy:Disease Progression;Genotypes AA + AG is associated with decreased likelihood of Coronary Restenosis or Disease Progression when treated with aspirin and clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Coronary Disease
;ALLOPURINOL;CYCSP5;rs3099844;A;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol as compared to allele C.; 
;ALLOPURINOL;;rs1634776;T;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;Allele T is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol as compared to allele C.; 
;PACLITAXEL;ABCB1;rs1128503;AA + AG;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel in people with Breast Neoplasms or Colorectal Neoplasms as compared to genotype GG.;in people with Breast Neoplasms, Colorectal Neoplasms
;SALBUTAMOL;;rs11252394;A;Efficacy;increased   Efficacy:bronchodilator response (FEV1);Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G.;in Disease:Asthma
;SORAFENIB;SLCO1B1;rs4149056;CT + TT;Toxicity;increased  likelihood of Side Effect:Thrombocytopenia;Genotypes CT + TT are associated with increased likelihood of Thrombocytopenia when treated with sorafenib as compared to genotype CC.; 
;COCAINE;GABRA2;rs11503014;G;Toxicity;increased  severity of Other:Cocaine dependence;Allele G is associated with increased severity of Cocaine-Related Disorders due to cocaine as compared to allele C.; 
;COCAINE;OPRM1;rs2236256;C;Toxicity;decreased severity of Other:Cocaine dependence;Allele C is associated with decreased severity of Cocaine-Related Disorders due to cocaine as compared to allele A.; 
;SORAFENIB;SLCO1B1;rs2306283;AG + GG;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Genotypes AG + GG are associated with increased likelihood of Hyperbilirubinemia when treated with sorafenib as compared to genotype AA.; 
;SORAFENIB;SLCO1B1;rs2306283;AG + GG;Toxicity;decreased likelihood of Side Effect:Diarrhea;Genotypes AG + GG are associated with decreased likelihood of Diarrhea when treated with sorafenib as compared to genotype AA.; 
;METHOTREXATE;ABCB1;rs1128503;A;Toxicity;increased  risk of Side Effect:Mucositis;Allele A is associated with increased risk of mucositis when treated with methotrexate in children with Lymphoma, Osteosarcoma or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Lymphoma, Osteosarcoma, Acute lymphoblastic leukemia
;;AGT;rs699;A;Other;decreased severity of Other:COVID-19;Allele A is associated with decreased severity of COVID-19 in people with COVID-19 as compared to allele G.;in people with COVID-19
;CANGRELOR;P2RY12;rs9859552;TT;Other;Other:20% and 17% less inhibition of platelet aggregation with crangrelor (0.05 and 0.25 microM) in-vitro;Genotype TT is associated with 20% and 17% less inhibition of platelet aggregation with crangrelor (0.05 and 0.25 microM) in-vitro when exposed to cangrelor as compared to genotype GG.; 
;SORAFENIB;NOS3;rs2070744;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.;in people with Disease:Hepatocellular Carcinoma
;RADIOTHERAPY;TANC1;rs10497203;C;Toxicity;increased  risk of Side Effect:toxicity;Allele C is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele A.;in men with Disease:Prostatic Neoplasms
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Disease:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with azathioprine and mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;SORAFENIB;NOS3;rs1799983;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;NOS3;rs1799983;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes GT + TT.;in people with Disease:Hepatocellular Carcinoma
;GLUCOCORTICOIDS;GLCCI1;rs37973;GG;Efficacy;increased  likelihood of Efficacy:poor response;Genotype GG is associated with increased likelihood of poor response when treated with glucocorticoids in people with Asthma as compared to genotype AA.;in people with Disease:Asthma
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;Efficacy;increased   Efficacy:tumor response rate;Allele A is associated with increased tumor response rate when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;SORAFENIB;NOS3;rs2070744;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.;in people with Disease:Hepatocellular Carcinoma
;AZATHIOPRINE;NUDT15;rs116855232;T;Toxicity;decreased  Side Effect:interval of therapy to leukopenia onset;Allele T is associated with decreased interval of therapy to leukopenia onset when treated with azathioprine in people with Leukopenia as compared to allele C.;in people with Disease:Leukopenia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;rs3087243;AG + GG;Toxicity;decreased risk of Side Effect:Psoriasis;Genotypes AG + GG is associated with decreased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype AA.;in people with Disease:Psoriasis
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased  Other:warfarin dose;Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Disease:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with azathioprine and mercaptopurine in people with Crohn Disease as compared to allele C.;in people with Disease:Crohn Disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;rs10782001;GG;Toxicity;increased  risk of Side Effect:Psoriasis;Genotype GG is associated with increased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AA + AG.;in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;rs11209026;AG;Toxicity;increased  risk of Side Effect:Psoriasis;Genotype AG is associated with increased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype GG.;in people with Disease:Psoriasis
;AZATHIOPRINE;NUDT15;rs116855232;TT;Toxicity;increased  severity of Disease:Leukopenia;Genotype TT is associated with increased severity of Leukopenia when treated with azathioprine in people with Crohn Disease as compared to genotype CC.;in people with Disease:Crohn Disease
;METHOTREXATE;MTHFR;rs1801133;A;Metabolism/PK;increased  risk of PK:prolonged high concentrations;Allele A is associated with increased risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele G.;in children with Disease:Leukemia
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased  Other:warfarin dose;Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;ETHANOL;OPRM1;rs1799971;G;Toxicity;increased  risk of Disease:Alcohol abuse;Allele G is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele A.; 
;MORPHINE;ABCB1;rs2032582;CC;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotype CC is associated with decreased likelihood of Nausea and Vomiting due to morphine in people with Pain, Postoperative.;in people with Disease:Pain, Postoperative
;COLISTIMETHATE;SLC15A2;rs2257212;T;Toxicity;increased  likelihood of Side Effect:Nephrotoxicity;Allele T is associated with increased likelihood of nephrotoxicity when treated with colistimethate in people with Bacterial Infections as compared to allele C.;in people with Bacterial Infections
;HEROIN;OPRM1;rs1799971;G;Toxicity;increased  risk of Disease:Heroin Dependence;Allele G is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele A.; 
;ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801133;AA + AG;Toxicity;increased  severity of Side Effect:Folic Acid Deficiency Anemia;Genotypes AA + AG is associated with increased severity of Folic Acid Deficiency when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801131;GT + TT;Toxicity;increased  risk of Side Effect:Mucositis;Genotypes GT + TT is associated with increased risk of mucositis when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;WARFARIN;GGCX;rs699664;CT + TT;Dosage;decreased  Other:warfarin dose;Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.; 
;CETUXIMAB;FCGR3A;rs396991;A;Efficacy;increased   Efficacy:overall survival and progression-free survival;Allele A is associated with increased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;WARFARIN;CYP2C9;rs28371685;CT;Dosage;decreased  Other:warfarin dose;Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.; 
;CETUXIMAB;CCND1;rs9344;G;Efficacy;decreased  Efficacy:overall survival and progression-free survival;Allele G is associated with decreased overall survival and progression-free survival when treated with cetuximab in people with Colorectal Neoplasms as compared to allele A.;in people with Disease:Colorectal Neoplasms
;WARFARIN;F7;rs510335;GT + TT;Dosage;decreased  Other:warfarin dose;Genotypes GT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype GG.; 
;TACROLIMUS;IL10;rs1800871;AA;Efficacy;increased  likelihood of Efficacy:Transplant rejection;Genotype AA is associated with increased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;ESCITALOPRAM;HTR1B;rs11568817;AC + CC;Toxicity;increased  risk of Side Effect:adverse cognitive effects;Genotypes AC + CC is associated with increased risk of adverse cognitive effects when treated with escitalopram in people with Anxiety Disorders as compared to genotype AA.;in people with Disease:Anxiety Disorders
;CETUXIMAB;CCND1;rs9344;AA;Efficacy;decreased  Efficacy:survival;Genotype AA is associated with decreased survival when treated with cetuximab in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;decreased risk of Side Effect:adverse events;Genotype TT is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Rheumatoid arthritis
;FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;rs1160351;A;Toxicity;increased  risk of Side Effect:sexsual dysfunction;Allele A is associated with increased risk of sexsual dysfunction when treated with fluvoxamine, milnacipran or paroxetine in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;rs429358;CC + CT;Toxicity;increased   Side Effect:non-HDL cholesterol;Genotypes CC + CT are associated with increased non-HDL cholesterol when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;ESCITALOPRAM;HTR2A;rs6311;CT + TT;Toxicity;increased  risk of Side Effect:adverse cognitive effects;Genotypes CT + TT is associated with increased risk of adverse cognitive effects when treated with escitalopram in people with Anxiety Disorders as compared to genotype CC.;in people with Disease:Anxiety Disorders
;TACROLIMUS;IL10;rs1800872;TT;Efficacy;increased  likelihood of Efficacy:Transplant rejection;Genotype TT is associated with increased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;;;rs17234657;G;;increased  risk of Disease:Crohn Disease;Allele G is associated with increased risk of Crohn Disease.; 
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased   Other:warfarin dose;Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.; 
;LEVODOPA;HOMER1;rs4704559;AG + GG;Toxicity;decreased risk of Disease:Dyskinesias;Genotypes AG + GG is associated with decreased risk of Dyskinesias when treated with levodopa in people with Parkinson Disease as compared to genotype AA.;in people with Disease:Parkinson Disease
;CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;rs4880;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes AG + GG is associated with increased likelihood of drug-induced liver injury when treated with cyclophosphamide, docetaxel and epirubicin in women with Breast Neoplasms as compared to genotype AA.;in women with Breast Neoplasms
;LEVODOPA;HOMER1;rs4704559;AG + GG;Toxicity;decreased risk of Disease:Hallucinations;Genotypes AG + GG is associated with decreased risk of Hallucinations when treated with levodopa in people with Parkinson Disease as compared to genotype AA.;in people with Disease:Parkinson Disease
;;;rs2200733;T;;increased  risk of Disease:Atrial Fibrillation;Allele T is associated with increased risk of Atrial Fibrillation.; 
;ESTRADIOL;NFE2L2;rs6721961;T;Toxicity;increased  risk of Disease:Venous thromboembolism;Allele T is associated with increased risk of venous thromboembolism when treated with estradiol as compared to genotype CC.; 
;HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;Efficacy;increased   Efficacy:reduction in blood pressure;Genotype CC is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotypes CT + TT.;in people with Disease:Hypertension
;CAPECITABINE;DPYD;rs3918290;CT;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;WARFARIN;F2;rs5896;CT + TT;Dosage;decreased  Other:warfarin dose;Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.; 
;;HLA-DRA;rs3135388;A;;increased  risk of Disease:Multiple Sclerosis;Allele A is associated with increased risk of Multiple Sclerosis.; 
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in women with Lymphoma, Non-Hodgkin as compared to genotypes CC + CT.;in women with Non-Hodgkin Lymphoma
;;NOD2;rs17221417;G;;increased  risk of Disease:Crohn Disease;Allele G is associated with increased risk of Crohn Disease.; 
;CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;Efficacy;decreased  Efficacy:one year progression free survival;Genotypes CG + GG are associated with decreased one year progression free survival when treated with cisplatin and paclitaxel in people with Stomach Neoplasms as compared to genotype GG.;in people with Disease:Stomach Neoplasms
;AZATHIOPRINE;ITPA;rs1127354;AC;Toxicity;increased  likelihood of Side Effect:flu-like symptoms;Genotype AC is associated with increased likelihood of flu-like symptoms when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Disease:Inflammatory Bowel Diseases
;CLOPIDOGREL;CES1;rs71647871;CT;PD;increased  likelihood of Efficacy:platelet reactivity;Genotype CT is associated with increased likelihood of platelet reactivity when treated with clopidogrel as compared to genotype CC.; 
;;TCF7L2;rs12255372;T;;increased  risk of Disease:Diabetes Mellitus, Type 2;Allele T is associated with increased risk of Diabetes Mellitus, Type 2.; 
;;IL6;rs1800797;AG + GG;Other;increased  severity of Other:Pain;Genotypes AG + GG is associated with increased severity of Pain in children with Neoplasms as compared to genotype AA.;in children with Neoplasms
;;TCF7L2;rs12243326;C;;increased  risk of Disease:Diabetes Mellitus, Type 2;Allele C is associated with increased risk of Diabetes Mellitus, Type 2.; 
;;TCF7L2;rs4506565;T;;increased  risk of Disease:Diabetes Mellitus, Type 2;Allele T is associated with increased risk of Diabetes Mellitus, Type 2.; 
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased  Other:warfarin dose;Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.; 
;ETHANOL;ADH1B;rs1229984;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;WARFARIN;VKORC1;rs9934438;AG;Dosage;increased   Other:warfarin dose;Genotype AG is associated with increased warfarin dose when treated with warfarin as compared to genotype AA.; 
;;CDKN2B-AS1;rs10965219;G;Other;increased   Other:platelet reactivity;Allele G is associated with increased platelet reactivity.; 
;MORPHINE;COMT;rs4680;AA;Efficacy;increased   Efficacy:numerical rating scale (NRS) score for pain during painful procedure;Genotype AA is associated with increased numerical rating scale (NRS) score for pain during painful procedure when treated with morphine as compared to genotype GG.; 
;ETHANOL;RABGAP1L;rs61826952;G;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele G is associated with decreased risk of Alcoholism due to ethanol as compared to allele A.; 
;MORPHINE;COMT;rs4680;AA;Efficacy;increased   Efficacy:overall mean numerical rating scale (NRS) score for pain;Genotype AA is associated with increased overall mean numerical rating scale (NRS) score for pain when treated with morphine as compared to genotype GG.; 
;;CDKN2B-AS1;rs10965219;G;Other;increased  risk of Disease:Coronary Artery Disease;Allele G is associated with increased risk of Coronary Artery Disease.; 
;TRAMADOL;CYP2D6;rs1058172;CC;Toxicity;increased  likelihood of Side Effect:Overdose;Genotype CC is associated with increased likelihood of Overdose when treated with tramadol in people with Death as compared to genotype CT.;in people with Death
;CLOZAPINE;CYP2D6;rs16947;GG;Toxicity;increased  severity of Side Effect:Leukopenia;Genotype GG is associated with increased severity of Leukopenia when treated with clozapine in people with Schizophrenia as compared to genotypes AA + AG.;in people with Schizophrenia
;TRAMADOL;CYP2B6;rs4803419;CC;Toxicity;increased  likelihood of Side Effect:Overdose;Genotype CC is associated with increased likelihood of Overdose when treated with tramadol in people with Death as compared to genotype CT.;in people with Death
;;ACE2;rs4240157;CC;Other;increased  risk of Other:Death;Genotype CC is associated with increased risk of Death in people with COVID-19 as compared to genotypes CT + TT.;in people with COVID-19
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:dose-adjusted trough concentrations;Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased  PK:dose-adjusted trough concentrations;Genotypes CT + TT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;;ACE2;rs4240157;C;Other;increased  likelihood of Other:COVID-19;Allele C is associated with increased likelihood of COVID-19 in people with as compared to allele T.;in people with 
;CLOZAPINE;CYP2D6;rs1065852;AA;Toxicity;increased  severity of Side Effect:Elevated circulating creatine kinase concentration, Side Effect:Elevated liver enzymes;Genotype AA is associated with increased severity of increased creatine kinase level and elevated liver enzymes when treated with clozapine in people with Schizophrenia as compared to genotypes AG + GG.;in people with Schizophrenia
;CLOZAPINE;CYP2D6;rs1065852;AA;Toxicity;increased  severity of Side Effect:Leukopenia;Genotype AA is associated with increased severity of Leukopenia when treated with clozapine in people with Schizophrenia as compared to genotypes AG + GG.;in people with Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:concentration-to-adjusted dose ratio;Genotype CC is associated with increased concentration-to-adjusted dose ratio of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;increased  likelihood of Side Effect:Mucositis, Side Effect:Neutropenia, Side Effect:Pancreatitis, Side Effect:Vomiting;Genotype TT is associated with increased likelihood of mucositis, Neutropenia, Pancreatitis or Vomiting when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;CLOZAPINE;CYP2D6;rs16947;GG;Toxicity;increased  severity of Side Effect:Elevated circulating creatine kinase concentration, Side Effect:Elevated liver enzymes;Genotype GG is associated with increased severity of increased creatine kinase level and elevated liver enzymes when treated with clozapine in people with Schizophrenia as compared to genotypes AA + AG.;in people with Schizophrenia
;HMG COA REDUCTASE INHIBITORS;COQ5;rs10849757;AA + AG;Efficacy;increased  likelihood of Side Effect:statin-related myopathy;Genotypes AA + AG is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotype GG.;in people with Stroke
;AZATHIOPRINE;ITPA;rs1127354;AC;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotype AC is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Inflammatory Bowel Diseases
;ZOLEDRONATE;FDPS;rs2297480;TT;Toxicity;increased  likelihood of Side Effect:osteonecrosis;Genotype TT is associated with increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;HMG COA REDUCTASE INHIBITORS;COQ3;rs11548336;TT;Efficacy;increased  likelihood of Side Effect:statin-related myopathy;Genotype TT is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotypes CC + CT.;in people with Stroke
;IMATINIB;CYP2B6;rs3745274;GG;Toxicity;increased  risk of Side Effect:side effects;Genotype GG is associated with increased risk of side effects when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes GT + TT.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;CG + GG;Efficacy;increased  likelihood of Side Effect:statin-related myopathy;Genotypes CG + GG is associated with increased likelihood of statin-related myopathy when treated with hmg coa reductase inhibitors in people with Stroke as compared to genotype CC.;in people with Stroke
;CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;CT + TT;Efficacy;decreased  Efficacy:survival;Genotypes CT + TT are associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes AC + CC.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3211371;T;Toxicity;increased  likelihood of Side Effect:dose delay;Allele T is associated with increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;rs8014194;A;Efficacy;Efficacy:change in total cholesterol;Allele A is associated with change in total cholesterol when treated with atorvastatin, pravastatin or simvastatin.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs12721655;AG;Efficacy;decreased  Efficacy:survival;Genotype AG is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA.;in women with Disease:Breast Neoplasms
;NINTEDANIB;DSP;rs2076295;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with nintedanib in people with Pulmonary Fibrosis as compared to genotypes GG + GT.;in people with Pulmonary Fibrosis
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;decreased  Other:warfarin dose;Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;CT;Efficacy;decreased  Efficacy:time to progression;Genotype CT is associated with decreased time to progression when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;FLUOROURACIL, LEUCOVORIN;MTHFR;rs1801133;GG;Toxicity;decreased severity of Disease:Drug Toxicity;Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;WARFARIN;F2;rs5896;CT + TT;Dosage;decreased  Other:warfarin dose;Genotypes CT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.; 
;BUSULFAN;CYP2C19;rs12248560;CC;Metabolism/PK;increased   PK:metabolic ratio;Genotype CC is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to genotypes CT + TT.;in children with Disease:hemopoietic stem cell transplant
;CAPECITABINE;MTHFR;rs1801131;TT;Toxicity;decreased  Disease:Drug Toxicity;Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT.;in people with Disease:Colorectal Neoplasms
;WARFARIN;F7;rs510317;GG;Dosage;decreased  Other:warfarin dose;Genotype GG is associated with decreased warfarin dose when treated with warfarin as compared to genotype AA.; 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;rs1135216;CT;Toxicity;decreased risk of Side Effect:Psoriasis;Genotype CT is associated with decreased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype TT.;in people with Disease:Psoriasis
;OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;rs1800497;AA;Toxicity;increased  risk of Disease:Headache;Genotype AA is associated with increased risk of Headache when treated with olanzapine, quetiapine or risperidone in healthy individuals as compared to genotype GG.;in healthy individuals 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;rs651630;AA;Toxicity;decreased risk of Side Effect:Psoriasis;Genotype AA is associated with decreased risk of Psoriasis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG.;in people with Disease:Psoriasis
;RADIOTHERAPY;TANC1;rs264588;A;Toxicity;increased  risk of Side Effect:toxicity;Allele A is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.;in men with Disease:Prostatic Neoplasms
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity, Metabolism/PK;increased   PK:plasma concentration;Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;RADIOTHERAPY;TANC1;rs264631;G;Toxicity;increased  risk of Side Effect:toxicity;Allele G is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.;in men with Disease:Prostatic Neoplasms
;BUSULFAN;CYP2C9;rs1799853;CT + TT;Metabolism/PK;increased   PK:metabolic ratio;Genotypes CT + TT is associated with increased metabolic ratio of busulfan in children with hemopoietic stem cell transplant as compared to genotype CC.;in children with Disease:hemopoietic stem cell transplant
;CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;C;Toxicity;decreased likelihood of Side Effect:dose delay;Allele C is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women Breast Neoplasms as compared to allele T.;in women Disease:Breast Neoplasms
;RADIOTHERAPY;TANC1;rs7582141;T;Toxicity;increased  risk of Side Effect:toxicity;Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele G.;in men with Disease:Prostatic Neoplasms
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;Toxicity;increased  risk of Side Effect:grade 3-4 nonhematological toxicity;Allele A is associated with increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;RADIOTHERAPY;TANC1;rs6432512;T;Toxicity;increased  risk of Side Effect:toxicity;Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.;in men with Disease:Prostatic Neoplasms
;RADIOTHERAPY;TANC1;rs264663;T;Toxicity;increased  risk of Side Effect:toxicity;Allele T is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele C.;in men with Disease:Prostatic Neoplasms
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;rs2032582;CC;Efficacy;Efficacy:overall survival;Genotype CC is associated with overall survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colorectal Neoplasms
;RADIOTHERAPY;TANC1;rs264651;G;Toxicity;increased  risk of Side Effect:toxicity;Allele G is associated with increased risk of toxicity when treated with radiotherapy in men with Prostatic Neoplasms as compared to allele A.;in men with Disease:Prostatic Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3745274;T;Toxicity;decreased likelihood of Side Effect:dose reduction;Allele T is associated with decreased likelihood of dose reduction when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;T;Toxicity;increased  likelihood of Side Effect:dose delay;Allele T is associated with increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;Toxicity;decreased risk of Side Effect:Gastrointestinal toxicity, Side Effect:Hematologic Disorder, Side Effect:Leukopenia;Genotypes AA + AG are associated with decreased risk of gastrointestinal toxicity, Hematologic Diseases and Leukopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;SECUKINUMAB;ERAP2;rs2248374;GG;Efficacy;increased  likelihood of Efficacy:Treatment failure;Genotype GG is associated with increased likelihood of treatment failure when treated with secukinumab in people with Psoriasis as compared to genotypes AA + AG.;in people with Psoriasis
;CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs12210538;G;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs723685;G;Toxicity;decreased likelihood of Side Effect:dose delay;Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs6907567;G;Toxicity;decreased likelihood of Side Effect:dose delay;Allele G is associated with decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;ASPIRIN;LTC4S;rs730012;C;Toxicity;increased  risk of Side Effect:Urticaria;Allele C is associated with increased risk of Urticaria when treated with aspirin.; 
;ATORVASTATIN, ROSUVASTATIN;COQ2;rs4693075;G;Toxicity;increased  risk of Disease:Muscular Diseases;Allele G is associated with increased risk of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Hyperlipoproteinemia Type II as compared to allele C.;in people with Disease:Hyperlipoproteinemia Type II
;ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;rs35719165;A;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele A is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele G.; 
;METHOTREXATE;MTHFD1;rs2236225;AA + AG;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotypes AA + AG are associated with decreased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;WARFARIN;VKORC1;rs2884737;CC;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype CC is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype AA.; 
;EFAVIRENZ, NELFINAVIR;ABCB1;rs1045642;AA;Efficacy, Other;increased   Efficacy:rise in CD4-cell count;Genotype AA is associated with increased rise in CD4-cell count when treated with efavirenz or nelfinavir in people with HIV Infections as compared to genotypes AG + GG.;in people with Disease:HIV infectious disease
;EFAVIRENZ;ABCB1;rs1045642;AA;Efficacy;increased  likelihood of Efficacy:favorable virologic responses;Genotype AA is associated with increased likelihood of favorable virologic responses when treated with efavirenz in people with HIV as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;rs1862167;T;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele T is associated with increased likelihood of Drug-induced liver injury when treated with atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab or pembrolizumab as compared to allele C.; 
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:trough concentration;Genotype CC is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:trough concentrations;Genotype CC is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;DOXORUBICIN;ABCC2;rs17222723;A;Toxicity, Metabolism/PK;increased  risk of Side Effect:cardiotoxicity;Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele T.;in people with Disease:Non-Hodgkin Lymphoma
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2032583;AG + GG;Efficacy;increased  likelihood of Efficacy:remission;Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.;in people with Disease:Depression
;AZATHIOPRINE;XDH;rs2295475;AA + AG;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Genotypes AA + AG is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases, Lupus Erythematosus, Systemic or Neuromyelitis Optica as compared to genotype GG.;in people with Inflammatory Bowel Diseases, Systemic lupus erythematosus, Neuromyelitis Optica
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Genotypes CT + TT is associated with increased likelihood of Myelosuppression when treated with azathioprine in people with Inflammatory Bowel Diseases, Lupus Erythematosus, Systemic or Neuromyelitis Optica as compared to genotype CC.;in people with Inflammatory Bowel Diseases, Systemic lupus erythematosus, Neuromyelitis Optica
;;ATP8B3;rs10421558;G;Toxicity;decreased likelihood of Other:Aspirin-induced asthma;Allele G is associated with decreased likelihood of aspirin-induced asthma in people with Asthma as compared to allele A.;in people with Asthma
;;ABCB1;rs1045642;AA;Other;increased  likelihood of Disease:Breast Neoplasms;Genotype AA is associated with increased likelihood of Breast Neoplasms.; 
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;T;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;Allele A is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ANTHRACYCLINES AND RELATED SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;rs1045642;GG;Efficacy;increased   Efficacy:time to progression;Genotype GG is associated with increased time to progression when treated with anthracyclines and related substances, doxorubicin and epirubicin in people with Breast Neoplasms as compared to genotypes AA + AG.;in people with Disease:Breast Neoplasms
;RITONAVIR;APOC3;rs2854117;T;Toxicity;increased  risk of Disease:Hypertriglyceridemia;Allele T is associated with increased risk of Hypertriglyceridemia when treated with ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;;AGTR1;rs5186;CC;Other;increased  risk of Disease:Ischemia;Genotype CC is associated with increased risk of Ischemia in people with Coronary Artery Disease as compared to genotypes AA + AC.;in people with Disease:Coronary Artery Disease
;IMATINIB;ARID5B;rs10821936;TT;Efficacy;increased  likelihood of Efficacy:Treatment failure;Genotype TT is associated with increased likelihood of treatment failure when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CT.;in people with Chronic myelogenous leukemia, BCR-ABL1 positive
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;T;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1801280;C;Toxicity, Metabolism/PK;increased  risk of Disease:Toxic liver disease;Allele C is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;FEXOFENADINE;ABCB1;rs1045642;AA;Dosage, Metabolism/PK;decreased  PK:plasma concentration;Genotype AA is associated with decreased plasma concentration of fexofenadine in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;EFAVIRENZ;CYP2B6;rs28399499;C;Metabolism/PK;increased   PK:plasma Cmin values;Allele C is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele T.;in Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs4803419;T;Metabolism/PK;increased   PK:plasma Cmin values;Allele T is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele C.;in Disease:HIV infectious disease
;IMATINIB;ATIC;rs2372536;G;Efficacy;increased  likelihood of Efficacy:Treatment failure;Allele G is associated with increased likelihood of treatment failure when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CC + CG.;in people with Chronic myelogenous leukemia, BCR-ABL1 positive
;ATORVASTATIN, SIMVASTATIN;CYP3A4;rs2740574;CC + CT;Other;decreased risk of Other:dose decrease or drug switching;Genotypes CC + CT are associated with decreased risk of dose decrease or drug switching when treated with atorvastatin or simvastatin as compared to genotype TT.; 
;FEXOFENADINE;ABCB1;rs2032582;AA;Dosage, Metabolism/PK;decreased  PK:plasma concentration;Genotype AA is associated with decreased plasma concentration of fexofenadine in healthy individuals as compared to genotypes AC + CC.;in healthy individuals 
;RITODRINE;KCNMB2;rs7625907;GG;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype GG is associated with decreased likelihood of Drug Toxicity when treated with ritodrine as compared to allele A.; 
;EFAVIRENZ;CYP2B6;rs3745274;T;Metabolism/PK;increased   PK:plasma Cmin values;Allele T is associated with increased plasma Cmin values when treated with efavirenz in HIV Infections as compared to allele G.;in Disease:HIV infectious disease
;DOXORUBICIN;ABCC1;rs45511401;T;Toxicity, Metabolism/PK;increased  risk of Side Effect:cardiotoxicity;Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.;in people with Disease:Non-Hodgkin Lymphoma
;DOXORUBICIN;ABCC2;rs8187710;A;Toxicity, Metabolism/PK;increased  risk of Side Effect:cardiotoxicity;Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.;in people with Disease:Non-Hodgkin Lymphoma
;CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;rs4939827;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with capecitabine, FOLFOX or tegafur in people with Colorectal Neoplasms as compared to allele A.;in people with Colorectal Neoplasms
;DOXORUBICIN;NCF4;rs1883112;AA;Toxicity;increased  risk of Side Effect:cardiotoxicity;Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.;in people with Disease:Non-Hodgkin Lymphoma
;;ATP8B3;rs10403288;A;Toxicity;decreased likelihood of Other:Aspirin-induced asthma;Allele A is associated with decreased likelihood of aspirin-induced asthma in people with Asthma as compared to allele G.;in people with Asthma
;SIMVASTATIN;ABCB1;rs1128503;A;Efficacy;decreased risk of Side Effect:Myalgia;Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.;in people with Disease:Hypercholesterolemia
;;ACE2;rs2074192;T;Other;increased  severity of Other:COVID-19;Allele T is associated with increased severity of COVID-19 as compared to allele C.; 
;DOXORUBICIN;CYBA;rs4673;A;Toxicity;increased  risk of Side Effect:cardiotoxicity;Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele G.;in people with Disease:Non-Hodgkin Lymphoma
;SIMVASTATIN;ABCB1;rs1045642;A;Efficacy;decreased risk of Side Effect:Myalgia;Allele A is associated with decreased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia as compared to allele G.;in people with Disease:Hypercholesterolemia
;DOXORUBICIN;RAC2;rs13058338;T;Toxicity;increased  risk of Side Effect:cardiotoxicity;Allele T is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to allele A.;in people with Disease:Non-Hodgkin Lymphoma
;SIMVASTATIN;ABCB1;rs2032582;C;Efficacy;increased  risk of Side Effect:Myalgia;Allele C is associated with increased risk of Myalgia when treated with simvastatin in people with Hypercholesterolemia.;in people with Disease:Hypercholesterolemia
;;ABO;rs8176746;T;;increased   Other:ACE activity;Allele T is associated with increased ACE activity in people with Hypertension.;in people with Disease:Hypertension
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased  PK:concentration-to-adjusted dose ratio;Genotypes CT + TT is associated with decreased concentration-to-adjusted dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.;in people with Disease:Liver transplantation
;ATORVASTATIN, SIMVASTATIN;PON1;rs705379;AA + AG;Efficacy;Efficacy:change in HDL-cholesterol;Genotypes AA + AG are associated with change in HDL-cholesterol when treated with atorvastatin or simvastatin in people with Hypercholesterolemia.;in people with Disease:Hypercholesterolemia
;ATORVASTATIN, SIMVASTATIN;PON1;rs662;CC + CT;Efficacy;Efficacy:change in HDL-cholesterol;Genotypes CC + CT are associated with change in HDL-cholesterol when treated with atorvastatin or simvastatin in people with Hypercholesterolemia.;in people with Disease:Hypercholesterolemia
;ATORVASTATIN;PON1;rs705379;GG;Other;decreased  Other:oxidative stress;Genotype GG is associated with decreased oxidative stress when treated with atorvastatin in people with Hypercholesterolemia as compared to genotype AA.;in people with Disease:Hypercholesterolemia
;CLOZAPINE;TACR1;rs58933792;C;Toxicity;increased  likelihood of Side Effect:Dry mouth;Allele C is associated with increased likelihood of dry mouth when treated with clozapine as compared to allele A.; 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Metabolism/PK;decreased  PK:concentration/dose ratio;Genotypes CT + TT is associated with decreased concentration/dose ratio of tacrolimus in people with liver transplantation as compared to genotype CC.;in people with Disease:Liver transplantation
;FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased  PK:time to reach stable dose of tacrolimus;Genotype CC is associated with decreased time to reach stable dose of tacrolimus when treated with fluconazole and tacrolimus in children with Transplantation.;in children with Disease:Transplantation
;FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;Dosage;decreased  PK:dose of tacrolimus;Genotype CC is associated with decreased dose of tacrolimus when treated with fluconazole and tacrolimus in children with Transplantation.;in children with Disease:Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Dosage;increased   PK:time to reach stable dose;Genotypes CT + TT are associated with increased time to reach stable dose of tacrolimus in children with Transplantation as compared to genotype CC.;in children with Disease:Transplantation
;TAMOXIFEN;SLCO1A2;rs10841795;AG + GG;Toxicity;decreased severity of Side Effect:Dizziness;Genotypes AG + GG is associated with decreased severity of Dizziness when treated with tamoxifen in women with Breast Neoplasms as compared to genotype AA.;in women with Breast Neoplasms
;CLOZAPINE;ERBB4;rs3942465;C;Toxicity;increased  likelihood of Side Effect:Dry mouth;Allele C is associated with increased likelihood of dry mouth when treated with clozapine as compared to allele T.; 
;DIAZEPAM;CYP2C19;rs4244285;AA + AG;Toxicity;increased  severity of Side Effect:adverse events;Genotypes AA + AG is associated with increased severity of adverse events when treated with diazepam in men with Alcoholism as compared to genotype GG.;in men with Alcohol abuse
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;rs1042713;GG;Other;increased  risk of Other:emergency department and hospital utliization;Genotype GG is associated with increased risk of emergency department and hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AA + AG.;in people with Disease:Heart Failure
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AA + AC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotypes AA + AC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;in people with Chronic hepatitis C virus infection
;L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs1049674;AT;Toxicity;increased  likelihood of Side Effect:Cushing Syndrome;Genotype AT is associated with increased likelihood of Cushing Syndrome when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;rs1799983;TT;Other;increased  risk of Other:emergency department utliization;Genotype TT is associated with increased risk of emergency department utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes GG + GT.;in people with Disease:Heart Failure
;EFAVIRENZ, LOPINAVIR, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, RITONAVIR;;rs2853826;G;Toxicity;increased   Side Effect:baseline adiponectin and with greater adiponectin decline;Allele G is associated with increased baseline adiponectin and with greater adiponectin decline when treated with efavirenz, lopinavir, Nucleoside and nucleotide reverse transcriptase inhibitors or ritonavir in people with HIV Infections as compared to allele A.;in people with Disease:HIV infectious disease
;DIAZEPAM;CYP2C19;rs12248560;CT + TT;Toxicity;decreased severity of Side Effect:adverse events;Genotypes CT + TT is associated with decreased severity of adverse events when treated with diazepam in men with Alcoholism as compared to genotype CC.;in men with Alcohol abuse
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;rs1801253;GG;Other;decreased risk of Other:Emergencies;Genotype GG is associated with decreased risk of Emergencies when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes CC + CG.;in people with Disease:Heart Failure
;L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;rs9282564;CT;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Genotype CT is associated with increased likelihood of Neurotoxicity Syndromes when treated with l-asparagine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;OLANZAPINE;UGT1A4;rs2011425;GG + GT;Toxicity;decreased severity of Side Effect:Autonomic Nervous System Disorder;Genotypes GG + GT is associated with decreased severity of Autonomic Nervous System Diseases when treated with olanzapine in people with Schizophrenia as compared to genotype TT.;in people with Schizophrenia
;OLANZAPINE;CYP3A4;rs2740574;CC + CT;Toxicity;increased  likelihood of Disease:Dry mouth;Genotypes CC + CT is associated with increased likelihood of dry mouth when exposed to olanzapine in healthy individuals as compared to genotype TT.;in healthy individuals 
;CABAZITAXEL;ABCB1;rs17327624;T;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele T is associated with increased likelihood of Drug Toxicity when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele G.;in people with Metastatic neoplasm, Prostatic Neoplasms
;SIMVASTATIN;ABCB1;rs1128503;AA;Efficacy;increased   Efficacy:reduction in total cholesterol;Genotype AA is associated with increased reduction in total cholesterol when treated with simvastatin as compared to genotype GG.; 
;OLANZAPINE;UGT1A4;rs2011425;GG + GT;Metabolism/PK;increased   PK:glucuronidated metabolites of olanzapine;Genotypes GG + GT are associated with increased glucuronidated metabolites of olanzapine when treated with olanzapine as compared to genotype TT.; 
;;COL1A1;rs1800012;AA + AC;;increased  risk of Disease:Fractures, Bone;Genotypes AA + AC are associated with increased risk of Fractures, Bone as compared to genotype CC.; 
;CYCLOSPORINE;ABCB1;rs1045642;AG;Toxicity;increased  severity of Disease:Gingival Hyperplasia;Genotype AG is associated with increased severity of Gingival Hyperplasia when treated with cyclosporine in people with Kidney Transplantation as compared to genotypes AA + GG.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT;Efficacy;increased  risk of Efficacy:acute rejection;Genotype CT is associated with increased risk of acute rejection when treated with tacrolimus in children with Kidney Transplantation as compared to genotype CC.;in children with Disease:Kidney Transplantation
;CLOPIDOGREL;P2RY12;rs6785930;AA + AG;Efficacy;increased  likelihood of Efficacy:Drug Resistance;Genotypes AA + AG is associated with increased likelihood of Drug Resistance when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Coronary Disease
;CABAZITAXEL;ABCB1;rs2235040;T;Toxicity;decreased likelihood of Side Effect:Asthenia;Allele T is associated with decreased likelihood of Asthenia when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele C.;in people with Metastatic neoplasm, Prostatic Neoplasms
;TACROLIMUS;NOD2;rs2066844;CC;Other;increased   Other:hospital stay;Genotype CC is associated with increased hospital stay when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;TT;Efficacy;increased  risk of Other:acute rejection;Genotype TT is associated with increased risk of acute rejection when treated with tacrolimus in Kidney Transplantation as compared to genotypes CC + CT.;in Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CT;Efficacy;increased  risk of Other:acute rejection;Genotype CT is associated with increased risk of acute rejection when treated with tacrolimus in Kidney Transplantation as compared to genotype CC.;in Disease:Kidney Transplantation
;CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;CT;Toxicity;increased  likelihood of Side Effect:Transplant rejection;Genotype CT is associated with increased likelihood of transplant rejection when treated with cyclosporine or tacrolimus in people with as compared to genotype TT.;in people with 
;WARFARIN;VKORC1;rs2359612;AA + AG;Efficacy;decreased  Efficacy:time to the first INR within the therapeutic range;Genotypes AA + AG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype GG.; 
;AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CC;Toxicity;decreased risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotype CC is associated with decreased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.;in people with Ulcerative Colitis, Crohn Disease
;OSELTAMIVIR;CES1;rs121912777;CT + TT;Metabolism/PK;PK:significantly larger mean AUC of oseltamivir, lower Cmax of oseltamivir carboxylate, and a smaller oseltamivir carboxylate-to-oseltamivir AUC ratio;Genotypes CT + TT are associated with significantly larger mean AUC of oseltamivir, lower Cmax of oseltamivir carboxylate, and a smaller oseltamivir carboxylate-to-oseltamivir AUC ratio when exposed to oseltamivir in healthy individuals as compared to genotype CC.;in healthy individuals 
;AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CT;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotype CT is associated with increased risk of Leukopenia or Neutropenia when treated with azathioprine or mercaptopurine in people with Colitis, Ulcerative or Crohn Disease as compared to genotype TT.;in people with Ulcerative Colitis, Crohn Disease
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:PBMC concentrations;Genotype CC is associated with increased PBMC concentrations of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;CABAZITAXEL;CYP2C8;rs11572093;T;Toxicity;increased  likelihood of Side Effect:Asthenia;Allele T is associated with increased likelihood of Asthenia when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele C.;in people with Metastatic neoplasm, Prostatic Neoplasms
;WARFARIN;VKORC1;rs9923231;CT + TT;Efficacy;decreased  Efficacy:time to the first INR within the therapeutic range;Genotypes CT + TT is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.; 
;CITALOPRAM;CYP2C19;rs4244285;A;Toxicity;increased   Side Effect:intolerance;Allele A is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs9934438;AA + AG;Efficacy;decreased  Efficacy:time to the first INR within the therapeutic range;Genotypes AA + AG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype GG.; 
;NORTRIPTYLINE;GNB3;rs5443;TT;Toxicity;Disease:Weight gain;Genotype TT is associated with Weight gain when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes CC + CT.;in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs8050894;CG + GG;Efficacy;decreased  Efficacy:time to the first INR within the therapeutic range;Genotypes CG + GG is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype CC.; 
;NORTRIPTYLINE;GNB3;rs5443;TT;Toxicity;decreased likelihood of Side Effect:Sleep Initiation and Maintenance Disorders;Genotype TT is associated with decreased likelihood of Sleep Initiation and Maintenance Disorders when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes CC + CT.;in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs2884737;AC + CC;Efficacy;decreased  Efficacy:time to the first INR within the therapeutic range;Genotypes AC + CC is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype AA.; 
;NORTRIPTYLINE;GNB3;rs5443;TT;Efficacy;Efficacy:improvements in neurovegetative symptoms;Genotype TT is associated with improvements in neurovegetative symptoms when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes CC + CT.;in people with Disease:Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:trough concentration;Genotype CC is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;WARFARIN;VKORC1;rs9934438;A;Efficacy;decreased  Efficacy:time to therapeutic inr;Allele A is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele G.; 
;TACROLIMUS;CYP3A5;rs776746;CC;Metabolism/PK;increased   PK:trough concentration;Genotype CC is associated with increased trough concentration of tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;;SLC19A1;rs1051266;C;Other;increased  likelihood of Other:Down Syndrome;Allele C is associated with increased likelihood of Down Syndrome in women with Pregnancy as compared to allele T.;in women with Pregnancy
;DIGOXIN;ABCB1;rs1045642;AA;Metabolism/PK;decreased  PK:duodenal absorption of digoxin after direct delivery to the surface of the duodenum by endoscope;Genotype AA is associated with decreased duodenal absorption of digoxin after direct delivery to the surface of the duodenum by endoscope when assayed with digoxin as compared to genotype GG.; 
;OLANZAPINE;HTR2A;rs7997012;AA;Toxicity;increased  risk of Side Effect:side effects;Genotype AA is associated with increased risk of side effects when treated with olanzapine in people with psychiatric disorders as compared to allele G.;in people with psychiatric disorders
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;T;Toxicity;increased  risk of Disease:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.;in people with Disease:Neoplasms
;CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;Toxicity;increased  risk of Disease:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms.;in people with Disease:Neoplasms
;OLANZAPINE;ABCB1;rs1045642;A;Efficacy;Efficacy:positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype;Allele A is associated with positive relationship between olanzapine plasma levels and positive symptom reduction compared to subjects with the GG genotype when treated with olanzapine.; 
;OLANZAPINE;CYP1A2;rs762551;AA;Metabolism/PK;decreased  PK:plasma concentrations;Genotype AA is associated with decreased plasma concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C.;in people with psychiatric disorders
;NICOTINE;OPRM1;rs1799971;AA;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG.; 
;OLANZAPINE;DRD2;rs6275;A;Other, Metabolism/PK;increased   Other:prolactin;Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele G.;in women 
;ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;rs9024;GG;Toxicity;increased  risk of Disease:Cardiomyopathies;Genotype GG is associated with increased risk of Cardiomyopathies when treated with anthracyclines and related substances in people with Neoplasms as compared to genotypes AA + AG.;in people with Disease:Neoplasms
;OLANZAPINE;DRD2;rs6279;G;Other, Metabolism/PK;increased   Other:prolactin;Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.;in women 
;CEPHALEXIN;;rs34545984;T;Toxicity;increased  risk of Side Effect:adverse events;Allele T is associated with increased risk of adverse events when treated with cephalexin as compared to allele G.; 
;OLANZAPINE;DRD2;rs1124493;T;Other, Metabolism/PK;increased   Other:prolactin;Allele T is associated with increased prolactin when treated with olanzapine in women as compared to allele G.;in women 
;OLANZAPINE;DRD2;rs2734841;A;Other, Metabolism/PK;increased   Other:prolactin;Allele A is associated with increased prolactin when treated with olanzapine in women as compared to allele C.;in women 
;ASPIRIN;;rs115346678;A;Toxicity;increased  risk of Side Effect:adverse events;Allele A is associated with increased risk of adverse events when treated with aspirin as compared to allele G.; 
;METHOTREXATE;MTHFD1;rs2236225;A;Efficacy;decreased likelihood of Efficacy:event free survival;Allele A is associated with decreased likelihood of event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in people with Disease:Acute lymphoblastic leukemia
;SIMVASTATIN;PPARA;rs4253728;AA;Efficacy;increased   Efficacy:reduction in total cholesterol and LDL-cholesterol;Genotype AA is associated with increased reduction in total cholesterol and LDL-cholesterol when treated with simvastatin as compared to genotype GG.; 
;METHOTREXATE;MTHFR;rs1801133;A;Efficacy;increased  risk of Efficacy:Recurrence;Allele A is associated with increased risk of Recurrence when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in people with Disease:Acute lymphoblastic leukemia
;CODEINE;WBP2NL;rs9620007;G;Toxicity;decreased risk of Side Effect:adverse events;Allele G is associated with decreased risk of adverse events when treated with codeine as compared to allele C.; 
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased  Other:warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy;Allele A is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to allele G.; 
;CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;rs62436463;T;Toxicity;decreased risk of Side Effect:adverse events;Allele T is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele C.; 
;METFORMIN;SLC22A2;rs316009;CC;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT.;in people with Diabetes Mellitus, Type 2
;METFORMIN;SLC22A2;rs316019;CC;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AC.;in people with Diabetes Mellitus, Type 2
;SIMVASTATIN;PPARA;rs4823613;GG;Efficacy;increased   Efficacy:reduction in total cholesterol and LDL-cholesterol;Genotype GG is associated with increased reduction in total cholesterol and LDL-cholesterol when treated with simvastatin as compared to genotype AA.; 
;;ANKK1;rs1800497;GG;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype GG is associated with increased likelihood of smoking cessation as compared to genotypes AA + AG.; 
;NICOTINE;COMT;rs4680;GG;Efficacy;increased  likelihood of Efficacy:relapse;Genotype GG is associated with increased likelihood of relapse when treated with nicotine.; 
;ESCITALOPRAM;HTR2A;rs6311;CT + TT;Toxicity;increased  likelihood of Side Effect:suicidal ideation, Side Effect:adverse events, Side Effect:deliberate self-harm;Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) .;in children with Depression, Anxiety Disorders
;NICOTINE;ANKK1;rs1800497;AA + AG;Efficacy;increased  likelihood of Efficacy:Smoking Cessation;Genotypes AA + AG is associated with increased likelihood of cessation when treated with nicotine as compared to genotype GG.; 
;AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;Toxicity;increased  risk of Disease:Torsades de Pointes;Allele T is associated with increased risk of Torsades de Pointes when treated with amiodarone, Antibiotics, antipsychotics, diuretics, quinidine or sotalol as compared to allele C.; 
;NICOTINE;OPRM1;rs1799971;GG;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype GG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype AA.; 
;NICOTINE;OPRM1;rs1799971;AG;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype AG is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotype AA.; 
;BUPROPION;ANKK1;rs1800497;GG;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype GG is associated with increased likelihood of smoking cessation when treated with bupropion as compared to genotypes AA + AG.; 
;OLANZAPINE;DRD2;rs2734842;G;Other, Metabolism/PK;increased   Other:prolactin;Allele G is associated with increased prolactin when treated with olanzapine in women as compared to allele C.;in women 
;METHOTREXATE;MTHFR;rs1801133;A;Toxicity;increased  likelihood of Side Effect:adverse events;Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;PYRIMIDINE ANALOGUES;DPYD;rs1801160;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with Pyrimidine analogues as compared to genotype CC.; 
;ROSUVASTATIN;ABCG2;rs2231142;GG;Efficacy;decreased  Efficacy:percentage change in LDL-cholesterol levels;Genotype GG is associated with decreased percentage change in LDL-cholesterol levels when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype TT.;in people with Disease:Hypercholesterolemia
;AMITRIPTYLINE;CYP2C19;rs4244285;AA;Other, Metabolism/PK;increased   PK:log metabolic ratio of amitriptyline/nortriptyline;Genotype AA is associated with increased log metabolic ratio of amitriptyline/nortriptyline when treated with amitriptyline as compared to genotype GG.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:cardiovascular death, myocardial infarction, or stroke;Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;ROSUVASTATIN;SLCO1B1;rs4149056;TT;Metabolism/PK;decreased  PK:plasma concentrations of rosuvastatin;Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.;in people with Disease:Hypercholesterolemia
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased  risk of Efficacy:cardiovascular death, myocardial infarction, or stroke;Allele A is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;ROSUVASTATIN;ABCG2;rs2231142;TT;Metabolism/PK;increased   PK:plasma concentrations of rosuvastatin;Genotype TT is associated with increased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotype GG.;in people with Disease:Hypercholesterolemia
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;increased  risk of Efficacy:cardiovascular death, myocardial infarction, or stroke;Genotype AA is associated with increased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;increased  likelihood of Efficacy:Coronary Restenosis;Genotype AA is associated with increased likelihood of Coronary Restenosis when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotypes AG + GG.;in people with Disease:Peripheral Vascular Diseases
;CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;rs1024611;GG;Toxicity;increased  severity of Side Effect:Anemia;Genotype GG is associated with increased severity of Anemia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotypes AA + AG.;"in people with ""Carcinoma, Squamous Cell"", ""Adenocarcinoma"", ""Adenosquamous Carcinoma"", ""Neoplasm of esophagus"""
;;SERPINE1;rs7242;T;Other;increased  likelihood of Disease:Major Depressive Disorder;Allele T is associated with increased likelihood of Depressive Disorder, Major as compared to allele G.; 
;;SERPINE1;rs2227684;G;Other;increased  likelihood of Disease:Major Depressive Disorder;Allele G is associated with increased likelihood of Depressive Disorder, Major as compared to allele A.; 
;METHOTREXATE;MTHFR;rs1801131;G;Efficacy;increased  likelihood of Efficacy:clinical response;Allele G is associated with increased likelihood of clinical response when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;GEMCITABINE;CDA;rs60369023;A;Toxicity, Metabolism/PK;increased  severity of Disease:Neutropenia;Allele A is associated with increased severity of Neutropenia when treated with gemcitabine in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;METHOTREXATE;GGH;rs3758149;AA;Toxicity;increased  likelihood of Side Effect:Anemia;Genotype AA is associated with increased likelihood of Anemia when treated with methotrexate in people with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in people with Non-Hodgkin Lymphoma, Acute lymphoblastic leukemia
;BISPHOSPHONATES;IL1B;rs16944;GG;Efficacy;increased  likelihood of PK:resistance;Genotype GG is associated with increased likelihood of resistance when treated with Bisphosphonates in people with Osteitis Deformans as compared to genotypes AA + AG.;in people with Disease:Osteitis Deformans
;CLODRONATE;VDR;rs1544410;C;Efficacy;increased  likelihood of Efficacy:resistance;Allele C is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans.;in people with Disease:Osteitis Deformans
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:over anti-coagulation;Genotypes CT + TT is associated with increased likelihood of over anti-coagulation when treated with warfarin as compared to genotype CC.; 
;CLODRONATE;VDR;rs731236;A;Efficacy;increased  likelihood of Efficacy:resistance;Allele A is associated with increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to allele G.;in people with Disease:Osteitis Deformans
;CYTARABINE, IDARUBICIN;NT5C3A;rs3750117;GG;Efficacy;increased  risk of Efficacy:induction failure;Genotype GG is associated with increased risk of induction failure when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in people with Disease:Leukemia, Myeloid, Acute
;ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;rs662799;AG + GG;Efficacy;decreased  Efficacy:reduction in LDLc;Genotypes AG + GG are associated with decreased reduction in LDLc when treated with atorvastatin, lovastatin or simvastatin in people with Hyperlipidemias as compared to genotype AA.;in people with Disease:Hyperlipidemias
;CITALOPRAM, SERTRALINE;HTR2A;rs6311;T;Toxicity;increased  likelihood of Side Effect:Physiological sexual disorder;Allele T is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.;in people with Major Depressive Disorder
;CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;rs1800796;CC;Toxicity;increased  likelihood of Side Effect:Thrombocytopenia;Genotype CC is associated with increased likelihood of Thrombocytopenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotypes CG + GG.;"in people with ""Carcinoma, Squamous Cell"", ""Adenocarcinoma"", ""Adenosquamous Carcinoma"", ""Neoplasm of esophagus"""
;CITALOPRAM;HTR2A;rs6313;AA;Toxicity;increased  likelihood of Side Effect:Physiological sexual disorder;Genotype AA is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram in people with Depressive Disorder, Major as compared to genotypes AG + GG.;in people with Major Depressive Disorder
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype AA is associated with increased likelihood of Leukopenia, Thrombocytopenia or Anemia when treated with methotrexate in people with Lymphoma, Non-Hodgkin or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in people with Non-Hodgkin Lymphoma, Acute lymphoblastic leukemia
;BUPRENORPHINE / NALOXONE;OPRM1;rs648893;AG + GG;Toxicity;decreased severity of Side Effect:Depression;Genotypes AG + GG is associated with decreased severity of Depression when treated with buprenorphine / naloxone in people with Opioid-Related Disorders as compared to genotype AA.;in people with Opioid-Related Disorders
;METHOTREXATE;ADORA2A;rs2267076;T;Toxicity;increased  risk of Side Effect:adverse events;Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ADORA2A;rs2236624;T;Toxicity;increased  risk of Side Effect:adverse events;Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ADORA2A;rs2298383;T;Toxicity;increased  risk of Side Effect:adverse events;Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Other;increased   PK:blood pressure;Genotypes CT + TT are associated with increased blood pressure when exposed to tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;METHOTREXATE;ADORA2A;rs3761422;T;Toxicity;increased  risk of Side Effect:adverse events;Allele T is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;rs1799964;CC + CT;Toxicity;increased  likelihood of Side Effect:Thrombocytopenia;Genotypes CC + CT is associated with increased likelihood of Thrombocytopenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotype TT.;"in people with ""Carcinoma, Squamous Cell"", ""Adenocarcinoma"", ""Adenosquamous Carcinoma"", ""Neoplasm of esophagus"""
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;increased  likelihood of Efficacy:Drug Resistance;Genotype AA is associated with increased likelihood of Drug Resistance when treated with clopidogrel in people with Stroke as compared to genotypes AG + GG.;in people with Stroke
;ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;Efficacy;decreased  Efficacy:platelet aggregation;Genotypes AA + AG is associated with decreased platelet aggregation when treated with aspirin and clopidogrel as compared to genotype GG.; 
;CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;rs717620;CT + TT;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes CT + TT is associated with increased severity of Neutropenia when treated with cisplatin, docetaxel and fluorouracil in people with Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Adenosquamous or Esophageal Neoplasms as compared to genotype CC.;"in people with ""Carcinoma, Squamous Cell"", ""Adenocarcinoma"", ""Adenosquamous Carcinoma"", ""Neoplasm of esophagus"""
;HYDROCHLOROTHIAZIDE;NELL1;rs12279250;C;Metabolism/PK;increased   Side Effect:plasma triglycerides;Allele C is associated with increased plasma triglycerides when treated with hydrochlorothiazide in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;BUPRENORPHINE / NALOXONE;OPRD1;rs678849;TT;Toxicity;decreased severity of Side Effect:Anxiety Disorders;Genotype TT is associated with decreased severity of Anxiety Disorders when treated with buprenorphine / naloxone in people with Opioid-Related Disorders as compared to genotypes CC + CT.;in people with Opioid-Related Disorders
;ARIPIPRAZOLE;DAOA;rs2391191;A;Efficacy;decreased  Efficacy:brief psychiatric rating scale scores;Allele A is associated with decreased brief psychiatric rating scale scores when treated with aripiprazole in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;BUPRENORPHINE / NALOXONE;OPRD1;rs569356;A;Efficacy;decreased likelihood of Efficacy:Craving;Allele A is associated with decreased likelihood of craving when treated with buprenorphine / naloxone in people with Opioid-Related Disorders as compared to allele G.;in people with Opioid-Related Disorders
;OLANZAPINE;HTR2C;rs6318;C;Toxicity;increased  severity of Side Effect:Weight gain;Allele C is associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype GG.;in people with Disease:Schizophrenia
;TACROLIMUS;CYP3A5;rs776746;T;Toxicity;increased  risk of Other:tacrolimus nephrotoxicity;Allele T is associated with increased risk of tacrolimus nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A5;rs776746;CC;Efficacy, Toxicity;increased  risk of Other:subclinical allograft nephropathy;Genotype CC is associated with increased risk of subclinical allograft nephropathy when treated with tacrolimus in Kidney Transplantation as compared to genotypes CT + TT.;in Disease:Kidney Transplantation
;SIMVASTATIN;CYBA;rs4673;AA + AG;Efficacy;increased   Efficacy:reduction in DNA damage;Genotypes AA + AG are associated with increased reduction in DNA damage when treated with simvastatin in people with Hypercholesterolemia as compared to genotype GG.;in people with Disease:Hypercholesterolemia
;BUPROPION;CYP2B6;rs3211371;CT;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype CT is associated with increased likelihood of smoking cessation when treated with bupropion in people with female gender as compared to genotype CC.;in people with female gender
;ASPIRIN;ABCB1;rs1045642;AG + GG;Efficacy;increased  likelihood of Efficacy:Drug Resistance;Genotypes AG + GG is associated with increased likelihood of Drug Resistance when treated with aspirin in people with Stroke as compared to genotype AA.;in people with Stroke
;OLANZAPINE;DRD3;rs6280;CC;Efficacy;Efficacy:greater positive symptom improvement and positive symptom remission;Genotype CC is associated with greater positive symptom improvement and positive symptom remission when treated with olanzapine in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotypes CT + TT are associated with increased risk of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in people with Crohn Disease as compared to genotype CC.;in people with Disease:Crohn Disease
;OLANZAPINE;RGS4;rs951439;CT;Efficacy;increased  likelihood of Efficacy:response;Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;CABAZITAXEL;TUBB1;rs151352;G;Efficacy;increased   Efficacy:Overall survival;Allele G is associated with increased overall survival when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele A.;in people with Metastatic neoplasm, Prostatic Neoplasms
;RISPERIDONE;RGS4;rs951439;TT;Efficacy;increased  likelihood of Efficacy:response;Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT.;in people with Disease:Schizophrenia
;OLANZAPINE, PERPHENAZINE;RGS4;rs951439;CC;Efficacy;increased  likelihood of Efficacy:positive response;Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;CABAZITAXEL;CYP2C8;rs1341164;C;Efficacy;increased   Efficacy:Overall survival;Allele C is associated with increased overall survival when treated with cabazitaxel in people with Neoplasm Metastasis and Prostatic Neoplasms as compared to allele T.;in people with Metastatic neoplasm, Prostatic Neoplasms
;OLANZAPINE;LEP;rs4731426;GG;Toxicity;increased  risk of Disease:Weight gain;Genotype GG is associated with increased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.;in people with Disease:Schizophrenia
;HEROIN;GRM3;rs13242038;T;Other;increased  risk of Disease:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C.; 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235015;A;Efficacy;increased  likelihood of Efficacy:remission;Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;;ACE;rs4343;G;Metabolism/PK;increased   Other:ACE activity;Allele G is associated with increased ACE activity in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;ANTIDEPRESSANTS;HTR1A;rs6295;GG;Efficacy;decreased  Efficacy:treatment response;Genotype GG is associated with decreased treatment response when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + CG.;in people with Disease:Major Depressive Disorder
;OPIOIDS;ABCB1;rs9282564;CC + CT;Toxicity;decreased risk of Other:Death;Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT.;in people with Opioid-Related Disorders
;ANTHRACYCLINES AND RELATED SUBSTANCES, TAXANES;ABCB1;rs1045642;AA;Efficacy, Metabolism/PK;increased  likelihood of Efficacy:complete response;Genotype AA is associated with increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to genotypes AG + GG.;in people with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;PAROXETINE, SERTRALINE;HTR1A;rs6295;CC;Efficacy;increased  likelihood of Efficacy:non-response;Genotype CC is associated with increased likelihood of non-response when treated with paroxetine and sertraline in people with Panic Disorder as compared to genotypes CG + GG.;in people with Disease:Panic Disorder
;OPIOIDS;KCNJ6;rs2070995;TT;Efficacy;increased   Efficacy:frequency of rescue analgesic administration;Genotype TT is associated with increased frequency of rescue analgesic administration when treated with opioids in people with Pain as compared to genotypes CC + CT.;in people with Disease:Pain
;WARFARIN;VKORC1;rs8050894;G;Dosage, Efficacy;Efficacy:decreased warfarin dose and increased  risk of over-anticoagulation;Allele G is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.; 
;WARFARIN;VKORC1;rs9923231;T;Dosage, Efficacy;Efficacy:decreased warfarin dose and increased  risk of over-anticoagulation;Allele T is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to allele C.; 
;NEVIRAPINE;CYP2B6;rs28399499;CT;Other;increased  likelihood of Side Effect:Elevated liver enzymes;Genotype CT is associated with increased likelihood of Elevated liver enzymes when treated with nevirapine in people with HIV infectious disease as compared to genotype TT.;in people with Disease:HIV infectious disease
;NEVIRAPINE;CYP3A5;rs776746;CC + CT;Other;increased  likelihood of Side Effect:Elevated liver enzymes;Genotypes CC + CT is associated with increased likelihood of Elevated liver enzymes when treated with nevirapine in people with HIV infectious disease as compared to genotype TT.;in people with Disease:HIV infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs3849942;T;Efficacy;increased  risk of Efficacy:non-response;Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;METHAMPHETAMINE;DTNBP1;rs3213207;C;Toxicity;increased  risk of Side Effect:Psychotic Disorder;Allele C is associated with increased risk of Psychotic Disorders when exposed to methamphetamine.; 
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs2814707;T;Efficacy;increased  risk of Efficacy:non-response;Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;METHAMPHETAMINE;PICK1;rs2076369;T;Toxicity;increased  likelihood of Side Effect:relapse of psychosis;Allele T is associated with increased likelihood of relapse of psychosis when exposed to methamphetamine.; 
;NEVIRAPINE;CYP2B6;rs12721646;CT + TT;Other;increased  likelihood of Side Effect:Elevated liver enzymes;Genotypes CT + TT is associated with increased likelihood of Elevated liver enzymes when treated with nevirapine in people with HIV infectious disease as compared to genotype CC.;in people with Disease:HIV infectious disease
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;rs928655;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;FLUOROURACIL;DPYD;rs1801265;AG + GG;Toxicity;decreased likelihood of Side Effect:overall gastrointestinal toxicity;Genotypes AG + GG are associated with decreased likelihood of overall gastrointestinal toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs774359;C;Efficacy;increased  risk of Efficacy:non-response;Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;rs983332;T;Efficacy;increased  risk of Efficacy:non-response;Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs868856;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;MTHFR;rs1801131;G;Toxicity;increased  risk of Side Effect:side effects;Allele G is associated with increased risk of side effects when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;MTHFR;rs1801131;TT;Efficacy;increased   Efficacy:response base on Disease Activity Score in 44 joints improvement at 6 months of treatment;Genotype TT is associated with increased response base on Disease Activity Score in 44 joints improvement at 6 months of treatment when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;SLC19A1;rs1051266;TT;Efficacy;decreased  Efficacy: disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints;Genotype TT is associated with decreased disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Disease:Rheumatoid arthritis
;GEFITINIB;EGFR;rs712829;GT + TT;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Genotypes GT + TT are associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIANDROGENS;AKR1C3;rs12529;CC;Efficacy;increased  risk of Efficacy:prostate cancer-specific mortality;Genotype CC is associated with increased risk of prostate cancer-specific mortality when treated with Antiandrogens in men with Prostatic Neoplasms as compared to genotypes CG + GG.;in men with Disease:Prostatic Neoplasms
;WARFARIN;VKORC1;rs9934438;AA + AG;Dosage;decreased  Other:maintenance dose of warfarin;Genotypes AA + AG is associated with decreased maintenance dose of warfarin when treated with warfarin as compared to genotype GG.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG;Toxicity;increased  risk of Disease:Nephrotoxicity;Genotype AG is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype GG.;in people with Disease:Ovarian Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;Toxicity;increased  severity of Disease:Neutropenia;Genotype GG is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CC + CG.;in people with Disease:Ovarian Neoplasms
;PACLITAXEL;CYP2C8;rs11572080;TT;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes;Genotype TT is associated with increased risk of Neurotoxicity Syndromes when treated with paclitaxel in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;METHOTREXATE;ABCC1;rs2238476;GG;Toxicity;increased  risk of Side Effect:toxicity;Genotype GG is associated with increased risk of toxicity when treated with methotrexate in people with Psoriasis as compared to genotypes AA + AG.;in people with Disease:Psoriasis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6028945;T;Efficacy;increased  risk of Efficacy:non-response;Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;OLANZAPINE;HTR2C;rs3813929;T;Toxicity;decreased risk of Side Effect:Weight gain;Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Depressive Disorder or Schizophrenia as compared to allele C.;in people with Disease:Depressive Disorder, Disease:Schizophrenia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6071980;C;Efficacy;increased  risk of Efficacy:non-response;Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotype CT is associated with increased likelihood of mucositis when treated with fluorouracil in women with Neoplasms as compared to genotype CC.;in women with Disease:Neoplasms
;OLANZAPINE;HTR2C;rs3813929;T;Toxicity;decreased risk of Side Effect:Weight gain;Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;rs6138150;T;Efficacy;increased  risk of Efficacy:non-response;Allele T is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;OLANZAPINE;HTR2C;rs3813929;T;Toxicity;decreased risk of Side Effect:Weight gain;Allele T is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;Efficacy, Metabolism/PK;increased   Efficacy:progression free survival;Genotype AA is associated with increased progression free survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes AG + GG.;in people with Disease:Ovarian Neoplasms
;ANTIPSYCHOTICS;CLCN6, MTHFR;rs1801133;A;Toxicity;increased  likelihood of Disease:Metabolic Syndrome;Allele A is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics in people with Schizophrenia.;in people with Disease:Schizophrenia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854548;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854555;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele C.;in people with Disease:Rheumatoid arthritis
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs7046653;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;BUPRENORPHINE;CYP3A4;rs2740574;CC + CT;Efficacy;increased  risk of Other:Substance Withdrawal Syndrome;Genotypes CC + CT is associated with increased risk of Substance Withdrawal Syndrome when treated with buprenorphine in people with Opioid-Related Disorders as compared to genotype TT.;in people with Opioid-Related Disorders
;WARFARIN;VKORC1;rs9934438;AG;Efficacy;decreased  Efficacy:time in therapeutic range of INR (TTR);Genotype AG is associated with decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotypes AA + GG.; 
;DOCETAXEL;;rs11185648;CT;Toxicity;increased  severity of Disease:Anemia;Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CC.;in people with Disease:Nasopharyngeal Neoplasms
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose in Japanese patients;Allele T is associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to allele C.; 
;DOCETAXEL;RXRA;rs11185647;AG;Toxicity;increased  severity of Disease:Anemia, Disease:Neutropenia;Genotype AG is associated with increased severity of Anemia and Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;CISPLATIN;TPMT;rs12201199;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;DOCETAXEL;RXRA;rs2234753;AG;Toxicity;increased  severity of Disease:Anemia;Genotype AG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;RXRA;rs6413517;GT;Toxicity;increased  severity of Disease:Anemia;Genotype GT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.;in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;RXRA;rs62576288;GG;Toxicity;increased  severity of Disease:Anemia;Genotype GG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;;DRD2;rs1799732;GG;;increased  likelihood of Disease:Schizophrenia;Genotype GG is associated with increased likelihood of Schizophrenia as compared to genotypes G/del + del/del.; 
;;SCN1A;rs2298771;CT;Other;increased  likelihood of Disease:Epilepsy;Genotype CT is associated with increased likelihood of Epilepsy.; 
;METHOTREXATE;;rs9345389;G;Toxicity;Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance.;Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. when treated with methotrexate as compared to allele A.; 
;DOCETAXEL;HNF4A;rs6130615;TT;Toxicity;increased  severity of Disease:Anemia;Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.;in people with Disease:Nasopharyngeal Neoplasms
;ANTIPSYCHOTICS;HTR2A;rs7997012;GG;Efficacy;increased  likelihood of Efficacy:Drug Resistance;Genotype GG is associated with increased likelihood of Drug Resistance when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AG.;in people with Schizophrenia
;SIMVASTATIN;;rs76103438;A;Toxicity;increased  risk of Side Effect:adverse events;Allele A is associated with increased risk of adverse events when treated with simvastatin as compared to allele T.; 
;DIAZEPAM;CYP3A4;rs35599367;GG;Toxicity;increased  severity of Side Effect:adverse events;Genotype GG is associated with increased severity of adverse events when treated with diazepam in men with Alcoholism as compared to genotypes AA + AG.;in men with Alcohol abuse
;ANTIPSYCHOTICS;HTR2A;rs6314;AG;Efficacy;increased  likelihood of Efficacy:Drug Resistance;Genotype AG is associated with increased likelihood of Drug Resistance when treated with antipsychotics in people with Schizophrenia as compared to genotype GG.;in people with Schizophrenia
;DOCETAXEL;HNF4A;rs2273618;CT;Toxicity;increased  severity of Disease:Anemia;Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.;in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;HNF4A;rs3746574;CT;Toxicity;increased  severity of Disease:Anemia;Genotype CT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype TT.;in people with Disease:Nasopharyngeal Neoplasms
;WARFARIN;VKORC1;rs9934438;A;Dosage, Efficacy;Other:a more rapid attainment of target INR and higher frequency of dose adjustments;Allele A is associated with a more rapid attainment of target INR and higher frequency of dose adjustments when treated with warfarin as compared to allele G.; 
;DOCETAXEL;NR1I2;rs3732360;TT;Toxicity;increased  severity of Disease:Anemia;Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.;in people with Disease:Nasopharyngeal Neoplasms
;;NRXN1;rs985919;C;Other;increased  likelihood of Disease:Tobacco Use Disorder;Allele C is associated with increased likelihood of Tobacco Use Disorder as compared to allele A.; 
;"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;rs4149601;AG + GG;Efficacy;decreased risk of Other:cardiovascular events;Genotypes AG + GG are associated with decreased risk of cardiovascular events when treated with Beta blocking agents, selective or diuretics in people with Hypertension as compared to genotype AA.;in people with Disease:Hypertension
;MEPERIDINE;SERINC5;rs185462714;C;Toxicity;increased  risk of Side Effect:adverse events;Allele C is associated with increased risk of adverse events when treated with meperidine as compared to allele A.; 
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA;Efficacy;increased   Efficacy:overall survival;Genotype AA is associated with increased overall survival when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes AG + GG.;in people with Disease:Ovarian Neoplasms
;DOCETAXEL;NR1I2;rs3732359;AA;Toxicity;increased  severity of Disease:Anemia;Genotype AA is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AG.;in people with Disease:Nasopharyngeal Neoplasms
;;CHRNA5;rs17408276;C;Other;increased  likelihood of Disease:Tobacco Use Disorder;Allele C is associated with increased likelihood of Tobacco Use Disorder as compared to allele T.; 
;BETA BLOCKING AGENTS;;rs139945292;T;Toxicity;increased  risk of Side Effect:adverse cardiovascular events;Allele T is associated with increased risk of adverse cardiovascular events when treated with Beta Blocking Agents in people with Hypertension as compared to allele C.;in people with Hypertension
;NICOTINE;COMT;rs4680;AA;Efficacy;increased  likelihood of Efficacy:smoking cessation;Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG.; 
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Disease:Muscular Diseases;Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with simvastatin as compared to genotype TT.; 
;PENICILLIN G, PENICILLIN V;;rs115200108;A;Toxicity;increased  risk of Side Effect:adverse events;Allele A is associated with increased risk of adverse events when treated with penicillin g or penicillin v as compared to allele C.; 
;NICOTINE;COMT;rs4680;AG;Efficacy;increased  likelihood of Efficacy:relapse;Genotype AG is associated with increased likelihood of relapse when treated with nicotine.; 
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased  Other:warfarin dose;Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.; 
;DOCETAXEL;NR1I2;rs3814058;CC + TT;Toxicity;increased  severity of Disease:Anemia;Genotypes CC + TT are associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT.;in people with Disease:Nasopharyngeal Neoplasms
;;CHRNA5;rs16969968;A;Other;increased  likelihood of Disease:Tobacco Use Disorder;Allele A is associated with increased likelihood of Tobacco Use Disorder as compared to allele G.; 
;;NRXN1;rs1882296;C;Other;increased  likelihood of Disease:Tobacco Use Disorder;Allele C is associated with increased likelihood of Tobacco Use Disorder as compared to allele T.; 
;DOCETAXEL;NR1I3;rs10538494;TT;Toxicity;increased  severity of Disease:Neutropenia;Genotype TT is associated with increased severity of Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AT.;in people with Disease:Nasopharyngeal Neoplasms
;CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;rs739296;A;Toxicity;decreased risk of Side Effect:adverse events;Allele A is associated with decreased risk of adverse events when treated with codeine, hydrocodone, oxycodone or tramadol as compared to allele G.; 
;MEPERIDINE;FIP1L1;rs113100019;G;Toxicity;increased  risk of Side Effect:adverse events;Allele G is associated with increased risk of adverse events when treated with meperidine as compared to allele T.; 
;DOCETAXEL;NR1I3;rs75114882;AG;Toxicity;increased  severity of Disease:Neutropenia;Genotype AG is associated with increased severity of Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;;NRXN1;rs10865246;C;Other;increased  severity of Disease:Tobacco Use Disorder;Allele C is associated with increased severity of Tobacco Use Disorder as compared to allele A.; 
;CISPLATIN;COMT;rs9332377;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.;in children with Disease:Neoplasms
;DOCETAXEL;NR1I3;rs2501873;CC;Toxicity;decreased severity of Disease:Anemia;Genotype CC is associated with decreased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT.;in people with Disease:Nasopharyngeal Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;Toxicity;increased  severity of Disease:Neutropenia;Genotype CT is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms.;in people with Disease:Ovarian Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AC;Toxicity;increased  risk of Disease:Nephrotoxicity;Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype AA.;in people with Disease:Ovarian Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;rs25487;CC;Toxicity;increased  severity of Disease:Neutropenia;Genotype CC is associated with increased severity of Neutropenia when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotypes CT + TT.;in people with Disease:Ovarian Neoplasms
;MEPERIDINE;;rs11049274;A;Toxicity;increased  risk of Side Effect:adverse events;Allele A is associated with increased risk of adverse events when treated with meperidine as compared to allele G.; 
;DOCETAXEL;RXRA;rs1536475;AG;Toxicity;increased  severity of Disease:Anemia;Genotype AG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AA.;in people with Disease:Nasopharyngeal Neoplasms
;CISPLATIN;XPC;rs2228001;G;Toxicity;increased  risk of Disease:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T.;in people with Disease:Osteosarcoma
;DOCETAXEL;NR1I3;rs2502815;GG;Toxicity;increased  severity of Disease:Anemia;Genotype GG is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Nasopharyngeal Neoplasms
;DOCETAXEL;NR1I3;rs9725457;AA;Toxicity;increased  severity of Disease:Anemia;Genotype AA is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Nasopharyngeal Neoplasms
;CISPLATIN;ERCC2, KLC3;rs13181;G;Efficacy;decreased  Efficacy:event free survival;Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT.;in people with Disease:Osteosarcoma
;ETHANOL;ACSS2;rs6088638;T;Toxicity;increased  risk of Other:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;CAPECITABINE, FLUOROURACIL;DPYD;rs17376848;AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ETHANOL;OPRM1;rs1799971;G;Toxicity;increased  risk of Disease:Alcohol abuse;Allele G is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele A.; 
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1058164;C;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele C is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele G.;in people with Hypertension
;CISPLATIN;ERCC1;rs11615;G;Efficacy;increased   Efficacy:overall survival and progression-free survival;Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele A.;in people with Disease:Neoplasm of esophagus
;;APOE;rs429358;CC;Other;increased  severity of Other:COVID-19;Genotype CC is associated with increased severity of COVID-19 as compared to genotype TT.; 
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy, Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1985842;T;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele T is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele G.;in people with Hypertension
;;NAT2;rs1801280;T;Other;increased  severity of Disease:Insulin Resistance;Allele T is associated with increased severity of Insulin Resistance as compared to allele C.; 
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1135840;G;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele G is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele C.;in people with Hypertension
;CLOPIDOGREL;CYP2C19;rs28399504;G;Efficacy, Toxicity;increased  risk of Side Effect:cardiovascular events;Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA.;in people with Disease:Myocardial Infarction
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371713;G;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele G is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele A.;in people with Hypertension
;;NAT2;rs1208;A;Other;increased  severity of Disease:Insulin Resistance;Allele A is associated with increased severity of Insulin Resistance as compared to allele G.; 
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;;rs72631546;C;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele C is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin as compared to allele T.; 
;GEFITINIB;ABCG2;rs2231142;GT;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotype GT is associated with increased likelihood of Diarrhea when treated with gefitinib in people with Lung Neoplasms as compared to genotype GG.;in people with Disease:Lung Neoplasms
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs112568578;G;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele G is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele C.;in people with Hypertension
;CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;rs895819;C;Toxicity;increased  likelihood of Side Effect:Neutropenia;Allele C is associated with increased likelihood of Neutropenia when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.;in people with Neoplasms
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;Disease:Neutropenia;Genotype CT is associated with Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele A is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate as compared to allele G.; 
;MORPHINE;OPRM1;rs1799971;AA;Toxicity;increased  severity of Side Effect:Sleep Apnea Syndromes;Genotype AA is associated with increased severity of Sleep Apnea Syndromes when treated with morphine in men as compared to genotype AG.;in men 
;COCAINE;CNR1;rs6454674;GT + TT;Other;increased  risk of Disease:Cocaine dependence;Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG.; 
;;PTGS2;rs20417;G;;increased  risk of Disease:Stroke;Allele G is associated with increased risk of Stroke as compared to allele C.; 
;ATENOLOL, BETA BLOCKING AGENTS, CARVEDILOL, METOPROLOL;PPARA;rs4253778;GG;Efficacy;decreased  Other:cardiac rehospitalization;Genotype GG is associated with decreased cardiac rehospitalization when treated with atenolol, Beta Blocking Agents, carvedilol or metoprolol in people with Acute coronary syndrome as compared to genotypes CC + CG.;in people with Disease:Acute coronary syndrome
;DOXORUBICIN;RARG;rs2229774;AG;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotype AG is associated with increased likelihood of cardiotoxicity when assayed with doxorubicin as compared to genotype GG.; 
;FLUVASTATIN;ABCG2;rs2231142;GT + TT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes GT + TT are associated with increased likelihood of adverse events when treated with fluvastatin in people with Kidney Transplantation as compared to genotype GG.;in people with Kidney Transplantation
;ASPIRIN;TMEM196;rs9886152;T;Toxicity;decreased risk of Side Effect:Aspirin-induced asthma;Allele T is associated with decreased risk of aspirin-induced asthma when treated with aspirin in people with Asthma as compared to allele C.;in people with Disease:Asthma
;PAZOPANIB;HIF1A;rs11549467;AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AG is associated with decreased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;;CLOCK;rs1801260;AA + AG;Other;increased  likelihood of Other:Attention Deficit Disorder with Hyperactivity;Genotypes AA + AG is associated with increased likelihood of Attention Deficit Disorder with Hyperactivity in children as compared to genotype GG.;in children 
;MERCAPTOPURINE, METHOTREXATE;ITPA;rs7270101;CC;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Disease:Acute lymphoblastic leukemia
;COCAINE;CNR1;rs6454674;GT + TT;Other;increased  risk of Disease:Cocaine dependence;Genotypes GT + TT is associated with increased risk of Cocaine-Related Disorders when exposed to cocaine as compared to genotype GG.; 
;RITUXIMAB;FCGR3A;rs396991;C;Efficacy;increased   Efficacy:complete response rate;Allele C is associated with increased complete response rate when treated with rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to allele A.;in people with Disease:Lymphoma, Large B-Cell, Diffuse
;MERCAPTOPURINE, METHOTREXATE;IMPDH1;rs2278293;CT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype CT is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;RITUXIMAB;FCGR3A;rs396991;AA;;decreased  Other:levels of IgG;Genotype AA is associated with decreased levels of IgG when treated with rituximab in people with non-Hodgkin's lymphoma and stem cell transplantation as compared to genotypes AC + CC.;in people with non-Hodgkin's lymphoma and stem cell transplantation
;COCAINE;CNR1;rs806368;C;Other;decreased risk of Disease:Cocaine dependence;Allele C is associated with decreased risk of Cocaine-Related Disorders when exposed to cocaine as compared to allele T.; 
;MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype CC is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AC.;in children with Disease:Acute lymphoblastic leukemia
;ALENDRONATE, RALOXIFENE;VDR;rs1544410;CC;Efficacy;increased   Efficacy:improvement in bone mineral density;Genotype CC is associated with increased improvement in bone mineral density when treated with alendronate and raloxifene in people with Osteoporosis, Postmenopausal as compared to genotype TT.;in people with Disease:Osteoporosis, Postmenopausal
;ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;rs7142143;CC + CT;Dosage;increased  risk of Efficacy:relapse;Genotypes CC + CT are associated with increased risk of relapse when treated with asparaginase, dexamethasone or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;INTERFERONS;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;PAZOPANIB;CXCL8;rs4073;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes AT + TT.;in people with Disease:Renal Cell Carcinoma
;ERLOTINIB;EGFR;rs121434569;T;Efficacy;decreased  Efficacy:progression-free survival (PFS) time;Allele T is associated with decreased progression-free survival (PFS) time when exposed to erlotinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.;in people with EGFR mutation positive non-small-cell lung cancer
;ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;Efficacy;decreased  Efficacy:progression-free survival (PFS) time;Allele T is associated with decreased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele C.;in people with EGFR mutation positive non-small-cell lung cancer
;INTERFERONS;IFNL3;rs8099917;TT;Efficacy;increased   Efficacy:response (SVR) to interferon monotherapy in HCV genotype 1 patients;Genotype TT is associated with increased response (SVR) to interferon monotherapy in HCV genotype 1 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;rs17376848;AG;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype AG is associated with increased severity of Drug Toxicity when exposed to capecitabine, irinotecan and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;;rs4888024;G;Toxicity;Side Effect:end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance;Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance when treated with methotrexate as compared to allele A.; 
;TACROLIMUS;ABCB1;rs1128503;AG;Metabolism/PK;increased   PK:trough concentrations;Genotype AG is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;TACROLIMUS;ABCB1;rs2032582;AC + CT;Metabolism/PK;increased   PK:trough concentrations;Genotypes AC + CT is associated with increased trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;METHOTREXATE;ABCC1;rs3784862;AA;Toxicity;increased  likelihood of Side Effect:toxicity;Genotype AA is associated with increased likelihood of toxicity when treated with methotrexate in people with Psoriasis as compared to genotypes AG + GG.;in people with Disease:Psoriasis
;ETHANOL;OPRM1;rs1799971;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol in men as compared to allele G.;in men 
;CAPECITABINE;DPYD;rs2297595;CT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype CT is associated with increased severity of Drug Toxicity when exposed to capecitabine in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;ABCB1;rs1045642;A;Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.; 
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs945665113;A;Efficacy;increased   Efficacy:Progression-free survival;Allele A is associated with increased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele G.;in people with Lung Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased   Efficacy:platelet reactivity;Genotypes AA + AG are associated with increased platelet reactivity when treated with clopidogrel in PCI-scheduled patients as compared to genotype GG.;in PCI-scheduled patients
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased   Efficacy:response (SVR) in HCV genotype 1 patients;Genotype TT is associated with increased response (SVR) in HCV genotype 1 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;Toxicity;decreased risk of Side Effect:adverse events;Genotypes AA + AG is associated with decreased risk of adverse events when treated with antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotype GG.;in people with Bipolar Disorder, Depression, Major Depressive Disorder
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;SUNITINIB;SLC22A5;rs2631367;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele G.;in people with Disease:Gastrointestinal Stromal Tumors
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:Overall survival (OS) time;Allele G is associated with increased Overall survival (OS) time when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Efficacy, Toxicity;increased  risk of Side Effect:primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis;Genotype AA is associated with increased risk of primary clinical endpoint of death due to cardiovascular causes, non-fatal MI or stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with erlotinib in people with Adenocarcinoma as compared to allele T.;in people with Disease:Adenocarcinoma
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with erlotinib in people with Adenocarcinoma as compared to allele T.;in people with Disease:Adenocarcinoma
;SUNITINIB;SLC22A5;rs2631370;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele T.;in people with Disease:Gastrointestinal Stromal Tumors
;;PTGS2;rs20417;CG + GG;;decreased risk of Disease:Stroke;Genotypes CG + GG are associated with decreased risk of Stroke as compared to genotype CC.; 
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs376695472;G;Efficacy;increased   Efficacy:Progression-free survival;Allele G is associated with increased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele A.;in people with Lung Neoplasms
;ANTIDEPRESSANTS;HTR2A;rs6311;CC;Toxicity;increased  risk of Side Effect:adverse events;Genotype CC is associated with increased risk of adverse events when treated with antidepressants in people with Bipolar Disorder, Depression or Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Bipolar Disorder, Depression, Major Depressive Disorder
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel as compared to allele G.; 
;BETA BLOCKING AGENTS;ADRB2;rs1042713;GG;Efficacy;decreased risk of Efficacy:Death;Genotype GG is associated with decreased risk of Death when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Acute coronary syndrome
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;Toxicity;increased  likelihood of Side Effect:Discontinuation;Genotype CC is associated with increased likelihood of discontinuation when treated with hmg coa reductase inhibitors in people with Acute coronary syndrome and Myocardial Infarction as compared to genotype TT.;in people with Acute coronary syndrome, Myocardial Infarction
;FLUOROURACIL;DPYS;rs2959023;G;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele G is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;SUNITINIB;IL4R;rs1805015;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele T.;in people with Disease:Gastrointestinal Stromal Tumors
;OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;rs20417;CG + GG;Other;increased  risk of Disease:Colonic Neoplasms;Genotypes CG + GG are associated with increased risk of Colonic Neoplasms when exposed to omega-3 polyunsaturated fatty acids as compared to genotype CC.; 
;;PTGS2;rs20417;CG + GG;Other;decreased risk of Disease:Myocardial Infarction;Genotypes CG + GG are associated with decreased risk of Myocardial Infarction as compared to genotype CC.; 
;FLUOROURACIL;DPYS;rs2669429;G;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Allele G is associated with decreased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;Toxicity;increased  risk of Side Effect:Myelosuppression;Genotype AG is associated with increased risk of Myelosuppression due to methotrexate in people with Primary central nervous system lymphoma as compared to genotype GG.;in people with Primary central nervous system lymphoma
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;SUNITINIB;SLC22A5;rs2631372;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele G.;in people with Disease:Gastrointestinal Stromal Tumors
;CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;GG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;SUNITINIB;IL4R;rs1801275;G;Efficacy;decreased  Efficacy:Overall survival;Allele G is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele A.;in people with Disease:Gastrointestinal Stromal Tumors
;HEROIN;BDNF;rs16917234;TT;Toxicity;decreased age at onset of Side Effect:Heroin Dependence;Genotype TT is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes CC + CT.; 
;AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606619;T;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele C.; 
;TENOFOVIR;ABCC4;rs1751034;CC + CT;Metabolism/PK;increased   PK:intracellular tenofovir diphosphate (TFV-DP) concentrations;Genotypes CC + CT are associated with increased intracellular tenofovir diphosphate (TFV-DP) concentrations when treated with tenofovir in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;AZITHROMYCIN, ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;Toxicity;increased  likelihood of Side Effect:Pain, Side Effect:Diarrhea;Genotypes AA + AG is associated with increased likelihood of Pain or Diarrhea when treated with azithromycin or erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.;in people with Bacterial Infections, Influenza
;CORTICOSTEROIDS;DTNBP1;rs35514893;T;Efficacy;decreased severity of Disease:Asthma;Allele T is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele C.;in children with Disease:Asthma
;;CYP1B1;rs1056836;CC + CG;Other;increased  risk of Disease:Breast Neoplasms;Genotypes CC + CG are associated with increased risk of Breast Neoplasms in women with Tobacco Use Disorder as compared to genotype GG.;in women with Disease:Tobacco Use Disorder
;THIOTEPA;GSTP1;rs1138272;T;Other;increased   PK:non-inducible thiotepa clearance and decreased tepa clearance;Allele T is associated with increased non-inducible thiotepa clearance and decreased tepa clearance when treated with thiotepa.; 
;TENOFOVIR;ABCC4;rs1751034;TT;Other;increased   PK:tenofovir renal clearance, and lower AUC;Genotype TT is associated with increased tenofovir renal clearance, and lower AUC when treated with tenofovir as compared to genotypes CC + CT.; 
;FLUOROURACIL;DPYD;rs2786783;A;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele G.;in people with Colorectal Neoplasms
;;G6PD;rs72554664;T;Other;increased  likelihood of Other:Diabetes Mellitus, Type 2;Allele T is associated with increased likelihood of Diabetes Mellitus, Type 2 as compared to genotype CC.; 
;OPIOIDS;;rs12442183;T;Toxicity;increased  likelihood of Disease:Opioid-Related Disorders;Allele T is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to allele C.; 
;CORTICOSTEROIDS;KL;rs450789;G;Efficacy;decreased severity of Disease:Asthma;Allele G is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele A.;in children with Disease:Asthma
;INTERFERON BETA-1A, INTERFERON BETA-1B;IRF6;rs2205986;G;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele G is associated with increased risk of drug-induced liver injury due to interferon beta-1a or interferon beta-1b in people with Multiple Sclerosis as compared to allele A.;in people with Disease:Multiple Sclerosis
;METHOTREXATE;NR1I2;rs3814058;C;Toxicity;decreased risk of Disease:Toxic liver disease;Allele C is associated with decreased risk of Toxic liver disease when treated with methotrexate in children with Osteosarcoma as compared to allele T.;in children with Disease:Osteosarcoma
;METHOTREXATE;ABCC2;rs2273697;A;Toxicity;increased  risk of Side Effect:Bone Marrow Disorder;Allele A is associated with increased risk of Bone Marrow Diseases when treated with methotrexate in children with Osteosarcoma as compared to allele G.;in children with Disease:Osteosarcoma
;FLUOROURACIL;WNT5B;rs2010851;CC;Efficacy;decreased  Other:time to tumor recurrence (TTR);Genotype CC is associated with decreased time to tumor recurrence (TTR) when treated with fluorouracil in people with Colonic Neoplasms as compared to genotypes AA + AC.;in people with Disease:Colonic Neoplasms
;CORTICOSTEROIDS;ME3;rs2125362;A;Efficacy;increased  severity of Disease:Asthma;Allele A is associated with increased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele G.;in children with Disease:Asthma
;HEROIN;OPRD1;rs508448;GG;Toxicity;decreased age at onset of Side Effect:Heroin Dependence;Genotype GG is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes AA + AG.; 
;METHOTREXATE;NR1I2;rs6785049;G;Toxicity;decreased risk of Side Effect:Toxic liver disease;Allele G is associated with decreased risk of Toxic liver disease when treated with methotrexate in children with Osteosarcoma as compared to allele A.;in children with Disease:Osteosarcoma
;CORTICOSTEROIDS;LHX2;rs7851998;A;Efficacy;decreased severity of Disease:Asthma;Allele A is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele G.;in children with Disease:Asthma
;FLUOROURACIL;DPYD;rs2811178;C;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele C is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele T.;in people with Colorectal Neoplasms
;CORTICOSTEROIDS;LHFPL3;rs61585310;G;Efficacy;decreased severity of Disease:Asthma;Allele G is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele T.;in children with Disease:Asthma
;ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;rs1800896;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with asparaginase, corticosteroids, cyclophosphamide, cytarabine, mercaptopurine, methotrexate and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in children with Acute lymphoblastic leukemia
;METHOTREXATE;GSK3B;rs3732361;A;Metabolism/PK;decreased risk of Side Effect:Bone Marrow Disorder, Side Effect:Toxic liver disease;Allele A is associated with decreased risk of Bone Marrow Diseases and Toxic liver disease when treated with methotrexate in children with Osteosarcoma as compared to allele G.;in children with Disease:Osteosarcoma
;HEROIN;BDNF;rs6265;TT;Toxicity;decreased age at onset of Side Effect:Heroin Dependence;Genotype TT is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes CC + CT.; 
;MORPHINE;SLC22A1;rs12208357;T;Toxicity;increased  likelihood of Side Effect:Postoperative Nausea and Vomiting;Allele T is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with morphine in children as compared to allele C.;in children 
;CORTICOSTEROIDS;TRDN;rs4897302;T;Efficacy;increased  severity of Disease:Asthma;Allele T is associated with increased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele C.;in children with Disease:Asthma
;NICOTINE;CHRNA5;rs55781567;G;Toxicity;increased   Disease:Tobacco Use Disorder;Allele G is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele C.; 
;HEROIN;OPRD1;rs4654327;AA;Toxicity;decreased risk of Side Effect:Heroin Dependence;Genotype AA is associated with decreased risk of Heroin Dependence due to heroin as compared to genotypes AG + GG.; 
;OLANZAPINE;GIPR;rs10423928;AA + AT;Toxicity;increased  severity of Side Effect:Weight gain;Genotypes AA + AT are associated with increased severity of Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype TT.;in people with Disease:Schizophrenia
;NICOTINE;CHRNA5;rs16969968;A;Toxicity;increased   Disease:Tobacco Use Disorder;Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;NICOTINE;CHRNA5;rs503464;A;Toxicity;increased   Disease:Tobacco Use Disorder;Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele T.; 
;ALLOPURINOL;CYCSP5;rs9469003;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.; 
;FLUOROURACIL;DPYD;rs1801265;G;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele G is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele A.;in people with Colorectal Neoplasms
;DAUNORUBICIN, DOXORUBICIN;SLC22A17;rs4982753;T;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele T is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.;in children with Disease:Neoplasms
;WARFARIN;VKORC1;rs9923231;TT;Efficacy;increased   Efficacy:time in therapeutic range;Genotype TT is associated with increased time in therapeutic range when treated with warfarin as compared to genotypes CC + CT.; 
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;rs9469003;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.; 
;NICOTINE;CHRNA5;rs55853698;G;Toxicity;increased   Disease:Tobacco Use Disorder;Allele G is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele T.; 
;AMANTADINE, ANTICHOLINERGICS, DOPAMINE AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;Dosage, Efficacy, Toxicity;increased  risk of Disease:Death;Allele C is associated with increased risk of Death when treated with amantadine, Anticholinergics, Dopamine agonists, levodopa or selegiline in people with Parkinson Disease.;in people with Disease:Parkinson Disease
;MELPHALAN;POLR1G;rs967591;A;Efficacy, Toxicity;increased   Efficacy:overall survival and time-to-treat failure;Allele A is associated with increased overall survival and time-to-treat failure when treated with melphalan in people with Multiple Myeloma as compared to allele G.;in people with Disease:Multiple Myeloma
;CORTICOSTEROIDS;ACOT7;rs11121611;G;Efficacy;decreased severity of Disease:Asthma;Allele G is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele T.;in children with Disease:Asthma
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;Toxicity;increased  risk of Side Effect:anemia;Genotype CC is associated with increased risk of anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;MORPHINE;TLR2;rs3804100;CC + CT;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Cognitive disorder, Side Effect:Constipation, Side Effect:adverse events;Genotypes CC + CT is associated with decreased likelihood of Nausea, Fatigue, cognitive dysfunction, Constipation or adverse events when treated with morphine in people with Pain and Neoplasms.;in people with Pain, Neoplasms
;DAUNORUBICIN, DOXORUBICIN;SLC22A7;rs4149178;G;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele G is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;ROSUVASTATIN;SCAP;rs12487736;CC + CT;Efficacy;decreased severity of Efficacy:Hyperlipidemias;Genotypes CC + CT is associated with decreased severity of Hyperlipidemias when treated with rosuvastatin in people with Metabolic Syndrome as compared to genotype TT.;in people with Disease:Metabolic Syndrome
;ALLOPURINOL;PSORS1C3;rs3094188;A;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C.; 
;CORTICOSTEROIDS;APOBEC3B;rs5995653;A;Efficacy;decreased severity of Disease:Asthma;Allele A is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele G.;in children with Disease:Asthma
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;rs3094188;A;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C.; 
;MORPHINE;COMT;rs4680;AA + AG;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotypes AA + AG is associated with decreased likelihood of Nausea, Fatigue or Depression when treated with morphine in people with Pain and Neoplasms as compared to genotype GG.;in people with Pain, Neoplasms
;GEMCITABINE, PACLITAXEL;CDA;rs2072671;CC;Toxicity;increased  risk of Side Effect:Nausea;Genotype CC is associated with increased risk of Nausea when treated with gemcitabine and paclitaxel in people with Pancreatic Neoplasms as compared to genotypes AA + AC.;in people with Pancreatic Neoplasms
;MONTELUKAST;ABCC1;rs119774;CT;Efficacy;increased   Efficacy:changes in FEV1;Genotype CT is associated with increased changes in FEV1 when treated with montelukast in people with Asthma as compared to genotype CC.;in people with Disease:Asthma
;TRIAMCINOLONE;HCG22;rs2523864;T;Toxicity;increased   Side Effect:Ocular Hypertension;Allele T is associated with increased Ocular Hypertension when treated with triamcinolone in people with Retinal Diseases as compared to allele C.;in people with Disease:Retinal Diseases
;ANTIDEPRESSANTS;CREB1, METTL21A;rs7569963;GG;Efficacy;increased  likelihood of Efficacy:remission;Genotype GG is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder, Major as compared to genotypes AA + AG.;in people with Disease:Major Depressive Disorder
;MORPHINE;IL6;rs10499563;CC;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotype CC is associated with increased likelihood of Nausea, Fatigue or Depression when treated with morphine in people with Pain and Neoplasms as compared to genotypes CT + TT.;in people with Pain, Neoplasms
;ALLOPURINOL;POU5F1;rs3130501;G;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele G is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele A.; 
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130501;G;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele G is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele A.; 
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs184278615;A;Efficacy;decreased  Efficacy:Progression-free survival;Allele A is associated with decreased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele G.;in people with Lung Neoplasms
;CITALOPRAM;;rs4675690;T;Toxicity;increased  likelihood of Side Effect:treatment-emergent suicidality;Allele T is associated with increased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;CITALOPRAM;CREB1, METTL21A;rs7569963;A;Toxicity;decreased likelihood of Side Effect:treatment-emergent suicidality;Allele A is associated with decreased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs201469165;T;Efficacy;decreased  Efficacy:Progression-free survival;Allele T is associated with decreased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele A.;in people with Lung Neoplasms
;"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;rs7412;T;Toxicity;increased  risk of Side Effect:Hypertriglyceridemia;Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;ALLOPURINOL;POU5F1;rs3130931;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.; 
;TRIAMCINOLONE;HCG22;rs3873352;G;Toxicity;increased   Side Effect:Ocular Hypertension;Allele G is associated with increased Ocular Hypertension when treated with triamcinolone in people with Retinal Diseases as compared to allele C.;in people with Disease:Retinal Diseases
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;rs3815087;A;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G.; 
;MORPHINE;IL6R;rs2228145;AC + CC;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotypes AC + CC is associated with decreased likelihood of Nausea, Fatigue or Depression when treated with morphine in people with Pain and Neoplasms as compared to genotype AA.;in people with Pain, Neoplasms
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130931;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.; 
;MORPHINE;BDNF;rs6265;TT;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotype TT is associated with decreased likelihood of Nausea, Fatigue or Depression when treated with morphine in people with Pain and Neoplasms as compared to genotypes CC + CT.;in people with Pain, Neoplasms
;ALLOPURINOL;PSORS1C1;rs3815087;A;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G.; 
;MORPHINE;IL2;rs2069762;AC + CC;Toxicity;decreased likelihood of Side Effect:Nausea, Side Effect:Fatigue, Side Effect:Depression;Genotypes AC + CC is associated with decreased likelihood of Nausea, Fatigue or Depression when treated with morphine in people with Pain and Neoplasms as compared to genotype AA.;in people with Pain, Neoplasms
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs1071748;C;Efficacy;decreased  Efficacy:Progression-free survival;Allele C is associated with decreased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele T.;in people with Lung Neoplasms
;ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;Efficacy;decreased  Efficacy:platelet aggregation;Genotypes CT + TT is associated with decreased platelet aggregation when treated with aspirin and clopidogrel as compared to genotype CC.; 
;METHOTREXATE;ABCB1;rs1128503;AA + AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;ALLOPURINOL;;rs2844665;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele T.; 
;MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AA;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype AA is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;CHLORTHALIDONE;NPPA;rs5065;G;Efficacy;decreased  Efficacy:Major Adverse Cardiac Events (MACE);Allele G is associated with decreased major adverse cardiac events (mace) when treated with chlorthalidone in people with Hypertension as compared to genotype AA.;in people with Disease:Hypertension
;METHOTREXATE;ABCB1;rs1045642;AA + AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AT is associated with increased risk of Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE;SOD2;rs4880;G;Efficacy;decreased  Efficacy:survival;Allele G is associated with decreased survival when treated with cyclophosphamide in people with Breast Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;C;Toxicity;decreased risk of Side Effect:Primary ovarian failure;Allele C is associated with decreased risk of Ovarian Failure, Premature when treated with cyclophosphamide in people with Breast Neoplasms as compared to genotype TT.;in people with Disease:Breast Neoplasms
;DOXORUBICIN;SLC22A16;rs714368;CC;Toxicity, Metabolism/PK;increased   PK:doxorubicinol AUC;Genotype CC is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes CT + TT.;in people with Disease:Breast Neoplasms
;MERCAPTOPURINE, METHOTREXATE;SLC29A1;rs747199;CC;Toxicity;decreased risk of Side Effect:Agranulocytosis, Side Effect:Leukopenia;Genotype CC is associated with decreased risk of Agranulocytosis and Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CG + GG.;in children with Disease:Acute lymphoblastic leukemia
;ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;;rs2844665;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.; 
;CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;Toxicity, Metabolism/PK;increased  risk of Side Effect:oral mucositis;Genotypes AG + GG are associated with increased risk of oral mucositis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype AA.;in people with recipients of HLA-identical hematopoietic stem cell transplantation
;CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT + TT;Toxicity, Metabolism/PK;increased  risk of Side Effect:hemorrhagic cystitis;Genotypes CT + TT are associated with increased risk of hemorrhagic cystitis when treated with cyclophosphamide in people with recipients of HLA-identical hematopoietic stem cell transplantation as compared to genotype CC.;in people with recipients of HLA-identical hematopoietic stem cell transplantation
;EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;rs973541788;G;Efficacy;decreased  Efficacy:Progression-free survival;Allele G is associated with decreased progression-free survival when treated with Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in people with Lung Neoplasms as compared to allele C.;in people with Lung Neoplasms
;AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;rs3129880;T;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele T is associated with increased risk of drug-induced liver injury when treated with amoxicillin, clavulanate or flucloxacillin as compared to allele C.; 
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;Toxicity, Metabolism/PK;decreased risk of Side Effect:venoocclusive disease of the liver;Genotypes GT + TT are associated with decreased risk of venoocclusive disease of the liver when treated with cyclophosphamide in people with HLA-identical hematopoietic stem cell transplantation as compared to genotype GG.;in people with HLA-identical hematopoietic stem cell transplantation
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371725;C;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele C is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele T.;in people with Hypertension
;OPIOIDS;OPRM1;rs1799971;GG;Toxicity;increased  severity of Side Effect:Sleep Disorders;Genotype GG is associated with increased severity of Sleep Disorders due to opioids in people with Pain as compared to genotypes AA + AG.;in people with Pain
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased   Efficacy:platelet aggregation;Genotypes AA + AG are associated with increased platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;CYCLOSPORINE, METHOTREXATE;MTHFR;rs1801133;A;Other;Side Effect:graft vs host disease;Allele A is associated with graft vs host disease when treated with cyclosporine and methotrexate in people with recipients of HLA-identical hematopoietic stem cell transplantation.;in people with recipients of HLA-identical hematopoietic stem cell transplantation
;CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;rs1695;AG + GG;Efficacy;increased  risk of Efficacy:Death;Genotypes AG + GG is associated with increased risk of Death when treated with carboplatin, cisplatin or gemcitabine in people with Gallbladder Neoplasms as compared to genotype AA.;in people with Gallbladder Neoplasms
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs2004511;T;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele T is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele C.;in people with Hypertension
;MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;CC;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotype CC is associated with increased risk of Leukopenia and Neutropenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AC.;in children with Disease:Acute lymphoblastic leukemia
;DOXORUBICIN;CBR3;rs8133052;G;Efficacy;decreased  Efficacy:tumor response;Allele G is associated with decreased tumor response when treated with doxorubicin in people with Breast Neoplasms as compared to genotype AA.;in people with Disease:Breast Neoplasms
;DOXORUBICIN;CBR3;rs8133052;G;Toxicity, Metabolism/PK;decreased severity of Disease:Neutropenia;Allele G is associated with decreased severity of Neutropenia when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms
;DOXORUBICIN;CBR3;rs1056892;A;Dosage, Metabolism/PK;increased   PK:doxorubicinol AUC;Allele A is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;ANTIHYPERTENSIVES;ATP2B1;rs1401982;AA + AG;Efficacy;increased  likelihood of Efficacy:resistant hypertension;Genotypes AA + AG is associated with increased likelihood of resistant hypertension when treated with Antihypertensives in people with Hypertension as compared to genotype GG.;in people with Hypertension
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371702;A;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure;Allele A is associated with decreased severity of Elevated diastolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to allele C.;in people with Hypertension
;MORPHINE;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:Pruritus;Genotype AA is associated with increased likelihood of Pruritus due to morphine in women with Pain, Postoperative as compared to genotypes AG + GG.;in women with Pain, Postoperative
;MERCAPTOPURINE, METHOTREXATE;SLC28A3;rs10868138;CC + CT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CC + CT is associated with increased risk of Leukopenia when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;HEROIN;GRM3;rs724226;A;Other;increased  risk of Disease:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele G.; 
;ACENOCOUMAROL;VKORC1;rs7294;T;Other;decreased likelihood of Side Effect:Hemorrhage;Allele T is associated with decreased likelihood of Hemorrhage when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to allele C.;in people with Disease:Atrial Fibrillation, Disease:Atrial Flutter, Disease:Venous Thrombosis
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased   Efficacy:residual platelet reactivity;Genotypes AA + AG are associated with increased residual platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose;Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;CORTICOSTEROIDS;CRHR1;rs242941;AA;Efficacy;increased   Efficacy:percent change in FEV;Genotype AA is associated with increased percent change in FEV when treated with corticosteroids in people with Asthma as compared to genotypes AC + CC.;in people with Disease:Asthma
;METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Osteosarcoma as compared to genotypes AG + GG.;in children with Disease:Osteosarcoma
;CORTICOSTEROIDS;FKBP5;rs4713916;AA + AG;Efficacy;increased  likelihood of Efficacy:glucocorticoid responsiveness;Genotypes AA + AG are associated with increased likelihood of glucocorticoid responsiveness when treated with corticosteroids in people with Crohn Disease as compared to genotype GG.;in people with Disease:Crohn Disease
;BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs242941;AA;Efficacy;PK:delayed cortisol response to stress;Genotype AA is associated with delayed cortisol response to stress when treated with budesonide or fluticasone propionate in children with Asthma as compared to genotypes AC + CC.;in children with Disease:Asthma
;OPIOIDS;ABCB1;rs1045642;G;Toxicity;increased  likelihood of Side Effect:Nausea;Allele G is associated with increased likelihood of Nausea due to opioids in people with Low Back Pain as compared to allele A.;in people with Low Back Pain
;CORTICOSTEROIDS;CRHR1;rs1876828;TT;Efficacy;increased   Efficacy:percent change in FEV;Genotype TT is associated with increased percent change in FEV when treated with corticosteroids in people with Asthma as compared to genotypes CC + CT.;in people with Disease:Asthma
;GEMCITABINE;;rs1155463;C;Toxicity;increased  risk of Disease:Neutropenia;Allele C is associated with increased risk of Neutropenia when treated with gemcitabine as compared to allele A.; 
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Toxicity;increased  likelihood of Side Effect:Central Nervous System Disorder;Genotypes GT + TT are associated with increased likelihood of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes AA + AT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs1876828;TT;Efficacy;PK:delayed cortisol response to stress;Genotype TT is associated with delayed cortisol response to stress when treated with budesonide or fluticasone propionate in children with Asthma as compared to genotype CT.;in children with Disease:Asthma
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes CC + CT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;rs955434;AA + AG;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;;rs61824877;A;Efficacy, Toxicity;increased  severity of Side Effect:Hyperglycemia;Allele A is associated with increased severity of Hyperglycemia when treated with chlorothiazide or hydrochlorothiazide in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;WARFARIN;VKORC1;rs9923231;CT + TT;Efficacy;decreased  Efficacy:time to therapeutic inr;Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.; 
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes CT + TT is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;TRAMADOL;OPRM1;rs1799971;GG;Toxicity;decreased likelihood of Disease:Nausea;Genotype GG is associated with decreased likelihood of Nausea when treated with tramadol as compared to genotype AA.; 
;CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;rs9943291;G;Efficacy, Toxicity;increased  severity of Side Effect:Hyperglycemia;Allele G is associated with increased severity of Hyperglycemia when treated with chlorothiazide or hydrochlorothiazide in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AG is associated with increased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;METHADONE;DAO;rs55944529;TT;Efficacy;increased  severity of Efficacy:Substance Withdrawal Syndrome;Genotype TT is associated with increased severity of Substance Withdrawal Syndrome when treated with methadone in people with Heroin Dependence as compared to genotypes CC + CT.;in people with Heroin Dependence
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in children with Acute lymphoblastic leukemia
;;KCNIP1, KCNMB1;rs11739136;CT + TT;Other;decreased risk of Disease:Hypertension;Genotypes CT + TT are associated with decreased risk of Hypertension as compared to genotype CC.; 
;INFLIXIMAB;IL1B;rs1143634;GG;Efficacy;decreased likelihood of Efficacy:Treatment failure;Genotype GG is associated with decreased likelihood of treatment failure when treated with infliximab in people with Crohn Disease as compared to genotypes AA + AG.;in people with Crohn Disease
;IRINOTECAN;UGT1A1;rs10929302;AA;Toxicity;increased  risk of Side Effect:Neutropenia, Side Effect:Vomiting;Genotype AA is associated with increased risk of Neutropenia and Vomiting when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;ATAZANAVIR;ABCB1;rs2032582;AT;Toxicity;increased  risk of Disease:Hyperbilirubinemia;Genotype AT is associated with increased risk of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections.;in people with Disease:HIV infectious disease
;DABIGATRAN;ABCB1;rs4148738;CC + CT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes CC + CT is associated with increased likelihood of Hemorrhage when treated with dabigatran in people with Stroke as compared to genotype TT.;in people with Stroke
;NICOTINE;CHRNA5;rs16969968;A;Other;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;Toxicity;decreased severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes AA + AG is associated with decreased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;INFLIXIMAB;IL23R;rs10489629;TT;Efficacy;decreased likelihood of Efficacy:Treatment failure;Genotype TT is associated with decreased likelihood of treatment failure when treated with infliximab in people with Crohn Disease as compared to genotypes CC + CT.;in people with Crohn Disease
;IRINOTECAN;UGT1A1;rs10929302;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotypes AG + GG.;in people with Disease:Neoplasms
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in children with Acute lymphoblastic leukemia
;INFLIXIMAB;SLCO1C1;rs3794271;GG;Efficacy;decreased likelihood of Efficacy:Treatment failure;Genotype GG is associated with decreased likelihood of treatment failure when treated with infliximab in people with Crohn Disease as compared to genotypes AA + AG.;in people with Crohn Disease
;NICOTINE;CHRNA3;rs578776;A;Other;decreased risk of Disease:Tobacco Use Disorder;Allele A is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;CARVEDILOL;ADRB1;rs1801253;CC;Efficacy;increased   Efficacy:improvement in left ventricular function (LVEF);Genotype CC is associated with increased improvement in left ventricular function (LVEF) when treated with carvedilol in people with Heart Failure as compared to genotype GG.;in people with Disease:Heart Failure
;PEGINTERFERON ALFA-2A;ABCB1;rs1045642;AA + AG;Efficacy;increased  likelihood of Efficacy:Cryoglobulinemia;Genotypes AA + AG is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with as compared to genotype GG.;in people with 
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;rs16906115;A;Toxicity;increased  likelihood of Side Effect:adverse events;Allele A is associated with increased likelihood of adverse events when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Neoplasms as compared to allele G.;in people with Neoplasms
;IRINOTECAN;ABCC1;rs3743527;CT + TT;Toxicity;decreased severity of Side Effect:Neutropenia;Genotypes CT + TT are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;NICOTINE;CHRNA3;rs1051730;A;Other;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;IRINOTECAN;ABCB1;rs12720066;AC + CC;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;NICOTINE;CHRNA3;rs3743078;C;Other;decreased risk of Disease:Tobacco Use Disorder;Allele C is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Acute lymphoblastic leukemia
;NICOTINE;CHRNB4;rs3813567;G;Other;decreased risk of Disease:Tobacco Use Disorder;Allele G is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.; 
;IRINOTECAN;ABCC1;rs17501331;AG + GG;Toxicity;decreased severity of Side Effect:Neutropenia;Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;CARVEDILOL;ADRB1;rs1801253;CC;Efficacy;Efficacy:significantly greater improvement in left ventricular ejection fraction (LVEF);Genotype CC is associated with significantly greater improvement in left ventricular ejection fraction (LVEF) when treated with carvedilol in people with Heart Failure as compared to genotypes CG + GG.;in people with Disease:Heart Failure
;PEGINTERFERON ALFA-2A;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased  likelihood of Efficacy:Cryoglobulinemia;Genotype CC is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with.;in people with 
;PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;Efficacy;increased  likelihood of Efficacy:Cryoglobulinemia;Genotype TT is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with.;in people with 
;;UGT1A1;rs4148323;AA;Efficacy;increased  likelihood of Side Effect:adverse events, Side Effect:Cerebral Palsy, Side Effect:Hearing Loss;Genotype AA is associated with increased likelihood of adverse events, Cerebral Palsy or Hearing Loss in children with Neonatal hyperbilirubinemia as compared to genotype GG.;in children with Neonatal hyperbilirubinemia
;PEGINTERFERON ALFA-2A;NT5C2;rs10883841;CT;Efficacy;decreased likelihood of Efficacy:Cryoglobulinemia;Genotype CT is associated with decreased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with as compared to genotype TT.;in people with 
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.; 
;INFLIXIMAB;ADAM17;rs10929587;TT;Efficacy;decreased likelihood of Efficacy:Treatment failure;Genotype TT is associated with decreased likelihood of treatment failure when treated with infliximab in people with Crohn Disease as compared to genotypes AA + AT.;in people with Crohn Disease
;CLOPIDOGREL;MED12L, P2RY12;rs10935838;AG;Efficacy;decreased  Efficacy:platelet aggregation;Genotype AG is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;;ago-02;rs4961280;AA + AC;Other;decreased  Other:Progression-free survival;Genotypes AA + AC is associated with decreased progression-free survival in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Renal Cell Carcinoma
;STAVUDINE;TNF;rs1799964;C;Toxicity;increased  likelihood of Side Effect:neuropathy;Allele C is associated with increased likelihood of neuropathy when treated with stavudine in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;MED12L, P2RY12;rs2046934;AG;Efficacy;decreased  Efficacy:platelet aggregation;Genotype AG is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype AA.;in healthy individuals 
;CLOPIDOGREL;MED12L, P2RY12;rs6809699;AC;Efficacy;decreased  Efficacy:platelet aggregation;Genotype AC is associated with decreased platelet aggregation when exposed to clopidogrel in healthy individuals as compared to genotype CC.;in healthy individuals 
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;NICOTINE;CHRNA5;rs684513;G;Other;decreased risk of Disease:Tobacco Use Disorder;Allele G is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele C.; 
;AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606618;C;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele C is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele T.; 
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Acute lymphoblastic leukemia
;NICOTINE;CHRNA5;rs637137;A;Other;decreased risk of Disease:Tobacco Use Disorder;Allele A is associated with decreased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele T.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;;IL1A;rs1800587;A;Other;increased  severity of Disease:Pain;Allele A is associated with increased severity of Pain in people with Anemia, Sickle Cell as compared to allele G.;in people with Disease:Anemia, Sickle Cell
;FLUTICASONE / SALMETEROL;CRHR1;rs242941;CC;Efficacy;increased   Efficacy:mean change in FEV;Genotype CC is associated with increased mean change in FEV when treated with fluticasone/salmeterol in people with Pulmonary Disease, Chronic Obstructive as compared to genotype AC.;in people with Disease:Chronic Obstructive Pulmonary Disease
;PROPRANOLOL;COMT;rs4680;G;Efficacy;increased  severity of Efficacy:Pain;Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele A.;in women with Efficacy:Pain, Disease:Temporomandibular Joint Disorder
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2A;CYP27B1, METTL1;rs10877012;GT + TT;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Genotypes GT + TT is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a in people with Hepatitis B as compared to genotype GG.;in people with Disease:Hepatitis B virus infection
;PROPRANOLOL;COMT;rs4818;G;Efficacy;increased  severity of Efficacy:Pain;Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele C.;in women with Efficacy:Pain, Disease:Temporomandibular Joint Disorder
;CORTICOSTEROIDS;APOBEC3B;rs6001366;T;Efficacy;decreased severity of Disease:Asthma;Allele T is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele C.;in children with Disease:Asthma
;PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a in people with Hepatitis B as compared to genotypes CC + CT.;in people with Disease:Hepatitis B virus infection
;CORTICOSTEROIDS;KCNN1;rs2278992;C;Efficacy;decreased severity of Disease:Asthma;Allele C is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele T.;in children with Disease:Asthma
;PEGINTERFERON ALFA-2A;VDR;rs7975232;AA;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Genotype AA is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a in people with Hepatitis B as compared to genotypes AC + CC.;in people with Disease:Hepatitis B virus infection
;CORTICOSTEROIDS;ANKRD30B;rs12959468;A;Efficacy;decreased severity of Disease:Asthma;Allele A is associated with decreased severity of Asthma when treated with corticosteroids in children with Asthma as compared to allele G.;in children with Disease:Asthma
;ROSUVASTATIN;CRP;rs1205;CT + TT;Efficacy, Other, Metabolism/PK;decreased  Other:plasma level of high-sensitivity C-reactive protein;Genotypes CT + TT are associated with decreased plasma level of high-sensitivity C-reactive protein when treated with rosuvastatin in people with Coronary Disease as compared to genotype CC.;in people with Disease:Coronary Disease
;PROPRANOLOL;COMT;rs6269;G;Efficacy;increased  severity of Efficacy:Pain;Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele A.;in women with Efficacy:Pain, Disease:Temporomandibular Joint Disorder
;ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;Toxicity;increased  severity of Side Effect:Neutropenia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Anemia;Genotypes CC + CG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;RISPERIDONE;HTR2A;rs6311;TT;Toxicity;decreased likelihood of Side Effect:adverse events;Genotype TT is associated with decreased likelihood of adverse events when treated with risperidone in children as compared to genotypes CC + CT.;in children 
;HEROIN;GRM3;rs2189814;T;Other;increased  risk of Disease:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C.; 
;ROSUVASTATIN;;rs2808630;CC + CT;Efficacy, Other, Metabolism/PK;decreased  Other:plasma level of high-sensitivity C-reactive protein;Genotypes CC + CT are associated with decreased plasma level of high-sensitivity C-reactive protein when treated with rosuvastatin in people with Coronary Disease as compared to genotype TT.;in people with Disease:Coronary Disease
;METHADONE;OPRD1;rs204076;AT + TT;Efficacy;increased   Efficacy:Overall survival;Genotypes AT + TT is associated with increased overall survival when treated with methadone in people with Opioid-Related Disorders as compared to genotype AA.;in people with Opioid-Related Disorders
;ROSUVASTATIN;HNF1A;rs1169288;AC + CC;Efficacy, Other, Metabolism/PK;decreased  Other:plasma level of high-sensitivity C-reactive protein;Genotypes AC + CC are associated with decreased plasma level of high-sensitivity C-reactive protein when treated with rosuvastatin in people with Coronary Disease as compared to genotype AA.;in people with Disease:Coronary Disease
;METOPROLOL;ADRB1;rs1801253;CC;Efficacy;increased   Efficacy:improvement in left ventricular(LV) remodeling and greater increase in LVEF (left ventricular ejection fraction);Genotype CC is associated with increased improvement in left ventricular(LV) remodeling and greater increase in LVEF (left ventricular ejection fraction) when treated with metoprolol in people with Heart Failure as compared to genotypes CG + GG.;in people with Disease:Heart Failure
;PROPRANOLOL;COMT;rs4633;C;Efficacy;increased  severity of Efficacy:Pain;Allele C is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele T.;in women with Efficacy:Pain, Disease:Temporomandibular Joint Disorder
;BUCINDOLOL;ADRB1;rs1801253;CC;Efficacy;increased   Efficacy:response;Genotype CC is associated with increased response when treated with bucindolol in people with Heart Failure as compared to genotype GG.;in people with Disease:Heart Failure
;ERYTHROMYCIN;CYP3A4;rs35599367;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with erythromycin in people with Bacterial Infections and Influenza as compared to genotype GG.;in people with Bacterial Infections, Influenza
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Allele A is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;ASPIRIN;PEAR1;rs12041331;AA + AG;Toxicity;increased  risk of Disease:Myocardial Infarction;Genotypes AA + AG are associated with increased risk of Myocardial Infarction when treated with aspirin as compared to genotype GG.; 
;;KCNIP1, KCNMB1;rs11739136;CT + TT;Other;decreased  Other:blood pressure;Genotypes CT + TT are associated with decreased blood pressure in men as compared to genotype CC.;in men 
;TACROLIMUS;ABCB1;rs2032582;A;Efficacy;increased  likelihood of Efficacy:Transplant rejection;Allele A is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele C.;in children with Kidney Transplantation
;CAFFEINE, ISOFLURANE;RYR1;rs118192162;AC;Toxicity;Disease:Malignant Hyperthermia;Genotype AC is associated with Malignant Hyperthermia when exposed to caffeine or isoflurane as compared to genotype AA.; 
;RISPERIDONE;NR1I2;rs7643645;GG;Metabolism/PK;decreased  PK:9-hydroxy-risperidone levels;Genotype GG is associated with decreased 9-hydroxy-risperidone levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.;in people with Disease:Psychotic Disorder
;REPAGLINIDE;SLCO1B1;rs2306283;GG;Other, Metabolism/PK;decreased  PK:repaglinide plasma concentration (AUC) and Cmax;Genotype GG is associated with decreased repaglinide plasma concentration (AUC) and Cmax when exposed to repaglinide in healthy individuals as compared to genotype AA.;in healthy individuals 
;HALOTHANE;RYR1;rs118192161;CT;Toxicity;Disease:Malignant Hyperthermia;Genotype CT is associated with Malignant Hyperthermia when exposed to halothane as compared to genotype CC.; 
;RISPERIDONE;NR1I2;rs7643645;GG;Metabolism/PK;decreased  PK:active moiety levels;Genotype GG is associated with decreased active moiety levels when treated with risperidone in people with Psychotic Disorders as compared to genotype AA.;in people with Disease:Psychotic Disorder
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy, Toxicity;increased  risk of Side Effect:stent thrombosis;Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.;in people with Disease:Myocardial Infarction
;TACROLIMUS;ABCB1;rs1045642;G;Efficacy;increased  likelihood of Efficacy:Transplant rejection;Allele G is associated with increased likelihood of transplant rejection when treated with tacrolimus in children with Kidney Transplantation as compared to allele A.;in children with Kidney Transplantation
;GEFITINIB;CYP2D6;rs1065852;AA + AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AG is associated with decreased progression-free survival when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Non-Small Cell Lung Carcinoma
;DALCETRAPIB;ADCY9;rs1967309;AA;Efficacy;decreased risk of Efficacy:Major Adverse Cardiac Events (MACE);Genotype AA is associated with decreased risk of major adverse cardiac events (mace) when treated with dalcetrapib in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;EGFR INHIBITORS;PIK3CA;rs6443624;C;Toxicity;decreased likelihood of Disease:Exanthema;Allele C is associated with decreased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;EGFR INHIBITORS;PIK3CA;rs2677760;T;Toxicity;decreased likelihood of Disease:Exanthema;Allele T is associated with decreased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;MISOPROSTOL;SLCO1B1;rs4149087;GG;Toxicity;increased  likelihood of Side Effect:Fever;Genotype GG is associated with increased likelihood of Fever when treated with misoprostol in women with Postpartum hemorrhage NOS as compared to genotypes GT + TT.;in women with Disease:Post-partum hemorrhage
;MISOPROSTOL;ABCC4;rs11568658;AA;Toxicity;increased  likelihood of Side Effect:Fever;Genotype AA is associated with increased likelihood of Fever when treated with misoprostol in women with Postpartum hemorrhage NOS or Therapeutic abortion as compared to genotypes AC + CC.;in women with Disease:Post-partum hemorrhage, Disease:Therapeutic abortion
;ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;A;Efficacy;decreased  Efficacy:collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration;Allele A is associated with decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration when treated with aspirin and clopidogrel as compared to allele G.; 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;TT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CC + CT.;in people with Disease:Tuberculosis
;CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;rs11710163;AG;Efficacy;increased   Efficacy:Overall survival;Genotype AG is associated with increased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs12248560;T;Toxicity;decreased risk of Disease:Myocardial Infarction;Allele T is associated with decreased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.;in people with Disease:Coronary Artery Disease
;ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;Toxicity;increased   Side Effect:cardiovascular events in patients undergoing PCI;Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.; 
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased risk of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;OLANZAPINE;GSTP1;rs1695;AG + GG;Toxicity;increased  severity of Side Effect:Elevated liver enzymes;Genotypes AG + GG is associated with increased severity of elevated liver enzymes when treated with olanzapine in people with Schizophrenia or schizoaffective disorder as compared to genotype AA.;in people with Schizophrenia, Schizoaffective disorder
;ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;Toxicity;increased   Side Effect:cardiovascular events in patients undergoing PCI;Genotypes AA + AG are associated with increased cardiovascular events in patients undergoing PCI when treated with aspirin and clopidogrel as compared to genotype GG.; 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;ALOX15;rs3892408;C;Toxicity;increased  likelihood of Side Effect:Aspirin-induced asthma;Allele C is associated with increased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele T.;in people with Disease:Asthma
;METHADONE;CCL11;rs1129844;A;Toxicity;increased   Side Effect:Insomnia;Allele A is associated with increased insomnia due to methadone in people with Opioid-Related Disorders as compared to allele G.;in people with Disease:Opioid-Related Disorders
;EGFR INHIBITORS;PIK3CA;rs2699905;C;Toxicity;decreased likelihood of Disease:Exanthema;Allele C is associated with decreased likelihood of Exanthema when treated with egfr inhibitors in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;FLUOXETINE;;rs2433320;GG;Efficacy;decreased  Efficacy:HAMD scores;Genotype GG is associated with decreased HAMD scores when treated with fluoxetine in people with Depressive Disorder, Major as compared to genotypes AA + AG.;in people with Disease:Major Depressive Disorder
;ANTIPSYCHOTICS;MTHFR;rs1801133;G;Toxicity;increased   Side Effect:Weight gain;Allele G is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to allele A.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotypes CG + GG are associated with increased risk of Toxic liver disease when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs5789;C;Toxicity;decreased likelihood of Side Effect:Aspirin-induced asthma;Allele C is associated with decreased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele A.;in people with Disease:Asthma
;CLOZAPINE, OLANZAPINE;MTHFR;rs1801131;GG;Toxicity;increased   Side Effect:Weight gain;Genotype GG is associated with increased Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotype GT.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotype CT is associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype CC.;in people with Disease:Tuberculosis
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;rs738409;G;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Allele G is associated with increased likelihood of elevated liver enzymes when treated with cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mercaptopurine, methotrexate, pegaspargase, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;Toxicity;increased  severity of Side Effect:Diarrhea, Side Effect:Drug Toxicity;Genotype CC is associated with increased severity of Diarrhea or Drug Toxicity when treated with leucovorin and tegafur in people with Rectal Neoplasms as compared to genotypes CG + GG.;in people with Rectal Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;GEFITINIB;EGFR;rs121434568;T;Efficacy;decreased  Efficacy:progression-free survival (PFS) time;Allele T is associated with decreased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation negative non-small-cell lung cancer.;in people with EGFR mutation negative non-small-cell lung cancer
;CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs726501;AA + AG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;Toxicity;decreased likelihood of Disease:Maculopapular Exanthema;Genotypes CT + TT are associated with decreased likelihood of Maculopapular Exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype CC.;in people with Disease:Tuberculosis
;ANTHRACYCLINES AND RELATED SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;rs17102977;AA;Efficacy;increased   Efficacy:event-free survival;Genotype AA is associated with increased event-free survival when treated with anthracyclines and related substances, cyclophosphamide, fluorouracil or taxanes in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Breast Neoplasms
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;rs1142345;C;Toxicity;decreased likelihood of Side Effect:Elevated liver enzymes;Allele C is associated with decreased likelihood of elevated liver enzymes when treated with cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mercaptopurine, methotrexate, pegaspargase, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.;in children with Acute lymphoblastic leukemia
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;Toxicity;decreased likelihood of Disease:Maculopapular Exanthema;Genotypes AA + AG are associated with decreased likelihood of Maculopapular Exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;SIMVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:dose decrease or switch to another cholesterol-lowering drug;Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.; 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;A;Toxicity;increased  likelihood of Side Effect:Aspirin-induced asthma;Allele A is associated with increased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele T.;in people with Disease:Asthma
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;IMATINIB;SLC22A1;rs683369;CG + GG;Efficacy;decreased  Disease:event-free survival;Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;ANTIPSYCHOTICS;GABRG3;rs2061051;A;Toxicity;increased  severity of Disease:Tardive Dyskinesia;Allele A is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;GEMCITABINE;;rs642990;CT + TT;Toxicity;decreased risk of Disease:Neutropenia;Genotypes CT + TT is associated with decreased risk of Neutropenia when treated with gemcitabine as compared to genotype CC.; 
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:longer median progression-free survival time;Allele G is associated with increased longer median progression-free survival time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs16886403;CC + CT;Efficacy;decreased  Efficacy:Overall survival;Genotypes CC + CT are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;GEMCITABINE;RRM1;rs1042858;A;Dosage;decreased risk of Side Effect:neutropenia;Allele A is associated with decreased risk of neutropenia when treated with gemcitabine in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;;rs17661089;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;rs17309872;AT;Efficacy;decreased  Efficacy:Overall survival;Genotype AT is associated with decreased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;ABCC1;rs246240;AG + GG;Toxicity;decreased risk of Side Effect:onset of toxicity;Genotypes AG + GG are associated with decreased risk of onset of toxicity when treated with methotrexate in people with Psoriasis as compared to genotype AA.;in people with Disease:Psoriasis
;BUPROPION, NICOTINE;EPB41;rs6702335;AA;Efficacy;increased   Efficacy:abstinence;Genotype AA is associated with increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to genotype GG.;in men with Disease:Tobacco Use Disorder
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;rs62328061;G;Toxicity;decreased risk of Side Effect:Leukopenia;Allele G is associated with decreased risk of Leukopenia when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.;in people with Tuberculosis
;;IL17F;rs763780;CC;Other;increased  likelihood of Other:Recurrent pregnancy loss;Genotype CC is associated with increased likelihood of Abortion, Habitual in women with Pregnancy as compared to genotypes CT + TT.;in women with Pregnancy
;DAUNORUBICIN;NOS3;rs1799983;GG;Efficacy;increased   Efficacy:Overall survival;Genotype GG is associated with increased overall survival when treated with daunorubicin in people with Leukemia, Myeloid, Acute as compared to genotypes GT + TT.;in people with Disease:Leukemia, Myeloid, Acute
;;IL17A;rs2275913;AA;Other;increased  likelihood of Other:Recurrent pregnancy loss;Genotype AA is associated with increased likelihood of Abortion, Habitual in women with Pregnancy as compared to genotypes AG + GG.;in women with Pregnancy
;ACE INHIBITORS, PLAIN;KCNIP4;rs145489027;A;Other;increased  likelihood of Side Effect:Cough;Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele G.; 
;PEMETREXED;ATIC;rs12995526;C;Efficacy;increased   Efficacy:Overall survival;Allele C is associated with increased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;OPIOIDS;PDYN;rs910080;A;Toxicity;increased  risk of Side Effect:Opioid-Related Disorders;Allele A is associated with increased risk of Opioid-Related Disorders due to opioids as compared to allele G.; 
;IRINOTECAN;UGT1A1;rs4148323;AA + AG;Toxicity;increased  risk of Disease:Neutropenia;Genotypes AA + AG is associated with increased risk of Neutropenia when treated with irinotecan in people with biliary tract neoplasms and Pancreatic Neoplasms as compared to genotype GG.;in people with Disease:Biliary tract neoplasm, Disease:Pancreatic Neoplasms
;ACE INHIBITORS, PLAIN;KCNIP4;rs1495509;C;Other;increased  likelihood of Side Effect:Cough;Allele C is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele T.; 
;FOLFIRI, FOLFOX, XELOX;MTHFR;rs1801131;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes GT + TT.;in people with Colorectal Neoplasms
;GEMCITABINE;ALG10;rs1705772;AA + AG;Toxicity;decreased risk of Side Effect:toxicity;Genotypes AA + AG is associated with decreased risk of toxicity when treated with gemcitabine as compared to genotype GG.; 
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  risk of Side Effect:Myelosuppression;Genotypes CT + TT is associated with increased risk of Myelosuppression when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;rs887829;T;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with cyclophosphamide, cytarabine, daunorubicin, doxorubicin, mercaptopurine, methotrexate, pegaspargase, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;RITONAVIR;APOC3;rs2854116;C;Other;increased  risk of Disease:Hypertriglyceridemia;Allele C is associated with increased risk of Hypertriglyceridemia when treated with ritonavir in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;PEMETREXED;GGH;rs16930092;CT + TT;Efficacy;increased   Efficacy:Progression-free survival;Genotypes CT + TT is associated with increased progression-free survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANASTROZOLE;UGT1A4;rs3732218;GG;Metabolism/PK;increased   PK:glucuronidation;Genotype GG is associated with increased glucuronidation of anastrozole in human liver microsomes as compared to genotypes AA + AG.;in human liver microsomes
;HALOPERIDOL;CYP2D6;rs3892097;CT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype CT is associated with increased likelihood of adverse events when treated with haloperidol in men with Alcohol Withdrawal Delirium as compared to genotype CC.;in men with Alcohol Withdrawal Delirium
;FOLFIRI, FOLFOX, XELOX;ABCB1;rs1045642;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Colorectal Neoplasms
;ACE INHIBITORS, PLAIN;KCNIP4;rs7675300;A;Other;increased  likelihood of Side Effect:Cough;Allele A is associated with increased likelihood of Cough when treated with Ace Inhibitors, Plain as compared to allele C.; 
;CYCLOPHOSPHAMIDE;VEGFA;rs2010963;CC;Efficacy;decreased  Efficacy:progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with cyclophosphamide in people with Prostatic Neoplasms as compared to genotypes CG + GG.;in people with Disease:Prostatic Neoplasms
;NICOTINE;CHRNA3;rs1051730;A;Other;increased  likelihood of Other:smoking;Allele A is associated with increased likelihood of smoking when exposed to nicotine in women smokers who are pregnant as compared to allele G.;in women smokers who are pregnant
;NEVIRAPINE;TRAF3IP2;rs76228616;C;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in people with HIV as compared to allele G.;in people with Disease:HIV infectious disease
;GEMCITABINE;ALOX5AP;rs4769060;AG + GG;Metabolism/PK;decreased  PK:Cmax and a lower mean AUC;Genotypes AG + GG is associated with decreased Cmax and a lower mean AUC when treated with gemcitabine as compared to genotype AA.; 
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;SUFENTANIL;OPRM1;rs1799971;AG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype AG is associated with increased likelihood of adverse events due to sufentanil in people with Pain, Postoperative as compared to genotype AA.;in people with Pain, Postoperative
;IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;rs16906115;AA + AG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes AA + AG is associated with increased likelihood of adverse events when treated with ipilimumab, nivolumab or pembrolizumab as compared to genotype GG.; 
;GEMTUZUMAB OZOGAMICIN;CD33;rs1803254;CC + CG;Toxicity;increased   Side Effect:Death;Genotypes CC + CG are associated with increased Death when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to genotype GG.;in children with Disease:Leukemia, Myeloid, Acute
;FOLFIRI, FOLFOX, XELOX;BRAF;rs113488022;T;Efficacy;decreased  Efficacy:Overall survival;Allele T is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.;in people with Colorectal Neoplasms
;METHOTREXATE;CLCN6, MTHFR;rs1801133;AG + GG;Toxicity;increased  severity of Side Effect:Leukopenia;Genotypes AG + GG are associated with increased severity of Leukopenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;OPIOIDS;TH;rs2070762;G;Toxicity;increased  risk of Disease:Opioid-Related Disorders;Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.; 
;GEMTUZUMAB OZOGAMICIN;CD33;rs35112940;GG;Efficacy;increased   Efficacy:Overall survival;Genotype GG is associated with increased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in children with Disease:Leukemia, Myeloid, Acute
;ISONIAZID, RIFAMPIN;CYP2E1, DUX1;rs6413432;AT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype AT is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;CISPLATIN;SLC22A2;rs316019;A;Toxicity;decreased risk of Side Effect:Ototoxicity;Allele A is associated with decreased risk of Ototoxicity when treated with cisplatin as compared to allele C.; 
;ANTINEOPLASTIC AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;rs1059829;AG + GG;Efficacy;increased   Efficacy:time to tumor recurrence;Genotypes AG + GG are associated with increased time to tumor recurrence when treated with antineoplastic agents, fluorouracil and leucovorin in people with Stomach Neoplasms as compared to genotype AA.;in people with Disease:Stomach Neoplasms
;OPIOIDS;DBH;rs1611131;G;Toxicity;decreased risk of Disease:Opioid-Related Disorders;Allele G is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.; 
;ANTIPSYCHOTICS;HSPG2;rs2445142;C;Toxicity;increased  severity of Disease:Tardive Dyskinesia;Allele C is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;FOLFIRI, FOLFOX, XELOX;DPYD;rs1801265;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with FOLFIRI, FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.;in people with Colorectal Neoplasms
;ANTIPSYCHOTICS;HSPG2;rs878949;T;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Allele T is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;QUETIAPINE;RIMS1;rs502046;CC + CT;Efficacy, Toxicity;decreased likelihood of Efficacy:Discontinuation;Genotypes CC + CT is associated with decreased likelihood of discontinuation when treated with quetiapine in people with Schizophrenia as compared to genotype TT.;in people with Disease:Schizophrenia
;ETHANOL;TAS2R16;rs846664;C;Other;increased  risk of Disease:Alcohol abuse;Allele C is associated with increased risk of Alcoholism due to ethanol as compared to allele A.; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;G;Toxicity;decreased likelihood of Side Effect:Drug-induced liver injury;Allele G is associated with decreased likelihood of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele A.;in people with Tuberculosis
;METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;GG + GT;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes GG + GT are associated with increased severity of Neutropenia due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in people with EGFR mutation positive non-small-cell lung cancer.;in people with EGFR mutation positive non-small-cell lung cancer
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.;in women 
;SORAFENIB;KDR;rs2239702;CT + TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes CT + TT are associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;FLUOROURACIL;SCN1A;rs3812718;CC;Other;decreased  Other:time to tumor recurrence (TTR);Genotype CC is associated with decreased time to tumor recurrence (TTR) when treated with fluorouracil in Colorectal Neoplasms as compared to genotypes CT + TT.;in Disease:Colorectal Neoplasms
;EFAVIRENZ;CYP2B6;rs3745274;GT + TT;Efficacy;increased  likelihood of Efficacy:Discontinuation;Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs510769;CT + TT;Efficacy;decreased severity of Efficacy:Pain;Genotypes CT + TT is associated with decreased severity of Pain when treated with acetaminophen, antiepileptics, Antiinflammatory agents, non-steroids or opioids in people with Colorectal Neoplasms and Metastatic neoplasm as compared to genotype CC.;in people with Colorectal Neoplasms, Metastatic neoplasm
;WARFARIN;VKORC1;rs9934438;A;Efficacy;decreased  Efficacy:time in therapeutic range;Allele A is associated with decreased time in therapeutic range when treated with warfarin as compared to allele G.; 
;OPIOIDS;DRD2;rs1076560;A;Toxicity;increased  risk of Disease:Opioid-Related Disorders;Allele A is associated with increased risk of Opioid-Related Disorders due to opioids as compared to allele C.; 
;EFAVIRENZ;NR1I2;rs2472677;TT;Efficacy;decreased likelihood of Efficacy:Discontinuation;Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.;in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Efficacy;increased   Efficacy:virological response;Genotype TT is associated with increased virological response when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;CETUXIMAB;KRAS;rs112445441;T;Efficacy;increased   Efficacy:Overall survival;Allele T is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;rs1801133;AA;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in children with Osteosarcoma as compared to genotypes AG + GG.;in children with Disease:Osteosarcoma
;SORAFENIB;VEGFA;rs2010963;CG + GG;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotypes CG + GG are associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;rs1805087;GG;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype GG is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to genotypes AA + AG.;in people with Disease:Osteosarcoma
;SORAFENIB;ABCB1;rs1045642;AA + AG;Toxicity;increased  risk of Side Effect:Hypertension;Genotypes AA + AG are associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;SORAFENIB;VEGFA;rs1570360;AA + AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AG are associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;ATORVASTATIN;ABCG2;rs2231142;GT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Muscular Diseases, Side Effect:Rhabdomyolysis, Side Effect:Toxic liver disease;Genotypes GT + TT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis or Toxic liver disease when treated with atorvastatin as compared to genotype GG.; 
;COCAINE, HEROIN;OPRM1;rs62638690;T;Toxicity;decreased likelihood of Disease:Cocaine dependence, Disease:Heroin Dependence;Allele T is associated with decreased likelihood of Cocaine-Related Disorders or Heroin Dependence due to cocaine or heroin as compared to allele G.; 
;SORAFENIB;KDR;rs2239702;CT + TT;Efficacy;decreased  Efficacy:Overall survival;Genotypes CT + TT are associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;EFAVIRENZ;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Central Nervous System Disorder;Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;CETUXIMAB, PANITUMUMAB;KRAS;rs112445441;A;Efficacy;increased   Efficacy:Overall survival;Allele A is associated with increased overall survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;rs1799853;T;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.;in women 
;;MTR;rs1805087;GG;Other;increased  likelihood of Disease:Rheumatoid arthritis;Genotype GG is associated with increased likelihood of Arthritis, Rheumatoid as compared to genotypes AA + AG.; 
;METHOTREXATE;MTR;rs1805087;GG;Toxicity;increased  likelihood of Side Effect:methotrexate-induced nodulosis;Genotype GG is associated with increased likelihood of methotrexate-induced nodulosis when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.;in people with Disease:Rheumatoid arthritis
;"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;rs2236861;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AG + GG is associated with increased likelihood of Drug Toxicity when treated with acetaminophen, antiepileptics, Antiinflammatory agents, non-steroids or opioids in people with Colorectal Neoplasms and Metastatic neoplasm as compared to genotype AA.;in people with Colorectal Neoplasms, Metastatic neoplasm
;PRAVASTATIN;SLCO1B1;rs4149056;CT;Metabolism/PK;increased   PK:AUC0-12;Genotype CT is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype TT.;in healthy individuals 
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele A is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele G.;in women 
;EFAVIRENZ;CYP2B6;rs3745274;TT;Efficacy;increased  risk of Efficacy:Discontinuation;Genotype TT is associated with increased risk of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;FLUOROURACIL;SCN1A;rs3812718;TT;Other;decreased  Other:time to tumor recurrence (TTR);Genotype TT is associated with decreased time to tumor recurrence (TTR) when treated with fluorouracil in Colorectal Neoplasms as compared to genotypes CC + CT.;in Disease:Colorectal Neoplasms
;ATAZANAVIR;UGT1A1;rs887829;T;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with atazanavir in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;SIMVASTATIN;SLCO1B1;rs4363657;CC;Toxicity;increased  likelihood of Side Effect:Muscular Diseases;Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.;in people with Disease:Myocardial Infarction
;EFAVIRENZ;CYP2B6;rs28399499;CC + CT;Toxicity;decreased risk of Side Effect:Central Nervous System Disorder;Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.; 
;TACROLIMUS;CYP3A5;rs776746;CT;Toxicity;increased  risk of Disease:Nephrotoxicity;Genotype CT is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;SIMVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  likelihood of Disease:Muscular Diseases;Genotype CC is associated with increased likelihood of Muscular Diseases when treated with simvastatin in people with Myocardial Infarction as compared to genotype TT.;in people with Disease:Myocardial Infarction
;EFAVIRENZ;CYP2B6;rs4803419;CT + TT;Toxicity;increased  risk of Side Effect:Central Nervous System Disorder;Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC.;in people with Disease:HIV infectious disease
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.; 
;FLUOROURACIL;DPYD;rs1801160;CT;Metabolism/PK;decreased  PK:DPD activity;Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype CC.;in healthy individuals 
;ALLOPURINOL;PSORS1C1;rs3131003;AG + GG;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;Genotypes AG + GG is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype AA.; 
;FLUOROURACIL;MTHFR;rs1801133;GG;Efficacy;increased   Disease:event-free survival, Disease:Overall survival;Genotype GG is associated with increased event-free survival and overall survival when treated with fluorouracil in people with Rectal Neoplasms as compared to genotype AA.;in people with Disease:Rectal Neoplasms
;OPIOIDS;PDYN;rs1997794;CT + TT;Toxicity;increased  likelihood of Disease:Opioid-Related Disorders;Genotypes CT + TT is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to genotype CC.; 
;ONDANSETRON;ABCB1;rs1045642;GG;Efficacy;increased  likelihood of Side Effect:Vomiting;Genotype GG is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.;in people with Disease:Leukemia, Myeloid, Acute
;DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;Toxicity;increased  likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotype GG is associated with increased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotypes CC + CG.;in children with surgery
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs1799971;AA;Efficacy;increased  likelihood of Efficacy:Pain;Genotype AA is associated with increased likelihood of Pain when treated with acetaminophen, antiepileptics, Antiinflammatory agents, non-steroids or opioids in people with Colorectal Neoplasms and Metastatic neoplasm as compared to genotypes AG + GG.;in people with Colorectal Neoplasms, Metastatic neoplasm
;OPIOIDS;PDYN;rs1022563;CC;Toxicity;increased  likelihood of Disease:Opioid-Related Disorders;Genotype CC is associated with increased likelihood of Opioid-Related Disorders due to opioids as compared to genotypes CT + TT.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;Efficacy:Sustained virological response (SVR);Genotype CC is associated with sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;RISPERIDONE;LEP;rs7799039;GG;Toxicity;increased  likelihood of Side Effect:Obesity;Genotype GG is associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AA + AG.;in children with Disease:Atypical behavior, Disease:Mental Disorders
;PERINDOPRIL;AGTR1;rs5182;TT;Efficacy;decreased risk of Efficacy:cardiac events;Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes CC + CT.;in people with Disease:Coronary Artery Disease
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;Efficacy:sustained virological response (SVR) and changes in viral load after 4 weeks of treatment;Genotype TT is associated with sustained virological response (SVR) and changes in viral load after 4 weeks of treatment when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;GEMCITABINE;CDA;rs2072671;AC + CC;Toxicity;increased  risk of Side Effect:severe neutropenia;Genotypes AC + CC are associated with increased risk of severe neutropenia due to gemcitabine in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;CYTARABINE;CDA;rs602950;GG;Efficacy, Metabolism/PK;increased   Efficacy:cytotoxicity;Genotype GG is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.;in people with Disease:Leukemia, Myeloid
;HALOPERIDOL;CYP2D6;rs3892097;CC;Toxicity;decreased likelihood of Side Effect:adverse events;Genotype CC is associated with decreased likelihood of adverse events when treated with haloperidol in men with Alcohol-Related Disorders, Alcoholic psychosis NOS and Alcoholism as compared to genotype CT.;in men with Disease:Alcoholic psychosis, Disease:Alcohol abuse, Disease:Alcohol-Related Disorders
;CYTARABINE;CDA;rs532545;TT;Efficacy, Metabolism/PK;increased   Efficacy:cytotoxicity;Genotype TT is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype CC.;in people with Disease:Leukemia, Myeloid
;ALLOPURINOL;CYCSP5;rs3099844;AA + AC;Toxicity;increased  risk of Disease:Severe Cutaneous Adverse Reactions;Genotypes AA + AC are associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype CC.; 
;BISPHOSPHONATES;RBMS3;rs17024608;A;Toxicity;increased  likelihood of Disease:Osteonecrosis;Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G.; 
;;NEDD4L;rs4149601;AG;Other;increased  risk of Disease:Cardiovascular Disease;Genotype AG is associated with increased risk of Cardiovascular Diseases in people with Hypertension.;in people with Disease:Hypertension
;FLUOROURACIL;DPYD;rs55886062;AC;Metabolism/PK;decreased  PK:DPD activity;Genotype AC is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype AA.;in healthy individuals 
;ANTIPSYCHOTICS;INSIG2;rs17587100;C;Other;increased  severity of Side Effect:weight gain;Allele C is associated with increased severity of weight gain when treated with antipsychotics in people with Schizophrenia as compared to allele A.;in people with Disease:Schizophrenia
;ONDANSETRON;ABCB1;rs2032582;CC;Efficacy;increased  likelihood of Side Effect:Vomiting;Genotype CC is associated with increased likelihood of Vomiting when treated with ondansetron in people with Leukemia, Myeloid, Acute.;in people with Disease:Leukemia, Myeloid, Acute
;;CTLA4;rs3087243;A;Other;decreased risk of Disease:Rheumatoid arthritis;Allele A is associated with decreased risk of Arthritis, Rheumatoid as compared to allele G.; 
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780094;CC + CT;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CT is associated with increased overall survival when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT.;in people with Disease:Stomach Neoplasms
;FLUOROURACIL;DPYD;rs115232898;CT;Metabolism/PK;decreased  PK:DPD activity;Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype TT.;in healthy individuals 
;RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with ribavirin and sofosbuvir in people with Hepatitis C, Chronic and Liver Cirrhosis as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection, Disease:Liver Cirrhosis
;TENOFOVIR;ABCC4;rs1059751;G;Toxicity;increased  likelihood of Disease:Kidney Disorder;Allele G is associated with increased likelihood of Kidney Diseases when treated with tenofovir in people with HIV Infections as compared to allele A.;in people with Disease:HIV infectious disease
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs6769511;C;Efficacy;increased  likelihood of Efficacy:Disease Progression;Allele C is associated with increased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to allele T.;in people with Disease:Stomach Neoplasms
;WARFARIN;VKORC1;rs9934438;A;Efficacy;decreased  Efficacy:time to therapeutic inr;Allele A is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele G.; 
;CYTARABINE;CDA;rs2072671;CC;Efficacy, Metabolism/PK;increased   Efficacy:cytotoxicity;Genotype CC is associated with increased cytotoxicity when exposed to cytarabine in people with Leukemia, Myeloid as compared to genotype AA.;in people with Disease:Leukemia, Myeloid
;WARFARIN;VKORC1;rs9934438;A;Toxicity;increased  risk of Side Effect:over-anticoagulation;Allele A is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele G.; 
;ALLOPURINOL;NOTCH4;rs367398;AA + AG;Toxicity;decreased risk of Disease:Severe Cutaneous Adverse Reactions;Genotypes AA + AG are associated with decreased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to genotype GG.; 
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;rs163182;CC + GG;Efficacy;decreased likelihood of Efficacy:Disease Progression;Genotypes CC + GG is associated with decreased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CG.;in people with Disease:Stomach Neoplasms
;;NQO1;rs1800566;AA;Other;decreased likelihood of Other:survival;Genotype AA is associated with decreased likelihood of survival in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;Efficacy:rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients;Genotype TT is associated with rapid viral response (RVR) to PEG-IFN/ribavirin therapy at 4 weeks in HCV genotype 3 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;in people with Disease:Hepatitis C virus infection
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs4402960;G;Efficacy;decreased likelihood of Efficacy:Disease Progression;Allele G is associated with decreased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to allele T.;in people with Disease:Stomach Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;Efficacy:rapid virological response (rvr);Genotype CC is associated with rapid virological response (rvr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in chemorefractory advanced non-small-cell lung cancer patients as compared to allele T.;in Efficacy:chemorefractory advanced non-small-cell lung cancer patients
;ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with erlotinib or gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;EFAVIRENZ;CYP2B6;rs3745274;GG;Efficacy;increased  risk of Efficacy:immunological failure;Genotype GG is associated with increased risk of immunological failure when treated with efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Disease:Inflammatory Bowel Diseases
;CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;rs1800566;AA;Toxicity;decreased likelihood of Other:survival;Genotype AA is associated with decreased likelihood of survival when treated with cyclophosphamide, epirubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;METHOTREXATE;SLCO1B1;rs2306283;AG + GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Gastrointestinal toxicity, Side Effect:Toxic liver disease;Genotypes AG + GG is associated with increased likelihood of Drug Toxicity, gastrointestinal toxicity or Toxic liver disease when treated with methotrexate in children with Juvenile Rheumatoid Arthritis as compared to genotype AA.;in children with Juvenile Rheumatoid Arthritis
;EFAVIRENZ;CYP2B6;rs3745274;GT;Toxicity;increased  likelihood of Disease:Sleep Disorders;Genotype GT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;SUNITINIB;ABCB1;rs1045642;AA;Toxicity;decreased risk of Side Effect:Neutropenia;Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.;in people with Disease:Renal Cell Carcinoma
;VERAPAMIL;CACNA1C;rs1051375;AA;Efficacy;decreased risk of Other:primary outcome;Genotype AA is associated with decreased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.;in people with Disease:Coronary Artery Disease
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:median survival time (MST);Allele G is associated with increased median survival time (MST) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.;in Efficacy:advanced non-small-cell lung cancer patients
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;Toxicity;increased  severity of Disease:Thrombocytopenia;Genotypes AA + AG are associated with increased severity of Thrombocytopenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.;in women with Disease:Female reproductive system neoplasm
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:overall survival (OS) time;Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;SUNITINIB;ABCB1;rs1045642;AA + AG;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes AA + AG is associated with decreased risk of Diarrhea when treated with sunitinib in people with Carcinoma, Renal Cell.;in people with Disease:Renal Cell Carcinoma
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;EFAVIRENZ;CYP2B6;rs3745274;GT;Metabolism/PK;increased   PK:plasma level;Genotype GT is associated with increased plasma level of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;Toxicity;increased  severity of Disease:Diarrhea;Genotypes AA + AG are associated with increased severity of Diarrhea when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.;in women with Disease:Female reproductive system neoplasm
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:overall survival (OS) time;Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;EFAVIRENZ;CYP2A6;rs28399433;AC + CC;Metabolism/PK;increased   PK:plasma concentration;Genotypes AC + CC are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype AA.;in people with Disease:HIV infectious disease
;;DRD2;rs1800497;AA + AG;Toxicity;increased  likelihood of Disease:Death;Genotypes AA + AG is associated with increased likelihood of Death in people with Alcoholism as compared to genotype GG.;in people with Disease:Alcohol abuse
;EFAVIRENZ;CYP2B6;rs28399499;CC + CT;Metabolism/PK;increased   PK:plasma concentration;Genotypes CC + CT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma concentration;Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;VERAPAMIL;CACNA1C;rs1051375;GG;Efficacy;increased  risk of Efficacy:primary outcome;Genotype GG is associated with increased risk of primary outcome when treated with verapamil in people with Coronary Artery Disease.;in people with Disease:Coronary Artery Disease
;EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780093;CC + CT;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CT is associated with increased overall survival when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype TT.;in people with Disease:Stomach Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;SIMVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Side Effect:dose decrease or switch to another cholesterol-lowering drug;Genotype CC is associated with increased risk of dose decrease or switch to another cholesterol-lowering drug when treated with simvastatin as compared to genotype TT.; 
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg;Genotypes CC + CT are associated with increased risk of dose decrease or switch to another cholesterol-lowering drug in users with a starting dose of more than 20 mg when treated with atorvastatin as compared to genotype TT.; 
;CARBOPLATIN, CISPLATIN, GEMCITABINE;;rs12118636;AG;Efficacy;decreased  Efficacy:Overall survival;Genotype AG is associated with decreased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Side Effect:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;Toxicity;increased  severity of Disease:Neutropenia;Genotypes AA + AG are associated with increased severity of Neutropenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG.;in women with Disease:Female reproductive system neoplasm
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;Toxicity;Side Effect:Alopecia;Genotype TT is associated with Alopecia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotypes CC + CT.;in people with Disease:Inflammatory Bowel Diseases
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.;in Efficacy:advanced non-small-cell lung cancer patients
;ANTINEOPLASTIC AGENTS;ABCB1;rs1045642;AG;Toxicity;increased  severity of Side Effect:Nausea;Genotype AG is associated with increased severity of Nausea when treated with antineoplastic agents in people with Neoplasms as compared to genotypes AA + GG.;in people with Disease:Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:median survial time;Allele G is associated with increased median survial time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:overall survival (OS) time;Allele G is associated with increased overall survival (OS) time when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.;in people with Efficacy:non-small-cell lung cancer
;CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;rs1065634;CT;Efficacy;decreased  Efficacy:Overall survival;Genotype CT is associated with decreased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with non-small-cell lung cancer as compared to allele T.;in people with Efficacy:non-small-cell lung cancer
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;rs451774;AG + GG;Efficacy;increased   Efficacy:Overall survival;Genotypes AG + GG are associated with increased overall survival due to carboplatin, cisplatin or gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;VINCRISTINE;ACTG1;rs1135989;A;Toxicity;increased  risk of Side Effect:Neurotoxicity Syndromes;Allele A is associated with increased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Allele T is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.;in people with Disease:Venous thromboembolism
;METHADONE;CYP2B6;rs3745274;GG;Toxicity;increased  severity of Other:Neonatal Abstinence Syndrome;Genotype GG is associated with increased severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype GT.;in infants 
;CARBOPLATIN, TAXANES;ATP7B;rs1801249;AA;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype AA is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AG + GG.;in women with Disease:Ovarian Neoplasms
;VINCRISTINE;CAPG;rs3770102;T;Toxicity;decreased risk of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.;in children with Disease:Acute lymphoblastic leukemia
;VALPROIC ACID;COL1A1;rs1800012;AA + AC;Toxicity;decreased  Side Effect:bone density;Genotypes AA + AC is associated with decreased bone density when treated with valproic acid in people with Epilepsy as compared to genotype CC.;in people with Disease:Epilepsy
;VINCRISTINE;ABCB1;rs4728709;A;Toxicity;decreased risk of Side Effect:Neurotoxicity Syndromes;Allele A is associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;DOXORUBICIN;AKR1C3;rs1937840;GG;Other;decreased  Other:absolute leucocyte and neutrophil counts on day 15;Genotype GG is associated with decreased absolute leucocyte and neutrophil counts on day 15 when treated with doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CG.;in women with Disease:Breast Neoplasms
;METHADONE;CYP2B6;rs2279343;AA;Toxicity;increased  severity of Other:Neonatal Abstinence Syndrome;Genotype AA is associated with increased severity of Neonatal Abstinence Syndrome due to methadone in infants as compared to genotype AG.;in infants 
;KETOPROFEN;CYP2C9;rs1799853;CC;Toxicity;decreased severity of Side Effect:Dyspepsia;Genotype CC is associated with decreased severity of Dyspepsia when treated with ketoprofen in people with Pain, Postoperative as compared to genotype CT.;in people with Pain, Postoperative
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;Efficacy;increased   Other:time to therapeutic inr;Allele T is associated with increased time to therapeutic inr when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C.;in people with Disease:Venous thromboembolism
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype GG is associated with increased likelihood of gastrointestinal toxicity when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.;in people with Kidney Transplantation
;REMIFENTANIL;OPRM1;rs1799971;GG;Toxicity;decreased severity of Side Effect:Postoperative Nausea and Vomiting;Genotype GG is associated with decreased severity of Postoperative Nausea and Vomiting due to remifentanil in women with Pain, Postoperative as compared to genotypes AA + AG.;in women with Disease:Pain, Postoperative
;WARFARIN;VKORC1;rs9934438;AA + AG;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes AA + AG are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype GG.; 
;MERCAPTOPURINE;ITPA;rs1127354;AA + AC;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotypes AA + AC is associated with increased severity of Myelosuppression when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma or Leukemia as compared to genotype CC.;in people with Acute lymphoblastic leukemia, Leukemia
;CARBOPLATIN, TAXANES;GSR;rs3594;CC;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype CC is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AA + AC.;in women with Disease:Ovarian Neoplasms
;ACENOCOUMAROL, WARFARIN;APOE;rs429358;C;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T.;in people with Disease:Venous thromboembolism
;ETHANOL;SLC6A4;rs4251417;T;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C.; 
;CARBOPLATIN, TAXANES;VEGFA;rs6900017;TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Ovarian Neoplasms
;ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;C;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele A.;in people with Disease:Venous thromboembolism
;METHYLPHENIDATE;COMT;rs4680;AA + AG;Toxicity;decreased likelihood of Side Effect:adverse events;Genotypes AA + AG is associated with decreased likelihood of adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.;in children with Attention Deficit Disorder with Hyperactivity
;NALOXONE;OPRM1;rs1799971;G;Efficacy;increased   Efficacy:cortisol response;Allele G is associated with increased cortisol response when treated with naloxone as compared to genotype AA.; 
;ETHANOL;SLC6A4;rs25531;C;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele C is associated with decreased risk of Alcoholism due to ethanol as compared to allele T.; 
;INTERFERONS, RIBAVIRIN;VDR;rs2228570;AG + GG;Toxicity;decreased risk of Side Effect:Cryoglobulinemia;Genotypes AG + GG are associated with decreased risk of cryoglobulinemia when treated with interferons and ribavirin in people with Hepatitis C as compared to genotype AA.;in people with Disease:Hepatitis C virus infection
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose;Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;EGFR INHIBITORS;PIK3CA;rs2677760;C;Toxicity;increased  likelihood of Disease:Diarrhea;Allele C is associated with increased likelihood of Diarrhea when treated with egfr inhibitors in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;CETUXIMAB;EGFR;rs2227983;AA + AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AG are associated with decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to genotype GG.;in people with Disease:Head and Neck Neoplasms
;EGFR INHIBITORS;PIK3CA;rs2459693;T;Toxicity;increased  likelihood of Disease:Diarrhea;Allele T is associated with increased likelihood of Diarrhea when treated with egfr inhibitors in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;IRINOTECAN;CES1;rs7187684;CC;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotype CC is associated with decreased likelihood of Thrombocytopenia when treated with irinotecan in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms or Stomach Neoplasms as compared to genotypes CT + TT.;in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
;METHOTREXATE;ATIC;rs2372536;GG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype GG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CG.;in people with Disease:Rheumatoid arthritis
;ETHANOL;SLC6A4;rs2066713;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;CORTICOSTEROIDS, SALMETEROL;ADRB2;rs1042713;AA;Efficacy;increased  risk of Efficacy:exacerbations;Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;ANTIPSYCHOTICS;IL1B;rs4849127;AA + AG;Toxicity;increased   Side Effect:Weight gain;Genotypes AA + AG is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype GG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;BETA BLOCKING AGENTS;CYP2D6;rs1065852;GG;Toxicity;increased  likelihood of Side Effect:Bradycardia;Genotype GG is associated with increased likelihood of Bradycardia when treated with Beta Blocking Agents in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Acute coronary syndrome
;FLUOROURACIL;DPYD;rs1801265;GG;Metabolism/PK;increased   PK:DPD activity;Genotype GG is associated with increased DPD activity when exposed to fluorouracil in healthy individuals without the rs115232898 A>G variant (DPYD Y186C) as compared to genotype AA.;in healthy individuals without the rs115232898 A>G variant (DPYD Y186C)
;EGFR INHIBITORS;PIK3CA;rs6443624;C;Efficacy;decreased  Efficacy:overall survival;Allele C is associated with decreased overall survival when treated with egfr inhibitors in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;ANTIPSYCHOTICS;IL1B;rs16944;AG;Toxicity;increased   Side Effect:Weight gain;Genotype AG is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + GG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs885004;A;Toxicity;decreased likelihood of Disease:Cardiotoxicity;Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.;in children with Disease:Neoplasms
;CYCLOSPORINE;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Gingival Overgrowth;Genotype AA is associated with increased likelihood of Gingival Overgrowth when treated with cyclosporine in people with heart transplantation, Kidney Transplantation, liver transplantation or Transplantation as compared to genotypes AG + GG.;in people with Disease:Heart transplantation, Disease:Kidney Transplantation, Disease:Liver transplantation, Disease:Transplantation
;EGFR INHIBITORS;PIK3CA;rs2677760;T;Efficacy;decreased  Efficacy:overall survival;Allele T is associated with decreased overall survival when treated with egfr inhibitors in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;CORTICOSTEROIDS;ADRB2;rs1042713;AA;Efficacy;increased  risk of Efficacy:uncontrolled asthma;Genotype AA is associated with increased risk of uncontrolled asthma when treated with corticosteroids in children with Asthma as compared to genotype GG.;in children with Disease:Asthma
;IRINOTECAN;CES1;rs2244614;AA + AG;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotypes AA + AG is associated with decreased likelihood of Thrombocytopenia when treated with irinotecan in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms or Stomach Neoplasms as compared to genotype GG.;in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
;EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AA;Toxicity;decreased  Side Effect:bone density;Genotype AA is associated with decreased bone density when treated with exemestane and letrozole in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;ANTIPSYCHOTICS;IL1B;rs1143634;AA;Toxicity;decreased  Side Effect:Weight gain;Genotype AA is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;Toxicity;decreased  Side Effect:Weight gain;Genotypes CT + TT is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype CC.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;METHYLPHENIDATE;ADGRL3;rs2345039;CG + GG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes CG + GG is associated with increased likelihood of adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype GG.;in children with Attention Deficit Disorder with Hyperactivity
;DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs7853758;A;Toxicity;decreased likelihood of Disease:Cardiotoxicity;Allele A is associated with decreased likelihood of cardiotoxicity when exposed to daunorubicin and doxorubicin in children with Neoplasms as compared to allele G.;in children with Disease:Neoplasms
;MERCAPTOPURINE;NUDT15;rs116855232;CT;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotype CT is associated with increased severity of Myelosuppression when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma or Leukemia as compared to genotype CC.;in people with Acute lymphoblastic leukemia, Leukemia
;WARFARIN;CYP2C9;rs1799853;T;Efficacy;Efficacy:time to therapeutic inr;Allele T is associated with time to therapeutic inr when treated with warfarin as compared to allele C.; 
;CARBOPLATIN, TAXANES;ATP7B;rs1061472;TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Ovarian Neoplasms
;IRINOTECAN;UGT1A1;rs4148323;AG;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AG is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;Toxicity;increased  risk of Side Effect:Muscular Diseases;Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.; 
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;rs4379368;T;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.;in women 
;;FMO3;rs2266780;AG + GG;Other;decreased severity of Disease:Tobacco Use Disorder;Genotypes AG + GG is associated with decreased severity of Tobacco Use Disorder in people with Tobacco Use Disorder as compared to genotype AA.;in people with Disease:Tobacco Use Disorder
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;rs710446;C;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele T.;in women 
;FLUOROURACIL;DPYD;rs1801265;AA;Efficacy;increased   Efficacy:event-free survival;Genotype AA is associated with increased event-free survival when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Disease:Acute lymphoblastic leukemia
;IRINOTECAN;ABCG2;rs2231142;GT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes GT + TT is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms or Stomach Neoplasms as compared to genotype GG.;in people with Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
;ASPIRIN;LPA;rs3798220;CT;Efficacy;decreased risk of Disease:Myocardial Infarction;Genotype CT is associated with decreased risk of Myocardial Infarction when treated with aspirin in women.;in women 
;METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;CYP2C19;rs3814637;T;Toxicity;risk of Side Effect:over-anticoagulation;Allele T is associated with risk of over-anticoagulation when treated with warfarin as compared to allele C.; 
;FLUOROURACIL;DPYD;rs72728438;CT;Metabolism/PK;decreased  PK:DPD activity;Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype TT.;in healthy individuals 
;FLUOROURACIL;ABCC11;rs7194667;GG + GT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes GG + GT are associated with increased risk of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;EGFR INHIBITORS;PIK3CA;rs2699905;C;Efficacy;decreased  Efficacy:overall survival;Allele C is associated with decreased overall survival when treated with egfr inhibitors in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs115632870;CT;Metabolism/PK;decreased  PK:DPD activity;Genotype CT is associated with decreased DPD activity when exposed to fluorouracil in healthy individuals as compared to genotype CC.;in healthy individuals 
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs56392308;del;Toxicity;decreased risk of Side Effect:Venous Thrombosis;Allele del is associated with decreased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele G.;in women 
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;ETHANOL;SLC6A3;rs6350;AG;Toxicity;increased  risk of Disease:Alcohol abuse;Genotype AG is associated with increased risk of Alcoholism when exposed to ethanol as compared to genotype GG.; 
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype AT is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs8176719;C;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele del.;in women 
;METHOTREXATE;SLCO1B1;rs4149056;TT;Toxicity;decreased risk of Side Effect:Nephrotoxicity;Genotype TT is associated with decreased risk of nephrotoxicity when treated with methotrexate in people with Neoplasms as compared to genotypes CC + CT.;in people with Disease:Neoplasms
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;rs9574;G;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele G is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women.;in women 
;HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;rs2289252;T;Toxicity;increased  risk of Side Effect:Venous Thrombosis;Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C.;in women 
;METHOTREXATE;SLCO1B1;rs2306283;AG + GG;Toxicity;increased  risk of Side Effect:Nephrotoxicity;Genotypes AG + GG are associated with increased risk of nephrotoxicity when treated with methotrexate in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased   Side Effect:Infectious disease, Side Effect:Toxic liver disease;Genotype CT is associated with increased Infection and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;DEXMEDETOMIDINE;NR1I2;rs3814057;CC;Toxicity;increased  likelihood of Side Effect:Bradycardia, Side Effect:Hypotensive disorder;Genotype CC is associated with increased likelihood of Bradycardia or Hypotensive disorder when treated with dexmedetomidine in children with Surgical procedure as compared to genotypes AA + AC.;in children with surgery
;;MAOA;rs1137070;TT;Toxicity;decreased risk of Side Effect:Tobacco Use Disorder;Genotype TT is associated with decreased risk of Tobacco Use Disorder in women as compared to genotypes CC + CT.;in women 
;;MAOB;rs1799836;CC;Toxicity;increased  risk of Side Effect:Tobacco Use Disorder;Genotype CC is associated with increased risk of Tobacco Use Disorder in women as compared to genotypes CT + TT.;in women 
;CAPECITABINE;;rs9936750;C;Toxicity;increased  risk of Side Effect:toxicity;Allele C is associated with increased risk of toxicity when treated with capecitabine in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs1801265;AG + GG;Toxicity;increased   Side Effect:Infectious disease, Side Effect:Nephrotoxicity, Side Effect:Toxic liver disease;Genotypes AG + GG is associated with increased Infection, nephrotoxicity and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Disease:Acute lymphoblastic leukemia
;DOXORUBICIN;ABCB1;rs1045642;A;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele A is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;DOXORUBICIN;CBR3;rs1056892;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of cardiotoxicity when treated with doxorubicin in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CAPECITABINE;DPYD;rs3918290;T;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;FOLFIRI;UGT1A1;rs4124874;GG;Toxicity;increased  severity of Side Effect:Myelosuppression;Genotype GG is associated with increased severity of Myelosuppression when treated with FOLFIRI as compared to genotype TT.; 
;CAPECITABINE;DPYD;rs67376798;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;CETUXIMAB;EGF;rs4444903;GG;Efficacy;increased  likelihood of Efficacy:complete pathologic response;Genotype GG is associated with increased likelihood of complete pathologic response when treated with cetuximab in people with Rectal Neoplasms as compared to genotype AA.;in people with Disease:Rectal Neoplasms
;AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;rs2261988;TT;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype TT is associated with decreased likelihood of overall survival and progression-free survival when treated with afatinib, erlotinib or gefitinib in people with Lung Neoplasms as compared to genotypes GG + GT.;in people with Lung Neoplasms
;;HAVCR2;rs10515746;AA + AC;Efficacy;decreased likelihood of Side Effect:Graft vs Host Disease;Genotypes AA + AC is associated with decreased likelihood of Graft vs Host Disease in people with hematopoietic stem cell transplantation as compared to genotype CC.;in people with Hematopoietic stem cell transplantation
;;HAVCR2;rs1036199;AC + CC;Efficacy;decreased likelihood of Side Effect:Graft vs Host Disease;Genotypes AC + CC is associated with decreased likelihood of Graft vs Host Disease in people with hematopoietic stem cell transplantation as compared to genotype AA.;in people with Hematopoietic stem cell transplantation
;AFATINIB, ERLOTINIB, GEFITINIB;DVL2;rs2074216;AA;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype AA is associated with decreased likelihood of overall survival and progression-free survival when treated with afatinib, erlotinib or gefitinib in people with Lung Neoplasms as compared to genotypes AG + GG.;in people with Lung Neoplasms
;GLATIRAMER ACETATE;;rs12459996;T;Toxicity;increased  risk of Disease:Coronary Artery Disease;Allele T is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.;in people with Disease:Multiple Sclerosis
;WARFARIN;VKORC1;rs9923231;T;Efficacy;decreased  Efficacy:time to therapeutic inr;Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.; 
;WARFARIN;VKORC1;rs9923231;T;Toxicity;increased  risk of Side Effect:over-anticoagulation;Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.; 
;FLUOROURACIL;OR10AE3P, PSMB3P;rs10876844;A;Toxicity;increased  likelihood of Disease:Diarrhea;Allele A is associated with increased likelihood of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:toxicity;Genotype AA is associated with increased risk of toxicity when treated with methotrexate as compared to genotype GG.; 
;HEROIN;BDNF;rs6265;TT;Other;increased  risk of Other:addiction;Genotype TT is associated with increased risk of addiction due to heroin as compared to genotype CC.; 
;METHAMPHETAMINE;BDNF;rs6265;T;Other;increased  risk of Other:addiction;Allele T is associated with increased risk of addiction due to methamphetamine as compared to allele C.; 
;DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;rs2235047;C;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Allele C is associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;rs1056892;A;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Allele A is associated with increased risk of cardiotoxicity when treated with doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;FENTANYL;OPRM1;rs540825;T;Toxicity;increased  likelihood of Side Effect:Vomiting;Allele T is associated with increased likelihood of Vomiting due to fentanyl in women with Pain, Postoperative as compared to allele A.;in women with Disease:Pain, Postoperative
;ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;AA;Efficacy;decreased  Efficacy:platelet aggregation;Genotype AA is associated with decreased platelet aggregation when treated with aspirin and ticagrelor in people with Acute coronary syndrome and Myocardial Infarction as compared to genotypes AT + TT.;in people with Disease:Acute coronary syndrome, Disease:Myocardial Infarction
;CLOPIDOGREL;ABCB1;rs2032582;T;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele T is associated with increased risk of Hemorrhage when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;AFATINIB, ERLOTINIB, GEFITINIB;NUP62;rs9523;CC;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype CC is associated with decreased likelihood of overall survival and progression-free survival when treated with afatinib, erlotinib or gefitinib in people with Lung Neoplasms as compared to genotypes CT + TT.;in people with Lung Neoplasms
;;;rs2207418;GG;Other;increased  risk of Disease:Death;Genotype GG is associated with increased risk of Death in people with Heart Failure as compared to genotype AA.;in people with Disease:Heart Failure
;ALFENTANIL;OPRM1;rs1799971;GG;Toxicity;decreased severity of Side Effect:Respiratory Insufficiency;Genotype GG is associated with decreased severity of Respiratory Insufficiency due to alfentanil in healthy individuals as compared to genotypes AA + AG.;in healthy individuals 
;WARFARIN;CYP2C9;rs9332197;C;Efficacy;Efficacy:time to achieve stable dose;Allele C is associated with time to achieve stable dose when treated with warfarin as compared to allele T.; 
;WARFARIN;CYP2C9;rs1057910;C;Toxicity;risk of Side Effect:over-anticoagulation;Allele C is associated with risk of over-anticoagulation when treated with warfarin as compared to allele A.; 
;WARFARIN;CYP2C18;rs2901783;AG + GG;Efficacy;increased   Efficacy:time to therapeutic inr;Genotypes AG + GG are associated with increased time to therapeutic inr when treated with warfarin as compared to genotype AA.; 
;WARFARIN;F5;rs6018;G;Toxicity;risk of Side Effect:Hemorrhage;Allele G is associated with risk of Hemorrhage when treated with warfarin as compared to allele T.; 
;WARFARIN;PROS1;rs8178607;AA;Efficacy;decreased  Efficacy:time to achieve stable dose;Genotype AA is associated with decreased time to achieve stable dose when treated with warfarin as compared to genotypes AG + GG.; 
;;CHRM3;rs2165870;GG;Toxicity;increased  risk of Disease:Postoperative Nausea and Vomiting;Genotype GG is associated with increased risk of Postoperative Nausea and Vomiting as compared to genotypes AA + AG.; 
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.; 
;CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;Toxicity;increased  risk of Side Effect:toxicity;Genotype AA is associated with increased risk of toxicity due to cisplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AC + CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CAPECITABINE;DPYD;rs1801265;G;Toxicity;decreased risk of Side Effect:Drug Toxicity;Allele G is associated with decreased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;DOXORUBICIN;GSTP1;rs1695;GG;Toxicity;increased   Side Effect:micronucleated binucleated cells;Genotype GG is associated with increased micronucleated binucleated cells when exposed to doxorubicin.; 
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.; 
;METHOTREXATE;MTHFR;rs1801131;TT;Efficacy;increased   Efficacy:event free survival;Genotype TT is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801133;GG;Efficacy;increased   Efficacy:event-free survival;Genotype GG is associated with increased event-free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in people with Disease:Acute lymphoblastic leukemia
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG;Efficacy;decreased  Efficacy:Disease activity score 28 in rheumatoid arthritis;Genotype AG is associated with decreased disease activity score 28 joint in rheumatoid arthritis when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to genotype AA.;in people with Disease:Rheumatoid arthritis
;;SCN5A;rs7626962;GT + TT;Other;increased  likelihood of Disease:Cardiac rhythm disease;Genotypes GT + TT are associated with increased likelihood of Arrhythmias, Cardiac.; 
;CARBOPLATIN, TAXANES;VEGFA;rs879825;GG;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype GG is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes AA + AG.;in women with Disease:Ovarian Neoplasms
;EXEMESTANE, LETROZOLE;ESR1;rs4870061;CT + TT;Toxicity;decreased  Side Effect:bone density;Genotypes CT + TT are associated with decreased bone density when treated with exemestane or letrozole in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;METHOTREXATE;MTRR;rs1801394;AG + GG;Metabolism/PK;decreased likelihood of Side Effect:Toxic liver disease;Genotypes AG + GG is associated with decreased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in people with Acute lymphoblastic leukemia
;CARBOPLATIN, TAXANES;SCN10A;rs9825762;TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Ovarian Neoplasms
;CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype CC is associated with increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes in women with Ovarian Neoplasms as compared to genotypes CT + TT.;in women with Disease:Ovarian Neoplasms
;LETROZOLE;ESR1;rs4870061;TT;Toxicity;decreased  Side Effect:bone density;Genotype TT is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;rs1057910;CC;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin in men as compared to genotypes AA + AC.;in men 
;METHOTREXATE;ABCC2;rs2273697;AA + AG;Metabolism/PK;increased  likelihood of Side Effect:Toxic liver disease;Genotypes AA + AG is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in people with Acute lymphoblastic leukemia
;EXEMESTANE, LETROZOLE;ESR1;rs9322335;TT;Toxicity;decreased  Side Effect:bone density;Genotype TT is associated with decreased bone density when treated with exemestane or letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;LETROZOLE;ESR1;rs9322335;TT;Toxicity;decreased  Side Effect:bone density;Genotype TT is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;CISPLATIN, ETOPOSIDE;NQO1;rs1800566;AA;Other;decreased  Other:overall survival;Genotype AA is associated with decreased overall survival when treated with cisplatin and etoposide in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;CISPLATIN;SLC22A2;rs316019;AC;Toxicity;increased  severity of Side Effect:Nephrotoxicity;Genotype AC is associated with increased severity of nephrotoxicity due to cisplatin in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;LETROZOLE;ESR2;rs10140457;CC;Toxicity;decreased  Side Effect:bone density;Genotype CC is associated with decreased bone density when treated with letrozole in women with Breast Neoplasms as compared to genotype AC.;in women with Disease:Breast Neoplasms
;EXEMESTANE;ESR1;rs2813543;AA;Toxicity;decreased  Side Effect:bone density;Genotype AA is associated with decreased bone density when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;EXEMESTANE;CYP19A1;rs6493497;AA;Toxicity;decreased  Side Effect:bone density;Genotype AA is associated with decreased bone density when treated with exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotypes CC + CT is associated with increased likelihood of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Metabolism/PK;increased  likelihood of Side Effect:Neutropenia;Genotypes CC + CT is associated with increased likelihood of Neutropenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in people with Acute lymphoblastic leukemia
;BISPHOSPHONATES;;rs2736308;C;Toxicity;increased  risk of Side Effect:Osteonecrosis of the jaw;Allele C is associated with increased risk of osteonecrosis of jaw caused by drug when treated with Bisphosphonates in people with Neoplasms as compared to allele T.;in people with Neoplasms
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Thrombocytopenia;Genotypes CC + CT is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;BISPHOSPHONATES;;rs2736308;C;Toxicity;increased  risk of Side Effect:Osteonecrosis of the jaw;Allele C is associated with increased risk of osteonecrosis of jaw caused by drug when treated with Bisphosphonates in people with Osteoporosis as compared to allele T.;in people with Osteoporosis
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;TT;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotype TT is associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AT.;in people with Disease:Acute coronary syndrome
;BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;rs67376798;AT;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype AT is associated with increased risk of hand-foot syndrome when treated with bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotype TT.;in people with Disease:Stomach Neoplasms
;CARBOPLATIN, GEMCITABINE;TNF;rs1800629;A;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;SORAFENIB;KDR;rs2305948;CC;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype CC is associated with increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;;COMT;rs4680;AG + GG;Other;decreased  Other:length of hospital stay;Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA.;in infants with Disease:Neonatal Abstinence Syndrome
;CARBOPLATIN, GEMCITABINE;PRRC2A;rs11229;G;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;PRRC2A;rs10885;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;METHADONE, MORPHINE;COMT;rs4680;AG + GG;Other;decreased likelihood of Other:treatment;Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.;in infants with Neonatal Abstinence Syndrome
;SORAFENIB;FLT1;rs664393;TT;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype TT is associated with decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CT.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;KDR;rs2071559;AA;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype AA is associated with decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AG + GG.;in people with Disease:Hepatocellular Carcinoma
;CARBOPLATIN, GEMCITABINE;MSH5;rs3115672;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AA + AG;Efficacy;increased  likelihood of Side Effect:Anemia;Genotypes AA + AG is associated with increased likelihood of Anemia when treated with cyclophosphamide, doxorubicin, FEC100 or fluorouracil in people with Breast Neoplasms as compared to genotype GG.;in people with Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;ATP2B1;rs17381194;T;Toxicity;increased  risk of Disease:Myalgia;Allele T is associated with increased risk of Myalgia unspecified when treated with hmg coa reductase inhibitors in people with Hyperlipidemias as compared to allele C.;in people with Disease:Hyperlipidemias
;CARBOPLATIN, GEMCITABINE;DOCK8;rs10491684;A;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;HMG COA REDUCTASE INHIBITORS;;rs4693570;C;Toxicity;increased  risk of Disease:Myalgia;Allele C is associated with increased risk of Myalgia unspecified when treated with hmg coa reductase inhibitors in people with Hyperlipidemias as compared to allele T.;in people with Disease:Hyperlipidemias
;;EPO;rs1617640;A;Other;increased   Other:endogenous levels of EPO;Allele A is associated with increased endogenous levels of EPO protein in healthy individuals as compared to allele C.;in healthy individuals 
;HMG COA REDUCTASE INHIBITORS;DMPK;rs672348;G;Toxicity;increased  risk of Disease:Myalgia;Allele G is associated with increased risk of Myalgia unspecified when treated with hmg coa reductase inhibitors in people with Hyperlipidemias as compared to allele T.;in people with Disease:Hyperlipidemias
;ASPIRIN;EYA1;rs12678747;T;Toxicity;increased  risk of Side Effect:Peptic Ulcer Disease;Allele T is associated with increased risk of Peptic Ulcer due to aspirin as compared to allele A.; 
;CARBOPLATIN, GEMCITABINE;CYP2C8;rs1058932;A;Toxicity;decreased severity of Side Effect:Thrombocytopenia;Allele A is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;CYP2C8;rs11572078;A;Toxicity;decreased severity of Side Effect:Thrombocytopenia;Allele A is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele del.;in people with Non-Small Cell Lung Carcinoma
;AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;Toxicity;increased  likelihood of Side Effect:Acquired Long QT Syndrome (aLQTS);Allele T is associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with azithromycin, chlorpromazine, cilostazol, ciprofloxacin, citalopram, clarithromycin, dofetilide, donepezil, dronedarone, erythromycin, escitalopram, flecainide, fluconazole, haloperidol, hydroxychloroquine, levofloxacin, methadone, moxifloxacin, ondansetron, oxaliplatin, papaverine, pentamidine, procainamide, propofol, quinidine or sotalol as compared to allele C.; 
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in non-small-cell lung cancer patients as compared to allele T.;in Efficacy:non-small-cell lung cancer patients
;CARBOPLATIN, GEMCITABINE;C6orf15;rs2233980;A;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;CDSN;rs3130985;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;ETOPOSIDE, PLATINUM COMPOUNDS;DYNC2H1;rs716274;AG + GG;Efficacy;increased  risk of Disease:Death;Genotypes AG + GG are associated with increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to genotype AA.;in people with Disease:Small cell carcinoma
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.;in Efficacy:bronchioloalveolar carcinoma and adenocarcinoma patients
;METHADONE, MORPHINE;OPRM1;rs1799971;AG + GG;Other;decreased likelihood of Other:treatment;Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA.;in infants with Disease:Neonatal Abstinence Syndrome
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;rs1800566;AA + AG;Efficacy;decreased likelihood of Side Effect:Anemia, Side Effect:Neutropenia, Side Effect:Gastrointestinal toxicity;Genotypes AA + AG is associated with decreased likelihood of Anemia, Neutropenia or gastrointestinal toxicity when treated with cyclophosphamide, doxorubicin, FEC100 or fluorouracil in people with Breast Neoplasms as compared to genotype GG.;in people with Breast Neoplasms
;ETOPOSIDE, PLATINUM COMPOUNDS;YAP1;rs10895256;GT + TT;Efficacy;increased  risk of Disease:Death;Genotypes GT + TT are associated with increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to genotype GG.;in people with Disease:Small cell carcinoma
;HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;Toxicity;increased  risk of Side Effect:statin intolerance, defined primarily through muscle symptomatology;Allele A is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele G.; 
;HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;Toxicity;increased  risk of Side Effect:statin intolerance, defined primarily through muscle symptomatology;Allele G is associated with increased risk of statin intolerance, defined primarily through muscle symptomatology when treated with hmg coa reductase inhibitors as compared to allele C.; 
;CARBOPLATIN, GEMCITABINE;HLA-C;rs1049709;C;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Non-Small Cell Lung Carcinoma
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib in bronchioloalveolar carcinoma and adenocarcinoma patients as compared to allele T.;in Efficacy:bronchioloalveolar carcinoma and adenocarcinoma patients
;CARBOPLATIN, GEMCITABINE;HCP5;rs3130907;G;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Non-Small Cell Lung Carcinoma
;LENALIDOMIDE;CTNNB1;rs4135385;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with lenalidomide in people with Multiple Myeloma as compared to genotypes AG + GG.;in people with Disease:Multiple Myeloma
;CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;rs121434568;G;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;Allele G is associated with increased overall survival and progression-free survival when treated with carboplatin, erlotinib and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;SERPINC1;rs5877;C;Toxicity;decreased severity of Side Effect:Thrombocytopenia;Allele C is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Non-Small Cell Lung Carcinoma
;IBRUTINIB;KCNQ1;rs2237895;AA;Toxicity;increased  likelihood of Side Effect:Cardiac rhythm disease, Side Effect:Cardiotoxicity;Genotype AA is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes AC + CC.;"in people with ""Leukemia, Lymphocytic, Chronic, B-Cell"", ""Waldenstrom Macroglobulinemia"", ""Mantle cell lymphoma"""
;TAMOXIFEN;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased  Efficacy:Overall survival;Genotypes CC + CT are associated with decreased overall survival when treated with tamoxifen in women with Breast Neoplasms as compared to genotype TT.;in women with Disease:Breast Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;CC;Toxicity;increased  severity of Side Effect:mucositis;Genotype CC is associated with increased severity of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in people with Disease:Acute lymphoblastic leukemia
;;SCN5A;rs7626962;GG;Other;increased  likelihood of Disease:Sudden Infant Death;Genotype GG is associated with increased likelihood of Sudden Infant Death.; 
;LENALIDOMIDE;CTNNB1;rs4533622;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with lenalidomide in people with Multiple Myeloma as compared to genotypes AC + CC.;in people with Disease:Multiple Myeloma
;CARBOPLATIN, GEMCITABINE;;rs886423;C;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;;rs886424;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;Efficacy;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to genotype AA.; 
;CARBOPLATIN, GEMCITABINE;ATAT1;rs9262132;C;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Non-Small Cell Lung Carcinoma
;SORAFENIB;VEGFA;rs2010963;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CG.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;VEGFA;rs2010963;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CC + CG.;in people with Disease:Hepatocellular Carcinoma
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;;ABO;rs495828;GG;Metabolism/PK;increased   Other:ACE activity;Genotype GG is associated with increased ACE activity in people with Hypertension as compared to genotypes GT + TT.;in people with Disease:Hypertension
;CARBOPLATIN, GEMCITABINE;PPP1R18;rs9262143;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;;OPRM1;rs1799971;AG + GG;Other;decreased  Other:length of hospital stay;Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA.;in infants with Disease:Neonatal Abstinence Syndrome
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate;Allele G is associated with increased response rate when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;SORAFENIB;;rs4604006;CC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;IBRUTINIB;KCNQ1;rs163182;GG;Toxicity;increased  likelihood of Side Effect:Cardiac rhythm disease, Side Effect:Cardiotoxicity;Genotype GG is associated with increased likelihood of Cardiac rhythm disease or Cardiotoxicity when treated with ibrutinib in people with Leukemia, Lymphocytic, Chronic, B-Cell, Waldenstrom Macroglobulinemia or Mantle cell lymphoma as compared to genotypes CC + CG.;"in people with ""Leukemia, Lymphocytic, Chronic, B-Cell"", ""Waldenstrom Macroglobulinemia"", ""Mantle cell lymphoma"""
;CARBOPLATIN, GEMCITABINE;MUCL3;rs3094086;A;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;OLANZAPINE;GIPR;rs10423928;AA;Toxicity;increased   Side Effect:plasma insulin levels;Genotype AA is associated with increased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to genotypes AT + TT.;in people with Disease:Schizophrenia
;SORAFENIB;;rs4604006;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;VEGFA;rs25648;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;ANTHRACYCLINES AND RELATED SUBSTANCES;;rs28714259;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of cardiotoxicity when treated with anthracyclines and related substances in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE;CTLA4;rs231775;A;Toxicity;increased  likelihood of Side Effect:Gingival Overgrowth;Allele A is associated with increased likelihood of Gingival Overgrowth when treated with cyclosporine in people with Kidney Transplantation as compared to allele G.;in people with Disease:Kidney Transplantation
;SORAFENIB;VEGFA;rs833061;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;VEGFA;rs699947;CC;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype CC is associated with increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes AA + AC.;in people with Disease:Hepatocellular Carcinoma
;SORAFENIB;VEGFA;rs25648;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;FENTANYL;OPRM1;rs9397685;AG;Toxicity;decreased severity of Side Effect:Nausea, Side Effect:Vomiting;Genotype AG is associated with decreased severity of Nausea or Vomiting due to fentanyl in people with Pain, Postoperative as compared to genotype AA.;in people with Disease:Pain, Postoperative
;SORAFENIB;VEGFA;rs833061;CC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT.;in people with Disease:Hepatocellular Carcinoma
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy;Efficacy:Decreased glomerular filtration rate;Genotypes CT + TT are associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;;ABCC4;rs2274407;AA + AC;Efficacy;decreased likelihood of Efficacy:event-free survival;Genotypes AA + AC is associated with decreased likelihood of event-free survival in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with EGFR mutation positive non-small-cell lung cancer as compared to allele T.;in people with EGFR mutation positive non-small-cell lung cancer
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:physical and life well-being quality of life (QoL) scales;Allele G is associated with increased physical and life well-being quality of life (QoL) scales when treated with gefitinib in people with EGFR mutation positive advanced non-small-cell lung cancer.;in people with EGFR mutation positive advanced non-small-cell lung cancer
;ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.;in EGFR mutation positive non-small-cell lung cancer patients
;ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:overall survival (OS) time;Allele G is associated with increased overall survival (OS) time when treated with erlotinib or gefitinib in EGFR mutation positive non-small-cell lung cancer patients as compared to allele T.;in EGFR mutation positive non-small-cell lung cancer patients
;WARFARIN;VKORC1;rs9923231;TT;Dosage, Efficacy, Toxicity;increased  risk of Efficacy:over-anticoagulation;Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin.; 
;PAZOPANIB;HFE;rs2858996;TT;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype TT is associated with increased likelihood of drug-induced liver injury when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;PACLITAXEL;ABCB1;rs1128503;AA;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotypes AA + AG are associated with increased risk of Leukopenia or Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;;;rs2207418;GG;Other;increased  risk of Disease:Heart Failure;Genotype GG is associated with increased risk of Heart Failure as compared to genotype AA.; 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy, Metabolism/PK;decreased  PK:trough concentrations;Genotypes CT + TT are associated with decreased trough concentrations when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;GLATIRAMER ACETATE;;rs75041078;A;Toxicity;increased  risk of Disease:Coronary Artery Disease;Allele A is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.;in people with Disease:Multiple Sclerosis
;GLATIRAMER ACETATE;;rs1056854;A;Toxicity;increased  risk of Disease:Coronary Artery Disease;Allele A is associated with increased risk of Coronary Artery Disease when treated with glatiramer acetate in people with Multiple Sclerosis as compared to allele G.;in people with Disease:Multiple Sclerosis
;METHAMPHETAMINE;GAD2;rs2236418;AG + GG;Other;increased  likelihood of Disease:Methamphetamine dependence, Disease:Psychotic Disorder, Disease:Substance-Related Disorders;Genotypes AG + GG is associated with increased likelihood of methamphetamine dependence, Psychotic Disorders and Substance-Related Disorders when exposed to methamphetamine as compared to genotype AA.; 
;GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;rs757110;CC;Efficacy;increased  likelihood of Efficacy:Treatment failure;Genotype CC is associated with increased likelihood of treatment failure when treated with glibenclamide or gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotypes AA + AC.;in people with Diabetes Mellitus, Type 2
;ERLOTINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when exposed to erlotinib in people with advanced non-small-cell lung cancer as compared to allele T.;in people with Efficacy:advanced non-small-cell lung cancer
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;AA + AC;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotypes AA + AC are associated with increased likelihood of Recurrence when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;in people with Disease:Chronic hepatitis C virus infection
;TACROLIMUS;ABCB1;rs2229109;CT + TT;Efficacy;increased  risk of Efficacy:Renal transplant failure;Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy;increased  likelihood of Side Effect:Transplant rejection;Genotypes CT + TT are associated with increased likelihood of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;FENTANYL;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Hypoventilation;Genotype AA is associated with increased likelihood of Hypoventilation due to fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG.;in people with Disease:Pain, Postoperative
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy, Metabolism/PK;decreased  PK:trough levels;Genotypes CT + TT are associated with decreased trough levels of tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;AFATINIB, ERLOTINIB, GEFITINIB;ARF1;rs11541557;GT + TT;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes GT + TT is associated with decreased likelihood of overall survival and progression-free survival when treated with afatinib, erlotinib or gefitinib in people with Lung Neoplasms as compared to genotype GG.;in people with Lung Neoplasms
;DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;rs2031920;CT + TT;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotypes CT + TT are associated with increased risk of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype CC.;in people with Disease:Tuberculosis
;OSELTAMIVIR;ABCB1;rs1045642;AG + GG;Toxicity;increased  risk of Side Effect:Depression, Side Effect:Gastritis, Side Effect:Hypersensitivity;Genotypes AG + GG are associated with increased risk of Depression, Gastritis or Hypersensitivity when treated with oseltamivir in people with acute respiratory diseases and suspected influenza A/H1N1 infection as compared to genotype AA.;in people with acute respiratory diseases, suspected influenza A/H1N1 infection
;METHOTREXATE;ABCC3;rs9895420;AA + AT;Toxicity, Metabolism/PK;increased   Side Effect:plasma levels;Genotypes AA + AT are associated with increased plasma levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;ABCC3;rs9895420;AA + AT;Efficacy;decreased  Efficacy:event free survival;Genotypes AA + AT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in people with Disease:Acute lymphoblastic leukemia
;COCAINE;OPRD1;rs678849;T;Toxicity;decreased risk of Other:Cocaine dependence;Allele T is associated with decreased risk of Cocaine-Related Disorders due to cocaine as compared to allele C.; 
;CERIVASTATIN;RYR2;rs2819742;AA;Toxicity;decreased risk of Disease:Rhabdomyolysis;Genotype AA is associated with decreased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype GG.; 
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs1891059;A;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele A is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;ANTIEPILEPTICS;ABCC2;rs2273697;A;Efficacy;increased   Efficacy:probability of antiepileptic drug response;Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G.;in children with Disease:Epilepsy
;METHOTREXATE;ABCC3;rs9895420;AA + AT;Efficacy;increased  risk of Efficacy:relapse in the central nervous system;Genotypes AA + AT are associated with increased risk of relapse in the central nervous system when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in people with Disease:Acute lymphoblastic leukemia
;;CYP1A2;rs35694136;T;Other;increased  likelihood of Disease:Chronic Obstructive Pulmonary Disease;Allele T is associated with increased likelihood of Pulmonary Disease, Chronic Obstructive as compared to allele del.; 
;ANTITHYMOCYTE GLOBULIN;FCGR3A;rs396991;AC + CC;Other;increased   Other:sensitive to antilymphocyte serum;Genotypes AC + CC is associated with increased sensitive to antilymphocyte serum when treated with antithymocyte globulin in people with Kidney Transplantation as compared to genotype AA.;in people with Disease:Kidney Transplantation
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;rs141059755;G;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele G is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs17021408;C;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele C is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.;in children with Disease:Acute lymphoblastic leukemia
;PEGASPARGASE;ARHGAP28;rs9958628;T;Toxicity;increased  risk of Side Effect:Hypersensitivity;Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A.; 
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;rs117532069;A;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele A is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs80223967;G;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele G is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Disease:Acute lymphoblastic leukemia
;CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;rs3114020;CT + TT;Efficacy;increased  risk of Side Effect:Death;Genotypes CT + TT is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype CC.;in children with Central Nervous System Cancer
;THEOPHYLLINE;CYP1A2;rs35694136;T/del + TT;Efficacy;increased  severity of Disease:Chronic Obstructive Pulmonary Disease;Genotypes TT + T/del are associated with increased severity of Pulmonary Disease, Chronic Obstructive when treated with theophylline in people with Pulmonary Disease, Chronic Obstructive as compared to genotype del/del.;in people with Disease:Chronic Obstructive Pulmonary Disease
;THEOPHYLLINE;CYP1A2;rs35694136;T;Efficacy, Metabolism/PK;decreased  PK:plasma drug levels;Allele T is associated with decreased plasma drug levels when treated with theophylline in people with Pulmonary Disease, Chronic Obstructive as compared to allele del.;in people with Disease:Chronic Obstructive Pulmonary Disease
;;CYP1A2;rs762551;C;Other;increased  likelihood of Disease:Chronic Obstructive Pulmonary Disease;Allele C is associated with increased likelihood of Pulmonary Disease, Chronic Obstructive as compared to allele A.; 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;rs1061472;CC;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype CC is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotypes CT + TT.;in people with Tuberculosis
;VERAPAMIL;NR1H3;rs2279238;T;Efficacy;increased  risk of Efficacy:Myocardial Infarction, Efficacy:Stroke;Allele T is associated with increased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele C.;in people with Disease:Coronary Artery Disease, Disease:Hypertension
;VERAPAMIL;NR1H3;rs12221497;A;Efficacy;decreased risk of Efficacy:Myocardial Infarction, Efficacy:Stroke;Allele A is associated with decreased risk of Myocardial Infarction and Stroke when treated with verapamil in people with Coronary Artery Disease and Hypertension as compared to allele G.;in people with Disease:Coronary Artery Disease, Disease:Hypertension
;;DDC;rs921451;T;;severity of Disease:Tobacco Use Disorder;Allele T is associated with severity of Tobacco Use Disorder.; 
;ATENOLOL, VERAPAMIL;NR1H3;rs11039149;G;Efficacy;decreased risk of Efficacy:Myocardial Infarction, Efficacy:Stroke;Allele G is associated with decreased risk of Myocardial Infarction and Stroke when treated with atenolol and verapamil in people with Coronary Artery Disease and Hypertension as compared to allele A.;in people with Disease:Coronary Artery Disease, Disease:Hypertension
;;DDC;rs3735273;C;;severity of Disease:Tobacco Use Disorder;Allele C is associated with severity of Tobacco Use Disorder.; 
;SEVOFLURANE;KCNK2;rs6686529;CC + CG;Efficacy;increased   Efficacy:sedation;Genotypes CC + CG are associated with increased sedation when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype GG.;in people with otorhinolaryngology surgery
;;DDC;rs1451371;T;;severity of Disease:Tobacco Use Disorder;Allele T is associated with severity of Tobacco Use Disorder.; 
;CHOP, RITUXIMAB;SLC35F4;rs74832512;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype CT.;in people with Lymphoma, Large B-Cell, Diffuse
;PROTEASE INHIBITORS;APOC3;rs2854116;CC + CT;Efficacy;decreased severity of Side Effect:Hypertriglyceridemia;Genotypes CC + CT are associated with decreased severity of Hypertriglyceridemia when treated with protease inhibitors as compared to genotype TT.; 
;VARENICLINE;CHRNB1, ZBTB4;rs2302764;C;Toxicity;increased  severity of Disease:Nausea;Allele C is associated with increased severity of Nausea when treated with varenicline in people with Tobacco Use Disorder as compared to allele T.;in people with Disease:Tobacco Use Disorder
;PROTEASE INHIBITORS;APOC3;rs2854117;CT + TT;Toxicity;decreased severity of Side Effect:Hypertriglyceridemia;Genotypes CT + TT are associated with decreased severity of Hypertriglyceridemia when treated with protease inhibitors as compared to genotype CC.; 
;VARENICLINE;CHRNB2;rs2072661;A;Toxicity;increased  severity of Disease:Nausea;Allele A is associated with increased severity of Nausea when treated with varenicline in people with Tobacco Use Disorder as compared to allele G.;in people with Disease:Tobacco Use Disorder
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;rs79085477;T;Toxicity;increased  risk of Side Effect:Osteonecrosis;Allele T is associated with increased risk of Osteonecrosis when exposed to cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;VARENICLINE;CHRNB2;rs4292956;T;Toxicity;increased  severity of Disease:Nausea;Allele T is associated with increased severity of Nausea when treated with varenicline in people with Tobacco Use Disorder as compared to allele C.;in people with Disease:Tobacco Use Disorder
;VARENICLINE;CHRNB2;rs2072660;C;Toxicity;increased  severity of Disease:Nausea;Allele C is associated with increased severity of Nausea when treated with varenicline in people with Tobacco Use Disorder as compared to allele T.;in people with Disease:Tobacco Use Disorder
;CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;rs1045642;AA + AG;Efficacy;increased  risk of Side Effect:Death;Genotypes AA + AG is associated with increased risk of Death when treated with carboplatin, etoposide and ifosfamide in children with Central Nervous System Neoplasms as compared to genotype GG.;in children with Central Nervous System Cancer
;AZATHIOPRINE;DDRGK1, ITPA;rs1127354;A;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele A is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;MORPHINE;FAAH;rs324420;AA;Toxicity;increased  likelihood of Side Effect:Respiratory Insufficiency;Genotype AA is associated with increased likelihood of Respiratory Insufficiency when treated with morphine in children with Kyphosis and Scoliosis as compared to genotypes AC + CC.;in children with Disease:Kyphosis, Disease:Scoliosis
;CHOP, RITUXIMAB;OXNAD1;rs11721010;TT;Efficacy;increased   Efficacy:Overall survival;Genotype TT is associated with increased overall survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype CT.;in people with Lymphoma, Large B-Cell, Diffuse
;MORPHINE;FAAH;rs11576941;TT;Toxicity;increased  likelihood of Side Effect:Postoperative Nausea and Vomiting;Genotype TT is associated with increased likelihood of Postoperative Nausea and Vomiting when treated with morphine in children with Kyphosis and Scoliosis as compared to genotypes GG + GT.;in children with Disease:Kyphosis, Disease:Scoliosis
;PROTEASE INHIBITORS;APOC3;rs5128;CG + GG;Toxicity;decreased  Side Effect:Hypertriglyceridemia;Genotypes CG + GG are associated with decreased Hypertriglyceridemia when treated with protease inhibitors as compared to genotype CC.; 
;SUNITINIB;ABCB1;rs2032582;AC;Efficacy;increased   Efficacy:Progression-free survival;Genotype AC is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.;in people with Disease:Renal Cell Carcinoma
;DOCETAXEL;SLCO1B3;rs11045585;G;Toxicity;increased  risk of Disease:Leukopenia;Allele G is associated with increased risk of Leukopenia when treated with docetaxel as compared to allele A.; 
;APIXABAN;ABCB1;rs4148738;CT + TT;Toxicity;decreased risk of Side Effect:Hemorrhage;Genotypes CT + TT are associated with decreased risk of Hemorrhage when treated with apixaban as compared to genotype CC.; 
;DOCETAXEL;ABCC2;rs12762549;G;Toxicity;increased  risk of Side Effect:Leukopenia;Allele G is associated with increased risk of Leukopenia when treated with docetaxel.; 
;;DTNBP1;rs3213207;T;;decreased risk of Disease:Bipolar Disorder;Allele T is associated with decreased risk of Bipolar Disorder.; 
;ASPIRIN;ITGB3;rs5918;CT;Other;increased   Other:sensitivity to aspirin;Genotype CT is associated with increased sensitivity to aspirin when assayed with aspirin as compared to genotypes CC + TT.; 
;CHOP, RITUXIMAB;CIDEA;rs75614943;TT;Efficacy;increased   Efficacy:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype CT.;in people with Lymphoma, Large B-Cell, Diffuse
;CYTARABINE;CDA;rs3215400;C/del + del/del;Toxicity;increased   Disease:Drug Toxicity;Genotypes C/del + del/del are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype CC.; 
;METHAMPHETAMINE;BDNF;rs6265;CC;Other;increased  likelihood of Disease:Substance-Related Disorders;Genotype CC is associated with increased likelihood of Substance-Related Disorders of methamphetamine in men as compared to genotypes CT + TT.;in men 
;CHOP, RITUXIMAB;NOS1;rs77241831;GG;Efficacy;increased   Efficacy:Progression-free survival;Genotype GG is associated with increased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AG.;in people with Lymphoma, Large B-Cell, Diffuse
;METHAMPHETAMINE;BDNF;rs6265;CC;Other;decreased likelihood of Side Effect:Psychotic Disorder;Genotype CC is associated with decreased likelihood of Psychotic Disorders when exposed to methamphetamine in men with Substance-Related Disorders as compared to genotypes CT + TT.;in men with Disease:Substance-Related Disorders
;CYTARABINE;CDA;rs2072671;AC + CC;Toxicity;increased   Disease:Drug Toxicity;Genotypes AC + CC are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype AA.; 
;ANTIPSYCHOTICS;;rs9346455;GG + GT;Toxicity;increased   Side Effect:Weight gain;Genotypes GG + GT are associated with increased Weight gain when treated with antipsychotics in people with Schizophrenia as compared to genotype TT.;in people with Disease:Schizophrenia
;;DTNBP1;rs3213207;T;;decreased severity of Other:Manic Symptoms in Psychosis;Allele T is associated with decreased severity of Manic Symptoms in Psychosis.; 
;SUFENTANIL;ABCB1;rs1045642;GG;Efficacy;increased  severity of Efficacy:Pain, Postoperative;Genotype GG is associated with increased severity of Pain, Postoperative when treated with sufentanil in children with Pain, Postoperative as compared to genotypes AA + AG.;in children with Pain, Postoperative
;;DTNBP1;rs2619539;C;;decreased severity of Other:Manic Symptoms in Psychosis;Allele C is associated with decreased severity of Manic Symptoms in Psychosis.; 
;CYTARABINE;CDA;rs602950;AG + GG;Toxicity;increased   Disease:Drug Toxicity;Genotypes AG + GG are associated with increased Drug Toxicity when treated with cytarabine as compared to genotype AA.; 
;HEROIN;OPRD1;rs2236857;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;CYTARABINE;CDA;rs532545;CT + TT;Toxicity;increased   Disease:Drug Toxicity;Genotypes CT + TT are associated with increased Drug Toxicity when exposed to cytarabine in healthy individuals as compared to genotype CC.;in healthy individuals 
;HEROIN;OPRD1;rs2236855;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;SUNITINIB;ABCB1;rs1128503;AG;Efficacy;increased   Efficacy:Progression-free survival;Genotype AG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype AA.;in people with Disease:Renal Cell Carcinoma
;RIVAROXABAN;ABCB1;rs1045642;AA + AG;Toxicity;decreased risk of Side Effect:Thromboembolism;Genotypes AA + AG are associated with decreased risk of Thromboembolism when treated with rivaroxaban as compared to genotype GG.; 
;HEROIN;OPRD1;rs3766951;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;NICOTINE;NRXN1;rs2193225;C;Other;Other:smoking quantity;Allele C is associated with smoking quantity when exposed to nicotine in smokers.;in smokers
;HEROIN;OPRD1;rs2298897;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.; 
;NICOTINE;NRXN1;rs2193225;C;Other;Other:smoking quantity, heaviness of smoking index and Fagerstrom test for nicotine dependence;Allele C is associated with smoking quantity, heaviness of smoking index and Fagerstrom test for nicotine dependence when exposed to nicotine in smokers.;in smokers
;NICOTINE;NRXN1;rs6721498;A;Other;Other:smoking quantity, heaviness of smoking index and Fagerstrom test for nicotine dependence;Allele A is associated with smoking quantity, heaviness of smoking index and Fagerstrom test for nicotine dependence when exposed to nicotine in smokers.;in smokers
;SUNITINIB;ABCB1;rs1045642;AG;Efficacy;increased   Efficacy:Progression-free survival;Genotype AG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;CHOP, RITUXIMAB;;rs1607795;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype CT.;in people with Lymphoma, Large B-Cell, Diffuse
;SUFENTANIL;COMT;rs4680;AA;Efficacy;increased  severity of Efficacy:Pain, Postoperative;Genotype AA is associated with increased severity of Pain, Postoperative when treated with sufentanil in children with Pain, Postoperative as compared to genotypes AG + GG.;in children with Pain, Postoperative
;;DTNBP1;rs2619538;T;;decreased severity of Other:Manic Symptoms in Psychosis;Allele T is associated with decreased severity of Manic Symptoms in Psychosis.; 
;ETHANOL;FUT2;rs492602;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;ETHANOL;FTO;rs9937709;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;PLATINUM;RICTOR;rs6878291;GG;Toxicity;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIDEPRESSANTS;NR3C1;rs852977;G;Efficacy;increased   PK:antidepressant response;Allele G is associated with increased antidepressant response when exposed to antidepressants.; 
;CERIVASTATIN;SLCO1B1;rs4149056;CC;Toxicity;increased  risk of Disease:Rhabdomyolysis;Genotype CC is associated with increased risk of Rhabdomyolysis when treated with cerivastatin as compared to genotype TT.; 
;PAROXETINE;HTR3B;rs1176744;AA;Toxicity;increased  risk of Disease:Nausea;Genotype AA is associated with increased risk of Nausea when treated with paroxetine in people with Mental Disorders as compared to genotypes AC + CC.;in people with Disease:Mental Disorders
;ETHANOL;;rs1783835;A;Toxicity;decreased risk of Side Effect:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;CHOP, RITUXIMAB;TNIP3;rs116665727;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes CG + GG.;in people with Lymphoma, Large B-Cell, Diffuse
;CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;rs1760944;GG;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotype GG is associated with decreased likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotypes GT + TT.;in men with Carcinoma, Squamous Cell
;CHOP, RITUXIMAB;IL10;rs1800871;AG + GG;Efficacy;increased   Efficacy:Progression-free survival, Efficacy:Overall survival;Genotypes AG + GG is associated with increased progression-free survival and overall survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AA.;in people with Lymphoma, Large B-Cell, Diffuse
;SUNITINIB;ABCB1;rs2032582;A;Efficacy;decreased  Efficacy:Progression-free survival;Allele A is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Disease:Renal Cell Carcinoma
;CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;rs3219489;CG + GG;Efficacy;decreased likelihood of Efficacy:Progression-free survival;Genotypes CG + GG are associated with decreased likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy in men with Carcinoma, Squamous Cell as compared to genotype CC.;in men with Carcinoma, Squamous Cell
;ETHANOL;SLC4A8;rs12296477;C;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele C is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;ASPIRIN;ITGB3;rs5918;CC + CT;Other;Other:shorter bleeding time;Genotypes CC + CT are associated with shorter bleeding time when exposed to aspirin in healthy individuals as compared to genotype TT.;in healthy individuals 
;;NR3C1;rs10482633;G;;increased   Efficacy:antidepressant response;Allele G is associated with increased antidepressant response.; 
;ESCITALOPRAM;HTR2A;rs9316233;C;Efficacy;increased   Efficacy:antidepressant response;Allele C is associated with increased antidepressant response when treated with escitalopram in people with Depressive Disorder as compared to allele G.;in people with Disease:Depressive Disorder
;ETHANOL;ARID4A;rs61974485;T;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;ETHANOL;;rs8008020;T;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C.; 
;NICOTINE;OPRM1;rs1799971;AG;Toxicity;increased  severity of Other:Tobacco Use Disorder;Genotype AG is associated with increased severity of Tobacco Use Disorder due to nicotine as compared to genotype AA.; 
;ETHANOL;TNRC6A;rs72768626;A;Toxicity;increased  risk of Side Effect:Alcohol abuse;Allele A is associated with increased risk of Alcoholism due to ethanol as compared to allele G.; 
;GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;rs10494366;T;Toxicity;increased  risk of Other:Hypoglycemia;Allele T is associated with increased risk of Hypoglycemia when treated with glibenclamide, glimepiride or glipizide in people with Diabetes Mellitus, Type 2 as compared to allele G.;in people with Diabetes Mellitus, Type 2
;KETOROLAC;;rs2562456;CC;Efficacy;Efficacy:slower analgesic onset in European Americans undergoing oral surgery;Genotype CC is associated with slower analgesic onset in European Americans undergoing oral surgery when treated with ketorolac as compared to genotypes CT + TT.; 
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage;decreased likelihood of Side Effect:Vomiting;Genotypes AG + GG are associated with decreased likelihood of Vomiting due to opioids as compared to genotype AA.; 
;AZATHIOPRINE;ABCC1;rs2074087;CC + CG;Toxicity;increased  likelihood of Side Effect:Lymphopenia;Genotypes CC + CG is associated with increased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype GG.;in children with Disease:Inflammatory Bowel Diseases
;FLUVASTATIN;SREBF1;rs60282872;CC;Efficacy;increased   Efficacy:apolipoprotein A1 and C3;Genotype CC is associated with increased apolipoprotein A1 and C3 when treated with fluvastatin in people with Coronary Artery Disease.;in people with Disease:Coronary Artery Disease
;BEVACIZUMAB, PEMETREXED;SLC19A1;rs1051298;G;Efficacy;increased   Efficacy:Progression-free survival;Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.;in people with Disease:Lung Neoplasms
;CISPLATIN, RADIOTHERAPY;TP53;rs1042522;CG;Efficacy;increased   Efficacy:Overall survival;Genotype CG is associated with increased overall survival when treated with cisplatin and radiotherapy in women with Uterine Cervical Neoplasms as compared to genotypes CC + GG.;in women with Uterine Cervical Neoplasm
;;SLC30A8;rs13266634;C;Other, Metabolism/PK;increased   Other:baseline proinsulin levels after adjusting for insulin levels;Allele C is associated with increased baseline proinsulin levels after adjusting for insulin levels in people with suspected increased risk of diabetes as compared to allele T.;in people with suspected increased risk of diabetes
;OPIOIDS;OPRM1;rs1799971;AG + GG;Dosage;decreased likelihood of Side Effect:Postoperative Nausea and Vomiting;Genotypes AG + GG are associated with decreased likelihood of Postoperative Nausea and Vomiting due to opioids in people with Pain, Postoperative as compared to genotype AA.;in people with Pain, Postoperative
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs943580;GG;Toxicity;decreased likelihood of Disease:Acute coronary syndrome;Genotype GG is associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Disease:Acute coronary syndrome
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs2071230;AG + GG;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotypes AG + GG are associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;LEVONORGESTREL;ADAMTS10;rs7255721;CG;Toxicity;decreased likelihood of Side Effect:adverse events;Genotype CG is associated with decreased likelihood of adverse events when treated with levonorgestrel in women as compared to genotype CC.;in women 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs7945189;CT + TT;Toxicity;decreased likelihood of Disease:Acute coronary syndrome;Genotypes CT + TT are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;CITALOPRAM;HTR2A;rs6313;AA;Toxicity;decreased risk of Side Effect:heart palpitations;Genotype AA is associated with decreased risk of heart palpitations when treated with citalopram in people with Depression as compared to genotype GG.;in people with Disease:Depression
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs12353214;TT;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotype TT is associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes CC + CT.;in people with Disease:Acute coronary syndrome
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;KL;rs211247;CG + GG;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotypes CG + GG are associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CRP;rs1205;CT + TT;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotypes CT + TT are associated with increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;NICOTINE;CHRNA4;rs1044396;AG;Other;increased  likelihood of Other:smoking initiation;Genotype AG is associated with increased likelihood of smoking initiation when exposed to nicotine in men.;in men 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CDKN2B-AS1;rs10757274;AA + AG;Toxicity;decreased likelihood of Disease:Acute coronary syndrome;Genotypes AA + AG are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;NICOTINE;CHRNA4;rs1044396;GG;Toxicity;increased  likelihood of Disease:Tobacco Use Disorder;Genotype GG is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine in men.;in men 
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs699;GG;Toxicity;decreased likelihood of Disease:Acute coronary syndrome;Genotype GG is associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Disease:Acute coronary syndrome
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;NICOTINE;CHRNA4;rs1044397;CC;Toxicity;increased  likelihood of Disease:Tobacco Use Disorder;Genotype CC is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine in men.;in men 
;COXIBS;PTGS2;rs20417;CG + GG;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotypes CG + GG are associated with increased likelihood of Acute coronary syndrome when exposed to Coxibs in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;COXIBS;PTGS2;rs4648276;AG + GG;Toxicity;increased  likelihood of Disease:Acute coronary syndrome;Genotypes AG + GG are associated with increased likelihood of Acute coronary syndrome when exposed to Coxibs in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;SEVOFLURANE;FASTKD3, MTRR;rs3733784;CC + CT;Efficacy;increased   Efficacy:vol% end-tidal sevoflurane concentration;Genotypes CC + CT are associated with increased vol% end-tidal sevoflurane concentration when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype TT.;in people with otorhinolaryngology surgery
;HEROIN;OPRM1;rs524731;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;HEROIN;OPRM1;rs511435;T;Toxicity;increased  risk of Other:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;HEROIN;OPRM1;rs495491;G;Toxicity;increased  risk of Other:Heroin Dependence;Allele G is associated with increased risk of Heroin Dependence due to heroin as compared to allele A.; 
;AZATHIOPRINE;ADK;rs10824095;TT;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotype TT is associated with increased likelihood of Neutropenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotypes CC + CT.;in children with Disease:Inflammatory Bowel Diseases
;HEROIN;OPRM1;rs510769;T;Toxicity;increased  risk of Other:Heroin Dependence;Allele T is associated with increased risk of Heroin Dependence due to heroin as compared to allele C.; 
;CISPLATIN;ACYP2;rs1872328;A;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele A is associated with increased risk of Ototoxicity when exposed to cisplatin in children with Brain Neoplasms as compared to allele G.;in children with Disease:Brain Neoplasms
;AZATHIOPRINE;SLC29A1;rs747199;CG + GG;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotypes CG + GG is associated with increased likelihood of Neutropenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype CC.;in children with Disease:Inflammatory Bowel Diseases
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased   Efficacy:on-treatment platelet aggregation;Genotypes AA + AG is associated with increased on-treatment platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;AZATHIOPRINE;IMPDH2;rs11706052;AG + GG;Toxicity;increased  likelihood of Side Effect:Lymphopenia;Genotypes AG + GG is associated with increased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype AA.;in children with Disease:Inflammatory Bowel Diseases
;HEROIN;OPRM1;rs3778151;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;AZATHIOPRINE;IMPDH1;rs2278294;CT + TT;Toxicity;decreased likelihood of Side Effect:Lymphopenia;Genotypes CT + TT is associated with decreased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype CC.;in children with Disease:Inflammatory Bowel Diseases
;CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs2228622;A;Toxicity;increased  risk of Side Effect:obsessive-compulsive symptoms;Allele A is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.;in people with Disease:Schizophrenia
;HEROIN;OPRM1;rs3823010;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.; 
;CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780413;G;Toxicity;increased  risk of Side Effect:obsessive-compulsive symptoms;Allele G is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.;in people with Disease:Schizophrenia
;CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780412;C;Toxicity;increased  risk of Side Effect:obsessive-compulsive symptoms;Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia.;in people with Disease:Schizophrenia
;HEROIN;;rs9478495;A;Toxicity;increased  risk of Other:Heroin Dependence;Allele A is associated with increased risk of Heroin Dependence due to heroin as compared to allele G.; 
;;;rs9424490;G;;increased  risk of Other:current smoking;Allele G is associated with increased risk of current smoking.; 
;;USH2A;rs12126638;C;;increased  risk of Other:current smoking;Allele C is associated with increased risk of current smoking.; 
;;AK4;rs1109374;C;;increased  risk of Other:current smoking;Allele C is associated with increased risk of current smoking.; 
;ASPIRIN, CLOPIDOGREL;ITGA2;rs1062535;AA + AG;Efficacy;increased  risk of Efficacy:residual platelet reactivity;Genotypes AA + AG are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype GG.;in people with Disease:Myocardial Infarction
;;ITGB1;rs1187075;AA;Efficacy;increased  risk of Efficacy:Death;Genotype AA is associated with increased risk of Death in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;HEROIN;OPRM1;rs562859;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;FLUOROURACIL;DPYD;rs3918290;T;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil.; 
;LETROZOLE;;rs1324052;A;Toxicity;increased  likelihood of Side Effect:Musculoskeletal pain, Side Effect:Arthritis, Other:Discontinuation;Allele A is associated with increased likelihood of Musculoskeletal pain, Arthritis and Discontinuation when treated with letrozole in women with Breast Neoplasms as compared to allele G.;in women with Breast Neoplasms
;PLATINUM, VINORELBINE;STMN1;rs182455;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with platinum and vinorelbine in people with as compared to genotypes AG + GG.;in people with 
;TEGAFUR;DPYD;rs1801159;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with tegafur in people with Stomach Neoplasms as compared to genotypes CC + CT.;in people with Disease:Stomach Neoplasms
;;ITGB1;rs2230395;GG;Efficacy;increased  risk of Efficacy:Death;Genotype GG is associated with increased risk of Death in people with Colorectal Neoplasms as compared to genotypes GT + TT.;in people with Disease:Colorectal Neoplasms
;HEROIN;OPRM1;rs3778150;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;BEVACIZUMAB, PEMETREXED;GGH;rs3780126;G;Efficacy;increased   Efficacy:Overall survival;Allele G are associated with increased overall survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.;in people with Disease:Lung Neoplasms
;;TPH2;rs1843809;TT;Other;decreased likelihood of Side Effect:Aggression, Side Effect:Depression;Genotype TT is associated with decreased likelihood of aggression and Depression in people with Alcoholism as compared to genotypes GG + GT.;in people with Disease:Alcohol abuse
;ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;Efficacy;increased  risk of Efficacy:residual platelet reactivity;Genotypes CT + TT are associated with increased risk of residual platelet reactivity when treated with aspirin and clopidogrel in people with Myocardial Infarction as compared to genotype CC.;in people with Disease:Myocardial Infarction
;HEROIN;;rs9384169;C;Toxicity;increased  risk of Other:Heroin Dependence;Allele C is associated with increased risk of Heroin Dependence due to heroin as compared to allele T.; 
;ANTIPSYCHOTICS;CYP1A2;rs762551;AC + CC;Toxicity;increased   Side Effect:QT interval;Genotypes AC + CC are associated with increased QT interval when treated with antipsychotics in people with Schizophrenia as compared to genotype AA.;in people with Disease:Schizophrenia
;PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes AA + AC are associated with increased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;Toxicity;increased  severity of Side Effect:Toxic liver disease;Genotypes AA + AC are associated with increased severity of Toxic liver disease when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;rs1799971;G;Toxicity;increased  risk of Other:Cardiac Arrest, Other:Respiratory Insufficiency;Allele G is associated with increased risk of Heart Arrest or Respiratory Insufficiency due to antidepressants, antipsychotics, benzodiazepine derivatives, opioids or Sympathomimetics Overdose as compared to allele A.; Overdose
;BEVACIZUMAB, PEMETREXED;GGH;rs11545077;CT;Efficacy;increased   Efficacy:Overall survival;Genotype CT is associated with increased overall survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to genotype CC.;in people with Disease:Lung Neoplasms
;DIGOXIN;NOS1AP;rs10494366;GG;Toxicity;increased   Side Effect:Shortened QT interval;Genotype GG is associated with increased Shortened QT interval of digoxin as compared to genotypes GT + TT.; 
;SUNITINIB;ABCB1;rs2032582;CC;Toxicity;increased  likelihood of Side Effect:adverse events, Side Effect:Hand-foot syndrome, Side Effect:Hypertension;Genotype CC is associated with increased likelihood of adverse events, hand-foot syndrome and Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell.;in people with Disease:Renal Cell Carcinoma
;ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;Efficacy;increased   Efficacy:platelet aggregation after stimuli with adenosine diphosphate, collagen, and epinephrine;Genotypes CT + TT are associated with increased platelet aggregation after stimuli with adenosine diphosphate, collagen, and epinephrine when treated with aspirin and clopidogrel in people with Coronary Disease as compared to genotype CC.;in people with Disease:Coronary Disease
;FENTANYL;OPRM1;rs1799971;GG;Dosage;Efficacy:higher fentanyl dose requirement to achieve adequate pain relief in Chinese women undergoing gynecologic surgery;Genotype GG is associated with higher fentanyl dose requirement to achieve adequate pain relief in Chinese women undergoing gynecologic surgery when treated with fentanyl as compared to genotypes AA + AG.; 
;CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;rs1799971;G;Toxicity;decreased risk of Other:Substance-Related Disorders;Allele G is associated with decreased risk of Substance-Related Disorders due to cannabinoids, cocaine, ethanol, nicotine or opioids as compared to allele A.; 
;CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Neoplasms
;SUNITINIB;FLT1;rs7993418;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.;in people with Disease:Renal Cell Carcinoma
;CISPLATIN;NFE2L2;rs6721961;GG + GT;Toxicity;increased  likelihood of Side Effect:Ototoxicity;Genotypes GG + GT is associated with increased likelihood of Ototoxicity when treated with cisplatin in people with Head and Neck Neoplasms as compared to genotype TT.;in people with Head and Neck Neoplasms
;SUNITINIB;FLT1;rs9582036;CC;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype CC is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AC.;in people with Disease:Renal Cell Carcinoma
;FENTANYL;OPRM1;rs1799971;AG + GG;Dosage, Efficacy;Efficacy:higher responsiveness to opioids and required less analgesic drugs in laboring women;Genotypes AG + GG is associated with higher responsiveness to opioids and required less analgesic drugs in laboring women when treated with fentanyl in women as compared to genotype AA.;in women 
;FLUVOXAMINE;HTR2A;rs6311;CC + CT;Toxicity;increased  risk of Side Effect:gastrointestinal side effects;Genotypes CC + CT are associated with increased risk of gastrointestinal side effects when treated with fluvoxamine in people with Depressive Disorder as compared to genotype TT.;in people with Disease:Depressive Disorder
;FENTANYL;OPRM1;rs1799971;AG + GG;Efficacy;Efficacy:less pain control in Japanese patients undergoing painful orofacial cosmetic surgery;Genotypes AG + GG is associated with less pain control in Japanese patients undergoing painful orofacial cosmetic surgery when treated with fentanyl as compared to genotype AA.; 
;OLANZAPINE;FMO3;rs2266780;GG;Metabolism/PK;decreased  PK:dose-adjusted serum olanzapine N-oxide concentrations;Genotype GG is associated with decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to genotypes AA + AG.; 
;METOPROLOL;CYP2D6;rs3892097;T;Efficacy, Metabolism/PK;increased   PK:plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs.;Allele T is associated with increased plasma concentrations of metoprolol and greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure in PMs than in non-PMs. when treated with metoprolol as compared to allele C.; 
;SUNITINIB;FLT1;rs9554320;AA;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.;in people with Disease:Renal Cell Carcinoma
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:residual platelet reactivity;Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;Efficacy;decreased risk of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes AA + AC is associated with decreased risk of overall survival and progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype CC.;in people with Lung Neoplasms
;ASPIRIN;ITGB3;rs5918;CC + CT;Efficacy;increased  risk of Efficacy:the lack of aspirin effect;Genotypes CC + CT are associated with increased risk of the lack of aspirin effect when treated with aspirin in men as compared to genotype TT.;in men 
;SUNITINIB;FLT1;rs9554320;AA;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.;in people with Disease:Renal Cell Carcinoma
;OLANZAPINE;FMO1;rs12720462;AA + AC;Metabolism/PK;increased   PK:dose-adjusted serum olanzapine concentrations;Genotypes AA + AC are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy, Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + AC.;in people with Disease:Ovarian Neoplasms
;ARIPIPRAZOLE;DRD2;rs2514218;CC;Toxicity;increased  severity of Side Effect:Psychomotor Agitation;Genotype CC is associated with increased severity of Psychomotor Agitation due to aripiprazole in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT.;in people with Psychotic Disorder, Schizoaffective disorder, Schizophrenia
;PLATINUM COMPOUNDS, TAXANES;GSTP1;rs1695;AA;Toxicity, Metabolism/PK;increased  risk of Side Effect:hematological toxicity;Genotype AA is associated with increased risk of hematological toxicity when treated with Platinum compounds and taxanes in people with Ovarian Neoplasms as compared to genotypes AG + GG.;in people with Disease:Ovarian Neoplasms
;PLATINUM, TAXANES;ABCB1;rs2032582;CC;Toxicity, Metabolism/PK;decreased risk of Side Effect:grade 3 or 4 gastrointestinal toxicity;Genotype CC is associated with decreased risk of grade 3 or 4 gastrointestinal toxicity when treated with platinum and taxanes in people with Ovarian Neoplasms.;in people with Disease:Ovarian Neoplasms
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy, Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;SUNITINIB;FLT1;rs9582036;CC;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotype CC is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AC.;in people with Disease:Renal Cell Carcinoma
;OLANZAPINE;FMO1;rs7877;CT + TT;Metabolism/PK;increased   PK:dose-adjusted serum olanzapine concentrations;Genotypes CT + TT are associated with increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to genotype CC.; 
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased   Efficacy:residual platelet reactivity;Allele A is associated with increased residual platelet reactivity when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;rs1529927;C;Efficacy;increased   Efficacy:24-h excretion of chloride and potassium;Allele C is associated with increased 24-h excretion of chloride and potassium when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele G.;in healthy individuals 
;AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;rs9829896;C;Toxicity;decreased risk of Other:Substance-Related Disorders;Allele C is associated with decreased risk of Substance-Related Disorders due to amphetamine, cannabinoids, cocaine or opioids as compared to allele A.; 
;PACLITAXEL;EPHA5;rs7349683;TT;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Breast Neoplasms
;IMATINIB;ABCG2;rs2231142;TT;Efficacy;increased   Efficacy:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GG + GT.;in people with Disease:Gastrointestinal Stromal Tumors
;ASPIRIN;NAT2;rs4271002;C;Toxicity;increased  risk of Side Effect:intolerance;Allele C is associated with increased risk of intolerance of aspirin in people with Asthma as compared to allele G.;in people with Disease:Asthma
;OPIOIDS;OPRM1;rs1799971;AG + GG;Toxicity;decreased likelihood of Side Effect:Nausea;Genotypes AG + GG are associated with decreased likelihood of Nausea due to opioids in people with Pain or Pain, Postoperative as compared to genotype AA.;"in people with ""Pain"", ""Pain, Postoperative"""
;METHADONE;ARRB2;rs3786047;AA;Efficacy;increased  risk of Efficacy:nonresponse to methadone maintenance treatment;Genotype AA is associated with increased risk of nonresponse to methadone maintenance treatment when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Disease:Opioid-Related Disorders
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5723;G;Efficacy;decreased  Efficacy:24-h excretion of calcium and decreased urinary volume;Allele G is associated with decreased 24-h excretion of calcium and decreased urinary volume when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele C.;in healthy individuals 
;PLATINUM COMPOUNDS;CCN4;rs2929973;GG + GT;Efficacy;decreased risk of Efficacy:Progression-free survival;Genotypes GG + GT is associated with decreased risk of progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype TT.;in people with Lung Neoplasms
;ENALAPRIL;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Cough;Genotypes CC + CT are associated with increased likelihood of Cough when treated with enalapril in people with Essential hypertension as compared to genotype TT.;in people with Disease:Essential hypertension
;ANTIPSYCHOTICS;HTR2A;rs6311;TT;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Genotype TT is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CC + CT.;in people with Disease:Schizophrenia
;METHADONE;ARRB2;rs1045280;CC;Efficacy;increased  risk of Efficacy:nonresponse to methadone maintenance treatment;Genotype CC is associated with increased risk of nonresponse to methadone maintenance treatment when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.;in people with Disease:Opioid-Related Disorders
;METHADONE;MYOCD;rs1714984;AA + AG;Efficacy;Efficacy:increased  risk of being nonresponders;Genotypes AA + AG is associated with increased risk of being nonresponders when treated with methadone as compared to genotype GG.; 
;METHADONE;ARRB2;rs2036657;GG;Efficacy;increased  risk of Efficacy:nonresponse to methadone maintenance treatment;Genotype GG is associated with increased risk of nonresponse to methadone maintenance treatment when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AA + AG.;in people with Disease:Opioid-Related Disorders
;BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5729;A;Efficacy;decreased  Efficacy:24-h excretion of calcium and decreased urinary volume;Allele A is associated with decreased 24-h excretion of calcium and decreased urinary volume when treated with bumetanide, furosemide or torasemide in healthy individuals as compared to allele T.;in healthy individuals 
;ANTIPSYCHOTICS;CYP1A2;rs762551;CC;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Genotype CC is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC.;in people with Disease:Schizophrenia
;ANTIPSYCHOTICS;CYP2D6;rs1065852;A;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Allele A is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;OLANZAPINE;HTR2C;rs518147;C;Toxicity;decreased risk of Disease:Weight gain;Allele C is associated with decreased risk of Weight gain when treated with olanzapine in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;PRAVASTATIN;CETP;rs708272;AG;Efficacy;decreased severity of Efficacy:Coronary Artery Disease;Genotype AG is associated with decreased severity of Coronary Artery Disease when treated with pravastatin in men with Coronary Artery Disease.;in men with Coronary Artery Disease
;ATORVASTATIN;KIF6;rs20455;AG + GG;Efficacy;increased   Efficacy:benefit;Genotypes AG + GG are associated with increased benefit when treated with atorvastatin in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;ASPIRIN;ITGB3;rs5918;TT;Efficacy;Efficacy:aspirin-depressed thrombin generation and prolonged bleeding time after aspirin;Genotype TT is associated with aspirin-depressed thrombin generation and prolonged bleeding time after aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotypes CC + CT.;in people with Disease:Coronary Artery Disease
;ASPIRIN;F13A1;rs5985;AA + AC;Efficacy;increased   Efficacy:inhibition of FXIII activation by aspirin;Genotypes AA + AC are associated with increased inhibition of FXIII activation by aspirin when treated with aspirin in men as compared to genotype CC.;in men 
;VERAPAMIL;ADRB1;rs1801253;CC + CG;Efficacy;increased  risk of Disease:Death;Genotypes CC + CG are associated with increased risk of Death when treated with verapamil in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;AZATHIOPRINE;ITPA;rs1127354;C;Efficacy;decreased likelihood of Efficacy:Transplant rejection;Allele C is associated with decreased likelihood of transplant rejection when treated with azathioprine in people with liver transplantation as compared to allele A.;in people with Liver transplantation
;CHOP, RITUXIMAB;NCF4;rs1883112;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes AA + AG.;in people with Lymphoma, Large B-Cell, Diffuse
;IVACAFTOR;CFTR;rs75527207;AA + AG;Efficacy;decreased severity of Side Effect:bone density;Genotypes AA + AG is associated with decreased severity of bone density when treated with ivacaftor in people with Cystic Fibrosis as compared to genotype GG.;in people with Disease:Cystic Fibrosis
;CHOP, RITUXIMAB;ABCG2;rs2231137;CC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CC is associated with decreased progression-free survival when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes CT + TT.;in people with Lymphoma, Large B-Cell, Diffuse
;PRAVASTATIN;CETP;rs708272;GG;Efficacy;decreased  Efficacy:reduction in luminal diameter;Genotype GG is associated with decreased reduction in luminal diameter when treated with pravastatin in men with Coronary Artery Disease.;in men with Disease:Coronary Artery Disease
;AMIODARONE, DIURETICS, SOTALOL;NOS1AP;rs10800397;T;Toxicity;Side Effect:drug-induced ventricular arrhythmia and QT prolongation;Allele T is associated with drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone, diuretics or sotalol as compared to allele C.; 
;ANTIPSYCHOTICS;;rs6977820;CT + TT;Toxicity;increased  likelihood of Disease:Tardive Dyskinesia;Genotypes CT + TT are associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype CC.;in people with Disease:Schizophrenia
;AMIODARONE;NOS1AP;rs10800397;T;Toxicity;Side Effect:amiodarone-induced ventricular arrhythmia and QT prolongation;Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.; 
;WARFARIN;VKORC1;rs17880887;T;Dosage;Efficacy:lower levels of transthyretin precuror;Allele T is associated with lower levels of transthyretin precuror when exposed to warfarin as compared to allele G.; 
;AMIODARONE;NOS1AP;rs10919035;T;Toxicity;Side Effect:amiodarone-induced ventricular arrhythmia and QT prolongation;Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.; 
;ASPIRIN;HNMT;rs1050891;G;Toxicity;decreased risk of Side Effect:acetylsalicylic acid-intolerant chronic urticaria;Allele G is associated with decreased risk of acetylsalicylic acid-intolerant chronic urticaria when exposed to aspirin as compared to genotype AA.; 
;AMIODARONE;NOS1AP;rs10919035;T;Toxicity;Side Effect:amiodarone-induced ventricular arrhythmia and QT prolongation;Allele T is associated with amiodarone-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to allele C.; 
;ASPIRIN;LTC4S;rs730012;AC + CC;Toxicity;increased  risk of Side Effect:sensitivity to aspirin;Genotypes AC + CC are associated with increased risk of sensitivity to aspirin when exposed to aspirin as compared to genotype AA.; 
;ANTIPSYCHOTICS;SMYD3;rs2485914;T;Toxicity;increased  likelihood of Disease:Tardive Dyskinesia;Allele T is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;TT;Toxicity;increased  risk of Side Effect:hepatotoxicty;Genotype TT is associated with increased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;CC;Toxicity;decreased risk of Side Effect:hepatotoxicty;Genotype CC is associated with decreased risk of hepatotoxicty when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis.;in people with Disease:Tuberculosis
;CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;Efficacy;increased  likelihood of Efficacy:Complete Remission;Genotype GG is associated with increased likelihood of Complete Remission when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in people with Disease:Leukemia, Myeloid, Acute
;WARFARIN;CYP2C9;rs1057910;AC;Dosage;decreased  Other:warfarin dose requirements on day 14;Genotype AC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.; 
;LEVONORGESTREL;TP53;rs1042522;CG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype CG is associated with increased likelihood of adverse events when treated with levonorgestrel in women.;in women 
;ASPIRIN;GP6;rs1613662;AG;Efficacy;increased  risk of Efficacy:non-response to aspirin;Genotype AG is associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;rs1799793;CT + TT;Efficacy;increased   Efficacy:event free survival;Genotypes CT + TT are associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype CC.;in people with Disease:Osteosarcoma
;CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;Efficacy;increased  likelihood of Efficacy:3-year Event Free Survival;Genotype GG is associated with increased likelihood of 3-year Event Free Survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in people with Disease:Leukemia, Myeloid, Acute
;CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;rs13181;GG;Efficacy;increased   Efficacy:event free survival;Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT.;in people with Disease:Osteosarcoma
;ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;rs2108622;CT + TT;Dosage;Efficacy:8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR);Genotypes CT + TT are associated with 8.3% higher mean daily coumarin dose to reach a stable international normalized ratio (INR) when treated with acenocoumarol, phenprocoumon or warfarin as compared to genotype CC.; 
;ASPIRIN;ITGB3;rs5918;CT;Toxicity;increased   Side Effect:blood loss;Genotype CT is associated with increased blood loss when exposed to aspirin in people with Coronary Artery Disease as compared to genotype TT.;in people with Disease:Coronary Artery Disease
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Thrombocytopenia;Genotypes AA + AG are associated with increased risk of Leukopenia or Thrombocytopenia due to methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG.;in children with Non-Hodgkin Lymphoma
;SUNITINIB;KDR;rs2305948;C;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele C is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell and Gastrointestinal Stromal Tumors as compared to allele T.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;rs1695;GG;Efficacy;increased   Efficacy:Overall survival;Genotype GG is associated with increased overall survival when treated with capecitabine, epirubicin and platinum in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;increased   Efficacy:on-clopidogrel platelet reactivity (HPR);Genotypes CT + TT is associated with increased on-clopidogrel platelet reactivity (HPR) when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;;ITGB3;rs5918;CC + CT;Other;Other:shorter bleeding time;Genotypes CC + CT are associated with shorter bleeding time in healthy individuals as compared to genotype TT.;in healthy individuals 
;BETA BLOCKING AGENTS;GRK5;rs2230345;AA;Other;increased  risk of Other:Death;Genotype AA is associated with increased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotypes AT + TT.;in people with Heart Failure
;FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;rs1799971;AG + GG;Efficacy;increased  likelihood of Efficacy:Pain;Genotypes AG + GG is associated with increased likelihood of Pain when treated with fentanyl, hydromorphone or oxycodone in people with Neoplasms as compared to genotype AA.;in people with Neoplasms
;CLOPIDOGREL;PON1;rs662;CT + TT;Efficacy;increased   Efficacy:ADP-induced platelet aggregation;Genotypes CT + TT is associated with increased ADP-induced platelet aggregation when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype CC.;in people with Disease:Acute coronary syndrome
;BEVACIZUMAB;CXCR4;rs2228014;AA + AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AG is associated with decreased progression-free survival when treated with bevacizumab in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;Other;decreased risk of Other:Death;Genotype CC is associated with decreased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotypes CG + GG.;in people with Heart Failure
;DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;rs147451859;G;Toxicity;decreased likelihood of Side Effect:Amenorrhea;Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele C.;in women with Breast Neoplasms
;SUNITINIB;FLT4;rs6877011;GG;Efficacy;decreased likelihood of Efficacy:Disease Progression;Genotype GG is associated with decreased likelihood of Disease Progression when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotype CG.;in people with Disease:Gastrointestinal Stromal Tumors
;HALOPERIDOL;ABCB5;rs17143212;CT;Toxicity;increased   Side Effect:Drug Toxicity;Genotype CT is associated with increased Drug Toxicity when treated with haloperidol in people with Psychotic Disorders as compared to genotype CC.;in people with Disease:Psychotic Disorder
;DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;;rs17587029;G;Toxicity;decreased likelihood of Side Effect:Amenorrhea;Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele A.;in women with Breast Neoplasms
;SUNITINIB;ABCG2;rs2231142;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Disease:Renal Cell Carcinoma
;OPIOIDS;CNIH3;rs10799590;A;Toxicity;decreased risk of Side Effect:Opioid-Related Disorders;Allele A is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele G.; 
;AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;Toxicity;increased  likelihood of Side Effect:Thrombocytopenia;Genotypes AC + CC is associated with increased likelihood of Thrombocytopenia when treated with azathioprine or mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Disease:Acute lymphoblastic leukemia
;SUNITINIB;VEGFA;rs3025039;CT + TT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.;in people with Disease:Gastrointestinal Stromal Tumors
;ANTIPSYCHOTICS;CYP1A2;rs762551;CC;Toxicity;increased  severity of Disease:Tardive Dyskinesia;Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC.;in people with Disease:Schizophrenia
;METHOTREXATE;MTHFR;rs1801133;A;Efficacy;decreased likelihood of Efficacy:event-free survival;Allele A is associated with decreased likelihood of event-free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG.;in people with Disease:Non-Hodgkin Lymphoma
;CISPLATIN;SLC22A2;rs316019;A;Toxicity;decreased risk of Side Effect:Ototoxicity;Allele A is associated with decreased risk of Ototoxicity when treated with cisplatin in people with Neoplasms.;in people with Disease:Neoplasms
;SUNITINIB;CYP3A4;rs4646437;AA + AG;Toxicity;increased  likelihood of Side Effect:Hypertension;Genotypes AA + AG is associated with increased likelihood of Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype GG.;in people with Disease:Renal Cell Carcinoma
;ATORVASTATIN;ABCB1;rs2032582;C;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele C is associated with increased risk of drug-induced liver injury when treated with atorvastatin as compared to allele T.; 
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs6025;CT + TT;Toxicity;increased  risk of Side Effect:Angioedema;Genotypes CT + TT is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists as compared to genotype CC.; 
;CISPLATIN;NFE2L2;rs6721961;T;Toxicity;decreased risk of Side Effect:Ototoxicity;Allele T is associated with decreased risk of Ototoxicity when treated with cisplatin in people with Neoplasms.;in people with Disease:Neoplasms
;CARVEDILOL;ADRB2;rs1042714;CC;Efficacy;decreased likelihood of Efficacy:improved left ventricular ejection fraction;Genotype CC is associated with decreased likelihood of improved left ventricular ejection fraction when treated with carvedilol in people with Heart Failure as compared to genotypes CG + GG.;in people with Disease:Heart Failure
;TACROLIMUS;FOXP3;rs3761548;GT + TT;Toxicity;increased  risk of Side Effect:Nephrotoxicity;Genotypes GT + TT are associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;TACROLIMUS;CYP3A4;rs2740574;CC + CT;Toxicity;decreased likelihood of Side Effect:Diabetes Mellitus;Genotypes CC + CT is associated with decreased likelihood of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.;in people with Kidney Transplantation
;METHOTREXATE;RAVER2;rs72675408;A;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Allele A is associated with increased likelihood of Elevated liver enzymes when treated with methotrexate in people with Rheumatoid arthritis as compared to allele T.;in people with Rheumatoid arthritis
;PHENYTOIN;CYP2C9;rs1057910;C;Efficacy;increased  risk of Side Effect:Ataxia, Side Effect:Diplopia, Side Effect:Dizziness, Side Effect:Dysarthria;Allele C is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele A.;in people with Epilepsy
;PHENYTOIN;CYP2C9;rs1799853;T;Efficacy;increased  risk of Side Effect:Ataxia, Side Effect:Diplopia, Side Effect:Dizziness, Side Effect:Dysarthria;Allele T is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele C.;in people with Epilepsy
;CAPECITABINE, FLUOROURACIL;PPARD;rs2016520;T;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.;in people with Neoplasms
;EFAVIRENZ;CYP2B6;rs8192719;CT + TT;Metabolism/PK;increased   PK:plasma concentration;Genotypes CT + TT are associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype CC.;in people with Disease:HIV infectious disease
;;SULT1A1, SULT1A2;rs1801030;CC + CT;Other;increased  likelihood of Disease:Hot Flashes;Genotypes CC + CT are associated with increased likelihood of Hot Flashes in people with menopause as compared to genotype TT.;in people with menopause
;OPIOIDS;MCOLN1;rs116181528;A;Toxicity;increased  severity of Side Effect:Overdose;Allele A is associated with increased severity of Overdose due to opioids as compared to allele C.; 
;CERIVASTATIN, HMG COA REDUCTASE INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:Muscular Diseases;Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with cerivastatin, hmg coa reductase inhibitors, rosuvastatin or simvastatin as compared to genotype TT.; 
;;AKT1;rs2494732;CC;Other;increased  likelihood of Disease:Psychotic Disorder;Genotype CC is associated with increased likelihood of Psychotic Disorders in people with Marijuana Abuse as compared to genotypes CT + TT.;in people with Disease:Marijuana Abuse
;CAPECITABINE;MTHFR;rs1801131;GG;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes GT + TT.;in people with Disease:Gastrointestinal Neoplasms
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased  Other:warfarin dose requirements on day 14;Allele G is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.; 
;BEVACIZUMAB;KCNAB1;rs6770663;G;Toxicity;increased  risk of Side Effect:Hypertension;Allele G is associated with increased risk of Hypertension when treated with bevacizumab in people with Neoplasms.;in people with Neoplasms
;WARFARIN;VKORC1;rs9934438;A;Dosage;decreased  Other:warfarin dose requirements on day 14;Allele A is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele G.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;Toxicity;decreased severity of Side Effect:toxicity;Genotypes AA + AG are associated with decreased severity of toxicity when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;ASPIRIN;CEP68;rs7572857;AA;Toxicity;increased   Side Effect:decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation;Genotype AA is associated with increased decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes AG + GG.;in people with Disease:Asthma
;OPIOIDS;MCOLN1;rs114077267;T;Toxicity;increased  severity of Side Effect:Overdose;Allele T is associated with increased severity of Overdose due to opioids as compared to allele C.; 
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Efficacy;decreased  Efficacy:time to achieve stable dose;Genotype TT is associated with decreased time to achieve stable dose when treated with acenocoumarol as compared to genotypes CC + CT.; 
;PLATINUM COMPOUNDS;MDM2;rs2279744;GT + TT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes GT + TT is associated with increased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Non-Small Cell Lung Carcinoma
;SUNITINIB;FLT3;rs1933437;AG + GG;Toxicity;decreased likelihood of Side Effect:Leukopenia;Genotypes AG + GG is associated with decreased likelihood of Leukopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma concentration;Genotype TT is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;ASPIRIN;ITGB3;rs5918;CT;Efficacy;decreased  Efficacy:platelet inhibition by aspirin;Genotype CT is associated with decreased platelet inhibition by aspirin when exposed to aspirin in people with Coronary Artery Disease as compared to genotype TT.;in people with Disease:Coronary Artery Disease
;;SLC2A9;rs62293298;AG;Other;decreased likelihood of Other:Hyperuricemia;Genotype AG is associated with decreased likelihood of Hyperuricemia in people with Coronary Artery Disease as compared to genotype AA.;in people with Coronary Artery Disease
;EFAVIRENZ;CYP2B6;rs2279343;GG;Metabolism/PK;increased   PK:plasma concentration;Genotype GG is associated with increased plasma concentration of efavirenz in people with HIV Infections as compared to genotypes AA + AG.;in people with Disease:HIV infectious disease
;ASPIRIN;TLR3;rs3775291;CT + TT;Toxicity;increased  risk of Side Effect:Aspirin-Exacerbated Respiratory Disease;Genotypes CT + TT are associated with increased risk of Aspirin-Exacerbated Respiratory Disease when exposed to aspirin in people with Asthma as compared to genotype CC.;in people with Disease:Asthma
;EFAVIRENZ;CYP2B6;rs2279345;CC + CT;Metabolism/PK;decreased  PK:plasma concentration;Genotypes CC + CT are associated with decreased plasma concentration of efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;OPIOIDS;MCOLN1;rs115208233;G;Toxicity;increased  severity of Side Effect:Overdose;Allele G is associated with increased severity of Overdose due to opioids as compared to allele C.; 
;TACROLIMUS;CYP3A4;rs2740574;CC + CT;Efficacy;increased  likelihood of Efficacy:Acute cellular rejection;Genotypes CC + CT is associated with increased likelihood of acute cellular rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.;in people with Kidney Transplantation
;NICOTINE;DRD2;rs1800497;AA + AG;Toxicity;increased   Side Effect:Craving;Genotypes AA + AG is associated with increased craving of nicotine in children as compared to genotype GG.;in children 
;NICOTINE;DRD2;rs1800497;GG;Toxicity;increased  severity of Side Effect:Craving;Genotype GG is associated with increased severity of craving when exposed to nicotine in children as compared to genotypes AA + AG.;in children 
;WARFARIN;VKORC1;rs2884737;CC;Dosage;decreased  Other:warfarin dose requirements on day 14;Genotype CC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CG + GG.;in people with Disease:Chronic hepatitis C virus infection
;;ABCG2;rs2231142;GT + TT;Other;increased  likelihood of Other:Hyperuricemia;Genotypes GT + TT is associated with increased likelihood of Hyperuricemia in people with Coronary Artery Disease as compared to genotype GG.;in people with Coronary Artery Disease
;ACENOCOUMAROL, WARFARIN;CYP2C9;rs72558189;AG;Efficacy;increased   Efficacy:time to achieve stable dose;Genotype AG are associated with increased time to achieve stable dose when treated with acenocoumarol or warfarin as compared to genotype GG.; 
;TELBIVUDINE;TK2;rs3826160;CC + CT;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Genotypes CC + CT is associated with increased likelihood of increased creatine kinase level when treated with telbivudine in people with Hepatitis B, Chronic as compared to genotype TT.;in people with Hepatitis B, Chronic
;SUNITINIB;FLT1;rs9582036;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AC.;in people with Disease:Renal Cell Carcinoma
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose requirements on day 14;Allele T is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to allele C.; 
;;SLC22A12;rs3825017;CT;Other;increased  likelihood of Other:Hyperuricemia;Genotype CT is associated with increased likelihood of Hyperuricemia in people with Coronary Artery Disease as compared to genotype CC.;in people with Coronary Artery Disease
;ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;Efficacy;increased   Efficacy:time to achieve stable dose;Genotypes CT + TT are associated with increased time to achieve stable dose when treated with acenocoumarol or warfarin as compared to genotype CC.; 
;SUNITINIB;CYP1A1;rs1048943;C;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Mucositis;Allele C is associated with increased likelihood of Leukopenia and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to allele T.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;OLANZAPINE;DRD2;rs2440390;T;Toxicity;increased   Disease:Weight gain;Allele T is associated with increased Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C.;in people with Disease:Mental Disorders
;PRAVASTATIN;ADAMTS1;rs428785;GG;Efficacy;decreased likelihood of Efficacy:fatal coronary disease or nonfatal myocardial infarction;Genotype GG is associated with decreased likelihood of fatal coronary disease or nonfatal myocardial infarction when treated with pravastatin in men as compared to genotypes CC + CG.;in men 
;OLANZAPINE;HTR2C;rs6318;G;Toxicity;increased   Disease:Weight gain;Allele G is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele C.;in women with Disease:Mental Disorders
;CAFFEINE;CYP1A2;rs762551;AA;Toxicity;increased  likelihood of Disease:Neural Tube Defects;Genotype AA is associated with increased likelihood of Neural Tube Defects when exposed to caffeine in women who are pregnant as compared to genotypes AC + CC.;in women who are pregnant
;OLANZAPINE;HTR2C;rs2497538;C;Toxicity;increased   Disease:Weight gain;Allele C is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele A.;in women with Disease:Mental Disorders
;OLANZAPINE;HTR2C;rs1414334;G;Toxicity;increased   Disease:Weight gain;Allele G is associated with increased Weight gain when treated with olanzapine in women with Mental Disorders as compared to allele C.;in women with Disease:Mental Disorders
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Disease:Acute lymphoblastic leukemia
;PIOGLITAZONE;LPL;rs328;CG + GG;Efficacy;decreased  Efficacy:response rate after 10 weeks of pioglitazone treatment;Genotypes CG + GG are associated with decreased response rate after 10 weeks of pioglitazone treatment when treated with pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Disease:Diabetes Mellitus, Type 2
;PACLITAXEL;EPHA5;rs7349683;CT + TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes CT + TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel as compared to genotype CC.; 
;;SCN1A;rs3812718;T;Other;increased  risk of Disease:Seizures, Febrile;Allele T is associated with increased risk of Seizures, Febrile in people with Epilepsy as compared to allele C.;in people with Disease:Epilepsy
;;UGT1A1;rs4148323;AA + AG;Other;increased  severity of Other:Neonatal hyperbilirubinemia, Other:Hyperbilirubinemia;Genotypes AA + AG is associated with increased severity of Jaundice, Neonatal and Hyperbilirubinemia in children as compared to genotype GG.;in children 
;;CHRNA5;rs16969968;A;Other;increased  severity of Other:Tobacco Use Disorder;Allele A is associated with increased severity of Tobacco Use Disorder in people with Tobacco Use Disorder.;in people with Tobacco Use Disorder
;PACLITAXEL;ABCB1;rs3213619;AG + GG;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes AG + GG is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel as compared to genotype AA.; 
;VERAPAMIL;NOS1AP;rs10494366;GG;Toxicity;increased  risk of Side Effect:QTc prolongation;Genotype GG is associated with increased risk of QTc prolongation when treated with verapamil as compared to genotype TT.; 
;MERCAPTOPURINE;PACSIN2;rs2413739;TT;Toxicity;increased  risk of Side Effect:adverse events;Genotype TT is associated with increased risk of adverse events when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;;;rs1051730;A;Other;increased  severity of Other:Tobacco Use Disorder;Allele A is associated with increased severity of Tobacco Use Disorder in people with Tobacco Use Disorder as compared to allele G.;in people with Tobacco Use Disorder
;;CYP2R1;rs12794714;A;Other;increased  likelihood of Other:Vitamin D Deficiency;Allele A is associated with increased likelihood of Vitamin D Deficiency as compared to allele G.; 
;OLANZAPINE;ABCB1;rs1045642;AA;Efficacy;increased   Efficacy:social and clinical needs;Genotype AA is associated with increased social and clinical needs when treated with olanzapine in people with Psychotic Disorders as compared to allele G.;in people with Disease:Psychotic Disorder
;PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;A;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele A is associated with increased likelihood of Toxic liver disease when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to allele G.;in people with Tuberculosis
;;CYP2R1;rs10741657;A;Other;decreased likelihood of Other:Vitamin D Deficiency;Allele A is associated with decreased likelihood of Vitamin D Deficiency as compared to allele G.; 
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele T is associated with increased likelihood of Toxic liver disease when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to allele C.;in people with Tuberculosis
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.; 
;PAROXETINE;HTR1A;rs6295;GG;Efficacy;increased   Efficacy:response at 4 weeks after the initiation of treatment;Genotype GG is associated with increased response at 4 weeks after the initiation of treatment when treated with paroxetine in people with Panic Disorder as compared to genotypes CC + CG.;in people with Disease:Panic Disorder
;TAMOXIFEN;E2F7;rs310786;CC;Toxicity;increased   Side Effect:lumbar bone loss;Genotype CC is associated with increased lumbar bone loss when treated with tamoxifen in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Disease:Breast Neoplasms
;ALENDRONATE;DKK1;rs2241529;AA;Efficacy;decreased  Efficacy:bone density;Genotype AA is associated with decreased bone density when treated with alendronate in women with Bone Diseases, Metabolic or Osteoporosis as compared to genotype AG.;in women with Disease:Metabolic Bone Disorder, Disease:Osteoporosis
;CLOPIDOGREL;CES1;rs8192950;G;Efficacy;decreased risk of Efficacy:Transient Ischemic Attack, Efficacy:Stroke;Allele G is associated with decreased risk of Transient Ischemic Attack and Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to allele T.;in people with Cerebrovascular Disorders
;ANTIPSYCHOTICS;DRD2;rs1799732;GG;Toxicity;increased  likelihood of Side Effect:side effects;Genotype GG is associated with increased likelihood of side effects when exposed to antipsychotics as compared to allele del.; 
;SUNITINIB;KDR;rs2305948;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell.;in people with Disease:Renal Cell Carcinoma
;WARFARIN;CYP2C9;rs4918758;C;Dosage;decreased  Other:warfarin dose requirement in mechanical heart valve replacement patients;Allele C is associated with decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to allele T.; 
;SUNITINIB;VEGFA;rs3025039;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell.;in people with Disease:Renal Cell Carcinoma
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.; 
;OLANZAPINE;ANKK1;rs1800497;GG;Other;decreased  PK:area under the curve from baseline to the last measured concentration;Genotype GG is associated with decreased area under the curve from baseline to the last measured concentration when exposed to olanzapine in healthy individuals as compared to genotypes AA + AG.;in healthy individuals 
;EXEMESTANE;ESR1;rs9322336;CC;Toxicity;increased  likelihood of Side Effect:musculoskeletal toxicity;Genotype CC is associated with increased likelihood of musculoskeletal toxicity when treated with exemestane in women with Breast Neoplasms.;in women with Disease:Breast Neoplasms
;WARFARIN;CYP2C9;rs9332096;T;Dosage;decreased  Other:warfarin dose requirement in mechanical heart valve replacement patients;Allele T is associated with decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to allele C.; 
;OLANZAPINE;ANKK1;rs1800497;GG;Other;decreased  Other:peak plasma concentration of increased  prolactin;Genotype GG is associated with decreased peak plasma concentration of increased prolactin when exposed to olanzapine in healthy individuals as compared to genotypes AA + AG.;in healthy individuals 
;SUNITINIB;VEGFA;rs2010963;G;Toxicity;increased  likelihood of Side Effect:Hypertension;Allele G is associated with increased likelihood of Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Disease:Renal Cell Carcinoma
;SUNITINIB;FLT4;rs6877011;C;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;Allele C is associated with increased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Disease:Renal Cell Carcinoma
;OLANZAPINE;GSTP1;rs1695;AA;Toxicity;increased  likelihood of Disease:Syncope;Genotype AA is associated with increased likelihood of Syncope when exposed to olanzapine in healthy individuals as compared to genotypes AG + GG.;in healthy individuals 
;SUNITINIB;NR1I2;rs2276707;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased   Other:warfarin dose;Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.; 
;ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;AA;Toxicity;increased  risk of Disease:Cardiomyopathies;Genotype AA is associated with increased risk of Cardiomyopathies when exposed to anthracyclines and related substances in children with Neoplasms as compared to genotype GG.;in children with Disease:Neoplasms
;WARFARIN;VKORC1;rs9923231;T;Dosage;decreased  Other:warfarin dose;Allele T is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;SUNITINIB;FLT3;rs1933437;AG + GG;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotypes AG + GG is associated with decreased likelihood of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.;in people with Disease:Renal Cell Carcinoma, Disease:Gastrointestinal Stromal Tumors
;NORTRIPTYLINE;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Disease:Orthostatic Hypotension;Genotype AA is associated with increased likelihood of Hypotension, Orthostatic when treated with nortriptyline in people with Depressive Disorder, Major as compared to genotypes AG + GG.;in people with Disease:Major Depressive Disorder
;WARFARIN;VKORC1;rs2359612;A;Dosage;decreased  Other:warfarin dose;Allele A is associated with decreased warfarin dose when treated with warfarin as compared to allele G.; 
;MORPHINE, OXYCODONE;OPRM1;rs1799971;GG;Toxicity;decreased likelihood of Side Effect:Somnolence;Genotype GG is associated with decreased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.;in people with Lung Neoplasms
;MORPHINE, OXYCODONE;COMT;rs4680;GG;Toxicity;increased  likelihood of Side Effect:Somnolence;Genotype GG is associated with increased likelihood of somnolence due to morphine or oxycodone in people with Lung Neoplasms as compared to genotypes AA + AG.;in people with Lung Neoplasms
;CARBAMAZEPINE;HNF4A;rs2071197;GG;Efficacy;increased   PK:concentration-to-dose ratios;Genotype GG is associated with increased concentration-to-dose ratios when treated with carbamazepine in people with Epilepsy as compared to genotypes AA + AG.;in people with Disease:Epilepsy
;WARFARIN;VKORC1;rs8050894;G;Dosage;decreased  Other:warfarin dose;Allele G is associated with decreased warfarin dose when treated with warfarin as compared to allele C.; 
;PRAVASTATIN;MTHFR;rs1801133;GG;Efficacy;decreased likelihood of Disease:Coronary Artery Disease, Disease:Myocardial Infarction;Genotype GG is associated with decreased likelihood of Coronary Artery Disease and Myocardial Infarction when treated with pravastatin in people with Hypertension.;in people with Disease:Hypertension
;SUNITINIB;ABCB1;rs1128503;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.;in people with Disease:Renal Cell Carcinoma
;SUNITINIB;VEGFA;rs833061;CC + CT;Efficacy;increased   Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes CC + CT is associated with increased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.;in people with Disease:Renal Cell Carcinoma
;CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG + GG;Efficacy;increased  risk of Disease:Transplant rejection;Genotypes AG + GG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.;in people with Disease:Kidney Transplantation
;CYCLOSPORINE, MYCOPHENOLATE MOFETIL;TNF;rs1800629;AA + AG;Efficacy;increased  risk of Disease:Transplant rejection;Genotypes AA + AG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;METHOTREXATE;MTHFR;rs1801131;GG;Toxicity;increased  risk of Side Effect:mucositis;Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GT + TT.;in people with Disease:Non-Hodgkin Lymphoma
;CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IL10;rs1800872;TT;Efficacy;increased  risk of Efficacy:transplant rejection;Genotype TT is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes GG + GT.;in people with Disease:Kidney Transplantation
;SUNITINIB;ABCB1;rs2032582;AA + AT;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC.;in people with Disease:Renal Cell Carcinoma
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased  risk of Efficacy:Transient Ischemic Attack, Efficacy:Stroke;Allele A is associated with increased risk of Transient Ischemic Attack and Stroke when treated with clopidogrel in people with Cerebrovascular Disorders as compared to allele G.;in people with Cerebrovascular Disorders
;SUNITINIB;VEGFA;rs2010963;G;Efficacy;increased   Efficacy:Progression-free survival;Allele G is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Disease:Renal Cell Carcinoma
;NICOTINE;CHRNA5;rs16969968;A;Other;increased  severity of Other:smoking;Allele A is associated with increased severity of smoking when exposed to nicotine in people with Schizophrenia who are smokers as compared to allele G.;in people with Schizophrenia who are smokers
;NICOTINE;CHRNA5;rs16969968;A;Other;increased  severity of Other:smoking;Allele A is associated with increased severity of smoking when exposed to nicotine in people with smoking as compared to allele G.;in people with smoking
;;CHRNA5;rs16969968;A;Other;increased  likelihood of Disease:Schizophrenia;Allele A is associated with increased likelihood of Schizophrenia.; 
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.;in people with Disease:Non-Hodgkin Lymphoma
;CLOPIDOGREL;N6AMT1;rs2254638;GG;Efficacy;increased  likelihood of Efficacy:high on-treatment platelet reactivity;Genotype GG is associated with increased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Acute coronary syndrome
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;increased   Efficacy:Overall survival;Genotype AA is associated with increased overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease;Genotype AA is associated with increased risk of Thrombocytopenia or Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG.;in people with Disease:Non-Hodgkin Lymphoma
;NICOTINE;GALR1;rs2717162;CT + TT;Other;increased  severity of Other:craving;Genotypes CT + TT are associated with increased severity of craving due to nicotine in people with Tobacco Use Disorder.;in people with Disease:Tobacco Use Disorder
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;ERYTHROMYCIN;SLCO1B1;rs4149056;C;Metabolism/PK;decreased  PK:erythromycin metabolism;Allele C is associated with decreased erythromycin metabolism when treated with erythromycin in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;PAZOPANIB, SIMVASTATIN;ABCG2;rs2231142;GT + TT;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotypes GT + TT is associated with increased likelihood of Toxic liver disease when treated with pazopanib and simvastatin in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;GENTAMICIN;MT-RNR1;rs267606617;G;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with gentamicin in infants as compared to allele A.;in infants 
;CYCLOSPORINE, TACROLIMUS;LEP;rs2167270;A;Toxicity;increased  likelihood of Disease:Diabetes Mellitus;Allele A is associated with increased likelihood of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to allele G.;in people with Disease:Kidney Transplantation
;ERLOTINIB;ABCB1;rs1045642;AA;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.;in people with Disease:Non-Small Cell Lung Carcinoma
;MERCAPTOPURINE;NUDT15;rs73189762;GT;Dosage;increased  likelihood of Side Effect:Myelosuppression;Genotype GT is associated with increased likelihood of Myelosuppression when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;ETHANOL;HTR3B;rs1176744;C;Other;increased  likelihood of Disease:Alcohol abuse;Allele C is associated with increased likelihood of Alcoholism when exposed to ethanol in men as compared to allele A.;in men 
;CLOPIDOGREL;CYP2C19;rs12248560;T;Toxicity;decreased  Side Effect:cardiovascular events;Allele T is associated with decreased cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome.;in people with Disease:Acute coronary syndrome
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  severity of Side Effect:Mucositis;Genotype AA is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype GG.;in people with Disease:Hematopoietic stem cell transplantation
;METHOTREXATE;ADORA2A, SPECC1L;rs5760410;G;Toxicity;increased  risk of Side Effect:adverse events;Allele G is associated with increased risk of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele A.;in people with Disease:Rheumatoid arthritis
;CALCIUM CHANNEL BLOCKERS, NITRENDIPINE;KCNH2;rs1137617;AA + AG;Efficacy;increased   Efficacy:reduction in blood pressure;Genotypes AA + AG are associated with increased reduction in blood pressure when treated with calcium channel blockers or nitrendipine in people with Essential hypertension as compared to genotype GG.;in people with Disease:Essential hypertension
;CLOPIDOGREL;KDR;rs7667298;CC;Toxicity;decreased likelihood of Side Effect:Angina Pectoris;Genotype CC is associated with decreased likelihood of Angina Pectoris when treated with clopidogrel in people with Coronary Disease as compared to genotypes CT + TT.;in people with Disease:Coronary Disease
;METHOTREXATE;MTHFR;rs1801131;G;Efficacy;increased  risk of Disease:Graft vs Host Disease;Allele G is associated with increased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;decreased risk of Disease:Graft vs Host Disease;Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;NICOTINE;GALR1;rs2717162;CT + TT;Other;increased  severity of Other:craving;Genotypes CT + TT are associated with increased severity of craving due to nicotine in people with Tobacco Use Disorder.;in people with Disease:Tobacco Use Disorder
;ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;rs1801133;GG;Efficacy;increased   Efficacy:progression free survival;Genotype GG is associated with increased progression free survival when treated with antineoplastic agents in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotypes AA + AG.;in people with Disease:Leukemia, Lymphocytic, Chronic, B-Cell
;IRINOTECAN;UGT1A1;rs4148323;AG;Toxicity;increased  severity of Disease:Neutropenia;Genotype AG is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;;MTHFR;rs1801131;G;Efficacy;increased   Efficacy:progression free survival;Allele G is associated with increased progression free survival in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype TT.;in people with Disease:Leukemia, Lymphocytic, Chronic, B-Cell
;BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with busulfan, cyclophosphamide and methotrexate as compared to genotype GG.; 
;ERLOTINIB;ABCB1;rs1128503;AA;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;MTHFR;rs1801131;GG;Efficacy;decreased risk of Efficacy:relapse;Genotype GG is associated with decreased risk of relapse when treated with methotrexate in people with allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia. as compared to genotype TT.;in people with allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia.
;CLOPIDOGREL;KDR;rs2305948;TT;Toxicity;increased  risk of Side Effect:Angina Pectoris, Side Effect:Myocardial Infarction;Genotype TT is associated with increased risk of Angina Pectoris and Myocardial Infarction when treated with clopidogrel in people with Coronary Disease as compared to genotypes CC + CT.;in people with Disease:Coronary Disease
;METHOTREXATE;ABCB1;rs1128503;GG;Toxicity;increased  severity of Side Effect:Mucositis;Genotype GG is associated with increased severity of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;METHOTREXATE;MTHFR;rs1801131;GG;Toxicity;decreased severity of Side Effect:oral mucositis;Genotype GG is associated with decreased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype TT.;in people with hematopoietic-cell-transplantation
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotypes AG + GG.;in people with Disease:Leukemia
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.;in people with Disease:Atrial Fibrillation
;ERLOTINIB;ABCB1;rs2032582;AA;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with erlotinib in people with Carcinoma, Non-Small-Cell Lung.;in people with Disease:Non-Small Cell Lung Carcinoma
;WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotype TT is associated with increased risk of over-anticoagulation when treated with warfarin in people with Atrial Fibrillation as compared to genotype CC.;in people with Disease:Atrial Fibrillation
;PACLITAXEL;ARHGEF10;rs9657362;C;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Allele C is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;;FKBP5;rs1360780;CC + CT;;increased  risk of Other:post-traumatic stress disorder (PTSD);Genotypes CC + CT are associated with increased risk of post-traumatic stress disorder (PTSD) in people with history of Child Abuse.;in people with history of Child Abuse
;;FKBP5;rs3800373;AA + AC;Other;increased  risk of Disease:Attention Deficit Disorder with Hyperactivity;Genotypes AA + AC are associated with increased risk of Attention Deficit Disorder with Hyperactivity in people with history of Child Abuse as compared to genotype CC.;in people with history of Child Abuse
;PACLITAXEL;ARHGEF10;rs9657362;C;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Allele C is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with paclitaxel in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;;TBX21;rs17244587;A;;increased  risk of Disease:Major Depressive Disorder;Allele A is associated with increased risk of Depressive Disorder, Major.; 
;;PSMB4;rs2296840;T;Other;increased  risk of Disease:Major Depressive Disorder;Allele T is associated with increased risk of Depressive Disorder, Major.; 
;METFORMIN;SLC22A1;rs34059508;A;Dosage, Metabolism/PK;increased   PK:bioavailability;Allele A is associated with increased bioavailability when exposed to metformin.; 
;METFORMIN;SLC22A1;rs12208357;C;Dosage, Metabolism/PK;increased   PK:bioavailability (AUC, CL & AUC/CL ratio);Allele C is associated with increased bioavailability (AUC, CL & AUC/CL ratio) when exposed to metformin.; 
;CLOPIDOGREL;CYP2C19;rs12248560;T;Toxicity;increased  risk of Side Effect:bleeding events;Allele T is associated with increased risk of bleeding events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:Death;Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;;CHRNA5;rs680244;C;Other;increased  risk of Disease:Tobacco Use Disorder;Allele C is associated with increased risk of Tobacco Use Disorder.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:ischaemic events;Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with percutaneous coronary intervention as compared to allele G.;in people with percutaneous coronary intervention
;METHOTREXATE;PTPN22;rs2476601;AA;Toxicity;increased  likelihood of Side Effect:discontinuation;Genotype AA is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;;CHRNA3;rs1051730;G;;increased  risk of Disease:Tobacco Use Disorder;Allele G is associated with increased risk of Tobacco Use Disorder.; 
;METHOTREXATE;TNFAIP3;rs6920220;A;Toxicity;increased  likelihood of Side Effect:discontinuation;Allele A is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to allele G.;in people with Disease:Arthritis
;;CHRNA3, CHRNA5;rs578776;G;;increased  risk of Disease:Tobacco Use Disorder;Allele G is associated with increased risk of Tobacco Use Disorder.; 
;SUNITINIB;ABCG2;rs2231142;TT;Toxicity;decreased risk of Side Effect:Neutropenia;Genotype TT is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes GG + GT.;in people with Disease:Renal Cell Carcinoma
;;CHRNA5;rs16969968;A;;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder.; 
;RISPERIDONE;ABCB1;rs1045642;AA;Metabolism/PK;increased  severity of Side Effect:Hyperprolactinemia;Genotype AA is associated with increased severity of Hyperprolactinemia when treated with risperidone in women with Bipolar Disorder, schizoaffective disorder or Schizophrenia as compared to genotypes AG + GG.;in women with Disease:Bipolar Disorder, Disease:Schizoaffective disorder, Disease:Schizophrenia
;;CHRNA5;rs569207;C;;increased  risk of Disease:Tobacco Use Disorder;Allele C is associated with increased risk of Tobacco Use Disorder.; 
;CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;CYP1A1;rs2606345;A;Efficacy, Metabolism/PK;increased  risk of Disease:Seizures;Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.;in people with Disease:Epilepsy
;;SLCO1B3;rs2417940;C;Other;increased  severity of Other:Neonatal hyperbilirubinemia, Other:Hyperbilirubinemia;Allele C is associated with increased severity of Jaundice, Neonatal and Hyperbilirubinemia in children as compared to allele T.;in children 
;SERTRALINE;;rs13432159;G;Toxicity;increased   Side Effect:general side-effects;Allele G is associated with increased general side-effects when treated with sertraline in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;TAMOXIFEN;CYP2D6;rs3892097;TT;Efficacy;increased   Efficacy:disease free survival;Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.;in people with Disease:Breast Neoplasms
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.; 
;TAMOXIFEN;CYP2D6;rs3892097;TT;Efficacy;decreased  Efficacy:disease free survival;Genotype TT is associated with decreased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.;in people with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;rs3892097;TT;Efficacy;decreased  Efficacy:relapse free time;Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.;in people with Disease:Breast Neoplasms
;;KIF6;rs20455;AG + GG;Other;increased  risk of Disease:Myocardial Infarction;Genotypes AG + GG are associated with increased risk of Myocardial Infarction as compared to genotype AA.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;Toxicity;decreased  Side Effect:anemia;Allele A is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;in people with Disease:Chronic hepatitis C virus infection
;ROSUVASTATIN;GATM;rs9806699;AA + AG;Toxicity;decreased risk of Side Effect:statin-related myopathy;Genotypes AA + AG are associated with decreased risk of statin-related myopathy when treated with rosuvastatin as compared to genotype GG.; 
;TAMOXIFEN;CYP2D6;rs3892097;T;Efficacy;decreased  Efficacy:event-free survival;Allele T is associated with decreased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.;in people with Disease:Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;Toxicity;decreased risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with decreased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;Toxicity;decreased  Side Effect:anemia;Allele C is associated with decreased anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.;in people with Disease:Chronic hepatitis C virus infection
;IRINOTECAN;UGT1A1;rs4148323;AA;Toxicity;increased  severity of Disease:Neutropenia;Genotype AA is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;rs1695;AA;Toxicity;increased  risk of Disease:Neurotoxicity Syndromes, Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neurotoxicity Syndromes and Neutropenia when treated with fluorouracil, irinotecan or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;PRAVASTATIN;IL1B;rs16944;GG;Other;increased   Other:coronary flow reserve;Genotype GG is associated with increased coronary flow reserve when treated with pravastatin in men as compared to genotypes AA + AG.;in men 
;HMG COA REDUCTASE INHIBITORS;;rs116561224;G;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele G is associated with increased risk of drug-induced liver injury when treated with hmg coa reductase inhibitors as compared to allele A.; 
;;KCNH2;rs3815459;T;Other;increased   Other:QT interval;Allele T is associated with increased QT interval.; 
;FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;;rs114577328;C;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele C is associated with increased risk of drug-induced liver injury when treated with fenofibrate, sertraline, terbinafine or ticlopidine as compared to allele G.; 
;ANTIDEPRESSANTS;HTR2A;rs17288723;CC;Efficacy;increased  likelihood of Efficacy:remission;Genotype CC is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to genotypes CT + TT.;in people with Disease:Depressive Disorder
;;KCNH2;rs3807375;CT + TT;Other;increased   Other:QT interval;Genotypes CT + TT are associated with increased QT interval as compared to genotype CC.; 
;CITALOPRAM;GRIK4;rs1954787;C;Efficacy;decreased likelihood of Efficacy:non-response;Allele C is associated with decreased likelihood of non-response when treated with citalopram in people with Depression as compared to allele T.;in people with Disease:Depression
;;KCNH2;rs1805123;GT + TT;Other;increased   Other:QT interval;Genotypes GT + TT are associated with increased QT interval as compared to genotype GG.; 
;CYCLOSPORINE;NR1I2;rs2276707;C;Dosage, Metabolism/PK;decreased  PK:bioavailability;Allele C is associated with decreased bioavailability of cyclosporine in people with Kidney Transplantation as compared to allele T.;in people with Disease:Kidney Transplantation
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT + TT;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes CT + TT is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to genotype CC (assigned as intermediate acetylator and rapid acetylator phenotype) .; 
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799930;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes AA + AG is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to genotype GG (assigned as intermediate acetylator and rapid acetylator phenotype) .; 
;PLATINUM COMPOUNDS;GSTP1;rs1695;G;Toxicity, Metabolism/PK;decreased risk of Disease:Neutropenia;Allele G is associated with decreased risk of Neutropenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOZAPINE;;rs149104283;T;Toxicity;increased  risk of Side Effect:Neutropenia;Allele T is associated with increased risk of Neutropenia when treated with clozapine in people with Schizophrenia as compared to allele C.;in people with Disease:Schizophrenia
;DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotypes AA + AG is associated with increased likelihood of Drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis as compared to genotype GG (assigned as intermediate acetylator and rapid acetylator phenotype) .; 
;;KCNH2;rs1805123;G;Other;decreased  Other:QT interval;Allele G is associated with decreased QT interval as compared to genotype TT.; 
;ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotypes CG + GG are associated with increased risk of Toxic liver disease when treated with asparaginase, cyclophosphamide, daunorubicin, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;;KCNH2;rs3807375;T;Other;increased   Other:QT interval;Allele T is associated with increased QT interval as compared to allele C.; 
;OXALIPLATIN;GSTP1;rs1695;GG;Toxicity;increased  severity of Disease:Neurotoxicity Syndromes;Genotype GG is associated with increased severity of Neurotoxicity Syndromes when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;;KCNQ1;rs757092;G;Other;increased   Other:QT interval;Allele G is associated with increased QT interval.; 
;;KCNH2;rs3815459;T;Other;increased   Other:QT interval;Allele T is associated with increased QT interval as compared to genotype CC.; 
;PRAVASTATIN;IL1B;rs16944;GG;Other;increased   Other:adenosine-stimulated myocardial flow;Genotype GG is associated with increased adenosine-stimulated myocardial flow when treated with pravastatin in men as compared to genotypes AA + AG.;in men 
;;VEGFA;rs2010963;CG + GG;Other;increased  risk of Other:Premature Birth;Genotypes CG + GG is associated with increased risk of Premature Birth in women as compared to genotype CC.;in women 
;;KCNH2;rs1805123;GG;Other;decreased  Other:QT interval;Genotype GG is associated with decreased QT interval as compared to genotypes GT + TT.; 
;;KCNQ1;rs757092;G;Other;increased   Other:QT interval;Allele G is associated with increased QT interval as compared to allele A.; 
;OXALIPLATIN;GSTP1;rs1695;AA;Toxicity, Metabolism/PK;increased  severity of Disease:Peripheral Nervous System Diseases;Genotype AA is associated with increased severity of Peripheral Nervous System Diseases when treated with oxaliplatin in people with Gastrointestinal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Gastrointestinal Neoplasms
;METHOTREXATE;SLCO1B1;rs4149056;TT;Toxicity;increased  severity of Side Effect:Infectious disease;Genotype TT is associated with increased severity of Infection when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;CYCLOSPORINE;NR1I2;rs2276707;T;Dosage, Metabolism/PK;increased   PK:bioavailability;Allele T is associated with increased bioavailability of cyclosporine in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;RIFAMPIN;NR1I2;rs3814055;TT;Other;increased   PK:erythromycin breath test;Genotype TT is associated with increased erythromycin breath test when treated with rifampin as compared to genotype CC.; 
;PLATINUM COMPOUNDS;CCN4;rs2977549;CC + CT;Efficacy;decreased risk of Efficacy:Progression-free survival;Genotypes CC + CT is associated with decreased risk of progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype TT.;in people with Lung Neoplasms
;CITALOPRAM;HTR2A;rs7997012;AA;Efficacy;increased  likelihood of Efficacy:response;Genotype AA is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to genotype GG.;in people with Disease:Depression
;TACROLIMUS;CYP3A4;rs2740574;CC + TT;Toxicity, Metabolism/PK;increased  risk of Side Effect:Nephrotoxicity;Genotypes CC + TT are associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.;in people with Disease:Kidney Transplantation
;CITALOPRAM;HTR2A;rs7997012;A;Efficacy;increased  likelihood of Efficacy:response;Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.;in people with Disease:Depression
;TACROLIMUS;CYP3A5;rs776746;T;Toxicity, Metabolism/PK;increased  risk of Side Effect:Nephrotoxicity;Allele T is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to allele C.;in people with Disease:Kidney Transplantation
;CYCLOSPORINE;NR1I2;rs3814055;C;Dosage, Metabolism/PK;decreased  PK:bioavailabilty;Allele C is associated with decreased bioavailabilty of cyclosporine in people with Kidney Transplantation as compared to genotype TT.;in people with Disease:Kidney Transplantation
;ASPIRIN, CLOPIDOGREL;MYOM2;rs17064642;CC + CT;Efficacy;increased  risk of Efficacy:Major Adverse Cardiac Events (MACE);Genotypes CC + CT are associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT.;in people with Acute coronary syndrome
;ANTIDEPRESSANTS;HTR2A;rs7997012;G;Efficacy;increased  likelihood of Efficacy:remission;Allele G is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to allele A.;in people with Disease:Depressive Disorder
;CITALOPRAM;HTR2A;rs7997012;A;Efficacy;increased  likelihood of Efficacy:response;Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.;in people with Disease:Depression
;SUFENTANIL;COMT;rs4680;AA + AG;Dosage;increased  severity of Efficacy:Pain;Genotypes AA + AG is associated with increased severity of Pain when treated with sufentanil in people with Pregnancy as compared to genotype GG.;in people with Pregnancy
;ANTIDEPRESSANTS;GRIK4;rs1954787;CC;Efficacy;increased  likelihood of Efficacy:remission;Genotype CC is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder.;in people with Disease:Depressive Disorder
;SUFENTANIL;OPRM1;rs1799971;AG + GG;Dosage;decreased severity of Efficacy:Pain;Genotypes AG + GG is associated with decreased severity of Pain when treated with sufentanil in people with Pregnancy as compared to genotype AA.;in people with Pregnancy
;ANTIDEPRESSANTS;GRIK4;rs12800734;GG;Efficacy;increased  likelihood of Efficacy:remission;Genotype GG is associated with increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to genotypes AA + AG.;in people with Disease:Depressive Disorder
;PRAVASTATIN;KIF6;rs20455;AG + GG;Efficacy;decreased risk of Disease:Myocardial Infarction;Genotypes AG + GG are associated with decreased risk of Myocardial Infarction when treated with pravastatin.; 
;;KIF6;rs20455;AG + GG;Other;increased  risk of Disease:Coronary Disease;Genotypes AG + GG are associated with increased risk of Coronary Disease as compared to genotype AA.; 
;PRAVASTATIN;SLCO1B1;rs2306283;G;Metabolism/PK;decreased  PK:plasma AUC;Allele G is associated with decreased plasma AUC of pravastatin.; 
;PRAVASTATIN;SLCO1B1;rs4149015;AG;Other, Metabolism/PK;increased   PK:AUC0-12;Genotype AG is associated with increased AUC0-12 when exposed to pravastatin in healthy individuals as compared to genotype GG.;in healthy individuals 
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Acute lymphoblastic leukemia
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotypes CT + TT is associated with increased likelihood of Neutropenia when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Acute lymphoblastic leukemia
;PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;Efficacy;decreased risk of Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes CC + CT is associated with decreased risk of overall survival and progression-free survival when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype TT.;in people with Lung Neoplasms
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;decreased likelihood of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with decreased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AG + GG.;in people with Acute coronary syndrome
;FLUOROURACIL;TP53;rs1042522;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with fluorouracil in people with Stomach Neoplasms as compared to genotypes CC + CG.;in people with Disease:Stomach Neoplasms
;PEGINTERFERON ALFA-2A, RIBAVIRIN;ITPA;rs6051702;AC + CC;Toxicity;decreased risk of Side Effect:Anemia;Genotypes AC + CC is associated with decreased risk of Anemia when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotype AA.;in people with Disease:Hepatitis C virus infection
;NICOTINE;CHRNA3, CHRNA5;rs578776;GG;Toxicity;increased  likelihood of Other:Smoking Cessation;Genotype GG is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AA + AG.;in people with Lung Neoplasms
;NICOTINE;CHRNA4;rs1044396;AA;Toxicity;increased  likelihood of Other:Smoking Cessation;Genotype AA is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AG + GG.;in people with Lung Neoplasms
;NICOTINE;CHRNA4;rs2229959;CC;Toxicity;increased  likelihood of Other:Smoking Cessation;Genotype CC is associated with increased likelihood of cessation of nicotine in people with Lung Neoplasms as compared to genotypes AA + AC.;in people with Lung Neoplasms
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;rs13306278;T;Efficacy;decreased likelihood of Efficacy:remission;Allele T is associated with decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major.;in people with Disease:Major Depressive Disorder
;PRAVASTATIN;TLR4;rs4986790;AG + GG;Efficacy;decreased risk of Efficacy:cardiovascular events;Genotypes AG + GG are associated with decreased risk of cardiovascular events when treated with pravastatin in men with Coronary Artery Disease as compared to genotype AA.;in men with Disease:Coronary Artery Disease
;PHENPROCOUMON;VKORC1;rs9923231;TT;Efficacy;increased  risk of Side Effect:over-anticoagulation;Genotype TT is associated with increased risk of over-anticoagulation when treated with phenprocoumon as compared to genotype CT.; 
;AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606617;G;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with aminoglycoside antibacterials as compared to allele A.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;VDR;rs1544410;TT;Toxicity;increased  risk of Side Effect:Anemia;Genotype TT is associated with increased risk of Anemia when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.;in people with Disease:Hepatitis C virus infection
;PHENPROCOUMON;VKORC1;rs9923231;TT;Toxicity;increased   Side Effect:time above therapeutic range;Genotype TT is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CT.; 
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:time above therapeutic range;Genotypes CT + TT are associated with increased likelihood of time above therapeutic range when treated with acenocoumarol as compared to genotype CC.; 
;FLUOROURACIL;IGFBP3;rs2854746;CC;Efficacy;Other:better survival outcome;Genotype CC is associated with better survival outcome when treated with fluorouracil in people with Stomach Neoplasms as compared to genotype GG.;in people with Disease:Stomach Neoplasms
;PHENPROCOUMON;VKORC1;rs9923231;TT;Efficacy;increased   Efficacy:time to achieve stable dose;Genotype TT is associated with increased time to achieve stable dose when treated with phenprocoumon as compared to genotype CT.; 
;PLATINUM COMPOUNDS;GSTP1;rs1695;AA;Efficacy;increased  risk of Efficacy:dying;Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;PLATINUM COMPOUNDS;ERCC2, KLC3;rs13181;GG;Efficacy;increased  risk of Efficacy:dying;Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;PHENPROCOUMON;EPHX1;rs1051740;CC;Toxicity;increased   Side Effect:time above therapeutic range;Genotype CC is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype TT.; 
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA;Efficacy;increased  risk of Efficacy:dying;Genotype AA is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;CLOPIDOGREL;ABCB1;rs2032582;AA;Efficacy;decreased likelihood of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with decreased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AC + CC.;in people with Acute coronary syndrome
;PLATINUM COMPOUNDS;GSTP1;rs1695;AA;Efficacy;increased  risk of Efficacy:disease progression;Genotype AA is associated with increased risk of disease progression when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;CARBOPLATIN, PACLITAXEL;NR1I2;rs1523130;TT;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotype TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms and Uterine Neoplasms as compared to genotypes CC + CT.;in people with Disease:Lung Neoplasms, Disease:Peritoneum cancer, Disease:Neoplasms, Disease:Ovarian Neoplasms, Disease:Uterine Neoplasms
;AZATHIOPRINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Side Effect:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases, Disease:Acute lymphoblastic leukemia
;CETUXIMAB;EGF;rs4444903;AA;Efficacy;increased   Efficacy:survival;Genotype AA is associated with increased survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;CARBOPLATIN, PACLITAXEL;NR1I2;rs1523127;CC;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotype CC is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms and Uterine Neoplasms as compared to genotypes AA + AC.;in people with Disease:Lung Neoplasms, Disease:Peritoneum cancer, Disease:Neoplasms, Disease:Ovarian Neoplasms, Disease:Uterine Neoplasms
;IRINOTECAN;UGT1A1;rs10929302;AA + AG;Toxicity;increased  severity of Side Effect:Neutropenia;Genotypes AA + AG are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GT + TT;Toxicity;decreased likelihood of Side Effect:Thrombocytopenia;Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.;in people with Disease:Lung Neoplasms, Disease:Peritoneum cancer, Disease:Neoplasms, Disease:Ovarian Neoplasms, Disease:Uterine Neoplasms
;NICOTINE;CHRNA4;rs1044396;G;Other;increased  risk of Disease:Tobacco Use Disorder;Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.; 
;CISPLATIN;LRP2;rs2075252;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;CETUXIMAB;EGF;rs4444903;AA;Efficacy;decreased  Efficacy:overall survival;Genotype AA is associated with decreased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;CDA;rs3215400;C/del + CC;Toxicity;decreased likelihood of Side Effect:Hand-foot syndrome;Genotypes C/del + CC are associated with decreased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to genotype del/del.;in people with Disease:Neoplasms
;CLOPIDOGREL;POR;rs2286823;GG;Efficacy;decreased likelihood of Efficacy:high on-treatment platelet reactivity;Genotype GG is associated with decreased likelihood of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Acute coronary syndrome
;SUNITINIB;POR;rs1057868;TT;Efficacy;increased   Efficacy:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.;in people with Disease:Gastrointestinal Stromal Tumors
;SUNITINIB;SLCO1B3;rs4149117;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.;in people with Efficacy:Gastrointestinal Stromal Tumors
;METHOTREXATE;SLC19A1;rs1051266;CC + CT;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity;Genotypes CC + CT is associated with increased risk of gastrointestinal toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;PHENPROCOUMON;VKORC1;rs9923231;TT;Toxicity;increased   Side Effect:time above therapeutic range;Genotype TT are associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype CC.; 
;CAPECITABINE;CDA;rs532545;T;Toxicity;increased  likelihood of Disease:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;CLOPIDOGREL;CES1P1;rs3785161;AC + CC;Efficacy;increased   Efficacy:on-treatment platelet activity;Genotypes AC + CC are associated with increased on-treatment platelet activity when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.;in people with Disease:Coronary Disease
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes CT + TT are associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.; 
;METHOTREXATE;ATIC;rs2372536;G;;severity of Disease:Rheumatoid arthritis;Allele G is associated with severity of Arthritis, Rheumatoid when treated with methotrexate.; 
;LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;rs1801394;GG;Toxicity;increased  severity of Disease:Stomatitis;Genotype GG is associated with increased severity of Stomatitis when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;DPYD;rs67376798;A;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.;in people with Disease:Colorectal Neoplasms
;LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;Toxicity;increased  severity of Disease:Diarrhea;Genotype CC is associated with increased severity of Diarrhea when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes CG + GG.;in people with Disease:Colorectal Neoplasms
;LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;Toxicity;increased  likelihood of Side Effect:any grade 3 adverse event;Genotype CC is associated with increased likelihood of any grade 3 adverse event when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes CG + GG.;in people with Disease:Colorectal Neoplasms
;ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;Efficacy;increased  risk of Disease:Death;Genotypes AA + AC is associated with increased risk of Death when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;PAZOPANIB;CXCL8;rs1126647;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes AA + AT.;in people with Disease:Renal Cell Carcinoma
;WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype CC.; 
;NICOTINE;CHRNA4;rs2236196;G;Other;increased  risk of Disease:Tobacco Use Disorder;Allele G is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.; 
;ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;Efficacy;decreased severity of Efficacy:Elevated diastolic blood pressure, Efficacy:Elevated systolic blood pressure;Genotype CT is associated with decreased severity of Elevated diastolic blood pressure and Elevated systolic blood pressure when treated with Angiotensin II Antagonists in people with Hypertension as compared to genotype TT.;in people with Hypertension
;METHOTREXATE;SLC19A1;rs1051266;CT + TT;Toxicity;decreased risk of Side Effect:Mucositis;Genotypes CT + TT are associated with decreased risk of mucositis due to methotrexate in children with Osteosarcoma as compared to genotype CC.;in children with Osteosarcoma
;NICOTINE;CHRNA3;rs1051730;AA + AG;Toxicity;decreased  Side Effect:lung function;Genotypes AA + AG are associated with decreased lung function when exposed to nicotine in people with Tobacco Use Disorder as compared to genotype GG.;in people with Disease:Tobacco Use Disorder
;CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;rs1801133;A;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotype TT is associated with increased likelihood of Recurrence when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotype CC.;in people with Disease:Chronic hepatitis C virus infection
;CARBAMAZEPINE;HSPA1A;rs1043620;T;Toxicity;decreased severity of Side Effect:Hypersensitivity;Allele T is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele C.; 
;ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;Efficacy;increased  risk of Disease:Myocardial Infarction;Genotypes AA + AC is associated with increased risk of Myocardial Infarction when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;CARBAMAZEPINE;HSPA1A;rs506770;G;Toxicity;decreased severity of Side Effect:Hypersensitivity;Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele C.; 
;ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA;Efficacy;decreased  Efficacy:fibrin clot formation time;Genotype AA is associated with decreased fibrin clot formation time when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;rs1042522;G;Toxicity;increased  likelihood of Disease:Drug Toxicity;Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms
;CARBAMAZEPINE;HSPA1L;rs2227956;G;Toxicity;decreased severity of Side Effect:Hypersensitivity;Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele A.; 
;CLOPIDOGREL;P2RY12;rs6787801;AG + GG;Efficacy;Efficacy:high on-treatment platelet reactivity in CYP2C19*1/*1 carriers;Genotypes AG + GG are associated with high on-treatment platelet reactivity in CYP2C19*1/*1 carriers when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to genotype AA.;in patients undergoing percutaneous coronary intervention
;CLOZAPINE;ABCB1;rs1045642;AG + GG;Toxicity;increased   Side Effect:Hypertension;Genotypes AG + GG is associated with increased Hypertension when treated with clozapine in people with Schizophrenia as compared to genotype AA.;in people with Disease:Schizophrenia
;RIBAVIRIN;ITPA;rs1127354;CC;Toxicity;increased  likelihood of Side Effect:Dose reduction, Side Effect:Treatment interruption;Genotype CC is associated with increased likelihood of dose reduction or treatment interruptions when treated with ribavirin in people with Hepatitis C as compared to genotypes AA + AC.;in people with Disease:Hepatitis C virus infection
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:exposure;Genotype TT is associated with increased exposure of efavirenz in women with HIV Infections as compared to genotypes GG + GT.;in women with Disease:HIV infectious disease
;CLOZAPINE;ABCC1;rs212090;AT + TT;Toxicity;increased   Side Effect:Hypertension;Genotypes AT + TT is associated with increased Hypertension when treated with clozapine in men with Schizophrenia as compared to genotype AA.;in men with Disease:Schizophrenia
;CARBAMAZEPINE;MLN;rs2894342;A;Toxicity;increased  risk of Side Effect:Hypersensitivity Syndrome;Allele A is associated with increased risk of Hypersensitivity Syndrome when treated with carbamazepine as compared to allele C.; 
;EFAVIRENZ;CYP2B6;rs28399499;CC + CT;Metabolism/PK;increased   PK:exposure;Genotypes CC + CT are associated with increased exposure of efavirenz in women with HIV Infections as compared to genotype TT.;in women with Disease:HIV infectious disease
;CLOZAPINE;ABCB1;rs1045642;AG + GG;Toxicity;increased   Side Effect:Weight gain;Genotypes AG + GG is associated with increased Weight gain when treated with clozapine in men with Schizophrenia as compared to genotype AA.;in men with Disease:Schizophrenia
;CLOZAPINE;ABCC1;rs212090;AT + TT;Toxicity;increased   Side Effect:Weight gain;Genotypes AT + TT is associated with increased Weight gain when treated with clozapine in men with as compared to genotype AA.;in men with 
;CAFFEINE;ADORA2A;rs5751876;TT;Toxicity;increased   Side Effect:anxiety;Genotype TT is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype CC.;in people with no disease
;CAFFEINE;ADORA2A;rs2298383;CC;Toxicity;increased   Side Effect:anxiety;Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype TT.;in people with no disease
;CAFFEINE;;rs4822492;CC;Toxicity;increased   Side Effect:anxiety;Genotype CC is associated with increased anxiety when exposed to caffeine in people with no disease as compared to genotype GG.;in people with no disease
;;MT-RNR1;rs267606617;G;Other;increased  likelihood of Other:Hearing Loss, Sensorineural;Allele G is associated with increased likelihood of Hearing Loss, Sensorineural as compared to allele A.; 
;CARBAMAZEPINE;;rs3130690;T;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;Allele T is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele G.; 
;CAFFEINE;ADORA2A;rs5751876;CC;Efficacy;increased  likelihood of Efficacy:being sensitive to caffeine;Genotype CC is associated with increased likelihood of being sensitive to caffeine when exposed to caffeine as compared to genotype TT.; 
;CAFFEINE;ADORA2A;rs5751876;CC;Toxicity;increased  likelihood of Side Effect:insomnia;Genotype CC is associated with increased likelihood of insomnia when exposed to caffeine as compared to genotype TT.; 
;ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;rs2133896;T;Toxicity;increased  risk of Side Effect:Alcohol abuse, Side Effect:Heroin Dependence, Side Effect:Methamphetamine dependence;Allele T is associated with increased risk of Alcoholism, Heroin Dependence or methamphetamine dependence due to ethanol, heroin or methamphetamine as compared to allele G.; 
;CARBAMAZEPINE;MICA;rs2848716;C;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele G.; 
;"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs2965667;TT;Other;decreased risk of Disease:Colorectal Neoplasms;Genotype TT is associated with decreased risk of Colorectal Neoplasms when exposed to Antiinflammatory agents, non-steroids and aspirin as compared to genotypes AA + AT.; 
;CAFFEINE;ADORA2A;rs5751876;TT;Dosage;decreased  Other:habitual consumption;Genotype TT is associated with decreased habitual consumption of caffeine as compared to genotypes CC + CT.; 
;CARBAMAZEPINE;BAG6, PRRC2A;rs750332;C;Toxicity;increased  risk of Disease:Stevens-Johnson Syndrome;Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele T.; 
;"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs16973225;AA;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotype AA is associated with decreased likelihood of Colorectal Neoplasms when exposed to Antiinflammatory agents, non-steroids and aspirin.; 
;;CHRNA5;rs588765;T;Efficacy;Efficacy:decreased chance of achieving 6 month abstinence in the placebo group;Allele T is associated with decreased chance of achieving 6 month abstinence in the placebo group as compared to allele C.; 
;WARFARIN;VKORC1;rs9934438;AG + GG;Dosage;increased   Other:warfarin dose;Genotypes AG + GG are associated with increased warfarin dose when treated with warfarin as compared to genotype AA.; 
;RIBAVIRIN;ITPA;rs7270101;AA;Toxicity;increased  likelihood of Side Effect:Hemolytic Anemia;Genotype AA is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AC + CC.;in people with Disease:Hepatitis C virus infection
;SIMVASTATIN;LEPR;rs1137101;GG;Efficacy;increased   Efficacy:percentage change in HDL-C levels;Genotype GG is associated with increased percentage change in HDL-C levels when treated with simvastatin in people with Coronary Disease as compared to genotype AA.;in people with Disease:Coronary Disease
;ALENDRONATE;SOST;rs1234612;CC;Efficacy;increased   Efficacy:bone density;Genotype CC is associated with increased bone density when treated with alendronate in women with Bone Diseases, Metabolic and Osteoporosis as compared to genotypes CT + TT.;in women with Disease:Metabolic Bone Disorder, Disease:Osteoporosis
;CYTARABINE, DAUNORUBICIN;ABCB1;rs1128503;GG;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotype GG is associated with increased likelihood of cardiotoxicity when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in children with Leukemia, Myeloid, Acute
;CYTARABINE, DAUNORUBICIN;CDA;rs532545;CC;Toxicity;decreased likelihood of Side Effect:Colitis;Genotype CC is associated with decreased likelihood of Colitis when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AC.;in children with Leukemia, Myeloid, Acute
;CYTARABINE, DAUNORUBICIN;ABCB1;rs1045642;GG;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Genotype GG is associated with increased likelihood of elevated liver enzymes when treated with cytarabine and daunorubicin in children with Leukemia, Myeloid, Acute as compared to genotypes AA + AG.;in children with Leukemia, Myeloid, Acute
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;Efficacy:high on-treatment platelet reactivity;Allele A is associated with high on-treatment platelet reactivity when treated with clopidogrel in patients undergoing percutaneous coronary intervention as compared to allele G.;in patients undergoing percutaneous coronary intervention
;ALENDRONATE;SOST;rs865429;GG;Efficacy;decreased  Efficacy:bone density;Genotype GG is associated with decreased bone density when treated with alendronate in women with Bone Diseases, Metabolic and Osteoporosis as compared to genotypes AA + AG.;in women with Disease:Metabolic Bone Disorder, Disease:Osteoporosis
;RIBAVIRIN;ITPA;rs1127354;CC;Toxicity;increased  likelihood of Side Effect:Hemolytic Anemia;Genotype CC is associated with increased likelihood of Anemia, Hemolytic when treated with ribavirin in people with Hepatitis C as compared to genotypes AA + AC.;in people with Disease:Hepatitis C virus infection
;CYTARABINE;ABCB1;rs1128503;AA + AG;Efficacy;increased   Efficacy:Overall survival;Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;CLOPIDOGREL;MED12L, P2RY12;rs6801273;T;Efficacy;decreased  Efficacy:residual on-clopidogrel platelet reactivity;Allele T is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.;in people with Disease:Coronary Artery Disease
;CYTARABINE;ABCB1;rs2032582;AA + AC;Efficacy;increased   Efficacy:Overall survival;Genotypes AA + AC is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.;in people with Disease:Leukemia, Myeloid, Acute
;CLOPIDOGREL;MED12L;rs6798347;G;Efficacy;decreased  Efficacy:residual on-clopidogrel platelet reactivity;Allele G is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;Efficacy;decreased  Efficacy:progression free survival (PFS) time;Allele T is associated with decreased progression free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYTARABINE;ABCB1;rs1045642;AA + AG;Efficacy;increased   Efficacy:Overall survival;Genotypes AA + AG is associated with increased overall survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;SEVOFLURANE;ABCB1;rs1128503;GG;Other;decreased likelihood of Other:adverse events;Genotype GG is associated with decreased likelihood of adverse events when exposed to sevoflurane in children with tonsillectomy as compared to genotypes AA + AG.;in children with tonsillectomy
;TACROLIMUS;KCNJ11;rs5219;CT + TT;Toxicity;increased  risk of Side Effect:Diabetes Mellitus, Type 2;Genotypes CT + TT is associated with increased risk of Diabetes Mellitus, Type 2 when treated with tacrolimus in people with heart transplantation or Kidney Transplantation as compared to genotype CC.;in people with Disease:Heart transplantation, Disease:Kidney Transplantation
;ACE INHIBITORS, PLAIN;ETV6;rs2724635;GG;Toxicity;increased  likelihood of Side Effect:Angioedema;Genotype GG is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to genotypes AA + AG.; 
;ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;SUNITINIB;ABCB1;rs1128503;AA;Toxicity;decreased risk of Side Effect:Neutropenia;Genotype AA is associated with decreased risk of Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.;in people with Disease:Renal Cell Carcinoma
;ASPIRIN;TAPBP;rs2071888;CC + CG;Toxicity;increased   Side Effect:FEV1 decrease after aspirin challenge;Genotypes CC + CG are associated with increased FEV1 decrease after aspirin challenge when exposed to aspirin in people with Asthma as compared to genotype GG.;in people with Disease:Asthma
;DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;rs3740065;AG + GG;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotypes AG + GG are associated with decreased risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype AA.;in people with Tuberculosis
;ESCITALOPRAM;HTR2A;rs6311;CT + TT;Toxicity;increased  risk of Side Effect:Physiological sexual disorder;Genotypes CT + TT are associated with increased risk of Sexual Dysfunctions, Psychological when treated with escitalopram in people with Anxiety Disorders as compared to genotype CC.;in people with Anxiety Disorders
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Toxicity;increased  risk of Side Effect:composite outcome of non-fatal MI, all cause death and stent thrombosis;Genotype AA is associated with increased risk of composite outcome of non-fatal MI, all cause death and stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;HYDROCHLOROTHIAZIDE;KCNJ1;rs12795437;C;Toxicity;increased  likelihood of Disease:Diabetes Mellitus;Allele C is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;PHENPROCOUMON;VKORC1;rs9934438;AA + AG;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes AA + AG are associated with increased likelihood of Hemorrhage when treated with phenprocoumon as compared to genotype GG.; 
;VALPROIC ACID;LEPR;rs1137101;AA + AG;Toxicity;increased   Side Effect:Weight gain;Genotypes AA + AG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype GG.;in people with Disease:Epilepsy
;PHENYTOIN;CFHR4;rs78239784;G;Toxicity;increased  risk of Disease:Maculopapular Exanthema;Allele G is associated with increased risk of Maculopapular Exanthema due to phenytoin as compared to allele T.; 
;HYDROCHLOROTHIAZIDE;KCNJ1;rs11600347;A;Toxicity;increased  likelihood of Disease:Diabetes Mellitus;Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;CABAZITAXEL;ABCB1;rs2032582;A;Toxicity;decreased likelihood of Side Effect:Gastrointestinal toxicity;Allele A is associated with decreased likelihood of gastrointestinal toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele C.;in people with Disease:Transitional cell carcinoma
;VALPROIC ACID;ANKK1;rs1800497;AG + GG;Toxicity;increased   Side Effect:Weight gain;Genotypes AG + GG is associated with increased Weight gain when treated with valproic acid in people with Epilepsy as compared to genotype AA.;in people with Disease:Epilepsy
;HYDROCHLOROTHIAZIDE;KCNJ1;rs658903;A;Toxicity;decreased likelihood of Disease:Diabetes Mellitus;Allele A is associated with decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;CABAZITAXEL;ABCB1;rs1045642;A;Toxicity;decreased likelihood of Side Effect:Gastrointestinal toxicity;Allele A is associated with decreased likelihood of gastrointestinal toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele G.;in people with Disease:Transitional cell carcinoma
;CLOPIDOGREL;P2RY12;rs6787801;G;Efficacy;decreased  Efficacy:residual on-clopidogrel platelet reactivity;Allele G is associated with decreased residual on-clopidogrel platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;CABAZITAXEL;CYP3A5;rs776746;T;Toxicity;decreased likelihood of Side Effect:Gastrointestinal toxicity;Allele T is associated with decreased likelihood of gastrointestinal toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele C.;in people with Disease:Transitional cell carcinoma
;ACE INHIBITORS, PLAIN;PRKCQ;rs500766;CT + TT;Toxicity;decreased likelihood of Side Effect:Angioedema;Genotypes CT + TT is associated with decreased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to genotype CC.; 
;HYDROCHLOROTHIAZIDE;KCNJ1;rs675388;A;Toxicity;increased  likelihood of Disease:Diabetes Mellitus;Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;DOXORUBICIN;GSTP1;rs1695;GG;Efficacy;decreased risk of Efficacy:chemoresistance;Genotype GG is associated with decreased risk of chemoresistance when treated with doxorubicin in people with Breast Neoplasms as compared to genotypes AA + AG.;in people with Disease:Breast Neoplasms
;CABAZITAXEL;ABCB1;rs1128503;A;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Allele A is associated with decreased likelihood of Drug Toxicity when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to allele G.;in people with Disease:Transitional cell carcinoma
;PROPOFOL;DRD2;rs2283265;AA + AC;Other;decreased  Other:heart rate;Genotypes AA + AC is associated with decreased heart rate when exposed to propofol as compared to genotype CC.; 
;NICOTINE;CHRNA4;rs2236196;A;Other;increased  likelihood of Other:nicotine dependence;Allele A is associated with increased likelihood of nicotine dependence when exposed to nicotine as compared to allele G.; 
;ACETAMINOPHEN;UGT1A;rs1042640;CG + GG;Toxicity;decreased risk of Disease:Liver Failure, Acute;Genotypes CG + GG are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.; 
;CLOPIDOGREL;ABCB1;rs1045642;AA;Toxicity;decreased  Side Effect:bleeding events;Genotype AA is associated with decreased bleeding events when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;ACETAMINOPHEN;UGT1A;rs8330;CG + GG;Toxicity;decreased risk of Disease:Liver Failure, Acute;Genotypes CG + GG are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.; 
;GEFITINIB;EGFR;rs121434569;T;Efficacy;decreased  Efficacy:response rate (RR);Allele T is associated with decreased response rate (RR) when treated with gefitinib in non-small-cell lung cancer patients as compared to allele C.;in Efficacy:non-small-cell lung cancer patients
;HYDROCHLOROTHIAZIDE;KCNJ1;rs59172778;AG;Toxicity;increased   Side Effect:serum potassium;Genotype AG is associated with increased serum potassium when treated with hydrochlorothiazide in people with Hypertension as compared to genotype AA.;in people with Disease:Hypertension
;ETHANOL;CACNA1C;rs1034936;TT;Toxicity;increased  risk of Side Effect:Alcohol abuse;Genotype TT is associated with increased risk of Alcoholism due to ethanol in people with Bipolar Disorder as compared to genotypes CC + CT.;in people with Bipolar Disorder
;DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Thrombocytopenia;Genotype AA is associated with increased risk of Anemia and Thrombocytopenia when treated with doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Disease:Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Toxicity;increased  risk of Disease:Myocardial Infarction;Genotype AA is associated with increased risk of Myocardial Infarction when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;WARFARIN;EPHA7;rs114504854;A;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele A is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele G.; 
;ACETAMINOPHEN;UGT1A;rs10929303;CT + TT;Toxicity;decreased risk of Disease:Liver Failure, Acute;Genotypes CT + TT are associated with decreased risk of Liver Failure, Acute when treated with acetaminophen as compared to genotype CC.; 
;ACE INHIBITORS, PLAIN;XPNPEP2;rs2050011;T;Toxicity;increased  likelihood of Side Effect:Angioedema;Allele T is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele G.; 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;rs1800629;AA + AG;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;NICOTINE;ADGRL3;rs2271339;AG;Toxicity;increased  risk of Other:Tobacco Use Disorder;Genotype AG is associated with increased risk of Tobacco Use Disorder due to nicotine in people with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + GG.;in people with Attention Deficit Disorder with Hyperactivity
;NICOTINE;ADGRL3;rs1456862;AT;Toxicity;increased  risk of Other:Tobacco Use Disorder;Genotype AT is associated with increased risk of Tobacco Use Disorder due to nicotine in people with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.;in people with Attention Deficit Disorder with Hyperactivity
;GEFITINIB;EGFR;rs2293347;CC;Efficacy;increased   Efficacy:response rate (RR);Genotype CC is associated with increased response rate (RR) when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes CT + TT.;in Efficacy:advanced non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs2293347;CC;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Genotype CC is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to genotypes CT + TT.;in Efficacy:advanced non-small-cell lung cancer patients
;ETHANOL;MAP2K4;rs2159140;CT;Toxicity;increased  risk of Other:Alcohol abuse;Genotype CT is associated with increased risk of Alcoholism due to ethanol in people with Attention Deficit Disorder with Hyperactivity as compared to genotype CC.;in people with Attention Deficit Disorder with Hyperactivity
;SUNITINIB;ABCB1;rs1045642;GG;Toxicity;increased  risk of Side Effect:Exanthema, Side Effect:Mucositis;Genotype GG is associated with increased risk of Exanthema and mucositis when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AG.;in people with Disease:Renal Cell Carcinoma
;SORAFENIB;UGT1A9;rs17868320;T;Toxicity;increased  risk of Disease:Diarrhea;Allele T is associated with increased risk of Diarrhea when treated with sorafenib in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.;in Efficacy:advanced non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:overall survival (OS) time;Allele G is associated with increased overall survival (OS) time when treated with gefitinib in advanced non-small-cell lung cancer patients as compared to allele T.;in Efficacy:advanced non-small-cell lung cancer patients
;GEFITINIB;EGFR;rs712829;GT + TT;Efficacy;increased   Efficacy:response rate (RR);Genotypes GT + TT are associated with increased response rate (RR) when treated with gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes AA + AG is associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype GG.; 
;MORPHINE;OPRM1;rs1799971;AA;Toxicity;increased  risk of Side Effect:Hypoventilation;Genotype AA is associated with increased risk of Hypoventilation when treated with morphine in children as compared to genotypes AG + GG.;in children 
;ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;Toxicity;increased  likelihood of Side Effect:Angioedema;Allele A is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to allele C.; 
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Toxicity;increased  risk of Side Effect:major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg;Genotypes AA + AG are associated with increased risk of major adverse cardiovascular events (MACE) (more than one year) when receiving a loading dose of 300 mg when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;DOCETAXEL;ABCC10;rs2125739;CT;Toxicity;decreased severity of Side Effect:Neutropenia;Genotype CT is associated with decreased severity of Neutropenia when treated with docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Non-Small Cell Lung Carcinoma
;;ARNT;rs2228099;CG + GG;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes CG + GG are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype CC.; 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs3813867;GG;Toxicity;increased  severity of Disease:Toxic liver disease;Genotype GG is associated with increased severity of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Toxic liver disease as compared to genotypes CC + CG.;in people with Disease:Toxic liver disease
;CLOPIDOGREL;ABCB1;rs1045642;AA + AG;Toxicity;increased  risk of Side Effect:early major adverse cardiovascular events (MACE);Genotypes AA + AG are associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;;DEPTOR;rs4871827;AA + AG;Other;increased   Other:HDL cholesterol;Genotypes AA + AG is associated with increased HDL cholesterol in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Diabetes Mellitus, Type 2
;CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;Efficacy;decreased  Efficacy:overall survival;Genotype CC is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes CT + TT.;in people with Disease:Small cell carcinoma
;;DEPTOR;rs4871827;AG;Other;decreased likelihood of Other:Brain Ischemia, Other:Myocardial Infarction, Other:Peripheral Vascular Diseases;Genotype AG is associated with decreased likelihood of Brain Ischemia, Myocardial Infarction or Peripheral Vascular Diseases in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Diabetes Mellitus, Type 2
;"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;rs3745274;TT;Toxicity;increased  risk of Disease:Drug-induced liver injury;Genotype TT is associated with increased risk of drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.;in people with HIV and tuberculosis co-infection
;;DEPTOR;rs4871827;AG;Other;decreased likelihood of Other:Diabetic Retinopathy, Other:Chronic Kidney Failure;Genotype AG is associated with decreased likelihood of Diabetic Retinopathy or Kidney Failure, Chronic in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Diabetes Mellitus, Type 2
;LOSARTAN;STK39;rs6749447;GG + GT;Efficacy;decreased  Efficacy:reduction in ambulatory blood pressure;Genotypes GG + GT are associated with decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to genotype TT.;in men with Disease:Hypertension
;CLOPIDOGREL;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:early major adverse cardiovascular events (MACE);Genotype AA is associated with increased risk of early major adverse cardiovascular events (MACE) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;;AHR;rs2066853;AA + AG;Other;increased  risk of Other:adenomatous and hyperplastic polyps;Genotypes AA + AG are associated with increased risk of adenomatous and hyperplastic polyps in people with a NAT1 rapid acetylator genotype and high meat consumption.;in people with a NAT1 rapid acetylator genotype and high meat consumption
;RISPERIDONE;HTR6;rs9659997;CC + CT;Toxicity;increased  severity of Side Effect:Hyperprolactinemia;Genotypes CC + CT is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotype TT.;in children with Disease:Autism
;CISPLATIN, IRINOTECAN;DCBLD1;rs17574269;AG;Efficacy;decreased  Efficacy:overall survival;Genotype AG is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA.;in people with Disease:Small cell carcinoma
;CISPLATIN, IRINOTECAN;;rs7186128;AG + GG;Efficacy;decreased  Efficacy:overall survival;Genotypes AG + GG are associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA.;in people with Disease:Small cell carcinoma
;RISPERIDONE;TYMS;rs3786362;A;Toxicity;increased  risk of Side Effect:Hyperprolactinemia;Allele A is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to allele G.;in children with Disease:Autism Spectrum Disorder
;;TNF;rs1800630;C;Efficacy;increased  severity of Efficacy:Leukocytosis;Allele C is associated with increased severity of Leukocytosis in children with Acute lymphoblastic leukemia as compared to allele A.;in children with Acute lymphoblastic leukemia
;CISPLATIN, IRINOTECAN;;rs2166219;TT;Efficacy;decreased  Efficacy:overall survival;Genotype TT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes CC + CT.;in people with Disease:Small cell carcinoma
;RISPERIDONE;HTR2A;rs6311;CC;Toxicity;increased  severity of Side Effect:Hyperprolactinemia;Genotype CC is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotypes CT + TT.;in children with Disease:Autism
;CISPLATIN, IRINOTECAN;;rs4655567;CC;Efficacy;decreased  Efficacy:overall survival;Genotype CC is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes CG + GG.;in people with Disease:Small cell carcinoma
;ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity, Side Effect:Neurotoxicity Syndromes;Genotypes AA + AC is associated with increased risk of gastrointestinal toxicity and Neurotoxicity Syndromes when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;CISPLATIN, IRINOTECAN;;rs2018683;TT;Efficacy;decreased  Efficacy:overall survival;Genotype TT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes GG + GT.;in people with Disease:Small cell carcinoma
;RISPERIDONE;BDNF;rs6265;CT + TT;Toxicity;increased  severity of Side Effect:Hyperprolactinemia;Genotypes CT + TT is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to genotype CC.;in children with Disease:Autism
;ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ADORA2A;rs2236624;CC;Toxicity;increased  risk of Side Effect:Neurotoxicity Syndromes;Genotype CC is associated with increased risk of Neurotoxicity Syndromes when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in children with Disease:Acute lymphoblastic leukemia
;LEUCOVORIN, METHOTREXATE;ABCC2;rs717620;CT + TT;Metabolism/PK;increased   PK:distribution volume;Genotypes CT + TT are associated with increased distribution volume when treated with leucovorin and methotrexate in people with Lymphoma as compared to genotype CC.;in people with Disease:Lymphoma
;CISPLATIN, IRINOTECAN;;rs2018683;TT;Efficacy;increased  risk of Efficacy:resistant relapse;Genotype TT is associated with increased risk of resistant relapse when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes GG + GT.;in people with Disease:Small cell carcinoma
;;OPRM1;rs1799971;G;Toxicity;increased  likelihood of Disease:Heroin Dependence;Allele G is associated with increased likelihood of Heroin Dependence as compared to allele A.; 
;CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;Efficacy;increased  risk of Efficacy:resistant relapse;Genotype CC is associated with increased risk of resistant relapse when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes CT + TT.;in people with Disease:Small cell carcinoma
;CISPLATIN, IRINOTECAN;;rs4655567;CC;Efficacy;increased  risk of Efficacy:resistant relapse;Genotype CC is associated with increased risk of resistant relapse when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotypes CG + GG.;in people with Disease:Small cell carcinoma
;METHOTREXATE;ABCC4;rs7317112;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Disease:Acute lymphoblastic leukemia
;RISPERIDONE;UGT1A1;rs1976391;AG;Toxicity;increased  risk of Side Effect:Hyperprolactinemia;Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype AA.;in children with Disease:Autism Spectrum Disorder
;RISPERIDONE;HTR2C;rs6318;C;Toxicity;increased  severity of Side Effect:Hyperprolactinemia;Allele C is associated with increased severity of Hyperprolactinemia when treated with risperidone in children with Autistic Disorder as compared to allele G.;in children with Disease:Autism
;CYCLOSPORINE;;rs2275913;GG;Efficacy;increased  likelihood of Efficacy:Transplant rejection;Genotype GG is associated with increased likelihood of transplant rejection when treated with cyclosporine in people with liver transplantation as compared to genotypes AA + AG.;in people with Disease:Liver transplantation
;LENALIDOMIDE;ABCB1;rs2032582;AA;Toxicity;decreased likelihood of Side Effect:Myelosuppression;Genotype AA is associated with decreased likelihood of Myelosuppression when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AC + CC.;in people with Mantle cell lymphoma
;HEROIN;DBH;rs1611114;TT;Toxicity;decreased risk of Side Effect:Memory impairment;Genotype TT is associated with decreased risk of Memory Disorders due to heroin in people with Heroin Dependence as compared to genotypes CC + CT.;in people with Heroin Dependence
;DILTIAZEM;PLCD3;rs12946454;T;Efficacy;increased   Efficacy:reduction in blood pressure;Allele T is associated with increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;rs1801131;GG;Efficacy;decreased  Efficacy:event-free survival, Efficacy:Overall survival;Genotype GG is associated with decreased event-free survival and overall survival when treated with capecitabine, fluorouracil or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;Toxicity;decreased severity of Side Effect:Anemia;Genotype AC is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype CC.;in people with Disease:Hepatitis C virus infection
;DOCETAXEL;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotype AA is associated with increased likelihood of Neutropenia when treated with docetaxel as compared to genotypes AG + GG.; 
;"""BETA BLOCKING AGENTS"", ""THIAZIDES, PLAIN""";;rs11191548;C;Efficacy;increased   Efficacy:reduction in diastolic blood pressure;Allele C is associated with increased reduction in diastolic blood pressure when treated with Beta Blocking Agents or Thiazides, plain in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;NICOTINE;COMT;rs4680;GG;Other;increased  severity of Side Effect:withdrawal;Genotype GG is associated with increased severity of withdrawal in people not taking nicotine in women Tobacco Use Disorder as compared to genotypes AA + AG.;in women Disease:Tobacco Use Disorder
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:minimum plasma concentrations;Genotype TT is associated with increased minimum plasma concentrations of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;MORPHINE;ABCB1;rs9282564;CC + CT;Toxicity;increased  risk of Side Effect:Hypoventilation;Genotypes CC + CT is associated with increased risk of Hypoventilation when treated with morphine in children as compared to genotype TT.;in children 
;ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ABCC1;rs246240;GG;Toxicity;increased  risk of Side Effect:Neurotoxicity Syndromes;Genotype GG is associated with increased risk of Neurotoxicity Syndromes when treated with antineoplastic agents and corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Disease:Acute lymphoblastic leukemia
;LENALIDOMIDE;NCF4;rs1883112;AA + AG;Toxicity;decreased likelihood of Side Effect:Myelosuppression;Genotypes AA + AG is associated with decreased likelihood of Myelosuppression when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotype GG.;in people with Mantle cell lymphoma
;NICOTINE;COMT;rs4680;GG;Other;increased   Other:blood pressure;Genotype GG is associated with increased blood pressure when treated with nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG.;in people with Disease:Tobacco Use Disorder
;LENALIDOMIDE;GSTP1;rs1695;GG;Toxicity;decreased likelihood of Side Effect:Myelosuppression;Genotype GG is associated with decreased likelihood of Myelosuppression when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AA + AG.;in people with Mantle cell lymphoma
;CISPLATIN, IRINOTECAN;ABCC4;rs16950650;CT;Efficacy;decreased  Efficacy:overall survival;Genotype CT is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype CC.;in people with Disease:Small cell carcinoma
;ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;Other;increased   Other:collagen-induced platelet aggregation;Genotypes CT + TT are associated with increased collagen-induced platelet aggregation when treated with aspirin and clopidogrel in patients undergoing coronary stenting as compared to genotype CC.;in patients undergoing coronary stenting
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;Toxicity;increased  risk of Disease:Diarrhea;Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;rs1045642;GG;Toxicity;decreased likelihood of Side Effect:Exanthema;Genotype GG is associated with decreased likelihood of Exanthema when treated with efavirenz, lamivudine and tenofovir in people with HIV Infections as compared to genotypes AA + AG.;in people with HIV infectious disease
;GEMCITABINE;SLC29A3;rs780668;CT + TT;Efficacy;increased   Efficacy:Overall survival;Genotypes CT + TT are associated with increased overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;Toxicity;decreased severity of Side Effect:Anemia;Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;in people with Disease:Chronic hepatitis C virus infection
;MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;Toxicity;increased  risk of Disease:Diarrhea;Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GT.;in people with Disease:Kidney Transplantation
;ATORVASTATIN;SLCO1B1;rs4149056;C;Toxicity;increased  risk of Side Effect:Muscular Diseases;Allele C is associated with increased risk of Muscular Diseases when treated with atorvastatin.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;Toxicity;decreased severity of Side Effect:Anemia;Allele C is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A.;in people with Disease:Chronic hepatitis C virus infection
;CAFFEINE;CYP1A2;rs762551;AC + CC;Toxicity;increased  likelihood of Side Effect:Albuminuria, Side Effect:Hypertension;Genotypes AC + CC is associated with increased likelihood of Albuminuria or Hypertension when exposed to caffeine.; 
;GEMCITABINE;ABCG2;rs2231142;GT + TT;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Genotypes GT + TT are associated with increased severity of Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA;Efficacy;increased  risk of Disease:Death;Genotype AA is associated with increased risk of Death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.;in women Disease:Ovarian Neoplasms
;CAPECITABINE;CDA;rs1048977;CT + TT;Toxicity;increased  likelihood of Side Effect:Discontinuation;Genotypes CT + TT is associated with increased likelihood of discontinuation when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Colorectal Neoplasms
;CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;Metabolism/PK;decreased  PK:exposure to clopidogrel active metabolite;Genotypes CT + TT are associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.;in healthy individuals 
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Muscular Diseases, Side Effect:Rhabdomyolysis, Side Effect:Toxic liver disease;Genotypes CC + CT is associated with increased likelihood of Drug Toxicity, Muscular Diseases, Rhabdomyolysis and Toxic liver disease when treated with atorvastatin as compared to genotype TT.; 
;ALLOPURINOL;CFLAR;rs1594;A;Toxicity;Side Effect:Severe Cutaneous Adverse Reactions;Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.; 
;OXYCODONE;ABCB1;rs1045642;AA + AG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes AA + AG is associated with increased likelihood of adverse events when treated with oxycodone in people with Pain and Neoplasms as compared to genotype GG.;in people with Pain, Neoplasms
;CAPECITABINE;CES2;rs11075646;CG + GG;Efficacy;increased   Efficacy:time to progression;Genotypes CG + GG are associated with increased time to progression when treated with capecitabine in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;PLATINUM COMPOUNDS;ERCC1;rs11615;AA;Efficacy;increased  risk of Efficacy:recurrence of disease;Genotype AA is associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype GG.;in women Disease:Ovarian Neoplasms
;CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;Efficacy;decreased  Efficacy:inhibition of platelet aggregation and poor-responder status;Genotypes CT + TT are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype CC.;in healthy individuals 
;PLATINUM COMPOUNDS;HSPA5;rs430397;TT;Efficacy;decreased  Other:progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:inhibition of platelet aggregation and poor-responder status;Allele A is associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to allele G.;in healthy individuals 
;ASPIRIN;AGT;rs5050;GG;Toxicity;increased  risk of Disease:Peptic Ulcer Hemorrhage;Genotype GG is associated with increased risk of Peptic Ulcer Hemorrhage when treated with aspirin as compared to genotypes GT + TT.; 
;SUNITINIB;NR1I2;rs6785049;A;Toxicity;increased  risk of Side Effect:Hypertension;Allele A is associated with increased risk of Hypertension when treated with sunitinib in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;BUPROPION;SACM1L;rs2251954;C;Toxicity;decreased  Side Effect:sexual side-effects;Allele C is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;ROSUVASTATIN;GATM;rs9806699;AA;Toxicity;decreased risk of Side Effect:Muscular Diseases;Genotype AA are associated with decreased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotypes AG + GG.;in people with Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;rs4244285;A;Metabolism/PK;decreased  PK:exposure to clopidogrel active metabolite;Allele A is associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to allele G.;in healthy individuals 
;BUPROPION;SACM1L;rs2742421;G;Toxicity;decreased  Side Effect:sexual side-effects;Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;rs28371759;AG;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Genotype AG is associated with increased likelihood of drug-induced liver injury when treated with ethambutol and isoniazid / pyrazinamide / rifampin in people with Tuberculosis as compared to genotype AA.;in people with Tuberculosis
;ROSUVASTATIN;SLCO1B1;rs4149081;AG;Efficacy;increased   Efficacy:LDL-C reduction;Genotype AG is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;BUPROPION;SACM1L;rs2742423;G;Toxicity;decreased  Side Effect:sexual side-effects;Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity;Side Effect:early (< 3 months) termination of efavirenz therapy;Genotype TT is associated with early (< 3 months) termination of efavirenz therapy when treated with efavirenz as compared to genotypes GG + GT.; 
;CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;Metabolism/PK;decreased  PK:exposure to clopidogrel active metabolite;Genotypes AC + CC are associated with decreased exposure to clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype AA.;in healthy individuals 
;BUPROPION;SACM1L;rs1969624;T;Toxicity;decreased  Side Effect:sexual side-effects;Allele T is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;EFAVIRENZ;NR1I3;rs2307424;GG;Toxicity;Side Effect:early (< 3 months) termination of efavirenz therapy;Genotype GG is associated with early (< 3 months) termination of efavirenz therapy when treated with efavirenz as compared to genotypes AA + AG.; 
;BUPROPION;SACM1L;rs2245705;C;Toxicity;decreased  Side Effect:sexual side-effects;Allele C is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele T.;in people with Disease:Major Depressive Disorder
;BUPROPION;SACM1L;rs2742435;G;Toxicity;decreased  Side Effect:sexual side-effects;Allele G is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;Efficacy;decreased  Efficacy:inhibition of platelet aggregation and poor-responder status;Genotypes AC + CC are associated with decreased inhibition of platelet aggregation and poor-responder status when treated with clopidogrel in healthy individuals as compared to genotype AA.;in healthy individuals 
;BUPROPION;SACM1L;rs2742390;A;Toxicity;decreased  Side Effect:sexual side-effects;Allele A is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;SIMVASTATIN;SLCO1B1;rs4149081;AG;Efficacy;increased   Efficacy:LDL-C reduction;Genotype AG is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;PLATINUM COMPOUNDS;HSPA5;rs430397;TT;Efficacy;increased  likelihood of Other:early relapse;Genotype TT is associated with increased likelihood of early relapse when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;SIMVASTATIN;SLCO1B1;rs4149081;AA;Efficacy;increased   Efficacy:LDL-C reduction;Genotype AA is associated with increased LDL-C reduction when treated with simvastatin in people with Coronary Disease as compared to genotypes AG + GG.;in people with Disease:Coronary Disease
;PEMETREXED;DHFR;rs442767;GG;Toxicity;increased  risk of Disease:Fatigue;Genotype GG is associated with increased risk of Fatigue when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;FLUOROURACIL;MTHFR;rs1801131;GG;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype GG is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes GT + TT.;in people with Disease:Colorectal Neoplasms
;BUPROPION;SACM1L;rs2742417;T;Toxicity;decreased  Side Effect:sexual side-effects;Allele T is associated with decreased sexual side-effects when treated with bupropion in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;TEMSIROLIMUS;NR1I2;rs3814055;T;Toxicity;decreased likelihood of Side Effect:adverse events;Allele T is associated with decreased likelihood of adverse events when treated with temsirolimus in people with Urinary Bladder Neoplasms as compared to allele C.;in people with Disease:Urinary Bladder Neoplasms
;PHENPROCOUMON;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with phenprocoumon as compared to genotype CC.; 
;SUNITINIB;FLT3;rs1933437;AA;Toxicity;increased  risk of Side Effect:Leukopenia, Side Effect:Neutropenia;Genotype AA is associated with increased risk of Leukopenia and Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.;in people with Disease:Renal Cell Carcinoma
;CAPECITABINE;CES1;rs71647871;CT + TT;Toxicity;increased  severity of Side Effect:Hand-foot syndrome, Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased severity of hand-foot syndrome or Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC.;in people with Colorectal Neoplasms
;ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:Muscular Diseases;Genotypes CC + CT are associated with increased risk of Muscular Diseases when treated with rosuvastatin in people with Coronary Artery Disease as compared to genotype TT.;in people with Coronary Artery Disease
;GEMCITABINE;ABCG2;rs2231142;GT + TT;Efficacy;increased   Efficacy:Progression-free survival;Genotypes GT + TT are associated with increased progression-free survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;HSPA5;rs430397;TT;Efficacy;increased  risk of Disease:Death;Genotype TT is associated with increased risk of Death when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;ROSUVASTATIN;SLCO1B1;rs4149081;AA;Efficacy;increased   Efficacy:LDL-C reduction;Genotype AA is associated with increased LDL-C reduction when treated with rosuvastatin in people with Coronary Disease as compared to genotypes AG + GG.;in people with Disease:Coronary Disease
;NALTREXONE;OPRD1;rs4654327;A;Efficacy;increased   Efficacy:naltrexone-induced blunting of alcohol stimulation and alcohol craving;Allele A is associated with increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone in people with Alcoholism as compared to genotype GG.;in people with Disease:Alcohol abuse
;IRINOTECAN;UGT1A;rs11563250;AG + GG;Toxicity;decreased risk of Side Effect:Neutropenia;Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ATORVASTATIN, SIMVASTATIN;RYR2;rs2819742;A;Toxicity;increased  likelihood of Disease:Muscular Diseases, Disease:Myalgia;Allele A is associated with increased likelihood of Muscular Diseases and Myalgia unspecified when exposed to atorvastatin or simvastatin in people with Cardiovascular Diseases as compared to allele G.;in people with Disease:Cardiovascular Disease
;CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs2347128;GG;Efficacy;increased   Other:Progression-free survival;Genotype GG is associated with increased progression-free survival when treated with capecitabine, fluorouracil or gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CG.;in people with Disease:Pancreatic Neoplasms
;;MET;rs40239;AG + GG;Other;increased   Other:Overall survival;Genotypes AG + GG is associated with increased overall survival in men Stomach Neoplasms as compared to genotype AA.;in men Disease:Stomach Neoplasms
;AZATHIOPRINE;ITPA;rs7270101;AC + CC;Toxicity;increased  likelihood of Side Effect:Myelosuppression, Side Effect:Drug Toxicity, Side Effect:adverse events;Genotypes AC + CC is associated with increased likelihood of Myelosuppression, Drug Toxicity and adverse events when treated with azathioprine in people with Crohn Disease as compared to genotype AA.;in people with Crohn Disease
;CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs17718347;TT;Efficacy;increased   Other:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with capecitabine, fluorouracil or gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CC + CT.;in people with Disease:Pancreatic Neoplasms
;;MET;rs40239;AG + GG;Other;increased   Other:Overall survival;Genotypes AG + GG is associated with increased overall survival in people with Stomach Neoplasms as compared to genotype AA.;in people with Disease:Stomach Neoplasms
;"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;rs1045642;AA;Toxicity, Metabolism/PK;increased  risk of Disease:Drug-induced liver injury;Genotype AA is associated with increased risk of Drug-induced liver injury when treated with Antivirals for treatment of HIV infections, combinations and Drugs For Treatment Of Tuberculosis in people with HIV and tuberculosis co-infection as compared to genotype GG.;in people with HIV and tuberculosis co-infection
;EFAVIRENZ;CYP2B6;rs3745274;T;Other, Metabolism/PK;increased   PK:plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy;Allele T is associated with increased plasma efavirenz exposure (AUC) during the first 24 weeks of antiretroviral therapy when treated with efavirenz in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;EFAVIRENZ;CYP2B6;rs3745274;T;Toxicity;increased  risk of Disease:Central Nervous System Disorder;Allele T is associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs112563513;A;Other;increased  risk of Disease:Malignant Hyperthermia;Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;EFAVIRENZ;CYP3A4;rs2740574;C;Other, Metabolism/PK;increased   PK:plasma efavirenz exposure;Allele C is associated with increased plasma efavirenz exposure when treated with efavirenz in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype AT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Side Effect:Discontinuation;Genotypes AA + AG are associated with increased risk of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;EFAVIRENZ;CYP3A5;rs776746;C;Metabolism/PK;decreased  PK:plasma efavirenz exposure;Allele C is associated with decreased plasma efavirenz exposure when treated with efavirenz in people with HIV as compared to allele T.;in people with PK:HIV
;CLOPIDOGREL;ABCB1;rs1045642;GG;Toxicity;increased  risk of Side Effect:ischaemic events;Genotype GG is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotypes AA + AG.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Toxicity;increased  risk of Side Effect: cardiovascular events;Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;CLOPIDOGREL;CYP2C19;rs4986893;A;Toxicity;increased  risk of Side Effect:ischaemic events;Allele A is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;ACE INHIBITORS, PLAIN;MME;rs989692;CT + TT;Toxicity;increased  likelihood of Side Effect:Angioedema;Genotypes CT + TT is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to genotype CC.; 
;HMG COA REDUCTASE INHIBITORS;LILRB5;rs12975366;TT;Dosage, Toxicity;increased  likelihood of Side Effect:adverse events;Genotype TT is associated with increased likelihood of adverse events when treated with hmg coa reductase inhibitors as compared to genotypes CC + CT.; 
;ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;rs6311;TT;Toxicity;increased  likelihood of Other:Physiological sexual disorder;Genotype TT is associated with increased likelihood of Sexual Dysfunctions, Psychological when treated with escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine in men with Depressive Disorder, Major as compared to genotypes CC + CT.;in men with Major Depressive Disorder
;CABAZITAXEL;CYP3A5;rs776746;CT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype CT is associated with decreased progression-free survival when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to genotype CC.;in people with Disease:Transitional cell carcinoma
;CLOPIDOGREL;CYP2C19;rs4986893;AA;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs6311;CC;Toxicity;increased  likelihood of Side Effect:Physiological sexual disorder;Genotype CC is associated with increased likelihood of Sexual Dysfunctions, Psychological when treated with citalopram, escitalopram, fluoxetine, paroxetine or sertraline in people with Depression as compared to genotypes CT + TT.;in people with Depression
;CABAZITAXEL;TUBB1;rs463312;AC;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AC is associated with decreased progression-free survival when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to genotype AA.;in people with Disease:Transitional cell carcinoma
;CLOPIDOGREL;CYP2C19;rs28399504;G;Toxicity;increased  risk of Side Effect:ischaemic events;Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Disease:Acute coronary syndrome
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;CLOPIDOGREL;CYP2C19;rs4986893;AA;Toxicity;increased  risk of Side Effect:cardiovascular events;Genotype AA is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;NEVIRAPINE;CYP2B6;rs28399499;C;Metabolism/PK;increased   Other:plasma level;Allele C is associated with increased plasma level when treated with nevirapine in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;;SLC2A9;rs16890979;T;Metabolism/PK;decreased  PK:serum uric acid;Allele T is associated with decreased serum uric acid in healthy individuals as compared to allele C.;in healthy individuals 
;CYCLOPHOSPHAMIDE;IKZF3;rs9908694;CC;Efficacy;increased   Disease:event-free survival;Genotype CC is associated with increased event-free survival when treated with cyclophosphamide in children with Neuroblastoma as compared to genotypes CT + TT.;in children with Disease:Neuroblastoma
;METHOTREXATE;ABCB1;rs1045642;AG;Toxicity;decreased risk of Disease:Drug Toxicity;Genotype AG is associated with decreased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192122;A;Other;increased  risk of Disease:Malignant Hyperthermia;Allele A is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922816;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.; 
;METHAMPHETAMINE;DRD4;rs1800955;CC + CT;Toxicity;decreased likelihood of Side Effect:Drug psychosis;Genotypes CC + CT is associated with decreased likelihood of Paranoid psychosis NOS when exposed to methamphetamine in people with methamphetamine dependence as compared to genotype TT.;in people with Methamphetamine dependence
;BEVACIZUMAB;GC;rs4588;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival when treated with bevacizumab in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to genotypes GG + GT.;in people with Disease:Colorectal Neoplasms, Disease:Metastatic neoplasm
;CETUXIMAB;GC;rs4588;TT;Efficacy;increased   Efficacy:Overall survival;Genotype TT is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms and Neoplasm Metastasis as compared to genotypes GG + GT.;in people with Disease:Colorectal Neoplasms, Disease:Metastatic neoplasm
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs28933397;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele C.; 
;ASPIRIN;TAPBP;rs1059288;AG + GG;Toxicity;increased   Side Effect:FEV1 decrease after aspirin challenge;Genotypes AG + GG are associated with increased FEV1 decrease after aspirin challenge when exposed to aspirin in people with Asthma as compared to genotype AA.;in people with Disease:Asthma
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs140530655;CT;Toxicity;increased  risk of Side Effect:Angioedema;Genotype CT is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AG;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;GEFITINIB;IKBKB;rs2272733;CC;Toxicity;decreased risk of Side Effect:Exanthema;Genotype CC is associated with decreased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Non-Small Cell Lung Carcinoma
;"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs628031;AA + AG;Efficacy;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotypes AA + AG is associated with increased likelihood of gastrointestinal toxicity metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Diabetes Mellitus, Type 2
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotype AA is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922772;T;Other;increased  risk of Disease:Malignant Hyperthermia;Allele T is associated with increased risk of Malignant Hyperthermia when exposed to desflurane, enflurane, halothane, isoflurane, sevoflurane or succinylcholine as compared to allele G.; 
;CLOPIDOGREL;CYP2C19;rs4986893;AG;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotype AG is associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;FENOTEROL;SLC22A1;rs12208357;T;Toxicity;increased  likelihood of Side Effect:adverse events;Allele T are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele C.;in healthy individuals 
;FENOTEROL;SLC22A1;rs34130495;A;Toxicity;increased  likelihood of Side Effect:adverse events;Allele A are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele G.;in healthy individuals 
;ACE INHIBITORS, PLAIN;AGT;rs699;GG;Efficacy;decreased risk of Disease:Stroke;Genotype GG is associated with decreased risk of Stroke when treated with Ace Inhibitors, Plain in people with Hypertension.;in people with Disease:Hypertension
;;P2RY12;rs2046934;G;Other;increased  risk of Disease:Peripheral Vascular Diseases;Allele G is associated with increased risk of Peripheral Vascular Diseases as compared to allele A.; 
;GEFITINIB;RELA;rs11227247;CC;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotype CC is associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC.;in people with Non-Small Cell Lung Carcinoma
;FENOTEROL;SLC22A1;rs55918055;C;Toxicity;increased  likelihood of Side Effect:adverse events;Allele C are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele T.;in healthy individuals 
;IRINOTECAN;KCNQ5;rs9351963;C;Toxicity;increased  likelihood of Side Effect:Diarrhea;Allele C is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;FENOTEROL;SLC22A1;rs34059508;A;Toxicity;increased  likelihood of Side Effect:adverse events;Allele A are associated with increased likelihood of adverse events when exposed to fenoterol in healthy individuals as compared to allele G.;in healthy individuals 
;;P2RY12;rs2046934;G;Other;increased   Efficacy:platelet aggregation;Allele G is associated with increased platelet aggregation.; 
;GEFITINIB;IKBKE;rs2151222;AG + GG;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;ISONIAZID, PHENYTOIN;NAT2;rs1801280;C;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele T.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;ISONIAZID, PHENYTOIN;NAT2;rs1799931;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;TAMOXIFEN;CYP2D6;rs28371725;T;Efficacy;increased  risk of Efficacy:recurrence;Allele T is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;rs3892097;C;Efficacy;increased  risk of Efficacy:recurrence;Allele C is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms
;TAMOXIFEN;CYP2D6;rs1065852;A;Efficacy;increased  risk of Efficacy:recurrence;Allele A is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;PAROXETINE;HTR2A;rs6314;AG;Efficacy;Efficacy:improved response;Genotype AG is associated with improved response when treated with paroxetine in people with Depression as compared to genotypes AA + GG.;in people with Disease:Depression
;GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;Toxicity;increased  risk of Side Effect:adverse events;Genotype AG is associated with increased risk of adverse events when treated with gabapentin or pregabalin in people with neuropathic pain as compared to genotype GG.;in people with Neuropathic pain
;BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;rs2230054;TT;Efficacy;decreased  Efficacy:progression free survival;Genotype TT is associated with decreased progression free survival when treated with bevacizumab and cyclophosphamide in women with Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Ovarian Neoplasms
;PAROXETINE;HTR2A;rs6314;AG;Efficacy;increased  likelihood of Efficacy:remission;Genotype AG is associated with increased likelihood of remission when treated with paroxetine in people with Depression as compared to genotypes AA + GG.;in people with Disease:Depression
;TAMOXIFEN;CYP2C19;rs12248560;T;Efficacy;decreased risk of Efficacy:Recurrence;Allele T is associated with decreased risk of Recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.;in people with Disease:Breast Neoplasms
;GEMCITABINE;SLCO1B1;rs4149086;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.;in people with Disease:Pancreatic Neoplasms
;PAROXETINE;HTR2A;rs6313;GG;Toxicity;increased  risk of Side Effect:adverse drug reaction;Genotype GG is associated with increased risk of adverse drug reaction when treated with paroxetine in people with Depression as compared to genotypes AA + AG.;in people with Disease:Depression
;HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;rs5443;TT;Efficacy;increased   Efficacy:reduction in blood pressure;Genotype TT is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype CC.;in people with Disease:Essential hypertension
;BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;Other;decreased risk of Disease:Death;Genotypes AT + TT are associated with decreased risk of Death in people not taking Beta Blocking Agents in people with Heart Failure as compared to genotype AA.;in people with Disease:Heart Failure
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to genotype CC.; 
;;CHRNA3;rs1051730;A;Other;increased  risk of Disease:Lung Neoplasms;Allele A is associated with increased risk of Lung Neoplasms in people with who have ever been smokers as compared to allele G.;in people with who have ever been smokers
;CITALOPRAM;GRIK2;rs2518224;CC;Toxicity;increased  risk of Side Effect:treatment-emergent suicidal ideation;Genotype CC is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression.;in people with Disease:Depression
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9934438;AA + AG;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes AA + AG are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to genotype GG.; 
;IRINOTECAN;UGT1A9;rs7586110;G;Toxicity;increased  risk of Disease:Anemia;Allele G is associated with increased risk of Anemia when treated with irinotecan in people with Neoplasms.;in people with Disease:Neoplasms
;ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;Toxicity;decreased risk of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with decreased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to genotype CC.; 
;;HYKK;rs8034191;C;Other;increased  risk of Disease:Lung Neoplasms;Allele C is associated with increased risk of Lung Neoplasms in people with who have ever been smokers as compared to allele T.;in people with who have ever been smokers
;ISONIAZID, PHENYTOIN;NAT2;rs1041983;T;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain or Tuberculous meningitis NOS as compared to allele C.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;TACROLIMUS;TCF7L2;rs290487;CC + CT;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotypes CC + CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with liver transplantation as compared to genotype TT.;in people with Disease:Liver transplantation
;ACE INHIBITORS, PLAIN;AGT;rs699;GG;Efficacy;decreased risk of Disease:Stroke;Genotype GG is associated with decreased risk of Stroke when treated with Ace Inhibitors, Plain in people with Hypertension as compared to genotypes AA + AG.;in people with Disease:Hypertension
;GEMCITABINE;POLR2A;rs2228130;CC;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Genotype CC is associated with increased severity of Thrombocytopenia when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;VALPROIC ACID;CYP2C9;rs1057910;AC;Other, Metabolism/PK;increased   PK:mean plasma drug concentrations;Genotype AC is associated with increased mean plasma drug concentrations of valproic acid in people with Epilepsy as compared to genotype AA.;in people with Disease:Epilepsy
;CITALOPRAM;GRIA3;rs4825476;G;Toxicity;increased  risk of Side Effect:treatment-emergent suicidal ideation;Allele G is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression.;in people with Disease:Depression
;IMATINIB;SLC22A5;rs274558;AA + AG;Toxicity;decreased risk of Side Effect:Drug Toxicity, Side Effect:Eye Diseases;Genotypes AA + AG is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.;in people with Disease:Gastrointestinal Stromal Tumors
;ISONIAZID, PHENYTOIN;NAT2;rs1208;G;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele A.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;ANTIPSYCHOTICS;COMT;rs4818;CC + CG;Toxicity;increased  severity of Side Effect:Tardive Dyskinesia;Genotypes CC + CG is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG.;in people with Schizophrenia
;;CHRNA3;rs1051730;A;Other;increased  likelihood of Disease:Peripheral Vascular Diseases;Allele A is associated with increased likelihood of Peripheral Vascular Diseases in people with Tobacco Use Disorder as compared to allele G.;in people with Disease:Tobacco Use Disorder
;;CHRNA3;rs1051730;A;Other;increased  likelihood of Disease:Lung Neoplasms;Allele A is associated with increased likelihood of Lung Neoplasms in people with Tobacco Use Disorder as compared to allele G.;in people with Disease:Tobacco Use Disorder
;DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;Toxicity;increased  likelihood of Disease:Breast Neoplasms;Genotypes AA + AG are associated with increased likelihood of Breast Neoplasms when treated with dacarbazine and procarbazine in people with Hodgkin Disease as compared to genotype GG.;in people with Disease:Hodgkin Disease
;ISONIAZID, PHENYTOIN;NAT2;rs1799930;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;;CHRNA3;rs1051730;A;Other;increased   Other:number of cigarettes smoked per day;Allele A is associated with increased number of cigarettes smoked per day in people with Tobacco Use Disorder as compared to allele G.;in people with Disease:Tobacco Use Disorder
;ISONIAZID, PHENYTOIN;NAT2;rs1799929;T;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele C.;in people with Disease:Central nervous system tuberculosis, Disease:Meningeal Tuberculosis
;IMATINIB;ABCB1;rs2235040;CT;Toxicity;decreased risk of Side Effect:Drug Toxicity, Side Effect:Eye Diseases;Genotype CT is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.;in people with Disease:Gastrointestinal Stromal Tumors
;DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs2032582;AA + AC;Efficacy;increased   Efficacy:overall survival;Genotypes AA + AC are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype CC.;in people with Disease:Multiple Myeloma
;DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;Toxicity;increased  likelihood of Disease:Therapy-related acute myeloid leukemia (t-AML);Genotypes AA + AG are associated with increased likelihood of therapy-related acute myeloid leukemia (t-ML) when treated with dacarbazine and procarbazine in people with Hodgkin Disease as compared to genotype GG.;in people with Disease:Hodgkin Disease
;IMATINIB;EGFR;rs10258429;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity, Side Effect:Eye Diseases;Genotypes CT + TT is associated with increased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.;in people with Disease:Gastrointestinal Stromal Tumors
;ANTIPSYCHOTICS;COMT;rs165599;AG;Toxicity;increased  severity of Side Effect:Tardive Dyskinesia;Genotype AG is associated with increased severity of tardive dyskinesia when treated with antipsychotics in men with Schizophrenia as compared to genotype AA.;in men with Schizophrenia
;IMATINIB;SLC22A1;rs683369;CG + GG;Toxicity;increased  risk of Side Effect:Drug Toxicity, Side Effect:Eye Diseases;Genotypes CG + GG is associated with increased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.;in people with Disease:Gastrointestinal Stromal Tumors
;RISPERIDONE;CYP2D6;rs1065852;AA;Toxicity;increased  likelihood of Side Effect:Obesity;Genotype AA is associated with increased likelihood of Obesity when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AG + GG.;in children with Disease:Atypical behavior, Disease:Mental Disorders
;DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with daclatasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;rs6305;A;Other;increased  likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Allele A is associated with increased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele G.; 
;ASPIRIN;TBXA2R;rs4523;AA;Efficacy;increased  risk of Other:high on-aspirin residual platelet reactivity;Genotype AA is associated with increased risk of high on-aspirin residual platelet reactivity when treated with aspirin in people with off-pump coronary artery bypass grafting as compared to genotypes AG + GG.;in people with off-pump coronary artery bypass grafting
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;rs1611115;T;Other;decreased likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C.; 
;RISPERIDONE;DRD2;rs1799978;CT;Toxicity;increased  likelihood of Side Effect:Insulin Resistance;Genotype CT is associated with increased likelihood of Insulin Resistance when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT.;in children with Disease:Atypical behavior, Disease:Mental Disorders
;PACLITAXEL;ABCB1;rs2032582;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AC + CC.;in people with Disease:Neoplasms
;PACLITAXEL;ABCB1;rs1045642;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with paclitaxel in people with Neoplasms as compared to genotypes AG + GG.;in people with Disease:Neoplasms
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;rs1799971;G;Other;increased  likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Allele G is associated with increased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele A.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Chronic hepatitis C virus infection
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;rs6265;T;Other;decreased likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C.; 
;ANTIPSYCHOTICS;COMT;rs4680;AA;Toxicity;increased  severity of Side Effect:Tardive Dyskinesia;Genotype AA is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AG + GG.;in people with Schizophrenia
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Chronic hepatitis C virus infection
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;rs4680;AA;Other;decreased likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG.; 
;RISPERIDONE;CYP2D6;rs1065852;AA;Toxicity;increased  likelihood of Side Effect:Hypertension;Genotype AA is associated with increased likelihood of Hypertension when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotypes AG + GG.;in children with Disease:Atypical behavior, Disease:Mental Disorders
;TACROLIMUS;CAPN10;rs5030952;CT;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotype CT is associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;WARFARIN;CYP2C18;rs2901783;G;Dosage;Other:outcome time to stable dose;Allele G is associated with outcome time to stable dose of warfarin.; 
;IDARUBICIN;RAC2;rs13058338;AA;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotype AA is associated with decreased risk of Drug Toxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.;in people with Disease:Leukemia, Myeloid, Acute
;"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;rs6275;AA;Other;decreased likelihood of Disease:Headache Disorders, Disease:Substance Withdrawal Syndrome;Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG.; 
;IDARUBICIN;NCF4;rs1883112;AA;Toxicity;increased  risk of Side Effect:Cardiotoxicity;Genotype AA is associated with increased risk of cardiotoxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;OPIOIDS;OPRM1;rs9479757;AG;Other;decreased risk of Disease:Opioid-Related Disorders;Genotype AG is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype GG.; 
;TACROLIMUS;CYP3A5;rs776746;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype CC is associated with increased likelihood of Hemorrhage when treated with tacrolimus in people with liver transplantation.;in people with Liver transplantation
;PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;ITPA;rs1127354;AA + AC;Toxicity;decreased risk of Side Effect:Anemia;Genotypes AA + AC is associated with decreased risk of Anemia when treated with peginterferon alfa-2b, protease inhibitors and ribavirin in people with Hepatitis C as compared to genotype CC.;in people with Disease:Hepatitis C virus infection
;OPIOIDS;GAL;rs948854;CC;Other;increased  risk of Disease:Opioid-Related Disorders;Genotype CC is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype CT.; 
;OPIOIDS;ABCB1;rs1045642;GG;Other;decreased risk of Disease:Opioid-Related Disorders;Genotype GG is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to genotype AG.; 
;OPIOIDS;OPRD1;rs2236861;A;Other;decreased risk of Disease:Opioid-Related Disorders;Allele A is associated with decreased risk of Opioid-Related Disorders when exposed to opioids as compared to allele G.; 
;IDARUBICIN;CYBA;rs4673;AG + GG;Efficacy;increased   Efficacy:Overall survival;Genotypes AG + GG is associated with increased overall survival when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype AA.;in people with Disease:Leukemia, Myeloid, Acute
;HYDROCHLOROTHIAZIDE;NOS3;rs1799983;GG;Efficacy;increased   Efficacy:reduction in diastolic blood pressure;Genotype GG is associated with increased reduction in diastolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes GT + TT.;in people with Disease:Essential hypertension
;IDARUBICIN;CYBA;rs4673;AA + AG;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;PRAVASTATIN;CETP;rs708272;A;Efficacy;increased  risk of Disease:Death;Allele A is associated with increased risk of Death when treated with pravastatin in men with Coronary Artery Disease as compared to allele G.;in men with Disease:Coronary Artery Disease
;PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;SLC28A2;rs11854484;TT;Toxicity;increased  risk of Side Effect:Anemia;Genotype TT is associated with increased risk of Anemia when treated with peginterferon alfa-2b, protease inhibitors and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.;in people with Disease:Hepatitis C virus infection
;DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with daclatasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;DIURETICS;PDE4D;rs702553;TT;Efficacy;decreased  Efficacy:baseline mean arterial blood pressure;Genotype TT is associated with decreased baseline mean arterial blood pressure when treated with diuretics in people with Nephrosclerosis as compared to genotypes AA + AT.;in people with Disease:Nephrosclerosis
;CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2235040;T;Toxicity;increased  likelihood of Side Effect:adverse effects;Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.;in people with Disease:Major Depressive Disorder
;ESCITALOPRAM;KCNE1;rs1805127;C;Toxicity;increased  likelihood of Side Effect:Acquired Long QT Syndrome (aLQTS);Allele C is associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with escitalopram as compared to allele T.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:platelet inhibition;Allele A is associated with decreased platelet inhibition when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;ESCITALOPRAM;KCNE1;rs4817668;TT;Toxicity;increased  likelihood of Side Effect:Acquired Long QT Syndrome (aLQTS);Genotype TT is associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with escitalopram as compared to genotypes CC + CT.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Other:High Platelet Reactivity;Allele A is associated with increased risk of High Platelet Reactivity when treated with clopidogrel in people with coronary artery disease undergoing stent implantation as compared to allele G.;in people with coronary artery disease undergoing stent implantation
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs588765;T;Efficacy;Efficacy:increased  chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy);Allele T is associated with increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to allele C.; 
;;CHRNA3;rs1051730;A;Efficacy;Efficacy:decreased chance of achieving 6 month abstinence in the placebo group;Allele A is associated with decreased chance of achieving 6 month abstinence in the placebo group as compared to allele G.; 
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  risk of Side Effect:Pancytopenia, Side Effect:Thrombocytopenia;Allele T is associated with increased risk of Pancytopenia or Thrombocytopenia due to azathioprine or mercaptopurine in people with Autoimmune Diseases or Inflammatory Bowel Diseases as compared to allele C.;in people with Autoimmune Diseases, Inflammatory Bowel Diseases
;DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;rs1051730;A;Efficacy;Efficacy:increased  chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy);Allele A is associated with increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to allele G.; 
;CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2032583;G;Toxicity;increased  likelihood of Side Effect:adverse effects;Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;FLUOROURACIL;DPYD;rs1801159;CC;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Leukopenia;Genotype CC is associated with increased likelihood of Leukopenia when treated with fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;FLUOROURACIL;DPYD;rs1801159;CC;Toxicity, Metabolism/PK;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotype CC is associated with increased likelihood of Nausea and Vomiting when treated with fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs4148737;C;Efficacy;increased  risk of Efficacy:death;Allele C is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.;in people with Disease:Osteosarcoma
;CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;rs4148416;T;Efficacy;increased  risk of Efficacy:death;Allele T is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele C.;in people with Disease:Osteosarcoma
;;FOXO3;rs4946936;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival in children with Rhabdomyosarcoma as compared to genotypes CC + CT.;in children with Rhabdomyosarcoma
;NEVIRAPINE;ABCB1;rs1045642;A;Toxicity;decreased risk of Disease:Toxic liver disease;Allele A is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;;FOXO3;rs17069665;GG;Efficacy;decreased  Efficacy:Overall survival;Genotype GG is associated with decreased overall survival in children with Rhabdomyosarcoma as compared to genotypes AA + AG.;in children with Rhabdomyosarcoma
;;ARNT;rs3215133;T/del + del/del;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes T/del + del/del are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype TT.; 
;METHADONE;ARRB2;rs2036657;GG;Efficacy;increased  severity of Efficacy:Pain;Genotype GG is associated with increased severity of Pain when treated with methadone in people with Neoplasms as compared to genotypes AA + AG.;in people with Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs2032582;A;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;ETHANOL;GHSR;rs2232165;AG;Other;Other:heavy consumption;Genotype AG is associated with heavy consumption of ethanol.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs1045642;G;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs10276036;C;Efficacy;increased  risk of Efficacy:Overall survival;Allele C is associated with increased risk of overall survival when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele T.;in people with Disease:Osteosarcoma
;ANTIPSYCHOTICS;NEFM;rs1379357;G;Efficacy;Efficacy:response time;Allele G is associated with response time when treated with antipsychotics in people with Schizophrenia.;in people with Disease:Schizophrenia
;CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs1128503;G;Efficacy;increased  risk of Efficacy:death;Allele G is associated with increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate and vincristine in people with Osteosarcoma as compared to allele A.;in people with Disease:Osteosarcoma
;ANTIPSYCHOTICS;NEFM;rs1457266;G;Efficacy;Efficacy:response time;Allele G is associated with response time when treated with antipsychotics in people with Schizophrenia.;in people with Disease:Schizophrenia
;;ARNT;rs12410394;AA + AG;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes AA + AG are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype GG.; 
;CELECOXIB;IL23R;rs7518660;A;Toxicity;increased  risk of Disease:Adenoma;Allele A is associated with increased risk of Adenoma when treated with celecoxib in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;CELECOXIB;ALOX12;rs11078659;A;Toxicity;increased  risk of Disease:Adenoma;Allele A is associated with increased risk of Adenoma when treated with celecoxib in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;;CYP1A2;rs2470890;CT + TT;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes CT + TT are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype CC.; 
;;;rs11072508;CT + TT;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes CT + TT are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype CC.; 
;CELECOXIB;PTGES;rs2302821;C;Toxicity;increased  risk of Side Effect:cardiovascular toxicity and symptoms;Allele C is associated with increased risk of cardiovascular toxicity and symptoms when treated with celecoxib in people with Colorectal Neoplasms as compared to allele A.;in people with Disease:Colorectal Neoplasms
;;CSK;rs4886410;CG + GG;Other;decreased likelihood of Disease:Colorectal Neoplasms;Genotypes CG + GG are associated with decreased likelihood of Colorectal Neoplasms as compared to genotype CC.; 
;CELECOXIB;PTGER4;rs4133101;T;Toxicity;increased  risk of Side Effect:gastrointestinal toxicities;Allele T is associated with increased risk of gastrointestinal toxicities when treated with celecoxib in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;rs2228100;CC + CG;Toxicity;increased  likelihood of Disease:Cystitis;Genotypes CC + CG are associated with increased likelihood of Cystitis when treated with carboplatin, cyclophosphamide and thiotepa in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;TAMOXIFEN;ABCC2;rs3740065;AA;Efficacy, Metabolism/PK;increased  risk of Efficacy:recurrence of breast cancer;Genotype AA is associated with increased risk of recurrence of breast cancer when treated with tamoxifen in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;CAFFEINE;CYP1A2;rs762551;AA;Toxicity;increased  likelihood of Side Effect:Insomnia;Genotype AA is associated with increased likelihood of insomnia due to caffeine as compared to genotypes AC + CC.; 
;DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs1045642;GG;Efficacy;decreased  Efficacy:survival;Genotype GG is associated with decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to genotype AA.;in people with Disease:Multiple Myeloma
;FARGLITAZAR, INSULINS AND ANALOGUES;SCNN1B;rs34241435;A;Toxicity;Side Effect:oedema;Allele A is associated with oedema when treated with Farglitazar and Insulins And Analogues in people with Diabetes Mellitus, Type 2.;in people with Disease:Diabetes Mellitus, Type 2
;HYDROCHLOROTHIAZIDE;SCNN1G;rs5723;CC;Efficacy;decreased  Efficacy:reduction in office diastolic blood pressure;Genotype CC is associated with decreased reduction in office diastolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes CG + GG.;in people with Disease:Essential hypertension
;FARGLITAZAR, GLYBURIDE;SCNN1B;rs889299;A;Toxicity;Side Effect:oedema;Allele A is associated with oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to allele G.;in people with Disease:Diabetes Mellitus, Type 2
;HYDROCHLOROTHIAZIDE;SCNN1G;rs5729;TT;Efficacy;decreased  Efficacy:reduction in office diastolic blood pressure;Genotype TT is associated with decreased reduction in office diastolic blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes AA + AT.;in people with Disease:Essential hypertension
;GEFITINIB;IKBKE;rs12142086;CC;Toxicity;increased  risk of Side Effect:Exanthema;Genotype CC is associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Non-Small Cell Lung Carcinoma
;NICOTINE;CHRNA5;rs680244;C;Other;decreased likelihood of Other:abstinence;Allele C is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.;in people with Disease:Tobacco Use Disorder
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Mucositis, Side Effect:Oral Ulcer;Genotypes AA + AG is associated with increased likelihood of mucositis or Oral Ulcer when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;METHADONE;ARRB2;rs1045280;CC;Efficacy;increased  severity of Efficacy:Pain;Genotype CC is associated with increased severity of Pain when treated with methadone in people with Neoplasms as compared to genotypes CT + TT.;in people with Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CT;Efficacy;decreased  Efficacy:dose-adjusted tacrolimus blood concentration;Genotype CT is associated with decreased dose-adjusted tacrolimus blood concentration when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.;in people with Disease:Kidney Transplantation
;LORAZEPAM;UGT2B15;rs1902023;AA;Metabolism/PK;increased   PK:area under the visual analog scale-time curve during the induced state;Genotype AA is associated with increased area under the visual analog scale-time curve during the induced state when exposed to lorazepam as compared to genotype CC.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs3213619;G;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele G is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;rs9501929;C;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;Allele C is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;NALOXONE, OXYCODONE;COMT;rs4680;GG;Toxicity;increased  likelihood of Side Effect:Erythema;Genotype GG is associated with increased likelihood of Erythema when treated with naloxone and oxycodone in people with Pain as compared to genotypes AA + AG.;in people with Pain
;TACROLIMUS;CYP3A4;rs2740574;CT;Metabolism/PK;decreased  PK:dose-adjusted tacrolimus blood concentrations;Genotype CT is associated with decreased dose-adjusted tacrolimus blood concentrations when treated with tacrolimus in people with Kidney Transplantation as compared to genotype TT.;in people with Disease:Kidney Transplantation
;NICOTINE;CHRNA5;rs16969968;A;Other;decreased likelihood of Other:abstinence;Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder.;in people with Disease:Tobacco Use Disorder
;METHADONE;ARRB2;rs3786047;AA;Efficacy;increased  severity of Efficacy:Pain;Genotype AA is associated with increased severity of Pain when treated with methadone in people with Neoplasms as compared to genotypes AG + GG.;in people with Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Elevated liver enzymes;Genotypes AA + AG is associated with increased likelihood of elevated liver enzymes when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;BISOPROLOL;CYP3A5;rs776746;TT;Efficacy;increased  severity of Efficacy:Elevated systolic blood pressure, Efficacy:Elevated diastolic blood pressure;Genotype TT is associated with increased severity of Elevated systolic blood pressure and Elevated diastolic blood pressure when treated with bisoprolol in people with Acute coronary syndrome as compared to genotypes CC + CT.;in people with Acute coronary syndrome
;NALOXONE, OXYCODONE;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:Erythema;Genotype AA is associated with increased likelihood of Erythema when treated with naloxone and oxycodone in people with Pain as compared to genotypes AG + GG.;in people with Pain
;PAZOPANIB;VEGFA;rs2010963;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes CG + GG.;in people with Disease:Renal Cell Carcinoma
;HYDROCHLOROTHIAZIDE;WNK1;rs1159744;GG;Efficacy;increased   Efficacy:reduction in whole day ambulatory blood pressure;Genotype GG is associated with increased reduction in whole day ambulatory blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype CC.;in people with Disease:Essential hypertension
;TAMOXIFEN;CYP2C19;rs12248560;T;Efficacy;increased   Efficacy:event-free survival;Allele T is associated with increased event-free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.;in people with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotype TT is associated with decreased risk of Toxic liver disease when treated with cyclophosphamide in people with Lupus Nephritis as compared to genotypes GG + GT.;in people with Lupus Nephritis
;;SLC22A3;rs2504938;TT;Efficacy;decreased  Efficacy:Overall survival;Genotype TT is associated with decreased overall survival in people with Pancreatic Neoplasms as compared to genotype CC.;in people with Disease:Pancreatic Neoplasms
;NALOXONE, OXYCODONE;COMT;rs4680;AA;Toxicity;increased  likelihood of Side Effect:Vomiting;Genotype AA is associated with increased likelihood of Vomiting when treated with naloxone and oxycodone in people with Pain as compared to genotypes AG + GG.;in people with Pain
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT;Toxicity;increased  risk of Side Effect:Diarrhea;Genotype GT is associated with increased risk of Diarrhea when treated with cyclophosphamide in people with Lupus Nephritis as compared to genotypes GG + TT.;in people with Lupus Nephritis
;FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC + CG;Toxicity, Metabolism/PK;Disease:Diarrhea;Genotypes CC + CG are associated with Diarrhea when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotype GG.;in people with Disease:Adenocarcinoma
;FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC;Toxicity, Metabolism/PK;increased  likelihood of Disease:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with fluorouracil and leucovorin in people with Adenocarcinoma as compared to genotypes CG + GG.;in people with Disease:Adenocarcinoma
;BUPRENORPHINE, METHADONE;COMT;rs4680;AG + GG;Efficacy;decreased severity of Efficacy:Pain;Genotypes AG + GG is associated with decreased severity of Pain when treated with buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotype AA.;in people with Opioid-Related Disorders
;CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;Toxicity;increased  severity of Disease:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;;SLC22A3;rs512077;AA;Efficacy;increased   Efficacy:Overall survival;Genotype AA is associated with increased overall survival in people with Pancreatic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Pancreatic Neoplasms
;BUPRENORPHINE, METHADONE;OPRM1;rs1799971;AG + GG;Efficacy;decreased severity of Efficacy:Pain;Genotypes AG + GG is associated with decreased severity of Pain when treated with buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotype AA.;in people with Opioid-Related Disorders
;CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC + CT;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotypes CC + CT are associated with increased severity of Drug Toxicity when treated with capecitabine or fluorouracil in people with Breast Neoplasms and gastroesophageal cancer as compared to genotype TT.;in people with Disease:Breast Neoplasms, Disease:Gastroesophageal Cancer
;GLUCARPIDASE;ABCC4;rs7317112;AG + GG;Toxicity;increased  risk of Other:Nephrotoxicity;Genotypes AG + GG are associated with increased risk of nephrotoxicity requiring treatment with Glucarpidase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;HYDROCHLOROTHIAZIDE;ADRB2;rs2400707;AA + AG;Efficacy;increased   Efficacy:reduction in whole day ambulatory blood pressure;Genotypes AA + AG are associated with increased reduction in whole day ambulatory blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG.;in people with Disease:Essential hypertension
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype TT are associated with increased risk of Drug Toxicity when treated with cyclophosphamide in people with Lupus Nephritis as compared to genotype GG.;in people with Lupus Nephritis
;NICOTINE;CHRNA5;rs16969968;GG;Other;increased   Other:functional MRI reactivity to smoking images;Genotype GG is associated with increased functional MRI reactivity to smoking images due to nicotine in women with nicotine dependence as compared to genotypes AA + AG.;in women with nicotine dependence
;HYDROCHLOROTHIAZIDE;WNK1;rs1159744;CC;Other;increased   Side Effect:urinary potassium excretion;Genotype CC is associated with increased urinary potassium excretion when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes CG + GG.;in people with Disease:Essential hypertension
;HEROIN;DRD2;rs1076560;A;Toxicity;increased  likelihood of Disease:Heroin Dependence;Allele A is associated with increased likelihood of Heroin Dependence due to heroin as compared to allele C.; 
;SUFENTANIL;ABCB1;rs1128503;GG;Efficacy;decreased severity of Efficacy:Pain, Postoperative;Genotype GG is associated with decreased severity of Pain, Postoperative when treated with sufentanil in people with Surgical procedure and Bone Fracture as compared to genotypes AA + AG.;"in people with ""surgery"", ""Fractures, Bone"""
;HYDROCHLOROTHIAZIDE;WNK1;rs2107614;CC + CT;Efficacy;increased   Efficacy:reduction in whole day ambulatory blood pressure;Genotypes CC + CT are associated with increased reduction in whole day ambulatory blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype TT.;in people with Disease:Essential hypertension
;HYDROCHLOROTHIAZIDE;RAD52, WNK1;rs2277869;CC;Efficacy;increased   Efficacy:reduction in whole day ambulatory blood pressure;Genotype CC is associated with increased reduction in whole day ambulatory blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes CT + TT.;in people with Disease:Essential hypertension
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;rs1799782;AA + AG;Toxicity;increased  likelihood of Side Effect:Myelosuppression;Genotypes AA + AG is associated with increased likelihood of Myelosuppression when treated with asparaginase, cyclophosphamide, cytarabine, doxorubicin, mercaptopurine, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;METFORMIN;SLC47A2;rs34399035;T;Metabolism/PK;decreased  PK:metformin uptake in HEK-293 cells and reduction in protein expression levels;Allele T is associated with decreased metformin uptake in HEK-293 cells and reduction in protein expression levels when exposed to metformin as compared to allele C.; 
;OXALIPLATIN;ABCB1;rs1128503;AA;Efficacy;increased   Efficacy:overall survival;Genotype AA is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;Toxicity;increased  likelihood of Side Effect:Hypertension, Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of Hypertension or Hand-foot syndrome when treated with anlotinib, apatinib, axitinib, bevacizumab, sorafenib or sunitinib in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma or Neoplasms as compared to allele T.;in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Neoplasms
;CYTARABINE, IDARUBICIN;CBR3;rs8133052;GG;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotype GG is associated with decreased risk of Toxic liver disease when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype AA.;in people with Leukemia, Myeloid, Acute
;WARFARIN;;rs16871327;T;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele T is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele A.; 
;WARFARIN;EPHA7;rs78132896;C;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele C is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele T.; 
;FENOFIBRATE;FABP1;rs2241883;CC + CT;Toxicity;increased  risk of Disease:Hypertriglyceridemia;Genotypes CC + CT are associated with increased risk of Hypertriglyceridemia when treated with fenofibrate in people with Hypertriglyceridemia as compared to genotype TT.;in people with Disease:Hypertriglyceridemia
;ANTIPSYCHOTICS;SNAP25;rs1051312;TT;Toxicity;decreased likelihood of Side Effect:Weight gain;Genotype TT is associated with decreased likelihood of Weight gain when treated with antipsychotics as compared to genotypes CC + CT.; 
;GEFITINIB;TAB2;rs577001;CT + TT;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes CT + TT are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Non-Small Cell Lung Carcinoma
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFIT1;rs304478;TT;Efficacy;increased   Efficacy:SVR (sustained virological response);Genotype TT is associated with increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT.;in people with Disease:Hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;OASL;rs12819210;T;Efficacy;increased   Efficacy:Sustained virological response (SVR);Allele T is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CC + CT.;in people with Disease:Hepatitis C virus infection
;OXALIPLATIN;ABCB1;rs1045642;AG;Efficacy;increased   Efficacy:recurrence-free survival;Genotype AG is associated with increased recurrence-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes CT + TT.;in people with Disease:Hepatitis C virus infection
;PAZOPANIB;VEGFA;rs833061;TT;Efficacy;increased   Efficacy:Progression-free survival;Genotype TT is associated with increased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;COCAINE;SLC6A3;rs6347;TT;Toxicity;increased  risk of Disease:Death;Genotype TT is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to genotypes CC + CT.;in people with Disease:Cocaine dependence
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate (RR);Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.;in people with Disease:Adenocarcinoma
;ATORVASTATIN;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotype AA is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to genotypes AG + GG.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs8187710;A;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:progression-free survival (PFS) time;Allele G is associated with increased progression-free survival (PFS) time when treated with gefitinib in people with Adenocarcinoma as compared to allele T.;in people with Disease:Adenocarcinoma
;COCAINE;DRD2;rs1076560;A;Toxicity;increased  risk of Disease:Death;Allele A is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to allele C.;in people with Disease:Cocaine dependence
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal Hemorrhage;Genotypes CT + TT is associated with increased likelihood of Gastrointestinal Hemorrhage when treated with Antiinflammatory agents, non-steroids as compared to genotype CC.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs17222723;A;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele A is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;rs1056836;C;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele C is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Allele A is associated with increased likelihood of Progression-free survival when treated with anlotinib, apatinib, axitinib, bevacizumab, sorafenib or sunitinib in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma or Neoplasms as compared to allele T.;in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Neoplasms
;GEFITINIB;EGFR;rs121434568;G;Efficacy;increased   Efficacy:response rate (RR);Allele G is associated with increased response rate (RR) when treated with gefitinib in people with Adenocarcinoma as compared to allele T.;in people with Disease:Adenocarcinoma
;GEFITINIB;NFKBIA;rs2233407;AA + AT;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotypes AA + AT are associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;rs6473187;G;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;Allele G is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;GEFITINIB;NR1H2;rs2695121;CT + TT;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes CT + TT are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;rs3829306;T;Toxicity;decreased likelihood of Disease:Peripheral Nervous System Diseases;Allele T is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;SUNITINIB;VEGFA;rs2010963;CG + GG;Efficacy;increased   Efficacy:Progression-free survival;Genotypes CG + GG is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;rs301927;G;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;Allele G is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;WARFARIN;;rs115112393;G;Toxicity;increased  risk of Side Effect:Hemorrhage;Allele G is associated with increased risk of Hemorrhage when treated with warfarin as compared to allele A.; 
;ANTIPSYCHOTICS;HTR2C;rs6318;GG;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype GG is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele C.; 
;ANTIPSYCHOTICS;HTR2C;rs3813929;CC;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype CC is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele T.; 
;ANTIPSYCHOTICS;HTR2C;rs518147;GG;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype GG is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele C.; 
;ATORVASTATIN;ABCB1;rs2032582;AA;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Genotype AA is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to genotypes AC + CC.; 
;COCAINE;DRD2;rs2283265;A;Toxicity;increased  risk of Disease:Death;Allele A is associated with increased risk of Death due to cocaine in people with Cocaine-Related Disorders as compared to allele C.;in people with Disease:Cocaine dependence
;ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2305948;CT + TT;Efficacy;decreased likelihood of Efficacy:Overall survival;Genotypes CT + TT is associated with decreased likelihood of overall survival when treated with anlotinib, apatinib, axitinib, bevacizumab, sorafenib or sunitinib in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma or Neoplasms as compared to genotype CC.;in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Neoplasms
;ANTIPSYCHOTICS;DRD2;rs6275;A;Toxicity;increased  likelihood of Side Effect:Weight gain;Allele A is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele G.; 
;ANTIPSYCHOTICS;DRD2;rs7131056;CC;Toxicity;decreased likelihood of Side Effect:Weight gain;Genotype CC is associated with decreased likelihood of Weight gain when treated with antipsychotics as compared to genotypes AA + AC.; 
;ANTIPSYCHOTICS;INSIG2;rs17047764;C;Toxicity;increased  likelihood of Side Effect:Weight gain;Allele C is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele G.; 
;ANTIPSYCHOTICS;GNB3;rs5443;TT;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype TT is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to genotypes CC + CT.; 
;ANTIPSYCHOTICS;MC4R;rs489693;AA;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype AA is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to genotypes AC + CC.; 
;TIANEPTINE;OPRM1;rs1799971;AA;Toxicity;increased  risk of Other:suicidal ideation;Genotype AA is associated with increased risk of suicidal ideation due to tianeptine in people with Depressive Disorder, Major as compared to genotypes AG + GG.;in people with Major Depressive Disorder
;ATORVASTATIN;ABCB1;rs1128503;A;Toxicity;increased  likelihood of Side Effect:statin-related myopathy;Allele A is associated with increased likelihood of statin-related myopathy when exposed to atorvastatin as compared to allele G.; 
;ANTIPSYCHOTICS;BDNF, BDNF-AS;rs6265;CC;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype CC is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to genotypes CT + TT.; 
;ANTIPSYCHOTICS;ADRA2A;rs1800544;G;Toxicity;increased  likelihood of Side Effect:Weight gain;Allele G is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele C.; 
;ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2071559;G;Efficacy;decreased likelihood of Efficacy:Progression-free survival;Allele G is associated with decreased likelihood of Progression-free survival when treated with anlotinib, apatinib, axitinib, bevacizumab, sorafenib or sunitinib in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma or Neoplasms as compared to allele A.;in people with Colorectal Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Osteosarcoma, Neoplasms
;THEOPHYLLINE;CYP1A2;rs2069514;GG;Metabolism/PK;increased   PK:ratio of 1,3 DMU/theophylline;Genotype GG is associated with increased ratio of 1,3 DMU/theophylline when treated with theophylline in people with Asthma as compared to genotypes AA + AG.;in people with Disease:Asthma
;ANTIPSYCHOTICS;DRD2;rs1799732;del;Toxicity;increased  likelihood of Side Effect:Weight gain;Allele del is associated with increased likelihood of Weight gain when treated with antipsychotics as compared to allele G.; 
;GEFITINIB;NFKBIA;rs2233409;AG + GG;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;GEFITINIB;NFKBIA;rs8904;AG + GG;Toxicity;increased  risk of Side Effect:Exanthema;Genotypes AG + GG are associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased  risk of Efficacy:clopidogrel resistance;Allele A is associated with increased risk of clopidogrel resistance when treated with clopidogrel in patients who underwent successful percutaneous coronary intervention as compared to allele G.;in patients who underwent successful percutaneous coronary intervention
;GEFITINIB;NFKBIB;rs2053071;CC;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotype CC is associated with decreased risk of Toxic liver disease due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CG + GG.;in people with Non-Small Cell Lung Carcinoma
;LEVODOPA;DRD3;rs6280;CT + TT;Toxicity;increased  likelihood of Side Effect:Hallucinations;Genotypes CT + TT are associated with increased likelihood of Hallucinations due to levodopa in people with Parkinson Disease as compared to genotype CC.;in people with Parkinson Disease
;GEFITINIB;NFKBIA;rs2233406;AG + GG;Toxicity;decreased risk of Side Effect:Diarrhea;Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;ITGB3;rs5918;C;Efficacy;Efficacy:less decrease in the platelet reactivity after 600 mg of clopidogrel;Allele C is associated with less decrease in the platelet reactivity after 600 mg of clopidogrel when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype TT.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;ITGB3;rs5918;CT;Efficacy;decreased  Efficacy:antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention;Genotype CT is associated with decreased antiplatelet effect to a 300 mg clopidogrel loading-dose up to 24 h following intervention when treated with clopidogrel in patients undergoing coronary stent implantation as compared to genotype TT.;in patients undergoing coronary stent implantation
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2070673;A;Toxicity;decreased likelihood of Disease:Toxic liver disease;Allele A is associated with decreased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.;in people with Disease:Leukemia, Myeloid, Acute
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2515641;T;Toxicity;decreased likelihood of Disease:Toxic liver disease;Allele T is associated with decreased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.;in people with Disease:Leukemia, Myeloid, Acute
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLCO1B1;rs4149056;C;Toxicity;increased  likelihood of Disease:Toxic liver disease;Allele C is associated with increased likelihood of Toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele T.;in people with Disease:Leukemia, Myeloid, Acute
;PERINDOPRIL;AGTR1;rs275651;TT;Efficacy;decreased risk of Efficacy:cardiac events;Genotype TT is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes AA + AT.;in people with Disease:Coronary Artery Disease
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SULT2B1;rs2302948;T;Toxicity;decreased likelihood of Disease:Fever;Allele T is associated with decreased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.;in people with Disease:Leukemia, Myeloid, Acute
;ESCITALOPRAM;KCNH2;rs3807372;AA;Toxicity;increased  likelihood of Side Effect:Acquired Long QT Syndrome (aLQTS);Genotype AA is associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with escitalopram as compared to genotypes AG + GG.; 
;HEROIN;OPRM1;rs1799971;AA + AG;Other;decreased likelihood of Other:addiction;Genotypes AA + AG are associated with decreased likelihood of addiction due to heroin as compared to genotype GG.; 
;GEFITINIB;IKBKB;rs9694958;AA;Toxicity;increased  risk of Side Effect:Exanthema;Genotype AA is associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Non-Small Cell Lung Carcinoma
;CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLC22A12;rs11231825;TT;Toxicity;increased  likelihood of Disease:Fever;Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT.;in people with Disease:Leukemia, Myeloid, Acute
;GEFITINIB;IKBKE;rs3748022;CC + CT;Toxicity;increased  risk of Side Effect:Exanthema;Genotypes CC + CT are associated with increased risk of Exanthema due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Non-Small Cell Lung Carcinoma
;ASPIRIN;FSIP1;rs7179742;G;Toxicity;increased  risk of Side Effect:aspirin-intolerant asthma;Allele G is associated with increased risk of aspirin-intolerant asthma when treated with aspirin in people with Asthma as compared to allele A.;in people with Disease:Asthma
;ASPIRIN;PTGS1;rs10306114;G;Efficacy;increased  risk of Efficacy:non-response to aspirin;Allele G is associated with increased risk of non-response to aspirin when treated with aspirin in people with Coronary Artery Disease as compared to genotype AA.;in people with Disease:Coronary Artery Disease
;DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;rs4430924;AA;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotypes AG + GG.;in people with Tuberculosis
;ASPIRIN;CEP68;rs7572857;AA + AG;Toxicity;increased  risk of Side Effect:aspirin-intolerant asthma;Genotypes AA + AG are associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype GG.;in people with Disease:Asthma
;CYCLOSPORINE, MYCOPHENOLATE MOFETIL;ABCB1;rs2032582;A;Efficacy;increased  risk of Disease:Transplant rejection;Allele A is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;PAROXETINE;HTR2A;rs6311;CC;Toxicity;increased  severity of Side Effect:Nausea;Genotype CC is associated with increased severity of Nausea when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Major Depressive Disorder
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs10945919;G;Efficacy;increased  risk of Efficacy:non-response;Allele G is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.;in people with Disease:Rheumatoid arthritis
;AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;rs5030655;A/DELA;Toxicity;increased  risk of Side Effect:extrapyramidal symptoms;Genotype A/DELA is associated with increased risk of extrapyramidal symptoms when treated with amisulpride, clozapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone or zuclopenthixol in people with Schizophrenia, Bipolar Disorder, Personality Disorders, Psychotic Disorders or Obsessive-Compulsive Disorder as compared to genotype AA.;in people with Schizophrenia, Bipolar Disorder, Personality Disorder, Psychotic Disorder, Obsessive-Compulsive Disorder
;DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;rs7853758;AA + AG;Toxicity;increased  likelihood of Side Effect:Left Ventricular Dysfunction;Genotypes AA + AG is associated with increased likelihood of Ventricular Dysfunction, Left when treated with daunorubicin, doxorubicin or epirubicin in children with Neoplasms as compared to genotype GG.;in children with Neoplasms
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;AA;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype AA is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;AG;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype AG is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;AC + CC;Efficacy;increased   Disease:Progression-free survival;Genotypes AC + CC is associated with increased progression-free survival when treated with cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;TT;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype TT is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype CC.;in people with Disease:Tuberculosis
;CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;rs351855;GG;Efficacy;increased  likelihood of Other:Disease Free Survival;Genotype GG is associated with increased likelihood of Disease Free Survival when treated with cyclophosphamide, fluorouracil and methotrexate in women with Breast Neoplasms as compared to genotypes AA + AG.;in women with Disease:Breast Neoplasms
;TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;Efficacy;increased  risk of Efficacy:non-response;Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;CLOPIDOGREL;CES1;rs71647871;CT;Metabolism/PK;increased   PK:levels of clopidogrel active metabolite;Genotype CT is associated with increased levels of clopidogrel active metabolite when treated with clopidogrel in healthy individuals as compared to genotype CC.;in healthy individuals 
;CLOPIDOGREL;CES1;rs71647871;CT;Efficacy;decreased  Efficacy: on-treatment ADP-induced platelet aggregation;Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype CC.;in healthy individuals 
;CLOPIDOGREL;CES1;rs71647871;CT;Efficacy;decreased  Efficacy:on-treatment ADP-induced platelet aggregation;Genotype CT is associated with decreased on-treatment ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.;in people with Disease:Coronary Disease
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;decreased  PK:Cmax of the active metabolite;Allele A is associated with decreased Cmax of the active metabolite when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  PK:Cmax of the active metabolite;Allele A is associated with decreased Cmax of the active metabolite when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;CARBOPLATIN, PEMETREXED;MTHFR;rs1801133;AA;Efficacy;increased   Efficacy:Progression-free survival;Genotype AA is associated with increased progression-free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;VEMURAFENIB;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with vemurafenib in people with Melanoma as compared to genotypes AG + GG.;in people with Melanoma
;VEMURAFENIB;CYP3A4;rs35599367;AA + AG;Toxicity;"increased  likelihood of ""Side Effect:Carcinoma, Squamous Cell"", ""Side Effect:Hyperbilirubinemia"", ""Side Effect:Nausea""";Genotypes AA + AG is associated with increased likelihood of Carcinoma, Squamous Cell, Hyperbilirubinemia or Nausea when treated with vemurafenib in people with Melanoma as compared to genotype GG.;in people with Melanoma
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:platelet reactivity index (PRI) at 4 h after the dosing;Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs7997012;AA;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with citalopram, escitalopram, fluoxetine, paroxetine or sertraline as compared to genotypes AG + GG.; 
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased   Efficacy:platelet reactivity index (PRI) at 4 h after the dosing;Allele A is associated with increased platelet reactivity index (PRI) at 4 h after the dosing when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;WARFARIN;VKORC1;rs9923231;TT;Efficacy;decreased  Efficacy:time to therapeutic inr;Genotype TT is associated with decreased time to therapeutic inr when treated with warfarin as compared to genotypes CC + CT.; 
;FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;rs861539;GG;Efficacy;decreased  Efficacy:progression free survival;Genotype GG is associated with decreased progression free survival when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Colorectal Neoplasms
;TACROLIMUS;CYP3A5;rs776746;TT;Dosage, Metabolism/PK;PK:risk of being underdosed;Genotype TT is associated with risk of being underdosed when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;OPIOIDS;SLC18A2;rs363332;A;Other;increased  likelihood of Side Effect:Opioid-Related Disorders;Allele A is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids as compared to allele G.; 
;OPIOIDS;SLC18A2;rs363334;G;Other;increased  likelihood of Side Effect:Opioid-Related Disorders;Allele G is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids.; 
;OPIOIDS;SLC18A2;rs363338;C;Other;increased  likelihood of Side Effect:Opioid-Related Disorders;Allele C is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids as compared to allele T.; 
;CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;rs8110536;G;Toxicity;increased  likelihood of Disease:Peripheral Nervous System Diseases;Allele G is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;Efficacy;Efficacy:higher P2Y12 reaction units (PRU) and lower percent inhibition;Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.;in people with Disease:Cerebrovascular Disorders
;PACLITAXEL;EPHA5;rs7349683;TT;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms or Ovarian Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms, Disease:Ovarian Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:non-response to clopidogrel;Allele A is associated with increased risk of non-response to clopidogrel when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;SUNITINIB;VEGFA;rs699947;AA + AC;Efficacy;increased   Efficacy:Progression-free survival;Genotypes AA + AC is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype CC.;in people with Disease:Renal Cell Carcinoma
;PAZOPANIB;VEGFA;rs699947;CC;Efficacy;increased   Efficacy:Progression-free survival;Genotype CC is associated with increased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotypes AA + AC.;in people with Disease:Renal Cell Carcinoma
;CYTARABINE, IDARUBICIN;NQO2;rs1143684;CC;Toxicity;increased  risk of Side Effect:Gastrointestinal toxicity;Genotype CC is associated with increased risk of gastrointestinal toxicity when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype TT.;in people with Leukemia, Myeloid, Acute
;PACLITAXEL;EPHA6;rs301927;G;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Allele G is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms and Ovarian Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms, Disease:Ovarian Neoplasms
;TACROLIMUS;CYP3A5;rs776746;CC;Toxicity;increased  risk of Disease:Hyperlipidemias;Genotype CC is associated with increased risk of Hyperlipidemias when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Disease:Kidney Transplantation
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;increased  risk of Efficacy:non-response to clopidogrel;Allele A is associated with increased risk of non-response to clopidogrel when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;WARFARIN;VEGFA;rs35410204;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype CC is associated with increased likelihood of Hemorrhage when treated with warfarin in people with Heart valve replacement as compared to genotypes CT + TT.;in people with Heart valve replacement
;PACLITAXEL;EPHA8;rs209709;G;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Allele G is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms and Ovarian Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms, Disease:Ovarian Neoplasms
;URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype TT is associated with increased likelihood of adverse events when treated with ursodeoxycholic acid in people with Cholangitis as compared to genotype CC.;in people with Cholangitis
;GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;rs1944294;AT + TT;Toxicity;decreased  Side Effect:bone density;Genotypes AT + TT is associated with decreased bone density when exposed to glucocorticoids, methotrexate and radiotherapy in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.;in children with Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:platelet reactivity;Allele A is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG;Toxicity;decreased risk of Disease:Lymphopenia;Genotype AG is associated with decreased risk of Lymphopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype AA.;in people with Disease:Kidney Transplantation
;PACLITAXEL;EPHA5;rs7349683;TT;Toxicity;decreased risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;Efficacy:higher P2Y12 reaction units (PRU) and lower percent inhibition;Genotypes AA + AG are associated with higher P2Y12 reaction units (PRU) and lower percent inhibition when treated with clopidogrel in people with Cerebrovascular Disorders as compared to genotype GG.;in people with Disease:Cerebrovascular Disorders
;CYTARABINE, IDARUBICIN;NQO1;rs1800566;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Leukemia, Myeloid, Acute
;WARFARIN;VEGFA;rs866236;AA;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype AA is associated with increased likelihood of Hemorrhage when treated with warfarin in people with Heart valve replacement as compared to genotypes AG + GG.;in people with Heart valve replacement
;PACLITAXEL;ABCG1;rs492338;AA;Toxicity;increased  risk of Disease:Peripheral Nervous System Diseases;Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;CISPLATIN;AQP1;rs1049305;CC + CG;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes CC + CG are associated with increased risk of Leukopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.;in people with Mesothelioma
;OXALIPLATIN;ABCB1;rs1128503;AG;Efficacy;increased   Efficacy:overall survival;Genotype AG is associated with increased overall survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;PACLITAXEL;EPHA6;rs301927;AA;Toxicity;decreased risk of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;;SULT1A1;rs1042028;T;Other;increased  likelihood of Disease:Breast Neoplasms;Allele T is associated with increased likelihood of Breast Neoplasms as compared to allele C.; 
;;SULT1A1;rs1042028;T;Other;increased  likelihood of Disease:Lung Neoplasms;Allele T is associated with increased likelihood of Lung Neoplasms.; 
;;SULT1A1;rs1042028;T;Other;increased  likelihood of Other:lymph node metastasis;Allele T is associated with increased likelihood of lymph node metastasis in people with Breast Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AG;Efficacy;decreased  Efficacy:platelet responsiveness to clopidogrel;Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;Toxicity;increased  risk of Side Effect:Side Effects;Genotype TT is associated with increased risk of Side Effects when treated with amitriptyline, clomipramine, doxepin, imipramine, maprotiline, nortriptyline or opipramol in people with Depression as compared to genotype CC.;in people with Disease:Depression
;CALCIUM;VDR;rs731236;G;Efficacy;increased  risk of Disease:Fractures, Bone;Allele G is associated with increased risk of Fractures, Bone when treated with calcium.; 
;;SULT1A1;rs1042028;T;Other;decreased likelihood of Disease:Urologic Neoplasms;Allele T is associated with decreased likelihood of Urologic Neoplasms.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AG;Efficacy;decreased  Efficacy:platelet responsiveness to clopidogrel;Genotype AG is associated with decreased platelet responsiveness to clopidogrel when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;;SULT1A1;rs1042028;T;Other;increased  likelihood of Disease:Breast Neoplasms;Allele T is associated with increased likelihood of Breast Neoplasms.; 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235040;T;Efficacy;increased  likelihood of Efficacy:remission;Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs12720067;T;Efficacy;increased  likelihood of Efficacy:remission;Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;ASPIRIN, CLOPIDOGREL;IRS1;rs13431554;AG + GG;Efficacy;increased   Efficacy:platelet reactivity;Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to genotype AA.;"in people with ""Disease:Coronary Artery Disease"", ""Disease:Diabetes Mellitus, Type 2"""
;DOCETAXEL;VAC14;rs875858;T;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with docetaxel in men with Prostatic Neoplasms as compared to allele C.;in men with Disease:Prostatic Neoplasms
;CLOPIDOGREL;CYP3A4;rs2242480;CT + TT;Efficacy;Efficacy:reduced GP IIb/IIIa activation and lower platelet activation;Genotypes CT + TT are associated with reduced GP IIb/IIIa activation and lower platelet activation when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Disease:Coronary Artery Disease
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10280101;C;Efficacy;increased  likelihood of Efficacy:remission;Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.;in people with Disease:Depression
;DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;FGG;rs1800792;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype CC is associated with increased likelihood of Hemorrhage when treated with Direct factor Xa inhibitors null Direct thrombin inhibitors as compared to genotypes CT + TT.; 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs7787082;A;Efficacy;increased  likelihood of Efficacy:remission;Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.;in people with Disease:Depression
;OPIOIDS;COMT;rs6269;AG + GG;Other;increased  likelihood of Other:requiring postoperative intervention;Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA.;in children with adenotonsillectomy
;FLUINDIONE;VKORC1;rs9934438;AA;Efficacy;decreased  Efficacy:the time to achieve a first INR within the therapeutic range;Genotype AA is associated with decreased the time to achieve a first INR within the therapeutic range when exposed to fluindione in people with venous thromboembolism as compared to genotype GG.;in people with Disease:Venous thromboembolism
;FLUINDIONE;VKORC1;rs9934438;AA;Efficacy;decreased  Efficacy:the time to achieve a first INR within the therapeutic range;Genotype AA is associated with decreased the time to achieve a first INR within the therapeutic range when exposed to fluindione in people with venous thromboembolism as compared to genotype AG.;in people with Disease:Venous thromboembolism
;OSIMERTINIB;EGFR;rs121434569;T;Efficacy;increased  likelihood of Efficacy:Progression-free survival, Efficacy:Overall survival;Allele T is associated with increased likelihood of progression-free survival or overall survival when treated with osimertinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148739;C;Efficacy;increased  likelihood of Efficacy:remission;Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.;in people with Disease:Depression
;FLUINDIONE;VKORC1;rs9934438;AA;Efficacy;Efficacy:shorter time to have over-anticoagulation (INR >4) risk;Genotype AA is associated with shorter time to have over-anticoagulation (INR >4) risk when exposed to fluindione in people with venous thromboembolism as compared to genotype GG.;in people with Disease:Venous thromboembolism
;OPIOIDS;COMT;rs4680;AG + GG;Other;increased  likelihood of Other:requiring postoperative intervention;Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA.;in children with adenotonsillectomy
;ETHANOL;ADH1B;rs1229984;TT;Metabolism/PK;increased   PK:Vmax;Genotype TT is associated with increased Vmax of ethanol in healthy individuals as compared to genotypes CC + CT.;in healthy individuals 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs11983225;C;Efficacy;increased  likelihood of Efficacy:remission;Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.;in people with Disease:Depression
;FLUINDIONE;VKORC1;rs9934438;AA;Efficacy;Efficacy:shorter time to have over-anticoagulation (INR >4) risk;Genotype AA is associated with shorter time to have over-anticoagulation (INR >4) risk when exposed to fluindione in people with venous thromboembolism as compared to genotype AG.;in people with Disease:Venous thromboembolism
;OPIOIDS;COMT;rs4818;CG + GG;Other;increased  likelihood of Other:requiring postoperative intervention;Genotypes CG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype CC.;in children with adenotonsillectomy
;FLUINDIONE;VKORC1;rs9934438;AA;Efficacy;decreased  Efficacy:average daily dose during the first period of stability;Genotype AA is associated with decreased average daily dose during the first period of stability when exposed to fluindione in people with venous thromboembolism as compared to genotype GG.;in people with Disease:Venous thromboembolism
;OPIOIDS;COMT;rs4633;CC + CT;Other;increased  likelihood of Other:requiring postoperative intervention;Genotypes CC + CT is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype TT.;in children with adenotonsillectomy
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10248420;G;Efficacy;increased  likelihood of Efficacy:remission;Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.;in people with Disease:Depression
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;A;Toxicity, Metabolism/PK;increased  risk of Side Effect:Toxic liver disease;Allele A is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to allele G.;in people with Disease:Tuberculosis
;ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;TT;Efficacy;increased   Efficacy:event-free survival;Genotype TT is associated with increased event-free survival when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma and Hyperbilirubinemia as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia, Side Effect:Hyperbilirubinemia
;DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;F2;rs5896;TT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotype TT is associated with increased likelihood of Hemorrhage when treated with Direct factor Xa inhibitors null Direct thrombin inhibitors as compared to genotypes CC + CT.; 
;BORTEZOMIB;PKNOX1;rs2839629;A;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with increased severity of Peripheral Nervous System Diseases when treated with bortezomib in people with Multiple Myeloma as compared to allele G.;in people with Multiple Myeloma
;ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;T;Toxicity;increased  likelihood of Side Effect:Hyperbilirubinemia;Allele T is associated with increased likelihood of Hyperbilirubinemia when treated with antineoplastic agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;SUNITINIB;VEGFA;rs699947;A;Toxicity;increased   Side Effect:systolic blood pressure and increased  risk of developing grade 3 hypertension;Allele A is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele C.; 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235067;T;Efficacy;increased  likelihood of Efficacy:remission;Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;ATENOLOL;FTO;rs9940629;G;Other;Disease:Hypercholesterolemia;Allele G is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;SUNITINIB;VEGFA;rs833061;C;Toxicity;increased   Side Effect:systolic blood pressure and increased  risk of developing grade 3 hypertension;Allele C is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele T.; 
;ALFENTANIL, FENTANYL;OPRM1;rs1799971;AG + GG;Efficacy;increased  severity of Efficacy:Pain, Postoperative;Genotypes AG + GG is associated with increased severity of Pain, Postoperative when treated with alfentanil or fentanyl in children with tonsillectomy as compared to genotype AA.;in children with tonsillectomy
;SUNITINIB;VEGFA;rs2010963;G;Toxicity;increased   Side Effect:systolic blood pressure and increased  risk of developing grade 3 hypertension;Allele G is associated with increased systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to allele C.; 
;AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148740;G;Efficacy;increased  likelihood of Efficacy:remission;Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.;in people with Disease:Depression
;ATENOLOL;ABCB1;rs10267099;G;Other;increased  risk of Disease:Hypercholesterolemia;Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Other;decreased  Other:platelet function;Genotypes AA + AG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype GG.;in people with Disease:Acute coronary syndrome
;ATENOLOL;ABCB1;rs3213619;G;Other;increased  risk of Disease:Hypercholesterolemia;Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;CORTICOSTEROIDS;DCAF4;rs7160796;CC;Efficacy;increased   Efficacy:change in forced expiratory volume in 1 s (FEV1);Genotype CC is associated with increased change in forced expiratory volume in 1 s (FEV1) when treated with corticosteroids in people with Asthma as compared to genotypes CG + GG.;in people with Disease:Asthma
;SUNITINIB;NOS3;rs2070744;CC + CT;Toxicity;increased  risk of Side Effect:grade 3 hypertension;Genotypes CC + CT are associated with increased risk of grade 3 hypertension when treated with sunitinib as compared to genotype TT.; 
;ATENOLOL;PRKCB;rs11649514;GT + TT;Toxicity, Other;increased  likelihood of Side Effect:Hyperglycemia;Genotypes GT + TT is associated with increased likelihood of Hyperglycemia when treated with atenolol in people with Essential hypertension as compared to genotype GG.;in people with Disease:Essential hypertension
;ATENOLOL;FTO;rs12595985;AA;Other;increased  risk of Disease:Hypercholesterolemia;Genotype AA is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to genotypes AC + CC.;in people with Disease:Hypertension
;CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;Toxicity;decreased likelihood of Side Effect:Drug Toxicity, Side Effect:Treatment modification;Genotypes CT + TT is associated with decreased likelihood of Drug Toxicity or treatment modification when treated with cyclophosphamide in people with Breast Neoplasms or Neoplasms as compared to genotype CC.;in people with Breast Neoplasms, Neoplasms
;CLOPIDOGREL;P2RY12;rs2046934;AG + GG;Other;decreased  Other:platelet function;Genotypes AG + GG are associated with decreased platelet function when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;ATENOLOL;GALNT2;rs2144297;T;Other;Disease:Hypercholesterolemia;Allele T is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;ATENOLOL;GALNT2;rs2144300;C;Other;Disease:Hypercholesterolemia;Allele C is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;ETHANOL;ANKK1, DRD2;rs1800497;A;Toxicity;increased  risk of Disease:Alcohol abuse;Allele A is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele G.; 
;WARFARIN;CYP2C9;rs1057910;AC;Dosage, Metabolism/PK;decreased  PK:in vivo metabolism of (S)-warfarin but not (R)-warfarin;Genotype AC is associated with decreased in vivo metabolism of (S)-warfarin but not (R)-warfarin when treated with warfarin as compared to genotype AA.; 
;ATENOLOL;PLA2G4A;rs10157410;C;Other;increased  risk of Disease:Hypercholesterolemia;Allele C is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased   Efficacy:platelet aggregation values;Genotypes AA + AG are associated with increased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;ATENOLOL;PTGS2;rs4648287;G;Other;increased  likelihood of Disease:Hypercholesterolemia;Allele G is associated with increased likelihood of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;ISONIAZID, RIFAMPIN;NOS2;rs11080344;CC;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotype CC is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes CT + TT.;in people with Disease:Tuberculosis
;ENALAPRIL;SLCO1B1;rs2306283;AA;Toxicity;increased  likelihood of Side Effect:Cough;Genotype AA is associated with increased likelihood of Cough when treated with enalapril in people with Hypertension as compared to genotypes AG + GG.;in people with Hypertension
;ISONIAZID, RIFAMPIN;BACH1;rs2070401;GG;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotype GG is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AA + AG.;in people with Disease:Tuberculosis
;CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;Efficacy;decreased  Efficacy:platelet aggregation values;Genotypes CT + TT are associated with decreased platelet aggregation values when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype CC.;in people with Efficacy:Coronary Artery Disease
;ISONIAZID, RIFAMPIN;MAFK;rs4720833;AA + AG;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;ISONIAZID, RIFAMPIN;XPO1;rs11125883;AC + CC;Toxicity;decreased likelihood of Disease:Toxic liver disease;Genotypes AC + CC are associated with decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotype AA.;in people with Disease:Tuberculosis
;CLOPIDOGREL;CYP2C19;rs12248560;CC;Efficacy;Efficacy:greater platelet inhibition 2 h after a 600-mg dose;Genotype CC is associated with greater platelet inhibition 2 h after a 600-mg dose when treated with clopidogrel in people with Coronary Artery Disease as compared to genotypes CT + TT.;in people with Disease:Coronary Artery Disease
;ISONIAZID;NAT2;rs1041983;T;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele T is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C.;in people with Disease:Tuberculosis
;ISONIAZID;NAT2;rs1495741;G;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Allele G is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele A.;in people with Disease:Tuberculosis
;CLOPIDOGREL;CYP2C9;rs1057910;C;Efficacy;decreased  Efficacy:platelet inhibition 7h after a clopidogrel 600-mg loading dose;Allele C is associated with decreased platelet inhibition 7h after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased likelihood of Efficacy:platelet aggregation inhibition;Genotypes AA + AG are associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype GG.;in people with Disease:Coronary Disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;AA;Toxicity;increased  risk of Side Effect:Anemia;Genotype AA is associated with increased risk of Anemia when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes AC + CC.;in people with Disease:Hepatitis C virus infection
;ANASTROZOLE, LETROZOLE;ESR1;rs9340799;A;Other;increased  risk of Disease:Musculoskeletal pain;Allele A is associated with increased risk of musculoskeletal pain when exposed to anastrozole and letrozole in women with early breast cancer as compared to allele G.;in women with early breast cancer
;CLOPIDOGREL;CYP3A5;rs776746;CT + TT;Efficacy;decreased likelihood of Efficacy:platelet aggregation inhibition;Genotypes CT + TT is associated with decreased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype CC.;in people with Disease:Coronary Disease
;ANASTROZOLE, LETROZOLE;ESR1;rs2234693;C;Other;increased  risk of Disease:Musculoskeletal pain;Allele C is associated with increased risk of musculoskeletal pain when exposed to anastrozole and letrozole in women with early breast cancer as compared to allele T.;in women with early breast cancer
;CLOPIDOGREL;P2RY12;rs2046934;AG + GG;Efficacy;increased  likelihood of Efficacy:platelet aggregation inhibition;Genotypes AG + GG are associated with increased likelihood of platelet aggregation inhibition when treated with clopidogrel in people with Coronary Disease as compared to genotype AA.;in people with Disease:Coronary Disease
;;CYP3A4;rs2740574;CC;Other;increased  likelihood of Other:Elevated circulating creatine kinase concentration;Genotype CC is associated with increased likelihood of Elevated circulating creatine kinase concentration in people with Cardiovascular Disease or Hyperlipidemias as compared to genotypes CT + TT.;in people with Cardiovascular Disease, Hyperlipidemias
;OPIOIDS;OPRM1;rs1799971;AA + AG;Other;decreased likelihood of Other:addiction;Genotypes AA + AG are associated with decreased likelihood of addiction due to opioids as compared to genotype GG.; 
;CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;C;Dosage, Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms.;in people with Disease:Neoplasms
;REPAGLINIDE;NEUROD1;rs1801262;CT + TT;Efficacy;decreased  Efficacy:difference in postprandial plasma glucose (before and after drug treatment);Genotypes CT + TT are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Disease:Diabetes Mellitus, Type 2
;REPAGLINIDE;PAX4;rs114202595;AA + AG;Efficacy;decreased  Efficacy:difference in postprandial plasma glucose (before and after drug treatment);Genotypes AA + AG are associated with decreased difference in postprandial plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.;in people with Disease:Diabetes Mellitus, Type 2
;;CYP3A4;rs2740574;CT;Other;increased  risk of Disease:Endometrial Neoplasms;Genotype CT is associated with increased risk of Endometrial Neoplasms as compared to genotype TT.; 
;VINCRISTINE;COCH;rs1045644;CG + GG;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes CG + GG are associated with decreased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;rs712830;CC;Toxicity;increased  severity of Side Effect:Drug Toxicity;Genotype CC is associated with increased severity of Drug Toxicity when exposed to cetuximab, irinotecan, leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotype AC.;in people with Disease:Colorectal Neoplasms
;TAMOXIFEN;CYP3A4;rs2740574;CT;Other;increased  risk of Disease:Endometrial Neoplasms;Genotype CT is associated with increased risk of Endometrial Neoplasms when treated with tamoxifen in people with Breast Neoplasms as compared to genotype TT.;in people with Disease:Breast Neoplasms
;VINCRISTINE;;rs7963521;C;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Allele C is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;REPAGLINIDE;NEUROD1;rs1801262;CT + TT;Efficacy;decreased  Efficacy:difference in fasting plasma glucose (before and after drug treatment);Genotypes CT + TT are associated with decreased difference in fasting plasma glucose (before and after drug treatment) when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.;in people with Disease:Diabetes Mellitus, Type 2
;;VDR;rs3782905;G;Other;increased  risk of Disease:Asthma;Allele G is associated with increased risk of Asthma.; 
;OPIOIDS;OPRL1;rs6090043;C;Toxicity;increased  risk of Disease:Opioid-Related Disorders;Allele C is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele T.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:high-on clopidogrel platelet reactivity;Genotypes AA + AG are associated with increased risk of high-on clopidogrel platelet reactivity when treated with clopidogrel in patients undergoing elective coronary stent placement as compared to genotype GG.;in patients undergoing elective coronary stent placement
;CLOPIDOGREL;P2RY12;rs6785930;A;Efficacy;increased  risk of Side Effect:neurological events;Allele A is associated with increased risk of neurological events when treated with clopidogrel in people with Peripheral Vascular Diseases as compared to genotype GG.;in people with Disease:Peripheral Vascular Diseases
;OPIOIDS;COMT;rs165599;AA + AG;Toxicity;increased  likelihood of Side Effect:Somnolence;Genotypes AA + AG is associated with increased likelihood of somnolence when treated with opioids in people with Pain and Neoplasms as compared to genotype GG.;in people with Pain, Neoplasms
;DOCETAXEL, PACLITAXEL;ABCB1;rs2032582;A;Toxicity;decreased likelihood of Side Effect:Leukopenia;Allele A is associated with decreased likelihood of Leukopenia when treated with docetaxel or paclitaxel in people with Breast Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms
;;VDR;rs2239185;G;;increased  risk of Disease:Asthma;Allele G is associated with increased risk of Asthma.; 
;;VDR;rs1540339;T;;increased  risk of Disease:Asthma;Allele T is associated with increased risk of Asthma.; 
;CISPLATIN;AQP1;rs1049305;CC + CG;Toxicity;increased  risk of Side Effect:Alopecia;Genotypes CC + CG are associated with increased risk of Alopecia due to cisplatin in people with Mesothelioma as compared to genotype GG.;in people with Mesothelioma
;CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;Efficacy;decreased  Efficacy:antiplatelet effect;Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;CALCITRIOL;VDR;rs2228570;A;Efficacy;increased  risk of Disease:Fractures, Bone;Allele A is associated with increased risk of Fractures, Bone when treated with calcitriol.; 
;CISPLATIN;AQP1;rs1049305;CC + CG;Toxicity;decreased risk of Side Effect:Anemia;Genotypes CC + CG are associated with decreased risk of Anemia due to cisplatin in people with Mesothelioma as compared to genotype GG.;in people with Mesothelioma
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:high post-treatment platelet reactivity;Allele A is associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;PERINDOPRIL;BDKRB1;rs12050217;AA;Efficacy;decreased risk of Efficacy:cardiac events;Genotype AA is associated with decreased risk of cardiac events when treated with perindopril in people with Coronary Artery Disease as compared to genotypes AG + GG.;in people with Disease:Coronary Artery Disease
;CISPLATIN;AQP1;rs1049305;CC;Toxicity;increased  risk of Side Effect:Thrombocytopenia;Genotype CC is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.;in people with Mesothelioma
;ATENOLOL, VERAPAMIL;GRK4;rs1801058;TT;Efficacy, Toxicity, Other;increased  risk of Side Effect:adverse cardiovascular outcomes;Genotype TT is associated with increased risk of adverse cardiovascular outcomes when treated with atenolol or verapamil in people with hypertension and coronory artery disease.;in people with hypertension and coronory artery disease
;CLOZAPINE;CYP1A2;rs762551;AA;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Genotype AA is associated with increased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC.;in people with Disease:Schizophrenia, Disease:Tobacco Use Disorder
;MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;CT + TT;Toxicity;decreased risk of Side Effect:biopsy-proven acute rejection;Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with kidney transplant as compared to genotype CC.;in people with kidney transplant
;PLATINUM COMPOUNDS;HLA-DOB;rs2071554;CT + TT;Efficacy;increased  risk of Disease:Death;Genotypes CT + TT is associated with increased risk of Death when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype CC.;in people with Disease:Lung Neoplasms
;PLATINUM COMPOUNDS;;rs2900420;AA + AG;Efficacy;decreased risk of Disease:Death;Genotypes AA + AG is associated with decreased risk of Death when treated with Platinum compounds in people with Lung Neoplasms as compared to genotype GG.;in people with Disease:Lung Neoplasms
;CLOZAPINE;CYP1A2;rs762551;AA;Toxicity;decreased likelihood of Side Effect:Metabolic Syndrome;Genotype AA is associated with decreased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to genotypes AC + CC.;in people with Disease:Schizophrenia
;CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;rs639174;T;Toxicity;increased  risk of Disease:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;OPIOIDS;DRD2;rs6275;AG + GG;Toxicity;increased  likelihood of Side Effect:Somnolence;Genotypes AG + GG is associated with increased likelihood of somnolence when treated with opioids in people with Pain and Neoplasms as compared to genotype AA.;in people with Pain, Neoplasms
;CISPLATIN;TPMT;rs12201199;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs6413432;A;Toxicity;increased  likelihood of Disease:Toxic liver disease;Allele A is associated with increased likelihood of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in children with Tuberculosis as compared to allele T.;in children with Disease:Tuberculosis
;CISPLATIN;;rs3746444;AG + GG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AG + GG is associated with decreased overall survival when treated with cisplatin in people with Lung Neoplasms as compared to genotype AA.;in people with Disease:Lung Neoplasms
;ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;CC;Toxicity;increased  likelihood of Side Effect:Hemorrhage, Side Effect:adverse events;Genotype CC is associated with increased likelihood of Hemorrhage and adverse events when treated with acenocoumarol or warfarin in people with heart valve replacement as compared to genotypes AA + AC.;in people with Heart valve replacement
;ASPIRIN;PTGS2;rs20417;G;Other;decreased risk of Disease:Coronary Disease;Allele G is associated with decreased risk of Coronary Disease when treated with aspirin as compared to allele C.; 
;CISPLATIN;AQP1;rs28362731;AG;Toxicity;increased  risk of Side Effect:Thrombocytopenia;Genotype AG is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG.;in people with Mesothelioma
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CC;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype CC is associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotypes CT + TT.;in people with Disease:Tuberculosis
;ASPIRIN;PTGS2;rs20417;G;Other;increased  risk of Disease:Coronary Disease;Allele G is associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C.; 
;CLOPIDOGREL;CYP2C19;rs4986893;A;Efficacy;decreased  Efficacy:clopidogrel inhibition of ADP-induced platelet aggregation;Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;FOLFIRI;ABCC1;rs17501011;AA + AG;Efficacy;decreased  Efficacy:Overall survival;Genotypes AA + AG is associated with decreased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotype GG.;in people with Colorectal Neoplasms
;OPIOIDS;OPRL1;rs6090041;G;Toxicity;increased  risk of Disease:Opioid-Related Disorders;Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;decreased  Efficacy:antiplatelet effect;Genotypes AA + AG are associated with decreased antiplatelet effect when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;ANTIDEPRESSANTS;CUX1;rs365836;G;Efficacy;likelihood of Efficacy:non-response;Allele G is associated with likelihood of non-response when treated with antidepressants in people with Depressive Disorder, Major as compared to allele A.;in people with Disease:Major Depressive Disorder
;;SULT1A1;rs1042028;CC + CT;;increased  risk of Disease:Prostatic Neoplasms;Genotypes CC + CT are associated with increased risk of Prostatic Neoplasms as compared to genotype TT.; 
;;SULT1A1;rs1042028;CT + TT;Other;increased  risk of Disease:Breast Neoplasms;Genotypes CT + TT are associated with increased risk of Breast Neoplasms in women with Tobacco Use Disorder as compared to genotype CC.;in women with Disease:Tobacco Use Disorder
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:clopidogrel inhibition of ADP-induced platelet aggregation;Allele A is associated with decreased clopidogrel inhibition of ADP-induced platelet aggregation when treated with clopidogrel in healthy individuals as compared to genotype GG.;in healthy individuals 
;;SULT1A1;rs1042028;CT + TT;Other;decreased likelihood of Disease:Breast Neoplasms;Genotypes CT + TT are associated with decreased likelihood of Breast Neoplasms in people with at least three pregnancies and premenopausal as compared to genotype CC.;in people with at least three pregnancies and premenopausal
;CLOZAPINE;LEPR;rs1137101;AG + GG;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Genotypes AG + GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to genotype AA.;in people with Disease:Schizophrenia
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;TT;Toxicity;increased  likelihood of Side Effect:Hemorrhage, Side Effect:adverse events;Genotype TT is associated with increased likelihood of Hemorrhage and adverse events when treated with acenocoumarol or warfarin in people with heart valve replacement as compared to genotypes CC + CT.;in people with Heart valve replacement
;ANTIDEPRESSANTS;CUX1;rs201522;A;Efficacy;likelihood of Efficacy:non-response;Allele A is associated with likelihood of non-response when treated with antidepressants in people with Depressive Disorder, Major as compared to allele G.;in people with Disease:Major Depressive Disorder
;BORTEZOMIB;PKNOX1;rs2839629;AA;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases, Side Effect:Pain, Side Effect:Neuropathic pain;Genotype AA is associated with increased likelihood of Peripheral Nervous System Diseases, Pain and neuropathic pain when treated with bortezomib in people with Multiple Myeloma as compared to genotypes AG + GG.;in people with Multiple Myeloma
;CISPLATIN;COMT;rs9332377;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.;in children with Disease:Neoplasms
;WARFARIN;VKORC1;rs9923231;CT + TT;Efficacy;decreased  Efficacy:time to therapeutic inr;Genotypes CT + TT are associated with decreased time to therapeutic inr when treated with warfarin as compared to genotype CC.; 
;CISPLATIN;COMT;rs4646316;C;Toxicity;increased  risk of Disease:Ototoxicity;Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.;in children with Disease:Neoplasms
;CAPECITABINE;ENOSF1;rs2741171;T;Toxicity;increased  risk of Disease:Hand-foot syndrome;Allele T is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;ENOSF1;rs2612091;C;Toxicity;increased  risk of Disease:Hand-foot syndrome;Allele C is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased   Disease:Drug Toxicity;Genotypes AA + AG is associated with increased Drug Toxicity when treated with methotrexate in children with as compared to genotype GG.;in children with 
;CISPLATIN;ABCC3;rs1051640;G;Toxicity;increased  risk of Disease:Ototoxicity;Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Disease:Neoplasms
;CAPECITABINE;DPYD;rs12022243;T;Toxicity;increased  severity of Disease:Diarrhea;Allele T is associated with increased severity of Diarrhea when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;FOLFIRI;CES1;rs9921399;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotypes CT + TT.;in people with Colorectal Neoplasms
;DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;rs4532;CC;Toxicity;increased  severity of Other:social withdrawal;Genotype CC is associated with increased severity of social withdrawal when treated with dextroamphetamine or methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.;in children with Disease:Attention Deficit Disorder with Hyperactivity
;CISPLATIN;TPMT;rs1142345;C;Toxicity;increased  risk of Disease:Ototoxicity;Allele C is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele T.;in children with Disease:Neoplasms
;METHAMPHETAMINE;GRIN1;rs1126442;GG;Toxicity;increased  risk of Disease:Psychotic Disorder;Genotype GG is associated with increased risk of Psychotic Disorders when exposed to methamphetamine in men with methamphetamine dependence as compared to genotypes AA + AG.;in men with Disease:Methamphetamine dependence
;FOLFIRI;UGT1A10, UGT1A8;rs1113193;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Colorectal Neoplasms
;CISPLATIN;TPMT;rs1800460;T;Toxicity;increased  risk of Disease:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele C.;in children with Disease:Neoplasms
;CAPECITABINE;ENOSF1;rs2741171;T;Toxicity;increased  risk of Disease:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;ENOSF1;rs2612091;C;Toxicity;increased  risk of Disease:Drug Toxicity;Allele C is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele T.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;DPYD;rs12022243;T;Toxicity;increased  severity of Disease:Drug Toxicity;Allele T is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele C.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:response rate to pegIFN-alpha/RBV treatment at week 20/24;Genotype CC is associated with increased response rate to pegIFN-alpha/RBV treatment at week 20/24 when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;Toxicity;increased  likelihood of Side Effect:Sialoadenitis;Genotype AA is associated with increased likelihood of Sialoadenitis NOS when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes AG + GG.;in people with Thyroid tumor
;NICOTINE;CHRNA5;rs588765;CT + TT;Efficacy;increased  likelihood of Efficacy:Smoking Cessation;Genotypes CT + TT is associated with increased likelihood of Smoking Cessation when treated with nicotine in smokers as compared to genotype CC.;in smokers
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;Efficacy;increased  risk of Efficacy:Treatment failure;Genotypes GG + GT are associated with increased risk of treatment failure when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;CAPECITABINE;DPYD;rs76387818;A;Toxicity;increased  severity of Disease:Hand-foot syndrome;Allele A is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;DPYD;rs12132152;A;Toxicity;increased  severity of Disease:Hand-foot syndrome;Allele A is associated with increased severity of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;CAPECITABINE;DPYD;rs76387818;A;Toxicity;increased  severity of Disease:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;ATENOLOL;DPYS;rs2669429;AG + GG;Toxicity;increased  severity of Side Effect:Hyperglycemia;Genotypes AG + GG is associated with increased severity of Hyperglycemia when treated with atenolol in people with Hypertension as compared to genotype AA.;in people with Disease:Hypertension
;LENALIDOMIDE;ABCB1;rs1045642;AA + AG;Toxicity;increased  severity of Side Effect:adverse events;Genotypes AA + AG is associated with increased severity of adverse events when treated with lenalidomide in people with Multiple Myeloma, Lymphoma or Myelodysplastic Syndromes as compared to genotype GG.;in people with Multiple Myeloma, Lymphoma, Myelodysplastic Syndromes
;CAPECITABINE;DPYD;rs12132152;A;Toxicity;increased  severity of Disease:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to allele G.;in people with Disease:Colorectal Neoplasms
;;IFNL3, IFNL4;rs12979860;CC;Other;increased   Other:spontaneous HCV clearance;Genotype CC is associated with increased spontaneous HCV clearance in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;RISPERIDONE;LEP;rs7799039;G;Other;increased  risk of Side Effect:Weight gain;Allele G is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele A.;in children with Disease:Autism Spectrum Disorder
;WARFARIN;VKORC1;rs9923231;T;Efficacy, Toxicity;increased   Side Effect:Blood Coagulation Disorders;Allele T is associated with increased Blood Coagulation Disorders when treated with warfarin as compared to allele C.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;Toxicity;increased  likelihood of Side Effect:Fatigue;Genotype CC is associated with increased likelihood of Fatigue when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CT + TT.;in people with Thyroid tumor
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;rs1656402;CC;Efficacy;decreased  Efficacy:survival;Genotype CC is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AG;Toxicity;decreased likelihood of Side Effect:Fatigue;Genotype AG is associated with decreased likelihood of Fatigue when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG.;in people with Thyroid tumor
;NICOTINE;;rs2056527;CT + TT;Efficacy;decreased likelihood of Efficacy:Smoking Cessation;Genotypes CT + TT is associated with decreased likelihood of Smoking Cessation when treated with nicotine in smokers as compared to genotype CC.;in smokers
;NICOTINE;;rs2056527;CT + TT;Efficacy;decreased likelihood of Efficacy:Smoking Cessation;Genotypes CT + TT is associated with decreased likelihood of Smoking Cessation when treated with nicotine in smokers as compared to genotype CC.;in smokers
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;Toxicity;increased  risk of Side Effect:Diarrhea;Genotypes AA + AT is associated with increased risk of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;PIRFENIDONE;TOLLIP;rs5743890;CC + CT;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CT is associated with increased overall survival when treated with pirfenidone in people with Pulmonary Fibrosis as compared to genotype TT.;in people with Pulmonary Fibrosis
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;WARFARIN;VKORC1;rs9923231;T;Efficacy;decreased  Efficacy:time to therapeutic inr;Allele T is associated with decreased time to therapeutic inr when treated with warfarin as compared to allele C.; 
;IMATINIB;ABCB1;rs1045642;GG;Toxicity;decreased severity of Side Effect:Drug Toxicity;Genotype GG is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AA + AG.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;PLATINUM COMPOUNDS;XBP1;rs2269577;GG;Toxicity;increased  risk of Disease:Nausea;Genotype GG is associated with increased risk of Nausea when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;IMATINIB;SLC22A1;rs683369;CC;Toxicity;decreased severity of Side Effect:Drug Toxicity;Genotype CC is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG.;in people with Disease:Chronic myelogenous leukemia, BCR-ABL1 positive
;CARBOPLATIN, PACLITAXEL;DSCAM;rs9981861;TT;Efficacy;decreased  Efficacy:survival;Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;CARBOPLATIN, PACLITAXEL;ETS2;rs1209950;CT + TT;Efficacy;decreased  Efficacy:survival;Genotypes CT + TT are associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;Toxicity;increased  likelihood of Side Effect:Dizziness, Side Effect:Headache;Genotype CC is associated with increased likelihood of Dizziness or Headache when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CT + TT.;in people with Thyroid tumor
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;Toxicity;increased  likelihood of Side Effect:Dizziness, Side Effect:Headache;Genotype AA is associated with increased likelihood of Dizziness or Headache when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes AG + GG.;in people with Thyroid tumor
;WARFARIN;VKORC1;rs9923231;T;Efficacy;increased  risk of Side Effect:over-anticoagulation;Allele T is associated with increased risk of over-anticoagulation when treated with warfarin as compared to allele C.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs1864183;TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased likelihood of gastrointestinal toxicity when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CC + CT.;in people with Thyroid tumor
;MERCAPTOPURINE;NUDT15;rs186364861;A;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele A is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs17782313;CC;Other;increased  risk of Side Effect:Weight gain;Genotype CC is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes CT + TT.; 
;AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;A;Other;increased  risk of Side Effect:Weight gain;Allele A is associated with increased risk of Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to allele C.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele T is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;AA;Other;increased  likelihood of Disease:Hypertriglyceridemia, Side Effect:Weight gain;Genotype AA is associated with increased likelihood of Hypertriglyceridemia and Weight gain when exposed to amisulpride, aripiprazole, clozapine, haloperidol, quetiapine, risperidone or ziprasidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AC + CC.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;ATENOLOL, VERAPAMIL;PLEKHH2;rs11124945;G;Toxicity;decreased risk of Disease:Diabetes Mellitus;Allele G is associated with decreased risk of Diabetes Mellitus when exposed to atenolol or verapamil in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;CLOPIDOGREL;CYP2C19;rs4244285;AG;Efficacy;increased   Disease:platelet aggregation;Genotype AG is associated with increased platelet aggregation when treated with clopidogrel in people with Angina Pectoris and Myocardial Infarction as compared to genotype AA.;in people with Disease:Angina Pectoris, Disease:Myocardial Infarction
;REGADENOSON;AMPD1;rs17602729;AA + AG;Efficacy;increased  severity of Side Effect:Elevated systolic blood pressure;Genotypes AA + AG is associated with increased severity of Elevated systolic blood pressure when exposed to regadenoson as compared to genotype GG.; 
;EFAVIRENZ;CYP2B6;rs3745274;T;Toxicity;increased  severity of Side Effect:Somnolence;Allele T is associated with increased severity of somnolence when treated with efavirenz in people with HIV Infections.;in people with Disease:HIV infectious disease
;CLOPIDOGREL;CYP2C19;rs4244285;AA;Efficacy;increased   Other:platelet reactivity;Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;;;rs2952768;CC;Efficacy;decreased severity of Other:Substance-Related Disorders;Genotype CC is associated with decreased severity of Substance-Related Disorders in people with methamphetamine dependence, Alcoholism or Eating Disorders as compared to genotypes CT + TT.;in people with Methamphetamine dependence, Alcohol abuse, Eating Disorders
;CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;Efficacy;increased  likelihood of Efficacy:overall survival;Genotype CT is associated with increased likelihood of overall survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.;in women with Disease:Ovarian Neoplasms
;ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage, Side Effect:Stroke;Genotypes CT + TT is associated with increased risk of Hemorrhage or Stroke when treated with acenocoumarol or warfarin in people with Atrial Fibrillation or venous thromboembolism.;in people with Disease:Atrial Fibrillation, Disease:Venous thromboembolism
;NICOTINE;DBH;rs1541333;CC;Efficacy;decreased likelihood of Efficacy:end of treatment abstinence;Genotype CC is associated with decreased likelihood of end of treatment abstinence due to nicotine in smokers with low dependency as compared to genotype GG.;in smokers with low dependency
;REGADENOSON;AMPD1;rs17602729;AA + AG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with regadenoson as compared to genotype GG.; 
;RISPERIDONE;CNR1;rs806378;T;Other;increased  risk of Side Effect:Weight gain;Allele T is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele C.;in children with Disease:Autism Spectrum Disorder
;RISPERIDONE;CNR1;rs1049353;C;Other;increased  risk of Side Effect:Weight gain;Allele C is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T.;in children with Disease:Autism Spectrum Disorder
;MERCAPTOPURINE;ABCC4;rs3765534;T;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele T is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Disease:Acute lymphoblastic leukemia
;ASPARAGINASE;NFATC2;rs6021191;T;Toxicity;increased  risk of Side Effect:Hypersensitivity;Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Disease:Acute lymphoblastic leukemia
;ASPARAGINASE;HLA-DRB1;rs17885382;T;Toxicity;increased  risk of Side Effect:Hypersensitivity;Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide and epirubicin in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;IVACAFTOR;CFTR;rs75527207;A;Efficacy;decreased likelihood of Disease:Cystic fibrosis pulmonary exacerbation;Allele A is associated with decreased likelihood of cystic fibrosis pulmonary exacerbation when treated with ivacaftor in people with Cystic Fibrosis.;in people with Disease:Cystic Fibrosis
;VANCOMYCIN;;rs2789047;A;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Allele A is associated with increased likelihood of Elevated circulating creatine kinase concentration when exposed to vancomycin as compared to allele C.; 
;LISINOPRIL;MMP3;rs35068180;AA;Efficacy;increased  risk of Side Effect:Stroke;Genotype AA is associated with increased risk of Stroke when treated with lisinopril in people with Hypertension.;in people with Disease:Hypertension
;CARBOPLATIN, GEMCITABINE;SERPINA5;rs6113;C;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele C is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;Efficacy:suboptimal reperfusion (post-PCI TIMI flow <3);Allele A is associated with suboptimal reperfusion (post-PCI TIMI flow <3) when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.;in people with Disease:Myocardial Infarction
;CARBOPLATIN, GEMCITABINE;SERPINA5;rs6118;T;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele T is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;XYLT2;rs6504649;G;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Non-Small Cell Lung Carcinoma
;CARBOPLATIN, GEMCITABINE;SERPINA5;rs6119;G;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele G is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Non-Small Cell Lung Carcinoma
;ETHANOL;CAT;rs1001179;T;Other;increased  risk of Disease:Alcohol abuse;Allele T is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele C.; 
;CARBOPLATIN, GEMCITABINE;ETS2;rs73450548;A;Toxicity;increased  severity of Side Effect:Thrombocytopenia;Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Non-Small Cell Lung Carcinoma
;BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;Efficacy;increased   Efficacy:anti-VEGF injections;Genotype CC is associated with increased anti-VEGF injections when treated with bevacizumab, pegaptanib or ranibizumab in people with Choroidal Neovascularization as compared to genotypes CG + GG.;in people with Disease:Choroidal Neovascularization
;CLOPIDOGREL;ABCB1;rs1045642;AA;Efficacy;increased   Other:platelet reactivity;Genotype AA is associated with increased platelet reactivity when treated with clopidogrel in people with Myocardial Infarction as compared to genotypes AG + GG.;in people with Disease:Myocardial Infarction
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;increased  likelihood of Disease:Recurrence;Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Disease:Acute lymphoblastic leukemia
;DOXORUBICIN;GSTA1;rs3957357;AA;Efficacy;increased   Efficacy:progression-free survival;Genotype AA is associated with increased progression-free survival when treated with doxorubicin in people with Sarcoma as compared to genotypes AG + GG.;in people with Disease:Sarcoma
;AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs489693;AA;Other;increased  risk of Side Effect:Weight gain;Genotype AA is associated with increased risk of Weight gain when exposed to amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone as compared to genotypes AC + CC.; 
;ETHANOL;CAT;rs1001179;T;Other;increased  severity of Disease:Alcohol abuse;Allele T is associated with increased severity of Alcoholism when exposed to ethanol in people with Alcoholism as compared to allele C.;in people with Disease:Alcohol abuse
;;ERCC1;rs3212986;AC;Other;decreased  Other:disease-free survival and overall survival;Genotype AC is associated with decreased disease-free survival and overall survival in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;DEXMEDETOMIDINE;GABRA2;rs279847;GG;Toxicity;decreased  Side Effect:heart rate;Genotype GG is associated with decreased heart rate when treated with dexmedetomidine in women as compared to genotypes GT + TT.;in women 
;TAMOXIFEN;ESR1;rs9340799;AG + GG;Toxicity;increased  risk of Side Effect:Venous thromboembolism;Genotypes AG + GG are associated with increased risk of Venous thromboembolism when treated with tamoxifen in people with Breast Neoplasms.;in people with Breast Neoplasms
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs149389480;AG;Toxicity;increased  risk of Side Effect:Angioedema;Genotype AG is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists.; 
;MORPHINE;FAAH;rs3766246;AA + AG;Toxicity;increased  risk of Side Effect:Postoperative Nausea and Vomiting;Genotypes AA + AG is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.;in children 
;CLOZAPINE, OLANZAPINE;TBC1D1;rs9852;CC;Toxicity;increased   Disease:Weight gain;Genotype CC is associated with increased Weight gain when treated with clozapine or olanzapine in people with Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizophrenia
;FLUOROURACIL;DPYD;rs67376798;AT;Efficacy;decreased  Efficacy:Overall survival;Genotype AT is associated with decreased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.;in people with Colorectal Neoplasms
;MORPHINE;FAAH;rs4141964;CT + TT;Toxicity;increased  risk of Side Effect:Postoperative Nausea and Vomiting;Genotypes CT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC.;in children 
;;ABCB11;rs2287622;GG;Toxicity;increased  risk of Side Effect:hepatocellular injury;Genotype GG is associated with increased risk of hepatocellular injury as compared to genotypes AA + AG.; 
;HYDROCODONE;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Side Effect:Hypoventilation;Genotypes AG + GG is associated with increased risk of Hypoventilation when treated with hydrocodone in women with Pregnancy as compared to genotype AA.;in women with Disease:Pregnancy
;HYDROCODONE;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Side Effect:side effects;Genotypes AG + GG is associated with increased risk of side effects when treated with hydrocodone in women with Pregnancy as compared to genotype AA.;in women with Disease:Pregnancy
;;DRD2;rs1800497;AA + AG;Toxicity;increased  likelihood of Disease:Alcohol abuse, Disease:Substance-Related Disorders;Genotypes AA + AG is associated with increased likelihood of Alcoholism and Substance-Related Disorders as compared to genotype GG.; 
;OPIOIDS;GNB3;rs5443;CT + TT;Toxicity, Other;increased  likelihood of Side Effect:increased  pulse rate;Genotypes CT + TT are associated with increased likelihood of increased pulse rate due to opioids in people with withdrawal from opioid addiction as compared to genotype CC.;in people with Side Effect:withdrawal from opioid addiction
;ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;rs324420;A;Toxicity;increased  likelihood of Disease:Weight gain;Allele A is associated with increased likelihood of Weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone in people with Psychotic Disorders as compared to allele C.;in people with Disease:Psychotic Disorder
;MORPHINE;FAAH;rs2295632;GT + TT;Toxicity;increased  risk of Side Effect:Postoperative Nausea and Vomiting;Genotypes GT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.;in children 
;CAFFEINE;CYP1A2;rs762551;AC + CC;Other;decreased risk of Disease:Breast Neoplasms;Genotypes AC + CC are associated with decreased risk of Breast Neoplasms when exposed to caffeine in people with BRCA1 mutations.;in people with BRCA1 mutations
;MORPHINE;FAAH;rs324420;AA + AC;Toxicity;increased  risk of Side Effect:Postoperative Nausea and Vomiting;Genotypes AA + AC is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC.;in children 
;PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;AA + AG;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;;ABCB11;rs2287622;GG;Toxicity;increased  risk of Disease:Drug-induced liver injury;Genotype GG is associated with increased risk of drug-induced liver injury as compared to genotypes AA + AG.; 
;PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;rs1127354;CC;Toxicity;increased  risk of Side Effect:Anemia;Genotype CC is associated with increased risk of Anemia when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes AA + AC.;in people with Disease:Chronic hepatitis C virus infection
;DOCETAXEL;NR1I3;rs3003593;AA;Toxicity;increased  severity of Side Effect:Neutropenia;Genotype AA is associated with increased severity of Neutropenia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype AG.;in people with Disease:Nasopharyngeal Neoplasms
;ANTITHYROID PREPARATIONS;EHMT2;rs652888;G;Toxicity;increased  likelihood of Disease:Agranulocytosis;Allele G is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;TNF;rs1800629;AG;Toxicity;increased  likelihood of Side Effect:Pain;Genotype AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG.;in people with Disease:Thyroid tumor
;HYDROCODONE;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Disease:Constipation;Genotypes AG + GG is associated with increased risk of Constipation when treated with hydrocodone in women with Pregnancy as compared to genotype AA.;in women with Disease:Pregnancy
;HMG COA REDUCTASE INHIBITORS;HLA-G;rs1063320;G;Other;decreased likelihood of Disease:Asthma;Allele G is associated with decreased likelihood of Asthma when exposed to hmg coa reductase inhibitors in people with Asthma as compared to allele C.;in people with Disease:Asthma
;HYDROCODONE;OPRM1;rs1799971;AG + GG;Toxicity;increased  risk of Disease:Dry mouth;Genotypes AG + GG is associated with increased risk of dry mouth when treated with hydrocodone in women with Pregnancy as compared to genotype AA.;in women with Disease:Pregnancy
;DEXMEDETOMIDINE;CYP2A6;rs28399433;C;Efficacy;increased   Efficacy:sedation;Allele C is associated with increased sedation when treated with dexmedetomidine in women as compared to allele A.;in women 
;DEFERIPRONE;UGT1A6;rs6759892;GG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with deferiprone in people with beta-Thalassemia as compared to genotype TT.;in people with Disease:Beta-thalassemia and related diseases
;DEFERIPRONE;UGT1A6;rs6759892;GG;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with deferiprone in people with beta-Thalassemia as compared to genotypes GT + TT.;in people with Disease:Beta-thalassemia and related diseases
;ANTITHYROID PREPARATIONS;;rs111618861;del;Toxicity;increased  likelihood of Disease:Agranulocytosis;Allele del is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A.; 
;ANTITHYROID PREPARATIONS;HLA-B;rs1071816;C;Toxicity;increased  likelihood of Disease:Agranulocytosis;Allele C is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele T.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AA + AG;Toxicity;increased  likelihood of Side Effect:Pain;Genotypes AA + AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG.;in people with Disease:Thyroid tumor
;EFAVIRENZ;IL10;rs1800896;TT;Toxicity;increased  likelihood of Side Effect:Drug Hypersensitivity;Genotype TT is associated with increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT.;in people with Disease:HIV infectious disease
;ETHANOL;ANKK1, DRD2;rs1800497;A;Other;increased  risk of Disease:Alcohol abuse;Allele A is associated with increased risk of Alcoholism when exposed to ethanol.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;NFKB1;rs230493;AT;Toxicity;decreased likelihood of Side Effect:Pain;Genotype AT is associated with decreased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype TT.;in people with Disease:Thyroid tumor
;OPIOIDS;OPRM1;rs1799971;G;Toxicity;decreased risk of Other:Opioid-Related Disorders;Allele G is associated with decreased risk of Opioid-Related Disorders due to opioids as compared to allele A.; 
;ETHANOL;DRD2;rs1800497;A;Other;increased  risk of Disease:Alcohol abuse;Allele A is associated with increased risk of Alcoholism when exposed to ethanol.; 
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs2241716;TT;Toxicity;increased  likelihood of Side Effect:Pain;Genotype TT is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CC + CT.;in people with Disease:Thyroid tumor
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;GG;Toxicity;increased  likelihood of Side Effect:Pain;Genotype GG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes AA + AG.;in people with Disease:Thyroid tumor
;ANTITHYROID PREPARATIONS;FOXF2;rs199564443;del;Toxicity;increased  likelihood of Disease:Agranulocytosis;Allele del is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele TTTT.; 
;CAPECITABINE;CES1P1;rs7187684;T;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;;rs6977967;GG;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotype GG is associated with increased likelihood of mucositis when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, hydrocortisone, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Disease:Acute lymphoblastic leukemia
;CAPECITABINE;CES1P1;rs11861118;G;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;PLATINUM;XRCC1;rs25487;TT;Efficacy;Other:worse overall survival outcome;Genotype TT is associated with worse overall survival outcome when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM;ERCC1;rs11615;AG + GG;Efficacy;increased  likelihood of Efficacy:response;Genotypes AG + GG are associated with increased likelihood of response when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;CAPECITABINE;CES1;rs2244613;G;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;PLATINUM;ERCC1;rs3212986;AA + AC;Efficacy;increased   Efficacy:Overall survival;Genotypes AA + AC are associated with increased overall survival when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOZAPINE, ETHANOL;CYP1A2;rs2069514;GG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype GG is associated with increased likelihood of adverse events when treated with clozapine and ethanol in people with Psychotic Disorders as compared to genotypes AA + AG.;in people with Psychotic Disorder
;MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;CT + TT;Efficacy;increased  risk of Efficacy:Recurrence;Genotypes CT + TT is associated with increased risk of Recurrence when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;rs4674470;CC + CT;Toxicity;decreased likelihood of Side Effect:Mucositis;Genotypes CC + CT is associated with decreased likelihood of mucositis when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, hydrocortisone, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Disease:Acute lymphoblastic leukemia
;CAPECITABINE;CES1;rs2244614;G;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;Efficacy;decreased  Efficacy:Sustained virological response (SVR);Genotypes CT + TT are associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype CC.;in people with Disease:Chronic hepatitis C virus infection
;CITALOPRAM;CYP2C19;rs4244285;AG;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype AG is associated with increased likelihood of adverse events due to citalopram in men with Alcoholism and Depressive Disorder, Major as compared to genotype GG.;in men with Alcohol abuse, Major Depressive Disorder
;IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs620815;TT;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotype TT is associated with increased likelihood of gastrointestinal toxicity when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype CC.;in people with Disease:Thyroid tumor
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;TT;Efficacy;increased  risk of Efficacy:treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients;Genotype TT is associated with increased risk of treatment failure to pegylated interferon-alpha/ribavirin therapy in HCV/HIV-1 coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to genotype CC.; 
;TENOFOVIR;ABCC2;rs17222723;A;Toxicity;decreased risk of Side Effect:renal proximal tubulopathy;Allele A is associated with decreased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele T.;in people with Disease:HIV infectious disease
;TENOFOVIR;ABCC2;rs2273697;A;Toxicity;increased  risk of Side Effect:renal proximal tubulopathy;Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;FLUOROURACIL;DPYD;rs1801160;CT;Efficacy;decreased  Efficacy:Overall survival;Genotype CT is associated with decreased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Colorectal Neoplasms
;CYTARABINE, IDARUBICIN;;rs12036333;AA + AG;Efficacy;decreased  Efficacy:event-free survival;Genotypes AA + AG is associated with decreased event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;rs8667;AA + AG;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotypes AA + AG is associated with increased likelihood of Diarrhea when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, hydrocortisone, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;NEVIRAPINE;CYP2B6;rs28399499;CC + CT;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Genotypes CC + CT is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP2R1;rs10741657;AA + AG;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotypes AA + AG are associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;rs12402181;AA + AG;Toxicity;decreased likelihood of Side Effect:Vomiting;Genotypes AA + AG is associated with decreased likelihood of Vomiting when treated with asparaginase, cyclophosphamide, cytarabine, daunorubicin, hydrocortisone, methotrexate, prednisone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;NEVIRAPINE;CYP2B6;rs3745274;T;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele T is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele G.;in women with Disease:HIV infectious disease
;TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;rs2248359;TT;Toxicity;increased  severity of Side Effect:Nephrotoxicity;Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.;in people with HIV infectious disease
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  risk of Disease:Toxic liver disease;Genotypes AA + AG is associated with increased risk of Toxic liver disease when treated with methotrexate in children with Neoplasms as compared to genotype GG.;in children with Disease:Neoplasms
;CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;GG;Toxicity;increased  risk of Side Effect:toxicity;Genotype GG is associated with increased risk of toxicity when treated with cyclophosphamide in women with Lupus Erythematosus, Systemic as compared to genotypes AA + AG.;in women with Disease:Systemic lupus erythematosus
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;rs4646536;GG;Toxicity;decreased severity of Side Effect:Nephrotoxicity;Genotype GG is associated with decreased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes AA + AG.;in people with HIV infectious disease
;NICOTINE;DDC;rs2060761;C;Other;increased  risk of Disease:Tobacco Use Disorder;Allele C is associated with increased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele T.;in smokers
;DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;rs10946737;AA + AG;Toxicity;increased  risk of Side Effect:Drug-induced liver injury;Genotypes AA + AG is associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to genotype GG.;in people with Disease:Tuberculosis
;NICOTINE;DDC;rs12718541;A;Other;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele G.;in smokers
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1;Genotype CC is associated with increased response (rapid and sustained virological response) for patients with hepatitis C virus genotype 1 when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT.;in people with Disease:Chronic hepatitis C virus infection
;IMIPRAMINE;CYP2C19;rs12248560;CT + TT;Metabolism/PK;decreased  PK:dose-corrected plasma concentrations;Genotypes CT + TT are associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to genotype CC.;in people with Disease:Depressive Disorder
;IMIPRAMINE;CYP2C19;rs11188072;CT + TT;Metabolism/PK;decreased  PK:dose-corrected plasma concentrations;Genotypes CT + TT are associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to genotype CC.;in people with Disease:Depressive Disorder
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GG.;in people with Disease:Chronic hepatitis C virus infection
;;CXCL5;rs352046;GG;Other;increased  risk of Disease:Death;Genotype GG is associated with increased risk of Death in people with Acute coronary syndrome as compared to genotypes CC + CG.;in people with Disease:Acute coronary syndrome
;NEVIRAPINE;CYP2B6;rs28399499;C;Toxicity;increased  likelihood of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Allele C is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with nevirapine in women with HIV Infections as compared to allele T.;in women with Disease:HIV infectious disease
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;WARFARIN;VKORC1;rs9934438;AA + AG;Toxicity;increased  risk of Side Effect:over-anticoagulation;Genotypes AA + AG are associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype GG.; 
;CAPECITABINE;CDA;rs602950;G;Toxicity;increased  risk of Side Effect:Diarrhea;Allele G is associated with increased risk of Diarrhea when treated with capecitabine in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;CAPECITABINE;CDA;rs532545;T;Toxicity;increased  risk of Side Effect:Diarrhea;Allele T is associated with increased risk of Diarrhea when treated with capecitabine in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;TENOFOVIR DISOPROXIL FUMARATE;ABCC2;rs717620;TT;Toxicity;increased  severity of Side Effect:Nephrotoxicity;Genotype TT is associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotypes CC + CT.;in people with HIV infectious disease
;CAPECITABINE;CDA;rs6690069;A;Toxicity;increased  risk of Side Effect:Hand-foot syndrome;Allele A is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;TENOFOVIR;ABCC2;rs717620;CC;Toxicity;increased  risk of Side Effect:kidney tubular dysfunction;Genotype CC is associated with increased risk of kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to genotypes CT + TT.;in people with Disease:HIV infectious disease
;METHYLPHENIDATE;DRD1;rs4532;CC;Toxicity;increased  severity of Other:social withdrawal;Genotype CC is associated with increased severity of social withdrawal when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT.;in children with Disease:Attention Deficit Disorder with Hyperactivity
;CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AA + AT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:subclinical intra-stent thrombus;Genotypes AA + AG are associated with increased risk of subclinical intra-stent thrombus when treated with clopidogrel in patients undergoing drug-eluting stent (DES) implantation as compared to genotype GG.;in patients undergoing drug-eluting stent (DES) implantation
;CAPECITABINE;CES1;rs3217164;G;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele G is associated with increased risk of Drug Toxicity when treated with capecitabine in people with Neoplasms as compared to allele del.;in people with Disease:Neoplasms
;CAPECITABINE;CDA;rs10916825;A;Toxicity;increased  risk of Side Effect:Diarrhea;Allele A is associated with increased risk of Diarrhea when treated with capecitabine in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;rs11854484;CT + TT;Toxicity;increased  severity of Side Effect:Nephrotoxicity;Genotypes CT + TT are associated with increased severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype CC.;in people with HIV infectious disease
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;Toxicity;decreased likelihood of Side Effect:Dizziness;Genotype CC is associated with decreased likelihood of Dizziness when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Major Depressive Disorder
;CAPECITABINE;NSUN3;rs144470777;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CAPECITABINE;PHC1;rs187805828;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;ALENDRONATE;VDR;rs1544410;CC;Efficacy;decreased  Efficacy:serum osteocalcin;Genotype CC is associated with decreased serum osteocalcin when treated with alendronate in people with Osteoporosis as compared to genotype TT.;in people with Disease:Osteoporosis
;ASPIRIN;ITGB3;rs5918;TT;Efficacy;increased  risk of Efficacy:inadequate inhibition of platelet activity;Genotype TT is associated with increased risk of inadequate inhibition of platelet activity when treated with aspirin as compared to genotypes CC + CT.; 
;CAPECITABINE;FAT1;rs116134453;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CISPLATIN;XPC;rs2228001;GG + GT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT.;in people with Disease:Urinary Bladder Neoplasms
;CAPECITABINE;TENM4;rs141531882;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;TICAGRELOR;ABCB1;rs1045642;AA + AG;Toxicity;increased  likelihood of Side Effect:Dyspnea;Genotypes AA + AG is associated with increased likelihood of Dyspnea when treated with ticagrelor in people with Acute coronary syndrome as compared to genotype GG.;in people with Acute coronary syndrome
;WARFARIN;CYP4F2;rs2108622;T;Dosage;Efficacy:a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans;Allele T is associated with a 22% increase in therapeutic warfarin dose requirement after adjustment for clinical and genetic covariates in Hispanic-Americans when treated with warfarin as compared to allele C.; 
;AMOXICILLIN, CLAVULANATE;HLA-DQB1;rs9274407;A;Toxicity;increased  likelihood of Side Effect:drug induced liver injury;Allele A is associated with increased likelihood of drug induced liver injury when treated with amoxicillin and clavulanate in people with Drug Toxicity as compared to allele T.;in people with Disease:Drug Toxicity
;CAPECITABINE;CD96;rs77475703;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;METHOTREXATE;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Acute lymphoblastic leukemia as compared to genotype GG.;"in people with ""Disease:Burkitt Lymphoma"", ""Disease:Lymphoma, T-Cell"", ""Disease:Acute lymphoblastic leukemia"""
;CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;rs4149056;TT;Toxicity;increased  risk of Side Effect:Amenorrhea;Genotype TT is associated with increased risk of Amenorrhea when treated with cyclophosphamide, docetaxel, doxorubicin, epirubicin, fluorouracil or goserelin in women with Breast Neoplasms as compared to genotype CT.;in women with Disease:Breast Neoplasms
;WARFARIN;NQO1;rs1800566;A;Dosage;Efficacy:a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans;Allele A is associated with a 34% increase in therapeutic warfarin dose requirement while holding clinical and genetic predictors constant in Hispanic-Americans when treated with warfarin as compared to allele G.; 
;CAPECITABINE;ZMIZ1;rs117484357;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CAPECITABINE;VPS13D;rs138385713;G;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CETUXIMAB;RASSF1;rs2236947;CC;Efficacy;increased   Efficacy:Overall survival;Genotype CC is associated with increased overall survival when treated with cetuximab in people with Colorectal Neoplasms as compared to genotypes AA + AC.;in people with Disease:Colorectal Neoplasms
;PAROXETINE;CYP1A2;rs4646425;CC;Efficacy;increased   Efficacy:slower response time;Genotype CC is associated with increased slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Disease:Major Depressive Disorder
;CAPECITABINE;CCDC77;rs141213385;G;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;ANTIPSYCHOTICS;RGS2;rs4606;C;Toxicity;increased  severity of Side Effect:extrapyramidal symptoms, Side Effect:Parkinsonian Disorder;Allele C is associated with increased severity of extrapyramidal symptoms and Parkinsonian Disorders when treated with antipsychotics in people with Schizophrenia as compared to allele G.;in people with Disease:Schizophrenia
;PRAVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC);Allele C is associated with increased pravastatin plasma concentrations (AUC) when exposed to pravastatin in healthy individuals as compared to allele T.;in healthy individuals 
;DEXMEDETOMIDINE;WBP2NL;rs5758550;AA;Efficacy;increased  severity of Efficacy:sedation;Genotype AA is associated with increased severity of sedation when treated with dexmedetomidine in people with surgery as compared to genotypes AG + GG.;in people with surgery
;CAPECITABINE;ADGRG7;rs117308378;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CARBOPLATIN, CISPLATIN;AKT1;rs1130214;AA + AC;Efficacy;decreased risk of Efficacy:Disease Progression;Genotypes AA + AC are associated with decreased risk of Disease Progression when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs2280055;CC;Efficacy;Efficacy:Decreased glomerular filtration rate;Genotype CC is associated with Decreased glomerular filtration rate when treated with cyclosporine, mycophenolic acid and prednisone in people with Kidney Transplantation as compared to genotypes CT + TT.;in people with Kidney Transplantation
;ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;Efficacy;increased  risk of Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death;Allele T is associated with increased risk of Myocardial Infarction, Stroke or Death when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Acute coronary syndrome
;CARBOPLATIN, CISPLATIN;;rs2498804;AA + AC;Efficacy;decreased risk of Efficacy:Disease Progression;Genotypes AA + AC are associated with decreased risk of Disease Progression when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;rs4436578;CC;Toxicity;increased  risk of Side Effect:body weight gain;Genotype CC is associated with increased risk of body weight gain when treated with clozapine, olanzapine or risperidone in people with Schizophrenia.;in people with Disease:Schizophrenia
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;VINCRISTINE;ABCC2;rs12826;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;EFAVIRENZ;CYP2B6;rs3745274;TT;Metabolism/PK;increased   PK:plasma exposure;Genotype TT is associated with increased plasma exposure of efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;NICOTINE;GRIN3A;rs10121600;C;Other;increased  risk of Disease:Tobacco Use Disorder;Allele C is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele T.; 
;ASPIRIN, CLOPIDOGREL;CYP1A2;rs762551;C;Efficacy;increased  risk of Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death;Allele C is associated with increased risk of Myocardial Infarction, Stroke or Death when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Acute coronary syndrome
;WARFARIN;VKORC1;rs9923231;TT;Efficacy;increased   Efficacy:mean peak INR during week 1 of warfarin therapy;Genotype TT is associated with increased mean peak INR during week 1 of warfarin therapy when treated with warfarin in children as compared to genotypes CC + CT.;in children 
;ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death;Allele A is associated with increased risk of Myocardial Infarction, Stroke or Death when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Acute coronary syndrome
;CITALOPRAM;HTR1B;rs6296;CC;Toxicity;increased  risk of Side Effect:Agitation;Genotype CC is associated with increased risk of Agitation when treated with citalopram in children with Anxiety Disorders or Major Depressive Disorder as compared to genotypes CG + GG.;in children with Disease:Anxiety Disorders, Disease:Major Depressive Disorder
;PRAVASTATIN;ABCA1;rs2230806;TT;Efficacy;increased   Efficacy:HDL-cholesterol;Genotype TT is associated with increased HDL-cholesterol when treated with pravastatin in people with Coronary Disease as compared to genotype CC.;in people with Disease:Coronary Disease
;ASPIRIN, CLOPIDOGREL;PON1;rs662;T;Efficacy;increased  risk of Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death;Allele T is associated with increased risk of Myocardial Infarction, Stroke or Death when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele C.;in people with Acute coronary syndrome
;DEXMEDETOMIDINE;ABCG2;rs2231142;GG;Efficacy;increased  severity of Efficacy:sedation;Genotype GG is associated with increased severity of sedation when treated with dexmedetomidine in people with surgery as compared to genotypes GT + TT.;in people with surgery
;PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;rs1057910;C;Toxicity;increased  risk of Side Effect:gastrointestinal bleeding;Allele C is associated with increased risk of gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib, diclofenac, ibuprofen, naproxen or piroxicam as compared to allele A.; 
;CAPECITABINE;DPYD;rs75267292;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;NICOTINE;GRIN3A;rs11788456;G;Other;risk of Disease:Tobacco Use Disorder;Allele G is associated with risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.; 
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity;increased  likelihood of Disease:Fatigue;Genotype TT is associated with increased likelihood of Fatigue when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;rs1057910;C;Toxicity;increased  risk of Side Effect:acute gastrointestinal bleeding;Allele C is associated with increased risk of acute gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib or diclofenac as compared to allele A.; 
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity;increased  likelihood of Disease:Sleep Disorders;Genotype TT is associated with increased likelihood of Sleep Disorders when treated with efavirenz in people with HIV Infections as compared to genotypes GG + GT.;in people with Disease:HIV infectious disease
;PRAVASTATIN;KIF6;rs20455;AG + GG;Efficacy;decreased risk of Disease:Coronary Disease;Genotypes AG + GG are associated with decreased risk of Coronary Disease when treated with pravastatin in people with prior vascular disease as compared to genotype AA.;in people with prior vascular disease
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;"in people with ""Disease:Burkitt Lymphoma"", ""Disease:Lymphoma, T-Cell"", ""Disease:Acute lymphoblastic leukemia"""
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs368967198;AG;Toxicity;increased  risk of Side Effect:Angioedema;Genotype AG is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists.; 
;CAPECITABINE;SSU72;rs146898897;C;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele C is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;Efficacy;decreased risk of Efficacy:Myocardial Infarction, Efficacy:Stroke, Efficacy:Death;Allele T is associated with decreased risk of Myocardial Infarction, Stroke or Death when treated with aspirin and clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Acute coronary syndrome
;BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;Other;decreased  Other:heart rate;Genotypes CT + TT are associated with decreased heart rate when treated with Beta Blocking Agents as compared to genotype CC.; 
;CARBOPLATIN, CISPLATIN;PIK3CA;rs2699887;CC;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with increased likelihood of Drug Toxicity when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;Other;decreased  Other:heart rate;Genotypes CT + TT are associated with decreased heart rate when treated with Beta Blocking Agents as compared to genotype CC.; 
;CARBOPLATIN, CISPLATIN;PTEN;rs2299939;AC + CC;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotypes AC + CC are associated with decreased likelihood of Drug Toxicity when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.;in people with Disease:Non-Small Cell Lung Carcinoma
;CAPECITABINE;MAN1A1;rs185346775;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CARBOPLATIN, CISPLATIN;AKT1;rs3803304;C;Efficacy;risk of Efficacy:Disease Progression;Allele C is associated with risk of Disease Progression when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung.;in people with Disease:Non-Small Cell Lung Carcinoma
;COCAINE;BCHE;rs1803274;TT;Other;Disease:Cocaine dependence;Genotype TT is associated with Cocaine-Related Disorders when exposed to cocaine in as compared to genotypes CC + CT.;in 
;PRAVASTATIN;SLCO1B1;rs4149056;CC;Metabolism/PK;increased   PK:mean peak concentration in plasma and area under the plasma concentration;Genotype CC is associated with increased mean peak concentration in plasma and area under the plasma concentration when exposed to pravastatin in men as compared to genotypes CT + TT.;in men 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;EGFR;rs11506105;AA;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;GG;Efficacy;decreased  Efficacy:survival rate;Genotype GG is associated with decreased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes AA + AG.;in people with Disease:Neoplasm of esophagus
;ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;Efficacy;increased   Efficacy:platelet reactivity;Genotypes AG + GG are associated with increased platelet reactivity when treated with aspirin and clopidogrel as compared to genotype AA.; 
;HMG COA REDUCTASE INHIBITORS;STAT4;rs7574865;T;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;Allele T is associated with increased likelihood of drug-induced liver injury when treated with hmg coa reductase inhibitors in people with drug-induced liver injury as compared to allele G.;in people with Disease:Drug-induced liver injury
;CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;AA + AG;Efficacy;decreased risk of Efficacy:lymph node metastases;Genotypes AA + AG are associated with decreased risk of lymph node metastases when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype GG.;in people with Disease:Neoplasm of esophagus
;MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;HEROIN;ALDH2;rs671;AA + AG;Other;increased   Disease:Heroin Dependence;Genotypes AA + AG are associated with increased Heroin Dependence due to heroin as compared to genotype GG.; 
;FENTANYL;CALCA;rs145837941;GG;Dosage;decreased severity of Side Effect:Postoperative Nausea and Vomiting;Genotype GG is associated with decreased severity of Postoperative Nausea and Vomiting when treated with fentanyl in women with Pain, Postoperative and cesarean section as compared to genotypes AA + AG.;"in women with ""Pain, Postoperative"", ""Caesarian section"""
;"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";KCNJ11;rs5219;T;Efficacy;increased  likelihood of Efficacy:treatment failure;Allele T is associated with increased likelihood of treatment failure when treated with metformin and sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to allele C.;in people with Disease:Diabetes Mellitus, Type 2
;ANTIHYPERTENSIVES, BETA BLOCKING AGENTS, DIURETICS;ADRB1;rs1801253;CC;Efficacy;increased  likelihood of Efficacy:Stroke;Genotype CC is associated with increased likelihood of Stroke when treated with Antihypertensives, Beta Blocking Agents or diuretics in people with Hypertension as compared to genotypes CG + GG.;in people with Hypertension
;NICOTINE;GRIN3A;rs17189632;T;Other;risk of Disease:Tobacco Use Disorder;Allele T is associated with risk of Tobacco Use Disorder when exposed to nicotine as compared to allele A.; 
;FLUOROURACIL;DPYD;rs3918290;CT + TT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;HMG COA REDUCTASE INHIBITORS;SLCO1A2;rs4149000;T;Toxicity;increased  risk of Side Effect:Muscular Diseases;Allele T is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele C.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:poor-response to clopidogrel;Genotypes AA + AG are associated with increased risk of poor-response to clopidogrel when treated with clopidogrel in patients undergoing percutaneous coronary intervention (PCI) as compared to genotype GG.;in patients undergoing percutaneous coronary intervention (PCI)
;TRAMADOL;SLC22A1;rs35167514;del;Metabolism/PK;increased   PK:plasma concentrations of O-desmethyltramadol;Allele del is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele A.;in healthy individuals 
;EFAVIRENZ;CYP2B6;rs3745274;TT;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype TT is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype GG.;in people with Disease:HIV infectious disease
;SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;Efficacy;increased   Efficacy:vol% end-tidal sevoflurane concentration;Genotypes AA + AG are associated with increased vol% end-tidal sevoflurane concentration when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype GG.;in people with otorhinolaryngology surgery
;ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;Toxicity;increased  risk of Side Effect:Major Adverse Cardiac Events (MACE);Genotypes AG + GG are associated with increased risk of major adverse cardiac events (mace) when treated with aspirin and clopidogrel as compared to genotype AA.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;METHOTREXATE;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Leukopenia, Side Effect:Neutropenia, Side Effect:Mucositis;Genotype AA is associated with increased likelihood of Leukopenia, Neutropenia or mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Acute lymphoblastic leukemia
;TRAMADOL;SLC22A1;rs34130495;A;Metabolism/PK;increased   PK:plasma concentrations of O-desmethyltramadol;Allele A is associated with increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals.;in healthy individuals 
;TRAMADOL;SLC22A1;rs12208357;T;Metabolism/PK;PK:higher plasma concentrations of O-desmethyltramadol;Allele T is associated with higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to allele C.;in healthy individuals 
;METHADONE;KCNJ6;rs2070995;TT;Toxicity;decreased risk of Side Effect:withdrawal effects;Genotype TT is associated with decreased risk of withdrawal effects when treated with methadone in people with Heroin Dependence as compared to genotypes CC + CT.;in people with Disease:Heroin Dependence
;IMATINIB;SLCO1A2;rs3764043;CC;Metabolism/PK;decreased  PK:imatinib clearance;Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.; 
;IMATINIB;SLCO1A2;rs4148978;CC;Metabolism/PK;increased   PK:imatinib clearance;Genotype CC is associated with increased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.; 
;VINCRISTINE;ABCC2;rs3740066;T;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele T is associated with decreased likelihood of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in children with Acute lymphoblastic leukemia
;IMATINIB;SLCO1A2;rs4148977;CC;Metabolism/PK;increased   PK:imatinib clearance;Genotype CC is associated with increased imatinib clearance when treated with imatinib as compared to genotypes CT + TT.; 
;FLUOROURACIL;DPYD;rs55886062;AC;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AC is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype AA.;in people with Disease:Neoplasms
;FLUCLOXACILLIN;NR1I2;rs3814055;CC;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype CC is associated with increased risk of Toxic liver disease when treated with flucloxacillin.; 
;CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs3894049;CC;Efficacy;decreased likelihood of Efficacy:Transplant rejection;Genotype CC is associated with decreased likelihood of transplant rejection when treated with cyclosporine, mycophenolic acid and prednisone in people with Kidney Transplantation as compared to genotype CG.;in people with Disease:Kidney Transplantation
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;Efficacy;increased   Efficacy:vol% end-tidal sevoflurane concentration;Genotypes AG + GG are associated with increased vol% end-tidal sevoflurane concentration when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype AA.;in people with otorhinolaryngology surgery
;FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;EFAVIRENZ;CYP2B6;rs28399499;CC;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotype CC is associated with decreased likelihood of Drug Toxicity when treated with efavirenz in people with HIV Infections as compared to genotype TT.;in people with Disease:HIV infectious disease
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs143509841;GT;Toxicity;increased  risk of Side Effect:Angioedema;Genotype GT is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;G;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T.;in people with Disease:Chronic hepatitis C virus infection
;"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs200157005;AG;Toxicity;increased  risk of Side Effect:Angioedema;Genotype AG is associated with increased risk of Angioedema when treated with Ace Inhibitors, Plain or Angiotensin II Antagonists.; 
;PAROXETINE;CYP1A2;rs4646427;TT;Efficacy;Efficacy:slower response time;Genotype TT is associated with slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.;in people with Disease:Major Depressive Disorder
;CARBAMAZEPINE;SCN1A;rs3812718;CC;Other;increased   Other:cortical silent period duration;Genotype CC is associated with increased cortical silent period duration due to carbamazepine in healthy individuals as compared to genotype TT.;in healthy individuals 
;METHOTREXATE;MIR1206;rs2114358;GG;Toxicity;increased  risk of Side Effect:Mucositis;Genotype GG is associated with increased risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in children with Disease:Acute lymphoblastic leukemia
;PAROXETINE;CYP1A2;rs4646425;CC;Efficacy;increased   Efficacy:slower response time;Genotype CC is associated with increased slower response time when treated with paroxetine in people with Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Disease:Major Depressive Disorder
;ATORVASTATIN;SLCO1B1;rs2306283;G;Metabolism/PK;decreased  PK:plasma concentrations;Allele G is associated with decreased plasma concentrations of atorvastatin as compared to allele A.; 
;ATORVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased   PK:plasma concentrations;Allele C is associated with increased plasma concentrations of atorvastatin as compared to allele T.; 
;FOLIC ACID, METHOTREXATE;ABCB1;rs1045642;A;Toxicity;increased  risk of Side Effect:adverse drug event;Allele A is associated with increased risk of adverse drug event when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;CYTARABINE, IDARUBICIN;BRD10;rs10758713;AA + AG;Efficacy;decreased  Efficacy:event-free survival;Genotypes AA + AG is associated with decreased event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;Toxicity;increased  risk of Side Effect:Muscular Diseases;Allele C is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele T.; 
;SORAFENIB;KDR;rs4864950;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with sorafenib in people with Neoplasms as compared to allele T.;in people with Neoplasms
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;Efficacy;decreased likelihood of Efficacy:Sustained virological response (SVR);Allele T is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele C.;in people with Disease:Chronic hepatitis C virus infection
;SORAFENIB;PIK3R5;rs444904;T;Toxicity;increased  risk of Side Effect:Hypertension;Allele T is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Renal Cell Carcinoma
;IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;Toxicity;increased  risk of Side Effect:diarrhea within 24 hours and Thrombocytopenia;Allele G is associated with increased risk of diarrhea within 24 hours and Thrombocytopenia when treated with irinotecan in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;CYTARABINE, IDARUBICIN;;rs2897047;AG;Efficacy;increased   Efficacy:Overall survival;Genotype AG is associated with increased overall survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG.;in people with Disease:Leukemia, Myeloid, Acute
;METHOTREXATE;ABCC2;rs2273697;AA;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG.;in people with Disease:Rheumatoid arthritis
;CYTARABINE, IDARUBICIN;;rs6550826;GG;Efficacy;increased  risk of Efficacy:event-free survival;Genotype GG is associated with increased risk of event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype CC.;in people with Disease:Leukemia, Myeloid, Acute
;METHOTREXATE;ABCB1;rs1128503;AG;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;AZATHIOPRINE, MERCAPTOPURINE;ABCC4;rs3765534;CT + TT;Toxicity;increased  likelihood of Disease:Leukopenia;Genotypes CT + TT are associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Disease:Inflammatory Bowel Diseases
;METHOTREXATE;ABCC2;rs4148396;CC + CT;Toxicity;increased   Side Effect:time to discontinuation or dose reduction;Genotypes CC + CT are associated with increased time to discontinuation or dose reduction when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;ABCC2;rs4148396;CC;Toxicity;increased  likelihood of Disease:Alopecia;Genotype CC is associated with increased likelihood of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.;in people with Disease:Rheumatoid arthritis
;CYTARABINE, IDARUBICIN;;rs9883101;CC;Efficacy;increased  risk of Efficacy:event-free survival;Genotype CC is associated with increased risk of event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype AA.;in people with Disease:Leukemia, Myeloid, Acute
;FOLIC ACID, METHOTREXATE;TLR4;rs4986790;G;Toxicity;increased  risk of Side Effect:adverse drug events;Allele G is associated with increased risk of adverse drug events when treated with folic acid and methotrexate in people with Arthritis, Rheumatoid as compared to allele A.;in people with Disease:Rheumatoid arthritis
;ROSUVASTATIN;ABCG2;rs2231142;T;Metabolism/PK;increased   PK:plasma concentrations;Allele T is associated with increased plasma concentrations of rosuvastatin as compared to allele G.; 
;ROSUVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased   PK:plasma concentrations;Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.; 
;FLUOROURACIL, LEUCOVORIN;DPYD;rs67376798;AT;Toxicity;increased  severity of Disease:Drug Toxicity;Genotype AT is associated with increased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;PRAVASTATIN;SLCO1B1;rs4149056;C;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC) and Cmax;Allele C is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin as compared to allele T.; 
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype AA is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:rapid virological response (rvr), Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  severity of Disease:Drug Toxicity;Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC.;in people with Disease:Colorectal Neoplasms
;HYDROCHLOROTHIAZIDE;;rs10792367;G;Efficacy;decreased  Efficacy:blood pressure (BP) reduction;Allele G is associated with decreased blood pressure (BP) reduction when treated with hydrochlorothiazide in people with Hypertension as compared to genotype CC.;in people with Disease:Hypertension
;IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;Dosage;increased  likelihood of Side Effect:necessity to reduce irinotecan dosage;Allele G is associated with increased likelihood of necessity to reduce irinotecan dosage when treated with irinotecan in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;;HMGCR;rs12654264;AT + TT;Other;increased   Other:serum total cholesterol;Genotypes AT + TT are associated with increased serum total cholesterol as compared to genotype AA.; 
;DOXORUBICIN;SLC28A3;rs7853758;AA + AG;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Genotypes AA + AG is associated with decreased likelihood of cardiotoxicity when treated with doxorubicin in children with Neoplasms, Wilms Tumor, Sarcoma, Ewing's, Hodgkin Disease, Lymphoma, Non-Hodgkin, Osteosarcoma or Neuroblastoma as compared to genotype GG.;"in children with ""Neoplasms"", ""Wilms Tumor"", ""Sarcoma, Ewing's"", ""Hodgkin Disease"", ""Non-Hodgkin Lymphoma"", ""Osteosarcoma"", ""Neuroblastoma"""
;HMG COA REDUCTASE INHIBITORS;ABCB1;rs1045642;AA;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.; 
;NICOTINE;CHRNA3;rs3743075;T;Toxicity;decreased severity of Side Effect:Tobacco Use Disorder;Allele T is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele C.;in men 
;NICOTINE;CHRNB4;rs7178270;G;Toxicity;decreased severity of Side Effect:Tobacco Use Disorder;Allele G is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele C.;in men 
;VINCRISTINE;NDRG1;rs2272653;G;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Allele G is associated with increased severity of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to allele A.;in children with Acute lymphoblastic leukemia, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma, Glioma
;NICOTINE;CHRNB4;rs1948;A;Toxicity;decreased severity of Side Effect:Tobacco Use Disorder;Allele A is associated with decreased severity of Tobacco Use Disorder due to nicotine in men as compared to allele G.;in men 
;PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes AA + AG is associated with decreased overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1719247;T;Toxicity;decreased likelihood of Disease:Muscular Diseases;Allele T is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors or simvastatin as compared to allele C.; 
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;AA;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotype AG.; 
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Genotype CC is associated with increased likelihood of Elevated circulating creatine kinase concentration when exposed to hmg coa reductase inhibitors as compared to genotypes CT + TT.; 
;HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1346268;C;Toxicity;decreased likelihood of Disease:Muscular Diseases;Allele C is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors or simvastatin as compared to allele T.; 
;PRAVASTATIN;SLCO1B1;rs4149056;CT;Metabolism/PK;increased   PK:pravastatin plasma concentrations (AUC) and Cmax;Genotype CT is associated with increased pravastatin plasma concentrations (AUC) and Cmax when exposed to pravastatin in healthy individuals as compared to genotype TT.;in healthy individuals 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;CT + TT;Toxicity;increased  risk of Side Effect:Nausea;Genotypes CT + TT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;IMATINIB;UGT2A1;rs11249454;CC;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype CC is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CT + TT.;in people with Disease:Gastrointestinal Stromal Tumors
;ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;rs11155012;A;Efficacy;increased  risk of Disease:Death;Allele A is associated with increased risk of Death when treated with anthracyclines and related substances in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;ABCB1;rs1128503;AA;Toxicity;increased  likelihood of Side Effect:Elevated circulating creatine kinase concentration;Genotype AA is associated with increased likelihood of Elevated circulating creatine kinase concentration when treated with hmg coa reductase inhibitors as compared to genotypes AG + GG.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA;Toxicity;increased  risk of Side Effect:Vomiting;Genotype AA is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;GEMCITABINE;SLC28A1;rs3825876;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Pancreatic Neoplasms
;ATORVASTATIN;SLCO1B1;rs4149056;CC;Metabolism/PK;increased   PK:AUC;Genotype CC is associated with increased AUC when exposed to atorvastatin in healthy individuals as compared to genotype TT.;in healthy individuals 
;GEMCITABINE;CDA;rs2072671;AC + CC;Toxicity;decreased risk of Side Effect:Neutropenia;Genotypes AC + CC are associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA.;in people with Disease:Pancreatic Neoplasms
;RISPERIDONE;ABCB1;rs1045642;AA + AG;Toxicity;increased   Side Effect:Prolonged QTc interval;Genotypes AA + AG is associated with increased electrocardiogram qt prolonged when treated with risperidone in people with Schizophrenia as compared to genotype GG.;in people with Disease:Schizophrenia
;PITAVASTATIN;SLCO1B1;rs2306283;AG + GG;Metabolism/PK;increased   PK:pitavastatin plasma concentrations (AUC) and Cmax;Genotypes AG + GG are associated with increased pitavastatin plasma concentrations (AUC) and Cmax when exposed to pitavastatin in healthy individuals as compared to genotype AA.;in healthy individuals 
;SORAFENIB;EGFR;rs2330951;C;Toxicity;increased  risk of Side Effect:Hypertension;Allele C is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.;in people with Renal Cell Carcinoma
;ROSUVASTATIN;SLCO1B1;rs4149056;CC;Metabolism/PK;increased   PK:AUC (p=0.002) and Cmax (p=0.003);Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.;in healthy individuals 
;HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;Toxicity;decreased likelihood of Disease:Muscular Diseases;Allele A is associated with decreased likelihood of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele G.; 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Side Effect:stent thrombosis;Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased  risk of Other:major adverse cardiovascular events;Allele A is associated with increased risk of major adverse cardiovascular events when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;EVEROLIMUS;ABCB1;rs2032582;A;Toxicity, Other;increased  likelihood of Side Effect:Lymphopenia;Allele A is associated with increased likelihood of Lymphopenia when treated with everolimus in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;Toxicity;increased  risk of Side Effect:Nausea;Genotype CC is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CG + GG.;in women with Disease:Breast Neoplasms
;AZATHIOPRINE, MERCAPTOPURINE;;rs2647087;C;Toxicity;increased  risk of Side Effect:Pancreatitis;Allele C is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele A.;in people with Disease:Inflammatory Bowel Diseases
;EVEROLIMUS;RPTOR;rs9906827;T;Toxicity, Other;decreased likelihood of Side Effect:Pneumonitis;Allele T is associated with decreased likelihood of pneumonitis when treated with everolimus in women with Breast Neoplasms as compared to allele C.;in women with Disease:Breast Neoplasms
;RADIOTHERAPY;XPC;rs2228001;G;Toxicity;decreased likelihood of Side Effect:Exanthema;Allele G is associated with decreased likelihood of Exanthema when exposed to radiotherapy in people with Head and Neck Neoplasms as compared to allele T.;in people with Head and Neck Neoplasms
;EVEROLIMUS;ABCB1;rs1045642;A;Toxicity, Other;increased  likelihood of Side Effect:Mucositis;Allele A is associated with increased likelihood of mucositis when treated with everolimus in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA + AG;Toxicity;increased  risk of Side Effect:Nausea;Genotypes AA + AG are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;C;Toxicity;increased  risk of Side Effect:Leukopenia;Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.;in people with Disease:Irritable Bowel Syndrome
;PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;Efficacy;increased  likelihood of Efficacy:Myocardial Infarction, Efficacy:Myocardial Ischemia, Efficacy:Stroke;Genotypes AA + AG is associated with increased likelihood of Myocardial Infarction, Myocardial Ischemia or Stroke when treated with Platelet aggregation inhibitors excl. heparin in people with Coronary Artery Disease as compared to genotype GG.;in people with Coronary Artery Disease
;SUNITINIB;VEGFA;rs833061;CC + CT;Efficacy;increased   Efficacy:Progression-free survival;Genotypes CC + CT is associated with increased progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT.;in people with Disease:Renal Cell Carcinoma
;AZACITIDINE;MTHFR;rs1801133;AA;Efficacy;decreased  Efficacy:Overall survival;Genotype AA is associated with decreased overall survival when treated with azacitidine in people with Myelodysplastic Syndromes as compared to genotypes AG + GG.;in people with Disease:Myelodysplastic Syndromes
;CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;Efficacy;increased  risk of Efficacy:high post-treatment platelet reactivity;Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.;in patients treated with percutaneous coronary intervention (PCI)
;PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;Efficacy;increased  likelihood of Efficacy:Myocardial Infarction, Efficacy:Myocardial Ischemia, Efficacy:Stroke;Genotype AA is associated with increased likelihood of Myocardial Infarction, Myocardial Ischemia or Stroke when treated with Platelet aggregation inhibitors excl. heparin in people with Coronary Artery Disease as compared to genotypes AC + CC.;in people with Coronary Artery Disease
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs3212986;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AC + CC.;in women with Disease:Breast Neoplasms
;IMATINIB;SLC22A1;rs628031;GG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype GG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.;in people with Disease:Gastrointestinal Stromal Tumors
;ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs6500265;CT + TT;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Genotypes CT + TT are associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype CC.; 
;IMATINIB;SLC19A1;rs1051266;TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype TT is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.;in people with Disease:Gastrointestinal Stromal Tumors
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;rs1994862;CC;Other;decreased risk of Side Effect:arousal dysfunction;Genotype CC is associated with decreased risk of arousal dysfunction when treated with Selective serotonin reuptake inhibitors in people with Depression as compared to genotypes CG + GG.;in people with Disease:Depression
;EVEROLIMUS;RPTOR;rs9906827;CT + TT;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotypes CT + TT are associated with increased likelihood of progression-free survival when treated with everolimus in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;IMATINIB;CHST1;rs9787901;AA + AG;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.;in people with Disease:Gastrointestinal Stromal Tumors
;IMATINIB;CYP2F1;rs305968;AA;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AA is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AG + GG.;in people with Disease:Gastrointestinal Stromal Tumors
;ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs9933632;GT + TT;Toxicity;increased  risk of Side Effect:Toxic Epidermal Necrolysis, Side Effect:Stevens-Johnson Syndrome;Genotypes GT + TT are associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen, ibuprofen, loxoprofen or salicylamide as compared to genotype GG.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;rs20572;TT;Toxicity;increased  risk of Side Effect:Vomiting;Genotype TT is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;rs1042522;GG;Toxicity;increased  risk of Side Effect:Vomiting;Genotype GG is associated with increased risk of Vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CG.;in women with Disease:Breast Neoplasms
;SORAFENIB;PRKCE;rs11125039;G;Toxicity;increased  risk of Side Effect:Hypertension;Allele G is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.;in people with Renal Cell Carcinoma
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs714368;CC + CT;Toxicity;increased  risk of Side Effect:Nausea;Genotypes CC + CT are associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype TT.;in women with Disease:Breast Neoplasms
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;IL10;rs1800896;C;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;Allele C is associated with increased risk of Drug Hypersensitivity due to Antiinflammatory agents, non-steroids as compared to allele T.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;rs25487;CT + TT;Toxicity;increased  risk of Side Effect:Nausea;Genotypes CT + TT is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CTLA4;rs231775;G;Toxicity;decreased risk of Side Effect:Drug Hypersensitivity;Allele G is associated with decreased risk of Drug Hypersensitivity due to Antiinflammatory agents, non-steroids as compared to allele A.; 
;;ADH7;rs971074;CT + TT;Other;increased  severity of Other:Pain;Genotypes CT + TT is associated with increased severity of Pain in people with Anemia, Sickle Cell as compared to genotype CC.;in people with Anemia, Sickle Cell
;SORAFENIB;ADAMTS18;rs1346563;A;Toxicity;increased  risk of Side Effect:Hypertension;Allele A is associated with increased risk of Hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Renal Cell Carcinoma
;PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;Efficacy;increased   Efficacy:Overall survival;Genotypes CT + TT is associated with increased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;rs1695;AA + AG;Toxicity;increased  risk of Side Effect:Nausea;Genotypes AA + AG is associated with increased risk of Nausea when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;CISPLATIN;SLC31A1;rs10981694;GG + GT;Toxicity;increased  severity of Disease:Ototoxicity;Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs12248560;CC;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype CC is associated with increased risk of Leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;TT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype TT is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes CC + CT.;in women with Disease:Breast Neoplasms
;DEXMEDETOMIDINE;ABCC9;rs11046209;AA;Efficacy;increased  severity of Efficacy:sedation;Genotype AA is associated with increased severity of sedation when treated with dexmedetomidine in people with surgery as compared to genotypes AT + TT.;in people with surgery
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;rs1045642;GG;Toxicity;increased  risk of Side Effect:Anemia;Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.;in women with Disease:Breast Neoplasms
;VINCRISTINE;CEP72;rs12522955;A;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in people with Medulloblastoma, Glioma or Brain Neoplasms as compared to allele C.;in people with Medulloblastoma, Glioma, Brain Neoplasms
;CAPECITABINE;;rs72765700;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;rs2231142;GT;Toxicity;increased  risk of Side Effect:Anemia;Genotype GT is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;Toxicity;increased  severity of Disease:Thrombocytopenia;Genotype AC is associated with increased severity of Thrombocytopenia when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;AZATHIOPRINE, MERCAPTOPURINE;FTO;rs79206939;A;Toxicity;increased  risk of Side Effect:Leukopenia;Allele A is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele G.;in people with Disease:Irritable Bowel Syndrome
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Leukopenia;Genotypes CG + GG are associated with increased risk of Anemia and Leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;Efficacy;decreased  Efficacy:event free survival;Genotype AC is associated with decreased event free survival when treated with antineoplastic agents, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;PRAVASTATIN;HMGCR;rs17238540;GT;Efficacy;decreased  Efficacy:reduction in total cholesterol;Genotype GT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype TT.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:high post-treatment platelet reactivity;Genotypes AA + AG are associated with increased risk of high post-treatment platelet reactivity when treated with clopidogrel in patients treated with percutaneous coronary intervention (PCI) as compared to genotype GG.;in patients treated with percutaneous coronary intervention (PCI)
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs2273697;GG;Toxicity;increased  risk of Side Effect:Anemia;Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG.;in women with Disease:Breast Neoplasms
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs6907567;AA;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;EVEROLIMUS;FGFR4;rs351855;A;Toxicity, Other;decreased likelihood of Other:Discontinuation;Allele A is associated with decreased likelihood of discontinuation when treated with everolimus in women with Breast Neoplasms as compared to allele G.;in women with Disease:Breast Neoplasms
;VINCRISTINE;CEP72;rs924607;TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotype TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in people with Medulloblastoma, Glioma, Brain Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell, Leukemia, Sarcoma, Ewing's or Lymphoma, Non-Hodgkin as compared to genotypes CC + CT.;"in people with ""Medulloblastoma"", ""Glioma"", ""Brain Neoplasms"", ""Acute lymphoblastic leukemia"", ""Lymphoma, B-Cell"", ""Leukemia"", ""Sarcoma, Ewing's"", ""Non-Hodgkin Lymphoma"""
;AZATHIOPRINE, MERCAPTOPURINE;;rs2834826;T;Toxicity;increased  risk of Side Effect:Leukopenia;Allele T is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele C.;in people with Disease:Irritable Bowel Syndrome
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs4244285;AA + AG;Toxicity;increased  risk of Side Effect:Neutropenia;Genotypes AA + AG is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype GG.;in women with Disease:Breast Neoplasms
;IMATINIB;SLC19A1;rs12659;AG + GG;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotypes AG + GG is associated with decreased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.;in people with Disease:Gastrointestinal Stromal Tumors
;AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;C;Toxicity;increased  risk of Side Effect:Leukopenia;Allele C is associated with increased risk of Leukopenia when treated with azathioprine or mercaptopurine in people with Irritable Bowel Syndrome as compared to allele T.;in people with Disease:Irritable Bowel Syndrome
;AZACITIDINE;XRCC1;rs25487;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with azacitidine in people with Myelodysplastic Syndromes as compared to genotypes CT + TT.;in people with Disease:Myelodysplastic Syndromes
;IMATINIB;NQO1;rs10517;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.;in people with Disease:Gastrointestinal Stromal Tumors
;EVEROLIMUS;PIK3R1;rs10515074;G;Toxicity, Other;decreased likelihood of Side Effect:Hyperglycemia;Allele G is associated with decreased likelihood of Hyperglycemia when treated with everolimus in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;DESLORATADINE;HRH1;rs901865;CC;Toxicity;increased  severity of Side Effect:sedation;Genotype CC is associated with increased severity of sedation due to desloratadine in people with Urticaria as compared to genotypes CT + TT.;in people with Urticaria
;IMATINIB;ABCC2;rs2273697;GG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG.;in people with Disease:Gastrointestinal Stromal Tumors
;CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;rs1799983;TT;Toxicity;decreased  Side Effect:IQ;Genotype TT is associated with decreased IQ when treated with cytarabine, doxorubicin, leucovorin, methotrexate, prednisone and vincristine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.;in people with Disease:Acute lymphoblastic leukemia
;IMATINIB;ABCB4;rs1202283;AA + AG;Efficacy;increased   Efficacy:Progression-free survival;Genotypes AA + AG is associated with increased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.;in people with Disease:Gastrointestinal Stromal Tumors
;EVEROLIMUS;PIK3R1;rs10515074;G;Toxicity, Other;increased  likelihood of Side Effect:Leukopenia;Allele G is associated with increased likelihood of Leukopenia when treated with everolimus in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;CAPECITABINE;MIR2054;rs10024471;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;AZATHIOPRINE;NUDT15;rs116855232;CT + TT;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotypes CT + TT is associated with increased likelihood of Neutropenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to genotype CC.;in people with Disease:Autoimmune Diseases, Disease:Systemic lupus erythematosus, Disease:Sjogren's Syndrome
;METHOTREXATE;DHFR;rs1105525;CT + TT;Efficacy;decreased  Efficacy:event free survival;Genotypes CT + TT are associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;rs3766522;TT;Toxicity;decreased severity of Side Effect:Weight gain;Genotype TT is associated with decreased severity of Weight gain when treated with antipsychotics, clozapine or olanzapine in people with schizoaffective disorder or Schizophrenia as compared to genotypes AA + AT.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;METHADONE;NECTIN4;rs11265549;AA;Toxicity;increased  likelihood of Side Effect:Pruritus;Genotype AA is associated with increased likelihood of Pruritus when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Opioid-Related Disorders
;CAPECITABINE;SPRY2;rs117876855;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;AZATHIOPRINE;NUDT15;rs116855232;T;Toxicity;increased  likelihood of Side Effect:Leukopenia;Allele T is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Autoimmune Diseases, Lupus Erythematosus, Systemic or Sjogren's Syndrome as compared to allele C.;in people with Disease:Autoimmune Diseases, Disease:Systemic lupus erythematosus, Disease:Sjogren's Syndrome
;CAPECITABINE;SPRY2;rs139544515;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;Efficacy;decreased risk of Disease:Colonic Neoplasms;Genotype AA is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors.; 
;RIVAROXABAN;CYP3A4;rs2246709;AA;Toxicity;decreased likelihood of Side Effect:Hemorrhage;Genotype AA is associated with decreased likelihood of Hemorrhage when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.;in people with Atrial Fibrillation
;METHOTREXATE;GGH;rs11545078;A;Toxicity;increased  likelihood of Disease:Thrombocytopenia;Allele A is associated with increased likelihood of Thrombocytopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in people with Disease:Acute lymphoblastic leukemia
;CAPECITABINE;NCOA7;rs185217050;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;CAPECITABINE;CCDC70;rs139368788;A;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele A is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes AA + AG are associated with increased likelihood of Drug Toxicity due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG.;in children with Juvenile Rheumatoid Arthritis
;;HMGCR;rs12654264;AT + TT;Other;increased   Other:serum LDL;Genotypes AT + TT are associated with increased serum LDL as compared to genotype AA.; 
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs11615;AG + GG;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Nephrotoxicity;Genotypes AG + GG are associated with increased risk of Anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotype AA.;in women with Disease:Breast Neoplasms
;CAPECITABINE;TMEM131L;rs117412990;G;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;PRAVASTATIN;HMGCR;rs17244841;AT;Efficacy;decreased  Efficacy:reduction in total cholesterol;Genotype AT is associated with decreased reduction in total cholesterol when treated with pravastatin as compared to genotype AA.; 
;HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;TT;Efficacy;decreased risk of Disease:Colonic Neoplasms;Genotype TT is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors.; 
;CAPECITABINE;SIRPA;rs191934521;G;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele G is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;rs10789038;AA;Toxicity;decreased severity of Side Effect:Weight gain;Genotype AA is associated with decreased severity of Weight gain when treated with antipsychotics, clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;RIVAROXABAN;CYP3A4;rs3735451;TT;Toxicity;decreased likelihood of Side Effect:Hemorrhage;Genotype TT is associated with decreased likelihood of Hemorrhage when treated with rivaroxaban in people with Atrial Fibrillation as compared to genotypes CC + CT.;in people with Atrial Fibrillation
;CAPECITABINE;LMNTD1;rs146644707;T;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome;Allele T is associated with increased likelihood of hand-foot syndrome when treated with capecitabine in people with Breast Neoplasms, Colorectal Neoplasms and Neoplasms as compared to allele C.;in people with Disease:Breast Neoplasms, Disease:Colorectal Neoplasms, Disease:Neoplasms
;METHOTREXATE;MTHFR;rs1801133;GG;Toxicity;decreased risk of Side Effect:Drug Toxicity;Genotype GG is associated with decreased risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes AA + AG.;in children with Disease:Neoplasms
;ANTINEOPLASTIC AGENTS;RBFOX1;rs6500843;G;Efficacy;increased  risk of Disease:Death;Allele G is associated with increased risk of Death when treated with antineoplastic agents in women with Breast Neoplasms as compared to allele A.;in women with Disease:Breast Neoplasms
;HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;Efficacy;decreased risk of Disease:Colonic Neoplasms;Genotype AA is associated with decreased risk of Colonic Neoplasms when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;PLATINUM;XRCC5;rs1051685;G;Toxicity;decreased severity of Disease:Anemia, Disease:Leukopenia, Disease:Neutropenia, Disease:Thrombocytopenia;Allele G is associated with decreased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to allele A.;in people with Disease:Lung Neoplasms
;CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;rs7799039;AG + GG;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Genotypes AG + GG is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with Schizophrenia as compared to genotype AA.;in people with Disease:Schizophrenia
;IRINOTECAN;ABCC1;rs17287570;A;Toxicity;decreased likelihood of Side Effect:severe myelosuppression;Allele A is associated with decreased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;SORAFENIB;EPAS1;rs1868089;C;Toxicity;increased  risk of Side Effect:dermatologic toxicity;Allele C is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.;in people with Renal Cell Carcinoma
;PLATINUM;XRCC5;rs6941;A;Toxicity;increased  severity of Disease:Anemia, Disease:Leukopenia, Disease:Neutropenia, Disease:Thrombocytopenia;Allele A is associated with increased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to allele C.;in people with Disease:Lung Neoplasms
;CYCLOPHOSPHAMIDE;CYP2A6;rs143731390;A;Toxicity;increased  likelihood of Side Effect:Death;Allele A is associated with increased likelihood of Death when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele T.;in people with Hematopoietic stem cell transplantation
;IRINOTECAN;ABCG2;rs2622604;T;Toxicity;increased  likelihood of Side Effect:severe myelosuppression;Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;FOLIC ACID;MTHFD1;rs2236225;AA;Other;decreased likelihood of Other:Diabetes, Gestational;Genotype AA is associated with decreased likelihood of Diabetes, Gestational when treated with folic acid in women with Pregnancy as compared to genotypes AG + GG.;in women with Pregnancy
;METHOTREXATE;DHFR;rs442767;GG;Efficacy;decreased  Efficacy:event-free survival;Genotype GG is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.;in children with Disease:Acute lymphoblastic leukemia
;IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs11692021;CT + TT;Toxicity;decreased likelihood of Side Effect:severe myelosuppression;Genotypes CT + TT are associated with decreased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;PLATINUM;AQP2;rs10875989;T;Toxicity;increased  severity of Disease:Anemia, Disease:Leukopenia, Disease:Neutropenia, Disease:Thrombocytopenia;Allele T is associated with increased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to allele C.;in people with Disease:Lung Neoplasms
;APIXABAN, RIVAROXABAN;ABCG2;rs3114018;AA + AC;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes AA + AC is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.;in people with Atrial Fibrillation
;IRINOTECAN;SLCO1B3;rs7977213;G;Toxicity;increased  likelihood of Side Effect:severe myelosuppression;Allele G is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;METHOTREXATE;DHFR;rs408626;TT;Efficacy;decreased  Efficacy:event-free survival;Genotype TT is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;Toxicity;decreased likelihood of Side Effect:Graft vs Host Disease;Allele T is associated with decreased likelihood of Graft vs Host Disease when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele G.;in people with Hematopoietic stem cell transplantation
;PLATINUM;AQP2;rs3759125;AA + AC;Toxicity;increased  severity of Disease:Anemia, Disease:Leukopenia, Disease:Neutropenia, Disease:Thrombocytopenia;Genotypes AA + AC is associated with increased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to genotype CC.;in people with Disease:Lung Neoplasms
;IRINOTECAN;SLCO1B3;rs10841661;T;Toxicity;increased  likelihood of Side Effect:severe myelosuppression;Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;METHOTREXATE;DHFR;rs1650697;AA;Efficacy;decreased  Efficacy:event-free survival;Genotype AA is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in children with Disease:Acute lymphoblastic leukemia
;APIXABAN, RIVAROXABAN;ABCG2;rs2622604;CT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotype CC.;in people with Atrial Fibrillation
;PLATINUM;AQP2;rs461872;A;Toxicity;decreased severity of Disease:Diarrhea, Disease:Nausea, Disease:Vomiting;Allele A is associated with decreased severity of Diarrhea, Nausea and Vomiting when treated with platinum in people with Lung Neoplasms as compared to allele G.;in people with Disease:Lung Neoplasms
;PLATINUM;AQP2;rs7305534;CC + CT;Toxicity;increased  severity of Disease:Diarrhea, Disease:Nausea, Disease:Vomiting;Genotypes CC + CT is associated with increased severity of Diarrhea, Nausea and Vomiting when treated with platinum in people with Lung Neoplasms as compared to genotype TT.;in people with Disease:Lung Neoplasms
;MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;rs41291556;C;Metabolism/PK;PK:dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide;Allele C is associated with dramatic (approximately 90% and 70%) reduction in the metabolism of S-mephenytoin and tolbutamide when exposed to mephenytoin and tolbutamide as compared to allele T.; 
;PLATINUM;CD74;rs2748249;A;Toxicity;increased  severity of Disease:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Disease:Non-Small Cell Lung Carcinoma
;ASPIRIN;TBXAS1;rs6962291;AA;Other;decreased risk of Side Effect:intolerance;Genotype AA is associated with decreased risk of intolerance when treated with aspirin in people with Asthma as compared to genotype TT.;in people with Disease:Asthma
;PLATINUM;CD74;rs1560661;C;Toxicity;decreased severity of Disease:Drug Toxicity;Allele C is associated with decreased severity of Drug Toxicity when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYTARABINE;CDA;rs2072671;AA;Toxicity, Metabolism/PK;decreased risk of Side Effect:grade III/IV liver toxicity;Genotype AA is associated with decreased risk of grade III/IV liver toxicity when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotypes AC + CC.;in people with Disease:Leukemia, Myeloid, Acute
;WARFARIN;;rs12777823;A;Dosage;Efficacy:reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3.;Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.; 
;WARFARIN;;rs12777823;A;Dosage;Efficacy:reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3.;Allele A is associated with reduced warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. when treated with warfarin as compared to allele G.; 
;;ALDH1A2;rs12915901;A;Other;increased  likelihood of Other:Osteoarthritis;Allele A is associated with increased likelihood of Osteoarthritis as compared to allele G.; 
;RALOXIFENE, TAMOXIFEN;;rs10030044;G;Efficacy;increased  risk of Efficacy:occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy;Allele G is associated with increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele T.;in people with Disease:Breast Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CT + TT;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome, Side Effect:Mucositis, Side Effect:Peripheral Nervous System Diseases;Genotypes CT + TT is associated with increased likelihood of hand-foot syndrome, mucositis or Peripheral Nervous System Diseases when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;;SLC2A1;rs841844;CG + GG;Toxicity;increased  severity of Disease:Drug Toxicity;Genotypes CG + GG is associated with increased severity of Drug Toxicity when treated with in people with Lung Neoplasms as compared to genotype CC.;in people with Disease:Lung Neoplasms
;CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;TT;Toxicity;increased  severity of Side Effect:Diarrhea;Genotype TT is associated with increased severity of Diarrhea when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotypes CC + CT.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  risk of Efficacy:insufficient antiplatelet response to clopidogrel;Genotypes AA + AG are associated with increased risk of insufficient antiplatelet response to clopidogrel when treated with clopidogrel in patients undergoing elective coronary stent implantation as compared to genotype GG.;in patients undergoing elective coronary stent implantation
;DASATINIB;ABL1;rs121913459;CT;Other, Metabolism/PK;decreased  PK:AUC 0-4 hours;Genotype CT is associated with decreased AUC 0-4 hours of dasatinib in people with Leukemia as compared to genotype CC.;in people with Disease:Leukemia
;PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;Efficacy;decreased severity of Disease:Hepatitis C virus infection;Genotype TT is associated with decreased severity of Hepatitis C when treated with peginterferon alfa-2b and ribavirin as compared to genotypes GG + GT.; 
;HYDROCHLOROTHIAZIDE;AGT;rs5051;T;Efficacy;increased   Efficacy:reduction in blood pressure;Allele T is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in women with Essential hypertension as compared to allele C.;in women with Disease:Essential hypertension
;HYDROCHLOROTHIAZIDE;AGTR1;rs5186;A;Efficacy;increased   Efficacy:reduction in blood pressure;Allele A is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in women with Essential hypertension as compared to allele C.;in women with Disease:Essential hypertension
;TAMOXIFEN;ESR2;rs4986938;CC;Other;increased   Side Effect:triglycerides in postmenopausal woman;Genotype CC is associated with increased triglycerides in postmenopausal woman when treated with tamoxifen as compared to genotype TT.; 
;AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;Toxicity;increased  severity of Side Effect:Leukopenia, Side Effect:Neutropenia;Allele T is associated with increased severity of Leukopenia and Neutropenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to allele C.;in people with Disease:Inflammatory Bowel Diseases
;ONDANSETRON;ABCB1;rs1045642;AA;Efficacy;decreased likelihood of Disease:Postoperative Nausea and Vomiting;Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron as compared to genotypes AG + GG.; 
;TAMOXIFEN;ESR1;rs9340799;GG;Other;decreased  Side Effect:in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women;Genotype GG is associated with decreased in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women when treated with tamoxifen as compared to genotypes AA + AG.; 
;TALINOLOL;ABCC2;rs2273697;A;Other;increased   PK:residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol;Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol when exposed to talinolol as compared to allele G.; 
;CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder or Schizophrenia as compared to allele G.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;DOXORUBICIN;CBR3;rs8133052;G;Toxicity, Metabolism/PK;increased   PK:doxorubicinol AUC;Allele G is associated with increased doxorubicinol AUC when treated with doxorubicin in people with Breast Neoplasms as compared to allele A.;in people with Disease:Breast Neoplasms
;ONDANSETRON;ABCB1;rs2032582;AA;Efficacy;decreased likelihood of Disease:Postoperative Nausea and Vomiting;Genotype AA is associated with decreased likelihood of Postoperative Nausea and Vomiting when treated with ondansetron.; 
;CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;C;Toxicity;increased  likelihood of Side Effect:Metabolic Syndrome;Allele C is associated with increased likelihood of Metabolic Syndrome when treated with clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;BEVACIZUMAB, CYANOCOBALAMIN, FOLIC ACID, PEMETREXED;MTHFR;rs1801131;GG + GT;Efficacy;increased   Efficacy:overall survival;Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT.;in people with Disease:Head and Neck Neoplasms
;ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;CT;Toxicity;increased  risk of Side Effect:moderate anemia;Genotype CT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.;in children 
;RALOXIFENE, TAMOXIFEN;ZNF423;rs8060157;A;Efficacy;decreased risk of Efficacy:occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy;Allele A is associated with decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele G.;in people with Disease:Breast Neoplasms
;TACROLIMUS;ABCB1;rs1045642;AA + AG;Efficacy;Efficacy:Decreased glomerular filtration rate;Genotypes AA + AG is associated with Decreased glomerular filtration rate when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Kidney Transplantation
;CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;Toxicity, Metabolism/PK;increased  risk of Side Effect:neurological ADR;Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.;in people with Disease:Epilepsy
;ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;TT;Other;increased  risk of Side Effect:moderate anemia;Genotype TT is associated with increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine in children as compared to genotype CC.;in children 
;SORAFENIB;VEGFB;rs12366035;T;Toxicity;increased  risk of Side Effect:dermatologic toxicity;Allele T is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Renal Cell Carcinoma
;CYTARABINE;CDA;rs532545;TT;Efficacy;decreased  Efficacy:5 year survival;Genotype TT is associated with decreased 5 year survival when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.;in people with Disease:Leukemia, Myeloid, Acute
;CYTARABINE;CDA;rs532545;TT;Efficacy;increased  risk of Disease:Death;Genotype TT is associated with increased risk of Death when treated with cytarabine in people with Leukemia, Myeloid, Acute as compared to genotype CC.;in people with Disease:Leukemia, Myeloid, Acute
;VINCRISTINE;CEP72;rs71585289;C;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Allele C is associated with increased severity of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to allele G.;in children with Acute lymphoblastic leukemia, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma, Glioma
;CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;AA + AG;Efficacy;increased  risk of Disease:Infectious disease;Genotypes AA + AG is associated with increased risk of Infection when treated with cyclosporine and tacrolimus in people with heart transplantation as compared to genotype GG.;in people with Disease:Heart transplantation
;CLOPIDOGREL;P2RY12;rs2046934;GG;Toxicity;increased  likelihood of Side Effect:Acute coronary syndrome;Genotype GG is associated with increased likelihood of Acute coronary syndrome when treated with clopidogrel as compared to genotypes AA + AG.; 
;VINCRISTINE;MIR6076;rs35650931;CC + CG;Toxicity;decreased risk of Side Effect:Neurotoxicity Syndromes;Genotypes CC + CG are associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;SORAFENIB;WWOX;rs9927200;A;Toxicity;increased  risk of Side Effect:Diarrhea;Allele A is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Renal Cell Carcinoma
;DOXEPIN;CYP2C19;rs4244285;AA;Metabolism/PK;decreased  PK:median oral clearance of doxepin;Genotype AA is associated with decreased median oral clearance of doxepin when treated with doxepin in healthy individuals as compared to genotype GG.;in healthy individuals 
;ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;Toxicity;increased  risk of Disease:Cardiotoxicity;Allele A is associated with increased risk of cardiotoxicity when treated with anthracyclines and related substances in children with Neoplasms as compared to allele G.;in children with Disease:Neoplasms
;VINCRISTINE;MIR4481;rs7896283;G;Toxicity;increased  risk of Side Effect:Neurotoxicity Syndromes;Allele G are associated with increased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.;in children with Disease:Acute lymphoblastic leukemia
;CLOMIPRAMINE;CYP2C19;rs4244285;AG;Metabolism/PK;increased   PK:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine;Genotype AG is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to genotype GG.;in people with Disease:Mental Disorders
;CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC;Efficacy;decreased  Efficacy:event-free survival;Genotype CC is associated with decreased event-free survival when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype TT.;in people with Disease:Colorectal Neoplasms
;METHOTREXATE;SLC19A1;rs1051266;CT;Efficacy;increased  risk of Other:Toxic liver disease;Genotype CT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;CORTICOSTEROIDS;ACP1;rs11553746;TT;Toxicity;increased  likelihood of Side Effect:Osteonecrosis;Genotype TT is associated with increased likelihood of Osteonecrosis when treated with corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in children with Acute lymphoblastic leukemia
;SORAFENIB;MAP2K6;rs11651488;C;Toxicity;increased  risk of Side Effect:Diarrhea;Allele C is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.;in people with Renal Cell Carcinoma
;METHOTREXATE;MTHFR;rs1801131;GT;Efficacy;decreased risk of Other:Toxic liver disease;Genotype GT is associated with decreased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;SORAFENIB;CDH13;rs17682789;C;Toxicity;decreased risk of Side Effect:Diarrhea;Allele C is associated with decreased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.;in people with Renal Cell Carcinoma
;TACROLIMUS;CYP3A5;rs776746;CC;Efficacy;decreased likelihood of Efficacy:Recurrence;Genotype CC is associated with decreased likelihood of Recurrence when treated with tacrolimus in children with Nephrotic Syndrome as compared to genotype CT.;in children with Nephrotic Syndrome
;CLOMIPRAMINE;CYP2C19;rs4244285;AA;Metabolism/PK;increased   PK:mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine;Genotype AA is associated with increased mean clomipramine concentrations corrected for dose and weight and higher metabolic ratio of clomipramine/desmethylclomipramine when treated with clomipramine in people with Mental Disorders as compared to genotype GG.;in people with Disease:Mental Disorders
;PAROXETINE;FKBP5;rs1360780;T;Other;increased  risk of Side Effect:suicidal ideation;Allele T is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele C.;in people with Disease:Depression
;CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;rs1360780;T;Other;increased  risk of Side Effect:suicidal ideation;Allele T is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;ILOPERIDONE;CYP2D6;rs1065852;GG;Other;increased   Side Effect:QTc interval;Genotype GG is associated with increased QTc interval when treated with iloperidone in people with Schizophrenia as compared to genotypes AA + AG.;in people with Disease:Schizophrenia
;GEMCITABINE;SLC28A1;rs12148896;A;Toxicity;decreased risk of Side Effect:Neutropenia;Allele A is associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to allele G.;in people with Disease:Pancreatic Neoplasms
;METHOTREXATE;MTHFR;rs1801133;AA;Efficacy;increased  risk of Side Effect:Myelosuppression;Genotype AA is associated with increased risk of Myelosuppression due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Acute lymphoblastic leukemia
;CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;rs130058;A;Efficacy;decreased risk of Side Effect:suicidal ideation;Allele A is associated with decreased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine in people with Depression as compared to allele T.;in people with Disease:Depression
;PAROXETINE;HTR1B;rs130058;A;Other;increased  risk of Side Effect:suicidal ideation;Allele A is associated with increased risk of suicidal ideation when treated with paroxetine in people with Depression as compared to allele T.;in people with Disease:Depression
;GEMCITABINE;CDA;rs471760;A;Toxicity;decreased risk of Side Effect:Neutropenia;Allele A is associated with decreased risk of Neutropenia due to gemcitabine in people with Pancreatic Neoplasms as compared to allele G.;in people with Disease:Pancreatic Neoplasms
;CANNABIDIOL;ABCC5;rs3749442;AA + AG;Toxicity;increased  likelihood of Side Effect:sedation;Genotypes AA + AG are associated with increased likelihood of sedation when treated with cannabidiol in people with Epilepsy as compared to genotype GG.;in people with Epilepsy
;CISPLATIN;ACYP2;rs1872328;AG;Toxicity;increased  risk of Side Effect:Ototoxicity;Genotype AG is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to genotype GG.;in people with Disease:Osteosarcoma
;CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;rs2032582;A;Other;increased  risk of Side Effect:suicidal ideation;Allele A is associated with increased risk of suicidal ideation when treated with clomipramine, liothyronine, lithium, nefazodone, paroxetine or venlafaxine in people with Depression as compared to allele C.;in people with Disease:Depression
;MELPHALAN;SLC7A5;rs4240803;AA + AG;Toxicity;decreased risk of Side Effect:Gastrointestinal toxicity;Genotypes AA + AG is associated with decreased risk of gastrointestinal toxicity when treated with melphalan in people with Multiple Myeloma as compared to genotype GG.;in people with Disease:Multiple Myeloma
;ANTIPSYCHOTICS;MC4R;rs17782313;CC + CT;Other;increased  risk of Disease:Weight gain;Genotypes CC + CT are associated with increased risk of Weight gain when treated with antipsychotics as compared to genotype TT.; 
;PLATINUM;SLC2A1;rs3738514;T;Toxicity;decreased severity of Disease:Drug Toxicity;Allele T is associated with decreased severity of Drug Toxicity when treated with platinum in people with Lung Neoplasms as compared to allele C.;in people with Disease:Lung Neoplasms
;DOXORUBICIN;RARG;rs2229774;AA;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Genotype AA is associated with increased likelihood of cardiotoxicity when treated with doxorubicin in children with Neoplasms, Wilms Tumor, Sarcoma, Ewing's, Hodgkin Disease, Lymphoma, Non-Hodgkin, Osteosarcoma or Neuroblastoma as compared to genotypes AG + GG.;"in children with ""Neoplasms"", ""Wilms Tumor"", ""Sarcoma, Ewing's"", ""Hodgkin Disease"", ""Non-Hodgkin Lymphoma"", ""Osteosarcoma"", ""Neuroblastoma"""
;VINCRISTINE;GARS1;rs1049402;G;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Allele G is associated with increased severity of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to allele C.;in children with Acute lymphoblastic leukemia, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma, Glioma
;SORAFENIB;EGFR;rs917881;A;Toxicity;increased  risk of Side Effect:Diarrhea;Allele A is associated with increased risk of Diarrhea when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Renal Cell Carcinoma
;VINCRISTINE;FGD4;rs12823621;A;Toxicity;increased  severity of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with increased severity of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma or Glioma as compared to allele G.;in children with Acute lymphoblastic leukemia, Hodgkin Disease, Rhabdomyosarcoma, Medulloblastoma, Glioma
;CARBOPLATIN, CISPLATIN;SLC31A1;rs7851395;AA;Efficacy;increased   Efficacy:overall survival;Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;VINCRISTINE;MIR3117;rs12402181;AA + AG;Toxicity;decreased risk of Side Effect:Neurotoxicity Syndromes;Genotypes AA + AG are associated with decreased risk of Neurotoxicity Syndromes when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;rs13181;GT;Efficacy;increased   Efficacy:progression-free survival;Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT.;in people with Disease:Colorectal Neoplasms
;PLATINUM;SLC2A1;rs4658;CC;Toxicity;decreased severity of Disease:Drug Toxicity;Genotype CC is associated with decreased severity of Drug Toxicity when treated with platinum in people with as compared to genotypes CG + GG.;in people with 
;PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;Toxicity;increased  severity of Side Effect:Anemia;Genotype CC is associated with increased severity of Anemia when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes AA + AC.;in people with Disease:Hepatitis C virus infection
;FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;Efficacy;increased   Efficacy:overall survival;Genotypes AG + GG are associated with increased overall survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotype AA.;in people with Disease:Colorectal Neoplasms
;;ADD1;rs4961;GT + TT;Other;increased   Other:ambulatory blood pressure;Genotypes GT + TT are associated with increased ambulatory blood pressure in people with Hypertension as compared to genotype GG.;in people with Disease:Hypertension
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs238406;GT + TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotypes GT + TT are associated with increased risk of Leukopenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype GG.;in men with Disease:Testicular Neoplasms
;ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with atorvastatin as compared to genotype TT.; 
;CLOPIDOGREL;CYP3A5;rs776746;CC + CT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotypes CC + CT are associated with increased likelihood of adverse events when treated with clopidogrel in people with Stroke as compared to genotype TT.;in people with Disease:Stroke
;HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with hmg coa reductase inhibitors as compared to genotype TT.; 
;;RAD52, WNK1;rs2277869;CC;Other;increased   Other:ambulatory blood pressure;Genotype CC is associated with increased ambulatory blood pressure in people with Hypertension as compared to genotypes CT + TT.;in people with Disease:Hypertension
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs13422094;C;Efficacy;Efficacy:opioids response;Allele C is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;SUNITINIB;IL13;rs1800925;TT;Other;increased  severity of Side Effect:Drug Toxicity;Genotype TT is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs12211463;G;Efficacy;Efficacy:opioids response;Allele G is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7757130;A;Efficacy;Efficacy:opioids response;Allele A is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;FENTANYL;OPRM1;rs1799971;AG + GG;Toxicity;increased  likelihood of Side Effect:Somnolence;Genotypes AG + GG are associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype AA.;in healthy individuals 
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2473967;G;Efficacy;Efficacy:opioids response;Allele G is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;THIAZIDES, PLAIN;ADD1;rs4961;GG;Efficacy;decreased risk of Disease:Myocardial Infarction;Genotype GG is associated with decreased risk of Myocardial Infarction when treated with Thiazides, plain in people with Hypertension.;in people with Disease:Hypertension
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs1799793;TT;Toxicity;increased  risk of Side Effect:Anemia;Genotype TT is associated with increased risk of Anemia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CC + CT.;in men with Disease:Testicular Neoplasms
;SUNITINIB;IL13;rs1800925;TT;Other;increased  risk of Side Effect:Leukopenia;Genotype TT is associated with increased risk of Leukopenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes CC + CT.;in people with Disease:Renal Cell Carcinoma
;FENTANYL;COMT;rs4680;AG;Toxicity;increased  likelihood of Side Effect:Somnolence;Genotype AG is associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype GG.;in healthy individuals 
;SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;Toxicity;increased  risk of Side Effect:statin-related myopathy;Genotypes CC + CT are associated with increased risk of statin-related myopathy when treated with simvastatin as compared to genotype TT.; 
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;rs12948783;AA + AG;Efficacy;decreased  Efficacy:efficact as measured by lower pain relief to opioids;Genotypes AA + AG are associated with decreased efficact as measured by lower pain relief to opioids when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to genotype GG.;in people with Disease:Neoplasms
;ACE INHIBITORS, PLAIN;SH2B1;rs192613545;T;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele T is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain.; 
;RADIOTHERAPY;OSMR;rs1239344;T;Toxicity;increased  risk of Side Effect:Esophagitis;Allele T is associated with increased risk of Esophagitis when treated with radiotherapy as compared to allele C.; 
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;Toxicity;increased  risk of Side Effect:Pain;Genotype CC is associated with increased risk of Pain due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CT + TT.;in men with Disease:Testicular Neoplasms
;RADIOTHERAPY;CDK1;rs10711;G;Toxicity;increased  risk of Side Effect:Pneumonitis;Allele G is associated with increased risk of pneumonitis when treated with radiotherapy as compared to allele T.; 
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;Toxicity;increased  risk of Side Effect:Alopecia;Genotype CC is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes CT + TT.;in men with Disease:Testicular Neoplasms
;CELECOXIB;CYP2C9;rs1799853;CT;Metabolism/PK;PK:higher plasma concentrations of celecoxib;Genotype CT is associated with higher plasma concentrations of celecoxib when exposed to celecoxib in healthy individuals as compared to genotype CC.;in healthy individuals 
;HYDROCHLOROTHIAZIDE;REN;rs11240688;GG;Efficacy;increased   Efficacy:reduction in SBP;Genotype GG is associated with increased reduction in SBP when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotypes AA + AG.;in people with Disease:Essential hypertension
;HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;C;Efficacy;increased   Efficacy:reduction in blood pressure;Allele C is associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to allele T.;in people with Disease:Essential hypertension
;ACE INHIBITORS, PLAIN;RBFOX3;rs62063838;C;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele C is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain as compared to allele T.; 
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;Efficacy;increased   Efficacy:reduction in blood pressure;Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.;in people with Disease:Hypertension
;RADIOTHERAPY;PRKCE;rs940052;G;Toxicity;decreased risk of Side Effect:Esophagitis;Allele G is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele A.; 
;ACE INHIBITORS, PLAIN;MBOAT1;rs10946364;T;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele T is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain.; 
;RADIOTHERAPY;PRKCE;rs11125035;T;Toxicity;decreased risk of Side Effect:Esophagitis;Allele T is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele A.; 
;ROFECOXIB;PTGS1;rs3842787;T;Efficacy;Efficacy:reduction in COX-1 inhibition and depression of the urinary thromboxane metabolite;Allele T is associated with reduction in COX-1 inhibition and depression of the urinary thromboxane metabolite when exposed to rofecoxib in healthy individuals as compared to allele C.;in healthy individuals 
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs11615;AA;Toxicity;increased  risk of Side Effect:Febrile neutropenia;Genotype AA is associated with increased risk of febrile neutropenia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.;in men with Disease:Testicular Neoplasms
;RADIOTHERAPY;RIGI;rs11795343;C;Toxicity;increased  risk of Side Effect:Pneumonitis;Allele C is associated with increased risk of pneumonitis when treated with radiotherapy as compared to allele T.; 
;CISPLATIN;TPMT;rs12201199;T;Toxicity;increased  risk of Side Effect:Ototoxicity;Allele T is associated with increased risk of Ototoxicity when treated with cisplatin in children with Neoplasms as compared to allele A.;in children with Neoplasms
;DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Genotype AA is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis as compared to genotypes AG + GG.; 
;ACE INHIBITORS, PLAIN;RBFOX3;rs56044629;G;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele G is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain.; 
;HYDROCHLOROTHIAZIDE;WNK1;rs880054;TT;Efficacy;decreased  Efficacy:reduction in SBP;Genotype TT is associated with decreased reduction in SBP when treated with hydrochlorothiazide in people with Hypertension as compared to genotypes CC + CT.;in people with Disease:Hypertension
;RADIOTHERAPY;;rs7259857;C;Toxicity;decreased risk of Side Effect:Esophagitis;Allele C is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele T.; 
;CELECOXIB;PTGS1;rs3842787;T;Efficacy;Efficacy:reduction in COX-1 inhibition;Allele T is associated with reduction in COX-1 inhibition when exposed to celecoxib in healthy individuals as compared to allele C.;in healthy individuals 
;;COL1A1;rs1800012;AA + AC;;increased  risk of Disease:Fractures, Bone;Genotypes AA + AC are associated with increased risk of Fractures, Bone.; 
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;T;Efficacy;decreased  Efficacy:absolute mean blood pressure;Allele T is associated with decreased absolute mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.;in people with Disease:Hypertension
;ACE INHIBITORS, PLAIN;GABRG2;rs77370934;G;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele G is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain as compared to allele T.; 
;;COL1A1;rs1800012;AA + AC;;decreased  Other:bone mineral density (BMD);Genotypes AA + AC are associated with decreased bone mineral density (BMD).; 
;VINCRISTINE;BAHD1;rs3803357;AA + AC;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AC is associated with decreased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;ACE INHIBITORS, PLAIN;RBFOX3;rs56209714;G;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele G is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain as compared to allele A.; 
;CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colonic Neoplasms as compared to genotype CC.;in people with Disease:Colonic Neoplasms
;METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;rs1045642;AA;Toxicity;decreased risk of Side Effect:Osteonecrosis;Genotype AA is associated with decreased risk of Osteonecrosis when treated with methylprednisolone and prednisolone in people with Kidney Transplantation as compared to genotypes AG + GG.;in people with Disease:Kidney Transplantation
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;Toxicity;increased  risk of Side Effect:Infectious disease;Genotype GG is associated with increased risk of Infection due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AA + AG.;in men with Disease:Testicular Neoplasms
;ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;rs8113308;C;Efficacy;decreased  Efficacy:Overall survival;Allele C is associated with decreased overall survival when treated with anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to allele T.;in women with Disease:Breast Neoplasms
;PIRFENIDONE;CYP1A2;rs762551;AA;Toxicity;decreased likelihood of Side Effect:adverse events;Genotype AA is associated with decreased likelihood of adverse events when treated with pirfenidone in people with Pulmonary Fibrosis as compared to genotypes AC + CC.;in people with Pulmonary Fibrosis
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs13181;GG + GT;Toxicity;increased  risk of Side Effect:Alopecia;Genotypes GG + GT are associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT.;in men with Disease:Testicular Neoplasms
;CISPLATIN;OTOS;rs2291767;CC + CT;Toxicity;decreased risk of Side Effect:Ototoxicity;Genotypes CC + CT is associated with decreased risk of Ototoxicity when treated with cisplatin in people with Neoplasms as compared to genotype TT.;in people with Disease:Neoplasms
;ACE INHIBITORS, PLAIN;RBFOX3;rs2061538;G;Toxicity;increased  likelihood of Side Effect:Discontinuation;Allele G is associated with increased likelihood of discontinuation when treated with Ace Inhibitors, Plain as compared to allele A.; 
;SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;Toxicity;increased  likelihood of Side Effect:Diminished ability to concentrate;Genotype CC is associated with increased likelihood of Diminished ability to concentrate when treated with Selective serotonin reuptake inhibitors in people with Major Depressive Disorder as compared to genotypes CT + TT.;in people with Major Depressive Disorder
;CITALOPRAM;HTR2A;rs6311;CC;Toxicity;increased  likelihood of Side Effect:Nausea, Side Effect:Vomiting;Genotype CC is associated with increased likelihood of Nausea and Vomiting due to citalopram in people with Depressive Disorder, Major as compared to genotypes CT + TT.;in people with Major Depressive Disorder
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Toxicity;increased  risk of Side Effect:Nephrotoxicity;Genotypes CT + TT is associated with increased risk of nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;MERCAPTOPURINE, METHOTREXATE;MTHFR;rs1801131;GG;Toxicity;decreased risk of Disease:Myelosuppression;Genotype GG is associated with decreased risk of Myelosuppression when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT.;in people with Disease:Acute lymphoblastic leukemia
;SUNITINIB;CXCL8;rs1126647;TT;Other;increased  likelihood of Side Effect:Hypertension;Genotype TT is associated with increased likelihood of Hypertension when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AA + AT.;in people with Disease:Renal Cell Carcinoma
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;rs2302273;AA + AG;Efficacy;increased   Efficacy:Progression-free survival;Genotypes AA + AG is associated with increased progression-free survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;ETHANOL;PNPLA3;rs738409;GG;Toxicity;increased  risk of Other:Alcohol abuse;Genotype GG is associated with increased risk of Alcoholism due to ethanol in men as compared to genotypes CC + CG.;in men 
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs2661280;CC + CG;Efficacy;increased   Efficacy:Overall survival;Genotypes CC + CG is associated with increased overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;SORAFENIB;EPAS1;rs9973653;T;Toxicity;decreased risk of Side Effect:Drug Toxicity;Allele T is associated with decreased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Renal Cell Carcinoma
;;WT1;rs16754;CC + CT;Other;increased  likelihood of Disease:event-free survival;Genotypes CC + CT is associated with increased likelihood of event-free survival in children with as compared to genotype TT.;in children with 
;TACROLIMUS;CYP3A5;rs776746;CT + TT;Efficacy;increased  risk of Efficacy:Transplant rejection;Genotypes CT + TT is associated with increased risk of transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;MERCAPTOPURINE;ITPA;rs1127354;A;Toxicity;increased  risk of Disease:Neutropenia;Allele A is associated with increased risk of Neutropenia when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;CANNABINOIDS;FAAH;rs324420;AA;Toxicity;decreased risk of Disease:Substance-Related Disorders;Genotype AA is associated with decreased risk of Substance-Related Disorders when exposed to cannabinoids as compared to genotypes AC + CC.; 
;SORAFENIB;;rs315498;C;Toxicity;decreased risk of Side Effect:Drug Toxicity;Allele C is associated with decreased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele T.;in people with Renal Cell Carcinoma
;CYCLOPHOSPHAMIDE;GSTA1;rs3957357;A;Toxicity;increased  likelihood of Side Effect:Death;Allele A is associated with increased likelihood of Death when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele G.;in people with Hematopoietic stem cell transplantation
;VINCRISTINE;MRPL47;rs10513762;CT + TT;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes CT + TT is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in children with Disease:Acute lymphoblastic leukemia
;FLUOROURACIL;DPYD;rs67376798;AT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype TT.;in people with Disease:Colonic Neoplasms
;VINCRISTINE;SYNE2;rs2781377;A;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.;in children with Disease:Acute lymphoblastic leukemia
;SORAFENIB;EPAS1;rs4035887;A;Toxicity;increased  risk of Side Effect:Drug Toxicity;Allele A is associated with increased risk of Drug Toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele G.;in people with Renal Cell Carcinoma
;ANTIPSYCHOTICS;COMT;rs4680;AA + AG;Toxicity;increased  likelihood of Side Effect:Elevated diastolic blood pressure, Side Effect:Elevated systolic blood pressure;Genotypes AA + AG is associated with increased likelihood of Elevated diastolic blood pressure and Elevated systolic blood pressure when treated with antipsychotics in children as compared to genotype GG.;in children 
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;increased   Efficacy:on-treatment platelet reactivity;Allele A is associated with increased on-treatment platelet reactivity when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG.;in people with Disease:Juvenile Rheumatoid Arthritis
;METHOTREXATE;DHFR;rs408626;CC;Efficacy;decreased  Other:event-free survival, Other:Overall survival;Genotype CC is associated with decreased event-free survival and overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801131;G;Toxicity;increased  likelihood of Side Effect:elevated transaminases;Allele G is associated with increased likelihood of elevated transaminases when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.;in people with Disease:Rheumatoid arthritis
;CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;Toxicity;increased  likelihood of Side Effect:Death;Allele C is associated with increased likelihood of Death when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele T.;in people with Hematopoietic stem cell transplantation
;EFAVIRENZ;ABCB1;rs1045642;A;Toxicity;increased  likelihood of Side Effect:toxicity-related treatment failure;Allele A is associated with increased likelihood of toxicity-related treatment failure when treated with efavirenz in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;DOXORUBICIN;GALNT14;rs9679162;TT;Efficacy;increased   Efficacy:Overall survival;Genotype TT is associated with increased overall survival when treated with doxorubicin in people with Carcinoma, Hepatocellular as compared to genotypes GG + GT.;in people with Disease:Hepatocellular Carcinoma
;ASPIRIN;CYP2D6;rs28360521;CC;Toxicity, Other;increased  risk of Side Effect:Gastrointestinal Hemorrhage;Genotype CC is associated with increased risk of Gastrointestinal Hemorrhage when treated with aspirin as compared to genotypes CT + TT.; 
;DESFLURANE, PROPOFOL;ATP8B3;rs45574836;CT + TT;Toxicity;increased  likelihood of Side Effect:Postoperative Nausea and Vomiting, Side Effect:Vomiting;Genotypes CT + TT is associated with increased likelihood of Postoperative Nausea and Vomiting and Vomiting when exposed to desflurane or propofol in people with surgery as compared to genotype CC.;in people with surgery
;LOSARTAN;CAMK1D;rs10752271;AG + GG;Efficacy;decreased severity of Efficacy:Elevated systolic blood pressure;Genotypes AG + GG is associated with decreased severity of Elevated systolic blood pressure when treated with losartan in people with Essential hypertension as compared to genotype AA.;in people with Disease:Essential hypertension
;METHOTREXATE;MTHFR;rs1801133;AA;Toxicity;increased  risk of Disease:Toxic liver disease;Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Arthritis, Psoriatic as compared to genotypes AG + GG.;in people with Disease:Arthritis, Psoriatic
;METHOTREXATE;DHFR;rs408626;TT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype TT is associated with increased risk of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;LOSARTAN;CAMK1D;rs10737062;AG + GG;Efficacy;decreased severity of Efficacy:Elevated systolic blood pressure;Genotypes AG + GG is associated with decreased severity of Elevated systolic blood pressure when treated with losartan in people with Essential hypertension as compared to genotype AA.;in people with Disease:Essential hypertension
;CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;Toxicity;decreased likelihood of Side Effect:Graft vs Host Disease;Allele C is associated with decreased likelihood of Graft vs Host Disease when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele T.;in people with Hematopoietic stem cell transplantation
;METHOTREXATE;MTHFR;rs1801131;T;Toxicity;increased  likelihood of Side Effect:adverse events;Allele T is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;DHFR;rs442767;GT;Toxicity;increased  risk of Side Effect:Leukopenia;Genotype GT is associated with increased risk of Leukopenia when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.;in people with Disease:Acute lymphoblastic leukemia
;CELECOXIB;CYP2C9;rs1057910;C;Efficacy;decreased risk of Disease:Adenoma;Allele C is associated with decreased risk of Adenoma when treated with celecoxib in people with Adenoma.;in people with Disease:Adenoma
;MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;Toxicity;increased  likelihood of Side Effect:treatment interruptions;Genotypes CT + TT are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;rs2740574;CT;Toxicity;increased  risk of Side Effect:Alopecia;Genotype CT is associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT.;in men with Disease:Testicular Neoplasms
;MERCAPTOPURINE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Treatment interruption;Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;increased  likelihood of Side Effect:Treatment interruption;Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;EFAVIRENZ;ABCB1;rs1045642;A;Efficacy;decreased likelihood of Efficacy:emerging viral drug resistance;Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele G.;in people with Disease:HIV infectious disease
;BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;rs1127648;AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AG is associated with decreased progression-free survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;SORAFENIB;;rs10958704;G;Toxicity;increased  risk of Side Effect:dermatologic toxicity;Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.;in people with Renal Cell Carcinoma
;METHOTREXATE;SHMT1;rs1979277;AG;Toxicity;decreased likelihood of Disease:Toxic liver disease;Genotype AG is associated with decreased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.;in people with Disease:Acute lymphoblastic leukemia
;METHOTREXATE;FASTKD3, MTRR;rs1801394;AG;Toxicity;increased   Side Effect:speed of platelet recovery;Genotype AG is associated with increased speed of platelet recovery when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG.;in people with Disease:Acute lymphoblastic leukemia
;SORAFENIB;EPAS1;rs7557402;G;Toxicity;increased  risk of Side Effect:dermatologic toxicity;Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele C.;in people with Renal Cell Carcinoma
;METHOTREXATE;MTHFR;rs1801131;TT;Toxicity;increased  likelihood of Side Effect:red blood cell transfusions;Genotype TT is associated with increased likelihood of red blood cell transfusions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT.;in people with Disease:Acute lymphoblastic leukemia
;CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;Toxicity;increased  likelihood of Side Effect:Graft vs Host Disease;Allele T is associated with increased likelihood of Graft vs Host Disease when treated with cyclophosphamide in people with hematopoietic stem cell transplantation as compared to allele C.;in people with Hematopoietic stem cell transplantation
;APIXABAN, RIVAROXABAN;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotype AA is associated with increased risk of Hemorrhage when treated with apixaban or rivaroxaban in people with Atrial Fibrillation as compared to genotypes AG + GG.;in people with Atrial Fibrillation
;EFAVIRENZ;ABCB1;rs2032582;A;Efficacy;decreased likelihood of Efficacy:emerging viral drug resistance;Allele A is associated with decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to allele C.;in people with Disease:HIV infectious disease
;CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;rs1570360;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with cyclophosphamide and docetaxel in people with Prostatic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Prostatic Neoplasms
;CARBOPLATIN, GEMCITABINE;OR4D6;rs1453542;CC;Toxicity;increased  severity of Side Effect:Neutropenia;Genotype CC is associated with increased severity of Neutropenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CG + GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;SORAFENIB;MAP2K6;rs12948059;G;Toxicity;increased  risk of Side Effect:dermatologic toxicity;Allele G is associated with increased risk of dermatologic toxicity when treated with sorafenib in people with Carcinoma, Renal Cell as compared to allele A.;in people with Renal Cell Carcinoma
;CARBOPLATIN, GEMCITABINE;DDX53;rs5925720;T;Toxicity;decreased severity of Side Effect:Thrombocytopenia;Allele T is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;MTHFD1;rs2236225;AA;Other;increased   PK:red blood cell folate;Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;FASTKD3, MTRR;rs1801394;AA;Other;increased   PK:red blood cell folate;Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;IRINOTECAN;SEMA3C;rs11979430;T;Toxicity;increased  severity of Disease:Neutropenia;Allele T is associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIPSYCHOTICS;DRD2;rs1800497;A;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele A is associated with increased likelihood of Drug Toxicity when exposed to antipsychotics as compared to allele G.; 
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Toxicity;increased  risk of Side Effect:cardiovascular events;Genotypes AA + AG are associated with increased risk of cardiovascular events when treated with clopidogrel as compared to genotype GG.; 
;ANTIPSYCHOTICS;COMT;rs4680;AA + AG;Toxicity;decreased risk of Disease:Tardive Dyskinesia;Genotypes AA + AG are associated with decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG.;in people with Disease:Schizophrenia
;IRINOTECAN;SEMA3C;rs7779029;C;Toxicity;increased  severity of Disease:Neutropenia;Allele C is associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIEPILEPTICS;ABCB1;rs2032582;C;Efficacy;Efficacy:protection from drug resistance;Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;ANTIPSYCHOTICS;DRD2;rs1800497;G;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Allele G is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele A.;in people with Disease:Schizophrenia
;ANTIEPILEPTICS;ABCB1;rs2032582;C;Efficacy;Efficacy:protection from drug resistance;Allele C is associated with protection from drug resistance when treated with antiepileptics in men with Epilepsy.;in men with Disease:Epilepsy
;ANTIPSYCHOTICS;DRD2;rs1800497;G;Toxicity;increased  risk of Disease:Tardive Dyskinesia;Allele G is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to allele A.;in people with Disease:Schizophrenia
;IRINOTECAN;;rs1661167;G;Toxicity;increased  severity of Disease:Diarrhea;Allele G is associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.;in people with Disease:Non-Small Cell Lung Carcinoma
;ANTIEPILEPTICS;ABCB1;rs2032582;C;Efficacy;Efficacy:protection from drug resistance;Allele C is associated with protection from drug resistance when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs498207;AA;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype AA is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs6413432;TT;Efficacy;increased   Efficacy:progression-free survival;Genotype TT is associated with increased progression-free survival when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype AT.;in women with Disease:Ovarian Neoplasms
;BUDESONIDE;FCER2;rs28364072;G;Other;Other:severe exacerbations with asthma;Allele G is associated with severe exacerbations with asthma when treated with budesonide in people with Asthma as compared to allele A.;in people with Disease:Asthma
;CYCLOPHOSPHAMIDE;NOS3;rs1799983;TT;Efficacy;increased   Efficacy:disease free survival;Genotype TT is associated with increased disease free survival in people not taking cyclophosphamide in women with Breast Neoplasms as compared to genotypes GG + GT.;in women with Disease:Breast Neoplasms
;AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813928;GG;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype GG is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes AA + AG.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;MYCOPHENOLATE MOFETIL;IL12A;rs568408;A;Toxicity;increased  risk of Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant;Allele A is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele G.; 
;IRINOTECAN;PLCB1;rs2745761;C;Toxicity;increased  severity of Disease:Diarrhea;Allele C is associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;CYCLOPHOSPHAMIDE;NOS3;rs2070744;CC;Efficacy;increased   Efficacy:disease free survival;Genotype CC is associated with increased disease free survival in people not taking cyclophosphamide in women with Breast Neoplasms as compared to genotypes CT + TT.;in women with Disease:Breast Neoplasms
;AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813929;CC;Toxicity;increased  likelihood of Side Effect:Weight gain;Genotype CC is associated with increased likelihood of Weight gain when treated with amisulpride, clozapine, olanzapine, quetiapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to genotypes CT + TT.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;rs1799983;GG + GT;Efficacy;increased   Efficacy:disease free survival;Genotypes GG + GT are associated with increased disease free survival when treated with cyclophosphamide, doxorubicin, fluorouracil and methotrexate in people with Breast Neoplasms as compared to genotype TT.;in people with Disease:Breast Neoplasms
;IRINOTECAN;PDZRN3;rs11128347;C;Toxicity;increased  severity of Disease:Neutropenia;Allele C is associated with increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHADONE;UGT2B7;rs4554144;TT;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype TT is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CT.;in people with Disease:Opioid-Related Disorders
;DAPSONE;HLA-DRB1;rs201929247;A;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;Allele A is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele G.; 
;OLANZAPINE;PPARG;rs1801282;CG;Other;increased   Disease:Weight gain;Genotype CG is associated with increased Weight gain when treated with olanzapine in people with Schizophrenia as compared to genotype CC.;in people with Disease:Schizophrenia
;METHADONE;UGT2B7;rs11940316;CC;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.;in people with Disease:Opioid-Related Disorders
;CORTICOSTEROIDS;BCL2L11;rs2241843;AA;Toxicity;increased  risk of Side Effect:Osteonecrosis;Genotype AA is associated with increased risk of Osteonecrosis when treated with corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC.;in children with Disease:Acute lymphoblastic leukemia
;METHADONE;UGT2B7;rs7438135;AA;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype AA is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Disease:Opioid-Related Disorders
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;METHADONE;UGT2B7;rs7662029;GG;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AA + AG.;in people with Disease:Opioid-Related Disorders
;CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;Toxicity;increased  likelihood of Disease:Anemia;Genotypes AA + AG are associated with increased likelihood of Anemia when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype GG.;in women with Disease:Ovarian Neoplasms
;OXALIPLATIN;PIN1;rs2233678;CC + CG;Efficacy;decreased  Efficacy:Overall survival, Efficacy:Progression-free survival;Genotypes CC + CG is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;METHADONE;UGT2B7;rs7668258;CC;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.;in people with Disease:Opioid-Related Disorders
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;Toxicity;decreased risk of Side Effect:Maculopapular Exanthema;Genotypes CT + TT are associated with decreased risk of Maculopapular Exanthema due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis.;in people with Tuberculosis
;METHOTREXATE;ABCG2;rs2231142;TT;Toxicity;decreased likelihood of Side Effect:adverse events;Genotype TT is associated with decreased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;METHOTREXATE;AMPD1;rs17602729;AG;Toxicity;increased  likelihood of Side Effect:CNS adverse events;Genotype AG is associated with increased likelihood of CNS adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG.;in people with Disease:Rheumatoid arthritis
;ANTIEPILEPTICS;ABCB1;rs1045642;A;Efficacy;increased  risk of Efficacy:drug resistance;Allele A is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.;in men with Disease:Epilepsy
;METHADONE;UGT2B7;rs7439366;CC;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.;in people with Disease:Opioid-Related Disorders
;ANTIEPILEPTICS;ABCB1;rs1128503;A;Efficacy;increased  risk of Efficacy:drug resistance;Allele A is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;ANTIEPILEPTICS;ABCB1;rs3789243;G;Efficacy;increased  risk of Efficacy:drug resistance;Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy.;in men with Disease:Epilepsy
;METHADONE;UGT2B7;rs4292394;GG;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG.;in people with Disease:Opioid-Related Disorders
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;Toxicity;decreased risk of Side Effect:Maculopapular Exanthema;Genotypes AA + AG are associated with decreased risk of Maculopapular Exanthema due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype GG.;in people with Tuberculosis
;CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs2070676;CG;Toxicity;increased  risk of Side Effect:severe emesis;Genotype CG is associated with increased risk of severe emesis when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC.;in women with Disease:Ovarian Neoplasms
;ANTIEPILEPTICS;ABCB1;rs3789243;G;Efficacy;increased  risk of Efficacy:drug resistance;Allele G is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy.;in people with Disease:Epilepsy
;FLUOROURACIL;DPYD;rs3918290;CT;Toxicity;increased  risk of Side Effect:Drug Toxicity, Side Effect:Leukopenia, Side Effect:Mucositis;Genotype CT is associated with increased risk of Drug Toxicity, Leukopenia and mucositis when treated with fluorouracil in people with Neoplasms as compared to genotype CC.;in people with Disease:Neoplasms
;THIAZIDES, PLAIN;GNB3;rs5443;CC;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotype CC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CT + TT.; 
;AMLODIPINE;RYR3;rs877087;TT;Efficacy;increased  risk of Disease:Heart Failure;Genotype TT is associated with increased risk of Heart Failure when treated with amlodipine in people with Hypertension.;in people with Disease:Hypertension
;FLUOROURACIL;GSTP1;rs1695;GG;Toxicity;decreased risk of Side Effect:haematological toxicity;Genotype GG is associated with decreased risk of haematological toxicity when exposed to fluorouracil in people with Rectal Neoplasms as compared to genotype AA.;in people with Disease:Rectal Neoplasms
;;COL1A1;rs1800012;AA;;decreased  Other:bone mineral density at femoral neck and lumbar spine;Genotype AA is associated with decreased bone mineral density at femoral neck and lumbar spine as compared to genotypes AC + CC.; 
;METHADONE;UGT2B7;rs6600879;GG;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype GG is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CC + CG.;in people with Disease:Opioid-Related Disorders
;;COL1A1;rs1800012;AA + AC;;decreased  Other:BMD values at the lumbar spine and femoral neck;Genotypes AA + AC are associated with decreased BMD values at the lumbar spine and femoral neck as compared to genotype CC.; 
;METHADONE;UGT2B7;rs6600880;AA;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype AA is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes AT + TT.;in people with Disease:Opioid-Related Disorders
;PLATINUM COMPOUNDS;EIF3A;rs10510050;A;Toxicity;increased  risk of Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting;Allele A is associated with increased risk of Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;CAPECITABINE;DPYD;rs67376798;AT;Toxicity;increased  risk of Side Effect:Drug Toxicity;Genotype AT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype TT.;in women with Disease:Breast Neoplasms
;THIAZIDES, PLAIN;AGTR1;rs5186;AA + AC;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotypes AA + AC is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotype CC.; 
;THIAZIDES, PLAIN;ACE;rs4341;GG;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotype GG is associated with increased risk of Diabetes Mellitus when treated with Thiazides, plain as compared to genotypes CC + CG.; 
;ATORVASTATIN, RIFAMPIN;SLCO1B1;rs4149056;TT;Metabolism/PK;PK:a nearly tripled increased  percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin;Genotype TT is associated with a nearly tripled increased percentage of atorvastatin AUC(0 - 48) values after a single oral dose of rifampicin when exposed to atorvastatin and rifampin as compared to genotype CC.; 
;CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;C;Toxicity;risk of Side Effect:Drug Toxicity;Allele C is associated with risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;ATORVASTATIN;FDPS;rs2297480;TT;Toxicity;increased   Side Effect:bone density;Genotype TT is associated with increased bone density when treated with atorvastatin in people with Coronary Disease as compared to genotypes GG + GT.;in people with Disease:Coronary Disease
;ETHANOL;OPRM1;rs1799971;G;;increased   Other:subjective feelings of intoxication, stimulation, sedation, and happiness;Allele G is associated with increased subjective feelings of intoxication, stimulation, sedation, and happiness when exposed to ethanol as compared to allele A.; 
;;ABCC2;rs3740066;C;Metabolism/PK;Other:allelic imbalence;Allele C is associated with allelic imbalence as compared to allele T.; 
;CISPLATIN;GSTM4;rs560018;CC;Efficacy, Toxicity;increased   Efficacy:IC-50;Genotype CC is associated with increased IC-50 when exposed to cisplatin as compared to genotype TT.; 
;ATORVASTATIN;FDPS;rs11264359;AA;Toxicity;increased   Side Effect:bone density;Genotype AA is associated with increased bone density when treated with atorvastatin in people with Coronary Disease as compared to genotypes AG + GG.;in people with Disease:Coronary Disease
;IRINOTECAN;C8orf34;rs1517114;C;Toxicity;increased  severity of Disease:Diarrhea;Allele C is associated with increased severity of Diarrhea when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;DICLOXACILLIN, PROBENECID;ABCB1;rs1045642;GG;Other, Metabolism/PK;increased   PK:clearance of dicloxacillin;Genotype GG is associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG.; 
;ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;Toxicity;increased  likelihood of Side Effect:Obesity;Allele C is associated with increased likelihood of Obesity when treated with antipsychotics, clozapine, olanzapine or risperidone in people with schizoaffective disorder and Schizophrenia as compared to allele G.;in people with Disease:Schizoaffective disorder, Disease:Schizophrenia
;ETHANOL;OPRM1;rs1799971;G;Other;risk of Disease:Alcohol abuse;Allele G is associated with risk of Alcoholism when exposed to ethanol.; 
;CYCLOSPORINE, DICLOXACILLIN;ABCB1;rs2032582;CC;Other, Metabolism/PK;increased   PK:clearance of dicloxacillin;Genotype CC is associated with increased clearance of dicloxacillin when treated with cyclosporine and dicloxacillin as compared to genotype AA.; 
;ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CT + TT;Toxicity;decreased risk of Side Effect:Toxic liver disease;Genotypes CT + TT are associated with decreased risk of Toxic liver disease due to ethambutol, isoniazid, pyrazinamide or rifampin in people with Tuberculosis as compared to genotype CC.;in people with Tuberculosis
;ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC;;increased   Other:cholesterol synthesis rate;Genotype CC is associated with increased cholesterol synthesis rate when exposed to atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin as compared to genotype TT.; 
;PLATINUM COMPOUNDS;MDM2;rs1690924;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.;in people with Disease:Non-Small Cell Lung Carcinoma
;METHOTREXATE;SLC19A1;rs1051266;TT;Metabolism/PK;increased   PK:plasma drug levels;Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:platelet inhibition after a clopidogrel 600-mg loading dose;Allele A is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;SEVOFLURANE;GRIN2B;rs1806201;AA + AG;Other;increased   Other:mean arterial pressure;Genotypes AA + AG are associated with increased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype GG.;in people with otorhinolaryngology surgery
;CLOPIDOGREL;CYP2C19;rs28399504;G;Efficacy;decreased  Efficacy:platelet inhibition after a clopidogrel 600-mg loading dose;Allele G is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A.;in people with Disease:Coronary Artery Disease
;DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;rs1042714;GG;Efficacy;increased   Other:Status asthmaticus;Genotype GG is associated with increased exacerbation of asthma when treated with Drugs For Obstructive Airway Diseases in children with Asthma as compared to genotypes CG + GG.;in children with Disease:Asthma
;METHOTREXATE;CCND1;rs9344;AA;Toxicity;decreased severity of Disease:Drug Toxicity;Genotype AA is associated with decreased severity of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in people with Disease:Acute lymphoblastic leukemia
;RISPERIDONE;ABCB1;rs1045642;A;Toxicity;increased   Side Effect:Weight gain;Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele G.;in women with Disease:Schizophrenia
;METHOTREXATE;MTHFR;rs1801133;AA + AG;Toxicity;decreased severity of Disease:Leukopenia;Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.;in children with Disease:Acute lymphoblastic leukemia
;PACLITAXEL;SOD2;rs4880;AA;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CT + TT;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotypes CT + TT are associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.;in people with Disease:Acute lymphoblastic leukemia
;METHYLPHENIDATE;ABCB1;rs2032582;AA;Toxicity;increased   Side Effect:adverse events;Genotype AA is associated with increased adverse events when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AC + CC.;in children with Disease:Attention Deficit Disorder with Hyperactivity
;DOCETAXEL;ERCC2;rs13181;TT;Toxicity;increased  risk of Side Effect:Neutropenia;Genotype TT is associated with increased risk of Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to genotypes GG + GT.;in women with Disease:Breast Neoplasms
;CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;Toxicity;increased  risk of Side Effect:Hyperlipidemias;Genotype AA is associated with increased risk of Hyperlipidemias when treated with cyclosporine or tacrolimus in people with Kidney Transplantation as compared to genotypes AG + GG.;in people with Disease:Kidney Transplantation
;DOCETAXEL;ERCC1;rs11615;AA;Toxicity;increased  risk of Side Effect:Mucositis;Genotype AA is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;CLOPIDOGREL;CYP2C19;rs12248560;T;Efficacy;decreased  Efficacy:rates of target lesion revascularization and major adverse cardiovascular events;Allele T is associated with decreased rates of target lesion revascularization and major adverse cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele C.;in people with Disease:Myocardial Infarction
;METFORMIN;SP1;rs2683511;C;Metabolism/PK;decreased  PK:metformin secretory clearance;Allele C is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele T.;in healthy individuals 
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes CT + TT is associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype CC.; 
;NICOTINE;CHRNA3, CHRNA5;rs16969968;A;Toxicity;increased  risk of Disease:Tobacco Use Disorder;Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G.; 
;METFORMIN;;rs10747673;G;Efficacy;decreased  Efficacy:post-HbA1c levels;Allele G is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele A.;in people with Disease:Diabetes Mellitus, Type 2
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  likelihood of Efficacy:to be classified as clopidogrel poor responders;Genotypes AA + AG are associated with increased likelihood of to be classified as clopidogrel poor responders when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype GG.;in people with Disease:Cardiovascular Disease
;METFORMIN;;rs10747673;G;Metabolism/PK;decreased  PK:metformin secretory clearance;Allele G is associated with decreased metformin secretory clearance when exposed to metformin in healthy individuals as compared to allele A.;in healthy individuals 
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:Hemorrhage;Genotypes CT + TT is associated with increased likelihood of Hemorrhage when treated with acenocoumarol as compared to genotype CC.; 
;METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;CLOPIDOGREL;ATP10A;rs12913988;AA + AG;Efficacy;increased  likelihood of Side Effect:Major Adverse Cardiac Events (MACE);Genotypes AA + AG are associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.;in people with Disease:Coronary Artery Disease
;PLATINUM COMPOUNDS;EIF3A;rs4752220;A;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting;Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;CHOP, RITUXIMAB;NCF4;rs1883112;AG + GG;Toxicity;decreased risk of Side Effect:toxicity;Genotypes AG + GG are associated with decreased risk of toxicity when treated with CHOP and rituximab in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AA.;in people with Disease:Lymphoma, Large B-Cell, Diffuse
;CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;Efficacy;increased  risk of Efficacy:clopidogrel poor response;Genotypes AC + CC are associated with increased risk of clopidogrel poor response when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype AA.;in people with Disease:Cardiovascular Disease
;PLATINUM COMPOUNDS;EIF3A;rs1409314;A;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting;Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease or Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.;in people with Disease:Non-Small Cell Lung Carcinoma
;PLATINUM COMPOUNDS;EIF3A;rs4752219;C;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting;Allele C is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.;in people with Disease:Non-Small Cell Lung Carcinoma
;CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;Efficacy;increased  risk of Efficacy:high on-treatment platelet reactivity;Genotypes AC + CC are associated with increased risk of high on-treatment platelet reactivity when treated with clopidogrel in people with Cardiovascular Diseases as compared to genotype AA.;in people with Disease:Cardiovascular Disease
;MERCAPTOPURINE, METHOTREXATE;GSTP1;rs1695;GG;Toxicity;increased  likelihood of Disease:Drug Toxicity;Genotype GG is associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.;in people with Disease:Acute lymphoblastic leukemia
;CLOZAPINE;HTR2C;rs3813929;T;Toxicity;decreased risk of Side Effect:Weight gain;Allele T is associated with decreased risk of Weight gain when treated with clozapine in people with Schizophrenia.;in people with Disease:Schizophrenia
;ACENOCOUMAROL;ABCB1;rs1045642;GG + GT;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes GG + GT are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype TT.; 
;RISPERIDONE;ABCB1;rs2032582;A;Toxicity;increased   Side Effect:Weight gain;Allele A is associated with increased Weight gain when treated with risperidone in women with Schizophrenia as compared to allele C.;in women with Disease:Schizophrenia
;METHOTREXATE;SLC19A1;rs1051266;TT;Metabolism/PK;increased   PK:plasma drug levels;Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;SEVOFLURANE;KCNK3;rs1275988;CT + TT;Other;increased   Other:mean arterial pressure;Genotypes CT + TT are associated with increased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype CC.;in people with otorhinolaryngology surgery
;LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CC;Toxicity;increased  likelihood of Disease:Toxic liver disease;Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in people with Disease:Acute lymphoblastic leukemia
;LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;increased  likelihood of Disease:Myelosuppression;Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;DOCETAXEL;CYP3A4;rs2740574;CC + CT;Toxicity;increased  risk of Side Effect:infusion related reaction;Genotypes CC + CT is associated with increased risk of infusion related reaction when treated with docetaxel in women with Breast Neoplasms as compared to genotype TT.;in women with Disease:Breast Neoplasms
;METFORMIN;SP1;rs784888;G;Efficacy;decreased severity of Disease:Hyperglycemia;Allele G is associated with decreased severity of Hyperglycemia when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.;in people with Disease:Diabetes Mellitus, Type 2
;PLATINUM COMPOUNDS;MTR;rs1805087;AA + AG;Efficacy;decreased  Efficacy:Progression-free survival;Genotypes AA + AG is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.;in people with Disease:Non-Small Cell Lung Carcinoma
;SEVOFLURANE;GABRA2;rs279858;CC + CT;Other;decreased  Other:mean arterial pressure;Genotypes CC + CT are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype TT.;in people with otorhinolaryngology surgery
;LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;Efficacy;increased  likelihood of Efficacy:staying in remission;Genotype TT is associated with increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.;in people with Disease:Acute lymphoblastic leukemia
;ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype CC.; 
;PLATINUM COMPOUNDS;EIF3A;rs7091672;T;Toxicity;increased  risk of Side Effect:Anemia, Side Effect:Leukopenia, Side Effect:Thrombocytopenia, Side Effect:Toxic liver disease, Side Effect:Vomiting;Allele T is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease and Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.;in people with Disease:Non-Small Cell Lung Carcinoma
;PACLITAXEL;CYP2C8;rs1113129;CG + GG;Toxicity;increased  risk of Side Effect:Anemia;Genotypes CG + GG is associated with increased risk of Anemia when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;METFORMIN;PPARA;rs149711321;T;Efficacy;decreased  Efficacy:post-HbA1c levels;Allele T is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele C.;in people with Disease:Diabetes Mellitus, Type 2
;;COL1A1;rs1800012;AA;;increased  risk of Disease:Fractures, Bone;Genotype AA is associated with increased risk of Fractures, Bone as compared to genotype CC.; 
;ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;Toxicity;decreased likelihood of Side Effect:over-anticoagulation;Genotypes CT + TT are associated with decreased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype CC.; 
;PLATINUM COMPOUNDS;SLC19A1;rs1051266;TT;Efficacy;decreased  Efficacy:Progression-free survival;Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.;in people with Disease:Non-Small Cell Lung Carcinoma
;PACLITAXEL;CYP2C8;rs1934951;CT + TT;Toxicity;increased  risk of Side Effect:Anemia;Genotypes CT + TT is associated with increased risk of Anemia when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;LENALIDOMIDE;VEGFA;rs699947;AA;Efficacy;decreased  Efficacy:Progression-free survival;Genotype AA is associated with decreased progression-free survival when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AC + CC.;in people with Mantle cell lymphoma
;METFORMIN;SP1;rs2683511;C;Efficacy;decreased  Efficacy:post-HbA1c levels;Allele C is associated with decreased post-HbA1c levels when treated with metformin in people with Diabetes Mellitus, Type 2 as compared to allele T.;in people with Disease:Diabetes Mellitus, Type 2
;SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;Other;decreased  Other:mean arterial pressure;Genotypes AG + GG are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype AA.;in people with otorhinolaryngology surgery
;CLOPIDOGREL;CYP2C19;rs28399504;G;Toxicity;increased  risk of Disease:Death;Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A.;in people with Disease:Acute coronary syndrome
;BUPROPION, NICOTINE;DRD1;rs2168631;A;Efficacy;increased  likelihood of Efficacy:smoking abstinence within slow nicotine metabolizers;Allele A is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele G.;in people with Disease:Tobacco Use Disorder
;SIMVASTATIN;HMGCR;rs17238540;TT;Efficacy;increased   Efficacy:reduction of LDL cholesterol;Genotype TT is associated with increased reduction of LDL cholesterol when treated with simvastatin as compared to genotypes GG + GT.; 
;;NR3C1;rs9324918;C;Other;increased   Disease:Sickle cell pain crisis;Allele C is associated with increased pain crisis in people with Anemia, Sickle Cell as compared to allele T.;in people with Disease:Anemia, Sickle Cell
;CLOPIDOGREL;CYP2C19;rs4986893;A;Toxicity;increased  risk of Disease:Death;Allele A is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;Other;decreased  Other:mean arterial pressure;Genotypes AA + AG are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype GG.;in people with otorhinolaryngology surgery
;PACLITAXEL;ERCC1;rs3212986;AA + AC;Toxicity;increased  risk of Side Effect:Peripheral Nervous System Diseases;Genotypes AA + AC is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC.;in women with Disease:Breast Neoplasms
;MORPHINE;ABCC3;rs1978153;C;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele C is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele G.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;;P2RY12;rs2046934;G;;increased  risk of Side Effect:Coronary Artery Disease;Allele G is associated with increased risk of Coronary Artery Disease as compared to allele A.; 
;CLOPIDOGREL;CYP2C19;rs12248560;T;Toxicity;increased  risk of Side Effect:bleeding;Allele T is associated with increased risk of bleeding when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.;in people with Disease:Coronary Artery Disease
;BUPROPION, NICOTINE;DRD1;rs11749035;T;Efficacy;increased  likelihood of Efficacy:smoking abstinence within slow nicotine metabolizers;Allele T is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele C.;in people with Disease:Tobacco Use Disorder
;CLOPIDOGREL;CYP2C19;rs12248560;T;Efficacy;decreased  Efficacy:ADP-induced platelet aggregation;Allele T is associated with decreased ADP-induced platelet aggregation when treated with clopidogrel in people with Coronary Artery Disease as compared to allele C.;in people with Disease:Coronary Artery Disease
;PAZOPANIB, SUNITINIB;CXCL8;rs1126647;T;Efficacy;decreased  Efficacy:Overall survival;Allele T is associated with decreased overall survival when treated with pazopanib or sunitinib in people with Carcinoma, Renal Cell as compared to allele A.;in people with Disease:Renal Cell Carcinoma
;;NR3C1;rs2963155;G;Other;increased   Disease:Sickle cell pain crisis;Allele G is associated with increased pain crisis in people with Anemia, Sickle Cell as compared to allele A.;in people with Disease:Anemia, Sickle Cell
;MORPHINE;ABCC3;rs733392;G;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele A.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;METHADONE;UGT2B7;rs6600893;CC;Efficacy, Metabolism/PK;increased  severity of Other:opiate withdrawal symptoms;Genotype CC is associated with increased severity of opiate withdrawal symptoms when treated with methadone in people with Opioid-Related Disorders as compared to genotypes CT + TT.;in people with Disease:Opioid-Related Disorders
;FENTANYL;MYD88;rs6853;G;Toxicity;decreased risk of Side Effect:Cognitive disorder;Allele G is associated with decreased risk of cognitive dysfunction when treated with fentanyl in people with Neoplasms as compared to allele A.;in people with Disease:Neoplasms
;METHOTREXATE, PREDNISONE;SLC19A1;rs1051266;TT;Efficacy;increased  likelihood of Efficacy:remission;Genotype TT is associated with increased likelihood of remission when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotype CC.;in people with Disease:Rheumatoid arthritis
;BUPROPION, NICOTINE;DRD1;rs11746641;G;Efficacy;increased  likelihood of Efficacy:smoking abstinence within slow nicotine metabolizers;Allele G is associated with increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine in people with Tobacco Use Disorder as compared to allele T.;in people with Disease:Tobacco Use Disorder
;;NR3C1;rs33389;T;Other;increased   Disease:Sickle cell pain crisis;Allele T is associated with increased pain crisis in people with Anemia, Sickle Cell as compared to allele C.;in people with Disease:Anemia, Sickle Cell
;SPIRONOLACTONE;ACE;rs4343;AA + AG;Efficacy;Efficacy:improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume;Genotypes AA + AG are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume when treated with spironolactone in people with chronic heart failure as compared to genotype GG.;in people with chronic heart failure
;SIMVASTATIN;HMGCR;rs17244841;AA;Efficacy;increased   Efficacy:reduction of LDL cholesterol;Genotype AA is associated with increased reduction of LDL cholesterol when treated with simvastatin.; 
;DOCETAXEL;ERCC1;rs3212986;CC;Toxicity;increased  risk of Side Effect:Mucositis;Genotype CC is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AC.;in women with Disease:Breast Neoplasms
;SEVOFLURANE;CYP2E1;rs3813867;CC + CG;Other;decreased  Other:mean arterial pressure;Genotypes CC + CG are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype GG.;in people with otorhinolaryngology surgery
;CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;rs3957357;AA + AG;Efficacy;increased  likelihood of Efficacy:Event-Free Survival;Genotypes AA + AG are associated with increased likelihood of Event-Free Survival when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype GG.;in people with Disease:Lymphoma, Large B-Cell, Diffuse
;SEVOFLURANE;CYP2E1, DUX1;rs2031920;CT + TT;Other;decreased  Other:mean arterial pressure;Genotypes CT + TT are associated with decreased mean arterial pressure when exposed to sevoflurane in people with otorhinolaryngology surgery as compared to genotype CC.;in people with otorhinolaryngology surgery
;ANTIHYPERTENSIVES, DIURETICS;NOS3;rs2070744;CC;Efficacy;increased  risk of Efficacy:resistant hypertension;Genotype CC is associated with increased risk of resistant hypertension when treated with Antihypertensives and diuretics in people with Hypertension as compared to genotypes CT + TT.;in people with Disease:Hypertension
;CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;rs4673;AA;Efficacy;decreased likelihood of Efficacy:Event-Free Survival;Genotype AA is associated with decreased likelihood of Event-Free Survival when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotypes AG + GG.;in people with Disease:Lymphoma, Large B-Cell, Diffuse
;IBUPROFEN;PTGS2;rs20417;CG + GG;Efficacy;increased   Efficacy:pain relief;Genotypes CG + GG are associated with increased pain relief when treated with ibuprofen as compared to genotype CC.; 
;DIFLOMOTECAN;ABCG2;rs2231142;T;Metabolism/PK;increased   PK:plasma concentrations of diflomotecan;Allele T is associated with increased plasma concentrations of diflomotecan when treated with diflomotecan as compared to allele G.; 
;CYCLOSPORINE;ABCB1;rs2032582;AA;Efficacy;increased  risk of Efficacy:resistance;Genotype AA is associated with increased risk of resistance when treated with cyclosporine in people with Colitis, Ulcerative as compared to genotypes AC + CC.;in people with Disease:Ulcerative Colitis
;CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;Toxicity;increased  risk of Side Effect:Diabetes Mellitus;Genotype AA is associated with increased risk of Diabetes Mellitus when treated with cyclosporine or tacrolimus in people with Transplantation as compared to genotypes AG + GG.;in people with Disease:Transplantation
;ROFECOXIB;PTGS2;rs20417;CC;Efficacy;increased   Efficacy:pain relief;Genotype CC is associated with increased pain relief when treated with rofecoxib as compared to genotypes CG + GG.; 
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2884129;G;Efficacy;Efficacy:opioids response;Allele G is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele T.;in people with Disease:Neoplasms
;HMG COA REDUCTASE INHIBITORS;;rs13210472;C;Toxicity;increased  risk of Other:Neoplasms;Allele C is associated with increased risk of Neoplasms when treated with hmg coa reductase inhibitors in women as compared to allele A.;in women 
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7104613;T;Efficacy;Efficacy:opioids response;Allele T is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele C.;in people with Disease:Neoplasms
;PAZOPANIB, SUNITINIB;CXCL8;rs4073;A;Efficacy;decreased  Efficacy:Overall survival;Allele A is associated with decreased overall survival when treated with pazopanib or sunitinib in people with Carcinoma, Renal Cell as compared to allele T.;in people with Disease:Renal Cell Carcinoma
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;Toxicity;increased  risk of Side Effect:Nausea;Genotype GG is associated with increased risk of Nausea due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AA + AG.;in men with Disease:Testicular Neoplasms
;FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs10413396;T;Efficacy;Efficacy:opioids response;Allele T is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele G.;in people with Disease:Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy;decreased  Efficacy:pharmacodynamic response;Allele A is associated with decreased pharmacodynamic response when exposed to clopidogrel in healthy individuals as compared to allele G.;in healthy individuals 
;METHOTREXATE;CCND1;rs9344;AA;Efficacy;decreased  Efficacy:event free survival;Genotype AA is associated with decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.;in people with Disease:Acute lymphoblastic leukemia
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs3212986;AC + CC;Toxicity;decreased risk of Side Effect:Vomiting;Genotypes AC + CC are associated with decreased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype AA.;in men with Disease:Testicular Neoplasms
;ASPIRIN;PTGS1;rs10306114;AA + AG;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotypes AA + AG is associated with increased likelihood of Recurrence when treated with aspirin in people with Cerebral Infarction as compared to genotype GG.;in people with Cerebral Infarction
;FLUOROURACIL;DPYD;rs67376798;A;Toxicity;increased  severity of Side Effect:Drug Toxicity;Allele A is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to allele T.;in people with Disease:Colonic Neoplasms
;ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs2032582;CC;Efficacy;increased  risk of Efficacy:resistance;Genotype CC is associated with increased risk of resistance when treated with anthracyclines and related substances in people with Breast Neoplasms as compared to genotype AC.;in people with Disease:Breast Neoplasms
;CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA + AG;Toxicity;increased   Side Effect:Weight gain;Genotypes AA + AG are associated with increased Weight gain when treated with cyclosporine or tacrolimus in people with Transplantation as compared to genotype GG.;in people with Disease:Transplantation
;CLOPIDOGREL;CYP2C19;rs4244285;A;Metabolism/PK;decreased  PK:plasma exposure to the active metabolite of clopidogrel;Allele A is associated with decreased plasma exposure to the active metabolite of clopidogrel when exposed to clopidogrel in healthy individuals as compared to allele G.;in healthy individuals 
;ACENOCOUMAROL;VKORC1;rs9923231;TT;Dosage;decreased  Efficacy:acenocoumarol dose;Genotype TT is associated with decreased acenocoumarol dose when treated with acenocoumarol in people with Atrial Fibrillation as compared to genotype CC.;in people with Disease:Atrial Fibrillation
;FLUOROURACIL;DPYD;rs1801160;T;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Allele T is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms or Colorectal Neoplasms as compared to allele C.;in people with Disease:Colonic Neoplasms, Disease:Colorectal Neoplasms
;CLOPIDOGREL;CYP2C19;rs4244285;A;Toxicity;increased  risk of Side Effect:stent thrombosis;Allele A is associated with increased risk of stent thrombosis when treated with clopidogrel in people with Acute coronary syndrome as compared to allele G.;in people with Disease:Acute coronary syndrome
;MORPHINE;ABCC3;rs886493;G;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele G is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele T.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;rs1045642;AA;Toxicity;increased  risk of Side Effect:Vomiting;Genotype AA is associated with increased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotypes AG + GG.;in men with Disease:Testicular Neoplasms
;MORPHINE;ABCC3;rs7216383;T;Toxicity;increased  severity of Side Effect:Hypoventilation;Allele T is associated with increased severity of Hypoventilation when treated with morphine in children with Sleep Apnea Syndromes and Tonsillectomy as compared to allele C.;in children with Disease:Sleep Apnea Syndromes, Disease:tonsillectomy
;METHOTREXATE;ABCB1;rs1045642;A;Toxicity;decreased likelihood of Side Effect:Neurotoxicity Syndromes;Allele A is associated with decreased likelihood of Neurotoxicity Syndromes when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele G.;in children with Acute lymphoblastic leukemia
;ETHANOL;;rs10516440;A;Toxicity;decreased risk of Other:Alcohol abuse;Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G.; 
;TRAMADOL;ABCB1;rs1045642;A;Efficacy;increased  likelihood of Efficacy:a decrease in visual analog scale >30mm within 6 hours;Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele G.;in people with Disease:Fractures, Bone
;CITALOPRAM;CYP2C19;rs12248560;TT;Metabolism/PK;decreased  PK:metabolic ratio CIT/DCIT values;Genotype TT is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to genotype CC.; 
;TRAMADOL;ABCB1;rs2032582;A;Efficacy;increased  likelihood of Efficacy:a decrease in visual analog scale >30mm within 6 hours;Allele A is associated with increased likelihood of a decrease in visual analog scale >30mm within 6 hours when treated with tramadol in people with Fractures, Bone as compared to allele C.;in people with Disease:Fractures, Bone
;PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased  likelihood of Efficacy:Sustained virological response (SVR);Genotype CC is associated with increased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;Toxicity;decreased severity of Side Effect:Anemia;Allele A is associated with decreased severity of Anemia when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele C.;in people with Disease:Hepatitis C virus infection
;CLOPIDOGREL;CYP2C19;rs4244285;A;Efficacy, Toxicity;increased  risk of Side Effect:cardiovascular events;Allele A is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to allele G.;in people with Disease:Myocardial Infarction
;METHOTREXATE;ABCC2;rs17222723;A;Toxicity;increased  likelihood of Side Effect:Neurotoxicity Syndromes;Allele A is associated with increased likelihood of Neurotoxicity Syndromes when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele T.;in children with Acute lymphoblastic leukemia
;RISPERIDONE;UGT1A1;rs887829;CT;Toxicity;increased  risk of Side Effect:Hyperprolactinemia;Genotype CT is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype CC.;in children with Disease:Autism Spectrum Disorder
;FLUOXETINE;CRHR1;rs242941;CC;Efficacy;increased   Efficacy:response;Genotype CC is associated with increased response when treated with fluoxetine in people with major depression and high anxiety as compared to allele A.;in people with major depression and high anxiety
;RISPERIDONE;UGT1A1;rs10929302;AG;Toxicity;increased  risk of Side Effect:Hyperprolactinemia;Genotype AG is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to genotype GG.;in children with Disease:Autism Spectrum Disorder
;SARILUMAB;IL6R;rs11265618;CC;Efficacy;increased  likelihood of Side Effect:Toxic liver disease;Genotype CC is associated with increased likelihood of Toxic liver disease when treated with sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;in people with Rheumatoid arthritis
;CISPLATIN;ERCC2;rs1799793;CT + TT;Efficacy;increased   Efficacy:event-free survival;Genotypes CT + TT is associated with increased event-free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC.;in people with Disease:Osteosarcoma
;CISPLATIN;GSTP1;rs1138272;CT + TT;Efficacy;decreased  Efficacy:event-free survival, Efficacy:Overall survival;Genotypes CT + TT is associated with decreased event-free survival and overall survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC.;in people with Disease:Osteosarcoma
;SARILUMAB;IL6R;rs4845625;TT;Efficacy;increased  likelihood of Side Effect:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Rheumatoid arthritis
;VITAMIN K ANTAGONISTS;CYP4F2;rs2108622;TT;Efficacy;increased  risk of Efficacy:Stroke;Genotype TT is associated with increased risk of Stroke when treated with Vitamin K antagonists in people with Atrial Fibrillation as compared to genotypes CC + CT.;in people with Disease:Atrial Fibrillation
;RISPERIDONE;HTR2C;rs6318;GG;Toxicity;increased  severity of Side Effect:Weight gain;Genotype GG is associated with increased severity of Weight gain when treated with risperidone in children with Autistic Disorder as compared to allele C.;in children with Disease:Autism
;WARFARIN;CRP;rs1205;CT + TT;Toxicity;increased  risk of Side Effect:Hemorrhage;Genotypes CT + TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotype CC.; 
;HYDROCHLOROTHIAZIDE;TCF7L2;rs4132670;A;Toxicity;increased  risk of Side Effect:diabetes;Allele A is associated with increased risk of diabetes when treated with hydrochlorothiazide in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;HYDROCHLOROTHIAZIDE;TCF7L2;rs7917983;T;Toxicity;increased  risk of Disease:Diabetes Mellitus;Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C.;in people with Disease:Hypertension
;ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;rs17238540;GT;Efficacy;decreased likelihood of Efficacy:reaching target cholesterol levels;Genotype GT is associated with decreased likelihood of reaching target cholesterol levels when treated with atorvastatin, cerivastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin in people with Diabetes Mellitus as compared to genotype TT.;in people with Disease:Diabetes Mellitus
;HYDROCHLOROTHIAZIDE;TCF7L2;rs4506565;T;Toxicity;increased  risk of Disease:Diabetes Mellitus;Allele T is associated with increased risk of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele A.;in people with Disease:Hypertension
;CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;Efficacy;increased  likelihood of Efficacy:Recurrence;Genotypes AA + AG is associated with increased likelihood of Recurrence when treated with clopidogrel in people with Stroke as compared to genotype GG.;in people with Stroke
;CITALOPRAM;CYP2C19;rs4244285;AA;Metabolism/PK;increased   PK:metabolic ratio CIT/DCIT values and mean citalopram dose;Genotype AA is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to genotype GG.; 
;LENALIDOMIDE;ABCB1;rs2032582;CC;Efficacy;decreased  Efficacy:Overall survival;Genotype CC is associated with decreased overall survival when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes AA + AC.;in people with Mantle cell lymphoma
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;Other;Other:later onset of sensory neuropathy;Genotype CC is associated with later onset of sensory neuropathy when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colonic Neoplasms
;DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;Toxicity;increased  risk of Side Effect:toxicity;Allele A is associated with increased risk of toxicity when treated with docetaxel and thalidomide in people with Prostatic Neoplasms as compared to allele G.;in people with Disease:Prostatic Neoplasms
;IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;Toxicity;increased  likelihood of Side Effect:Neutropenia;Genotypes T/del + del/del is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Stomach Neoplasms as compared to genotype TT.;in people with Stomach Neoplasms
;BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA;Toxicity;increased  likelihood of Side Effect:Vomiting;Genotype AA is associated with increased likelihood of Vomiting when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Opioid-Related Disorders
;SARILUMAB;IL6R;rs4537545;CC;Efficacy;increased  likelihood of Side Effect:Dyslipidaemia;Genotype CC is associated with increased likelihood of Dyslipidaemia when treated with sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.;in people with Rheumatoid arthritis
;CALCIUM, ETIDRONIC ACID;VDR;rs1544410;TT;Efficacy;increased   Efficacy:Mean spinal bone mineral density changes;Genotype TT is associated with increased Mean spinal bone mineral density changes when treated with calcium and etidronic acid in people with Osteoporosis, Postmenopausal as compared to genotype CC.;in people with Disease:Osteoporosis, Postmenopausal
;SARILUMAB;IL6R;rs2228145;AA;Efficacy;increased  likelihood of Side Effect:Dyslipidaemia;Genotype AA is associated with increased likelihood of Dyslipidaemia when treated with sarilumab in people with Arthritis, Rheumatoid as compared to genotypes AC + CC.;in people with Rheumatoid arthritis
;BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;rs2234918;CT;Toxicity;decreased likelihood of Side Effect:Physiological sexual disorder;Genotype CT is associated with decreased likelihood of Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes CC + TT.;in people with Opioid-Related Disorders
;VALPROIC ACID;SOD2;rs4880;AA + AG;Toxicity;decreased likelihood of Side Effect:Drug Toxicity;Genotypes AA + AG are associated with decreased likelihood of Drug Toxicity when exposed to valproic acid in people with Epilepsy as compared to genotype GG.;in people with Disease:Epilepsy
;SARILUMAB;IL6R;rs4329505;TT;Efficacy;increased  likelihood of Side Effect:Toxic liver disease;Genotype TT is associated with increased likelihood of Toxic liver disease when treated with sarilumab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.;in people with Rheumatoid arthritis
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:complete early virological response;Genotype CC is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;rs1045280;TT;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype TT is associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes CC + CT.;in people with Opioid-Related Disorders
;PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;Efficacy;increased   Efficacy:complete early virological response;Genotype GG is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;in people with Disease:Chronic hepatitis C virus infection
;BISPHOSPHONATES;CYP2C8;rs1934951;TT;Toxicity;increased  risk of Side Effect:Osteonecrosis of the jaw;Genotype TT is associated with increased risk of Osteonecrosis of the jaw when treated with Bisphosphonates in people with Multiple Myeloma as compared to genotypes CC + CT.;in people with Disease:Multiple Myeloma
;BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AG + GG;Toxicity;increased  likelihood of Side Effect:Nausea;Genotypes AG + GG are associated with increased likelihood of Nausea when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AA.;in people with Opioid-Related Disorders
;BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;Toxicity;increased  likelihood of Side Effect:Exanthema;Genotype AG is associated with increased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG.;in people with Opioid-Related Disorders
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype AA is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:adverse events;Genotype AA is associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Opioid-Related Disorders
;BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA + GG;Toxicity;increased  likelihood of Side Effect:adverse events, Side Effect:Physiological sexual disorder;Genotypes AA + GG are associated with increased likelihood of adverse events or Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG.;in people with Opioid-Related Disorders
;;IFNL3, IFNL4;rs12979860;CC;Other;increased  likelihood of Disease:Jaundice;Genotype CC is associated with increased likelihood of Jaundice in women Hepatitis C as compared to genotypes CT + TT.;in women Disease:Hepatitis C virus infection
;BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:Nausea;Genotype AA is associated with increased likelihood of Nausea when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG.;in people with Opioid-Related Disorders
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;CC;Toxicity;increased  risk of Disease:Drug Toxicity;Genotype CC is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colonic Neoplasms
;BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA + AG;Toxicity;increased  likelihood of Side Effect:Gastrointestinal toxicity;Genotypes AA + AG are associated with increased likelihood of gastrointestinal toxicity when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype GG.;in people with Opioid-Related Disorders
;LENALIDOMIDE;CRBN;rs1705814;CC;Dosage, Toxicity;increased  likelihood of Side Effect:Dose reduction, Side Effect:Discontinuation;Genotype CC is associated with increased likelihood of dose reduction or discontinuation when treated with lenalidomide in people with Lymphoma, Mantle-Cell as compared to genotypes CT + TT.;in people with Mantle cell lymphoma
;BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;Toxicity;decreased likelihood of Side Effect:Exanthema;Genotype AG is associated with decreased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG.;in people with Opioid-Related Disorders
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colonic Neoplasms
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;Toxicity;decreased risk of Disease:Peripheral Nervous System Diseases;Genotype CC is associated with decreased risk of Peripheral Nervous System Diseases when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes CT + TT.;in people with Disease:Colonic Neoplasms
;RIFAMPIN;NR1I2;rs2472677;T;Other, Metabolism/PK;decreased  PK:CYP3A4 acitvity;Allele T is associated with decreased CYP3A4 acitvity when exposed to rifampin.; 
;CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;rs2304016;A;Efficacy;Efficacy:drug resistance;Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.;in people with Disease:Epilepsy
;CAPECITABINE, OXALIPLATIN;PTGS2;rs5275;AA;Efficacy;increased   Other:progression-free survival and overall survival;Genotype AA is associated with increased progression-free survival and overall survival when treated with capecitabine and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colorectal Neoplasms
;;CETP;rs708272;A;;Other:variance in LDL, HDL and LDL/HDL;Allele A is associated with variance in LDL, HDL and LDL/HDL.; 
;HMG COA REDUCTASE INHIBITORS;CETP;rs708272;A;Efficacy;decreased risk of Efficacy:cardiovascular events;Allele A is associated with decreased risk of cardiovascular events when treated with hmg coa reductase inhibitors in people with Coronary Artery Disease as compared to allele G.;in people with Disease:Coronary Artery Disease
;DIURETICS;ADD1;rs4961;GT + TT;Efficacy;decreased likelihood of Disease:Myocardial Infarction;Genotypes GT + TT are associated with decreased likelihood of Myocardial Infarction when treated with diuretics in people with Hypertension.;in people with Disease:Hypertension
;WARFARIN;VKORC1;rs9923231;CT + TT;Dosage;Efficacy:lower warfarin dose requirement;Genotypes CT + TT are associated with lower warfarin dose requirement when treated with warfarin as compared to genotype CC.; 
;ETHANOL;DRD2;rs1076560;A;Other;increased  risk of Disease:Alcohol abuse;Allele A is associated with increased risk of Alcoholism when exposed to ethanol as compared to allele C.; 
;CLOPIDOGREL;P2RY12;rs2046934;AG + GG;Efficacy;increased   Efficacy:platelet activation response to ADP;Genotypes AG + GG are associated with increased platelet activation response to ADP when treated with clopidogrel in people with Acute coronary syndrome as compared to genotype AA.;in people with Disease:Acute coronary syndrome
;METHOTREXATE;ABCC2;rs717620;CT + TT;Toxicity;increased  likelihood of Side Effect:Drug Toxicity;Genotypes CT + TT is associated with increased likelihood of Drug Toxicity methotrexate in children with Acute lymphoblastic leukemia as compared to genotype CC.;in children with Acute lymphoblastic leukemia
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;Efficacy;increased   Efficacy:reduction in mean blood pressure;Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.;in people with Disease:Hypertension
;FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;Toxicity;increased  risk of Disease:Neutropenia;Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG.;in people with Disease:Colonic Neoplasms
;BROMPERIDOL, NEMONAPRIDE;DRD2;rs1799732;GG;Efficacy;increased   Efficacy:improvement in Anxiety-Depression symptoms;Genotype GG is associated with increased improvement in Anxiety-Depression symptoms when treated with bromperidol and nemonapride in people with Schizophrenia as compared to genotypes G/del + del/del.;in people with Disease:Schizophrenia
;THIAZIDES, PLAIN;SLC12A3;rs13306673;CC;Efficacy;increased   Efficacy:reduction in mean blood pressure;Genotype CC is associated with increased reduction in mean blood pressure when treated with Thiazides, plain in people with Essential hypertension as compared to genotypes CT + TT.;in people with Disease:Essential hypertension
;VALPROIC ACID;ABCB1;rs3789243;GG;Efficacy;decreased likelihood of Side Effect:Gastrointestinal toxicity;Genotype GG is associated with decreased likelihood of gastrointestinal toxicity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.;in children with Epilepsy
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;Efficacy;increased   Efficacy:rapid virological response (rvr);Genotype CC is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.;in people with Disease:Chronic hepatitis C virus infection
;AZATHIOPRINE;ITPA;rs1127354;AC;Toxicity;increased  risk of Disease:Leukopenia;Genotype AC is associated with increased risk of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Disease:Inflammatory Bowel Diseases
;VALPROIC ACID;ABCB1;rs3789243;GG;Efficacy;increased  likelihood of Side Effect:Exanthema, Side Effect:Alopecia, Side Effect:Hypersensitivity;Genotype GG is associated with increased likelihood of Exanthema, Alopecia or Hypersensitivity when treated with valproic acid in children with Epilepsy as compared to genotypes GT + TT.;in children with Epilepsy
;ATORVASTATIN, ROSUVASTATIN;CYP3A5;rs776746;CC;Toxicity;increased  likelihood of Side Effect:Muscular Diseases;Genotype CC is associated with increased likelihood of Muscular Diseases when treated with atorvastatin or rosuvastatin in people with Diabetes Mellitus, Hyperlipidemias, Hypertension or Obesity as compared to genotypes CT + TT.;in people with Disease:Diabetes Mellitus, Disease:Hyperlipidemias, Disease:Hypertension, Disease:Obesity
;METHOTREXATE;SLCO1B1;rs4149056;CC + CT;Efficacy;decreased likelihood of Efficacy:Recurrence;Genotypes CC + CT is associated with decreased likelihood of Recurrence when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype TT.;in children with Acute lymphoblastic leukemia
;THIAZIDES, PLAIN;ADRB3;rs4994;AA;Efficacy;increased   Efficacy:reduction in mean blood pressure;Genotype AA is associated with increased reduction in mean blood pressure when treated with Thiazides, plain in people with Essential hypertension as compared to genotypes AG + GG.;in people with Disease:Essential hypertension
;TRASTUZUMAB;FCGR2A;rs1801274;AA;Efficacy;increased   Efficacy:progression free survival;Genotype AA is associated with increased progression free survival when treated with trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG.;in women with Disease:Breast Neoplasms
;IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;Toxicity;increased  likelihood of Side Effect:Diarrhea;Genotypes T/del + del/del is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to genotype TT.;in people with Stomach Neoplasms
;ASPARAGINASE;CPA2;rs199695765;T;Toxicity;increased  risk of Side Effect:Pancreatitis;Allele T is associated with increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C.;in people with Disease:Acute lymphoblastic leukemia
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype AA is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;Efficacy;increased   Efficacy:complete early virological response;Genotype AA is associated with increased complete early virological response when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AG + GG.;in people with Disease:Chronic hepatitis C virus infection
;DAPSONE;HLA-DRB1;rs701829;T;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;Allele T is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele C.; 
;TACROLIMUS;POR;rs1057868;CT + TT;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotypes CT + TT are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC.;in people with Disease:Kidney Transplantation
;WARFARIN;THBD;rs1042580;CC + CT;Toxicity;decreased risk of Side Effect:Hemorrhage;Genotypes CC + CT is associated with decreased risk of Hemorrhage when treated with warfarin as compared to genotype TT.; 
;PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT.;in people with Disease:Chronic hepatitis C virus infection
;METHYLPHENIDATE;CES1;rs3815583;AC + CC;Toxicity;increased  risk of Side Effect:appetite suppression;Genotypes AC + CC are associated with increased risk of appetite suppression when treated with methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA.;in children with Disease:Attention Deficit Disorder with Hyperactivity
;ACE INHIBITORS, PLAIN;BDKRB2;rs8012552;C;Toxicity;increased  risk of Disease:Cough;Allele C is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;CORTICOSTEROIDS;BCL2L11;rs724710;CC;Toxicity;increased  risk of Side Effect:Osteonecrosis;Genotype CC is associated with increased risk of Osteonecrosis when treated with corticosteroids in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.;in children with Disease:Acute lymphoblastic leukemia
;ACE INHIBITORS, PLAIN;MME;rs2016848;A;Toxicity;increased  risk of Disease:Cough;Allele A is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele G.;in people with Disease:Hypertension
;IRINOTECAN;PIN1;rs2233678;CC + CG;Efficacy;increased   Efficacy:Progression-free survival;Genotypes CC + CG is associated with increased progression-free survival when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG.;in people with Disease:Colorectal Neoplasms
;PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;Efficacy;increased   Efficacy:Sustained virological response (SVR);Genotype GG is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG.;in people with Disease:Chronic hepatitis C virus infection
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT;Efficacy;increased   Efficacy:reduction in mean arterial pressure;Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG.;in people with Disease:Essential hypertension
;ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;Toxicity;increased  likelihood of Side Effect:over-anticoagulation;Genotypes AA + AG is associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to genotype GG.; 
;ASPIRIN;ACE;rs4291;AT + TT;Toxicity;increased  risk of Side Effect:aspirin intolerance;Genotypes AT + TT are associated with increased risk of aspirin intolerance when exposed to aspirin in people with Asthma as compared to genotype AA.;in people with Disease:Asthma
;MYCOPHENOLATE MOFETIL;CYP2C8;rs11572103;A;Toxicity;increased  risk of Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant;Allele A is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele T.; 
;HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;Efficacy;increased   Efficacy:reduction in mean blood pressure;Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG.;in people with Disease:Hypertension
;MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;T;Toxicity;increased  risk of Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant;Allele T is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele C.; 
;ACE INHIBITORS, PLAIN;PTGER3;rs11209716;C;Toxicity;decreased risk of Disease:Cough;Allele C is associated with decreased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele T.;in people with Disease:Hypertension
;MYCOPHENOLATE MOFETIL;HUS1;rs1056663;T;Toxicity;decreased risk of Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant;Allele T is associated with decreased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele C.; 
;DAPSONE;HLA-DRB1;rs17211071;A;Toxicity;increased  risk of Side Effect:Drug Hypersensitivity;Allele A is associated with increased risk of Drug Hypersensitivity due to dapsone as compared to allele G.; 
;TACROLIMUS;PPARA;rs4253728;AA + AG;Toxicity;increased  risk of Disease:Diabetes Mellitus;Genotypes AA + AG are associated with increased risk of Diabetes Mellitus when treated with tacrolimus in people with Kidney Transplantation as compared to genotype GG.;in people with Disease:Kidney Transplantation
;MYCOPHENOLATE MOFETIL;HUS1;rs2037483;A;Toxicity;decreased risk of Side Effect:time to anemia in patients undergoing living or deceased donor kidney transplant;Allele A is associated with decreased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele G.; 
;;ADD1;rs4961;GT + TT;Other;increased  likelihood of Disease:Hypertension;Genotypes GT + TT are associated with increased likelihood of Hypertension as compared to genotype GG.; 
;FLUOROURACIL;ABCB1;rs2032582;C;Toxicity;decreased likelihood of Side Effect:Exanthema;Allele C is associated with decreased likelihood of Exanthema when treated with fluorouracil in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;FLUOROURACIL;SLCO1B1;rs2306283;A;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Allele A is associated with increased likelihood of Peripheral Nervous System Diseases when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele G.;in people with Colorectal Neoplasms
;;ARG1;rs2781666;TT;Other;increased  severity of Other:Asthma;Genotype TT is associated with increased severity of Asthma as compared to genotypes GG + GT.; 
;TACROLIMUS;CYP3A4;rs2740574;TT;Efficacy;decreased likelihood of Efficacy:Transplant rejection;Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.;in people with Kidney Transplantation
;EPIRUBICIN;ABCC1;rs246221;CT;Toxicity;increased  likelihood of Side Effect:Left Ventricular Dysfunction;Genotype CT is associated with increased likelihood of Left Ventricular Dysfunction when treated with epirubicin in people with Breast Neoplasms as compared to genotype TT.;in people with Breast Neoplasms
;LEVODOPA;COMT;rs4680;AA;Toxicity;increased  likelihood of Side Effect:Dyskinesia, Drug-Induced;Genotype AA is associated with increased likelihood of Dyskinesia, Drug-Induced when treated with levodopa in people with Parkinson Disease as compared to genotypes AG + GG.;in people with Parkinson Disease
;METHOTREXATE;SLC19A1;rs1051266;TT;Toxicity;increased  risk of Side Effect:Toxic liver disease;Genotype TT is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Acute lymphoblastic leukemia as compared to genotype CC.;"in people with ""Disease:Burkitt Lymphoma"", ""Disease:Lymphoma, T-Cell"", ""Disease:Acute lymphoblastic leukemia"""
;DAUNORUBICIN, DOXORUBICIN;ABCC2;rs8187710;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele G.;in children with Neoplasms
;FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);Efficacy;decreased likelihood of Efficacy:Recurrence free survival;DPYD c.1129-5923C>G, c.1236G>A (HapB3) is associated with decreased likelihood of Recurrence free survival when treated with FOLFOX in people with Rectal Neoplasms.;in people with Rectal Neoplasms
;DAUNORUBICIN, DOXORUBICIN;HFE;rs1799945;G;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele G is associated with decreased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;GPR35;rs12468485;T;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele T is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;UGT1A6;rs17863783;T;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele T is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele G.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;GSTA2;rs2180314;G;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Allele G is associated with decreased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;ETFB;rs79338777;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele G.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;HNMT;rs17583889;A;Toxicity;increased  likelihood of Side Effect:Cardiotoxicity;Allele A is associated with increased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.;in children with Neoplasms
;DAUNORUBICIN, DOXORUBICIN;ABCC5;rs7627754;AA + AT;Toxicity;decreased likelihood of Side Effect:Cardiotoxicity;Genotypes AA + AT is associated with decreased likelihood of Cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to genotype TT.;in children with Neoplasms
;CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;HLA-A*02:01;*02:01;Toxicity;increased  likelihood of Side Effect:Drug-induced liver injury;HLA-A *02:01 is associated with increased likelihood of Drug-induced liver injury when treated with cefazolin, cefdinir, ceftriaxone, cefuroxime or cephalexin.; 
;TACROLIMUS;CYP2B6;rs3745274;GT;Efficacy;decreased likelihood of Efficacy:Transplant rejection;Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;CORTICOSTEROIDS;WNT7B;rs73175102;A;Toxicity;increased  likelihood of Side Effect:Osteonecrosis;Allele A is associated with increased likelihood of Osteonecrosis when treated with corticosteroids in children with Leukemia or Lymphoma as compared to allele G.;in children with Leukemia, Lymphoma
;CORTICOSTEROIDS;POGK;rs115587273;A;Toxicity;increased  likelihood of Side Effect:Osteonecrosis;Allele A is associated with increased likelihood of Osteonecrosis when treated with corticosteroids in children with Leukemia or Lymphoma as compared to allele C.;in children with Leukemia, Lymphoma
;CORTICOSTEROIDS;FAM240C;rs78233573;A;Toxicity;increased  likelihood of Side Effect:Osteonecrosis;Allele A is associated with increased likelihood of Osteonecrosis when treated with corticosteroids in children with Leukemia or Lymphoma as compared to allele G.;in children with Leukemia, Lymphoma
;CORTICOSTEROIDS;ZNF37A;rs376867011;A;Toxicity;increased  likelihood of Side Effect:Osteonecrosis;Allele A is associated with increased likelihood of Osteonecrosis when treated with corticosteroids in children with Leukemia or Lymphoma as compared to allele G.;in children with Leukemia, Lymphoma
;CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;Efficacy;increased  likelihood of Efficacy:Emergencies, Efficacy:Pain;CYP2D6 intermediate metabolizer and poor metabolizer is associated with increased likelihood of Emergencies and Pain when treated with codeine, hydrocodone or tramadol in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer.;in people with Pain
;GANCICLOVIR, VALGANCICLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*2 + *3 + *4;;increased  likelihood of Side Effect:Neutropenia;NUDT15 *2 + *3 + *4 is associated with increased likelihood of Neutropenia when treated with ganciclovir and valganciclovir in children with Liver transplantation and Cytomegalovirus Infection as compared to NUDT15 *1/*1.;in children with Liver transplantation, Cytomegalovirus Infection
;VALPROIC ACID;ACOT1;rs758109;T;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele T is associated with increased likelihood of Toxic liver disease when treated with valproic acid in people with Epilepsy as compared to allele C.;in people with Epilepsy
;TACROLIMUS;SLCO1B1;rs2306283;AA + AG;Toxicity;decreased likelihood of Side Effect:Nephrotoxicity;Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;AZATHIOPRINE;MOCOS;rs73430958;GT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotype GT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype TT.;in people with Inflammatory Bowel Diseases
;VALPROIC ACID;GABPA;rs59288687;CC;Toxicity;decreased likelihood of Side Effect:Toxic liver disease;Genotype CC is associated with decreased likelihood of Toxic liver disease when treated with valproic acid in people with Epilepsy as compared to genotypes CT + TT.;in people with Epilepsy
;VALPROIC ACID;NQO1;rs10517;GG;Toxicity;decreased likelihood of Side Effect:Toxic liver disease;Genotype GG is associated with decreased likelihood of Toxic liver disease when treated with valproic acid in people with Epilepsy as compared to genotypes AA + AG.;in people with Epilepsy
;VALPROIC ACID;PPARA;rs881740;G;Toxicity;increased  likelihood of Side Effect:Toxic liver disease;Allele G is associated with increased likelihood of Toxic liver disease when treated with valproic acid in people with Epilepsy as compared to allele A.;in people with Epilepsy
;METHOTREXATE;SLCO1B3;rs7311358;AA;Toxicity;increased  likelihood of Side Effect:Anemia;Genotype AA is associated with increased likelihood of Anemia when treated with methotrexate in people with Rheumatoid arthritis as compared to genotypes AG + GG.;in people with Rheumatoid arthritis
;METHOTREXATE;SLCO1B3;rs4149117;GG;Toxicity;increased  likelihood of Side Effect:Anemia;Genotype GG is associated with increased likelihood of Anemia when treated with methotrexate in people with Rheumatoid arthritis as compared to genotype TT.;in people with Rheumatoid arthritis
;METHOTREXATE;SLCO1B1;rs2306283;AA + AG;Toxicity;increased  likelihood of Side Effect:Anemia;Genotypes AA + AG is associated with increased likelihood of Anemia when treated with methotrexate in people with Rheumatoid arthritis as compared to genotype GG.;in people with Rheumatoid arthritis
;APIXABAN;APOE;rs7412;C;Toxicity;increased  likelihood of Side Effect:Intracranial Hemorrhages;Allele C is associated with increased likelihood of Intracranial Hemorrhages when treated with apixaban in people with Atrial Fibrillation.;in people with Atrial Fibrillation
;APIXABAN;APOE;rs429358;C;Toxicity;increased  likelihood of Side Effect:Intracranial Hemorrhages;Allele C is associated with increased likelihood of Intracranial Hemorrhages when treated with apixaban in people with Atrial Fibrillation.;in people with Atrial Fibrillation
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs8099917;GG;Toxicity;increased  likelihood of Side Effect:Pneumonitis;Genotype GG is associated with increased likelihood of Pneumonitis when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Lung Neoplasms and Tobacco Use Disorder as compared to genotypes GT + TT.;in people with Lung Neoplasms, Tobacco Use Disorder
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12980275;GG;Toxicity;increased  likelihood of Side Effect:Pneumonitis;Genotype GG is associated with increased likelihood of Pneumonitis when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Lung Neoplasms as compared to genotypes AA + AG.;in people with Lung Neoplasms
;PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12979860;TT;Toxicity;increased  likelihood of Side Effect:Pneumonitis;Genotype TT is associated with increased likelihood of Pneumonitis when treated with PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors in people with Lung Neoplasms and Tobacco Use Disorder.;in people with Lung Neoplasms, Tobacco Use Disorder
;TACROLIMUS;ABCB1;rs9282564;TT;Efficacy;decreased risk of Efficacy:Death;Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT.;in people with Kidney Transplantation
;TACROLIMUS;ABCC2;rs2273697;GG;Efficacy;increased  likelihood of Efficacy:Overall survival;Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG.;in people with Kidney Transplantation
;TACROLIMUS;SLCO1B1;rs4149056;TT;Efficacy;decreased likelihood of Efficacy:Transplant rejection;Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;TACROLIMUS;CYP2C19;rs4244285;AA;Toxicity;increased  likelihood of Side Effect:Nephrotoxicity;Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation.;in people with Kidney Transplantation
;AZATHIOPRINE;NUDT15;rs116855232;CT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotype CT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype CC.;in people with Inflammatory Bowel Diseases
;AZATHIOPRINE;RRM1;rs1735053;AG + GG;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes AG + GG is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype AA.;in people with Inflammatory Bowel Diseases
;AZATHIOPRINE;TPMT;rs9465102;GT + TT;Toxicity;increased  likelihood of Side Effect:Leukopenia;Genotypes GT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Inflammatory Bowel Diseases as compared to genotype GG.;in people with Inflammatory Bowel Diseases
;CISPLATIN;TRPA1;rs920829;TT;Toxicity;decreased likelihood of Side Effect:Nephrotoxicity;Genotype TT is associated with decreased likelihood of Nephrotoxicity when treated with cisplatin in people with Carcinoma, Squamous Cell, Carcinoma or Adenocarcinoma as compared to genotypes CC + CT.;"in people with ""Carcinoma, Squamous Cell"", ""Carcinoma"", ""Adenocarcinoma"""
;FOLFOX, XELOX;DPYD;rs1801265;AG + GG;Toxicity;increased  likelihood of Side Effect:Peripheral Nervous System Diseases;Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA.;in people with Colorectal Neoplasms
;FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;Efficacy, Toxicity;increased  likelihood of Side Effect:Treatment modification;CYP2D6 poor metabolizer and ultrarapid metabolizer is associated with increased likelihood of Treatment modification when treated with fluoxetine as compared to CYP2D6 normal metabolizer.; 
;CYCLOSPORINE;SLC29A1;rs693955;AA;Efficacy;decreased likelihood of Efficacy:Overall survival, Efficacy:Recurrence free survival;Genotype AA is associated with decreased likelihood of overall survival or Recurrence free survival when treated with cyclosporine in children with Hematopoietic stem cell transplantation and Leukemia as compared to genotypes AC + CC.;in children with Hematopoietic stem cell transplantation, Leukemia
;AFATINIB, ERLOTINIB, GEFITINIB;AKT1;rs2494750;CC;Efficacy;increased  likelihood of Efficacy:Progression-free survival;Genotype CC is associated with increased likelihood of Progression-free survival when treated with afatinib, erlotinib or gefitinib in people with Non-Small Cell Lung Carcinoma as compared to genotypes CG + GG.;in people with Non-Small Cell Lung Carcinoma
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*44:03;*44:03;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *44:03 is associated with increased likelihood of Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole / trimethoprim.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:01;*38:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-B *38:01 is associated with increased likelihood of Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole / trimethoprim.; 
;SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*04:01;*04:01;Toxicity;increased  likelihood of Side Effect:Severe Cutaneous Adverse Reactions;HLA-C *04:01 is associated with increased likelihood of Severe Cutaneous Adverse Reactions when treated with sulfamethoxazole / trimethoprim.; 
;FOLFOX, XELOX;GSTP1;rs1695;GG;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression;Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Colorectal Neoplasms
;FOLFOX, XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;Toxicity;decreased likelihood of Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression;Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;FOLFOX, XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;Toxicity;increased  likelihood of Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity;Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms.;in people with Colorectal Neoplasms
;FOLFOX, XELOX;GSTP1;rs1695;GG;Toxicity;increased  likelihood of Side Effect:Mucositis;Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.;in people with Colorectal Neoplasms
;AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;Toxicity;increased  likelihood of Side Effect:Pancreatitis;HLA-DQA1 *02:01 is associated with increased likelihood of Pancreatitis when treated with azathioprine in people with Inflammatory Bowel Diseases.;in people with Inflammatory Bowel Diseases
;AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;Toxicity;increased  likelihood of Side Effect:Pancreatitis;HLA-DRB1 *07:01 is associated with increased likelihood of Pancreatitis when treated with azathioprine in people with Inflammatory Bowel Diseases.;in people with Inflammatory Bowel Diseases
;HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;Toxicity;increased  likelihood of Side Effect:Drug Toxicity, Side Effect:Toxic liver disease;Allele T is associated with increased likelihood of Drug Toxicity or Toxic liver disease when treated with hmg coa reductase inhibitors as compared to allele G.; 
;AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;Toxicity;increased  risk of Side Effect:Drug Toxicity;CYP2D6 *1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10 are associated with increased risk of Drug Toxicity when treated with amitriptyline in people with Major Depressive Disorder as compared to CYP2D6 *1/*1 + *1/*2 + *2/*1xN + *2/*2 + *1/*41 + *1/*10 + *2/*41.;in people with Disease:Major Depressive Disorder
;AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;Toxicity;increased  likelihood of Side Effect:Leukopenia;TPMT *3A + *3B + *3C is associated with increased likelihood of Leukopenia when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases as compared to TPMT *1/*1.;in people with Inflammatory Bowel Diseases
;RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;Toxicity;increased  likelihood of Side Effect:adverse events;CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) .;in children 
;CODEINE, MORPHINE, OXYCODONE;OPRM1;rs1799971;AA;Toxicity;increased  likelihood of Side Effect:Urinary Retention, Side Effect:Constipation, Side Effect:Nausea, Side Effect:Vomiting, Side Effect:Abdominal Pain, Side Effect:Exanthema, Side Effect:Wheezing, Side Effect:adverse events;Genotype AA is associated with increased likelihood of Urinary Retention, Constipation, Nausea, Vomiting, Abdominal Pain, Exanthema, Wheezing or adverse events when treated with codeine, morphine or oxycodone in people with Neoplasms and Pain as compared to genotypes AG + GG.;in people with Neoplasms, Pain
